[
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 HD00100 ddrug11 , ddrug12 gi motility agents : DB00604",
        "label": "NA"
    },
    {
        "text": "haemodynamic effects of DB09341 and HD00071 were additive when ddrug2 was co-administered but not under basal conditions .",
        "label": "NA"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , ddrug3 HD00388 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 HD00100 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "differences in DB01592 balance were only observed between both dietary concentrations , showing a higher absolute but a lower relative absorption as well as retention in the groups fed further DB01592 , { abstract truncated at # words }",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and DB00759 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , DB01601 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "other drugs drug interactions have been reported with concomitant administration of DB00199 and other medications , including ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , DB00313 , ddrug9 , and ddrug10 .",
        "label": "int"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , DB00908 ddrug4 : ddrug5 , ddrug6 antimigraine : HD00870 ddrug8 : ddrug9 ddrug10 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "side effects { DB00181 } the most common adverse reaction during treatment with DB00181 is transient drowsiness { 10 - 63 % } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , DB00529 , and ddrug2 : drugs such as ddrug3 , ddrug4 , and ddrug5 may increase the risk of developing peripheral_neuropathies or other ddrug6 - associated adverse events by interfering with the renal clearance of DB00943 { thereby raising systemic exposure } .",
        "label": "NA"
    },
    {
        "text": "DB01294 : ddrug1 , given concomitantly with ddrug2 or # minutes following ddrug3 administration , decreased DB00467 bioavailability by approximately 25 % .",
        "label": "NA"
    },
    {
        "text": "coadministration of ddrug0 and DB00717 1/35 increased the exposure of ddrug2 and DB00977 by 20 % and 34 % , respectively .",
        "label": "NA"
    },
    {
        "text": "in clinical studies performed with ddrug0 , the concomitant use of oral ddrug1 { DB00682 } , ddrug3 { ddrug4 } , ddrug5 { ddrug6 } , and ddrug7 did not significantly affect the pharmacokinetics/pharmacodynamics of DB00569 .",
        "label": "NA"
    },
    {
        "text": "the following medications have been administered in clinical trials with DB00074 with no increase in adverse reactions : atg/alg , ddrug1 , ddrug2 , ddrug3 , DB00688 , and ddrug5 .",
        "label": "NA"
    },
    {
        "text": "immediate and extended release tablets the hypoglycemic action of ddrug0 may be potentiated by certain drugs including HD00518 , some ddrug2 and other drugs that are highly protein bound , ddrug3 , ddrug4 , ddrug5 , DB01032 , ddrug7 , ddrug8 , and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "the concomitant administration of ddrug0 including DB01059 with ddrug2 { a HD00887 } has , on rare occasions , resulted in severe hypoglycemia .",
        "label": "NA"
    },
    {
        "text": "effect of ddrug0 and DB00683 on the antinociceptive effect of ddrug2 , DB04817 and ddrug4 in mice .",
        "label": "NA"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 HD00871 : ddrug9 HD00100 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { DB00316 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , DB00224 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "the coadministration of DB00945 decreases the biologic half-life of DB00573 because of an increase in metabolic clearance that results in a greater amount of ddrug2 in the urine .",
        "label": "mechanism"
    },
    {
        "text": "the potential effects of increased plasma concentrations of DB00683 or other ddrug1 metabolized via cyp3a4 { ddrug2 , ddrug3 } should be considered when coadministering these agents with DB00673 .",
        "label": "advise"
    },
    {
        "text": "HD00326 including coumarin derivatives , indandione derivatives , and ddrug1 such as ddrug2 { ddrug3 } , and ddrug4 may increase the risk of bleeding when administered concomitantly with DB00407 .",
        "label": "effect"
    },
    {
        "text": "drugs metabolized by cytochrome p450 enzymes the drug interaction study evaluating the effect of DB00365 on ddrug1 indicates that ddrug2 inhibits DB00277 metabolism , which is mediated by cyp1a2 .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect : ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , DB00668 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 { e , g , , in oral HD00283 } .",
        "label": "NA"
    },
    {
        "text": "agents causing renin release : the antihypertensive effect of ddrug0 and DB00584 iv is augmented by ddrug2 that cause renin release { e , g , , HD00218 } .",
        "label": "effect"
    },
    {
        "text": "before taking DB00222 , tell your doctor if you are taking any of the following medicines : - ddrug1 or another ddrug2 such as ddrug3 { ddrug4 } , ddrug5 { ddrug6 , others } , ddrug7 { ddrug8 } , ddrug9 { ddrug10 } , or ddrug11 { DB06724 } ;",
        "label": "advise"
    },
    {
        "text": "HD00285 , such as ddrug1 and DB01064 ;",
        "label": "NA"
    },
    {
        "text": "in clinical trials , DB01240 was used with ddrug1 , ddrug2 , ddrug3 , oral ddrug4 , and supplemental ddrug5 , in a pharmacokinetic substudy in patients with congestive heart failure receiving ddrug6 or DB00390 in whom therapy with ddrug8 was initiated , apparent oral clearance values for ddrug9 { n = 23 } and ddrug10 { n = 30 } were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .",
        "label": "NA"
    },
    {
        "text": "the effects DB00482 on the pharmacokinetics and/or pharmacodynamics of ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , and DB00682 have been studied in vivo and clinically important interactions have not been found .",
        "label": "NA"
    },
    {
        "text": "it was established that both angiotensins inhibited gastric acid secretion stimulated by DB00183 but not by DB05381 .",
        "label": "NA"
    },
    {
        "text": "concomitant treatment with HD00364 { eg , rt-pa or ddrug1 } may : - increase the risk of bleeding complications - considerably enhance the effect of DB00001 on aptt prolongation",
        "label": "NA"
    },
    {
        "text": "population pharmacokinetic analyses revealed that ddrug0 , HD00203 , ddrug2 , and ddrug3 did not influence DB01281 clearance .",
        "label": "NA"
    },
    {
        "text": "DB00091 : after introduction of DB00608 { oral form } , a sudden increase in serum ddrug2 level has been reported .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the concomitant administration of ddrug1 { DB00270 } and DB00390 in a single-dose pharmacokinetic study did not affect renal , nonrenal and total body clearance of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "medications can interfere with folate utilization , including : ddrug0 { such as DB00252 , and ddrug2 } ddrug3 { sometimes prescribed to control blood sugar in type # diabetes } ddrug4 { used to control inflammation associated with crohn_disease and ulcerative colitis } ddrug5 { a HD00295 } ddrug7 there has been concern about the interaction between ddrug8 and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "DB00343 plasma levels were not significantly affected by DB00227 or ddrug2 .",
        "label": "NA"
    },
    {
        "text": "DB01118 inhibits HD00301 .",
        "label": "NA"
    },
    {
        "text": "HD00063 may be active in inhibiting cryptosporidium parvum growth in vitro upon combination with either ddrug1 or DB01017 .",
        "label": "effect"
    },
    {
        "text": "drugs that lower seizure threshold : concurrent administration of DB01156 and agents { e , g , , ddrug1 , other ddrug2 , ddrug3 , systemic HD00356 , etc , } that lower seizure threshold should be undertaken only with extreme caution .",
        "label": "advise"
    },
    {
        "text": "because of this , the dosage of DB01195 should be adjusted when these HD00096 are administered concomitantly .",
        "label": "NA"
    },
    {
        "text": "HD00290 , other , especially ddrug1 , or pre ddrug2 and anesthetic agents used in surgery or HD00785 , nondepolarizing , used in surgery",
        "label": "NA"
    },
    {
        "text": "patients taking these drugs with DB00190 and DB01235 or ddrug2 - ddrug3 combination products should be carefully observed for loss of therapeutic response .",
        "label": "NA"
    },
    {
        "text": "DB01053 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and ddrug7 have no influence in vitro on the protein binding of DB00586 in human serum .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , DB00863 : in normal volunteers { n = 9 } , pretreatment with DB00501 or ddrug3 did not affect ddrug4 pharmacokinetics except that a small { 13 % } but statistically significant increase in the area under the serum concentration curve of ddrug5 resulted with ddrug6 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB01432 may increase the clearance of HD00175 .",
        "label": "mechanism"
    },
    {
        "text": "although the interaction between ddrug0 and other potent cyp3a4 inhibitors { e , g , , ddrug1 , DB00503 , and ddrug3 } has not been studied , increased exposures to DB00918 may be expected when ddrug5 is used concomitantly with these medications .",
        "label": "NA"
    },
    {
        "text": "DB00328 - concomitant use of DB00130 and ddrug2 may ameliorate increased intestinal permeability caused by ddrug3 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration of DB00701 and DB00333 can decrease plasma levels of ddrug3 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : ddrug1 , HD00323 , ddrug3 , or ddrug4 may interfere with the bactericidal effect of HD00124 .",
        "label": "effect"
    },
    {
        "text": "the use of HD00374 should be considered in place of ddrug1 or HD00587 in patients receiving ddrug3 therapy .",
        "label": "NA"
    },
    {
        "text": "severe hypoglycemia has been reported in patients concomitantly receiving HD00639 and oral HD00062 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : in vitro data indicate that DB00224 and ddrug2 markedly inhibit the metabolism of DB00604 which can result in an increase in plasma ddrug4 levels and prolongation of the qt interval on the ecg .",
        "label": "mechanism"
    },
    {
        "text": "although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic HD00268 , including ddrug1 , HD00093 , and ddrug3 , the effect of ddrug4 gel on the steady-state concentrations of these drugs is not known .",
        "label": "NA"
    },
    {
        "text": "administration of repeat doses of DB01155 had no effect on the repeat dose pharmacokinetics of ddrug1 , ddrug2 or an ddrug3 / levonorgestrol oral HD00750 in healthy subjects .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the effect of an ddrug1 - and DB09104 - containing ddrug3 { HD00467 } * on the pharmacokinetics of ddrug5 was investigated in # cancer patients .",
        "label": "NA"
    },
    {
        "text": "the anxiogenic effects of ddrug0 were reduced by pretreatment with HD00184 , an a2-selective agonist , but not by ddrug2 { HD00186 } , an a1-selective agonist .",
        "label": "NA"
    },
    {
        "text": "DB00819 decreases urinary excretion of DB00182 and may enhance the magnitude and duration of their effect .",
        "label": "mechanism"
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of ddrug0 such as DB00565 include certain ddrug2 { e , g , , ddrug3 , HD00239 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 } , ddrug11 salts , ddrug12 , local ddrug13 , ddrug14 , and ddrug15 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : ddrug1 like other HD00233 , has been shown to affect bleeding parameters in patients receiving HD00738 , and serious clinical bleeding has been reported .",
        "label": "effect"
    },
    {
        "text": "longitudinal assessment of DB01590 in de novo renal transplant recipients over the first post-transplant year : pharmacokinetics , exposure-response relationships , and influence on DB00091 .",
        "label": "NA"
    },
    {
        "text": "drug interactions : the central ddrug0 syndrome can occur when anticholinergic agents such as ddrug1 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain HD00424 such as ddrug3 , the ddrug4 and other ddrug5 , ddrug6 , certain ddrug7 such as the DB00908 salts , and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , DB00446 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , ddrug12 } , HD00297 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "HD00293 such as ddrug1 , DB00384 , or ddrug3 , or ddrug4 supplements should be given only for documented hypokalemia , and then with caution , since they may lead to a significant increase of serum potassium .",
        "label": "NA"
    },
    {
        "text": "DB01064 should be used with caution , if at all , when potent inhalational HD00264 such as ddrug2 are employed because of potential to sensitize the myocardium to effects of ddrug3 .",
        "label": "advise"
    },
    {
        "text": "HD00269 : ddrug1 , DB01601 , ddrug3 , and ddrug4 have been shown to decrease plasma levels of ddrug5 ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 , ddrug2 { DB00627 , DB00199 , ddrug5 : skeletal muscle .",
        "label": "NA"
    },
    {
        "text": "DB01118 may suppress certain cyp450 enzymes , including ddrug1 , HD00097 , ddrug3 , and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "DB00501 , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of ddrug1 , DB00252 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , certain ddrug7 , ddrug8 , ddrug9 and ddrug10 , thereby delaying elimination and increasing blood levels of these drugs .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : coadministration of DB00615 and DB00220 resulted in a 32 % decrease in ddrug3 plasma auc and a 207 % increase in ddrug4 plasma a , c.",
        "label": "mechanism"
    },
    {
        "text": "HD00444 : concurrent administration of certain ddrug1 , such as ddrug2 and ddrug3 , would be expected to compromise the beneficial effects of DB00604 .",
        "label": "NA"
    },
    {
        "text": "these results suggest that both DB01234 and ddrug1 , and possibly other ddrug2 and ddrug3 , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of HD00071 and ddrug5 .",
        "label": "effect"
    },
    {
        "text": "in a 12-month controlled trial that included a # mcg once daily DB01274 dose , # of the # ddrug1 - treated subjects received concomitant DB00277 at study entry .",
        "label": "NA"
    },
    {
        "text": "limited clinical experience indicates that requirements for HD00265 are reduced by # to 50 % for the first sixty { 60 } minutes following ddrug1 induction the concomitant use of ddrug2 with ddrug3 can significantly inhibit DB00802 clearance and may increase the risk of prolonged or delayed respiratory depression .",
        "label": "NA"
    },
    {
        "text": "- HD00420 or ddrug1 { with hepatotoxic potential } must not be administered together with HD00414 or ddrug3 .",
        "label": "advise"
    },
    {
        "text": "when combined with ddrug0 , HD00050 exhibited strong synergistic activity while only additive effects were observed with the combination of DB01045 { or ddrug3 } and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "interactions with other ddrug0 : significant decreases in the auc of DB00705 { 20 % } and ddrug2 { 84 % } occurred following simultaneous administration of these agents with DB00900 .",
        "label": "mechanism"
    },
    {
        "text": "such individuals are referred to as poor metabolizers of drugs such as DB04840 , ddrug1 , the HD00043 , and ddrug3 .",
        "label": "NA"
    },
    {
        "text": "DB00501 reduces the clearance of DB00802 .",
        "label": "mechanism"
    },
    {
        "text": "in vitro mixing of an HD00494 with beta-lactamtype HD00002 { ddrug2 or ddrug3 } may result in a significant mutual inactivation .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { DB00091 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , DB01601 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : following co-administration of two 250-mg DB00954 tablets administered once daily with 200-mg DB00277 tablets administered twice daily for # days to # healthy subjects , the steady-state plasma concentration of ddrug3 was not significantly altered .",
        "label": "NA"
    },
    {
        "text": "before taking ddrug0 , tell your doctor if you are taking any of the following medicines : - DB00945 or another ddrug2 such as ddrug3 { ddrug4 } , ddrug5 { ddrug6 , others } , ddrug7 { ddrug8 } , ddrug9 { HD00758 } , or ddrug11 { ddrug12 } ;",
        "label": "NA"
    },
    {
        "text": "DB06799 therapy urinary excretion of HD00401 is increased , and efficacy is reduced by acidifying agents used in ddrug2 therapy .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a single dose study { n = 6 } , ingestion of an ddrug1 containing # - gram of DB09104 with 500-mg of DB00784 increased the cmax and auc of ddrug4 by 125 % and 36 % , respectively , a number of compounds are inhibitors of cyp2c9 including ddrug5 , ddrug6 and ddrug7 .",
        "label": "mechanism"
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the HD00555 of drugs may be potentiated by ddrug1 , HD00543 , ddrug3 , ddrug4 , ddrug5 , the ddrug6 , ddrug7 and ddrug8 , ddrug9 and the ddrug10 , and by other ddrug11 .",
        "label": "effect"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of HD00071 : ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , DB00668 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the effects of DB00682 and HD00203 on gi bleeding are synergistic , such that users of both drugs together have a risk of serious gi bleeding higher than that of users of either drug alone .",
        "label": "effect"
    },
    {
        "text": "DB01167 ddrug1 ddrug2 ddrug3 ddrug4 ddrug5 DB01149 ddrug7 large quantities of grapefruit juice { # quart daily }",
        "label": "NA"
    },
    {
        "text": "ddrug0 : a literature article reported that when a 60-mg controlled-release ddrug1 capsule was administered # hours prior to a 600-mg ddrug2 capsule { n = 12 } , mean DB00996 auc increased by 44 % compared to ddrug4 administered without DB00295 .",
        "label": "NA"
    },
    {
        "text": "DB00277 - related adverse effects have occurred in patients when ddrug1 and DB00467 were coadministered .",
        "label": "NA"
    },
    {
        "text": "results of studies in multiple sclerosis patients taking ddrug0 and concomitant ddrug1 { ddrug2 # mcg i m once weekly } or ddrug3 were inconclusive with regard to the need for dose adjustment of the HD00868 or DB05259 .",
        "label": "NA"
    },
    {
        "text": "the use of DB01073 wwox injection in combination with DB00552 is not recommended due to the risk of severe pulmonary toxicity .",
        "label": "advise"
    },
    {
        "text": "persons taking most ddrug0 , ddrug1 and ddrug2 invalidate DB00158 and DB00115 diagnostic blood assays .",
        "label": "NA"
    },
    {
        "text": "and ddrug0 when ddrug1 is given with ddrug2 agents or ddrug3 drugs , including DB00668 combined with local HD00264 , close supervision and careful adjustment of dosages are required .",
        "label": "NA"
    },
    {
        "text": "no interactions have been observed with ddrug0 , ddrug1 , HD00029 and ddrug3 and HD00106 .",
        "label": "NA"
    },
    {
        "text": "DB00955 should not be administered concomitantly with potent HD00105 such as ddrug2 and ddrug3 as the potential for ototoxicity is enhanced by the combination .",
        "label": "advise"
    },
    {
        "text": "concomitant administration of DB01039 { equivalent to 145 mg DB01039 } with ddrug2 { 40 mg } once daily for # days has been shown to increase the mean cmax and auc values for ddrug3 by 36 % { range from 69 % decrease to 321 % increase } and 28 % { range from 54 % decrease to 128 % increase } , respectively , and for # - hydroxy-iso-pravastatin by 55 % { range from 32 % decrease to 314 % increase } and 39 % { range from 24 % decrease to 261 % increase } , respectively in # healthy adults .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of ddrug1 , DB00252 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , certain ddrug7 , ddrug8 , ddrug9 and DB00916 , thereby delaying elimination and increasing blood levels of these drugs .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : clinical studies , as well as post marketing observations , have shown that ddrug1 can reduce the natriuretic effect of DB00695 and HD00217 in some patients .",
        "label": "NA"
    },
    {
        "text": "drugs demonstrated to be cyp 3a inhibitors of possible clinical significance on the basis of clinical studies involving DB00404 { caution is recommended during coadministration with ddrug1 } : coadministration of DB00472 with ddrug3 increased the maximum plasma concentration of ddrug4 by 46 % , decreased clearance by 21 % , increased half-life by 17 % , and decreased measured psychomotor performance .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - a drug interaction study of DB00700 with DB14507 has not been conducted .",
        "label": "NA"
    },
    {
        "text": "it may increase excretion of ddrug0 , ddrug1 , and DB00945 and may also increase the toxicity of HD00328 .",
        "label": "NA"
    },
    {
        "text": "in monkeys , ddrug0 was about # times more potent than ddrug1 in decreasing responding , whereas in pigeons HD00157 was about equipotent with HD00156 .",
        "label": "NA"
    },
    {
        "text": "potential drug interactions between DB01202 and other ddrug1 { ddrug2 , ddrug3 , ddrug4 , DB01174 , ddrug6 , ddrug7 and ddrug8 } were also assessed by evaluating the serum concentrations of ddrug9 and these ddrug10 during placebo-controlled clinical studies .",
        "label": "NA"
    },
    {
        "text": "results : DB00203 has demonstrated effectiveness in men with erectile dysfunction associated with prostatectomy , radiation therapy , diabetes mellitus , certain neurologic disorders , and drug therapy { eg , HD00113 -lsb- ddrug2 -rsb- } .",
        "label": "NA"
    },
    {
        "text": "- drugs whose efficacy is impaired by DB00252 include : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , oral ddrug8 , ddrug9 , DB00908 , ddrug11 , ddrug12 .",
        "label": "effect"
    },
    {
        "text": "because DB01242 is highly bound to serum protein , the administration of ddrug1 to patients taking other drugs that are highly bound to protein { e , g , , ddrug2 , DB00390 } may cause an increase in plasma concentrations of these drugs , potentially resulting in adverse effects .",
        "label": "NA"
    },
    {
        "text": "other drugs : in healthy volunteers , ddrug0 , ddrug1 , DB01016 , ddrug3 , ddrug4 , hormone replacement therapy { a combination of conjugated ddrug5 and ddrug6 } , ddrug7 { DB06723 and ddrug9 } and ddrug10 did not affect the pharmacokinetics of ddrug11 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00184 may provoke vasoconstriction in some patients , predisposing to a greater ischemic response to HD00624 therapy .",
        "label": "effect"
    },
    {
        "text": "ddrug0 and foods fortified with ddrug1 concomitant administration of DB00535 with a therapeutic HD00490 containing # mg of elemental ddrug4 { as feso4 } or ddrug5 supplemented with # mg of elemental ddrug6 reduced extent of absorption by 80 % and 31 % , respectively .",
        "label": "NA"
    },
    {
        "text": "ddrug0 regimens consisted of two HD00057 and one HD00058 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration of ddrug1 with ddrug2 resulted in an 83 % increase in DB00220 plasma auc and a 51 % increase in DB00224 plasma a , c.",
        "label": "NA"
    },
    {
        "text": "coadministration of DB01026 tablets with ddrug1 or DB00897 has resulted in elevated plasma concentrations of the latter two drugs .",
        "label": "mechanism"
    },
    {
        "text": "DB00701 plus DB01045 was well tolerated .",
        "label": "NA"
    },
    {
        "text": "elevated plasma levels of DB00277 have been reported with concomitant use of some HD00532 .",
        "label": "mechanism"
    },
    {
        "text": "although HD00115 have been shown to reduce ddrug1 - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with ddrug2 may reduce the antitumor effectiveness of DB00041 and thus should be avoided , # ddrug4 and other ddrug5 may potentiate the hypotension seen with ddrug6 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 / ddrug1 / ddrug2 / ddrug3 : co-administration of DB00633 with ddrug5 , ddrug6 , ddrug7 , and HD00263 is likely to lead to an enhancement of effects .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : DB00316 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , DB01232 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving ddrug0 in combination with DB00503 than those receiving DB00224 # mg q8h .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 : DB00364 and ddrug3 containing DB14513 or ddrug5 , as well as formulations containing divalent and trivalent cations such as ddrug6 { ddrug7 } , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with ddrug8 and interfere with its bioavailability .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { ddrug1 } { e , g , , ddrug2 , ddrug3 , DB00715 , ddrug5 } have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with HD00277 .",
        "label": "effect"
    },
    {
        "text": "synergism between HD00659 { e , g , , ddrug1 } , ddrug2 , and other HD00660 has been reported .",
        "label": "effect"
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a ddrug0 , including ddrug1 , with multivalent cation-containing products such as DB14513 or ddrug3 ddrug4 , ddrug5 , ddrug6 chewable/buffered tablets or pediatric powder , or products containing ddrug7 , ddrug8 , or DB01593 may substantially decrease the absorption of ddrug10 , resulting in serum and urine levels considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "these six volunteers received DB00342 alone { 60 mg twice daily } for # days , followed by ddrug1 in combination with DB00954 { 500 mg once daily } for # days .",
        "label": "NA"
    },
    {
        "text": "concomitant treatment with ddrug0 { ddrug1 , ddrug2 } , ddrug3 , or HD00218 may potentiate any hypokalemic effect of HD00355 .",
        "label": "effect"
    },
    {
        "text": "HD00374 containing ddrug1 , ddrug2 , or DB01373 ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 - in subjects who had received # days of # mg/day racemic ddrug1 , combined administration of ddrug2 and ddrug3 { single dose of # mg } did not significantly affect the pharmacokinetics of either DB00215 or DB00390 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : administration of DB00712 to volunteers under fasting conditions , or with DB06724 suspension yielded similar serum ddrug3 time profiles in young subjects { n = 12 } .",
        "label": "NA"
    },
    {
        "text": "commonly used drugs such as DB00397 and DB00852 have been specifically studied .",
        "label": "NA"
    },
    {
        "text": "infusion requirements of DB00565 in patients administered DB00202 prior to infusions of ddrug2 were comparable to or slightly greater than when ddrug3 was not administered .",
        "label": "NA"
    },
    {
        "text": "HD00369 { ddrug1 , ddrug2 , and possibly ddrug3 } : concomitant administration with DB00945 may increase the risk of gastrointestinal ulceration .",
        "label": "effect"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of HD00071 : ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , ddrug5 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 { e , g , , in oral HD00283 } .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of ddrug0 : ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , ddrug5 , ddrug6 , ddrug7 } , ddrug8 , HD00808 , ddrug10 , ddrug11 , ddrug12 , HD00810 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { DB00316 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , DB00503 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "drug-drug interactions DB01001 - ddrug1 should be administered with caution to patients being treated with systemically-administered { oral or intravenous } ddrug2 { or other HD00381 } because the action of ddrug4 on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure .",
        "label": "NA"
    },
    {
        "text": "no important interactions to date DB00922 does not have clinically important pharmacokinetic interactions with ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , DB01136 , ddrug8 or ddrug9 .",
        "label": "NA"
    },
    {
        "text": "HD00175 : DB01234 : ddrug2 , when given as a regimen of 125 mg with ddrug3 coadministered orally as # mg on day 1 , and ddrug4 when given as # mg/day with ddrug5 coadministered orally as # mg on days # through 5 , increased the auc of ddrug6 , a cyp3a4 substrate by # - fold , on days # and 5 .",
        "label": "NA"
    },
    {
        "text": "therefore , co-administration of DB00476 with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index , including certain ddrug1 { ddrug2 -lsb- ddrug3 -rsb- , such as ddrug4 , DB00321 , and ddrug6 } , ddrug7 and ddrug8 { e , g , , ddrug9 , ddrug10 } , should be approached with caution .",
        "label": "advise"
    },
    {
        "text": "DB02325 , HD00026 , or ddrug2 : potentiation of orthostatic hypotension may occur .",
        "label": "NA"
    },
    {
        "text": "combinations of DB00363 and DB03575 : effects on drug discrimination and behavioral inhibition in rats .",
        "label": "NA"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { ddrug1 s } , DB00564 , ddrug3 { ddrug4 may decrease the effects of these medicines } , ddrug5 { using these medicines with ddrug6 may result in increased cns depressant effects } , ddrug7 , ddrug8 { using these medicines with ddrug9 may change the amount of either medicine that you need to take } , and oral HD00283 containing ddrug11 { ddrug12 may decrease the effectiveness of these oral ddrug13 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "DB00125 , in the absence of DB09341 or ddrug2 , caused excessive gcg release in the diabetics and undetectable insulin release in either diabetics or normals .",
        "label": "NA"
    },
    {
        "text": "the effect of a HD00014 extract from bovine lung , ddrug1 , on the dissolution rate of aerosol particles of DB01222 was determined .",
        "label": "NA"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : HD00870 ddrug8 : ddrug9 HD00100 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "both ddrug0 and HD00022 ameliorate HD00023 withdrawal signs .",
        "label": "NA"
    },
    {
        "text": "avoid the concomitant use of DB01239 and ddrug1 { DB00193 } .",
        "label": "advise"
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit ddrug0 binding to serum proteins or alter the concentrations of serum binding proteins : HD00657 and related ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , DB00812 , ddrug15 , ddrug16 , ddrug17 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , HD00282 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { DB00295 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "HD00394 : { oral agents and HD00071 } - dosage adjustment of the ddrug2 may be required .",
        "label": "NA"
    },
    {
        "text": "the use of DB00514 may result in additive cns depressant effects when coadministered with ddrug1 , ddrug2 , HD00565 or other drugs that produce cns depression .",
        "label": "effect"
    },
    {
        "text": "other cardiovascular agents : ddrug0 and DB00584 iv have been used concomitantly with ddrug2 , ddrug3 , ddrug4 , HD00674 , ddrug6 , ddrug7 and ddrug8 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : when coadministered with DB00828 , DB01233 , a drug which increases gastrointestinal motility , lowers the serum concentration and urinary excretion of ddrug3 .",
        "label": "mechanism"
    },
    {
        "text": "avoid the use of preparations such as ddrug0 and local HD00264 which contain any ddrug2 { e , g , , DB00668 , ddrug4 } , since it has been reported that ddrug5 can potentiate the effects of catecholamines .",
        "label": "NA"
    },
    {
        "text": "-lsb- the gaba-ergic system and brain edema -rsb- it has been shown in rats with experimental toxic and traumatic edemas that DB00466 { 1 mg/kg } removes the antiedematous action of DB00829 , ddrug2 , ddrug3 and ddrug4 and reduces the action of ddrug5 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 reduced or eliminated the increases in fi responding produced by intermediate doses of either ddrug1 or DB03575 in pigeons , but did not antagonize the decreases in fi or fr responding produced by high doses of pgpep1 or either stereoisomer of HD00155 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 may enhance the effects of : other ddrug3 s , ddrug4 , general ddrug5 , ddrug6 such as ddrug7 , HD00460 , or other HD00261 , causing increased cns depression .",
        "label": "NA"
    },
    {
        "text": "DB00472 does not affect the pharmacokinetics of DB01068 .",
        "label": "NA"
    },
    {
        "text": "when used in therapeutic doses , DB00207 had a modest effect on the pharmacokinetics of ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , DB00277 { intravenous and oral } , ddrug12 , ddrug13 / ddrug14 or ddrug15 .",
        "label": "mechanism"
    },
    {
        "text": "DB00580 steady state plasma concentrations { 40 mg bid } were not affected significantly with multiple doses of DB00338 { 40 mg qd } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , DB00273 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , DB00231 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : a study in normal healthy volunteers has shown that concomitant administration of DB00270 { ddrug2 } and DB00999 does not result in altered pharmacoktnetics of either drug .",
        "label": "NA"
    },
    {
        "text": "repeated oral administration of ddrug0 in sheep : interactions of DB11390 with HD00159 , ddrug3 , and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "the purpose of this study was to evaluate the effect of ddrug0 { HD00072 } and HD00067 { ddrug3 } conjugates on the intestinal permeation of ddrug4 { ddrug5 } and model peptide drugs , ddrug6 and ddrug7 .",
        "label": "NA"
    },
    {
        "text": "although there was no effect of ddrug0 on the plasma auc of ddrug1 or ddrug2 determined on day 3 , there was a 34 % decrease in HD00348 { a cyp2c9 substrate } trough concentration accompanied by a 14 % decrease in the prothrombin time { reported as international normalized ratio or inr } # days after completion of dosing with DB00673 .",
        "label": "mechanism"
    },
    {
        "text": "the pharmacokinetics and protein binding of ddrug0 , ddrug1 , and ddrug2 were not altered when DB00829 and DB01320 were concurrently administered in single submaximal doses .",
        "label": "NA"
    },
    {
        "text": "in vitro studies demonstrated that the plasma protein binding of HD00528 was not affected by DB00682 or ddrug2 , indicating no potential for protein binding-based drug interactions .",
        "label": "NA"
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of HD00472 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 { 1 } , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 { 1 } , ddrug10 , ddrug11 , grapefruit juice , ddrug12 , ddrug13 , ddrug14 , DB00455 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21 , ddrug22 , ddrug23 , ddrug24 { 1 } , ddrug25 , ddrug26 .",
        "label": "mechanism"
    },
    {
        "text": "co-administration of DB00042 and ddrug1 or other agents interfering with neuromuscular transmission { e , g , , HD00436 } should only be performed with caution as the effect of the ddrug3 may be potentiated .",
        "label": "advise"
    },
    {
        "text": "after multiple dosing , ddrug0 { DB02325 # mcg i m once weekly } reduced DB00108 clearance by approximately 30 % .",
        "label": "mechanism"
    },
    {
        "text": "therefore , it is theoretically possible that DB00448 may interfere with the absorption of drugs where gastric ph is an important determinant of bioavailability { e , g , ddrug1 , ddrug2 esters , DB01592 salts , ddrug4 } .",
        "label": "mechanism"
    },
    {
        "text": "no dose adjustment is necessary when ddrug0 is added to triple-immunosuppression regimens including DB00091 , ddrug2 , and either DB00993 or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "DB00695 : clinical studies , as well as post-marketing observations , have shown that ddrug1 can reduce the natriuretic effect of ddrug2 and HD00217 in some patients .",
        "label": "NA"
    },
    {
        "text": "while all the ddrug0 { HD00114 } , e , g , , ddrug2 , ddrug3 , ddrug4 , and DB00176 , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .",
        "label": "NA"
    },
    {
        "text": "nonetheless , individual patients may require additional titration of their DB00277 dosage when DB00448 is started or stopped to ensure clinically effective blood levels .",
        "label": "advise"
    },
    {
        "text": "epidemiological studies of the case-control and cohort design that have demonstrated an association between use of HD00456 that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an ddrug1 or DB00945 potentiated the risk of bleeding .",
        "label": "effect"
    },
    {
        "text": "HD00378 may exacerbate the rebound hypertension which can follow the withdrawal of DB00575 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 should be used with care when ddrug1 or inhibitors of av conduction , such as certain ddrug2 { particularly of the HD00426 -lsb- ddrug4 -rsb- and ddrug5 -lsb- ddrug6 -rsb- classes } , or ddrug7 , such as DB00280 , are used concurrently .",
        "label": "NA"
    },
    {
        "text": "the potential effects of increased plasma concentrations of ddrug0 or other HD00100 metabolized via cyp3a4 { DB00404 , ddrug3 } should be considered when coadministering these agents with ddrug4 .",
        "label": "NA"
    },
    {
        "text": "single dose bioavailability studies in normal volunteers have failed to wshow an effect of DB00945 on DB01050 blood levels .",
        "label": "NA"
    },
    {
        "text": "the concomitant administration of HD00532 including ddrug1 with ddrug2 { a HD00887 } has , on rare occasions , resulted in severe hypoglycemia .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and other HD00203 can reduce the antihypertensive effect of ddrug2 and other HD00254 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB00199 , and ddrug7 have no influence in vitro on the protein binding of DB00586 in human serum .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 , and ddrug2 : drugs such as ddrug3 , DB00529 , and ddrug5 may increase the risk of developing peripheral_neuropathies or other DB00943 - associated adverse events by interfering with the renal clearance of ddrug7 { thereby raising systemic exposure } .",
        "label": "effect"
    },
    {
        "text": "HD00596 / ddrug1 : ddrug2 , DB00897",
        "label": "NA"
    },
    {
        "text": "ddrug0 : as with other HD00487 , ddrug2 inhibits the renal excretion of ddrug3 , resulting in an approximate doubling in a , c , a 54 % increase in peak DB00535 plasma levels , and a 50 % prolongation in the apparent elimination half-life .",
        "label": "NA"
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of HD00472 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 { 1 } , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 { 1 } , DB00472 , ddrug11 , grapefruit juice , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21 , ddrug22 , ddrug23 , ddrug24 { 1 } , ddrug25 , ddrug26 .",
        "label": "mechanism"
    },
    {
        "text": "such individuals are referred to as poor metabolizers of drugs such as DB04840 , ddrug1 , and the HD00043 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 or ddrug1 increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered HD00439 , such as DB00988 .",
        "label": "NA"
    },
    {
        "text": "if a patient requires ddrug0 and ddrug1 therapy , it is suggested that ddrug2 , ddrug3 , or ddrug4 { ddrug5 and DB09104 } be used as alternatives to ddrug7 , as these agents have no effect on the pharmacokinetic profile of DB00204 .",
        "label": "NA"
    },
    {
        "text": "HD00175 : ddrug1 : ddrug2 , when given as a regimen of 125 mg with DB01234 coadministered orally as # mg on day 1 , and ddrug4 when given as # mg/day with ddrug5 coadministered orally as # mg on days # through 5 , increased the auc of ddrug6 , a cyp3a4 substrate by # - fold , on days # and 5 .",
        "label": "NA"
    },
    {
        "text": "this indicates that DB00996 does not undergo renal tubular secretion by the pathway that is blocked by DB01032 .",
        "label": "NA"
    },
    {
        "text": "methods : from the beginning of the experiment , rats were given # weekly subcutaneous injections of HD00039 { # mg/kg body weight } and subcutaneous injections of DB11724 { 40 microg/kg body weight } every other day , and from week 16 , intraperitoneal injections of ddrug2 { 10 or # mg/kg body weight } every other day until the end fo the experiment in week 45 .",
        "label": "NA"
    },
    {
        "text": "consequently , concomitant administration of DB00673 with strong cyp3a4 inhibitors { e , g , , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB00503 , ddrug7 } should be approached with caution .",
        "label": "advise"
    },
    {
        "text": "DB01124 : ddrug1 , when given as # mg on day # and # mg/day on days # and 3 , decreased the auc of ddrug2 { a cyp2c9 substrate } by 23 % on day 4 , 28 % on day 8 , and 15 % on day 15 , when a single dose of ddrug3 # mg was admini , stered orally prior to the administration of the 3-day regimen of DB00673 and on days 4,8 , and 15 .",
        "label": "NA"
    },
    {
        "text": "dosage adjustment may be required if ddrug0 , ddrug1 , or DB00959 are given concomitantly with DB01026 tablets .",
        "label": "NA"
    },
    {
        "text": "ddrug0 can interact with ddrug1 or other HD00261 { may potentiate the cns depressant effects of either these medications or ddrug3 } , ddrug4 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug5 } , and ddrug6 { concurrent use with HD00388 may prolong and intensify the anticholinergic and cns depressant effects of ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "dose adjustment of ddrug0 may be required and pth and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong cyp3a4 inhibitor { e , g , , ddrug1 , DB00199 , DB01167 ;",
        "label": "NA"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { ddrug1 s } , ddrug2 , ddrug3 { ddrug4 may decrease the effects of these medicines } , ddrug5 { using these medicines with HD00026 may result in increased cns depressant effects } , ddrug7 , DB00313 { using these medicines with ddrug9 may change the amount of either medicine that you need to take } , and oral ddrug10 containing ddrug11 { ddrug12 may decrease the effectiveness of these oral ddrug13 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "data from a randomized trial of DB00488 and ddrug1 plus or minus ddrug2 in ovarian_cancer indicated that DB00165 significantly reduced neurotoxicity ;",
        "label": "NA"
    },
    {
        "text": "medications can interfere with folate utilization , including : ddrug0 { such as ddrug1 , and ddrug2 } ddrug3 { sometimes prescribed to control blood sugar in type # diabetes } ddrug4 { used to control inflammation associated with crohn_disease and ulcerative colitis } ddrug5 { a HD00295 } DB00563 there has been concern about the interaction between ddrug8 and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "- ddrug0 { e , g , , DB00532 } use of DB00891 with these medicines may increase the chance of side effects of these medicines",
        "label": "NA"
    },
    {
        "text": "DB00440 alone or in combination with DB01015 : concomitant use of ddrug2 alone or in combination with ddrug3 is contraindicated .",
        "label": "NA"
    },
    {
        "text": "DB01592 salts may reduce the bioavailability of DB00190 and ddrug2 .",
        "label": "mechanism"
    },
    {
        "text": "in normal volunteers receiving ddrug0 , the administration of DB00861 decreased the renal clearance and significantly increased the plasma levels of DB00328 .",
        "label": "mechanism"
    },
    {
        "text": "data from in vitro studies of ddrug0 suggest a possible drug interaction with DB00404 for the following : ddrug2 and DB00715 .",
        "label": "int"
    },
    {
        "text": "reports suggest that HD00203 may diminish the antihypertensive effect of HD00106 , including ddrug2 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 at # mg bid { the usual prescription dose } co-administered with DB00204 { 500 mcg bid } for # days has been shown to increase DB00204 plasma levels by 58 % .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 , metal cations , DB00152 HD00532 form chelates with alkaline earth and transition metal cations .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and DB01015 have no influence in vitro on the protein binding of DB00586 in human serum .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : concomitant administration of ddrug1 oral and DB01032 resulted in decreased clearance of ddrug3 and significant increases in DB00465 plasma levels { total auc increased approximately threefold from # to # m g/h/ml } and terminal half-life increased approximately twofold from # to # hours .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , DB00446 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , DB01035 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - combined administration of racemic DB00215 { titrated to # mg/day for # days } and the cyp3a4 substrate ddrug2 { single dose of # mg } did not significantly affect the pharmacokinetics of either ddrug3 or DB00897 .",
        "label": "NA"
    },
    {
        "text": "in a ten-subject study , coadministration of DB00343 { 120 mg bid } with ddrug1 resulted in a 3 - 4 times increase in mean ddrug2 auc and cmax vs , DB00227 alone ;",
        "label": "NA"
    },
    {
        "text": "concomitant use with other DB01373 - containing medicines { including HD00374 } may cause too much ddrug2 in the blood or urine , which may increase the chance of side effects .",
        "label": "NA"
    },
    {
        "text": "close supervision and careful adjustment of dosage are required when this drug is given concomitantly with HD00315 or HD00390 .",
        "label": "NA"
    },
    {
        "text": "HD00282 : in a pharmacokinetic study , maximum plasma concentrations of ddrug1 were considerably lower in epileptic patients on long-term ddrug2 therapy { eg , ddrug3 , DB00564 , or ddrug5 } than in healthy volunteers .",
        "label": "NA"
    },
    {
        "text": "DB00682 , ddrug1 , ddrug2 , and ddrug3 the in vitro binding of ddrug4 to plasma proteins is only slightly reduced by ddrug5 { # % control vs # % } when DB00465 plasma concentrations reach # to10 m g/ml .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in vitro and/or in vivo data show that ddrug1 , ddrug2 , and DB13179 markedly inhibit the metabolism of DB00604 , which can result in an increase in plasma ddrug5 levels and prolongation of the qt interval on the ecg .",
        "label": "mechanism"
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit ddrug0 binding to serum proteins or alter the concentrations of serum binding proteins : HD00657 and related ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 , DB00544 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 .",
        "label": "NA"
    },
    {
        "text": "hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose DB00041 and ddrug1 , specifically , DB00851 , ddrug3 , ddrug4 and ddrug5 .",
        "label": "effect"
    },
    {
        "text": "use of DB00722 with HD00293 { e , g , , ddrug2 , ddrug3 , or ddrug4 } , ddrug5 supplements , or potassium-containing salt substitutes may lead to significant increases in serum potassium .",
        "label": "effect"
    },
    {
        "text": "the risk of a potential interaction between DB00036 and HD00568 concentrates has not been adequately evaluated in preclinical or clinical studies .",
        "label": "NA"
    },
    {
        "text": "the potentiating action of ddrug0 must be considered when the drug is used in conjunction with ddrug1 such as HD00543 , HD00790 and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "based on adult data , lower doses of ddrug0 may be needed following coadministration of drugs which are reported to decrease DB00201 elimination { e , g , , ddrug2 and DB01026 } and higher ddrug4 doses may be needed following coadministration of drugs that increase ddrug5 elimination { e , g , , ddrug6 and ddrug7 } .",
        "label": "NA"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { ddrug1 s } , ddrug2 , ddrug3 { ddrug4 may decrease the effects of these medicines } , ddrug5 { using these medicines with ddrug6 may result in increased cns depressant effects } , ddrug7 , ddrug8 { using these medicines with HD00026 may change the amount of either medicine that you need to take } , and oral ddrug10 containing ddrug11 { ddrug12 may decrease the effectiveness of these oral HD00283 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral HD00811 , ddrug1 , DB00280 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 { e , g , , ddrug9 } , ddrug10 .",
        "label": "NA"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { ddrug1 s } , ddrug2 , ddrug3 { ddrug4 may decrease the effects of these medicines } , ddrug5 { using these medicines with HD00026 may result in increased cns depressant effects } , ddrug7 , ddrug8 { using these medicines with ddrug9 may change the amount of either medicine that you need to take } , and oral ddrug10 containing ddrug11 { ddrug12 may decrease the effectiveness of these oral HD00283 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "literature reports suggest that oral HD00085 may be used in combination with HD00244 when heart function is normal , but should be avoided in patients with impaired cardiac function .",
        "label": "advise"
    },
    {
        "text": "as with some other HD00541 , the time of onset of neuromuscular block induced by ddrug1 is lengthened and the duration of block is shortened in patients receiving ddrug2 or DB00564 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 reversible increases in serum ddrug1 concentrations and toxicity have been reported during concomitant administration of DB14507 with HD00106 , and with some ddrug4 .",
        "label": "mechanism"
    },
    {
        "text": "when therapeutic concentrations of ddrug0 , DB00571 , ddrug2 , ddrug3 , ddrug4 , or ddrug5 were added to human plasma { in vitro } , the plasma protein binding of DB00622 was not altered .",
        "label": "NA"
    },
    {
        "text": "conjugation at ddrug0 with DB00151 moieties significantly improves the intestinal permeation of the hydrophilic molecule HD00070 and the model peptide drugs ddrug3 and ddrug4 in vitro , therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future .",
        "label": "NA"
    },
    {
        "text": "unmodified HD00072 { 1 % m/v } significantly improved the transport ratio { r = p { app } polymer / p { app } control } of ddrug1 to # and 1 % { m/v } ddrug2 conjugated with DB00151 further enhanced the permeation .",
        "label": "NA"
    },
    {
        "text": "ddrug0 can interact with ddrug1 or other HD00261 { may potentiate the cns depressant effects of either these medications or ddrug3 } , ddrug4 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug5 } , and ddrug6 { concurrent use with HD00388 may prolong and intensify the anticholinergic and cns depressant effects of ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "there were no reports of skeletal myopathy in a placebo-controlled phase i trial in which # healthy subjects on stable DB00641 therapy were treated concurrently with DB00080 { 4 mg/kg once every # hours } for # days .",
        "label": "NA"
    },
    {
        "text": "these results suggest that both ddrug0 and ddrug1 , and possibly other ddrug2 and HD00150 , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of ddrug4 and HD00148 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : a literature article reported that when a 60-mg controlled-release ddrug1 capsule was administered # hours prior to a 600-mg DB00996 capsule { n = 12 } , mean DB00996 auc increased by 44 % compared to ddrug4 administered without ddrug5 .",
        "label": "NA"
    },
    {
        "text": "the antihypertensive effects of ddrug0 , DB00657 , ddrug2 , and ddrug3 may be reduced by HD00391 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 alone or in combination with ddrug1 : concomitant use of DB00440 alone or in combination with DB01015 is contraindicated .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 should be used with caution in patients receiving - ddrug2 blocking agents { e , g , , ddrug3 , a HD00302 inhibitor } or ddrug5 antagonists { e , g , , ddrug6 , a ddrug7 substrate , and DB00343 , a ddrug9 inhibitor } because of the possible potentiation of bradycardia , sinus arrest , and av block ;",
        "label": "NA"
    },
    {
        "text": "DB00294 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , DB01232 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "int"
    },
    {
        "text": "the hypoglycemic action of ddrug0 may be potentiated by certain drugs including HD00518 and other drugs that are highly protein bound , ddrug2 , ddrug3 , ddrug4 , DB01032 , ddrug6 , ddrug7 , and ddrug8 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00749 has no apparent pharmacokinetic interaction when administered with DB01016 .",
        "label": "NA"
    },
    {
        "text": "there have been reports of interactions of DB00199 with ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , DB01200 , ddrug11 , ddrug12 , and ddrug13 .",
        "label": "int"
    },
    {
        "text": "ddrug0 : other ddrug1 drugs , such as ddrug2 , DB01035 , ddrug4 , and ddrug5 , have been used concurrently with DB01118 .",
        "label": "NA"
    },
    {
        "text": "HD00477 may decrease thyroidal uptake of ddrug1 , a rebound in uptake may occur up to # days after sudden withdrawal of DB00389 .",
        "label": "NA"
    },
    {
        "text": "the serum estrogen concentrations of DB00783 + ddrug1 - treated rats decreased by 50 % , while those of the HD00168 - treated rats increased { 2 - to 5-fold } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 can interact with DB02325 or other ddrug2 { may potentiate the cns depressant effects of either these medications or HD00388 } , ddrug4 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug5 } , and ddrug6 { concurrent use with ddrug7 may prolong and intensify the anticholinergic and cns depressant effects of ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : administration of HD00620 concomitantly with DB00091 has been associated with an increase in ddrug3 - induced toxicity , possibly due to decreased synthesis of renal prostacyclin .",
        "label": "mechanism"
    },
    {
        "text": "in addition , DB00569 neither influenced the pharmacodynamics of ddrug1 , ddrug2 , ddrug3 , and ddrug4 , nor the pharmacokinetics of DB00390 at steady state .",
        "label": "NA"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , ddrug3 ddrug4 : ddrug5 , DB00342 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 DB00683 , ddrug12 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "blunting of the antihypertensive effect of ddrug0 by HD00803 including DB00328 has been reported .",
        "label": "NA"
    },
    {
        "text": "DB00604 should not be used concomitantly with other drugs known to prolong the qt interval : certain ddrug1 , including those of class ia { such as DB00908 and ddrug3 } and class iii { such as ddrug4 } ;",
        "label": "advise"
    },
    {
        "text": "this antagonistic effect of DB01032 on DB00887 natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of ddrug2 .",
        "label": "mechanism"
    },
    {
        "text": "the steady state plasma concentrations of DB00458 and DB01151 have been reported to be increased an average of 31 % and 20 % , respectively , by the concomitant administration of ddrug2 tablets in doses up to # mg/day .",
        "label": "NA"
    },
    {
        "text": "therefore , the potential exists for a drug interaction between DB01156 and drugs that affect the cyp2b6 isoenzyme { e , g , , ddrug1 and DB00531 } .",
        "label": "int"
    },
    {
        "text": "dose adjustment is not recommended , DB01202 had no effect on plasma concentrations of ddrug1 , ddrug2 , DB00273 , or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : as with other ddrug1 , DB01032 inhibits the renal excretion of DB00535 , resulting in an approximate doubling in a , c , a 54 % increase in peak ddrug4 plasma levels , and a 50 % prolongation in the apparent elimination half-life .",
        "label": "mechanism"
    },
    {
        "text": "drug interactions : the central ddrug0 syndrome can occur when anticholinergic agents such as ddrug1 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain ddrug2 such as ddrug3 , the ddrug4 and other ddrug5 , HD00043 , certain ddrug7 such as the ddrug8 salts , and HD00388 .",
        "label": "NA"
    },
    {
        "text": "DB00328 given concomitantly with DB00390 has been reported to increase the serum concentration and prolong the half-life of ddrug2 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : in an interaction study of rheumatoid_arthritis patients taking DB00563 , DB00482 did not have a significant effect on the pharmacokinetics of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "spontaneous reports of serotonin syndrome associated with co-administration of ddrug0 and HD00851 , including ddrug2 such as HD00113 { ddrug4 } , have been reported .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { ddrug1 , ddrug2 , ddrug3 , ddrug4 , DB00273 } : increase the metabolism of DB00977 and/or some ddrug7 , leading to possible decrease in contraceptive effectiveness .",
        "label": "mechanism"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other HD00216 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 HD00542 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "the potentiating action of ddrug0 must be considered when the drug is used in conjunction with HD00389 such as ddrug2 , HD00790 and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 should be used with care when ddrug1 or inhibitors of av conduction , such as certain ddrug2 { particularly of the ddrug3 -lsb- ddrug4 -rsb- and HD00427 -lsb- ddrug6 -rsb- classes } , or HD00428 , such as ddrug8 , are used concurrently .",
        "label": "NA"
    },
    {
        "text": "HD00645 did not inhibit the antitumor activity of four ddrug1 { DB00515 , ddrug3 , ddrug4 , ddrug5 } in four murine models .",
        "label": "NA"
    },
    {
        "text": "HD00075 : disturbances of blood glucose , including hyperglycemia and hypoglycemia , have been reported in patients treated concomitantly with HD00532 and an ddrug2 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - in subjects who had received # days of # mg/day racemic DB00215 , combined administration of ddrug2 and DB00390 { single dose of # mg } did not significantly affect the pharmacokinetics of either ddrug4 or ddrug5 .",
        "label": "NA"
    },
    {
        "text": "therefore , if DB00277 is co-administered with DB00176 , its dose should be reduced to one third of the usual daily maintenance dose and plasma concentrations of ddrug2 should to monitored .",
        "label": "advise"
    },
    {
        "text": "ddrug0 and DB01171 increased blood DB09341 at different times after the glucose overload .",
        "label": "NA"
    },
    {
        "text": "pharmacokinetic data from these patients demonstrated a decrease in DB01229 clearance of approximately 33 % when ddrug1 was administered following DB00515 .",
        "label": "NA"
    },
    {
        "text": "therefore , the concomitant administration of ddrug0 and DB01016 is contraindicated , and alternative HD00062 should be considered .",
        "label": "NA"
    },
    {
        "text": "garlic capsules garlic capsules should not be used while taking ddrug0 { ddrug1 } as the sole HD00058 due to the risk of decreased DB01232 plasma concentrations .",
        "label": "NA"
    },
    {
        "text": "the effects of concomitant administration of DB00501 on the pharmacokinetics of DB01156 and its active metabolites were studied in # healthy young male volunteers .",
        "label": "NA"
    },
    {
        "text": "a study of interaction between DB00187 and ddrug1 showed that concomitant administration of ddrug2 and DB00682 does not alter ddrug4 plasma levels .",
        "label": "NA"
    },
    {
        "text": "in addition , most HD00375 are contraindicated in patients receiving DB00342 therapy who have pre-existing cardiac abnormalities { arrhythmia , bradycardia , qt c interval prolongation , ischemic heart disease , congestive heart failure , etc , } or electrolyte disturbances .",
        "label": "advise"
    },
    {
        "text": "- a HD00764 such as ddrug1 { ddrug2 , ddrug3 , others } , ddrug4 { ddrug5 , others } , ddrug6 { HD00712 , ddrug8 , others } , and others ;",
        "label": "NA"
    },
    {
        "text": "further , no effects on either ddrug0 levels or prothrombin times were observed in a study involving concomitant administration of DB00682 and DB01095 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 potentiates other ddrug1 such as DB00202 or HD00661 and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration of ddrug1 and ddrug2 resulted in a 32 % decrease in DB00220 plasma auc and a 207 % increase in DB00615 plasma a , c.",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in normal volunteers , a small decrease in DB00861 levels was observed when multiple doses of ddrug2 and DB00945 were administered concomitantly .",
        "label": "NA"
    },
    {
        "text": "DB00759 , a ddrug1 , may antagonize the bactercidal effect of HD00284 and concurrent use of these drugs should be avoided .",
        "label": "effect"
    },
    {
        "text": "ddrug0 - and/or ddrug1 - containing ddrug2 , products containing DB01373 { ddrug4 } , HD00752 containing ddrug6 or other metal cations , or ddrug7 { ddrug8 } chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after ddrug9 .",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , ddrug3 , or ddrug4 , with DB00364 , with metal cations such as ddrug6 , or with ddrug7 containing DB01592 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { ddrug1 s } , ddrug2 , DB01285 { HD00026 may decrease the effects of these medicines } , ddrug5 { using these medicines with ddrug6 may result in increased cns depressant effects } , ddrug7 , ddrug8 { using these medicines with ddrug9 may change the amount of either medicine that you need to take } , and oral ddrug10 containing ddrug11 { ddrug12 may decrease the effectiveness of these oral ddrug13 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "other concomitant therapy although specific interaction studies were not performed , ddrug0 doses of # mg or more were concomitantly used in clinical studies with ddrug1 , ddrug2 , a-blockers , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , cardiac ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 { also referred to as HD00203 } , and HD00729 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "HD00388 may have additive effects with ddrug1 and other HD00261 , e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 and other HD00434 : co-administration of DB00559 decreased the plasma concentrations of ddrug3 { a cyp3a4 substrate } , and its active - hydroxy acid metabolite , by approximately 50 % .",
        "label": "NA"
    },
    {
        "text": "while all the selective ddrug0 { HD00114 } , e , g , , ddrug2 , ddrug3 , and DB00715 , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as DB00415 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { HD00712 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the effects of DB09026 on DB00682 pharmacokinetics have not been evaluated in a well-controlled clinical trial .",
        "label": "NA"
    },
    {
        "text": "ddrug0 / ddrug1 : the coadministration of DB00252 or ddrug3 will not affect plasma concentrations of ddrug4 , but may reduce endogenous plasma levels of DB00136 / ergocalcitriol by accelerating metabolism .",
        "label": "mechanism"
    },
    {
        "text": "in vitro studies evaluating the minimum inhibitory concentration { mic } of ddrug0 , ddrug1 , DB00415 , ddrug3 / flucoxacillin , ddrug4 , ddrug5 , and ddrug6 demonstrated no evidence of incompatibility of these ddrug7 with DB00702 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : a relationship of functional antagonism exists between DB11094 analogues , which promote calcium absorption , and HD00175 , which inhibit calcium absorption .",
        "label": "effect"
    },
    {
        "text": "interactions for ddrug0 { ddrug1 , ddrug2 , ddrug3 , and ddrug4 } : ddrug5 : DB01432 has been reported to reduce intestinal absorption of HD00465 ;",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : ddrug1 should be used with caution in patients receiving - ddrug2 blocking agents { e , g , , DB00571 , a ddrug4 inhibitor } or ddrug5 antagonists { e , g , , ddrug6 , a HD00302 substrate , and ddrug8 , a ddrug9 inhibitor } because of the possible potentiation of bradycardia , sinus arrest , and av block ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 : clinical studies , as well as post-marketing observations , have shown that HD00203 can reduce the natriuretic effect of ddrug2 and HD00217 in some patients .",
        "label": "effect"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : ddrug1 ; ddrug2 ; DB01159 ; certain ddrug4 , especially the HD00249 and ddrug6 ; ddrug7 ; ddrug8 salts ; ddrug9 ; and ddrug10 .",
        "label": "NA"
    },
    {
        "text": "in patients with mild to moderate hypertension , administration of # mg daily of HD00897 with the ddrug1 DB00542 , # to # mg for # weeks , was associated with an average increase in mean arterial pressure of about # mm hg compared to ddrug3 alone .",
        "label": "effect"
    },
    {
        "text": "if signs and symptoms suggestive of ddrug0 toxicity occur when DB00467 and ddrug2 are given concomitantly , physicians are advised to obtain serum DB00390 levels and adjust ddrug4 doses appropriately .",
        "label": "NA"
    },
    {
        "text": "other drugs : based on the results of drug interaction studies , no dosage adjustment is recommended when DB00625 { ddrug1 } is given with the following : ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , DB00186 , ddrug9 , ddrug10 , and ddrug11 .",
        "label": "NA"
    },
    {
        "text": "DB01026 : coadministration of ddrug1 with ddrug2 resulted in a 35 % increase in DB00220 plasma a , c.",
        "label": "NA"
    },
    {
        "text": "the actions of the HD00100 may be potentiated by HD00026 , ddrug2 , ddrug3 , ddrug4 or other ddrug5 .",
        "label": "effect"
    },
    {
        "text": "no dose adjustment is necessary when DB00074 is added to triple-immunosuppression regimens including ddrug1 , ddrug2 , and either ddrug3 or DB00688 .",
        "label": "NA"
    },
    {
        "text": "some HD00532 , including ddrug1 , have also been shown to interfere with the metabolism of DB00201 .",
        "label": "mechanism"
    },
    {
        "text": "before taking ddrug0 , tell your doctor if you are taking any of the following medicines : - DB00945 or another ddrug2 such as HD00755 { ddrug4 } , ddrug5 { ddrug6 , others } , ddrug7 { ddrug8 } , ddrug9 { ddrug10 } , or ddrug11 { ddrug12 } ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 { cns } drugs including ddrug1 , HD00216 , ddrug3 , ddrug4 , blood pressure medications { ddrug5 , ddrug6 , ddrug7 } , motion sickness medications , HD00542 , ddrug9 , ddrug10 , sleeping pills and ddrug11",
        "label": "NA"
    },
    {
        "text": "HD00870 : DB00320 , ddrug2 , ddrug3 , ddrug4 contraindicated due to potential for serious and life-threatening reactions such as acute ddrug5 toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues .",
        "label": "NA"
    },
    {
        "text": "delayed adverse reactions to ddrug0 : a review of the literature revealed that # % { range 11 - 28 % } of # patients treated with various HD00256 containing regimens who were subsequently administered HD00257 experienced acute , atypical adverse reactions .",
        "label": "effect"
    },
    {
        "text": "injection : ddrug0 injection , like other injectable ddrug1 , produces depression of the central nervous system when administered with DB00898 , ddrug3 , ddrug4 , ddrug5 , and other HD00216 , when ddrug7 is used concomitantly with injectable ddrug8 , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .",
        "label": "NA"
    },
    {
        "text": "other drugs : in healthy volunteers , ddrug0 , ddrug1 , ddrug2 , DB00863 , ddrug4 , hormone replacement therapy { a combination of conjugated ddrug5 and ddrug6 } , ddrug7 { ddrug8 and ddrug9 } and ddrug10 did not affect the pharmacokinetics of DB00204 .",
        "label": "NA"
    },
    {
        "text": "concurrent administration of drugs possessing nephrotoxic { e , g , , ddrug0 , ddrug1 } , myelotoxic { e , g , , HD00250 chemotherapy } , cardiotoxic { e , g , , ddrug3 } or hepatotoxic { e , g , , ddrug4 , ddrug5 } effects with DB00041 may increase toxicity in these organ systems .",
        "label": "effect"
    },
    {
        "text": "serum ddrug0 concentrations appeared to be unaffected by baseline use of medications for the treatment of crohn s disease including HD00175 , ddrug2 { ddrug3 or DB00537 } and aminosalicylates .",
        "label": "NA"
    },
    {
        "text": "agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of HD00472 are the following : ddrug1 , ddrug2 , DB00949 , ddrug4 , ddrug5 , ddrug6 { 2 } , ddrug7 , ddrug8 , and ddrug9 thus , if a patient has been titrated to a stable dosage on ddrug10 , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for ddrug11 may be necessary .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , HD00002 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , DB00091 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "DB00995 should be avoided by patients with a history of serious reaction to any ddrug1 , including HD00387 and ddrug3 .",
        "label": "advise"
    },
    {
        "text": "potential drug interactions between ddrug0 and other ddrug1 { ddrug2 , ddrug3 , DB00555 , ddrug5 , ddrug6 , ddrug7 and ddrug8 } were also assessed by evaluating the serum concentrations of DB01202 and these ddrug10 during placebo-controlled clinical studies .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the concomitant use of DB01244 with long - and short-acting DB14049 has been safely tolerated in patients with stable angina pectoris .",
        "label": "NA"
    },
    {
        "text": "to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma { hiv-nhl } , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the ddrug0 , ddrug1 , ddrug2 , and DB00898 { chop } chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen { i , e , , ddrug4 , ddrug5 , DB00444 , and ddrug7 with ddrug8 plus ddrug9 } without receiving ddrug10 therapy .",
        "label": "NA"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : ddrug1 ; ddrug2 ; ddrug3 ; certain ddrug4 , especially the ddrug5 and ddrug6 ; DB14507 ; ddrug8 salts ; DB01035 ; and ddrug10 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration of a single dose of ddrug1 # mg and multiple doses of ddrug2 er { extended release } # mg did not result in any significant changes in the pharmacokinetics of either DB00962 or DB00285 .",
        "label": "NA"
    },
    {
        "text": "a similar association , though less marked , has been suggested with ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , DB00273 , and possibly with DB00415 and ddrug7 72 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { e , g , ddrug1 and ddrug2 } : agents of the ddrug3 , of which ddrug4 { ddrug5 } injection , usp is a member , have been shown to interact with HD00002 of the HD00626 , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .",
        "label": "NA"
    },
    {
        "text": "a potential interaction between oral DB01110 and oral HD00062 leading to severe hypoglycemia has been reported .",
        "label": "effect"
    },
    {
        "text": "coingestion of DB00316 with ddrug1 , DB01174 with ddrug3 , and ddrug4 with ddrug5 at high to toxic concentrations decreases the binding of the target drug .",
        "label": "NA"
    },
    {
        "text": "DB00695 : in normal volunteers , the concomitant administration of DB00861 and ddrug2 had no effect on the diuretic activity of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "coadministration of DB00701 and DB00333 as compared to a non-matched historicalcontrol group resulted in a 30 % , 27 % , and 25 % decrease in serum ddrug2 auc , cmax , andcmin , respectively .",
        "label": "mechanism"
    },
    {
        "text": "patients who are applying DB00523 gel should not concurrently use products that contain DB11282 { n , ddrug2 } , a common component of insect repellent products .",
        "label": "advise"
    },
    {
        "text": "DB00321 in combination with ddrug1 enhances the manifestation of corneal lesions in rats epidural injection ddrug2 may potentiate the cns-depressive effect of DB02325 , ddrug4 or other ddrug5 .",
        "label": "NA"
    },
    {
        "text": "other potentially important drug interactions : ddrug0 : HD00100 metabolized by hepatic oxidation { e , g , , ddrug2 , ddrug3 , DB00897 elc , } should be used with caution because the clearance of these drugs is likely to be reduced by ddrug5 .",
        "label": "NA"
    },
    {
        "text": "here we show that a combination of HD00098 or 3_7_dihydroxyflavone with DB00512 may be used to sensitize resistant strains of enterococcus faecalis and enterococcus faecium to the level of vancomycin-sensitive strains .",
        "label": "NA"
    },
    {
        "text": "DB00710 should be taken at least # minutes before any oral medications containing multivalent cations { including HD00374 , supplements or ddrug2 } .",
        "label": "advise"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , DB00295 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , DB00231 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { e , g , , ddrug1 , ddrug2 , ddrug3 , ddrug4 , etc , } : in vitro and animal studies with the combination of ddrug5 and ddrug6 suggest that HD00319 may induce fungal resistance to DB00681 .",
        "label": "effect"
    },
    {
        "text": "limited comparative data in patients with high viral loads treated with DB00238 - or DB00705 - based regimens currently exist .",
        "label": "NA"
    },
    {
        "text": "thus , when DB01050 and ddrug1 are administered concurrently , subjects should be observed carefully for signs of DB14507 toxicity .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { eg , ddrug1 } and other drugs , including ether , ddrug2 , HD00576 , ddrug4 and ddrug5 , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with DB01111 parenteral .",
        "label": "effect"
    },
    {
        "text": "evidence supporting the conclusion that it is inadvisable to co-administer ddrug0 and DB00829 is derived from a study in which healthy volunteers taking # mg/day of DB00176 were administered a single oral dose of # mg of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "additional reductions in blood pressure may occur when ddrug0 is administered with HD00218 , HD00366 , or other ddrug3 .",
        "label": "NA"
    },
    {
        "text": "drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on HD00849 therapy : ddrug1 , HD00175 , ddrug3 , oral ddrug4 containing ddrug5 , ddrug6 - containing preparations and the numerous preparations containing ddrug7 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , DB01167 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , DB00277 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "-lsb- stimulation by ddrug0 -- an analog of the octapeptide cholecystokinin -- of ddrug1 binding after the long-term administration of ddrug2 -rsb- it has been established in experiments on white male rats that prolonged administration { twice a day for # days } of DB00502 { # mg/kg } and HD00138 { # mg/kg } resulted in the reduced interaction between ddrug5 and low affinity binding sites for ddrug6 in subcortical structures , whereas ddrug7 binding with high affinity binding sites for ddrug8 increased both in the frontal cortex and subcortical structures of the forebrain .",
        "label": "NA"
    },
    {
        "text": "it is recommended to avoid concurrent administration of DB00330 with ddrug1 containing HD00374 for at least # hours following ddrug3 administration .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : plasma DB00390 levels and ddrug2 clearance at steady-state were not affected by co-administration of # mg HD00503 .",
        "label": "NA"
    },
    {
        "text": "compared with DB00734 , DB00334 has also been reported to decrease overall treatment costs , despite the several-fold higher daily acquisition cost of the drug .",
        "label": "NA"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : ddrug1 ; DB00753 ; ddrug3 ; certain ddrug4 , especially the HD00249 and ddrug6 ; ddrug7 ; ddrug8 salts ; ddrug9 ; and ddrug10 .",
        "label": "NA"
    },
    {
        "text": "the oral bioavailability of DB00467 is reduced by 60 % with coadministration of DB00863 .",
        "label": "mechanism"
    },
    {
        "text": "these include DB01032 , ddrug1 , and some ddrug2 { e , g , ddrug3 , rifamipicin , DB00415 and ddrug5 } .",
        "label": "NA"
    },
    {
        "text": "although there was a slight reduction in blood sugar concentrations during concomitant administration of DB00712 and HD00062 , there were no signs or symptoms of hypoglycemia .",
        "label": "effect"
    },
    {
        "text": "no clinically important pharmacokinetic interactions occurred when ddrug0 was used concomitantly with DB00571 or DB00999 .",
        "label": "NA"
    },
    {
        "text": "DB00199 and ddrug1 { and possibly other ddrug2 } and ddrug3 may increase ddrug4 absorption in patients who inactivate ddrug5 by bacterial metabolism in the lower intestine , so that HD00118 intoxication may result .",
        "label": "NA"
    },
    {
        "text": "HD00343 prolong and intensify the anticholinergic effects of HD00388 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , DB00273 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , DB00860 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : ddrug1 ; ddrug2 ; ddrug3 ; certain ddrug4 , especially the ddrug5 and ddrug6 ; DB14507 ; DB14513 salts ; ddrug9 ; and ddrug10 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : a literature article reported that when a 60-mg controlled-release ddrug1 capsule was administered # hours prior to a 600-mg DB00996 capsule { n = 12 } , mean ddrug3 auc increased by 44 % compared to DB00996 administered without ddrug5 .",
        "label": "NA"
    },
    {
        "text": "DB00681 or ddrug1 { ddrug2 and related drugs , DB00903 and ddrug4 } enhanced hypokalemia .",
        "label": "NA"
    },
    {
        "text": "garlic capsules garlic capsules should not be used while taking DB01232 { ddrug1 } as the sole HD00058 due to the risk of decreased ddrug3 plasma concentrations .",
        "label": "NA"
    },
    {
        "text": "since ddrug0 is frequently co-administered with DB00316 , it is of clinical interest to study the effect of DB00201 on the hepatotoxicity of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , DB01026 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as HD00269 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "DB00224 concentration DB00503 concentration",
        "label": "NA"
    },
    {
        "text": "ddrug0 : based on reports of profound hypotension and loss of consciousness when DB00714 was administered with DB00904 , the concomitant use of ddrug3 with drugs of the ddrug4 { including , for example , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 } is contraindicated .",
        "label": "effect"
    },
    {
        "text": "DB00196 , and the ddrug1 ddrug2 { ddrug3 } and DB00889 { ddrug5 } have all been used with ddrug6 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { e , g , , ddrug1 } and ddrug2 containing carbohydrate-splitting enzymes { e , g , , ddrug3 , DB00085 } may reduce the effect of DB00284 and should not be taken concomitantly .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : as with other HD00487 , co-administration of ddrug2 with DB01066 resulted in an increase in the plasma exposure of ddrug4 , with a 49 % increase in mean cmax , a 122 % increase in mean auc , and a 53 % increase in half-life .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 - HD00485 containing side chains of n-methylthiotetrazole { DB00267 , ddrug3 , ddrug4 , ddrug5 , ddrug6 } or methylthiadiazole { ddrug7 } can cause vitamin_k_deficiency and hypoprothrombinemia .",
        "label": "NA"
    },
    {
        "text": "ddrug0 / ddrug1 : DB00437 inhibits the enzymatic oxidation of ddrug3 and DB00993 to ddrug5 .",
        "label": "mechanism"
    },
    {
        "text": "similarly , DB00731 had no influence on the serum protein binding of ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB00945 , and ddrug7 in vitro .",
        "label": "NA"
    },
    {
        "text": "HD00575 { eg , ddrug1 } and other drugs , including ether , ddrug2 , ddrug3 , DB01245 and ddrug5 , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with ddrug6 parenteral .",
        "label": "NA"
    },
    {
        "text": "in patients receiving ddrug0 { DB01033 } or DB00993 { ddrug3 } , the concomitant administration of 300 - 600 mg of ddrug4 per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of ddrug5 or ddrug6 .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of ddrug0 { equivalent to # mg DB01039 } with ddrug2 { 20 mg } once daily for # days resulted in approximately 17 % decrease { range from 67 % decrease to 44 % increase } in DB01076 auc values in # healthy males .",
        "label": "NA"
    },
    {
        "text": "in patients receiving nonselective ddrug0 { ddrug1 } { e , g , , DB01037 } in combination with ddrug3 { e , g , , ddrug4 , ddrug5 , DB00715 , ddrug7 , ddrug8 } , there have been reports of serious , sometimes fatal , reactions .",
        "label": "effect"
    },
    {
        "text": "DB00514 is a substrate for both ddrug1 and HD00302 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : studies in normal volunteers have shown that ddrug1 like other HD00233 , can interfere with the effects of DB00695 .",
        "label": "effect"
    },
    {
        "text": "HD00445 prolong and intensify the anticholinergic effects of HD00388 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and DB00759 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , DB00295 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration of DB01045 and DB00220 resulted in an 82 % decrease in ddrug3 plasma a , c.",
        "label": "mechanism"
    },
    {
        "text": "in addition , neuromuscular blocking action is enhanced by general HD00264 , local ddrug1 like ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB14509 , and ddrug7 .",
        "label": "NA"
    },
    {
        "text": "little or no change in the pharmacokinetics of either drug was observed when DB00220 was coadministered with DB00709 or ddrug2 .",
        "label": "NA"
    },
    {
        "text": "decreasing the concentration of ddrug0 , exhibiting # % { m/m } of immobilised DB00151 { cmc-cys # } from 1 % { m/v } to # % { m/v } decreased the r-value of HD00070 from # to # .",
        "label": "NA"
    },
    {
        "text": "in a study in which the # mg ddrug0 orally disintegrating tablet was administered with and without ddrug1 { an ddrug2 with multiple effects on the gi tract } to healthy volunteers , the auc of DB01068 was 10 % lower and the cmax of ddrug4 was 20 % lower when the orally disintegrating tablet was given with DB00782 compared to when it was given alone .",
        "label": "NA"
    },
    {
        "text": "exert particular caution in combining DB01239 with other HD00522 { ddrug2 and ddrug3 } : particularly the elderly may develop delirium , high fever , severe obstipation , even ileus and glaucoma .",
        "label": "advise"
    },
    {
        "text": "rarely HD00372 toxicity may occur in patients who discontinue ddrug1 after concurrent high-dose DB00945 therapy .",
        "label": "NA"
    },
    {
        "text": "DB00269 may interact with ddrug1 , ddrug2 , ddrug3 , DB01200 , ddrug5 supplements , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , and ddrug13 .",
        "label": "int"
    },
    {
        "text": "HD00388 : ddrug1 * , DB00342 * contraindicated due to potential for serious and/or life-threatening cardiac arrhythmias .",
        "label": "NA"
    },
    {
        "text": "co-administration of DB01029 reduced DB09026 cmax up to 50 % after multiple dosing .",
        "label": "mechanism"
    },
    {
        "text": "HD00043 have been reported to blunt the hypotensive effect of systemic ddrug1 , it is not known whether the concurrent use of these agents with DB00484 in humans can lead to resulting interference with the iop lowering effect .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration of DB01232 { using an experimental soft-gelatin capsule formulation of ddrug2 1200 mg } with DB00220 resulted in an 18 % increase in ddrug4 plasma auc and a 4-fold increase in ddrug5 plasma a , c.",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , DB00564 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { HD00712 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , DB01026 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , DB00812 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "other concomitant therapy : although specific interaction studies were not performed , in clinical studies , HD00503 was used concomitantly with ddrug1 , ddrug2 , ddrug3 , ddrug4 , and ddrug5 { HD00203 } without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "concomitant use of DB01254 and drugs that inhibit cyp3a4 { eg , ddrug1 , DB01167 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 } may increase exposure to ddrug12 and should be avoided .",
        "label": "mechanism"
    },
    {
        "text": "also , concomitant administration of HD00532 with products containing ddrug1 , ddrug2 containing ddrug3 , or ddrug4 { DB00900 } chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels .",
        "label": "mechanism"
    },
    {
        "text": "agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of ddrug0 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 { 2 } , ddrug7 , DB05246 , and ddrug9 thus , if a patient has been titrated to a stable dosage on ddrug10 , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for HD00472 may be necessary .",
        "label": "NA"
    },
    {
        "text": "in vivo interaction studies in humans have demonstrated that DB00390 and ddrug1 do not affect the pk properties of ddrug2 , nor does DB00261 affect the pk properties of ddrug4 or ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a pharmacokinetic study , maximum plasma concentrations of ddrug1 were considerably lower in epileptic patients on long-term HD00329 therapy { eg , ddrug3 , DB00564 , or ddrug5 } than in healthy volunteers .",
        "label": "NA"
    },
    {
        "text": "use with ddrug0 : the use of HD00209 to control hypertension in patients on DB00993 has been reported to induce severe leukopenia .",
        "label": "effect"
    },
    {
        "text": "the doses of DB01183 required to antagonize the effects of ddrug1 were more than # times higher than those required to antagonize the effects of DB00295 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : since DB01109 is contraindicated in patients with ddrug2 - induced thrombocytopenia , the co-administration of DB00278 and ddrug4 is unlikely for this indication .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : HD00093 have been reported to cause a significant decrease in HD00579 clearance .",
        "label": "mechanism"
    },
    {
        "text": "DB01274 , as with other HD00360 , should be administered with extreme caution to patients being treated with ddrug2 , ddrug3 , or drugs known to prolong the qtc interval because the action of ddrug4 on the cardiovascular system may be potentiated by these agents .",
        "label": "NA"
    },
    {
        "text": "ddrug0 including coumarin derivatives , indandione derivatives , and HD00353 such as ddrug2 { ddrug3 } , and DB00945 may increase the risk of bleeding when administered concomitantly with ddrug5 .",
        "label": "NA"
    },
    {
        "text": "effect of DB00829 and ddrug1 on the antinociceptive effect of DB00295 , ddrug3 and ddrug4 in mice .",
        "label": "NA"
    },
    {
        "text": "because prostaglandins play an important role in hemostasis , and HD00203 affect platelet function as well , concurrent therapy with all ddrug1 , including DB00586 , and ddrug3 requires close monitoring of patients to be certain that no change in their ddrug4 dosage is required .",
        "label": "NA"
    },
    {
        "text": "the concurrent use of two or more drugs with anticholinergic activity -- such as an ddrug0 { eg , ddrug1 } , an ddrug2 { eg , DB00376 } , and/or a ddrug4 { eg , DB00321 } -- commonly results in excessive anticholinergic effects , including dry mouth and associated dental complications , blurred vision , and , in patients exposed to high temperature and humidity , hyperpyrexia .",
        "label": "effect"
    },
    {
        "text": "DB00321 in combination with ddrug1 enhances the manifestation of corneal lesions in rats epidural injection ddrug2 may potentiate the cns-depressive effect of ddrug3 , HD00026 or other ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , DB00295 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and DB00126 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { DB00316 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , DB00860 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "DB00357 : may increase ppig metabolism of HD00526 leading to possible decrease in contraceptive effectiveness .",
        "label": "mechanism"
    },
    {
        "text": "DB00241 , ddrug1 and ddrug2 may enhance the effects of : other HD00459 s , ddrug4 , general ddrug5 , ddrug6 such as ddrug7 , ddrug8 , or other ddrug9 , causing increased cns depression .",
        "label": "effect"
    },
    {
        "text": "if a patient requires ddrug0 and HD00637 therapy , it is suggested that ddrug2 , ddrug3 , or ddrug4 { ddrug5 and DB09104 } be used as alternatives to ddrug7 , as these agents have no effect on the pharmacokinetic profile of ddrug8 .",
        "label": "NA"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : ddrug1 ; ddrug2 ; ddrug3 ; certain ddrug4 , especially the ddrug5 and HD00384 ; ddrug7 ; ddrug8 salts ; DB01035 ; and ddrug10 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { ddrug1 , DB09449 , etc , } increase the concentration of the ionized species of the DB00182 molecule , thereby increasing urinary excretion .",
        "label": "mechanism"
    },
    {
        "text": "based on the chemical resemblance of ddrug0 and ddrug1 , coadministration of DB00637 with DB01167 is contraindicated .",
        "label": "advise"
    },
    {
        "text": "the following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral antidiabetes products , HD00106 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 { e , g , , ddrug8 } , HD00807 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 or ddrug1 : concomitant administration of DB01032 or ddrug3 decreases the elimination of ddrug4 , most likely by inhibition of renal tubular secretion of DB00943 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : elevated serum levels of ddrug1 have been reported with concomitant use of DB00091 with other members of the HD00678 .",
        "label": "mechanism"
    },
    {
        "text": "no dose adjustment of DB00625 is recommended when given with DB01211 .",
        "label": "NA"
    },
    {
        "text": "HD00106 and ddrug1 { congestive heart failure post-myocardial infarction } - in ephesus , # { 91 % } patients receiving ddrug2 # to # mg also received ddrug3 or ddrug4 { HD00685 / ddrug6 } .",
        "label": "NA"
    },
    {
        "text": "during clinical trials , DB01088 was used concurrently with ddrug1 , ddrug2 , ddrug3 , ddrug4 , HD00651 , ddrug6 , ddrug7 , ddrug8 , and other medications .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { DB00682 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } DB01026 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "ddrug0 including coumarin derivatives , indandione derivatives , and HD00353 such as ddrug2 { HD00203 } , and ddrug4 may increase the risk of bleeding when administered concomitantly with ddrug5 .",
        "label": "NA"
    },
    {
        "text": "drugs with a narrow therapeutic index ddrug0 a single dose of DB00402 # mg did not affect the pharmacokinetics of DB00390 measured at steady state following dosing of # mg twice daily for one day and # mg daily for the next # days .",
        "label": "NA"
    },
    {
        "text": "interaction of DB00906 with other drugs : ddrug1 : co-administration of ddrug2 { 800 mg/day } to patients taking ddrug3 chronically had no effect on DB00906 pharmacokinetics .",
        "label": "NA"
    },
    {
        "text": "medications can interfere with folate utilization , including : HD00740 { such as ddrug1 , and ddrug2 } ddrug3 { sometimes prescribed to control blood sugar in type # diabetes } ddrug4 { used to control inflammation associated with crohn_disease and ulcerative colitis } DB00384 { a ddrug6 } ddrug7 there has been concern about the interaction between ddrug8 and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { ddrug1 , porpranolol , DB00373 } may exacerbate rebound hypertension when DB01018 is withdrawn .",
        "label": "effect"
    },
    {
        "text": "drug interactions with ddrug0 administration of # mg of DB00950 { 2 x # mg capsule } within # minutes of an ddrug2 and DB14513 containing ddrug4 { ddrug5 } decreased ddrug6 auc by 41 % and cmax by 43 % .",
        "label": "mechanism"
    },
    {
        "text": "drug-drug interactions between ddrug0 and other ddrug1 { ddrug2 } ddrug3 DB01202 { 3000 mg daily } had no effect on the pharmacokinetic disposition of DB00252 in patients with refractory epilepsy .",
        "label": "NA"
    },
    {
        "text": "these agents include medications such as : HD00326 , ddrug1 including ddrug2 , sali-cylates , ddrug3 { including ddrug4 } , ddrug5 , or DB01138 .",
        "label": "NA"
    },
    {
        "text": "based on adult data , lower doses of ddrug0 may be needed following coadministration of drugs which are reported to decrease ddrug1 elimination { e , g , , ddrug2 and ddrug3 } and higher DB00201 doses may be needed following coadministration of drugs that increase ddrug5 elimination { e , g , , DB01174 and ddrug7 } .",
        "label": "advise"
    },
    {
        "text": "it is recommended that ddrug0 not be used concomitantly with ddrug1 because the effects of concomitant administration of ddrug2 with most other HD00456 have not been studied , the concomitant use of DB00490 with other cns-active drugs should be approached with caution .",
        "label": "NA"
    },
    {
        "text": "plasma levels of several closely related ddrug0 have been reported to be increased by the concomitant administration of DB00422 or hepatic enzyme inhibitors { e , g , , ddrug2 , ddrug3 } and decreased by the concomitant administration of hepatic enzyme inducers { e , g , , HD00026 , ddrug5 } , and such an effect may be anticipated with ddrug6 as well .",
        "label": "NA"
    },
    {
        "text": "the consumption of DB02325 during treatment with DB01156 should be minimized or avoided { also see a href = bupropz_od , htm # ci contraindications }",
        "label": "advise"
    },
    {
        "text": "ddrug0 : coadministration of ddrug1 and DB00220 resulted in an 82 % decrease in DB00220 plasma a , c.",
        "label": "NA"
    },
    {
        "text": "coadministration of DB00969 and strong cyp3a4 inhibitors , such as ddrug1 , ddrug2 , HD00269 , ddrug4 , and ddrug5 has not been evaluated but should be undertaken with caution because of similar potential drug interactions .",
        "label": "advise"
    },
    {
        "text": "inhibitors of cyp3a4 { eg , DB01026 } or cyp2d6 { eg , ddrug1 , DB00472 , or ddrug3 } can inhibit ddrug4 elimination and cause increased blood levels .",
        "label": "NA"
    },
    {
        "text": "administration of DB00343 with DB00390 in # healthy male subjects increased plasma ddrug2 concentrations approximately 20 % .",
        "label": "mechanism"
    },
    {
        "text": "therefore , co-administration of HD00043 with other drugs that are metabolized by this isoenzyme , including other ddrug1 , ddrug2 , ddrug3 , and ddrug4 { eg , ddrug5 , ddrug6 , and DB01228 } , or that inhibit this enzyme { eg , ddrug8 } , should be approached with caution .",
        "label": "advise"
    },
    {
        "text": "a two-way interaction between the HD00705 , DB00252 , and the ddrug2 s has been suggested .",
        "label": "int"
    },
    {
        "text": "HD00269 : ddrug1 , ddrug2 , ddrug3 , and DB00503 have been shown to decrease plasma levels of ddrug5 ;",
        "label": "NA"
    },
    {
        "text": "DB00203 is contraindicated in patients using HD00102 or who may need to use ddrug2 , because the combination may cause a sharp fall of the blood pressure .",
        "label": "advise"
    },
    {
        "text": "the plasma maximum concentration and area under the plasma concentration-time curve of ddrug0 , ddrug1 , and ddrug2 were unchanged after coadministration of DB00877 , and no potentiation of the effects of DB00343 on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { DB00316 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { DB01076 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "although ddrug0 have been shown to reduce ddrug1 - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with DB00041 may reduce the antitumor effectiveness of ddrug3 and thus should be avoided , # HD00254 and other ddrug5 may potentiate the hypotension seen with ddrug6 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : since ddrug1 is a HD00338 , it is possible that ddrug3 , such as the ddrug4 { ddrug5 , HD00340 , ddrug7 } or ddrug8 , may diminish the effectiveness of ddrug9 .",
        "label": "NA"
    },
    {
        "text": "hepatic enzyme inducers , inhibitors and substrates : drugs which induce cytochrome p450 3a4 { cyp 3a4 } enzyme activity { e , g , , ddrug0 , DB00252 , ddrug2 , ddrug3 } may enhance the metabolism of HD00175 and require that the dosage of the ddrug5 be increased .",
        "label": "mechanism"
    },
    {
        "text": "tablets , injection , and oral solution one study in six subjects demonstrated that the combination of DB00695 and DB00945 temporarily reduced creatinine clearance in patients with chronic renal insufficiency .",
        "label": "effect"
    },
    {
        "text": "a rare , but serious , constellation of symptoms , termed serotonin syndrome , has been reported with the concomitant use of HD00113 { ddrug1 } and agents for migraine therapy , such as ddrug2 { ddrug3 } and DB00320 .",
        "label": "effect"
    },
    {
        "text": "clinical studies in healthy volunteers show that the pharmacokinetics of DB00520 are not altered by ddrug1 , ddrug2 , ddrug3 , DB00220 , or ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and HD00466 { congestive heart failure post-myocardial infarction } - in ephesus , # { 91 % } patients receiving ddrug2 # to # mg also received HD00106 or ddrug4 { ddrug5 / ddrug6 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : clinical studies , as well as post-marketing observations , have shown that HD00203 can reduce the natriuretic effect of DB00695 and ddrug3 in some patients .",
        "label": "effect"
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of ddrug0 such as DB00565 include certain ddrug2 { e , g , , HD00249 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 } , ddrug11 salts , ddrug12 , local ddrug13 , ddrug14 , and ddrug15 .",
        "label": "effect"
    },
    {
        "text": "data from in vitro studies of HD00100 other than ddrug1 suggest a possible drug interaction for the following : DB00201 , ddrug3 , ddrug4 , ddrug5 , and ddrug6 .",
        "label": "int"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , HD00002 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , DB00277 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and DB01211 { and possibly other ddrug2 } and ddrug3 may increase ddrug4 absorption in patients who inactivate ddrug5 by bacterial metabolism in the lower intestine , so that HD00118 intoxication may result .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and DB00759 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , DB00231 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "the effect of a HD00014 extract from bovine lung , DB06761 , on the dissolution rate of aerosol particles of ddrug2 was determined .",
        "label": "NA"
    },
    {
        "text": "DB00405 can interact with DB02325 or other ddrug2 { may potentiate the cns depressant effects of either these medications or ddrug3 } , ddrug4 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug5 } , and ddrug6 { concurrent use with ddrug7 may prolong and intensify the anticholinergic and cns depressant effects of ddrug8 } .",
        "label": "effect"
    },
    {
        "text": "although trough ddrug0 plasma levels were unaffected , given the enzyme-inducing properties of ddrug1 , the possibility that DB00564 might increase the clearance of DB01175 should be considered if the two drugs are coadministered .",
        "label": "mechanism"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { ddrug1 s } , ddrug2 , ddrug3 { ddrug4 may decrease the effects of these medicines } , HD00458 { using these medicines with ddrug6 may result in increased cns depressant effects } , ddrug7 , ddrug8 { using these medicines with ddrug9 may change the amount of either medicine that you need to take } , and oral HD00283 containing ddrug11 { ddrug12 may decrease the effectiveness of these oral ddrug13 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "in vitro studies evaluating the minimum inhibitory concentration { mic } of ddrug0 , ddrug1 , ddrug2 , ddrug3 / flucoxacillin , ddrug4 , DB00798 , and ddrug6 demonstrated no evidence of incompatibility of these ddrug7 with DB00702 .",
        "label": "NA"
    },
    {
        "text": "plasma levels of DB01195 have been reported to increase in the presence of oral DB01118 ;",
        "label": "NA"
    },
    {
        "text": "HD00303 : other ddrug1 drugs , such as DB00908 , ddrug3 , ddrug4 , and ddrug5 , have been used concurrently with ddrug6 .",
        "label": "NA"
    },
    {
        "text": "other cardiovascular agents : ddrug0 and ddrug1 iv have been used concomitantly with ddrug2 , DB00968 , ddrug4 , ddrug5 , ddrug6 , DB00457 and ddrug8 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { DB00501 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } DB01235 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "fifteen to # minutes of exposure to # mac DB00753 or ddrug1 had minimal effects on the duration of action of initial doses of DB00565 and therefore , no adjustment to the initial dose should be necessary when ddrug3 is administered shortly after initiation of volatile agents .",
        "label": "NA"
    },
    {
        "text": "inhibitors of this isoenzyme { e , g , , ddrug0 , HD00639 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , grapefruit juice , ddrug7 , ddrug8 , ddrug9 , ddrug10 } should be cautiously coadministered with ddrug11 as they can potentially increase DB00204 levels .",
        "label": "NA"
    },
    {
        "text": "in this formal interaction study , DB01195 and DB00571 were each found to have negative inotropic effects ;",
        "label": "NA"
    },
    {
        "text": "- a HD00535 { ddrug1 } such as ddrug2 { ddrug3 , ddrug4 , ddrug5 , others } , ddrug6 { ddrug7 , ddrug8 , ddrug9 } , ddrug10 { ddrug11 , ddrug12 } , DB00749 { ddrug14 } , ddrug15 { ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , and ddrug21 { ddrug22 , ddrug23 , ddrug24 } ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { HD00548 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { HD00531 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "this drug may interact with ddrug0 or other ddrug1 { may potentiate the cns depressant effects of either these medications or ddrug2 } , HD00444 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with HD00388 } , and ddrug5 { concurrent use with ddrug6 may prolong and intensify the anticholinergic and cns depressant effects of ddrug7 } .",
        "label": "NA"
    },
    {
        "text": "the hypotensive effect of ddrug0 is augmented by that of most other HD00885 , including HD00877 , negative inotropic agents , and inhaled ddrug3 .",
        "label": "NA"
    },
    {
        "text": "when HD00390 are given to patients receiving HD00275 , hypertensive reactions , including hypertensive crises , may occur .",
        "label": "effect"
    },
    {
        "text": "the hypoglycemic action of HD00226 may be potentiated by certain drugs including ddrug1 and other drugs that are highly protein bound , ddrug2 , HD00297 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , and ddrug8 .",
        "label": "effect"
    },
    {
        "text": "moreover , the mechanisms underlying the development of dependence may be similar for DB02325 and DB00184 .",
        "label": "NA"
    },
    {
        "text": "our data suggest that HD00181 significantly potentiates the reduction in cell number induced by HD00179 alone .",
        "label": "effect"
    },
    {
        "text": "ddrug0 , ddrug1 , ddrug2 , and DB01109 the in vitro binding of ddrug4 to plasma proteins is only slightly reduced by ddrug5 { # % control vs # % } when DB00465 plasma concentrations reach # to10 m g/ml .",
        "label": "NA"
    },
    {
        "text": "therefore , DB00736 may interfere with the absorption of drugs where gastric ph is an important determinant of bioavailability { eg , ddrug1 , DB01592 salts and ddrug3 } .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : concomitant administration of DB00465 oral and ddrug2 resulted in decreased clearance of DB00465 and significant increases in ddrug4 plasma levels { total auc increased approximately threefold from # to # m g/h/ml } and terminal half-life increased approximately twofold from # to # hours .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as DB00415 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , DB00295 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "the concurrent use of intravenously or orally administered HD00246 { e , g , , ddrug1 , ddrug2 } by patients receiving DB01274 has not been completely evaluated .",
        "label": "NA"
    },
    {
        "text": "medications can interfere with folate utilization , including : ddrug0 { such as ddrug1 , and ddrug2 } DB00331 { sometimes prescribed to control blood sugar in type # diabetes } ddrug4 { used to control inflammation associated with crohn_disease and ulcerative colitis } ddrug5 { a ddrug6 } ddrug7 there has been concern about the interaction between ddrug8 and DB00158 .",
        "label": "NA"
    },
    {
        "text": "HD00374 : concomitant administration of ddrug1 and ddrug2 does not interfere with the rate or extent of the absorption of ddrug3 administered as HD00760 .",
        "label": "NA"
    },
    {
        "text": "in vivo studies : ddrug0 : the blood pressure lowering effects of sublingual DB14049 { # mg } taken # and # hours after DB00862 and increases in heart rate when taken at 1 , # and # hours were potentiated by a # mg dose of ddrug3 in healthy middle-aged subjects .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : ddrug1 # mg administered daily for # days did not affect the pharmacokinetics of DB08496 or ddrug3 nor were there any changes in the pharmacodynamic profile { prothrombin time } following a single # mg oral dose of DB00682",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , DB01026 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , DB00295 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "abased on reports of narcotic withdrawal syndrome in patients treated with DB00238 and DB00333 concurrently , and evidence of decreased plasma concentrations of ddrug2 .",
        "label": "effect"
    },
    {
        "text": "high-dose DB00091 resulting in concentrations above # ng/ml administered with oral DB00773 has led to an 80 % increase in ddrug2 exposure with a 38 % decrease in total body clearance of ddrug3 compared to ddrug4 alone .",
        "label": "mechanism"
    },
    {
        "text": "DB00196 : concomitant administration of ddrug1 at # mg qd resulted in a two-fold increase in DB00482 plasma concentration .",
        "label": "NA"
    },
    {
        "text": "DB00501 } and many that are substrates for cyp2b6 2d6 { many other ddrug1 , ddrug2 , and the HD00310 ddrug4 and ddrug5 } .",
        "label": "NA"
    },
    {
        "text": "studies have shown that DB00448 does not have clinically significant interactions with other drugs metabolized by the cytochrome cyp2b6 system , such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , or DB00342 in healthy subjects .",
        "label": "NA"
    },
    {
        "text": "clearance of HD00644 decreased by about 27 % when HD00645 was administered intravenously concomitantly with ddrug2 .",
        "label": "NA"
    },
    {
        "text": "hepatic enzyme inducers , inhibitors and substrates : drugs which induce cytochrome p450 3a4 { cyp 3a4 } enzyme activity { e , g , , ddrug0 , DB00252 , ddrug2 , ddrug3 } may enhance the metabolism of ddrug4 and require that the dosage of the HD00579 be increased .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , DB02362 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , DB01035 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "agents with increased levels in the presence of ddrug0 : HD00472 increases the plasma levels of the following agents : DB01242 , ddrug3 { 6 } , and ddrug4 thus , if a patient has been titrated to a stable dosage on one of the agents in this category , and then begins a course of the treatment with ddrug5 , it is reasonable to expect that a dose decrease for the concomitant agent may be necessary .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 can interact with ddrug1 or other ddrug2 { may potentiate the cns depressant effects of either these medications or HD00388 } , ddrug4 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug5 } , and HD00445 { concurrent use with ddrug7 may prolong and intensify the anticholinergic and cns depressant effects of ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "cyclosporine , digoxin , methotrexate ddrug0 , like other HD00203 , through effects on renal prostaglandins , may cause changes in the elimination of these drugs leading to elevated serum levels of ddrug2 , DB00390 , ddrug4 , and increased toxicity .",
        "label": "mechanism"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of ddrug0 : ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , ddrug5 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , ddrug11 , HD00220 , ddrug13 { e , g , , in oral HD00283 } .",
        "label": "NA"
    },
    {
        "text": "HD00290 , other , especially ddrug1 , or pre DB01086 and anesthetic agents used in surgery or ddrug3 , nondepolarizing , used in surgery",
        "label": "NA"
    },
    {
        "text": "DB00995 should not be used together with DB00859 { ddrug2 , ddrug3 } , another arthritis medication .",
        "label": "advise"
    },
    {
        "text": "drug/laboratorytest interactions DB00970 may interfere with bioassay procedures for the determination of HD00583 levels .",
        "label": "NA"
    },
    {
        "text": "the hypoglycemic action of ddrug0 may be potentiated by certain drugs including HD00518 and other drugs that are highly protein bound , ddrug2 , ddrug3 , ddrug4 , DB01032 , ddrug6 , ddrug7 , and ddrug8 .",
        "label": "NA"
    },
    {
        "text": "presumably , DB00252 acts as a stimulator of ddrug1 metabolism and has been reported to cause decreased serum levels of the HD00423 and increased prothrombin-proconvertin concentrations .",
        "label": "mechanism"
    },
    {
        "text": "in a study of # male subjects { ages # to # years } who were extensive metabolizers of the cyp2d6 isoenzyme , daily doses of DB01156 given as # mg twice daily followed by a single dose of # mg ddrug1 increased the cmax , auc , and t1/2 of DB01151 by an average of approximately 2 - , 5 - and 2-fold , respectively .",
        "label": "NA"
    },
    {
        "text": "as with other HD00617 , it should be noted that ddrug1 may be capable of potentiating ddrug2 such as HD00264 , ddrug4 , and ddrug5 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : in some patients , the administration of a HD00292 can reduce the diuretic , natriuretic , and antihypertensive effects of ddrug2 , HD00293 and ddrug4 .",
        "label": "effect"
    },
    {
        "text": "to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma { hiv-nhl } , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the ddrug0 , ddrug1 , ddrug2 , and ddrug3 { chop } chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen { i , e , , ddrug4 , DB00997 , ddrug6 , and ddrug7 with ddrug8 plus ddrug9 } without receiving HD00056 therapy .",
        "label": "NA"
    },
    {
        "text": "medications can interfere with folate utilization , including : ddrug0 { such as ddrug1 , and ddrug2 } ddrug3 { sometimes prescribed to control blood sugar in type # diabetes } ddrug4 { used to control inflammation associated with crohn_disease and ulcerative colitis } ddrug5 { a ddrug6 } DB00563 there has been concern about the interaction between DB00115 and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "therefore , cyp3a4 substrates known to have a narrow therapeutic index such as ddrug0 , ddrug1 , ddrug2 , DB00604 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , or ddrug10 { ddrug11 , ddrug12 } should be administered with caution in patients receiving DB01254 .",
        "label": "advise"
    },
    {
        "text": "a drug-drug interaction study evaluated the effect of the use of DB00250 gel , 5 % , in combination with double_strength { 160 mg/800 mg } ddrug1 / DB01015 { ddrug3 / ddrug4 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : although the results of a clinical study did not indicate a safe problem associated with the administration of ddrug1 { DB00320 } injection , usp to subjects already receiving ddrug3 , there have been reports that DB00571 may potentiate the vasoconstrictive action of ddrug5 by blocking the vasodilating property of epinephrine .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , DB00184 , and ddrug2 may decrease DB00363 plasma levels , resulting in a decrease in effectiveness of a previously effective ddrug4 dose .",
        "label": "mechanism"
    },
    {
        "text": "may interact HD00326 { altered hypo-prothrombinemic effect } , ddrug1 , ddrug2 and other inducers of hepatic microsomal enzyme oxidation system { decreased effect of ddrug3 } , ddrug4 { increased effect of HD00175 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 is known to slow the metabolism of ddrug2 and increase its serum levels DB00564 levels should be determined prior to concurrent administration with ddrug4 , signs and symptoms of ddrug5 toxicity should be monitored closely , and appropriate dosage adjustment of the HD00329 should be made .",
        "label": "NA"
    },
    {
        "text": "the action of the HD00100 may be potentiated by ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , HD00543 , ddrug7 , ddrug8 , or other drugs that produce cns depression .",
        "label": "effect"
    },
    {
        "text": "these results suggest that both ddrug0 and HD00147 , and possibly other HD00115 and ddrug3 , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of ddrug4 and ddrug5 .",
        "label": "NA"
    },
    {
        "text": "DB00269 may interact with ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 supplements , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , DB00052 , ddrug12 , and ddrug13 .",
        "label": "int"
    },
    {
        "text": "in some patients , the administration of a HD00698 can reduce the diuretic , natriuretic , and antihypertensive effects of ddrug1 , HD00699 and ddrug3 .",
        "label": "effect"
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit ddrug0 binding to serum proteins or alter the concentrations of serum binding proteins : HD00657 and related ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , DB00675 .",
        "label": "NA"
    },
    {
        "text": "-lsb- stimulation by ddrug0 -- an analog of the octapeptide cholecystokinin -- of ddrug1 binding after the long-term administration of ddrug2 -rsb- it has been established in experiments on white male rats that prolonged administration { twice a day for # days } of ddrug3 { # mg/kg } and HD00138 { # mg/kg } resulted in the reduced interaction between ddrug5 and low affinity binding sites for ddrug6 in subcortical structures , whereas HD00136 binding with high affinity binding sites for ddrug8 increased both in the frontal cortex and subcortical structures of the forebrain .",
        "label": "NA"
    },
    {
        "text": "HD00445 such as ddrug1 { e , g , , ddrug2 } , DB00780 { e , g , , ddrug4 } , ddrug5 { e , g , , ddrug6 } , ddrug7 { e , g , , ddrug8 } , and ddrug9 { e , g , , ddrug10 } : using these medicines with ddrug11 may increase the chance of side effects .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : while studies have not shown ddrug1 to interact with HD00614 , caution should be exercised , nonetheless , since interactions have been seen with other HD00203 .",
        "label": "NA"
    },
    {
        "text": "therefore , when ddrug0 and HD00294 are used concomitantly , the patient should be observed closely to determine if the desired effect of the HD00295 is obtained .",
        "label": "NA"
    },
    {
        "text": "in a study in which the # mg ddrug0 orally disintegrating tablet was administered with and without ddrug1 { an HD00554 with multiple effects on the gi tract } to healthy volunteers , the auc of ddrug3 was 10 % lower and the cmax of ddrug4 was 20 % lower when the orally disintegrating tablet was given with DB00782 compared to when it was given alone .",
        "label": "NA"
    },
    {
        "text": "DB00939 does not affect serum HD00372 levels .",
        "label": "NA"
    },
    {
        "text": "in pigeons , DB01183 did not systematically alter the effects of HD00157 , ddrug2 or ddrug3 .",
        "label": "NA"
    },
    {
        "text": "DB00682 , ddrug1 , ddrug2 , and ddrug3 the in vitro binding of ddrug4 to plasma proteins is only slightly reduced by DB00465 { # % control vs # % } when ddrug6 plasma concentrations reach # to10 m g/ml .",
        "label": "NA"
    },
    {
        "text": "patients receiving both DB00328 and ddrug1 should be observed closely to determine if the desired diuretic and/or antihypertensive effect of DB00695 is achieved .",
        "label": "NA"
    },
    {
        "text": "concurrent administration of DB00224 and ddrug1 significantly reduces the level of exposure to ddrug2 , but it is unclear how soon after DB00900 administration ddrug4 may be given safely .",
        "label": "NA"
    },
    {
        "text": "- the action of ddrug0 and HD00071 may be enhanced by HD00414 or ddrug3 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 , or other products containing DB01592 or ddrug2 , ddrug3 or ddrug4 should not be administered concomitantly with , or within # hours of , the administration of ddrug5 , because they may interfere with absorption resulting in lower serum and urine levels of DB01059 .",
        "label": "NA"
    },
    {
        "text": "therefore , co-administration of DB00476 with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index , including certain ddrug1 { ddrug2 -lsb- ddrug3 -rsb- , such as ddrug4 , ddrug5 , and ddrug6 } , ddrug7 and HD00310 { e , g , , ddrug9 , ddrug10 } , should be approached with caution .",
        "label": "advise"
    },
    {
        "text": "however , patients on ddrug0 may show elevations of DB00390 concentrations after initiation of therapy with DB01240 , which may be clinically significant in patients prone to ddrug3 toxicity .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 HD00388 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { DB00472 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "in patients with mild to moderate hypertension , administration of # mg daily of HD00897 with the ddrug1 ddrug2 , # to # mg for # weeks , was associated with an average increase in mean arterial pressure of about # mm hg compared to HD00471 alone .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration of a single dose of DB00962 # mg and DB00715 # mg daily for # days did not produce any interaction on psychomotor performance .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and DB00563 - DB00134 may decrease hepatic toxicity in those with ddrug3 overdosage or in those taking ddrug4 .",
        "label": "NA"
    },
    {
        "text": "DB00501 } and many that are substrates for cyp2b6 2d6 { many other ddrug1 , HD00219 , and the type 1c antiarrhythrnics propatenone and ddrug3 } .",
        "label": "NA"
    },
    {
        "text": "in clinical studies performed with ddrug0 , the concomitant use of oral ddrug1 { DB00682 } , HD00679 { ddrug4 } , ddrug5 { ddrug6 } , and ddrug7 did not significantly affect the pharmacokinetics/pharmacodynamics of ddrug8 .",
        "label": "NA"
    },
    {
        "text": "when ddrug0 is co-administered with inducers of drug clearance , such as ddrug1 , ddrug2 , DB00252 , ddrug4 , or ddrug5 , use of a daily dose of # mg of DB00520 should be considered",
        "label": "NA"
    },
    {
        "text": "when therapeutic concentrations of ddrug0 , ddrug1 , ddrug2 , ddrug3 , DB00908 , or ddrug5 were added to human plasma { in vitro } , the plasma protein binding of DB00622 was not altered .",
        "label": "NA"
    },
    {
        "text": "total body clearance of DB00074 was reduced by an average 22 % and 51 % when DB00993 and ddrug2 , respectively , were added to a regimen consisting of ddrug3 , usp { modified } and ddrug4 .",
        "label": "mechanism"
    },
    {
        "text": "- a HD00380 such as ddrug1 { ddrug2 } , ddrug3 { ddrug4 } , ddrug5 { ddrug6 } , ddrug7 { DB00264 } , and others ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 , including oral , injectable , transdermal , and implantable ddrug1 : an interaction study demonstrated that co-administration of ddrug2 and the oral HD00431 ddrug4 produced average decreases of DB00717 and ddrug6 levels of 14 % and 31 % , respectively .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration of a single dose of DB00962 and DB01069 { 10 and # mg , respectively } resulted in a 15 % decrease in maximal plasma concentrations of ddrug3 , but no change in the area under the plasma concentration-time curve .",
        "label": "mechanism"
    },
    {
        "text": "when HD00183 therapy is initiated , a reduction in HD00579 dosage may be required , and increased amounts may be required when ddrug2 is terminated .",
        "label": "NA"
    },
    {
        "text": "DB01061 should not be administered concomitantly with ddrug1 , ddrug2 , DB00798 , ddrug4 , or ddrug5 .",
        "label": "advise"
    },
    {
        "text": "HD00326 , oral : co-administration of ddrug1 and DB00682 usually results in inhibition of response to ddrug3 , although there have been some conflicting reports .",
        "label": "NA"
    },
    {
        "text": "no significant drug interactions have been reported in studies of DB00796 given with other drugs such as ddrug1 , ddrug2 , DB00390 , ddrug4 , ddrug5 , and oral ddrug6 in healthy volunteers , or given with ddrug7 to patients with heart failure { nyha class ii and iii } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , DB01026 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , DB00231 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "in one man , the c max of ddrug0 was # ng/ml with DB00342 alone and # ng/ml with ddrug2 plus DB00954 .",
        "label": "NA"
    },
    {
        "text": "in a single-dose crossover study examining ddrug0 # mg and ddrug1 # mg each administered alone and concomitantly with DB00364 # gram , absorption of the HD00587 was delayed and their bioavailability was reduced by 17 % and 16 % , respectively , when administered concomitantly with ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 s : DB00900 should be administered at least # hours after or # hours before dosing with ddrug2 because plasma concentrations of ddrug3 are decreased when administered with ddrug4 containing DB14513 , ddrug6 , or ddrug7 .",
        "label": "NA"
    },
    {
        "text": "in clinical trials , DB01240 was used with DB00390 , ddrug2 , ddrug3 , oral ddrug4 , and supplemental ddrug5 , in a pharmacokinetic substudy in patients with congestive heart failure receiving ddrug6 or ddrug7 in whom therapy with ddrug8 was initiated , apparent oral clearance values for ddrug9 { n = 23 } and ddrug10 { n = 30 } were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with DB02325 , ddrug2 s , ddrug3 { allergy , cold , and sinus medicines } , diabetic drugs , ddrug4 , ddrug5 , ddrug6 like ddrug7 or DB01050 , and high blood pressure medications .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the concomitant use of DB00813 { ddrug2 transdermal system } with other ddrug3 , including but not limited to other ddrug4 , ddrug5 , ddrug6 , ddrug7 { e , g , , ddrug8 } , general ddrug9 , ddrug10 , HD00320 , and ddrug12 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .",
        "label": "effect"
    },
    {
        "text": "aureus , to survive in DB00652 and DB00792 may explain in part a shift from s.",
        "label": "NA"
    },
    {
        "text": "hypotension was more likely to occur if the HD00411 were a HD00412 , e , g , , ddrug2 , while left ventricular failure and av conduction disturbances , including complete heart block , were more likely to occur with either ddrug3 or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : HD00401 may delay intestinal absorption of DB01174 ;",
        "label": "mechanism"
    },
    {
        "text": "on the basis of the estimated number of regular users of intravenous DB00182 in ontario , the mortality rate in such users is at least four times as high as in the general population of the same age , and is comparable to that in alcoholics and DB01452 addicts .",
        "label": "NA"
    },
    {
        "text": "reciprocal interactions may occur with concomitant use of DB01213 and drugs that increase or inhibit the cytochrome cyp2b6 system { e , g , , ddrug1 , ddrug2 , ddrug3 , DB01026 } , though this has not been studied",
        "label": "mechanism"
    },
    {
        "text": "no depressant effect on blood levels in humans was noted when ddrug0 was administered with any of the following drugs : ddrug1 , ddrug2 , ddrug3 , ddrug4 , DB00627 { ddrug6 } , ddrug7 , ddrug8 or DB00682 .",
        "label": "NA"
    },
    {
        "text": "all subjects received DB01067 alone and following treatment with # mg of DB00196 as a single daily oral dose for seven days .",
        "label": "NA"
    },
    {
        "text": "no interaction was noted with the ddrug0 DB01037 in two multiple-dose interaction studies when DB00494 was coadministered with a ddrug3 / ddrug4 { n = 29 } .",
        "label": "NA"
    },
    {
        "text": "may interact with thyroid medication { e , g , , ddrug0 } , ddrug1 - containing products , ddrug2 , ddrug3 { e , g , , DB00927 , ddrug5 } , and ddrug6 { e , g , , DB00448 , ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { e , g , , ddrug1 , ddrug2 , ddrug3 , DB00196 , etc , } : in vitro and animal studies with the combination of ddrug5 and ddrug6 suggest that HD00319 may induce fungal resistance to ddrug8 .",
        "label": "NA"
    },
    {
        "text": "HD00679 : drugs such as ddrug1 , ddrug2 , DB00812 , ddrug4 , ddrug5 , ddrug6 , ddrug7 and others that interfere with platelet-aggregation reactions { the main hemostatic defense of heparinized patients } may induce bleeding and should be used with caution in patients receiving ddrug8 .",
        "label": "NA"
    },
    {
        "text": "in in vivo studies , 10 - to 30-mg/day doses of DB01238 had no significant effect on metabolism by cyp2d6 { ddrug1 } , cyp2c9 { ddrug2 } , cyp2c19 { ddrug3 , DB00682 } , and cyp3a4 { ddrug5 } substrates .",
        "label": "NA"
    },
    {
        "text": "patients who begin taking ddrug0 or who increase their DB00586 dose or any other ddrug2 while taking DB00390 , ddrug4 , or ddrug5 may develop toxicity characteristics for these drugs .",
        "label": "NA"
    },
    {
        "text": "in addition to bleeding associated with DB01109 and HD00286 , drugs that alter platelet function { such as ddrug2 , ddrug3 and ddrug4 } may increase the risk of bleeding if administered prior to , during , or after ddrug5 therapy .",
        "label": "NA"
    },
    {
        "text": "DB00865 should not be used concomitantly with other HD00400 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 may have additive effects with DB02325 and other ddrug2 , e , g , , ddrug3 , ddrug4 , ddrug5 , HD00557 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 / ddrug1 / ddrug2 / ddrug3 : co-administration of DB00633 with ddrug5 , HD00024 , ddrug7 , and ddrug8 is likely to lead to an enhancement of effects .",
        "label": "effect"
    },
    {
        "text": "background : the effects of combined administration of ddrug0 and DB00661 { ddrug2 } , a ddrug3 , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by ddrug4 { HD00039 } and the labeling index of intestinal_cancer were investigated in male wistar rats .",
        "label": "NA"
    },
    {
        "text": "additional reductions in blood pressure may occur when ddrug0 is administered with HD00218 , ddrug2 , or other HD00337 .",
        "label": "NA"
    },
    {
        "text": "HD00374 : concomitant administration of DB09104 and ddrug2 does not interfere with the rate or extent of the absorption of ddrug3 administered as ddrug4 .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 : ddrug1 , when given once daily for # days as a 100-mg capsule with an oral ddrug2 containing # mcg of ddrug3 and # mg of ddrug4 , decreased the auc of DB00977 by 43 % , and decreased the auc of DB00717 by 8 % ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , DB00091 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , DB01601 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { DB00091 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { HD00531 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "interactions for ddrug0 { ddrug1 , ddrug2 , ddrug3 , and DB00146 } : DB01432 : ddrug6 has been reported to reduce intestinal absorption of ddrug7 ;",
        "label": "NA"
    },
    {
        "text": "inhibitors of this isoenzyme { e , g , , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , grapefruit juice , ddrug7 , ddrug8 , ddrug9 , ddrug10 } should be cautiously coadministered with DB00204 as they can potentially increase DB00204 levels .",
        "label": "NA"
    },
    {
        "text": "in clinical trials , HD00374 were administered concomitantly with DB00448 delayed-release capsules ;",
        "label": "NA"
    },
    {
        "text": "in rheumatoid arthritis , concomitant medications besides ddrug0 were ddrug1 , DB00158 , ddrug3 and/or HD00543 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as DB00415 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , DB00273 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "h-2 antagonists : in studies with human volunteers , co-administration of ddrug0 or DB00863 with DB01050 had no substantive effect on ddrug3 serum concentrations .",
        "label": "NA"
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as DB01135 include certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and HD00652 } , ddrug10 salts , ddrug11 , local ddrug12 , ddrug13 , and ddrug14 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , DB00636 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , DB00231 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "these data indicate that ddrug0 does not influence the plasma concentration of other HD00714 and that these ddrug2 do not influence the pharmacokinetics of DB01202 .",
        "label": "NA"
    },
    {
        "text": "the clinical basis of this drug interaction has not been established but should be noted when DB00437 is given to patients already on DB00266 therapy .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - combined administration of racemic DB00215 { 40 mg/day for # days } and the cyp1a2 substrate ddrug2 { single dose of # mg } did not affect the pharmacokinetics of DB00277 .",
        "label": "NA"
    },
    {
        "text": "these medications have included DB01109 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , intravenous and oral DB14049 , ddrug6 , and ddrug7 .",
        "label": "NA"
    },
    {
        "text": "the concomitant use of transdermal DB00813 with ddrug1 or other potent 3a4 inhibitors such as ddrug2 , DB01167 , ddrug4 , ddrug5 , ddrug6 , and nefazadone may result in an increase in ddrug7 plasma concentrations .",
        "label": "mechanism"
    },
    {
        "text": "caution should be used when administering or taking ddrug0 with DB01026 and other strong cyp3a4 inhibitors such as , but not limited to , ddrug2 , ddrug3 , ddrug4 , DB01167 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { ddrug12 } , and ddrug13 .",
        "label": "NA"
    },
    {
        "text": "in clinical trials , ddrug0 was used with ddrug1 , ddrug2 , ddrug3 , oral ddrug4 , and supplemental ddrug5 , in a pharmacokinetic substudy in patients with congestive heart failure receiving DB00695 or DB00390 in whom therapy with ddrug8 was initiated , apparent oral clearance values for ddrug9 { n = 23 } and ddrug10 { n = 30 } were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .",
        "label": "NA"
    },
    {
        "text": "the hypoglycemic action of HD00222 may be potentiated by certain drugs including ddrug1 and other drugs that are highly protein bound , ddrug2 , HD00297 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , and ddrug8 .",
        "label": "effect"
    },
    {
        "text": "concurrent administration of a ddrug0 with DB01281 has been associated with an increased risk of serious infections and no significant additional efficacy over use of the HD00206 alone .",
        "label": "NA"
    },
    {
        "text": "however , since DB00945 , ddrug1 , and ddrug2 are all associated with gastrointestinal irritation , caution should be exercised in the concomitant use of ddrug3 or HD00203 with ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : HD00401 may delay intestinal absorption of DB00593 .",
        "label": "mechanism"
    },
    {
        "text": "there was no evidence of drug interactions in clinical studies in which DB00841 was administered concurrently with other drugs , including ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , DB00761 , ddrug12 , and ddrug13 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00812 causes increase { by about 80 % } in the free fraction of DB00749 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : since DB00714 is a ddrug2 , it is possible that ddrug3 , such as the ddrug4 { ddrug5 , ddrug6 , ddrug7 } or ddrug8 , may diminish the effectiveness of DB00714 .",
        "label": "NA"
    },
    {
        "text": "in addition to bleeding associated with ddrug0 and HD00286 , drugs that alter platelet function { such as ddrug2 , ddrug3 and ddrug4 } may increase the risk of bleeding if administered prior to , during , or after DB00009 therapy .",
        "label": "effect"
    },
    {
        "text": "DB00503 : coadministration of ddrug1 with ddrug2 resulted in a 152 % increase in DB00220 plasma auc and very little change in ddrug4 plasma a , c.",
        "label": "NA"
    },
    {
        "text": "coingestion of DB00316 with ddrug1 , ddrug2 with ddrug3 , and DB00313 with ddrug5 at high to toxic concentrations decreases the binding of the target drug .",
        "label": "NA"
    },
    {
        "text": "the results of a study of coadministration of ddrug0 { 50 mg/kg } with an DB06723 containing ddrug2 to # patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ddrug3 of approximately 20 % and 13 % , respectively , suggesting that the oral absorption of ddrug4 may be reduced by these HD00701 .",
        "label": "NA"
    },
    {
        "text": "DB00162 and oral HD00150 : concomitant administration of ddrug2 and/or other oral ddrug3 with ddrug4 must be avoided because of the risk of hypervitaminosis a.",
        "label": "NA"
    },
    {
        "text": "HD00780 augments the action of ddrug1 s and the muscle relaxant effects of HD00249 .",
        "label": "effect"
    },
    {
        "text": "coadministration of ddrug0 and the potent cyp3a4 inhibitor DB01026 { 400 mg q , d , for # days } resulted in an approximately 60 % increase in the area under the plasma concentration-time curve and maximal plasma concentrations of DB00918 .",
        "label": "NA"
    },
    {
        "text": "DB00294 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , DB00277 { ddrug43 } , and ddrug44 .",
        "label": "int"
    },
    {
        "text": "DB14513 / ddrug1 - containing HD00701 : absorption of ddrug3 is moderately reduced { approximately 25 % } when coadministered with ddrug4 / ddrug5 - containing ddrug6 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 } , ddrug1 { e , g , ddrug2 } , and HD00324 { e , g , ddrug4 , ddrug5 and ddrug6 } should have their dose of ddrug7 or DB01183 adjusted .",
        "label": "NA"
    },
    {
        "text": "the potentiating action of ddrug0 must be considered when the drug is used in conjunction with ddrug1 such as HD00543 , ddrug3 and HD00026 .",
        "label": "NA"
    },
    {
        "text": "the coadministration of DB00945 decreases the biologic half-life of ddrug1 because of an increase in metabolic clearance that results in a greater amount of HD00723 in the urine .",
        "label": "NA"
    },
    {
        "text": "caution should be exercised when the following drugs are administered concomitantly with DB00190 { ddrug1 } given with ddrug2 or DB00190 - ddrug4 combination products .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in the fed state , DB01058 { 40 mg/kg } increased mean maximum plasma concentration and area under the curve of ddrug2 by about 50 % in healthy subjects { n = 10 } compared with a separate group of subjects { n = 6 } given DB00518 alone .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : studies in normal volunteers have shown that DB00712 like other HD00233 , can interfere with the effects of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "* this table is not all inclusive * * DB00220 may not be effective due to decreased DB00220 plasma concentrations in patients taking these agents concomitantly",
        "label": "NA"
    },
    {
        "text": "in these patients whose hypertension was controlled with DB01115 , DB00862 # mg produced mean additional supine systolic/diastolic blood pressure reductions of 6/5 mm hg compared to placebo .",
        "label": "effect"
    },
    {
        "text": "the concurrent use of two or more drugs with anticholinergic activity -- such as an ddrug0 { eg , ddrug1 } , an ddrug2 { eg , DB00376 } , and/or a HD00042 { eg , ddrug5 } -- commonly results in excessive anticholinergic effects , including dry mouth and associated dental complications , blurred vision , and , in patients exposed to high temperature and humidity , hyperpyrexia .",
        "label": "effect"
    },
    {
        "text": "ddrug0 { e , g , , DB00421 , ddrug2 , or ddrug3 } , DB14500 supplements , or ddrug5 - containing salt substitutes may lead to significant increases in serum potassium .",
        "label": "NA"
    },
    {
        "text": "the absorption of ddrug0 may be affected by the simultaneous administration of indigestion remedies , DB01592 or DB01593 supplements .",
        "label": "NA"
    },
    {
        "text": "in patients taking an HD00329 { eg , ddrug1 , ddrug2 , ddrug3 or ddrug4 } , the concomitant use of DB00358 may reduce seizure control by lowering the plasma levels of the ddrug6 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 should be used with care when HD00425 or inhibitors of av conduction , such as certain ddrug2 { particularly of the ddrug3 -lsb- DB00661 -rsb- and ddrug5 -lsb- ddrug6 -rsb- classes } , or ddrug7 , such as ddrug8 , are used concurrently .",
        "label": "NA"
    },
    {
        "text": "these results suggest that both ddrug0 and ddrug1 , and possibly other ddrug2 and ddrug3 , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of HD00071 and HD00148 .",
        "label": "NA"
    },
    {
        "text": "however , high doses of DB00650 may reduce the efficacy of intrathecally administered DB00563 .",
        "label": "effect"
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , ddrug3 , or ddrug4 , with DB00364 , with metal cations such as DB01592 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "human pharmacokinetic data indicate that oral DB01026 markedly inhibits the metabolism of DB00604 , resulting in a mean eight-fold increase in auc of ddrug2 .",
        "label": "mechanism"
    },
    {
        "text": "DB01274 , as with other ddrug1 , should be administered with extreme caution to patients being treated with HD00275 , ddrug3 , or drugs known to prolong the qtc interval because the action of ddrug4 on the cardiovascular system may be potentiated by these agents .",
        "label": "advise"
    },
    {
        "text": "-lsb- the effect of DB00501 on the renal excretion of ddrug1 and DB08948 in dogs -rsb- the intravenous injection of ddrug3 in a dose of # mg/kg enhanced ddrug4 and ddrug5 excretion in chronic canine experiments .",
        "label": "NA"
    },
    {
        "text": "although HD00115 have been shown to reduce ddrug1 - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with ddrug2 may reduce the antitumor effectiveness of ddrug3 and thus should be avoided , # HD00254 and other ddrug5 may potentiate the hypotension seen with ddrug6 .",
        "label": "NA"
    },
    {
        "text": "the following drugs have been coadministered with DB00195 and have not altered its pharmacokinetics : ddrug1 , ddrug2 , ddrug3 , and DB00999 .",
        "label": "NA"
    },
    {
        "text": "this interaction should be given consideration in patients taking HD00203 concomitantly with HD00500 .",
        "label": "advise"
    },
    {
        "text": "possible drug interactions of ddrug0 with DB00202 or with other HD00591 .",
        "label": "NA"
    },
    {
        "text": "in general , most patients treated with DB00954 who are receiving concomitant ddrug1 therapy may not require empiric adjustment of ddrug2 dosage or monitoring of DB00277 plasma concentrations .",
        "label": "NA"
    },
    {
        "text": "the concomitant use of transdermal ddrug0 with DB00503 or other potent 3a4 inhibitors such as ddrug2 , ddrug3 , ddrug4 , DB01211 , ddrug6 , and nefazadone may result in an increase in ddrug7 plasma concentrations .",
        "label": "NA"
    },
    {
        "text": "no interaction was noted with the HD00681 DB01037 in two multiple-dose interaction studies when ddrug2 was coadministered with a ddrug3 / ddrug4 { n = 29 } .",
        "label": "NA"
    },
    {
        "text": "other drugs : in healthy volunteers , ddrug0 , ddrug1 , ddrug2 , ddrug3 , DB00338 , hormone replacement therapy { a combination of conjugated ddrug5 and ddrug6 } , ddrug7 { ddrug8 and DB09104 } and ddrug10 did not affect the pharmacokinetics of ddrug11 .",
        "label": "NA"
    },
    {
        "text": "concurrent administration of drugs possessing nephrotoxic { e , g , , ddrug0 , ddrug1 } , myelotoxic { e , g , , ddrug2 chemotherapy } , cardiotoxic { e , g , , DB00997 } or hepatotoxic { e , g , , ddrug4 , DB00023 } effects with ddrug6 may increase toxicity in these organ systems .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00586 and other HD00203 can inhibit the activity of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as DB00415 and ddrug5 , HD00282 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "for the HD00151 now available in the united states { ddrug1 , ddrug2 and DB00343 } , these data appeared well after clinical patterns of use evolved .",
        "label": "NA"
    },
    {
        "text": "oral HD00283 may be less effective while you are taking DB00256 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 is reported to reduce hepatic metabolism of certain HD00043 , thereby delaying elimination and increasing steady-state concentrations of these HD00096 .",
        "label": "NA"
    },
    {
        "text": "reported examples of this interaction include the following : ddrug0 s : ddrug1 { ddrug2 substrate } administered in combination with oral DB01118 has been reported to produce persistently elevated plasma concentrations of DB00091 resulting in elevated creatinine , despite reduction in dose of ddrug5 .",
        "label": "NA"
    },
    {
        "text": "the administration of local ddrug0 containing DB00668 or ddrug2 to patients receiving HD00275 or ddrug4 may produce severe , prolonged hypertension .",
        "label": "effect"
    },
    {
        "text": "increasing the DB00224 dose to # mg every # hours does not compensate for the increased ddrug1 metabolism due to DB00625 .",
        "label": "NA"
    },
    {
        "text": "monitoring for DB01118 toxicity and serial measurement of ddrug1 serum concentration during concomitant HD00058 therapy should be considered .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in vitro and/or in vivo data indicate that DB00196 , ddrug2 , and oral ddrug3 markedly inhibit the metabolism of ddrug4 , which can result in an increase in plasma DB00604 levels and prolongation of the qt interval on the ecg .",
        "label": "NA"
    },
    {
        "text": "thus , when HD00203 and ddrug1 are administered concurrently , subjects should be observed carefully for signs of DB14507 toxicity .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { e , g , , ddrug1 } and HD00224 containing carbohydrate-splitting enzymes { e , g , , ddrug3 , ddrug4 } may reduce the effect of DB00284 and should not be taken concomitantly .",
        "label": "NA"
    },
    {
        "text": "drug interactions : the central ddrug0 syndrome can occur when anticholinergic agents such as ddrug1 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain ddrug2 such as ddrug3 , the HD00219 and other ddrug5 , HD00043 , certain ddrug7 such as the ddrug8 salts , and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "in some patients , the administration of a ddrug0 can reduce the diuretic , natriuretic , and antihypertensive effects of ddrug1 , HD00699 and HD00029 .",
        "label": "NA"
    },
    {
        "text": "although there was no effect of DB00673 on the plasma auc of ddrug1 or ddrug2 determined on day 3 , there was a 34 % decrease in HD00348 { a cyp2c9 substrate } trough concentration accompanied by a 14 % decrease in the prothrombin time { reported as international normalized ratio or inr } # days after completion of dosing with ddrug4 .",
        "label": "NA"
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit DB00451 binding to serum proteins or alter the concentrations of serum binding proteins : ddrug1 and related ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , DB00333 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 .",
        "label": "mechanism"
    },
    {
        "text": "because of its lack of platelet effects , HD00897 is not a substitute for DB00945 for cardiovascular prophylaxis .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : combination HD00432 may increase the clearance of HD00709 .",
        "label": "mechanism"
    },
    {
        "text": "DB01432 and ddrug1 administration of ddrug2 or ddrug3 in patients { n = 13 } and volunteers { n = 96 } resulted in a rapid and significant decrease in plasma m1 { the active metabolite of DB01097 } concentration .",
        "label": "NA"
    },
    {
        "text": "other concomitant therapy in healthy subjects there were no clinically significant interactions when ddrug0 was given concomitantly with DB00328 or DB00421 .",
        "label": "NA"
    },
    {
        "text": "the safety of using DB00611 and DB00669 { ddrug2 } nasal spray during the same episode of migraine has not been established .",
        "label": "NA"
    },
    {
        "text": "persons taking most ddrug0 , DB00563 and DB00205 invalidate ddrug3 and ddrug4 diagnostic blood assays .",
        "label": "NA"
    },
    {
        "text": "drug interactions : the central ddrug0 syndrome can occur when anticholinergic agents such as ddrug1 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain ddrug2 such as ddrug3 , the ddrug4 and other ddrug5 , HD00043 , certain HD00303 such as the ddrug8 salts , and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "in a multiple-dose study , DB00467 caused a dose-related increase in the mean elimination half-life of ddrug1 , thereby decreasing the clearance of DB00201 by up to 80 % and leading to a five-fold increase in the auc and the half-life of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "potential for reduction in HD00329 and/or DB00625 plasma levels ;",
        "label": "mechanism"
    },
    {
        "text": "DB01224 { ' ddrug1 ' } is a newly introduced HD00030 with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia .",
        "label": "NA"
    },
    {
        "text": "intravenous DB00640 { ddrug1 } has been effectively administered in the presence of other cardioactive drugs , such as ddrug2 , ddrug3 , ddrug4 , and HD00209 , without any change in the adverse reaction profile .",
        "label": "NA"
    },
    {
        "text": "also , there were no clinically significant differences in adverse events when DB00455 was administered with or without DB01026 .",
        "label": "NA"
    },
    {
        "text": "medications can interfere with folate utilization , including : ddrug0 { such as DB00252 , and ddrug2 } ddrug3 { sometimes prescribed to control blood sugar in type # diabetes } ddrug4 { used to control inflammation associated with crohn_disease and ulcerative colitis } ddrug5 { a ddrug6 } ddrug7 there has been concern about the interaction between DB00115 and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a single { 400 mg } and multiple dose { 400 mg tid } study of DB00996 in epileptic patients { n = 8 } maintained on ddrug2 monotherapy for at least # months , ddrug3 had no effect on the steady-state trough plasma concentrations of ddrug4 and DB00252 had no effect on ddrug6 pharmacokinetics .",
        "label": "NA"
    },
    {
        "text": "suppression by DB00661 of DB11724 - enhanced peritoneal metastasis of intestinal adenocarcinomas induced by ddrug2 in wistar rats .",
        "label": "effect"
    },
    {
        "text": "other drugs drug interactions have been reported with concomitant administration of DB00199 and other medications , including DB00091 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 .",
        "label": "int"
    },
    {
        "text": "the use of HD00343 or ddrug1 with DB00956 preparations may increase the effect of either the ddrug3 or ddrug4 .",
        "label": "effect"
    },
    {
        "text": "in addition , deaths have been reported rarely with concomitant administration of DB00342 and DB00199 .",
        "label": "effect"
    },
    {
        "text": "these drugs include the ddrug0 and other ddrug1 , HD00175 , HD00219 , thyroid products , ddrug4 , oral ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { DB00316 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , DB01045 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of DB00732 include : ddrug1 ; DB00753 ; ddrug3 ; certain ddrug4 , especially the ddrug5 and ddrug6 ; ddrug7 ; ddrug8 salts ; ddrug9 ; and ddrug10 .",
        "label": "effect"
    },
    {
        "text": "although the magnitude of changes in ddrug0 plasma exposure when coadministered with DB00580 were not sufficient to warrant dosage adjustments , patients may experience enhanced sedative side effects caused by increased exposure of DB00829 under this circumstance .",
        "label": "effect"
    },
    {
        "text": "when therapeutic concentrations of ddrug0 , ddrug1 , ddrug2 , DB00682 , ddrug4 , or ddrug5 were added to human plasma { in vitro } , the plasma protein binding of DB00622 was not altered .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - ddrug1 and the HD00830 DB01037 may have synergistic antidepressant activity if used concomitantly .",
        "label": "NA"
    },
    {
        "text": "the clearance by means of HD00088 and HD00089 was significantly reduced in both groups { ie , from # ml/h to # ml/h in the group that received # mg of ddrug2 per day and from # ml/h to # ml/h in the group that received # mg of ddrug3 per day } .",
        "label": "NA"
    },
    {
        "text": "administration of repeat doses of DB01155 had no effect on the repeat dose pharmacokinetics of ddrug1 , ddrug2 or an DB00977 / levonorgestrol oral ddrug4 in healthy subjects .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in vitro data indicate that ddrug1 and DB00503 markedly inhibit the metabolism of DB00604 which can result in an increase in plasma ddrug4 levels and prolongation of the qt interval on the ecg .",
        "label": "mechanism"
    },
    {
        "text": "other interactions : ddrug0 had no effect on the pharmacodynamics of DB01016 { glucose and irdn concentrations } and DB00682 { prothrombin time or other pharmacodynamic parameters } .",
        "label": "NA"
    },
    {
        "text": "DB00294 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , DB00776 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "int"
    },
    {
        "text": "during clinical trials , DB01088 was used concurrently with ddrug1 , ddrug2 , ddrug3 , HD00377 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and other medications .",
        "label": "NA"
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of HD00472 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 { 1 } , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 { 1 } , ddrug10 , ddrug11 , grapefruit juice , ddrug12 , ddrug13 , DB01026 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21 , ddrug22 , ddrug23 , ddrug24 { 1 } , ddrug25 , ddrug26 .",
        "label": "mechanism"
    },
    {
        "text": "- drugs whose efficacy is impaired by ddrug0 include : ddrug1 , HD00175 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , oral ddrug8 , ddrug9 , DB00908 , ddrug11 , ddrug12 .",
        "label": "NA"
    },
    {
        "text": "DB13984 or ddrug1 increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered HD00439 , such as ddrug3 .",
        "label": "effect"
    },
    {
        "text": "while all the selective HD00311 { ddrug1 } , e , g , , ddrug2 , DB01104 , and ddrug4 , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , DB01167 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , DB00295 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , HD00002 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { DB00091 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 DB00533 did not have any clinically important effect on the pharmacokinetics of ddrug2 and DB00717 .",
        "label": "NA"
    },
    {
        "text": "at a median follow-up of # months , the combination of DB01217 and DB00675 did not demonstrate any efficacy benefit when compared with ddrug2 in all patients as well as in the hormone receptor-positive subpopulation .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of HD00071 : ddrug1 , ddrug2 , HD00218 , ddrug4 { e , g , , ddrug5 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "after multiple dosing , DB00060 { DB02325 # mcg i m once weekly } reduced ddrug2 clearance by approximately 30 % .",
        "label": "NA"
    },
    {
        "text": "drugs that may alter ddrug0 plasma concentrations drugs that may increase ddrug1 plasma concentrations : caution is recommended when administering DB00619 with inhibitors of the cyp3a4 family { e , g , , DB01026 , ddrug4 , ddrug5 , ddrug6 } .",
        "label": "advise"
    },
    {
        "text": "the effects DB00482 on the pharmacokinetics and/or pharmacodynamics of DB01016 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , and ddrug6 have been studied in vivo and clinically important interactions have not been found .",
        "label": "NA"
    },
    {
        "text": "DB00357 diminishes the effect of DB04665 and ddrug2 .",
        "label": "effect"
    },
    {
        "text": "no significant difference was found between the mean values of the volume of distribution of DB01147 with and without DB01032 { # and # liters , respectively } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : DB00316 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and DB00126 .",
        "label": "NA"
    },
    {
        "text": "DB00924 may enhance the effects of ddrug1 , HD00026 , and other ddrug3 .",
        "label": "effect"
    },
    {
        "text": "repeated oral administration of DB11390 in sheep : interactions of ddrug1 with ddrug2 , ddrug3 , and DB01174 .",
        "label": "NA"
    },
    {
        "text": "DB00995 should not be used together with ddrug1 { DB00859 , ddrug3 } , another arthritis medication .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : the concomitant administration of HD00374 has no apparent effect on the extent of absorption of DB00749 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 HD00897 # , 25 , and # mg administered once daily for # days increased plasma ddrug2 concentrations { auc { 0 - } } by # to 60 % in healthy subjects administered a single 300-mg dose of DB00277 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the reports that the concomitant use of ddrug1 and HD00029 may contribute to the enhancement of DB00437 toxicity in some patients have been reviewed in an attempt to establish a cause-and-effect relationship and a mechanism of causation .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { DB01026 } ddrug15 ddrug16 HD00542 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and DB00759 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and DB00126 .",
        "label": "NA"
    },
    {
        "text": "synergism was observed when HD00006 was combined with DB01327 against bacillus subtilis and klebsiella oxytoca .",
        "label": "effect"
    },
    {
        "text": "DB00294 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , DB00949 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "int"
    },
    {
        "text": "a potential interaction between oral DB01110 and oral HD00062 leading to severe hypoglycemia has been reported .",
        "label": "int"
    },
    {
        "text": "in general , these are drugs that have one or more pharmacologic activities similar to ddrug0 , including HD00407 such as ddrug2 and ddrug3 , ddrug4 and HD00408 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration { n = 18 } of DB00788 capsules { 250 mg } with DB00996 { 125 mg } appears to increase the amount of ddrug3 absorbed by 12 % to 15 % .",
        "label": "mechanism"
    },
    {
        "text": "co-administration of DB00682 and ddrug1 did not alter the pharmacokinetics of HD00503 .",
        "label": "NA"
    },
    {
        "text": "in addition to bleeding associated with DB01109 and ddrug1 , drugs that alter platelet function { such as ddrug2 , ddrug3 and DB00054 } may increase the risk of bleeding if administered prior to , during , or after ddrug5 therapy .",
        "label": "NA"
    },
    {
        "text": "concurrent administration of DB00501 and ddrug1 can produce clinically significant increases in the plasma levels of the HD00043 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 , DB00627 { DB00627 , ddrug4 , ddrug5 : skeletal muscle .",
        "label": "NA"
    },
    {
        "text": "drug-drug interactions between ddrug0 and other ddrug1 { HD00714 } ddrug3 ddrug4 { 3000 mg daily } had no effect on the pharmacokinetic disposition of DB00252 in patients with refractory epilepsy .",
        "label": "NA"
    },
    {
        "text": "the pharmacokinetics of DB00220 are not altered to a clinically significant degree when it is administered with a light meal # hour after DB00900 .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 : ddrug1 , when given once daily for # days as a 100-mg capsule with an oral HD00349 containing # mcg of ddrug3 and # mg of ddrug4 , decreased the auc of DB00977 by 43 % , and decreased the auc of ddrug6 by 8 % ;",
        "label": "NA"
    },
    {
        "text": "HD00703 : potential interactions between ddrug1 and other HD00714 were assessed in clinical studies .",
        "label": "NA"
    },
    {
        "text": "results of studies in multiple sclerosis patients taking DB00108 and concomitant ddrug1 { ddrug2 # mcg i m once weekly } or ddrug3 were inconclusive with regard to the need for dose adjustment of the HD00868 or ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 : ddrug2 , when given as a regimen of 125 mg with ddrug3 coadministered orally as # mg on day 1 , and DB00673 when given as # mg/day with DB01234 coadministered orally as # mg on days # through 5 , increased the auc of ddrug6 , a cyp3a4 substrate by # - fold , on days # and 5 .",
        "label": "mechanism"
    },
    {
        "text": "if a patient requires DB00700 and ddrug1 therapy , it is suggested that ddrug2 , ddrug3 , or DB00196 { ddrug5 and ddrug6 } be used as alternatives to ddrug7 , as these agents have no effect on the pharmacokinetic profile of ddrug8 .",
        "label": "mechanism"
    },
    {
        "text": "administration of DB01219 may potentiate DB01339 - induced neuromuscular block .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : DB00316 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , DB00949 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "the effects of supplementary oral ddrug0 and ddrug1 , as well as the interaction between both at the absorption site , fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either # or # micrograms/kg of DB11588 and # or # mg/kg of DB01592 over a period of # days in a total of # rats .",
        "label": "NA"
    },
    {
        "text": "agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of HD00472 are the following : ddrug1 , HD00473 , ddrug3 , ddrug4 , ddrug5 , ddrug6 { 2 } , ddrug7 , ddrug8 , and ddrug9 thus , if a patient has been titrated to a stable dosage on ddrug10 , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for ddrug11 may be necessary .",
        "label": "mechanism"
    },
    {
        "text": "however , the antagonism of the ddrug0 - induced anxiogenic effects by ddrug1 was only observed in the time spent in the light zone , and ddrug2 - induced anxiogenic effects were neither reversed by HD00184 nor by HD00186 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 other HD00550 DB00627 { ddrug3 } { = 1 g/day }",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a study of # healthy male volunteers , ddrug1 treatment potentiated the blood glucose lowering effect of DB01016 { a HD00226 similar to ddrug4 } in # of the # subjects .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : available data suggest that there is no significant effect of ddrug1 on the clearance of DB00949 at steady state , therefore , the addition of DB00313 is not expected to cause a clinically important effect on ddrug4 { ddrug5 } plasma concentrations .",
        "label": "NA"
    },
    {
        "text": "therefore , use of DB00709 in combination with DB00943 is not recommended",
        "label": "advise"
    },
    {
        "text": "organic ddrug0 - DB00125 supplements theoretically may potentiate the effects of organic DB14049 if taken concomitantly .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : concomitant administration of DB00906 did not affect the steady-state pharmacokinetics of ddrug2 or the mean daily trough serum level of DB00390 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 should be used with care when ddrug1 or inhibitors of av conduction , such as certain ddrug2 { particularly of the ddrug3 -lsb- ddrug4 -rsb- and HD00427 -lsb- DB00343 -rsb- classes } , or ddrug7 , such as ddrug8 , are used concurrently .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - combined administration of racemic ddrug1 { 40 mg } and DB01026 { 200 mg } decreased the cmax and auc of ddrug3 by 21 % and 10 % , respectively , and did not significantly affect the pharmacokinetics of DB00215 .",
        "label": "NA"
    },
    {
        "text": "animal experience indicates that ddrug0 prolongs the sleeping time after DB01355 or after DB00898 , increases the inhibitory effects of ddrug3 , but does not exhibit maoa inhibition .",
        "label": "NA"
    },
    {
        "text": "DB01118 taken concomitantly with ddrug1 increases DB00908 serum concentration by 33 % after two days .",
        "label": "NA"
    },
    {
        "text": "- drugs whose efficacy is impaired by DB00252 include : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , DB00695 , oral ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : in a study in healthy volunteers , no clinically relevant pharmacokinetic or pharmacodynamic interaction between DB00270 and racemic ddrug2 was seen when two single oral doses of DB00682 { # mg/kg body weight } were administered during # days of multipledose treatment with # mg b , i , d , ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , ddrug8 { HD00398 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , DB01035 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "we report the case of an adolescent with altered consciousness caused by ddrug0 overdose with a positive HD00042 level to alert clinicians to the cross-reactivity of DB00564 with a toxicology screen for ddrug3 .",
        "label": "NA"
    },
    {
        "text": "although ddrug0 may increase the bioavailability of DB01235 by increasing gastric emptying , DB01233 may also adversely affect disease control by its dopamine receptor antagonistic properties .",
        "label": "NA"
    },
    {
        "text": "there have been reports of interactions of DB00199 with ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , DB00227 , ddrug10 , ddrug11 , ddrug12 , and ddrug13 .",
        "label": "int"
    },
    {
        "text": "ddrug0 significantly decreased the auc { ss } of DB00701 by 82 % , but ddrug2 had no effect on DB01045 pharmacokinetics .",
        "label": "NA"
    },
    {
        "text": "in clinical studies performed with DB00569 , the concomitant use of oral ddrug1 { ddrug2 } , ddrug3 { ddrug4 } , ddrug5 { DB00554 } , and ddrug7 did not significantly affect the pharmacokinetics/pharmacodynamics of ddrug8 .",
        "label": "NA"
    },
    {
        "text": "when concomitant treatment with ddrug0 and DB00575 is to be terminated , the HD00483 should be discontinued first .",
        "label": "NA"
    },
    {
        "text": "dosage adjustment of DB00289 may be necessary when coadministered with cyp2d6 inhibitors , e , g , , DB00715 , ddrug2 , and ddrug3 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : HD00401 may delay intestinal absorption of DB00252 ;",
        "label": "mechanism"
    },
    {
        "text": "because of the pronounced intersubject variability in the extent of the DB00877 - DB00343 interaction , whole blood ddrug2 concentrations should be monitored closely in patients treated with the two drugs .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : combination ddrug1 may decrease the clearance of some ddrug2 { ddrug3 , ddrug4 , DB00829 } and increase the clearance of others { DB00186 , ddrug7 , ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "patients receiving other ddrug0 , ddrug1 , HD00557 , or other ddrug3 { including ddrug4 } concomitantly with DB00956 and ddrug6 tablets may exhibit an additive cns depression .",
        "label": "effect"
    },
    {
        "text": "HD00020 { ddrug1 } and HD00021 : comparison of antiaddictive efficacy , toxicity , and mechanisms of action .",
        "label": "NA"
    },
    {
        "text": "potential drug interactions between DB01202 and other ddrug1 { ddrug2 , ddrug3 , DB00555 , ddrug5 , ddrug6 , ddrug7 and ddrug8 } were also assessed by evaluating the serum concentrations of ddrug9 and these ddrug10 during placebo-controlled clinical studies .",
        "label": "NA"
    },
    {
        "text": "DB01432 HD00524 may delay or reduce the absorption of concomitant oral medication such as ddrug2 , ddrug3 , ddrug4 { acidic } or ddrug5 { basic } , as well as ddrug6 ddrug7 , ddrug8 , thyroid and ddrug9 preparations , ddrug10 and ddrug11 , and ddrug12 .",
        "label": "NA"
    },
    {
        "text": "certain drugs , including ddrug0 { HD00203 } , ddrug2 , ddrug3 , and ddrug4 may potentiate the hypoglycemic action of DB00731 and other oral ddrug6 .",
        "label": "effect"
    },
    {
        "text": "therefore , coadministration of ddrug0 with drugs that strongly induce cyp3a4 activity { e , g , , ddrug1 , DB00564 , ddrug3 } may result in reduced plasma concentrations of DB00673 that may result in decreased efficacy of ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { e , g , ddrug1 and ddrug2 } : agents of the HD00625 , of which ddrug4 { ddrug5 } injection , usp is a member , have been shown to interact with HD00002 of the ddrug7 , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .",
        "label": "NA"
    },
    {
        "text": "this drug may interact with DB02325 or other ddrug1 { may potentiate the cns depressant effects of either these medications or ddrug2 } , ddrug3 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug4 } , and ddrug5 { concurrent use with HD00388 may prolong and intensify the anticholinergic and cns depressant effects of ddrug7 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , DB01167 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , DB01232 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "the following agents may increase certain actions or side effects of ddrug0 , DB00915 ddrug2 of class { e , g , ddrug3 } , ddrug4 ddrug5 { e , g , ddrug6 } , HD00100 .",
        "label": "NA"
    },
    {
        "text": "DB14507 generally should not be given with HD00218 because they reduce its renal clearance and add a high risk of lithium toxicity .",
        "label": "advise"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other HD00216 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } DB01026 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "in patients receiving ddrug0 { DB01033 } or ddrug2 { ddrug3 } , the concomitant administration of 300 - 600 mg of ddrug4 per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of DB01033 or ddrug6 .",
        "label": "NA"
    },
    {
        "text": "therefore , a slower onset can be anticipated if DB00611 is administered concomitantly with , or immediately following , a HD00462 .",
        "label": "effect"
    },
    {
        "text": "although studies designed to examine drug interactions have not been done , it was noted that ddrug0 or DB01285 treatment of relapses for periods of up to # days has been administered to patients { n = 180 } receiving DB00068 .",
        "label": "NA"
    },
    {
        "text": "the co-administration of ddrug0 with iv HD00337 such as ddrug2 , ddrug3 , ddrug4 , or iv ddrug5 has not been evaluated { these drugs were not co-administered with DB04899 in clinical trials } .",
        "label": "NA"
    },
    {
        "text": "DB00392 may interact with DB02325 or other ddrug2 , causing increased sedative effects .",
        "label": "effect"
    },
    {
        "text": "activity of HD00063 alone and in combination with ddrug1 and DB01017 against cryptosporidium parvum in cell culture .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and DB00281 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , HD00029 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { ddrug1 s } , ddrug2 , ddrug3 { HD00026 may decrease the effects of these medicines } , ddrug5 { using these medicines with ddrug6 may result in increased cns depressant effects } , ddrug7 , ddrug8 { using these medicines with ddrug9 may change the amount of either medicine that you need to take } , and oral ddrug10 containing HD00220 { ddrug12 may decrease the effectiveness of these oral ddrug13 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "appropriate laboratory testing should be considered prior to initiating combination therapy with DB00701 and DB00503 and at periodic intervals or if any clinical signs or symptoms of hyperlipidemia or elevated liver function tests occur during therapy .",
        "label": "advise"
    },
    {
        "text": "in a comparison of ddrug0 tolerance in dogs anesthetized with DB01221 , ddrug2 , or DB00312 , the dosage of ddrug4 needed to cause ventricular tachycardia was significantly higher , as was the ld50 of ddrug5 , with ddrug6 or ddrug7 than with ddrug8 .",
        "label": "NA"
    },
    {
        "text": "co-administration of DB01076 resulted in about a 50 % increase in DB09026 cmax and auc after multiple dosing .",
        "label": "mechanism"
    },
    {
        "text": "the following medications have been administered in clinical trials with DB00074 with no increase in adverse reactions : atg/alg , ddrug1 , HD00175 , ddrug3 , ddrug4 , and ddrug5 .",
        "label": "NA"
    },
    {
        "text": "however , in a well-controlled study of patients with lymphoma on combination therapy , ddrug0 did not increase the marrow toxicity of patients treated with ddrug1 , ddrug2 , ddrug3 , DB01168 and/or DB00888 .",
        "label": "NA"
    },
    {
        "text": "two of # subjects dosed simultaneously with DB00862 # mg and DB00706 # mg experienced a standing systolic blood pressure below # mm hg .",
        "label": "effect"
    },
    {
        "text": "DB00943 inhibited DB00709 phosphorylation at high concentration ratios { 10 and 100 } ;",
        "label": "effect"
    },
    {
        "text": "HD00377 , ddrug1 : e , g , , ddrug2 , DB01115 , ddrug4",
        "label": "NA"
    },
    {
        "text": "in clinical studies , coadministration of DB00930 with ddrug1 , DB00227 , or ddrug3 did not interfere with the lipid-lowering activity of the ddrug4 .",
        "label": "NA"
    },
    {
        "text": "the effects of HD00018 and HD00019 upon ddrug2 { ddrug3 } - induced locomotion and behavioral changes in mice .",
        "label": "NA"
    },
    {
        "text": "caution should be used when administering or taking DB00530 with ddrug1 and other strong cyp3a4 inhibitors such as , but not limited to , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , DB01232 , ddrug10 , ddrug11 { ddrug12 } , and ddrug13 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 , ddrug1 , ddrug2 , DB01182 , ddrug4 , ddrug5 , ddrug6 , and ddrug7 raise the serum DB00390 concentration due to a reduction in clearance and/or in volume of distribution of the drug , with the implication that ddrug9 intoxication may result .",
        "label": "mechanism"
    },
    {
        "text": "HD00095 : DB00227 , ddrug2",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 - pectin , ddrug2 , ddrug3 , ddrug4 , certain anticancer drugs , and DB01233 may interfere with intestinal DB00390 absorption , resulting in unexpectedly low serum concentrations .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 and ddrug1 { and possibly other ddrug2 } and DB00759 may increase DB00390 absorption in patients who inactivate ddrug5 by bacterial metabolism in the lower intestine , so that ddrug6 intoxication may result .",
        "label": "mechanism"
    },
    {
        "text": "DB00701 significantly decreases clearance of DB00615 and ddrug2 , and the combination is poorly tolerated .",
        "label": "mechanism"
    },
    {
        "text": "DB00107 or other HD00628 { concurrent use with ddrug2 may result in uterine hypertonus , possibly causing uterine rupture or cervical laceration , especially in the absence of adequate cervical dilatation ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 levels may be decreased ; increased dosages may be required to prevent symptoms of ddrug1 withdrawal , ddrug2 maintained patients beginning DB00238 therapy should be monitored forevidence of withdrawal and DB00333 dose should be adjusted accordingly .",
        "label": "NA"
    },
    {
        "text": "if a HD00295 is also used , it may increase the risk of DB14507 toxicity .",
        "label": "effect"
    },
    {
        "text": "of the # patients who had HD00638 added to their concomitant medications in the diamond trials , the patients on DB00204 had a non-significantly reduced relative risk for death of # { 95 % ci # , # } .",
        "label": "NA"
    },
    {
        "text": "drug interactions : the central ddrug0 syndrome can occur when anticholinergic agents such as DB00810 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain ddrug2 such as ddrug3 , the HD00219 and other ddrug5 , ddrug6 , certain ddrug7 such as the ddrug8 salts , and ddrug9 .",
        "label": "effect"
    },
    {
        "text": "in diabetic patients , the metabolic effects of HD00657 may decrease blood glucose and therefore , HD00071 requirements .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : the concomitant use of ddrug1 { DB00813 transdermal system } with other ddrug3 , including but not limited to other ddrug4 , ddrug5 , ddrug6 , ddrug7 { e , g , , ddrug8 } , general ddrug9 , HD00219 , ddrug11 , and ddrug12 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .",
        "label": "effect"
    },
    {
        "text": "ddrug0 - and/or DB01370 - containing ddrug2 , products containing ddrug3 { DB01592 } , ddrug5 containing ddrug6 or other metal cations , or ddrug7 { ddrug8 } chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after ddrug9 .",
        "label": "NA"
    },
    {
        "text": "in addition , studies in healthy volunteers have shown that DB00204 does not affect the pharmacokinetics or pharmacodynamics of DB00682 , or the pharmacokinetics of ddrug2 { 40 mg twice daily } , ddrug3 , ddrug4 , or oral ddrug5 .",
        "label": "NA"
    },
    {
        "text": "when combined with DB01165 , ddrug1 exhibited strong synergistic activity while only additive effects were observed with the combination of ddrug2 { or DB00615 } and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "when other ddrug0 or HD00326 are used concomitantly , there is the potential for DB01240 to increase the risk of bleeding .",
        "label": "effect"
    },
    {
        "text": "substrates , in vitro data suggest similar effects of DB00365 in cyp3a4 mediated metabolism and DB00277 metabolism .",
        "label": "NA"
    },
    {
        "text": "the effectiveness of ddrug0 - only pills is reduced by hepatic enzyme-inducing drugs such as the HD00282 DB00252 , ddrug3 , and ddrug4 , and the ddrug5 ddrug6 .",
        "label": "NA"
    },
    {
        "text": "caution should be used when administering or taking DB00530 with ddrug1 and other strong cyp3a4 inhibitors such as , but not limited to , ddrug2 , ddrug3 , ddrug4 , DB01167 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { ddrug12 } , and ddrug13 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 ddrug1 ddrug2 DB01211 ddrug4 HD00324 ddrug6 ddrug7 large quantities of grapefruit juice { # quart daily }",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other HD00216 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } DB01235 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "caution is advised when DB01169 is coadministered with other medications that can prolong the qt interval { e , g , certain ddrug1 or ddrug2 } or lead to electrolyte abnormalities { such as HD00218 or ddrug4 } .",
        "label": "advise"
    },
    {
        "text": "the possibility of hypotensive effects with ddrug0 can be minimized by either discontinuing the HD00295 or increasing the salt intake approximately one week prior to initiation of treatment with ddrug2 { DB01197 tablets , usp } or initiating therapy with small doses { # or # mg } .",
        "label": "NA"
    },
    {
        "text": "for this reason , the dose of the HD00025 should be reduced by # - 50 % at the start of treatment with ddrug1 or HD00414 retard and then titrated according to the blood clotting parameters",
        "label": "advise"
    },
    {
        "text": "- oral HD00283 { birth control pills } containing HD00183 or",
        "label": "NA"
    },
    {
        "text": "in clinical trials , ddrug0 was used with ddrug1 , ddrug2 , ddrug3 , oral ddrug4 , and supplemental ddrug5 , in a pharmacokinetic substudy in patients with congestive heart failure receiving ddrug6 or ddrug7 in whom therapy with DB01240 was initiated , apparent oral clearance values for ddrug9 { n = 23 } and DB00390 { n = 30 } were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the rate and extent of absorption of ddrug1 was bioequivalent when ddrug2 was given alone or when DB00537 was given # hours after DB00338 at the dose that maximally suppresses gastric acid secretion .",
        "label": "NA"
    },
    {
        "text": "however , no deleterious interactions were seen when DB01205 was administered after HD00543 , inhalational ddrug2 , ddrug3 and muscle relaxant antagonists administered in conjunction with sedation or anesthesia .",
        "label": "NA"
    },
    {
        "text": "although specific drug interaction studies have not been conducted with DB00484 , the possibility of an additive or potentiating effect with ddrug1 { ddrug2 , ddrug3 , ddrug4 , ddrug5 , or HD00264 } should be considered .",
        "label": "advise"
    },
    {
        "text": "ddrug0 / ddrug1 - containing ddrug2 : absorption of DB00943 is moderately reduced { approximately 25 % } when coadministered with ddrug4 / DB01370 - containing ddrug6 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { 20 mg qd } increased the concentration of DB00476 { 40 mg qd } by about 60 % , and greater degrees of inhibition are expected with higher doses of DB00715 .",
        "label": "NA"
    },
    {
        "text": "DB01032 depresses tubular secretion of certain weak acids such as DB00345 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : clinical studies , as well as post-marketing observations , have shown that HD00203 can reduce the natriuretic effect of ddrug2 and HD00217 in some patients .",
        "label": "effect"
    },
    {
        "text": "drug interactions : DB00875 may interact with some drugs , like HD00275 { ddrug2 } : ddrug3 could theoretically affect ddrug4 pharmacodynamics - ddrug5 - jzqyavbxjcqsok_uhfffaoysa_n - ddrug6 : ddrug7 and ddrug8 cause additive cns depression - ddrug9 : ddrug10 increases the effect of ddrug11",
        "label": "int"
    },
    {
        "text": "however , other published reports describe modest elevations { less than two-fold } of ddrug0 and metabolite concentrations when DB00363 was taken with ddrug2 , ddrug3 , and DB01104 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 - and/or ddrug1 - containing HD00374 , products containing ddrug3 { ddrug4 } , ddrug5 containing ddrug6 or other metal cations , or DB00900 { ddrug8 } chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after ddrug9 .",
        "label": "NA"
    },
    {
        "text": "although no interaction between HD00343 and DB00854 has been observed , it is not recommended for use with ddrug2 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 / ddrug1 : pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between ddrug2 and concomitantly administered ddrug3 { # mg orally given # and # hours prior to initiation of DB00278 # g/kg/min , over # hours } or DB00316 { 1000 mg orally given 12 , # and # hours prior to , and # and # hours subsequent to , initiation of ddrug6 # g/kg/min , over # hours } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 , when given as # mg on day # and # mg/day on days # and 3 , decreased the auc of DB01124 { a cyp2c9 substrate } by 23 % on day 4 , 28 % on day 8 , and 15 % on day 15 , when a single dose of ddrug3 # mg was admini , stered orally prior to the administration of the 3-day regimen of DB00673 and on days 4,8 , and 15 .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { DB00564 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } DB01026 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "DB00924 may enhance the effects of ddrug1 , ddrug2 , and other HD00261 .",
        "label": "effect"
    },
    {
        "text": "it may be necessary to adjust the dosage of oral HD00326 upon beginning or stopping ddrug1 , since DB00822 may prolong prothrombin time .",
        "label": "NA"
    },
    {
        "text": "DB00695 : clinical studies , as well as post marketing observations , have shown that HD00203 can reduce the natriuretic effect of ddrug2 and ddrug3 in some patients .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of ddrug0 and DB00316 in dogs , but not in rats , at approximately # times the recommended maximum human therapeutic dose of each { 40 to # mg/kg/day of DB00861 / ddrug3 } resulted in greater gastrointestinal toxicity than when either drug was administered alone .",
        "label": "NA"
    },
    {
        "text": "other ddrug0 that inhibit prostaglandin synthesis have been shown to interfere with HD00029 in some studies and with HD00293 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 concentrations in bile and cystic fluid were increased { about 2-fold } in hydatid cyst patients treated with DB00501 { 10 mg/kg/day } { n = 7 } compared with DB00518 { 20 mg/kg/day } alone { n = 12 } .",
        "label": "NA"
    },
    {
        "text": "the mean { sd } cumulative urinary excretion of immunoreactive DB00390 after concurrent treatment with DB00533 or placebo was # { + / - # } and # { + / - # } micrograms/120 hours , respectively .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 DB00264 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { DB00472 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "DB00753 or DB00228 administered with ddrug2 / ddrug3 to achieve # mac -lsb- minimum alveolar concentration -rsb- may prolong the clinically effective duration of action of initial and maintenance doses of ddrug4 and decrease the required infusion rate of ddrug5 .",
        "label": "NA"
    },
    {
        "text": "since DB01005 may raise the serum uric_acid level , dosage adjustment of HD00789 may be necessary",
        "label": "effect"
    },
    {
        "text": "the increase of DB01174 level , however , is small { 15 % } when given with DB00776 .",
        "label": "mechanism"
    },
    {
        "text": "caution is advised when ddrug0 is coadministered with other medications that can prolong the qt interval { e , g , certain ddrug1 or DB00679 } or lead to electrolyte abnormalities { such as ddrug3 or DB00681 } .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of ddrug0 capsules and DB01241 resulted in substantial increases in plasma concentrations of DB00307 , probably at least partially related to cyp3a4 inhibition by ddrug3 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , HD00002 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , DB01026 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { DB00472 } sporal { DB01167 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "the interaction of intramuscularly injected DB01221 and its n-demethylated metabolite { metabolite i } with DB01159 was evaluated in rats .",
        "label": "NA"
    },
    {
        "text": "it is , however , possible that concomitant use of other known HD00299 such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , HD00297 and ddrug6 might increase the photosensitivity reaction of actinic_keratosis treated with the ddrug7 for topical solution .",
        "label": "NA"
    },
    {
        "text": "concomitant treatment with ddrug0 { eg , rt-pa or DB00086 } may : - increase the risk of bleeding complications - considerably enhance the effect of DB00001 on aptt prolongation",
        "label": "NA"
    },
    {
        "text": "DB00364 administered # hours before DB00978 resulted in a slower absorption { mean c max decreased by 30 % and mean t max increased by # hour } and a lesser extent of absorption { mean auc decreased by approximately 25 % } .",
        "label": "mechanism"
    },
    {
        "text": "in a study with concomitant administration of ddrug0 and DB00492 , the bioavailability of unbound DB14207 was not altered .",
        "label": "NA"
    },
    {
        "text": "drug interactions : ddrug0 may interact with some drugs , like ddrug1 { ddrug2 } : ddrug3 could theoretically affect ddrug4 pharmacodynamics - ddrug5 - jzqyavbxjcqsok_uhfffaoysa_n - ddrug6 : DB00875 and ddrug8 cause additive cns depression - HD00043 : ddrug10 increases the effect of ddrug11",
        "label": "NA"
    },
    {
        "text": "concomitant use of ddrug0 and drugs that inhibit cyp3a4 { eg , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , DB00220 , ddrug10 , ddrug11 } may increase exposure to DB01254 and should be avoided .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB01076 had no clinically significant effect on prothrombin time when administered to patients receiving chronic DB00682 treatment .",
        "label": "NA"
    },
    {
        "text": "however , there are limited in vivo data suggesting a modest cyp2d6 inhibitory effect for DB01175 , i , e , , coadministration of ddrug1 { 20 mg/day for # days } with the ddrug2 DB01151 { single dose of # mg } , a substrate for cyp2d6 , resulted in a 40 % increase in cmax and a 100 % increase in auc of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "HD00113 { ddrug1 } : ddrug2 { e , g , , ddrug3 , ddrug4 , DB00715 , ddrug6 } have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with ddrug7 .",
        "label": "NA"
    },
    {
        "text": "when combined with ddrug0 , ddrug1 exhibited strong synergistic activity while only additive effects were observed with the combination of DB01045 { or ddrug3 } and DB01165 .",
        "label": "effect"
    },
    {
        "text": "treatment with DB00008 once weekly for # weeks in healthy subjects was associated with an inhibition of cyp2b6 1a2 and a 25 % increase in DB00277 auc .",
        "label": "mechanism"
    },
    {
        "text": "HD00084 , ddrug1 , ddrug2 { ddrug3 , ddrug4 , HD00270 : skeletal muscle .",
        "label": "NA"
    },
    {
        "text": "moreover , additional interaction studies with ddrug0 and DB00571 have not demonstrated any effect on ddrug2 plasma levels , and administration to a patient population chronically receiving DB00390 resulted in no difference in the extent of bioavailability of ddrug4 relative to control data .",
        "label": "NA"
    },
    {
        "text": "cns-active drugs DB00898 an additive effect on psychomotor performance was seen with coadministration of DB00402 and ddrug2 # g/kg for up to # hours after ddrug3 administration .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , or other products containing DB01592 or ddrug2 , ddrug3 or ddrug4 should not be administered concomitantly with , or within # hours of , the administration of DB01059 , because they may interfere with absorption resulting in lower serum and urine levels of ddrug6 .",
        "label": "advise"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 DB00264 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 HD00542 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "increased toxicity { cns depression } : ddrug0 , HD00343 , ddrug2 , HD00219 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration of ddrug1 with ddrug2 resulted in a 152 % increase in DB00220 plasma auc and very little change in DB00503 plasma a , c.",
        "label": "NA"
    },
    {
        "text": "molecular basis for the selective toxicity of DB00681 for yeast and HD00121 for animal cells .",
        "label": "NA"
    },
    {
        "text": "patients taking low-dose DB00945 plus DB01050 were not studied .",
        "label": "NA"
    },
    {
        "text": "although HD00115 have been shown to reduce ddrug1 - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with ddrug2 may reduce the antitumor effectiveness of ddrug3 and thus should be avoided , # ddrug4 and other ddrug5 may potentiate the hypotension seen with DB00041 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 altered coagulation parameters and/or bleeding have been reported in patients taking DB01101 concomitantly with ddrug2 such as DB00682 and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "pharmacologic studies indicate that there may be additive effects in prolonging av conduction when using HD00254 or HD00118 concomitantly with ddrug2 .",
        "label": "NA"
    },
    {
        "text": "potential drug interactions between DB01202 and other ddrug1 { ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , DB00794 and ddrug8 } were also assessed by evaluating the serum concentrations of ddrug9 and these ddrug10 during placebo-controlled clinical studies .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : hallucinations have been reported when DB00465 was used in patients taking ddrug2 { ddrug3 , ddrug4 , DB00404 } .",
        "label": "effect"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { ddrug1 s } , ddrug2 , DB01285 { ddrug4 may decrease the effects of these medicines } , ddrug5 { using these medicines with ddrug6 may result in increased cns depressant effects } , ddrug7 , ddrug8 { using these medicines with HD00026 may change the amount of either medicine that you need to take } , and oral ddrug10 containing ddrug11 { ddrug12 may decrease the effectiveness of these oral ddrug13 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "drugs demonstrated to be cyp 3a inhibitors of possible clinical significance on the basis of clinical studies involving ddrug0 { caution is recommended during coadministration with DB00404 } : coadministration of DB00472 with ddrug3 increased the maximum plasma concentration of ddrug4 by 46 % , decreased clearance by 21 % , increased half-life by 17 % , and decreased measured psychomotor performance .",
        "label": "NA"
    },
    {
        "text": "post-marketing reports of changes in prothrombin measures have been received among patients on concomitant DB00682 and DB00736 therapy .",
        "label": "NA"
    },
    {
        "text": "potential drug interactions between ddrug0 and other ddrug1 { ddrug2 , DB00996 , ddrug4 , ddrug5 , ddrug6 , ddrug7 and ddrug8 } were also assessed by evaluating the serum concentrations of ddrug9 and these HD00714 during placebo-controlled clinical studies .",
        "label": "NA"
    },
    {
        "text": "dose reduction of DB00615 to half the standard dose and a dose increase of DB00224 to # mg { three 333-mg capsules } every # hours are recommended when ddrug2 and ddrug3 are coadministered .",
        "label": "NA"
    },
    {
        "text": "in separate studies of patients receiving maintenance doses of ddrug0 , ddrug1 , or DB00390 , ddrug3 administration for # days had no effect on the pharmacodynamics of DB00682 { prothrombin time } or pharmacokinetics of ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 with DB01151 or DB00344 and possibly other ddrug3 cause striking and sustained increases in the concentration of ddrug4 in the brain ;",
        "label": "NA"
    },
    {
        "text": "therefore , co-administration of ddrug0 with other drugs that are metabolized by this isozyme , including ddrug1 , HD00219 , ddrug3 , and ddrug4 { e , g , , ddrug5 , ddrug6 and ddrug7 } , or that inhibit this enzyme { e , g , , DB00908 } , should be approached with caution .",
        "label": "NA"
    },
    {
        "text": "by the nonlinear kinetic characteristics for DB00661 and DB00343 { and probably for ddrug2 , as well } and the derivative implications for decreased dosing frequency requirements ;",
        "label": "NA"
    },
    {
        "text": "experience with HD00233 { ddrug1 } suggests the potential for interactions with ddrug2 and HD00106 .",
        "label": "int"
    },
    {
        "text": "other depressasnts such as ddrug0 , ddrug1 , and HD00546 may enhance cns depression when administered with DB00189 .",
        "label": "effect"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : DB01118 , ddrug3 HD00388 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 : concomitant treatment with ddrug3 , HD00356 , or ddrug5 may potentiate a possible hypokalemic effect of HD00742",
        "label": "effect"
    },
    {
        "text": "although a dose adjustment of ddrug0 is not recommended when administered in combination with DB00220 , close monitoring for known side effects of DB00207 , such as liver enzyme abnormalities and hearing impairment , is warranted .",
        "label": "NA"
    },
    {
        "text": "concomitant use of ddrug0 and drugs that inhibit cyp3a4 { eg , DB01026 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 } may increase exposure to DB01254 and should be avoided .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : when DB00749 is administered with ddrug2 , its protein binding is reduced , although the clearance of free DB00749 is not altered .",
        "label": "NA"
    },
    {
        "text": "ddrug0 / ddrug1 : DB00897 , DB00683 contraindicated due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression .",
        "label": "NA"
    },
    {
        "text": "although it has not been established that there is an interaction between DB00363 and ddrug1 or other ddrug2 , caution is advised when ddrug3 is initiated in patients taking a ddrug4 or any other HD00564 .",
        "label": "NA"
    },
    {
        "text": "if ddrug0 is to be combined with other ddrug1 such as HD00262 or HD00596 / ddrug4 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of ddrug5 and ddrug6 { e , g , , ddrug7 or ddrug8 } are additive .",
        "label": "NA"
    },
    {
        "text": "if ddrug0 is given concomitantly with HD00263 , the ddrug2 dose should be reduced { by approx , 50 % } , because DB01239 amplifies the therapeutic actions and side-effects of ddrug4 massively .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } HD00220 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { DB01026 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "drug interaction during pregnancy : DB01003 and DB01064 were studied following subcutaneous injections in pregnant mice .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : since ddrug1 may bind other drugs given concurrently , patients should take DB01039 at least # hour before or 4 - 6 hours after a HD00719 to avoid impeding its absorption .",
        "label": "mechanism"
    },
    {
        "text": "injection : ddrug0 injection , like other injectable ddrug1 , produces depression of the central nervous system when administered with DB00898 , ddrug3 , ddrug4 , ddrug5 , and other ddrug6 , when DB00747 is used concomitantly with injectable ddrug8 , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .",
        "label": "NA"
    },
    {
        "text": "HD00219 - taking DB00592 and a ddrug2 together may increase the risk of convulsions { seizures } .",
        "label": "NA"
    },
    {
        "text": "DB00695 : clinical studies , as well as post-marketing observations , have shown that HD00203 can reduce the natriuretic effect of ddrug2 and ddrug3 in some patients .",
        "label": "NA"
    },
    {
        "text": "coadministration of DB00442 with ddrug1 , DB00718 , or ddrug3 did not result in significant drug interactions .",
        "label": "NA"
    },
    {
        "text": "- HD00330 : in some patients , the administration of a ddrug1 can reduce the diuretic , natriuretic , and antihypertensive effects of ddrug2 , ddrug3 and HD00029 .",
        "label": "NA"
    },
    {
        "text": "therefore , if HD00296 replacement is needed , DB14539 should be prescribed .",
        "label": "NA"
    },
    {
        "text": "however , the effects of stress and HD00115 on the subjective and behavioral effects of HD00116 have not been well studied in humans .",
        "label": "NA"
    },
    {
        "text": "if a patient requires ddrug0 and ddrug1 therapy , it is suggested that ddrug2 , ddrug3 , or HD00374 { ddrug5 and ddrug6 } be used as alternatives to DB00501 , as these agents have no effect on the pharmacokinetic profile of ddrug8 .",
        "label": "NA"
    },
    {
        "text": "potential interactions between DB01229 , a substrate of cyp3a4 , and ddrug1 { ddrug2 , ddrug3 , DB00224 , and ddrug5 } , which are substrates and/or inhibitors of cyp3a4 , have not been evaluated in clinical trials .",
        "label": "NA"
    },
    {
        "text": "caution should be used if DB00788 is administered concomitantly with DB00563 .",
        "label": "advise"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , ddrug3 HD00388 : DB00637 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "HD00577 may enhance the nephrotoxicity of DB01111 parenteral .",
        "label": "effect"
    },
    {
        "text": "moreover , additional interaction studies with DB00627 and DB00571 have not demonstrated any effect on ddrug2 plasma levels , and administration to a patient population chronically receiving ddrug3 resulted in no difference in the extent of bioavailability of ddrug4 relative to control data .",
        "label": "NA"
    },
    {
        "text": "additive depressant effect when used with general ddrug0 , ddrug1 , ddrug2 , ddrug3 , DB02325 , and other HD00611 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - and/or ddrug1 - containing ddrug2 , products containing DB01373 { ddrug4 } , ddrug5 containing ddrug6 or other metal cations , or ddrug7 { ddrug8 } chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after DB01155 .",
        "label": "advise"
    },
    {
        "text": "DB00248 should not be administered concurrently with d2-antagonists , such as HD00219 , ddrug2 , ddrug3 , or ddrug4 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : multiple oral doses of DB00962 { 20 mg q24h for # days } did not affect the pharmacokinetics of ddrug2 { r + } - or { s - } - enantiomers or the pharmacodynamics { prothrombin time } following a single 25-mg oral dose of DB00682 .",
        "label": "NA"
    },
    {
        "text": "in case of ddrug0 toxicity and/or elevated serum ddrug1 levels , the dose of DB00277 should be reduced while the patient is receiving concomitant DB00199 therapy .",
        "label": "advise"
    },
    {
        "text": "ddrug0 injection and potassium-depleting agents : when HD00175 are administered concomitantly with potassium-depleting agents { e , g , , ddrug2 , HD00218 } , patients should be observed closely for development of hypokalemia .",
        "label": "advise"
    },
    {
        "text": "results from human in vitro metabolism studies and nonclinical studies show that DB00480 { ddrug1 } is neither metabolized by nor inhibits or induces the cytochrome cyp2b6 pathway suggesting that DB00480 is not likely to cause or be subject to p450-based metabolic drug interactions in man .",
        "label": "NA"
    },
    {
        "text": "immediate and extended release tablets the hypoglycemic action of ddrug0 may be potentiated by certain drugs including HD00518 , some ddrug2 and other drugs that are highly protein bound , HD00328 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "the safety of using DB00611 and ddrug1 { DB00669 } nasal spray during the same episode of migraine has not been established .",
        "label": "NA"
    },
    {
        "text": "oral HD00326 may potentiate the hypoglycemic action of ddrug1 , eg , DB01124 and ddrug3 , by inhibiting their metabolism in the liver .",
        "label": "mechanism"
    },
    {
        "text": "consequently , concomitant administration of DB00673 with strong cyp3a4 inhibitors { e , g , , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , DB00220 } should be approached with caution .",
        "label": "advise"
    },
    {
        "text": "DB00313 diminished binding of DB01174 by a net change of # % { percentage increase in fdf , # % } at # micromol/l .",
        "label": "mechanism"
    },
    {
        "text": "the majority of patients in ra clinical studies received one or more of the following concomitant medications with DB01281 : DB00563 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , and ddrug11 .",
        "label": "NA"
    },
    {
        "text": "DB00682 : ddrug1 , including DB00467 , decrease the clearance of ddrug3 , the less active isomer of racemic ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : although the results of a clinical study did not indicate a safe problem associated with the administration of DB00320 { ddrug2 } injection , usp to subjects already receiving ddrug3 , there have been reports that ddrug4 may potentiate the vasoconstrictive action of DB00201 by blocking the vasodilating property of epinephrine .",
        "label": "NA"
    },
    {
        "text": "care should be taken if DB00598 is used concomitantly with ddrug1 s of the DB00661 type .",
        "label": "NA"
    },
    {
        "text": "DB00695 : clinical studies , as well as post-marketing observations , have shown that ddrug1 can reduce the natriuretic effect of ddrug2 and HD00217 in some patients .",
        "label": "NA"
    },
    {
        "text": "no clinically significant effect of ddrug0 , DB00313 , or ddrug2 was seen on the pharmacokinetics of DB01238 { see clinical pharmacology : drug - drug interactions } .",
        "label": "NA"
    },
    {
        "text": "therefore , co-administration of DB01156 with drugs that are metabolized by cyp2d6 isoenzyme including certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , DB01104 } , ddrug8 { e , g , , ddrug9 , ddrug10 , ddrug11 } , ddrug12 { e , g , , ddrug13 } , and ddrug14 { e , g , , ddrug15 , ddrug16 } , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .",
        "label": "advise"
    },
    {
        "text": "if ddrug0 is to be combined with other ddrug1 such as ddrug2 or ddrug3 / HD00214 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of ddrug5 and ddrug6 { e , g , , DB00475 or ddrug8 } are additive .",
        "label": "NA"
    },
    {
        "text": "among DB00945 or ddrug1 users , the incidence of upper gastrointestinal adverse events in patients treated with DB00710 # mg daily { # % } was similar to that in placebo-treated patients { # % } .",
        "label": "NA"
    },
    {
        "text": "DB00455 { 10 mg once daily } has been coadministered with therapeutic doses of ddrug1 , DB00501 , and ddrug3 in controlled clinical pharmacology studies in adult volunteers .",
        "label": "NA"
    },
    {
        "text": "these in vitro studies suggest that concomitant administration of ddrug0 and ddrug1 in humans may result in sub-therapeutic concentrations of active phosphorylated ddrug2 , which may lead to a decreased HD00056 effect of DB00943 .",
        "label": "NA"
    },
    {
        "text": "other drug interactions oral ddrug0 ddrug1 { 500 mg twice daily } did not influence the pharmacokinetics of an oral HD00349 containing # mg DB00977 and # mg ddrug4 , or of the luteinizing hormone and progesterone levels , indicating that impairment of contraceptive efficacy is unlikely .",
        "label": "NA"
    },
    {
        "text": "HD00026 may decrease the effectiveness of oral ddrug1 , certain ddrug2 , DB00908 , ddrug4 , ddrug5 , ddrug6 , and ddrug7 .",
        "label": "effect"
    },
    {
        "text": "in psoriatic arthritis clinical trials , concomitant medications included DB00563 in approximately half of the patients as well as HD00518 , ddrug2 and ddrug3 .",
        "label": "NA"
    },
    {
        "text": "HD00679 : drugs such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 and others that interfere with platelet-aggregation reactions { the main hemostatic defense of heparinized patients } may induce bleeding and should be used with caution in patients receiving DB01109 .",
        "label": "NA"
    },
    {
        "text": "use lowest possible dose of ddrug0 with careful monitoring , or consider ddrug1 that are not primarily metabolized by cyp3a4 , such as ddrug2 , DB01095 , or ddrug4 in combination with DB00224 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : when a single 125-mg dose of ddrug1 was administered on day5 of a 10-day regimen of # mg/day of DB01026 , a strong cyp3a4 inhibitor , the auc of ddrug3 increased approximately 5-fold and the mean terminal half-life of DB00673 increased approximately 3-fold .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 may enhance the effects of : other ddrug3 s , DB02325 , general ddrug5 , ddrug6 such as ddrug7 , HD00460 , or other ddrug9 , causing increased cns depression .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in patients with mild to moderate hypertension , administration of ddrug1 once daily , as a tablet formulation comparable to # mg of the capsule formulation , with ddrug2 # mg # times daily for # days , resulted in a 2-fold increase of DB00673 auc and a simultaneous # - fold increase of DB00343 auc .",
        "label": "NA"
    },
    {
        "text": "numerous drug interactions are possible with some ddrug0 , such as DB01174 and DB00252 , which affect hepatic microsomal enzyme systems .",
        "label": "NA"
    },
    {
        "text": "when DB00862 dosing was separated from DB01162 # mg by # hours , # of # subjects who received # mg of ddrug2 experienced a decrease in standing systolic blood pressure below # mm hg .",
        "label": "effect"
    },
    {
        "text": "effects of ddrug0 on other antiepilepsy drugs { HD00714 } : DB00252 : ddrug3 had no effect on the steady-state plasma concentrations of ddrug4 in patients with epilepsy .",
        "label": "NA"
    },
    {
        "text": "serious toxicity may result if DB00514 is coadministered with HD00275 { ddrug2 } .",
        "label": "effect"
    },
    {
        "text": "ddrug0 { e , g , ddrug1 and ddrug2 } : agents of the ddrug3 , of which DB00320 { ddrug5 } injection , usp is a member , have been shown to interact with HD00002 of the ddrug7 , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .",
        "label": "NA"
    },
    {
        "text": "when therapeutic concentrations of DB00695 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , or ddrug5 were added to human plasma { in vitro } , the plasma protein binding of DB00622 was not altered .",
        "label": "NA"
    },
    {
        "text": "when DB00520 is co-administered with inducers of drug clearance , such as ddrug1 , DB00238 , ddrug3 , ddrug4 , or ddrug5 , use of a daily dose of # mg of ddrug6 should be considered",
        "label": "advise"
    },
    {
        "text": "before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : ddrug0 { e , g , , ddrug1 , ddrug2 } , ddrug3 , DB00091 , ddrug5 drugs { e , g , , ddrug6 } , DB00864 , ddrug8 .",
        "label": "NA"
    },
    {
        "text": "interaction of ddrug0 with other drugs : DB00501 : co-administration of ddrug2 { 800 mg/day } to patients taking ddrug3 chronically had no effect on DB00906 pharmacokinetics .",
        "label": "NA"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { ddrug1 s } , ddrug2 , ddrug3 { ddrug4 may decrease the effects of these medicines } , ddrug5 { using these medicines with ddrug6 may result in increased cns depressant effects } , ddrug7 , DB00313 { using these medicines with HD00026 may change the amount of either medicine that you need to take } , and oral ddrug10 containing ddrug11 { ddrug12 may decrease the effectiveness of these oral ddrug13 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 : HD00374 and DB01575 can reduce absorption of ddrug4 ;",
        "label": "NA"
    },
    {
        "text": "drug interactions with ddrug0 administration of # mg of ddrug1 { 2 x # mg capsule } within # minutes of an ddrug2 and ddrug3 containing DB06724 { ddrug5 } decreased DB00950 auc by 41 % and cmax by 43 % .",
        "label": "NA"
    },
    {
        "text": "- a ddrug0 { HD00725 } such as ddrug2 { ddrug3 } , ddrug4 { ddrug5 } , or DB00780 { ddrug7 } ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , DB00503 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { HD00531 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "drug/laboratory test interaction DB00492 may cause a false low measurement of serum ddrug1 levels with the digi - tab ria kit for DB00390 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 / HD00024 / ddrug2 / ddrug3 : co-administration of ddrug4 with ddrug5 , ddrug6 , HD00214 , and ddrug8 is likely to lead to an enhancement of effects .",
        "label": "NA"
    },
    {
        "text": "the use of DB00318 may result in additive cns depressant effects when coadministered with ddrug1 , ddrug2 , HD00565 or other drugs that produce cns depression .",
        "label": "effect"
    },
    {
        "text": "DB00310 may add to or potentiate the action of other HD00448 .",
        "label": "effect"
    },
    {
        "text": "patients receiving high doses of ddrug0 concomitantly with DB00695 , as in rheumatic disease , may experience HD00372 toxicity at lower doses because of competitive renal excretory sites .",
        "label": "NA"
    },
    {
        "text": "in healthy subjects , no significant drug-drug interaction was observed when DB00280 was coadministered with either ddrug1 or DB00829 .",
        "label": "NA"
    },
    {
        "text": "drugs metabolized by cytochrome p450iid6 { cyp2d6 } : many drugs , including most ddrug0 { ssris , many ddrug1 } , HD00254 , HD00303 , and ddrug4 are metabolized by the cyp2d6 isoenzyme .",
        "label": "NA"
    },
    {
        "text": "total body clearance of ddrug0 was reduced by an average 22 % and 51 % when ddrug1 and DB00688 , respectively , were added to a regimen consisting of DB00091 , usp { modified } and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "HD00343 : ddrug1 , as well as a metabolite of ddrug2 , slow DB00182 metabolism .",
        "label": "NA"
    },
    {
        "text": "physicians are provided this information to increase awareness of the potential for serious interactions when DB00827 and certain HD00518 are administered concomitantly .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : ddrug1 causes an approximate 50 % increase in the clearance of ddrug2 at steady state and , therefore , the addition of DB00564 results in an approximate 40 % decrease in the steady-state trough concentrations of DB00949 as compared to the same dose of ddrug5 given as monotherapy .",
        "label": "mechanism"
    },
    {
        "text": "another oral ddrug0 , DB01026 , inhibits the metabolism of ddrug2 , resulting in elevated plasma concentrations of DB00637 and its active metabolite ddrug4 which may prolong qt intervals .",
        "label": "NA"
    },
    {
        "text": "plasma exposure of DB00829 { 10 mg bid } was increased by 28 % following administration of ddrug1 { 40 mg bid } for # days , while plasma exposure of DB00580 { 40 mg bid } was not substantially increased following administration of ddrug3 { 10 mg bid } for # days .",
        "label": "NA"
    },
    {
        "text": "agents having vasodilator activity : data on the effect of concomitant use of other HD00337 in patients receiving DB01197 for heart failure are not available ;",
        "label": "NA"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { ddrug1 s } , ddrug2 , ddrug3 { ddrug4 may decrease the effects of these medicines } , ddrug5 { using these medicines with HD00026 may result in increased cns depressant effects } , ddrug7 , ddrug8 { using these medicines with ddrug9 may change the amount of either medicine that you need to take } , and oral HD00283 containing ddrug11 { ddrug12 may decrease the effectiveness of these oral ddrug13 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "expected changes in laboratory assessments of pt and inr were observed after DB00682 administration , but these changes were not affected by concomitant DB00480 administration .",
        "label": "NA"
    },
    {
        "text": "effect of HD00064 on the pharmacokinetics of DB00390 .",
        "label": "NA"
    },
    {
        "text": "because DB00876 is not metabolized by the cytochrome cyp2b6 system , inhibitors of cyp450 enzyme would not be expected to affect its metabolism , and DB01026 and ddrug2 , potent inhibitors of cytochrome_p450_family_3_subfamily_a and 2c9 , respectively , have been shown to have no effect on ddrug3 pharmacokinetics .",
        "label": "NA"
    },
    {
        "text": "consequently , DB01215 should be avoided in patients receiving DB01026 and ddrug2 , which are very potent inhibitors of cyp3a .",
        "label": "advise"
    },
    {
        "text": "DB00753 potentiates the muscle relaxant effect of all ddrug1 , most notably HD00816 , and mac { minimum alveolar concentration } is reduced by concomitant administration of n 2o .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , DB00564 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , DB00295 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : two hundred mg of DB00201 { equivalent to # to # cups of american coffee } was administered to # normal , healthy volunteers who had achieved steady-state blood concentrations of DB00978 after being dosed at # mg qd .",
        "label": "NA"
    },
    {
        "text": "similar events have been reported in patients taking other HD00456 or even DB00363 by itself .",
        "label": "NA"
    },
    {
        "text": "inhibitors of this isoenzyme { e , g , , HD00093 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , grapefruit juice , ddrug7 , ddrug8 , ddrug9 , ddrug10 } should be cautiously coadministered with DB00204 as they can potentially increase ddrug12 levels .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : sporadic cases of seizures have been reported during concomitant use of DB00465 and ddrug2 { ddrug3 , DB00564 } .",
        "label": "effect"
    },
    {
        "text": "- a HD00380 such as ddrug1 { DB00571 } , ddrug3 { ddrug4 } , ddrug5 { ddrug6 } , ddrug7 { ddrug8 } , and others ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 / HD00214 : DB00897 , ddrug3 contraindicated due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , DB00564 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , DB00277 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "the effectiveness of HD00237 - only pills is reduced by hepatic enzyme-inducing drugs such as the HD00282 ddrug2 , ddrug3 , and ddrug4 , and the ddrug5 ddrug6 .",
        "label": "NA"
    },
    {
        "text": "DB00564 : elevated ddrug1 levels have been reported in postmarketing experience when DB00671 is administered concomitantly .",
        "label": "NA"
    },
    {
        "text": "DB00342 , ddrug1 and ddrug2 are all metabolized by the cytochrome p450iiia4 isozyme , and it has been demonstrated that DB01026 , a potent inhibitor of iiia4 , blocks the metabolism of these drugs , resulting in increased plasma concentrations of parent drug .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 / DB01370 - containing ddrug2 : absorption of ddrug3 is moderately reduced { approximately 25 % } when coadministered with DB14513 / ddrug5 - containing ddrug6 .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral HD00811 , ddrug1 , ddrug2 , ddrug3 , DB00472 , ddrug5 , ddrug6 , ddrug7 , ddrug8 { e , g , , ddrug9 } , ddrug10 .",
        "label": "NA"
    },
    {
        "text": "DB01576 with DB01151 or ddrug2 and possibly other ddrug3 cause striking and sustained increases in the concentration of ddrug4 in the brain ;",
        "label": "mechanism"
    },
    {
        "text": "reciprocal interactions may occur with concomitant use of DB01213 and drugs that increase or inhibit the cytochrome cyp2b6 system { e , g , , ddrug1 , DB00564 , ddrug3 , ddrug4 } , though this has not been studied",
        "label": "mechanism"
    },
    {
        "text": "interactions may also occur with the following : HD00515 / ddrug1 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 pain medication { e , g , , ddrug12 } , drugs used to aid sleep , drowsiness-causing HD00388 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "the effects of mixing DB01306 with ddrug1 of animal source or HD00071 preparations produced by other manufacturers have not been studied .",
        "label": "NA"
    },
    {
        "text": "drug/laboratory test interferences : DB00266 and HD00334 , including ddrug2 , or their metabolites may color alkaline urine red-orange , which may interfere with spectrophotometrically determined urinary laboratory tests .",
        "label": "NA"
    },
    {
        "text": "like ddrug0 { 40 mg/kg } , HD00022 { 40 mg/kg } decreases the intravenous self-administration of ddrug2 and ddrug3 and the oral self-administration of DB00898 and ddrug5 in rats ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 can interact with ddrug1 or other ddrug2 { may potentiate the cns depressant effects of either these medications or ddrug3 } , ddrug4 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with HD00388 } , and HD00445 { concurrent use with ddrug7 may prolong and intensify the anticholinergic and cns depressant effects of ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : patients on ddrug1 therapy may exhibit a diminished response to toxoids and HD00599 or HD00600 due to inhibition of antibody response .",
        "label": "NA"
    },
    {
        "text": "other ddrug0 { eg , ddrug1 , ddrug2 , ddrug3 , DB00571 } have occasionally been used concurrently with DB00280 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : use of HD00221 with DB00458 and other ddrug3 may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed .",
        "label": "effect"
    },
    {
        "text": "the effect of orally ingested HD00892 or DB00811 from breast milk on the nursing infant has not been evaluated .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00813 is not recommended for use in patients who have received ddrug2 within # days because severe and unpredictable potentiation by ddrug3 has been reported with HD00726",
        "label": "NA"
    },
    {
        "text": "pharmacokinetic interaction studies with DB00341 in adults were conducted with ddrug1 , ddrug2 , ddrug3 , DB00199 and ddrug5 .",
        "label": "NA"
    },
    {
        "text": "administration of repeat doses of ddrug0 had no effect on the repeat dose pharmacokinetics of ddrug1 , DB00390 or an DB00977 / levonorgestrol oral ddrug4 in healthy subjects .",
        "label": "NA"
    },
    {
        "text": "because both of these drugs have negative inotropic properties and the effects of coadministration with DB01195 are unknown , neither ddrug1 nor DB00661 should be administered concurrently with ddrug3 unless , in the judgment of the physician , the benefits of this combination outweigh the risks .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - coadministration of racemic ddrug1 { 40 mg/day for # days } and DB14507 { 30 mmol/day for # days } had no significant effect on the pharmacokinetics of DB00215 or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , DB00091 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { DB00295 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "co-medications that induce cyp 3a4 { e , g , , ddrug0 , ddrug1 , ddrug2 , DB01174 , or st , john s wort } may significantly decrease exposure to DB00990 .",
        "label": "mechanism"
    },
    {
        "text": "interactions for ddrug0 { ddrug1 , DB00169 , ddrug3 , and ddrug4 } : DB01432 : ddrug6 has been reported to reduce intestinal absorption of ddrug7 ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 absorption : the following agents may bind and decrease absorption of DB00451 from the gastrointestinal tract : ddrug2 , ddrug3 resin , DB00375 , ddrug5 , ddrug6 , soybean flour { e , g , , infant formula } , ddrug7 .",
        "label": "mechanism"
    },
    {
        "text": "in dogs , DB00501 unchanged the secretion of HD00192 , a test agent for anionic transport .",
        "label": "NA"
    },
    {
        "text": "in a comparison of HD00118 tolerance in dogs anesthetized with ddrug1 , ddrug2 , or ddrug3 , the dosage of DB01092 needed to cause ventricular tachycardia was significantly higher , as was the ld50 of ddrug5 , with ddrug6 or ddrug7 than with ddrug8 .",
        "label": "NA"
    },
    {
        "text": "the ecg changes and/or hypokalemia that may result from the administration of ddrug0 { such as HD00105 or ddrug2 } can be acutely worsened by HD00358 , especially when the recommended dose of the ddrug4 is exceeded .",
        "label": "effect"
    },
    {
        "text": "DB00501 is reported to reduce hepatic metabolism of certain HD00043 , thereby delaying elimination and increasing steady-state concentrations of these ddrug2 .",
        "label": "mechanism"
    },
    {
        "text": "in clinical trials , ddrug0 was used with ddrug1 , ddrug2 , ddrug3 , oral HD00337 , and supplemental ddrug5 , in a pharmacokinetic substudy in patients with congestive heart failure receiving ddrug6 or ddrug7 in whom therapy with ddrug8 was initiated , apparent oral clearance values for DB00695 { n = 23 } and ddrug10 { n = 30 } were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .",
        "label": "NA"
    },
    {
        "text": "DB00520 reduced the blood auc0 - 12 of ddrug1 by approximately 20 % , peak blood concentration { cmax } by 16 % , and 12-hour blood concentration { c12hr } by 26 % in healthy subjects when DB00864 { 2 doses of # mg/kg # hours apart } was administered on the 10th day of ddrug3 # mg daily , as compared to results from a control period in which ddrug4 was administered alone .",
        "label": "NA"
    },
    {
        "text": "patients receiving other ddrug0 , ddrug1 , ddrug2 , or other ddrug3 { including DB02325 } concomitantly with ddrug5 and DB00316 tablets may exhibit an additive cns depression .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , DB00224 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , DB00231 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : a clinical study in # insulin-dependent diabetic patients demonstrated no effect of ddrug1 on ddrug2 absorption from the peritoneal cavity or on HD00071 s ability to control blood glucose when ddrug4 was administered intraperitoneally with DB00702 .",
        "label": "NA"
    },
    {
        "text": "therefore , cyp3a4 substrates known to have a narrow therapeutic index such as ddrug0 , DB00637 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , or ddrug10 { ddrug11 , ddrug12 } should be administered with caution in patients receiving DB01254 .",
        "label": "advise"
    },
    {
        "text": "potentiation of the hypotensive effects of ddrug0 for patients with ischemic_heart_disease has not been evaluated , and concomitant use of DB00862 and DB14049 is contraindicated .",
        "label": "advise"
    },
    {
        "text": "however , co administration of ddrug0 with either DB01026 or DB00199 led to increased plasma concentrations of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "DB01234 had a similar effect in the presence of HD00071 .",
        "label": "NA"
    },
    {
        "text": "studies showed that DB00343 increased the auc of ddrug1 and DB00897 by 3 - 4 fold and the cmax by 2-fold , compared to placebo .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : DB00712 like other HD00233 , has been shown to affect bleeding parameters in patients receiving ddrug3 , and serious clinical bleeding has been reported .",
        "label": "NA"
    },
    {
        "text": "medications can interfere with folate utilization , including : ddrug0 { such as ddrug1 , and ddrug2 } ddrug3 { sometimes prescribed to control blood sugar in type # diabetes } ddrug4 { used to control inflammation associated with crohn_disease and ulcerative colitis } DB00384 { a ddrug6 } ddrug7 there has been concern about the interaction between ddrug8 and DB00158 .",
        "label": "NA"
    },
    {
        "text": "hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose DB00041 and ddrug1 , specifically , ddrug2 , ddrug3 , ddrug4 and HD00253 .",
        "label": "effect"
    },
    {
        "text": "other drug interactions oral HD00283 ddrug1 { 500 mg twice daily } did not influence the pharmacokinetics of an oral ddrug2 containing # mg DB00977 and # mg ddrug4 , or of the luteinizing hormone and progesterone levels , indicating that impairment of contraceptive efficacy is unlikely .",
        "label": "NA"
    },
    {
        "text": "if DB00252 or other hepatic enzyme inducers are taken concurrently with ddrug1 or ddrug2 , lower plasma levels of DB00280 may occur .",
        "label": "NA"
    },
    {
        "text": "injection : ddrug0 injection , like other injectable ddrug1 , produces depression of the central nervous system when administered with ddrug2 , ddrug3 , ddrug4 , ddrug5 , and other HD00216 , when ddrug7 is used concomitantly with injectable DB00186 , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .",
        "label": "NA"
    },
    {
        "text": "specific and aspecific treatments of ddrug0 depletion are tricky using for example ddrug1 , pharmacological doses of DB00165 , physiological doses of ddrug3 and of DB11127 .",
        "label": "NA"
    },
    {
        "text": "animal experience indicates that DB00628 prolongs the sleeping time after ddrug1 or after ddrug2 , increases the inhibitory effects of DB00477 , but does not exhibit maoa inhibition .",
        "label": "effect"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { ddrug1 s } , ddrug2 , ddrug3 { HD00026 may decrease the effects of these medicines } , ddrug5 { using these medicines with ddrug6 may result in increased cns depressant effects } , ddrug7 , ddrug8 { using these medicines with ddrug9 may change the amount of either medicine that you need to take } , and oral HD00283 containing ddrug11 { ddrug12 may decrease the effectiveness of these oral ddrug13 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "compounds in these categories result in a decreased efficacy of ddrug0 : ddrug1 , DB00502 , DB01233 , ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , DB00636 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , DB00503 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "because HD00374 may interfere with the absorption of HD00352 , simultaneous use of these drugs should be avoided .",
        "label": "mechanism"
    },
    {
        "text": "in vitro studies have shown that the metabolism of DB01248 may be modified by the concomitant administration of compounds that induce , inhibit , or are metabolized by cytochrome p450 3a4 , such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , and DB13179 .",
        "label": "mechanism"
    },
    {
        "text": "DB00522 may interact with DB00316 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "int"
    },
    {
        "text": "the following agents may increase certain actions or side effects of ddrug0 , DB00915 HD00428 of class { e , g , ddrug3 } , ddrug4 ddrug5 { e , g , ddrug6 } , ddrug7 .",
        "label": "NA"
    },
    {
        "text": "as with other HD00617 , it should be noted that ddrug1 may be capable of potentiating ddrug2 such as ddrug3 , ddrug4 , and DB02325 .",
        "label": "effect"
    },
    {
        "text": "exogenous DB00783 also appeared to influence the percentage of HD00168 - induced deaths in a dose-dependent manner .",
        "label": "effect"
    },
    {
        "text": "in a multiple dose study of DB00277 { 400 mg once daily for # days } and ddrug1 { 20 mg once daily for # days } , a 16 % decrease in the clearance of DB00341 was observed .",
        "label": "NA"
    },
    {
        "text": "co-administration of DB09026 did not significantly affect the pharmacokinetics of ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB00482 , ddrug7 , ddrug8 , ddrug9 or ddrug10 .",
        "label": "NA"
    },
    {
        "text": "although the interactions observed in these studies do not appear to be of major clinical importance , DB00187 should be titrated with caution in patients being treated concurrently with DB00390 , ddrug2 , ddrug3 or ddrug4 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 and ddrug1 : ddrug2 and HD00374 containing ddrug4 or ddrug5 , as well as formulations containing divalent and trivalent cations such as ddrug6 { DB00900 } , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with ddrug8 and interfere with its bioavailability .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : combination HD00432 may inhibit the metabolism of DB00091 , leading to increased plasma concentrations ;",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : ddrug1 , DB01253 , ddrug3 , ddrug4 contraindicated due to potential for serious and life-threatening reactions such as acute HD00624 toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 : in normal volunteers { n = 9 } , pretreatment with DB00501 or ddrug3 did not affect ddrug4 pharmacokinetics except that a small { 13 % } but statistically significant increase in the area under the serum concentration curve of DB00712 resulted with ddrug6 .",
        "label": "NA"
    },
    {
        "text": "agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of ddrug0 are the following : DB00515 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 { 2 } , ddrug7 , ddrug8 , and ddrug9 thus , if a patient has been titrated to a stable dosage on ddrug10 , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for HD00472 may be necessary .",
        "label": "NA"
    },
    {
        "text": "medications can interfere with folate utilization , including : ddrug0 { such as ddrug1 , and DB00794 } ddrug3 { sometimes prescribed to control blood sugar in type # diabetes } ddrug4 { used to control inflammation associated with crohn_disease and ulcerative colitis } DB00384 { a ddrug6 } ddrug7 there has been concern about the interaction between ddrug8 and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "in vitro displacement studies with highly protein-bound drugs such as ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and DB00331 showed no influence on the extent of DB00731 protein binding .",
        "label": "NA"
    },
    {
        "text": "the availability of potent HD00110 { ddrug1 } - based regimens for ddrug2 therapy and concerns regarding ddrug3 { HD00111 } - related metabolic disturbances have led to significant shifts in treatment practices in hiv infection .",
        "label": "NA"
    },
    {
        "text": "other drugs : based on the results of drug interaction studies , no dosage adjustment is recommended when ddrug0 { DB00625 } is given with the following : ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , and DB00495 .",
        "label": "NA"
    },
    {
        "text": "the effects of DB00640 are antagonized by HD00246 such as ddrug2 and ddrug3 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : elevated serum levels of DB00091 have been reported with concomitant use of ddrug2 with other members of the HD00678 .",
        "label": "NA"
    },
    {
        "text": "both ddrug0 and ddrug1 have been compared to triple therapy with the HD00111 ddrug3 over # weeks as initial therapy , with similar responses being observed with ddrug4 regimens and superiority observed with DB00625 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , DB01174 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , DB01045 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "there have been reports of interactions of DB00199 with ddrug1 , ddrug2 , DB00864 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , and ddrug13 .",
        "label": "int"
    },
    {
        "text": "limited clinical experience indicates that requirements for HD00265 are reduced by # to 50 % for the first sixty { 60 } minutes following DB00802 induction the concomitant use of ddrug2 with ddrug3 can significantly inhibit ddrug4 clearance and may increase the risk of prolonged or delayed respiratory depression .",
        "label": "mechanism"
    },
    {
        "text": "oral ddrug0 multiple doses of ddrug1 had no effect on the pharmacokinetics of DB00977 , the estrogenic component in most oral HD00283 .",
        "label": "NA"
    },
    {
        "text": "since DB01432 HD00524 may bind other drugs given concurrently , it is recommended that patients take other drugs at least # hour before or # to # hours after ddrug2 ddrug3 { or at as rxfp2 an interval as possible } to avoid impeding their absorption .",
        "label": "NA"
    },
    {
        "text": "studies in humans show that the absorption of DB00880 as reflected in urinary excretion is markedly decreased even when administered one hour before DB00375 .",
        "label": "mechanism"
    },
    {
        "text": "clinically significant interactions would not be expected since the HD00672 are metabolized via a different route than DB00625 and would be unlikely to compete for the same metabolic enzymes and elimination pathways .",
        "label": "NA"
    },
    {
        "text": "neurochemical and functional consequences following ddrug0 { HD00146 } and DB01577 .",
        "label": "NA"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / ddrug1 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , HD00516 pain medication { e , g , , ddrug12 } , drugs used to aid sleep , drowsiness-causing ddrug13 { e , g , , DB14487 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "DB00522 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , ddrug12 } , HD00297 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "int"
    },
    {
        "text": "in a 12-week endoscopy study conducted in oa patients there was no difference in the cumulative incidence of endoscopic gastroduodenal ulcers in patients taking low-dose { 81 mg } enteric coated DB00945 plus ddrug1 # mg daily , as compared to those taking DB01050 # mg daily alone .",
        "label": "NA"
    },
    {
        "text": "however , in clinical studies the consequences of concomitant DB01029 on the pharmacodynamics of DB00682 were negligible .",
        "label": "NA"
    },
    {
        "text": "the purpose of this study was to evaluate the effect of ddrug0 { ddrug1 } and HD00067 { ddrug3 } conjugates on the intestinal permeation of ddrug4 { ddrug5 } and model peptide drugs , ddrug6 and HD00071 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : animal studies wshow that DB00945 given with HD00518 , including ddrug3 , yields a net decrease in anti-inflammatory activity with lowered blood levels of the non-aspirin drug .",
        "label": "effect"
    },
    {
        "text": "ddrug0 and DB09278 administration of DB01432 or ddrug3 in patients { n = 13 } and volunteers { n = 96 } resulted in a rapid and significant decrease in plasma m1 { the active metabolite of ddrug4 } concentration .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 HD00388 DB00564 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "in addition , DB00776 and ddrug1 induce a subgroup of the cytochrome cyp2b6 3a family { cyp3a4 and cyp3a5 } responsible for the metabolism of ddrug2 and oral HD00283 , resulting in a lower plasma concentration of these drugs .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 similarly inhibit and stimulate HD00148 - or HD00071 - induced proliferation of prostatic epithelium .",
        "label": "NA"
    },
    {
        "text": "HD00828 - including ddrug1 , ddrug2 and DB01626 hc1 .",
        "label": "NA"
    },
    {
        "text": "the concurrent use of DB00465 with HD00542 has not been formally studied .",
        "label": "NA"
    },
    {
        "text": "it was concluded that oral DB00497 and DB01137 can be administered concomitantly without a significant decrease in auc , cmax , or tmax .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in patients with mild to moderate hypertension , administration of ddrug1 once daily , as a tablet formulation comparable to # mg of the capsule formulation , with DB00343 # mg # times daily for # days , resulted in a 2-fold increase of DB00673 auc and a simultaneous # - fold increase of ddrug4 auc .",
        "label": "NA"
    },
    {
        "text": "co-administration of DB00227 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 and ddrug10 did not result in clinically significant increases in DB09026 exposure .",
        "label": "NA"
    },
    {
        "text": "conjugation at HD00072 with ddrug1 moieties significantly improves the intestinal permeation of the hydrophilic molecule ddrug2 and the model peptide drugs ddrug3 and HD00071 in vitro , therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future .",
        "label": "NA"
    },
    {
        "text": "drug interaction studies have shown that DB00736 does not have any clinically significant interactions with DB00252 , ddrug2 , ddrug3 , ddrug4 or ddrug5 .",
        "label": "NA"
    },
    {
        "text": "the results of a study of coadministration of ddrug0 { 50 mg/kg } with an ddrug1 containing DB06724 to # patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of DB00330 of approximately 20 % and 13 % , respectively , suggesting that the oral absorption of ddrug4 may be reduced by these ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 or DB00364 substantially interfere with the absorption of some HD00532 , resulting in low urine levels .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 should be used with care when ddrug1 or inhibitors of av conduction , such as certain ddrug2 { particularly of the ddrug3 -lsb- DB00661 -rsb- and HD00427 -lsb- ddrug6 -rsb- classes } , or ddrug7 , such as ddrug8 , are used concurrently .",
        "label": "NA"
    },
    {
        "text": "this drug may interact with ddrug0 or other ddrug1 { may potentiate the cns depressant effects of either these medications or ddrug2 } , HD00444 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug4 } , and ddrug5 { concurrent use with ddrug6 may prolong and intensify the anticholinergic and cns depressant effects of HD00388 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , DB00295 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and DB00126 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00365 is a competitive inhibitor of the metabolism of DB00277 .",
        "label": "mechanism"
    },
    {
        "text": "methods : from the beginning of the experiment , rats were given # weekly subcutaneous injections of ddrug0 { # mg/kg body weight } and subcutaneous injections of DB11724 { 40 microg/kg body weight } every other day , and from week 16 , intraperitoneal injections of DB00661 { 10 or # mg/kg body weight } every other day until the end fo the experiment in week 45 .",
        "label": "NA"
    },
    {
        "text": "particular caution is recommended when administering DB00619 with cyp3a4 substrates that have a narrow therapeutic window { e , g , , ddrug1 or DB01100 } .",
        "label": "advise"
    },
    {
        "text": "other agents : ddrug0 has been used concomitantly with DB14049 and/or DB00390 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 HD00871 : DB01045 ddrug10 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "DB01167 ddrug1 ddrug2 ddrug3 ddrug4 ddrug5 ddrug6 DB00091 large quantities of grapefruit juice { # quart daily }",
        "label": "NA"
    },
    {
        "text": "on the basis of the metabolism of ddrug0 by cytochrome p450 3a4 , ddrug1 , ddrug2 , DB00199 , ddrug4 , grapefruit juice , and other inhibitors of cyp3a4 would be expected to lead to an increase in plasma DB00307 concentrations .",
        "label": "mechanism"
    },
    {
        "text": "it is believed that the toxicity may have resulted from a previously unrecognized interaction between DB00951 and DB00316 and a molecular basis for this interaction has been proposed .",
        "label": "effect"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of ddrug0 : ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , ddrug5 , DB01001 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , HD00809 , ddrug12 , ddrug13 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "in patients who have received HD00542 , DB00561 may temporarily mask the residual effects of ddrug2 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in patients with mild to moderate hypertension , administration of DB00673 once daily , as a tablet formulation comparable to # mg of the capsule formulation , with DB00343 # mg # times daily for # days , resulted in a 2-fold increase of ddrug3 auc and a simultaneous # - fold increase of ddrug4 auc .",
        "label": "mechanism"
    },
    {
        "text": "nevertheless , caution is indicated in the co-administration of HD00594 with any of the HD00114 and also in switching from one class to the other .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : combination ddrug1 may decrease the clearance of some ddrug2 { DB00404 , ddrug4 , ddrug5 } and increase the clearance of others { ddrug6 , DB00842 , ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , and the ddrug1 DB00904 { ddrug3 } and DB00889 { ddrug5 } have all been used with ddrug6 .",
        "label": "NA"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 DB00683 , DB00897 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "{ in some patients , the ddrug0 can reduce the diuretic , natriuretic , and antihypertensive effects of HD00105 , ddrug2 , and HD00029 .",
        "label": "NA"
    },
    {
        "text": "other HD00276 concomitant use of other ddrug1 within # hours of treatment with DB00918 is contraindicated .",
        "label": "NA"
    },
    {
        "text": "drug-drug interactions between ddrug0 and other HD00703 { ddrug2 } ddrug3 DB01202 { 3000 mg daily } had no effect on the pharmacokinetic disposition of ddrug5 in patients with refractory epilepsy .",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with HD00374 containing ddrug2 , ddrug3 , or ddrug4 , with ddrug5 , with metal cations such as ddrug6 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { DB00900 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "ddrug0 DB01412 ddrug2 , like other ddrug3 , may inhibit the metabolism of DB00201 and ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 / ddrug1 , HD00375 , including DB00199",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , DB00860 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , DB00277 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 is not recommended for use in patients who have received ddrug2 within # days because severe and unpredictable potentiation by HD00343 has been reported with HD00726",
        "label": "advise"
    },
    {
        "text": "no significant drug interactions have been reported in studies of DB00796 given with other drugs such as ddrug1 , ddrug2 , ddrug3 , DB00682 , ddrug5 , and oral ddrug6 in healthy volunteers , or given with ddrug7 to patients with heart failure { nyha class ii and iii } .",
        "label": "NA"
    },
    {
        "text": "if ddrug0 is given concomitantly with ddrug1 , the HD00023 dose should be reduced { by approx , 50 % } , because DB01239 amplifies the therapeutic actions and side-effects of ddrug4 massively .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 is known to slow the metabolism of ddrug2 and increase its serum levels ddrug3 levels should be determined prior to concurrent administration with DB00951 , signs and symptoms of ddrug5 toxicity should be monitored closely , and appropriate dosage adjustment of the HD00329 should be made .",
        "label": "NA"
    },
    {
        "text": "to determine whether injection of ddrug0 would permit larger doses of ddrug1 to be administered , a fixed # - g/m2 dose of HD00158 was given intravenously over three hours concurrently with escalating doses of DB00515 .",
        "label": "NA"
    },
    {
        "text": "however , it has been established that DB00459 interferes with the contraceptive effect of microdosed HD00237 minipill preparations .",
        "label": "effect"
    },
    {
        "text": "this drug may interact with ddrug0 or other ddrug1 { may potentiate the cns depressant effects of either these medications or ddrug2 } , ddrug3 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug4 } , and HD00445 { concurrent use with HD00388 may prolong and intensify the anticholinergic and cns depressant effects of ddrug7 } .",
        "label": "NA"
    },
    {
        "text": "use lowest possible dose of ddrug0 with careful monitoring , or consider HD00095 that are not primarily metabolized by cyp3a4 , such as ddrug2 , ddrug3 , or DB01098 in combination with ddrug5 .",
        "label": "NA"
    },
    {
        "text": "drugs that reduce the number of blood platelets by causing bone marrow depression { such as ddrug0 } or drugs which inhibit platelet function { eg , DB00945 and other ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 } may increase the bleeding tendency produced by HD00326 without altering prothrombin time determinations .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , DB01601 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and DB00126 .",
        "label": "NA"
    },
    {
        "text": "DB00715 produced only minor changes in the levels of DB00363 and its metabolites .",
        "label": "mechanism"
    },
    {
        "text": "however , # patients who switched from therapy with HD00753 to DB05259 did not report any serious and unexpected adverse reactions thought to be related to treatment .",
        "label": "NA"
    },
    {
        "text": "DB00945 : concurrent administration of ddrug1 and ddrug2 resulted in 50 % lower serum DB00712 concentrations .",
        "label": "NA"
    },
    {
        "text": "ergot derivatives : ddrug0 , ddrug1 , DB00201 , DB00353",
        "label": "NA"
    },
    {
        "text": "- drugs whose efficacy is impaired by ddrug0 include : ddrug1 , HD00175 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , oral ddrug8 , ddrug9 , ddrug10 , ddrug11 , DB11094 .",
        "label": "NA"
    },
    {
        "text": "a similar association , though less marked , has been suggested with ddrug0 , ddrug1 , DB00252 , ddrug3 , ddrug4 , ddrug5 , and possibly with ddrug6 and HD00239 72 .",
        "label": "NA"
    },
    {
        "text": "certain ddrug0 , especially the HD00249 and HD00384 ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { DB00400 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { DB00295 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "in separate single or multiple dose pharmacokinetic interaction studies with ddrug0 , ddrug1 , ddrug2 , DB00999 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , and ddrug8 , the bioavailability of DB14207 was not altered by coadministration of ddrug10 with any one of these drugs .",
        "label": "NA"
    },
    {
        "text": "ddrug0 } , ddrug1 { e , g , ddrug2 } , and ddrug3 { e , g , ddrug4 , ddrug5 and DB01232 } should have their dose of DB00921 or ddrug8 adjusted .",
        "label": "NA"
    },
    {
        "text": "in the same study it was shown that DB00900 and DB00649 had no significant effect on the intracellular phosphorylation of ddrug2 in peripheral blood mononuclear cells .",
        "label": "NA"
    },
    {
        "text": "other concomitant therapy although specific interaction studies were not performed , DB01216 doses of # mg or more were concomitantly used in clinical studies with ddrug1 , ddrug2 , a-blockers , ddrug3 , ddrug4 , ddrug5 , HD00100 , ddrug7 , ddrug8 , cardiac ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 { also referred to as ddrug14 } , and ddrug15 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "coadministration of DB00220 and drugs primarily metabolized by cytochrome_p450_family_3_subfamily_a { e , g , , HD00798 } may result in increased plasma concentrations of the other drug that could increase or prolong both its therapeutic and adverse effects .",
        "label": "NA"
    },
    {
        "text": "DB00987 , a HD00731 , has been reported to inactivate the antifungal activity of ddrug2 by competitive inhibition .",
        "label": "NA"
    },
    {
        "text": "in a comparison of ddrug0 tolerance in dogs anesthetized with ddrug1 , ddrug2 , or ddrug3 , the dosage of DB01092 needed to cause ventricular tachycardia was significantly higher , as was the ld50 of ddrug5 , with ddrug6 or ddrug7 than with DB00312 .",
        "label": "NA"
    },
    {
        "text": "DB00429 may augment the activity of other HD00480 .",
        "label": "effect"
    },
    {
        "text": "because oral HD00326 may interfere with the hepatic metabolism of DB00252 , toxic levels of the ddrug2 may occur when an oral ddrug3 and ddrug4 are administered concurrently .",
        "label": "mechanism"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , ddrug3 ddrug4 : ddrug5 , DB00342 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 ddrug11 , ddrug12 gi motility agents : DB00604",
        "label": "NA"
    },
    {
        "text": "effects of other ddrug0 on ddrug1 ddrug2 : DB00252 causes an approximate doubling of the clearance of ddrug4 { DB00949 } at steady state and , therefore , the addition of ddrug6 causes an approximate 45 % decrease in the steady-state trough concentrations of ddrug7 as compared to the same dose of ddrug8 given as monotherapy .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 or ddrug1 administered with ddrug2 / DB09140 to achieve # mac -lsb- minimum alveolar concentration -rsb- may prolong the clinically effective duration of action of initial and maintenance doses of ddrug4 and decrease the required infusion rate of DB00565 .",
        "label": "NA"
    },
    {
        "text": "these include DB01032 , ddrug1 , and some ddrug2 { e , g , ddrug3 , rifamipicin , ddrug4 and DB00446 } .",
        "label": "NA"
    },
    {
        "text": "in vitro , DB00490 does not displace tightly bound drugs like ddrug1 , DB00571 , and ddrug3 from serum proteins .",
        "label": "NA"
    },
    {
        "text": "other cardiovascular agents : ddrug0 and ddrug1 iv have been used concomitantly with ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB01275 , DB00457 and ddrug8 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "these include DB01032 , ddrug1 , and some HD00002 { e , g , ddrug3 , rifamipicin , ddrug4 and ddrug5 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of HD00530 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , certain ddrug7 , ddrug8 , DB00277 and ddrug10 , thereby delaying elimination and increasing blood levels of these drugs .",
        "label": "NA"
    },
    {
        "text": "DB09098 / ddrug1 : excessive concurrent use of HD00849 may accelerate epiphyseal closure .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , DB00316 and ddrug2 may enhance the effects of : other HD00459 s , ddrug4 , general ddrug5 , ddrug6 such as ddrug7 , ddrug8 , or other ddrug9 , causing increased cns depression .",
        "label": "effect"
    },
    {
        "text": "the effectiveness of HD00237 - only pills is reduced by hepatic enzyme-inducing drugs such as the ddrug1 ddrug2 , ddrug3 , and ddrug4 , and the HD00886 ddrug6 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a single dose study { n = 6 } , ingestion of an DB06724 containing # - gram of ddrug2 with 500-mg of DB00784 increased the cmax and auc of ddrug4 by 125 % and 36 % , respectively , a number of compounds are inhibitors of cyp2c9 including ddrug5 , ddrug6 and ddrug7 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 should be used with caution in patients receiving - HD00305 blocking agents { e , g , , ddrug3 , a ddrug4 inhibitor } or ddrug5 antagonists { e , g , , ddrug6 , a ddrug7 substrate , and DB00343 , a ddrug9 inhibitor } because of the possible potentiation of bradycardia , sinus arrest , and av block ;",
        "label": "NA"
    },
    {
        "text": "may interact with thyroid medication { e , g , , ddrug0 } , ddrug1 - containing products , ddrug2 , ddrug3 { e , g , , ddrug4 , DB00863 } , and HD00587 { e , g , , ddrug7 , ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , DB00295 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { HD00531 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration { n = 18 } of ddrug1 capsules { 250 mg } with DB00996 { 125 mg } appears to increase the amount of DB00996 absorbed by 12 % to 15 % .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : since ddrug1 is a ddrug2 , it is possible that HD00339 , such as the ddrug4 { ddrug5 , ddrug6 , HD00341 } or ddrug8 , may diminish the effectiveness of ddrug9 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 can interact with DB02325 or other ddrug2 { may potentiate the cns depressant effects of either these medications or HD00388 } , ddrug4 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug5 } , and ddrug6 { concurrent use with ddrug7 may prolong and intensify the anticholinergic and cns depressant effects of ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "thus , concomitant administration of DB00467 and DB01294 should be avoided .",
        "label": "advise"
    },
    {
        "text": "DB00634 preparations are incompatible with DB12965 preparations .",
        "label": "int"
    },
    {
        "text": "DB01211 exposure was significantly decreased by DB00238 ;",
        "label": "mechanism"
    },
    {
        "text": "concomitant administration of ddrug0 and DB06724 , ddrug2 , ddrug3 , or an ddrug4 / DB00396 oral ddrug6 produced minor changes in the pharmacokinetics of ddrug7 , which were considered to be without clinical significance .",
        "label": "NA"
    },
    {
        "text": "drugs which inhibit cyp 3a4 { e , g , , ddrug0 , HD00093 such as DB00199 } have the potential to result in increased plasma concentrations of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "when DB00328 is given to patients receiving DB01032 , the plasma levels of ddrug2 are likely to be increased .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 # mg qd or ddrug1 / DB00384 50/100 mg qd was co-administered with DB00204 { 500 mcg bid } for # days { following # days of ddrug4 use at half dose } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { e , g , ddrug1 and ddrug2 } : agents of the HD00625 , of which ddrug4 { ddrug5 } injection , usp is a member , have been shown to interact with ddrug6 of the HD00626 , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .",
        "label": "mechanism"
    },
    {
        "text": "if treatment with inhibitors of cyp3a4 activity { such as DB01026 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , etc , } is indicated , reduction of the DB01222 dose should be considered .",
        "label": "advise"
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the ddrug0 of drugs may be potentiated by ddrug1 , ddrug2 , HD00026 , ddrug4 , ddrug5 , the ddrug6 , ddrug7 and ddrug8 , HD00275 and the ddrug10 , and by other ddrug11 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , DB01076 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { DB01045 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "inhibitors or substrates of cyp2d6 { i , e , , DB00908 , ddrug1 -lsb- HD00114 -rsb- } may increase the plasma concentration of ddrug3 when administered concomitantly .",
        "label": "NA"
    },
    {
        "text": "other depressasnts such as ddrug0 , HD00026 , and ddrug2 may enhance cns depression when administered with DB00189 .",
        "label": "effect"
    },
    {
        "text": "in vitro studies have shown that the metabolism of DB01248 may be modified by the concomitant administration of compounds that induce , inhibit , or are metabolized by cytochrome p450 3a4 , such as ddrug1 , ddrug2 , DB01026 , ddrug4 , and ddrug5 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and DB00759 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { DB01045 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "therefore , co-administration of DB00363 with other drugs that are metabolized by this isozyme , including ddrug1 , ddrug2 , ddrug3 , and ddrug4 { e , g , , ddrug5 , DB01195 and ddrug7 } , or that inhibit this enzyme { e , g , , ddrug8 } , should be approached with caution .",
        "label": "advise"
    },
    {
        "text": "DB00898 or DB00897 : no significant differences were observed in the pharmacokinetics of ddrug2 { # mg } and ddrug3 { 10 mg } when given together as a single dose .",
        "label": "NA"
    },
    {
        "text": "lack of an effect of DB00207 on the disposition of ddrug1 and DB00900 in hiv-infected patients .",
        "label": "NA"
    },
    {
        "text": "DB01026 } , ddrug1 { e , g , ddrug2 } , and ddrug3 { e , g , ddrug4 , ddrug5 and ddrug6 } should have their dose of DB00921 or ddrug8 adjusted .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and DB01081 , by decreasing gut motility , may increase DB00390 absorption .",
        "label": "mechanism"
    },
    {
        "text": "DB00224 has been shown to increase plasma levels of HD00710 .",
        "label": "mechanism"
    },
    {
        "text": "use of HD00287 DB00945 and ddrug2 have been administered concomitantly with and following infusions of ddrug3 in the management of acute myocardial infarction or pulmonary embolism .",
        "label": "NA"
    },
    {
        "text": "in ewes given # mg of DB01174 / kg for # days intraperitoneally { ip } , the anticholinesterase effect of # mg of DB11390 / kg was significantly reduced and signs of toxicity were not present .",
        "label": "effect"
    },
    {
        "text": "HD00093 { e , g , DB00199 and ddrug2 } : agents of the ddrug3 , of which ddrug4 { ddrug5 } injection , usp is a member , have been shown to interact with ddrug6 of the ddrug7 , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : when DB00176 { 100 mg qd } and ddrug2 { 1 mg q , d , were co-administered to steady state , plasma concentration and other pharmacokinetics parameters { auc , cmax , t1/2 , } of ddrug3 were approximately twice those observed when DB00404 was administered alone ;",
        "label": "NA"
    },
    {
        "text": "a similar association , though less marked , has been suggested with ddrug0 , phenyl-butazone , DB00252 , ddrug2 and possibly with DB00400 , ddrug4 , and ddrug5 { 72 }",
        "label": "NA"
    },
    {
        "text": "certain drugs , including ddrug0 { ddrug1 } , HD00328 , ddrug3 , and ddrug4 may potentiate the hypoglycemic action of ddrug5 and other oral HD00394 .",
        "label": "effect"
    },
    {
        "text": "HD00522 may antagonize the effects of the drugs that alter gastrointestinal motility , such as DB01233 .",
        "label": "mechanism"
    },
    {
        "text": "antagonism between DB01627 and DB00199 in vitro has been demonstrated .",
        "label": "effect"
    },
    {
        "text": "interactions with other cns agents : concurrent use of DB00854 with all ddrug1 { eg , ddrug2 , ddrug3 , HD00214 , other ddrug5 , general ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 and ddrug12 } may result in additive central nervous system depressant effects .",
        "label": "effect"
    },
    {
        "text": "coadministration of DB00390 did not have effects on either the safety or efficacy of DB00308 in the clinical trials .",
        "label": "NA"
    },
    {
        "text": "if a patient requires ddrug0 and ddrug1 therapy , it is suggested that ddrug2 , ddrug3 , or HD00374 { ddrug5 and ddrug6 } be used as alternatives to ddrug7 , as these agents have no effect on the pharmacokinetic profile of DB00204 .",
        "label": "NA"
    },
    {
        "text": "DB00945 : in normal volunteers , a small decrease in ddrug1 levels was observed when multiple doses of DB00861 and ddrug3 were administered concomitantly .",
        "label": "NA"
    },
    {
        "text": "HD00512 reduce the renal clearance of ddrug1 and add a high risk of DB14507 toxicity .",
        "label": "effect"
    },
    {
        "text": "these medications have included ddrug0 , ddrug1 , ddrug2 , HD00208 , ddrug4 , intravenous and oral ddrug5 , ddrug6 , and DB00945 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 DB01412 ddrug2 , like other HD00532 , may inhibit the metabolism of ddrug4 and ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 / ddrug1 : DB00437 inhibits the enzymatic oxidation of DB01033 and ddrug4 to ddrug5 .",
        "label": "mechanism"
    },
    {
        "text": "patients receiving other ddrug0 , HD00031 , ddrug2 , or other ddrug3 { including ddrug4 } concomitantly with DB00956 and ddrug6 tablets may exhibit an additive cns depression .",
        "label": "effect"
    },
    {
        "text": "drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving ddrug0 metabolized similarly to ddrug1 or on the basis of in vitro studies with ddrug2 or other ddrug3 { caution is recommended during coadministration with ddrug4 } : available data from clinical studies of ddrug5 other than ddrug6 suggest a possible drug interaction with DB00404 for the following : ddrug8 , ddrug9 , HD00093 such as ddrug11 and ddrug12 , and grapefruit juice .",
        "label": "int"
    },
    {
        "text": "DB00897 - combined administration of racemic DB00215 { titrated to # mg/day for # days } and the cyp3a4 substrate ddrug2 { single dose of # mg } did not significantly affect the pharmacokinetics of either ddrug3 or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "however , prudent medical practice dictates careful monitoring of prothrombin time in all patients treated with DB00207 and DB00682 concomitantly .",
        "label": "advise"
    },
    {
        "text": "studies with HD00106 in combination with HD00218 indicate that the dose of the ddrug2 can be reduced when it is given with a ddrug3 .",
        "label": "NA"
    },
    {
        "text": "when given concomitantly with DB01023 , the DB00864 blood concentration should be followed and the tacrolimus dose may need to be adjusted .",
        "label": "NA"
    },
    {
        "text": "the effectiveness of HD00237 - only pills is reduced by hepatic enzyme-inducing drugs such as the ddrug1 ddrug2 , ddrug3 , and HD00026 , and the ddrug5 ddrug6 .",
        "label": "effect"
    },
    {
        "text": "in monkeys , the effects of HD00157 , but not ddrug1 or DB03575 , were antagonized by ddrug3 ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { DB00316 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , DB00812 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "administration of HD00532 with ddrug1 containing ddrug2 , ddrug3 , or ddrug4 , with ddrug5 , with metal cations such as ddrug6 , or with ddrug7 containing DB01592 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "mechanism"
    },
    {
        "text": "although the interaction between ddrug0 and other potent cyp3a4 inhibitors { e , g , , ddrug1 , ddrug2 , and DB00199 } has not been studied , increased exposures to ddrug4 may be expected when DB00918 is used concomitantly with these medications .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : increased inr { international normalized ratio } when DB01097 and DB00682 were co-administered has been rarely reported .",
        "label": "effect"
    },
    {
        "text": "the effects of supplementary oral DB14574 and ddrug1 , as well as the interaction between both at the absorption site , fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either # or # micrograms/kg of ddrug2 and # or # mg/kg of DB01592 over a period of # days in a total of # rats .",
        "label": "NA"
    },
    {
        "text": "if a patient requires DB00204 and ddrug1 therapy , it is suggested that ddrug2 , ddrug3 , or ddrug4 { DB06723 and ddrug6 } be used as alternatives to ddrug7 , as these agents have no effect on the pharmacokinetic profile of ddrug8 .",
        "label": "NA"
    },
    {
        "text": "coadministration of ddrug0 tablets with DB00683 or DB00897 has resulted in elevated plasma concentrations of the latter two drugs .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { DB00316 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , DB00564 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : concomitant administration of HD00374 containing ddrug2 or DB01370 with ddrug4 chewable/dispersible buffered tablets or pediatric powder for oral solution may potentiate adverse events associated with the ddrug5 components .",
        "label": "NA"
    },
    {
        "text": "HD00244 should be withdrawn at least # hours before conducting an DB01102 - mediated stress test .",
        "label": "advise"
    },
    {
        "text": "DB00269 may interact with ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 supplements , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , and DB00682 .",
        "label": "int"
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma ddrug0 concentrations include : acute DB02325 intake , ddrug2 , chboramphenicol , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , DB00422 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21",
        "label": "NA"
    },
    {
        "text": "subjects treated with # mg of DB00900 twice daily for # days received # mg of DB00207 or an equivalent amount of placebo/day for days # to 21 .",
        "label": "NA"
    },
    {
        "text": "therefore , co-administration of DB01156 with drugs that are metabolized by cyp2d6 isoenzyme including certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } , ddrug8 { e , g , , ddrug9 , ddrug10 , ddrug11 } , ddrug12 { e , g , , DB00264 } , and ddrug14 { e , g , , ddrug15 , ddrug16 } , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .",
        "label": "advise"
    },
    {
        "text": "the influence of DB00683 and ddrug1 on antinociceptive effect of ddrug2 { 10 mg/kg } , DB04817 { 500 mg/kg } and ddrug4 { 10 mg/kg } was investigated in a mouse model using the tail-flick and hot-plate tests .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : HD00536 appear to have no significant effect on the bioavailability of DB00537 .",
        "label": "NA"
    },
    {
        "text": "DB01075 has additive effects with ddrug1 and other HD00261 { ddrug3 , ddrug4 , ddrug5 , etc } .",
        "label": "effect"
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a HD00533 , including ddrug1 , with multivalent cation-containing products such as ddrug2 or ddrug3 HD00374 , ddrug5 , ddrug6 chewable/buffered tablets or pediatric powder , or products containing ddrug7 , ddrug8 , or ddrug9 may substantially decrease the absorption of ddrug10 , resulting in serum and urine levels considerably lower than desired .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 should be avoided by patients with a history of serious reaction to any ddrug1 , including HD00387 and DB09276 .",
        "label": "NA"
    },
    {
        "text": "we demonstrate that the conversion of ddrug0 to HD00077 by an nad + - dependent oxidation is the rate-limiting step in the synthesis of the toxic product , HD00078 from ddrug3 .",
        "label": "NA"
    },
    {
        "text": "before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : ddrug0 { e , g , , ddrug1 , ddrug2 } , DB00681 , ddrug4 , ddrug5 drugs { e , g , , ddrug6 } , ddrug7 , DB00512 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { DB00900 } chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with , or within # hours of , the administration of DB01059 , because these products may interfere with absorption resulting in lower serum and urine levels of ddrug3 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , HD00002 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , DB01601 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "DB01234 at 10 { -10 } m or HD00147 at about # x 10 { -9 } m inhibits proliferation stimulated by ddrug2 .",
        "label": "NA"
    },
    {
        "text": "effects of ddrug0 on low-dose HD00717 a group of # nonsmoking , healthy white female volunteers established on an oral ddrug2 regimen containing # mg DB00977 and # mg ddrug4 for at least # months received # mg/day of ddrug5 from midcycle { day 15 } to midcycle { day 14 } of two consecutive oral ddrug6 cycles .",
        "label": "NA"
    },
    {
        "text": "the purpose of this study was to evaluate the effect of ddrug0 { HD00072 } and ddrug2 { ddrug3 } conjugates on the intestinal permeation of ddrug4 { HD00070 } and model peptide drugs , ddrug6 and ddrug7 .",
        "label": "NA"
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the ddrug0 of drugs may be potentiated by DB02325 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , the ddrug6 , ddrug7 and ddrug8 , HD00275 and the ddrug10 , and by other ddrug11 .",
        "label": "NA"
    },
    {
        "text": "the following are examples of drugs known to inhibit the metabolism of other related ddrug0 , presumably through inhibition of cyp3a : ddrug1 , ddrug2 , ddrug3 , DB00343 , ddrug5 , and some HD00093 .",
        "label": "NA"
    },
    {
        "text": "the auc of DB00537 was decreased an average of 15-fold in # healthy subjects given ddrug1 and DB00900 - placebo tablets concurrently .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a clinical pharmacology study , coadministration of an ddrug1 { ddrug2 , ddrug3 , and ddrug4 } with ddrug5 reduced serum levels and urinary excretion of ddrug6 as compared with DB00492 administered alone , suggesting that HD00374 may impair absorption of ddrug9 .",
        "label": "NA"
    },
    {
        "text": "in clinical trials , ddrug0 was used with ddrug1 , HD00218 , ddrug3 , oral ddrug4 , and supplemental ddrug5 , in a pharmacokinetic substudy in patients with congestive heart failure receiving ddrug6 or ddrug7 in whom therapy with ddrug8 was initiated , apparent oral clearance values for DB00695 { n = 23 } and ddrug10 { n = 30 } were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .",
        "label": "NA"
    },
    {
        "text": "although neither ddrug0 nor ddrug1 affected the proliferation of prostatic epithelium in rpmi1640 containing HD00149 alone , they modify the mitogenic effect of ddrug3 and HD00071 .",
        "label": "NA"
    },
    {
        "text": "HD00282 : in a pharmacokinetic study , maximum plasma concentrations of ddrug1 were considerably lower in epileptic patients on long-term ddrug2 therapy { eg , ddrug3 , ddrug4 , or DB01174 } than in healthy volunteers .",
        "label": "NA"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { ddrug1 s } , DB00564 , ddrug3 { ddrug4 may decrease the effects of these medicines } , ddrug5 { using these medicines with ddrug6 may result in increased cns depressant effects } , ddrug7 , ddrug8 { using these medicines with ddrug9 may change the amount of either medicine that you need to take } , and oral ddrug10 containing ddrug11 { HD00026 may decrease the effectiveness of these oral ddrug13 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose ddrug0 and HD00251 , specifically , ddrug2 , ddrug3 , DB00675 and ddrug5 .",
        "label": "NA"
    },
    {
        "text": "DB00788 and other ddrug1 can reduce the antihypertensive effect of ddrug2 and other HD00254 .",
        "label": "effect"
    },
    {
        "text": "medications can interfere with folate utilization , including : ddrug0 { such as ddrug1 , and ddrug2 } ddrug3 { sometimes prescribed to control blood sugar in type # diabetes } ddrug4 { used to control inflammation associated with crohn_disease and ulcerative colitis } ddrug5 { a ddrug6 } DB00563 there has been concern about the interaction between ddrug8 and DB00158 .",
        "label": "NA"
    },
    {
        "text": "DB00562 may interact with ddrug1 , ddrug2 s , HD00404 { allergy , cold , and sinus medicines } , diabetic drugs , ddrug4 , ddrug5 , ddrug6 like ddrug7 or ddrug8 , and high blood pressure medications .",
        "label": "int"
    },
    {
        "text": "agents with increased levels in the presence of ddrug0 : HD00472 increases the plasma levels of the following agents : ddrug2 , ddrug3 { 6 } , and DB00794 thus , if a patient has been titrated to a stable dosage on one of the agents in this category , and then begins a course of the treatment with ddrug5 , it is reasonable to expect that a dose decrease for the concomitant agent may be necessary .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : combination ddrug1 may decrease the clearance of some ddrug2 { ddrug3 , DB00475 , ddrug5 } and increase the clearance of others { DB00186 , ddrug7 , ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and DB00759 , HD00282 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "if ddrug0 is to be combined with other ddrug1 such as ddrug2 or HD00596 / ddrug4 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of ddrug5 and HD00100 { e , g , , ddrug7 or ddrug8 } are additive .",
        "label": "NA"
    },
    {
        "text": "DB00390 and DB00661 use may be rarely associated with ventricular fibrillation when combined with ddrug2 .",
        "label": "NA"
    },
    {
        "text": "if ddrug0 or other hepatic enzyme inducers are taken concurrently with ddrug1 or DB00280 , lower plasma levels of DB00280 may occur .",
        "label": "NA"
    },
    {
        "text": "both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when DB00802 is administered in combination with other HD00261 such as ddrug2 , ddrug3 , ddrug4 , or inhalation general ddrug5 .",
        "label": "effect"
    },
    {
        "text": "DB00819 may prevent the urinary antiseptic effect of DB06799 .",
        "label": "effect"
    },
    {
        "text": "both HD00021 and HD00022 block ddrug2 - induced and ddrug3 - induced dopamine release in the nucleus accumbens ;",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect : ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , ddrug5 , ddrug6 , ddrug7 } , ddrug8 , HD00808 , ddrug10 , ddrug11 , ddrug12 , HD00810 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "effects of ddrug0 on low-dose ddrug1 a group of # nonsmoking , healthy white female volunteers established on an oral HD00349 regimen containing # mg DB00977 and # mg ddrug4 for at least # months received # mg/day of ddrug5 from midcycle { day 15 } to midcycle { day 14 } of two consecutive oral ddrug6 cycles .",
        "label": "NA"
    },
    {
        "text": "ddrug0 should not be used concomitantly with other drugs known to prolong the qt interval : certain ddrug1 , including those of class ia { such as ddrug2 and DB01035 } and class iii { such as DB00489 } ;",
        "label": "NA"
    },
    {
        "text": "coadministration of DB00220 and drugs that induce cytochrome_p450_family_3_subfamily_a may decrease DB00220 plasma concentrations and reduce its therapeutic effect .",
        "label": "NA"
    },
    {
        "text": "in vitro studies indicate that DB00303 does not inhibit p-glycoprotein-mediated transport of DB00390 or ddrug2 and that ddrug3 is not a substrate for p-glycoprotein-mediated transport .",
        "label": "NA"
    },
    {
        "text": "HD00343 ddrug1 , as well as a metabolite of ddrug2 , slow DB00182 metabolism .",
        "label": "NA"
    },
    {
        "text": "this drug may interact with ddrug0 or other HD00261 { may potentiate the cns depressant effects of either these medications or ddrug2 } , ddrug3 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug4 } , and HD00445 { concurrent use with ddrug6 may prolong and intensify the anticholinergic and cns depressant effects of ddrug7 } .",
        "label": "NA"
    },
    {
        "text": "HD00095 : ddrug1 , DB00641",
        "label": "NA"
    },
    {
        "text": "based on adult data , lower doses of ddrug0 may be needed following coadministration of drugs which are reported to decrease ddrug1 elimination { e , g , , DB00501 and ddrug3 } and higher ddrug4 doses may be needed following coadministration of drugs that increase ddrug5 elimination { e , g , , DB01174 and ddrug7 } .",
        "label": "NA"
    },
    {
        "text": "the action of the HD00100 may be potentiated by ddrug1 , ddrug2 , ddrug3 , HD00026 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , or other drugs that produce cns depression .",
        "label": "effect"
    },
    {
        "text": "because ddrug0 is highly bound to serum protein , the administration of DB01242 to patients taking other drugs that are highly bound to protein { e , g , , DB00682 , ddrug3 } may cause an increase in plasma concentrations of these drugs , potentially resulting in adverse effects .",
        "label": "mechanism"
    },
    {
        "text": "this article looks at five commonly used HD00084 in turn { ddrug1 , ddrug2 , DB00993 , ddrug4 , ddrug5 } , discussing the main , non-infection , unwanted effects , ways to avoid them and what to do if problems arise .",
        "label": "NA"
    },
    {
        "text": "the concomitant administration of ddrug0 including DB01059 with DB01016 { a ddrug3 } has , on rare occasions , resulted in severe hypoglycemia .",
        "label": "effect"
    },
    {
        "text": "because there is a theoretical basis that these effects may be additive , use of DB00201 - containing or ddrug1 { like ddrug2 or ddrug3 } and DB00918 within # hours of each other should be avoided .",
        "label": "advise"
    },
    {
        "text": "ddrug0 or DB00228 administered with DB06690 / ddrug3 to achieve # mac -lsb- minimum alveolar concentration -rsb- may prolong the clinically effective duration of action of initial and maintenance doses of ddrug4 and decrease the required infusion rate of ddrug5 .",
        "label": "NA"
    },
    {
        "text": "- ddrug0 or HD00421 { with hepatotoxic potential } must not be administered together with HD00414 or ddrug3 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 { ' DB01224 ' } is a newly introduced HD00030 with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia .",
        "label": "NA"
    },
    {
        "text": "other drugs : in healthy volunteers , ddrug0 , DB00252 , ddrug2 , ddrug3 , ddrug4 , hormone replacement therapy { a combination of conjugated ddrug5 and ddrug6 } , ddrug7 { ddrug8 and DB09104 } and ddrug10 did not affect the pharmacokinetics of ddrug11 .",
        "label": "NA"
    },
    {
        "text": "because oral ddrug0 may interfere with the hepatic metabolism of DB00252 , toxic levels of the HD00329 may occur when an oral ddrug3 and ddrug4 are administered concurrently .",
        "label": "NA"
    },
    {
        "text": "drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on ddrug0 therapy : ddrug1 , ddrug2 , ddrug3 , oral HD00283 containing ddrug5 , DB11119 - containing preparations and the numerous preparations containing ddrug7 .",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing DB01370 , ddrug3 , or ddrug4 , with ddrug5 , with metal cations such as ddrug6 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as DB00900 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "alternatives to DB01211 , such as DB00207 , should be considered .",
        "label": "NA"
    },
    {
        "text": "administration of DB01045 concomitantly with oral ddrug1 has been shown to result in decreases in serum concentrations of DB01118 and ddrug3 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 / DB00052 : excessive concurrent use of HD00849 may accelerate epiphyseal closure .",
        "label": "NA"
    },
    {
        "text": "other drug interactions oral ddrug0 ddrug1 { 500 mg twice daily } did not influence the pharmacokinetics of an oral HD00349 containing # mg ddrug3 and # mg DB00367 , or of the luteinizing hormone and progesterone levels , indicating that impairment of contraceptive efficacy is unlikely .",
        "label": "NA"
    },
    {
        "text": "the incidence of upper gastrointestinal events in patients concomitantly taking DB00945 or HD00203 was similar in patients taking ddrug2 # mg daily { # % } and # mg once monthly { # % } .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 : in one study , ddrug1 was given to adult diabetics who were already receiving DB01016 { n = 4 } , ddrug3 { n = 2 } ddrug4 with ddrug5 { n = 3 } or ddrug6 with DB00914 { n = 6 } .",
        "label": "NA"
    },
    {
        "text": "until data on possible interactions between ddrug0 and DB00280 are obtained , ddrug2 should not be administered within # hours before or # hours after DB00661 administration .",
        "label": "NA"
    },
    {
        "text": "co-administration of DB01032 with DB00787 has been shown to increase the mean half-life and the area under the concentration-time curve .",
        "label": "mechanism"
    },
    {
        "text": "based on the results of these studies , it is concluded that DB00207 may be safely coadministered with both ddrug1 and DB00900 .",
        "label": "NA"
    },
    {
        "text": "other drug interactions ddrug0 , ddrug1 and DB00647 had no effect on the pharmacokinetics of HD00888 .",
        "label": "NA"
    },
    {
        "text": "if ddrug0 is to be combined with other ddrug1 such as ddrug2 or ddrug3 / ddrug4 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of DB01151 and HD00100 { e , g , , ddrug7 or ddrug8 } are additive .",
        "label": "effect"
    },
    {
        "text": "ddrug0 including DB00752 , ddrug2 , and DB01626 hc1 : concomitant use of ddrug4 and non-selective ddrug5 may cause hypertension .",
        "label": "NA"
    },
    {
        "text": "concomitant treatment with HD00246 { ddrug1 , ddrug2 } , ddrug3 , or ddrug4 may potentiate any hypokalemic effect of HD00355 .",
        "label": "effect"
    },
    {
        "text": "in vitro studies have shown no binding displacement between DB00494 and other highly bound drugs , such as ddrug1 , ddrug2 , DB00812 , and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "possible extrarenal mechanisms of action of DB00501 on ddrug1 and DB08948 transport were also examined .",
        "label": "NA"
    },
    {
        "text": "the possibility of increased interaction should be kept in mind when HD00760 doses greater than # mg as a single dose or # mg of DB01009 per day are used concomitantly with highly bound drugs .",
        "label": "NA"
    },
    {
        "text": "the effect of DB00465 on plasma ddrug1 has not been studied , but cases of increased DB14507 plasma levels during ddrug3 therapy have been reported .",
        "label": "NA"
    },
    {
        "text": "since ddrug0 { DB00593 } may interact with concurrently administered ddrug2 , periodic serum level determinations of these drugs may be necessary { eg , ddrug3 may elevate DB00252 serum levels and ddrug5 has been reported to both increase and decrease ddrug6 levels } .",
        "label": "NA"
    },
    {
        "text": "therefore , when ddrug0 is given with DB00266 or DB00682 , a period of at least # hours after the last intravenous dose or # hours after the last subcutaneous dose should elapse before blood is drawn if a valid prothrombin time is to be obtained .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : since DB00714 is a ddrug2 , it is possible that ddrug3 , such as the ddrug4 { ddrug5 , ddrug6 , ddrug7 } or DB01233 , may diminish the effectiveness of ddrug9 .",
        "label": "NA"
    },
    {
        "text": "however , co administration of ddrug0 with either ddrug1 or DB00199 led to increased plasma concentrations of DB00950 .",
        "label": "NA"
    },
    {
        "text": "since ddrug0 { ddrug1 } may interact with concurrently administered HD00703 , periodic serum level determinations of these drugs may be necessary { eg , DB00593 may elevate ddrug4 serum levels and ddrug5 has been reported to both increase and decrease ddrug6 levels } .",
        "label": "NA"
    },
    {
        "text": "in vivo interaction studies in humans have demonstrated that ddrug0 and DB00682 do not affect the pk properties of ddrug2 , nor does ddrug3 affect the pk properties of DB00390 or ddrug5 .",
        "label": "NA"
    },
    {
        "text": "tablets simultaneous administration of DB00364 and ddrug1 tablets may reduce the natriuretic and antihypertensive effects of DB00695 .",
        "label": "NA"
    },
    {
        "text": "additional DB01592 significantly inhibited the absorption of ddrug1 in both dietary DB14574 treatments .",
        "label": "mechanism"
    },
    {
        "text": "immediate and extended release tablets the hypoglycemic action of ddrug0 may be potentiated by certain drugs including ddrug1 , some HD00768 and other drugs that are highly protein bound , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and HD00520 .",
        "label": "NA"
    },
    {
        "text": "caution should be exercised when the following drugs are administered concomitantly with ddrug0 { DB00190 } given with ddrug2 or ddrug3 - DB01235 combination products .",
        "label": "NA"
    },
    {
        "text": "an adequate period of observation must be provided for any patient in whom either ddrug0 { such as DB00829 } or large doses of ddrug2 { such as # mg of DB00683 } have been used .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 iv/im reduced the HD00295 response to DB00695 in normovolemic healthy subjects by approximately 20 % { mean sodium and urinary output decreased 17 % } .",
        "label": "NA"
    },
    {
        "text": "this appears to be the only clinically relevant interaction of this kind with DB00358 , although theoretically , coadministration of other drugs known to alter cardiac conduction { eg , ddrug1 or ddrug2 , HD00377 , ddrug4 or ddrug5 , ddrug6 and ddrug7 } might also contribute to a prolongation of the qtc interval .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : coadministration of DB01045 and ddrug2 suspension results in a significant decrease in average steady - state plasma DB01117 concentrations .",
        "label": "NA"
    },
    {
        "text": "although a causal mechanism and a cause-and-effect relationship have not been established , current evidence suggests that renal function should be monitored in patients on HD00029 and DB00437 even in the absence of renal failure , and dosage levels should be even more conservatively adjusted in those patients on such combined therapy if diminished renal function is detected , .",
        "label": "advise"
    },
    {
        "text": "co-administration of DB00864 and ddrug1 resulted in markedly increased plasma concentrations of DB00559 in animals .",
        "label": "NA"
    },
    {
        "text": "DB11058 - concomitant intake of ddrug1 and DB01022 may reduce the absorption of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "DB14513 / ddrug1 - containing ddrug2 : absorption of ddrug3 is moderately reduced { approximately 25 % } when coadministered with ddrug4 / ddrug5 - containing HD00701 .",
        "label": "NA"
    },
    {
        "text": "the principal drugs given { number of patients in parentheses } were : ddrug0 { 115 } , ddrug1 and ddrug2 { 103 } , HD00778 { 52 } , oral ddrug4 { 45 } , cough and cold preparations { 45 } , ddrug5 { 38 } , ddrug6 { 29 } , HD00779 { 24 } , oral ddrug8 { 18 } , ddrug9 { 13 } , ddrug10 { 10 } , and ddrug11 { 10 } .",
        "label": "NA"
    },
    {
        "text": "the concurrent use of two or more drugs with anticholinergic activity -- such as an ddrug0 { eg , DB00477 } , an ddrug2 { eg , ddrug3 } , and/or a ddrug4 { eg , DB00321 } -- commonly results in excessive anticholinergic effects , including dry mouth and associated dental complications , blurred vision , and , in patients exposed to high temperature and humidity , hyperpyrexia .",
        "label": "effect"
    },
    {
        "text": "inhibitors of this isoenzyme { e , g , , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , grapefruit juice , HD00641 , ddrug8 , ddrug9 , ddrug10 } should be cautiously coadministered with ddrug11 as they can potentially increase DB00204 levels .",
        "label": "NA"
    },
    {
        "text": "there is a significant increase in exposure to DB00619 when DB00619 is coadministered with ddrug2 { cyp3a4 inhibitor } .",
        "label": "NA"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { ddrug1 s } , ddrug2 , ddrug3 { ddrug4 may decrease the effects of these medicines } , ddrug5 { using these medicines with ddrug6 may result in increased cns depressant effects } , DB00313 , ddrug8 { using these medicines with HD00026 may change the amount of either medicine that you need to take } , and oral ddrug10 containing ddrug11 { ddrug12 may decrease the effectiveness of these oral ddrug13 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "no interaction with the ddrug0 DB00458 was shown in a single-dose study with ddrug2 without coadministered DB01235 / ddrug4 .",
        "label": "NA"
    },
    {
        "text": "in two controlled crossover clinical pharmacology studies in healthy male { n = 12 in each study } a nd female { n = 12 in each study } volunteers , ddrug0 # mg { # times the daily dose } once daily was coadministered with DB00199 # mg every # hours or DB01026 # mg every # hours for # days .",
        "label": "NA"
    },
    {
        "text": "DB01032 : as with other ddrug1 , ddrug2 inhibits the renal excretion of DB00535 , resulting in an approximate doubling in a , c , a 54 % increase in peak ddrug4 plasma levels , and a 50 % prolongation in the apparent elimination half-life .",
        "label": "NA"
    },
    {
        "text": "the use of DB00640 in patients receiving HD00118 may be rarely associated with ventricular fibrillation .",
        "label": "effect"
    },
    {
        "text": "drugs decreasing ddrug0 effect : ddrug1 , ddrug2 , ddrug3 , or HD00388 may partially counteract the anticoagulant action of DB01109 .",
        "label": "effect"
    },
    {
        "text": "coadministration of DB01045 with ddrug1 lowered the DB00343 plasma concentrations to undetectable levels .",
        "label": "NA"
    },
    {
        "text": "in long surgical procedures during ddrug0 or DB00753 anesthesia , less frequent maintenance dosing , lower maintenance doses , or reduced infusion rates of DB00565 may be necessary .",
        "label": "advise"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , HD00002 such as ddrug4 and DB00759 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "however , co administration of DB00950 with either DB01026 or ddrug2 led to increased plasma concentrations of ddrug3 .",
        "label": "mechanism"
    },
    {
        "text": "DB00825 / ddrug1 { e , g , , ddrug2 , DB00945 , ddrug4 and ddrug5 combinations , ddrug6 , ddrug7 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 should be administered with caution to patients who are taking other ddrug1 or HD00261 , including DB02325 , ddrug4 and ddrug5 , or to those with a history of psychiatric disorder { including manic-depressive illness and schizophrenia } .",
        "label": "NA"
    },
    {
        "text": "a direct causal relationship has not been established , but physicians should consider the possibility that ddrug0 may alter a diabetic patient s response to HD00071 or oral HD00062 .",
        "label": "NA"
    },
    {
        "text": "DB00503 and DB00224 : upon concomitant administration of # mg of ddrug2 with # mg bid ddrug3 , the cmax and auc of ddrug4 were reduced by approximately 20 % .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { ddrug1 } : ddrug2 { e , g , , DB00472 , ddrug4 , ddrug5 , ddrug6 } have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with HD00277 .",
        "label": "effect"
    },
    {
        "text": "the pharmacokinetics of ddrug0 and its acid metabolite and the electrocardiographic qt c interval were measured during both periods : with ddrug1 alone , and with DB00342 plus DB00954 .",
        "label": "NA"
    },
    {
        "text": "although DB00661 administered at either dose had little or no effect on the enhancement of intestinal carcinogenesis by DB11724 or on the location , histologic type , depth of involvement , labeling index , apoptotic index or tumor vascularity of intestinal cancers , it significantly decreased the incidence of cancer metastasis .",
        "label": "NA"
    },
    {
        "text": "DB00640 effects are potentiated by DB00975 .",
        "label": "effect"
    },
    {
        "text": "drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on HD00849 therapy : ddrug1 , ddrug2 , ddrug3 , oral ddrug4 containing HD00220 , ddrug6 - containing preparations and the numerous preparations containing ddrug7 .",
        "label": "NA"
    },
    {
        "text": "DB00829 at doses of # mg/kg and # mg/kg injected with DB00295 was found to decrease the antinociceptive effect of ddrug2 .",
        "label": "effect"
    },
    {
        "text": "induction of apoptosis in breast cancer cells in response to DB11094 and HD00177 .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 : in one study , ddrug1 was given to adult diabetics who were already receiving ddrug2 { n = 4 } , DB00331 { n = 2 } DB00672 with ddrug5 { n = 3 } or ddrug6 with ddrug7 { n = 6 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00320 { ddrug2 } injection , usp should not be used with HD00623 because the combination may cause synergistic elevation of blood pressure .",
        "label": "effect"
    },
    {
        "text": "co-administration of ddrug0 and HD00249 or other agents interfering with neuromuscular transmission { e , g , , ddrug2 } should only be performed with caution as the effect of the HD00437 may be potentiated .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { HD00712 } , DB01045 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "caution should be used when administering or taking ddrug0 with DB01026 and other strong cyp3a4 inhibitors such as , but not limited to , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , DB00220 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { ddrug12 } , and ddrug13 .",
        "label": "NA"
    },
    {
        "text": "the HD00100 , including DB00404 , produce additive cns depressant effects when co-administered with other ddrug2 , ddrug3 , ddrug4 , ddrug5 , and other drugs which themselves produce cns depression .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a clinical pharmacology study , coadministration of an ddrug1 { ddrug2 , ddrug3 , and ddrug4 } with ddrug5 reduced serum levels and urinary excretion of ddrug6 as compared with ddrug7 administered alone , suggesting that HD00374 may impair absorption of DB00492 .",
        "label": "mechanism"
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit DB00451 binding to serum proteins or alter the concentrations of serum binding proteins : ddrug1 and related ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , DB00252 , ddrug16 , ddrug17 .",
        "label": "mechanism"
    },
    {
        "text": "effects of other ddrug0 on ddrug1 ddrug2 : DB00252 causes an approximate doubling of the clearance of ddrug4 { ddrug5 } at steady state and , therefore , the addition of ddrug6 causes an approximate 45 % decrease in the steady-state trough concentrations of DB00949 as compared to the same dose of ddrug8 given as monotherapy .",
        "label": "NA"
    },
    {
        "text": "coadministration of single , oral doses of ddrug0 with DB00199 { 10 mg and # mg , respectively } , a strong , selective cyp3a4 inhibitor produced a 34 % increase in DB00962 s maximal plasma concentrations and a 20 % increase in the area under the plasma concentration-time curve .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and DB01285 { ddrug2 } : may potentiate DB00681 - induced hypokalemia which may predispose the patient to cardiac dysfunction .",
        "label": "effect"
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 : ddrug3 has no significant pharmacokinetic interactions with ddrug4 and DB00393 , and DB00678 has no significant effect on plasma levels of ddrug7 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , DB00446 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , ddrug12 } , HD00297 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00402 # mg administered daily for # days did not affect the pharmacokinetics of ddrug2 or DB14055 nor were there any changes in the pharmacodynamic profile { prothrombin time } following a single # mg oral dose of ddrug4",
        "label": "NA"
    },
    {
        "text": "DB00294 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , DB01045 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "int"
    },
    {
        "text": "administration of DB00343 concomitantly with ddrug1 in five normal volunteers resulted in increased DB00571 levels in all subjects and bioavailability of ddrug3 was increased approximately 50 % .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : although the results of a clinical study did not indicate a safe problem associated with the administration of DB00320 { ddrug2 } injection , usp to subjects already receiving ddrug3 , there have been reports that DB00571 may potentiate the vasoconstrictive action of ddrug5 by blocking the vasodilating property of epinephrine .",
        "label": "NA"
    },
    {
        "text": "increases in plasma levels of ddrug0 , and in the frequency and severity of side effects , particularly ddrug1 , have been reported when DB00501 was added to the HD00317 regimen .",
        "label": "NA"
    },
    {
        "text": "the concurrent use of ddrug0 injection with other HD00444 or medications with anticholinergic activity , such as ddrug2 , ddrug3 , or HD00043 , may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects .",
        "label": "NA"
    },
    {
        "text": "when combined with ddrug0 , HD00050 exhibited strong synergistic activity while only additive effects were observed with the combination of ddrug2 { or DB00615 } and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "the administration of DB01018 concomitantly with known microsomal enzyme inducer { DB01174 or ddrug2 } to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : DB00316 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , DB01174 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "may interact ddrug0 { altered hypo-prothrombinemic effect } , ddrug1 , ddrug2 and other inducers of hepatic microsomal enzyme oxidation system { decreased effect of DB00255 } , ddrug4 { increased effect of HD00175 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : as with other HD00501 , the renal excretion of DB00567 is inhibited by ddrug3 .",
        "label": "NA"
    },
    {
        "text": "other agents : DB00722 has been used concomitantly with ddrug1 and/or DB00390 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "- a ddrug0 { HD00725 } such as ddrug2 { ddrug3 } , ddrug4 { DB00752 } , or ddrug6 { ddrug7 } ;",
        "label": "NA"
    },
    {
        "text": "this observed increase in the bioavailability of DB00950 may be due to transport-related effects , such as p-glycoprotein , in vivo animal studies also suggest that in addition to enhancing absorption , DB01026 decreases ddrug2 gastrointestinal secretion , while ddrug3 may also decrease biliary excretion .",
        "label": "NA"
    },
    {
        "text": "while the effects of chronic DB00252 or ddrug1 therapy on the action of DB00565 are unknown , slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher .",
        "label": "effect"
    },
    {
        "text": "interactions may also occur with the following : HD00515 / ddrug1 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , HD00516 pain medication { e , g , , ddrug12 } , drugs used to aid sleep , drowsiness-causing ddrug13 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "certain drugs including HD00217 , ddrug1 , ddrug2 , and ddrug3 may reduce the hypoglycemic action of DB00731 and other oral ddrug5 .",
        "label": "effect"
    },
    {
        "text": "DB00898 : clinical evidence has shown that DB00926 can be formed with concurrent ingestion of ddrug2 and ddrug3 .",
        "label": "NA"
    },
    {
        "text": "increasing the DB00949 dose to # mg/day in six of these subjects increased the steady-state DB00252 cmin to # 7 micrograms/ml .",
        "label": "mechanism"
    },
    {
        "text": "therefore , coadministration of DB00673 with drugs that strongly induce cyp3a4 activity { e , g , , ddrug1 , ddrug2 , DB00252 } may result in reduced plasma concentrations of ddrug4 that may result in decreased efficacy of ddrug5 .",
        "label": "mechanism"
    },
    {
        "text": "as with other ddrug0 , the antihypertensive effect of DB00678 may be blunted by the ddrug2 DB00328",
        "label": "effect"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 DB00264 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 DB00472 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "pharmacologic studies indicate that there may be additive effects in prolonging av conduction when using ddrug0 or HD00118 concomitantly with DB00343 .",
        "label": "effect"
    },
    {
        "text": "other drugs drug interactions have been reported with concomitant administration of DB00199 and other medications , including ddrug1 , DB01355 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 .",
        "label": "int"
    },
    {
        "text": "the incidence of upper gastrointestinal events in patients concomitantly taking DB00945 or ddrug1 was similar in patients taking DB00710 # mg daily { # % } and # mg once monthly { # % } .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 : in one study , ddrug1 was given to adult diabetics who were already receiving ddrug2 { n = 4 } , DB00331 { n = 2 } ddrug4 with ddrug5 { n = 3 } or DB01016 with ddrug7 { n = 6 } .",
        "label": "NA"
    },
    {
        "text": "however , this sample size is too small to allow for any conclusions to be drawn regarding the risk of rashes with concomitant DB01060 and DB00437 use .",
        "label": "NA"
    },
    {
        "text": "activity of HD00063 alone and in combination with DB00207 and ddrug2 against cryptosporidium parvum in cell culture .",
        "label": "NA"
    },
    {
        "text": "the clearance of ddrug0 metabolized by glucuronidation { e , g , , ddrug1 , ddrug2 , DB00231 } is unlikely to be affected by DB00176 .",
        "label": "NA"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { ddrug1 s } , ddrug2 , ddrug3 { HD00026 may decrease the effects of these medicines } , ddrug5 { using these medicines with ddrug6 may result in increased cns depressant effects } , ddrug7 , DB00313 { using these medicines with ddrug9 may change the amount of either medicine that you need to take } , and oral ddrug10 containing ddrug11 { ddrug12 may decrease the effectiveness of these oral ddrug13 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "interactions with ddrug0 : HD00842 { eg , ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 } should not be administered to a patient who has received or is receiving a course of therapy with a HD00843 such as ddrug8 .",
        "label": "NA"
    },
    {
        "text": "in vitro studies have shown that the metabolism of DB01248 may be modified by the concomitant administration of compounds that induce , inhibit , or are metabolized by cytochrome p450 3a4 , such as ddrug1 , DB00342 , ddrug3 , ddrug4 , and ddrug5 .",
        "label": "mechanism"
    },
    {
        "text": "DB00294 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { DB01045 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "int"
    },
    {
        "text": "DB00316 : may increase plasma concentration of HD00706 , possibly by inhibiting conjugation .",
        "label": "mechanism"
    },
    {
        "text": "a drug-drug interaction study evaluated the effect of the use of DB00250 gel , 5 % , in combination with double_strength { 160 mg/800 mg } DB00440 / ddrug2 { ddrug3 / ddrug4 } .",
        "label": "NA"
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma ddrug0 concentrations include : acute DB02325 intake , ddrug2 , chboramphenicol , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , HD00745 , ddrug19 , ddrug20 , ddrug21",
        "label": "NA"
    },
    {
        "text": "HD00056 regimens consisted of two ddrug1 and one HD00058 .",
        "label": "NA"
    },
    {
        "text": "DB00405 can interact with ddrug1 or other ddrug2 { may potentiate the cns depressant effects of either these medications or ddrug3 } , ddrug4 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug5 } , and HD00445 { concurrent use with ddrug7 may prolong and intensify the anticholinergic and cns depressant effects of ddrug8 } .",
        "label": "int"
    },
    {
        "text": "DB00876 doses of up to # mg b , i , d , have been safely used concomitantly with sustained-release ddrug1 { sustained-release DB01115 } with no clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 , and DB00199 may increase plasma levels of DB00363 , potentially resulting in adverse effects .",
        "label": "mechanism"
    },
    {
        "text": "the anxiogenic effects of ddrug0 were reduced by pretreatment with HD00184 , an a2-selective agonist , but not by HD00185 { ddrug3 } , an a1-selective agonist .",
        "label": "NA"
    },
    {
        "text": "since higher doses of DB01026 { 400 mg daily } may result in higher increases in cmax and auc , a single # mg dose of DB00862 should not be exceeded in a 24-hour period when used in combination with ddrug2 # mg daily .",
        "label": "NA"
    },
    {
        "text": "DB00502 reduced or eliminated the increases in fi responding produced by intermediate doses of either HD00156 or ddrug2 in pigeons , but did not antagonize the decreases in fi or fr responding produced by high doses of pgpep1 or either stereoisomer of ddrug3 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : the concomitant use of ddrug1 { ddrug2 transdermal system } with other HD00389 , including but not limited to other ddrug4 , ddrug5 , ddrug6 , ddrug7 { e , g , , HD00100 } , general ddrug9 , ddrug10 , ddrug11 , and ddrug12 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .",
        "label": "NA"
    },
    {
        "text": "DB14513 - and/or ddrug1 - containing ddrug2 , products containing ddrug3 { ddrug4 } , HD00752 containing ddrug6 or other metal cations , or ddrug7 { ddrug8 } chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after ddrug9 .",
        "label": "NA"
    },
    {
        "text": "the most significant drug interactions following administration of DB01320 are expected to occur with drugs that interact with DB00252 .",
        "label": "NA"
    },
    {
        "text": "toxicology studies of ddrug0 - related deaths reveal frequent involvement of other HD00389 , including ddrug2 , ddrug3 such as ddrug4 { DB00829 } , and , to a rising degree , ddrug6 .",
        "label": "NA"
    },
    {
        "text": "in addition , ddrug0 neither influenced the pharmacodynamics of ddrug1 , ddrug2 , DB00554 , and ddrug4 , nor the pharmacokinetics of DB00390 at steady state .",
        "label": "NA"
    },
    {
        "text": "however , other published reports describe modest elevations { less than two-fold } of DB00363 and metabolite concentrations when ddrug1 was taken with DB00715 , ddrug3 , and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 ddrug2 : absorption of DB00999 is impaired in the presence of HD00783 .",
        "label": "mechanism"
    },
    {
        "text": "in the first study , concomitant administration of # mg HD00503 and # g DB01432 resulted in decreases of more than 22 % for auc and 40 % for cmax when compared to dosing ddrug2 alone .",
        "label": "mechanism"
    },
    {
        "text": "oral DB00994 may enhance the effect of ddrug1 in HD00326 by decreasing vitamin k availability .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : HD00203 have produced an elevation of plasma ddrug2 levels and a reduction in renal DB14507 clearance .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 , ddrug2 , ddrug3 , DB00328 , ddrug5 , ddrug6 , and ddrug7 raise the serum ddrug8 concentration due to a reduction in clearance and/or in volume of distribution of the drug , with the implication that HD00118 intoxication may result .",
        "label": "NA"
    },
    {
        "text": "in another report , nine patients with breast cancer were reported to have decreased symptoms of DB00563 - related toxicity when given supplemental DB00130 at a dose of # gram/kilogram/day .",
        "label": "effect"
    },
    {
        "text": "in a patient with a nonfunctioning thyroid gland who is receiving thyroid replacement therapy , free ddrug0 may be decreased when HD00220 are started thus increasing DB00451 requirements .",
        "label": "NA"
    },
    {
        "text": "although HD00115 have been shown to reduce ddrug1 - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with DB00041 may reduce the antitumor effectiveness of ddrug3 and thus should be avoided , # ddrug4 and other ddrug5 may potentiate the hypotension seen with ddrug6 .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of DB00195 with the oral HD00025 ddrug2 has been shown not to potentiate the anticoagulant effect of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "co-administration of DB01026 , a strong inhibitor of cyp3a4 , increased DB01012 exposure following a single # mg dose of ddrug2 by # fold .",
        "label": "mechanism"
    },
    {
        "text": "DB00590 has been administered without any evidence of an adverse drug interaction to patients receiving ddrug1 , ddrug2 s , and HD00233 .",
        "label": "NA"
    },
    {
        "text": "background : the effects of combined administration of ddrug0 and ddrug1 { ddrug2 } , a HD00038 , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by HD00037 { ddrug5 } and the labeling index of intestinal_cancer were investigated in male wistar rats .",
        "label": "NA"
    },
    {
        "text": "co-administration of DB00704 with ddrug1 produced a 25 % increase in auc and a 33 % increase in the cmax of DB00659 .",
        "label": "NA"
    },
    {
        "text": "as HD00888 , the predominant plasma substrate , is only a weak inducer of udp-glucuronyl transferase , it is unlikely to have an effect on drugs that are mainly eliminated by conjugation through udp-glucuronyl transferase { e , g , , ddrug1 , DB00555 } .",
        "label": "NA"
    },
    {
        "text": "when DB01432 ddrug1 is given for long periods of time , concomitant supplementation with water-miscible { or parenteral } forms of HD00527 should be considered .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , DB00091 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , DB01045 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { eg , DB01199 } and other drugs , including ether , ddrug2 , HD00576 , ddrug4 and ddrug5 , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with ddrug6 parenteral .",
        "label": "NA"
    },
    {
        "text": "{ in some patients , the HD00787 can reduce the diuretic , natriuretic , and antihypertensive effects of ddrug1 , ddrug2 , and HD00029 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local HD00264 { e , g , , ddrug6 and ddrug7 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some DB00152 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 DB00564 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } DB01026 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "HD00374 increase the rate of absorption of ddrug1 , while DB01575 decreases it .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00999 , given concomitantly with DB01009 , produces a reduction in urinary potassium and chloride excretion compared to ddrug3 alone .",
        "label": "effect"
    },
    {
        "text": "the anxiogenic effects of DB00277 were reduced by pretreatment with HD00184 , an a2-selective agonist , but not by ddrug2 { ddrug3 } , an a1-selective agonist .",
        "label": "effect"
    },
    {
        "text": "ventricular tachycardia induced by DB01092 was generally converted to sinus rhythm following administration of ddrug1 , ddrug2 , or ddrug3 but not after administration of ddrug4 alone or after DB00312 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : concomitant administration of ddrug1 containing ddrug2 or DB01370 with DB00900 chewable/dispersible buffered tablets or pediatric powder for oral solution may potentiate adverse events associated with the ddrug5 components .",
        "label": "effect"
    },
    {
        "text": "DB00224 steady-state cmax , a , c , and cmin were decreased by 22 % , 38 % , and 27 % , respectively , by concomitant DB00701 .",
        "label": "mechanism"
    },
    {
        "text": "combination of ddrug0 with other HD00304 therapy should be reserved for patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to DB01118 .",
        "label": "NA"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , HD00326 { ddrug1 s } , ddrug2 , ddrug3 { ddrug4 may decrease the effects of these medicines } , ddrug5 { using these medicines with ddrug6 may result in increased cns depressant effects } , ddrug7 , ddrug8 { using these medicines with ddrug9 may change the amount of either medicine that you need to take } , and oral HD00283 containing ddrug11 { ddrug12 may decrease the effectiveness of these oral ddrug13 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "other drugs : in small groups of patients { 7 - 10 / interaction study } , the concomitant administration of DB00993 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , or ddrug6 did not significantly affect the peak levels and auc values of DB00586 .",
        "label": "NA"
    },
    {
        "text": "when ddrug0 was applied to the muscle in the presence of DB00692 , both first and second contractile responses to HD00140 were abolished .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { DB00682 } other ddrug2 ddrug3 ddrug4 DB00564 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "most of the above effects concerning HD00218 have been attributed , at least in part , to mechanisms involving inhibition of prostaglandin synthesis by DB00328 .",
        "label": "effect"
    },
    {
        "text": "HD00326 including coumarin derivatives , indandione derivatives , and ddrug1 such as ddrug2 { HD00203 } , and ddrug4 may increase the risk of bleeding when administered concomitantly with ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 ddrug1 ddrug2 ddrug3 DB00976 ddrug5 ddrug6 DB00091 large quantities of grapefruit juice { # quart daily }",
        "label": "NA"
    },
    {
        "text": "in one man , the c max of DB00342 was # ng/ml with ddrug1 alone and # ng/ml with ddrug2 plus DB00954 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - and/or ddrug1 - containing HD00374 , products containing ddrug3 { ddrug4 } , HD00752 containing ddrug6 or other metal cations , or ddrug7 { ddrug8 } chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after ddrug9 .",
        "label": "NA"
    },
    {
        "text": "- a HD00535 { ddrug1 } such as ddrug2 { ddrug3 , DB01050 , ddrug5 , others } , ddrug6 { ddrug7 , ddrug8 , ddrug9 } , ddrug10 { ddrug11 , ddrug12 } , ddrug13 { ddrug14 } , ddrug15 { ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , and ddrug21 { ddrug22 , ddrug23 , ddrug24 } ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 altered coagulation parameters and/or bleeding have been reported in patients taking ddrug1 concomitantly with ddrug2 such as DB00682 and DB00946 .",
        "label": "NA"
    },
    {
        "text": "in some patients , combined use of DB00328 and DB00861 has been associated with fatal gastrointestinal hemorrhage .",
        "label": "effect"
    },
    {
        "text": "ddrug0 , ddrug1 and DB00201 may enhance the effects of : other ddrug3 s , ddrug4 , general ddrug5 , ddrug6 such as ddrug7 , ddrug8 , or other HD00261 , causing increased cns depression .",
        "label": "effect"
    },
    {
        "text": "although the interaction between DB00918 and other potent cyp3a4 inhibitors { e , g , , DB01167 , ddrug2 , and ddrug3 } has not been studied , increased exposures to ddrug4 may be expected when ddrug5 is used concomitantly with these medications .",
        "label": "NA"
    },
    {
        "text": "the in vitro anti-cryptosporidial activity of HD00063 alone and in combination with ddrug1 and DB01017 was investigated .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 HD00388 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } DB01026 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "other cardiovascular agents : ddrug0 and ddrug1 iv have been used concomitantly with ddrug2 , DB00968 , ddrug4 , ddrug5 , ddrug6 , ddrug7 and DB00390 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "ddrug0 can interact with DB02325 or other ddrug2 { may potentiate the cns depressant effects of either these medications or ddrug3 } , ddrug4 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug5 } , and ddrug6 { concurrent use with HD00388 may prolong and intensify the anticholinergic and cns depressant effects of ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 { eg , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , DB00404 , and ddrug15 } may have elevated plasma concentrations when coadministered with DB01232 ;",
        "label": "mechanism"
    },
    {
        "text": "DB00252 , ddrug1 , and ddrug2 may decrease DB00363 plasma levels , resulting in a decrease in effectiveness of a previously effective ddrug4 dose .",
        "label": "mechanism"
    },
    {
        "text": "-lsb- the gaba-ergic system and brain edema -rsb- it has been shown in rats with experimental toxic and traumatic edemas that DB00466 { 1 mg/kg } removes the antiedematous action of ddrug1 , ddrug2 , HD00134 and ddrug4 and reduces the action of ddrug5 .",
        "label": "effect"
    },
    {
        "text": "in a single-dose crossover study examining DB00448 # mg and ddrug1 # mg each administered alone and concomitantly with ddrug2 # gram , absorption of the HD00587 was delayed and their bioavailability was reduced by 17 % and 16 % , respectively , when administered concomitantly with ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : combination HD00432 may decrease the clearance of some ddrug2 { DB00404 , ddrug4 , ddrug5 } and increase the clearance of others { ddrug6 , ddrug7 , ddrug8 } .",
        "label": "mechanism"
    },
    {
        "text": "because of reports of prolongation of the prothrombin time beyond the therapeutic range in patients taking concurrent DB00848 and ddrug1 , it is suggested that the prothrombin time be monitored carefully , and the dose of DB00682 or other ddrug3 - like drugs should be adjusted accordingly , in patients taking both drugs .",
        "label": "NA"
    },
    {
        "text": "-lsb- a pharmacological analysis of the effect of ddrug0 on stimulated gastric secretion -rsb- chronic experiments on dogs with gastric fistulas were carried out to study the influence of HD00196 and ddrug2 on ddrug3 - and DB05381 - induced gastric acid secretion .",
        "label": "NA"
    },
    {
        "text": "in comparison with ddrug0 , the adverse events reported significantly more frequently with DB00334 in > or = # % of patients were dry mouth , bodyweight gain and increased appetite and compared with DB00734 , only bodyweight gain occurred significantly more frequently with ddrug3 .",
        "label": "NA"
    },
    {
        "text": "therefore , administration of HD00532 with ddrug1 containing ddrug2 , ddrug3 , or DB01370 ;",
        "label": "NA"
    },
    {
        "text": "patients receiving other ddrug0 s , general ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 or other HD00261 { including ddrug7 } concomitantly with DB00327 may exhibit an additive cns depression .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { HD00548 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , DB01045 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with ddrug1 , ddrug2 s , ddrug3 { allergy , cold , and sinus medicines } , diabetic drugs , ddrug4 , ddrug5 , ddrug6 like DB00788 or DB01050 , and high blood pressure medications .",
        "label": "NA"
    },
    {
        "text": "caution should be observed when DB00913 is coadministered with other ddrug1 , ddrug2 , ddrug3 , or HD00264 , as these agents may increase respiratory and circulatory depression .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : DB00467 is a potent inhibitor of the cyp4f3 isozymes responsible for the metabolism of HD00246 .",
        "label": "mechanism"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 DB00264 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { DB01026 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "HD00574 may also interfere with the absorption of oral DB14503 supplements and ddrug2 .",
        "label": "mechanism"
    },
    {
        "text": "no dose adjustment is necessary when ddrug0 is added to triple-immunosuppression regimens including ddrug1 , HD00175 , and either ddrug3 or DB00688 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may enhance the effects of ddrug1 , HD00026 , and other HD00261 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , HD00002 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , DB01167 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "agents increasing serum potassium : ddrug0 and DB00584 iv attenuate potassium loss caused by HD00675 .",
        "label": "effect"
    },
    {
        "text": "no formal clinical studies have been conducted to assess if there is an interactive effect on bone loss between HD00819 and DB00982 .",
        "label": "NA"
    },
    {
        "text": "accordingly , careful patient monitoring and dose adjustment of DB00331 is recommended in patients concomitantly taking DB00567 and ddrug2 .",
        "label": "NA"
    },
    {
        "text": "interaction of ddrug0 with other drugs : DB00501 : co-administration of ddrug2 { 800 mg/day } to patients taking DB00906 chronically had no effect on ddrug4 pharmacokinetics .",
        "label": "NA"
    },
    {
        "text": "- drugs that may either increase or decrease plasma DB00252 concentrations include : DB01174 , vaiproic acid , and ddrug2 .",
        "label": "mechanism"
    },
    {
        "text": "DB00068 administration to three cancer patients over a dose range of # mg to # mg led to a dose-dependent inhibition of DB01435 elimination # the effect of alternate-day administration of # mg of ddrug2 on drug metabolism in ms patients is unknown .",
        "label": "mechanism"
    },
    {
        "text": "therefore , DB00736 may interfere with the absorption of drugs where gastric ph is an important determinant of bioavailability { eg , ddrug1 , ddrug2 salts and DB00390 } .",
        "label": "mechanism"
    },
    {
        "text": "notably , systemic exposure { auc0 - 12 } of HD00584 { ddrug1 } was more than doubled in the presence of ddrug2 / DB01015 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in hypercholesterolemic patients , steady-state DB00439 auc and cmax increased approximately 50 % and 24 % respectively after # days with co-administration of DB00199 , a known inhibitor of cytochrome p450 3a4 .",
        "label": "mechanism"
    },
    {
        "text": "resistance to the neuromuscular blocking action of ddrug0 has been demonstrated in patients chronically administered DB00252 or DB00564 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in vitro and/or in vivo data show that DB01211 , ddrug2 , and ddrug3 markedly inhibit the metabolism of DB00604 , which can result in an increase in plasma ddrug5 levels and prolongation of the qt interval on the ecg .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of ddrug1 , ddrug2 , ddrug3 , ddrug4 , DB00475 , ddrug6 , certain ddrug7 , ddrug8 , ddrug9 and DB00916 , thereby delaying elimination and increasing blood levels of these drugs .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration of a single dose of ddrug1 and DB01069 { 10 and # mg , respectively } resulted in a 15 % decrease in maximal plasma concentrations of DB00962 , but no change in the area under the plasma concentration-time curve .",
        "label": "NA"
    },
    {
        "text": "patients who have been treated with HD00343 within two to three weeks prior to the administration of DB00988 should receive initial doses of ddrug2 no greater than one-tenth { 1/10 } of the usual dose .",
        "label": "advise"
    },
    {
        "text": "use of HD00287 ddrug1 and DB01109 have been administered concomitantly with and following infusions of ddrug3 in the management of acute myocardial infarction or pulmonary embolism .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : drugs such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , DB00328 , ddrug6 , ddrug7 and others that interfere with platelet-aggregation reactions { the main hemostatic defense of heparinized patients } may induce bleeding and should be used with caution in patients receiving DB01109 .",
        "label": "effect"
    },
    {
        "text": "other drugs drug interactions have been reported with concomitant administration of DB00199 and other medications , including ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and DB00227 .",
        "label": "int"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { DB00400 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , DB00812 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "other drugs : in healthy volunteers , ddrug0 , ddrug1 , ddrug2 , ddrug3 , DB00338 , hormone replacement therapy { a combination of conjugated ddrug5 and ddrug6 } , ddrug7 { DB06723 and ddrug9 } and ddrug10 did not affect the pharmacokinetics of ddrug11 .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of ddrug0 and ddrug1 , ddrug2 , DB00338 , or an HD00183 / ddrug5 oral ddrug6 produced minor changes in the pharmacokinetics of ddrug7 , which were considered to be without clinical significance .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 : in one study , DB00712 was given to adult diabetics who were already receiving ddrug2 { n = 4 } , DB00331 { n = 2 } ddrug4 with ddrug5 { n = 3 } or ddrug6 with ddrug7 { n = 6 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 / ddrug1 : DB00533 did not have any clinically important effect on the pharmacokinetics of DB00860 or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "in in vivo studies , 10 - to 30-mg/day doses of ddrug0 had no significant effect on metabolism by cyp2d6 { ddrug1 } , cyp2c9 { DB00682 } , cyp2c19 { ddrug3 , ddrug4 } , and cyp3a4 { DB00514 } substrates .",
        "label": "NA"
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of ddrug0 such as ddrug1 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 } , DB14513 salts , ddrug12 , local ddrug13 , DB01035 , and ddrug15 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { DB01370 - or ddrug2 - containing } : concomitant administration of 300-mg ddrug3 capsules with # ml HD00382 suspension reduces the rate { cmax } and extent { auc } of absorption by approximately 40 % .",
        "label": "NA"
    },
    {
        "text": "the antihypertensive effects of ddrug0 , ddrug1 , DB00206 , and ddrug3 may be reduced by HD00391 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : based on reports of profound hypotension and loss of consciousness when ddrug1 was administered with DB00904 , the concomitant use of DB00714 with drugs of the ddrug4 { including , for example , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 } is contraindicated .",
        "label": "NA"
    },
    {
        "text": "interactions for ddrug0 analogues { DB00153 , ddrug2 , ddrug3 , and ddrug4 } : DB01432 : ddrug6 has been reported to reduce intestinal absorption of ddrug7 ;",
        "label": "NA"
    },
    {
        "text": "therefore , the potential exists for a drug interaction between DB01156 and drugs that affect the cyp2b6 isoenzyme { e , g , , DB01173 and ddrug2 } .",
        "label": "int"
    },
    {
        "text": "- a ddrug0 { HD00615 } such as ddrug2 { ddrug3 , ddrug4 , ddrug5 , others } , ddrug6 { ddrug7 , ddrug8 , ddrug9 } , ddrug10 { ddrug11 , ddrug12 } , ddrug13 { ddrug14 } , ddrug15 { ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , and ddrug21 { ddrug22 , DB00788 , ddrug24 } ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 or DB00501 : concomitant administration of ddrug2 or ddrug3 decreases the elimination of ddrug4 , most likely by inhibition of renal tubular secretion of DB00943 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 and other HD00203 can inhibit the activity of HD00218 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , HD00668 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , DB00231 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "DB00520 did not increase the plasma levels of DB00091 .",
        "label": "NA"
    },
    {
        "text": "in seven experiments reactions to DB00368 and DB00107 were ddrug2 .",
        "label": "NA"
    },
    {
        "text": "the concurrent use of ddrug0 injection with other HD00444 or medications with anticholinergic activity , such as ddrug2 , HD00769 , or ddrug4 , may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects .",
        "label": "NA"
    },
    {
        "text": "consequently , concomitant administration of DB00673 with strong cyp3a4 inhibitors { e , g , , DB01026 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } should be approached with caution .",
        "label": "advise"
    },
    {
        "text": "patients in a clinical study who were on established therapy with DB00795 , to which DB09145 was added , were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ddrug2 ci or ddrug3 alone .",
        "label": "effect"
    },
    {
        "text": "caution should be taken when DB00496 is used concomitantly with medications that are predominantly metabolized by cyp2d6 and which have a narrow therapeutic window , such as DB01195 , ddrug2 and ddrug3 { see clinical pharmacology } .",
        "label": "advise"
    },
    {
        "text": "in the present study , the HD00030 DB00363 was tested in combination with an active dose of ddrug2 in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates { drl } procedures .",
        "label": "NA"
    },
    {
        "text": "effect of ddrug0 and DB00683 on the antinociceptive effect of DB00295 , ddrug3 and ddrug4 in mice .",
        "label": "NA"
    },
    {
        "text": "these results suggest that both DB01234 and ddrug1 , and possibly other HD00115 and ddrug3 , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of ddrug4 and ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { DB00252 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , DB00295 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "HD00476 { e , g , , ddrug1 , ddrug2 , ddrug3 } and ddrug4 may reduce the therapeutic effects of DB01235 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , HD00002 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , DB00295 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in normal volunteers , the concomitant administration of DB00861 and DB00695 had no effect on the diuretic activity of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "therefore , co-administration of ddrug0 with drugs that are metabolized by cyp2d6 isoenzyme including certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } , ddrug8 { e , g , , ddrug9 , DB00734 , ddrug11 } , ddrug12 { e , g , , DB00264 } , and ddrug14 { e , g , , ddrug15 , ddrug16 } , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .",
        "label": "NA"
    },
    {
        "text": "these drugs include the ddrug0 and other HD00218 , ddrug2 , HD00219 , ddrug4 , ddrug5 , oral ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , and ddrug11 .",
        "label": "NA"
    },
    {
        "text": "should it be decided to discontinue therapy in patients receiving ddrug0 and DB00575 concurrently , the HD00380 should be discontinued slowly over several days before the gradual withdrawal of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "caution should be exercised when the following drugs are administered concomitantly with ddrug0 { ddrug1 } given with ddrug2 or DB00190 - DB01235 combination products .",
        "label": "NA"
    },
    {
        "text": "HD00009 alone was found to have no effect on cas , but can completely block HD00007 - induced phosphorylation of this protein in mda-mb-435 cells .",
        "label": "effect"
    },
    {
        "text": "drugs decreasing DB01109 effect : HD00118 , ddrug2 , ddrug3 , or ddrug4 may partially counteract the anticoagulant action of ddrug5 .",
        "label": "NA"
    },
    {
        "text": "sinus bradycardia has been reported with oral DB01118 in combination with DB00281 { ddrug2 substrate } given for local ddrug3 .",
        "label": "NA"
    },
    {
        "text": "more than # parkinsons disease patients in clinical trials have used ddrug0 in combination with DB00494 and ddrug2 / HD00680 .",
        "label": "NA"
    },
    {
        "text": "DB00571 increases DB01275 s serum concentrations .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 { ddrug1 } : HD00114 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 } have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with HD00277 .",
        "label": "effect"
    },
    {
        "text": "there are no significant effects on DB00535 pharmacokinetics if the DB06724 is administered # hours before or # hours after ddrug2 .",
        "label": "NA"
    },
    {
        "text": "transient delirium has been reported in patients who were treated with one gram of DB00189 and # - # mg of HD00314 .",
        "label": "effect"
    },
    {
        "text": "as the primary effect of DB00640 is to decrease conduction through the a-v node , higher degrees of heart block may be produced in the presence of DB00564 .",
        "label": "effect"
    },
    {
        "text": "the co-administration of ddrug0 with iv ddrug1 such as DB00727 , ddrug3 , ddrug4 , or iv HD00106 has not been evaluated { these drugs were not co-administered with ddrug6 in clinical trials } .",
        "label": "NA"
    },
    {
        "text": "in a study involving healthy subjects receiving DB01195 and ddrug1 concurrently , plasma DB01195 levels were increased about 20 % and ddrug3 levels were increased about 30 % compared to control values .",
        "label": "NA"
    },
    {
        "text": "however , administration of DB01213 { 90 mg kg { -1 } body weight } to rats # hours prior to HD00077 { 100 mg kg { -1 } body weight } was ineffective in preventing ddrug2 synthesis and did not diminish fluoride or citrate accumulation in vivo .",
        "label": "NA"
    },
    {
        "text": "interactions may occur between DB00159 supplements and DB00945 and other ddrug2 and herbs such as garlic { allium sativum } and ddrug3 { ddrug4 } .",
        "label": "int"
    },
    {
        "text": "concomitant medications were grouped as ddrug0 , oral ddrug1 , ddrug2 , ddrug3 , HD00345 , inducers of cyp3a4 , substrates and inhibitors of cyp3a4 , substrates and inhibitors of p-glycoprotein , ddrug5 , ddrug6 , ddrug7 , HD00643 , ddrug9 , substrates and inhibitors of tubular organic cation transport , and qtc-prolonging drugs .",
        "label": "NA"
    },
    {
        "text": "in vivo interaction studies in humans have demonstrated that ddrug0 and DB00682 do not affect the pk properties of DB00261 , nor does ddrug3 affect the pk properties of ddrug4 or ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , DB01086 and ddrug7 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some DB00152 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : concomitant treatment with DB00982 and ddrug2 should be avoided because ddrug3 use has been associated with a number of cases of idiopathic_intracranial_hypertension { benign intracranial hypertension } , some of which involved concomitant use of HD00239",
        "label": "NA"
    },
    {
        "text": "- a HD00535 { ddrug1 } such as ddrug2 { ddrug3 , ddrug4 , ddrug5 , others } , ddrug6 { ddrug7 , ddrug8 , ddrug9 } , ddrug10 { ddrug11 , ddrug12 } , ddrug13 { ddrug14 } , ddrug15 { DB00328 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , and ddrug21 { ddrug22 , ddrug23 , ddrug24 } ;",
        "label": "NA"
    },
    {
        "text": "therefore , co-administration of DB00476 with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index , including certain ddrug1 { ddrug2 -lsb- ddrug3 -rsb- , such as ddrug4 , ddrug5 , and ddrug6 } , ddrug7 and ddrug8 { e , g , , ddrug9 , DB01195 } , should be approached with caution .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : combination HD00432 may decrease the clearance of some ddrug2 { ddrug3 , ddrug4 , ddrug5 } and increase the clearance of others { DB00186 , ddrug7 , ddrug8 } .",
        "label": "mechanism"
    },
    {
        "text": "- a HD00535 { ddrug1 } such as ddrug2 { ddrug3 , ddrug4 , ddrug5 , others } , ddrug6 { ddrug7 , ddrug8 , ddrug9 } , ddrug10 { ddrug11 , ddrug12 } , ddrug13 { ddrug14 } , ddrug15 { ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , and ddrug21 { ddrug22 , DB00788 , ddrug24 } ;",
        "label": "NA"
    },
    {
        "text": "the effectiveness of ddrug0 - only pills is reduced by hepatic enzyme-inducing drugs such as the ddrug1 DB00252 , ddrug3 , and ddrug4 , and the HD00886 ddrug6 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , DB01076 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , DB00224 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 treatment resulted in a 42 % decrease in the DB06730 auc 0 - 24 , but no clinically relevant effect was observed on the pharmacokinetic parameters of DB00977 .",
        "label": "NA"
    },
    {
        "text": "additionally , DB00715 did not alter the pharmacokinetics of DB00962 , reflecting the absence of a role of cyp2d6 in ddrug2 s metabolism .",
        "label": "NA"
    },
    {
        "text": "injection : ddrug0 injection , like other injectable HD00100 , produces depression of the central nervous system when administered with ddrug2 , ddrug3 , HD00026 , ddrug5 , and other ddrug6 , when ddrug7 is used concomitantly with injectable ddrug8 , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .",
        "label": "effect"
    },
    {
        "text": "ddrug0 such as DB00421 , ddrug2 , or ddrug3 , or DB14500 supplements should be given only for documented hypokalemia , and then with caution , since they may lead to a significant increase of serum potassium .",
        "label": "NA"
    },
    {
        "text": "in rats , simultaneous ingestion of ddrug0 and DB12529 in the diet for # weeks has been reported to cause tumors , and it has been suggested that DB00822 may react with ddrug3 in the rat stomach to form a nitrosamine , which is tumorigenic .",
        "label": "NA"
    },
    {
        "text": "DB00294 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , DB01601 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "int"
    },
    {
        "text": "since ddrug0 { DB00593 } may interact with concurrently administered HD00703 , periodic serum level determinations of these drugs may be necessary { eg , ddrug3 may elevate ddrug4 serum levels and ddrug5 has been reported to both increase and decrease ddrug6 levels } .",
        "label": "int"
    },
    {
        "text": "ddrug0 { ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 } : increase the metabolism of DB00977 and/or some HD00526 , leading to possible decrease in contraceptive effectiveness .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : DB00316 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { DB00400 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : when coadministered with DB00828 , ddrug2 , a drug which increases gastrointestinal motility , lowers the serum concentration and urinary excretion of DB00828 .",
        "label": "NA"
    },
    {
        "text": "although no clinical studies have been conducted , it is likely that the metabolism of DB01002 may be affected by the known cyp3a4 inducers { such as ddrug1 , ddrug2 , ddrug3 } , cyp3a4 inhibitors { azole antimycotics e , g , , DB01026 ;",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { DB00701 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , DB00277 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , as with other HD00360 , should be administered with extreme caution to patients being treated with ddrug2 , ddrug3 , or drugs known to prolong the qtc interval because the action of HD00355 on the cardiovascular system may be potentiated by these agents .",
        "label": "NA"
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the ddrug0 of drugs may be potentiated by ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , the ddrug6 , ddrug7 and ddrug8 , HD00275 and the HD00043 , and by other ddrug11 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { DB00316 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , DB01174 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "other drugs : based on the results of drug interaction studies , no dosage adjustment is recommended when DB00625 { ddrug1 } is given with the following : ddrug2 , ddrug3 , ddrug4 , DB00927 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , and ddrug11 .",
        "label": "NA"
    },
    {
        "text": "pharmacoeconomic analyses indicate that DB00334 does not significantly increase , and may even decrease , the overall direct treatment costs of schizophrenia , compared with DB00502 .",
        "label": "NA"
    },
    {
        "text": "avoid the use of preparations such as HD00799 and local ddrug1 which contain any ddrug2 { e , g , , DB00668 , ddrug4 } , since it has been reported that ddrug5 can potentiate the effects of catecholamines .",
        "label": "NA"
    },
    {
        "text": "HD00645 did not inhibit the antitumor activity of four ddrug1 { ddrug2 , ddrug3 , DB00997 , ddrug5 } in four murine models .",
        "label": "NA"
    },
    {
        "text": "however , the systemic administration of some HD00532 has been shown to elevate plasma concentrations of DB00277 , interfere with the metabolism of ddrug2 , and enhance the effects of the oral ddrug3 ddrug4 and its derivatives , and has been associated with transient elevations in serum creatinine in patients receiving systemic ddrug5 concomitantly .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : coadministration of ddrug1 { using an experimental soft-gelatin capsule formulation of ddrug2 1200 mg } with DB00220 resulted in an 18 % increase in DB00220 plasma auc and a 4-fold increase in ddrug5 plasma a , c.",
        "label": "NA"
    },
    {
        "text": "the use of DB00318 may result in additive cns depressant effects when coadministered with DB02325 , ddrug2 , ddrug3 or other drugs that produce cns depression .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , HD00002 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , DB00860 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "sinus bradycardia has been reported with oral DB01118 in combination with ddrug1 { ddrug2 substrate } given for local HD00308 .",
        "label": "NA"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / HD00517 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , ddrug4 , ddrug5 , DB01170 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 pain medication { e , g , , ddrug12 } , drugs used to aid sleep , drowsiness-causing ddrug13 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "coadministration of DB00580 { 40 mg bid { day 1 } and # mg qd { days 2 - 7 } } with ddrug1 { 10 mg DB01016 bid } resulted in 21 % increase in ddrug3 auc0 - 12 and a 16 % increase in ddrug4 cmax leading to a 16 % decrease in glucose auc0 - 24 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in vitro data indicate that DB00224 and DB00503 markedly inhibit the metabolism of ddrug3 which can result in an increase in plasma ddrug4 levels and prolongation of the qt interval on the ecg .",
        "label": "NA"
    },
    {
        "text": "ddrug0 including coumarin derivatives , indandione derivatives , and ddrug1 such as HD00233 { ddrug3 } , and DB00945 may increase the risk of bleeding when administered concomitantly with ddrug5 .",
        "label": "NA"
    },
    {
        "text": "DB00125 , in the absence of ddrug1 or DB00277 , caused excessive gcg release in the diabetics and undetectable insulin release in either diabetics or normals .",
        "label": "NA"
    },
    {
        "text": "DB00825 / ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 and DB00318 combinations , ddrug6 , ddrug7 } .",
        "label": "NA"
    },
    {
        "text": "cardiovasculars : ddrug0 : in patients receiving DB00390 therapy , administration of oral DB01118 regularly results in an increase in serum ddrug3 concentration that may reach toxic levels with resultant clinical toxicity .",
        "label": "NA"
    },
    {
        "text": "avoid the use of preparations such as ddrug0 and local ddrug1 which contain any ddrug2 { e , g , , ddrug3 , DB00368 } , since it has been reported that HD00043 can potentiate the effects of catecholamines .",
        "label": "advise"
    },
    {
        "text": "avoid the concomitant use of DB01239 and DB00193 { ddrug2 } .",
        "label": "advise"
    },
    {
        "text": "since the concomitant administration of DB00682 with ddrug1 increases the prothrombin time by 100 % after # to # days , the dose of the HD00025 should be reduced by one-third to one-half , and prothrombin times should be monitored closely .",
        "label": "NA"
    },
    {
        "text": "data from a randomized trial of ddrug0 and DB00515 plus or minus DB00165 in ovarian_cancer indicated that ddrug3 significantly reduced neurotoxicity ;",
        "label": "NA"
    },
    {
        "text": "as with other HD00366 , the antihypertensive effect of ddrug1 may be blunted by the HD00860 ddrug3",
        "label": "NA"
    },
    {
        "text": "drug interactions : DB00875 may interact with some drugs , like ddrug1 { HD00725 } : ddrug3 could theoretically affect ddrug4 pharmacodynamics - ddrug5 - jzqyavbxjcqsok_uhfffaoysa_n - ddrug6 : ddrug7 and ddrug8 cause additive cns depression - ddrug9 : ddrug10 increases the effect of ddrug11",
        "label": "int"
    },
    {
        "text": "ddrug0 , ddrug1 , ddrug2 : DB00586 , like other HD00203 , may affect renal prostaglandins and increase the toxicity of certain drugs .",
        "label": "NA"
    },
    {
        "text": "although DB01609 has a lower affinity for ddrug1 than for ddrug2 , ddrug3 should not be taken with DB01370 - containing ddrug5 .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { DB00564 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 HD00542 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "in patients receiving ddrug0 { ddrug1 } or DB00993 { ddrug3 } , the concomitant administration of 300 - 600 mg of DB00437 per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of ddrug5 or ddrug6 .",
        "label": "NA"
    },
    {
        "text": "in one controlled clinical study , the ureidopenicillins , including DB00319 , were reported to prolong the action of DB01339 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 { e , g , , DB01026 , ddrug2 , ddrug3 , ddrug4 , etc , } : in vitro and animal studies with the combination of DB00681 and ddrug6 suggest that ddrug7 may induce fungal resistance to ddrug8 .",
        "label": "NA"
    },
    {
        "text": "if taken # hour before ddrug0 { ddrug1 } , DB00900 does not affect HD00033 exposure , despite persistent buffering effects .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect : ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , ddrug5 , ddrug6 , ddrug7 } , DB00951 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , HD00810 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "concurrent use of DB01045 increases the metabolic clearance of ddrug1 , resulting in a shortened elimination half-life of DB00612 .",
        "label": "NA"
    },
    {
        "text": "when concomitant administration of DB01026 with DB01238 occurs , ddrug2 dose should be reduced to one-half of its normal dose .",
        "label": "advise"
    },
    {
        "text": "DB00390 : concomitant administration of DB00199 and ddrug2 has been reported to result in elevated ddrug3 serum levels .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , HD00002 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , HD00668 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { ddrug1 s } , ddrug2 , ddrug3 { ddrug4 may decrease the effects of these medicines } , ddrug5 { using these medicines with ddrug6 may result in increased cns depressant effects } , ddrug7 , ddrug8 { using these medicines with HD00026 may change the amount of either medicine that you need to take } , and oral ddrug10 containing HD00220 { ddrug12 may decrease the effectiveness of these oral ddrug13 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "these studies indicate that DB01026 or DB00199 co-administration enhances ddrug2 gastrointestinal absorption .",
        "label": "NA"
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the ddrug0 of drugs may be potentiated by ddrug1 , ddrug2 , ddrug3 , HD00556 , ddrug5 , the ddrug6 , ddrug7 and ddrug8 , HD00275 and the ddrug10 , and by other ddrug11 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 , like other HD00203 , may cause changes in the elimination of DB00563 leading to elevated serum levels of the drug and increased toxicity .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : since ddrug1 is a HD00338 , it is possible that ddrug3 , such as the ddrug4 { HD00219 , ddrug6 , ddrug7 } or ddrug8 , may diminish the effectiveness of ddrug9 .",
        "label": "NA"
    },
    {
        "text": "catecholamine-depleting drugs , e , g , , DB00206 , may have an additive effect when given with HD00694 .",
        "label": "effect"
    },
    {
        "text": "data from in vitro studies of ddrug0 other than DB00404 suggest a possible drug interaction for the following : DB00201 , ddrug3 , ddrug4 , ddrug5 , and ddrug6 .",
        "label": "int"
    },
    {
        "text": "ddrug0 HD00524 may delay or reduce the absorption of concomitant oral medication such as ddrug2 , DB00682 , ddrug4 { acidic } or ddrug5 { basic } , as well as ddrug6 ddrug7 , ddrug8 , thyroid and ddrug9 preparations , ddrug10 and ddrug11 , and ddrug12 .",
        "label": "NA"
    },
    {
        "text": "there have been reports of qtc prolongation , with or without tdp , in patients taking DB01118 when ddrug1 , HD00093 , or azoles were administered concomitantly .",
        "label": "NA"
    },
    {
        "text": "because there is a theoretical basis that these effects may be additive , use of DB00201 - containing or ddrug1 { like ddrug2 or DB00247 } and ddrug4 within # hours of each other should be avoided .",
        "label": "NA"
    },
    {
        "text": "ddrug0 or ddrug1 : concomitant administration of ddrug2 or DB00501 decreases the elimination of ddrug4 , most likely by inhibition of renal tubular secretion of DB00943 .",
        "label": "NA"
    },
    {
        "text": "other drugs : based on the results of drug interaction studies , no dosage adjustment is recommended when ddrug0 { DB00625 } is given with the following : ddrug2 , DB00207 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , and ddrug11 .",
        "label": "NA"
    },
    {
        "text": "-lsb- the effect of ddrug0 on the renal excretion of ddrug1 and ddrug2 in dogs -rsb- the intravenous injection of ddrug3 in a dose of # mg/kg enhanced HD00191 and DB08948 excretion in chronic canine experiments .",
        "label": "NA"
    },
    {
        "text": "however , no clinically or statistically significant differences in prothrombin time ratio or ddrug0 enantiomer pharmacokinetics were observed in a small study of # healthy males who received both DB00682 and DB00978 under steady-state conditions .",
        "label": "NA"
    },
    {
        "text": "while additional research is needed , the initial clinical data in kidney recipients suggest that ddrug0 , in combination with DB00091 or DB00864 , might have the potential to reduce the frequency of rejection episodes , permit reductions in ddrug3 or ddrug4 dosage , and permit steroid withdrawal { kelly , 1999 } .",
        "label": "NA"
    },
    {
        "text": "drugs that induce hepatic enzymes such as DB01174 , ddrug1 and ddrug2 may increase the clearance of ddrug3 and may require increases in HD00579 dose to achieve the desired response .",
        "label": "advise"
    },
    {
        "text": "based on adult data , lower doses of ddrug0 may be needed following coadministration of drugs which are reported to decrease ddrug1 elimination { e , g , , ddrug2 and ddrug3 } and higher ddrug4 doses may be needed following coadministration of drugs that increase DB00201 elimination { e , g , , ddrug6 and DB00252 } .",
        "label": "NA"
    },
    {
        "text": "although HD00115 have been shown to reduce DB00041 - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with ddrug2 may reduce the antitumor effectiveness of ddrug3 and thus should be avoided , # ddrug4 and other ddrug5 may potentiate the hypotension seen with ddrug6 .",
        "label": "effect"
    },
    {
        "text": "HD00128 : ddrug1 , ddrug2 , DB00877",
        "label": "NA"
    },
    {
        "text": "HD00352 may affect gastrointestinal absorption of various drugs , such as slowly dissolving dosage forms of DB00390 ;",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { DB00316 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , DB00295 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "although the interaction between DB00918 and other potent cyp3a4 inhibitors { e , g , , ddrug1 , ddrug2 , and DB00199 } has not been studied , increased exposures to ddrug4 may be expected when ddrug5 is used concomitantly with these medications .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 : concomitant treatment with HD00741 , ddrug4 , or ddrug5 may potentiate a possible hypokalemic effect of HD00742",
        "label": "effect"
    },
    {
        "text": "nephrotoxicity has been reported following concomitant administration of HD00485 with ddrug1 or potent ddrug2 such as DB00695 .",
        "label": "effect"
    },
    {
        "text": "however , DB12750 { 100 and # micromol/l } did not alter the effects of HD00032 on arteries from dietary-obese rats , giving superimposed concentration-responses curves .",
        "label": "NA"
    },
    {
        "text": "the auc of ddrug0 was decreased an average of 15-fold in # healthy subjects given DB00537 and DB00900 - placebo tablets concurrently .",
        "label": "mechanism"
    },
    {
        "text": "these data suggest that ddrug0 are negatively coupled to three types of calcium channels in bovine chromaffin cell , including an HD00047 - sensitive { n-type } channel , an ddrug2 - sensitive { p-type } channel and DB00393 / ddrug4 / ddrug5 - resistant { presumptive q-type } channel .",
        "label": "NA"
    },
    {
        "text": "the effects of ddrug0 may be potentiated by DB13179 which inhibits the metabolism of DB00201 .",
        "label": "mechanism"
    },
    {
        "text": "- a ddrug0 { HD00615 } such as ddrug2 { ddrug3 , ddrug4 , ddrug5 , others } , ddrug6 { ddrug7 , ddrug8 , ddrug9 } , ddrug10 { ddrug11 , ddrug12 } , ddrug13 { ddrug14 } , ddrug15 { ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { DB00991 } , and ddrug21 { ddrug22 , ddrug23 , ddrug24 } ;",
        "label": "NA"
    },
    {
        "text": "HD00100 : combination ddrug1 may decrease the clearance of some ddrug2 { ddrug3 , ddrug4 , ddrug5 } and increase the clearance of others { ddrug6 , ddrug7 , DB00231 } .",
        "label": "NA"
    },
    {
        "text": "DB01239 may increase the plasma-level of concomitantly given DB14507 .",
        "label": "mechanism"
    },
    {
        "text": "in clinical trials , ddrug0 was used with ddrug1 , ddrug2 , ddrug3 , oral ddrug4 , and supplemental ddrug5 , in a pharmacokinetic substudy in patients with congestive heart failure receiving ddrug6 or DB00390 in whom therapy with DB01240 was initiated , apparent oral clearance values for ddrug9 { n = 23 } and ddrug10 { n = 30 } were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .",
        "label": "mechanism"
    },
    {
        "text": "in monkeys , HD00157 was about # times more potent than HD00156 in decreasing responding , whereas in pigeons ddrug2 was about equipotent with ddrug3 .",
        "label": "NA"
    },
    {
        "text": "intraventricular injection of HD00144 and DB00295 produced an inhibition of the tail-flick response to the heat stimulus in rats .",
        "label": "NA"
    },
    {
        "text": "in clinical trials , ddrug0 was used with ddrug1 , HD00218 , ddrug3 , oral ddrug4 , and supplemental ddrug5 , in a pharmacokinetic substudy in patients with congestive heart failure receiving DB00695 or ddrug7 in whom therapy with ddrug8 was initiated , apparent oral clearance values for ddrug9 { n = 23 } and ddrug10 { n = 30 } were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .",
        "label": "NA"
    },
    {
        "text": "therefore , co-administration of ddrug0 with other drugs that are metabolized by this isoenzyme , including other ddrug1 , ddrug2 , ddrug3 , and HD00310 { eg , ddrug5 , ddrug6 , and ddrug7 } , or that inhibit this enzyme { eg , DB00908 } , should be approached with caution .",
        "label": "NA"
    },
    {
        "text": "these agents include medications such as : ddrug0 , HD00679 including ddrug2 , sali-cylates , ddrug3 { including ddrug4 } , ddrug5 , or DB01138 .",
        "label": "NA"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 HD00303 : ddrug2 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 ddrug11 , DB00897 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "a possible interaction between ddrug0 and ddrug1 , a HD00754 , has been reported , resulting in a potentiation of the hypoglycemic action of DB01016 .",
        "label": "NA"
    },
    {
        "text": "in another study with intravenous administration of DB00683 , ddrug1 was given as # mg on day # and # mg/day on days # and 3 , and ddrug2 # mg iv was given prior to the administration of the 3-day regimen of DB00673 and on days 4 , 8 , and 15 .",
        "label": "NA"
    },
    {
        "text": "in addition to bleeding associated with DB01109 and ddrug1 , drugs that alter platelet function { such as ddrug2 , DB00975 and ddrug4 } may increase the risk of bleeding if administered prior to , during , or after ddrug5 therapy .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { DB00316 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , DB00636 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00813 is not recommended for use in patients who have received HD00725 within # days because severe and unpredictable potentiation by ddrug3 has been reported with ddrug4",
        "label": "advise"
    },
    {
        "text": "it is , however , possible that concomitant use of other known ddrug0 such as DB00400 , ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 might increase the photosensitivity reaction of actinic_keratosis treated with the DB00855 for topical solution .",
        "label": "effect"
    },
    {
        "text": "ddrug0 usually does not alter the plasma levels of ddrug1 , however , serum DB00390 levels should be evaluated after concomitant therapy with DB00622 is initiated .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : DB01032 is known to interact with the metabolism or renal tubular excretion of many drugs { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , DB00887 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 agents , ddrug14 , and ddrug15 } .",
        "label": "mechanism"
    },
    {
        "text": "in separate single or multiple dose pharmacokinetic interaction studies with ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB00782 , ddrug7 , and ddrug8 , the bioavailability of ddrug9 was not altered by coadministration of DB00492 with any one of these drugs .",
        "label": "NA"
    },
    {
        "text": "in some patients , the administration of ddrug0 can reduce the diuretic , natriuretic , and antihypertensive effects of HD00105 , ddrug2 , and HD00029 .",
        "label": "NA"
    },
    {
        "text": "DB00501 , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , certain HD00043 , ddrug8 , ddrug9 and ddrug10 , thereby delaying elimination and increasing blood levels of these drugs .",
        "label": "mechanism"
    },
    {
        "text": "however , because bleeding has been reported when ddrug0 and other HD00518 have been administered to patients on ddrug2 , the physician should be cautious when administering ddrug3 to patients on HD00326 .",
        "label": "NA"
    },
    {
        "text": "blood levels of ddrug0 increased 24 % when ddrug1 was coadministered with DB00501 { nonselective inhibitor of cytochrome p-450 } for # days , and decreased 28 % with coadministration of DB01045 { potent inducer of cytochrome p-450 } for # days .",
        "label": "NA"
    },
    {
        "text": "co-administration of ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , DB00177 , ddrug9 and ddrug10 did not result in clinically significant increases in DB09026 exposure .",
        "label": "NA"
    },
    {
        "text": "DB01432 ddrug1 may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation , the discontinuance of ddrug2 ddrug3 could pose a hazard to health if a potentially toxic drug such as ddrug4 has been filtrated to a maintenance level while the patient was taking ddrug5 HD00524 .",
        "label": "NA"
    },
    {
        "text": "DB01234 and HD00147 similarly inhibit and stimulate ddrug2 - or ddrug3 - induced proliferation of prostatic epithelium .",
        "label": "NA"
    },
    {
        "text": "may interact with the following : DB01432 , DB00375 { use with ddrug2 may prevent the ddrug3 from working properly ;",
        "label": "NA"
    },
    {
        "text": "the purpose of this study was to evaluate the effect of ddrug0 { ddrug1 } and ddrug2 { ddrug3 } conjugates on the intestinal permeation of ddrug4 { ddrug5 } and model peptide drugs , DB00781 and HD00071 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , DB00564 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , DB00231 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "in clinical studies performed with DB00569 , the concomitant use of oral ddrug1 { ddrug2 } , HD00679 { ddrug4 } , ddrug5 { ddrug6 } , and ddrug7 did not significantly affect the pharmacokinetics/pharmacodynamics of ddrug8 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 : DB00364 and HD00374 containing ddrug4 or ddrug5 , as well as formulations containing divalent and trivalent cations such as ddrug6 { ddrug7 } , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with ddrug8 and interfere with its bioavailability .",
        "label": "NA"
    },
    {
        "text": "DB00311 may increase the action of ddrug1 , HD00401 , ddrug3 , and ddrug4 .",
        "label": "effect"
    },
    {
        "text": "interactions with other cns agents : concurrent use of DB00854 with all ddrug1 { eg , DB02325 , ddrug3 , ddrug4 , other ddrug5 , general ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 and ddrug12 } may result in additive central nervous system depressant effects .",
        "label": "effect"
    },
    {
        "text": "when ddrug0 at an increased dose { 1000 mg every # hours } was given with DB00625 { 600 mg once daily } , the DB00224 auc and cmin were decreased on average by 33 - 46 % and 39 - 57 % , respectively , compared to when ddrug3 { 800 mg every # hours } was given alone .",
        "label": "NA"
    },
    {
        "text": "DB00201 : concurrent use of DB00199 and ddrug2 or ddrug3 has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia .",
        "label": "NA"
    },
    {
        "text": "therefore , co-administration of HD00043 with other drugs that are metabolized by this isoenzyme , including other ddrug1 , HD00219 , ddrug3 , and ddrug4 { eg , ddrug5 , ddrug6 , and ddrug7 } , or that inhibit this enzyme { eg , ddrug8 } , should be approached with caution .",
        "label": "advise"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { ddrug1 s } , ddrug2 , ddrug3 { ddrug4 may decrease the effects of these medicines } , HD00458 { using these medicines with ddrug6 may result in increased cns depressant effects } , ddrug7 , ddrug8 { using these medicines with ddrug9 may change the amount of either medicine that you need to take } , and oral ddrug10 containing HD00220 { ddrug12 may decrease the effectiveness of these oral ddrug13 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "in a phase i trial using escalating doses of ddrug0 { 110 - 200 mg/m2 } and ddrug1 { 50 or # mg/m2 } given as sequential infusions , myelosuppression was more profound when ddrug2 was given after ddrug3 than with the alternate sequence { ie , DB01229 before DB00515 } .",
        "label": "NA"
    },
    {
        "text": "although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 { eg , ddrug0 , ddrug1 , ddrug2 , ddrug3 , DB01118 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , and ddrug15 } may have elevated plasma concentrations when coadministered with DB01232 ;",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , DB01086 and ddrug7 } , ddrug8 { HD00398 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "when used in therapeutic doses , DB00207 had a modest effect on the pharmacokinetics of ddrug1 , ddrug2 , ddrug3 , DB00900 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { intravenous and oral } , ddrug12 , ddrug13 / ddrug14 or ddrug15 .",
        "label": "mechanism"
    },
    {
        "text": "concomitant administration of DB00343 with DB00564 has been reported to result in elevated serum levels of ddrug2 { 40 % to 72 % increase } , resulting in toxicity in some cases .",
        "label": "mechanism"
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , ddrug3 , or ddrug4 , with ddrug5 , with metal cations such as ddrug6 , or with DB00152 containing DB01592 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "other drugs : in healthy volunteers , ddrug0 , ddrug1 , DB01016 , ddrug3 , ddrug4 , hormone replacement therapy { a combination of conjugated ddrug5 and ddrug6 } , ddrug7 { ddrug8 and ddrug9 } and DB00277 did not affect the pharmacokinetics of ddrug11 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , DB00446 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , DB02362 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "coadministration of oral HD00283 increased the maximum plasma concentration of DB00404 by 18 % , decreased clearance by 22 % , and increased half-life by 29 % .",
        "label": "mechanism"
    },
    {
        "text": "other potentially important drug interactions : ddrug0 : HD00100 metabolized by hepatic oxidation { e , g , , ddrug2 , DB00683 , ddrug4 elc , } should be used with caution because the clearance of these drugs is likely to be reduced by ddrug5 .",
        "label": "NA"
    },
    {
        "text": "co-administration of DB00704 with DB00659 produced a 25 % increase in auc and a 33 % increase in the cmax of ddrug2 .",
        "label": "mechanism"
    },
    {
        "text": "results of studies in multiple sclerosis patients taking DB00108 and concomitant ddrug1 { DB02325 # mcg i m once weekly } or ddrug3 were inconclusive with regard to the need for dose adjustment of the ddrug4 or ddrug5 .",
        "label": "NA"
    },
    {
        "text": "since DB01166 is extensively metabolized by cyp4f3 isoenzymes , caution should be exercised when ddrug1 is coadministered with inhibitors of c , p , a , such as DB01026 and ddrug3 or inhibitors of cyp2c19 such as ddrug4 .",
        "label": "NA"
    },
    {
        "text": "DB01045 : coadministration of ddrug1 and DB00220 resulted in an 82 % decrease in ddrug3 plasma a , c.",
        "label": "NA"
    },
    {
        "text": "may interact ddrug0 { altered hypo-prothrombinemic effect } , ddrug1 , DB01045 and other inducers of hepatic microsomal enzyme oxidation system { decreased effect of ddrug3 } , HD00175 { increased effect of ddrug5 } .",
        "label": "NA"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / HD00517 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , DB00248 , ddrug10 , ddrug11 pain medication { e , g , , ddrug12 } , drugs used to aid sleep , drowsiness-causing ddrug13 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "concomitantly given HD00029 did not interfere with the absorption of a tablet of DB00390 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 can interact with ddrug1 or other HD00261 { may potentiate the cns depressant effects of either these medications or ddrug3 } , ddrug4 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with HD00388 } , and ddrug6 { concurrent use with ddrug7 may prolong and intensify the anticholinergic and cns depressant effects of ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : concomitant treatment with ddrug1 and ddrug2 should be avoided because DB00982 use has been associated with a number of cases of idiopathic_intracranial_hypertension { benign intracranial hypertension } , some of which involved concomitant use of HD00239",
        "label": "effect"
    },
    {
        "text": "ddrug0 : because DB00091 can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine , and because renal excretion is the primary elimination route of ddrug2 including DB01039 , there is a risk that an interaction will lead to deterioration .",
        "label": "effect"
    },
    {
        "text": "in the experiments reported here , we examined the interactions between HD00179 and the ddrug1 ddrug2 { HD00181 } , which also induces apoptosis in mcf-7 cells .",
        "label": "NA"
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a ddrug0 , including ddrug1 , with multivalent cation-containing products such as ddrug2 or ddrug3 HD00374 , ddrug5 , ddrug6 chewable/buffered tablets or pediatric powder , or products containing ddrug7 , DB01592 , or ddrug9 may substantially decrease the absorption of ddrug10 , resulting in serum and urine levels considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "treatment of HD00011 with -lsb- { 14 } c -rsb- - HD00010 revealed concentration dependent labelling of histidine residues on the toxin molecules .",
        "label": "NA"
    },
    {
        "text": "- a HD00766 such as DB00477 { ddrug2 } , ddrug3 { ddrug4 , ddrug5 } , ddrug6 { ddrug7 } , ddrug8 { ddrug9 } , and others ;",
        "label": "NA"
    },
    {
        "text": "drugs that reduce the number of blood platelets by causing bone marrow depression { such as ddrug0 } or drugs which inhibit platelet function { eg , ddrug1 and other ddrug2 , ddrug3 , HD00331 , ddrug5 , ddrug6 } may increase the bleeding tendency produced by HD00326 without altering prothrombin time determinations .",
        "label": "effect"
    },
    {
        "text": "when intravenous ddrug0 and DB00187 were concomitantly administered in normal subjects , no effect on ddrug2 blood levels was seen , but ddrug3 steady-state blood levels were increased by 46 % in the presence of DB00295 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in post-marketing experience , there have been reports of both increases and decreases in DB00252 levels with DB01234 co-administration , leading to alterations in seizure control .",
        "label": "mechanism"
    },
    {
        "text": "both ddrug0 and HD00021 are sequestered in fat and , like ddrug2 , HD00022 probably has an active metabolite .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : population pharmacokinetic analyses indicate that DB00906 clearance is 60 % greater in patients taking ddrug2 with or without other enzyme - inducing HD00714 .",
        "label": "NA"
    },
    {
        "text": "this interaction should be given consideration in patients taking HD00203 concomitantly with HD00106 .",
        "label": "advise"
    },
    {
        "text": "no interaction was noted with the HD00681 ddrug1 in two multiple-dose interaction studies when ddrug2 was coadministered with a ddrug3 / HD00680 { n = 29 } .",
        "label": "NA"
    },
    {
        "text": "other HD00545 should be used with caution in patients taking DB00574 , since the effects may be additive .",
        "label": "advise"
    },
    {
        "text": "concomitant administration of other HD00571 may potentiate the undesirable effects of DB00983 .",
        "label": "effect"
    },
    {
        "text": "a similar association , though less marked , has been suggested with ddrug0 , phenyl-butazone , DB00252 , ddrug2 and possibly with ddrug3 , ddrug4 , and HD00239 { 72 }",
        "label": "NA"
    },
    {
        "text": "ddrug0 also should be used cautiously with other drugs { e , g , , ddrug1 , HD00684 } that sensitize the myocardium to the actions of HD00390 .",
        "label": "NA"
    },
    {
        "text": "the concurrent use of DB00986 injection with other ddrug1 or medications with anticholinergic activity , such as ddrug2 , ddrug3 , or HD00043 , may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects .",
        "label": "effect"
    },
    {
        "text": "ddrug0 , ddrug1 : e , g , , ddrug2 , DB01115 , DB00622",
        "label": "NA"
    },
    {
        "text": "the effect of ddrug0 on the DB00682 requirement of our patient appeared to be maximal # to # days after the initiation of DB01045 and extended a similar length of time after ddrug3 withdrawal .",
        "label": "NA"
    },
    {
        "text": "the hypoglycemic action of HD00222 may be potentiated by certain drugs including ddrug1 and other drugs that are highly protein bound , ddrug2 , ddrug3 , ddrug4 , ddrug5 , HD00519 , ddrug7 , and ddrug8 .",
        "label": "effect"
    },
    {
        "text": "therefore , co-administration of ddrug0 with drugs that are metabolized by cyp2d6 isoenzyme including certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } , ddrug8 { e , g , , ddrug9 , ddrug10 , DB00679 } , HD00254 { e , g , , ddrug13 } , and ddrug14 { e , g , , ddrug15 , ddrug16 } , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .",
        "label": "NA"
    },
    {
        "text": "ddrug0 / ddrug1 : an increase in the frequency of skin rash has been reported among patients receiving ddrug2 or DB01060 concurrently with DB00437 compared to patients who are not receiving both drugs .",
        "label": "effect"
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit ddrug0 binding to serum proteins or alter the concentrations of serum binding proteins : HD00657 and related ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , HD00328 , ddrug17 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : increased serum ddrug1 levels and symptoms of DB14507 toxicity have been reported in patients receiving HD00106 during therapy with ddrug4 .",
        "label": "NA"
    },
    {
        "text": "HD00095 : HD00585 may cause myopathy , which is manifested as muscle_pain or weakness associated with elevated levels of cpk .",
        "label": "NA"
    },
    {
        "text": "although not studied with DB00969 , inhibition of n-acetyltransferase may have clinically relevant consequences for drugs such as DB00951 , ddrug2 , and ddrug3 .",
        "label": "effect"
    },
    {
        "text": "when the DB00611 was administered # minutes after the DB00669 nasal spray , the auc of ddrug2 increased 11 % and cmax decreased 18 % .",
        "label": "mechanism"
    },
    {
        "text": "DB01109 injection should not be mixed with DB00997 , ddrug2 , ddrug3 , or ddrug4 , since it has been reported that these drugs are incompatible with ddrug5 and a precipitate may form .",
        "label": "NA"
    },
    {
        "text": "- a HD00535 { ddrug1 } such as ddrug2 { ddrug3 , ddrug4 , ddrug5 , others } , ddrug6 { ddrug7 , ddrug8 , ddrug9 } , ddrug10 { ddrug11 , ddrug12 } , ddrug13 { ddrug14 } , ddrug15 { ddrug16 } , DB00461 { ddrug18 } , ddrug19 { ddrug20 } , and ddrug21 { ddrug22 , ddrug23 , ddrug24 } ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 , ddrug2 , and ddrug3 the in vitro binding of DB00682 to plasma proteins is only slightly reduced by DB00465 { # % control vs # % } when ddrug6 plasma concentrations reach # to10 m g/ml .",
        "label": "mechanism"
    },
    {
        "text": "since DB00593 { ddrug1 } may interact with concurrently administered ddrug2 , periodic serum level determinations of these drugs may be necessary { eg , ddrug3 may elevate ddrug4 serum levels and ddrug5 has been reported to both increase and decrease DB00593 levels } .",
        "label": "NA"
    },
    {
        "text": "no depressant effect on blood levels in humans was noted when ddrug0 was administered with any of the following drugs : ddrug1 , ddrug2 , ddrug3 , DB00968 , ddrug5 { ddrug6 } , ddrug7 , ddrug8 or DB00682 .",
        "label": "NA"
    },
    {
        "text": "it is recommended that if DB01128 is started in patients already receiving HD00423 , prothrombin times should be closely monitored and adjustment of the ddrug2 dose may be necessary .",
        "label": "advise"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , DB00091 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , DB00295 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "when DB00303 is co-administered with ddrug1 { 500 mg p , o , every # hours } , DB01032 competes for active tubular secretion and reduces the renal clearance of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 should be used with caution in patients receiving - HD00305 blocking agents { e , g , , DB00571 , a ddrug4 inhibitor } or ddrug5 antagonists { e , g , , ddrug6 , a ddrug7 substrate , and ddrug8 , a ddrug9 inhibitor } because of the possible potentiation of bradycardia , sinus arrest , and av block ;",
        "label": "NA"
    },
    {
        "text": "total body clearance of ddrug0 was reduced by an average 22 % and 51 % when DB00993 and ddrug2 , respectively , were added to a regimen consisting of DB00091 , usp { modified } and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "HD00239 : concomitant treatment with ddrug1 and ddrug2 should be avoided because DB00982 use has been associated with a number of cases of idiopathic_intracranial_hypertension { benign intracranial hypertension } , some of which involved concomitant use of ddrug4",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 : ddrug2 and HD00374 containing DB14513 or ddrug5 , as well as formulations containing divalent and trivalent cations such as ddrug6 { ddrug7 } , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with ddrug8 and interfere with its bioavailability .",
        "label": "NA"
    },
    {
        "text": "DB00999 : in normal volunteers , concomitant administration of DB00861 and ddrug2 resulted in significantly increased plasma levels of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "potential drug interactions between ddrug0 and other ddrug1 { DB00564 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 and ddrug8 } were also assessed by evaluating the serum concentrations of ddrug9 and these HD00714 during placebo-controlled clinical studies .",
        "label": "NA"
    },
    {
        "text": "in vitro , DB00490 does not displace tightly bound drugs like DB00252 , ddrug2 , and ddrug3 from serum proteins .",
        "label": "NA"
    },
    {
        "text": "ddrug0 reduced or eliminated the increases in fi responding produced by intermediate doses of either HD00156 or DB03575 in pigeons , but did not antagonize the decreases in fi or fr responding produced by high doses of pgpep1 or either stereoisomer of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "substances that are potent inhibitors of cyp3a4 activity { eg , DB01026 and ddrug1 } decrease DB00317 metabolism and increase ddrug3 plasma concentrations .",
        "label": "mechanism"
    },
    {
        "text": "when used in external subcutaneous infusion pumps for HD00071 , DB01306 should not be mixed with any other ddrug2 or diluent .",
        "label": "NA"
    },
    {
        "text": "potential for other drugs to affect DB01238 DB01238 is not a substrate of cyp1a1 , cyp1a2 , cyp2a6 , cyp2b6 , cyp2c8 , cyp2c9 , cyp2c19 , or cyp2e1 enzymes .",
        "label": "NA"
    },
    {
        "text": "as with most psychoactive medications , patients should be advised to avoid DB02325 while taking DB01238",
        "label": "advise"
    },
    {
        "text": "in addition , drugs that are actively secreted via this route { e , g , , DB00384 , ddrug1 and ddrug2 } should be co-administered with care as they might increase DB00204 levels .",
        "label": "advise"
    },
    {
        "text": "therefore , cyp3a4 substrates known to have a narrow therapeutic index such as ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , DB00813 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , or ddrug10 { ddrug11 , ddrug12 } should be administered with caution in patients receiving DB01254 .",
        "label": "advise"
    },
    {
        "text": "drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on HD00849 therapy : ddrug1 , ddrug2 , ddrug3 , oral ddrug4 containing ddrug5 , ddrug6 - containing preparations and the numerous preparations containing HD00328 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : concomitant administration of DB00563 and some HD00203 has been reported to reduce the clearance of ddrug3 , enhancing the toxicity of ddrug4 .",
        "label": "mechanism"
    },
    {
        "text": "in clinical trials , ddrug0 was used with ddrug1 , ddrug2 , HD00326 , oral ddrug4 , and supplemental ddrug5 , in a pharmacokinetic substudy in patients with congestive heart failure receiving ddrug6 or ddrug7 in whom therapy with DB01240 was initiated , apparent oral clearance values for ddrug9 { n = 23 } and ddrug10 { n = 30 } were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .",
        "label": "NA"
    },
    {
        "text": "DB00571 attenuated the heart rate increase following administration of immediate release DB00401 .",
        "label": "effect"
    },
    {
        "text": "therefore , cyp3a4 substrates known to have a narrow therapeutic index such as DB00802 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , or ddrug10 { ddrug11 , ddrug12 } should be administered with caution in patients receiving DB01254 .",
        "label": "advise"
    },
    {
        "text": "DB00294 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , DB00860 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "int"
    },
    {
        "text": "the interaction is a consequence of blocking hepatic metabolism of DB00862 by DB00503 , a highly potent cyp3a4 inhibitor , which also inhibits cyp2c9 .",
        "label": "mechanism"
    },
    {
        "text": "increased nephrotoxicity has been reported following concomitant administration of HD00485 and HD00447 .",
        "label": "effect"
    },
    {
        "text": "tablets : the ddrug0 , including DB00186 , produce cns-depressant effects when administered with such medications as ddrug2 or DB02325 .",
        "label": "effect"
    },
    {
        "text": "DB00571 : in normal volunteers , there was no clinically significant pharmacokinetic or pharmacodynamic interaction with concomitant administration of single doses of DB00227 and ddrug2 .",
        "label": "NA"
    },
    {
        "text": "drug/laboratory test interaction DB00492 may cause a false low measurement of serum DB00390 levels with the digi - tab ria kit for ddrug2 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - concomitant intake of DB00375 and DB01022 may reduce the absorption of ddrug3 .",
        "label": "mechanism"
    },
    {
        "text": "the HD00123 , DB01110 , inhibits the growth of several species of candida .",
        "label": "NA"
    },
    {
        "text": "toxicology studies of ddrug0 - related deaths reveal frequent involvement of other ddrug1 , including ddrug2 , ddrug3 such as ddrug4 { DB00829 } , and , to a rising degree , DB00333 .",
        "label": "NA"
    },
    {
        "text": "concurrent administration of DB00651 and DB01032 , which competes for tubular secretion , has been shown to increase the plasma half-life of ddrug2 .",
        "label": "mechanism"
    },
    {
        "text": "methods : healthy subjects who were # to # years old participated in an open , three-period , randomized , crossover study of the pharmacokinetics of a single 10-mg oral dose of DB00877 , a single oral 120-mg dose of DB00343 , and the two drugs given together .",
        "label": "NA"
    },
    {
        "text": "drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving ddrug0 metabolized similarly to ddrug1 or on the basis of in vitro studies with ddrug2 or other ddrug3 { caution is recommended during coadministration with ddrug4 } : available data from clinical studies of ddrug5 other than ddrug6 suggest a possible drug interaction with ddrug7 for the following : ddrug8 , DB00951 , ddrug10 such as DB00199 and ddrug12 , and grapefruit juice .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : administration of DB00342 with DB00220 resulted in the appearance of unchanged ddrug3 in plasma ;",
        "label": "NA"
    },
    {
        "text": "DB01026 : co-administration of # mg twice-daily ddrug1 with DB09026 resulted in an approximate 80 % increase in plasma levels of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 should be used with caution , if at all , when potent inhalational HD00264 such as DB01159 are employed because of potential to sensitize the myocardium to effects of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and DB00759 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , DB00295 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "in patients receiving ddrug0 { ddrug1 } or ddrug2 { ddrug3 } , the concomitant administration of 300 - 600 mg of DB00437 per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of DB01033 or ddrug6 .",
        "label": "advise"
    },
    {
        "text": "- DB01432 and ddrug1 HD00510 : ddrug3 and ddrug4 ddrug5 have the potential of binding ddrug6 and reducing ddrug7 absorption from the gastrointestinal tract",
        "label": "NA"
    },
    {
        "text": "HD00622 : ddrug1 { DB00320 } injection , usp should not be used with ddrug3 because the combination may cause synergistic elevation of blood pressure .",
        "label": "NA"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : ddrug1 ; ddrug2 ; ddrug3 ; certain ddrug4 , especially the ddrug5 and ddrug6 ; ddrug7 ; ddrug8 salts ; DB01035 ; and DB00908 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and oral HD00150 : concomitant administration of ddrug2 and/or other oral ddrug3 with DB00459 must be avoided because of the risk of hypervitaminosis a.",
        "label": "NA"
    },
    {
        "text": "in monkeys , the effects of HD00157 , but not HD00156 or ddrug2 , were antagonized by ddrug3 ;",
        "label": "NA"
    },
    {
        "text": "concomitant administration of DB00358 and other related compounds { eg , ddrug1 , ddrug2 and DB00608 } may produce electrocardiographic abnormalities and increase the risk of convulsions .",
        "label": "effect"
    },
    {
        "text": "the co-administration of ddrug0 with iv HD00337 such as ddrug2 , DB00325 , ddrug4 , or iv ddrug5 has not been evaluated { these drugs were not co-administered with ddrug6 in clinical trials } .",
        "label": "NA"
    },
    {
        "text": "even when an HD00494 and a HD00284 - type drug are administered separately by different routes , a reduction in ddrug2 serum half-life or serum levels has been reported in patients with impaired renal function and in some patients with normal renal function .",
        "label": "mechanism"
    },
    {
        "text": "because prostaglandins play an important role in hemostasis , and ddrug0 affect platelet function as well , concurrent therapy with all HD00203 , including DB00586 , and ddrug3 requires close monitoring of patients to be certain that no change in their ddrug4 dosage is required .",
        "label": "NA"
    },
    {
        "text": "it is recommended to avoid concurrent administration of ddrug0 with DB06723 containing ddrug2 for at least # hours following DB00330 administration .",
        "label": "NA"
    },
    {
        "text": "a rare , but serious , constellation of symptoms , termed serotonin syndrome , has been reported with the concomitant use of ddrug0 { HD00114 } and agents for migraine therapy , such as ddrug2 { DB00669 } and ddrug4 .",
        "label": "effect"
    },
    {
        "text": "this decrease in bioavailability was about 5 % when DB00996 was administered # hours after HD00467 .",
        "label": "mechanism"
    },
    {
        "text": "because of the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of DB00679 , DB00476 and ddrug2 should not be co-administered .",
        "label": "NA"
    },
    {
        "text": "influence of ddrug0 and DB00396 on the sensitivity of rat thoracic aorta to DB00368 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and other HD00203 can reduce the antihypertensive effect of DB00571 and other ddrug3 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : a single # mg dose of DB00906 did not affect the pharmacokinetics of DB00277 at steady state .",
        "label": "NA"
    },
    {
        "text": "in comparison with DB00502 , the adverse events reported significantly more frequently with DB00334 in > or = # % of patients were dry mouth , bodyweight gain and increased appetite and compared with ddrug2 , only bodyweight gain occurred significantly more frequently with ddrug3 .",
        "label": "NA"
    },
    {
        "text": "HD00227 , such as ddrug1 , may have an additive effect when given with HD00228 .",
        "label": "effect"
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , ddrug3 , or DB01373 , with DB00364 , with metal cations such as ddrug6 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "in seven experiments reactions to DB00368 and ddrug1 were HD00041 .",
        "label": "NA"
    },
    {
        "text": "drugs that may alter DB00619 plasma concentrations drugs that may increase ddrug1 plasma concentrations : caution is recommended when administering ddrug2 with inhibitors of the cyp3a4 family { e , g , , ddrug3 , DB01167 , ddrug5 , ddrug6 } .",
        "label": "NA"
    },
    {
        "text": "drugs that should not be coadministered with DB00220 ddrug1 : ddrug2 , ddrug3 HD00388 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "label": "advise"
    },
    {
        "text": "the plasma concentration of DB00458 may increase when the drug is given concomitantly with hepatic enzyme inhibitors { e , g , , ddrug1 , ddrug2 } and decrease by concomitant administration of hepatic enzyme inducers { e , g , , HD00026 , ddrug4 } , and adjustment of the dosage of ddrug5 may therefore be necessary .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , DB01076 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , DB00503 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "although no clinical studies have been conducted , it is likely that the metabolism of ddrug0 may be affected by the known cyp3a4 inducers { such as ddrug1 , ddrug2 , DB01045 } , cyp3a4 inhibitors { azole antimycotics e , g , , DB01026 ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 : DB00559 has no significant pharmacokinetic interactions with ddrug4 and DB00393 , and ddrug6 has no significant effect on plasma levels of ddrug7 .",
        "label": "NA"
    },
    {
        "text": "when HD00414 or ddrug1 is used at the same time as other medicines or substances the following interactions must be taken into account : - ddrug2 and ddrug3 may enhance the action of HD00240 .",
        "label": "NA"
    },
    {
        "text": "as with some other ddrug0 , the time of onset of neuromuscular block induced by ddrug1 is lengthened and the duration of block is shortened in patients receiving DB00252 or DB00564 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 ddrug1 ddrug2 , like other ddrug3 , may inhibit the metabolism of DB00201 and DB01412 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , DB00316 and ddrug2 may enhance the effects of : other ddrug3 s , ddrug4 , general ddrug5 , HD00262 such as ddrug7 , ddrug8 , or other ddrug9 , causing increased cns depression .",
        "label": "effect"
    },
    {
        "text": "the effect of DB00465 on DB00563 clearance has not been studied .",
        "label": "NA"
    },
    {
        "text": "DB00695 : clinical studies , as well as post-marketing observations , have shown that HD00203 can reduce the natriuretic effect of ddrug2 and ddrug3 in some patients .",
        "label": "NA"
    },
    {
        "text": "because there is a theoretical basis that these effects may be additive , use of ddrug0 - containing or HD00274 { like ddrug2 or ddrug3 } and DB00918 within # hours of each other should be avoided .",
        "label": "advise"
    },
    {
        "text": "coadministration of ddrug0 with DB00252 or any known cyp3a4 inducer should be avoided and alternative HD00876 therapy should be considered .",
        "label": "NA"
    },
    {
        "text": "drug-drug interactions in vitro studies using human liver microsomes indicate that DB01039 and DB13873 are not inhibitors of cytochrome { cyp } cyp2b6 isoforms cyp3a4 , cyp2d6 , cyp2e1 , or cyp1a2 .",
        "label": "NA"
    },
    {
        "text": "-lsb- stimulation by ddrug0 -- an analog of the octapeptide cholecystokinin -- of ddrug1 binding after the long-term administration of ddrug2 -rsb- it has been established in experiments on white male rats that prolonged administration { twice a day for # days } of ddrug3 { # mg/kg } and ddrug4 { # mg/kg } resulted in the reduced interaction between ddrug5 and low affinity binding sites for ddrug6 in subcortical structures , whereas HD00136 binding with high affinity binding sites for DB00714 increased both in the frontal cortex and subcortical structures of the forebrain .",
        "label": "NA"
    },
    {
        "text": "effect of HD00714 in pediatric patients there was about a 22 % increase of apparent total body clearance of DB01202 when it was co-administered with enzyme-inducing ddrug2 .",
        "label": "NA"
    },
    {
        "text": "because ddrug0 may enhance the serotonergic effects of ddrug1 , caution should be exercised when DB01175 and DB14507 are coadministered .",
        "label": "advise"
    },
    {
        "text": "DB00199 : in hypercholesterolemic patients , steady-state DB00439 auc and cmax increased approximately 50 % and 24 % respectively after # days with co-administration of ddrug2 , a known inhibitor of cytochrome p450 3a4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , and the ddrug1 ddrug2 { DB00904 } and DB00889 { ddrug5 } have all been used with ddrug6 .",
        "label": "NA"
    },
    {
        "text": "the pharmacokinetics of DB01029 were not affected by coadministration of DB01115 or ddrug2",
        "label": "NA"
    },
    {
        "text": "HD00461 { cns } drugs including ddrug1 , ddrug2 , ddrug3 , ddrug4 , blood pressure medications { ddrug5 , ddrug6 , ddrug7 } , motion sickness medications , ddrug8 , HD00543 , ddrug10 , sleeping pills and ddrug11",
        "label": "NA"
    },
    {
        "text": "it is concluded that HD00163 modulates in an opposite way the function of the enkephalinergic neurons and the central action of HD00166 .",
        "label": "effect"
    },
    {
        "text": "other concomitant therapy although specific interaction studies were not performed , DB01216 doses of # mg or more were concomitantly used in clinical studies with ddrug1 , ddrug2 , a-blockers , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , cardiac ddrug9 , HD00218 , ddrug11 , ddrug12 , ddrug13 { also referred to as ddrug14 } , and ddrug15 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a single { 400 mg } and multiple dose { 400 mg tid } study of ddrug1 in epileptic patients { n = 8 } maintained on ddrug2 monotherapy for at least # months , DB00996 had no effect on the steady-state trough plasma concentrations of ddrug4 and DB00252 had no effect on ddrug6 pharmacokinetics .",
        "label": "NA"
    },
    {
        "text": "DB01167 ddrug1 DB00199 ddrug3 ddrug4 ddrug5 ddrug6 ddrug7 large quantities of grapefruit juice { # quart daily }",
        "label": "NA"
    },
    {
        "text": "HD00838 should be used with caution in patients receiving other local HD00264 or agents structurally related to amide-type local anesthetics since the toxic effects of these drugs could be additive .",
        "label": "advise"
    },
    {
        "text": "dose reduction of DB00224 to # mg every # hours should be considered when taking DB00705 # mg three times a day .",
        "label": "advise"
    },
    {
        "text": "it is desirable to monitor HD00312 plasma levels whenever an agent of the HD00552 including ddrug2 is going to be co-administered with another drug known to be an inhibitor of cyp2b6 2d6 { and/or p450 1a2 } .",
        "label": "NA"
    },
    {
        "text": "therefore , cyp3a4 substrates known to have a narrow therapeutic index such as ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , DB00877 , ddrug9 , or ddrug10 { ddrug11 , ddrug12 } should be administered with caution in patients receiving DB01254 .",
        "label": "advise"
    },
    {
        "text": "co-administration of DB00220 at steady-state with a single dose of DB00207 .",
        "label": "NA"
    },
    {
        "text": "the gonadotropin levels may be transiently elevated by DB00421 , minimally elevated by ddrug1 , and suppressed by oral HD00283 and ddrug3 .",
        "label": "NA"
    },
    {
        "text": "HD00343 : DB00813 is not recommended for use in patients who have received ddrug2 within # days because severe and unpredictable potentiation by ddrug3 has been reported with ddrug4",
        "label": "NA"
    },
    {
        "text": "since ddrug0 is extensively metabolized by cyp4f3 isoenzymes , caution should be exercised when DB01166 is coadministered with inhibitors of c , p , a , such as DB01026 and ddrug3 or inhibitors of cyp2c19 such as ddrug4 .",
        "label": "advise"
    },
    {
        "text": "the effect of DB00277 on the pharmacokinetics of DB00215 was not evaluated .",
        "label": "NA"
    },
    {
        "text": "there was no evidence of any pharmacokinetic interactions between DB00002 and DB00762 .",
        "label": "NA"
    },
    {
        "text": "a rare , but serious , constellation of symptoms , termed serotonin syndrome , has been reported with the concomitant use of ddrug0 { HD00114 } and agents for migraine therapy , such as ddrug2 { ddrug3 } and DB00320 .",
        "label": "effect"
    },
    {
        "text": "before taking ddrug0 , tell your doctor if you are taking any of the following medicines : - ddrug1 or another HD00372 such as ddrug3 { ddrug4 } , ddrug5 { ddrug6 , others } , ddrug7 { ddrug8 } , ddrug9 { HD00758 } , or ddrug11 { ddrug12 } ;",
        "label": "NA"
    },
    {
        "text": "poor metabolizers of ddrug0 : interactions of DB01136 with strong inhibitors of cyp2d6 { such as ddrug2 , ddrug3 , DB00715 , and ddrug5 } have not been studied , but these drugs would be expected to increase blood levels of the r { + } enantiomer of ddrug6 .",
        "label": "NA"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : HD00870 HD00871 : ddrug9 ddrug10 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "cyclosporine , digoxin , methotrexate ddrug0 , like other HD00203 , through effects on renal prostaglandins , may cause changes in the elimination of these drugs leading to elevated serum levels of ddrug2 , ddrug3 , DB00563 , and increased toxicity .",
        "label": "mechanism"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / ddrug1 , drugs used to treat an overactive thyroid , HD00254 { e , g , , ddrug3 } , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 pain medication { e , g , , ddrug12 } , drugs used to aid sleep , drowsiness-causing HD00388 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "when coadministered with DB00625 in treatment-naive patients , the recommended dose of ddrug1 is # mg with DB00503 # mg and ddrug3 # mg { all once daily } .",
        "label": "NA"
    },
    {
        "text": "the hypoglycemic action of ddrug0 may be potentiated by certain drugs including HD00518 and other drugs that are highly protein bound , ddrug2 , ddrug3 , DB00446 , ddrug5 , ddrug6 , ddrug7 , and ddrug8 .",
        "label": "NA"
    },
    {
        "text": "moreover , additional interaction studies with ddrug0 and ddrug1 have not demonstrated any effect on DB01095 plasma levels , and administration to a patient population chronically receiving ddrug3 resulted in no difference in the extent of bioavailability of DB00390 relative to control data .",
        "label": "NA"
    },
    {
        "text": "in vivo interaction studies in humans have demonstrated that ddrug0 and DB00682 do not affect the pk properties of ddrug2 , nor does DB00261 affect the pk properties of ddrug4 or ddrug5 .",
        "label": "NA"
    },
    {
        "text": "- a HD00764 such as ddrug1 { ddrug2 , ddrug3 , others } , ddrug4 { DB00959 , others } , ddrug6 { ddrug7 , ddrug8 , others } , and others ;",
        "label": "NA"
    },
    {
        "text": "inhibitors of cyp3a4 { eg , DB01026 } or cyp2d6 { eg , ddrug1 , ddrug2 , or ddrug3 } can inhibit DB01238 elimination and cause increased blood levels .",
        "label": "mechanism"
    },
    {
        "text": "plasma concentrations of DB00091 should therefore be closely monitored , and its dosage reduced accordingly , in patients treated with DB00622 .",
        "label": "advise"
    },
    {
        "text": "in patients receiving DB00573 and a ddrug1 concomitantly , any reduction in ddrug2 dosage should be gradual in order to avoid the possible complications of sudden HD00429 withdrawal .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - administration of # mg/day racemic DB00215 for # days did not affect the pharmacokinetics of DB00682 , a cyp3a4 substrate .",
        "label": "NA"
    },
    {
        "text": "co-administration of ddrug0 with DB00661 resulted in increases in ddrug2 peak plasma levels of 42 % , although overall exposure to DB00204 was not significantly increased .",
        "label": "NA"
    },
    {
        "text": "although neither DB01234 nor ddrug1 affected the proliferation of prostatic epithelium in rpmi1640 containing ddrug2 alone , they modify the mitogenic effect of ddrug3 and HD00071 .",
        "label": "effect"
    },
    {
        "text": "similarly , the effects of DB00252 on ddrug1 , ddrug2 and sodium plasma DB00313 concentrations are unpredictable",
        "label": "effect"
    },
    {
        "text": "potential drug interactions between ddrug0 and other ddrug1 { ddrug2 , DB00996 , ddrug4 , ddrug5 , ddrug6 , ddrug7 and ddrug8 } were also assessed by evaluating the serum concentrations of DB01202 and these ddrug10 during placebo-controlled clinical studies .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , DB00564 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { DB01045 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "DB14513 - and/or DB01370 - containing ddrug2 , products containing ddrug3 { ddrug4 } , ddrug5 containing ddrug6 or other metal cations , or ddrug7 { ddrug8 } chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after ddrug9 .",
        "label": "NA"
    },
    {
        "text": "abased on reports of narcotic withdrawal syndrome in patients treated with DB00238 and ddrug1 concurrently , and evidence of decreased plasma concentrations of DB00333 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { e , g , , ddrug1 , ddrug2 , DB00734 } and DB00951 may reduce the therapeutic effects of ddrug5 .",
        "label": "NA"
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as DB01135 include certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 } , DB14513 salts , ddrug11 , local ddrug12 , ddrug13 , and ddrug14 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : a literature article reported that when a 60-mg controlled-release DB00295 capsule was administered # hours prior to a 600-mg DB00996 capsule { n = 12 } , mean ddrug3 auc increased by 44 % compared to ddrug4 administered without ddrug5 .",
        "label": "mechanism"
    },
    {
        "text": "in separate single or multiple dose pharmacokinetic interaction studies with ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , DB00390 , and ddrug8 , the bioavailability of DB14207 was not altered by coadministration of ddrug10 with any one of these drugs .",
        "label": "NA"
    },
    {
        "text": "if a patient requires ddrug0 and ddrug1 therapy , it is suggested that ddrug2 , ddrug3 , or ddrug4 { DB06723 and ddrug6 } be used as alternatives to ddrug7 , as these agents have no effect on the pharmacokinetic profile of DB00204 .",
        "label": "NA"
    },
    {
        "text": "in a study in hypertensive patients , addition of DB00270 to existing DB00999 therapy did not result in any unexpected adverse effects , and ddrug2 had an additional antihypertensive effect .",
        "label": "NA"
    },
    {
        "text": "however , the systemic administration of some ddrug0 has been shown to elevate plasma concentrations of ddrug1 , interfere with the metabolism of DB00201 , and enhance the effects of the oral ddrug3 DB00682 and its derivatives , and has been associated with transient elevations in serum creatinine in patients receiving systemic ddrug5 concomitantly .",
        "label": "NA"
    },
    {
        "text": "DB00503 { 600 mg b , i , d , } co-administered with DB00862 # mg resulted in a 49-fold increase in ddrug2 auc and a 13-fold increase in ddrug3 cmax .",
        "label": "mechanism"
    },
    {
        "text": "another study showed that ddrug0 had no clinically significant effect on plasma concentrations of the oral HD00280 ddrug2 and DB00367 { cyp3a4 substrates } .",
        "label": "NA"
    },
    {
        "text": "it is not known if HD00432 differ in their effectiveness when used with DB00982 .",
        "label": "NA"
    },
    {
        "text": "interactions for ddrug0 analogues { ddrug1 , DB00169 , ddrug3 , and ddrug4 } : DB01432 : ddrug6 has been reported to reduce intestinal absorption of ddrug7 ;",
        "label": "NA"
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma ddrug0 concentrations include : acute DB02325 intake , ddrug2 , chboramphenicol , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , DB00951 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21",
        "label": "NA"
    },
    {
        "text": "there was no apparent pharmacokinetic interaction between DB00962 and DB01050 following single dose administration { 10 mg and # mg , respectively } of each drug .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { HD00548 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , DB01601 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 containing ddrug1 and DB09104 reduce the oral absorption of DB00467 by 75 % .",
        "label": "mechanism"
    },
    {
        "text": "preliminary studies indicate that the concomitant use of DB00841 and DB00325 results in a higher cardiac output and , usually , a lower pulmonary wedge pressure than when either drug is used alone .",
        "label": "effect"
    },
    {
        "text": "interaction of HD00198 and DB13295 in anaesthetised horses .",
        "label": "int"
    },
    {
        "text": "ddrug0 : ddrug1 should be used with caution in patients receiving - ddrug2 blocking agents { e , g , , DB00571 , a ddrug4 inhibitor } or ddrug5 antagonists { e , g , , ddrug6 , a ddrug7 substrate , and ddrug8 , a HD00302 inhibitor } because of the possible potentiation of bradycardia , sinus arrest , and av block ;",
        "label": "NA"
    },
    {
        "text": "injection of DB00783 # min before a nonlethal dose of HD00168 changed the serum sex steroid hormone response of male rats to ddrug2 .",
        "label": "effect"
    },
    {
        "text": "other drugs : in healthy volunteers , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , hormone replacement therapy { a combination of conjugated ddrug5 and HD00642 } , ddrug7 { ddrug8 and ddrug9 } and ddrug10 did not affect the pharmacokinetics of DB00204 .",
        "label": "NA"
    },
    {
        "text": "DB01032 or ddrug1 : concomitant administration of ddrug2 or ddrug3 decreases the elimination of DB00943 , most likely by inhibition of renal tubular secretion of ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { cns } drugs including ddrug1 , ddrug2 , HD00388 , ddrug4 , blood pressure medications { DB00206 , ddrug6 , ddrug7 } , motion sickness medications , ddrug8 , ddrug9 , ddrug10 , sleeping pills and ddrug11",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB01032 is known to interact with the metabolism or renal tubular excretion of many drugs { e , g , , ddrug2 , ddrug3 , ddrug4 , DB00233 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 agents , ddrug14 , and ddrug15 } .",
        "label": "mechanism"
    },
    {
        "text": "concomitant single dose administration of DB00580 # mg with multiple doses of ddrug1 and DB00196 produced a significant increase in exposure of ddrug3 .",
        "label": "mechanism"
    },
    {
        "text": "DB00316 and ddrug1 - ddrug2 may decrease hepatic toxicity in those with ddrug3 overdosage or in those taking DB00563 .",
        "label": "NA"
    },
    {
        "text": "- drugs that may decrease plasma ddrug0 concentrations include : ddrug1 , chronic DB02325 abuse , DB00206",
        "label": "NA"
    },
    {
        "text": "poor metabolizers of ddrug0 : interactions of ddrug1 with strong inhibitors of cyp2d6 { such as ddrug2 , ddrug3 , DB00715 , and ddrug5 } have not been studied , but these drugs would be expected to increase blood levels of the r { + } enantiomer of DB01136 .",
        "label": "effect"
    },
    {
        "text": "inhibitors of this isoenzyme { e , g , , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , grapefruit juice , ddrug7 , DB01059 , ddrug9 , ddrug10 } should be cautiously coadministered with ddrug11 as they can potentially increase DB00204 levels .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , DB01232 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and DB00126 .",
        "label": "NA"
    },
    {
        "text": "the extent to which ddrug0 - HD00312 interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the HD00278 involved .",
        "label": "NA"
    },
    {
        "text": "pharmacological/pharmacodynamic interactions with ddrug0 concomitant administration of DB00564 and DB14507 may increase the risk of neurotoxic side effects .",
        "label": "effect"
    },
    {
        "text": "results of studies in multiple sclerosis patients taking ddrug0 and concomitant DB00060 { DB02325 # mcg i m once weekly } or ddrug3 were inconclusive with regard to the need for dose adjustment of the ddrug4 or ddrug5 .",
        "label": "NA"
    },
    {
        "text": "interactions with other cns agents : concurrent use of DB00854 with all ddrug1 { eg , ddrug2 , ddrug3 , ddrug4 , other ddrug5 , general ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , HD00320 and ddrug12 } may result in additive central nervous system depressant effects .",
        "label": "effect"
    },
    {
        "text": "in a comparison of HD00118 tolerance in dogs anesthetized with DB01221 , ddrug2 , or ddrug3 , the dosage of ddrug4 needed to cause ventricular tachycardia was significantly higher , as was the ld50 of ddrug5 , with ddrug6 or ddrug7 than with ddrug8 .",
        "label": "NA"
    },
    {
        "text": "no inhibition of DB01609 metabolism by DB01005 is expected based on the results of an in vitro study .",
        "label": "NA"
    },
    {
        "text": "experience with ddrug0 { HD00203 } suggests the potential for interactions with DB00695 and ddrug3 .",
        "label": "int"
    },
    {
        "text": "HD00336 s and HD00337 : the following adverse events were experienced more commonly in patients receiving concomitant ddrug2 or ddrug3 { n = 94 } compared to patients not receiving these concomitant drugs { n = 456 } : hypotension 10 % vs 4 % , myocardial infarction 3 % vs 1 % , serious pneumonias 5 % vs 3 % , serious falls 9 % vs 3 % , and bone and joint injuries 6 % vs 2 % .",
        "label": "NA"
    },
    {
        "text": "coingestion of ddrug0 with ddrug1 , DB01174 with ddrug3 , and DB00313 with ddrug5 at high to toxic concentrations decreases the binding of the target drug .",
        "label": "NA"
    },
    {
        "text": "DB01064 should be used with caution , if at all , when potent inhalational ddrug1 such as DB01159 are employed because of potential to sensitize the myocardium to effects of ddrug3 .",
        "label": "advise"
    },
    {
        "text": "the pharmacokinetics of DB01029 were not affected by coadministration of ddrug1 or DB00999",
        "label": "NA"
    },
    {
        "text": "other potentially important drug interactions : ddrug0 : HD00100 metabolized by hepatic oxidation { e , g , , ddrug2 , ddrug3 , ddrug4 elc , } should be used with caution because the clearance of these drugs is likely to be reduced by DB00176 .",
        "label": "mechanism"
    },
    {
        "text": "it is recommended that ddrug0 not be used concomitantly with HD00343 because the effects of concomitant administration of ddrug2 with most other ddrug3 have not been studied , the concomitant use of DB00490 with other cns-active drugs should be approached with caution .",
        "label": "NA"
    },
    {
        "text": "thus , when HD00897 and DB14507 are administered concurrently , subjects should be observed carefully for signs of ddrug2 toxicity .",
        "label": "advise"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { DB00400 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as HD00269 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : as with other ddrug1 , the renal excretion of DB00567 is inhibited by DB01032 .",
        "label": "mechanism"
    },
    {
        "text": "in addition , studies in healthy volunteers have shown that ddrug0 does not affect the pharmacokinetics or pharmacodynamics of ddrug1 , or the pharmacokinetics of DB00571 { 40 mg twice daily } , ddrug3 , ddrug4 , or oral HD00283 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00091 , DB00864 , ddrug3",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 { DB00270 } has been safely coadministered with DB00727 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00813 is not recommended for use in patients who have received ddrug2 within # days because severe and unpredictable potentiation by HD00343 has been reported with ddrug4",
        "label": "NA"
    },
    {
        "text": "ddrug0 : there is no significant pharmacokinetic interaction between DB00495 and DB00943 which has been confirmed clinically .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - ddrug1 containing side chains of n-methylthiotetrazole { ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB04570 } or methylthiadiazole { DB01327 } can cause vitamin_k_deficiency and hypoprothrombinemia .",
        "label": "NA"
    },
    {
        "text": "coadministration of DB00311 with other ddrug1 , DB00681 , and ddrug3 may cause hypokalemia .",
        "label": "effect"
    },
    {
        "text": "HD00518 { ddrug1 } : concomitant use of DB00945 { or other ddrug3 } and ddrug4 increases the risk of gastrointestinal side effects .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , DB01167 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , DB00860 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "effects of other ddrug0 on ddrug1 ddrug2 : DB00252 causes an approximate doubling of the clearance of DB00949 { ddrug5 } at steady state and , therefore , the addition of ddrug6 causes an approximate 45 % decrease in the steady-state trough concentrations of ddrug7 as compared to the same dose of ddrug8 given as monotherapy .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 , ddrug1 , HD00394 , ddrug3 , HD00118 .",
        "label": "NA"
    },
    {
        "text": "among the risk factors studied , two appear to increase the risk of are : the prescription of DB00730 to treat strongyloidiasis during the DB12864 cure and the bad general clinical conditions of patients .",
        "label": "effect"
    },
    {
        "text": "conversely , DB00937 may interfere with ddrug1 { i , e , , ddrug2 , HD00619 } .",
        "label": "int"
    },
    {
        "text": "-lsb- dose-time effects of competitive displacement of ddrug0 by ddrug1 following oral and intravenous administration -rsb- the effect of various doses of HD00126 in several dose fractions on the extent and the time scale of displacement of HD00125 , in dependence on application mode , was studied .",
        "label": "NA"
    },
    {
        "text": "patients who begin taking ddrug0 or who increase their ddrug1 dose or any other HD00615 while taking DB00390 , ddrug4 , or ddrug5 may develop toxicity characteristics for these drugs .",
        "label": "effect"
    },
    {
        "text": "several HD00043 have been reported to block the pharmacologic effects of ddrug1 , ddrug2 , or similar agents , and such an effect may be anticipated with HD00551 because of its structural similarity to other ddrug4 .",
        "label": "effect"
    },
    {
        "text": "the pharmacokinetics and protein binding of DB01320 , ddrug1 , and ddrug2 were not altered when DB00829 and ddrug4 were concurrently administered in single submaximal doses .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as DB00415 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , DB00564 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "therophylline : a recent study has shown that concomitan administration of ddrug0 and DB00277 may cause elevated plasma levels of ddrug2 , and in some instances a slight decrease in the elimination of DB00951 .",
        "label": "NA"
    },
    {
        "text": "the effect of a ddrug0 extract from bovine lung , DB06761 , on the dissolution rate of aerosol particles of DB01222 was determined .",
        "label": "NA"
    },
    {
        "text": "patients taking these drugs with ddrug0 and ddrug1 or DB00190 - DB01235 combination products should be carefully observed for loss of therapeutic response .",
        "label": "NA"
    },
    {
        "text": "DB00294 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and DB00759 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "int"
    },
    {
        "text": "this observed increase in the bioavailability of ddrug0 may be due to transport-related effects , such as p-glycoprotein , in vivo animal studies also suggest that in addition to enhancing absorption , DB01026 decreases ddrug2 gastrointestinal secretion , while DB00199 may also decrease biliary excretion .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of DB01045 with DB01026 tablets reduces the blood levels of the latter .",
        "label": "mechanism"
    },
    {
        "text": "certain drugs , including ddrug0 { ddrug1 } , ddrug2 , ddrug3 , and HD00869 may potentiate the hypoglycemic action of DB00731 and other oral ddrug6 .",
        "label": "effect"
    },
    {
        "text": "in order to provide information for the appropriate package insert labeling of ddrug0 { HD00004 } in the us , a comprehensive review was made of ddrug2 { # mg } and DB00717 { # mg } , with the clinical differences indicated where applicable .",
        "label": "NA"
    },
    {
        "text": "like ddrug0 { 40 mg/kg } , HD00022 { 40 mg/kg } decreases the intravenous self-administration of ddrug2 and ddrug3 and the oral self-administration of ddrug4 and DB00184 in rats ;",
        "label": "NA"
    },
    {
        "text": "potential interactions between DB01229 , a substrate of cyp3a4 , and ddrug1 { ddrug2 , DB01232 , ddrug4 , and ddrug5 } , which are substrates and/or inhibitors of cyp3a4 , have not been evaluated in clinical trials .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { HD00548 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and DB00126 .",
        "label": "NA"
    },
    {
        "text": "HD00374 increase the rate of absorption of DB00852 , while ddrug2 decreases it .",
        "label": "mechanism"
    },
    {
        "text": "method : this study was a multicenter randomized double-blind study of # patients who were randomly assigned 1:1:1 to receive DB01590 tablets at doses of # mg , # mg , or # mg twice daily with DB00091 and ddrug2 .",
        "label": "NA"
    },
    {
        "text": "the possibility of hypotensive effects with DB01197 can be minimized by either discontinuing the HD00295 or increasing the salt intake approximately one week prior to initiation of treatment with ddrug2 { ddrug3 tablets , usp } or initiating therapy with small doses { # or # mg } .",
        "label": "effect"
    },
    {
        "text": "in rats , simultaneous ingestion of ddrug0 and ddrug1 in the diet for # weeks has been reported to cause tumors , and it has been suggested that DB00822 may react with HD00635 in the rat stomach to form a nitrosamine , which is tumorigenic .",
        "label": "effect"
    },
    {
        "text": "as with some other ddrug0 , the time of onset of neuromuscular block induced by DB01135 is lengthened and the duration of block is shortened in patients receiving DB00252 or ddrug3 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : concomitant administration of HD00374 may reduce plasma levels of DB00861 .",
        "label": "mechanism"
    },
    {
        "text": "therefore concomitant administration of DB01026 tablets with DB00604 is contraindicated .",
        "label": "advise"
    },
    {
        "text": "ddrug0 , ddrug1 , HD00372 , and ddrug3 the in vitro binding of DB00682 to plasma proteins is only slightly reduced by ddrug5 { # % control vs # % } when ddrug6 plasma concentrations reach # to10 m g/ml .",
        "label": "NA"
    },
    {
        "text": "however , in vivo drug interaction studies of DB01026 with DB11094 have not been investigated .",
        "label": "NA"
    },
    {
        "text": "for example , when ddrug0 are administered concomitantly with DB00665 , prothrombin time should be carefully monitored and if necessary , the dosage of HD00286 should be reduced .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 : in one study , ddrug1 was given to adult diabetics who were already receiving ddrug2 { n = 4 } , DB00331 { n = 2 } ddrug4 with DB00914 { n = 3 } or ddrug6 with ddrug7 { n = 6 } .",
        "label": "NA"
    },
    {
        "text": "DB00405 can interact with ddrug1 or other ddrug2 { may potentiate the cns depressant effects of either these medications or ddrug3 } , ddrug4 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug5 } , and ddrug6 { concurrent use with ddrug7 may prolong and intensify the anticholinergic and cns depressant effects of HD00388 } .",
        "label": "NA"
    },
    {
        "text": "there are case reports of patients who developed increased bun , serum creatinine and serum potassium levels , and weight gain when DB00695 was used in conjunction with HD00203 .",
        "label": "effect"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / ddrug1 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , DB00571 } , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 pain medication { e , g , , DB00318 } , drugs used to aid sleep , drowsiness-causing ddrug13 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "in vitro mixing of an HD00494 with beta-lactamtype ddrug1 { ddrug2 or HD00485 } may result in a significant mutual inactivation .",
        "label": "effect"
    },
    {
        "text": "cardiac effects of DB00988 are antagonized by ddrug1 , such as ddrug2 and DB00264 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 or DB00501 : concomitant administration of DB01032 or ddrug3 decreases the elimination of ddrug4 , most likely by inhibition of renal tubular secretion of ddrug5 .",
        "label": "NA"
    },
    {
        "text": "effects of DB00949 on low-dose ddrug1 a group of # nonsmoking , healthy white female volunteers established on an oral ddrug2 regimen containing # mg DB00977 and # mg ddrug4 for at least # months received # mg/day of ddrug5 from midcycle { day 15 } to midcycle { day 14 } of two consecutive oral ddrug6 cycles .",
        "label": "NA"
    },
    {
        "text": "co-administration with HD00247 such as ddrug1 or DB01167 is not recommended .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may have a clinically important interaction with the following other drugs : ddrug1 : when DB00476 and ddrug3 were administered several hours apart so that peak concentrations of each would coincide , ddrug4 did not increase the impairment of mental and motor skills caused by DB02325 .",
        "label": "NA"
    },
    {
        "text": "concomitant single dose administration of ddrug0 # mg with multiple doses of DB01026 and ddrug2 produced a significant increase in exposure of DB00580 .",
        "label": "NA"
    },
    {
        "text": "considerable caution should be exercised if DB00754 is administered concurrently with ddrug1 { DB01121 } since paranoid symptoms have been reported during therapy with this combination .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : a study in # healthy volunteers has shown a significant increase in peak ddrug1 plasma levels { 80 % } and area-under-the-curve { 74 % } after a # week course of DB00501 at # mg per day and DB01115 at # mg per day .",
        "label": "mechanism"
    },
    {
        "text": "drug interactions with HD00254 : concomitant use of DB00800 with ddrug2 should be avoided .",
        "label": "NA"
    },
    {
        "text": "in a comparison of HD00118 tolerance in dogs anesthetized with ddrug1 , HD00119 , or ddrug3 , the dosage of ddrug4 needed to cause ventricular tachycardia was significantly higher , as was the ld50 of ddrug5 , with ddrug6 or ddrug7 than with ddrug8 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 or ddrug1 : concomitant administration of ddrug2 or DB00501 decreases the elimination of DB00943 , most likely by inhibition of renal tubular secretion of ddrug5 .",
        "label": "mechanism"
    },
    {
        "text": "while all the ddrug0 { HD00114 } , e , g , , DB00215 , ddrug3 , ddrug4 , ddrug5 , and ddrug6 , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { DB00091 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , DB00224 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "methods : clinical studies , case reports , and commentaries and editorials concerning DB00203 published in the international literature between january # and august # were identified through searches of medline , premedline , and international pharmaceutical abstracts , using the terms ddrug1 , DB00203 , and erectile dysfunction .",
        "label": "NA"
    },
    {
        "text": "there was no evidence of drug interactions in clinical studies in which DB00841 was administered concurrently with other drugs , including ddrug1 , ddrug2 , ddrug3 , ddrug4 , DB00727 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , and ddrug13 .",
        "label": "NA"
    },
    {
        "text": "DB01194 { ddrug1 ophthalmic suspension } 1 % contains a HD00441 .",
        "label": "NA"
    },
    {
        "text": "if the DB00530 dose is adjusted upward , the dose will need to be reduced upon discontinuation of DB01045 or other inducers .",
        "label": "advise"
    },
    {
        "text": "while all the ddrug0 { HD00114 } , e , g , , ddrug2 , DB01104 , and ddrug4 , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .",
        "label": "NA"
    },
    {
        "text": "therefore , cyp3a4 substrates known to have a narrow therapeutic index such as ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , or ddrug10 { DB00201 , ddrug12 } should be administered with caution in patients receiving DB01254 .",
        "label": "advise"
    },
    {
        "text": "inhibitors of this isoenzyme { e , g , , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , grapefruit juice , ddrug7 , DB01059 , ddrug9 , ddrug10 } should be cautiously coadministered with DB00204 as they can potentially increase ddrug12 levels .",
        "label": "advise"
    },
    {
        "text": "agents causing renin release : the antihypertensive effect of DB00584 and ddrug1 iv is augmented by HD00366 that cause renin release { e , g , , ddrug3 } .",
        "label": "effect"
    },
    {
        "text": "therefore , co-administration of DB01156 with drugs that are metabolized by cyp2d6 isoenzyme including certain ddrug1 { e , g , , DB00540 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } , ddrug8 { e , g , , ddrug9 , ddrug10 , ddrug11 } , ddrug12 { e , g , , ddrug13 } , and ddrug14 { e , g , , ddrug15 , ddrug16 } , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .",
        "label": "advise"
    },
    {
        "text": "concomitant use of ddrug0 and drugs that inhibit cyp3a4 { eg , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , DB01149 , ddrug9 , ddrug10 , ddrug11 } may increase exposure to DB01254 and should be avoided .",
        "label": "NA"
    },
    {
        "text": "ddrug0 HD00524 may delay or reduce the absorption of concomitant oral medication such as ddrug2 , ddrug3 , ddrug4 { acidic } or ddrug5 { basic } , as well as DB00759 ddrug7 , ddrug8 , thyroid and ddrug9 preparations , ddrug10 and ddrug11 , and ddrug12 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 , as well as other HD00233 , probably reduces the tubular secretion of DB00563 based on in vitro studies in rabbit kidney slices .",
        "label": "mechanism"
    },
    {
        "text": "interaction of DB00906 with other drugs : ddrug1 : co-administration of ddrug2 { 800 mg/day } to patients taking DB00906 chronically had no effect on ddrug4 pharmacokinetics .",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with HD00374 containing ddrug2 , ddrug3 , or ddrug4 , with ddrug5 , with metal cations such as ddrug6 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of HD00532 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 - containing preparations { eg , HD00374 } may cause hypermagnesemia and should therefore not be taken during therapy with DB11094 by patients on chronic renal dialysis .",
        "label": "advise"
    },
    {
        "text": "co-administration of ddrug0 and DB00675 resulted in a reduction of DB01217 plasma levels by 27 % compared with those achieved with ddrug3 alone .",
        "label": "NA"
    },
    {
        "text": "concomitant use of DB01200 with other HD00443 is not recommended .",
        "label": "advise"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / ddrug1 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , ddrug4 , DB00365 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 pain medication { e , g , , DB00318 } , drugs used to aid sleep , drowsiness-causing ddrug13 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "it is concluded that DB01563 and DB04833 may be administered safely without additional caution in prothrombin test monitoring during oral ddrug2 therapy .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 interaction studies with DB00682 and DB01418 failed to identify any clinically important effects on the serum concentrations or clinical effects of these ddrug3 .",
        "label": "NA"
    },
    {
        "text": "in # other schizophrenic patients treated with oral DB00502 and ddrug1 , discontinuation of DB01045 produced a mean # - fold increase in ddrug3 concentrations .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00467 is a potent inhibitor of the cyp4f3 isozymes responsible for the metabolism of HD00246 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 , or other products containing ddrug1 or DB01593 , ddrug3 or ddrug4 should not be administered concomitantly with , or within # hours of , the administration of ddrug5 , because they may interfere with absorption resulting in lower serum and urine levels of DB01059 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 s : HD00525 increases the adrenergic effect of catecholamines such as DB00668 and ddrug3 .",
        "label": "effect"
    },
    {
        "text": "in several well-controlled studies , DB01018 was administered together with HD00218 with no drug interactions reported .",
        "label": "NA"
    },
    {
        "text": "other drug interactions : no pharmacokinetic interactions were observed between ddrug0 and the following drugs : ddrug1 , ddrug2 , DB00390 , ddrug4 , and DB00863 .",
        "label": "NA"
    },
    {
        "text": "DB01432 - concomitant intake of ddrug1 and DB01022 may reduce the absorption of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "several ddrug0 have been reported to block the pharmacologic effects of ddrug1 , DB00575 , or similar agents , and such an effect may be anticipated with ddrug3 because of its structural similarity to other HD00043 .",
        "label": "NA"
    },
    {
        "text": "this antagonistic effect of DB01032 on ddrug1 natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of DB00887 .",
        "label": "NA"
    },
    {
        "text": "alternatives to DB01045 should be considered during the course of pgpep1 treatment with DB01117 .",
        "label": "advise"
    },
    {
        "text": "therapeutic concentrations of ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB00252 andtolbutamide did not alter DB00465 protein binding .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , DB00295 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { HD00531 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "if a patient requires DB00204 and ddrug1 therapy , it is suggested that DB00338 , ddrug3 , or ddrug4 { ddrug5 and ddrug6 } be used as alternatives to ddrug7 , as these agents have no effect on the pharmacokinetic profile of ddrug8 .",
        "label": "NA"
    },
    {
        "text": "DB00977 and ddrug1 : coadministration of ddrug2 with HD00872 resulted in a 47 % decrease in ddrug4 and an 18 % decrease in ddrug5 plasma concentrations .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { cns } drugs including DB02325 , ddrug2 , ddrug3 , ddrug4 , blood pressure medications { DB00206 , ddrug6 , ddrug7 } , motion sickness medications , ddrug8 , ddrug9 , ddrug10 , sleeping pills and ddrug11",
        "label": "NA"
    },
    {
        "text": "HD00106 and ddrug1 { congestive heart failure post-myocardial infarction } - in ephesus , # { 91 % } patients receiving DB00700 # to # mg also received ddrug3 or ddrug4 { ddrug5 / ddrug6 } .",
        "label": "NA"
    },
    {
        "text": "clinical experience with concomitant administration of DB00559 and DB00682 in patients with pulmonary arterial hypertension did not show clinically relevant changes in inr or ddrug2 dose { baseline vs , end of the clinical studies } , and the need to change the ddrug3 dose during the trials due to changes in inr or due to adverse events was similar among ddrug4 - and placebo-treated patients .",
        "label": "NA"
    },
    {
        "text": "- a ddrug0 { HD00615 } such as DB01050 { ddrug3 , ddrug4 , ddrug5 , others } , ddrug6 { ddrug7 , ddrug8 , ddrug9 } , ddrug10 { ddrug11 , ddrug12 } , ddrug13 { ddrug14 } , ddrug15 { ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , and ddrug21 { ddrug22 , ddrug23 , ddrug24 } ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB01026 # mg daily did not have any clinically important effect on the pharmacokinetics of DB00533 .",
        "label": "NA"
    },
    {
        "text": "other drugs drug interactions have been reported with concomitant administration of DB00199 and other medications , including ddrug1 , ddrug2 , ddrug3 , DB00802 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 .",
        "label": "int"
    },
    {
        "text": "the concomitant use of transdermal ddrug0 with DB00503 or other potent 3a4 inhibitors such as ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB00220 , and nefazadone may result in an increase in ddrug7 plasma concentrations .",
        "label": "NA"
    },
    {
        "text": "poor metabolizers of DB04840 : interactions of ddrug1 with strong inhibitors of cyp2d6 { such as ddrug2 , ddrug3 , ddrug4 , and DB01182 } have not been studied , but these drugs would be expected to increase blood levels of the r { + } enantiomer of ddrug6 .",
        "label": "NA"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / ddrug1 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , DB00571 } , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 pain medication { e , g , , ddrug12 } , drugs used to aid sleep , drowsiness-causing HD00388 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : clinical studies , as well as post marketing observations , have shown that HD00203 can reduce the natriuretic effect of DB00695 and ddrug3 in some patients .",
        "label": "effect"
    },
    {
        "text": "drugs whose absorption is sensitive to ph may be negatively impacted by concomitant administration of DB00338 and DB00580 .",
        "label": "NA"
    },
    {
        "text": "in patients who have received ddrug0 , DB00561 may temporarily mask the residual effects of HD00654 .",
        "label": "effect"
    },
    {
        "text": "other drug interactions DB00501 , ddrug1 and ddrug2 had no effect on the pharmacokinetics of HD00888 .",
        "label": "NA"
    },
    {
        "text": "DB01057 potentiates other ddrug1 such as ddrug2 or HD00661 and ddrug4 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with HD00339 , HD00340 , and certain other agents .",
        "label": "NA"
    },
    {
        "text": "when ddrug0 is co-administered with ddrug1 { 500 mg p , o , every # hours } , DB01032 competes for active tubular secretion and reduces the renal clearance of DB00303 .",
        "label": "mechanism"
    },
    {
        "text": "DB02325 - although DB01175 did not potentiate the cognitive and motor effects of ddrug2 in a clinical trial , as with other ddrug3 , the use of ddrug4 by patients taking ddrug5 is not recommended .",
        "label": "NA"
    },
    {
        "text": "therefore , administration of HD00532 with ddrug1 containing DB01373 , ddrug3 , or ddrug4 ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration of DB00949 with ddrug2 causes an increase in ddrug3 plasma concentrations , in # otherwise healthy male volunteers ingesting DB01174 , the steady-state trough { cmin } ddrug5 concentration was # micrograms/ml .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration of single doses of DB00402 # mg and DB00715 # mg daily for # days produced no pharmacokinetic or pharmacodynamic interaction .",
        "label": "NA"
    },
    {
        "text": "in patients taking an ddrug0 { eg , ddrug1 , ddrug2 , DB01174 or ddrug4 } , the concomitant use of DB00358 may reduce seizure control by lowering the plasma levels of the ddrug6 .",
        "label": "effect"
    },
    {
        "text": "oral ddrug0 : in pharmacokinetic studies of DB00227 in hypercholesterolemic noninsulin dependent diabetic patients , there was no drug interaction with DB01067 or with ddrug3",
        "label": "NA"
    },
    {
        "text": "consider additive sedative effects and confusional states to emerge , if DB01239 is given with HD00100 or ddrug2 .",
        "label": "effect"
    },
    {
        "text": "patients in a clinical study who were on established therapy with ddrug0 , to which ddrug1 was added , were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either DB09145 ci or DB00795 alone .",
        "label": "NA"
    },
    {
        "text": "patients receiving other ddrug0 , ddrug1 , ddrug2 , or other HD00261 { including ddrug4 } concomitantly with ddrug5 and DB00316 tablets may exhibit an additive cns depression .",
        "label": "NA"
    },
    {
        "text": "a study of interaction between ddrug0 and ddrug1 showed that concomitant administration of DB00187 and ddrug3 does not alter DB00682 plasma levels .",
        "label": "NA"
    },
    {
        "text": "ddrug0 injection should not be mixed with ddrug1 , ddrug2 , DB00537 , or ddrug4 , since it has been reported that these drugs are incompatible with DB01109 and a precipitate may form .",
        "label": "NA"
    },
    {
        "text": "HD00044 - induced oxidative stress in rat brain and liver is prevented by ddrug1 or DB00437 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 , ddrug1 , ddrug2 salts , and DB02325 may either potentiate or weaken the blood-glucose-lowering effect of HD00071 .",
        "label": "effect"
    },
    {
        "text": "drugs metabolized by cytochrome p450 enzymes the drug interaction study evaluating the effect of ddrug0 on ddrug1 indicates that DB00365 inhibits DB00277 metabolism , which is mediated by cyp1a2 .",
        "label": "mechanism"
    },
    {
        "text": "no significant drug interactions have been reported in studies of DB00796 given with other drugs such as DB01016 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , and oral ddrug6 in healthy volunteers , or given with ddrug7 to patients with heart failure { nyha class ii and iii } .",
        "label": "NA"
    },
    {
        "text": "DB00448 has also been shown to have no clinically significant interaction with DB01060 .",
        "label": "NA"
    },
    {
        "text": "HD00470 add some further antihypertensive effect to DB01197 , but the overall response is less than additive .",
        "label": "effect"
    },
    {
        "text": "the clinical significance of this reduction is not known , hence DB00943 is not recommended to be ingested simultaneously with DB14513 / ddrug2 - containing ddrug3 .",
        "label": "advise"
    },
    {
        "text": "it is important for older adults to be aware of the relationship between DB00158 and DB00115 because they are at greater risk of having a vitamin b12 deficiency .",
        "label": "NA"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / ddrug1 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , ddrug4 , ddrug5 , ddrug6 , DB00226 , ddrug8 , ddrug9 , ddrug10 , ddrug11 pain medication { e , g , , DB00318 } , drugs used to aid sleep , drowsiness-causing ddrug13 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "HD00544 - ddrug1 may sterilize the bowel and decrease the DB01022 contribution to the body by the intestinal microflora .",
        "label": "NA"
    },
    {
        "text": "caution in using concomitant drugs such as ddrug0 { ophthalmic and systemic } , HD00440 and/or HD00345 is advised .",
        "label": "NA"
    },
    {
        "text": "the hypoglycemic action of HD00226 may be potentiated by certain drugs including ddrug1 and other drugs that are highly protein bound , ddrug2 , ddrug3 , ddrug4 , DB01032 , ddrug6 , ddrug7 , and ddrug8 .",
        "label": "effect"
    },
    {
        "text": "therefore , HD00587 should be taken at least # minutes prior to DB00364 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { DB00091 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , DB01232 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "DB00788 : coadministration { n = 18 } of ddrug1 capsules { 250 mg } with ddrug2 { 125 mg } appears to increase the amount of DB00996 absorbed by 12 % to 15 % .",
        "label": "NA"
    },
    {
        "text": "ddrug0 including ddrug1 , ddrug2 , and ddrug3 hc1 : concomitant use of DB00135 and non-selective HD00343 may cause hypertension .",
        "label": "effect"
    },
    {
        "text": "DB01432 , an anionic-binding resin , has a considerable effect in lowering the rate and extent of DB01095 bioavailability .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : in a clinical pharmacology study , coadministration of an DB06724 { ddrug2 , ddrug3 , and ddrug4 } with ddrug5 reduced serum levels and urinary excretion of ddrug6 as compared with ddrug7 administered alone , suggesting that ddrug8 may impair absorption of DB00492 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 has been shown to have no effect on the pharmacokinetics of DB00390 and the pharmacodynamics of DB00682 and ddrug3 .",
        "label": "NA"
    },
    {
        "text": "- a HD00766 such as ddrug1 { ddrug2 } , DB00623 { ddrug4 , ddrug5 } , ddrug6 { ddrug7 } , ddrug8 { ddrug9 } , and others ;",
        "label": "NA"
    },
    {
        "text": "although specific drug interaction studies have not been conducted with DB00484 , the possibility of an additive or potentiating effect with ddrug1 { DB02325 , ddrug3 , ddrug4 , ddrug5 , or ddrug6 } should be considered .",
        "label": "advise"
    },
    {
        "text": "the potentiating action of DB00557 must be considered when the drug is used in conjunction with ddrug1 such as ddrug2 , ddrug3 and HD00026 .",
        "label": "effect"
    },
    {
        "text": "DB00486 should be administered with caution to patients who are taking other ddrug1 or ddrug2 , including DB02325 , ddrug4 and ddrug5 , or to those with a history of psychiatric disorder { including manic-depressive illness and schizophrenia } .",
        "label": "advise"
    },
    {
        "text": "inhibitors of cyp3a4 { eg , DB01026 } or cyp2d6 { eg , ddrug1 , ddrug2 , or DB00715 } can inhibit ddrug4 elimination and cause increased blood levels .",
        "label": "NA"
    },
    {
        "text": "while all the ddrug0 { HD00114 } , e , g , , ddrug2 , DB01175 , ddrug4 , ddrug5 , and ddrug6 , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .",
        "label": "NA"
    },
    {
        "text": "DB00233 may decrease the amount of DB00390 { ddrug2 , ddrug3 } that gets absorbed into your body .",
        "label": "mechanism"
    },
    {
        "text": "for the HD00151 now available in the united states { DB00661 , ddrug2 and ddrug3 } , these data appeared well after clinical patterns of use evolved .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 - pectin , DB00795 , ddrug3 , ddrug4 , certain anticancer drugs , and ddrug5 may interfere with intestinal DB00390 absorption , resulting in unexpectedly low serum concentrations .",
        "label": "mechanism"
    },
    {
        "text": "DB00316 and DB00563 - ddrug2 may decrease hepatic toxicity in those with ddrug3 overdosage or in those taking ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a study of # healthy male volunteers , DB00459 treatment potentiated the blood glucose lowering effect of ddrug2 { a HD00226 similar to ddrug4 } in # of the # subjects .",
        "label": "NA"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { ddrug1 s } , ddrug2 , ddrug3 { HD00026 may decrease the effects of these medicines } , ddrug5 { using these medicines with ddrug6 may result in increased cns depressant effects } , ddrug7 , ddrug8 { using these medicines with ddrug9 may change the amount of either medicine that you need to take } , and oral ddrug10 containing ddrug11 { ddrug12 may decrease the effectiveness of these oral HD00283 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "caution should be used when administering or taking DB00530 with ddrug1 and other strong cyp3a4 inhibitors such as , but not limited to , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , DB00976 , ddrug11 { ddrug12 } , and ddrug13 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , DB00636 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and DB00126 .",
        "label": "NA"
    },
    {
        "text": "products containing ddrug0 and other multivalent cations { such as DB01370 , ddrug2 , ddrug3 } are likely to interfere with absorption of DB00710 .",
        "label": "mechanism"
    },
    {
        "text": "in an in vitro study in human liver microsomes , inhibition of cyp2a6 hydroxylation of DB04665 by DB00569 { 200 m.m . m i , e , , # mg/l } was 17 - 28 % .",
        "label": "mechanism"
    },
    {
        "text": "studies showed that ddrug0 increased the auc of DB00683 and DB00897 by 3 - 4 fold and the cmax by 2-fold , compared to placebo .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : potentiation of ddrug1 - type { ddrug2 and HD00302 substrate } ddrug4 response is almost always seen in patients receiving DB01118 and can result in serious or fatal bleeding .",
        "label": "NA"
    },
    {
        "text": "DB00328 reduces basal plasma renin activity { pra } , as well as those elevations of pra induced by DB00695 administration , or salt or volume depletion .",
        "label": "NA"
    },
    {
        "text": "DB00199 { 500 mg t , i , d } produced a 4-fold increase in ddrug1 auc and a 3-fold increase in cmax when co-administered with DB00862 # mg in healthy volunteers .",
        "label": "NA"
    },
    {
        "text": "DB01247 should be administered with caution to patients receiving DB00822 { ddrug2 , wyeth-ayerst laboratories } .",
        "label": "advise"
    },
    {
        "text": "ddrug0 may interact with the following medications : DB00316 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , DB00503 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 plasma levels were not significantly affected by DB00227 or DB00175 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : clinical studies , as well as post-marketing observations , have shown that ddrug1 can reduce the natriuretic effect of DB00695 and HD00217 in some patients .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as DB00415 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , DB00295 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "DB01274 , as with other ddrug1 , should be administered with extreme caution to patients being treated with ddrug2 , ddrug3 , or drugs known to prolong the qtc interval because the action of HD00355 on the cardiovascular system may be potentiated by these agents .",
        "label": "NA"
    },
    {
        "text": "DB00201 ddrug1 ddrug2 , like other ddrug3 , may inhibit the metabolism of ddrug4 and DB01412 .",
        "label": "NA"
    },
    {
        "text": "in em individuals treated with ddrug0 or DB00472 , the auc of ddrug2 is approximately 6 - to 8-fold and css , max is about 3 - to 4-fold greater than DB00289 alone .",
        "label": "NA"
    },
    {
        "text": "in a study in # patients with mild to moderate hypertension where the antihypertensive effects of DB00722 alone were compared to ddrug1 given concomitantly with ddrug2 , the use of DB00328 was associated with a reduced antihypertensive effect , although the difference between the two regimens was not significant .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : it should be borne in mind that DB02325 ingestion may increase the danger inherent in any intentional or unintentional DB01142 overdosage .",
        "label": "mechanism"
    },
    {
        "text": "toxicology studies of DB01452 - related deaths reveal frequent involvement of other ddrug1 , including DB02325 , ddrug3 such as ddrug4 { ddrug5 } , and , to a rising degree , ddrug6 .",
        "label": "effect"
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , DB14513 , or ddrug4 , with ddrug5 , with metal cations such as DB01592 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "although these results do not indicate a significant interaction between ddrug0 and DB00682 or ddrug2 , the administration of DB00465 to patients taking ddrug4 should be done extremely cautiously , and patients should be closely monitored .",
        "label": "NA"
    },
    {
        "text": "ddrug0 should not be used concomitantly with other drugs known to prolong the qt interval : certain ddrug1 , including those of class ia { such as DB00908 and ddrug3 } and class iii { such as DB00489 } ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration of DB00564 { 200 mg bid } , a potent cyp3a4 inducer , with ddrug2 { 30 mg qd } resulted in an approximate 70 % decrease in cmax and auc values of both ddrug3 and its active metabolite , HD00368 .",
        "label": "NA"
    },
    {
        "text": "- when ddrug0 or HD00415 is used concurrently with ddrug2 { e , g , HD00419 } , an interval of at least # hours should be maintained between the two medicines , since the absorption of ddrug4 or ddrug5 is impaired",
        "label": "advise"
    },
    {
        "text": "in separate single or multiple dose pharmacokinetic interaction studies with ddrug0 , ddrug1 , ddrug2 , ddrug3 , DB00501 , ddrug5 , ddrug6 , ddrug7 , and ddrug8 , the bioavailability of ddrug9 was not altered by coadministration of DB00492 with any one of these drugs .",
        "label": "NA"
    },
    {
        "text": "- a HD00380 such as ddrug1 { ddrug2 } , ddrug3 { DB00335 } , ddrug5 { ddrug6 } , ddrug7 { ddrug8 } , and others ;",
        "label": "NA"
    },
    {
        "text": "the serum concentration of DB00252 increased dramatically from # to # microg/ml when DB00176 was coadministered , although the daily dosage of ddrug2 and other ddrug3 had not changed .",
        "label": "NA"
    },
    {
        "text": "ddrug0 or ddrug1 excess may decrease the effect of DB00389 , and an DB11119 deficiency can increase the effect of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "cohort # then received DB00701 plus DB00615 for # days , and cohort # received ddrug2 plus ddrug3 for # days .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , DB00636 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , DB00224 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a clinical pharmacology study , coadministration of an ddrug1 { DB06723 , ddrug3 , and ddrug4 } with ddrug5 reduced serum levels and urinary excretion of ddrug6 as compared with DB00492 administered alone , suggesting that ddrug8 may impair absorption of ddrug9 .",
        "label": "NA"
    },
    {
        "text": "DB00472 and ddrug1 increased blood DB09341 at different times after the glucose overload .",
        "label": "NA"
    },
    {
        "text": "DB00342 : administration of ddrug1 with DB00220 resulted in the appearance of unchanged ddrug3 in plasma ;",
        "label": "NA"
    },
    {
        "text": "while all the ddrug0 { HD00114 } , e , g , , ddrug2 , ddrug3 , and DB00715 , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .",
        "label": "NA"
    },
    {
        "text": "- HD00899 , oral { diabetes medicine you take by mouth } use of oral ddrug1 with DB00891 may increase the chance of side effects affecting the blood and/or the side effects or oral ddrug3",
        "label": "NA"
    },
    {
        "text": "ddrug0 DB01026 ddrug2 DB01211 ddrug4 ddrug5 ddrug6 ddrug7 large quantities of grapefruit juice { # quart daily }",
        "label": "NA"
    },
    {
        "text": "DB00502 : ddrug1 blocks dopamine receptors , thus inhibiting the central stimulant effects of HD00401 .",
        "label": "NA"
    },
    {
        "text": "because DB01242 is highly bound to serum protein , the administration of ddrug1 to patients taking other drugs that are highly bound to protein { e , g , , DB00682 , ddrug3 } may cause an increase in plasma concentrations of these drugs , potentially resulting in adverse effects .",
        "label": "NA"
    },
    {
        "text": "HD00106 and ddrug1 { hypertension } - in clinical studies of patients with hypertension , the addition of DB00700 # to # mg to ddrug3 and ddrug4 increased mean serum potassium slightly { about # # meq/l } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : reports suggest that HD00203 may diminish the antihypertensive effect of HD00500 .",
        "label": "effect"
    },
    {
        "text": "in a study in diabetics with microalbuminuria ddrug0 # mg combined with the HD00471 ddrug2 # mg increased the frequency of hyperkalemia { serum potassium # meq/l } from 17 % on DB00584 alone to 38 % .",
        "label": "NA"
    },
    {
        "text": "- a HD00764 such as ddrug1 { ddrug2 , ddrug3 , others } , ddrug4 { ddrug5 , others } , ddrug6 { ddrug7 , DB14631 , others } , and others ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 should be used with care when ddrug1 or inhibitors of av conduction , such as certain ddrug2 { particularly of the HD00426 -lsb- ddrug4 -rsb- and ddrug5 -lsb- ddrug6 -rsb- classes } , or HD00428 , such as ddrug8 , are used concurrently .",
        "label": "NA"
    },
    {
        "text": "no interactions have been observed with HD00104 , ddrug1 , ddrug2 and HD00105 and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "HD00330 : in some patients , the administration of a ddrug1 can reduce the diuretic , natriuretic , and antihypertensive effects of HD00105 , ddrug3 and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , HD00502 , ddrug2 { ddrug3 , ddrug4 , HD00270 : skeletal muscle .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , DB00636 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , DB00812 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 generally should not be given with HD00218 because they reduce DB14507 s renal clearance and add a high risk of ddrug3 toxicity .",
        "label": "NA"
    },
    {
        "text": "HD00377 , ddrug1 : e , g , , DB01023 , ddrug3 , ddrug4",
        "label": "NA"
    },
    {
        "text": "DB00522 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , DB01086 and ddrug7 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "int"
    },
    {
        "text": "ddrug0 : the effect of an DB06723 - and ddrug2 - containing DB06724 { ddrug4 } * on the pharmacokinetics of ddrug5 was investigated in # cancer patients .",
        "label": "NA"
    },
    {
        "text": "if DB01045 therapy is required , ddrug1 concentrations and therapeutic effects are likely to be markedly reduced or abolished as a consequence of increased metabolism and higher clearance of DB00270 .",
        "label": "NA"
    },
    {
        "text": "drugs that may alter ddrug0 plasma concentrations drugs that may increase ddrug1 plasma concentrations : caution is recommended when administering DB00619 with inhibitors of the cyp3a4 family { e , g , , ddrug3 , DB01167 , ddrug5 , ddrug6 } .",
        "label": "advise"
    },
    {
        "text": "effects of HD00374 on DB00949 the rate and extent of absorption of a # mg dose of ddrug2 as monotherapy given as tablets was not affected when coadministered with ddrug3 .",
        "label": "NA"
    },
    {
        "text": "DB00661 produced a decrease of 20 % -lsb- 90 % ci : 18 - 27 -rsb- of the plasma levels of HD00888 .",
        "label": "NA"
    },
    {
        "text": "therefore , close monitoring of prothrombin time is recommended and adjustment of the HD00025 dose may be necessary when DB00499 capsules are administered concomitantly with ddrug2 .",
        "label": "NA"
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of HD00472 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 { 1 } , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 { 1 } , ddrug10 , ddrug11 , grapefruit juice , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , HD00269 , ddrug20 , ddrug21 , ddrug22 , ddrug23 , ddrug24 { 1 } , ddrug25 , ddrug26 .",
        "label": "mechanism"
    },
    {
        "text": "activity of ddrug0 alone and in combination with DB00207 and DB01017 against cryptosporidium parvum in cell culture .",
        "label": "NA"
    },
    {
        "text": "data from in vitro studies of ddrug0 suggest a possible drug interaction with ddrug1 for the following : DB01104 and DB00715 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 such as HD00219 or DB00502 ;",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with HD00374 containing ddrug2 , DB14513 , or ddrug4 , with ddrug5 , with metal cations such as ddrug6 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "and ddrug0 when ddrug1 is given with HD00315 agents or ddrug3 drugs , including DB00668 combined with local ddrug5 , close supervision and careful adjustment of dosages are required .",
        "label": "NA"
    },
    {
        "text": "DB00682 : in subjects receiving ddrug1 , no significant change in clotting time was observed when DB00365 was coadministered .",
        "label": "NA"
    },
    {
        "text": "while the effects of chronic ddrug0 or DB00564 therapy on the action of DB00565 are unknown , slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher .",
        "label": "effect"
    },
    {
        "text": "the homodimeric disintegrin ddrug0 was compared directly to the monomeric disintegrins HD00008 and HD00009 for the ability to affect protein tyrosine phosphorylation in tumor cells .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of ddrug0 and ddrug1 , ddrug2 , DB00338 , or an ddrug4 / DB00396 oral ddrug6 produced minor changes in the pharmacokinetics of ddrug7 , which were considered to be without clinical significance .",
        "label": "NA"
    },
    {
        "text": "in patients receiving concurrent therapy with ddrug0 , if therapy is to be discontinued , it is suggested that DB00612 be discontinued for several days before the withdrawal of DB00575 .",
        "label": "advise"
    },
    {
        "text": "therefore , co-administration of HD00043 with other drugs that are metabolized by this isoenzyme , including other ddrug1 , ddrug2 , ddrug3 , and HD00310 { eg , ddrug5 , ddrug6 , and ddrug7 } , or that inhibit this enzyme { eg , ddrug8 } , should be approached with caution .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : in vitro data indicate that ddrug1 and DB00503 markedly inhibit the metabolism of ddrug3 which can result in an increase in plasma DB00604 levels and prolongation of the qt interval on the ecg .",
        "label": "NA"
    },
    {
        "text": "if ddrug0 is to be combined with other HD00595 such as ddrug2 or ddrug3 / ddrug4 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of DB01151 and ddrug6 { e , g , , ddrug7 or ddrug8 } are additive .",
        "label": "NA"
    },
    {
        "text": "conjugation at HD00072 with ddrug1 moieties significantly improves the intestinal permeation of the hydrophilic molecule ddrug2 and the model peptide drugs DB00781 and ddrug4 in vitro , therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future .",
        "label": "NA"
    },
    {
        "text": "other drugs : in small groups of patients { 7 - 10 / interaction study } , the concomitant administration of ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , DB00254 , or ddrug6 did not significantly affect the peak levels and auc values of DB00586 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a study conducted in healthy subjects , mean steady-state ddrug1 plasma levels increased approximately 17 % in subjects receiving DB14507 # mg bid with DB00482 # mg bid as compared to subjects receiving ddrug4 alone .",
        "label": "mechanism"
    },
    {
        "text": "while it is not known whether this interaction occurs with ddrug0 other than DB01241 , myopathy and rhabdomyolysis have occasionally been associated with the use of ddrug2 alone , including DB00636 .",
        "label": "NA"
    },
    {
        "text": "the effectiveness of ddrug0 - only pills is reduced by hepatic enzyme-inducing drugs such as the ddrug1 ddrug2 , ddrug3 , and HD00026 , and the ddrug5 DB01045 .",
        "label": "NA"
    },
    {
        "text": "another oral HD00820 , ddrug1 , inhibits the metabolism of DB00637 , resulting in elevated plasma concentrations of ddrug3 and its active metabolite ddrug4 which may prolong qt intervals .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , DB00091 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , DB00812 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "in addition , neuromuscular blocking action is enhanced by general HD00264 , local ddrug1 like ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and DB00871 .",
        "label": "NA"
    },
    {
        "text": "DB00248 should not be administered concurrently with d2-antagonists , such as ddrug1 , ddrug2 , ddrug3 , or DB01233 .",
        "label": "advise"
    },
    {
        "text": "caution should be used when administering or taking DB00530 with ddrug1 and other strong cyp3a4 inhibitors such as , but not limited to , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , DB00503 , ddrug9 , ddrug10 , ddrug11 { ddrug12 } , and ddrug13 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : coadministration of DB00949 with ddrug2 causes an increase in DB01174 plasma concentrations , in # otherwise healthy male volunteers ingesting ddrug4 , the steady-state trough { cmin } ddrug5 concentration was # micrograms/ml .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { DB00316 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , DB01601 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "DB01115 did not alter the plasma levels of DB00862 when taken in combination .",
        "label": "NA"
    },
    {
        "text": "concomitant DB00531 , ddrug1 , ddrug2 , and DB00898 chemotherapy plus ddrug4 therapy in patients with human immunodeficiency virus-related , non-hodgkin lymphoma .",
        "label": "NA"
    },
    {
        "text": "DB01069 : coadministration of a single dose of DB00962 and ddrug2 { 10 and # mg , respectively } resulted in a 15 % decrease in maximal plasma concentrations of ddrug3 , but no change in the area under the plasma concentration-time curve .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect : ddrug0 , ddrug1 , ddrug2 , HD00218 , ddrug4 { e , g , , ddrug5 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , HD00810 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "DB00199 and ddrug1 { and possibly other ddrug2 } and ddrug3 may increase ddrug4 absorption in patients who inactivate DB00390 by bacterial metabolism in the lower intestine , so that ddrug6 intoxication may result .",
        "label": "NA"
    },
    {
        "text": "DB00091 , DB00864 , ddrug2",
        "label": "NA"
    },
    {
        "text": "standard therapy includes HD00002 , such as ddrug1 and DB00798 ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , DB00636 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , DB01045 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } HD00220 ddrug10 { DB00472 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "the use of DB00565 before DB00202 to attenuate some of the side effects of ddrug2 has not been studied .",
        "label": "NA"
    },
    {
        "text": "DB00280 does not increase serum DB00390 levels .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00224 { 800 mg t , i , d , } co-administered with ddrug2 # mg resulted in a 16-fold increase in DB00862 auc , a 7-fold increase in ddrug4 cmax and a 2-fold increase in ddrug5 half-life .",
        "label": "NA"
    },
    {
        "text": "clinical trials have indicated that ddrug0 can be effectively and safely used in conjunction with standard cystic_fibrosis therapies including oral , inhaled and/or parenteral ddrug1 , HD00650 , enzyme supplements , ddrug3 , oral or inhaled HD00175 , and ddrug5 .",
        "label": "NA"
    },
    {
        "text": "single doses of either ddrug0 or DB00375 HD00510 bind the ddrug3 and reduce its absorption from the gastrointestinal tract by up to # and # percent , respectively .",
        "label": "NA"
    },
    {
        "text": "the pharmacokinetic variables for ddrug0 were determined after a # mg intravenous dose of DB00390 in each subject , before and after oral DB01118 , # mg daily for # weeks .",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , DB14513 , or ddrug4 , with DB00364 , with metal cations such as ddrug6 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "HD00485 - ddrug1 containing side chains of n-methylthiotetrazole { ddrug2 , DB01329 , ddrug4 , ddrug5 , ddrug6 } or methylthiadiazole { ddrug7 } can cause vitamin_k_deficiency and hypoprothrombinemia .",
        "label": "NA"
    },
    {
        "text": "DB00152 , or other products containing ddrug1 or ddrug2 , ddrug3 or DB00364 should not be administered concomitantly with , or within # hours of , the administration of ddrug5 , because they may interfere with absorption resulting in lower serum and urine levels of ddrug6 .",
        "label": "NA"
    },
    {
        "text": "coadministration of DB00390 did not influence the pharmacokinetics of DB01202 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coagulation parameters should be tested more frequently and monitored regularly during simultaneous administration of high doses of DB01109 , oral HD00326 , or other drugs that may affect the blood coagulation system or the thrombocyte function .",
        "label": "NA"
    },
    {
        "text": "subsequent adjustment of doses of DB01033 or DB00993 should be made on the basis of therapeutic response and the appearance of toxic effects .",
        "label": "NA"
    },
    {
        "text": "effects of other ddrug0 on ddrug1 ddrug2 : ddrug3 causes an approximate doubling of the clearance of ddrug4 { DB00949 } at steady state and , therefore , the addition of ddrug6 causes an approximate 45 % decrease in the steady-state trough concentrations of ddrug7 as compared to the same dose of DB00949 given as monotherapy .",
        "label": "NA"
    },
    {
        "text": "in vitro studies demonstrated that the plasma protein binding of HD00528 was not affected by ddrug1 or DB00645 , indicating no potential for protein binding-based drug interactions .",
        "label": "NA"
    },
    {
        "text": "since bacteriostatic drugs , such as the HD00592 of HD00002 , may interfere with the bactericidal action of ddrug2 , it is not advisable to administer these drugs concomitantly .",
        "label": "NA"
    },
    {
        "text": "HD00175 : ddrug1 : ddrug2 , when given as a regimen of 125 mg with ddrug3 coadministered orally as # mg on day 1 , and DB00673 when given as # mg/day with ddrug5 coadministered orally as # mg on days # through 5 , increased the auc of ddrug6 , a cyp3a4 substrate by # - fold , on days # and 5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : DB00316 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { DB01076 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "administration of # - mg/kg { 2 x ed95 } DB00565 at 10 % or 95 % recovery following an intubating dose of DB00202 { 1 mg/kg } produced 95 % neuromuscular block .",
        "label": "effect"
    },
    {
        "text": "serum ddrug0 levels should be monitored frequently if DB00700 is administered concomitantly with DB14507 .",
        "label": "advise"
    },
    {
        "text": "patients receiving other ddrug0 s , general ddrug1 , ddrug2 , HD00262 , ddrug4 , ddrug5 or other ddrug6 { including ddrug7 } concomitantly with DB00327 may exhibit an additive cns depression .",
        "label": "effect"
    },
    {
        "text": "co-administration with HD00247 such as DB01026 or ddrug2 is not recommended .",
        "label": "NA"
    },
    {
        "text": "DB00415 / DB01060 : an increase in the frequency of skin rash has been reported among patients receiving ddrug2 or ddrug3 concurrently with ddrug4 compared to patients who are not receiving both drugs .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - theoretically , DB00125 supplements taken concomitantly with DB00203 , may potentiate the effects of the drug .",
        "label": "effect"
    },
    {
        "text": "this change was not considered clinically significant and no dose adjustment is needed when DB01026 and DB00220 are coadministered .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of DB01155 and ddrug1 , ddrug2 , ddrug3 , or an ddrug4 / ddrug5 oral ddrug6 produced minor changes in the pharmacokinetics of DB01155 , which were considered to be without clinical significance .",
        "label": "NA"
    },
    {
        "text": "certain drugs including HD00217 , ddrug1 , ddrug2 , and ddrug3 may reduce the hypoglycemic action of ddrug4 and other oral HD00394 .",
        "label": "effect"
    },
    {
        "text": "if a patient requires ddrug0 and ddrug1 therapy , it is suggested that ddrug2 , ddrug3 , or ddrug4 { DB06723 and ddrug6 } be used as alternatives to DB00501 , as these agents have no effect on the pharmacokinetic profile of ddrug8 .",
        "label": "NA"
    },
    {
        "text": "because of the possible additive effects of drugs that may depress the nervous system , DB00898 or ddrug1 should be used cautiously in combination with DB00906 .",
        "label": "advise"
    },
    {
        "text": "in patients receiving DB01033 { ddrug1 } or DB00993 { ddrug3 } , the concomitant administration of 300 - 600 mg of ddrug4 per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of ddrug5 or ddrug6 .",
        "label": "NA"
    },
    {
        "text": "before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : ddrug0 { e , g , , ddrug1 , ddrug2 } , ddrug3 , ddrug4 , ddrug5 drugs { e , g , , ddrug6 } , DB00864 , DB00512 .",
        "label": "NA"
    },
    {
        "text": "because ddrug0 is highly bound to serum protein , the administration of DB01242 to patients taking other drugs that are highly bound to protein { e , g , , ddrug2 , DB00390 } may cause an increase in plasma concentrations of these drugs , potentially resulting in adverse effects .",
        "label": "mechanism"
    },
    {
        "text": "in a study in which the # mg DB01068 orally disintegrating tablet was administered with and without DB00782 { an ddrug2 with multiple effects on the gi tract } to healthy volunteers , the auc of ddrug3 was 10 % lower and the cmax of ddrug4 was 20 % lower when the orally disintegrating tablet was given with ddrug5 compared to when it was given alone .",
        "label": "mechanism"
    },
    {
        "text": "aerosol particles of DB01222 were generated from an DB00898 solution , dried , and collected by a cascade impactor for characterization or by a liquid impinger for dissolution experiments .",
        "label": "NA"
    },
    {
        "text": "because ddrug0 is eliminated from the body via conjugation with glutathione , use of ddrug1 prior to { # hours } or concurrent with ddrug2 may result in reduced DB01008 clearance based upon the known property of DB00316 to decrease glutathione levels in the blood and tissues .",
        "label": "NA"
    },
    {
        "text": "DB00294 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , DB00224 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "int"
    },
    {
        "text": "DB00979 may interfere with the anti-glaucoma action of DB00411 or ddrug2 ;",
        "label": "effect"
    },
    {
        "text": "drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving ddrug0 metabolized similarly to ddrug1 or on the basis of in vitro studies with ddrug2 or other ddrug3 { caution is recommended during coadministration with ddrug4 } : available data from clinical studies of ddrug5 other than ddrug6 suggest a possible drug interaction with DB00404 for the following : ddrug8 , ddrug9 , ddrug10 such as ddrug11 and DB01211 , and grapefruit juice .",
        "label": "int"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 HD00100 DB00683 , ddrug12 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "there is insufficient experience to assess the safety and efficacy of DB01281 administered concurrently with DB00026 , and therefore such use is not recommended .",
        "label": "advise"
    },
    {
        "text": "however , reports suggest that HD00203 may diminish the antihypertensive effect of HD00106 .",
        "label": "effect"
    },
    {
        "text": "the pharmacokinetics of DB01058 were unchanged following coadministration with DB00518 { 400 mg } .",
        "label": "NA"
    },
    {
        "text": "before taking ddrug0 , tell your doctor if you are taking any of the following medicines : - DB00945 or another ddrug2 such as ddrug3 { ddrug4 } , ddrug5 { ddrug6 , others } , ddrug7 { HD00757 } , ddrug9 { ddrug10 } , or ddrug11 { ddrug12 } ;",
        "label": "NA"
    },
    {
        "text": "DB00564 : coadministration of ddrug1 { 200 mg bid } , a potent cyp3a4 inducer , with ddrug2 { 30 mg qd } resulted in an approximate 70 % decrease in cmax and auc values of both DB01238 and its active metabolite , ddrug4 .",
        "label": "NA"
    },
    {
        "text": "an in vivo interaction study in humans demonstrated that a single 1 mg dose of DB00261 administered concomitantly with a single # mg dose of DB00945 was generally well tolerated .",
        "label": "NA"
    },
    {
        "text": "hormonal ddrug0 co-administration of DB00776 with an oral ddrug2 has been shown to influence the plasma concentrations of the two hormonal components , DB00977 { ee } and ddrug4 { lng } .",
        "label": "NA"
    },
    {
        "text": "HD00388 may enhance the effects of ddrug1 , HD00026 , ddrug3 , and other ddrug4 .",
        "label": "effect"
    },
    {
        "text": "in a study in which the # mg ddrug0 orally disintegrating tablet was administered with and without ddrug1 { an HD00554 with multiple effects on the gi tract } to healthy volunteers , the auc of ddrug3 was 10 % lower and the cmax of DB01068 was 20 % lower when the orally disintegrating tablet was given with ddrug5 compared to when it was given alone .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00586 and other ddrug2 can inhibit the activity of HD00218 .",
        "label": "effect"
    },
    {
        "text": "DB01432 ddrug1 may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation , the discontinuance of ddrug2 ddrug3 could pose a hazard to health if a potentially toxic drug such as HD00118 has been filtrated to a maintenance level while the patient was taking ddrug5 ddrug6 .",
        "label": "NA"
    },
    {
        "text": "the concomitant administration of HD00093 and other HD00094 have resulted in previous reports of rhabdomyolysis .",
        "label": "effect"
    },
    {
        "text": "caution should be taken when DB00496 is used concomitantly with medications that are predominantly metabolized by cyp2d6 and which have a narrow therapeutic window , such as ddrug1 , DB00679 and ddrug3 { see clinical pharmacology } .",
        "label": "advise"
    },
    {
        "text": "ddrug0 - DB00120 and the ddrug2 DB01037 may have synergistic antidepressant activity if used concomitantly .",
        "label": "effect"
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the ddrug0 of drugs may be potentiated by ddrug1 , ddrug2 , HD00026 , ddrug4 , ddrug5 , the ddrug6 , ddrug7 and HD00560 , ddrug9 and the ddrug10 , and by other ddrug11 .",
        "label": "NA"
    },
    {
        "text": "other drugs : in healthy volunteers , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , hormone replacement therapy { a combination of conjugated ddrug5 and ddrug6 } , ddrug7 { ddrug8 and DB09104 } and ddrug10 did not affect the pharmacokinetics of DB00204 .",
        "label": "NA"
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of HD00539 such as ddrug1 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , DB00781 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 } , ddrug11 salts , ddrug12 , local ddrug13 , ddrug14 , and ddrug15 .",
        "label": "effect"
    },
    {
        "text": "DB00264 - administration of # mg/day ddrug1 for # days in healthy volunteers resulted in a 50 % increase in cmax and 82 % increase in auc of the HD00693 ddrug3 { given in a single dose of # mg } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as DB00415 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , DB00949 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "plasma exposure { auc } to DB00580 was increased 62 % when coadministered with ddrug1 and 38 % when coadministered with DB01026 .",
        "label": "mechanism"
    },
    {
        "text": "when DB00224 at an increased dose { 1000 mg every # hours } was given with DB00625 { 600 mg once daily } , the ddrug2 auc and cmin were decreased on average by 33 - 46 % and 39 - 57 % , respectively , compared to when ddrug3 { 800 mg every # hours } was given alone .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { DB00400 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { DB00701 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "DB00563 : DB01009 , like other ddrug2 , may cause changes in the elimination of ddrug3 leading to elevated serum levels of the drug and increased toxicity .",
        "label": "NA"
    },
    {
        "text": "the following agents may increase certain actions or side effects of ddrug0 , DB00915 ddrug2 of class { e , g , ddrug3 } , ddrug4 ddrug5 { e , g , HD00219 } , ddrug7 .",
        "label": "NA"
    },
    {
        "text": "the higher HD00191 and DB08948 excretion was due to their increased renal tubular secretion .",
        "label": "NA"
    },
    {
        "text": "therapeutic concentrations of ddrug0 , ddrug1 , ddrug2 , ddrug3 , DB00554 , ddrug5 , ddrug6 andtolbutamide did not alter DB00465 protein binding .",
        "label": "NA"
    },
    {
        "text": "in view of the potential risk of dehydration secondary to vomiting and/or diarrhea induced by DB00762 , the physician may wish to withhold HD00218 during dosing with ddrug2 and , certainly , during periods of active vomiting or diarrhea .",
        "label": "NA"
    },
    {
        "text": "preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving DB00224 in combination with DB00503 than those receiving ddrug2 # mg q8h .",
        "label": "effect"
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as DB01135 include certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , DB00803 , and ddrug9 } , ddrug10 salts , ddrug11 , local ddrug12 , ddrug13 , and ddrug14 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : DB00637 * , DB00342 * contraindicated due to potential for serious and/or life-threatening cardiac arrhythmias .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , DB00091 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , DB00860 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a study in healthy volunteers , a one-week course of DB00501 at # mg b , i , d , with a single # mg dose of DB00270 on the sixth day showed an increase in ddrug3 mean peak plasma concentrations { 36 % } and significant increase in area under the curve { 50 % } .",
        "label": "mechanism"
    },
    {
        "text": "DB01118 may suppress certain cyp450 enzymes , including HD00300 , ddrug2 , ddrug3 , and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "in patients given very high doses { 3900 mg } of DB00945 daily , increases in serum HD00372 levels were seen when ddrug2 , # mg b , i , d , , was administered concurrently .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with DB00316 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some DB00152 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , DB01045 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { HD00531 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "DB01032 : concomitant administration of ddrug1 oral and ddrug2 resulted in decreased clearance of ddrug3 and significant increases in DB00465 plasma levels { total auc increased approximately threefold from # to # m g/h/ml } and terminal half-life increased approximately twofold from # to # hours .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { ddrug1 } : DB00439 plasma concentrations were not affected by co-administration of DB06724 .",
        "label": "NA"
    },
    {
        "text": "DB00996 pharmacokinetic parameters without and with DB01032 were comparable .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { HD00114 } : ddrug2 { e , g , , DB00472 , ddrug4 , ddrug5 , ddrug6 } have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with ddrug7 .",
        "label": "NA"
    },
    {
        "text": "also , concomitant administration of ddrug0 with products containing ddrug1 , DB00152 containing ddrug3 , or DB00900 { ddrug5 } chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels .",
        "label": "NA"
    },
    {
        "text": "DB00637 DB00683 , ddrug2 ddrug3 ergot derivatives ddrug4",
        "label": "NA"
    },
    {
        "text": "HD00518 { ddrug1 } : concomitant use of ddrug2 { or other HD00598 } and ddrug4 increases the risk of gastrointestinal side effects .",
        "label": "NA"
    },
    {
        "text": "plasma exposure of ddrug0 { 10 mg bid } was increased by 28 % following administration of ddrug1 { 40 mg bid } for # days , while plasma exposure of DB00580 { 40 mg bid } was not substantially increased following administration of DB00829 { 10 mg bid } for # days .",
        "label": "NA"
    },
    {
        "text": "numerous drug interactions are possible with some HD00065 , such as DB01174 and ddrug2 , which affect hepatic microsomal enzyme systems .",
        "label": "NA"
    },
    {
        "text": "DB00501 , ddrug1 : in normal volunteers { n = 9 } , pretreatment with ddrug2 or ddrug3 did not affect DB00712 pharmacokinetics except that a small { 13 % } but statistically significant increase in the area under the serum concentration curve of ddrug5 resulted with ddrug6 .",
        "label": "NA"
    },
    {
        "text": "ventricular tachycardia induced by ddrug0 was generally converted to sinus rhythm following administration of ddrug1 , DB01221 , or ddrug3 but not after administration of ddrug4 alone or after DB00312 .",
        "label": "NA"
    },
    {
        "text": "DB01294 : ddrug1 , given concomitantly with ddrug2 or # minutes following DB00467 administration , decreased ddrug4 bioavailability by approximately 25 % .",
        "label": "NA"
    },
    {
        "text": "HD00467 * coadministration of ddrug1 had no effect on DB00622 absorption .",
        "label": "NA"
    },
    {
        "text": "no interactions have been observed with HD00104 , ddrug1 , ddrug2 and ddrug3 and HD00106 .",
        "label": "NA"
    },
    {
        "text": "DB00467 interferes with the metabolism of ddrug1 resulting in a 42 % to 74 % dose-related decrease in DB00277 clearance and a subsequent 260 % to 350 % increase in serum theophylline levels .",
        "label": "NA"
    },
    {
        "text": "since the concomitant administration of these two drugs can lead to DB00252 intoxication , prior to administering DB00822 to a patient on ddrug2 therapy , a baseline ddrug3 serum level should be obtained .",
        "label": "NA"
    },
    {
        "text": "therefore , DB00220 should not be administered concurrently with DB00342 because of the potential for serious and/or life-threatening cardiac arrhythmias .",
        "label": "advise"
    },
    {
        "text": "in vitro , DB00490 does not displace tightly bound drugs like ddrug1 , ddrug2 , and DB00682 from serum proteins .",
        "label": "NA"
    },
    {
        "text": "the purpose of this study was to evaluate the effect of ddrug0 { ddrug1 } and HD00067 { ddrug3 } conjugates on the intestinal permeation of ddrug4 { ddrug5 } and model peptide drugs , DB00781 and ddrug7 .",
        "label": "NA"
    },
    {
        "text": "other drugs : in healthy volunteers , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , hormone replacement therapy { a combination of conjugated HD00220 and ddrug6 } , ddrug7 { ddrug8 and ddrug9 } and ddrug10 did not affect the pharmacokinetics of DB00204 .",
        "label": "NA"
    },
    {
        "text": "cns-active drugs ddrug0 : DB00962 # mg potentiated the cns-impairing effects of ddrug2 # g/kg on balance testing and reaction time for # hour after DB00898 administration and on the digit symbol substitution test { dsst } , symbol copying test , and the variability component of the divided attention test for # hours after ddrug4 administration .",
        "label": "NA"
    },
    {
        "text": "coadministration of DB00969 and strong cyp3a4 inhibitors , such as DB01211 , ddrug2 , ddrug3 , ddrug4 , and ddrug5 has not been evaluated but should be undertaken with caution because of similar potential drug interactions .",
        "label": "advise"
    },
    {
        "text": "concomitant use of DB00445 with other cardioactive compounds that could cause heart failure { e , g , , HD00377 } , requires close monitoring of cardiac function throughout treatment .",
        "label": "advise"
    },
    {
        "text": "administration of HD00532 with ddrug1 containing DB01370 , ddrug3 , or ddrug4 , with ddrug5 , with metal cations such as ddrug6 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 , HD00246 and ddrug2 : concomitant treatment with ddrug3 , ddrug4 , or ddrug5 may potentiate a possible hypokalemic effect of HD00742",
        "label": "NA"
    },
    {
        "text": "concomitant use of agents in the HD00552 { which includes ddrug1 } with drugs that can inhibit cyp2d6 may require lower doses than usually prescribed for either the HD00553 or the other drug .",
        "label": "NA"
    },
    {
        "text": "after prolonged administration of ddrug0 the displacing effect of DB00403 , an analog of cholecystokinin octapeptide , was replaced by the stimulant action on HD00136 binding .",
        "label": "NA"
    },
    {
        "text": "poor metabolizers of ddrug0 : interactions of ddrug1 with strong inhibitors of cyp2d6 { such as ddrug2 , DB00472 , ddrug4 , and ddrug5 } have not been studied , but these drugs would be expected to increase blood levels of the r { + } enantiomer of DB01136 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 } , ddrug1 { e , g , ddrug2 } , and ddrug3 { e , g , ddrug4 , DB00224 and ddrug6 } should have their dose of DB00921 or ddrug8 adjusted .",
        "label": "NA"
    },
    {
        "text": "while all the HD00113 { ddrug1 } , e , g , , ddrug2 , ddrug3 , DB00472 , ddrug5 , and ddrug6 , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .",
        "label": "NA"
    },
    {
        "text": "however , neither DB01174 nor DB00829 appears to affect ddrug2 metabolism .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { DB00564 } ddrug7 { ddrug8 } ddrug9 DB00472 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "ddrug0 with ddrug1 or ddrug2 and possibly other HD00609 cause striking and sustained increases in the concentration of DB01576 in the brain ;",
        "label": "NA"
    },
    {
        "text": "we report the case of an adolescent with altered consciousness caused by DB00564 overdose with a positive ddrug1 level to alert clinicians to the cross-reactivity of ddrug2 with a toxicology screen for HD00043 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB00829 , certain ddrug7 , ddrug8 , DB00277 and ddrug10 , thereby delaying elimination and increasing blood levels of these drugs .",
        "label": "NA"
    },
    {
        "text": "drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving HD00100 metabolized similarly to ddrug1 or on the basis of in vitro studies with ddrug2 or other ddrug3 { caution is recommended during coadministration with DB00404 } : available data from clinical studies of ddrug5 other than ddrug6 suggest a possible drug interaction with ddrug7 for the following : ddrug8 , ddrug9 , ddrug10 such as ddrug11 and ddrug12 , and grapefruit juice .",
        "label": "NA"
    },
    {
        "text": "since DB00593 { ddrug1 } may interact with concurrently administered ddrug2 , periodic serum level determinations of these drugs may be necessary { eg , ddrug3 may elevate ddrug4 serum levels and DB00313 has been reported to both increase and decrease ddrug6 levels } .",
        "label": "NA"
    },
    {
        "text": "absorption of ddrug0 is impaired by HD00374 containing DB01370 , ddrug3 , or ddrug4 , and ddrug5 - containing preparations .",
        "label": "NA"
    },
    {
        "text": "DB00987 , a ddrug1 , has been reported to inactivate the antifungal activity of DB01099 by competitive inhibition .",
        "label": "effect"
    },
    {
        "text": "ddrug0 HD00524 may delay or reduce the absorption of concomitant oral medication such as ddrug2 , ddrug3 , ddrug4 { acidic } or ddrug5 { basic } , as well as ddrug6 ddrug7 , ddrug8 , thyroid and ddrug9 preparations , HD00220 and ddrug11 , and ddrug12 .",
        "label": "NA"
    },
    {
        "text": "DB00668 also should be used cautiously with other drugs { e , g , , ddrug1 , ddrug2 } that sensitize the myocardium to the actions of HD00390 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 , ddrug2 { DB00627 , ddrug4 , HD00270 : skeletal muscle .",
        "label": "NA"
    },
    {
        "text": "nephrotoxic agents : concomitant administration of DB00369 and agents with nephrotoxic potential -lsb- e , g , , intravenous ddrug1 { e , g , , DB00684 , ddrug3 , and ddrug4 } , ddrug5 , ddrug6 , intravenous ddrug7 , ddrug8 , and ddrug9 -rsb- is contraindicated .",
        "label": "advise"
    },
    {
        "text": "ddrug0 , ddrug1 HD00401 may enhance the activity of ddrug3 or HD00571 ;",
        "label": "effect"
    },
    {
        "text": "although it has not been established that there is an interaction between ddrug0 and HD00100 or other ddrug2 , caution is advised when DB00363 is initiated in patients taking a ddrug4 or any other ddrug5 .",
        "label": "NA"
    },
    {
        "text": "some HD00532 , including ddrug1 , have been associated with transient elevations in serum creatinine in patients receiving DB00091 concomitantly .",
        "label": "effect"
    },
    {
        "text": "spontaneous reports of serotonin syndrome associated with co-administration of DB00601 and ddrug1 , including HD00216 such as ddrug3 { ddrug4 } , have been reported .",
        "label": "effect"
    },
    {
        "text": "conversely , the administration of DB00611 { 1 mg ddrug1 qid } did not alter the pharmacokinetics of a 300-mg dose of DB00501 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : if DB00459 is given concurrently with ddrug2 , the protein binding of DB00252 may be reduced .",
        "label": "NA"
    },
    {
        "text": "cns-active drugs ddrug0 : DB00962 # mg potentiated the cns-impairing effects of ddrug2 # g/kg on balance testing and reaction time for # hour after ddrug3 administration and on the digit symbol substitution test { dsst } , symbol copying test , and the variability component of the divided attention test for # hours after DB00898 administration .",
        "label": "NA"
    },
    {
        "text": "however , due to possible pharmacodynamic interactions , when co-administered with ddrug0 , a reduction in dosage of ddrug1 on the concomitant ddrug2 , HD00596 , ddrug4 or HD00023 may be required .",
        "label": "NA"
    },
    {
        "text": "when ddrug0 dosing was separated from DB01162 # mg by # hours , # of # subjects who received # mg of DB00862 experienced a decrease in standing systolic blood pressure below # mm hg .",
        "label": "NA"
    },
    {
        "text": "the effects of medicinal products with similar properties such as inotropes ddrug0 , ddrug1 , ddrug2 , HD00325 and ddrug4 may be exacerbated by DB00261 .",
        "label": "effect"
    },
    {
        "text": "although there was no effect of ddrug0 on the plasma auc of HD00347 or ddrug2 determined on day 3 , there was a 34 % decrease in ddrug3 { a cyp2c9 substrate } trough concentration accompanied by a 14 % decrease in the prothrombin time { reported as international normalized ratio or inr } # days after completion of dosing with DB00673 .",
        "label": "NA"
    },
    {
        "text": "the administration of local ddrug0 containing ddrug1 or DB00368 to patients receiving ddrug3 or HD00043 may produce severe , prolonged hypertension .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : DB00477 blocks dopamine and norepinephrine receptors , thus inhibiting the central stimulant effects of HD00401 and can be used to treat ddrug3 poisoning .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , DB00636 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , DB01232 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "in clinical trials , ddrug0 was used with DB00390 , ddrug2 , ddrug3 , oral ddrug4 , and supplemental DB09140 , in a pharmacokinetic substudy in patients with congestive heart failure receiving ddrug6 or ddrug7 in whom therapy with ddrug8 was initiated , apparent oral clearance values for ddrug9 { n = 23 } and ddrug10 { n = 30 } were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .",
        "label": "NA"
    },
    {
        "text": "although ddrug0 has a lower affinity for ddrug1 than for DB01592 , ddrug3 should not be taken with DB01370 - containing ddrug5 .",
        "label": "NA"
    },
    {
        "text": "HD00313 decrease the hypotensive effect of DB01018 .",
        "label": "effect"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : ddrug1 ; ddrug2 ; DB01159 ; certain ddrug4 , especially the ddrug5 and HD00384 ; ddrug7 ; ddrug8 salts ; ddrug9 ; and ddrug10 .",
        "label": "NA"
    },
    {
        "text": "certain drugs , including HD00518 { ddrug1 } , ddrug2 , ddrug3 , and ddrug4 may potentiate the hypoglycemic action of DB00731 and other oral ddrug6 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 - concomitant use of DB00130 and ddrug2 may ameliorate increased intestinal permeability caused by DB00328 .",
        "label": "NA"
    },
    {
        "text": "although this effect was noted even when DB01432 was given # hours prior to DB01095 , this regimen did not result in diminished efficacy .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : DB00949 causes an increase in steady-state DB00313 concentrations .",
        "label": "mechanism"
    },
    {
        "text": "there is limited experience with concomitant ddrug0 such as ddrug1 , ddrug2 , HD00106 , and ddrug4 { both HD00722 - like and loop } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with ddrug1 , ddrug2 s , HD00404 { allergy , cold , and sinus medicines } , diabetic drugs , ddrug4 , ddrug5 , ddrug6 like DB00788 or ddrug8 , and high blood pressure medications .",
        "label": "NA"
    },
    {
        "text": "in vivo studies : ddrug0 : the blood pressure lowering effects of sublingual DB14049 { # mg } taken # and # hours after ddrug2 and increases in heart rate when taken at 1 , # and # hours were potentiated by a # mg dose of DB00862 in healthy middle-aged subjects .",
        "label": "NA"
    },
    {
        "text": "several ddrug0 have been reported to block the pharmacologic effects of ddrug1 , ddrug2 , or similar agents , and such an effect may be anticipated with HD00551 because of its structural similarity to other HD00043 .",
        "label": "NA"
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma DB00252 concentrations include : acute ddrug1 intake , ddrug2 , chboramphenicol , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , HD00219 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 - and/or ddrug1 - containing HD00374 , products containing ddrug3 { ddrug4 } , ddrug5 containing DB01593 or other metal cations , or ddrug7 { ddrug8 } chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after ddrug9 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , DB00280 , DB00281",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 should be used with caution in patients receiving - ddrug2 blocking agents { e , g , , ddrug3 , a ddrug4 inhibitor } or HD00306 antagonists { e , g , , ddrug6 , a ddrug7 substrate , and ddrug8 , a HD00302 inhibitor } because of the possible potentiation of bradycardia , sinus arrest , and av block ;",
        "label": "NA"
    },
    {
        "text": "coadministration with ddrug0 { 40 mg bid for # days } resulted in a significant increase in DB00514 plasma levels suggesting that , at these doses , DB00580 is a weak inhibitor of 2d6 .",
        "label": "NA"
    },
    {
        "text": "therefore , to maximize the effects of DB00950 , it is recommended that DB00950 should be taken with water",
        "label": "NA"
    },
    {
        "text": "selective survival in DB00652 and DB00792 of pseudomonas aeruginosa serotype igkv2_40 from drug addicts .",
        "label": "NA"
    },
    {
        "text": "DB05259 has not been formally evaluated in combination with HD00753 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration of ddrug1 and DB00220 resulted in a 32 % decrease in ddrug3 plasma auc and a 207 % increase in DB00615 plasma a , c.",
        "label": "NA"
    },
    {
        "text": "the mechanism for this interaction probably is adsorption of DB00698 onto the surface of DB09281 .",
        "label": "mechanism"
    },
    {
        "text": "-lsb- stimulation by ddrug0 -- an analog of the octapeptide cholecystokinin -- of ddrug1 binding after the long-term administration of ddrug2 -rsb- it has been established in experiments on white male rats that prolonged administration { twice a day for # days } of ddrug3 { # mg/kg } and HD00138 { # mg/kg } resulted in the reduced interaction between ddrug5 and low affinity binding sites for DB00714 in subcortical structures , whereas ddrug7 binding with high affinity binding sites for ddrug8 increased both in the frontal cortex and subcortical structures of the forebrain .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { DB00564 } DB00501 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "HD00322 : ddrug1 , HD00323 , ddrug3 , or ddrug4 may interfere with the bactericidal effect of ddrug5 .",
        "label": "NA"
    },
    {
        "text": "DB01075 has additive effects with ddrug1 and other ddrug2 { HD00214 , ddrug4 , ddrug5 , etc } .",
        "label": "effect"
    },
    {
        "text": "- DB00252 { e , g , , ddrug1 } use of ddrug2 with DB00891 may increase the chance of side effects affecting the liver and/or the side effects of ddrug4",
        "label": "NA"
    },
    {
        "text": "although there have been no formal interaction studies other than with DB01435 , based on these in vivo and in vitro studies , it is unlikely that co-administration of a # mg dose of DB01217 with other drugs will result in clinically significant drug inhibition of cytochrome p450-mediated metabolism of the other drugs .",
        "label": "NA"
    },
    {
        "text": "persons taking most ddrug0 , ddrug1 and DB00205 invalidate DB00158 and ddrug4 diagnostic blood assays .",
        "label": "NA"
    },
    {
        "text": "in three separate controlled , parallel group clinical pharmacology studies , DB00967 at the clinical dose of # mg has been coadministered with ddrug1 # mg followed by # mg once daily for # days { n = 18 } or with DB00472 # mg once daily for # days after a # day pretreatment period with ddrug3 { n = 18 } or with ddrug4 # mg every # hours for # days { n = 18 } under steady state conditions to normal healthy male and female volunteers .",
        "label": "NA"
    },
    {
        "text": "effects of HD00391 are increased with HD00343 and ddrug2 .",
        "label": "effect"
    },
    {
        "text": "since ddrug0 is extensively metabolized by cyp4f3 isoenzymes , caution should be exercised when DB01166 is coadministered with inhibitors of c , p , a , such as ddrug2 and ddrug3 or inhibitors of cyp2c19 such as DB00338 .",
        "label": "advise"
    },
    {
        "text": "the concomitant use of HD00577 and DB01111 parenteral should be avoided .",
        "label": "advise"
    },
    {
        "text": "background : the effects of combined administration of ddrug0 and ddrug1 { DB00661 } , a ddrug3 , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by ddrug4 { HD00039 } and the labeling index of intestinal_cancer were investigated in male wistar rats .",
        "label": "NA"
    },
    {
        "text": "compounds in these categories result in a decreased efficacy of DB01200 : ddrug1 , DB00502 , ddrug3 , ddrug4 .",
        "label": "effect"
    },
    {
        "text": "DB00615 : coadministration of ddrug1 and DB00220 resulted in a 32 % decrease in ddrug3 plasma auc and a 207 % increase in ddrug4 plasma a , c.",
        "label": "NA"
    },
    {
        "text": "- concomitant use of HD00043 may reduce the efficacy of DB04948 .",
        "label": "effect"
    },
    {
        "text": "in clinical trials in patients undergoing ptca/pci , co-administration of DB00006 with ddrug1 , DB00682 , ddrug3 or glycoprotein iib/iiia inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , DB00091 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , DB00295 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "since chronic dosing is required for therapeutic efficacy of HD00031 , future studies should focus on investigation of chronic dosing effects of these drugs in combination with DB03575 .",
        "label": "NA"
    },
    {
        "text": "clinical interaction studies with ddrug0 and DB00682 indicated that the coadministration of DB01006 with these drugs does not result in clinically - significant drug interactions .",
        "label": "NA"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { ddrug1 s } , ddrug2 , ddrug3 { HD00026 may decrease the effects of these medicines } , ddrug5 { using these medicines with ddrug6 may result in increased cns depressant effects } , DB00313 , ddrug8 { using these medicines with ddrug9 may change the amount of either medicine that you need to take } , and oral ddrug10 containing ddrug11 { ddrug12 may decrease the effectiveness of these oral ddrug13 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "in healthy volunteers , DB01609 had no effect on the pharmacokinetics of DB00390 .",
        "label": "NA"
    },
    {
        "text": "DB00562 may interact with ddrug1 , ddrug2 s , ddrug3 { allergy , cold , and sinus medicines } , diabetic drugs , DB14507 , ddrug5 , ddrug6 like ddrug7 or ddrug8 , and high blood pressure medications .",
        "label": "int"
    },
    {
        "text": "ddrug0 , ddrug1 - pectin , ddrug2 , DB00994 , ddrug4 , certain anticancer drugs , and DB01233 may interfere with intestinal ddrug6 absorption , resulting in unexpectedly low serum concentrations .",
        "label": "NA"
    },
    {
        "text": "- a HD00295 { water pill } such as ddrug1 { ddrug2 , ddrug3 } , DB00880 { ddrug5 } , and others ;",
        "label": "NA"
    },
    {
        "text": "concurrent administration of drugs possessing nephrotoxic { e , g , , ddrug0 , ddrug1 } , myelotoxic { e , g , , ddrug2 chemotherapy } , cardiotoxic { e , g , , ddrug3 } or hepatotoxic { e , g , , DB00563 , ddrug5 } effects with DB00041 may increase toxicity in these organ systems .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and DB00281 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some DB00152 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "this report describes two cases in which DB00277 clearance accelerated markedly with concomitant DB00252 administration .",
        "label": "mechanism"
    },
    {
        "text": "DB00502 reduced or eliminated the increases in fi responding produced by intermediate doses of either ddrug1 or DB03575 in pigeons , but did not antagonize the decreases in fi or fr responding produced by high doses of pgpep1 or either stereoisomer of ddrug3 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : DB01118 should be used with caution in patients receiving - ddrug2 blocking agents { e , g , , ddrug3 , a ddrug4 inhibitor } or HD00306 antagonists { e , g , , ddrug6 , a ddrug7 substrate , and ddrug8 , a ddrug9 inhibitor } because of the possible potentiation of bradycardia , sinus arrest , and av block ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 should be used with caution in patients receiving - ddrug2 blocking agents { e , g , , DB00571 , a ddrug4 inhibitor } or ddrug5 antagonists { e , g , , ddrug6 , a ddrug7 substrate , and DB00343 , a ddrug9 inhibitor } because of the possible potentiation of bradycardia , sinus arrest , and av block ;",
        "label": "NA"
    },
    {
        "text": "preliminary data which suggest that DB00250 may inhibit the anti-inflammatory activity of DB00845 have not been confirmed .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , DB00295 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , DB00277 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "DB00501 , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of ddrug1 , ddrug2 , ddrug3 , ddrug4 , DB00475 , ddrug6 , certain ddrug7 , ddrug8 , ddrug9 and ddrug10 , thereby delaying elimination and increasing blood levels of these drugs .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : combination ddrug1 may decrease the clearance of some HD00100 { ddrug3 , ddrug4 , ddrug5 } and increase the clearance of others { ddrug6 , DB00842 , ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "because of the increased risk of adverse reactions in patients who have been taking HD00100 on a regular basis , it is particularly important that physicians query patients or their guardians carefully about ddrug1 , ddrug2 and ddrug3 use as part of the history prior to any procedure in which the use of DB01205 is planned .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { e , g , , ddrug1 , DB00384 , or ddrug3 } , DB14500 supplements , or ddrug5 - containing salt substitutes may lead to significant increases in serum potassium .",
        "label": "NA"
    },
    {
        "text": "the ratios of the aucs of unbound DB00313 to the aucs of the total ddrug1 were # % , # % , and # % , with coadministration of 0 , 1200 , and # mg/day of DB00949 , respectively .",
        "label": "NA"
    },
    {
        "text": "in the experiments reported here , we examined the interactions between ddrug0 and the HD00180 ddrug2 { HD00181 } , which also induces apoptosis in mcf-7 cells .",
        "label": "NA"
    },
    {
        "text": "the possibility of hypotensive effects with ddrug0 can be minimized by either discontinuing the HD00295 or increasing the salt intake prior to initiation of treatment with DB00722 .",
        "label": "effect"
    },
    {
        "text": "little has been studied of the adverse effects of the exposure of the liver to the interaction of DB00898 with its congeners and HD00176 , coexisting in the contents of alcoholic beverages .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as DB00415 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , DB00277 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 { DB01285 } : may potentiate DB00681 - induced hypokalemia which may predispose the patient to cardiac dysfunction .",
        "label": "effect"
    },
    {
        "text": "to determine whether ddrug0 has a direct effect on the distribution of ddrug1 , the elimination and distribution of DB01147 was studied in six patients , five lacking kidney function and one with a partially impaired renal function , in the presence or absence of DB01032 .",
        "label": "NA"
    },
    {
        "text": "HD00512 may decrease vascular response to pressor drugs such as DB00668 .",
        "label": "effect"
    },
    {
        "text": "cohort # then received ddrug0 plus DB00615 for # days , and cohort # received DB00701 plus ddrug3 for # days .",
        "label": "NA"
    },
    {
        "text": "combinations of these drugs have not been studied and coadministration of DB00224 and DB01072 is not recommended .",
        "label": "advise"
    },
    {
        "text": "drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving HD00100 metabolized similarly to DB00404 or on the basis of in vitro studies with ddrug2 or other ddrug3 { caution is recommended during coadministration with ddrug4 } : available data from clinical studies of ddrug5 other than ddrug6 suggest a possible drug interaction with ddrug7 for the following : ddrug8 , ddrug9 , ddrug10 such as ddrug11 and ddrug12 , and grapefruit juice .",
        "label": "NA"
    },
    {
        "text": "drugs decreasing ddrug0 effect : ddrug1 , ddrug2 , DB00184 , or ddrug4 may partially counteract the anticoagulant action of DB01109 .",
        "label": "effect"
    },
    {
        "text": "these drugs include the ddrug0 and other HD00218 , ddrug2 , HD00219 , thyroid products , ddrug4 , oral ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : HD00532 , including ddrug2 , decrease the clearance of DB08496 , the less active isomer of racemic ddrug4 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , DB01076 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , DB01601 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "absorption of DB00759 is impaired by DB01294 .",
        "label": "mechanism"
    },
    {
        "text": "antiacid , ddrug0 , ddrug1 , ddrug2 , ddrug3 , indanavir , ddrug4 , ddrug5 , phenobarbitol , DB00564 , ddrug7 , ddrug8 , ritanovir , DB01232 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 may enhance the effects of : other HD00459 s , ddrug4 , general ddrug5 , HD00262 such as ddrug7 , ddrug8 , or other ddrug9 , causing increased cns depression .",
        "label": "NA"
    },
    {
        "text": "coadministration of oral ddrug0 , ddrug1 , DB00252 , or ddrug3 did not seem to change the pharmacokinetic profile of DB00736 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in cases of DB00647 overdosage , DB00182 cns stimulation is potentiated and fatal convulsions can occur .",
        "label": "effect"
    },
    {
        "text": "pretreatment of rats with DB00437 { 100 mg/kg , ip } or DB00163 { 100 mg/kg per day , ig , for # days and a dose of # mg/kg on the 4th day } provided significant protection against the elevation of tbars levels in cerebral and hepatic tissues , induced by single high dose of oral ddrug2 administration within # h.",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of ddrug0 : ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , ddrug5 , ddrug6 , ddrug7 } , ddrug8 , HD00808 , ddrug10 , ddrug11 , ddrug12 , ddrug13 { e , g , , in oral HD00283 } .",
        "label": "NA"
    },
    {
        "text": "DB00316 / ddrug1 , ddrug2 / ddrug3 , ddrug4 / ddrug5 , ddrug6 / ddrug7 , ddrug8 / DB00281 , ddrug10 / ddrug11 , and ddrug12 / ddrug13 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , HD00002 such as ddrug4 and ddrug5 , HD00282 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : DB00316 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , DB00812 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "core temperature was decreased in rats in a dose-dependent manner when DB00898 was administered to rats treated with DB00822 # hours before the ddrug2 challenge .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : DB00270 { ddrug2 } has been safely coadministered with DB00727 .",
        "label": "NA"
    },
    {
        "text": "other concomitant therapies : in clinical trials , the safety profile in subjects treated with DB00659 concomitantly with ddrug1 , ddrug2 and ddrug3 { including HD00100 } , or ddrug5 was similar to that of subjects taking placebo with these concomitant medications .",
        "label": "NA"
    },
    {
        "text": "drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving ddrug0 metabolized similarly to ddrug1 or on the basis of in vitro studies with ddrug2 or other ddrug3 { caution is recommended during coadministration with ddrug4 } : available data from clinical studies of ddrug5 other than ddrug6 suggest a possible drug interaction with DB00404 for the following : DB00343 , ddrug9 , ddrug10 such as ddrug11 and ddrug12 , and grapefruit juice .",
        "label": "int"
    },
    {
        "text": "- a ddrug0 { HD00615 } such as ddrug2 { ddrug3 , ddrug4 , ddrug5 , others } , ddrug6 { ddrug7 , ddrug8 , ddrug9 } , ddrug10 { ddrug11 , ddrug12 } , ddrug13 { ddrug14 } , ddrug15 { ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , and DB00788 { ddrug22 , ddrug23 , ddrug24 } ;",
        "label": "NA"
    },
    {
        "text": "in addition , studies in healthy volunteers have shown that ddrug0 does not affect the pharmacokinetics or pharmacodynamics of DB00682 , or the pharmacokinetics of ddrug2 { 40 mg twice daily } , ddrug3 , DB00277 , or oral ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : a relationship of functional antagonism exists between HD00464 , which promote calcium absorption , and HD00175 , which inhibit calcium absorption .",
        "label": "mechanism"
    },
    {
        "text": "effects of other antiepilepsy drugs { HD00714 } on DB00906 : ddrug2 : population pharmacokinetic analyses indicate that ddrug3 clearance is 60 % greater in patients taking ddrug4 with or without other enzyme - inducing ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , HD00668 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , DB01232 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : other HD00304 drugs , such as DB00908 , ddrug3 , ddrug4 , and ddrug5 , have been used concurrently with ddrug6 .",
        "label": "NA"
    },
    {
        "text": "therefore , close monitoring of serum DB00091 level is recommended and , if necessary , DB00608 should be discontinued .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { DB00472 } sporal { ddrug12 } ddrug13 { ddrug14 } DB01235 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "lastly local use of the mucocutaneous and cytoprotective properties of DB14513 is still valid , in HD00194 and for preservation of transplants particularly .",
        "label": "NA"
    },
    {
        "text": "these medications have included ddrug0 , ddrug1 , ddrug2 , ddrug3 , HD00209 , intravenous and oral ddrug5 , DB00208 , and ddrug7 .",
        "label": "NA"
    },
    {
        "text": "the following specific interactions have been reported : itraconazole co-administration of another extended release formulation of DB01023 with DB01167 resulted in approximately 8-fold increase in the auc , more than 6 - fold increase in the cmax , and 2-fold prolongation in the half - life of ddrug2 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a study of # healthy male volunteers , DB00459 treatment potentiated the blood glucose lowering effect of DB01016 { a ddrug3 similar to ddrug4 } in # of the # subjects .",
        "label": "effect"
    },
    {
        "text": "DB00364 should not be taken within # hours of DB01155 .",
        "label": "advise"
    },
    {
        "text": "-lsb- the effect of ddrug0 on the renal excretion of HD00190 and DB08948 in dogs -rsb- the intravenous injection of ddrug3 in a dose of # mg/kg enhanced ddrug4 and ddrug5 excretion in chronic canine experiments .",
        "label": "NA"
    },
    {
        "text": "interactions with other cns agents : concurrent use of DB00854 with all ddrug1 { eg , ddrug2 , HD00024 , ddrug4 , other ddrug5 , general ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 and ddrug12 } may result in additive central nervous system depressant effects .",
        "label": "effect"
    },
    {
        "text": "poor metabolizers of DB04840 : interactions of ddrug1 with strong inhibitors of cyp2d6 { such as ddrug2 , DB00472 , ddrug4 , and ddrug5 } have not been studied , but these drugs would be expected to increase blood levels of the r { + } enantiomer of ddrug6 .",
        "label": "NA"
    },
    {
        "text": "phase ii clinical trial data , where DB00317 and DB00361 have been used concomitantly , indicate that ddrug2 may exacerbate the neutropenic effect of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "injection of vehicle { corn oil , # ml/day } , DB00783 { 10 microg/kg/day or # mg/kg/day } and/or DB00396 { 20 mg/kg/day } , for eight days .",
        "label": "NA"
    },
    {
        "text": "dose adjustment is not recommended , DB01202 had no effect on plasma concentrations of ddrug1 , DB00313 , ddrug3 , or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : HD00403 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { DB01026 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "a study of interaction between DB00187 and ddrug1 showed that concomitant administration of ddrug2 and ddrug3 does not alter DB00682 plasma levels .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , HD00002 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and DB00126 .",
        "label": "NA"
    },
    {
        "text": "DB14507 : generally should not be given with HD00218 .",
        "label": "advise"
    },
    {
        "text": "as with other HD00617 , it should be noted that DB00502 may be capable of potentiating ddrug2 such as ddrug3 , ddrug4 , and ddrug5 .",
        "label": "NA"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , ddrug3 ddrug4 : DB00637 , DB00342 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "DB00999 # mg qd or ddrug1 / ddrug2 50/100 mg qd was co-administered with DB00204 { 500 mcg bid } for # days { following # days of ddrug4 use at half dose } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB01032 is known to interact with the metabolism or renal tubular excretion of many drugs { e , g , , DB00316 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 agents , ddrug14 , and ddrug15 } .",
        "label": "mechanism"
    },
    {
        "text": "interactions with ddrug0 : ddrug1 { eg , ddrug2 , ddrug3 , ddrug4 , DB01209 and ddrug6 } should not be administered to a patient who has received or is receiving a course of therapy with a HD00843 such as ddrug8 .",
        "label": "NA"
    },
    {
        "text": "plasma levels of several closely related ddrug0 have been reported to be increased by the concomitant administration of ddrug1 or hepatic enzyme inhibitors { e , g , , ddrug2 , ddrug3 } and decreased by the concomitant administration of hepatic enzyme inducers { e , g , , HD00026 , ddrug5 } , and such an effect may be anticipated with HD00551 as well .",
        "label": "mechanism"
    },
    {
        "text": "DB00176 inhibits the cyp2c9 catalyzed biotransformation of DB01124 .",
        "label": "mechanism"
    },
    {
        "text": "DB00343 , ddrug1 , DB00661",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in vitro and/or in vivo data indicate that ddrug1 , DB01167 , and oral ddrug3 markedly inhibit the metabolism of DB00604 , which can result in an increase in plasma ddrug5 levels and prolongation of the qt interval on the ecg .",
        "label": "mechanism"
    },
    {
        "text": "the results indicate that a spinal ddrug0 - sensitive endorphinergic system is involved in the production of ddrug1 but not DB00295 - induced tail-flick inhibition , and suggest that intraventricular HD00144 and ddrug4 elicit their pharmacological actions via the activation of different descending pain inhibitory systems ;",
        "label": "NA"
    },
    {
        "text": "in HD00023 - dependent patients , HD00844 may precipitate withdrawal symptoms .",
        "label": "NA"
    },
    {
        "text": "DB01233 : when coadministered with ddrug1 , ddrug2 , a drug which increases gastrointestinal motility , lowers the serum concentration and urinary excretion of DB00828 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , including DB00827 , may enhance the effects of oral ddrug2 , such as DB00682 or its derivatives .",
        "label": "effect"
    },
    {
        "text": "these agents include medications such as : HD00326 , ddrug1 including ddrug2 , sali-cylates , HD00203 { including ddrug4 } , ddrug5 , or ddrug6 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in post-marketing experience , there have been rare reports of adverse neuropsychiatric events or reduced ddrug1 tolerance in patients who were drinking DB02325 during treatment with DB01156 .",
        "label": "effect"
    },
    {
        "text": "following oral administration of two 150-mg sustained-release tablets with and without # mg of DB00501 , the pharmacokinetics of DB01156 and ddrug2 were unaffected .",
        "label": "NA"
    },
    {
        "text": "a rare , but serious , constellation of symptoms , termed serotonin syndrome , has been reported with the concomitant use of ddrug0 { ddrug1 } and agents for migraine therapy , such as ddrug2 { DB00669 } and DB00320 .",
        "label": "NA"
    },
    {
        "text": "in vitro interaction of HD00040 and DB00107 in placental vessels .",
        "label": "int"
    },
    {
        "text": "potential for DB01238 to affect other drugs DB01238 is unlikely to cause clinically important pharmacokinetic interactions with drugs metabolized by cytochrome cyp2b6 enzymes .",
        "label": "NA"
    },
    {
        "text": "should it be decided to discontinue therapy in patients receiving HD00254 and DB00575 concurrently , the ddrug2 should be discontinued slowly over several days before the gradual withdrawal of ddrug3 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 such as ddrug1 , ddrug2 , or DB00594 , or DB14500 supplements should be given only for documented hypokalemia , and then with caution , since they may lead to a significant increase of serum potassium .",
        "label": "NA"
    },
    {
        "text": "in vitro studies evaluating the minimum inhibitory concentration { mic } of ddrug0 , ddrug1 , DB00415 , ddrug3 / flucoxacillin , ddrug4 , ddrug5 , and ddrug6 demonstrated no evidence of incompatibility of these HD00002 with ddrug8 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 should not be administered concomitantly with potent ddrug1 such as DB00695 and DB00903 as the potential for ototoxicity is enhanced by the combination .",
        "label": "NA"
    },
    {
        "text": "specific and aspecific treatments of DB14513 depletion are tricky using for example ddrug1 , pharmacological doses of DB00165 , physiological doses of ddrug3 and of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / ddrug1 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , ddrug4 , ddrug5 , ddrug6 , ddrug7 , DB01578 , ddrug9 , ddrug10 , ddrug11 pain medication { e , g , , DB00318 } , drugs used to aid sleep , drowsiness-causing ddrug13 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "co-administration of ddrug0 and HD00249 or other agents interfering with neuromuscular transmission { e , g , , HD00436 } should only be performed with caution as the effect of the ddrug3 may be potentiated .",
        "label": "NA"
    },
    {
        "text": "patients taking DB00682 or other HD00469 should be monitored regularly for changes in prothrombin time or inr",
        "label": "NA"
    },
    {
        "text": "the treatment of ewes with an intravenous { iv } injection of DB11473 , insufficient to produce significant inhibition of erythrocyte aces_human { ache } activity , appeared to produce additive effects with those produced by subsequent treatment with # mg of DB11390 / kg/day .",
        "label": "effect"
    },
    {
        "text": "the administration of local HD00449 containing ddrug1 or ddrug2 to patients receiving ddrug3 , HD00043 or ddrug5 may produce severe , prolonged hypotension or hypertension .",
        "label": "effect"
    },
    {
        "text": "the clinical significance of this reduction is not known , hence DB00943 is not recommended to be ingested simultaneously with ddrug1 / ddrug2 - containing HD00374 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 s : ddrug1 should be administered at least # hours after or # hours before dosing with ddrug2 because plasma concentrations of DB00537 are decreased when administered with ddrug4 containing DB14513 , ddrug6 , or ddrug7 .",
        "label": "mechanism"
    },
    {
        "text": "in these subjects , DB00482 did not alter the anticoagulant effect of DB00682 as determined by prothrombin time .",
        "label": "NA"
    },
    {
        "text": "DB00501 } and many that are substrates for cyp2b6 2d6 { many other HD00216 , ddrug2 , and the type 1c antiarrhythrnics propatenone and ddrug3 } .",
        "label": "NA"
    },
    {
        "text": "influence of DB00776 on HD00715 concentration { mean change , 90 % confidence interval }",
        "label": "NA"
    },
    {
        "text": "DB00572 , either alone or in combination with DB02325 , produced approximately the same degree of enhancement of component p2 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the concomitant administration of DB00861 and DB00788 in normal volunteers had no effect on the plasma levels of ddrug3 , but significantly decreased the urinary excretion of ddrug4 and its glucuronide metabolite .",
        "label": "mechanism"
    },
    {
        "text": "because severe hypoglycemia has been reported in patients concomitantly receiving oral DB01110 { an ddrug1 } and oral ddrug2 , such a potential interaction involving the latter agents when used concomitantly with ddrug3 tablets { an DB03366 } can not be ruled out .",
        "label": "NA"
    },
    {
        "text": "HD00106 and HD00466 { congestive heart failure post-myocardial infarction } - in ephesus , # { 91 % } patients receiving ddrug2 # to # mg also received ddrug3 or ddrug4 { ddrug5 / ddrug6 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : immediate release capsules : since there have been isolated reports of patients with elevated ddrug1 levels , and there is a possible interaction between ddrug2 and ddrug3 , it is recommended that DB00390 levels be monitored when initiating , adjusting , and discontinuing DB01115 to avoid possible over - or under-digitalization .",
        "label": "advise"
    },
    {
        "text": "pharmacokinetic interactions between DB00401 and ddrug1 { ddrug2 , DB00571 } were variable and not significant .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : when DB00862 # or # mg was given to healthy volunteers either simultaneously or # hours after a # mg dose of DB01162 , significant hypotension developed in a substantial number of subjects .",
        "label": "effect"
    },
    {
        "text": "patients receiving other HD00459 s , general ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 or other HD00261 { including ddrug7 } concomitantly with ddrug8 may exhibit an additive cns depression .",
        "label": "NA"
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a ddrug0 , including ddrug1 , with multivalent cation-containing products such as ddrug2 or ddrug3 ddrug4 , ddrug5 , DB00900 chewable/buffered tablets or pediatric powder , or products containing ddrug7 , DB01592 , or ddrug9 may substantially decrease the absorption of ddrug10 , resulting in serum and urine levels considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { ddrug1 s } , ddrug2 , ddrug3 { ddrug4 may decrease the effects of these medicines } , ddrug5 { using these medicines with ddrug6 may result in increased cns depressant effects } , DB00313 , ddrug8 { using these medicines with ddrug9 may change the amount of either medicine that you need to take } , and oral HD00283 containing ddrug11 { ddrug12 may decrease the effectiveness of these oral ddrug13 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 has additive effects with DB02325 and other ddrug2 { HD00214 , ddrug4 , ddrug5 , etc } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - and/or DB01370 - containing ddrug2 , products containing ddrug3 { ddrug4 } , ddrug5 containing ddrug6 or other metal cations , or DB00900 { ddrug8 } chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after ddrug9 .",
        "label": "NA"
    },
    {
        "text": "while additional research is needed , the initial clinical data in kidney recipients suggest that DB00877 , in combination with DB00091 or ddrug2 , might have the potential to reduce the frequency of rejection episodes , permit reductions in ddrug3 or ddrug4 dosage , and permit steroid withdrawal { kelly , 1999 } .",
        "label": "NA"
    },
    {
        "text": "HD00275 : coadministration of ddrug1 resulted in a 27 % decrease in DB00918 clearance and an increase in cmax of approximately 6 % .",
        "label": "NA"
    },
    {
        "text": "the absorption of oral ddrug0 is significantly reduced by the concomitant administration of an DB06724 containing ddrug2 and DB14513 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { e , g , , ddrug1 , ddrug2 , ddrug3 , DB00196 , etc , } : in vitro and animal studies with the combination of ddrug5 and HD00319 suggest that ddrug7 may induce fungal resistance to ddrug8 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - and/or DB01370 - containing ddrug2 , products containing ddrug3 { ddrug4 } , ddrug5 containing ddrug6 or other metal cations , or ddrug7 { ddrug8 } chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after DB01155 .",
        "label": "advise"
    },
    {
        "text": "plasma levels of several closely related ddrug0 have been reported to be increased by the concomitant administration of ddrug1 or hepatic enzyme inhibitors { e , g , , ddrug2 , DB00472 } and decreased by the concomitant administration of hepatic enzyme inducers { e , g , , HD00026 , ddrug5 } , and such an effect may be anticipated with ddrug6 as well .",
        "label": "NA"
    },
    {
        "text": "the aim of this paper was to study the interaction between HD00163 and both ddrug1 or its synthetic analogue HD00165 , or ddrug3 , on the antinonciceptive effect of these peptides in mice after intracisternal injection .",
        "label": "NA"
    },
    {
        "text": "drug-drug interactions given the primary cns effects of DB01238 , caution should be used when ddrug1 is taken in combination with other HD00365 and ddrug3 .",
        "label": "NA"
    },
    {
        "text": "inhibitors of this isoenzyme { e , g , , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , HD00640 , ddrug6 , grapefruit juice , ddrug7 , ddrug8 , ddrug9 , ddrug10 } should be cautiously coadministered with ddrug11 as they can potentially increase DB00204 levels .",
        "label": "NA"
    },
    {
        "text": "in order to avoid the occurrence of severe hypersensitivity reactions , all patients treated with DB01229 should be premedicated with ddrug1 { such as DB01234 } , diphen-hydramine and ddrug3 { such as ddrug4 or ddrug5 } .",
        "label": "NA"
    },
    {
        "text": "because severe hypoglycemia has been reported in patients concomitantly receiving oral ddrug0 { an ddrug1 } and oral ddrug2 , such a potential interaction involving the latter agents when used concomitantly with DB01026 tablets { an DB03366 } can not be ruled out .",
        "label": "NA"
    },
    {
        "text": "however , because some HD00532 have been reported to enhance the effects of ddrug1 or its derivatives , prothrombin time or other suitable anticoagulation test should be monitored closely if a ddrug2 is administered with DB00682 or its derivatives .",
        "label": "NA"
    },
    {
        "text": "administration of repeat doses of DB01155 had no effect on the repeat dose pharmacokinetics of ddrug1 , DB00390 or an ddrug3 / levonorgestrol oral ddrug4 in healthy subjects .",
        "label": "NA"
    },
    {
        "text": "these results suggest that both ddrug0 and ddrug1 , and possibly other HD00115 and HD00150 , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of ddrug4 and ddrug5 .",
        "label": "NA"
    },
    {
        "text": "because severe hypoglycemia has been reported in patients concomitantly receiving oral DB01110 { an ddrug1 } and oral ddrug2 , such a potential interaction involving the latter agents when used concomitantly with DB01026 tablets { an ddrug4 } can not be ruled out .",
        "label": "NA"
    },
    {
        "text": "ddrug0 should be used with caution , if at all , when potent inhalational ddrug1 such as DB01159 are employed because of potential to sensitize the myocardium to effects of HD00399 .",
        "label": "NA"
    },
    {
        "text": "in general , these are drugs that have one or more pharmacologic activities similar to ddrug0 , including HD00407 such as DB00908 and ddrug3 , ddrug4 and ddrug5 .",
        "label": "NA"
    },
    {
        "text": "DB01118 taken concomitantly with DB01035 for less than seven days increases plasma concentrations of ddrug2 and n_acetyl ddrug3 by 55 % and 33 % , respectively .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 HD00388 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { DB01167 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { ddrug1 s } , ddrug2 , ddrug3 { ddrug4 may decrease the effects of these medicines } , ddrug5 { using these medicines with ddrug6 may result in increased cns depressant effects } , ddrug7 , DB00313 { using these medicines with ddrug9 may change the amount of either medicine that you need to take } , and oral ddrug10 containing HD00220 { ddrug12 may decrease the effectiveness of these oral ddrug13 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect : ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , ddrug5 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , ddrug11 , HD00220 , ddrug13 { e , g , , in oral HD00283 } .",
        "label": "NA"
    },
    {
        "text": "the concurrent use of DB00986 injection with other HD00444 or medications with anticholinergic activity , such as ddrug2 , ddrug3 , or ddrug4 , may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects .",
        "label": "effect"
    },
    {
        "text": "DB00945 : concomitant administration of low-dose ddrug1 with HD00897 may result in an increased rate of gi ulceration or other complications , compared to use of ddrug3 alone .",
        "label": "NA"
    },
    {
        "text": "when therapeutic concentrations of ddrug0 , ddrug1 , DB00975 , ddrug3 , ddrug4 , or ddrug5 were added to human plasma { in vitro } , the plasma protein binding of DB00622 was not altered .",
        "label": "NA"
    },
    {
        "text": "HD00445 such as ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , DB00780 } , ddrug5 { e , g , , ddrug6 } , ddrug7 { e , g , , ddrug8 } , and ddrug9 { e , g , , ddrug10 } : using these medicines with ddrug11 may increase the chance of side effects .",
        "label": "NA"
    },
    {
        "text": "DB00503 - combined administration of a single dose of ddrug1 { 600 mg } , both a cyp3a4 substrate and a potent inhibitor of cyp3a4 , and DB01175 { 20 mg } did not affect the pharmacokinetics of either ddrug3 or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 potentiates other HD00632 such as ddrug2 or ddrug3 and HD00662 .",
        "label": "NA"
    },
    {
        "text": "DB00313 # mg twice daily did not modify the rate or extent of DB01202 absorption or its plasma clearance or urinary excretion .",
        "label": "NA"
    },
    {
        "text": "close supervision and careful adjustment of the dosage are required when DB00540 is used with other ddrug1 or HD00390 .",
        "label": "advise"
    },
    {
        "text": "although neither DB01234 nor HD00147 affected the proliferation of prostatic epithelium in rpmi1640 containing ddrug2 alone , they modify the mitogenic effect of ddrug3 and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "concurrent use of ddrug0 with ddrug1 { e , g , , ddrug2 , HD00026 , ddrug4 , and ddrug5 } may result in increased HD00461 effects .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 does not affect the pharmacokinetics of DB00828 when coadministered with DB00828 .",
        "label": "NA"
    },
    {
        "text": "catecholamine-depleting agents : patients taking both HD00482 and a drug that can deplete catecholamines { e , g , , DB00206 and ddrug2 } should be observed closely for signs of hypotension and/or severe bradycardia .",
        "label": "effect"
    },
    {
        "text": "increased ectopic pacemaker activity can occur when DB00852 is used concomitantly with HD00118 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 and ddrug1 { hypertension } - in clinical studies of patients with hypertension , the addition of ddrug2 # to # mg to HD00106 and HD00466 increased mean serum potassium slightly { about # # meq/l } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 reversible increases in serum DB14507 concentrations and toxicity have been reported during concomitant administration of ddrug2 with ddrug3 , and with some HD00466 .",
        "label": "NA"
    },
    {
        "text": "preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving DB00224 in combination with ddrug1 than those receiving DB00224 # mg q8h .",
        "label": "NA"
    },
    {
        "text": "when ddrug0 is co-administered with DB01032 { 500 mg p , o , every # hours } , ddrug2 competes for active tubular secretion and reduces the renal clearance of DB00303 .",
        "label": "NA"
    },
    {
        "text": "there have been reports of increased anticoagulant effects when DB00199 and oral HD00326 were used concomitantly .",
        "label": "effect"
    },
    {
        "text": "DB00945 : concomitant administration of DB00586 and ddrug2 is not recommended because ddrug3 is displaced from its binding sites during the concomitant administration of ddrug4 , resulting in lower plasma concentrations , peak plasma levels , and auc values .",
        "label": "NA"
    },
    {
        "text": "- a ddrug0 { HD00615 } such as ddrug2 { ddrug3 , ddrug4 , ddrug5 , others } , ddrug6 { ddrug7 , ddrug8 , ddrug9 } , ddrug10 { ddrug11 , ddrug12 } , ddrug13 { ddrug14 } , DB00328 { ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , and ddrug21 { ddrug22 , ddrug23 , ddrug24 } ;",
        "label": "NA"
    },
    {
        "text": "based on total DB00303 concentrations , DB01032 increased the auc by 25 % and reduced the plasma and renal clearances by 20 % and 35 % , respectively .",
        "label": "mechanism"
    },
    {
        "text": "other drugs : in healthy volunteers , ddrug0 , DB00252 , ddrug2 , ddrug3 , ddrug4 , hormone replacement therapy { a combination of conjugated ddrug5 and ddrug6 } , ddrug7 { ddrug8 and ddrug9 } and ddrug10 did not affect the pharmacokinetics of DB00204 .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 HD00388 ddrug5 { DB00564 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "the effects of ddrug0 { HD00054 } on DB03401 { ddrug3 } - induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura_2 microfluorometry .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB01234 : ddrug2 , when given as a regimen of 125 mg with ddrug3 coadministered orally as # mg on day 1 , and DB00673 when given as # mg/day with ddrug5 coadministered orally as # mg on days # through 5 , increased the auc of ddrug6 , a cyp3a4 substrate by # - fold , on days # and 5 .",
        "label": "NA"
    },
    {
        "text": "if a patient requires DB00204 and ddrug1 therapy , it is suggested that ddrug2 , ddrug3 , or ddrug4 { ddrug5 and DB09104 } be used as alternatives to ddrug7 , as these agents have no effect on the pharmacokinetic profile of ddrug8 .",
        "label": "NA"
    },
    {
        "text": "concurrent administration of DB03585 and HD00657 may result in elevated serum levels of ddrug2 .",
        "label": "mechanism"
    },
    {
        "text": "in addition , studies in healthy volunteers have shown that DB00204 does not affect the pharmacokinetics or pharmacodynamics of ddrug1 , or the pharmacokinetics of DB00571 { 40 mg twice daily } , ddrug3 , ddrug4 , or oral ddrug5 .",
        "label": "NA"
    },
    {
        "text": "nephrotoxicity has been reported following concomitant administration of other HD00485 with potent ddrug1 such as DB00695 .",
        "label": "effect"
    },
    {
        "text": "HD00356 enhance the renal toxicity of ddrug1 in animals , # HD00663 interferes with the action of ddrug3 preparations by chelating the ddrug4 , 7",
        "label": "NA"
    },
    {
        "text": "cardiac effects of ddrug0 are antagonized by ddrug1 , such as DB00571 and DB00264 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - prior ingestion of DB01231 may decrease the HD00627 response to ddrug3 in the treatment of poisoning .",
        "label": "NA"
    },
    {
        "text": "since ddrug0 is extensively metabolized by cyp4f3 isoenzymes , caution should be exercised when ddrug1 is coadministered with inhibitors of c , p , a , such as DB01026 and ddrug3 or inhibitors of cyp2c19 such as DB00338 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 has been shown to have no effect on the pharmacokinetics of ddrug1 and the pharmacodynamics of DB00682 and DB01016 .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of DB00307 capsules and DB01241 resulted in substantial increases in plasma concentrations of ddrug2 , probably at least partially related to cyp3a4 inhibition by ddrug3 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : the effect of DB00580 on the anticoagulant effect of ddrug2 { 1 - # mg/day } was studied in healthy subjects by coadministration of DB00580 # mg bid for # days .",
        "label": "NA"
    },
    {
        "text": "like ddrug0 { 40 mg/kg } , ddrug1 { 40 mg/kg } decreases the intravenous self-administration of DB00295 and ddrug3 and the oral self-administration of DB00898 and ddrug5 in rats ;",
        "label": "NA"
    },
    {
        "text": "patients taking HD00469 concomitantly with DB01101 should be monitored regularly for alterations in their coagulation parameters { pt or inr } .",
        "label": "advise"
    },
    {
        "text": "the serum concentration of ddrug0 increased dramatically from # to # microg/ml when DB00176 was coadministered , although the daily dosage of ddrug2 and other HD00096 had not changed .",
        "label": "NA"
    },
    {
        "text": "if DB01330 and an HD00494 are used concomitantly , renal function should be carefully monitored , because nephrotoxicity may be potentiated .",
        "label": "effect"
    },
    {
        "text": "the effects ddrug0 on the pharmacokinetics and/or pharmacodynamics of ddrug1 , ddrug2 , ddrug3 , ddrug4 , DB01124 , and DB00682 have been studied in vivo and clinically important interactions have not been found .",
        "label": "NA"
    },
    {
        "text": "other concomitant therapy although specific interaction studies were not performed , ddrug0 doses of # mg or more were concomitantly used in clinical studies with ddrug1 , ddrug2 , a-blockers , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , cardiac ddrug9 , ddrug10 , ddrug11 , HD00095 , ddrug13 { also referred to as HD00203 } , and ddrug15 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of ddrug0 and ddrug1 , ddrug2 , DB00338 , or an ddrug4 / ddrug5 oral ddrug6 produced minor changes in the pharmacokinetics of DB01155 , which were considered to be without clinical significance .",
        "label": "NA"
    },
    {
        "text": "injection : ddrug0 injection , like other injectable ddrug1 , produces depression of the central nervous system when administered with ddrug2 , ddrug3 , ddrug4 , HD00343 , and other HD00216 , when ddrug7 is used concomitantly with injectable ddrug8 , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in vitro studies in peripheral blood mononuclear cells , u937 and molt-4 cells revealed that DB00709 significantly inhibited DB00943 phosphorylation in a dose dependent manner .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : coadministration of DB01045 and ddrug2 resulted in an 82 % decrease in DB00220 plasma a , c.",
        "label": "NA"
    },
    {
        "text": "although specific drug interaction studies have not been conducted with DB00484 , the possibility of an additive or potentiating effect with ddrug1 { ddrug2 , ddrug3 , HD00344 , ddrug5 , or ddrug6 } should be considered .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : as with other HD00487 , renal excretion of ddrug2 is inhibited by DB01032 and resulted in an approximate 80 % increase in the auc for ddrug4 .",
        "label": "mechanism"
    },
    {
        "text": "patients receiving other ddrug0 s , general ddrug1 , HD00219 , ddrug3 , ddrug4 , ddrug5 or other ddrug6 { including ddrug7 } concomitantly with DB00327 may exhibit an additive cns depression .",
        "label": "effect"
    },
    {
        "text": "- ddrug0 : ddrug1 should generally not be given with HD00218 { such as ddrug3 } because they reduce its renal clearance and add a high risk of DB14507 toxicity .",
        "label": "NA"
    },
    {
        "text": "immediate and extended release tablets the hypoglycemic action of ddrug0 may be potentiated by certain drugs including ddrug1 , some HD00768 and other drugs that are highly protein bound , ddrug3 , ddrug4 , DB00446 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 should be used with caution in patients receiving - ddrug2 blocking agents { e , g , , ddrug3 , a ddrug4 inhibitor } or HD00306 antagonists { e , g , , DB00661 , a ddrug7 substrate , and ddrug8 , a ddrug9 inhibitor } because of the possible potentiation of bradycardia , sinus arrest , and av block ;",
        "label": "NA"
    },
    {
        "text": "in vitro studies indicate that DB00303 does not inhibit p-glycoprotein-mediated transport of ddrug1 or DB00570 and that ddrug3 is not a substrate for p-glycoprotein-mediated transport .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00501 increases DB00622 plasma levels .",
        "label": "mechanism"
    },
    {
        "text": "however , co-administration of ddrug0 with ddrug1 - and ddrug2 - containing ddrug3 { 51 meq } or ddrug4 with DB00927 , had no significant effect on the rate or extent of DB00476 absorption after administration of a 40-mg oral dose .",
        "label": "NA"
    },
    {
        "text": "DB00486 has been shown to have an additive cns depressant effect when given with either DB00829 , ddrug2 , ddrug3 or ddrug4 .",
        "label": "effect"
    },
    {
        "text": "in a ten-subject study , coadministration of DB00343 { 120 mg bid } with DB00227 resulted in a 3 - 4 times increase in mean ddrug2 auc and cmax vs , ddrug3 alone ;",
        "label": "mechanism"
    },
    {
        "text": "the purpose of this study was to evaluate the effect of HD00066 { ddrug1 } and ddrug2 { ddrug3 } conjugates on the intestinal permeation of ddrug4 { HD00070 } and model peptide drugs , ddrug6 and ddrug7 .",
        "label": "NA"
    },
    {
        "text": "other drugs : in healthy volunteers , DB00381 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , hormone replacement therapy { a combination of conjugated ddrug5 and ddrug6 } , DB06724 { ddrug8 and ddrug9 } and ddrug10 did not affect the pharmacokinetics of ddrug11 .",
        "label": "NA"
    },
    {
        "text": "pretreatment of healthy volunteers with multiple doses of DB01045 followed by a single dose of DB00619 , increased ddrug2 oral-dose clearance by # - fold , which significantly { p # } decreased mean cmax and auc { 0 - 8 } .",
        "label": "mechanism"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { HD00403 s } , ddrug2 , ddrug3 { ddrug4 may decrease the effects of these medicines } , ddrug5 { using these medicines with ddrug6 may result in increased cns depressant effects } , ddrug7 , ddrug8 { using these medicines with ddrug9 may change the amount of either medicine that you need to take } , and oral ddrug10 containing ddrug11 { HD00026 may decrease the effectiveness of these oral ddrug13 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "use in ambulatory patients the effects of DB01205 may wear off before a HD00734 is completely cleared from the body .",
        "label": "NA"
    },
    {
        "text": "DB00999 # mg qd or ddrug1 / ddrug2 50/100 mg qd was co-administered with ddrug3 { 500 mcg bid } for # days { following # days of HD00295 use at half dose } .",
        "label": "NA"
    },
    {
        "text": "DB01432 and ddrug1 ddrug2 : absorption of ddrug3 is impaired in the presence of HD00783 .",
        "label": "NA"
    },
    {
        "text": "HD00034 at # microm preferentially blocked the secretory effect of DB00411 and its synergism with camp , whereas it had no effect on histamine - or camp-stimulated acid secretion within # min .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : DB00641 { ddrug2 substrate } in combination with DB01118 has been associated with reports of myopathy/rhabdomyolysis .",
        "label": "NA"
    },
    {
        "text": "ddrug0 should be used with care when ddrug1 or inhibitors of av conduction , such as certain ddrug2 { particularly of the ddrug3 -lsb- ddrug4 -rsb- and ddrug5 -lsb- DB00343 -rsb- classes } , or HD00428 , such as ddrug8 , are used concurrently .",
        "label": "NA"
    },
    {
        "text": "therefore , ddrug0 or other DB14049 { as used for management of angina } or other drugs having vasodilator activity should , if possible , be discontinued before starting DB01197 .",
        "label": "advise"
    },
    {
        "text": "these drugs include the HD00217 and other ddrug1 , HD00175 , ddrug3 , ddrug4 , ddrug5 , oral ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , and ddrug11 .",
        "label": "NA"
    },
    {
        "text": "in monkeys , HD00157 was about # times more potent than ddrug1 in decreasing responding , whereas in pigeons ddrug2 was about equipotent with HD00156 .",
        "label": "NA"
    },
    {
        "text": "DB00709 and DB00943 may inhibit the intracellular phosphorylation of one another .",
        "label": "effect"
    },
    {
        "text": "these results suggest that both ddrug0 and ddrug1 , and possibly other HD00115 and ddrug3 , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of HD00071 and ddrug5 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 can interact with DB02325 or other ddrug2 { may potentiate the cns depressant effects of either these medications or ddrug3 } , ddrug4 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug5 } , and ddrug6 { concurrent use with ddrug7 may prolong and intensify the anticholinergic and cns depressant effects of HD00388 } .",
        "label": "NA"
    },
    {
        "text": "the influence of DB00683 and ddrug1 on antinociceptive effect of DB00295 { 10 mg/kg } , ddrug3 { 500 mg/kg } and ddrug4 { 10 mg/kg } was investigated in a mouse model using the tail-flick and hot-plate tests .",
        "label": "NA"
    },
    {
        "text": "drug interaction studies have shown that DB00736 does not have any clinically significant interactions with ddrug1 , ddrug2 , ddrug3 , ddrug4 or DB01060 .",
        "label": "NA"
    },
    {
        "text": "other drug interactions oral ddrug0 ddrug1 { 500 mg twice daily } did not influence the pharmacokinetics of an oral ddrug2 containing # mg DB00977 and # mg DB00367 , or of the luteinizing hormone and progesterone levels , indicating that impairment of contraceptive efficacy is unlikely .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : since ddrug1 is contraindicated in patients with ddrug2 - induced thrombocytopenia , the co-administration of DB00278 and DB01109 is unlikely for this indication .",
        "label": "NA"
    },
    {
        "text": "the daily dose of DB00496 should not exceed # mg when coadministered with potent cyp3a4 inhibitors { e , g , , ddrug1 , ddrug2 , ddrug3 , ddrug4 , DB01211 and nefazadone } .",
        "label": "advise"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { ddrug1 s } , ddrug2 , ddrug3 { ddrug4 may decrease the effects of these medicines } , ddrug5 { using these medicines with ddrug6 may result in increased cns depressant effects } , ddrug7 , DB00313 { using these medicines with ddrug9 may change the amount of either medicine that you need to take } , and oral HD00283 containing ddrug11 { ddrug12 may decrease the effectiveness of these oral ddrug13 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "at # hours postdose , a similar proportion of patients treated with ddrug0 alone { 94 % } and subsequently treated with ddrug1 co-administered with # mg of DB00533 { 88 % } had DB00563 plasma concentrations below the measurable limit { 5 ng/ml } .",
        "label": "NA"
    },
    {
        "text": "drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on ddrug0 therapy : ddrug1 , ddrug2 , HD00220 , oral HD00283 containing ddrug5 , ddrug6 - containing preparations and the numerous preparations containing ddrug7 .",
        "label": "NA"
    },
    {
        "text": "no change in DB00175 auc and cmax was observed during DB00343 coadministration .",
        "label": "NA"
    },
    {
        "text": "it is not known whether this potentiation of DB00415 rashes is due to DB00437 or the hyperuricemia present in these patients .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : as with other ddrug1 , DB01032 inhibits the renal excretion of ddrug3 , resulting in an approximate doubling in a , c , a 54 % increase in peak DB00535 plasma levels , and a 50 % prolongation in the apparent elimination half-life .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , HD00002 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , DB01232 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "the HD00146 - induced neuronal damage produced a tolerance to the disruptive effects of ddrug1 and a supersensitivity to the disruptive effects of DB00714 in rats responding in a schedule controlled paradigm .",
        "label": "effect"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } DB00501 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { DB01167 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB14513 - containing preparations { eg , HD00374 } may cause hypermagnesemia and should therefore not be taken during therapy with ddrug3 by patients on chronic renal dialysis .",
        "label": "NA"
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of ddrug0 such as DB00565 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , HD00384 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 } , ddrug11 salts , ddrug12 , local ddrug13 , ddrug14 , and ddrug15 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : the concomitant administration of DB00861 and ddrug2 in normal volunteers had no effect on the plasma levels of DB00788 , but significantly decreased the urinary excretion of ddrug4 and its glucuronide metabolite .",
        "label": "NA"
    },
    {
        "text": "therefore , co-administration of DB00476 with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index , including certain ddrug1 { HD00043 -lsb- ddrug3 -rsb- , such as ddrug4 , ddrug5 , and ddrug6 } , ddrug7 and ddrug8 { e , g , , ddrug9 , ddrug10 } , should be approached with caution .",
        "label": "advise"
    },
    {
        "text": "ddrug0 , DB00252 , or ddrug2 increased metabolic clearance of DB00687 because of the induction of hepatic enzymes .",
        "label": "mechanism"
    },
    {
        "text": "concurrent use of DB00712 and DB00945 is therefore not recommended .",
        "label": "advise"
    },
    {
        "text": "this appears to be the only clinically relevant interaction of this kind with DB00358 , although theoretically , coadministration of other drugs known to alter cardiac conduction { eg , ddrug1 or ddrug2 , ddrug3 , ddrug4 or ddrug5 , ddrug6 and HD00219 } might also contribute to a prolongation of the qtc interval .",
        "label": "effect"
    },
    {
        "text": "1 , HD00178 { ddrug1 } , the active metabolite of DB11094 , is a potent inhibitor of breast_cancer cell growth both in vivo and in vitro .",
        "label": "NA"
    },
    {
        "text": "toxicology studies of ddrug0 - related deaths reveal frequent involvement of other ddrug1 , including ddrug2 , HD00100 such as DB00829 { ddrug5 } , and , to a rising degree , ddrug6 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration of ddrug1 and DB01117 suspension results in a significant decrease in average steady - state plasma DB01117 concentrations .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : HD00403 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } HD00220 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "the co-administration of ddrug0 with iv HD00337 such as ddrug2 , ddrug3 , ddrug4 , or iv HD00106 has not been evaluated { these drugs were not co-administered with ddrug6 in clinical trials } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 - although not reported , DB00117 , via its metabolism to histamine , might decrease the efficacy of ddrug3 and HD00586 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : no clinically significant changes in ddrug1 pharmacokinetics { auc , c max , or t max } were observed when a single dose of DB00978 # mg was given after multiple doses of DB00338 { 20 mg qd } in # healthy volunteers .",
        "label": "NA"
    },
    {
        "text": "DB01274 , as with other ddrug1 , should be administered with extreme caution to patients being treated with ddrug2 , HD00043 , or drugs known to prolong the qtc interval because the action of ddrug4 on the cardiovascular system may be potentiated by these agents .",
        "label": "advise"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , DB01076 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , DB00812 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "drug interactions : the central HD00315 syndrome can occur when anticholinergic agents such as ddrug1 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain ddrug2 such as ddrug3 , the ddrug4 and other ddrug5 , ddrug6 , certain ddrug7 such as the ddrug8 salts , and HD00388 .",
        "label": "effect"
    },
    {
        "text": "oral ddrug0 : coadministration of DB01076 and an oral HD00349 increased auc values for ddrug3 and ddrug4 by approximately 30 % and 20 % .",
        "label": "mechanism"
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of HD00472 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 { 1 } , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 { 1 } , ddrug10 , ddrug11 , grapefruit juice , ddrug12 , DB01167 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21 , ddrug22 , ddrug23 , ddrug24 { 1 } , ddrug25 , ddrug26 .",
        "label": "mechanism"
    },
    {
        "text": "specific drug interaction studies have not been performed with ddrug0 and ddrug1 other than DB00709 and DB00495 .",
        "label": "NA"
    },
    {
        "text": "the purpose of this study was to evaluate the effect of HD00066 { ddrug1 } and ddrug2 { ddrug3 } conjugates on the intestinal permeation of HD00069 { ddrug5 } and model peptide drugs , ddrug6 and ddrug7 .",
        "label": "NA"
    },
    {
        "text": "however , because bleeding has been reported when ddrug0 and other ddrug1 have been administered to patients on HD00724 , the physician should be cautious when administering DB01050 to patients on ddrug4 .",
        "label": "NA"
    },
    {
        "text": "nephrotoxicity has been reported following concomitant administration of other HD00485 with potent HD00218 such as ddrug2 .",
        "label": "effect"
    },
    {
        "text": "drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on HD00849 therapy : ddrug1 , ddrug2 , ddrug3 , oral ddrug4 containing ddrug5 , DB11119 - containing preparations and the numerous preparations containing ddrug7 .",
        "label": "NA"
    },
    {
        "text": "rhabdomyolysis has been observed in patients receiving ddrug0 administered alone { at recommended dosages } or concomitantly with HD00084 including DB00091 .",
        "label": "NA"
    },
    {
        "text": "no depressant effect on blood levels in humans was noted when ddrug0 was administered with any of the following drugs : DB00945 , ddrug2 , ddrug3 , ddrug4 , ddrug5 { DB00627 } , ddrug7 , ddrug8 or ddrug9 .",
        "label": "NA"
    },
    {
        "text": "caution should be observed when DB00913 is coadministered with other ddrug1 , ddrug2 , HD00219 , or ddrug4 , as these agents may increase respiratory and circulatory depression .",
        "label": "advise"
    },
    {
        "text": "particular caution is recommended when administering DB00619 with cyp3a4 substrates that have a narrow therapeutic window { e , g , , DB00091 or ddrug2 } .",
        "label": "advise"
    },
    {
        "text": "DB00503 - combined administration of a single dose of ddrug1 { 600 mg } , both a cyp3a4 substrate and a potent inhibitor of cyp3a4 , and ddrug2 { 20 mg } did not affect the pharmacokinetics of either ddrug3 or DB01175 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 does not affect the clearance of the active s-isomer , and changes in clotting time have not been observed when DB00467 and DB00682 were coadministered .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and DB00572 may interact with ddrug2 in studies with male rats , HD00631 was found to inhibit the hepatic microsomal enzyme system at a dose of # mg/kg/day .",
        "label": "NA"
    },
    {
        "text": "this observed increase in the bioavailability of ddrug0 may be due to transport-related effects , such as p-glycoprotein , in vivo animal studies also suggest that in addition to enhancing absorption , DB01026 decreases DB00950 gastrointestinal secretion , while ddrug3 may also decrease biliary excretion .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , DB00949 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { DB00295 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "DB00962 did not affect the pharmacokinetics of DB00898 .",
        "label": "NA"
    },
    {
        "text": "in a placebo-controlled trial in normal volunteers , the administration of a single # mg dose of ddrug0 on day # of a four-day regimen of oral DB00501 { 400 mg twice daily } resulted in a 10 % increase in mean auc of DB00590 { p = # } , and a slight but not statistically significant increase in mean cmax and mean half-life of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "as with some other HD00541 , the time of onset of neuromuscular block induced by ddrug1 is lengthened and the duration of block is shortened in patients receiving DB00252 or ddrug3 .",
        "label": "effect"
    },
    {
        "text": "the purpose of this study was to evaluate the effect of ddrug0 { ddrug1 } and ddrug2 { ddrug3 } conjugates on the intestinal permeation of ddrug4 { HD00070 } and model peptide drugs , ddrug6 and HD00071 .",
        "label": "NA"
    },
    {
        "text": "however , because bleeding has been reported when ddrug0 and other HD00518 have been administered to patients on ddrug2 , the physician should be cautious when administering DB01050 to patients on ddrug4 .",
        "label": "NA"
    },
    {
        "text": "DB00224 : coadministration of ddrug1 with DB00220 resulted in an 83 % increase in ddrug3 plasma auc and a 51 % increase in ddrug4 plasma a , c.",
        "label": "NA"
    },
    {
        "text": "since there have been isolated reports of patients with elevated DB00390 levels , it is recommended that ddrug1 levels be monitored when initiating , adjusting , and discontinuing DB01115 to avoid possible over - or under-digitalization .",
        "label": "NA"
    },
    {
        "text": "although neither DB01234 nor ddrug1 affected the proliferation of prostatic epithelium in rpmi1640 containing ddrug2 alone , they modify the mitogenic effect of HD00148 and ddrug4 .",
        "label": "effect"
    },
    {
        "text": "spontaneous reports of serotonin syndrome associated with co-administration of ddrug0 and ddrug1 , including HD00216 such as ddrug3 { HD00114 } , have been reported .",
        "label": "NA"
    },
    {
        "text": "because oral HD00326 may interfere with the hepatic metabolism of ddrug1 , toxic levels of the HD00329 may occur when an oral ddrug3 and ddrug4 are administered concurrently .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may have additive effects with ddrug1 and other ddrug2 , e , g , , ddrug3 , HD00024 , ddrug5 , HD00557 .",
        "label": "NA"
    },
    {
        "text": "other concomitant therapy although specific interaction studies were not performed , DB01216 doses of # mg or more were concomitantly used in clinical studies with ddrug1 , DB00945 , a-blockers , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , cardiac ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 { also referred to as ddrug14 } , and ddrug15 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "in vitro data suggest that DB01167 also markedly inhibits the biotransformation system mainly responsible for the metabolism of DB00604 ;",
        "label": "mechanism"
    },
    {
        "text": "potential drug interactions between DB01202 and other HD00714 { ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 and ddrug8 } were also assessed by evaluating the serum concentrations of ddrug9 and these ddrug10 during placebo-controlled clinical studies .",
        "label": "NA"
    },
    {
        "text": "- drugs whose efficacy is impaired by DB00252 include : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , oral ddrug8 , DB01045 , ddrug10 , ddrug11 , ddrug12 .",
        "label": "effect"
    },
    {
        "text": "HD00670 : DB01232 / ddrug2 combination",
        "label": "NA"
    },
    {
        "text": "in long surgical procedures during DB00228 or ddrug1 anesthesia , less frequent maintenance dosing , lower maintenance doses , or reduced infusion rates of DB00565 may be necessary .",
        "label": "advise"
    },
    {
        "text": "in addition , ddrug0 is not associated with a risk of agranulocytosis as seen with DB00363 or clinically significant hyperprolactinemia as seen with DB00734 or prolongation of the qt interval .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the rate and extent of absorption of DB00537 was bioequivalent when ddrug2 was given alone or when ddrug3 was given # hours after DB00338 at the dose that maximally suppresses gastric acid secretion .",
        "label": "NA"
    },
    {
        "text": "{ DB00328 } ddrug1 are used concomitantly , the patient should be observed closely to determine if the desired effect of the HD00295 is obtained .",
        "label": "NA"
    },
    {
        "text": "HD00244 : concurrent use may blunt the response to DB01102 .",
        "label": "NA"
    },
    {
        "text": "HD00043 may antagonize the hypotensive effects of DB00575 .",
        "label": "effect"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect : ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , ddrug5 , ddrug6 , ddrug7 } , DB00951 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 { e , g , , in oral HD00283 } .",
        "label": "NA"
    },
    {
        "text": "after # days of co-administration , mean trough concentrations of ddrug0 and its metabolites , HD00566 and HD00567 , were elevated with ddrug3 by about three-fold compared to baseline concentrations .",
        "label": "NA"
    },
    {
        "text": "in clinical trials in patients undergoing ptca/pci , co-administration of DB00006 with ddrug1 , ddrug2 , HD00364 or glycoprotein iib/iiia inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications .",
        "label": "effect"
    },
    {
        "text": "standard monitoring of ddrug0 - related toxicity should be continued if HD00897 and DB00563 are administered concomitantly .",
        "label": "advise"
    },
    {
        "text": "the actions of the HD00100 may be potentiated by ddrug1 , ddrug2 , ddrug3 , ddrug4 or other HD00216 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : DB14513 - containing preparations { eg , ddrug2 } may cause hypermagnesemia and should therefore not be taken during therapy with DB11094 by patients on chronic renal dialysis .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : DB01032 increases both free and bound DB01009 by reducing the plasma clearance of ddrug3 to about one-third , as well as decreasing its protein binding .",
        "label": "mechanism"
    },
    {
        "text": "concurrent administration of ddrug0 and DB00900 significantly reduces the level of exposure to DB00224 , but it is unclear how soon after ddrug3 administration ddrug4 may be given safely .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB01118 should be used with caution in patients receiving - ddrug2 blocking agents { e , g , , DB00571 , a ddrug4 inhibitor } or ddrug5 antagonists { e , g , , ddrug6 , a ddrug7 substrate , and ddrug8 , a ddrug9 inhibitor } because of the possible potentiation of bradycardia , sinus arrest , and av block ;",
        "label": "NA"
    },
    {
        "text": "DB00542 has been used concomitantly with ddrug1 , ddrug2 , ddrug3 , ddrug4 , and DB01275 , without evidence of clinically important adverse interactions .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : as with some other ddrug1 , concurrent administration of DB00537 with ddrug3 may lead to elevated serum concentrations of DB00277 and prolongation of its elimination half-life .",
        "label": "NA"
    },
    {
        "text": "other drugs : based on the results of drug interaction studies , no dosage adjustment is recommended when ddrug0 { DB00625 } is given with the following : HD00671 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , and ddrug11 .",
        "label": "NA"
    },
    {
        "text": "DB00906 is considered to be a non-enzyme inducing HD00715 .",
        "label": "NA"
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as DB01135 include certain ddrug1 { e , g , , ddrug2 , ddrug3 , DB00781 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 } , ddrug10 salts , ddrug11 , local ddrug12 , ddrug13 , and ddrug14 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : DB01026 may inhibit both synthetic and catabolic enzymes of DB11094 .",
        "label": "mechanism"
    },
    {
        "text": "in view of the potential risk of dehydration secondary to vomiting and/or diarrhea induced by ddrug0 , the physician may wish to withhold HD00218 during dosing with DB00762 and , certainly , during periods of active vomiting or diarrhea .",
        "label": "effect"
    },
    {
        "text": "drug interactions : the central ddrug0 syndrome can occur when anticholinergic agents such as ddrug1 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain ddrug2 such as DB00454 , the ddrug4 and other ddrug5 , ddrug6 , certain ddrug7 such as the ddrug8 salts , and HD00388 .",
        "label": "NA"
    },
    {
        "text": "no important interactions to date DB00922 does not have clinically important pharmacokinetic interactions with DB01197 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 or ddrug9 .",
        "label": "NA"
    },
    {
        "text": "however , since ddrug0 , ddrug1 , and ddrug2 are all associated with gastrointestinal irritation , caution should be exercised in the concomitant use of ddrug3 or HD00203 with DB00710 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : HD00401 may antagonize the hypotensive effects of HD00255 .",
        "label": "effect"
    },
    {
        "text": "the administration of DB00952 with other HD00277 has not been evaluated in migraine patients .",
        "label": "NA"
    },
    {
        "text": "the results of a study of coadministration of ddrug0 { 50 mg/kg } with an ddrug1 containing ddrug2 to # patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of DB00330 of approximately 20 % and 13 % , respectively , suggesting that the oral absorption of ddrug4 may be reduced by these HD00701 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 or DB00501 : concomitant administration of ddrug2 or ddrug3 decreases the elimination of DB00943 , most likely by inhibition of renal tubular secretion of ddrug5 .",
        "label": "NA"
    },
    {
        "text": "since DB01118 is a substrate for HD00302 , there is the potential that the use of st , john s wort in patients receiving ddrug2 could result in reduced ddrug3 levels .",
        "label": "NA"
    },
    {
        "text": "other drugs : in small groups of patients { 7 - 10 / interaction study } , the concomitant administration of ddrug0 , ddrug1 , ddrug2 , DB00859 , ddrug4 , ddrug5 , or ddrug6 did not significantly affect the peak levels and auc values of DB00586 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - combined administration of racemic DB00215 { 40 mg } and DB01026 { 200 mg } decreased the cmax and auc of ddrug3 by 21 % and 10 % , respectively , and did not significantly affect the pharmacokinetics of ddrug4 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : the concomitant use of ddrug1 { DB00813 transdermal system } with other ddrug3 , including but not limited to other ddrug4 , ddrug5 , HD00214 , ddrug7 { e , g , , ddrug8 } , general ddrug9 , ddrug10 , ddrug11 , and ddrug12 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .",
        "label": "effect"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , DB00908 ddrug4 : ddrug5 , DB00342 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "DB00201 administered concurrently with DB01009 reduced the urine volume in # healthy volunteers .",
        "label": "effect"
    },
    {
        "text": "conversely , DB00937 may interfere with HD00448 { i , e , , ddrug2 , ddrug3 } .",
        "label": "int"
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , ddrug3 , or ddrug4 , with ddrug5 , with metal cations such as ddrug6 , or with ddrug7 containing DB01592 or DB01593 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "oral DB00994 inhibits the gastrointestinal absorption of ddrug1 , oral ddrug2 , DB00563 and ddrug4 .",
        "label": "mechanism"
    },
    {
        "text": "DB00501 , ddrug1 : in normal volunteers { n = 9 } , pretreatment with ddrug2 or DB00863 did not affect ddrug4 pharmacokinetics except that a small { 13 % } but statistically significant increase in the area under the serum concentration curve of ddrug5 resulted with ddrug6 .",
        "label": "NA"
    },
    {
        "text": "concomitant treatment of four patients in the united kingdom with DB00529 and intravenous DB00738 may have caused hypocalcemia ;",
        "label": "effect"
    },
    {
        "text": "DB00564 , ddrug1 , DB00593",
        "label": "NA"
    },
    {
        "text": "therefore , when DB00594 and ddrug1 are used concomitantly , the patient should be observed closely to determine if the desired effect of the HD00295 is obtained .",
        "label": "NA"
    },
    {
        "text": "- a sulfa-based drug such as DB01015 - ddrug1 { ddrug2 , ddrug3 } , ddrug4 { ddrug5 } , or DB00795 { ddrug7 } ;",
        "label": "NA"
    },
    {
        "text": "may interact with the following : DB01432 , ddrug1 { use with ddrug2 may prevent the HD00295 from working properly ;",
        "label": "NA"
    },
    {
        "text": "other drugs : in healthy volunteers , ddrug0 , ddrug1 , ddrug2 , ddrug3 , DB00338 , hormone replacement therapy { a combination of conjugated ddrug5 and ddrug6 } , ddrug7 { ddrug8 and ddrug9 } and DB00277 did not affect the pharmacokinetics of ddrug11 .",
        "label": "NA"
    },
    {
        "text": "in vivo interaction studies in humans have demonstrated that ddrug0 and ddrug1 do not affect the pk properties of DB00261 , nor does ddrug3 affect the pk properties of DB00390 or ddrug5 .",
        "label": "NA"
    },
    {
        "text": "the concomitant use of DB02325 or other HD00389 may have an additive effect .",
        "label": "NA"
    },
    {
        "text": "ddrug0 diminishes the effect of DB04665 and DB00682 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : HD00401 inhibit the hypotensive effect of HD00392 .",
        "label": "effect"
    },
    {
        "text": "oral HD00062 : in one study , ddrug1 was given to adult diabetics who were already receiving DB01016 { n = 4 } , ddrug3 { n = 2 } ddrug4 with ddrug5 { n = 3 } or ddrug6 with ddrug7 { n = 6 } .",
        "label": "NA"
    },
    {
        "text": "DB00574 may increase slightly the effect of ddrug1 , e , g , , ddrug2 , ddrug3 , DB00206 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as DB00415 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , DB01601 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "coadministration of DB00311 with other HD00218 , ddrug2 , and ddrug3 may cause hypokalemia .",
        "label": "effect"
    },
    {
        "text": "taking a HD00593 while you are taking or within # weeks of taking HD00343 may increase the risk of central nervous system depression or may cause a severe high blood pressure reaction .",
        "label": "effect"
    },
    {
        "text": "ventricular tachycardia induced by ddrug0 was generally converted to sinus rhythm following administration of ddrug1 , ddrug2 , or ddrug3 but not after administration of HD00120 alone or after DB00312 .",
        "label": "NA"
    },
    {
        "text": "initial doses of HD00852 , such as DB00988 or ddrug2 , should be reduced and titrated to achieve the desired response .",
        "label": "NA"
    },
    {
        "text": "HD00216 , ddrug1 HD00401 may enhance the activity of ddrug3 or ddrug4 ;",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 : DB00673 , when given once daily for # days as a 100-mg capsule with an oral HD00349 containing # mcg of ddrug3 and # mg of ddrug4 , decreased the auc of ddrug5 by 43 % , and decreased the auc of ddrug6 by 8 % ;",
        "label": "NA"
    },
    {
        "text": "additive cns depression may occur when HD00388 are administered concomitantly with other HD00261 including ddrug2 , ddrug3 , and ddrug4 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 { cns } drugs including ddrug1 , ddrug2 , ddrug3 , ddrug4 , blood pressure medications { DB00206 , ddrug6 , ddrug7 } , motion sickness medications , ddrug8 , ddrug9 , HD00024 , sleeping pills and ddrug11",
        "label": "NA"
    },
    {
        "text": "- drugs that may decrease plasma DB00252 concentrations include : DB00564 , chronic ddrug2 abuse , ddrug3",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : acute pulmonary toxicity has been reported in patients receiving intravenous DB00681 and HD00321 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 HD00524 may delay or reduce the absorption of concomitant oral medication such as ddrug2 , ddrug3 , ddrug4 { acidic } or ddrug5 { basic } , as well as ddrug6 ddrug7 , DB01174 , thyroid and ddrug9 preparations , ddrug10 and ddrug11 , and ddrug12 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration of ddrug1 { using an experimental soft-gelatin capsule formulation of DB01232 1200 mg } with ddrug3 resulted in an 18 % increase in DB00220 plasma auc and a 4-fold increase in ddrug5 plasma a , c.",
        "label": "NA"
    },
    {
        "text": "as with other HD00366 , the antihypertensive effect of DB00678 may be blunted by the ddrug2 ddrug3",
        "label": "NA"
    },
    {
        "text": "this drug may interact with ddrug0 or other HD00261 { may potentiate the cns depressant effects of either these medications or ddrug2 } , ddrug3 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with HD00388 } , and ddrug5 { concurrent use with ddrug6 may prolong and intensify the anticholinergic and cns depressant effects of ddrug7 } .",
        "label": "NA"
    },
    {
        "text": "because ddrug0 binds bile acids , DB01432 ddrug2 may interfere with normal fat digestion and absorption and thus may prevent absorption of HD00465 such as a , d , e , and k.",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 DB00811 can antagonize the in vitro antiviral activity of ddrug3 and DB00495 against hiv .",
        "label": "effect"
    },
    {
        "text": "however , in a well-controlled study of patients with lymphoma on combination therapy , ddrug0 did not increase the marrow toxicity of patients treated with ddrug1 , ddrug2 , DB00290 , ddrug4 and/or DB00888 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - and/or ddrug1 - containing ddrug2 , products containing ddrug3 { ddrug4 } , ddrug5 containing ddrug6 or other metal cations , or DB00900 { ddrug8 } chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after DB01155 .",
        "label": "advise"
    },
    {
        "text": "several HD00043 have been reported to block the pharmacologic effects of ddrug1 , DB00575 , or similar agents , and such an effect may be anticipated with ddrug3 because of its structural similarity to other ddrug4 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : ddrug1 coadministration leads to an increased peak plasma concentration and auc of DB00604 , there is no effect on ddrug3 absorption when it is coadministered with DB00863 .",
        "label": "NA"
    },
    {
        "text": "coadministration of DB00969 and strong cyp3a4 inhibitors , such as ddrug1 , ddrug2 , ddrug3 , DB00582 , and ddrug5 has not been evaluated but should be undertaken with caution because of similar potential drug interactions .",
        "label": "advise"
    },
    {
        "text": "to determine whether DB01032 has a direct effect on the distribution of DB01147 , the elimination and distribution of ddrug2 was studied in six patients , five lacking kidney function and one with a partially impaired renal function , in the presence or absence of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of ddrug0 are the following : DB00515 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 { 2 } , ddrug7 , ddrug8 , and ddrug9 thus , if a patient has been titrated to a stable dosage on HD00472 , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for ddrug11 may be necessary .",
        "label": "NA"
    },
    {
        "text": "- ddrug0 { e , g , , ddrug1 , HD00898 } use of DB00891 with these medicines may increase the chance of side effects affecting the blood",
        "label": "NA"
    },
    {
        "text": "the authors examined the effect of the cyclooxygenase-2 { cox-2 } inhibitor , DB00533 , at steady state on the pharmacokinetics of DB00390 following a single dose in healthy subjects .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : no significant differences were observed in the steady-state pharmacokinetics of DB08496 or DB14055 with the addition of ddrug3 given as a single dose .",
        "label": "NA"
    },
    {
        "text": "DB00334 , a HD00107 , is a ddrug2 which has proven efficacy against the positive and negative symptoms of schizophrenia .",
        "label": "NA"
    },
    {
        "text": "these medications have included ddrug0 , ddrug1 , ddrug2 , HD00208 , ddrug4 , intravenous and oral DB14049 , ddrug6 , and ddrug7 .",
        "label": "NA"
    },
    {
        "text": "other concomitant therapy although specific interaction studies were not performed , DB01216 doses of # mg or more were concomitantly used in clinical studies with ddrug1 , ddrug2 , a-blockers , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , cardiac ddrug9 , ddrug10 , ddrug11 , HD00095 , ddrug13 { also referred to as ddrug14 } , and ddrug15 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { e , g , , DB00421 , ddrug2 , or ddrug3 } , ddrug4 supplements , or DB14500 - containing salt substitutes may lead to significant increases in serum potassium .",
        "label": "NA"
    },
    {
        "text": "therefore , it is theoretically possible that DB00448 may interfere with the absorption of drugs where gastric ph is an important determinant of bioavailability { e , g , ddrug1 , DB00415 esters , ddrug3 salts , ddrug4 } .",
        "label": "mechanism"
    },
    {
        "text": "the administration of local ddrug0 containing DB00668 or ddrug2 to patients receiving HD00275 , ddrug4 or ddrug5 may produce severe , prolonged hypotension or hypertension .",
        "label": "effect"
    },
    {
        "text": "co-administration of DB09026 did not significantly affect the pharmacokinetics of ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , DB00178 or ddrug10 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 can interact with ddrug1 or other HD00261 { may potentiate the cns depressant effects of either these medications or ddrug3 } , ddrug4 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug5 } , and ddrug6 { concurrent use with ddrug7 may prolong and intensify the anticholinergic and cns depressant effects of HD00388 } .",
        "label": "NA"
    },
    {
        "text": "- ddrug0 { e , g , , DB00252 } use of ddrug2 with DB00891 may increase the chance of side effects affecting the liver and/or the side effects of ddrug4",
        "label": "NA"
    },
    {
        "text": "may interact with thyroid medication { e , g , , ddrug0 } , ddrug1 - containing products , HD00374 , ddrug3 { e , g , , ddrug4 , ddrug5 } , and ddrug6 { e , g , , ddrug7 , DB00338 } .",
        "label": "NA"
    },
    {
        "text": "no dose adjustment is necessary when DB00074 is added to triple-immunosuppression regimens including ddrug1 , ddrug2 , and either DB00993 or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "coadministration of DB00224 and other drugs that inhibit cyp3a4 may decrease the clearance of DB00224 and may result in increased plasma concentrations of ddrug2 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { DB00421 , ddrug2 , ddrug3 , and others } or DB14500 supplements can increase the risk of hyperkalemia .",
        "label": "NA"
    },
    {
        "text": "DB01032 or ddrug1 : concomitant administration of ddrug2 or ddrug3 decreases the elimination of ddrug4 , most likely by inhibition of renal tubular secretion of DB00943 .",
        "label": "NA"
    },
    {
        "text": "when ddrug0 is co-administered with inducers of drug clearance , such as ddrug1 , DB00238 , ddrug3 , ddrug4 , or ddrug5 , use of a daily dose of # mg of DB00520 should be considered",
        "label": "NA"
    },
    {
        "text": "a two-way interaction between the HD00705 , ddrug1 , and the HD00422 s has been suggested .",
        "label": "int"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , HD00002 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { DB00400 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , DB01026 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , DB00295 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "DB00199 has been reported to decrease the clearance of DB00897 and ddrug2 and thus may increase the pharmacologic effect of these ddrug3 .",
        "label": "mechanism"
    },
    {
        "text": "DB00390 , ddrug1 , ddrug2 : ddrug3 , like other HD00203 , may affect renal prostaglandins and increase the toxicity of certain drugs .",
        "label": "NA"
    },
    {
        "text": "the concomitant use of transdermal DB00813 with ddrug1 or other potent 3a4 inhibitors such as ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB00220 , and nefazadone may result in an increase in ddrug7 plasma concentrations .",
        "label": "mechanism"
    },
    {
        "text": "similarly , DB00731 had no influence on the serum protein binding of ddrug1 , ddrug2 , DB00622 , ddrug4 , ddrug5 , ddrug6 , and ddrug7 in vitro .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00672 s plasma half-life may be prolonged by ddrug2 , since DB00437 and ddrug4 may compete for excretion in the renal tubule .",
        "label": "NA"
    },
    {
        "text": "drugs that should not be coadministered with DB00220 HD00303 : ddrug2 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "label": "advise"
    },
    {
        "text": "ddrug0 : DB01026 may inhibit both synthetic and catabolic enzymes of DB11094 .",
        "label": "mechanism"
    },
    {
        "text": "the effects of HD00018 and ddrug1 upon DB03575 { ddrug3 } - induced locomotion and behavioral changes in mice .",
        "label": "NA"
    },
    {
        "text": "the concentrations of HD00413 , the active metabolite of ddrug1 , were on average 33 % higher in patients receiving bolus-ifl in combination with DB00112 when compared with bolus-ifl alone .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { DB01167 } ddrug13 { ddrug14 } DB01235 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "DB00501 - in subjects who had received # days of # mg/day racemic ddrug1 , combined administration of # mg/day ddrug2 for # days resulted in an increase in DB00215 auc and cmax of 43 % and 39 % , respectively .",
        "label": "NA"
    },
    {
        "text": "DB01026 : co-administration of ddrug1 # mg b , i , d , and ddrug2 , a potent cyp3a4 inhibitor , increased the plasma concentrations of DB00559 by approximately 2-fold .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00564 causes an approximate 50 % increase in the clearance of DB00949 at steady state and , therefore , the addition of ddrug3 results in an approximate 40 % decrease in the steady-state trough concentrations of ddrug4 as compared to the same dose of ddrug5 given as monotherapy .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 / ddrug1 : the coadministration of ddrug2 or ddrug3 will not affect plasma concentrations of DB11094 , but may reduce endogenous plasma levels of DB00136 / ergocalcitriol by accelerating metabolism .",
        "label": "NA"
    },
    {
        "text": "until further data are developed regarding drug interactions when DB00207 and these drugs are used concomitantly , careful monitoring of patients is advised : DB00390 elevated ddrug2 concentrations .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , DB01086 and ddrug7 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , HD00029 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "although it has not been established that there is an interaction between ddrug0 and ddrug1 or other ddrug2 , caution is advised when ddrug3 is initiated in patients taking a DB12537 or any other HD00564 .",
        "label": "NA"
    },
    {
        "text": "antiacid , ddrug0 , ddrug1 , ddrug2 , ddrug3 , indanavir , DB01026 , ddrug5 , phenobarbitol , ddrug6 , ddrug7 , ddrug8 , ritanovir , DB01232 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with ddrug1 , ddrug2 s , ddrug3 { allergy , cold , and sinus medicines } , diabetic drugs , DB14507 , ddrug5 , ddrug6 like DB00788 or ddrug8 , and high blood pressure medications .",
        "label": "NA"
    },
    {
        "text": "drug-drug interactions between DB01202 and other ddrug1 { HD00714 } ddrug3 ddrug4 { 3000 mg daily } had no effect on the pharmacokinetic disposition of ddrug5 in patients with refractory epilepsy .",
        "label": "NA"
    },
    {
        "text": "in an analysis of the supraventricular arrhythmia and diamond patient populations , the concomitant administration of DB00661 with DB00204 was associated with a higher occurrence of torsade de pointes .",
        "label": "effect"
    },
    {
        "text": "ddrug0 containing DB09281 , when administered concomitantly with DB00698 , reduce both the rate and extent of absorption .",
        "label": "mechanism"
    },
    {
        "text": "DB00026 : concurrent administration of ddrug1 { an HD00241 } and another ddrug3 has been associated with an increased risk of serious infections , an increased risk of neutropenia and no additional benefit compared to these medicinal products alone .",
        "label": "NA"
    },
    {
        "text": "interactions may also occur with the following : HD00515 / ddrug1 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , DB14507 , ddrug11 pain medication { e , g , , ddrug12 } , drugs used to aid sleep , drowsiness-causing ddrug13 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "may interact with thyroid medication { e , g , , ddrug0 } , ddrug1 - containing products , ddrug2 , ddrug3 { e , g , , DB00927 , ddrug5 } , and ddrug6 { e , g , , ddrug7 , DB00338 } .",
        "label": "NA"
    },
    {
        "text": "effects of DB00949 on low-dose ddrug1 a group of # nonsmoking , healthy white female volunteers established on an oral ddrug2 regimen containing # mg ddrug3 and # mg ddrug4 for at least # months received # mg/day of ddrug5 from midcycle { day 15 } to midcycle { day 14 } of two consecutive oral HD00349 cycles .",
        "label": "NA"
    },
    {
        "text": "the concomitant administration of DB00400 has been reported to reduce the efficacy of oral HD00283 and to increase the incidence of breakthrough bleeding .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with ddrug1 , ddrug2 s , ddrug3 { allergy , cold , and sinus medicines } , diabetic drugs , ddrug4 , DB00368 , ddrug6 like ddrug7 or DB01050 , and high blood pressure medications .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 { congestive heart failure post-myocardial infarction } - in ephesus , # { 91 % } patients receiving DB00700 # to # mg also received HD00106 or ddrug4 { ddrug5 / ddrug6 } .",
        "label": "NA"
    },
    {
        "text": "DB00363 may potentiate the hypotensive effects of ddrug1 and the anticholinergic effects of DB00572 - type drugs .",
        "label": "effect"
    },
    {
        "text": "when DB01092 was applied to the muscle in the presence of ddrug1 , both first and second contractile responses to HD00140 were abolished .",
        "label": "NA"
    },
    {
        "text": "the elimination half life of DB00683 and DB00897 also increased { # # fold } during coadministration with ddrug2 .",
        "label": "NA"
    },
    {
        "text": "immediate and extended release tablets the hypoglycemic action of ddrug0 may be potentiated by certain drugs including ddrug1 , some HD00768 and other drugs that are highly protein bound , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , HD00275 , and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "while it is not known whether this interaction occurs with ddrug0 other than DB01241 , myopathy and rhabdomyolysis have occasionally been associated with the use of HD00550 alone , including ddrug3 .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of DB00199 and ddrug1 has been reported to result in elevated DB00390 serum levels .",
        "label": "NA"
    },
    {
        "text": "toxicology studies of DB01452 - related deaths reveal frequent involvement of other ddrug1 , including ddrug2 , ddrug3 such as ddrug4 { ddrug5 } , and , to a rising degree , DB00333 .",
        "label": "effect"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } HD00220 DB00472 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "concurrent administration of HD00450 { for the treatment of hypotension related to obstetric blocks } and HD00451 may cause severe , persistent hypertension or cerebrovascular accidents .",
        "label": "effect"
    },
    {
        "text": "ddrug0 - ddrug1 containing side chains of n-methylthiotetrazole { ddrug2 , ddrug3 , ddrug4 , DB01326 , ddrug6 } or methylthiadiazole { DB01327 } can cause vitamin_k_deficiency and hypoprothrombinemia .",
        "label": "NA"
    },
    {
        "text": "DB00522 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , DB01035 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "int"
    },
    {
        "text": "DB01432 - concomitant intake of ddrug1 and ddrug2 may reduce the absorption of DB01022 .",
        "label": "NA"
    },
    {
        "text": "- ddrug0 , oral { diabetes medicine you take by mouth } use of oral ddrug1 with DB00891 may increase the chance of side effects affecting the blood and/or the side effects or oral HD00899",
        "label": "NA"
    },
    {
        "text": "HD00175 and ddrug1 { DB01285 } : may potentiate ddrug3 - induced hypokalemia which may predispose the patient to cardiac dysfunction .",
        "label": "NA"
    },
    {
        "text": "consider additive sedative effects and confusional states to emerge , if ddrug0 is given with HD00100 or HD00521 .",
        "label": "NA"
    },
    {
        "text": "although ddrug0 have been shown to reduce ddrug1 - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with DB00041 may reduce the antitumor effectiveness of ddrug3 and thus should be avoided , # ddrug4 and other HD00255 may potentiate the hypotension seen with ddrug6 .",
        "label": "NA"
    },
    {
        "text": "because of the low dietary DB14574 concentration as compared to the ddrug1 contents of the diets , no effect of ddrug2 on DB01592 absorption and excretion occurred .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 - pectin , ddrug2 , ddrug3 , DB01432 , certain anticancer drugs , and ddrug5 may interfere with intestinal DB00390 absorption , resulting in unexpectedly low serum concentrations .",
        "label": "mechanism"
    },
    {
        "text": "DB00186 : coadministration of single doses of DB00402 # mg and ddrug2 # mg did not have clinically relevant effects on the pharmacodynamics or pharmacokinetics of either drug .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : as with other HD00203 , concomitant administration of ddrug2 and DB00945 is not generally recommended because of the potential of increased adverse effects .",
        "label": "advise"
    },
    {
        "text": "ddrug0 / HD00214 : ddrug2 , DB00683 contraindicated due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression .",
        "label": "NA"
    },
    {
        "text": "ddrug0 s : ddrug1 should be administered at least # hours after or # hours before dosing with ddrug2 because plasma concentrations of ddrug3 are decreased when administered with HD00374 containing DB14513 , ddrug6 , or ddrug7 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the concomitant use of DB00813 { ddrug2 transdermal system } with other ddrug3 , including but not limited to other ddrug4 , ddrug5 , HD00214 , ddrug7 { e , g , , ddrug8 } , general ddrug9 , ddrug10 , ddrug11 , and ddrug12 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .",
        "label": "effect"
    },
    {
        "text": "infusion requirements of ddrug0 in patients administered DB00202 prior to infusions of DB00565 were comparable to or slightly greater than when ddrug3 was not administered .",
        "label": "effect"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , ddrug3 HD00388 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 DB00683 , ddrug12 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "pre-treatment with the cyp3a4 inducer DB01045 decreased DB00530 auc by about 2/3 .",
        "label": "mechanism"
    },
    {
        "text": "although the clinical significance is not known , it is not recommended that DB01066 be taken concomitantly with HD00492 .",
        "label": "NA"
    },
    {
        "text": "the objective of this study was to determine if there is a pharmacokinetic interaction when DB00701 is given with DB00615 or ddrug2 and to determine the effects of these drugs on the erythromycin breath test { ermbt } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the risk of myopathy/rhabdomyolysis is increased by concomitant administration of DB01406 particularly with higher doses of DB00227 { see warnings , myopathy/rhabdomyolysis } .",
        "label": "effect"
    },
    {
        "text": "in some patients , this may lead to reduced clearance , prolongation of plasma half-life , and enhanced effects of DB00201 and DB01412 .",
        "label": "NA"
    },
    {
        "text": "treatment with DB00494 coadministered with ddrug1 / HD00680 does not change these effects .",
        "label": "NA"
    },
    {
        "text": "drug interactions with HD00374 administration of # mg of DB00950 { 2 x # mg capsule } within # minutes of an ddrug2 and ddrug3 containing ddrug4 { ddrug5 } decreased ddrug6 auc by 41 % and cmax by 43 % .",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , ddrug3 , or ddrug4 , with ddrug5 , with metal cations such as ddrug6 , or with ddrug7 containing ddrug8 or DB01593 , or with formulations containing divalent and trivalent cations such as ddrug10 { DB00900 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "DB00334 , a ddrug1 , is a HD00108 which has proven efficacy against the positive and negative symptoms of schizophrenia .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00949 causes a decrease in the steady-state ddrug2 plasma concentrations and an increase in the steady-state HD00716 plasma concentration .",
        "label": "NA"
    },
    {
        "text": "therefore , it is recommended that DB00176 tablets not be used in combination with HD00546 , or within # days of discontinuing treatment with a ddrug2 .",
        "label": "advise"
    },
    {
        "text": "DB00949 treatment resulted in a 42 % decrease in the DB06730 auc 0 - 24 , but no clinically relevant effect was observed on the pharmacokinetic parameters of ddrug2 .",
        "label": "mechanism"
    },
    {
        "text": "HD00282 : in a pharmacokinetic study , maximum plasma concentrations of DB01023 were considerably lower in epileptic patients on long-term ddrug2 therapy { eg , ddrug3 , ddrug4 , or ddrug5 } than in healthy volunteers .",
        "label": "NA"
    },
    {
        "text": "thus , the results suggest that HD00044 exposure of rats results in free radical-mediated tissue damage , as indicated by elevated cerebral and hepatic lipid peroxidation , which was prevented by ddrug1 and DB00163 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 , HD00388 , ddrug2 , ddrug3 , HD00118 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : concomitant administration of HD00374 containing ddrug2 or ddrug3 with DB00900 chewable/dispersible buffered tablets or pediatric powder for oral solution may potentiate adverse events associated with the ddrug5 components .",
        "label": "effect"
    },
    {
        "text": "in patients with chronic hepatitis c treated with ddrug0 in combination with DB00811 , ddrug2 treatment did not affect DB00811 distribution or clearance .",
        "label": "NA"
    },
    {
        "text": "two percent of patients treated concurrently with DB00026 and DB00005 developed neutropenia { anc # x 109/l } .",
        "label": "effect"
    },
    {
        "text": "HD00388 may have additive effects with ddrug1 and other ddrug2 , e , g , , HD00214 , ddrug4 , ddrug5 , ddrug6 .",
        "label": "effect"
    },
    {
        "text": "before taking DB00222 , tell your doctor if you are taking any of the following medicines : - ddrug1 or another ddrug2 such as ddrug3 { ddrug4 } , ddrug5 { ddrug6 , others } , ddrug7 { HD00757 } , ddrug9 { ddrug10 } , or ddrug11 { ddrug12 } ;",
        "label": "advise"
    },
    {
        "text": "drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on ddrug0 therapy : ddrug1 , HD00175 , ddrug3 , oral ddrug4 containing ddrug5 , DB11119 - containing preparations and the numerous preparations containing ddrug7 .",
        "label": "NA"
    },
    {
        "text": "co-administration of multiple doses of # mg of ddrug0 had no effect on the single dose pharmacokinetics of HD00832 and HD00833 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 enhance the renal toxicity of ddrug1 in animals , # HD00663 interferes with the action of ddrug3 preparations by chelating the DB01593 , 7",
        "label": "NA"
    },
    {
        "text": "patients already stabilized on DB00580 should be closely monitored for loss of symptom control with DB00252 coadministration .",
        "label": "advise"
    },
    {
        "text": "may interact with the following : ddrug0 , DB00375 { use with HD00029 may prevent the ddrug3 from working properly ;",
        "label": "effect"
    },
    {
        "text": "other HD00093 , such as DB00199 , have not been studied in combination with ddrug2 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : a literature article reported that when a 60-mg controlled-release ddrug1 capsule was administered # hours prior to a 600-mg DB00996 capsule { n = 12 } , mean ddrug3 auc increased by 44 % compared to ddrug4 administered without DB00295 .",
        "label": "NA"
    },
    {
        "text": "DB00520 reduced the blood auc0 - 12 of DB00864 by approximately 20 % , peak blood concentration { cmax } by 16 % , and 12-hour blood concentration { c12hr } by 26 % in healthy subjects when ddrug2 { 2 doses of # mg/kg # hours apart } was administered on the 10th day of ddrug3 # mg daily , as compared to results from a control period in which ddrug4 was administered alone .",
        "label": "mechanism"
    },
    {
        "text": "drug interactions : the central ddrug0 syndrome can occur when anticholinergic agents such as DB00810 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain ddrug2 such as ddrug3 , the ddrug4 and other ddrug5 , ddrug6 , certain HD00303 such as the ddrug8 salts , and ddrug9 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 , ddrug1 : in normal volunteers { n = 9 } , pretreatment with DB00501 or ddrug3 did not affect DB00712 pharmacokinetics except that a small { 13 % } but statistically significant increase in the area under the serum concentration curve of ddrug5 resulted with ddrug6 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB11094 dosage must be determined with care in patients undergoing treatment with HD00118 , as hypercalcemia in such patients may precipitate cardiac arrhythmias .",
        "label": "advise"
    },
    {
        "text": "if concomitant treatment with DB00669 and an ddrug1 { e , g , , ddrug2 , DB00176 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } is clinically warranted , appropriate observation of the patient is advised .",
        "label": "advise"
    },
    {
        "text": "as with other ddrug0 , if ddrug1 is to be administered orally with HD00377 of the ddrug3 or DB00343 type , it is recommended that ecg and blood pressure be monitored .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 is known to slow the metabolism of DB00564 and increase its serum levels ddrug3 levels should be determined prior to concurrent administration with ddrug4 , signs and symptoms of ddrug5 toxicity should be monitored closely , and appropriate dosage adjustment of the HD00329 should be made .",
        "label": "NA"
    },
    {
        "text": "due to their similar mechanism of action , it is expected that the neuromuscular blockade produced by any of the HD00894 could be prolonged in the presence of DB00319 .",
        "label": "effect"
    },
    {
        "text": "DB00284 may affect ddrug1 bioavailabillty and may require dose adjustment of DB00390 by 16 % { 90 % confidence interval : 8 - 23 % } , decrease mean c max ddrug3 by 26 % { 90 % confidence interval : 16 - 34 % } and decrease mean trough concentrations of ddrug4 by 9 % { 90 % confidence limit : 19 % decrease to 2 % increase } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 may enhance the effects of : other ddrug3 s , ddrug4 , general ddrug5 , HD00262 such as ddrug7 , ddrug8 , or other HD00261 , causing increased cns depression .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , DB00364 , metal cations , ddrug2 HD00532 form chelates with alkaline earth and transition metal cations .",
        "label": "NA"
    },
    {
        "text": "concomitant medications were grouped as ddrug0 , oral ddrug1 , ddrug2 , ddrug3 , HD00345 , inducers of cyp3a4 , substrates and inhibitors of cyp3a4 , substrates and inhibitors of p-glycoprotein , ddrug5 , ddrug6 , HD00105 , ddrug8 , ddrug9 , substrates and inhibitors of tubular organic cation transport , and qtc-prolonging drugs .",
        "label": "NA"
    },
    {
        "text": "these increased exposures of ddrug0 and DB00977 should be taken into consideration when selecting an oral ddrug2 for women taking DB00580 .",
        "label": "NA"
    },
    {
        "text": "HD00043 have been reported to blunt the hypotensive effect of systemic DB00575 .",
        "label": "effect"
    },
    {
        "text": "drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on ddrug0 therapy : HD00657 , HD00175 , ddrug3 , oral ddrug4 containing ddrug5 , ddrug6 - containing preparations and the numerous preparations containing ddrug7 .",
        "label": "NA"
    },
    {
        "text": "the following drug interactions have been identified involving ddrug0 tablets and other drugs metabolized by the cyp3a4 enzyme system : DB01026 tablets inhibit the metabolism of DB00342 , resulting in an increased plasma concentration of ddrug3 and a delay in the elimination of its acid metabolite .",
        "label": "mechanism"
    },
    {
        "text": "oral ddrug0 : coadministration of ddrug1 and an oral ddrug2 increased auc values for DB00717 and DB00977 by approximately 30 % and 20 % .",
        "label": "NA"
    },
    {
        "text": "absorption of ddrug0 is impaired by ddrug1 containing ddrug2 , ddrug3 , or DB14513 , and DB01592 - containing preparations .",
        "label": "NA"
    },
    {
        "text": "when DB00682 is co-administered with DB00238 , anticoagulation levels should be monitored frequently .",
        "label": "advise"
    },
    {
        "text": "ddrug0 is contraindicated in patients using HD00102 or who may need to use HD00103 , because the combination may cause a sharp fall of the blood pressure .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : concomitant administration of DB00080 { 6 mg/kg once every # hours for # days } and DB00682 { 25 mg single oral dose } had no significant effect on the pharmacokinetics of either drug , and the inr was not significantly altered .",
        "label": "NA"
    },
    {
        "text": "in addition , results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance { ddrug0 , ddrug1 , ddrug2 , ddrug3 , or DB00564 } with DB00520 may result in clinically meaningful reductions in ddrug6 concentrations .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 / ddrug1 : the coadministration of ddrug2 or DB01174 will not affect plasma concentrations of DB11094 , but may reduce endogenous plasma levels of ddrug5 / ergocalcitriol by accelerating metabolism .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , DB00636 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , DB00295 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "DB01432 ddrug1 may delay or reduce the absorption of concomitant oral medication such as ddrug2 , ddrug3 , ddrug4 { acidic } or ddrug5 { basic } , as well as ddrug6 ddrug7 , ddrug8 , thyroid and ddrug9 preparations , ddrug10 and ddrug11 , and HD00118 .",
        "label": "mechanism"
    },
    {
        "text": "if DB01239 is given concomitantly with ddrug1 , the ddrug2 dose should be reduced { by approx , 50 % } , because ddrug3 amplifies the therapeutic actions and side-effects of HD00263 massively .",
        "label": "NA"
    },
    {
        "text": "HD00024 / HD00214 : ddrug2 , ddrug3 contraindicated due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression .",
        "label": "NA"
    },
    {
        "text": "effects of DB00949 on low-dose ddrug1 a group of # nonsmoking , healthy white female volunteers established on an oral ddrug2 regimen containing # mg ddrug3 and # mg DB06730 for at least # months received # mg/day of ddrug5 from midcycle { day 15 } to midcycle { day 14 } of two consecutive oral ddrug6 cycles .",
        "label": "NA"
    },
    {
        "text": "rarely HD00372 toxicity may occur in patients who discontinue HD00356 after concurrent high-dose ddrug2 therapy .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a study in healthy volunteers , a six-day course of DB01045 at # mg/day followed by a single # mg dose of ddrug2 resulted in a reduction in DB00270 levels to below detectable limits .",
        "label": "NA"
    },
    {
        "text": "other concomitant therapies : in clinical trials , the safety profile in subjects treated with DB00659 concomitantly with ddrug1 , HD00214 and ddrug3 { including ddrug4 } , or ddrug5 was similar to that of subjects taking placebo with these concomitant medications .",
        "label": "NA"
    },
    {
        "text": "to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma { hiv-nhl } , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the ddrug0 , ddrug1 , ddrug2 , and DB00898 { chop } chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen { i , e , , ddrug4 , DB00997 , ddrug6 , and ddrug7 with ddrug8 plus ddrug9 } without receiving ddrug10 therapy .",
        "label": "NA"
    },
    {
        "text": "HD00409 and HD00408 could exaggerate the prolongation of the qt interval observed with ddrug2 .",
        "label": "NA"
    },
    {
        "text": "no depressant effect on blood levels in humans was noted when DB00375 was administered with any of the following drugs : ddrug1 , DB01190 , ddrug3 , ddrug4 , ddrug5 { ddrug6 } , ddrug7 , ddrug8 or ddrug9 .",
        "label": "NA"
    },
    {
        "text": "the co-administration of DB04899 with iv ddrug1 such as ddrug2 , ddrug3 , DB00235 , or iv ddrug5 has not been evaluated { these drugs were not co-administered with ddrug6 in clinical trials } .",
        "label": "NA"
    },
    {
        "text": "the HD00100 , including ddrug1 , produce additive cns depressant effects when co-administered with other ddrug2 , HD00282 , ddrug4 , ddrug5 , and other drugs which themselves produce cns depression .",
        "label": "effect"
    },
    {
        "text": "the intensity , uniformity and time course of HD00025 interference by DB01174 , ddrug2 , ddrug3 , ddrug4 and ddrug5 were systematically investigated in # patients receiving ddrug6 therapy .",
        "label": "NA"
    },
    {
        "text": "because of the possible additive effects of drugs that may depress the nervous system , ddrug0 or DB00897 should be used cautiously in combination with DB00906 .",
        "label": "advise"
    },
    {
        "text": "although specific drug interaction studies have not been conducted with DB00484 , the possibility of an additive or potentiating effect with HD00261 { ddrug2 , ddrug3 , ddrug4 , ddrug5 , or ddrug6 } should be considered .",
        "label": "advise"
    },
    {
        "text": "in clinical trials , DB01240 was used with ddrug1 , ddrug2 , ddrug3 , oral ddrug4 , and supplemental ddrug5 , in a pharmacokinetic substudy in patients with congestive heart failure receiving ddrug6 or ddrug7 in whom therapy with ddrug8 was initiated , apparent oral clearance values for DB00695 { n = 23 } and ddrug10 { n = 30 } were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .",
        "label": "NA"
    },
    {
        "text": "because ddrug0 may enhance the serotonergic effects of DB01175 , caution should be exercised when ddrug2 and DB14507 are coadministered .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , DB00529 , and ddrug2 : drugs such as HD00795 , ddrug4 , and ddrug5 may increase the risk of developing peripheral_neuropathies or other ddrug6 - associated adverse events by interfering with the renal clearance of ddrug7 { thereby raising systemic exposure } .",
        "label": "NA"
    },
    {
        "text": "again , DB01104 neutralized the increase in glycemia after DB09341 overload both in diabetic and non-diabetic rats .",
        "label": "NA"
    },
    {
        "text": "drug/laboratory test interferences : DB00266 and ddrug1 , including DB01125 , or their metabolites may color alkaline urine red-orange , which may interfere with spectrophotometrically determined urinary laboratory tests .",
        "label": "NA"
    },
    {
        "text": "the plasma concentration of ddrug0 may increase when the drug is given concomitantly with hepatic enzyme inhibitors { e , g , , ddrug1 , DB00472 } and decrease by concomitant administration of hepatic enzyme inducers { e , g , , ddrug3 , DB00252 } , and adjustment of the dosage of ddrug5 may therefore be necessary .",
        "label": "NA"
    },
    {
        "text": "a study in eight healthy volunteers has shown a 50 % increase in mean peak ddrug0 plasma concentrations and a 90 % increase in mean area under the curve , after a one week course of DB00501 at 1,000 mg/day and DB00393 at # mg/day .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 , a HD00731 , has been reported to inactivate the antifungal activity of DB01099 by competitive inhibition .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , DB00091 } , hiv drugs classified as ddrug24 { ddrug25 , DB00224 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "immediate and extended release tablets the hypoglycemic action of ddrug0 may be potentiated by certain drugs including HD00518 , some HD00768 and other drugs that are highly protein bound , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 : ddrug1 , when given once daily for # days as a 100-mg capsule with an oral ddrug2 containing # mcg of DB00977 and # mg of ddrug4 , decreased the auc of ddrug5 by 43 % , and decreased the auc of DB00717 by 8 % ;",
        "label": "NA"
    },
    {
        "text": "DB00501 increased the auc of DB00445 by 50 % .",
        "label": "mechanism"
    },
    {
        "text": "the ratios of the aucs of unbound ddrug0 to the aucs of the total DB00313 were # % , # % , and # % , with coadministration of 0 , 1200 , and # mg/day of DB00949 , respectively .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { cns } drugs including DB02325 , ddrug2 , ddrug3 , ddrug4 , blood pressure medications { ddrug5 , ddrug6 , ddrug7 } , motion sickness medications , ddrug8 , HD00543 , ddrug10 , sleeping pills and ddrug11",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , DB01026 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , DB01601 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "HD00343 : ddrug1 , as well as a metabolite of DB00614 , slow ddrug3 metabolism .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00227 , DB00641 warning potential for serious reactions such as risk of myopathy including rhabdomyolysis .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 interaction studies with ddrug1 and DB01418 failed to identify any clinically important effects on the serum concentrations or clinical effects of these HD00326 .",
        "label": "NA"
    },
    {
        "text": "therefore , when DB01109 is given with DB00266 or ddrug2 , a period of at least # hours after the last intravenous dose or # hours after the last subcutaneous dose should elapse before blood is drawn if a valid prothrombin time is to be obtained .",
        "label": "advise"
    },
    {
        "text": "in clinical trials in patients undergoing ptca/pci , co-administration of DB00006 with DB01109 , ddrug2 , ddrug3 or glycoprotein iib/iiia inhibitors was associated with increased risks of major bleeding events compared to patients not receiving these concomitant medications .",
        "label": "effect"
    },
    {
        "text": "other strong selective cyp3a4 inhibitors such as DB01026 can also be expected to increase the exposure of DB00962 .",
        "label": "mechanism"
    },
    {
        "text": "drugs that reduce the number of blood platelets by causing bone marrow depression { such as ddrug0 } or drugs which inhibit platelet function { eg , ddrug1 and other ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB09255 } may increase the bleeding tendency produced by HD00326 without altering prothrombin time determinations .",
        "label": "effect"
    },
    {
        "text": "in contrast , in isolated single pancreatic acinar cells , HD00054 had no effect on HD00053 - induced responses .",
        "label": "NA"
    },
    {
        "text": "in the large , placebo-controlled osteoporosis treatment study , DB00945 and HD00233 were taken by 62 % of the # patients .",
        "label": "NA"
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma DB00252 concentrations include : acute ddrug1 intake , ddrug2 , chboramphenicol , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , HD00613 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 to healthy volunteers under steady-state conditions had no relevant effect on either drug s bioavailability , auc and cmax , differences were 20 % between ddrug1 given singly and in combination with ddrug2 , and between DB00571 given singly and in combination with DB00270 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , DB00091 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { DB00701 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "DB01234 and ddrug1 similarly inhibit and stimulate HD00148 - or ddrug3 - induced proliferation of prostatic epithelium .",
        "label": "effect"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { ddrug1 s } , ddrug2 , ddrug3 { ddrug4 may decrease the effects of these medicines } , ddrug5 { using these medicines with ddrug6 may result in increased cns depressant effects } , ddrug7 , ddrug8 { using these medicines with ddrug9 may change the amount of either medicine that you need to take } , and oral HD00283 containing ddrug11 { HD00026 may decrease the effectiveness of these oral ddrug13 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "in patients receiving nonselective ddrug0 { HD00546 } { e , g , , ddrug2 } in combination with HD00603 { e , g , , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 } , there have been reports of serious , sometimes fatal , reactions .",
        "label": "effect"
    },
    {
        "text": "cyclosporine , digoxin , methotrexate DB00749 , like other ddrug1 , through effects on renal prostaglandins , may cause changes in the elimination of these drugs leading to elevated serum levels of ddrug2 , DB00390 , ddrug4 , and increased toxicity .",
        "label": "mechanism"
    },
    {
        "text": "immediate and extended release tablets the hypoglycemic action of HD00222 may be potentiated by certain drugs including ddrug1 , some ddrug2 and other drugs that are highly protein bound , ddrug3 , ddrug4 , DB00446 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 .",
        "label": "effect"
    },
    {
        "text": "caution should be used when administering or taking DB00530 with ddrug1 and other strong cyp3a4 inhibitors such as , but not limited to , ddrug2 , DB01211 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { ddrug12 } , and ddrug13 .",
        "label": "advise"
    },
    {
        "text": "there is limited experience with concomitant ddrug0 such as ddrug1 , HD00721 , ddrug3 , and ddrug4 { both HD00722 - like and loop } .",
        "label": "NA"
    },
    {
        "text": "HD00795 , ddrug1 , and ddrug2 : drugs such as ddrug3 , ddrug4 , and HD00249 may increase the risk of developing peripheral_neuropathies or other ddrug6 - associated adverse events by interfering with the renal clearance of ddrug7 { thereby raising systemic exposure } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { DB01076 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , DB00295 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "HD00679 : drugs such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , DB00328 , ddrug6 , ddrug7 and others that interfere with platelet-aggregation reactions { the main hemostatic defense of heparinized patients } may induce bleeding and should be used with caution in patients receiving ddrug8 .",
        "label": "NA"
    },
    {
        "text": "however , since ddrug0 , ddrug1 , and ddrug2 are all associated with gastrointestinal irritation , caution should be exercised in the concomitant use of DB00945 or ddrug4 with DB00710 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 is also expected to reduce plasma concentrations of other HD00434 that have significant metabolism by cyp3a4 , such as ddrug2 and DB01076 .",
        "label": "NA"
    },
    {
        "text": "the response to HD00770 may be blunted by ddrug1 and HD00339 which cause a rise in prolactin .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : HD00203 have produced an elevation of plasma DB14507 levels and a reduction in renal ddrug3 clearance .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 , ddrug1 : HD00401 may enhance the activity of HD00351 or ddrug4 ;",
        "label": "effect"
    },
    {
        "text": "caution in using concomitant drugs such as HD00254 { ophthalmic and systemic } , HD00440 and/or ddrug2 is advised .",
        "label": "NA"
    },
    {
        "text": "concurrent administration of drugs possessing nephrotoxic { e , g , , ddrug0 , ddrug1 } , myelotoxic { e , g , , ddrug2 chemotherapy } , cardiotoxic { e , g , , ddrug3 } or hepatotoxic { e , g , , ddrug4 , DB00023 } effects with DB00041 may increase toxicity in these organ systems .",
        "label": "effect"
    },
    {
        "text": "however , co-administration of DB00476 with ddrug1 - and ddrug2 - containing ddrug3 { 51 meq } or ddrug4 with DB00927 , had no significant effect on the rate or extent of ddrug6 absorption after administration of a 40-mg oral dose .",
        "label": "NA"
    },
    {
        "text": "- a HD00766 such as ddrug1 { ddrug2 } , ddrug3 { ddrug4 , ddrug5 } , ddrug6 { ddrug7 } , ddrug8 { DB01069 } , and others ;",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of ddrug0 : ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , ddrug5 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , HD00809 , ddrug12 , ddrug13 { e , g , , in oral HD00283 } .",
        "label": "NA"
    },
    {
        "text": "concurrent use of HD00239 with oral ddrug1 may render oral HD00283 less effective .",
        "label": "NA"
    },
    {
        "text": "{ see clinical pharmacology } coadministration of ddrug0 and DB00675 # mg daily resulted in a reduction of DB01006 plasma levels by 38 % on average .",
        "label": "NA"
    },
    {
        "text": "additional reductions in blood pressure may occur when DB01240 is administered with ddrug1 , ddrug2 , or other HD00337 .",
        "label": "effect"
    },
    {
        "text": "although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of DB00964 # % ophthalmic solution , the possibility of an additive or potentiating effect with ddrug1 { ddrug2 , ddrug3 , ddrug4 , ddrug5 , HD00264 } should be considered .",
        "label": "advise"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , DB01232 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , DB00277 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of ddrug0 and DB06724 , ddrug2 , ddrug3 , or an ddrug4 / ddrug5 oral HD00349 produced minor changes in the pharmacokinetics of ddrug7 , which were considered to be without clinical significance .",
        "label": "NA"
    },
    {
        "text": "when concomitant treatment with HD00482 and ddrug1 is to be terminated , the HD00483 should be discontinued first .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { e , g , , ddrug1 , ddrug2 , ddrug3 , ddrug4 , etc , } : in vitro and animal studies with the combination of DB00681 and ddrug6 suggest that HD00319 may induce fungal resistance to ddrug8 .",
        "label": "NA"
    },
    {
        "text": "in addition , results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance { ddrug0 , ddrug1 , ddrug2 , ddrug3 , or ddrug4 } with DB00520 may result in clinically meaningful reductions in DB00520 concentrations .",
        "label": "NA"
    },
    {
        "text": "when coadministered with ddrug0 in treatment-naive patients , the recommended dose of ddrug1 is # mg with DB00503 # mg and DB00625 # mg { all once daily } .",
        "label": "NA"
    },
    {
        "text": "administration of DB00343 with ddrug1 in # healthy male subjects increased plasma DB00390 concentrations approximately 20 % .",
        "label": "NA"
    },
    {
        "text": "may interact with addictive medications , especially ddrug0 with habituating potential { prolonged concurrent use may increase the risk of habituation } , DB02325 or cns depression producing medications { concurrent use may increase the cns depressant effects of either these medications or DB01031 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - concomitant use of DB00130 and DB00052 may enhance nutrient absorption in those with severe short bowel syndrome .",
        "label": "mechanism"
    },
    {
        "text": "administration of ddrug0 with other cyp3a4 inhibitors { e , g , , ddrug1 # mg bid , DB00661 # mg qd , ddrug3 # mg tid , ddrug4 # mg qd } resulted in increases in cmax of DB00700 ranging from # - to # - fold and auc from # - to # - fold .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the effect of an ddrug1 - and ddrug2 - containing ddrug3 { HD00467 } * on the pharmacokinetics of DB01101 was investigated in # cancer patients .",
        "label": "NA"
    },
    {
        "text": "although ddrug0 have been shown to reduce ddrug1 - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with ddrug2 may reduce the antitumor effectiveness of DB00041 and thus should be avoided , # HD00254 and other ddrug5 may potentiate the hypotension seen with ddrug6 .",
        "label": "NA"
    },
    {
        "text": "strong inducers of cytochrome p450 enzymes { i , e , ddrug0 , ddrug1 and DB01174 } have been shown to decrease the plasma levels of HD00888 { 29 - 40 % } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - combined administration of a single dose of ddrug1 { 600 mg } , both a cyp3a4 substrate and a potent inhibitor of cyp3a4 , and DB01175 { 20 mg } did not affect the pharmacokinetics of either DB00503 or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "studies have shown that DB00448 does not have clinically significant interactions with other drugs metabolized by the cytochrome cyp2b6 system , such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , DB00252 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , or ddrug10 in healthy subjects .",
        "label": "NA"
    },
    {
        "text": "epidural DB00575 may prolong the duration of pharmacologic effects of epidural local HD00264 , including both sensory and motor blockade .",
        "label": "effect"
    },
    {
        "text": "HD00330 : in some patients , the administration of a HD00292 can reduce the diuretic , natriuretic , and antihypertensive effects of ddrug2 , ddrug3 and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in controlled clinical studies , HD00878 have been frequently administered concomitantly with DB00622 .",
        "label": "NA"
    },
    {
        "text": "DB00224 may not be effective due to decreased DB00224 concentrations in patients taking these agents concomitantly .",
        "label": "effect"
    },
    {
        "text": "medications can interfere with folate utilization , including : ddrug0 { such as ddrug1 , and ddrug2 } ddrug3 { sometimes prescribed to control blood sugar in type # diabetes } ddrug4 { used to control inflammation associated with crohn_disease and ulcerative colitis } ddrug5 { a HD00295 } ddrug7 there has been concern about the interaction between DB00115 and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "DB00501 , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of HD00530 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , certain ddrug7 , ddrug8 , ddrug9 and ddrug10 , thereby delaying elimination and increasing blood levels of these drugs .",
        "label": "mechanism"
    },
    {
        "text": "HD00377 , ddrug1 : e , g , , ddrug2 , ddrug3 , DB00622",
        "label": "NA"
    },
    {
        "text": "HD00374 : concomitant administration of ddrug1 and ddrug2 does not interfere with the rate or extent of the absorption of DB01009 administered as ddrug4 .",
        "label": "NA"
    },
    {
        "text": "in clinical studies performed with DB00569 , the concomitant use of oral ddrug1 { ddrug2 } , ddrug3 { ddrug4 } , HD00203 { ddrug6 } , and ddrug7 did not significantly affect the pharmacokinetics/pharmacodynamics of ddrug8 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , DB00091 { ddrug22 , ddrug23 } , hiv drugs classified as HD00269 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "as with other ddrug0 , the antihypertensive effect of ddrug1 may be blunted by the HD00860 DB00328",
        "label": "NA"
    },
    {
        "text": "however , the concomitant use of DB00278 and DB00682 { 5 # mg initial oral dose followed by # -6 mg/day orally for 6 - 10 days } results in prolongation of the prothrombin time { pt } and international normalized ratio { inr } .",
        "label": "effect"
    },
    {
        "text": "short-term pharmacokinetic studies have demonstrated that concomitant administration of ddrug0 and DB00749 { ddrug2 capsules and tablets } results in reduced protein binding of ddrug3 , but there was no change in the clearance of free DB00682 .",
        "label": "NA"
    },
    {
        "text": "the blood pressure effect of DB00401 tended to be greater in patients on ddrug1 than in patients on no other HD00876 therapy .",
        "label": "NA"
    },
    {
        "text": "in patients taking an ddrug0 { eg , DB00313 , ddrug2 , ddrug3 or ddrug4 } , the concomitant use of DB00358 may reduce seizure control by lowering the plasma levels of the ddrug6 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 - combined administration of racemic DB00215 { 40 mg/day for # days } and ddrug2 { titrated to # mg/day for # days } did not significantly affect the pharmacokinetics of DB00564 , a cyp3a4 substrate .",
        "label": "NA"
    },
    {
        "text": "DB00950 had no effect on the pharmacokinetics of either ddrug1 or DB01026 .",
        "label": "NA"
    },
    {
        "text": "certain drugs including ddrug0 , HD00175 , ddrug2 , and ddrug3 may reduce the hypoglycemic action of ddrug4 and other oral HD00394 .",
        "label": "effect"
    },
    {
        "text": "in vitro studies have shown that precipitation occurs when eye drops containing DB11590 are mixed with DB00654 .",
        "label": "NA"
    },
    {
        "text": "DB00563 - there is one report that ddrug1 may decrease the possible effectiveness of supplemental DB00130 for chemotherapy-induced mucositis .",
        "label": "NA"
    },
    {
        "text": "no depressant effect on blood levels in humans was noted when ddrug0 was administered with any of the following drugs : DB00945 , DB01190 , ddrug3 , ddrug4 , ddrug5 { ddrug6 } , ddrug7 , ddrug8 or ddrug9 .",
        "label": "NA"
    },
    {
        "text": "elevated plasma levels of DB00277 have been reported with concomitant HD00533 use .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 may enhance the effects of : other HD00459 s , ddrug4 , general ddrug5 , ddrug6 such as ddrug7 , ddrug8 , or other HD00261 , causing increased cns depression .",
        "label": "NA"
    },
    {
        "text": "this effect of DB00945 { which also lowers serum concentrations of other HD00233 given with it } has been demonstrated in patients with rheumatoid_arthritis { n = 15 } as well as normal volunteers { n = 16 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 including coumarin derivatives , indandione derivatives , and ddrug1 such as ddrug2 { HD00203 } , and ddrug4 may increase the risk of bleeding when administered concomitantly with DB00407 .",
        "label": "effect"
    },
    {
        "text": "in clinical trials , DB01240 was used with ddrug1 , ddrug2 , ddrug3 , oral ddrug4 , and supplemental DB09140 , in a pharmacokinetic substudy in patients with congestive heart failure receiving ddrug6 or ddrug7 in whom therapy with ddrug8 was initiated , apparent oral clearance values for ddrug9 { n = 23 } and ddrug10 { n = 30 } were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .",
        "label": "NA"
    },
    {
        "text": "concurrent administration of HD00450 { for the treatment of hypotension related to obstetric blocks } and HD00451 may cause severe , persistent hypertension or cerebrovascular accidents .",
        "label": "NA"
    },
    {
        "text": "HD00532 , including ddrug1 , may enhance the effects of oral HD00326 , such as ddrug3 or its derivatives .",
        "label": "effect"
    },
    {
        "text": "ddrug0 or ddrug1 : when DB00954 is administered immediately following ddrug3 or HD00498 , the absorption of ddrug5 is slightly enhanced .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , DB00564 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { DB00295 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of ddrug0 : HD00175 , ddrug2 , ddrug3 , ddrug4 { e , g , , ddrug5 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 { e , g , , in oral HD00283 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { HD00203 } : concomitant use of DB00945 { or other ddrug3 } and ddrug4 increases the risk of gastrointestinal side effects .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , DB00295 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { DB01045 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { DB00472 } sporal { ddrug12 } DB01026 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "conclusions : single-dose DB00343 coadministration leads to higher DB00877 exposure , presumably by inhibition of the first-pass metabolism of ddrug2 .",
        "label": "mechanism"
    },
    {
        "text": "DB00945 : concurrent administration of ddrug1 may lower DB00939 plasma levels , possibly by competing for protein-binding sites .",
        "label": "NA"
    },
    {
        "text": "since DB01432 ddrug1 may bind other drugs given concurrently , it is recommended that patients take other drugs at least # hour before or # to # hours after ddrug2 HD00524 { or at as rxfp2 an interval as possible } to avoid impeding their absorption .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 , DB00091 : ddrug3 , like other HD00203 , may affect renal prostaglandins and increase the toxicity of certain drugs .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , DB00636 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , DB01601 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : HD00203 have produced an elevation of plasma ddrug2 levels and a reduction in renal DB14507 clearance .",
        "label": "NA"
    },
    {
        "text": "the daily dose of DB00496 should not exceed # mg when coadministered with potent cyp3a4 inhibitors { e , g , , ddrug1 , DB01167 , ddrug3 , ddrug4 , ddrug5 and nefazadone } .",
        "label": "advise"
    },
    {
        "text": "these include ddrug0 , DB01432 , and some HD00002 { e , g , ddrug3 , rifamipicin , ddrug4 and ddrug5 } .",
        "label": "NA"
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit ddrug0 binding to serum proteins or alter the concentrations of serum binding proteins : ddrug1 and related ddrug2 , ddrug3 , ddrug4 , ddrug5 and HD00847 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , DB00675 .",
        "label": "NA"
    },
    {
        "text": "DB00238 and ddrug1 should not beadministered concomitantly becausedecreases in DB01026 plasmaconcentrations may reduce the efficacy of the drug .",
        "label": "NA"
    },
    {
        "text": "inhibitors of cyp3a4 { eg , ddrug0 } or cyp2d6 { eg , DB00908 , ddrug2 , or ddrug3 } can inhibit DB01238 elimination and cause increased blood levels .",
        "label": "mechanism"
    },
    {
        "text": "therefore , co-administration of DB01156 with drugs that are metabolized by cyp2d6 isoenzyme including certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } , HD00031 { e , g , , ddrug9 , ddrug10 , ddrug11 } , ddrug12 { e , g , , ddrug13 } , and ddrug14 { e , g , , ddrug15 , ddrug16 } , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .",
        "label": "advise"
    },
    {
        "text": "HD00143 , such as ddrug1 , ddrug2 and DB01115 , inhibit platelet activation in vitro , and decrease platelet adhesion intravascularly .",
        "label": "NA"
    },
    {
        "text": "concomitant use of agents in the ddrug0 { which includes DB01242 } with drugs that can inhibit cyp2d6 may require lower doses than usually prescribed for either the HD00553 or the other drug .",
        "label": "NA"
    },
    {
        "text": "when taken orally , ddrug0 like DB01026 may enhance the anticoagulant effect of DB04665 - like drugs .",
        "label": "effect"
    },
    {
        "text": "ddrug0 absorption : the following agents may bind and decrease absorption of ddrug1 from the gastrointestinal tract : ddrug2 , DB01432 resin , ddrug4 , ddrug5 , ddrug6 , soybean flour { e , g , , infant formula } , DB00364 .",
        "label": "NA"
    },
    {
        "text": "experience with ddrug0 { ddrug1 } suggests the potential for interactions with DB00695 and HD00106 .",
        "label": "NA"
    },
    {
        "text": "to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma { hiv-nhl } , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the ddrug0 , ddrug1 , ddrug2 , and ddrug3 { chop } chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen { i , e , , ddrug4 , ddrug5 , ddrug6 , and ddrug7 with DB00541 plus ddrug9 } without receiving HD00056 therapy .",
        "label": "NA"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { ddrug1 s } , ddrug2 , DB01285 { ddrug4 may decrease the effects of these medicines } , ddrug5 { using these medicines with ddrug6 may result in increased cns depressant effects } , ddrug7 , ddrug8 { using these medicines with ddrug9 may change the amount of either medicine that you need to take } , and oral HD00283 containing ddrug11 { ddrug12 may decrease the effectiveness of these oral ddrug13 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "although trough DB00215 plasma levels were unaffected , given the enzyme-inducing properties of ddrug1 , the possibility that DB00564 might increase the clearance of ddrug3 should be considered if the two drugs are coadministered .",
        "label": "NA"
    },
    {
        "text": "plasma levels of several closely related ddrug0 have been reported to be increased by the concomitant administration of ddrug1 or hepatic enzyme inhibitors { e , g , , DB00501 , ddrug3 } and decreased by the concomitant administration of hepatic enzyme inducers { e , g , , HD00026 , ddrug5 } , and such an effect may be anticipated with ddrug6 as well .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 may enhance the effects of : other HD00459 s , ddrug4 , general ddrug5 , ddrug6 such as DB00475 , ddrug8 , or other ddrug9 , causing increased cns depression .",
        "label": "NA"
    },
    {
        "text": "therefore , patients receiving DB01032 will have erroneously low erpf and tm DB00345 values .",
        "label": "effect"
    },
    {
        "text": "the addition of DB00906 in a limited number of patients in three well-controlled studies caused no systematic changes in ddrug1 or DB00794 concentrations when compared to placebo .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , HD00668 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { DB00295 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of HD00539 such as ddrug1 include certain HD00002 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 } , ddrug11 salts , ddrug12 , local ddrug13 , ddrug14 , and ddrug15 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : the mean steady-state trough serum DB00313 concentrations prior to and during concomitant DB00996 administration { 400 mg tid ;",
        "label": "NA"
    },
    {
        "text": "drug interactions : the central ddrug0 syndrome can occur when anticholinergic agents such as DB00810 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain HD00424 such as ddrug3 , the ddrug4 and other ddrug5 , ddrug6 , certain ddrug7 such as the ddrug8 salts , and ddrug9 .",
        "label": "effect"
    },
    {
        "text": "HD00216 , ddrug1 ddrug2 may enhance the activity of ddrug3 or HD00571 ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 { cns } drugs including ddrug1 , ddrug2 , ddrug3 , HD00031 , blood pressure medications { DB00206 , ddrug6 , ddrug7 } , motion sickness medications , ddrug8 , ddrug9 , ddrug10 , sleeping pills and ddrug11",
        "label": "NA"
    },
    {
        "text": "ddrug0 including ddrug1 , DB00780 , and ddrug3 hc1 : concomitant use of ddrug4 and non-selective HD00343 may cause hypertension .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { cns } drugs including ddrug1 , ddrug2 , ddrug3 , HD00031 , blood pressure medications { ddrug5 , ddrug6 , ddrug7 } , motion sickness medications , HD00542 , ddrug9 , ddrug10 , sleeping pills and ddrug11",
        "label": "NA"
    },
    {
        "text": "- HD00320 , nondepolarizing { e , g , , DB01199 } : possible increased responsiveness to the ddrug2",
        "label": "NA"
    },
    {
        "text": "a pharmacokinetic study evaluating the administration of a single dose of ddrug0 # mg with DB01026 # mg bid , a potent inhibitor of the cyp3a4 pathway , showed a # - fold increase in cmax of DB00700 and a # - fold increase in auc of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "- a HD00295 { water pill } such as DB00999 { ddrug2 , ddrug3 } , ddrug4 { ddrug5 } , and others ;",
        "label": "NA"
    },
    {
        "text": "improvements in general cognitive function seen with ddrug0 treatment in a 1-year controlled study of patients with early-phase schizophrenia , were significantly greater than changes seen with either DB00734 or DB00502 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : concomitant administration of DB00906 did not affect the steady-state pharmacokinetics of DB00390 or the mean daily trough serum level of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and DB00759 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , DB00949 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "some ddrug0 / substances are known to accelerate the metabolism of DB01118 by stimulating the synthesis of HD00302 { enzyme induction } .",
        "label": "NA"
    },
    {
        "text": "DB00241 , ddrug1 and ddrug2 may enhance the effects of : other ddrug3 s , ddrug4 , general ddrug5 , ddrug6 such as ddrug7 , HD00460 , or other ddrug9 , causing increased cns depression .",
        "label": "effect"
    },
    {
        "text": "therefore , when DB00903 and HD00700 are used concomitantly , the patient should be observed closely to determine if the desired effect of the ddrug2 is obtained .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : a single 125-mg dose of DB00673 was administered on day # and # mg/day on days # and # to healthy subjects who were stabilized on chronic DB00682 therapy .",
        "label": "NA"
    },
    {
        "text": "however , in a study of # normal subjects , concurrent administration of ddrug0 decreased ddrug1 protein binding and increased DB01009 plasma clearance from # l/kg/h without DB00945 to # l/kg/h with ddrug4 .",
        "label": "NA"
    },
    {
        "text": "coadministration of DB01016 with doses higher than # mg DB00580 { e , g , , # mg bid } have not been studied .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , ddrug8 { HD00398 } - containing preparations { e , g , , sunscreens and some DB00152 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "other concomitant therapy although specific interaction studies were not performed , ddrug0 doses of # mg or more were concomitantly used in clinical studies with ddrug1 , ddrug2 , a-blockers , HD00651 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , cardiac ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 { also referred to as HD00203 } , and ddrug15 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "endothelium-intact aortic rings from high - ddrug0 rats were supersensitive to DB00368 when compared to vehicle - , ddrug2 - and ddrug3 + high - DB00783 - treated rats { pd2 values = # + / # , # + / # , # + / # and # + / # , respectively } .",
        "label": "NA"
    },
    {
        "text": "may interact with thyroid medication { e , g , , ddrug0 } , DB11119 - containing products , ddrug2 , ddrug3 { e , g , , ddrug4 , ddrug5 } , and ddrug6 { e , g , , DB00448 , ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 , and ddrug2 : drugs such as ddrug3 , ddrug4 , and HD00249 may increase the risk of developing peripheral_neuropathies or other DB00943 - associated adverse events by interfering with the renal clearance of ddrug7 { thereby raising systemic exposure } .",
        "label": "effect"
    },
    {
        "text": "no clinically significant effect of DB00927 , ddrug1 , or ddrug2 was seen on the pharmacokinetics of DB01238 { see clinical pharmacology : drug - drug interactions } .",
        "label": "NA"
    },
    {
        "text": "co-administration of ddrug0 , ddrug1 , ddrug2 , DB00695 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 and ddrug10 did not result in clinically significant increases in DB09026 exposure .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 , ddrug2 , DB00201 , DB00353 contraindicated due to potential for serious and life-threatening reactions such as acute ddrug5 toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in some patients with compromised renal function who are being treated with HD00233 , the co-administration of DB00584 may result in a further deterioration of renal function .",
        "label": "effect"
    },
    {
        "text": "the antimicrobial effect of a HD00051 , ddrug1 , either alone or in combination with DB01165 , was evaluated in vitro against two type strains and six clinical isolates of mycobacterium ulcerans .",
        "label": "NA"
    },
    {
        "text": "some HD00096 / substances are known to accelerate the metabolism of DB01118 by stimulating the synthesis of ddrug2 { enzyme induction } .",
        "label": "NA"
    },
    {
        "text": "formulation of fluorescence labelled DB00781 and ddrug1 in unconjugated ddrug2 { 1 % m/v } did not significantly improve the permeation , however in the presence of 1 % { m/v } HD00068 # a significantly improved permeation was observed { r = # } .",
        "label": "NA"
    },
    {
        "text": "in a single-dose crossover study examining DB00448 # mg and DB00338 # mg each administered alone and concomitantly with ddrug2 # gram , absorption of the ddrug3 was delayed and their bioavailability was reduced by 17 % and 16 % , respectively , when administered concomitantly with ddrug4 .",
        "label": "NA"
    },
    {
        "text": "drug-drug interactions between ddrug0 and other ddrug1 { HD00714 } ddrug3 DB01202 { 3000 mg daily } had no effect on the pharmacokinetic disposition of ddrug5 in patients with refractory epilepsy .",
        "label": "NA"
    },
    {
        "text": "ddrug0 / ddrug1 : pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between ddrug2 and concomitantly administered DB00945 { # mg orally given # and # hours prior to initiation of ddrug4 # g/kg/min , over # hours } or ddrug5 { 1000 mg orally given 12 , # and # hours prior to , and # and # hours subsequent to , initiation of DB00278 # g/kg/min , over # hours } .",
        "label": "NA"
    },
    {
        "text": "the ddrug0 { DB00412 and ddrug2 } , a new class of oral HD00075 , are insulin sensitizers .",
        "label": "NA"
    },
    {
        "text": "HD00532 , including DB00779 , may enhance the effects of the oral ddrug2 ddrug3 or its derivatives .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , DB00091 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { HD00531 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 / DB01167 , HD00375 , including ddrug3",
        "label": "NA"
    },
    {
        "text": "in em individuals treated with ddrug0 or DB00472 , the auc of DB00289 is approximately 6 - to 8-fold and css , max is about 3 - to 4-fold greater than ddrug3 alone .",
        "label": "mechanism"
    },
    {
        "text": "however , because some HD00532 have been reported to enhance the effects of DB00682 or its derivatives , prothrombin time or other suitable anticoagulation test should be monitored closely if a ddrug2 is administered with ddrug3 or its derivatives .",
        "label": "effect"
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a ddrug0 , including ddrug1 , with multivalent cation-containing products such as ddrug2 or ddrug3 ddrug4 , ddrug5 , DB00900 chewable/buffered tablets or pediatric powder , or products containing ddrug7 , ddrug8 , or ddrug9 may substantially decrease the absorption of DB00537 , resulting in serum and urine levels considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "patients on oral ddrug0 receiving DB00188 treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their HD00430 .",
        "label": "NA"
    },
    {
        "text": "the peripheral vasoconstriction caused by high doses of DB00988 is antagonized by HD00647 .",
        "label": "effect"
    },
    {
        "text": "because of the potential for ddrug0 levels to continue to increase with multiple dosing , caution should be used if patients are to be receiving both DB01097 and DB01045 .",
        "label": "advise"
    },
    {
        "text": "drug interactions : ddrug0 may interact with some drugs , like ddrug1 { ddrug2 } : ddrug3 could theoretically affect ddrug4 pharmacodynamics - DB04365 - jzqyavbxjcqsok_uhfffaoysa_n - DB00898 : ddrug7 and ddrug8 cause additive cns depression - ddrug9 : ddrug10 increases the effect of ddrug11",
        "label": "NA"
    },
    {
        "text": "based on adult data , lower doses of DB00201 may be needed following coadministration of drugs which are reported to decrease ddrug1 elimination { e , g , , ddrug2 and ddrug3 } and higher ddrug4 doses may be needed following coadministration of drugs that increase ddrug5 elimination { e , g , , DB01174 and ddrug7 } .",
        "label": "NA"
    },
    {
        "text": "the principal drugs given { number of patients in parentheses } were : ddrug0 { 115 } , HD00024 and ddrug2 { 103 } , ddrug3 { 52 } , oral ddrug4 { 45 } , cough and cold preparations { 45 } , HD00203 { 38 } , ddrug6 { 29 } , ddrug7 { 24 } , oral ddrug8 { 18 } , ddrug9 { 13 } , ddrug10 { 10 } , and ddrug11 { 10 } .",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing DB01370 , ddrug3 , or ddrug4 , with ddrug5 , with metal cations such as ddrug6 , or with DB00152 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "alternatives to DB01211 , such as DB00207 , should be considered .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , DB00184 , and ddrug2 may decrease ddrug3 plasma levels , resulting in a decrease in effectiveness of a previously effective DB00363 dose .",
        "label": "NA"
    },
    {
        "text": "when DB00594 hydrochloride is administered concomitantly with an HD00291 , the risk of hyperkalemia may be increased .",
        "label": "effect"
    },
    {
        "text": "to avoid DB00252 intoxication , appropriate adjustment of the HD00329 should be made .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : DB00316 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { DB01045 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "both HD00021 and HD00022 ameliorate ddrug2 withdrawal signs .",
        "label": "NA"
    },
    {
        "text": "and ddrug0 e , g , , DB00661 } , cyp1a2 inducers { ddrug2 } and cyp1a2 inhibitors { DB14029 and ddrug4 } .",
        "label": "NA"
    },
    {
        "text": "the following are examples of drugs known to inhibit the metabolism of other related ddrug0 , presumably through inhibition of cyp3a : ddrug1 , DB00176 , ddrug3 , ddrug4 , ddrug5 , and some HD00093 .",
        "label": "NA"
    },
    {
        "text": "coadministration of DB00252 with # mg DB00401 tablets in epileptic patients lowered the ddrug2 plasma concentrations to undetectable levels .",
        "label": "mechanism"
    },
    {
        "text": "concomitant administration with racemic DB00215 ddrug1 - since ddrug2 is the active isomer of racemic ddrug3 { DB00215 } , the two agents should not be coadministered .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 , ddrug2 , ddrug3 , DB00328 , ddrug5 , ddrug6 , and ddrug7 raise the serum DB00390 concentration due to a reduction in clearance and/or in volume of distribution of the drug , with the implication that ddrug9 intoxication may result .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { DB00400 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , DB01232 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 } , ddrug1 { e , g , DB00199 } , and ddrug3 { e , g , ddrug4 , ddrug5 and ddrug6 } should have their dose of ddrug7 or DB01183 adjusted .",
        "label": "NA"
    },
    {
        "text": "this could lead to decreased HD00372 serum levels or increase the risk of ddrug1 toxicity when HD00579 is withdrawn .",
        "label": "NA"
    },
    {
        "text": "may lead to loss of virologic response and possible resistance to DB00224 or to the class of HD00269 .",
        "label": "NA"
    },
    {
        "text": "no clinically important pharmacokinetic interactions occurred when DB00722 was used concomitantly with ddrug1 or DB00999 .",
        "label": "NA"
    },
    {
        "text": "drug interactions with ddrug0 administration of # mg of DB00950 { 2 x # mg capsule } within # minutes of an DB01370 and ddrug3 containing ddrug4 { ddrug5 } decreased ddrug6 auc by 41 % and cmax by 43 % .",
        "label": "mechanism"
    },
    {
        "text": "the availability of potent ddrug0 { HD00112 } - based regimens for ddrug2 therapy and concerns regarding HD00058 { ddrug4 } - related metabolic disturbances have led to significant shifts in treatment practices in hiv infection .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 : DB00673 , when given as a regimen of 125 mg with ddrug3 coadministered orally as # mg on day 1 , and ddrug4 when given as # mg/day with ddrug5 coadministered orally as # mg on days # through 5 , increased the auc of DB01234 , a cyp3a4 substrate by # - fold , on days # and 5 .",
        "label": "NA"
    },
    {
        "text": "it is possible that the cardiovascular action of other HD00377 could be enhanced by the addition of DB00393 .",
        "label": "effect"
    },
    {
        "text": "in addition to bleeding associated with ddrug0 and ddrug1 , drugs that alter platelet function { such as DB00945 , ddrug3 and ddrug4 } may increase the risk of bleeding if administered prior to , during , or after DB00009 therapy .",
        "label": "int"
    },
    {
        "text": "nevertheless , clinical studies , as well as postmarketing observations have shown that ddrug0 can reduce the natriuretic effect of DB00695 and HD00217 in some patients .",
        "label": "NA"
    },
    {
        "text": "when DB00564 is withdrawn from the combination therapy , DB01238 dose should then be reduced .",
        "label": "advise"
    },
    {
        "text": "nucleoside analogues ddrug0 co-administration of DB00811 and DB00900 is not recommended .",
        "label": "advise"
    },
    {
        "text": "therefore , administration of HD00532 with HD00374 containing ddrug2 , ddrug3 , or ddrug4 ;",
        "label": "NA"
    },
    {
        "text": "- a HD00762 { ddrug1 } such as ddrug2 { DB01247 } , ddrug4 { ddrug5 } , or ddrug6 { ddrug7 } ;",
        "label": "NA"
    },
    {
        "text": "in addition , studies in healthy volunteers have shown that ddrug0 does not affect the pharmacokinetics or pharmacodynamics of DB00682 , or the pharmacokinetics of ddrug2 { 40 mg twice daily } , DB00252 , ddrug4 , or oral ddrug5 .",
        "label": "NA"
    },
    {
        "text": "DB00930 decreased the cmax and auc of sustained-release DB00661 { ddrug2 } by approximately 31 % and 11 % , respectively .",
        "label": "mechanism"
    },
    {
        "text": "more than # parkinsons disease patients in clinical trials have used DB01037 in combination with ddrug1 and ddrug2 / HD00680 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , DB01174 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , DB00295 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a clinical pharmacology study , coadministration of an ddrug1 { DB06723 , ddrug3 , and ddrug4 } with ddrug5 reduced serum levels and urinary excretion of ddrug6 as compared with ddrug7 administered alone , suggesting that HD00374 may impair absorption of ddrug9 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , DB01232 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , DB00277 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , DB01174 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and DB00126 .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { DB00682 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } DB01235 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "in a study involving healthy subjects receiving ddrug0 and ddrug1 concurrently , plasma DB01195 levels were increased about 20 % and DB00571 levels were increased about 30 % compared to control values .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration of DB00402 # mg and DB00334 # mg produced a decrease in dsst scores .",
        "label": "effect"
    },
    {
        "text": "ddrug0 can interact with ddrug1 or other ddrug2 { may potentiate the cns depressant effects of either these medications or ddrug3 } , ddrug4 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug5 } , and HD00445 { concurrent use with HD00388 may prolong and intensify the anticholinergic and cns depressant effects of ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration of DB01171 resulted in a 27 % decrease in DB00918 clearance and an increase in cmax of approximately 6 % .",
        "label": "mechanism"
    },
    {
        "text": "a pharmacokinetic study evaluating the administration of a single dose of DB00700 # mg with ddrug1 # mg bid , a potent inhibitor of the cyp3a4 pathway , showed a # - fold increase in cmax of ddrug2 and a # - fold increase in auc of DB00700 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , DB00776 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , DB00295 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "particular caution should be observed with ddrug0 since there are conflicting results for the effect of DB00375 on the availability of DB00390 and ddrug3 .",
        "label": "mechanism"
    },
    {
        "text": "may interact ddrug0 { altered hypo-prothrombinemic effect } , HD00026 , ddrug2 and other inducers of hepatic microsomal enzyme oxidation system { decreased effect of ddrug3 } , HD00175 { increased effect of ddrug5 } .",
        "label": "NA"
    },
    {
        "text": "DB00819 increases DB14507 excretion and the ddrug2 may be decreased .",
        "label": "mechanism"
    },
    {
        "text": "in this study we investigated the effect of DB14152 on high threshold voltage-dependent ca { 2 + } channel subtypes using their ddrug1 ddrug2 { l-type } , ddrug3 { n-type } , or HD00048 { p-type } in bovine chromaffin cells .",
        "label": "NA"
    },
    {
        "text": "co-administration of DB09026 did not significantly affect the pharmacokinetics of DB00227 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 or ddrug10 .",
        "label": "NA"
    },
    {
        "text": "withdrawal of DB01045 decreased the DB00682 requirement by 50 % .",
        "label": "mechanism"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { DB00501 } ddrug9 ddrug10 { ddrug11 } sporal { DB01167 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , DB00091 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , DB00277 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a ddrug0 , including ddrug1 , with multivalent cation-containing products such as ddrug2 or ddrug3 HD00374 , ddrug5 , ddrug6 chewable/buffered tablets or pediatric powder , or products containing ddrug7 , ddrug8 , or ddrug9 may substantially decrease the absorption of DB00537 , resulting in serum and urine levels considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "similarly , DB00731 had no influence on the serum protein binding of ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and DB01124 in vitro .",
        "label": "NA"
    },
    {
        "text": "HD00356 enhance the renal toxicity of HD00663 in animals , # ddrug2 interferes with the action of ddrug3 preparations by chelating the ddrug4 , 7",
        "label": "effect"
    },
    {
        "text": "the actions of the HD00100 may be potentiated by ddrug1 , ddrug2 , HD00219 , ddrug4 or other ddrug5 .",
        "label": "effect"
    },
    {
        "text": "HD00586 / HD00587 : long-term suppression of gastric acid secretion by ddrug2 or ddrug3 { eg , ddrug4 and ddrug5 } is likely to reduce ddrug6 exposure .",
        "label": "NA"
    },
    {
        "text": "this drug may interact with ddrug0 or other ddrug1 { may potentiate the cns depressant effects of either these medications or ddrug2 } , ddrug3 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug4 } , and HD00445 { concurrent use with ddrug6 may prolong and intensify the anticholinergic and cns depressant effects of HD00388 } .",
        "label": "NA"
    },
    {
        "text": "interactions for ddrug0 { DB00627 } : HD00876 therapy : ddrug3 may potentiate the effects of ddrug4 and vasoactive drugs resulting in postural hypotension .",
        "label": "NA"
    },
    {
        "text": "rarely ddrug0 toxicity may occur in patients who discontinue HD00356 after concurrent high-dose DB00945 therapy .",
        "label": "effect"
    },
    {
        "text": "ddrug0 DB01026 ddrug2 ddrug3 ddrug4 ddrug5 DB01149 ddrug7 large quantities of grapefruit juice { # quart daily }",
        "label": "NA"
    },
    {
        "text": "monitoring for ddrug0 toxicity and serial measurement of DB01118 serum concentration during concomitant HD00058 therapy should be considered .",
        "label": "advise"
    },
    {
        "text": "- a HD00535 { ddrug1 } such as ddrug2 { ddrug3 , ddrug4 , ddrug5 , others } , ddrug6 { ddrug7 , ddrug8 , ddrug9 } , ddrug10 { ddrug11 , ddrug12 } , ddrug13 { ddrug14 } , DB00328 { ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , and ddrug21 { ddrug22 , ddrug23 , ddrug24 } ;",
        "label": "NA"
    },
    {
        "text": "similarly , DB00829 decreased the antinociceptive effect of DB04817 { only in the tail-flick test } and ddrug2 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : it appears that DB01174 may reduce plasma DB00949 concentrations .",
        "label": "mechanism"
    },
    {
        "text": "other no clinically important pharmacokinetic interactions occurred when DB00542 was administered concomitantly with ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB00335 , ddrug7 , or ddrug8 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : concomitant treatment with DB00982 and HD00239 should be avoided because ddrug3 use has been associated with a number of cases of idiopathic_intracranial_hypertension { benign intracranial hypertension } , some of which involved concomitant use of ddrug4",
        "label": "advise"
    },
    {
        "text": "caution is advised when ddrug0 is coadministered with other medications that can prolong the qt interval { e , g , certain HD00303 or ddrug2 } or lead to electrolyte abnormalities { such as ddrug3 or DB00681 } .",
        "label": "NA"
    },
    {
        "text": "clinical trials have indicated that ddrug0 can be effectively and safely used in conjunction with standard cystic_fibrosis therapies including oral , inhaled and/or parenteral ddrug1 , ddrug2 , enzyme supplements , HD00489 , oral or inhaled HD00175 , and ddrug5 .",
        "label": "NA"
    },
    {
        "text": "synergism has been shown between DB01159 anesthesia and intravenously administered DB00598 .",
        "label": "effect"
    },
    {
        "text": "in a study in which patients with active ra were treated for up to # weeks with concurrent DB00026 and ddrug1 therapy , a 7 % rate of serious infections was observed , which was higher than that observed with DB00005 alone { 0 % } .",
        "label": "NA"
    },
    {
        "text": "although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 { eg , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , DB00564 , ddrug12 , ddrug13 , ddrug14 , and ddrug15 } may have elevated plasma concentrations when coadministered with DB01232 ;",
        "label": "mechanism"
    },
    {
        "text": "pharmacokinetic interaction studies with DB00341 in adults were conducted with ddrug1 , ddrug2 , DB01026 , ddrug4 and ddrug5 .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of DB00195 with the oral ddrug1 DB00682 has been shown not to potentiate the anticoagulant effect of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "although additional drug interaction studies have not been conducted , the most common medications used concomitantly with DB00261 in clinical trials were ddrug1 , DB00316 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and ddrug7 .",
        "label": "NA"
    },
    {
        "text": "also , concomitant administration of HD00532 with products containing DB01592 , ddrug2 containing ddrug3 , or ddrug4 { ddrug5 } chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels .",
        "label": "mechanism"
    },
    {
        "text": "this interaction should be given consideration in patients taking HD00203 concomitantly with HD00106 .",
        "label": "advise"
    },
    {
        "text": "when other potent parental ddrug0 , such as DB01119 , are used in combination with DB01275 , patients should be continuously observed for several hours for any excessive fall in blood pressure .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , DB01232 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , DB00231 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "therefore , when using doses of DB00776 greater than # mg/day during adjunctive therapy , a decrease in the dose of DB00252 may be required .",
        "label": "advise"
    },
    {
        "text": "because ddrug0 is not metabolized by the cytochrome cyp2b6 system , inhibitors of cyp450 enzyme would not be expected to affect its metabolism , and ddrug1 and DB00196 , potent inhibitors of cytochrome_p450_family_3_subfamily_a and 2c9 , respectively , have been shown to have no effect on DB00876 pharmacokinetics .",
        "label": "NA"
    },
    {
        "text": "marked symptomatic orthostatic hypotension has been reported when HD00377 and organic DB14049 were used in combination .",
        "label": "effect"
    },
    {
        "text": "DB00294 may interact with the following medications : ddrug1 { DB00316 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "int"
    },
    {
        "text": "DB01045 significantly decreased the auc { ss } of DB00701 by 82 % , but ddrug2 had no effect on ddrug3 pharmacokinetics .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 reduced the blood auc0 - 12 of ddrug1 by approximately 20 % , peak blood concentration { cmax } by 16 % , and 12-hour blood concentration { c12hr } by 26 % in healthy subjects when ddrug2 { 2 doses of # mg/kg # hours apart } was administered on the 10th day of DB00520 # mg daily , as compared to results from a control period in which DB00864 was administered alone .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in diabetic patients receiving DB00861 and DB01124 , no significant effects were seen on ddrug3 plasma levels or fasting blood glucose .",
        "label": "NA"
    },
    {
        "text": "many people use both DB02325 and DB00184 { i , e , , cigarettes and other tobacco products } .",
        "label": "NA"
    },
    {
        "text": "DB00501 } and many that are substrates for cyp2b6 2d6 { many other ddrug1 , ddrug2 , and the ddrug3 DB01182 and ddrug5 } .",
        "label": "NA"
    },
    {
        "text": "concurrent use of DB00611 with ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , and ddrug5 } may result in increased HD00461 effects .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { ddrug1 , ddrug2 , DB00384 , and others } or DB14500 supplements can increase the risk of hyperkalemia .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 - containing preparations { eg , HD00374 } may cause hypermagnesemia and should therefore not be taken during therapy with DB11094 by patients on chronic renal dialysis .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : DB00669 has been reported to cause coronary artery vasospasm , and its effect could be additive with ddrug2 { DB00320 } injection , usp .",
        "label": "effect"
    },
    {
        "text": "DB00294 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , DB00273 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "int"
    },
    {
        "text": "ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , DB01167 , ddrug6 , and ddrug7 raise the serum DB00390 concentration due to a reduction in clearance and/or in volume of distribution of the drug , with the implication that ddrug9 intoxication may result .",
        "label": "mechanism"
    },
    {
        "text": "however , co-administration of ddrug0 with DB01370 - and ddrug2 - containing ddrug3 { 51 meq } or DB00476 with ddrug5 , had no significant effect on the rate or extent of ddrug6 absorption after administration of a 40-mg oral dose .",
        "label": "NA"
    },
    {
        "text": "1 - adrenergic receptor antagonism , DB01238 has the potential to enhance the effect of certain HD00366 .",
        "label": "effect"
    },
    {
        "text": "the similarity of the DB00108 - associated adverse event profile between study # { without co-administered ddrug1 } and study # { with co-administered DB02325 } indicates that this alteration in clearance does not necessitate reduction of the ddrug3 dose to maintain safety , general } .",
        "label": "NA"
    },
    {
        "text": "conversely , decreases in plasma levels of the ddrug0 have been reported upon discontinuation of DB00501 which may result in the loss of the therapeutic efficacy of the HD00042 6 .",
        "label": "NA"
    },
    {
        "text": "this drug may interact with DB02325 or other ddrug1 { may potentiate the cns depressant effects of either these medications or ddrug2 } , ddrug3 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with HD00388 } , and ddrug5 { concurrent use with ddrug6 may prolong and intensify the anticholinergic and cns depressant effects of ddrug7 } .",
        "label": "NA"
    },
    {
        "text": "the effectiveness of ddrug0 - only pills is reduced by hepatic enzyme-inducing drugs such as the ddrug1 DB00252 , ddrug3 , and ddrug4 , and the ddrug5 DB01045 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00477 blocks dopamine and norepinephrine reuptake , thus inhibiting the central stimulant effects of HD00401 , and can be used to treat ddrug3 poisoning .",
        "label": "effect"
    },
    {
        "text": "ddrug0 - concomitant intake of DB11058 and ddrug2 may reduce the absorption of DB01022 .",
        "label": "NA"
    },
    {
        "text": "in some patients the combined use of DB00328 and DB00861 has been associated with fatal gastrointestinal hemorrhage .",
        "label": "effect"
    },
    {
        "text": "ddrug0 { cns } drugs including ddrug1 , ddrug2 , ddrug3 , ddrug4 , blood pressure medications { ddrug5 , ddrug6 , HD00254 } , motion sickness medications , ddrug8 , ddrug9 , HD00024 , sleeping pills and ddrug11",
        "label": "NA"
    },
    {
        "text": "the pharmacokinetics of ddrug0 and its acid metabolite and the electrocardiographic qt c interval were measured during both periods : with DB00342 alone , and with ddrug2 plus DB00954 .",
        "label": "NA"
    },
    {
        "text": "DB00455 { 10 mg once daily } has been coadministered with therapeutic doses of ddrug1 , ddrug2 , and DB01026 in controlled clinical pharmacology studies in adult volunteers .",
        "label": "NA"
    },
    {
        "text": "therefore , co-administration of DB01156 with drugs that are metabolized by cyp2d6 isoenzyme including certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } , ddrug8 { e , g , , ddrug9 , ddrug10 , ddrug11 } , HD00254 { e , g , , ddrug13 } , and ddrug14 { e , g , , ddrug15 , ddrug16 } , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .",
        "label": "advise"
    },
    {
        "text": "DB01563 may cause an increased prothrombin response by displacing the HD00025 from protein binding sites or a diminished prothrombin response through increased metabolism of the unbound drug by hepatic enzyme induction , thus leading to inter-patient variation in ultimate prothrombin effect .",
        "label": "mechanism"
    },
    {
        "text": "in clinical trials , DB01240 was used with ddrug1 , ddrug2 , ddrug3 , oral ddrug4 , and supplemental ddrug5 , in a pharmacokinetic substudy in patients with congestive heart failure receiving ddrug6 or ddrug7 in whom therapy with ddrug8 was initiated , apparent oral clearance values for ddrug9 { n = 23 } and DB00390 { n = 30 } were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { HD00548 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , DB00503 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when DB00802 is administered in combination with other ddrug1 such as ddrug2 , ddrug3 , HD00263 , or inhalation general ddrug5 .",
        "label": "effect"
    },
    {
        "text": "DB00861 decreased the hyperuricemic effect of DB00695 .",
        "label": "effect"
    },
    {
        "text": "HD00043 : use of ddrug1 with DB00458 and other ddrug3 may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed .",
        "label": "NA"
    },
    {
        "text": "co-administration of multiple doses of # mg of DB00480 had no effect on the single dose pharmacokinetics of HD00832 and ddrug2 .",
        "label": "NA"
    },
    {
        "text": "products containing DB01373 and other HD00260 likely will interfere with absorption of ddrug2 .",
        "label": "NA"
    },
    {
        "text": "the purpose of this study was to evaluate the effect of ddrug0 { ddrug1 } and ddrug2 { ddrug3 } conjugates on the intestinal permeation of HD00069 { ddrug5 } and model peptide drugs , DB00781 and ddrug7 .",
        "label": "NA"
    },
    {
        "text": "HD00071 or oral HD00484 : initiating thyroid replacement therapy may cause increases in ddrug2 or oral ddrug3 requirements .",
        "label": "NA"
    },
    {
        "text": "in a single-dose crossover study examining DB00448 # mg and ddrug1 # mg each administered alone and concomitantly with ddrug2 # gram , absorption of the ddrug3 was delayed and their bioavailability was reduced by 17 % and 16 % , respectively , when administered concomitantly with DB00364 .",
        "label": "NA"
    },
    {
        "text": "fifteen to # minutes of exposure to # mac DB00753 or ddrug1 had minimal effects on the duration of action of initial doses of ddrug2 and therefore , no adjustment to the initial dose should be necessary when DB00565 is administered shortly after initiation of volatile agents .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : since HD00718 may bind other drugs given concurrently , patients should take ddrug2 at least # hour before or 4 - 6 hours after a HD00719 to avoid impeding its absorption .",
        "label": "NA"
    },
    {
        "text": "coadministration of DB00401 with DB00252 or any known cyp3a4 inducer should be avoided and alternative ddrug2 therapy should be considered .",
        "label": "advise"
    },
    {
        "text": "the initiation of DB02325 or DB00184 use may be precipitated by similar personality characteristics in the user , such as impulsivity and sensation seeking .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { DB00316 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , DB01232 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , ddrug3 , or ddrug4 , with DB00364 , with metal cations such as ddrug6 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of HD00532 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "other drug interactions : no pharmacokinetic interactions were observed between DB00862 and the following drugs : ddrug1 , ddrug2 , ddrug3 , HD00467 , and ddrug5 .",
        "label": "NA"
    },
    {
        "text": "patients receiving other ddrug0 , ddrug1 , HD00557 , or other ddrug3 { including ddrug4 } concomitantly with ddrug5 and DB00316 tablets may exhibit an additive cns depression .",
        "label": "NA"
    },
    {
        "text": "DB00501 } and many that are substrates for cyp2b6 2d6 { many other ddrug1 , ddrug2 , and the HD00310 ddrug4 and ddrug5 } .",
        "label": "NA"
    },
    {
        "text": "these in vitro studies suggest that concomitant administration of DB00943 and DB00709 in humans may result in sub-therapeutic concentrations of active phosphorylated ddrug2 , which may lead to a decreased ddrug3 effect of ddrug4 .",
        "label": "effect"
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit ddrug0 binding to serum proteins or alter the concentrations of serum binding proteins : ddrug1 and related ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , DB00333 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , DB00675 .",
        "label": "NA"
    },
    {
        "text": "when patients being treated with DB00598 have a positive urine test for DB00182 using these techniques confirmation should be made by using more specific methods such as a gas chromatographic-mass spectrometer technique .",
        "label": "NA"
    },
    {
        "text": "oral HD00283 : coadministration of ddrug1 and an oral ddrug2 increased auc values for DB00717 and ddrug4 by approximately 30 % and 20 % .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { e , g , , ddrug1 , DB01110 , ddrug3 , ddrug4 , etc , } : in vitro and animal studies with the combination of ddrug5 and ddrug6 suggest that HD00319 may induce fungal resistance to ddrug8 .",
        "label": "NA"
    },
    {
        "text": "although ddrug0 have been shown to reduce ddrug1 - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with ddrug2 may reduce the antitumor effectiveness of ddrug3 and thus should be avoided , # ddrug4 and other HD00255 may potentiate the hypotension seen with DB00041 .",
        "label": "effect"
    },
    {
        "text": "immediate and extended release tablets the hypoglycemic action of HD00222 may be potentiated by certain drugs including ddrug1 , some ddrug2 and other drugs that are highly protein bound , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and HD00520 .",
        "label": "effect"
    },
    {
        "text": "DB00930 was found to have no significant effect on the bioavailability of ddrug1 , ddrug2 , ddrug3 , ddrug4 , DB00313 , and ddrug6 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and DB00295 { # and # mg/kg , s , c , } inhibited the HD00169 { # mg/kg , p , o , } - induced diarrhea in cecectomized rats .",
        "label": "effect"
    },
    {
        "text": "the hypoglycemic action of HD00226 may be potentiated by certain drugs including ddrug1 and other drugs that are highly protein bound , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , HD00275 , and ddrug8 .",
        "label": "effect"
    },
    {
        "text": "no interactions have been observed with ddrug0 , HD00085 , ddrug2 and ddrug3 and HD00106 .",
        "label": "NA"
    },
    {
        "text": "dose reduction of ddrug0 to half the standard dose and a dose increase of ddrug1 to # mg { three 333-mg capsules } every # hours are recommended when DB00615 and DB00224 are coadministered .",
        "label": "advise"
    },
    {
        "text": "may interact with thyroid medication { e , g , , DB00451 } , ddrug1 - containing products , ddrug2 , ddrug3 { e , g , , ddrug4 , ddrug5 } , and ddrug6 { e , g , , DB00448 , ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "additive cns depression may occur when ddrug0 are administered concomitantly with other HD00261 including ddrug2 , HD00262 , and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : HD00532 , including DB00467 , decrease the clearance of ddrug3 , the less active isomer of racemic ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB01076 increases the auc for DB00717 and ddrug3 .",
        "label": "mechanism"
    },
    {
        "text": "while all the HD00113 { ddrug1 } , e , g , , ddrug2 , DB01104 , and ddrug4 , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : potentiation of DB00682 - type { HD00097 and ddrug3 substrate } ddrug4 response is almost always seen in patients receiving ddrug5 and can result in serious or fatal bleeding .",
        "label": "NA"
    },
    {
        "text": "clinical trials have indicated that ddrug0 can be effectively and safely used in conjunction with standard cystic_fibrosis therapies including oral , inhaled and/or parenteral ddrug1 , ddrug2 , enzyme supplements , ddrug3 , oral or inhaled HD00175 , and HD00651 .",
        "label": "NA"
    },
    {
        "text": "DB01026 did not affect the conversion of ddrug1 to the active metabolite after intravenous administration of DB00678 , and ddrug3 had no clinically significant effect after oral administration .",
        "label": "NA"
    },
    {
        "text": "DB00876 has been shown to have no effect on the pharmacokinetics of ddrug1 and the pharmacodynamics of DB00682 and ddrug3 .",
        "label": "NA"
    },
    {
        "text": "the use of HD00343 or ddrug1 with ddrug2 preparations may increase the effect of either the ddrug3 or DB00956 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00673 , when given as # mg on day # and # mg/day on days # and 3 , decreased the auc of ddrug2 { a cyp2c9 substrate } by 23 % on day 4 , 28 % on day 8 , and 15 % on day 15 , when a single dose of DB01124 # mg was admini , stered orally prior to the administration of the 3-day regimen of ddrug4 and on days 4,8 , and 15 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 / ddrug1 / ddrug2 / ddrug3 : co-administration of DB00633 with HD00264 , ddrug6 , ddrug7 , and ddrug8 is likely to lead to an enhancement of effects .",
        "label": "effect"
    },
    {
        "text": "if DB00598 is used with DB00727 in patients with angina pectoris , additional antihypertensive effects may occur .",
        "label": "effect"
    },
    {
        "text": "in addition , DB00569 neither influenced the pharmacodynamics of DB00682 , ddrug2 , ddrug3 , and ddrug4 , nor the pharmacokinetics of ddrug5 at steady state .",
        "label": "NA"
    },
    {
        "text": "DB02325 : in post-marketing experience , there have been rare reports of adverse neuropsychiatric events or reduced ddrug1 tolerance in patients who were drinking ddrug2 during treatment with DB01156 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 : coadministration of DB00220 with ddrug3 resulted in a 47 % decrease in DB00977 and an 18 % decrease in ddrug5 plasma concentrations .",
        "label": "NA"
    },
    {
        "text": "DB00405 can interact with ddrug1 or other ddrug2 { may potentiate the cns depressant effects of either these medications or ddrug3 } , ddrug4 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug5 } , and ddrug6 { concurrent use with HD00388 may prolong and intensify the anticholinergic and cns depressant effects of ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "hepatic enzyme inducers , inhibitors and substrates : drugs which induce cytochrome p450 3a4 { cyp 3a4 } enzyme activity { e , g , , ddrug0 , ddrug1 , ddrug2 , DB01045 } may enhance the metabolism of HD00175 and require that the dosage of the ddrug5 be increased .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 can interact with ddrug1 or other ddrug2 { may potentiate the cns depressant effects of either these medications or ddrug3 } , ddrug4 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with HD00388 } , and HD00445 { concurrent use with ddrug7 may prolong and intensify the anticholinergic and cns depressant effects of ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "therefore , co-administration of DB01156 with drugs that are metabolized by cyp2d6 isoenzyme including certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } , ddrug8 { e , g , , ddrug9 , ddrug10 , ddrug11 } , ddrug12 { e , g , , ddrug13 } , and ddrug14 { e , g , , ddrug15 , DB01195 } , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .",
        "label": "advise"
    },
    {
        "text": "coadministration of oral HD00283 , ddrug1 , ddrug2 , or ddrug3 did not seem to change the pharmacokinetic profile of DB00736 .",
        "label": "NA"
    },
    {
        "text": "however , because bleeding has been reported when ddrug0 and other HD00518 have been administered to patients on HD00724 , the physician should be cautious when administering ddrug3 to patients on ddrug4 .",
        "label": "effect"
    },
    {
        "text": "administration of HD00532 with ddrug1 containing ddrug2 , ddrug3 , or ddrug4 , with ddrug5 , with metal cations such as DB01592 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "mechanism"
    },
    {
        "text": "beta-blocking agents a pharmacokinetic study of ddrug0 in conjunction with DB00264 demonstrated no significant effects on the pharmacokinetics of DB01023 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , DB00176 , ddrug2 , DB01104 } .",
        "label": "NA"
    },
    {
        "text": "on the basis of the metabolism of DB00307 by cytochrome p450 3a4 , ddrug1 , DB01167 , ddrug3 , ddrug4 , grapefruit juice , and other inhibitors of cyp3a4 would be expected to lead to an increase in plasma ddrug5 concentrations .",
        "label": "NA"
    },
    {
        "text": "in a comparison of ddrug0 tolerance in dogs anesthetized with DB01221 , ddrug2 , or ddrug3 , the dosage of ddrug4 needed to cause ventricular tachycardia was significantly higher , as was the ld50 of DB01092 , with ddrug6 or ddrug7 than with ddrug8 .",
        "label": "NA"
    },
    {
        "text": "the purpose of this study was to evaluate the effect of HD00066 { ddrug1 } and HD00067 { ddrug3 } conjugates on the intestinal permeation of ddrug4 { ddrug5 } and model peptide drugs , ddrug6 and ddrug7 .",
        "label": "NA"
    },
    {
        "text": "the concomitant administration of ddrug0 and DB01370 - containing HD00589 has not been formally studied .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may have additive effects with ddrug1 and other HD00261 , e , g , , ddrug3 , HD00024 , ddrug5 , ddrug6 .",
        "label": "NA"
    },
    {
        "text": "however , the absolute number of ddrug0 - related deaths is far greater than the number of deaths in DB00182 or DB01452 users .",
        "label": "NA"
    },
    {
        "text": "HD00795 , ddrug1 , and HD00249 : drugs such as ddrug3 , ddrug4 , and ddrug5 may increase the risk of developing peripheral_neuropathies or other ddrug6 - associated adverse events by interfering with the renal clearance of ddrug7 { thereby raising systemic exposure } .",
        "label": "NA"
    },
    {
        "text": "in vitro displacement studies with highly protein-bound drugs such as ddrug0 , ddrug1 , ddrug2 , DB00622 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 showed no influence on the extent of DB00731 protein binding .",
        "label": "NA"
    },
    {
        "text": "laboratory tests response to HD00202 should be monitored by measuring serum total DB00624 concentrations just prior to administration on day # and every # weeks thereafter .",
        "label": "NA"
    },
    {
        "text": "in some patients , the administration of a ddrug0 can reduce the diuretic , natriuretic , and antihypertensive effects of ddrug1 , HD00293 and HD00029 .",
        "label": "NA"
    },
    {
        "text": "injection : ddrug0 injection , like other injectable ddrug1 , produces depression of the central nervous system when administered with ddrug2 , ddrug3 , HD00026 , ddrug5 , and other ddrug6 , when DB00747 is used concomitantly with injectable ddrug8 , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may increase slightly the effect of HD00448 , e , g , , DB01170 , ddrug3 , ddrug4 .",
        "label": "NA"
    },
    {
        "text": "-lsb- stimulation by ddrug0 -- an analog of the octapeptide cholecystokinin -- of ddrug1 binding after the long-term administration of ddrug2 -rsb- it has been established in experiments on white male rats that prolonged administration { twice a day for # days } of ddrug3 { # mg/kg } and HD00138 { # mg/kg } resulted in the reduced interaction between HD00136 and low affinity binding sites for ddrug6 in subcortical structures , whereas ddrug7 binding with high affinity binding sites for ddrug8 increased both in the frontal cortex and subcortical structures of the forebrain .",
        "label": "NA"
    },
    {
        "text": "ddrug0 with ddrug1 or DB00344 and possibly other HD00609 cause striking and sustained increases in the concentration of ddrug4 in the brain ;",
        "label": "NA"
    },
    {
        "text": "the extent to which HD00278 - HD00312 interactions may pose clinical problems will depend on the degree of inhibition , and the pharmacokinetics of the ddrug2 involved .",
        "label": "int"
    },
    {
        "text": "co-medications that induce cyp 3a4 { e , g , , DB01045 , ddrug1 , ddrug2 , ddrug3 , or st , john s wort } may significantly decrease exposure to DB00990 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : enhanced bone marrow suppression by ddrug1 and other HD00273 has been reported among patients with neoplastic disease , except leukemia , in the presence of DB00437 .",
        "label": "effect"
    },
    {
        "text": "DB00753 or ddrug1 administered with ddrug2 / ddrug3 to achieve # mac -lsb- minimum alveolar concentration -rsb- may prolong the clinically effective duration of action of initial and maintenance doses of ddrug4 and decrease the required infusion rate of DB00565 .",
        "label": "effect"
    },
    {
        "text": "DB08983 elicited 62 % enhancement of post - DB01109 lipolytic activity and 100 % increase of 3h-triglyceride fractional clearance rate compared with placebo treatment .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , HD00668 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { HD00531 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , DB00091 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { DB01045 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "substances that are potent inhibitors of cyp3a4 activity { eg , ddrug0 and DB01167 } decrease DB00317 metabolism and increase ddrug3 plasma concentrations .",
        "label": "mechanism"
    },
    {
        "text": "in vivo interaction studies in humans have demonstrated that ddrug0 and ddrug1 do not affect the pk properties of DB00261 , nor does ddrug3 affect the pk properties of ddrug4 or DB00682 .",
        "label": "NA"
    },
    {
        "text": "HD00884 , such as ddrug1 and ddrug2 , can inhibit renal tubular secretion of DB00698 .",
        "label": "mechanism"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / ddrug1 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , DB01208 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 pain medication { e , g , , DB00318 } , drugs used to aid sleep , drowsiness-causing ddrug13 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "when intravenous ddrug0 and DB00187 were concomitantly administered in normal subjects , no effect on DB00295 blood levels was seen , but ddrug3 steady-state blood levels were increased by 46 % in the presence of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "urinary alkalinizers : decrease DB00945 effectiveness by increasing the rate of HD00372 renal excretion .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a clinical pharmacology study , coadministration of an ddrug1 { ddrug2 , ddrug3 , and DB11074 } with ddrug5 reduced serum levels and urinary excretion of ddrug6 as compared with DB00492 administered alone , suggesting that ddrug8 may impair absorption of ddrug9 .",
        "label": "NA"
    },
    {
        "text": "the pressor effects of ddrug0 such as DB00988 or ddrug2 are enhanced by HD00438 .",
        "label": "effect"
    },
    {
        "text": "drug interactions : the central ddrug0 syndrome can occur when anticholinergic agents such as ddrug1 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain ddrug2 such as DB00454 , the ddrug4 and other ddrug5 , ddrug6 , certain ddrug7 such as the DB00908 salts , and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 such as ddrug1 { e , g , , ddrug2 } , DB00780 { e , g , , ddrug4 } , ddrug5 { e , g , , ddrug6 } , ddrug7 { e , g , , ddrug8 } , and ddrug9 { e , g , , ddrug10 } : using these medicines with DB00150 may increase the chance of side effects .",
        "label": "NA"
    },
    {
        "text": "patients treated with HD00587 and DB00682 concomitantly may need to be monitored for increases in inr and prothrombin time .",
        "label": "effect"
    },
    {
        "text": "therefore , co-administration of ddrug0 with other drugs that are metabolized by this isozyme , including ddrug1 , ddrug2 , ddrug3 , and ddrug4 { e , g , , DB01182 , ddrug6 and ddrug7 } , or that inhibit this enzyme { e , g , , DB00908 } , should be approached with caution .",
        "label": "NA"
    },
    {
        "text": "the blockade of the spinal endorphinergic system by intrathecal DB01183 on the production of tail-flick inhibition induced by intraventricular HD00144 and ddrug2 was then studied .",
        "label": "NA"
    },
    {
        "text": "ddrug0 reversible increases in serum ddrug1 concentrations and toxicity have been reported during concomitant administration of ddrug2 with HD00106 , and with some HD00466 .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral HD00811 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 { e , g , , DB00104 } , ddrug10 .",
        "label": "NA"
    },
    {
        "text": "in clinical studies performed with DB00569 , the concomitant use of oral ddrug1 { DB00682 } , ddrug3 { ddrug4 } , ddrug5 { ddrug6 } , and ddrug7 did not significantly affect the pharmacokinetics/pharmacodynamics of ddrug8 .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of HD00071 : ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , ddrug5 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , ddrug11 , HD00220 , ddrug13 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "while the effects of chronic DB00252 or DB00564 therapy on the action of ddrug2 are unknown , slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher .",
        "label": "NA"
    },
    {
        "text": "ddrug0 / ddrug1 : the coadministration of DB00252 or DB01174 will not affect plasma concentrations of ddrug4 , but may reduce endogenous plasma levels of ddrug5 / ergocalcitriol by accelerating metabolism .",
        "label": "NA"
    },
    {
        "text": "however , since ddrug0 , HD00203 , and ddrug2 are all associated with gastrointestinal irritation , caution should be exercised in the concomitant use of ddrug3 or ddrug4 with DB00710 .",
        "label": "NA"
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the ddrug0 of drugs may be potentiated by DB02325 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , the ddrug6 , ddrug7 and ddrug8 , ddrug9 and the ddrug10 , and by other HD00561 .",
        "label": "NA"
    },
    {
        "text": "drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving ddrug0 metabolized similarly to ddrug1 or on the basis of in vitro studies with ddrug2 or other ddrug3 { caution is recommended during coadministration with ddrug4 } : available data from clinical studies of ddrug5 other than ddrug6 suggest a possible drug interaction with DB00404 for the following : ddrug8 , ddrug9 , ddrug10 such as DB00199 and ddrug12 , and grapefruit juice .",
        "label": "int"
    },
    {
        "text": "patients receiving other ddrug0 s , general ddrug1 , ddrug2 , ddrug3 , ddrug4 , HD00043 or other ddrug6 { including ddrug7 } concomitantly with DB00327 may exhibit an additive cns depression .",
        "label": "effect"
    },
    {
        "text": "may interact ddrug0 { altered hypo-prothrombinemic effect } , ddrug1 , ddrug2 and other inducers of hepatic microsomal enzyme oxidation system { decreased effect of DB00255 } , HD00175 { increased effect of ddrug5 } .",
        "label": "NA"
    },
    {
        "text": "catecholamine-depleting drugs { eg , DB00206 } may have an additive effect when given with HD00376 s.",
        "label": "effect"
    },
    {
        "text": "if ddrug0 is to be combined with other ddrug1 such as HD00262 or ddrug3 / ddrug4 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of DB01151 and ddrug6 { e , g , , ddrug7 or ddrug8 } are additive .",
        "label": "NA"
    },
    {
        "text": "interactions may occur between ddrug0 supplements and ddrug1 and other HD00330 and herbs such as garlic { allium sativum } and DB01381 { ddrug4 } .",
        "label": "NA"
    },
    {
        "text": "in vitro displacement studies with highly protein-bound drugs such as ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , DB01124 , and ddrug10 showed no influence on the extent of DB00731 protein binding .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , HD00002 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { HD00548 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "concomitantly administered DB01592 - fortified infant formula { # mg elemental ddrug1 / 6 oz } has no significant effect on DB00535 pharmacokinetics .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { HD00548 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , DB00231 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "in vitro studies have shown no binding displacement between DB00494 and other highly bound drugs , such as ddrug1 , DB00645 , ddrug3 , and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "until further data are developed regarding drug interactions when DB00207 and these drugs are used concomitantly , careful monitoring of patients is advised : ddrug1 elevated DB00390 concentrations .",
        "label": "NA"
    },
    {
        "text": "coadministration of DB00673 with these drugs or other drugs that are known to be metabolized by cyp2c9 , such as DB00252 , may result in lower plasma concentrations of these drugs .",
        "label": "mechanism"
    },
    {
        "text": "other drug interactions oral HD00283 ddrug1 { 500 mg twice daily } did not influence the pharmacokinetics of an oral ddrug2 containing # mg ddrug3 and # mg DB00367 , or of the luteinizing hormone and progesterone levels , indicating that impairment of contraceptive efficacy is unlikely .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { DB00316 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , DB01026 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 ddrug1 ddrug2 , like other HD00532 , may inhibit the metabolism of ddrug4 and DB01412 .",
        "label": "mechanism"
    },
    {
        "text": "moreover , additional interaction studies with DB00627 and ddrug1 have not demonstrated any effect on ddrug2 plasma levels , and administration to a patient population chronically receiving ddrug3 resulted in no difference in the extent of bioavailability of DB00390 relative to control data .",
        "label": "NA"
    },
    {
        "text": "studies have shown that DB00448 does not have clinically significant interactions with other drugs metabolized by the cytochrome cyp2b6 system , such as ddrug1 , ddrug2 , ddrug3 , DB01050 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , or ddrug10 in healthy subjects .",
        "label": "NA"
    },
    {
        "text": "although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of DB00964 # % ophthalmic solution , the possibility of an additive or potentiating effect with ddrug1 { ddrug2 , HD00026 , ddrug4 , ddrug5 , ddrug6 } should be considered .",
        "label": "advise"
    },
    {
        "text": "ddrug0 and DB00661 use may be rarely associated with ventricular fibrillation when combined with DB00640 .",
        "label": "effect"
    },
    {
        "text": "serum DB00065 concentrations appeared to be unaffected by baseline use of medications for the treatment of crohn s disease including HD00175 , ddrug2 { ddrug3 or ddrug4 } and aminosalicylates .",
        "label": "NA"
    },
    {
        "text": "coadministration of this oral HD00349 did not influence the pharmacokinetics of DB01202 .",
        "label": "NA"
    },
    {
        "text": "if ddrug0 is to be combined with other ddrug1 such as HD00262 or ddrug3 / ddrug4 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of ddrug5 and HD00100 { e , g , , ddrug7 or ddrug8 } are additive .",
        "label": "NA"
    },
    {
        "text": "dose adjustment is not recommended , DB01202 had no effect on plasma concentrations of ddrug1 , ddrug2 , ddrug3 , or DB00555 .",
        "label": "NA"
    },
    {
        "text": "although specific drug interaction studies have not been conducted with DB00484 , the possibility of an additive or potentiating effect with ddrug1 { ddrug2 , HD00026 , ddrug4 , ddrug5 , or ddrug6 } should be considered .",
        "label": "advise"
    },
    {
        "text": "previous studies have demonstrated a significant reduction in the oral bioavailability of ddrug0 and DB00537 when administered concomitantly with an intravenous HD00099 such as ddrug3 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and DB00759 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , DB00220 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 should be used with care when HD00425 or inhibitors of av conduction , such as certain ddrug2 { particularly of the ddrug3 -lsb- ddrug4 -rsb- and ddrug5 -lsb- DB00343 -rsb- classes } , or ddrug7 , such as ddrug8 , are used concurrently .",
        "label": "NA"
    },
    {
        "text": "DB00196 , and the ddrug1 ddrug2 { DB00904 } and ddrug4 { ddrug5 } have all been used with ddrug6 .",
        "label": "NA"
    },
    {
        "text": "notably , systemic exposure { auc0 - 12 } of ddrug0 { DB03756 } was more than doubled in the presence of DB01643 / ddrug3 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 reversible increases in serum DB14507 concentrations and toxicity have been reported during concomitant administration of ddrug2 with HD00106 , and with some ddrug4 .",
        "label": "NA"
    },
    {
        "text": "aim and background : the pharmacokinetic interaction between DB00877 , a ddrug1 metabolized by cyp3a4 , and the ddrug2 DB00343 was studied in # healthy subjects .",
        "label": "NA"
    },
    {
        "text": "-lsb- a pharmacological analysis of the effect of ddrug0 on stimulated gastric secretion -rsb- chronic experiments on dogs with gastric fistulas were carried out to study the influence of HD00196 and HD00197 on ddrug3 - and ddrug4 - induced gastric acid secretion .",
        "label": "NA"
    },
    {
        "text": "ddrug0 / ddrug1 - containing ddrug2 : absorption of DB00943 is moderately reduced { approximately 25 % } when coadministered with ddrug4 / ddrug5 - containing HD00701 .",
        "label": "NA"
    },
    {
        "text": "caution should be observed when DB00913 is coadministered with other ddrug1 , HD00024 , ddrug3 , or ddrug4 , as these agents may increase respiratory and circulatory depression .",
        "label": "advise"
    },
    {
        "text": "although ddrug0 have been shown to reduce DB00041 - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with ddrug2 may reduce the antitumor effectiveness of ddrug3 and thus should be avoided , # ddrug4 and other HD00255 may potentiate the hypotension seen with ddrug6 .",
        "label": "NA"
    },
    {
        "text": "however , in a well-controlled study of patients with lymphoma on combination therapy , ddrug0 did not increase the marrow toxicity of patients treated with DB00531 , ddrug2 , ddrug3 , ddrug4 and/or DB00888 .",
        "label": "NA"
    },
    {
        "text": "DB00284 did not interfere with the absorption or disposition of the HD00226 ddrug2 in diabetic patients .",
        "label": "NA"
    },
    {
        "text": "in order to avoid the occurrence of severe hypersensitivity reactions , all patients treated with DB01229 should be premedicated with ddrug1 { such as ddrug2 } , diphen-hydramine and ddrug3 { such as DB00501 or ddrug5 } .",
        "label": "NA"
    },
    {
        "text": "while all the selective ddrug0 { HD00114 } , e , g , , DB00472 , ddrug3 , and ddrug4 , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .",
        "label": "NA"
    },
    {
        "text": "other drugs drug interactions have been reported with concomitant administration of DB00199 and other medications , including ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , DB01200 , ddrug8 , ddrug9 , and ddrug10 .",
        "label": "int"
    },
    {
        "text": "HD00532 , including ddrug1 , may enhance the effects of oral ddrug2 , including DB00682 or its derivatives or similar agents .",
        "label": "effect"
    },
    {
        "text": "the effect may be mediated by DB00501 s known inhibition of hepatic cytochrome p-450 , the enzyme system responsible for the first-pass metabolism of DB00343 .",
        "label": "mechanism"
    },
    {
        "text": "the purpose of this study was to evaluate the effect of ddrug0 { ddrug1 } and ddrug2 { HD00068 } conjugates on the intestinal permeation of ddrug4 { HD00070 } and model peptide drugs , ddrug6 and ddrug7 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { DB00316 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , DB00091 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "administration of repeat doses of ddrug0 had no effect on the repeat dose pharmacokinetics of DB00277 , ddrug2 or an ddrug3 / levonorgestrol oral HD00750 in healthy subjects .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may potentiate the hypotensive effects of HD00448 and the anticholinergic effects of DB00572 - type drugs .",
        "label": "NA"
    },
    {
        "text": "population pharmacokinetic analyses revealed that ddrug0 , ddrug1 , HD00175 , and ddrug3 did not influence DB01281 clearance .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 , as well as a metabolite of DB00614 , slow DB00182 metabolism .",
        "label": "mechanism"
    },
    {
        "text": "also , concomitant administration of HD00532 with products containing ddrug1 , ddrug2 containing ddrug3 , or DB00900 { ddrug5 } chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels .",
        "label": "mechanism"
    },
    {
        "text": "caution should also be taken in concurrent or serial use of other HD00249 and HD00384 because they may enhance neomycin s nephrotoxicity and/or ototoxicity and potentiate ddrug2 neuromuscular blocking effects .",
        "label": "NA"
    },
    {
        "text": "the following medications have been administered in clinical trials with DB00074 with no increase in adverse reactions : atg/alg , DB00993 , ddrug2 , ddrug3 , ddrug4 , and ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , DB00776 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , DB00812 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 s : HD00525 increases the adrenergic effect of catecholamines such as ddrug2 and DB00368 .",
        "label": "effect"
    },
    {
        "text": "- a HD00766 such as ddrug1 { DB00477 } , ddrug3 { ddrug4 , ddrug5 } , ddrug6 { ddrug7 } , ddrug8 { ddrug9 } , and others ;",
        "label": "NA"
    },
    {
        "text": "DB01032 may decrease renal tubular secretion of ddrug1 when used concurrently , resulting in increased and more prolonged HD00486 blood levels .",
        "label": "NA"
    },
    {
        "text": "ddrug0 or oral ddrug1 : HD00482 may enhance the blood-sugar-reducing effect of HD00071 and oral ddrug4 .",
        "label": "effect"
    },
    {
        "text": "therefore , DB00328 and DB00861 should not be used concomitantly .",
        "label": "advise"
    },
    {
        "text": "while all the HD00113 { ddrug1 } , e , g , , DB00215 , ddrug3 , ddrug4 , ddrug5 , and ddrug6 , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .",
        "label": "NA"
    },
    {
        "text": "concomitant single dose administration of ddrug0 # mg with multiple doses of DB01026 and DB00196 produced a significant increase in exposure of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "the potential effects of increased plasma concentrations of DB00683 or other ddrug1 metabolized via cyp3a4 { DB00404 , ddrug3 } should be considered when coadministering these agents with ddrug4 .",
        "label": "NA"
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit ddrug0 binding to serum proteins or alter the concentrations of serum binding proteins : HD00657 and related ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 , ddrug7 , ddrug8 , HD00115 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 .",
        "label": "NA"
    },
    {
        "text": "-lsb- dose-time effects of competitive displacement of HD00125 by HD00126 following oral and intravenous administration -rsb- the effect of various doses of ddrug2 in several dose fractions on the extent and the time scale of displacement of ddrug3 , in dependence on application mode , was studied .",
        "label": "NA"
    },
    {
        "text": "in patients given very high doses { 3900 mg } of ddrug0 daily , increases in serum HD00372 levels were seen when DB00585 , # mg b , i , d , , was administered concurrently .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : estimates of steady-state pharmacokinetic parameters for DB01174 or DB00996 { 300 mg tid ;",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } HD00220 ddrug10 { ddrug11 } sporal { DB01167 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "ddrug0 reduced the blood auc0 - 12 of ddrug1 by approximately 20 % , peak blood concentration { cmax } by 16 % , and 12-hour blood concentration { c12hr } by 26 % in healthy subjects when DB00864 { 2 doses of # mg/kg # hours apart } was administered on the 10th day of DB00520 # mg daily , as compared to results from a control period in which ddrug4 was administered alone .",
        "label": "NA"
    },
    {
        "text": "however , the antagonism of the ddrug0 - induced anxiogenic effects by ddrug1 was only observed in the time spent in the light zone , and HD00188 - induced anxiogenic effects were neither reversed by ddrug3 nor by HD00186 .",
        "label": "NA"
    },
    {
        "text": "-lsb- stimulation by DB00403 -- an analog of the octapeptide cholecystokinin -- of ddrug1 binding after the long-term administration of HD00137 -rsb- it has been established in experiments on white male rats that prolonged administration { twice a day for # days } of ddrug3 { # mg/kg } and ddrug4 { # mg/kg } resulted in the reduced interaction between ddrug5 and low affinity binding sites for ddrug6 in subcortical structures , whereas ddrug7 binding with high affinity binding sites for ddrug8 increased both in the frontal cortex and subcortical structures of the forebrain .",
        "label": "NA"
    },
    {
        "text": "the use of ddrug0 or HD00043 with ddrug2 preparations may increase the effect of either the ddrug3 or DB00956 .",
        "label": "NA"
    },
    {
        "text": "DB01045 markedly increases the metabolic clearance of DB00701 , and coadministration is contraindicated .",
        "label": "mechanism"
    },
    {
        "text": "although it has not been definitively demonstrated that ddrug0 is a potent iiia4 inhibitor , it is likely to be , given the substantial interaction of DB00176 with DB00404 .",
        "label": "int"
    },
    {
        "text": "the majority of patients in ra clinical studies received one or more of the following concomitant medications with DB01281 : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , DB01097 , ddrug10 , and ddrug11 .",
        "label": "NA"
    },
    {
        "text": "DB00898 / DB00860 : ddrug2 did not have any clinically important effect on the pharmacokinetics of ddrug3 or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "myocardial injury , including myocardial infarction , myocarditis , ventricular hypokinesia , and severe rhabdomyolysis appear to be increased in patients receiving DB00041 and HD00253 concurrently .",
        "label": "effect"
    },
    {
        "text": "HD00871 : DB01045 contraindicated since the coadministration of this product with ddrug2 in an ddrug3 regimen reduces the plasma concentrations of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "when DB00564 is added to DB01238 therapy , ddrug2 dose should be doubled .",
        "label": "advise"
    },
    {
        "text": "conclusions : in contrast to the effects of HD00115 in rodent studies , these results indicate that an acute increase in cortisol does not enhance the psychostimulant effects of DB01576 in humans .",
        "label": "NA"
    },
    {
        "text": "by this procedure , it was observed that HD00141 is rapidly and essentially completely absorbed { 80 - 95 % } from the lumen at HD00142 concentrations up to # mm , declining to about 50 % absorption at # mm .",
        "label": "NA"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : ddrug1 ; ddrug2 ; ddrug3 ; certain HD00002 , especially the ddrug5 and ddrug6 ; ddrug7 ; ddrug8 salts ; ddrug9 ; and DB00908 .",
        "label": "NA"
    },
    {
        "text": "in clinical trials , ddrug0 was used with ddrug1 , ddrug2 , ddrug3 , oral ddrug4 , and supplemental ddrug5 , in a pharmacokinetic substudy in patients with congestive heart failure receiving DB00695 or ddrug7 in whom therapy with DB01240 was initiated , apparent oral clearance values for ddrug9 { n = 23 } and ddrug10 { n = 30 } were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : the concomitant use of ddrug1 { DB00813 transdermal system } with other ddrug3 , including but not limited to other HD00263 , ddrug5 , ddrug6 , ddrug7 { e , g , , ddrug8 } , general ddrug9 , ddrug10 , ddrug11 , and ddrug12 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .",
        "label": "effect"
    },
    {
        "text": "ddrug0 / ddrug1 / HD00214 / ddrug3 : co-administration of ddrug4 with HD00264 , ddrug6 , ddrug7 , and ddrug8 is likely to lead to an enhancement of effects .",
        "label": "NA"
    },
    {
        "text": "studies have shown that DB00448 does not have clinically significant interactions with other drugs metabolized by the cytochrome cyp2b6 system , such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , DB00898 , ddrug8 , ddrug9 , or ddrug10 in healthy subjects .",
        "label": "NA"
    },
    {
        "text": "HD00264 / HD00024 / ddrug2 / ddrug3 : co-administration of ddrug4 with ddrug5 , ddrug6 , ddrug7 , and ddrug8 is likely to lead to an enhancement of effects .",
        "label": "NA"
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma ddrug0 concentrations include : acute DB02325 intake , ddrug2 , chboramphenicol , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , DB00472 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21",
        "label": "NA"
    },
    {
        "text": "compromised DB00368 uptake-1 in functional class iv can not be further increased by ddrug1 and DB01151 .",
        "label": "NA"
    },
    {
        "text": "the purpose of this study was to evaluate the effect of HD00066 { ddrug1 } and ddrug2 { HD00068 } conjugates on the intestinal permeation of ddrug4 { ddrug5 } and model peptide drugs , ddrug6 and ddrug7 .",
        "label": "NA"
    },
    {
        "text": "may interact with the following : ddrug0 { these medicines may make your condition worse and prevent the HD00815 from working properly } and ddrug2 , ddrug3 , HD00219 , and ddrug5 { these medicines may increase the risk of heart problems } .",
        "label": "NA"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 HD00303 : ddrug2 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 HD00871 : ddrug9 ddrug10 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "DB00542 has been used concomitantly with ddrug1 , ddrug2 , ddrug3 , DB00390 , and ddrug5 , without evidence of clinically important adverse interactions .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { ddrug1 } : ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , DB01104 } have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with HD00277 .",
        "label": "effect"
    },
    {
        "text": "because oral ddrug0 may interfere with the hepatic metabolism of ddrug1 , toxic levels of the HD00329 may occur when an oral ddrug3 and DB00252 are administered concurrently .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 HD00388 ddrug5 { ddrug6 } ddrug7 { ddrug8 } HD00220 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "investigations into the effect of DB00459 on the protein binding of ddrug1 { DB00682 } revealed no interaction .",
        "label": "NA"
    },
    {
        "text": "the reduced risk of adverse events and therapeutic superiority compared with ddrug0 and DB00734 in the treatment of negative and depressive symptoms support the choice of DB00334 as a first-line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a pharmacokinetic study , maximum plasma concentrations of ddrug1 were considerably lower in epileptic patients on long-term HD00329 therapy { eg , ddrug3 , ddrug4 , or DB01174 } than in healthy volunteers .",
        "label": "NA"
    },
    {
        "text": "since animal studies suggest that the action of ddrug0 may be prolonged by therapy with DB00672 , HD00026 should be employed with caution .",
        "label": "NA"
    },
    {
        "text": "the pressor effects of ddrug0 such as ddrug1 or DB00368 are enhanced by HD00438 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { DB00252 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , DB00277 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB01045 contraindicated since the coadministration of this product with DB01232 in an ddrug3 regimen reduces the plasma concentrations of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "the use of DB01135 before DB00202 to attenuate some of the side effects of ddrug2 has not been studied .",
        "label": "NA"
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of HD00539 such as ddrug1 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 , DB01627 , ddrug8 , ddrug9 , and ddrug10 } , ddrug11 salts , ddrug12 , local ddrug13 , ddrug14 , and ddrug15 .",
        "label": "effect"
    },
    {
        "text": "when ddrug0 and ddrug1 are used together , the signs of atropinization { flushing , mydriasis , tachycardia , dryness of the mouth and nose } may occur earlier than might be expected than when DB00572 is used alone because DB00733 may potentiate the effect of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 s : ddrug1 should be administered at least # hours after or # hours before dosing with DB00537 because plasma concentrations of ddrug3 are decreased when administered with HD00374 containing ddrug5 , ddrug6 , or ddrug7 .",
        "label": "NA"
    },
    {
        "text": "in vitro displacement studies with highly protein-bound drugs such as ddrug0 , ddrug1 , ddrug2 , ddrug3 , DB00175 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 showed no influence on the extent of DB00731 protein binding .",
        "label": "NA"
    },
    {
        "text": "the pressor effects of ddrug0 such as DB00988 or DB00368 are enhanced by ddrug3 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 s : in a small clinical trial in which DB00227 was administered to DB00682 treated patients , no effect on prothrombin time was detected .",
        "label": "NA"
    },
    {
        "text": "DB00590 has been administered without any evidence of an adverse drug interaction to patients receiving ddrug1 , HD00376 s , and ddrug3 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 ddrug1 may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation , the discontinuance of ddrug2 HD00524 could pose a hazard to health if a potentially toxic drug such as HD00118 has been filtrated to a maintenance level while the patient was taking ddrug5 ddrug6 .",
        "label": "NA"
    },
    {
        "text": "nephrotoxicity has been reported following concomitant administration of HD00447 and HD00495 .",
        "label": "effect"
    },
    {
        "text": "plasma levels of several closely related HD00043 have been reported to be increased by the concomitant administration of ddrug1 or hepatic enzyme inhibitors { e , g , , DB00501 , ddrug3 } and decreased by the concomitant administration of hepatic enzyme inducers { e , g , , ddrug4 , ddrug5 } , and such an effect may be anticipated with ddrug6 as well .",
        "label": "mechanism"
    },
    {
        "text": "- ddrug0 and ddrug1 ddrug2 : ddrug3 and ddrug4 HD00510 have the potential of binding HD00029 and reducing ddrug7 absorption from the gastrointestinal tract",
        "label": "NA"
    },
    {
        "text": "patients receiving these drugs who are given DB00749 , or any other HD00615 , and particularly those patients with altered renal function , should be observed for the development of the specific toxicities of these drugs .",
        "label": "NA"
    },
    {
        "text": "therefore , co-administration of ddrug0 with drugs that are metabolized by cyp2d6 isoenzyme including certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } , HD00031 { e , g , , ddrug9 , ddrug10 , ddrug11 } , ddrug12 { e , g , , DB00264 } , and ddrug14 { e , g , , ddrug15 , ddrug16 } , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .",
        "label": "NA"
    },
    {
        "text": "the action of the HD00100 may be potentiated by HD00282 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , or other drugs that produce cns depression .",
        "label": "effect"
    },
    {
        "text": "drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving ddrug0 metabolized similarly to ddrug1 or on the basis of in vitro studies with ddrug2 or other ddrug3 { caution is recommended during coadministration with ddrug4 } : available data from clinical studies of ddrug5 other than ddrug6 suggest a possible drug interaction with ddrug7 for the following : DB00343 , ddrug9 , ddrug10 such as DB00199 and ddrug12 , and grapefruit juice .",
        "label": "NA"
    },
    {
        "text": "caution should be used when administering or taking DB00530 with ddrug1 and other strong cyp3a4 inhibitors such as , but not limited to , ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB01149 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { ddrug12 } , and ddrug13 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 { cns } drugs including ddrug1 , ddrug2 , HD00388 , ddrug4 , blood pressure medications { ddrug5 , ddrug6 , ddrug7 } , motion sickness medications , ddrug8 , HD00543 , ddrug10 , sleeping pills and ddrug11",
        "label": "NA"
    },
    {
        "text": "with the exception of DB01001 , there are no formal studies fully evaluating the interaction effects of DB00332 inhalation aerosol and these drugs with respect to effectiveness .",
        "label": "NA"
    },
    {
        "text": "DB01232 : coadministration of ddrug1 { using an experimental soft-gelatin capsule formulation of ddrug2 1200 mg } with ddrug3 resulted in an 18 % increase in DB00220 plasma auc and a 4-fold increase in ddrug5 plasma a , c.",
        "label": "NA"
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the HD00555 of drugs may be potentiated by ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , the ddrug6 , HD00559 and ddrug8 , ddrug9 and the ddrug10 , and by other ddrug11 .",
        "label": "effect"
    },
    {
        "text": "therefore , when DB00880 and ddrug1 are used concomitantly , the patient should be observed closely to determine if the desired effect of the HD00295 is obtained",
        "label": "NA"
    },
    {
        "text": "ddrug0 : reports indicate that DB00091 levels may be increased during concomitant treatment with DB00437 for injection .",
        "label": "mechanism"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect : ddrug0 , DB00627 , ddrug2 , ddrug3 , ddrug4 { e , g , , ddrug5 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 { e , g , , in oral HD00283 } .",
        "label": "NA"
    },
    {
        "text": "drugs that may alter DB00619 plasma concentrations drugs that may increase ddrug1 plasma concentrations : caution is recommended when administering ddrug2 with inhibitors of the cyp3a4 family { e , g , , ddrug3 , ddrug4 , ddrug5 , DB01211 } .",
        "label": "NA"
    },
    {
        "text": "the ddrug0 are a family of HD00199 and HD00200 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 { and possibly other ddrug2 } and ddrug3 may increase DB00390 absorption in patients who inactivate ddrug5 by bacterial metabolism in the lower intestine , so that HD00118 intoxication may result .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of DB00986 injection and DB00761 in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time .",
        "label": "mechanism"
    },
    {
        "text": "antiacid , ddrug0 , ddrug1 , DB00196 , ddrug3 , indanavir , ddrug4 , ddrug5 , phenobarbitol , ddrug6 , ddrug7 , DB01045 , ritanovir , ddrug9 .",
        "label": "NA"
    },
    {
        "text": "these data emphasize that apoptosis can be induced in mcf-7 cells either by activation of HD00182 - mediated signalling or disruption of HD00183 - dependent signalling .",
        "label": "NA"
    },
    {
        "text": "however , the systemic administration of some ddrug0 has been shown to elevate plasma concentrations of ddrug1 , interfere with the metabolism of ddrug2 , and enhance the effects of the oral HD00025 ddrug4 and its derivatives , and has been associated with transient elevations in serum creatinine in patients receiving systemic DB00091 concomitantly .",
        "label": "NA"
    },
    {
        "text": "concurrent therapy with DB01281 and HD00206 is not recommended .",
        "label": "advise"
    },
    {
        "text": "the response to ddrug0 may be blunted by HD00219 and HD00339 which cause a rise in prolactin .",
        "label": "NA"
    },
    {
        "text": "ddrug0 absorption : the following agents may bind and decrease absorption of ddrug1 from the gastrointestinal tract : ddrug2 , ddrug3 resin , ddrug4 , DB01373 , ddrug6 , soybean flour { e , g , , infant formula } , DB00364 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : isolated cases of conduction disturbance { rarely with hemodynamic compromise } have been observed when DB01136 is co-administered with DB00343 .",
        "label": "effect"
    },
    {
        "text": "DB00091 : elevated serum levels of ddrug1 have been reported with concomitant use of ddrug2 with other members of the HD00678 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , including oral , injectable , transdermal , and implantable ddrug1 : an interaction study demonstrated that co-administration of ddrug2 and the oral ddrug3 DB00717 produced average decreases of DB00717 and ddrug6 levels of 14 % and 31 % , respectively .",
        "label": "NA"
    },
    {
        "text": "caution should be exercised if DB00864 and DB00559 are used together .",
        "label": "advise"
    },
    {
        "text": "ddrug0 s : ddrug1 should be administered at least # hours after or # hours before dosing with DB00537 because plasma concentrations of ddrug3 are decreased when administered with ddrug4 containing DB14513 , ddrug6 , or ddrug7 .",
        "label": "NA"
    },
    {
        "text": "the administration of DB01018 concomitantly with known microsomal enzyme inducer { ddrug1 or DB00252 } to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { DB01045 } , st , johns wort , ddrug41 , DB00277 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "if intravenous DB00738 is required to treat pneumocystis carinii pneumonia , treatment with DB00943 should be interrupted .",
        "label": "advise"
    },
    {
        "text": "ddrug0 and DB00717 : coadministration of ddrug2 with ddrug3 resulted in a 47 % decrease in DB00977 and an 18 % decrease in ddrug5 plasma concentrations .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - and/or ddrug1 - containing ddrug2 , products containing ddrug3 { ddrug4 } , HD00752 containing ddrug6 or other metal cations , or DB00900 { ddrug8 } chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after ddrug9 .",
        "label": "NA"
    },
    {
        "text": "medications can interfere with folate utilization , including : ddrug0 { such as DB00252 , and ddrug2 } DB00331 { sometimes prescribed to control blood sugar in type # diabetes } ddrug4 { used to control inflammation associated with crohn_disease and ulcerative colitis } ddrug5 { a ddrug6 } ddrug7 there has been concern about the interaction between ddrug8 and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "HD00852 : some individuals receiving ddrug1 may experience a reversible enhancement of the pressor response to indirect-acting HD00571 , ddrug3 or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 : ddrug2 and DB01575 can reduce absorption of DB00608 ;",
        "label": "mechanism"
    },
    {
        "text": "DB00390 , DB00563 , ddrug2 : ddrug3 , like other ddrug4 , may affect renal prostaglandins and increase the toxicity of certain drugs .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { DB01076 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , DB00224 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "based on the chemical resemblance of ddrug0 and DB01026 , coadministration of ddrug2 with DB01167 is contraindicated .",
        "label": "NA"
    },
    {
        "text": "in a comparison of ddrug0 tolerance in dogs anesthetized with ddrug1 , HD00119 , or ddrug3 , the dosage of ddrug4 needed to cause ventricular tachycardia was significantly higher , as was the ld50 of ddrug5 , with DB01221 or ddrug7 than with ddrug8 .",
        "label": "NA"
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as DB01135 include certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 } , ddrug10 salts , DB14507 , local ddrug12 , ddrug13 , and ddrug14 .",
        "label": "effect"
    },
    {
        "text": "DB01223 DB00292 antagonism",
        "label": "NA"
    },
    {
        "text": "ddrug0 / HD00214 : DB00683 , ddrug3",
        "label": "NA"
    },
    {
        "text": "ddrug0 : when ddrug1 and HD00382 suspension were coadministered , plasma concentrations of DB01076 decreased approximately 35 % .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect : HD00175 , ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , ddrug5 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 { e , g , , in oral HD00283 } .",
        "label": "NA"
    },
    {
        "text": "other drugs : in small groups of patients { 7 - 10 / interaction study } , the concomitant administration of ddrug0 , ddrug1 , DB00608 , ddrug3 , ddrug4 , ddrug5 , or ddrug6 did not significantly affect the peak levels and auc values of DB00586 .",
        "label": "NA"
    },
    {
        "text": "drugs that induce cyp3a4 { ddrug0 } racemic DB01198 exposure was decreased 80 % by concomitant useof DB01045 , a potent inducer of cyp3a4 .",
        "label": "mechanism"
    },
    {
        "text": "in two controlled crossover clinical pharmacology studies in healthy male { n = 12 in each study } a nd female { n = 12 in each study } volunteers , DB00967 # mg { # times the daily dose } once daily was coadministered with DB00199 # mg every # hours or ddrug2 # mg every # hours for # days .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration of a 10-mg single dose of DB01238 with DB00908 { 166 mg/day for # days } , a potent inhibitor of cyp2d6 , increased the auc of ddrug3 by 112 % but decreased the auc of its active metabolite , ddrug4 , by 35 % .",
        "label": "mechanism"
    },
    {
        "text": "compounds in these categories result in a decreased efficacy of DB01200 : ddrug1 , ddrug2 , ddrug3 , DB01100 .",
        "label": "effect"
    },
    {
        "text": "the use of ddrug0 should be considered in place of ddrug1 or HD00587 in patients receiving DB01254 therapy .",
        "label": "advise"
    },
    {
        "text": "analysis of the concentration of DB01222 following ultracentrifugation indicated that there is rapid equilibration of ddrug1 between the DB06761 and aqueous phase .",
        "label": "NA"
    },
    {
        "text": "in addition , ddrug0 neither influenced the pharmacodynamics of DB00682 , ddrug2 , ddrug3 , and ddrug4 , nor the pharmacokinetics of DB00390 at steady state .",
        "label": "NA"
    },
    {
        "text": "in patients receiving nonselective ddrug0 { HD00546 } { e , g , , ddrug2 } in combination with ddrug3 { e , g , , DB00472 , ddrug5 , ddrug6 , ddrug7 , ddrug8 } , there have been reports of serious , sometimes fatal , reactions .",
        "label": "effect"
    },
    {
        "text": "- when HD00414 or ddrug1 is used concurrently with ddrug2 { e , g , HD00419 } , an interval of at least # hours should be maintained between the two medicines , since the absorption of ddrug4 or ddrug5 is impaired",
        "label": "advise"
    },
    {
        "text": "co-administration of DB09026 did not significantly affect the pharmacokinetics of ddrug1 , DB00390 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 or ddrug10 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : since DB00714 is a ddrug2 , it is possible that ddrug3 , such as the HD00137 { ddrug5 , ddrug6 , ddrug7 } or ddrug8 , may diminish the effectiveness of ddrug9 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { e , g , , ddrug1 , ddrug2 , DB00257 , ddrug4 , etc , } : in vitro and animal studies with the combination of ddrug5 and HD00319 suggest that ddrug7 may induce fungal resistance to ddrug8 .",
        "label": "NA"
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as ddrug0 include certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 } , DB14513 salts , DB14507 , local ddrug12 , ddrug13 , and ddrug14 .",
        "label": "NA"
    },
    {
        "text": "additionally , HD00474 , such as DB00608 and ddrug2 , may antagonize the activity of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 at 1 % { m/v } in the presence of free DB00151 had no significant effect on the r-value of ddrug2 compared to HD00072 alone .",
        "label": "NA"
    },
    {
        "text": "DB09499 is a neutralizing agent for DB00515 that protects against renal damage .",
        "label": "effect"
    },
    {
        "text": "other drugs : based on the results of drug interaction studies , no dosage adjustment is recommended when ddrug0 { DB00625 } is given with the following : ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , DB00186 , ddrug9 , ddrug10 , and ddrug11 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 at 1 % { m/v } in the presence of free ddrug1 had no significant effect on the r-value of HD00070 compared to HD00072 alone .",
        "label": "NA"
    },
    {
        "text": "wait # weeks after stopping an HD00455 before starting DB01175 .",
        "label": "advise"
    },
    {
        "text": "therefore , co-administration of ddrug0 with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index , including certain ddrug1 { ddrug2 -lsb- ddrug3 -rsb- , such as ddrug4 , ddrug5 , and ddrug6 } , HD00219 and ddrug8 { e , g , , DB01182 , ddrug10 } , should be approached with caution .",
        "label": "NA"
    },
    {
        "text": "these medications have included ddrug0 , ddrug1 , HD00207 , ddrug3 , ddrug4 , intravenous and oral ddrug5 , DB00208 , and ddrug7 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 generally should not be given with HD00218 because they reduce ddrug2 s renal clearance and add a high risk of DB14507 toxicity .",
        "label": "NA"
    },
    {
        "text": "additive adverse effects resulting from cholinergic blockade may occur when DB00424 is administered concomitantly with other HD00791 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 or some ddrug7 .",
        "label": "effect"
    },
    {
        "text": "concomitant administration with racemic ddrug0 ddrug1 - since DB01175 is the active isomer of racemic ddrug3 { DB00215 } , the two agents should not be coadministered .",
        "label": "advise"
    },
    {
        "text": "ddrug0 , ddrug1 , and HD00546 may increase anticholinergic effect of DB00771 .",
        "label": "effect"
    },
    {
        "text": "if DB01151 is to be combined with other ddrug1 such as HD00262 or ddrug3 / ddrug4 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of ddrug5 and ddrug6 { e , g , , ddrug7 or ddrug8 } are additive .",
        "label": "effect"
    },
    {
        "text": "we compared ddrug0 pharmacokinetics and gastric ph in # human immunodeficiency virus-positive patients by use of # mg of DB00224 alone versus # mg of ddrug2 administered # h after DB00900 administration .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : clinical evidence has shown that DB00926 can be formed with concurrent ingestion of ddrug2 and DB00898 .",
        "label": "NA"
    },
    {
        "text": "DB00501 , ddrug1 : in normal volunteers { n = 9 } , pretreatment with ddrug2 or ddrug3 did not affect ddrug4 pharmacokinetics except that a small { 13 % } but statistically significant increase in the area under the serum concentration curve of DB00712 resulted with ddrug6 .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 DB00264 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } DB01026 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "co-administration of cyp3a4 inhibitors { eg , ddrug0 , ddrug1 , ddrug2 , grapefruit juice , DB00501 } with ddrug4 may lead to several - fold increases in the plasma levels of DB01023 , either due to an increase in bioavailability or due to a decrease in metabolism .",
        "label": "NA"
    },
    {
        "text": "the urinary excretion of ddrug0 is unaffected by DB00945 , indicating no change in DB00939 absorption .",
        "label": "NA"
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit DB00451 binding to serum proteins or alter the concentrations of serum binding proteins : HD00657 and related ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 , ddrug1 , ddrug2 , and DB01109 the in vitro binding of ddrug4 to plasma proteins is only slightly reduced by DB00465 { # % control vs # % } when ddrug6 plasma concentrations reach # to10 m g/ml .",
        "label": "NA"
    },
    {
        "text": "there have been case reports of increased steady-state levels of ddrug0 , ddrug1 , and DB00252 during concomitant therapy with DB01118 .",
        "label": "NA"
    },
    {
        "text": "other cardiovascular agents : DB00584 and ddrug1 iv have been used concomitantly with ddrug2 , DB00968 , ddrug4 , ddrug5 , ddrug6 , ddrug7 and ddrug8 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { DB00316 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , DB00220 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of DB00732 include : ddrug1 ; ddrug2 ; ddrug3 ; certain ddrug4 , especially the ddrug5 and ddrug6 ; ddrug7 ; ddrug8 salts ; DB01035 ; and ddrug10 .",
        "label": "effect"
    },
    {
        "text": "potential DB00342 , DB00637 , and ddrug2 interactions",
        "label": "NA"
    },
    {
        "text": "DB00603 - DB00117 was observed to enhance { in tissue culture } the effect of ddrug2 in reducing the number of human breast_cancer cells that were in the s phase .",
        "label": "NA"
    },
    {
        "text": "the oral DB01234 doses should be reduced by approximately 50 % when coadministered with DB00673 , to achieve exposures of ddrug2 similar to those obtained when it is given without ddrug3 .",
        "label": "advise"
    },
    {
        "text": "prior administration of DB01213 { 90 mg kg { -1 } body weight } was shown to prevent the conversion of ddrug1 { 100 mg kg { -1 } body weight } to ddrug2 in vivo and to eliminate the fluoride and citrate elevations seen in HD00079 - intoxicated animals .",
        "label": "NA"
    },
    {
        "text": "since DB00328 and HD00293 , including ddrug2 , may each be associated with increased serum potassium levels , the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , DB01076 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , DB00860 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "however , patients on ddrug0 may show elevations of ddrug1 concentrations after initiation of therapy with DB01240 , which may be clinically significant in patients prone to DB00390 toxicity .",
        "label": "NA"
    },
    {
        "text": "comparison of DB00515 pharmacokinetics in patients treated with # mg/m2 plus ddrug1 to those in patients treated with # mg/m2 without HD00158 indicated that there were no changes in the elimination rate constant , volume of distribution , or total body clearance of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "the gonadotropin levels may be transiently elevated by ddrug0 , minimally elevated by ddrug1 , and suppressed by oral HD00283 and DB00390 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : some individuals receiving DB00601 may experience a reversible enhancement of the pressor response to indirect-acting HD00571 , ddrug3 or ddrug4 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , DB00636 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , DB01232 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "when DB00715 , a potent inhibitor of cyp2d6 , was co-administered with DB01274 at steady-state , exposure to either drug was not altered .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB01045 increases the metabolism of DB00977 and some ddrug3 { ddrug4 } resulting in decreased contraceptive effectiveness and increased menstrual irregularities .",
        "label": "mechanism"
    },
    {
        "text": "patients should be advised against the simultaneous use of other HD00545 , and cautioned that the effect of DB02325 may be increased .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : HD00403 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 DB14507 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "pretreatment of rats with DB00437 { 100 mg/kg , ip } or ddrug1 { 100 mg/kg per day , ig , for # days and a dose of # mg/kg on the 4th day } provided significant protection against the elevation of tbars levels in cerebral and hepatic tissues , induced by single high dose of oral HD00044 administration within # h.",
        "label": "effect"
    },
    {
        "text": "coadministration of DB00580 { 40 mg bid { day 1 } and # mg qd { days 2 - 7 } } with ddrug1 { 10 mg ddrug2 bid } resulted in 21 % increase in DB01016 auc0 - 12 and a 16 % increase in ddrug4 cmax leading to a 16 % decrease in glucose auc0 - 24 .",
        "label": "NA"
    },
    {
        "text": "drugs demonstrated to be cyp 3a inhibitors of possible clinical significance on the basis of clinical studies involving ddrug0 { caution is recommended during coadministration with ddrug1 } : coadministration of DB00472 with ddrug3 increased the maximum plasma concentration of DB00404 by 46 % , decreased clearance by 21 % , increased half-life by 17 % , and decreased measured psychomotor performance .",
        "label": "NA"
    },
    {
        "text": "in patients with chronic hepatitis c treated with ddrug0 in combination with DB00811 , DB00008 treatment did not affect ddrug3 distribution or clearance .",
        "label": "NA"
    },
    {
        "text": "the authors investigated the possibility of a similar interaction between DB00497 and DB01137 .",
        "label": "NA"
    },
    {
        "text": "the elimination half life of ddrug0 and DB00897 also increased { # # fold } during coadministration with DB00343 .",
        "label": "mechanism"
    },
    {
        "text": "discontinuation of ddrug0 in well-controlled patients receiving ddrug1 and DB00501 may decrease the plasma levels and efficacy of the HD00216 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00357 may diminish adrenal suppression by HD00175 .",
        "label": "effect"
    },
    {
        "text": "patients taking these drugs with ddrug0 and DB01235 or DB00190 - ddrug3 combination products should be carefully observed for loss of therapeutic response .",
        "label": "NA"
    },
    {
        "text": "similarly dialyzed were ddrug0 , ddrug1 , and DB00277 , both alone at therapeutic concentrations in serum and with DB00898 at three different concentrations in serum .",
        "label": "NA"
    },
    {
        "text": "no depressant effect on blood levels in humans was noted when ddrug0 was administered with any of the following drugs : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 { DB00627 } , ddrug7 , ddrug8 or DB00682 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : modest increases in mean trough DB00091 concentrations were observed following initiation of DB01136 treatment in # renal transplant patients suffering from chronic vascular rejection .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , DB00273 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , DB00812 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , HD00802 : e , g , , DB01023 , ddrug3 , ddrug4",
        "label": "NA"
    },
    {
        "text": "other cardiovascular agents : DB00584 and ddrug1 iv have been used concomitantly with ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB01275 , ddrug7 and ddrug8 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "DB00988 - induced renal and mesenteric vasodilation is not antagonized by either HD00647 or ddrug2 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , DB00295 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { HD00531 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 interaction studies with DB00682 and ddrug2 failed to identify any clinically important effects on the serum concentrations or clinical effects of these HD00326 .",
        "label": "NA"
    },
    {
        "text": "in a single subject given one dose of DB00537 # hours after a dose of DB00900 - placebo tablets , a greater than 50 % reduction in the auc of ddrug2 was observed .",
        "label": "mechanism"
    },
    {
        "text": "concurrent use of DB00611 with HD00389 { e , g , , ddrug2 , ddrug3 , ddrug4 , and ddrug5 } may result in increased ddrug6 effects .",
        "label": "effect"
    },
    {
        "text": "as HD00888 , the predominant plasma substrate , is only a weak inducer of udp-glucuronyl transferase , it is unlikely to have an effect on drugs that are mainly eliminated by conjugation through udp-glucuronyl transferase { e , g , , DB00313 , ddrug2 } .",
        "label": "NA"
    },
    {
        "text": "it is recommended that plasma DB14507 levels be monitored when DB01009 is coadministered with ddrug2 .",
        "label": "NA"
    },
    {
        "text": "prior administration of DB00202 has no clinically important effect on the neuromuscular blocking action of DB01135 .",
        "label": "NA"
    },
    {
        "text": "although the clinical significance is not known , it is not recommended that DB01066 be taken concomitantly with HD00374 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , HD00668 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , DB01601 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of ddrug0 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 { 2 } , DB00794 , ddrug8 , and ddrug9 thus , if a patient has been titrated to a stable dosage on HD00472 , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for ddrug11 may be necessary .",
        "label": "NA"
    },
    {
        "text": "concomitant use with other ddrug0 - containing medicines { including HD00374 } may cause too much DB01373 in the blood or urine , which may increase the chance of side effects .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { DB00400 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , DB00220 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "the concomitant use of DB00861 tablets and other HD00203 is not recommended due to the increased possibility of gastrointestinal toxicity , with little or no increase in efficacy .",
        "label": "effect"
    },
    {
        "text": "ddrug0 should be used with care when ddrug1 or inhibitors of av conduction , such as certain ddrug2 { particularly of the HD00426 -lsb- ddrug4 -rsb- and HD00427 -lsb- ddrug6 -rsb- classes } , or ddrug7 , such as ddrug8 , are used concurrently .",
        "label": "NA"
    },
    {
        "text": "these medications have included ddrug0 , DB00682 , ddrug2 , ddrug3 , ddrug4 , intravenous and oral DB14049 , ddrug6 , and ddrug7 .",
        "label": "NA"
    },
    {
        "text": "other drugs : in healthy volunteers , DB00381 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , hormone replacement therapy { a combination of conjugated ddrug5 and ddrug6 } , ddrug7 { DB06723 and ddrug9 } and ddrug10 did not affect the pharmacokinetics of ddrug11 .",
        "label": "NA"
    },
    {
        "text": "HD00461 { cns } drugs including ddrug1 , ddrug2 , ddrug3 , ddrug4 , blood pressure medications { ddrug5 , ddrug6 , HD00254 } , motion sickness medications , ddrug8 , ddrug9 , ddrug10 , sleeping pills and ddrug11",
        "label": "NA"
    },
    {
        "text": "may interact with thyroid medication { e , g , , ddrug0 } , ddrug1 - containing products , ddrug2 , ddrug3 { e , g , , ddrug4 , DB00863 } , and ddrug6 { e , g , , DB00448 , ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 : ddrug1 { 40 mg bid } did not induce the metabolism of the combination oral HD00349 DB00717 / ddrug4 { 1 mg / 35 mcg combination , ddrug5 1/35 } .",
        "label": "NA"
    },
    {
        "text": "coadministration of DB00401 with ddrug1 or any known cyp3a4 inducer should be avoided and alternative HD00876 therapy should be considered .",
        "label": "NA"
    },
    {
        "text": "because of the pronounced intersubject variability in the extent of the ddrug0 - DB00343 interaction , whole blood DB00877 concentrations should be monitored closely in patients treated with the two drugs .",
        "label": "NA"
    },
    {
        "text": "ddrug0 works differently from the HD00128 currently available , and except for increased lipid levels , the adverse reaction profile of ddrug2 does not appear to overlap to any great extent with that associated with ddrug3 or DB00864 .",
        "label": "NA"
    },
    {
        "text": "the hypotensive effect of DB00325 is augmented by that of most other ddrug1 , including HD00877 , negative inotropic agents , and inhaled ddrug3 .",
        "label": "effect"
    },
    {
        "text": "exposed histidines on HD00011 are available for ddrug1 chelation , and these have been exploited in the development of a novel purification protocol for ddrug2 using DB01593 - chelating chromatography .",
        "label": "NA"
    },
    {
        "text": "hormonal ddrug0 co-administration of ddrug1 with an oral HD00349 has been shown to influence the plasma concentrations of the two hormonal components , ddrug3 { ee } and DB00367 { lng } .",
        "label": "NA"
    },
    {
        "text": "reciprocal interactions may occur with concomitant use of DB01213 and drugs that increase or inhibit the cytochrome cyp2b6 system { e , g , , ddrug1 , ddrug2 , DB00501 , ddrug4 } , though this has not been studied",
        "label": "mechanism"
    },
    {
        "text": "as with other HD00482 , if ddrug1 is to be administered orally with HD00377 of the ddrug3 or ddrug4 type , it is recommended that ecg and blood pressure be monitored .",
        "label": "NA"
    },
    {
        "text": "other drugs : in healthy volunteers , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , hormone replacement therapy { a combination of conjugated ddrug5 and ddrug6 } , DB06724 { ddrug8 and ddrug9 } and ddrug10 did not affect the pharmacokinetics of DB00204 .",
        "label": "NA"
    },
    {
        "text": "other concomitant therapy although specific interaction studies were not performed , ddrug0 doses of # mg or more were concomitantly used in clinical studies with ddrug1 , ddrug2 , a-blockers , ddrug3 , ddrug4 , ddrug5 , HD00100 , ddrug7 , ddrug8 , cardiac ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 { also referred to as HD00203 } , and ddrug15 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "DB00522 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , DB02362 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "int"
    },
    {
        "text": "ddrug0 : since DB00714 is a ddrug2 , it is possible that ddrug3 , such as the ddrug4 { ddrug5 , HD00340 , ddrug7 } or ddrug8 , may diminish the effectiveness of ddrug9 .",
        "label": "NA"
    },
    {
        "text": "HD00374 : concomitant administration of DB06723 s and ddrug2 s does not interfere with absorption of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "however , since ddrug0 , ddrug1 , and ddrug2 are all associated with gastrointestinal irritation , caution should be exercised in the concomitant use of DB00945 or HD00203 with ddrug5 .",
        "label": "NA"
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit DB00451 binding to serum proteins or alter the concentrations of serum binding proteins : ddrug1 and related ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 , ddrug7 , DB00695 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 s : DB00900 should be administered at least # hours after or # hours before dosing with ddrug2 because plasma concentrations of DB00537 are decreased when administered with ddrug4 containing ddrug5 , ddrug6 , or ddrug7 .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 HD00388 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { DB01026 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "while HD00022 and ddrug1 have similar affinities for kappa opioid and possibly nicotinic receptors , ddrug2 has much lower affinities than HD00021 for n_methyl_d_aspartate and sigma-2 receptors , sodium channels , and the 5-ht transporter .",
        "label": "NA"
    },
    {
        "text": "ddrug0 such as ddrug1 , DB00384 , or ddrug3 , or DB14500 supplements should be given only for documented hypokalemia , and then with caution , since they may lead to a significant increase of serum potassium .",
        "label": "NA"
    },
    {
        "text": "DB01032 : as with other ddrug1 , ddrug2 inhibits the renal excretion of ddrug3 , resulting in an approximate doubling in a , c , a 54 % increase in peak DB00535 plasma levels , and a 50 % prolongation in the apparent elimination half-life .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the concomitant use of ddrug1 { ddrug2 transdermal system } with other HD00389 , including but not limited to other ddrug4 , HD00024 , ddrug6 , ddrug7 { e , g , , ddrug8 } , general ddrug9 , ddrug10 , ddrug11 , and ddrug12 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the effect of ddrug1 on the anticoagulant effect of DB00682 { 1 - # mg/day } was studied in healthy subjects by coadministration of DB00580 # mg bid for # days .",
        "label": "NA"
    },
    {
        "text": "since the pharmacokinetics of ddrug0 were studied in patients treated with DB00252 , the clearance of DB01008 at the recommended dose may be lower and exposure { auc } higher in patients not treated with ddrug3 .",
        "label": "NA"
    },
    {
        "text": "animals dosed with HD00077 did not display the 2 - 3 hour lag phase in either ddrug1 synthesis or in citrate and fluoride accumulation characteristic of animals dosed with HD00079 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , including DB01059 , may enhance the effects of oral HD00326 , including ddrug3 or its derivatives or similar agents .",
        "label": "effect"
    },
    {
        "text": "HD00218 : patients on ddrug1 , especially those in whom diuretic therapy was recently instituted , may occasionally experience an excessive reduction of blood pressure after initiation of therapy with DB00542 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and oral ddrug1 : concomitant administration of ddrug2 and/or other oral HD00150 with DB00459 must be avoided because of the risk of hypervitaminosis a.",
        "label": "advise"
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of HD00472 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 { 1 } , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 { 1 } , ddrug10 , ddrug11 , grapefruit juice , ddrug12 , ddrug13 , ddrug14 , ddrug15 , DB01149 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21 , ddrug22 , ddrug23 , ddrug24 { 1 } , ddrug25 , ddrug26 .",
        "label": "mechanism"
    },
    {
        "text": "radioligand binding experiments using the uptake inhibitor hydrogen-3 DB00579 revealed a significant decrease by approximately 30 % in DB00368 uptake-1 carrier density in functional classes ii to iii and iv myocardium versus nonfailing myocardium { p < # } .",
        "label": "NA"
    },
    {
        "text": "these drugs include the ddrug0 and other ddrug1 , ddrug2 , ddrug3 , HD00221 , HD00220 , oral ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , and ddrug11 .",
        "label": "NA"
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the ddrug0 of drugs may be potentiated by DB02325 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , the ddrug6 , ddrug7 and HD00560 , ddrug9 and the ddrug10 , and by other ddrug11 .",
        "label": "NA"
    },
    {
        "text": "when such drugs are withdrawn from patients receiving ddrug0 in combination with HD00222 or HD00071 , patients should be observed closely for any evidence of hypoglycemia .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : when DB00176 { 50 mg tid } was administered concomitantly with DB00682 for two weeks , ddrug3 plasma concentrations increased by 98 % and prothrombin times were prolonged .",
        "label": "mechanism"
    },
    {
        "text": "DB00862 { 20 mg } did not potentiate the hypotensive effects of DB02325 during the 4-hour observation period in healthy volunteers when administered with ddrug2 { # g/kg body weight } .",
        "label": "NA"
    },
    {
        "text": "in vitro data in human plasma indicate that DB00590 has no effect on protein binding of DB00390 , ddrug2 , ddrug3 or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "DB01432 ddrug1 may delay or reduce the absorption of concomitant oral medication such as ddrug2 , ddrug3 , ddrug4 { acidic } or ddrug5 { basic } , as well as ddrug6 ddrug7 , ddrug8 , thyroid and ddrug9 preparations , ddrug10 and HD00526 , and ddrug12 .",
        "label": "mechanism"
    },
    {
        "text": "immediate and extended release tablets the hypoglycemic action of ddrug0 may be potentiated by certain drugs including HD00518 , some ddrug2 and other drugs that are highly protein bound , ddrug3 , ddrug4 , DB00446 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 and DB00201 may enhance the effects of : other ddrug3 s , ddrug4 , general HD00264 , ddrug6 such as ddrug7 , ddrug8 , or other ddrug9 , causing increased cns depression .",
        "label": "effect"
    },
    {
        "text": "repeated oral administration of ddrug0 in sheep : interactions of DB11390 with ddrug2 , ddrug3 , and DB01174 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 ddrug1 may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation , the discontinuance of DB01432 HD00524 could pose a hazard to health if a potentially toxic drug such as ddrug4 has been filtrated to a maintenance level while the patient was taking ddrug5 ddrug6 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB01076 plasma concentrations and ldl-c reduction were not altered by coadministration of DB00501 .",
        "label": "NA"
    },
    {
        "text": "DB01238 dose should be reduced to one-half of its normal dose when concomitant administration of DB00908 with ddrug2 occurs .",
        "label": "NA"
    },
    {
        "text": "in addition , results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance { ddrug0 , ddrug1 , DB00252 , ddrug3 , or ddrug4 } with ddrug5 may result in clinically meaningful reductions in DB00520 concentrations .",
        "label": "NA"
    },
    {
        "text": "the effects ddrug0 on the pharmacokinetics and/or pharmacodynamics of ddrug1 , ddrug2 , DB00563 , ddrug4 , ddrug5 , and DB00682 have been studied in vivo and clinically important interactions have not been found .",
        "label": "NA"
    },
    {
        "text": "because there is a theoretical basis that these effects may be additive , use of ddrug0 - containing or ddrug1 { like DB00320 or ddrug3 } and DB00918 within # hours of each other should be avoided .",
        "label": "advise"
    },
    {
        "text": "ddrug0 { HD00114 } { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 } have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with HD00277 .",
        "label": "effect"
    },
    {
        "text": "DB01045 has been reported to increase the DB00682 requirements in human subjects ingesting these agents simultaneously .",
        "label": "mechanism"
    },
    {
        "text": "however , co-administration of ddrug0 with DB01370 - and DB14513 - containing ddrug3 { 51 meq } or ddrug4 with ddrug5 , had no significant effect on the rate or extent of ddrug6 absorption after administration of a 40-mg oral dose .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - and/or ddrug1 - containing ddrug2 , products containing ddrug3 { DB01592 } , ddrug5 containing DB01593 or other metal cations , or ddrug7 { ddrug8 } chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after ddrug9 .",
        "label": "NA"
    },
    {
        "text": "when taken orally , HD00824 like ddrug1 may enhance the anticoagulant effect of DB04665 - like drugs .",
        "label": "effect"
    },
    {
        "text": "certain drugs , including ddrug0 { ddrug1 } , ddrug2 , ddrug3 , and ddrug4 may potentiate the hypoglycemic action of DB00731 and other oral HD00394 .",
        "label": "NA"
    },
    {
        "text": "when initiating a multi-day course of ddrug0 in a patient maintained on ddrug1 , the DB00277 maintenance dose should be halved for the period of concurrent use of DB00365 and monitoring of serum ddrug4 concentrations should be initiated as a guide to further dosage adjustments .",
        "label": "advise"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , DB00295 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { DB01045 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : HD00870 ddrug8 : ddrug9 ddrug10 ddrug11 , DB00897 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit DB00451 binding to serum proteins or alter the concentrations of serum binding proteins : ddrug1 and related ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 , DB00544 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 .",
        "label": "mechanism"
    },
    {
        "text": "nevertheless , clinical studies , as well as postmarketing observations have shown that DB00749 can reduce the natriuretic effect of DB00695 and ddrug2 in some patients .",
        "label": "effect"
    },
    {
        "text": "caution should be exercised when taking this medicine certain HD00002 , such as DB00199 , ddrug2 , or ddrug3 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 should be used with caution in patients receiving - ddrug2 blocking agents { e , g , , ddrug3 , a ddrug4 inhibitor } or HD00306 antagonists { e , g , , ddrug6 , a ddrug7 substrate , and DB00343 , a ddrug9 inhibitor } because of the possible potentiation of bradycardia , sinus arrest , and av block ;",
        "label": "NA"
    },
    {
        "text": "DB00542 has been used concomitantly with ddrug1 , HD00396 , ddrug3 , ddrug4 , and ddrug5 , without evidence of clinically important adverse interactions .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of ddrug0 : ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , ddrug5 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , DB00052 , ddrug11 , ddrug12 , HD00810 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "concurrent administration of drugs possessing nephrotoxic { e , g , , ddrug0 , ddrug1 } , myelotoxic { e , g , , ddrug2 chemotherapy } , cardiotoxic { e , g , , DB00997 } or hepatotoxic { e , g , , ddrug4 , ddrug5 } effects with DB00041 may increase toxicity in these organ systems .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : steady-state trough concentrations of DB13871 were about 56 % higher when # mg DB01234 was coadministered with each dose of ddrug3 { 15 mg/kg/day } in eight neurocysticercosis patients .",
        "label": "NA"
    },
    {
        "text": "the concomitant use of ddrug0 s , vasoconstricting agents { such as DB01253 } and some HD00629 may result in severe hypertension .",
        "label": "effect"
    },
    {
        "text": "DB01563 and DB04833 interact pharmacologically with orally administered ddrug2 , but the effect is not clinically significant .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { cns } drugs including DB02325 , ddrug2 , ddrug3 , ddrug4 , blood pressure medications { ddrug5 , ddrug6 , ddrug7 } , motion sickness medications , HD00542 , ddrug9 , ddrug10 , sleeping pills and ddrug11",
        "label": "NA"
    },
    {
        "text": "ddrug0 may have additive effects with DB02325 and other ddrug2 , e , g , , HD00214 , ddrug4 , ddrug5 , ddrug6 .",
        "label": "NA"
    },
    {
        "text": "DB00501 } and many that are substrates for cyp2b6 2d6 { many other ddrug1 , ddrug2 , and the ddrug3 ddrug4 and DB01195 } .",
        "label": "NA"
    },
    {
        "text": "DB01001 , ddrug1 , ddrug2 , ddrug3 , HD00118 .",
        "label": "NA"
    },
    {
        "text": "DB00900 { ddrug1 } chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with , or within # hours of , the administration of DB01059 , because these products may interfere with absorption resulting in lower serum and urine levels of ddrug3 .",
        "label": "advise"
    },
    {
        "text": "DB00788 : coadministration { n = 18 } of ddrug1 capsules { 250 mg } with DB00996 { 125 mg } appears to increase the amount of ddrug3 absorbed by 12 % to 15 % .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the auc of DB00900 was increased about 4-fold when ddrug2 at # mg/day was coadministered with a single 200-mg dose of DB00900 to two patients with renal impairment { clcr = 15 and # ml/min } .",
        "label": "NA"
    },
    {
        "text": "in vitro studies evaluating the minimum inhibitory concentration { mic } of ddrug0 , DB01327 , ddrug2 , ddrug3 / flucoxacillin , ddrug4 , ddrug5 , and ddrug6 demonstrated no evidence of incompatibility of these ddrug7 with DB00702 .",
        "label": "NA"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , ddrug3 HD00388 : ddrug5 , ddrug6 antimigraine : HD00870 ddrug8 : ddrug9 ddrug10 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "catecholamine-depleting agents : patients taking both HD00482 and a drug that can deplete catecholamines { e , g , , ddrug1 and HD00275 } should be observed closely for signs of hypotension and/or severe bradycardia .",
        "label": "effect"
    },
    {
        "text": "in common with other ddrug0 , DB01060 may reduce the efficacy of oral HD00283",
        "label": "effect"
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of HD00539 such as ddrug1 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , DB01190 , ddrug9 , and ddrug10 } , ddrug11 salts , ddrug12 , local ddrug13 , ddrug14 , and ddrug15 .",
        "label": "effect"
    },
    {
        "text": "patients receiving ddrug0 and DB00437 concomitantly should have a dose reduction of DB00993 , to approximately 1/3 to 1/4 the usual dose .",
        "label": "NA"
    },
    {
        "text": "HD00326 , oral : co-administration of HD00175 and ddrug2 usually results in inhibition of response to ddrug3 , although there have been some conflicting reports .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the concomitant use of ddrug1 { ddrug2 transdermal system } with other ddrug3 , including but not limited to other ddrug4 , ddrug5 , ddrug6 , ddrug7 { e , g , , HD00100 } , general ddrug9 , HD00219 , ddrug11 , and ddrug12 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .",
        "label": "NA"
    },
    {
        "text": "DB00930 was found to have no significant effect on the bioavailability of ddrug1 , DB00227 , ddrug3 , ddrug4 , ddrug5 , and ddrug6 .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of ddrug0 : ddrug1 , DB01406 , ddrug3 , ddrug4 { e , g , , ddrug5 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , ddrug11 , HD00220 , ddrug13 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / ddrug1 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , DB14507 , HD00516 pain medication { e , g , , ddrug12 } , drugs used to aid sleep , drowsiness-causing ddrug13 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "concurrent administration of DB00224 and DB00900 significantly reduces the level of exposure to ddrug2 , but it is unclear how soon after ddrug3 administration ddrug4 may be given safely .",
        "label": "mechanism"
    },
    {
        "text": "some reports have shown that the concomitant administration of HD00217 with DB11094 causes hypercalcemia .",
        "label": "effect"
    },
    {
        "text": "DB00241 , ddrug1 and ddrug2 may enhance the effects of : other ddrug3 s , ddrug4 , general ddrug5 , ddrug6 such as ddrug7 , ddrug8 , or other HD00261 , causing increased cns depression .",
        "label": "effect"
    },
    {
        "text": "concomitant administration of DB01039 { equivalent to 145 mg ddrug1 } with DB00175 { 40 mg } once daily for # days has been shown to increase the mean cmax and auc values for ddrug3 by 36 % { range from 69 % decrease to 321 % increase } and 28 % { range from 54 % decrease to 128 % increase } , respectively , and for # - hydroxy-iso-pravastatin by 55 % { range from 32 % decrease to 314 % increase } and 39 % { range from 24 % decrease to 261 % increase } , respectively in # healthy adults .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : ddrug1 should be used with caution in patients receiving - ddrug2 blocking agents { e , g , , DB00571 , a ddrug4 inhibitor } or HD00306 antagonists { e , g , , ddrug6 , a ddrug7 substrate , and ddrug8 , a ddrug9 inhibitor } because of the possible potentiation of bradycardia , sinus arrest , and av block ;",
        "label": "NA"
    },
    {
        "text": "a possible drug interaction of DB00529 and intravenous DB00738 has been described .",
        "label": "int"
    },
    {
        "text": "the co-administration of ddrug0 with iv ddrug1 such as ddrug2 , ddrug3 , ddrug4 , or iv HD00106 has not been evaluated { these drugs were not co-administered with DB04899 in clinical trials } .",
        "label": "NA"
    },
    {
        "text": "although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 { eg , ddrug0 , ddrug1 , ddrug2 , DB00468 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , and ddrug15 } may have elevated plasma concentrations when coadministered with DB01232 ;",
        "label": "mechanism"
    },
    {
        "text": "in vitro data in human plasma indicate that DB00590 has no effect on protein binding of ddrug1 , DB00682 , ddrug3 or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "- the action of ddrug0 and HD00071 may be enhanced by ddrug2 or HD00415 .",
        "label": "effect"
    },
    {
        "text": "during clinical trials , DB01088 was used concurrently with HD00326 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and other medications .",
        "label": "NA"
    },
    {
        "text": "HD00388 may enhance the effects of ddrug1 , ddrug2 , ddrug3 , and other HD00261 .",
        "label": "effect"
    },
    {
        "text": "experience with co-administration of HD00095 and ddrug1 in patients is limited , therefore , consideration should be given to temporarily suspending use of ddrug2 in patients receiving DB00813 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and DB00495 DB00811 can antagonize the in vitro antiviral activity of ddrug3 and ddrug4 against hiv .",
        "label": "NA"
    },
    {
        "text": "when used in therapeutic doses , DB00207 had a modest effect on the pharmacokinetics of ddrug1 , ddrug2 , DB00341 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { intravenous and oral } , ddrug12 , ddrug13 / ddrug14 or ddrug15 .",
        "label": "mechanism"
    },
    {
        "text": "since blood level of DB00136 / ergocalcitriol will be reduced , higher doses of DB00136 may be necessary if these drugs are administered simultaneously .",
        "label": "NA"
    },
    {
        "text": "agents that induce cyp3a4 { eg , DB00564 } could cause an increase in DB01238 clearance and lower blood levels .",
        "label": "mechanism"
    },
    {
        "text": "and ddrug0 when ddrug1 is given with ddrug2 agents or HD00316 drugs , including ddrug4 combined with local HD00264 , close supervision and careful adjustment of dosages are required .",
        "label": "NA"
    },
    {
        "text": "such individuals are referred to as poor metabolizers of drugs such as DB04840 , ddrug1 , the ddrug2 , and DB00363 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 s : DB00900 should be administered at least # hours after or # hours before dosing with DB00537 because plasma concentrations of ddrug3 are decreased when administered with ddrug4 containing ddrug5 , ddrug6 , or ddrug7 .",
        "label": "advise"
    },
    {
        "text": "effects of ddrug0 on low-dose ddrug1 a group of # nonsmoking , healthy white female volunteers established on an oral ddrug2 regimen containing # mg ddrug3 and # mg DB06730 for at least # months received # mg/day of DB00949 from midcycle { day 15 } to midcycle { day 14 } of two consecutive oral ddrug6 cycles .",
        "label": "NA"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / ddrug1 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , ddrug4 , DB00365 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 pain medication { e , g , , ddrug12 } , drugs used to aid sleep , drowsiness-causing ddrug13 { e , g , , DB14487 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "both HD00021 and ddrug1 block DB00295 - induced and ddrug3 - induced dopamine release in the nucleus accumbens ;",
        "label": "effect"
    },
    {
        "text": "no significant drug interactions have been reported in studies of DB00796 given with other drugs such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , and oral ddrug6 in healthy volunteers , or given with DB00584 to patients with heart failure { nyha class ii and iii } .",
        "label": "NA"
    },
    {
        "text": "DB00285 : coadministration of a single dose of ddrug1 # mg and multiple doses of ddrug2 er { extended release } # mg did not result in any significant changes in the pharmacokinetics of either DB00962 or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "although not studied systematically in clinical trials , no drug interactions were observed when ddrug0 , ddrug1 , or DB13295 were administered following varying degrees of recovery from single doses or infusions of DB00565 .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of DB01032 doubled the auc for DB01150 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 - combined administration of racemic DB00215 { titrated to # mg/day for # days } and the cyp3a4 substrate DB00897 { single dose of # mg } did not significantly affect the pharmacokinetics of either ddrug3 or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "although it has not been established that there is an interaction between ddrug0 and ddrug1 or other ddrug2 , caution is advised when DB00363 is initiated in patients taking a DB12537 or any other ddrug5 .",
        "label": "advise"
    },
    {
        "text": "no depressant effect on blood levels in humans was noted when ddrug0 was administered with any of the following drugs : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 { DB00627 } , ddrug7 , DB00252 or ddrug9 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : while a synergistic relationship with DB00681 has been reported , concomitant use may increase the toxicity of DB01099 by possibly increasing its cellular uptake and/or impairing its renal excretion .",
        "label": "effect"
    },
    {
        "text": "inhibitors of this isoenzyme { e , g , , ddrug0 , ddrug1 , ddrug2 , HD00311 , ddrug4 , ddrug5 , ddrug6 , grapefruit juice , ddrug7 , ddrug8 , ddrug9 , ddrug10 } should be cautiously coadministered with DB00204 as they can potentially increase ddrug12 levels .",
        "label": "advise"
    },
    {
        "text": "co-administration of DB09026 did not significantly affect the pharmacokinetics of ddrug1 , ddrug2 , ddrug3 , DB00381 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 or ddrug10 .",
        "label": "NA"
    },
    {
        "text": "elevated DB00091 serum levels have been reported with the concomitant use of HD00532 and ddrug2 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , DB01026 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , DB00860 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "numerous drug interactions are possible with some HD00065 , such as ddrug1 and DB00252 , which affect hepatic microsomal enzyme systems .",
        "label": "NA"
    },
    {
        "text": "interactions with ddrug0 : HD00842 { eg , ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 } should not be administered to a patient who has received or is receiving a course of therapy with a ddrug7 such as DB00854 .",
        "label": "advise"
    },
    {
        "text": "oral HD00326 may potentiate the hypoglycemic action of HD00062 , eg , ddrug2 and ddrug3 , by inhibiting their metabolism in the liver .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 - combined administration of a single dose of DB00503 { 600 mg } , both a cyp3a4 substrate and a potent inhibitor of cyp3a4 , and ddrug2 { 20 mg } did not affect the pharmacokinetics of either ddrug3 or DB01175 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : combination ddrug1 may decrease the clearance of some ddrug2 { ddrug3 , DB00475 , ddrug5 } and increase the clearance of others { ddrug6 , DB00842 , ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "clinical studies of DB00008 alone or in combination with DB00811 did not include sufficient numbers of subjects aged # or over to determine whether they respond differently from younger subjects .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , DB01026 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { DB00701 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , HD00002 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { HD00531 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "serum ddrug0 concentrations appeared to be unaffected by baseline use of medications for the treatment of crohn s disease including HD00175 , HD00002 { ddrug3 or ddrug4 } and aminosalicylates .",
        "label": "NA"
    },
    {
        "text": "prior administration of DB00202 had no effect on the duration of neuromuscular block following initial or maintenance bolus doses of DB00565 .",
        "label": "NA"
    },
    {
        "text": "HD00219 and HD00340 may reduce or reverse the pressor effect of ddrug2 .",
        "label": "NA"
    },
    {
        "text": "other drug interaction information ddrug0 : studies in healthy volunteers have shown that DB00204 does not affect the pharmacokinetics of DB00390 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { cns } drugs including ddrug1 , ddrug2 , HD00388 , ddrug4 , blood pressure medications { ddrug5 , ddrug6 , ddrug7 } , motion sickness medications , ddrug8 , ddrug9 , ddrug10 , sleeping pills and HD00262",
        "label": "NA"
    },
    {
        "text": "ddrug0 should not be used in patients who have previously received the recommended maximum cumulative doses of DB00997 or DB00694 .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of ddrug0 : ddrug1 , DB01406 , ddrug3 , ddrug4 { e , g , , ddrug5 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 { e , g , , in oral HD00283 } .",
        "label": "NA"
    },
    {
        "text": "coadministration of DB00580 { 10 mg bid for # days } with ddrug1 { 5 mg qd or # mg bid } did not affect the pharmacokinetics { exposure } of DB01016 .",
        "label": "NA"
    },
    {
        "text": "certain drugs including ddrug0 , ddrug1 , ddrug2 , and HD00391 may reduce the hypoglycemic action of ddrug4 and other oral HD00394 .",
        "label": "effect"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of DB00732 include : ddrug1 ; ddrug2 ; ddrug3 ; certain HD00002 , especially the ddrug5 and ddrug6 ; ddrug7 ; ddrug8 salts ; ddrug9 ; and ddrug10 .",
        "label": "effect"
    },
    {
        "text": "plasma levels of several closely related HD00043 have been reported to be increased by the concomitant administration of ddrug1 or hepatic enzyme inhibitors { e , g , , ddrug2 , ddrug3 } and decreased by the concomitant administration of hepatic enzyme inducers { e , g , , ddrug4 , DB00252 } , and such an effect may be anticipated with ddrug6 as well .",
        "label": "mechanism"
    },
    {
        "text": "the effects of medicinal products with similar properties such as inotropes ddrug0 , DB04880 , ddrug2 , ddrug3 and ddrug4 may be exacerbated by DB00261 .",
        "label": "effect"
    },
    {
        "text": "these drugs include the ddrug0 and other ddrug1 , HD00175 , phe-nothiazines , ddrug3 , HD00220 , oral ddrug5 , ddrug6 , ddrug7 , sympathomimet-ics , ddrug8 , and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "other chemotherapy agents in a separate study , concomitant administration of DB01259 with ddrug1 did not meaningfully alter the pharmacokinetics of either agent { or the metabolites of DB01101 } .",
        "label": "NA"
    },
    {
        "text": "before taking ddrug0 , tell your doctor if you are taking any of the following medicines : - DB00945 or another ddrug2 such as ddrug3 { ddrug4 } , ddrug5 { ddrug6 , others } , ddrug7 { ddrug8 } , ddrug9 { ddrug10 } , or DB01294 { ddrug12 } ;",
        "label": "NA"
    },
    {
        "text": "- drugs whose efficacy is impaired by DB00252 include : ddrug1 , HD00175 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , oral ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 , DB00864 , DB00877",
        "label": "NA"
    },
    {
        "text": "ddrug0 / ddrug1 : pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between ddrug2 and concomitantly administered DB00945 { # mg orally given # and # hours prior to initiation of ddrug4 # g/kg/min , over # hours } or DB00316 { 1000 mg orally given 12 , # and # hours prior to , and # and # hours subsequent to , initiation of ddrug6 # g/kg/min , over # hours } .",
        "label": "NA"
    },
    {
        "text": "-lsb- stimulation by ddrug0 -- an analog of the octapeptide cholecystokinin -- of ddrug1 binding after the long-term administration of ddrug2 -rsb- it has been established in experiments on white male rats that prolonged administration { twice a day for # days } of DB00502 { # mg/kg } and ddrug4 { # mg/kg } resulted in the reduced interaction between HD00136 and low affinity binding sites for ddrug6 in subcortical structures , whereas ddrug7 binding with high affinity binding sites for ddrug8 increased both in the frontal cortex and subcortical structures of the forebrain .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : HD00401 may delay intestinal absorption of DB00252 ;",
        "label": "mechanism"
    },
    {
        "text": "since DB00964 may reduce pulse and blood pressure , caution in using drugs such as ddrug1 { ophthalmic and systemic } , ddrug2 , and HD00345 is advised .",
        "label": "advise"
    },
    {
        "text": "a case report of one patient taking DB01118 # mg and DB00224 # mg three times a day resulted in increases in ddrug2 concentrations from # mg/l to # mg/l .",
        "label": "mechanism"
    },
    {
        "text": "interactions may also occur with the following : HD00515 / ddrug1 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , ddrug4 , ddrug5 , DB01170 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 pain medication { e , g , , ddrug12 } , drugs used to aid sleep , drowsiness-causing ddrug13 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "additive depressant effect when used with general ddrug0 , ddrug1 , HD00612 , ddrug3 , ddrug4 , and other HD00611 .",
        "label": "NA"
    },
    {
        "text": "other cardiovascular agents : DB00584 and ddrug1 iv have been used concomitantly with ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , DB00457 and ddrug8 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "this drug may interact with ddrug0 or other ddrug1 { may potentiate the cns depressant effects of either these medications or HD00388 } , ddrug3 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug4 } , and HD00445 { concurrent use with ddrug6 may prolong and intensify the anticholinergic and cns depressant effects of ddrug7 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - and/or DB01370 - containing ddrug2 , products containing ddrug3 { ddrug4 } , HD00752 containing ddrug6 or other metal cations , or ddrug7 { ddrug8 } chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after ddrug9 .",
        "label": "NA"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , ddrug3 ddrug4 : DB00637 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 DB00683 , ddrug12 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "DB00955 should not be administered concomitantly with potent ddrug1 such as DB00695 and ddrug3 as the potential for ototoxicity is enhanced by the combination .",
        "label": "advise"
    },
    {
        "text": "only HD00021 enhances DB00907 - induced increases in accumbal dopamine .",
        "label": "effect"
    },
    {
        "text": "to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma { hiv-nhl } , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the ddrug0 , DB00997 , ddrug2 , and ddrug3 { chop } chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen { i , e , , ddrug4 , ddrug5 , ddrug6 , and ddrug7 with ddrug8 plus ddrug9 } without receiving HD00056 therapy .",
        "label": "NA"
    },
    {
        "text": "DB00945 : concomitant administration of low-dose ddrug1 with ddrug2 may result in an increased rate of gi ulceration or other complications , compared to use of HD00897 alone .",
        "label": "NA"
    },
    {
        "text": "the use of ddrug0 or ddrug1 with DB00956 preparations may increase the effect of either the HD00711 or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "therefore , when DB00328 and DB00390 are used concomitantly , serum ddrug2 levels should be closely monitored .",
        "label": "advise"
    },
    {
        "text": "drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving ddrug0 metabolized similarly to ddrug1 or on the basis of in vitro studies with ddrug2 or other ddrug3 { caution is recommended during coadministration with ddrug4 } : available data from clinical studies of ddrug5 other than DB00404 suggest a possible drug interaction with ddrug7 for the following : DB00343 , ddrug9 , ddrug10 such as ddrug11 and ddrug12 , and grapefruit juice .",
        "label": "NA"
    },
    {
        "text": "DB00008 should be used with caution in patients with creatinine clearance # ml/min and DB00811 should not be administered to patients with creatinine clearance # ml/min",
        "label": "NA"
    },
    {
        "text": "because of the increased risk of adverse reactions in patients who have been taking ddrug0 on a regular basis , it is particularly important that physicians query patients or their guardians carefully about ddrug1 , DB02325 and ddrug3 use as part of the history prior to any procedure in which the use of DB01205 is planned .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 may enhance the effects of : other ddrug3 s , DB02325 , general ddrug5 , ddrug6 such as DB00475 , ddrug8 , or other ddrug9 , causing increased cns depression .",
        "label": "NA"
    },
    {
        "text": "in a study of # male subjects { ages # to # years } who were extensive metabolizers of the cyp2d6 isoenzyme , daily doses of DB01156 given as # mg twice daily followed by a single dose of # mg DB01151 increased the cmax , auc , and t1/2 of ddrug2 by an average of approximately 2 - , 5 - and 2-fold , respectively .",
        "label": "mechanism"
    },
    {
        "text": "however , if DB00278 is to be initiated after cessation of DB01109 therapy , allow sufficient time for heparin effect on the aptt to decrease prior to initiation of ddrug2 therapy .",
        "label": "NA"
    },
    {
        "text": "it is assumed that increased interaction between HD00136 and high affinity binding sites for ddrug1 on dopamine2 - and serotonin2-receptors underlies the antipsychotic action of HD00137 after their prolonged administration .",
        "label": "NA"
    },
    {
        "text": "both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ddrug0 is administered in combination with other ddrug1 such as HD00026 , ddrug3 , ddrug4 , or inhalation general HD00264 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 injection and potassium-depleting agents : when HD00175 are administered concomitantly with potassium-depleting agents { e , g , , DB00681 , ddrug3 } , patients should be observed closely for development of hypokalemia .",
        "label": "advise"
    },
    {
        "text": "due to a theoretical risk of a pharmacodynamic interaction , use of DB00201 - containing or ddrug1 { like ddrug2 or ddrug3 } and DB00998 within # hours of each other should be avoided { see a href = frova_od , htm # ci contraindications } .",
        "label": "advise"
    },
    {
        "text": "hypotension , av conduction disturbances , and left ventricular failure have been reported in some patients receiving HD00244 when an oral HD00411 was added to the treatment regimen .",
        "label": "effect"
    },
    {
        "text": "HD00852 : some individuals receiving DB00601 may experience a reversible enhancement of the pressor response to indirect-acting ddrug2 , ddrug3 or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "additionally , higher than expected HD00042 levels have been observed when they are begun in patients already taking DB00501 .",
        "label": "mechanism"
    },
    {
        "text": "DB00943 also has no significant effect on the intracellular phosphorylation of DB00495 , as shown in vitro in peripheral blood mononuclear cells or in two other cell_line { u937 and molt-4 } .",
        "label": "effect"
    },
    {
        "text": "the purpose of this study was to evaluate the effect of HD00066 { ddrug1 } and ddrug2 { ddrug3 } conjugates on the intestinal permeation of ddrug4 { ddrug5 } and model peptide drugs , DB00781 and ddrug7 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { e , g , , HD00896 } - taking DB00592 and ddrug3 together may decrease the effects of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose DB00041 and HD00251 , specifically , ddrug2 , ddrug3 , ddrug4 and ddrug5 .",
        "label": "effect"
    },
    {
        "text": "specific drug interaction studies have not been performed with DB00625 and ddrug1 other than ddrug2 and DB00495 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : no clinically significant changes occurred in heart rate or corrected qt intervals , or in ddrug1 metabolite or ddrug2 pharmacokinetics , during concurrent administration of DB00978 and DB00342 at steady-state in # healthy males .",
        "label": "NA"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 HD00303 : ddrug2 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 ddrug11 , ddrug12 gi motility agents : DB00604",
        "label": "NA"
    },
    {
        "text": "ddrug0 - and/or ddrug1 - containing ddrug2 , products containing ddrug3 { ddrug4 } , ddrug5 containing DB01593 or other metal cations , or DB00900 { ddrug8 } chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after ddrug9 .",
        "label": "NA"
    },
    {
        "text": "HD00090 , a trans-3 , 4 - dimethyl-4 - { 3-hydroxyphenyl } piperidine , prevents gastrointestinal effects of intravenous DB00295 without affecting analgesia .",
        "label": "effect"
    },
    {
        "text": "when coadministered with ddrug0 in treatment-naive patients , the recommended dose of DB01072 is # mg with DB00503 # mg and ddrug3 # mg { all once daily } .",
        "label": "NA"
    },
    {
        "text": "coadministration of DB01167 with oral ddrug1 or DB00897 has resulted in elevated plasma concentrations of the latter two drugs .",
        "label": "mechanism"
    },
    {
        "text": "therefore , co-administration of DB00363 with other drugs that are metabolized by this isozyme , including ddrug1 , HD00219 , ddrug3 , and ddrug4 { e , g , , ddrug5 , ddrug6 and ddrug7 } , or that inhibit this enzyme { e , g , , ddrug8 } , should be approached with caution .",
        "label": "advise"
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit ddrug0 binding to serum proteins or alter the concentrations of serum binding proteins : ddrug1 and related ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , DB00252 , ddrug16 , DB00675 .",
        "label": "NA"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , ddrug3 ddrug4 : ddrug5 , DB00342 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 ddrug11 , DB00897 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "DB02325 - although ddrug1 did not potentiate the cognitive and motor effects of ddrug2 in a clinical trial , as with other HD00281 , the use of ddrug4 by patients taking ddrug5 is not recommended .",
        "label": "NA"
    },
    {
        "text": "the purpose of this study was to evaluate the effect of ddrug0 { ddrug1 } and ddrug2 { HD00068 } conjugates on the intestinal permeation of ddrug4 { ddrug5 } and model peptide drugs , ddrug6 and HD00071 .",
        "label": "NA"
    },
    {
        "text": "use lowest possible dose of ddrug0 with careful monitoring , or consider ddrug1 that are not primarily metabolized by cyp3a4 , such as DB00175 , ddrug3 , or ddrug4 in combination with DB00224 .",
        "label": "NA"
    },
    {
        "text": "patients receiving other ddrug0 , ddrug1 , ddrug2 , or other HD00261 { including ddrug4 } concomitantly with DB00956 and ddrug6 tablets may exhibit an additive cns depression .",
        "label": "effect"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , DB00908 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 ddrug11 , ddrug12 gi motility agents : DB00604",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect : ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , ddrug5 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , HD00809 , ddrug12 , HD00810 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "differential regulation of tyrosine phosphorylation in tumor cells by ddrug0 , a homodimeric disintegrin , and monomeric disintegrins HD00008 and HD00009 .",
        "label": "NA"
    },
    {
        "text": "the vasodilating effects of DB00883 may be additive with those of other HD00337 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 including ddrug1 , DB00780 , and DB01626 hc1 : concomitant use of ddrug4 and non-selective ddrug5 may cause hypertension .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in controlled studies in healthy volunteers , HD00406 either had no effect { one study } or was associated with modest increases , about 30 % { two studies } in steady-state serum DB00390 concentrations .",
        "label": "mechanism"
    },
    {
        "text": "no significant drug interactions have been reported in studies of ddrug0 given with other drugs such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , and oral HD00283 in healthy volunteers , or given with DB00584 to patients with heart failure { nyha class ii and iii } .",
        "label": "NA"
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of ddrug0 such as ddrug1 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 } , DB14513 salts , DB14507 , local ddrug13 , ddrug14 , and ddrug15 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : DB00316 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , DB00295 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "avoid the use of preparations such as HD00799 and local HD00264 which contain any ddrug2 { e , g , , ddrug3 , ddrug4 } , since it has been reported that ddrug5 can potentiate the effects of catecholamines .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , as with other HD00360 , should be administered with extreme caution to patients being treated with HD00275 , ddrug3 , or drugs known to prolong the qtc interval because the action of ddrug4 on the cardiovascular system may be potentiated by these agents .",
        "label": "advise"
    },
    {
        "text": "in addition , neuromuscular blocking action is enhanced by general HD00264 , local ddrug1 like ddrug2 , ddrug3 , HD00254 , ddrug5 , ddrug6 , and ddrug7 .",
        "label": "NA"
    },
    {
        "text": "effects of DB00906 on other antiepilepsy drugs { ddrug1 } : DB00252 : ddrug3 had no effect on the steady-state plasma concentrations of ddrug4 in patients with epilepsy .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00586 decreases ddrug2 renal clearance and increases DB14507 plasma levels .",
        "label": "mechanism"
    },
    {
        "text": "should it be decided to discontinue therapy in patients receiving ddrug0 and ddrug1 concurrently , the HD00380 should be discontinued slowly over several days before the gradual withdrawal of DB00575 .",
        "label": "advise"
    },
    {
        "text": "therophylline : a recent study has shown that concomitan administration of DB00951 and ddrug1 may cause elevated plasma levels of DB00277 , and in some instances a slight decrease in the elimination of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "DB00501 , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB00829 , certain ddrug7 , ddrug8 , ddrug9 and ddrug10 , thereby delaying elimination and increasing blood levels of these drugs .",
        "label": "mechanism"
    },
    {
        "text": "in some patients , the administration of a HD00698 can reduce the diuretic , natriuretic , and antihypertensive effects of HD00105 , ddrug2 and ddrug3 .",
        "label": "effect"
    },
    {
        "text": "DB01232 : the combination of DB00943 , ddrug2 , and ddrug3 has been studied { as triple combination } in adults .",
        "label": "NA"
    },
    {
        "text": "ddrug0 should be administered with caution to patients who are taking other HD00826 or ddrug2 , including ddrug3 , ddrug4 and HD00424 , or to those with a history of psychiatric disorder { including manic-depressive illness and schizophrenia } .",
        "label": "NA"
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the ddrug0 of drugs may be potentiated by ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , the ddrug6 , HD00559 and ddrug8 , ddrug9 and the ddrug10 , and by other HD00561 .",
        "label": "NA"
    },
    {
        "text": "- ddrug0 { e , g , , ddrug1 } use of ddrug2 with DB00891 may increase the chance of side effects affecting the liver and/or the side effects of DB00563",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , ddrug3 , or ddrug4 , with ddrug5 , with metal cations such as ddrug6 , or with ddrug7 containing DB01592 or ddrug9 , or with formulations containing divalent and trivalent cations such as DB00900 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "the majority of patients in ra clinical studies received one or more of the following concomitant medications with DB01281 : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , and DB00026 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - and/or ddrug1 - containing HD00374 , products containing ddrug3 { ddrug4 } , ddrug5 containing ddrug6 or other metal cations , or ddrug7 { DB00900 } chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after ddrug9 .",
        "label": "NA"
    },
    {
        "text": "spontaneous reports of serotonin syndrome associated with co-administration of ddrug0 and HD00851 , including HD00216 such as ddrug3 { ddrug4 } , have been reported .",
        "label": "NA"
    },
    {
        "text": "in a study of # schizophrenic patients coadministered oral ddrug0 and DB01045 , plasma DB00502 levels were decreased by a mean of 70 % and mean scores on the brief psychiatric rating scale were increased from baseline .",
        "label": "NA"
    },
    {
        "text": "medications can interfere with folate utilization , including : ddrug0 { such as DB00252 , and ddrug2 } ddrug3 { sometimes prescribed to control blood sugar in type # diabetes } ddrug4 { used to control inflammation associated with crohn_disease and ulcerative colitis } ddrug5 { a ddrug6 } ddrug7 there has been concern about the interaction between ddrug8 and DB00158 .",
        "label": "NA"
    },
    {
        "text": "because changes in glucose concentrations with DB00580 coadministration were within the normal variability and individual glucose concentrations were above or near # mg/dl , dose adjustment for DB01016 { 5 mg qd and # mg bid } with ddrug2 coadministration { up to # mg qd } is not indicated .",
        "label": "NA"
    },
    {
        "text": "alkalinizing agents : gastrointestinal alkalinizing agents { DB01390 , etc , } increase absorption of HD00401 .",
        "label": "mechanism"
    },
    {
        "text": "if replacing ddrug0 by HD00380 therapy , the introduction of ddrug2 should be delayed for several days after DB00575 administration has stopped .",
        "label": "NA"
    },
    {
        "text": "co-administration of ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB00999 , ddrug7 , ddrug8 , ddrug9 and ddrug10 did not result in clinically significant increases in DB09026 exposure .",
        "label": "NA"
    },
    {
        "text": "this interaction should be given consideration in patients taking DB00482 concomitantly with HD00500 .",
        "label": "advise"
    },
    {
        "text": "for information on the pharmacokinetics of DB00441 and DB00515 in combination , see drug interactions under clinical pharmacology section .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , DB01167 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , DB00220 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "and phase # { days 45 - 52 } : DB00604 # mg # times/day { days 45 - 51 } plus DB00472 # mg/day { days 45 - 52 } .",
        "label": "NA"
    },
    {
        "text": "and ddrug0 when ddrug1 is given with ddrug2 agents or HD00316 drugs , including DB00668 combined with local ddrug5 , close supervision and careful adjustment of dosages are required .",
        "label": "NA"
    },
    {
        "text": "it is desirable to monitor HD00312 plasma levels whenever an agent of the ddrug1 including DB01242 is going to be co-administered with another drug known to be an inhibitor of cyp2b6 2d6 { and/or p450 1a2 } .",
        "label": "NA"
    },
    {
        "text": "formulation of fluorescence labelled DB00781 and ddrug1 in unconjugated HD00072 { 1 % m/v } did not significantly improve the permeation , however in the presence of 1 % { m/v } ddrug3 # a significantly improved permeation was observed { r = # } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 should not be administered concomitantly with potent HD00105 such as DB00695 and ddrug3 as the potential for ototoxicity is enhanced by the combination .",
        "label": "NA"
    },
    {
        "text": "effects of ddrug0 on DB00949 the coadministration of DB00199 { 1000 mg/day } for # days did not alter the pharmacokinetic parameters of cmax , cmin , auc , ci/kg or tmax at ddrug3 daily doses of # or # mg/day in # otherwise healthy subjects with epilepsy .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - ddrug1 containing side chains of n-methylthiotetrazole { ddrug2 , ddrug3 , DB01330 , ddrug5 , ddrug6 } or methylthiadiazole { DB01327 } can cause vitamin_k_deficiency and hypoprothrombinemia .",
        "label": "NA"
    },
    {
        "text": "oral HD00283 ddrug1 did not have any clinically important effect on the pharmacokinetics of DB00977 and ddrug3 .",
        "label": "NA"
    },
    {
        "text": "in three separate controlled , parallel group clinical pharmacology studies , ddrug0 at the clinical dose of # mg has been coadministered with DB00207 # mg followed by # mg once daily for # days { n = 18 } or with ddrug2 # mg once daily for # days after a # day pretreatment period with DB00472 { n = 18 } or with ddrug4 # mg every # hours for # days { n = 18 } under steady state conditions to normal healthy male and female volunteers .",
        "label": "NA"
    },
    {
        "text": "HD00322 : DB00446 , ddrug2 , ddrug3 , or ddrug4 may interfere with the bactericidal effect of ddrug5 .",
        "label": "NA"
    },
    {
        "text": "DB01026 / ddrug1 , ddrug2 , including DB00199",
        "label": "NA"
    },
    {
        "text": "no drug interaction studies have been conducted for DB01014 , however the use of orally administered ddrug1 could , theoretically , interfere with the release of DB00244 in the colon .",
        "label": "NA"
    },
    {
        "text": "HD00374 { ddrug1 - or ddrug2 - containing } : concomitant administration of 300-mg ddrug3 capsules with # ml HD00382 suspension reduces the rate { cmax } and extent { auc } of absorption by approximately 40 % .",
        "label": "NA"
    },
    {
        "text": "concurrent administration of a HD00205 with DB01281 has been associated with an increased risk of serious infections and no significant additional efficacy over use of the ddrug2 alone .",
        "label": "effect"
    },
    {
        "text": "in a similar study with DB00706 in healthy volunteers , # of # subjects dosed with DB00862 # mg and ddrug2 # mg separated by # hours experienced a standing systolic blood pressure below # mm hg .",
        "label": "NA"
    },
    {
        "text": "results : during treatment with DB00176 , there was a statistically significant decrease in the median of the total clearance of DB01124 , from # ml/h to # ml/h , among the volunteers who received # mg/d .",
        "label": "mechanism"
    },
    {
        "text": "although neither ddrug0 nor HD00147 affected the proliferation of prostatic epithelium in rpmi1640 containing ddrug2 alone , they modify the mitogenic effect of HD00148 and ddrug4 .",
        "label": "effect"
    },
    {
        "text": "the combination of therapeutic doses of intravenous DB01219 and DB00661 in ddrug2 a-chloralose anesthetized swine has resulted in ventricular fibrillation and cardiovascular collapse in association with marked hyperkalemia .",
        "label": "NA"
    },
    {
        "text": "DB00390 did not affect DB00187 pharmacokinetics .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { DB01167 } ddrug13 { ddrug14 } ddrug15 ddrug16 HD00542 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "ddrug0 can interact with ddrug1 or other HD00261 { may potentiate the cns depressant effects of either these medications or ddrug3 } , ddrug4 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug5 } , and HD00445 { concurrent use with ddrug7 may prolong and intensify the anticholinergic and cns depressant effects of ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "since ddrug0 { DB00593 } may interact with concurrently administered ddrug2 , periodic serum level determinations of these drugs may be necessary { eg , ddrug3 may elevate ddrug4 serum levels and DB00313 has been reported to both increase and decrease ddrug6 levels } .",
        "label": "NA"
    },
    {
        "text": "therophylline : a recent study has shown that concomitan administration of DB00951 and DB00277 may cause elevated plasma levels of ddrug2 , and in some instances a slight decrease in the elimination of ddrug3 .",
        "label": "mechanism"
    },
    {
        "text": "resistance to the neuromuscular blocking action of HD00541 has been demonstrated in patients chronically administered DB00252 or ddrug2 .",
        "label": "effect"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of ddrug0 : ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , ddrug5 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , HD00809 , ddrug12 , HD00810 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "concomitant use of DB01254 and drugs that inhibit cyp3a4 { eg , ddrug1 , ddrug2 , ddrug3 , ddrug4 , DB00503 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 } may increase exposure to ddrug12 and should be avoided .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 with DB01151 or ddrug2 and possibly other HD00609 cause striking and sustained increases in the concentration of ddrug4 in the brain ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 : no drug interactions with other HD00676 have been identified that would warrant alteration of either the DB00109 dose or the dose of the other ddrug3 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the concomitant use of DB00813 { ddrug2 transdermal system } with other ddrug3 , including but not limited to other ddrug4 , ddrug5 , ddrug6 , ddrug7 { e , g , , ddrug8 } , general ddrug9 , HD00219 , ddrug11 , and ddrug12 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .",
        "label": "effect"
    },
    {
        "text": "cytochrome p-450 inducers , such as ddrug0 , ddrug1 and DB01174 , induce DB01068 metabolism , causing an approximately 30 % decrease in plasma ddrug4 levels .",
        "label": "mechanism"
    },
    {
        "text": "inhibitors of this isoenzyme { e , g , , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB00343 , grapefruit juice , ddrug7 , ddrug8 , ddrug9 , ddrug10 } should be cautiously coadministered with DB00204 as they can potentially increase ddrug12 levels .",
        "label": "advise"
    },
    {
        "text": "HD00461 { cns } drugs including ddrug1 , ddrug2 , HD00388 , ddrug4 , blood pressure medications { ddrug5 , ddrug6 , ddrug7 } , motion sickness medications , ddrug8 , ddrug9 , ddrug10 , sleeping pills and ddrug11",
        "label": "NA"
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma ddrug0 concentrations include : acute DB02325 intake , ddrug2 , chboramphenicol , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , DB01124 , ddrug21",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 binds both DB00451 and ddrug3 in the intestine , thus impairing absorption of these HD00809 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : because of the relationship of DB00982 to DB00162 , patients should be advised against taking ddrug3 containing ddrug4 to avoid additive toxic effects",
        "label": "effect"
    },
    {
        "text": "this study demonstrates that concurrent administration of HD00158 permits at least a twofold increase in dose and total exposure to DB00515 .",
        "label": "mechanism"
    },
    {
        "text": "both ddrug0 and ddrug1 have been compared to triple therapy with the HD00111 DB00224 over # weeks as initial therapy , with similar responses being observed with ddrug4 regimens and superiority observed with ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration of DB00615 and ddrug2 resulted in a 32 % decrease in DB00220 plasma auc and a 207 % increase in ddrug4 plasma a , c.",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in normal volunteers , concomitant administration of DB00861 and DB00316 resulted in an approximate 50 % increase in plasma levels of ddrug3 .",
        "label": "mechanism"
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the ddrug0 of drugs may be potentiated by ddrug1 , ddrug2 , HD00026 , ddrug4 , ddrug5 , the ddrug6 , ddrug7 and ddrug8 , ddrug9 and the ddrug10 , and by other HD00561 .",
        "label": "NA"
    },
    {
        "text": "HD00264 / ddrug1 / ddrug2 / ddrug3 : co-administration of ddrug4 with ddrug5 , ddrug6 , ddrug7 , and HD00263 is likely to lead to an enhancement of effects .",
        "label": "NA"
    },
    {
        "text": "HD00282 : DB00564 , ddrug2 , ddrug3",
        "label": "NA"
    },
    {
        "text": "ddrug0 : as with other HD00487 , renal excretion of DB00447 is inhibited by ddrug3 and resulted in an approximate 80 % increase in the auc for ddrug4 .",
        "label": "NA"
    },
    {
        "text": "in patients who have been reported to be well controlled on ddrug0 receiving concurrent ddrug1 therapy , discontinuation of DB00501 has been reported to decrease established steady-state serum HD00042 levels and compromise their therapeutic effects .",
        "label": "mechanism"
    },
    {
        "text": "protein binding in vitro , DB00586 interferes minimally or not at all with the protein binding of ddrug1 { 20 % decrease in binding } , ddrug2 , ddrug3 { 10 % decrease in binding } , or DB00682 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : DB00465 iv/im reduced the HD00295 response to ddrug3 in normovolemic healthy subjects by approximately 20 % { mean sodium and urinary output decreased 17 % } .",
        "label": "NA"
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the ddrug0 of drugs may be potentiated by ddrug1 , ddrug2 , ddrug3 , ddrug4 , HD00557 , the ddrug6 , ddrug7 and ddrug8 , HD00275 and the ddrug10 , and by other ddrug11 .",
        "label": "NA"
    },
    {
        "text": "in clinical studies performed with ddrug0 , the concomitant use of oral HD00326 { ddrug2 } , ddrug3 { ddrug4 } , ddrug5 { ddrug6 } , and ddrug7 did not significantly affect the pharmacokinetics/pharmacodynamics of DB00569 .",
        "label": "NA"
    },
    {
        "text": "rhabdomyolysis has been observed in patients receiving HD00095 administered alone { at recommended dosages } or concomitantly with ddrug1 including DB00091 .",
        "label": "effect"
    },
    {
        "text": "medications can interfere with folate utilization , including : ddrug0 { such as DB00252 , and ddrug2 } ddrug3 { sometimes prescribed to control blood sugar in type # diabetes } DB00795 { used to control inflammation associated with crohn_disease and ulcerative colitis } ddrug5 { a ddrug6 } ddrug7 there has been concern about the interaction between ddrug8 and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , certain ddrug7 , ddrug8 , DB00277 and DB00916 , thereby delaying elimination and increasing blood levels of these drugs .",
        "label": "NA"
    },
    {
        "text": "there have been reports of interactions of DB00199 with ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB00802 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , and ddrug13 .",
        "label": "int"
    },
    {
        "text": "in clinical studies performed with ddrug0 , the concomitant use of oral ddrug1 { ddrug2 } , ddrug3 { DB00945 } , ddrug5 { ddrug6 } , and ddrug7 did not significantly affect the pharmacokinetics/pharmacodynamics of DB00569 .",
        "label": "NA"
    },
    {
        "text": "potential drug interactions between ddrug0 and other ddrug1 { ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 and DB00313 } were also assessed by evaluating the serum concentrations of ddrug9 and these HD00714 during placebo-controlled clinical studies .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 , HD00372 , and ddrug3 the in vitro binding of ddrug4 to plasma proteins is only slightly reduced by DB00465 { # % control vs # % } when ddrug6 plasma concentrations reach # to10 m g/ml .",
        "label": "NA"
    },
    {
        "text": "other drugs : in healthy volunteers , ddrug0 , ddrug1 , ddrug2 , DB00863 , ddrug4 , hormone replacement therapy { a combination of conjugated ddrug5 and ddrug6 } , ddrug7 { DB06723 and ddrug9 } and ddrug10 did not affect the pharmacokinetics of ddrug11 .",
        "label": "NA"
    },
    {
        "text": "other concomitant therapy although specific interaction studies were not performed , ddrug0 doses of # mg or more were concomitantly used in clinical studies with ddrug1 , DB00945 , a-blockers , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , cardiac ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 { also referred to as HD00203 } , and ddrug15 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "the percentage of neurons hyperpolarized by HD00035 , HD00036 , and ddrug2 was significantly reduced when 1 % but not <",
        "label": "NA"
    },
    {
        "text": "DB00294 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { DB00701 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "int"
    },
    {
        "text": "plasma levels of several closely related ddrug0 have been reported to be increased by the concomitant administration of ddrug1 or hepatic enzyme inhibitors { e , g , , ddrug2 , ddrug3 } and decreased by the concomitant administration of hepatic enzyme inducers { e , g , , ddrug4 , DB00252 } , and such an effect may be anticipated with HD00551 as well .",
        "label": "mechanism"
    },
    {
        "text": "the oral ddrug0 doses should be reduced by approximately 50 % when coadministered with DB00673 , to achieve exposures of DB01234 similar to those obtained when it is given without ddrug3 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may have additive effects with ddrug1 and other HD00261 , e , g , , ddrug3 , ddrug4 , HD00262 , ddrug6 .",
        "label": "NA"
    },
    {
        "text": "HD00356 enhance the renal toxicity of ddrug1 in animals , # ddrug2 interferes with the action of HD00664 preparations by chelating the ddrug4 , 7",
        "label": "NA"
    },
    {
        "text": "repeating the study with # healthy male volunteers in the absence of DB01016 did not detect an effect of DB00459 on glucose tolerance .",
        "label": "NA"
    },
    {
        "text": "certain drugs including ddrug0 , HD00175 , ddrug2 , and ddrug3 may reduce the hypoglycemic action of DB00731 and other oral ddrug5 .",
        "label": "effect"
    },
    {
        "text": "absorption of ddrug0 is impaired by HD00374 containing ddrug2 , ddrug3 , or ddrug4 , and DB01592 - containing preparations .",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with other cyp3a4 inhibitors { e , g , , DB00199 # mg bid , DB00661 # mg qd , ddrug3 # mg tid , ddrug4 # mg qd } resulted in increases in cmax of ddrug5 ranging from # - to # - fold and auc from # - to # - fold .",
        "label": "NA"
    },
    {
        "text": "DB01124 : DB00673 , when given as # mg on day # and # mg/day on days # and 3 , decreased the auc of ddrug2 { a cyp2c9 substrate } by 23 % on day 4 , 28 % on day 8 , and 15 % on day 15 , when a single dose of ddrug3 # mg was admini , stered orally prior to the administration of the 3-day regimen of ddrug4 and on days 4,8 , and 15 .",
        "label": "NA"
    },
    {
        "text": "the absorption of DB00759 , ddrug1 , ddrug2 , ddrug3 , and ddrug4 was significantly decreased when given simultaneously with DB00375 ;",
        "label": "mechanism"
    },
    {
        "text": "DB00199 : in healthy individuals , plasma concentrations of DB01076 increased approximately 40 % with coadministration of ddrug2 and ddrug3 , a known inhibitor of cytochrome p450 3a4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - and ddrug1 - containing HD00374 , administered concomitantly with ddrug3 , significantly decreased the bioavailability { 48 % } of DB00978 .",
        "label": "NA"
    },
    {
        "text": "DB06761 increased the extent of dissolution of DB01222 in proportion to the added concentration , which was also verified by equilibrium solubilization studies .",
        "label": "NA"
    },
    {
        "text": "ventricular tachycardia induced by DB01092 was generally converted to sinus rhythm following administration of HD00117 , ddrug2 , or ddrug3 but not after administration of ddrug4 alone or after ddrug5 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 - DB00120 may potentiate the tardive dyskinesia side reactions of HD00831 if used concomitantly with them .",
        "label": "NA"
    },
    {
        "text": "ddrug0 anesthesia : severe hypotension has been reported during ddrug1 anesthesia with concomitant use of a HD00379 and a HD00038 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 or ddrug1 : no formal pharmacokinetic studies have been performed examining the addition of ddrug2 to regimens containing DB01174 or DB00794 .",
        "label": "NA"
    },
    {
        "text": "use lowest possible dose of ddrug0 with careful monitoring , or consider HD00095 that are not primarily metabolized by cyp3a4 , such as ddrug2 , DB01095 , or ddrug4 in combination with ddrug5 .",
        "label": "NA"
    },
    {
        "text": "HD00645 did not inhibit the antitumor activity of four ddrug1 { ddrug2 , ddrug3 , ddrug4 , DB00531 } in four murine models .",
        "label": "NA"
    },
    {
        "text": "hypotension patients on ddrug0 therapy : patients on ddrug1 and especially those in whom HD00295 therapy was recently instituted , as well as those on severe dietary salt restriction or dialysis , may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of DB01197 .",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with other cyp3a4 inhibitors { e , g , , DB00199 # mg bid , ddrug2 # mg qd , ddrug3 # mg tid , ddrug4 # mg qd } resulted in increases in cmax of DB00700 ranging from # - to # - fold and auc from # - to # - fold .",
        "label": "NA"
    },
    {
        "text": "because of the low dietary ddrug0 concentration as compared to the ddrug1 contents of the diets , no effect of DB14574 on DB01592 absorption and excretion occurred .",
        "label": "NA"
    },
    {
        "text": "DB00695 : clinical studies , as well as post-marketing observations , have shown that ddrug1 can reduce the natriuretic effect of ddrug2 and HD00217 in some patients .",
        "label": "NA"
    },
    {
        "text": "the plasma concentration of ddrug0 may increase when the drug is given concomitantly with hepatic enzyme inhibitors { e , g , , ddrug1 , ddrug2 } and decrease by concomitant administration of hepatic enzyme inducers { e , g , , ddrug3 , DB00252 } , and adjustment of the dosage of DB00458 may therefore be necessary .",
        "label": "NA"
    },
    {
        "text": "concurrent administration of ddrug0 and DB01032 , which competes for tubular secretion , has been shown to increase the plasma half-life of DB00651 .",
        "label": "NA"
    },
    {
        "text": "DB00604 should not be used concomitantly with other drugs known to prolong the qt interval : certain ddrug1 , including those of class ia { such as ddrug2 and DB01035 } and class iii { such as ddrug4 } ;",
        "label": "advise"
    },
    {
        "text": "effects of ddrug0 on low-dose ddrug1 a group of # nonsmoking , healthy white female volunteers established on an oral ddrug2 regimen containing # mg DB00977 and # mg ddrug4 for at least # months received # mg/day of DB00949 from midcycle { day 15 } to midcycle { day 14 } of two consecutive oral ddrug6 cycles .",
        "label": "NA"
    },
    {
        "text": "serious anticholinergic symptoms { i , e , , severe dry mouth , urinary retention and blurred vision } have been associated with elevations in the serum levels of HD00042 when DB00501 therapy is initiated .",
        "label": "effect"
    },
    {
        "text": "several ddrug0 have been reported to block the pharmacologic effects of ddrug1 , DB00575 , or similar agents , and such an effect may be anticipated with HD00551 because of its structural similarity to other ddrug4 .",
        "label": "NA"
    },
    {
        "text": "coadministration of DB00736 # mg and ddrug1 , a cyp2c19 substrate , resulted in a 45 % decrease in clearance of DB00829 .",
        "label": "NA"
    },
    {
        "text": "drugs such as DB13179 and DB01026 may inhibit the metabolism of ddrug2 and thus decrease their clearance .",
        "label": "NA"
    },
    {
        "text": "agents with increased levels in the presence of ddrug0 : HD00472 increases the plasma levels of the following agents : ddrug2 , DB00252 { 6 } , and ddrug4 thus , if a patient has been titrated to a stable dosage on one of the agents in this category , and then begins a course of the treatment with ddrug5 , it is reasonable to expect that a dose decrease for the concomitant agent may be necessary .",
        "label": "mechanism"
    },
    {
        "text": "caution should be exercised when DB00328 and HD00326 are administered concomitantly .",
        "label": "advise"
    },
    {
        "text": "DB00435 has been administered with ddrug1 , ddrug2 , ddrug3 , ddrug4 , HD00882 , and high-frequency ventilation .",
        "label": "NA"
    },
    {
        "text": "there is a single case report , which suggests that DB00364 may interfere with DB00261 absorption .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , DB00812 , ddrug37 { ddrug38 } , ddrug39 { DB01045 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "administration of HD00532 with ddrug1 containing ddrug2 , ddrug3 , or ddrug4 , with ddrug5 , with metal cations such as ddrug6 , or with ddrug7 containing ddrug8 or DB01593 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "mechanism"
    },
    {
        "text": "the effects of HD00018 and ddrug1 upon ddrug2 { DB03575 } - induced locomotion and behavioral changes in mice .",
        "label": "NA"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / HD00517 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 pain medication { e , g , , ddrug12 } , drugs used to aid sleep , drowsiness-causing HD00388 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "concomitant use of HD00388 with ddrug1 , ddrug2 , ddrug3 , or other HD00389 may have an additive effect .",
        "label": "effect"
    },
    {
        "text": "the concomitant use of transdermal ddrug0 with DB00503 or other potent 3a4 inhibitors such as DB01026 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and nefazadone may result in an increase in ddrug7 plasma concentrations .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and DB00375 ddrug2 : absorption of ddrug3 is impaired in the presence of HD00783 .",
        "label": "NA"
    },
    {
        "text": "in some patients , the administration of ddrug0 can reduce the diuretic , natriuretic , and antihypertensive effects of ddrug1 , HD00293 , and HD00029 .",
        "label": "NA"
    },
    {
        "text": "drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on ddrug0 therapy : HD00657 , ddrug2 , ddrug3 , oral ddrug4 containing ddrug5 , ddrug6 - containing preparations and the numerous preparations containing HD00328 .",
        "label": "NA"
    },
    {
        "text": "DB00715 { 20 mg qd } increased the concentration of DB00476 { 40 mg qd } by about 60 % , and greater degrees of inhibition are expected with higher doses of ddrug2 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and DB00759 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { HD00712 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of DB00788 and ddrug1 is not recommended because ddrug2 is displaced from its binding sites during the concomitant administration of DB00945 , resulting in lower plasma concentrations and peak plasma levels .",
        "label": "NA"
    },
    {
        "text": "with oral DB00250 treatment , ddrug1 such as DB00205 have been noted to possibly increase the likelihood of hematologic reactions",
        "label": "effect"
    },
    {
        "text": "edema has been reported in patients concomitantly receiving DB01167 and HD00798 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 ddrug1 may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation , the discontinuance of ddrug2 ddrug3 could pose a hazard to health if a potentially toxic drug such as HD00118 has been filtrated to a maintenance level while the patient was taking ddrug5 HD00524 .",
        "label": "NA"
    },
    {
        "text": "no significant drug interactions have been reported in studies of ddrug0 given with other drugs such as ddrug1 , ddrug2 , ddrug3 , DB00682 , ddrug5 , and oral ddrug6 in healthy volunteers , or given with DB00584 to patients with heart failure { nyha class ii and iii } .",
        "label": "NA"
    },
    {
        "text": "HD00388 may have additive effects with ddrug1 and other ddrug2 , e , g , , ddrug3 , ddrug4 , HD00262 , ddrug6 .",
        "label": "effect"
    },
    {
        "text": "drugs that should not be coadministered with DB00220 ddrug1 : ddrug2 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 HD00871 : ddrug9 ddrug10 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "label": "advise"
    },
    {
        "text": "injection : ddrug0 injection , like other injectable ddrug1 , produces depression of the central nervous system when administered with ddrug2 , ddrug3 , ddrug4 , ddrug5 , and other HD00216 , when DB00747 is used concomitantly with injectable ddrug8 , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { DB00252 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , DB00295 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "concomitant use of DB00390 and HD00391 increases the risk of cardiac arrhythmias .",
        "label": "effect"
    },
    {
        "text": "these include DB01032 , ddrug1 , and some ddrug2 { e , g , DB00199 , rifamipicin , ddrug4 and ddrug5 } .",
        "label": "NA"
    },
    {
        "text": "drugs metabolized by cytochrome p450 enzymes the drug interaction study evaluating the effect of ddrug0 on DB00277 indicates that DB00365 inhibits ddrug3 metabolism , which is mediated by cyp1a2 .",
        "label": "NA"
    },
    {
        "text": "therophylline : a recent study has shown that concomitan administration of ddrug0 and ddrug1 may cause elevated plasma levels of DB00277 , and in some instances a slight decrease in the elimination of DB00951 .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of ddrug0 and ddrug1 , ddrug2 , ddrug3 , or an ddrug4 / DB00396 oral ddrug6 produced minor changes in the pharmacokinetics of DB01155 , which were considered to be without clinical significance .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 and DB00604 are all metabolized by the cytochrome p450iiia4 isozyme , and it has been demonstrated that DB01026 , a potent inhibitor of iiia4 , blocks the metabolism of these drugs , resulting in increased plasma concentrations of parent drug .",
        "label": "mechanism"
    },
    {
        "text": "drug interactions : the central ddrug0 syndrome can occur when anticholinergic agents such as ddrug1 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain ddrug2 such as ddrug3 , the ddrug4 and other ddrug5 , ddrug6 , certain HD00303 such as the ddrug8 salts , and HD00388 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , DB00636 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , DB00295 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "DB14507 : increased serum ddrug1 levels and symptoms of ddrug2 toxicity have been reported in patients receiving concomitant ddrug3 and HD00471 therapy .",
        "label": "NA"
    },
    {
        "text": "patients using cyp3a4 metabolized HD00434 should have cholesterol levels monitored after DB00559 is initiated to see whether the ddrug2 dose needs adjustment .",
        "label": "advise"
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of HD00472 are the following : DB00819 , ddrug2 , ddrug3 , ddrug4 { 1 } , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 { 1 } , ddrug10 , ddrug11 , grapefruit juice , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21 , ddrug22 , ddrug23 , ddrug24 { 1 } , ddrug25 , ddrug26 .",
        "label": "mechanism"
    },
    {
        "text": "DB00328 was also ineffective in altering DB02709 activity in arteries from both lean and dietary-obese rats .",
        "label": "NA"
    },
    {
        "text": "background : the effects of combined administration of DB11724 and ddrug1 { ddrug2 } , a ddrug3 , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by HD00037 { ddrug5 } and the labeling index of intestinal_cancer were investigated in male wistar rats .",
        "label": "NA"
    },
    {
        "text": "possible extrarenal mechanisms of action of DB00501 on HD00191 and ddrug2 transport were also examined .",
        "label": "NA"
    },
    {
        "text": "patients receiving high doses of HD00328 concomitantly with DB00695 , as in rheumatic disease , may experience ddrug2 toxicity at lower doses because of competitive renal excretory sites .",
        "label": "effect"
    },
    {
        "text": "caution should be used when HD00203 are administered concomitantly with DB00563 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 increases enterohepatic elimination of DB01118 and may reduce its serum levels and HD00309 / 2 .",
        "label": "NA"
    },
    {
        "text": "the ecg changes and/or hypokalemia that may result from the administration of ddrug0 { such as HD00105 or ddrug2 } can be acutely worsened by ddrug3 , especially when the recommended dose of the HD00359 is exceeded .",
        "label": "NA"
    },
    {
        "text": "the plasma concentration of ddrug0 may increase when the drug is given concomitantly with hepatic enzyme inhibitors { e , g , , DB00501 , ddrug2 } and decrease by concomitant administration of hepatic enzyme inducers { e , g , , HD00026 , ddrug4 } , and adjustment of the dosage of ddrug5 may therefore be necessary .",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with other cyp3a4 inhibitors { e , g , , DB00199 # mg bid , ddrug2 # mg qd , DB01232 # mg tid , ddrug4 # mg qd } resulted in increases in cmax of ddrug5 ranging from # - to # - fold and auc from # - to # - fold .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the administration of DB00861 to normal volunteers receiving DB00328 decreased the renal clearance and significantly increased the plasma levels of ddrug3 .",
        "label": "mechanism"
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of HD00472 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 { 1 } , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 { 1 } , ddrug10 , ddrug11 , grapefruit juice , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , DB02701 , ddrug19 , ddrug20 , ddrug21 , ddrug22 , ddrug23 , ddrug24 { 1 } , ddrug25 , ddrug26 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , DB00564 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , DB00860 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "however , the systemic administration of some ddrug0 has been shown to elevate plasma concentrations of DB00277 , interfere with the metabolism of ddrug2 , and enhance the effects of the oral ddrug3 ddrug4 and its derivatives , and has been associated with transient elevations in serum creatinine in patients receiving systemic DB00091 concomitantly .",
        "label": "NA"
    },
    {
        "text": "DB00476 may have a clinically important interaction with the following other drugs : DB02325 : when ddrug2 and ddrug3 were administered several hours apart so that peak concentrations of each would coincide , ddrug4 did not increase the impairment of mental and motor skills caused by ddrug5 .",
        "label": "NA"
    },
    {
        "text": "in addition , we have shown that HD00054 is a useful pharmacological tool with which to examine the HD00053 - mediated responses of megakaryocytes .",
        "label": "NA"
    },
    {
        "text": "HD00326 : combination ddrug1 may increase or decrease the effects of HD00708 .",
        "label": "NA"
    },
    {
        "text": "although ddrug0 has a lower affinity for ddrug1 than for DB01592 , ddrug3 should not be taken with ddrug4 - containing HD00589 .",
        "label": "NA"
    },
    {
        "text": "higher concentrations of ddrug0 { 10 { -8 } - 10 { -6 } m } or HD00147 { 3 x 10 { -8 } - 10 { -7 } m } enhance the mitogenic activity of HD00148 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , DB00949 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { HD00712 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "DB00999 { ddrug1 } alone or in combination with ddrug2 : concomitant use of ddrug3 alone or in combination with DB00384 is contraindicated .",
        "label": "NA"
    },
    {
        "text": "prolonged recovery time may occur if HD00026 and/or ddrug1 are used concurrently with DB01221 .",
        "label": "effect"
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the HD00555 of drugs may be potentiated by ddrug1 , ddrug2 , ddrug3 , ddrug4 , HD00557 , the ddrug6 , ddrug7 and ddrug8 , ddrug9 and the ddrug10 , and by other ddrug11 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 { cns } drugs including ddrug1 , HD00216 , ddrug3 , ddrug4 , blood pressure medications { ddrug5 , ddrug6 , ddrug7 } , motion sickness medications , ddrug8 , ddrug9 , HD00024 , sleeping pills and ddrug11",
        "label": "NA"
    },
    {
        "text": "effects of DB00906 on other antiepilepsy drugs { HD00714 } : ddrug2 : ddrug3 had no effect on the steady-state plasma concentrations of ddrug4 in patients with epilepsy .",
        "label": "NA"
    },
    {
        "text": "because severe hypoglycemia has been reported in patients concomitantly receiving oral ddrug0 { an DB03366 } and oral ddrug2 , such a potential interaction involving the latter agents when used concomitantly with DB01026 tablets { an ddrug4 } can not be ruled out .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { DB00400 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , DB00503 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : concurrent administration of DB00945 and DB00712 resulted in 50 % lower serum ddrug3 concentrations .",
        "label": "mechanism"
    },
    {
        "text": "concomitant administration of DB00962 { 10 mg } and ddrug1 { 800 mg } produced an 85 % increase in the mean cmax and auc of DB00962 .",
        "label": "NA"
    },
    {
        "text": "DB00798 - DB00134 may protect against the ototoxic effects of ddrug2 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , ddrug8 { HD00398 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , ddrug12 } , HD00297 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in vitro and/or in vivo data indicate that ddrug1 , DB01167 , and oral DB01026 markedly inhibit the metabolism of ddrug4 , which can result in an increase in plasma ddrug5 levels and prolongation of the qt interval on the ecg .",
        "label": "NA"
    },
    {
        "text": "both HD00021 and HD00022 decrease extracellular levels of dopamine in the nucleus accumbens , but only ddrug2 increases extracellular levels of serotonin in the nucleus accumbens .",
        "label": "NA"
    },
    {
        "text": "ddrug0 ddrug1 may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation , the discontinuance of ddrug2 ddrug3 could pose a hazard to health if a potentially toxic drug such as ddrug4 has been filtrated to a maintenance level while the patient was taking DB01432 HD00524 .",
        "label": "NA"
    },
    {
        "text": "HD00827 and ddrug1 - although not reported , DB00117 , via its metabolism to histamine , might decrease the efficacy of ddrug3 and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "no significant drug interactions have been reported in studies of ddrug0 given with other drugs such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , DB00999 , and oral HD00283 in healthy volunteers , or given with ddrug7 to patients with heart failure { nyha class ii and iii } .",
        "label": "NA"
    },
    {
        "text": "HD00828 - including DB00780 , ddrug2 and ddrug3 hc1 .",
        "label": "NA"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / ddrug1 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , ddrug4 , ddrug5 , ddrug6 , ddrug7 , DB01578 , ddrug9 , ddrug10 , ddrug11 pain medication { e , g , , ddrug12 } , drugs used to aid sleep , drowsiness-causing HD00388 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : no significant differences were observed in the steady-state pharmacokinetics of DB08496 or ddrug2 with the addition of DB00906 given as a single dose .",
        "label": "NA"
    },
    {
        "text": "the HD00100 are a family of HD00199 and ddrug2 .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of ddrug0 : ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , ddrug5 , ddrug6 , ddrug7 } , DB00951 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , HD00810 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "no drug interaction studies have been conducted for ddrug0 , however the use of orally administered HD00002 could , theoretically , interfere with the release of DB00244 in the colon .",
        "label": "NA"
    },
    {
        "text": "caution should be used when administering or taking DB00530 with ddrug1 and other strong cyp3a4 inhibitors such as , but not limited to , DB01072 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { ddrug12 } , and ddrug13 .",
        "label": "advise"
    },
    {
        "text": "- a HD00535 { ddrug1 } such as ddrug2 { ddrug3 , ddrug4 , ddrug5 , others } , ddrug6 { ddrug7 , HD00761 , ddrug9 } , ddrug10 { ddrug11 , ddrug12 } , ddrug13 { ddrug14 } , ddrug15 { ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , and ddrug21 { ddrug22 , ddrug23 , ddrug24 } ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 { DB01370 - or ddrug2 - containing } : concomitant administration of 300-mg DB00535 capsules with # ml ddrug4 suspension reduces the rate { cmax } and extent { auc } of absorption by approximately 40 % .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral HD00811 , HD00106 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 { e , g , , ddrug9 } , ddrug10 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB01294 , given concomitantly with DB00467 or # minutes following ddrug3 administration , decreased ddrug4 bioavailability by approximately 25 % .",
        "label": "mechanism"
    },
    {
        "text": "conclusions : HD00093 inhibit the metabolism of ddrug1 that are metabolized by cyp3a4 { i , e , , ddrug2 , DB00439 , ddrug4 , ddrug5 } .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 { cns } drugs including ddrug1 , ddrug2 , HD00388 , ddrug4 , blood pressure medications { ddrug5 , ddrug6 , ddrug7 } , motion sickness medications , HD00542 , ddrug9 , ddrug10 , sleeping pills and ddrug11",
        "label": "NA"
    },
    {
        "text": "HD00183 , oral HD00283 : ddrug2 tend to increase serum serpina7 { tbg } .",
        "label": "NA"
    },
    {
        "text": "the risk of using ddrug0 in combination with other drugs has not been systematically evaluated , but DB02325 may potentiate the side effects of DB01200 .",
        "label": "effect"
    },
    {
        "text": "patients with haca titers may have allergic or hypersensitivity reactions when treated with other HD00210 or HD00211 .",
        "label": "NA"
    },
    {
        "text": "HD00374 : concomitant administration of ddrug1 s and ddrug2 s does not interfere with absorption of DB00939 .",
        "label": "NA"
    },
    {
        "text": "drugs decreasing DB01109 effect : ddrug1 , ddrug2 , DB00184 , or ddrug4 may partially counteract the anticoagulant action of ddrug5 .",
        "label": "NA"
    },
    {
        "text": "although the occurrence has not been reported with ddrug0 , nephrotoxicity has been reported following concomitant administration of other HD00485 and HD00249 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , DB00776 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , DB00231 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "there have been postmarketing reports of drug interactions when ddrug0 is coadministered with ddrug1 , resulting in qt prolongation , cardiac arrythmias , ventricular tachycardia , ventricular fibrulation , and torsades de pointes , most like due to inhibition of hepatic metabolism of DB00604 by DB00199 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : increased activity of both DB00091 and HD00175 may occur when the two are used concurrently .",
        "label": "effect"
    },
    {
        "text": "spontaneous reports of serotonin syndrome associated with co-administration of DB00601 and ddrug1 , including ddrug2 such as ddrug3 { HD00114 } , have been reported .",
        "label": "effect"
    },
    {
        "text": "we demonstrate that the conversion of ddrug0 to HD00077 by an nad + - dependent oxidation is the rate-limiting step in the synthesis of the toxic product , ddrug2 from HD00079 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB01045 increases the metabolism of ddrug2 and some HD00526 { ddrug4 } resulting in decreased contraceptive effectiveness and increased menstrual irregularities .",
        "label": "mechanism"
    },
    {
        "text": "DB00294 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { HD00548 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "int"
    },
    {
        "text": "although these results do not indicate a significant interaction between ddrug0 and DB00682 or ddrug2 , the administration of ddrug3 to patients taking HD00326 should be done extremely cautiously , and patients should be closely monitored .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in clinical drug interaction studies , DB00673 did not have clinically important effects on the pharmacokinetics of DB00904 or ddrug3 .",
        "label": "NA"
    },
    {
        "text": "in the diamond trials , # patients were treated with DB00204 and ddrug1 concomitantly of whom # died compared to # deaths among the # patients receiving placebo and HD00218 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration of ddrug1 { using an experimental soft-gelatin capsule formulation of DB01232 1200 mg } with DB00220 resulted in an 18 % increase in ddrug4 plasma auc and a 4-fold increase in ddrug5 plasma a , c.",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , DB14513 , or ddrug4 , with ddrug5 , with metal cations such as ddrug6 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { DB00900 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "the effects of DB00640 are antagonized by ddrug1 such as DB00201 and ddrug3 .",
        "label": "effect"
    },
    {
        "text": "tissue culture and animal studies indicate that DB00023 can diminish or abolish the effect of ddrug1 on malignant cells # this effect on DB00563 activity persists as long as plasma asparagine levels are suppressed .",
        "label": "NA"
    },
    {
        "text": "although specific drug interaction studies have not been conducted with DB00484 , the possibility of an additive or potentiating effect with ddrug1 { ddrug2 , ddrug3 , ddrug4 , HD00024 , or ddrug6 } should be considered .",
        "label": "advise"
    },
    {
        "text": "close supervision and careful adjustment of dosage are required when ddrug0 is administered with HD00315 or HD00390 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00224 { 800 mg t , i , d , } co-administered with DB00862 # mg resulted in a 16-fold increase in ddrug3 auc , a 7-fold increase in ddrug4 cmax and a 2-fold increase in ddrug5 half-life .",
        "label": "mechanism"
    },
    {
        "text": "DB00224 may be taken with a light meal # h following the administration of # mg of DB00900 .",
        "label": "advise"
    },
    {
        "text": "interaction of ddrug0 with other drugs : ddrug1 : co-administration of DB00501 { 800 mg/day } to patients taking ddrug3 chronically had no effect on DB00906 pharmacokinetics .",
        "label": "NA"
    },
    {
        "text": "before taking ddrug0 , tell your doctor if you are taking any of the following medicines : - ddrug1 or another HD00372 such as ddrug3 { ddrug4 } , DB01399 { ddrug6 , others } , ddrug7 { ddrug8 } , ddrug9 { ddrug10 } , or ddrug11 { ddrug12 } ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 and DB00375 HD00510 : absorption of ddrug3 is impaired in the presence of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "DB14513 - and/or ddrug1 - containing ddrug2 , products containing DB01373 { ddrug4 } , ddrug5 containing ddrug6 or other metal cations , or ddrug7 { ddrug8 } chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after ddrug9 .",
        "label": "NA"
    },
    {
        "text": "interactions with other cns agents : concurrent use of DB00854 with all ddrug1 { eg , ddrug2 , ddrug3 , ddrug4 , other ddrug5 , general ddrug6 , ddrug7 , ddrug8 , ddrug9 , HD00262 , ddrug11 and ddrug12 } may result in additive central nervous system depressant effects .",
        "label": "effect"
    },
    {
        "text": "no depressant effect on blood levels in humans was noted when DB00375 was administered with any of the following drugs : DB00945 , ddrug2 , ddrug3 , ddrug4 , ddrug5 { ddrug6 } , ddrug7 , ddrug8 or ddrug9 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may decrease thyroidal uptake of HD00478 , a rebound in uptake may occur up to # days after sudden withdrawal of DB00389 .",
        "label": "NA"
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma ddrug0 concentrations include : acute DB02325 intake , ddrug2 , chboramphenicol , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , DB00593 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21",
        "label": "NA"
    },
    {
        "text": "there have been reports of interactions of DB00199 with ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , DB00604 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , and ddrug13 .",
        "label": "int"
    },
    {
        "text": "ddrug0 - and/or DB01370 - containing ddrug2 , products containing ddrug3 { ddrug4 } , ddrug5 containing DB01593 or other metal cations , or ddrug7 { ddrug8 } chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after ddrug9 .",
        "label": "NA"
    },
    {
        "text": "as a consequence , when DB00328 and ddrug1 are given concomitantly , the patient should be carefully observed for signs of DB14507 toxicity .",
        "label": "NA"
    },
    {
        "text": "HD00175 : ddrug1 : ddrug2 , when given as a regimen of 125 mg with ddrug3 coadministered orally as # mg on day 1 , and ddrug4 when given as # mg/day with DB01234 coadministered orally as # mg on days # through 5 , increased the auc of ddrug6 , a cyp3a4 substrate by # - fold , on days # and 5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of ddrug1 , ddrug2 , DB00571 , ddrug4 , ddrug5 , ddrug6 , certain ddrug7 , ddrug8 , ddrug9 and DB00916 , thereby delaying elimination and increasing blood levels of these drugs .",
        "label": "NA"
    },
    {
        "text": "ddrug0 / ddrug1 : the coadministration of DB00252 or ddrug3 will not affect plasma concentrations of ddrug4 , but may reduce endogenous plasma levels of DB00136 / ergocalcitriol by accelerating metabolism .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the effect of steady-state DB00176 l50 mg bid on the pharmacokinetics of a single dose of ddrug2 { 375 mg } as # mg DB01223 was evaluated in # healthy non-smoking , male volunteers .",
        "label": "NA"
    },
    {
        "text": "-lsb- a pharmacological analysis of the effect of ddrug0 on stimulated gastric secretion -rsb- chronic experiments on dogs with gastric fistulas were carried out to study the influence of ddrug1 and HD00197 on ddrug3 - and DB05381 - induced gastric acid secretion .",
        "label": "NA"
    },
    {
        "text": "co-administration of cyp3a4 inhibitors { eg , DB01026 , ddrug1 , ddrug2 , grapefruit juice , ddrug3 } with ddrug4 may lead to several - fold increases in the plasma levels of DB01023 , either due to an increase in bioavailability or due to a decrease in metabolism .",
        "label": "NA"
    },
    {
        "text": "the concomitant use of DB00496 with other HD00352 may increase the frequency and/or severity of dry mouth , constipation , blurred vision and other anticholinergic pharmacological effects .",
        "label": "effect"
    },
    {
        "text": "consequently , the effect of DB01592 on the retention of DB14574 was lower than on absorption .",
        "label": "mechanism"
    },
    {
        "text": "administration of DB00700 with other cyp3a4 inhibitors { e , g , , ddrug1 # mg bid , DB00661 # mg qd , ddrug3 # mg tid , ddrug4 # mg qd } resulted in increases in cmax of ddrug5 ranging from # - to # - fold and auc from # - to # - fold .",
        "label": "mechanism"
    },
    {
        "text": "however , due to possible pharmacodynamic interactions , when co-administered with DB00633 , a reduction in dosage of ddrug1 on the concomitant ddrug2 , HD00596 , ddrug4 or ddrug5 may be required .",
        "label": "NA"
    },
    {
        "text": "{ HD00788 may increase the responsiveness to DB01199 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 can interact with ddrug1 or other ddrug2 { may potentiate the cns depressant effects of either these medications or ddrug3 } , ddrug4 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug5 } , and HD00445 { concurrent use with HD00388 may prolong and intensify the anticholinergic and cns depressant effects of ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , certain ddrug7 , DB00281 , ddrug9 and DB00916 , thereby delaying elimination and increasing blood levels of these drugs .",
        "label": "NA"
    },
    {
        "text": "median gastric ph was significantly higher when DB00224 was taken after DB00900 administration ;",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : although the results of a clinical study did not indicate a safe problem associated with the administration of DB00320 { ddrug2 } injection , usp to subjects already receiving DB00571 , there have been reports that ddrug4 may potentiate the vasoconstrictive action of ddrug5 by blocking the vasodilating property of epinephrine .",
        "label": "NA"
    },
    {
        "text": "particular caution is necessary when using DB01205 in cases of mixed drug overdosage since the toxic effects { such as convulsions and cardiac dysrhythmias } of other drugs taken in overdose { especially ddrug1 } may emerge with the reversal of the ddrug2 effect by DB01205 .",
        "label": "NA"
    },
    {
        "text": "it is not clear whether this represents an interaction with DB00204 or the presence of more severe structural heart disease in patients on DB00390 ;",
        "label": "NA"
    },
    {
        "text": "{ see clinical pharmacology } coadministration of DB01006 and DB00675 # mg daily resulted in a reduction of ddrug2 plasma levels by 38 % on average .",
        "label": "mechanism"
    },
    {
        "text": "patients in a clinical study who were on established therapy with DB00795 , to which ddrug1 was added , were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either DB09145 ci or ddrug3 alone .",
        "label": "NA"
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a ddrug0 , including DB00537 , with multivalent cation-containing products such as ddrug2 or ddrug3 ddrug4 , ddrug5 , ddrug6 chewable/buffered tablets or pediatric powder , or products containing DB01373 , ddrug8 , or ddrug9 may substantially decrease the absorption of ddrug10 , resulting in serum and urine levels considerably lower than desired .",
        "label": "mechanism"
    },
    {
        "text": "however , in the second study , administration of # g DB01432 # hour before the evening meal and # mg ddrug1 approximately # hours after the same evening meal resulted in a decrease in the ddrug2 auc of less than 8 % , and a decrease in cmax of about 30 % when compared to dosing HD00503 alone .",
        "label": "NA"
    },
    {
        "text": "in case of ddrug0 toxicity and/or elevated serum DB00277 levels , the dose of ddrug2 should be reduced while the patient is receiving concomitant DB00199 therapy .",
        "label": "NA"
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit DB00451 binding to serum proteins or alter the concentrations of serum binding proteins : ddrug1 and related ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , DB00675 .",
        "label": "mechanism"
    },
    {
        "text": "such individuals are referred to as poor metabolizers of drugs such as ddrug0 , DB00514 , the HD00043 , and ddrug3 .",
        "label": "NA"
    },
    {
        "text": "although not observed in this study , adverse effects could potentially arise from co-administration of DB00567 and DB00331 by inhibition of tubular secretion via organic cationic transporter systems .",
        "label": "mechanism"
    },
    {
        "text": "HD00273 : enhanced bone marrow suppression by ddrug1 and other ddrug2 has been reported among patients with neoplastic disease , except leukemia , in the presence of DB00437 .",
        "label": "NA"
    },
    {
        "text": "HD00326 : combination HD00432 may increase or decrease the effects of ddrug2 .",
        "label": "NA"
    },
    {
        "text": "therefore , co-administration of ddrug0 with other drugs that are metabolized by this isozyme , including ddrug1 , ddrug2 , ddrug3 , and ddrug4 { e , g , , ddrug5 , DB01195 and ddrug7 } , or that inhibit this enzyme { e , g , , DB00908 } , should be approached with caution .",
        "label": "NA"
    },
    {
        "text": "DB14513 - and ddrug1 - containing HD00374 , administered concomitantly with ddrug3 , significantly decreased the bioavailability { 48 % } of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { e , g , ddrug1 and ddrug2 } : agents of the ddrug3 , of which DB00320 { ddrug5 } injection , usp is a member , have been shown to interact with ddrug6 of the HD00626 , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 in combination with DB00575 enhances the manifestation of corneal lesions in rats epidural injection ddrug2 may potentiate the cns-depressive effect of DB02325 , ddrug4 or other ddrug5 .",
        "label": "NA"
    },
    {
        "text": "drugs that may alter ddrug0 plasma concentrations drugs that may increase DB00619 plasma concentrations : caution is recommended when administering ddrug2 with inhibitors of the cyp3a4 family { e , g , , DB01026 , ddrug4 , ddrug5 , ddrug6 } .",
        "label": "NA"
    },
    {
        "text": "if replacing ddrug0 by ddrug1 therapy , the introduction of HD00378 should be delayed for several days after DB00575 administration has stopped .",
        "label": "advise"
    },
    {
        "text": "in separate single or multiple dose pharmacokinetic interaction studies with ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , DB00390 , and ddrug8 , the bioavailability of ddrug9 was not altered by coadministration of DB00492 with any one of these drugs .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , HD00002 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , DB00812 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { e , g , DB00199 and ddrug2 } : agents of the ddrug3 , of which ddrug4 { ddrug5 } injection , usp is a member , have been shown to interact with HD00002 of the ddrug7 , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .",
        "label": "NA"
    },
    {
        "text": "preliminary animal and human studies have shown that small quantities of systemically administered DB00650 enter the lamc2 primarily as 5-methyltetrahydro-folate and , in humans , remain # to # orders of magnitude lower than the usual DB00563 concentrations following intrathecal administration .",
        "label": "NA"
    },
    {
        "text": "blood levels of ddrug0 increased 24 % when DB00757 was coadministered with ddrug2 { nonselective inhibitor of cytochrome p-450 } for # days , and decreased 28 % with coadministration of DB01045 { potent inducer of cytochrome p-450 } for # days .",
        "label": "mechanism"
    },
    {
        "text": "organic DB14049 - DB00125 supplements theoretically may potentiate the effects of organic ddrug2 if taken concomitantly .",
        "label": "NA"
    },
    {
        "text": "patients who are applying DB00523 gel should not concurrently use products that contain ddrug1 { n , HD00267 } , a common component of insect repellent products .",
        "label": "advise"
    },
    {
        "text": "- a HD00380 such as ddrug1 { ddrug2 } , ddrug3 { ddrug4 } , ddrug5 { ddrug6 } , DB00264 { ddrug8 } , and others ;",
        "label": "NA"
    },
    {
        "text": "however , there are limited in vivo data suggesting a modest cyp2d6 inhibitory effect for ddrug0 , i , e , , coadministration of ddrug1 { 20 mg/day for # days } with the HD00042 DB01151 { single dose of # mg } , a substrate for cyp2d6 , resulted in a 40 % increase in cmax and a 100 % increase in auc of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "tablets : the HD00100 , including DB00186 , produce cns-depressant effects when administered with such medications as ddrug2 or ddrug3 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and DB00759 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , DB01045 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , DB01026 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and DB00126 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : DB00316 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { DB00295 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "in a multiple-dose study , DB00467 caused a dose-related increase in the mean elimination half-life of DB00201 , thereby decreasing the clearance of ddrug2 by up to 80 % and leading to a five-fold increase in the auc and the half-life of ddrug3 .",
        "label": "mechanism"
    },
    {
        "text": "repeated oral administration of DB11390 in sheep : interactions of ddrug1 with ddrug2 , DB11473 , and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , DB01174 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , DB00231 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "drug interactions : the central ddrug0 syndrome can occur when anticholinergic agents such as DB00810 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain ddrug2 such as ddrug3 , the ddrug4 and other HD00031 , ddrug6 , certain ddrug7 such as the ddrug8 salts , and ddrug9 .",
        "label": "effect"
    },
    {
        "text": "although neither ddrug0 nor ddrug1 affected the proliferation of prostatic epithelium in rpmi1640 containing ddrug2 alone , they modify the mitogenic effect of HD00148 and HD00071 .",
        "label": "NA"
    },
    {
        "text": "moreover , additional interaction studies with DB00627 and ddrug1 have not demonstrated any effect on DB01095 plasma levels , and administration to a patient population chronically receiving ddrug3 resulted in no difference in the extent of bioavailability of ddrug4 relative to control data .",
        "label": "NA"
    },
    {
        "text": "ddrug0 altered coagulation parameters and/or bleeding have been reported in patients taking ddrug1 concomitantly with HD00469 such as DB00682 and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , DB00564 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { HD00531 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with HD00374 containing DB01370 , ddrug3 , or ddrug4 , with ddrug5 , with metal cations such as ddrug6 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , DB01167 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , DB00295 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of ddrug0 : ddrug1 , DB01406 , ddrug3 , ddrug4 { e , g , , ddrug5 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , DB00052 , ddrug11 , ddrug12 , ddrug13 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma DB00252 concentrations include : acute ddrug1 intake , ddrug2 , chboramphenicol , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , DB00472 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21",
        "label": "mechanism"
    },
    {
        "text": "DB01032 : as with other ddrug1 , co-administration of ddrug2 with ddrug3 resulted in an increase in the plasma exposure of DB01066 , with a 49 % increase in mean cmax , a 122 % increase in mean auc , and a 53 % increase in half-life .",
        "label": "NA"
    },
    {
        "text": "there was no evidence of drug interactions in clinical studies in which DB00841 was administered concurrently with other drugs , including ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB00883 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , and ddrug13 .",
        "label": "NA"
    },
    {
        "text": "HD00303 : ddrug1 , DB00281 { systemic } and ddrug3",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00669 has been reported to cause coronary artery vasospasm , and its effect could be additive with DB00320 { ddrug3 } injection , usp .",
        "label": "effect"
    },
    {
        "text": "although DB01609 has a lower affinity for ddrug1 than for DB01592 , ddrug3 should not be taken with ddrug4 - containing ddrug5 .",
        "label": "NA"
    },
    {
        "text": "other drug interactions : no pharmacokinetic interactions were observed between DB00862 and the following drugs : ddrug1 , DB00682 , ddrug3 , ddrug4 , and ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 ddrug1 ddrug2 ddrug3 ddrug4 ddrug5 DB01149 DB00091 large quantities of grapefruit juice { # quart daily }",
        "label": "NA"
    },
    {
        "text": "- ddrug0 or HD00421 { with hepatotoxic potential } must not be administered together with ddrug2 or HD00415 .",
        "label": "advise"
    },
    {
        "text": "while all the HD00113 { ddrug1 } , e , g , , DB00472 , seriraline , and ddrug3 , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .",
        "label": "NA"
    },
    {
        "text": "a drug interaction study was performed in which DB00002 was administered in combination with DB00762 .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 DB00472 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 DB14507 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "sinus bradycardia has been reported with oral ddrug0 in combination with DB00281 { ddrug2 substrate } given for local HD00308 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { DB00701 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , DB00231 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "these alterations in ddrug0 pharmacokinetics produced by DB01118 explain the increase in serum DB00390 level that has been observed when this drug combination has been used clinically .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : HD00403 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 HD00542 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "DB00252 : altered serum levels of ddrug1 { increased and decreased } have been reported in patients receiving concomitant DB00537 .",
        "label": "NA"
    },
    {
        "text": "DB00673 is unlikely to interact with drugs that are substrates for the p_glycoprotein transporter , as demonstrated by the lack of interaction of ddrug1 with DB00390 in a clinical drug interaction study .",
        "label": "NA"
    },
    {
        "text": "ddrug0 ddrug1 , DB00897 ddrug3 ergot derivatives DB00582",
        "label": "NA"
    },
    {
        "text": "ventricular tachycardia induced by ddrug0 was generally converted to sinus rhythm following administration of HD00117 , ddrug2 , or ddrug3 but not after administration of HD00120 alone or after ddrug5 .",
        "label": "NA"
    },
    {
        "text": "however , because some ddrug0 have been reported to enhance the anticoagulant effects of DB00682 or its derivatives in patients , the prothrombin time or other suitable coagulation test should be closely monitored if a HD00751 is administered concomitantly with ddrug3 or its derivatives .",
        "label": "NA"
    },
    {
        "text": "this indicates that DB00906 does not cause induction or inhibition of the hepatic microsomal enzyme systems responsible for the metabolism of DB01435 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may have additive effects with ddrug1 and other HD00261 , e , g , , HD00214 , ddrug4 , ddrug5 , ddrug6 .",
        "label": "NA"
    },
    {
        "text": "based on adult data , lower doses of ddrug0 may be needed following coadministration of drugs which are reported to decrease ddrug1 elimination { e , g , , ddrug2 and DB01026 } and higher ddrug4 doses may be needed following coadministration of drugs that increase DB00201 elimination { e , g , , ddrug6 and ddrug7 } .",
        "label": "NA"
    },
    {
        "text": "HD00485 - ddrug1 containing side chains of n-methylthiotetrazole { ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB04570 } or methylthiadiazole { ddrug7 } can cause vitamin_k_deficiency and hypoprothrombinemia .",
        "label": "NA"
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the ddrug0 of drugs may be potentiated by ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , the ddrug6 , HD00559 and ddrug8 , ddrug9 and the HD00043 , and by other ddrug11 .",
        "label": "NA"
    },
    {
        "text": "other potentially important drug interactions : ddrug0 : HD00100 metabolized by hepatic oxidation { e , g , , DB00404 , ddrug3 , ddrug4 elc , } should be used with caution because the clearance of these drugs is likely to be reduced by ddrug5 .",
        "label": "NA"
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the ddrug0 of drugs may be potentiated by ddrug1 , ddrug2 , ddrug3 , HD00556 , ddrug5 , the ddrug6 , ddrug7 and ddrug8 , ddrug9 and the ddrug10 , and by other HD00561 .",
        "label": "NA"
    },
    {
        "text": "the clearance of ddrug0 metabolized by glucuronidation { e , g , , ddrug1 , DB00842 , ddrug3 } is unlikely to be affected by DB00176 .",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , ddrug3 , or DB01373 , with ddrug5 , with metal cations such as ddrug6 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of HD00532 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "HD00021 attenuates , but HD00022 potentiates , the acute locomotor effects of ddrug2 ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , HD00002 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , DB00295 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "effect of ddrug0 in pediatric patients there was about a 22 % increase of apparent total body clearance of DB01202 when it was co-administered with enzyme-inducing HD00714 .",
        "label": "mechanism"
    },
    {
        "text": "HD00282 { ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 } : increase the metabolism of ddrug6 and/or some HD00526 , leading to possible decrease in contraceptive effectiveness .",
        "label": "mechanism"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : ddrug1 ; ddrug2 ; DB01159 ; certain ddrug4 , especially the ddrug5 and ddrug6 ; ddrug7 ; ddrug8 salts ; DB01035 ; and ddrug10 .",
        "label": "NA"
    },
    {
        "text": "there is limited experience with concomitant ddrug0 such as ddrug1 , ddrug2 , ddrug3 , and HD00218 { both HD00722 - like and loop } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the pharmacokinetics of DB00277 { ddrug2 # mg/kg infused over # minutes } were unchanged following a single oral dose of DB00518 { 400 mg } in # healthy subjects .",
        "label": "NA"
    },
    {
        "text": "ddrug0 has been administered to patients receiving HD00573 or HD00244 without adverse effects .",
        "label": "NA"
    },
    {
        "text": "patients taking these drugs with DB00190 and ddrug1 or DB00190 - ddrug3 combination products should be carefully observed for loss of therapeutic response .",
        "label": "NA"
    },
    {
        "text": "similarly , ddrug0 decreased the antinociceptive effect of DB04817 { only in the tail-flick test } and DB00328 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : since ddrug1 is a ddrug2 , it is possible that ddrug3 , such as the ddrug4 { HD00219 , ddrug6 , ddrug7 } or ddrug8 , may diminish the effectiveness of DB00714 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 , including ddrug1 , may enhance the effects of the oral HD00025 DB00682 or its derivatives .",
        "label": "NA"
    },
    {
        "text": "DB00788 , ddrug1 and other ddrug2 have been reported to reduce the tubular secretion of ddrug3 in an animal model , possibly increasing the toxicity of DB00563 .",
        "label": "NA"
    },
    {
        "text": "HD00374 : concomitant administration of ddrug1 containing DB14513 or ddrug3 with ddrug4 chewable/dispersible buffered tablets or pediatric powder for oral solution may potentiate adverse events associated with the ddrug5 components .",
        "label": "NA"
    },
    {
        "text": "the following agents may increase certain actions or side effects of ddrug0 , DB00915 ddrug2 of class { e , g , ddrug3 } , HD00388 ddrug5 { e , g , ddrug6 } , ddrug7 .",
        "label": "NA"
    },
    {
        "text": "drug-drug interactions between DB01202 and other HD00703 { ddrug2 } ddrug3 ddrug4 { 3000 mg daily } had no effect on the pharmacokinetic disposition of ddrug5 in patients with refractory epilepsy .",
        "label": "NA"
    },
    {
        "text": "there have been reports of DB00277 - related side effects in patients on concomitant therapy with DB01059 and ddrug2 .",
        "label": "NA"
    },
    {
        "text": "therefore , coadministration of DB00673 with drugs that strongly induce cyp3a4 activity { e , g , , DB01045 , ddrug2 , ddrug3 } may result in reduced plasma concentrations of ddrug4 that may result in decreased efficacy of ddrug5 .",
        "label": "mechanism"
    },
    {
        "text": "the use of HD00343 or ddrug1 with ddrug2 preparations may increase the effect of either the HD00711 or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "hormonal ddrug0 co-administration of DB00776 with an oral ddrug2 has been shown to influence the plasma concentrations of the two hormonal components , ddrug3 { ee } and DB00367 { lng } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : combination ddrug1 may decrease the clearance of some ddrug2 { DB00404 , ddrug4 , ddrug5 } and increase the clearance of others { DB00186 , ddrug7 , ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "HD00273 : enhanced bone marrow suppression by DB00531 and other ddrug2 has been reported among patients with neoplastic disease , except leukemia , in the presence of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "co-administration of ddrug0 and HD00249 or other agents interfering with neuromuscular transmission { e , g , , ddrug2 } should only be performed with caution as the effect of the HD00437 may be potentiated .",
        "label": "NA"
    },
    {
        "text": "the continued need for the other HD00304 agent should be reviewed after the effects of DB01118 have been established , and discontinuation ordinarily should be attempted .",
        "label": "NA"
    },
    {
        "text": "DB01075 has additive effects with ddrug1 and other ddrug2 { ddrug3 , HD00024 , ddrug5 , etc } .",
        "label": "effect"
    },
    {
        "text": "DB00983 should not be used as a substitute for oral or inhaled HD00175 .",
        "label": "NA"
    },
    {
        "text": "drugs that reduce the number of blood platelets by causing bone marrow depression { such as HD00251 } or drugs which inhibit platelet function { eg , ddrug1 and other ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB09255 } may increase the bleeding tendency produced by ddrug7 without altering prothrombin time determinations .",
        "label": "NA"
    },
    {
        "text": "because DB01008 is eliminated from the body via conjugation with glutathione , use of ddrug1 prior to { # hours } or concurrent with ddrug2 may result in reduced ddrug3 clearance based upon the known property of DB00316 to decrease glutathione levels in the blood and tissues .",
        "label": "NA"
    },
    {
        "text": "studies in rats have shown that DB00994 administration attenuates certain types of HD00161 dependent hypertension , including ddrug2 hypertension .",
        "label": "NA"
    },
    {
        "text": "DB00269 may interact with ddrug1 , ddrug2 , HD00026 , ddrug4 , ddrug5 supplements , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , and ddrug13 .",
        "label": "int"
    },
    {
        "text": "therapeutic concentrations of ddrug0 , ddrug1 , ddrug2 , DB00788 , ddrug4 , ddrug5 , ddrug6 andtolbutamide did not alter DB00465 protein binding .",
        "label": "NA"
    },
    {
        "text": "the effects DB00482 on the pharmacokinetics and/or pharmacodynamics of ddrug1 , DB01026 , ddrug3 , ddrug4 , ddrug5 , and ddrug6 have been studied in vivo and clinically important interactions have not been found .",
        "label": "NA"
    },
    {
        "text": "DB01592 salts may reduce the bioavailability of ddrug1 and DB01235 .",
        "label": "mechanism"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / ddrug1 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , DB00248 , ddrug10 , HD00516 pain medication { e , g , , ddrug12 } , drugs used to aid sleep , drowsiness-causing ddrug13 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "in clinical studies where patients were on chronic DB00277 therapy , DB00978 had no measurable effect on the mean distribution of ddrug2 concentrations or the mean estimates of ddrug3 clearance .",
        "label": "NA"
    },
    {
        "text": "previous studies have demonstrated a significant reduction in the oral bioavailability of DB00685 and ddrug1 when administered concomitantly with an intravenous ddrug2 such as DB00295 .",
        "label": "mechanism"
    },
    {
        "text": "drug interactions : a , drugs enhancing DB01109 effect : oral HD00326 : ddrug2 may prolong the one-stage prothrombin time .",
        "label": "NA"
    },
    {
        "text": "cardiac effects of DB00988 are antagonized by ddrug1 , such as DB00571 and ddrug3 .",
        "label": "effect"
    },
    {
        "text": "the incidence of upper gastrointestinal events in patients concomitantly taking ddrug0 or HD00203 was similar in patients taking DB00710 # mg daily { # % } and # mg once monthly { # % } .",
        "label": "NA"
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as DB01135 include certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 } , ddrug10 salts , ddrug11 , local ddrug12 , ddrug13 , and DB00908 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 containing DB06723 and ddrug2 reduce the oral absorption of DB00467 by 75 % .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : DB14507 toxicity has been reported in patients receiving ddrug2 concomitantly with drugs which cause elimination of sodium , including HD00106 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in in vitro studies , m1 was shown to cause increases ranging from # - 50 % in the free fraction of DB00586 and DB01050 at concentrations in the clinical range .",
        "label": "NA"
    },
    {
        "text": "although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic HD00268 , including ddrug1 , ddrug2 , and ddrug3 , the effect of DB00523 gel on the steady-state concentrations of these drugs is not known .",
        "label": "NA"
    },
    {
        "text": "although no studies have been conducted , concomitant administration of DB01167 and DB00252 may alter the metabolism of ddrug2 ;",
        "label": "mechanism"
    },
    {
        "text": "drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving ddrug0 metabolized similarly to ddrug1 or on the basis of in vitro studies with ddrug2 or other ddrug3 { caution is recommended during coadministration with ddrug4 } : available data from clinical studies of HD00100 other than ddrug6 suggest a possible drug interaction with ddrug7 for the following : ddrug8 , ddrug9 , ddrug10 such as DB00199 and ddrug12 , and grapefruit juice .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 : in normal volunteers { n = 9 } , pretreatment with ddrug2 or DB00863 did not affect ddrug4 pharmacokinetics except that a small { 13 % } but statistically significant increase in the area under the serum concentration curve of DB00712 resulted with ddrug6 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 } , ddrug1 { e , g , ddrug2 } , and ddrug3 { e , g , DB00503 , ddrug5 and ddrug6 } should have their dose of ddrug7 or DB01183 adjusted .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - HD00485 containing side chains of n-methylthiotetrazole { ddrug2 , DB01329 , ddrug4 , ddrug5 , ddrug6 } or methylthiadiazole { ddrug7 } can cause vitamin_k_deficiency and hypoprothrombinemia .",
        "label": "NA"
    },
    {
        "text": "there has been too little experience with the coadministration of DB01195 with ddrug1 or DB00343 to recommend concomitant use .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , including ddrug1 , may enhance the effects of oral HD00326 , such as DB00682 or its derivatives .",
        "label": "NA"
    },
    {
        "text": "an adequate period of observation must be provided for any patient in whom either HD00735 { such as ddrug1 } or large doses of HD00736 { such as # mg of ddrug3 } have been used .",
        "label": "NA"
    },
    {
        "text": "DB09319 { ddrug1 } blood levels may be increased and prolonged by concurrent administration of DB01032 .",
        "label": "mechanism"
    },
    {
        "text": "cimetidine co-administration of DB01023 with DB00501 { a non-specific cyp-450 inhibitor } resulted in an increase of approximately 50 % in the auc and the cmax , of ddrug2 .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 : DB00673 , when given once daily for # days as a 100-mg capsule with an oral ddrug2 containing # mcg of ddrug3 and # mg of ddrug4 , decreased the auc of DB00977 by 43 % , and decreased the auc of ddrug6 by 8 % ;",
        "label": "NA"
    },
    {
        "text": "HD00175 : concomitant administration with DB00945 may increase the risk of gastrointestinal ulceration and may reduce serum salicylate levels .",
        "label": "effect"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { ddrug1 s } , ddrug2 , ddrug3 { ddrug4 may decrease the effects of these medicines } , ddrug5 { using these medicines with ddrug6 may result in increased cns depressant effects } , ddrug7 , ddrug8 { using these medicines with HD00026 may change the amount of either medicine that you need to take } , and oral HD00283 containing ddrug11 { ddrug12 may decrease the effectiveness of these oral ddrug13 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "physiological changes resulting from smoking cessation , with or without DB00184 replacement , may alter the pharmacokinetics of certain concomitant medications , such as HD00043 and ddrug2 .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 may potentiate the hypoglycemic action of HD00062 , eg , ddrug2 and DB00672 , by inhibiting their metabolism in the liver .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - and/or DB01370 - containing ddrug2 , products containing DB01373 { ddrug4 } , ddrug5 containing ddrug6 or other metal cations , or ddrug7 { ddrug8 } chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after ddrug9 .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : HD00403 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { DB00472 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "because ddrug0 has not been shown to produce any additional effect beyond that obtained with ddrug1 alone and because ddrug2 increases the rate of excretion of ddrug3 , the concomitant use of DB00573 and HD00328 is not recommended .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : the effect of an DB06723 - and ddrug2 - containing ddrug3 { HD00467 } * on the pharmacokinetics of ddrug5 was investigated in # cancer patients .",
        "label": "NA"
    },
    {
        "text": "the use of HD00343 or HD00043 with ddrug2 preparations may increase the effect of either the ddrug3 or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 HD00524 may delay or reduce the absorption of concomitant oral medication such as ddrug2 , ddrug3 , ddrug4 { acidic } or DB00571 { basic } , as well as ddrug6 ddrug7 , ddrug8 , thyroid and ddrug9 preparations , ddrug10 and ddrug11 , and ddrug12 .",
        "label": "NA"
    },
    {
        "text": "dosage adjustment may be required if DB00091 , ddrug1 , or ddrug2 are given concomitantly with DB01026 tablets .",
        "label": "NA"
    },
    {
        "text": "and ddrug0 , { DB00900 } , chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of HD00532 , resulting in systemic levels considerably lower than desired .",
        "label": "mechanism"
    },
    {
        "text": "however , co-administration of ddrug0 with ddrug1 - and ddrug2 - containing HD00374 { 51 meq } or ddrug4 with ddrug5 , had no significant effect on the rate or extent of DB00476 absorption after administration of a 40-mg oral dose .",
        "label": "NA"
    },
    {
        "text": "conclusions : HD00093 inhibit the metabolism of ddrug1 that are metabolized by cyp3a4 { i , e , , ddrug2 , ddrug3 , DB00227 , ddrug5 } .",
        "label": "mechanism"
    },
    {
        "text": "DB00091 , ddrug1 , DB00877",
        "label": "NA"
    },
    {
        "text": "medications can interfere with folate utilization , including : ddrug0 { such as ddrug1 , and ddrug2 } ddrug3 { sometimes prescribed to control blood sugar in type # diabetes } ddrug4 { used to control inflammation associated with crohn_disease and ulcerative colitis } ddrug5 { a ddrug6 } ddrug7 there has been concern about the interaction between DB00115 and DB00158 .",
        "label": "int"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as DB00415 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and DB00126 .",
        "label": "NA"
    },
    {
        "text": "DB00501 , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of ddrug1 , ddrug2 , DB00571 , ddrug4 , ddrug5 , ddrug6 , certain ddrug7 , ddrug8 , ddrug9 and ddrug10 , thereby delaying elimination and increasing blood levels of these drugs .",
        "label": "mechanism"
    },
    {
        "text": "DB01026 - combined administration of racemic ddrug1 { 40 mg } and ddrug2 { 200 mg } decreased the cmax and auc of ddrug3 by 21 % and 10 % , respectively , and did not significantly affect the pharmacokinetics of DB00215 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , DB00091 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , DB00220 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "nephrotoxic agents : concomitant administration of DB00369 and agents with nephrotoxic potential -lsb- e , g , , intravenous ddrug1 { e , g , , ddrug2 , DB00798 , and ddrug4 } , ddrug5 , ddrug6 , intravenous ddrug7 , ddrug8 , and ddrug9 -rsb- is contraindicated .",
        "label": "advise"
    },
    {
        "text": "certain drugs , including ddrug0 { ddrug1 } , ddrug2 , ddrug3 , and HD00869 may potentiate the hypoglycemic action of ddrug5 and other oral HD00394 .",
        "label": "effect"
    },
    {
        "text": "concomitant administration of ddrug0 with DB01032 resulted in a 45 % increase in systemic exposure to DB01155 .",
        "label": "NA"
    },
    {
        "text": "because prostaglandins play an important role in hemostasis , and ddrug0 affect platelet function as well , concurrent therapy with all ddrug1 , including ddrug2 , and DB00682 requires close monitoring of patients to be certain that no change in their HD00025 dosage is required .",
        "label": "NA"
    },
    {
        "text": "HD00608 ddrug1 are inhibited by HD00401 .",
        "label": "NA"
    },
    {
        "text": "hyperpyrexia has been reported when HD00314 is administered with HD00315 agents or with ddrug2 drugs , particularly during hot weather .",
        "label": "effect"
    },
    {
        "text": "drug interaction studies with DB00625 and these HD00669 and ddrug2 have not been conducted .",
        "label": "NA"
    },
    {
        "text": "in vitro studies evaluating the minimum inhibitory concentration { mic } of ddrug0 , DB01327 , ddrug2 , ddrug3 / flucoxacillin , ddrug4 , ddrug5 , and ddrug6 demonstrated no evidence of incompatibility of these HD00002 with ddrug8 .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of ddrug0 and ddrug1 , ddrug2 , ddrug3 , or an HD00183 / ddrug5 oral HD00349 produced minor changes in the pharmacokinetics of ddrug7 , which were considered to be without clinical significance .",
        "label": "NA"
    },
    {
        "text": "the effect of DB01045 on the DB00682 requirement of our patient appeared to be maximal # to # days after the initiation of ddrug2 and extended a similar length of time after ddrug3 withdrawal .",
        "label": "effect"
    },
    {
        "text": "- drugs whose efficacy is impaired by DB00252 include : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , HD00220 , ddrug7 , oral ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 .",
        "label": "effect"
    },
    {
        "text": "concomitant use of DB01254 and drugs that inhibit cyp3a4 { eg , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , DB00220 , ddrug10 , ddrug11 } may increase exposure to ddrug12 and should be avoided .",
        "label": "mechanism"
    },
    {
        "text": "concomitant administration of DB00788 and DB00945 is not recommended because ddrug2 is displaced from its binding sites during the concomitant administration of ddrug3 , resulting in lower plasma concentrations and peak plasma levels .",
        "label": "advise"
    },
    {
        "text": "evidence supporting the conclusion that it is inadvisable to co-administer DB00176 and DB00829 is derived from a study in which healthy volunteers taking # mg/day of ddrug2 were administered a single oral dose of # mg of ddrug3 .",
        "label": "advise"
    },
    {
        "text": "because of its lack of anti-platelet effect DB00580 is not a substitute for DB00945 for cardiovascular prophylaxis .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : a literature article reported that when a 60-mg controlled-release ddrug1 capsule was administered # hours prior to a 600-mg ddrug2 capsule { n = 12 } , mean ddrug3 auc increased by 44 % compared to DB00996 administered without DB00295 .",
        "label": "NA"
    },
    {
        "text": "DB11156 { e , g , , ddrug1 } - taking ddrug2 and ddrug3 together may decrease the effects of DB00592 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 - in a controlled study , a single dose of DB01100 # mg co-administered with racemic DB00215 # mg given once daily for # days was associated with a mean increase in qtc values of approximately # msec compared to ddrug4 given alone .",
        "label": "effect"
    },
    {
        "text": "other drug interactions : no pharmacokinetic interactions were observed between ddrug0 and the following drugs : ddrug1 , DB00682 , ddrug3 , ddrug4 , and DB00863 .",
        "label": "NA"
    },
    {
        "text": "it is , however , possible that concomitant use of other known HD00299 such as ddrug1 , HD00029 , ddrug3 , ddrug4 , ddrug5 and ddrug6 might increase the photosensitivity reaction of actinic_keratosis treated with the ddrug7 for topical solution .",
        "label": "NA"
    },
    {
        "text": "the effects of HD00010 could be reversed by HD00012 treatment .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , DB00364 , metal cations , DB00152 ddrug3 form chelates with alkaline earth and transition metal cations .",
        "label": "NA"
    },
    {
        "text": "these data suggest that DB14152 are negatively coupled to three types of calcium channels in bovine chromaffin cell , including an ddrug1 - sensitive { n-type } channel , an ddrug2 - sensitive { p-type } channel and ddrug3 / ddrug4 / HD00049 - resistant { presumptive q-type } channel .",
        "label": "NA"
    },
    {
        "text": "hyperpyrexia has been reported when ddrug0 is administered with HD00315 agents or with DB06454 drugs , particularly during hot weather .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 , when given as # mg on day # and # mg/day on days # and 3 , decreased the auc of ddrug2 { a cyp2c9 substrate } by 23 % on day 4 , 28 % on day 8 , and 15 % on day 15 , when a single dose of DB01124 # mg was admini , stered orally prior to the administration of the 3-day regimen of DB00673 and on days 4,8 , and 15 .",
        "label": "mechanism"
    },
    {
        "text": "the effect of ddrug0 on plasma DB14507 has not been studied , but cases of increased ddrug2 plasma levels during DB00465 therapy have been reported .",
        "label": "NA"
    },
    {
        "text": "in a comparison of HD00118 tolerance in dogs anesthetized with ddrug1 , ddrug2 , or DB00312 , the dosage of ddrug4 needed to cause ventricular tachycardia was significantly higher , as was the ld50 of ddrug5 , with ddrug6 or ddrug7 than with ddrug8 .",
        "label": "NA"
    },
    {
        "text": "HD00485 - ddrug1 containing side chains of n-methylthiotetrazole { ddrug2 , ddrug3 , DB01330 , ddrug5 , ddrug6 } or methylthiadiazole { ddrug7 } can cause vitamin_k_deficiency and hypoprothrombinemia .",
        "label": "NA"
    },
    {
        "text": "products containing DB01373 and other multivalent cations { such as ddrug1 , DB14513 , ddrug3 } are likely to interfere with absorption of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "DB01032 : concomitant administration of ddrug1 oral and ddrug2 resulted in decreased clearance of DB00465 and significant increases in ddrug4 plasma levels { total auc increased approximately threefold from # to # m g/h/ml } and terminal half-life increased approximately twofold from # to # hours .",
        "label": "NA"
    },
    {
        "text": "it is advisable to check coagulation time within the first few days after the start and discontinuation of DB00604 therapy , with an appropriate adjustment of the HD00025 dose , if necessary .",
        "label": "advise"
    },
    {
        "text": "the resulting increase in DB00698 serum levels may increase toxicity , and the decreased urinary levels could lessen its efficacy as a urinary tract DB11121 .",
        "label": "NA"
    },
    {
        "text": "co-administration of DB00220 at steady-state with a single dose of DB00207 { 2 x # mg tablets } results in increased ddrug2 serum concentrations .",
        "label": "effect"
    },
    {
        "text": "HD00716 steady-state cmin concentrations increased 57 % from # # to # # micrograms/ml with the addition of DB00949 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 with DB01151 or ddrug2 and possibly other ddrug3 cause striking and sustained increases in the concentration of DB01576 in the brain ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , DB00091 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , DB00231 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "may interact with thyroid medication { e , g , , ddrug0 } , ddrug1 - containing products , ddrug2 , HD00613 { e , g , , ddrug4 , ddrug5 } , and HD00587 { e , g , , ddrug7 , ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 may enhance the effects of : other ddrug3 s , ddrug4 , general ddrug5 , HD00262 such as DB00475 , ddrug8 , or other ddrug9 , causing increased cns depression .",
        "label": "NA"
    },
    {
        "text": "the results of a study of coadministration of ddrug0 { 50 mg/kg } with an DB06723 containing ddrug2 to # patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of DB00330 of approximately 20 % and 13 % , respectively , suggesting that the oral absorption of ddrug4 may be reduced by these ddrug5 .",
        "label": "NA"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , HD00326 { ddrug1 s } , ddrug2 , ddrug3 { HD00026 may decrease the effects of these medicines } , ddrug5 { using these medicines with ddrug6 may result in increased cns depressant effects } , ddrug7 , ddrug8 { using these medicines with ddrug9 may change the amount of either medicine that you need to take } , and oral ddrug10 containing ddrug11 { ddrug12 may decrease the effectiveness of these oral ddrug13 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "DB00999 # mg qd or ddrug1 / DB00384 50/100 mg qd was co-administered with ddrug3 { 500 mcg bid } for # days { following # days of ddrug4 use at half dose } .",
        "label": "NA"
    },
    {
        "text": "in clinical trials , ddrug0 was used with DB00390 , ddrug2 , ddrug3 , oral ddrug4 , and supplemental ddrug5 , in a pharmacokinetic substudy in patients with congestive heart failure receiving ddrug6 or ddrug7 in whom therapy with DB01240 was initiated , apparent oral clearance values for ddrug9 { n = 23 } and ddrug10 { n = 30 } were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .",
        "label": "NA"
    },
    {
        "text": "HD00607 { ddrug1 , ddrug2 , etc , } increase the concentration of the ionized species of the DB00182 molecule , thereby increasing urinary excretion .",
        "label": "mechanism"
    },
    {
        "text": "therefore , caution should be used when administering DB00507 concurrently with other highly plasma protein-bound drugs with narrow therapeutic indices , as competition for binding sites may occur { e , g , , DB00682 } .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : concomitant administration of DB09104 and DB06723 does not interfere with the rate or extent of the absorption of ddrug3 administered as ddrug4 .",
        "label": "NA"
    },
    {
        "text": "before taking DB00222 , tell your doctor if you are taking any of the following medicines : - ddrug1 or another ddrug2 such as ddrug3 { ddrug4 } , ddrug5 { ddrug6 , others } , ddrug7 { ddrug8 } , ddrug9 { HD00758 } , or ddrug11 { ddrug12 } ;",
        "label": "advise"
    },
    {
        "text": "ddrug0 { cns } drugs including DB02325 , ddrug2 , ddrug3 , ddrug4 , blood pressure medications { ddrug5 , ddrug6 , ddrug7 } , motion sickness medications , ddrug8 , ddrug9 , HD00024 , sleeping pills and ddrug11",
        "label": "NA"
    },
    {
        "text": "other drug interactions oral ddrug0 DB01202 { 500 mg twice daily } did not influence the pharmacokinetics of an oral HD00349 containing # mg ddrug3 and # mg ddrug4 , or of the luteinizing hormone and progesterone levels , indicating that impairment of contraceptive efficacy is unlikely .",
        "label": "NA"
    },
    {
        "text": "DB00921 and ddrug1 should be prescribed with caution to patients on HD00100 or other drugs that act on the central nervous system , regardless of whether these drugs are taken on the advice of a physician or are taken as drugs of abuse .",
        "label": "advise"
    },
    {
        "text": "ddrug0 should be used with care when HD00425 or inhibitors of av conduction , such as certain ddrug2 { particularly of the ddrug3 -lsb- ddrug4 -rsb- and ddrug5 -lsb- ddrug6 -rsb- classes } , or ddrug7 , such as DB00280 , are used concurrently .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : co-administration of a single dose of intravenously administered DB00927 { 20 mg } reduced the oral absorption of a single # mg dose of DB01066 administered following a meal , as evidenced by a 27 % decrease in mean cmax and a 22 % decrease in mean auc .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 { e , g , , ddrug1 } - taking ddrug2 and DB11156 together may decrease the effects of DB00592 .",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with other cyp3a4 inhibitors { e , g , , ddrug1 # mg bid , ddrug2 # mg qd , DB01232 # mg tid , ddrug4 # mg qd } resulted in increases in cmax of DB00700 ranging from # - to # - fold and auc from # - to # - fold .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : reports suggest that HD00203 may diminish the antihypertensive effect of HD00499 .",
        "label": "effect"
    },
    {
        "text": "co-administration of cyp3a4 inhibitors { eg , ddrug0 , ddrug1 , ddrug2 , grapefruit juice , DB00501 } with DB01023 may lead to several - fold increases in the plasma levels of ddrug5 , either due to an increase in bioavailability or due to a decrease in metabolism .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as DB00415 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , DB00503 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "these data suggest that ddrug0 are negatively coupled to three types of calcium channels in bovine chromaffin cell , including an HD00047 - sensitive { n-type } channel , an HD00048 - sensitive { p-type } channel and ddrug3 / ddrug4 / ddrug5 - resistant { presumptive q-type } channel .",
        "label": "NA"
    },
    {
        "text": "the homodimeric disintegrin HD00007 was compared directly to the monomeric disintegrins ddrug1 and HD00009 for the ability to affect protein tyrosine phosphorylation in tumor cells .",
        "label": "NA"
    },
    {
        "text": "other HD00634 { eg , ddrug1 , ddrug2 , ddrug3 , ddrug4 } have occasionally been used concurrently with DB00280 .",
        "label": "NA"
    },
    {
        "text": "DB00945 : concurrent administration of ddrug1 and DB00712 resulted in 50 % lower serum ddrug3 concentrations .",
        "label": "NA"
    },
    {
        "text": "drugs that may alter ddrug0 plasma concentrations drugs that may increase DB00619 plasma concentrations : caution is recommended when administering ddrug2 with inhibitors of the cyp3a4 family { e , g , , ddrug3 , DB01167 , ddrug5 , ddrug6 } .",
        "label": "NA"
    },
    {
        "text": "under similar conditions , DB00307 concentrations were not affected by concomitant DB01076 administration .",
        "label": "NA"
    },
    {
        "text": "drug-drug interactions given the primary cns effects of DB01238 , caution should be used when ddrug1 is taken in combination with other ddrug2 and DB02325 .",
        "label": "NA"
    },
    {
        "text": "background : the effects of combined administration of DB11724 and ddrug1 { DB00661 } , a ddrug3 , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by ddrug4 { ddrug5 } and the labeling index of intestinal_cancer were investigated in male wistar rats .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { cns } drugs including ddrug1 , ddrug2 , ddrug3 , HD00031 , blood pressure medications { ddrug5 , ddrug6 , HD00254 } , motion sickness medications , ddrug8 , ddrug9 , ddrug10 , sleeping pills and ddrug11",
        "label": "NA"
    },
    {
        "text": "- a ddrug0 { HD00725 } such as ddrug2 { DB01247 } , ddrug4 { ddrug5 } , or ddrug6 { ddrug7 } ;",
        "label": "NA"
    },
    {
        "text": "based on adult data , lower doses of ddrug0 may be needed following coadministration of drugs which are reported to decrease DB00201 elimination { e , g , , ddrug2 and ddrug3 } and higher ddrug4 doses may be needed following coadministration of drugs that increase ddrug5 elimination { e , g , , ddrug6 and DB00252 } .",
        "label": "NA"
    },
    {
        "text": "both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ddrug0 is administered in combination with other HD00261 such as ddrug2 , HD00262 , ddrug4 , or inhalation general ddrug5 .",
        "label": "NA"
    },
    {
        "text": "in order to avoid the occurrence of severe hypersensitivity reactions , all patients treated with DB01229 should be premedicated with ddrug1 { such as ddrug2 } , diphen-hydramine and ddrug3 { such as ddrug4 or DB00863 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , DB01026 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { HD00531 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "DB00673 has been shown to induce the metabolism of HD00346 and ddrug2 , which are metabolized through cyp2c9 .",
        "label": "mechanism"
    },
    {
        "text": "therapeutic concentrations of ddrug0 , DB00682 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 andtolbutamide did not alter DB00465 protein binding .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 , ddrug2 , DB01182 , ddrug4 , ddrug5 , ddrug6 , and ddrug7 raise the serum ddrug8 concentration due to a reduction in clearance and/or in volume of distribution of the drug , with the implication that HD00118 intoxication may result .",
        "label": "NA"
    },
    {
        "text": "concurrent administration of DB00488 and HD00288 may cause severe orthostatic hypotension , ddrug2 , an inhibitor of microsomal drug metabolism , increased ddrug3 s half-life and toxicity in a rat model .",
        "label": "effect"
    },
    {
        "text": "ddrug0 , DB00316 and DB00201 may enhance the effects of : other ddrug3 s , ddrug4 , general ddrug5 , ddrug6 such as ddrug7 , ddrug8 , or other ddrug9 , causing increased cns depression .",
        "label": "NA"
    },
    {
        "text": "in a study in # patients with mild to moderate hypertension where the antihypertensive effects of ddrug0 alone were compared to DB00722 given concomitantly with ddrug2 , the use of DB00328 was associated with a reduced antihypertensive effect , although the difference between the two regimens was not significant .",
        "label": "NA"
    },
    {
        "text": "therefore , the concomitant administration of DB00559 and ddrug1 is contraindicated , and alternative HD00062 should be considered .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 , ddrug2 , ddrug3 , DB00353 contraindicated due to potential for serious and life-threatening reactions such as acute HD00624 toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues .",
        "label": "NA"
    },
    {
        "text": "HD00596 / HD00214 : ddrug2 , ddrug3",
        "label": "NA"
    },
    {
        "text": "DB00503 significantly prolonged the half-life of DB00862 to # hours .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 ddrug1 DB00199 ddrug3 ddrug4 ddrug5 DB01149 ddrug7 large quantities of grapefruit juice { # quart daily }",
        "label": "NA"
    },
    {
        "text": "ddrug0 - coadministration of racemic DB00215 { 40 mg/day for # days } and DB14507 { 30 mmol/day for # days } had no significant effect on the pharmacokinetics of ddrug3 or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic ddrug0 , including ddrug1 , HD00093 , and HD00270 , the effect of ddrug4 gel on the steady-state concentrations of these drugs is not known .",
        "label": "NA"
    },
    {
        "text": "in a 12-month controlled trial that included a # mcg once daily ddrug0 dose , # of the # DB01274 - treated subjects received concomitant DB00277 at study entry .",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , ddrug3 , or DB01373 , with ddrug5 , with metal cations such as DB01592 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "ddrug0 # mg qd or ddrug1 / DB00384 50/100 mg qd was co-administered with ddrug3 { 500 mcg bid } for # days { following # days of HD00295 use at half dose } .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { DB00564 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { DB01026 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "DB00501 } and many that are substrates for cyp2b6 2d6 { many other ddrug1 , HD00219 , and the ddrug3 ddrug4 and ddrug5 } .",
        "label": "NA"
    },
    {
        "text": "objective : our objective was to examine the interaction between DB00176 and DB01124 to confirm that ddrug2 inhibits cyp2c9 .",
        "label": "NA"
    },
    {
        "text": "drug/laboratory test interferences : ddrug0 and HD00334 , including DB01125 , or their metabolites may color alkaline urine red-orange , which may interfere with spectrophotometrically determined urinary laboratory tests .",
        "label": "NA"
    },
    {
        "text": "ddrug0 s : DB00900 should be administered at least # hours after or # hours before dosing with ddrug2 because plasma concentrations of ddrug3 are decreased when administered with ddrug4 containing ddrug5 , ddrug6 , or DB01370 .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of DB00199 and DB00390 has been reported to result in elevated ddrug2 serum levels .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : the effect of DB00712 on blood pressure response to DB00571 and ddrug3 was evaluated in men with mild uncomplicated hypertension { n = 10 } .",
        "label": "NA"
    },
    {
        "text": "HD00233 { ddrug1 } - a drug interaction study of DB00700 with an ddrug3 has not been conducted .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration of single doses of DB00962 # mg and DB00458 # mg produced additive effects on decreased alertness and impaired psychomotor performance for # to # hours after administration .",
        "label": "effect"
    },
    {
        "text": "there is a significant increase in exposure to DB00619 when ddrug1 is coadministered with DB01026 { cyp3a4 inhibitor } .",
        "label": "NA"
    },
    {
        "text": "while all the ddrug0 { HD00114 } , e , g , , ddrug2 , ddrug3 , ddrug4 , DB01104 , and ddrug6 , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .",
        "label": "NA"
    },
    {
        "text": "certain drugs including ddrug0 , ddrug1 , ddrug2 , and ddrug3 may reduce the hypoglycemic action of DB00731 and other oral HD00394 .",
        "label": "NA"
    },
    {
        "text": "DB00695 : clinical studies , as well as post-marketing observations , have shown that HD00203 can reduce the natriuretic effect of ddrug2 and ddrug3 in some patients .",
        "label": "NA"
    },
    {
        "text": "the ecg changes and/or hypokalemia that may result from the administration of ddrug0 { such as ddrug1 or HD00029 } can be acutely worsened by HD00358 , especially when the recommended dose of the ddrug4 is exceeded .",
        "label": "effect"
    },
    {
        "text": "this increase is due to the inhibition of DB00482 metabolism via cyp2b6 2c9 by DB00196 { see clinical pharmacology - pharmacokinetics : metabolism } .",
        "label": "mechanism"
    },
    {
        "text": "other ddrug0 { e , g , ddrug1 , ddrug2 , HD00263 and general ddrug4 } have additive or potentiating effects with DB00450 .",
        "label": "effect"
    },
    {
        "text": "in # other schizophrenic patients treated with oral DB00502 and DB01045 , discontinuation of ddrug2 produced a mean # - fold increase in ddrug3 concentrations .",
        "label": "NA"
    },
    {
        "text": "DB00294 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , DB00812 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "int"
    },
    {
        "text": "renal function should be monitored carefully if high doses of ddrug0 are to be administered with DB01413 because of the increased potential of nephrotoxicity and ototoxicity of HD00447 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interfere with the anti-glaucoma action of DB00411 or DB01085 ;",
        "label": "NA"
    },
    {
        "text": "the following agents may increase certain actions or side effects of ddrug0 , DB00915 ddrug2 of class { e , g , DB00908 } , ddrug4 ddrug5 { e , g , ddrug6 } , ddrug7 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration of once daily doses of ddrug1 , as a tablet formulation comparable to # mg or # mg of the capsule formulation , with DB00715 # mg once daily , resulted in a decrease in auc by approximately 25 % and cmax , by approximately 20 % of both DB00673 and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , DB02362 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , HD00029 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "however , co-administration of ddrug0 with ddrug1 - and ddrug2 - containing ddrug3 { 51 meq } or DB00476 with DB00927 , had no significant effect on the rate or extent of ddrug6 absorption after administration of a 40-mg oral dose .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { eg , ddrug1 } and other drugs , including ether , ddrug2 , ddrug3 , ddrug4 and DB09154 , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with DB01111 parenteral .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : since ddrug1 is a ddrug2 , it is possible that ddrug3 , such as the ddrug4 { HD00219 , ddrug6 , ddrug7 } or DB01233 , may diminish the effectiveness of ddrug9 .",
        "label": "NA"
    },
    {
        "text": "DB00316 and ddrug1 - DB00134 may decrease hepatic toxicity in those with ddrug3 overdosage or in those taking ddrug4 .",
        "label": "NA"
    },
    {
        "text": "however , in a well-controlled study of patients with lymphoma on combination therapy , DB00437 did not increase the marrow toxicity of patients treated with ddrug1 , ddrug2 , ddrug3 , ddrug4 and/or DB00888 .",
        "label": "NA"
    },
    {
        "text": "DB00241 , ddrug1 and ddrug2 may enhance the effects of : other ddrug3 s , DB02325 , general ddrug5 , ddrug6 such as ddrug7 , ddrug8 , or other ddrug9 , causing increased cns depression .",
        "label": "effect"
    },
    {
        "text": "DB00501 - in subjects who had received # days of # mg/day racemic DB00215 , combined administration of # mg/day ddrug2 for # days resulted in an increase in ddrug3 auc and cmax of 43 % and 39 % , respectively .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 is known to slow the metabolism of ddrug2 and increase its serum levels ddrug3 levels should be determined prior to concurrent administration with ddrug4 , signs and symptoms of DB00564 toxicity should be monitored closely , and appropriate dosage adjustment of the HD00329 should be made .",
        "label": "NA"
    },
    {
        "text": "because of the low dietary ddrug0 concentration as compared to the DB01592 contents of the diets , no effect of DB14574 on ddrug3 absorption and excretion occurred .",
        "label": "NA"
    },
    {
        "text": "drug interaction studies have shown that DB00736 does not have any clinically significant interactions with ddrug1 , DB00682 , ddrug3 , ddrug4 or ddrug5 .",
        "label": "NA"
    },
    {
        "text": "the administration of local ddrug0 containing ddrug1 or DB00368 to patients receiving HD00275 or ddrug4 may produce severe , prolonged hypertension .",
        "label": "effect"
    },
    {
        "text": "ddrug0 , including oral , injectable , transdermal , and implantable ddrug1 : an interaction study demonstrated that co-administration of DB00559 and the oral ddrug3 DB00717 produced average decreases of ddrug5 and ddrug6 levels of 14 % and 31 % , respectively .",
        "label": "mechanism"
    },
    {
        "text": "DB00294 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , DB00564 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "int"
    },
    {
        "text": "because ddrug0 is not metabolized by the cytochrome cyp2b6 system , inhibitors of cyp450 enzyme would not be expected to affect its metabolism , and DB01026 and ddrug2 , potent inhibitors of cytochrome_p450_family_3_subfamily_a and 2c9 , respectively , have been shown to have no effect on DB00876 pharmacokinetics .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : clinical studies , as well as random observations , have shown that DB01050 can reduce the natriuretic effect of DB00695 and ddrug3 in some patients .",
        "label": "effect"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { DB00501 } ddrug9 DB00472 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "ddrug0 works differently from the HD00128 currently available , and except for increased lipid levels , the adverse reaction profile of ddrug2 does not appear to overlap to any great extent with that associated with DB00091 or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "during clinical trials , DB01088 was used concurrently with ddrug1 , ddrug2 , HD00345 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and other medications .",
        "label": "NA"
    },
    {
        "text": "studies in rats have shown that ddrug0 administration attenuates certain types of HD00161 dependent hypertension , including DB01285 hypertension .",
        "label": "NA"
    },
    {
        "text": "HD00264 / ddrug1 / HD00214 / ddrug3 : co-administration of ddrug4 with ddrug5 , ddrug6 , ddrug7 , and ddrug8 is likely to lead to an enhancement of effects .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { DB00091 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , DB00503 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "DB00575 : concomitant administration of ddrug1 with HD00482 may potentiate blood-pressure - and heart-rate-lowering effects .",
        "label": "NA"
    },
    {
        "text": "in clinical studies performed with ddrug0 , the concomitant use of oral ddrug1 { ddrug2 } , ddrug3 { ddrug4 } , ddrug5 { DB00554 } , and ddrug7 did not significantly affect the pharmacokinetics/pharmacodynamics of DB00569 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 , DB01174 , DB00252",
        "label": "NA"
    },
    {
        "text": "this drug may interact with ddrug0 or other ddrug1 { may potentiate the cns depressant effects of either these medications or HD00388 } , HD00444 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug4 } , and ddrug5 { concurrent use with ddrug6 may prolong and intensify the anticholinergic and cns depressant effects of ddrug7 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 HD00401 may enhance the activity of HD00043 or ddrug4 ;",
        "label": "effect"
    },
    {
        "text": "erythromycin co-administration of ddrug0 { ddrug1 } with DB00199 resulted in approximately # - fold increase in the auc and cmax , and about 2 - fold prolongation in the half - life of DB01023 .",
        "label": "NA"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : ddrug1 ; ddrug2 ; ddrug3 ; certain HD00002 , especially the ddrug5 and ddrug6 ; ddrug7 ; ddrug8 salts ; DB01035 ; and ddrug10 .",
        "label": "NA"
    },
    {
        "text": "HD00303 : other ddrug1 drugs , such as ddrug2 , DB01035 , ddrug4 , and ddrug5 , have been used concurrently with ddrug6 .",
        "label": "NA"
    },
    {
        "text": "concurrent administration of ddrug0 and HD00657 may result in elevated serum levels of DB03585 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may decrease HD00627 response to DB00714 .",
        "label": "NA"
    },
    {
        "text": "patients receiving other ddrug0 s , general ddrug1 , ddrug2 , ddrug3 , HD00460 , ddrug5 or other ddrug6 { including ddrug7 } concomitantly with DB00327 may exhibit an additive cns depression .",
        "label": "effect"
    },
    {
        "text": "if ddrug0 is to be combined with other HD00595 such as ddrug2 or ddrug3 / ddrug4 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of ddrug5 and ddrug6 { e , g , , ddrug7 or DB00829 } are additive .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other HD00216 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { DB01167 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , DB14513 , or ddrug4 , with ddrug5 , with metal cations such as ddrug6 , or with DB00152 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "other concomitant therapy in healthy subjects there were no clinically significant interactions when DB01023 was given concomitantly with ddrug1 or DB00421 .",
        "label": "NA"
    },
    {
        "text": "based on adult data , lower doses of DB00201 may be needed following coadministration of drugs which are reported to decrease ddrug1 elimination { e , g , , DB00501 and ddrug3 } and higher ddrug4 doses may be needed following coadministration of drugs that increase ddrug5 elimination { e , g , , ddrug6 and ddrug7 } .",
        "label": "advise"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 DB00264 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 DB14507 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "in another study with intravenous administration of ddrug0 , ddrug1 was given as # mg on day # and # mg/day on days # and 3 , and DB00683 # mg iv was given prior to the administration of the 3-day regimen of DB00673 and on days 4 , 8 , and 15 .",
        "label": "NA"
    },
    {
        "text": "the concurrent use of DB00759 and ddrug1 { DB01028 } has been reported to result in fatal renal toxicity .",
        "label": "effect"
    },
    {
        "text": "however , neither DB01174 nor ddrug1 appears to affect DB01219 metabolism .",
        "label": "NA"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : ddrug1 ; ddrug2 ; ddrug3 ; certain ddrug4 , especially the HD00249 and ddrug6 ; ddrug7 ; ddrug8 salts ; DB01035 ; and ddrug10 .",
        "label": "NA"
    },
    {
        "text": "DB00091 : increased activity of both ddrug1 and HD00175 may occur when the two are used concurrently .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : because of the relationship of ddrug1 to DB00162 , patients should be advised against taking HD00818 containing ddrug4 to avoid additive toxic effects",
        "label": "NA"
    },
    {
        "text": "for this reason the dose of DB00668 should be restricted and an HD00782 administered as appropriate .",
        "label": "NA"
    },
    {
        "text": "while all the HD00113 { ddrug1 } , e , g , , ddrug2 , ddrug3 , and DB00715 , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : concurrent administration of # mg or # mg DB01012 with # mg ddrug2 increased DB00321 exposure and ddrug4 { active metabolite } exposure by approximately 20 % in cyp2d6 extensive metabolizers .",
        "label": "NA"
    },
    {
        "text": "may interact with thyroid medication { e , g , , ddrug0 } , ddrug1 - containing products , HD00374 , ddrug3 { e , g , , ddrug4 , ddrug5 } , and ddrug6 { e , g , , DB00448 , ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , HD00282 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , DB00231 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "antimicrobial activity of HD00005 alone and in combination with some HD00002 .",
        "label": "NA"
    },
    {
        "text": "additive depressant effect when used with general HD00264 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , and other HD00611 .",
        "label": "NA"
    },
    {
        "text": "co-administration : concomitant use of ddrug0 with HD00363 , ddrug2 , and other HD00326 may increase the risk of bleeding .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in patients with hypercholesterolemia , concomitant administration of DB00227 and DB00390 resulted in no effect on ddrug3 plasma concentrations .",
        "label": "NA"
    },
    {
        "text": "concomitant use of prophylactic low dose DB01109 did not appear to affect safety , however , its effects on the efficacy of DB00055 have not been evaluated in an adequate and well-controlled clinical trial .",
        "label": "NA"
    },
    {
        "text": "in a comparison of HD00118 tolerance in dogs anesthetized with ddrug1 , ddrug2 , or ddrug3 , the dosage of ddrug4 needed to cause ventricular tachycardia was significantly higher , as was the ld50 of ddrug5 , with ddrug6 or ddrug7 than with DB00312 .",
        "label": "NA"
    },
    {
        "text": "patients who begin taking ddrug0 or who increase their ddrug1 dose or any other HD00615 while taking ddrug3 , ddrug4 , or DB00091 may develop toxicity characteristics for these drugs .",
        "label": "effect"
    },
    {
        "text": "in a study in which the # mg DB01068 orally disintegrating tablet was administered with and without ddrug1 { an ddrug2 with multiple effects on the gi tract } to healthy volunteers , the auc of ddrug3 was 10 % lower and the cmax of ddrug4 was 20 % lower when the orally disintegrating tablet was given with DB00782 compared to when it was given alone .",
        "label": "NA"
    },
    {
        "text": "no depressant effect on blood levels in humans was noted when ddrug0 was administered with any of the following drugs : DB00945 , ddrug2 , ddrug3 , ddrug4 , ddrug5 { ddrug6 } , DB01124 , ddrug8 or ddrug9 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 , and DB00252 decrease the half-life of DB00254 .",
        "label": "mechanism"
    },
    {
        "text": "paralytic ileus may occur in patients taking HD00043 in combination with HD00315 - type drugs .",
        "label": "effect"
    },
    {
        "text": "other HD00545 { e , g , ddrug1 , ddrug2 , ddrug3 and general ddrug4 } have additive or potentiating effects with DB00450 .",
        "label": "effect"
    },
    {
        "text": "when taken orally , HD00824 like DB01026 may enhance the anticoagulant effect of ddrug2 - like drugs .",
        "label": "NA"
    },
    {
        "text": "in a small { n = 30 } combination study of DB01097 with DB00563 , a 2 - to 3-fold elevation in liver enzymes was seen in # of # patients .",
        "label": "effect"
    },
    {
        "text": "concurrent use of DB00611 with ddrug1 { e , g , , ddrug2 , HD00026 , ddrug4 , and ddrug5 } may result in increased ddrug6 effects .",
        "label": "effect"
    },
    {
        "text": "ddrug0 should be used with care when ddrug1 or inhibitors of av conduction , such as certain ddrug2 { particularly of the ddrug3 -lsb- ddrug4 -rsb- and HD00427 -lsb- ddrug6 -rsb- classes } , or ddrug7 , such as DB00280 , are used concurrently .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { HD00548 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { DB00701 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 } , ddrug1 { e , g , ddrug2 } , and HD00324 { e , g , ddrug4 , ddrug5 and ddrug6 } should have their dose of DB00921 or ddrug8 adjusted .",
        "label": "NA"
    },
    {
        "text": "ddrug0 DB01202 { 1000 mg twice daily } did not influence the pharmacokinetics and pharmacodynamics { ecg } of DB00390 given as a # mg dose every day .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : concurrent administration of certain ddrug1 , such as HD00538 and ddrug3 , would be expected to compromise the beneficial effects of DB00604 .",
        "label": "effect"
    },
    {
        "text": "because ddrug0 is a serotonin releaser and reuptake inhibitor , DB01191 should not be used concomitantly with a HD00455 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { DB00316 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { DB00252 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "another study showed that ddrug0 had no clinically significant effect on plasma concentrations of the oral HD00280 DB00977 and ddrug3 { cyp3a4 substrates } .",
        "label": "NA"
    },
    {
        "text": "DB01155 had no significant effect on the anticoagulant effect of ddrug1 in healthy subjects on stable DB00682 therapy .",
        "label": "NA"
    },
    {
        "text": "because DB01008 is eliminated from the body via conjugation with glutathione , use of ddrug1 prior to { # hours } or concurrent with DB01008 may result in reduced ddrug3 clearance based upon the known property of ddrug4 to decrease glutathione levels in the blood and tissues .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a clinical pharmacology study , coadministration of an DB06724 { ddrug2 , ddrug3 , and ddrug4 } with ddrug5 reduced serum levels and urinary excretion of DB14207 as compared with ddrug7 administered alone , suggesting that ddrug8 may impair absorption of ddrug9 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the effect of DB00482 on the anti-coagulant effect of DB00682 was studied in a group of healthy subjects receiving daily doses of 2 - 5 mg of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "may interact with thyroid medication { e , g , , ddrug0 } , ddrug1 - containing products , ddrug2 , ddrug3 { e , g , , DB00927 , ddrug5 } , and HD00587 { e , g , , ddrug7 , ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "DB00333 levels may be decreased ; increased dosages may be required to prevent symptoms of HD00099 withdrawal , ddrug2 maintained patients beginning ddrug3 therapy should be monitored forevidence of withdrawal and ddrug4 dose should be adjusted accordingly .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 have been reported to enhance the effects of the oral HD00025 DB00682 or its derivatives .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , DB00091 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { DB00295 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of DB00964 # % ophthalmic solution , the possibility of an additive or potentiating effect with ddrug1 { ddrug2 , ddrug3 , ddrug4 , HD00024 , ddrug6 } should be considered .",
        "label": "advise"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , ddrug3 ddrug4 : ddrug5 , DB00342 antimigraine : ddrug7 HD00871 : ddrug9 ddrug10 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "specific and aspecific treatments of ddrug0 depletion are tricky using for example HD00193 , pharmacological doses of ddrug2 , physiological doses of ddrug3 and of DB11127 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a pharmacokinetic study , maximum plasma concentrations of DB01023 were considerably lower in epileptic patients on long-term HD00329 therapy { eg , ddrug3 , ddrug4 , or ddrug5 } than in healthy volunteers .",
        "label": "mechanism"
    },
    {
        "text": "DB00701 significantly increased the area under the curve at steady state { auc { ss } } of ddrug1 by # - fold and the auc { ss } of HD00073 by # - fold .",
        "label": "mechanism"
    },
    {
        "text": "it may increase excretion of ddrug0 , DB14507 , and ddrug2 and may also increase the toxicity of HD00328 .",
        "label": "NA"
    },
    {
        "text": "in patients taking ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB00571 , and various chemotherapy agents , no effect was shown on the clearance of HD00644 .",
        "label": "NA"
    },
    {
        "text": "DB00334 : coadministration of DB00402 # mg and ddrug2 # mg produced a decrease in dsst scores .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : steady-state trough plasma DB00564 and ddrug2 concentrations were not affected by concomitant DB00996 { 400 mg tid ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 at 10 { -10 } m or HD00147 at about # x 10 { -9 } m inhibits proliferation stimulated by HD00148 .",
        "label": "effect"
    },
    {
        "text": "increases in plasma levels of HD00043 , and in the frequency and severity of side effects , particularly ddrug1 , have been reported when DB00501 was added to the ddrug3 regimen .",
        "label": "mechanism"
    },
    {
        "text": "DB00590 has been administered without any evidence of an adverse drug interaction to patients receiving HD00029 , ddrug2 s , and ddrug3 .",
        "label": "NA"
    },
    {
        "text": "it is recommended that the combination of intravenous DB01219 and HD00377 , such as ddrug2 , not be used together during the management of malignant hyperthermia crisis until the relevance of these findings to humans is established .",
        "label": "advise"
    },
    {
        "text": "HD00303 : DB01244 , ddrug2 { systemic } and ddrug3",
        "label": "NA"
    },
    {
        "text": "repeated doses of DB00375 given prior to a single dose of DB00571 in human trials have been reported to decrease ddrug2 absorption .",
        "label": "mechanism"
    },
    {
        "text": "in separate single or multiple dose pharmacokinetic interaction studies with ddrug0 , DB01115 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , and ddrug8 , the bioavailability of DB14207 was not altered by coadministration of ddrug10 with any one of these drugs .",
        "label": "NA"
    },
    {
        "text": "therefore , when DB01109 is given with ddrug1 or DB00682 , a period of at least # hours after the last intravenous dose or # hours after the last subcutaneous dose should elapse before blood is drawn if a valid prothrombin time is to be obtained .",
        "label": "advise"
    },
    {
        "text": "ddrug0 , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of ddrug1 , ddrug2 , DB00571 , ddrug4 , ddrug5 , ddrug6 , certain ddrug7 , ddrug8 , DB00277 and ddrug10 , thereby delaying elimination and increasing blood levels of these drugs .",
        "label": "NA"
    },
    {
        "text": "since ddrug0 ddrug1 may bind other drugs given concurrently , it is recommended that patients take other drugs at least # hour before or # to # hours after DB01432 HD00524 { or at as rxfp2 an interval as possible } to avoid impeding their absorption .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { ddrug1 , DB00949 , ddrug3 , ddrug4 , ddrug5 } : increase the metabolism of ddrug6 and/or some HD00526 , leading to possible decrease in contraceptive effectiveness .",
        "label": "mechanism"
    },
    {
        "text": "when coadministered with ddrug0 in treatment-naive patients , the recommended dose of DB01072 is # mg with ddrug2 # mg and DB00625 # mg { all once daily } .",
        "label": "NA"
    },
    {
        "text": "in monkeys , the effects of ddrug0 , but not HD00156 or DB03575 , were antagonized by ddrug3 ;",
        "label": "NA"
    },
    {
        "text": "oral HD00283 : ddrug1 , when given once daily for # days as a 100-mg capsule with an oral ddrug2 containing # mcg of ddrug3 and # mg of ddrug4 , decreased the auc of ddrug5 by 43 % , and decreased the auc of DB00717 by 8 % ;",
        "label": "NA"
    },
    {
        "text": "DB00520 has no effect on the pharmacokinetics of DB01167 , ddrug2 , or the active metabolite of mycophenolate .",
        "label": "NA"
    },
    {
        "text": "although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic HD00268 , including ddrug1 , ddrug2 , and HD00270 , the effect of ddrug4 gel on the steady-state concentrations of these drugs is not known .",
        "label": "NA"
    },
    {
        "text": "dosage adjustment of DB00289 may be necessary when coadministered with cyp2d6 inhibitors , e , g , , ddrug1 , DB00472 , and ddrug3 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and DB00759 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { HD00531 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "-lsb- the gaba-ergic system and brain edema -rsb- it has been shown in rats with experimental toxic and traumatic edemas that DB00466 { 1 mg/kg } removes the antiedematous action of ddrug1 , ddrug2 , ddrug3 and HD00135 and reduces the action of ddrug5 .",
        "label": "effect"
    },
    {
        "text": "in patients receiving nonselective ddrug0 { ddrug1 } { e , g , , DB01037 } in combination with ddrug3 { e , g , , DB00472 , ddrug5 , ddrug6 , ddrug7 , ddrug8 } , there have been reports of serious , sometimes fatal , reactions .",
        "label": "effect"
    },
    {
        "text": "DB00829 at doses of # mg/kg and # mg/kg injected with ddrug1 was found to decrease the antinociceptive effect of DB00295 .",
        "label": "NA"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / HD00517 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , DB01208 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 pain medication { e , g , , ddrug12 } , drugs used to aid sleep , drowsiness-causing ddrug13 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "the hypoglycemic action of ddrug0 may be potentiated by certain drugs including HD00518 and other drugs that are highly protein bound , ddrug2 , HD00297 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , and ddrug8 .",
        "label": "NA"
    },
    {
        "text": "drugs whose absorption can be affected by the level of acidity in the stomach : drugs such as DB01026 and DB01167 should be administered at least # hours prior to dosing with ddrug2 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 , ddrug2 , DB00220 , and ddrug4 have been shown to decrease plasma levels of HD00710 ;",
        "label": "mechanism"
    },
    {
        "text": "the potentiating action of DB00557 must be considered when the drug is used in conjunction with ddrug1 such as HD00543 , ddrug3 and ddrug4 .",
        "label": "effect"
    },
    {
        "text": "administration of DB00668 to patients receiving DB13984 or ddrug2 such as ddrug3 which sensitize the myocardium , may induce cardiac arrhythmia , .",
        "label": "effect"
    },
    {
        "text": "the concomitant administration of HD00532 including ddrug1 with DB01016 { a ddrug3 } has , on rare occasions , resulted in severe hypoglycemia .",
        "label": "effect"
    },
    {
        "text": "drugs that may alter DB00619 plasma concentrations drugs that may increase ddrug1 plasma concentrations : caution is recommended when administering DB00619 with inhibitors of the cyp3a4 family { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 } .",
        "label": "NA"
    },
    {
        "text": "before taking DB00222 , tell your doctor if you are taking any of the following medicines : - ddrug1 or another ddrug2 such as ddrug3 { ddrug4 } , ddrug5 { ddrug6 , others } , DB14006 { ddrug8 } , ddrug9 { ddrug10 } , or ddrug11 { ddrug12 } ;",
        "label": "advise"
    },
    {
        "text": "DB00673 , when given as a regimen of # mg on day # and # mg/day on days # and 3 , increased the auc of ddrug1 , a cyp3a4 substrate , by # - fold on day # and by # - fold on day 3 , when DB00959 was coadministered intravenously as # mg on day # and orally as # mg on days # and 3 .",
        "label": "NA"
    },
    {
        "text": "these medications have included ddrug0 , ddrug1 , HD00207 , ddrug3 , ddrug4 , intravenous and oral DB14049 , ddrug6 , and ddrug7 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : since ddrug1 is a ddrug2 , it is possible that ddrug3 , such as the ddrug4 { ddrug5 , ddrug6 , HD00341 } or ddrug8 , may diminish the effectiveness of DB00714 .",
        "label": "effect"
    },
    {
        "text": "it is concluded that ddrug0 and DB04833 may be administered safely without additional caution in prothrombin test monitoring during oral HD00025 therapy .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , HD00802 : e , g , , ddrug2 , ddrug3 , DB00622",
        "label": "NA"
    },
    {
        "text": "ddrug0 : since DB00714 is a HD00338 , it is possible that ddrug3 , such as the ddrug4 { ddrug5 , ddrug6 , ddrug7 } or ddrug8 , may diminish the effectiveness of ddrug9 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { DB01076 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , DB00503 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a ddrug0 , including ddrug1 , with multivalent cation-containing products such as ddrug2 or ddrug3 HD00374 , ddrug5 , ddrug6 chewable/buffered tablets or pediatric powder , or products containing ddrug7 , ddrug8 , or DB01593 may substantially decrease the absorption of ddrug10 , resulting in serum and urine levels considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "reports suggest that HD00203 may diminish the antihypertensive effect of ddrug1 , including DB00722 .",
        "label": "effect"
    },
    {
        "text": "in a comparison of ddrug0 tolerance in dogs anesthetized with DB01221 , ddrug2 , or ddrug3 , the dosage of ddrug4 needed to cause ventricular tachycardia was significantly higher , as was the ld50 of ddrug5 , with ddrug6 or HD00117 than with ddrug8 .",
        "label": "NA"
    },
    {
        "text": "while all the HD00113 { ddrug1 } , e , g , , ddrug2 , seriraline , and DB00715 , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .",
        "label": "NA"
    },
    {
        "text": "the following agents may increase certain actions or side effects of ddrug0 , ddrug1 HD00428 of class { e , g , ddrug3 } , ddrug4 ddrug5 { e , g , HD00219 } , ddrug7 .",
        "label": "NA"
    },
    {
        "text": "dosing recommendations for DB00625 and DB01072 in treatment-experienced patients have not been established .",
        "label": "NA"
    },
    {
        "text": "no significant drug interactions have been reported in studies of ddrug0 given with other drugs such as ddrug1 , ddrug2 , DB00390 , ddrug4 , ddrug5 , and oral HD00283 in healthy volunteers , or given with ddrug7 to patients with heart failure { nyha class ii and iii } .",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , ddrug3 , or DB01373 , with ddrug5 , with metal cations such as ddrug6 , or with DB00152 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "DB00295 pharmacokinetic parameter values were not affected by administration of DB00996 # hours after ddrug2 .",
        "label": "NA"
    },
    {
        "text": "the mean qt c interval { msec } was # with DB00342 alone and # with ddrug1 plus DB00954 .",
        "label": "NA"
    },
    {
        "text": "substances that are potent inhibitors of cyp3a4 activity { eg , ddrug0 and DB01167 } decrease ddrug2 metabolism and increase DB00317 plasma concentrations .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , DB00446 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some DB00152 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 DB01202 { 1000 mg twice daily } did not influence the pharmacokinetics of ddrug2 and HD00835 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 administration of DB01432 or ddrug3 in patients { n = 13 } and volunteers { n = 96 } resulted in a rapid and significant decrease in plasma m1 { the active metabolite of DB01097 } concentration .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : DB01050 , as well as other ddrug2 , probably reduces the tubular secretion of DB00563 based on in vitro studies in rabbit kidney slices .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { DB00316 } , HD00002 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "because of DB00529 s tendency to cause renal impairment , the use of ddrug1 should be avoided in combination with potentially nephrotoxic drugs such as ddrug2 , DB00681 and intravenous ddrug4 unless the potential benefits outweigh the risks to the patient .",
        "label": "NA"
    },
    {
        "text": "in monkeys , ddrug0 was about # times more potent than HD00156 in decreasing responding , whereas in pigeons HD00157 was about equipotent with ddrug3 .",
        "label": "NA"
    },
    {
        "text": "effects of other ddrug0 on ddrug1 ddrug2 : ddrug3 causes an approximate doubling of the clearance of ddrug4 { DB00949 } at steady state and , therefore , the addition of DB00252 causes an approximate 45 % decrease in the steady-state trough concentrations of ddrug7 as compared to the same dose of ddrug8 given as monotherapy .",
        "label": "NA"
    },
    {
        "text": "steady-state DB00559 plasma concentrations were 3 - to 4-fold higher than in the absence of HD00433 .",
        "label": "mechanism"
    },
    {
        "text": "in rats , simultaneous ingestion of DB00822 and ddrug1 in the diet for # weeks has been reported to cause tumors , and it has been suggested that ddrug2 may react with HD00635 in the rat stomach to form a nitrosamine , which is tumorigenic .",
        "label": "NA"
    },
    {
        "text": "in separate single or multiple dose pharmacokinetic interaction studies with ddrug0 , DB01115 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , and ddrug8 , the bioavailability of ddrug9 was not altered by coadministration of DB00492 with any one of these drugs .",
        "label": "NA"
    },
    {
        "text": "effects of ddrug0 on low-dose ddrug1 a group of # nonsmoking , healthy white female volunteers established on an oral HD00349 regimen containing # mg ddrug3 and # mg ddrug4 for at least # months received # mg/day of DB00949 from midcycle { day 15 } to midcycle { day 14 } of two consecutive oral ddrug6 cycles .",
        "label": "NA"
    },
    {
        "text": "the effects of DB00437 on DB00900 pharmacokinetics in subjects with normal renal function are not known .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { DB01167 } ddrug13 { DB01026 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "the concurrent use of intravenously or orally administered ddrug0 { e , g , , ddrug1 , DB00277 } by patients receiving DB01274 has not been completely evaluated .",
        "label": "NA"
    },
    {
        "text": "as with other HD00482 , if ddrug1 is to be administered orally with ddrug2 of the DB00661 or ddrug4 type , it is recommended that ecg and blood pressure be monitored .",
        "label": "NA"
    },
    {
        "text": "co-administration of ddrug0 and ddrug1 or other agents interfering with neuromuscular transmission { e , g , , HD00436 } should only be performed with caution as the effect of the HD00437 may be potentiated .",
        "label": "NA"
    },
    {
        "text": "in a comparison of HD00118 tolerance in dogs anesthetized with ddrug1 , ddrug2 , or ddrug3 , the dosage of ddrug4 needed to cause ventricular tachycardia was significantly higher , as was the ld50 of DB01092 , with ddrug6 or ddrug7 than with ddrug8 .",
        "label": "NA"
    },
    {
        "text": "rat kidney homogenates supplemented with coenzyme a , atp , oxaloacetate , and mg2 + converted HD00077 to HD00078 in vitro .",
        "label": "NA"
    },
    {
        "text": "consequently , it is recommended not to exceed a single # mg DB00862 dose in a 72-hour period when used in combination with DB00503 .",
        "label": "advise"
    },
    {
        "text": "in addition , DB00334 is not associated with a risk of agranulocytosis as seen with DB00363 or clinically significant hyperprolactinemia as seen with ddrug2 or prolongation of the qt interval .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - and/or ddrug1 - containing ddrug2 , products containing ddrug3 { ddrug4 } , HD00752 containing DB01593 or other metal cations , or ddrug7 { ddrug8 } chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after ddrug9 .",
        "label": "NA"
    },
    {
        "text": "immediate and extended release tablets the hypoglycemic action of ddrug0 may be potentiated by certain drugs including ddrug1 , some HD00768 and other drugs that are highly protein bound , ddrug3 , HD00297 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "drug interactions : the central ddrug0 syndrome can occur when anticholinergic agents such as ddrug1 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain ddrug2 such as DB00454 , the HD00219 and other ddrug5 , ddrug6 , certain ddrug7 such as the ddrug8 salts , and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "potential interactions between DB01229 , a substrate of cyp3a4 , and ddrug1 { ddrug2 , ddrug3 , ddrug4 , and DB00220 } , which are substrates and/or inhibitors of cyp3a4 , have not been evaluated in clinical trials .",
        "label": "NA"
    },
    {
        "text": "strong inducers of cytochrome p450 enzymes { i , e , DB00564 , ddrug1 and ddrug2 } have been shown to decrease the plasma levels of HD00888 { 29 - 40 % } .",
        "label": "NA"
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of HD00472 are the following : ddrug1 , ddrug2 , DB00501 , ddrug4 { 1 } , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 { 1 } , ddrug10 , ddrug11 , grapefruit juice , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21 , ddrug22 , ddrug23 , ddrug24 { 1 } , ddrug25 , ddrug26 .",
        "label": "mechanism"
    },
    {
        "text": "HD00374 containing DB14513 , ddrug2 , or ddrug3 ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 - pectin , ddrug2 , ddrug3 , DB01432 , certain anticancer drugs , and DB01233 may interfere with intestinal ddrug6 absorption , resulting in unexpectedly low serum concentrations .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , HD00002 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { DB01076 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { HD00712 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , DB00277 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "persons taking most HD00002 , ddrug1 and ddrug2 invalidate ddrug3 and DB00115 diagnostic blood assays .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of DB00280 and ddrug1 resulted in slight increases in plasma DB00280 levels and slight decreases in plasma ddrug3 levels .",
        "label": "NA"
    },
    {
        "text": "therefore , cyp3a4 substrates known to have a narrow therapeutic index such as ddrug0 , ddrug1 , DB00342 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , or ddrug10 { ddrug11 , ddrug12 } should be administered with caution in patients receiving DB01254 .",
        "label": "advise"
    },
    {
        "text": "in addition to the interactions noted above , chronic { # weeks } oral DB01118 administration impairs metabolism of ddrug1 , ddrug2 , and DB00563 .",
        "label": "NA"
    },
    {
        "text": "this article looks at five commonly used HD00084 in turn { ddrug1 , ddrug2 , ddrug3 , ddrug4 , DB00531 } , discussing the main , non-infection , unwanted effects , ways to avoid them and what to do if problems arise .",
        "label": "NA"
    },
    {
        "text": "the ddrug0 - induced neuronal damage produced a tolerance to the disruptive effects of DB00182 and a supersensitivity to the disruptive effects of DB00714 in rats responding in a schedule controlled paradigm .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : a recent case study has shown a possible increase in the plasma level of DB00313 when co administered with DB00951 .",
        "label": "mechanism"
    },
    {
        "text": "discontinuing ddrug0 could pose a hazard to health if a potentially toxic drug that is significantly bound to the HD00524 has been titrated to a maintenance level while the patient was taking DB00375 .",
        "label": "NA"
    },
    {
        "text": "DB01045 : coadministration of ddrug1 and ddrug2 suspension results in a significant decrease in average steady - state plasma DB01117 concentrations .",
        "label": "NA"
    },
    {
        "text": "DB00788 , ddrug1 and other ddrug2 have been reported to reduce the tubular secretion of DB00563 in an animal model , possibly increasing the toxicity of ddrug4 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 , ddrug1 and HD00218 : concomitant treatment with ddrug3 , HD00356 , or ddrug5 may potentiate a possible hypokalemic effect of ddrug6",
        "label": "NA"
    },
    {
        "text": "the gonadotropin levels may be transiently elevated by ddrug0 , minimally elevated by DB01235 , and suppressed by oral HD00283 and ddrug3 .",
        "label": "NA"
    },
    {
        "text": "although a 3-day regimen of DB00673 given concomitantly with oral HD00283 has not been studied , alternative or back-up methods of contraception should be used .",
        "label": "advise"
    },
    {
        "text": "ddrug0 should not be taken closely in time with ddrug1 and DB14513 containing HD00374 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 - containing preparations { eg , HD00374 } may cause hypermagnesemia and should therefore not be taken during therapy with DB11094 by patients on chronic renal dialysis .",
        "label": "effect"
    },
    {
        "text": "HD00024 / ddrug1 : ddrug2 , DB00683 contraindicated due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression .",
        "label": "NA"
    },
    {
        "text": "ddrug0 anesthesia : severe hypotension has been reported during DB00813 anesthesia with concomitant use of a HD00379 and a ddrug3 .",
        "label": "effect"
    },
    {
        "text": "DB00152 , or other products containing DB01592 or ddrug2 , ddrug3 or ddrug4 should not be administered concomitantly with , or within # hours of , the administration of ddrug5 , because they may interfere with absorption resulting in lower serum and urine levels of ddrug6 .",
        "label": "NA"
    },
    {
        "text": "DB00924 may have life-threatening interactions with HD00343 .",
        "label": "int"
    },
    {
        "text": "ddrug0 : available data suggest that there is no significant effect of ddrug1 on the clearance of DB00949 at steady state , therefore , the addition of ddrug3 is not expected to cause a clinically important effect on ddrug4 { DB00949 } plasma concentrations .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect : ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , DB00668 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , HD00810 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "and DB00822 when ddrug1 is given with ddrug2 agents or ddrug3 drugs , including ddrug4 combined with local HD00264 , close supervision and careful adjustment of dosages are required .",
        "label": "NA"
    },
    {
        "text": "in another drug interaction study , co-administration of orally inhaled ddrug0 and oral DB01026 , a potent inhibitor of cytochrome p450 3a4 , increased the exposure { auc } of HD00528 by approximately # - fold at steady state , while levels of ddrug3 remained unchanged .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00564 causes an approximate 50 % increase in the clearance of ddrug2 at steady state and , therefore , the addition of ddrug3 results in an approximate 40 % decrease in the steady-state trough concentrations of DB00949 as compared to the same dose of ddrug5 given as monotherapy .",
        "label": "NA"
    },
    {
        "text": "other drugs : in healthy volunteers , ddrug0 , ddrug1 , DB01016 , ddrug3 , ddrug4 , hormone replacement therapy { a combination of conjugated ddrug5 and ddrug6 } , ddrug7 { ddrug8 and DB09104 } and ddrug10 did not affect the pharmacokinetics of ddrug11 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 : upon concomitant administration of # mg of DB00862 with # mg bid ddrug3 , the cmax and auc of DB00503 were reduced by approximately 20 % .",
        "label": "NA"
    },
    {
        "text": "as with other HD00617 , it should be noted that ddrug1 may be capable of potentiating ddrug2 such as ddrug3 , HD00344 , and ddrug5 .",
        "label": "effect"
    },
    {
        "text": "co-administration of ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , DB00331 and ddrug10 did not result in clinically significant increases in DB09026 exposure .",
        "label": "NA"
    },
    {
        "text": "additive adverse effects resulting from cholinergic blockade may occur when DB00424 is administered concomitantly with other ddrug1 , ddrug2 , ddrug3 , HD00219 , ddrug5 , ddrug6 or some ddrug7 .",
        "label": "effect"
    },
    {
        "text": "the administration of local ddrug0 containing ddrug1 or DB00368 to patients receiving ddrug3 or HD00043 may produce severe , prolonged hypertension .",
        "label": "effect"
    },
    {
        "text": "ddrug0 or DB11119 excess may decrease the effect of DB00389 , and an ddrug3 deficiency can increase the effect of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "the potential for increased sedation when DB01018 is given with other HD00774 should be appreciated .",
        "label": "effect"
    },
    {
        "text": "in clinical trials , DB01240 was used with ddrug1 , HD00218 , ddrug3 , oral ddrug4 , and supplemental ddrug5 , in a pharmacokinetic substudy in patients with congestive heart failure receiving ddrug6 or ddrug7 in whom therapy with ddrug8 was initiated , apparent oral clearance values for ddrug9 { n = 23 } and ddrug10 { n = 30 } were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .",
        "label": "NA"
    },
    {
        "text": "these in vitro studies suggest that concomitant administration of ddrug0 and DB00709 in humans may result in sub-therapeutic concentrations of active phosphorylated ddrug2 , which may lead to a decreased ddrug3 effect of DB00943 .",
        "label": "NA"
    },
    {
        "text": "nephrotoxic agents : concomitant administration of DB00369 and agents with nephrotoxic potential -lsb- e , g , , intravenous ddrug1 { e , g , , ddrug2 , ddrug3 , and ddrug4 } , ddrug5 , ddrug6 , intravenous DB00738 , ddrug8 , and ddrug9 -rsb- is contraindicated .",
        "label": "advise"
    },
    {
        "text": "DB00252 / DB01174 : the coadministration of ddrug2 or ddrug3 will not affect plasma concentrations of ddrug4 , but may reduce endogenous plasma levels of ddrug5 / ergocalcitriol by accelerating metabolism .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 , including DB00467 , decrease the clearance of ddrug3 , the less active isomer of racemic DB00682 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 : in normal volunteers { n = 9 } , pretreatment with ddrug2 or DB00863 did not affect ddrug4 pharmacokinetics except that a small { 13 % } but statistically significant increase in the area under the serum concentration curve of ddrug5 resulted with DB00501 .",
        "label": "NA"
    },
    {
        "text": "this drug may interact with ddrug0 or other ddrug1 { may potentiate the cns depressant effects of either these medications or ddrug2 } , HD00444 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug4 } , and ddrug5 { concurrent use with HD00388 may prolong and intensify the anticholinergic and cns depressant effects of ddrug7 } .",
        "label": "NA"
    },
    {
        "text": "DB00501 } and many that are substrates for cyp2b6 2d6 { many other HD00216 , ddrug2 , and the ddrug3 ddrug4 and ddrug5 } .",
        "label": "NA"
    },
    {
        "text": "although not studied systematically in clinical trials , no drug interactions were observed when ddrug0 , DB01337 , or ddrug2 were administered following varying degrees of recovery from single doses or infusions of DB00565 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : although the results of a clinical study did not indicate a safe problem associated with the administration of ddrug1 { ddrug2 } injection , usp to subjects already receiving DB00571 , there have been reports that ddrug4 may potentiate the vasoconstrictive action of DB00201 by blocking the vasodilating property of epinephrine .",
        "label": "NA"
    },
    {
        "text": "HD00091 is a novel ddrug1 that may selectively prevent HD00023 - induced gastrointestinal effects without reversing analgesia .",
        "label": "effect"
    },
    {
        "text": "ddrug0 s : ddrug1 should be administered at least # hours after or # hours before dosing with ddrug2 because plasma concentrations of ddrug3 are decreased when administered with HD00374 containing ddrug5 , ddrug6 , or DB01370 .",
        "label": "NA"
    },
    {
        "text": "the following medications have been administered in clinical trials with DB00074 with no increase in adverse reactions : atg/alg , ddrug1 , ddrug2 , ddrug3 , ddrug4 , and DB00075 .",
        "label": "NA"
    },
    {
        "text": "coadministration with compounds that are potent inducers of cyp3a4 { eg , ddrug0 , ddrug1 , ddrug2 , DB00564 } may result in decreased plasma levels of DB01232 .",
        "label": "mechanism"
    },
    {
        "text": "DB00985 may decrease ddrug1 response to DB00714 .",
        "label": "effect"
    },
    {
        "text": "co-administration of single 25-mg dose DB00682 had no effect on the pharmacokinetics of total DB00480 .",
        "label": "NA"
    },
    {
        "text": "DB00945 / DB00316 : pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between ddrug2 and concomitantly administered ddrug3 { # mg orally given # and # hours prior to initiation of ddrug4 # g/kg/min , over # hours } or ddrug5 { 1000 mg orally given 12 , # and # hours prior to , and # and # hours subsequent to , initiation of ddrug6 # g/kg/min , over # hours } .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 : based on auc and half-life , multiple-dose pharmacokinetic profiles of ddrug1 and ddrug2 following administration of tablets containing # mg of DB00717 and # mcg of ddrug4 were similar with and without coadministration of DB00996 { 400 mg tid ;",
        "label": "NA"
    },
    {
        "text": "concomitant oral administration of DB01026 { a known inhibitor of cyp3a4 activity in the liver and in the intestinal mucosa } caused an eight-fold increase of the systemic exposure to oral DB01222 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 / HD00024 / ddrug2 / ddrug3 : co-administration of ddrug4 with HD00264 , ddrug6 , ddrug7 , and ddrug8 is likely to lead to an enhancement of effects .",
        "label": "NA"
    },
    {
        "text": "while no in vivo drug-drug interaction studies were conducted between ddrug0 and inducers of cyp3a , compounds that are potent cytochrome_p450_family_3_subfamily_a inducers { such as ddrug1 , DB00252 , ddrug3 , and ddrug4 } would be expected to decrease DB01215 concentrations .",
        "label": "NA"
    },
    {
        "text": "inhibitors or substrates of cyp2d6 { i , e , , DB00908 , ddrug1 -lsb- ddrug2 -rsb- } may increase the plasma concentration of DB01142 when administered concomitantly .",
        "label": "mechanism"
    },
    {
        "text": "HD00374 , ddrug1 , metal cations , ddrug2 HD00532 form chelates with alkaline earth and transition metal cations .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , and the ddrug1 ddrug2 { ddrug3 } and ddrug4 { DB00889 } have all been used with DB01008 .",
        "label": "NA"
    },
    {
        "text": "after prolonged administration of HD00137 the displacing effect of ddrug1 , an analog of cholecystokinin octapeptide , was replaced by the stimulant action on HD00136 binding .",
        "label": "NA"
    },
    {
        "text": "ddrug0 / ddrug1 / ddrug2 / HD00263 : co-administration of ddrug4 with ddrug5 , ddrug6 , HD00214 , and ddrug8 is likely to lead to an enhancement of effects .",
        "label": "NA"
    },
    {
        "text": "because there is a theoretical basis that these effects may be additive , use of DB00201 - containing or ddrug1 { like ddrug2 or DB00247 } and ddrug4 within # hours is contraindicated .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : HD00403 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { DB00501 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "DB00945 : concomitant administration of ddrug1 with DB00580 may result in an increased risk of gi ulceration and complications compared to ddrug3 alone .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , as with other ddrug1 , should be administered with extreme caution to patients being treated with ddrug2 , HD00043 , or drugs known to prolong the qtc interval because the action of HD00355 on the cardiovascular system may be potentiated by these agents .",
        "label": "effect"
    },
    {
        "text": "since DB01232 is coadministered with DB00503 , the ddrug2 label should be reviewed for additional drugs that should not be coadministered .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : some individuals receiving DB00601 may experience a reversible enhancement of the pressor response to indirect-acting ddrug2 , HD00649 or ddrug4 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : DB01026 has been reported to decrease the metabolism of certain HD00175 by up to 60 % , leading to increased risk of ddrug3 side effects .",
        "label": "mechanism"
    },
    {
        "text": "other drugs : in healthy volunteers , ddrug0 , ddrug1 , ddrug2 , DB00863 , ddrug4 , hormone replacement therapy { a combination of conjugated ddrug5 and ddrug6 } , ddrug7 { ddrug8 and ddrug9 } and DB00277 did not affect the pharmacokinetics of ddrug11 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00749 has no apparent pharmacokinetic interaction when administered with DB00252 .",
        "label": "NA"
    },
    {
        "text": "the purpose of this study was to evaluate the effect of ddrug0 { ddrug1 } and ddrug2 { ddrug3 } conjugates on the intestinal permeation of ddrug4 { HD00070 } and model peptide drugs , DB00781 and ddrug7 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 is unlikely to interact with drugs that are substrates for the p_glycoprotein transporter , as demonstrated by the lack of interaction of DB00673 with DB00390 in a clinical drug interaction study .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may enhance the effects of DB02325 , HD00026 , and other ddrug3 .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { DB00501 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 DB14507 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "DB01064 injection and DB00668 should not be administered simultaneously because both drugs are direct cardiac stimulants and their combined effects may induce serious arrhythmias .",
        "label": "advise"
    },
    {
        "text": "the possibility of hypotensive effects with DB00722 can be minimized by either discontinuing the HD00295 or increasing the salt intake prior to initiation of treatment with ddrug2 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB01118 should be used with caution in patients receiving - ddrug2 blocking agents { e , g , , ddrug3 , a ddrug4 inhibitor } or ddrug5 antagonists { e , g , , DB00661 , a ddrug7 substrate , and ddrug8 , a ddrug9 inhibitor } because of the possible potentiation of bradycardia , sinus arrest , and av block ;",
        "label": "NA"
    },
    {
        "text": "in some patients , the administration of a ddrug0 can reduce the diuretic , natriuretic , and antihypertensive effects of HD00105 , ddrug2 and HD00029 .",
        "label": "NA"
    },
    {
        "text": "no formal clinical studies have been conducted to assess if there is an interactive effect on bone loss between DB00252 and DB00982 .",
        "label": "NA"
    },
    {
        "text": "oral HD00326 : in some normal volunteers , the concomitant administration of ddrug1 and ddrug2 , ddrug3 , or DB00946 resulted in prolongation of prothrombin time .",
        "label": "NA"
    },
    {
        "text": "furthermore , HD00141 and DB14503 do not appear to share a common transport pathway in the duodenum and no evidence was obtained for any interaction between the two at this level .",
        "label": "NA"
    },
    {
        "text": "DB01576 with ddrug1 or DB00344 and possibly other ddrug3 cause striking and sustained increases in the concentration of ddrug4 in the brain ;",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { DB00091 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { DB00295 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "the rate of metabolism and the leukopenic activity of DB00531 reportedly are increased by chronic administration of high doses of DB01174 .",
        "label": "mechanism"
    },
    {
        "text": "diminished urinary excretion of DB01059 has been reported during the concomitant administration of DB01032 and ddrug2 .",
        "label": "NA"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / ddrug1 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , ddrug4 , ddrug5 , ddrug6 , DB00226 , ddrug8 , ddrug9 , ddrug10 , HD00516 pain medication { e , g , , ddrug12 } , drugs used to aid sleep , drowsiness-causing ddrug13 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { ddrug1 s } , ddrug2 , ddrug3 { ddrug4 may decrease the effects of these medicines } , ddrug5 { using these medicines with ddrug6 may result in increased cns depressant effects } , ddrug7 , ddrug8 { using these medicines with ddrug9 may change the amount of either medicine that you need to take } , and oral ddrug10 containing HD00220 { HD00026 may decrease the effectiveness of these oral ddrug13 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { ddrug1 } { e , g , , ddrug2 , DB00176 , ddrug4 , ddrug5 } have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with HD00277 .",
        "label": "effect"
    },
    {
        "text": "DB01026 { 200 mg once daily } produced a 10-fold increase in DB00862 auc and a 4-fold increase in cmax when co-administered with ddrug2 { 5 mg } in healthy volunteers .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : in a randomized , multiple-dose crossover study , patients with type # diabetes were administered # mg DB00731 three times a day before meals for # day in combination with DB01016 # mg daily .",
        "label": "NA"
    },
    {
        "text": "pharmacokinetic data from these patients demonstrated a decrease in ddrug0 clearance of approximately 33 % when DB01229 was administered following DB00515 .",
        "label": "mechanism"
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit DB00451 binding to serum proteins or alter the concentrations of serum binding proteins : ddrug1 and related ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 , ddrug7 , ddrug8 , HD00115 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 .",
        "label": "mechanism"
    },
    {
        "text": "protein binding in vitro , DB00586 interferes minimally or not at all with the protein binding of DB00645 { 20 % decrease in binding } , ddrug2 , ddrug3 { 10 % decrease in binding } , or ddrug4 .",
        "label": "mechanism"
    },
    {
        "text": "based on adult data , lower doses of ddrug0 may be needed following coadministration of drugs which are reported to decrease DB00201 elimination { e , g , , ddrug2 and ddrug3 } and higher ddrug4 doses may be needed following coadministration of drugs that increase ddrug5 elimination { e , g , , DB01174 and ddrug7 } .",
        "label": "NA"
    },
    {
        "text": "in patients on chronic DB00682 therapy , the prothrombin time { inr } should be closely monitored in the 2-week period , particularly at # to # days , following initiation of the 3-day regimen of DB00673 with each chemotherapy cycle .",
        "label": "advise"
    },
    {
        "text": "ddrug0 , ddrug1 and other HD00203 have been reported to reduce the tubular secretion of ddrug3 in an animal model , possibly increasing the toxicity of DB00563 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { ddrug1 } : steady state plasma exposure { auc } of DB00580 { 40 mg bid for # days } was decreased by 27 % when co-administered with multiple doses { 300 mg qd for # days } of DB00252 { a ppig 3a4 inducer } .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { HD00548 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , DB00860 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "HD00322 : ddrug1 , ddrug2 , HD00297 , or ddrug4 may interfere with the bactericidal effect of ddrug5 .",
        "label": "NA"
    },
    {
        "text": "both DB00625 and ddrug1 have been compared to triple therapy with the ddrug2 ddrug3 over # weeks as initial therapy , with similar responses being observed with DB00238 regimens and superiority observed with ddrug5 .",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with other cyp3a4 inhibitors { e , g , , ddrug1 # mg bid , ddrug2 # mg qd , DB01232 # mg tid , DB00196 # mg qd } resulted in increases in cmax of ddrug5 ranging from # - to # - fold and auc from # - to # - fold .",
        "label": "NA"
    },
    {
        "text": "DB00465 does not alter DB00390 protein binding .",
        "label": "NA"
    },
    {
        "text": "toxicology studies of ddrug0 - related deaths reveal frequent involvement of other ddrug1 , including DB02325 , ddrug3 such as DB00829 { ddrug5 } , and , to a rising degree , ddrug6 .",
        "label": "NA"
    },
    {
        "text": "drugs that induce hepatic enzymes such as ddrug0 , ddrug1 and DB01045 may increase the clearance of ddrug3 and may require increases in HD00579 dose to achieve the desired response .",
        "label": "advise"
    },
    {
        "text": "drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on ddrug0 therapy : ddrug1 , ddrug2 , HD00220 , oral ddrug4 containing ddrug5 , ddrug6 - containing preparations and the numerous preparations containing HD00328 .",
        "label": "NA"
    },
    {
        "text": "inhibitors of this isoenzyme { e , g , , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , grapefruit juice , ddrug7 , ddrug8 , DB00468 , ddrug10 } should be cautiously coadministered with DB00204 as they can potentially increase ddrug12 levels .",
        "label": "advise"
    },
    {
        "text": "the concentrations of HD00413 , the active metabolite of DB00762 , were on average 33 % higher in patients receiving bolus-ifl in combination with ddrug2 when compared with bolus-ifl alone .",
        "label": "NA"
    },
    {
        "text": "HD00518 { ddrug1 } : concomitant use of ddrug2 { or other ddrug3 } and HD00175 increases the risk of gastrointestinal side effects .",
        "label": "NA"
    },
    {
        "text": "agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of HD00472 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 { 2 } , ddrug7 , DB05246 , and ddrug9 thus , if a patient has been titrated to a stable dosage on ddrug10 , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for ddrug11 may be necessary .",
        "label": "mechanism"
    },
    {
        "text": "among DB00945 or HD00615 users , the incidence of upper gastrointestinal adverse events in patients treated with ddrug2 # mg daily { # % } was similar to that in placebo-treated patients { # % } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 has additive effects with DB02325 and other ddrug2 { ddrug3 , ddrug4 , HD00262 , etc } .",
        "label": "NA"
    },
    {
        "text": "DB14507 serum concentrations should be monitored closely when initiating or changing therapy with DB00580 in patients receiving ddrug2 .",
        "label": "NA"
    },
    {
        "text": "therefore , coadministration of ddrug0 with drugs that strongly induce cyp3a4 activity { e , g , , ddrug1 , DB00564 , ddrug3 } may result in reduced plasma concentrations of ddrug4 that may result in decreased efficacy of DB00673 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : as with other HD00501 , the renal excretion of ddrug2 is inhibited by DB01032 .",
        "label": "NA"
    },
    {
        "text": "and ddrug0 e , g , , ddrug1 } , cyp1a2 inducers { DB00338 } and cyp1a2 inhibitors { ddrug3 and DB01211 } .",
        "label": "NA"
    },
    {
        "text": "based on adult data , lower doses of ddrug0 may be needed following coadministration of drugs which are reported to decrease DB00201 elimination { e , g , , DB00501 and ddrug3 } and higher ddrug4 doses may be needed following coadministration of drugs that increase ddrug5 elimination { e , g , , ddrug6 and ddrug7 } .",
        "label": "NA"
    },
    {
        "text": "drugs that may have their plasma concentration altered by DB00619 ddrug1 increases the mean cmax and auc of DB00641 { cyp3a4 substrate } 2 - and # - fold , respectively , suggesting an inhibition of the cyp3a4 by ddrug3 .",
        "label": "NA"
    },
    {
        "text": "DB00788 and other HD00203 can reduce the antihypertensive effect of ddrug2 and other ddrug3 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , HD00282 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and DB00126 .",
        "label": "NA"
    },
    {
        "text": "although there are no study data to evaluate the possibility , ddrug0 , including ddrug1 and DB00727 , may have an additive effect with DB00435 on the risk of developing methemoglobinemia .",
        "label": "effect"
    },
    {
        "text": "DB00822 should be used with caution in those patients reveiving DB00252 and its congeners .",
        "label": "advise"
    },
    {
        "text": "in em individuals treated with DB00715 or DB00472 , the auc of ddrug2 is approximately 6 - to 8-fold and css , max is about 3 - to 4-fold greater than ddrug3 alone .",
        "label": "NA"
    },
    {
        "text": "ddrug0 therapy urinary excretion of HD00401 is increased , and efficacy is reduced by acidifying agents used in DB06799 therapy .",
        "label": "mechanism"
    },
    {
        "text": "therefore , patients without a functioning DB00451 gland who are on thyroid replacement therapy may need to increase their thyroid dose if ddrug1 or HD00183 - containing oral ddrug3 are given .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and DB00281 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , DB01035 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "drugs with a narrow therapeutic index ddrug0 : DB00962 { 10 mg } did not affect the pharmacokinetic or pharmacodynamic profile of DB00390 { # mg q24h for # days } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { DB00316 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , DB01076 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "DB00196 , an inhibitor of cyp2b6 2c9 , decreased active metabolite concentration and increased DB00678 concentration .",
        "label": "mechanism"
    },
    {
        "text": "these results suggest that both DB01234 and HD00147 , and possibly other ddrug2 and ddrug3 , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of ddrug4 and ddrug5 .",
        "label": "NA"
    },
    {
        "text": "however , the systemic administration of some ddrug0 has been shown to elevate plasma concentrations of DB00277 , interfere with the metabolism of ddrug2 , and enhance the effects of the oral ddrug3 DB00682 and its derivatives , and has been associated with transient elevations in serum creatinine in patients receiving systemic ddrug5 concomitantly .",
        "label": "NA"
    },
    {
        "text": "based on the chemical resemblance of DB01167 and DB01026 , coadministration of ddrug2 with ddrug3 is contraindicated .",
        "label": "NA"
    },
    {
        "text": "moreover , additional interaction studies with ddrug0 and ddrug1 have not demonstrated any effect on DB01095 plasma levels , and administration to a patient population chronically receiving DB00390 resulted in no difference in the extent of bioavailability of ddrug4 relative to control data .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and HD00586 - although not reported , ddrug2 , via its metabolism to histamine , might decrease the efficacy of HD00827 and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "although this interaction has not been reported with DB00827 , caution should be exercised when ddrug1 is given concomitantly with DB00201 - containing products .",
        "label": "NA"
    },
    {
        "text": "data from in vitro studies of ddrug0 other than DB00404 suggest a possible drug interaction for the following : ddrug2 , ddrug3 , ddrug4 , ddrug5 , and DB01115 .",
        "label": "int"
    },
    {
        "text": "in # other schizophrenic patients treated with oral ddrug0 and DB01045 , discontinuation of ddrug2 produced a mean # - fold increase in DB00502 concentrations .",
        "label": "NA"
    },
    {
        "text": "in patients receiving nonselective ddrug0 { ddrug1 } { e , g , , DB01037 } in combination with ddrug3 { e , g , , ddrug4 , DB00176 , ddrug6 , ddrug7 , ddrug8 } , there have been reports of serious , sometimes fatal , reactions .",
        "label": "effect"
    },
    {
        "text": "- when ddrug0 or HD00415 is used concurrently with HD00418 { e , g , ddrug3 } , an interval of at least # hours should be maintained between the two medicines , since the absorption of ddrug4 or ddrug5 is impaired",
        "label": "advise"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , DB00776 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , DB00277 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as DB00415 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { DB00701 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as ddrug0 include certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 } , DB14513 salts , ddrug11 , local ddrug12 , ddrug13 , and DB00908 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : studies in animals demonstrate that the acute toxicity of DB01156 is enhanced by the HD00455 ddrug3 .",
        "label": "NA"
    },
    {
        "text": "patients receiving other HD00459 s , general ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 or other ddrug6 { including DB02325 } concomitantly with ddrug8 may exhibit an additive cns depression .",
        "label": "NA"
    },
    {
        "text": "immediate and extended release tablets the hypoglycemic action of HD00222 may be potentiated by certain drugs including ddrug1 , some ddrug2 and other drugs that are highly protein bound , ddrug3 , HD00297 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { DB00400 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { HD00531 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "since ddrug0 in high doses has been associated with hepatotoxicity , concomitant administration of DB00861 and DB00316 should be used cautiously , with careful monitoring of patients .",
        "label": "advise"
    },
    {
        "text": "absorption of HD00239 is impaired by ddrug1 containing ddrug2 , DB01373 , or ddrug4 , and ddrug5 - containing preparations .",
        "label": "mechanism"
    },
    {
        "text": "this interaction , which has not been investigated using higher doses of ddrug0 , may be more pronounced if a # mg daily dose is co-administered , particularly since ddrug1 exhibits non-linear pharmacokinetics over the dosage range 100 - 300 mg , if DB00404 is co-administered with DB00176 tablets , the initial ddrug4 dosage should be at least halved and titration to the lowest effective dose is recommended .",
        "label": "advise"
    },
    {
        "text": "aortic rings with intact endothelium from the high-dose { 4 mg/kg/day } DB00783 group were supersensitive to DB00368 compared to the vehicle or low-dose { 10 microg/kg/day } estradiol groups { pd2 values = # + / # , # + / # and # + / # , respectively } .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : DB00945 may decrease the effects of DB01032 , ddrug3 , and ddrug4 .",
        "label": "effect"
    },
    {
        "text": "DB00820 dose should not exceed a maximum of # mg in a 72 - hour period in patients receiving concomitant DB00224 therapy .",
        "label": "advise"
    },
    {
        "text": "- a HD00535 { ddrug1 } such as ddrug2 { ddrug3 , ddrug4 , ddrug5 , others } , DB01009 { ddrug7 , ddrug8 , ddrug9 } , ddrug10 { ddrug11 , ddrug12 } , ddrug13 { ddrug14 } , ddrug15 { ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , and ddrug21 { ddrug22 , ddrug23 , ddrug24 } ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 { cns } drugs including ddrug1 , ddrug2 , ddrug3 , ddrug4 , blood pressure medications { ddrug5 , DB00968 , ddrug7 } , motion sickness medications , HD00542 , ddrug9 , ddrug10 , sleeping pills and ddrug11",
        "label": "NA"
    },
    {
        "text": "also , concomitant administration of ddrug0 with products containing DB01592 , ddrug2 containing ddrug3 , or DB00900 { ddrug5 } chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels .",
        "label": "NA"
    },
    {
        "text": "administration of DB00343 concomitantly with ddrug1 in five normal volunteers resulted in increased ddrug2 levels in all subjects and bioavailability of DB00571 was increased approximately 50 % .",
        "label": "NA"
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a ddrug0 , including ddrug1 , with multivalent cation-containing products such as ddrug2 or DB01370 ddrug4 , ddrug5 , ddrug6 chewable/buffered tablets or pediatric powder , or products containing ddrug7 , ddrug8 , or DB01593 may substantially decrease the absorption of ddrug10 , resulting in serum and urine levels considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "unlike HD00021 , HD00022 does not affect responding for a nondrug reinforcer { water } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , other , especially DB01119 , or pre ddrug2 and anesthetic agents used in surgery or HD00785 , nondepolarizing , used in surgery",
        "label": "NA"
    },
    {
        "text": "ddrug0 : other ddrug1 drugs , such as ddrug2 , ddrug3 , ddrug4 , and DB00252 , have been used concurrently with DB01118 .",
        "label": "NA"
    },
    {
        "text": "given the primary cns effects of DB00363 , caution is advised in using it concomitantly with other cns-active drugs or DB02325 .",
        "label": "effect"
    },
    {
        "text": "the following agents may increase certain actions or side effects of ddrug0 , DB00915 ddrug2 of class { e , g , ddrug3 } , ddrug4 HD00617 { e , g , ddrug6 } , ddrug7 .",
        "label": "NA"
    },
    {
        "text": "animal studies indicate that DB00841 may be ineffective if the patient has recently received a HD00636 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 and ddrug1 : coadministration of ddrug2 with ddrug3 resulted in a 47 % decrease in DB00977 and an 18 % decrease in DB00717 plasma concentrations .",
        "label": "NA"
    },
    {
        "text": "DB00825 / ddrug1 { e , g , , ddrug2 , ddrug3 , DB00318 and ddrug5 combinations , ddrug6 , ddrug7 } .",
        "label": "NA"
    },
    {
        "text": "since bacteriostatic drugs may interfere with the bactericidal action of ddrug0 , it is advisable to avoid giving HD00239 in conjunction with HD00284 .",
        "label": "advise"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , ddrug3 ddrug4 : ddrug5 , DB00342 antimigraine : ddrug7 ddrug8 : ddrug9 HD00100 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "the intensity , uniformity and time course of HD00025 interference by ddrug1 , DB00418 , ddrug3 , ddrug4 and ddrug5 were systematically investigated in # patients receiving ddrug6 therapy .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : drugs such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB00975 , ddrug7 and others that interfere with platelet-aggregation reactions { the main hemostatic defense of heparinized patients } may induce bleeding and should be used with caution in patients receiving DB01109 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { DB00295 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , DB00231 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the ddrug0 of drugs may be potentiated by ddrug1 , HD00543 , ddrug3 , ddrug4 , ddrug5 , the ddrug6 , ddrug7 and ddrug8 , ddrug9 and the ddrug10 , and by other HD00561 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : when DB00176 { 100 mg qd } and DB00404 { 1 mg q , d , were co-administered to steady state , plasma concentration and other pharmacokinetics parameters { auc , cmax , t1/2 , } of ddrug3 were approximately twice those observed when ddrug4 was administered alone ;",
        "label": "mechanism"
    },
    {
        "text": "such individuals are referred to as poor metabolizers of drugs such as ddrug0 , DB00514 , and the HD00043 .",
        "label": "NA"
    },
    {
        "text": "drugs that should not be coadministered with DB00220 ddrug1 : DB01118 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "label": "advise"
    },
    {
        "text": "ddrug0 and other ddrug1 : co-administration of DB00559 decreased the plasma concentrations of DB00641 { a cyp3a4 substrate } , and its active - hydroxy acid metabolite , by approximately 50 % .",
        "label": "mechanism"
    },
    {
        "text": "if concomitant treatment with DB00669 and an ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , DB01104 , ddrug6 , ddrug7 } is clinically warranted , appropriate observation of the patient is advised .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : in normal volunteers , concomitant administration of DB00861 and ddrug2 resulted in significantly increased plasma levels of DB00999 .",
        "label": "NA"
    },
    {
        "text": "- a ddrug0 { HD00615 } such as ddrug2 { DB01050 , ddrug4 , ddrug5 , others } , ddrug6 { ddrug7 , ddrug8 , ddrug9 } , ddrug10 { ddrug11 , ddrug12 } , ddrug13 { ddrug14 } , ddrug15 { ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , and ddrug21 { ddrug22 , ddrug23 , ddrug24 } ;",
        "label": "NA"
    },
    {
        "text": "the influence of ddrug0 and DB00829 on antinociceptive effect of ddrug2 { 10 mg/kg } , ddrug3 { 500 mg/kg } and DB00328 { 10 mg/kg } was investigated in a mouse model using the tail-flick and hot-plate tests .",
        "label": "NA"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / ddrug1 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , ddrug4 , ddrug5 , DB01170 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 pain medication { e , g , , ddrug12 } , drugs used to aid sleep , drowsiness-causing ddrug13 { e , g , , DB14487 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "ddrug0 did not affect the conversion of ddrug1 to the active metabolite after intravenous administration of DB00678 , and DB00199 had no clinically significant effect after oral administration .",
        "label": "NA"
    },
    {
        "text": "hypotension was more likely to occur if the HD00411 were a ddrug1 , e , g , , DB01115 , while left ventricular failure and av conduction disturbances , including complete heart block , were more likely to occur with either ddrug3 or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "interactions with ddrug0 : ddrug1 { eg , ddrug2 , ddrug3 , DB00611 , ddrug5 and ddrug6 } should not be administered to a patient who has received or is receiving a course of therapy with a HD00843 such as ddrug8 .",
        "label": "NA"
    },
    {
        "text": "other drug interactions : no pharmacokinetic interactions were observed between DB00862 and the following drugs : ddrug1 , ddrug2 , DB00390 , ddrug4 , and ddrug5 .",
        "label": "NA"
    },
    {
        "text": "the blockade of the spinal endorphinergic system by intrathecal ddrug0 on the production of tail-flick inhibition induced by intraventricular HD00144 and DB00295 was then studied .",
        "label": "NA"
    },
    {
        "text": "in clinical studies , coadministration of ddrug0 with ddrug1 , ddrug2 , or DB00641 did not interfere with the lipid-lowering activity of the HD00383 .",
        "label": "NA"
    },
    {
        "text": "the possibility of hypotensive effects can be minimized by either discontinuing the HD00295 or increasing salt intake prior to initiation of treatment with DB00492 .",
        "label": "effect"
    },
    {
        "text": "DB00522 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some DB00152 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "int"
    },
    {
        "text": "may interact with the following : ddrug0 { these medicines may make your condition worse and prevent the HD00815 from working properly } and ddrug2 , ddrug3 , ddrug4 , and DB01035 { these medicines may increase the risk of heart problems } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , DB01174 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { HD00712 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "the mean percentage increase in the DB01067 auc after DB00196 administration was # % { range : # to 81 } .",
        "label": "mechanism"
    },
    {
        "text": "plasma concentrations of ddrug0 are decreased when administered with HD00374 containing DB14513 , ddrug3 , or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "other cardiovascular agents : ddrug0 and DB00584 iv have been used concomitantly with ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , DB00457 and ddrug8 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { HD00548 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { HD00712 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "other cardiovascular agents : DB00584 and ddrug1 iv have been used concomitantly with ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 and DB00390 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "there are rare reports , however , from marketing experiences , of changes in effects of HD00071 or oral ddrug1 in the presence of DB00586 that necessitated changes in the doses of such agents .",
        "label": "effect"
    },
    {
        "text": "in a study involving healthy subjects receiving ddrug0 and DB00571 concurrently , plasma DB01195 levels were increased about 20 % and ddrug3 levels were increased about 30 % compared to control values .",
        "label": "NA"
    },
    {
        "text": "therefore , DB00861 and DB00328 should not be used concomitantly .",
        "label": "advise"
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a ddrug0 , including ddrug1 , with multivalent cation-containing products such as ddrug2 or ddrug3 ddrug4 , ddrug5 , ddrug6 chewable/buffered tablets or pediatric powder , or products containing DB01373 , ddrug8 , or ddrug9 may substantially decrease the absorption of DB00537 , resulting in serum and urine levels considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "and DB00822 when ddrug1 is given with ddrug2 agents or HD00316 drugs , including ddrug4 combined with local ddrug5 , close supervision and careful adjustment of dosages are required .",
        "label": "NA"
    },
    {
        "text": "in addition , results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance { DB00625 , ddrug1 , ddrug2 , ddrug3 , or ddrug4 } with DB00520 may result in clinically meaningful reductions in ddrug6 concentrations .",
        "label": "mechanism"
    },
    {
        "text": "nevertheless , caution is indicated in the co-administration of HD00313 with any of the HD00114 and also in switching from one class to the other .",
        "label": "advise"
    },
    {
        "text": "if HD00374 are required during ddrug1 therapy , DB00535 should be taken at least # hours before or after the ddrug3 .",
        "label": "NA"
    },
    {
        "text": "- HD00394 : { oral agents and HD00071 } dosage adjustment of the ddrug2 may be required",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 : in one study , ddrug1 was given to adult diabetics who were already receiving DB01016 { n = 4 } , ddrug3 { n = 2 } ddrug4 with DB00914 { n = 3 } or ddrug6 with ddrug7 { n = 6 } .",
        "label": "NA"
    },
    {
        "text": "the effects of ddrug0 and HD00019 upon DB03575 { ddrug3 } - induced locomotion and behavioral changes in mice .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a clinical pharmacology study , coadministration of an ddrug1 { DB06723 , ddrug3 , and ddrug4 } with ddrug5 reduced serum levels and urinary excretion of DB14207 as compared with ddrug7 administered alone , suggesting that ddrug8 may impair absorption of ddrug9 .",
        "label": "NA"
    },
    {
        "text": "therefore the , combination of ddrug0 with other HD00243 , including DB02325 , may also result i n similar toxicities .",
        "label": "NA"
    },
    {
        "text": "-lsb- stimulation by ddrug0 -- an analog of the octapeptide cholecystokinin -- of HD00136 binding after the long-term administration of HD00137 -rsb- it has been established in experiments on white male rats that prolonged administration { twice a day for # days } of ddrug3 { # mg/kg } and ddrug4 { # mg/kg } resulted in the reduced interaction between ddrug5 and low affinity binding sites for ddrug6 in subcortical structures , whereas ddrug7 binding with high affinity binding sites for ddrug8 increased both in the frontal cortex and subcortical structures of the forebrain .",
        "label": "NA"
    },
    {
        "text": "effects of other antiepilepsy drugs { ddrug0 } on ddrug1 : ddrug2 : population pharmacokinetic analyses indicate that DB00906 clearance is 60 % greater in patients taking DB00564 with or without other enzyme - inducing ddrug5 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 { cns } drugs including ddrug1 , ddrug2 , ddrug3 , HD00031 , blood pressure medications { ddrug5 , DB00968 , ddrug7 } , motion sickness medications , ddrug8 , ddrug9 , ddrug10 , sleeping pills and ddrug11",
        "label": "NA"
    },
    {
        "text": "ddrug0 can interact with ddrug1 or other ddrug2 { may potentiate the cns depressant effects of either these medications or ddrug3 } , HD00444 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with HD00388 } , and ddrug6 { concurrent use with ddrug7 may prolong and intensify the anticholinergic and cns depressant effects of ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "these in vitro studies suggest that concomitant administration of ddrug0 and DB00709 in humans may result in sub-therapeutic concentrations of active phosphorylated ddrug2 , which may lead to a decreased HD00056 effect of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "therefore , co-administration of DB00363 with other drugs that are metabolized by this isozyme , including ddrug1 , ddrug2 , ddrug3 , and ddrug4 { e , g , , DB01182 , ddrug6 and ddrug7 } , or that inhibit this enzyme { e , g , , ddrug8 } , should be approached with caution .",
        "label": "advise"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , DB00908 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 ddrug11 , DB00897 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , DB01045 { ddrug40 } , st , johns wort , DB00231 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "the following agents may increase certain actions or side effects of ddrug0 , ddrug1 HD00428 of class { e , g , DB00908 } , ddrug4 ddrug5 { e , g , ddrug6 } , ddrug7 .",
        "label": "NA"
    },
    {
        "text": "in a comparison of ddrug0 tolerance in dogs anesthetized with ddrug1 , ddrug2 , or ddrug3 , the dosage of DB01092 needed to cause ventricular tachycardia was significantly higher , as was the ld50 of ddrug5 , with DB01221 or ddrug7 than with ddrug8 .",
        "label": "NA"
    },
    {
        "text": "although DB01609 has a lower affinity for ddrug1 than for ddrug2 , ddrug3 should not be taken with ddrug4 - containing HD00589 .",
        "label": "NA"
    },
    {
        "text": "DB00712 pretreatment attenuated the hypotensive effect of a single dose of DB00571 but not ddrug2 .",
        "label": "effect"
    },
    {
        "text": "in study 1 , patients with colorectal cancer were given ddrug0 / ddrug1 / DB00650 { bolus-ifl } with or without DB00112 .",
        "label": "NA"
    },
    {
        "text": "the objective of this study was to determine if there is a pharmacokinetic interaction when DB00701 is given with ddrug1 or DB01045 and to determine the effects of these drugs on the erythromycin breath test { ermbt } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : since ddrug1 is a ddrug2 , it is possible that ddrug3 , such as the ddrug4 { ddrug5 , ddrug6 , HD00341 } or DB01233 , may diminish the effectiveness of ddrug9 .",
        "label": "NA"
    },
    {
        "text": "thus , when HD00203 and ddrug1 are administered concurrently , subjects should be observed carefully for signs of DB14507 toxicity .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 { and possibly other HD00093 } and ddrug3 may increase ddrug4 absorption in patients who inactivate DB00390 by bacterial metabolism in the lower intestine , so that ddrug6 intoxication may result .",
        "label": "NA"
    },
    {
        "text": "patients who begin taking ddrug0 or who increase their DB00586 dose or any other ddrug2 while taking ddrug3 , DB00563 , or ddrug5 may develop toxicity characteristics for these drugs .",
        "label": "NA"
    },
    {
        "text": "ddrug0 ddrug1 DB00365 , like other HD00532 , may inhibit the metabolism of ddrug4 and ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 } , HD00093 { e , g , ddrug2 } , and ddrug3 { e , g , ddrug4 , ddrug5 and ddrug6 } should have their dose of DB00921 or ddrug8 adjusted .",
        "label": "NA"
    },
    {
        "text": "ddrug0 has been shown to have no effect on the pharmacokinetics of DB00390 and the pharmacodynamics of ddrug2 and DB01016 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , DB01026 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , DB00503 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 : ddrug1 { 40 mg bid } did not induce the metabolism of the combination oral HD00349 ddrug3 / ddrug4 { 1 mg / 35 mcg combination , DB00717 1/35 } .",
        "label": "NA"
    },
    {
        "text": "in clinical trials , DB01240 was used with ddrug1 , ddrug2 , ddrug3 , oral ddrug4 , and supplemental ddrug5 , in a pharmacokinetic substudy in patients with congestive heart failure receiving DB00695 or ddrug7 in whom therapy with ddrug8 was initiated , apparent oral clearance values for ddrug9 { n = 23 } and ddrug10 { n = 30 } were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .",
        "label": "NA"
    },
    {
        "text": "in clinical trials , ddrug0 was used with ddrug1 , ddrug2 , ddrug3 , oral ddrug4 , and supplemental DB09140 , in a pharmacokinetic substudy in patients with congestive heart failure receiving ddrug6 or ddrug7 in whom therapy with DB01240 was initiated , apparent oral clearance values for ddrug9 { n = 23 } and ddrug10 { n = 30 } were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { DB00564 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 DB14507 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "HD00374 { ddrug1 - or ddrug2 - containing } : concomitant administration of 300-mg DB00535 capsules with # ml ddrug4 suspension reduces the rate { cmax } and extent { auc } of absorption by approximately 40 % .",
        "label": "NA"
    },
    {
        "text": "these alterations in DB00390 pharmacokinetics produced by DB01118 explain the increase in serum ddrug2 level that has been observed when this drug combination has been used clinically .",
        "label": "mechanism"
    },
    {
        "text": "although ddrug0 has a lower affinity for ddrug1 than for ddrug2 , DB01609 should not be taken with DB01370 - containing ddrug5 .",
        "label": "advise"
    },
    {
        "text": "of over # patients enrolled in the DB00710 osteoporosis treatment and prevention studies , 15 % used anti-peptic agents { primarily ddrug1 and HD00792 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : based on reports of profound hypotension and loss of consciousness when ddrug1 was administered with DB00904 , the concomitant use of ddrug3 with drugs of the ddrug4 { including , for example , ddrug5 , DB00889 , ddrug7 , ddrug8 , and ddrug9 } is contraindicated .",
        "label": "NA"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : ddrug1 ; DB00753 ; ddrug3 ; certain ddrug4 , especially the ddrug5 and HD00384 ; ddrug7 ; ddrug8 salts ; ddrug9 ; and ddrug10 .",
        "label": "NA"
    },
    {
        "text": "hypotension was more likely to occur if the ddrug0 were a ddrug1 , e , g , , DB01115 , while left ventricular failure and av conduction disturbances , including complete heart block , were more likely to occur with either ddrug3 or DB00343 .",
        "label": "NA"
    },
    {
        "text": "in patients taking ddrug0 , DB01115 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and various chemotherapy agents , no effect was shown on the clearance of HD00644 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 or DB00228 administered with ddrug2 / ddrug3 to achieve # mac -lsb- minimum alveolar concentration -rsb- may prolong the clinically effective duration of action of initial and maintenance doses of DB00565 and decrease the required infusion rate of ddrug5 .",
        "label": "effect"
    },
    {
        "text": "in general , most patients treated with DB00954 who are receiving concomitant DB00277 therapy may not require empiric adjustment of ddrug2 dosage or monitoring of ddrug3 plasma concentrations .",
        "label": "NA"
    },
    {
        "text": "interactions for HD00464 { ddrug1 , ddrug2 , ddrug3 , and ddrug4 } : DB01432 : ddrug6 has been reported to reduce intestinal absorption of ddrug7 ;",
        "label": "NA"
    },
    {
        "text": "drug interactions : the central ddrug0 syndrome can occur when anticholinergic agents such as ddrug1 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain ddrug2 such as DB00454 , the ddrug4 and other ddrug5 , HD00043 , certain ddrug7 such as the ddrug8 salts , and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "the administration of local HD00449 containing DB00668 or ddrug2 to patients receiving ddrug3 , ddrug4 or ddrug5 may produce severe , prolonged hypotension or hypertension .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : concomitant administration of DB00622 and DB00091 levels .",
        "label": "NA"
    },
    {
        "text": "HD00345 could exaggerate the depression of av nodal conduction observed with HD00406 .",
        "label": "effect"
    },
    {
        "text": "however , because bleeding has been reported when DB01050 and other ddrug1 have been administered to patients on HD00724 , the physician should be cautious when administering ddrug3 to patients on ddrug4 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 , DB00863 : in normal volunteers { n = 9 } , pretreatment with ddrug2 or ddrug3 did not affect DB00712 pharmacokinetics except that a small { 13 % } but statistically significant increase in the area under the serum concentration curve of ddrug5 resulted with ddrug6 .",
        "label": "NA"
    },
    {
        "text": "particular caution should be observed with HD00573 since there are conflicting results for the effect of ddrug1 on the availability of ddrug2 and DB01396 .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of HD00071 : ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , ddrug5 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , HD00810 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "DB01195 has been administered to patients receiving HD00573 or ddrug2 without adverse effects .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { DB01076 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , DB00860 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "injection : ddrug0 injection , like other injectable ddrug1 , produces depression of the central nervous system when administered with DB00898 , ddrug3 , ddrug4 , ddrug5 , and other ddrug6 , when ddrug7 is used concomitantly with injectable DB00186 , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .",
        "label": "NA"
    },
    {
        "text": "DB00701 significantly decreases clearance of ddrug1 and HD00073 , and the combination is poorly tolerated .",
        "label": "mechanism"
    },
    {
        "text": "although there are no study data to evaluate the possibility , ddrug0 , including DB00325 and ddrug2 , may have an additive effect with DB00435 on the risk of developing methemoglobinemia .",
        "label": "effect"
    },
    {
        "text": "in a comparison of ddrug0 tolerance in dogs anesthetized with ddrug1 , ddrug2 , or ddrug3 , the dosage of ddrug4 needed to cause ventricular tachycardia was significantly higher , as was the ld50 of ddrug5 , with DB01221 or HD00117 than with ddrug8 .",
        "label": "NA"
    },
    {
        "text": "in patients receiving ddrug0 { DB01033 } or ddrug2 { ddrug3 } , the concomitant administration of 300 - 600 mg of DB00437 per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of ddrug5 or ddrug6 .",
        "label": "NA"
    },
    {
        "text": "also , concomitant administration of ddrug0 with products containing DB01592 , DB00152 containing ddrug3 , or ddrug4 { ddrug5 } chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels .",
        "label": "NA"
    },
    {
        "text": "DB00695 may add to or potentiate the therapeutic effect of other HD00448 .",
        "label": "effect"
    },
    {
        "text": "other depressasnts such as DB02325 , ddrug1 , and ddrug2 may enhance cns depression when administered with DB00189 .",
        "label": "effect"
    },
    {
        "text": "serious toxicity may result if DB00514 is coadministered with ddrug1 { HD00546 } .",
        "label": "effect"
    },
    {
        "text": "ddrug0 { e , g , ddrug1 and DB13179 } : agents of the ddrug3 , of which ddrug4 { DB00320 } injection , usp is a member , have been shown to interact with ddrug6 of the ddrug7 , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .",
        "label": "NA"
    },
    {
        "text": "epidemiological studies of the case-control and cohort design that have demonstrated an association between use of HD00456 that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an HD00615 or ddrug2 potentiated the risk of bleeding .",
        "label": "effect"
    },
    {
        "text": "DB14500 supplements and ddrug1 benazepril can attenuate potassium loss caused by HD00029 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , or other products containing ddrug1 or ddrug2 , HD00374 or ddrug4 should not be administered concomitantly with , or within # hours of , the administration of DB01059 , because they may interfere with absorption resulting in lower serum and urine levels of ddrug6 .",
        "label": "advise"
    },
    {
        "text": "dose reduction of DB00224 to # mg every # hours is recommended when administering DB01167 concurrently .",
        "label": "advise"
    },
    {
        "text": "concomitant administration of DB00969 and DB00176 is contraindicated .",
        "label": "advise"
    },
    {
        "text": "DB00876 doses of up to # mg b , i , d , have been safely used concomitantly with sustained-release HD00377 { sustained-release ddrug2 } with no clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "DB01058 : in the fed state , ddrug1 { 40 mg/kg } increased mean maximum plasma concentration and area under the curve of ddrug2 by about 50 % in healthy subjects { n = 10 } compared with a separate group of subjects { n = 6 } given DB00518 alone .",
        "label": "NA"
    },
    {
        "text": "in particular , convulsions have been reported when DB00609 is administered with DB00260 and special care should be taken when the treatment regimen includes both of these drugs .",
        "label": "effect"
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a HD00533 , including DB00537 , with multivalent cation-containing products such as ddrug2 or ddrug3 ddrug4 , ddrug5 , ddrug6 chewable/buffered tablets or pediatric powder , or products containing ddrug7 , ddrug8 , or ddrug9 may substantially decrease the absorption of ddrug10 , resulting in serum and urine levels considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : drugs such as ddrug1 , DB09255 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 and others that interfere with platelet-aggregation reactions { the main hemostatic defense of heparinized patients } may induce bleeding and should be used with caution in patients receiving DB01109 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 - concomitant intake of DB00375 and ddrug2 may reduce the absorption of DB01022 .",
        "label": "NA"
    },
    {
        "text": "DB00679 : coadministration of single doses of DB00962 # mg and ddrug2 # mg produced additive effects on decreased alertness and impaired psychomotor performance for # to # hours after administration .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 , DB01118 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and ddrug7 raise the serum DB00390 concentration due to a reduction in clearance and/or in volume of distribution of the drug , with the implication that ddrug9 intoxication may result .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : hallucinations have been reported when DB00465 was used in patients taking ddrug2 { DB00472 , ddrug4 , ddrug5 } .",
        "label": "effect"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { DB00472 } sporal { ddrug12 } ddrug13 { DB01026 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "DB00294 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , DB00295 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "int"
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , ddrug3 , or ddrug4 , with ddrug5 , with metal cations such as DB01592 , or with DB00152 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "DB00668 also should be used cautiously with other drugs { e , g , , ddrug1 , HD00684 } that sensitize the myocardium to the actions of ddrug3 .",
        "label": "advise"
    },
    {
        "text": "compromised DB00368 uptake-1 in functional class iv can not be further increased by DB00907 and ddrug2 .",
        "label": "NA"
    },
    {
        "text": "inhibitors of cyp1a2 : concomitant use of DB00476 with DB00176 , an inhibitor of cyp1a2 , results in approximately a 6-fold increase in auc and about a # - fold increase in cmax of ddrug2 .",
        "label": "mechanism"
    },
    {
        "text": "serum concentration of DB00390 and DB01396 may increase when patients take ddrug2 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in patients with hypercholesterolemia , concomitant administration of DB00227 and ddrug2 resulted in no effect on DB00390 plasma concentrations .",
        "label": "NA"
    },
    {
        "text": "as with other ddrug0 , the antihypertensive effect of DB00678 may be blunted by the HD00860 ddrug3",
        "label": "NA"
    },
    {
        "text": "ddrug0 { cns } drugs including ddrug1 , HD00216 , ddrug3 , ddrug4 , blood pressure medications { ddrug5 , ddrug6 , ddrug7 } , motion sickness medications , ddrug8 , ddrug9 , ddrug10 , sleeping pills and HD00262",
        "label": "NA"
    },
    {
        "text": "pharmacokinetic evaluation of the DB00390 - DB01118 interaction .",
        "label": "NA"
    },
    {
        "text": "the concomitant use of other cyp3a4 inhibitors such as ddrug0 and DB00199 with transdermal DB00813 may also result in an increase in ddrug3 plasma concentrations , which could increase or prolong adverse drug effects and may cause serious respiratory depression .",
        "label": "mechanism"
    },
    {
        "text": "the effects of HD00018 were very strong and completely depressed the DB03575 - induced hyperlocomotion .",
        "label": "effect"
    },
    {
        "text": "caution should be used when administering or taking ddrug0 with DB01026 and other strong cyp3a4 inhibitors such as , but not limited to , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { ddrug12 } , and DB00582 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 or ddrug1 administered with DB06690 / ddrug3 to achieve # mac -lsb- minimum alveolar concentration -rsb- may prolong the clinically effective duration of action of initial and maintenance doses of ddrug4 and decrease the required infusion rate of DB00565 .",
        "label": "effect"
    },
    {
        "text": "other concomitant therapy although specific interaction studies were not performed , ddrug0 doses of # mg or more were concomitantly used in clinical studies with ddrug1 , ddrug2 , a-blockers , ddrug3 , ddrug4 , ddrug5 , ddrug6 , HD00378 , ddrug8 , cardiac ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 { also referred to as HD00203 } , and ddrug15 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "the optimal dose of DB00224 , when given in combination with DB00625 , is not known .",
        "label": "NA"
    },
    {
        "text": "when DB01118 is added to ddrug1 therapy , plasma ddrug2 levels may increase two-fold or more in some patients , if DB01195 dosage is not reduced .",
        "label": "NA"
    },
    {
        "text": "when used in therapeutic doses , DB00207 had a modest effect on the pharmacokinetics of ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { intravenous and oral } , DB00897 , ddrug13 / ddrug14 or ddrug15 .",
        "label": "mechanism"
    },
    {
        "text": "in vitro mixing of an HD00494 with beta-lactamtype ddrug1 { HD00124 or ddrug3 } may result in a significant mutual inactivation .",
        "label": "effect"
    },
    {
        "text": "caution is advised when DB01169 is coadministered with other medications that can prolong the qt interval { e , g , certain ddrug1 or DB00679 } or lead to electrolyte abnormalities { such as ddrug3 or ddrug4 } .",
        "label": "advise"
    },
    {
        "text": "the iv ddrug0 dose should be reduced by approximately 25 % , and the oral DB00959 dose should be reduced by approximately 50 % when coadministered with ddrug2 to achieve exposures of ddrug3 similar to those obtained when it is given without DB00673 .",
        "label": "NA"
    },
    {
        "text": "in a study involving healthy subjects receiving DB01195 and DB00571 concurrently , plasma ddrug2 levels were increased about 20 % and ddrug3 levels were increased about 30 % compared to control values .",
        "label": "mechanism"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect : ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , ddrug5 , DB01001 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 { e , g , , in oral HD00283 } .",
        "label": "NA"
    },
    {
        "text": "in vivo interaction studies in humans have demonstrated that ddrug0 and ddrug1 do not affect the pk properties of ddrug2 , nor does DB00261 affect the pk properties of ddrug4 or DB00682 .",
        "label": "NA"
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma ddrug0 concentrations include : acute DB02325 intake , ddrug2 , chboramphenicol , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , DB01159 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21",
        "label": "NA"
    },
    {
        "text": "HD00303 : DB01118 , ddrug2 , ddrug3 , ddrug4 , ddrug5 contraindicated due to potential for serious and/or life-threatening reactions .",
        "label": "NA"
    },
    {
        "text": "injection : ddrug0 injection , like other injectable HD00100 , produces depression of the central nervous system when administered with ddrug2 , HD00219 , ddrug4 , ddrug5 , and other ddrug6 , when ddrug7 is used concomitantly with injectable ddrug8 , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .",
        "label": "effect"
    },
    {
        "text": "DB00252 : in post-marketing experience , there have been reports of both increases and decreases in ddrug1 levels with DB01234 co-administration , leading to alterations in seizure control .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , DB00949 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { HD00531 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , HD00282 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , DB00295 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 / ddrug1 : the coadministration of ddrug2 or ddrug3 will not affect plasma concentrations of DB11094 , but may reduce endogenous plasma levels of DB00136 / ergocalcitriol by accelerating metabolism .",
        "label": "NA"
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit ddrug0 binding to serum proteins or alter the concentrations of serum binding proteins : ddrug1 and related ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 , DB00544 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , DB00675 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 / ddrug1 : long-term suppression of gastric acid secretion by HD00586 or ddrug3 { eg , ddrug4 and ddrug5 } is likely to reduce DB01254 exposure .",
        "label": "effect"
    },
    {
        "text": "ddrug0 / ddrug1 : the coadministration of DB00252 or DB01174 will not affect plasma concentrations of ddrug4 , but may reduce endogenous plasma levels of ddrug5 / ergocalcitriol by accelerating metabolism .",
        "label": "NA"
    },
    {
        "text": "DB01432 and ddrug1 administration of ddrug2 or DB09278 in patients { n = 13 } and volunteers { n = 96 } resulted in a rapid and significant decrease in plasma m1 { the active metabolite of ddrug4 } concentration .",
        "label": "NA"
    },
    {
        "text": "in study 1 , patients with colorectal cancer were given DB00762 / ddrug1 / ddrug2 { bolus-ifl } with or without DB00112 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : since ddrug1 is a ddrug2 , it is possible that ddrug3 , such as the HD00137 { ddrug5 , ddrug6 , ddrug7 } or DB01233 , may diminish the effectiveness of ddrug9 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 s : ddrug1 should be administered at least # hours after or # hours before dosing with ddrug2 because plasma concentrations of DB00537 are decreased when administered with HD00374 containing ddrug5 , ddrug6 , or ddrug7 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { e , g , DB00199 and ddrug2 } : agents of the ddrug3 , of which ddrug4 { DB00320 } injection , usp is a member , have been shown to interact with ddrug6 of the ddrug7 , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , DB01026 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , DB00224 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "HD00282 : ddrug1 DB01174 ddrug3",
        "label": "NA"
    },
    {
        "text": "the successive application of DB00145 { 5 or # mg/kg egg weight { e , w , } and HD00195 { 15 mg/kg e , w , } in a # min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of ddrug2 alone .",
        "label": "effect"
    },
    {
        "text": "use lowest possible dose of ddrug0 with careful monitoring , or consider HD00095 that are not primarily metabolized by cyp3a4 , such as ddrug2 , ddrug3 , or ddrug4 in combination with DB00224 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : combination ddrug1 may decrease the clearance of some HD00100 { ddrug3 , ddrug4 , ddrug5 } and increase the clearance of others { ddrug6 , ddrug7 , DB00231 } .",
        "label": "NA"
    },
    {
        "text": "the majority of patients in ra clinical studies received one or more of the following concomitant medications with DB01281 : ddrug1 , ddrug2 , ddrug3 , HD00204 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , and ddrug11 .",
        "label": "NA"
    },
    {
        "text": "the pharmacokinetic variables for DB00390 were determined after a # mg intravenous dose of ddrug1 in each subject , before and after oral DB01118 , # mg daily for # weeks .",
        "label": "NA"
    },
    {
        "text": "concurrent administration of ddrug0 and HD00657 may result in elevated serum levels of DB03585 .",
        "label": "NA"
    },
    {
        "text": "to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma { hiv-nhl } , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the DB00531 , ddrug1 , ddrug2 , and ddrug3 { chop } chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen { i , e , , ddrug4 , ddrug5 , DB00444 , and ddrug7 with ddrug8 plus ddrug9 } without receiving ddrug10 therapy .",
        "label": "NA"
    },
    {
        "text": "antiacid , ddrug0 , DB00900 , ddrug2 , ddrug3 , indanavir , ddrug4 , ddrug5 , phenobarbitol , ddrug6 , ddrug7 , DB01045 , ritanovir , ddrug9 .",
        "label": "NA"
    },
    {
        "text": "HD00405 such as HD00219 or ddrug2 ;",
        "label": "NA"
    },
    {
        "text": "if ddrug0 is to be combined with other ddrug1 such as HD00262 or ddrug3 / HD00214 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of ddrug5 and ddrug6 { e , g , , ddrug7 or ddrug8 } are additive .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - there is one report that DB00563 may decrease the possible effectiveness of supplemental DB00130 for chemotherapy-induced mucositis .",
        "label": "effect"
    },
    {
        "text": "DB00501 { 400 mg b , i , d , } had no effect on ddrug1 bioavailability { auc } and maximum concentration { cmax } of ddrug2 when co-administered with # mg DB00862 in healthy volunteers .",
        "label": "NA"
    },
    {
        "text": "an intravenous dose of # mg DB03138 was in respect of competitive suppression of organs actively concentrating ddrug1 as effective as intravenous # mg clo-4 - simultaneously or # mg orally # min before the injection of HD00125 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , DB00564 , and ddrug2 decrease the half-life of DB00254 .",
        "label": "mechanism"
    },
    {
        "text": "we report the case of an adolescent with altered consciousness caused by ddrug0 overdose with a positive ddrug1 level to alert clinicians to the cross-reactivity of DB00564 with a toxicology screen for HD00043 .",
        "label": "advise"
    },
    {
        "text": "DB14513 / ddrug1 - containing ddrug2 : absorption of ddrug3 is moderately reduced { approximately 25 % } when coadministered with ddrug4 / DB01370 - containing ddrug6 .",
        "label": "NA"
    },
    {
        "text": "multiple-dose administration of the potent cyp3a4 inducer DB01045 { 600 mg every # hours , q24h , for # days } , however , reduced DB00962 cmax and auc by approximately 80 % .",
        "label": "mechanism"
    },
    {
        "text": "HD00374 containing ddrug1 , when administered concomitantly with DB00698 , reduce both the rate and extent of absorption .",
        "label": "NA"
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma DB00252 concentrations include : acute ddrug1 intake , ddrug2 , chboramphenicol , ddrug3 , DB00501 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21",
        "label": "mechanism"
    },
    {
        "text": "intraventricular injection of ddrug0 at doses of # to # micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular HD00144 and DB00295 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - in subjects who had received # days of # mg/day racemic ddrug1 , combined administration of # mg/day DB00501 for # days resulted in an increase in DB00215 auc and cmax of 43 % and 39 % , respectively .",
        "label": "NA"
    },
    {
        "text": "DB11716 protects mouse tumour and normal tissues from the toxicity of oral HD00152 .",
        "label": "effect"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : ddrug1 ; ddrug2 ; ddrug3 ; certain HD00002 , especially the ddrug5 and ddrug6 ; DB14507 ; ddrug8 salts ; ddrug9 ; and ddrug10 .",
        "label": "NA"
    },
    {
        "text": "however , in a study of # normal subjects , concurrent administration of DB00945 decreased ddrug1 protein binding and increased DB01009 plasma clearance from # l/kg/h without ddrug3 to # l/kg/h with ddrug4 .",
        "label": "mechanism"
    },
    {
        "text": "the inhibition of cyp-2c19 by HD00889 and HD00888 , however , is clinically relevant .",
        "label": "NA"
    },
    {
        "text": "DB00501 , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , certain ddrug7 , ddrug8 , ddrug9 and DB00916 , thereby delaying elimination and increasing blood levels of these drugs .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { DB00091 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , DB00295 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "there have been inconsistent reports regarding the effects of other drugs { e , g , , DB00468 , ddrug1 } on serum DB00390 concentration .",
        "label": "NA"
    },
    {
        "text": "concurrent administration of ddrug0 and ddrug1 may cause severe orthostatic hypotension , DB00501 , an inhibitor of microsomal drug metabolism , increased DB00488 s half-life and toxicity in a rat model .",
        "label": "mechanism"
    },
    {
        "text": "HD00780 may augment the hypotension caused by the ganglionic-blocking effect of DB01199 .",
        "label": "effect"
    },
    {
        "text": "when DB01092 was applied to the muscle in the presence of DB00692 , both first and second contractile responses to ddrug2 were abolished .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : DB00672 s plasma half-life may be prolonged by DB00437 , since ddrug3 and ddrug4 may compete for excretion in the renal tubule .",
        "label": "mechanism"
    },
    {
        "text": "in this study we investigated the effect of DB14152 on high threshold voltage-dependent ca { 2 + } channel subtypes using their ddrug1 ddrug2 { l-type } , HD00047 { n-type } , or ddrug4 { p-type } in bovine chromaffin cells .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , DB01026 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , DB01045 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { DB00091 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , DB00231 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "DB00908 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and ddrug7 raise the serum ddrug8 concentration due to a reduction in clearance and/or in volume of distribution of the drug , with the implication that HD00118 intoxication may result .",
        "label": "NA"
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the ddrug0 of drugs may be potentiated by ddrug1 , ddrug2 , ddrug3 , HD00556 , ddrug5 , the ddrug6 , HD00559 and ddrug8 , ddrug9 and the ddrug10 , and by other ddrug11 .",
        "label": "NA"
    },
    {
        "text": "exposed histidines on ddrug0 are available for DB01593 chelation , and these have been exploited in the development of a novel purification protocol for HD00011 using ddrug3 - chelating chromatography .",
        "label": "NA"
    },
    {
        "text": "the availability of potent ddrug0 { ddrug1 } - based regimens for HD00056 therapy and concerns regarding HD00058 { ddrug4 } - related metabolic disturbances have led to significant shifts in treatment practices in hiv infection .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { HD00475 } blood levels may be increased and prolonged by concurrent administration of DB01032 .",
        "label": "mechanism"
    },
    {
        "text": "the intensity , uniformity and time course of HD00025 interference by ddrug1 , ddrug2 , DB01437 , ddrug4 and ddrug5 were systematically investigated in # patients receiving ddrug6 therapy .",
        "label": "NA"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of DB00732 include : ddrug1 ; ddrug2 ; ddrug3 ; certain ddrug4 , especially the ddrug5 and HD00384 ; ddrug7 ; ddrug8 salts ; ddrug9 ; and ddrug10 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 , DB00316 and ddrug2 may enhance the effects of : other ddrug3 s , ddrug4 , general ddrug5 , ddrug6 such as ddrug7 , HD00460 , or other ddrug9 , causing increased cns depression .",
        "label": "effect"
    },
    {
        "text": "although ddrug0 has a lower affinity for ddrug1 than for ddrug2 , ddrug3 should not be taken with DB01370 - containing HD00589 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 has a tendency to antagonize the skeletal muscle relaxing effect of DB01199 and may potentiate the action of DB00202 .",
        "label": "NA"
    },
    {
        "text": "DB01167 DB01026 ddrug2 ddrug3 ddrug4 ddrug5 ddrug6 ddrug7 large quantities of grapefruit juice { # quart daily }",
        "label": "NA"
    },
    {
        "text": "drug interactions : the central HD00315 syndrome can occur when anticholinergic agents such as DB00810 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain ddrug2 such as ddrug3 , the ddrug4 and other ddrug5 , ddrug6 , certain ddrug7 such as the ddrug8 salts , and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with DB00316 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , DB02362 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "this effect may be mediated by the known inhibition of hepatic cytochrome p - # by DB00501 , which could decrease first pass metabolism of DB00393 .",
        "label": "NA"
    },
    {
        "text": "potential drug interactions between ddrug0 and other ddrug1 { DB00564 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 and ddrug8 } were also assessed by evaluating the serum concentrations of DB01202 and these ddrug10 during placebo-controlled clinical studies .",
        "label": "NA"
    },
    {
        "text": "DB00343 plasma levels were not significantly affected by ddrug1 or DB00175 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the effect of DB00701 on total drug concentrations of other HD00324 in subjects receiving both agents was evaluated using comparisons to historical data .",
        "label": "NA"
    },
    {
        "text": "nephrotoxicity has been reported following concomitant administration of HD00485 with ddrug1 or potent HD00218 such as ddrug3 .",
        "label": "effect"
    },
    {
        "text": "DB00945 : in normal volunteers , a small decrease in DB00861 levels was observed when multiple doses of ddrug2 and ddrug3 were administered concomitantly .",
        "label": "NA"
    },
    {
        "text": "DB00612 should be used with care when ddrug1 or inhibitors of av conduction , such as certain ddrug2 { particularly of the ddrug3 -lsb- ddrug4 -rsb- and ddrug5 -lsb- ddrug6 -rsb- classes } , or ddrug7 , such as DB00280 , are used concurrently .",
        "label": "advise"
    },
    {
        "text": "ddrug0 or ddrug1 administered with DB06690 / ddrug3 to achieve # mac -lsb- minimum alveolar concentration -rsb- may prolong the clinically effective duration of action of initial and maintenance doses of DB00565 and decrease the required infusion rate of ddrug5 .",
        "label": "effect"
    },
    {
        "text": "the in vitro anti-cryptosporidial activity of HD00063 alone and in combination with DB00207 and ddrug2 was investigated .",
        "label": "NA"
    },
    {
        "text": "ddrug0 inhibits the ermbt , and DB01045 and DB00615 are equipotent inducers of the ermbt .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : a literature article reported that when a 60-mg controlled-release DB00295 capsule was administered # hours prior to a 600-mg ddrug2 capsule { n = 12 } , mean DB00996 auc increased by 44 % compared to ddrug4 administered without ddrug5 .",
        "label": "NA"
    },
    {
        "text": "conclusions : ddrug0 inhibit the metabolism of HD00095 that are metabolized by cyp3a4 { i , e , , ddrug2 , DB00439 , ddrug4 , ddrug5 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00477 blocks dopamine and norepinephrine receptors , thus inhibiting the central stimulant effects of ddrug2 and can be used to treat DB00182 poisoning .",
        "label": "NA"
    },
    {
        "text": "garlic capsules garlic capsules should not be used while taking ddrug0 { DB01232 } as the sole HD00058 due to the risk of decreased ddrug3 plasma concentrations .",
        "label": "NA"
    },
    {
        "text": "while all the selective HD00311 { ddrug1 } , e , g , , ddrug2 , ddrug3 , and DB00715 , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .",
        "label": "NA"
    },
    {
        "text": "medications can interfere with folate utilization , including : ddrug0 { such as ddrug1 , and ddrug2 } DB00331 { sometimes prescribed to control blood sugar in type # diabetes } DB00795 { used to control inflammation associated with crohn_disease and ulcerative colitis } ddrug5 { a ddrug6 } ddrug7 there has been concern about the interaction between ddrug8 and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "pregnancy ddrug0 and HD00183 - containing oral HD00283 increase tbg concentrations .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of DB01155 with DB01032 resulted in a 45 % increase in systemic exposure to ddrug2 .",
        "label": "mechanism"
    },
    {
        "text": "medications can interfere with folate utilization , including : ddrug0 { such as ddrug1 , and ddrug2 } ddrug3 { sometimes prescribed to control blood sugar in type # diabetes } DB00795 { used to control inflammation associated with crohn_disease and ulcerative colitis } ddrug5 { a ddrug6 } DB00563 there has been concern about the interaction between ddrug8 and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on ddrug0 therapy : HD00657 , ddrug2 , ddrug3 , oral HD00283 containing ddrug5 , ddrug6 - containing preparations and the numerous preparations containing ddrug7 .",
        "label": "NA"
    },
    {
        "text": "DB00945 did not alter the clearance { pharmacokinetics } of DB01088 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 works differently from the ddrug1 currently available , and except for increased lipid levels , the adverse reaction profile of DB00877 does not appear to overlap to any great extent with that associated with ddrug3 or DB00864 .",
        "label": "NA"
    },
    {
        "text": "accordingly , when DB00861 is administered with oral HD00326 , the prothrombin time should be closely monitored during and for several days after concomitant drug administration .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : since ddrug1 is a ddrug2 , it is possible that ddrug3 , such as the ddrug4 { ddrug5 , ddrug6 , ddrug7 } or DB01233 , may diminish the effectiveness of DB00714 .",
        "label": "effect"
    },
    {
        "text": "DB00622 usually does not alter the plasma levels of ddrug1 , however , serum DB00390 levels should be evaluated after concomitant therapy with ddrug3 is initiated .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , DB00446 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , DB01035 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "DB06761 also increased rate of dissolution , in a manner similar to DB00815 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : a study in normal healthy volunteers has shown that concomitant administration of ddrug1 { DB00270 } and DB00999 does not result in altered pharmacoktnetics of either drug .",
        "label": "NA"
    },
    {
        "text": "DB00261 demonstrates some limited inhibitory activity towards cyp1a2 which may present a theoretical potential for interaction with other coadministered medicinal products sharing that clearance mechanism e , g , DB00277 .",
        "label": "mechanism"
    },
    {
        "text": "the effectiveness of ddrug0 - only pills is reduced by hepatic enzyme-inducing drugs such as the HD00282 ddrug2 , ddrug3 , and ddrug4 , and the ddrug5 DB01045 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the concomitant use of ddrug1 { ddrug2 transdermal system } with other HD00389 , including but not limited to other HD00263 , ddrug5 , ddrug6 , ddrug7 { e , g , , ddrug8 } , general ddrug9 , ddrug10 , ddrug11 , and ddrug12 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .",
        "label": "NA"
    },
    {
        "text": "when used concurrently with such drugs , the dose of DB00611 should be the smallest effective dose and the frequency of dosing reduced as much as possible when administered concomitantly with drugs that potentiate the action of HD00263 .",
        "label": "NA"
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a ddrug0 , including ddrug1 , with multivalent cation-containing products such as ddrug2 or ddrug3 ddrug4 , ddrug5 , DB00900 chewable/buffered tablets or pediatric powder , or products containing DB01373 , ddrug8 , or ddrug9 may substantially decrease the absorption of ddrug10 , resulting in serum and urine levels considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "in a placebo-controlled trial in normal volunteers , the administration of a single # mg dose of ddrug0 on day # of a four-day regimen of oral DB00501 { 400 mg twice daily } resulted in a 10 % increase in mean auc of ddrug2 { p = # } , and a slight but not statistically significant increase in mean cmax and mean half-life of DB00590 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB01050 produced an elevation of plasma ddrug2 levels and a reduction in renal DB14507 clearance in a study of eleven normal volunteers .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the effect of an ddrug1 - and DB09104 - containing DB06724 { ddrug4 } * on the pharmacokinetics of ddrug5 was investigated in # cancer patients .",
        "label": "NA"
    },
    {
        "text": "ddrug0 / ddrug1 : the coadministration of DB00252 or DB01174 will not affect plasma concentrations of ddrug4 , but may reduce endogenous plasma levels of ddrug5 / ergocalcitriol by accelerating metabolism .",
        "label": "NA"
    },
    {
        "text": "although the specific drug interaction was not studied in a clinical trial , there have been more than # episodes of concomitant use of antifibrinolytic therapies { i , e , , DB00302 , ddrug1 } and DB00036 .",
        "label": "NA"
    },
    {
        "text": "the concomitant administration of DB01045 and ddrug1 resulted in the need for an unusually high maintenance dose of DB00682 { 20 mg per day } in order to produce a therapeutic effect .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 : in one study , DB00712 was given to adult diabetics who were already receiving ddrug2 { n = 4 } , ddrug3 { n = 2 } ddrug4 with ddrug5 { n = 3 } or DB01016 with ddrug7 { n = 6 } .",
        "label": "NA"
    },
    {
        "text": "may interact HD00326 { altered hypo-prothrombinemic effect } , ddrug1 , ddrug2 and other inducers of hepatic microsomal enzyme oxidation system { decreased effect of DB00255 } , ddrug4 { increased effect of ddrug5 } .",
        "label": "NA"
    },
    {
        "text": "in seven experiments reactions to ddrug0 and DB00107 were HD00041 .",
        "label": "NA"
    },
    {
        "text": "exaggerated hypertensive responses have been reported from the combined use of HD00230 and HD00231 , including those contained in proprietary cold remedies and vasoconstrictive nasal drops .",
        "label": "effect"
    },
    {
        "text": "although trough DB00215 plasma levels were unaffected , given the enzyme-inducing properties of DB00564 , the possibility that ddrug2 might increase the clearance of ddrug3 should be considered if the two drugs are coadministered .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : based on reports of profound hypotension and loss of consciousness when ddrug1 was administered with DB00904 , the concomitant use of ddrug3 with drugs of the HD00335 { including , for example , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 } is contraindicated .",
        "label": "NA"
    },
    {
        "text": "-lsb- the effect of ddrug0 on the renal excretion of ddrug1 and ddrug2 in dogs -rsb- the intravenous injection of DB00501 in a dose of # mg/kg enhanced HD00191 and ddrug5 excretion in chronic canine experiments .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 injection should not be mixed with ddrug1 , ddrug2 , ddrug3 , or DB01204 , since it has been reported that these drugs are incompatible with DB01109 and a precipitate may form .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : co - administration of ddrug1 and DB00439 to healthy volunteers did not result in any changes in prothrombin time or clotting factor vii when compared to co-administration of DB00682 and placebo .",
        "label": "NA"
    },
    {
        "text": "no depressant effect on blood levels in humans was noted when DB00375 was administered with any of the following drugs : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 { ddrug6 } , ddrug7 , DB00252 or ddrug9 .",
        "label": "NA"
    },
    {
        "text": "however , due to possible pharmacodynamic interactions , when co-administered with ddrug0 , a reduction in dosage of ddrug1 on the concomitant ddrug2 , ddrug3 , HD00604 or HD00023 may be required .",
        "label": "NA"
    },
    {
        "text": "ddrug0 HD00524 may delay or reduce the absorption of concomitant oral medication such as DB00812 , ddrug3 , ddrug4 { acidic } or ddrug5 { basic } , as well as ddrug6 ddrug7 , ddrug8 , thyroid and ddrug9 preparations , ddrug10 and ddrug11 , and ddrug12 .",
        "label": "NA"
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the HD00555 of drugs may be potentiated by ddrug1 , ddrug2 , HD00026 , ddrug4 , ddrug5 , the ddrug6 , ddrug7 and ddrug8 , ddrug9 and the ddrug10 , and by other ddrug11 .",
        "label": "effect"
    },
    {
        "text": "animal experience indicates that ddrug0 prolongs the sleeping time after DB01355 or after ddrug2 , increases the inhibitory effects of DB00477 , but does not exhibit maoa inhibition .",
        "label": "NA"
    },
    {
        "text": "data from in vitro studies of HD00100 other than ddrug1 suggest a possible drug interaction for the following : ddrug2 , DB00091 , ddrug4 , ddrug5 , and ddrug6 .",
        "label": "int"
    },
    {
        "text": "HD00264 / ddrug1 / ddrug2 / ddrug3 : co-administration of DB00633 with ddrug5 , ddrug6 , ddrug7 , and ddrug8 is likely to lead to an enhancement of effects .",
        "label": "NA"
    },
    {
        "text": "drug interactions with ddrug0 administration of # mg of ddrug1 { 2 x # mg capsule } within # minutes of an ddrug2 and DB14513 containing ddrug4 { ddrug5 } decreased DB00950 auc by 41 % and cmax by 43 % .",
        "label": "NA"
    },
    {
        "text": "DB00825 / HD00655 { e , g , , ddrug2 , ddrug3 , ddrug4 and ddrug5 combinations , ddrug6 , ddrug7 } .",
        "label": "NA"
    },
    {
        "text": "concomitant medications were grouped as ddrug0 , oral ddrug1 , ddrug2 , ddrug3 , HD00345 , inducers of cyp3a4 , substrates and inhibitors of cyp3a4 , substrates and inhibitors of p-glycoprotein , DB14049 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , substrates and inhibitors of tubular organic cation transport , and qtc-prolonging drugs .",
        "label": "NA"
    },
    {
        "text": "however , due to possible pharmacodynamic interactions , when co-administered with ddrug0 , a reduction in dosage of ddrug1 on the concomitant DB01086 , HD00596 , ddrug4 or ddrug5 may be required .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { ddrug1 , DB00949 , ddrug3 , ddrug4 , ddrug5 } : increase the metabolism of DB00977 and/or some ddrug7 , leading to possible decrease in contraceptive effectiveness .",
        "label": "mechanism"
    },
    {
        "text": "the potential for drug interactions with DB00879 has been studied in combination with ddrug1 , ddrug2 , DB00426 , and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and other HD00434 : co-administration of ddrug2 decreased the plasma concentrations of DB00641 { a cyp3a4 substrate } , and its active - hydroxy acid metabolite , by approximately 50 % .",
        "label": "NA"
    },
    {
        "text": "although the interaction between ddrug0 and other potent cyp3a4 inhibitors { e , g , , DB01167 , ddrug2 , and ddrug3 } has not been studied , increased exposures to DB00918 may be expected when ddrug5 is used concomitantly with these medications .",
        "label": "NA"
    },
    {
        "text": "the daily dose of DB00496 should not exceed # mg when coadministered with potent cyp3a4 inhibitors { e , g , , ddrug1 , ddrug2 , ddrug3 , DB00220 , ddrug5 and nefazadone } .",
        "label": "advise"
    },
    {
        "text": "DB00185 should be administered with caution to patients taking HD00507 , because of the possibility of conduction disturbances .",
        "label": "advise"
    },
    {
        "text": "when concomitant administration of DB01026 with ddrug1 occurs , DB01238 dose should be reduced to one-half of its normal dose .",
        "label": "NA"
    },
    {
        "text": "concurrent use of DB00759 may render oral HD00283 less effective .",
        "label": "effect"
    },
    {
        "text": "DB00798 did not interfere with the activity of DB01190 within the range of concentrations tested { # to # mug/ml } ;",
        "label": "NA"
    },
    {
        "text": "the urinary excretion of DB00939 is unaffected by DB00945 , indicating no change in ddrug2 absorption .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : DB00316 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , HD00668 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "other drugs : based on the results of drug interaction studies , no dosage adjustment is recommended when DB00625 { ddrug1 } is given with the following : ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , DB00715 , and ddrug11 .",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with HD00374 containing ddrug2 , ddrug3 , or ddrug4 , with DB00364 , with metal cations such as ddrug6 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "at 75 % recovery of fade , hoof twitch was # + / - 3 % for ddrug0 alone and # + / - 4 % for DB13295 plus HD00198 .",
        "label": "effect"
    },
    {
        "text": "the iv DB00959 dose should be reduced by approximately 25 % , and the oral ddrug1 dose should be reduced by approximately 50 % when coadministered with DB00673 to achieve exposures of ddrug3 similar to those obtained when it is given without ddrug4 .",
        "label": "advise"
    },
    {
        "text": "drugs which inhibit cyp 3a4 { e , g , , ddrug0 , HD00093 such as ddrug2 } have the potential to result in increased plasma concentrations of HD00175 .",
        "label": "mechanism"
    },
    {
        "text": "therefore , cyp3a4 substrates known to have a narrow therapeutic index such as ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , DB00908 , ddrug8 , ddrug9 , or ddrug10 { ddrug11 , ddrug12 } should be administered with caution in patients receiving DB01254 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 and ddrug1 { congestive heart failure post-myocardial infarction } - in ephesus , # { 91 % } patients receiving ddrug2 # to # mg also received HD00106 or HD00466 { ddrug5 / ddrug6 } .",
        "label": "NA"
    },
    {
        "text": "these drugs include the HD00217 and other ddrug1 , HD00175 , phe-nothiazines , ddrug3 , ddrug4 , oral ddrug5 , ddrug6 , ddrug7 , sympathomimet-ics , ddrug8 , and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "although the interactions observed in these studies do not appear to be of major clinical importance , DB00187 should be titrated with caution in patients being treated concurrently with ddrug1 , ddrug2 , DB00202 or ddrug4 .",
        "label": "advise"
    },
    {
        "text": "therefore , when DB00594 and HD00294 are used concomitantly , the patient should be observed closely to determine if the desired effect of the ddrug2 is obtained .",
        "label": "advise"
    },
    {
        "text": "both the toxicity of ddrug0 and the therapeutic value of DB00681 can be rationalized at the cellular and molecular level by the following observations : { i } these HD00122 showed differential effects on cells ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 / HD00024 / ddrug2 / ddrug3 : co-administration of DB00633 with ddrug5 , ddrug6 , ddrug7 , and ddrug8 is likely to lead to an enhancement of effects .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - administration of # mg/day ddrug1 for # days in healthy volunteers resulted in a 50 % increase in cmax and 82 % increase in auc of the HD00693 DB00264 { given in a single dose of # mg } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 # mg administered daily for # days did not affect the pharmacokinetics of DB08496 or DB14055 nor were there any changes in the pharmacodynamic profile { prothrombin time } following a single # mg oral dose of ddrug4",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 : HD00374 and ddrug3 can reduce absorption of DB00608 ;",
        "label": "mechanism"
    },
    {
        "text": "immediate and extended release tablets the hypoglycemic action of HD00222 may be potentiated by certain drugs including ddrug1 , some ddrug2 and other drugs that are highly protein bound , ddrug3 , ddrug4 , ddrug5 , ddrug6 , HD00519 , ddrug8 , and ddrug9 .",
        "label": "effect"
    },
    {
        "text": "in in vivo studies , 10 - to 30-mg/day doses of ddrug0 had no significant effect on metabolism by cyp2d6 { ddrug1 } , cyp2c9 { ddrug2 } , cyp2c19 { ddrug3 , DB00682 } , and cyp3a4 { DB00514 } substrates .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { ddrug1 } : population pharmacokinetic analyses indicate that DB00906 clearance is 60 % greater in patients taking DB01174 { ddrug4 } with or without other enzyme-inducing ddrug5 .",
        "label": "mechanism"
    },
    {
        "text": "toxicology studies of ddrug0 - related deaths reveal frequent involvement of other ddrug1 , including ddrug2 , HD00100 such as ddrug4 { ddrug5 } , and , to a rising degree , DB00333 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , DB01076 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { DB00701 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , DB01076 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , DB00295 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may enhance the effects of ddrug1 , ddrug2 , DB02325 , and other HD00261 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : plasma concentrations of ddrug1 decreased approximately 25 % when DB00375 and DB01076 were coadministered .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : since the excretion of ddrug1 is similar to that of urate , HD00272 , which increase the excretion of urate , are also likely to increase the excretion of DB05262 and thus lower the degree of inhibition of xanthine oxidase .",
        "label": "mechanism"
    },
    {
        "text": "pharmacokinetic studies have demonstrated that DB00338 and DB00199 significantly increased the systemic exposure of ddrug2 and/or its major metabolites .",
        "label": "NA"
    },
    {
        "text": "ddrug0 can interact with ddrug1 or other ddrug2 { may potentiate the cns depressant effects of either these medications or HD00388 } , HD00444 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug5 } , and ddrug6 { concurrent use with ddrug7 may prolong and intensify the anticholinergic and cns depressant effects of ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , DB01167 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { HD00531 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ventricular tachycardia induced by DB01092 was generally converted to sinus rhythm following administration of ddrug1 , DB01221 , or ddrug3 but not after administration of ddrug4 alone or after ddrug5 .",
        "label": "effect"
    },
    {
        "text": "in general , most patients treated with DB00954 who are receiving concomitant ddrug1 therapy may not require empiric adjustment of DB00277 dosage or monitoring of ddrug3 plasma concentrations .",
        "label": "NA"
    },
    {
        "text": "clinical studies with DB00482 have identified potentially significant interactions with ddrug1 and DB14507 .",
        "label": "int"
    },
    {
        "text": "because changes in glucose concentrations with ddrug0 coadministration were within the normal variability and individual glucose concentrations were above or near # mg/dl , dose adjustment for DB01016 { 5 mg qd and # mg bid } with DB00580 coadministration { up to # mg qd } is not indicated .",
        "label": "advise"
    },
    {
        "text": "HD00795 , ddrug1 , and ddrug2 : drugs such as ddrug3 , ddrug4 , and ddrug5 may increase the risk of developing peripheral_neuropathies or other DB00943 - associated adverse events by interfering with the renal clearance of ddrug7 { thereby raising systemic exposure } .",
        "label": "NA"
    },
    {
        "text": "however , the antagonism of the ddrug0 - induced anxiogenic effects by HD00187 was only observed in the time spent in the light zone , and ddrug2 - induced anxiogenic effects were neither reversed by HD00184 nor by ddrug4 .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { DB00472 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 HD00542 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "results of studies in multiple sclerosis patients taking ddrug0 and concomitant DB00060 { ddrug2 # mcg i m once weekly } or ddrug3 were inconclusive with regard to the need for dose adjustment of the HD00868 or ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { ddrug1 } : population pharmacokinetic analyses indicate that ddrug2 clearance is 60 % greater in patients taking DB01174 { ddrug4 } with or without other enzyme-inducing HD00714 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { e , g , , DB09278 } and ddrug2 containing carbohydrate-splitting enzymes { e , g , , ddrug3 , ddrug4 } may reduce the effect of DB00284 and should not be taken concomitantly .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 , DB00176 , ddrug2 { consider DB00404 dose reduction } .",
        "label": "advise"
    },
    {
        "text": "DB00813 anesthesia : severe hypotension has been reported during ddrug1 anesthesia with concomitant use of a HD00379 and a ddrug3 .",
        "label": "NA"
    },
    {
        "text": "phase ii clinical trial data , where DB00317 and ddrug1 have been used concomitantly , indicate that ddrug2 may exacerbate the neutropenic effect of DB00361 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 ddrug1 may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation , the discontinuance of DB01432 ddrug3 could pose a hazard to health if a potentially toxic drug such as HD00118 has been filtrated to a maintenance level while the patient was taking ddrug5 ddrug6 .",
        "label": "mechanism"
    },
    {
        "text": "co-administration of ddrug0 , a strong inhibitor of cyp3a4 , increased DB01012 exposure following a single # mg dose of DB01012 by # fold .",
        "label": "NA"
    },
    {
        "text": "interactions with ddrug0 : ddrug1 { eg , DB00652 , ddrug3 , ddrug4 , ddrug5 and ddrug6 } should not be administered to a patient who has received or is receiving a course of therapy with a HD00843 such as ddrug8 .",
        "label": "NA"
    },
    {
        "text": "co-administration of DB00042 and ddrug1 or other agents interfering with neuromuscular transmission { e , g , , ddrug2 } should only be performed with caution as the effect of the HD00437 may be potentiated .",
        "label": "NA"
    },
    {
        "text": "the iv ddrug0 dose should be reduced by approximately 25 % , and the oral ddrug1 dose should be reduced by approximately 50 % when coadministered with DB00673 to achieve exposures of DB00959 similar to those obtained when it is given without ddrug4 .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of DB00861 and ddrug1 in dogs , but not in rats , at approximately # times the recommended maximum human therapeutic dose of each { 40 to # mg/kg/day of ddrug2 / DB00316 } resulted in greater gastrointestinal toxicity than when either drug was administered alone .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of ddrug0 : ddrug1 , ddrug2 , ddrug3 , HD00571 { e , g , , ddrug5 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 { e , g , , in oral HD00283 } .",
        "label": "NA"
    },
    {
        "text": "in vitro displacement studies with highly protein-bound drugs such as ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , DB01016 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 showed no influence on the extent of DB00731 protein binding .",
        "label": "NA"
    },
    {
        "text": "DB00977 and ddrug1 : coadministration of DB00220 with ddrug3 resulted in a 47 % decrease in ddrug4 and an 18 % decrease in ddrug5 plasma concentrations .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of ddrug0 with the oral HD00025 ddrug2 has been shown not to potentiate the anticoagulant effect of DB00682 .",
        "label": "NA"
    },
    {
        "text": "DB00241 , ddrug1 and ddrug2 may enhance the effects of : other ddrug3 s , ddrug4 , general ddrug5 , ddrug6 such as DB00475 , ddrug8 , or other ddrug9 , causing increased cns depression .",
        "label": "effect"
    },
    {
        "text": "fulminant rhabdomyolysis has been seen as early as three weeks after initiation of combined therapy with another HD00549 and DB00227 but may be seen after several months .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : plasma concentrations of DB01076 decreased approximately 25 % when DB00375 and ddrug3 were coadministered .",
        "label": "NA"
    },
    {
        "text": "also , concomitant administration of ddrug0 with products containing ddrug1 , ddrug2 containing DB01593 , or ddrug4 { DB00900 } chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels .",
        "label": "NA"
    },
    {
        "text": "however , in patients treated with oral HD00442 , rare instances of drug interactions have occurred with high-dose HD00372 therapy .",
        "label": "int"
    },
    {
        "text": "ddrug0 : the concomitant use of DB00813 { ddrug2 transdermal system } with other ddrug3 , including but not limited to other ddrug4 , ddrug5 , ddrug6 , HD00262 { e , g , , ddrug8 } , general ddrug9 , ddrug10 , ddrug11 , and ddrug12 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .",
        "label": "effect"
    },
    {
        "text": "ddrug0 or ddrug1 : when ddrug2 is administered immediately following HD00374 or ddrug4 , the absorption of DB00954 is slightly enhanced .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 , and HD00249 : drugs such as ddrug3 , ddrug4 , and ddrug5 may increase the risk of developing peripheral_neuropathies or other DB00943 - associated adverse events by interfering with the renal clearance of ddrug7 { thereby raising systemic exposure } .",
        "label": "NA"
    },
    {
        "text": "certain drugs including ddrug0 , ddrug1 , HD00221 , and ddrug3 may reduce the hypoglycemic action of DB00731 and other oral ddrug5 .",
        "label": "effect"
    },
    {
        "text": "since ddrug0 HD00524 may bind other drugs given concurrently , it is recommended that patients take other drugs at least # hour before or # to # hours after DB01432 ddrug3 { or at as rxfp2 an interval as possible } to avoid impeding their absorption .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , HD00282 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , DB00860 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the HD00555 of drugs may be potentiated by ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , the HD00558 , ddrug7 and ddrug8 , ddrug9 and the ddrug10 , and by other ddrug11 .",
        "label": "effect"
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the HD00555 of drugs may be potentiated by DB02325 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , the ddrug6 , ddrug7 and ddrug8 , ddrug9 and the ddrug10 , and by other ddrug11 .",
        "label": "effect"
    },
    {
        "text": "HD00596 / ddrug1 : DB00683 , ddrug3",
        "label": "NA"
    },
    {
        "text": "other drugs drug interactions have been reported with concomitant administration of DB00199 and other medications , including ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB00252 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 .",
        "label": "int"
    },
    {
        "text": "administration of ddrug0 to patients receiving ddrug1 or HD00683 such as DB01159 which sensitize the myocardium , may induce cardiac arrhythmia , .",
        "label": "NA"
    },
    {
        "text": "in vitro , DB00490 may displace less firmly bound drugs like DB00390 .",
        "label": "mechanism"
    },
    {
        "text": "DB01026 : coadministration of ddrug1 { 200 mg/day for # days } with a 15-mg single dose of ddrug2 increased the auc of DB01238 and its active metabolite by 63 % and 77 % , respectively .",
        "label": "NA"
    },
    {
        "text": "HD00303 : ddrug1 , ddrug2 , ddrug3 , ddrug4 , DB00908 contraindicated due to potential for serious and/or life-threatening reactions .",
        "label": "NA"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , ddrug3 ddrug4 : ddrug5 , DB00342 antimigraine : HD00870 ddrug8 : ddrug9 ddrug10 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "in a multiple dose study of DB00277 { 400 mg once daily for # days } and DB00341 { 20 mg once daily for # days } , a 16 % decrease in the clearance of ddrug2 was observed .",
        "label": "mechanism"
    },
    {
        "text": "however , in the second study , administration of # g DB01432 # hour before the evening meal and # mg ddrug1 approximately # hours after the same evening meal resulted in a decrease in the DB00439 auc of less than 8 % , and a decrease in cmax of about 30 % when compared to dosing ddrug3 alone .",
        "label": "NA"
    },
    {
        "text": "if a patient requires ddrug0 and ddrug1 therapy , it is suggested that ddrug2 , ddrug3 , or ddrug4 { ddrug5 and DB09104 } be used as alternatives to DB00501 , as these agents have no effect on the pharmacokinetic profile of ddrug8 .",
        "label": "NA"
    },
    {
        "text": "hypotension was more likely to occur if the ddrug0 were a HD00412 , e , g , , DB01115 , while left ventricular failure and av conduction disturbances , including complete heart block , were more likely to occur with either ddrug3 or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "other HD00804 { including ddrug1 } used in combination with DB00026 may also result in similar toxicities .",
        "label": "effect"
    },
    {
        "text": "ddrug0 therapy : urinary excretion of HD00401 is increased , and efficacy is reduced , by ddrug2 used in DB06799 therapy .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , DB00295 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , DB00231 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "injection : ddrug0 injection , like other injectable ddrug1 , produces depression of the central nervous system when administered with ddrug2 , HD00219 , ddrug4 , ddrug5 , and other ddrug6 , when DB00747 is used concomitantly with injectable ddrug8 , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .",
        "label": "NA"
    },
    {
        "text": "although the clinical significance of these effects is not known , caution is advised in the co-administration of HD00358 with HD00357 .",
        "label": "advise"
    },
    {
        "text": "therefore , when DB00774 and ddrug1 are used concomitantly , the patient should be observed closely to determine if the desired effect of the HD00295 is obtained .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB14513 - containing preparations { eg , HD00374 } may cause hypermagnesemia and should therefore not be taken during therapy with ddrug3 by patients on chronic renal dialysis .",
        "label": "NA"
    },
    {
        "text": "the concomitant use of DB00328 with other HD00203 is not recommended due to the increased possibility of gastrointestinal toxicity , with little or no increase in efficacy .",
        "label": "advise"
    },
    {
        "text": "the following agents may increase certain actions or side effects of ddrug0 , ddrug1 ddrug2 of class { e , g , ddrug3 } , HD00388 ddrug5 { e , g , ddrug6 } , HD00100 .",
        "label": "NA"
    },
    {
        "text": "the effectiveness of HD00237 - only pills is reduced by hepatic enzyme-inducing drugs such as the ddrug1 ddrug2 , DB00564 , and ddrug4 , and the ddrug5 ddrug6 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 DB01412 DB00365 , like other ddrug3 , may inhibit the metabolism of ddrug4 and ddrug5 .",
        "label": "NA"
    },
    {
        "text": "cyclosporine , digoxin , methotrexate DB00749 , like other ddrug1 , through effects on renal prostaglandins , may cause changes in the elimination of these drugs leading to elevated serum levels of DB00091 , ddrug3 , ddrug4 , and increased toxicity .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : in a clinical pharmacology study , coadministration of an DB06724 { ddrug2 , ddrug3 , and ddrug4 } with DB00492 reduced serum levels and urinary excretion of ddrug6 as compared with ddrug7 administered alone , suggesting that ddrug8 may impair absorption of ddrug9 .",
        "label": "mechanism"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / ddrug1 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , DB01208 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 pain medication { e , g , , ddrug12 } , drugs used to aid sleep , drowsiness-causing ddrug13 { e , g , , DB14487 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , DB00273 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { HD00531 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "discussion : DB01211 is a potent inhibitor of cyp3a4 , the major enzyme responsible for DB00641 metabolism .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 in combination with other ddrug1 , general HD00264 , ddrug3 , ddrug4 , ddrug5 , or other ddrug6 { including DB02325 } has additive depressant effects .",
        "label": "NA"
    },
    {
        "text": "DB00501 has been shown to increase the bioavailability of DB00598 .",
        "label": "mechanism"
    },
    {
        "text": "these six volunteers received ddrug0 alone { 60 mg twice daily } for # days , followed by DB00342 in combination with DB00954 { 500 mg once daily } for # days .",
        "label": "NA"
    },
    {
        "text": "to investigate the effects of antimicrobial combinations of HD00006 with four kinds of ddrug1 { ddrug2 , ddrug3 , DB00595 and ddrug5 } , the fractional inhibitory concentration index { fici } was determined by checkerboard assay for each strain .",
        "label": "NA"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / ddrug1 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , DB01208 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , HD00516 pain medication { e , g , , ddrug12 } , drugs used to aid sleep , drowsiness-causing ddrug13 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , ddrug3 , or ddrug4 , with ddrug5 , with metal cations such as DB01592 , or with ddrug7 containing ddrug8 or DB01593 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "a smaller 24-week study has suggested DB00238 may be superior to the ddrug1 DB00220 .",
        "label": "NA"
    },
    {
        "text": "DB01576 with ddrug1 or ddrug2 and possibly other HD00609 cause striking and sustained increases in the concentration of ddrug4 in the brain ;",
        "label": "mechanism"
    },
    {
        "text": "DB00682 , DB00390 , ddrug2 , and ddrug3 the in vitro binding of ddrug4 to plasma proteins is only slightly reduced by ddrug5 { # % control vs # % } when ddrug6 plasma concentrations reach # to10 m g/ml .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { DB00999 } alone or in combination with ddrug2 : concomitant use of ddrug3 alone or in combination with DB00384 is contraindicated .",
        "label": "NA"
    },
    {
        "text": "in psoriatic arthritis clinical trials , concomitant medications included DB00563 in approximately half of the patients as well as ddrug1 , ddrug2 and HD00175 .",
        "label": "NA"
    },
    {
        "text": "DB00515 was administered over the last two hours of the HD00158 infusion .",
        "label": "NA"
    },
    {
        "text": "if additional HD00354 are to be administered by any route , they should be used with caution because the pharmacologically predictable sympathetic effects of DB01274 may be potentiated .",
        "label": "advise"
    },
    {
        "text": "ddrug0 - ddrug1 containing side chains of n-methylthiotetrazole { ddrug2 , DB01329 , ddrug4 , ddrug5 , ddrug6 } or methylthiadiazole { DB01327 } can cause vitamin_k_deficiency and hypoprothrombinemia .",
        "label": "NA"
    },
    {
        "text": "patients receiving other HD00424 , ddrug1 , ddrug2 , or other ddrug3 { including DB02325 } concomitantly with ddrug5 and ddrug6 tablets may exhibit an additive cns depression .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : co-administration of # mg twice-daily DB01026 with ddrug2 resulted in an approximate 80 % increase in plasma levels of DB09026 .",
        "label": "NA"
    },
    {
        "text": "the potential effects of increased plasma concentrations of DB00683 or other ddrug1 metabolized via cyp3a4 { ddrug2 , DB00897 } should be considered when coadministering these agents with ddrug4 .",
        "label": "NA"
    },
    {
        "text": "therefore , it is theoretically possible that DB00448 may interfere with the absorption of drugs where gastric ph is an important determinant of bioavailability { e , g , DB01026 , ddrug2 esters , ddrug3 salts , ddrug4 } .",
        "label": "mechanism"
    },
    {
        "text": "this drug may interact with ddrug0 or other ddrug1 { may potentiate the cns depressant effects of either these medications or ddrug2 } , HD00444 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug4 } , and HD00445 { concurrent use with ddrug6 may prolong and intensify the anticholinergic and cns depressant effects of ddrug7 } .",
        "label": "NA"
    },
    {
        "text": "in addition to bleeding associated with ddrug0 and HD00286 , drugs that alter platelet function { such as DB00945 , ddrug3 and ddrug4 } may increase the risk of bleeding if administered prior to , during , or after ddrug5 therapy .",
        "label": "NA"
    },
    {
        "text": "however , other published reports describe modest elevations { less than two-fold } of ddrug0 and metabolite concentrations when DB00363 was taken with DB00715 , ddrug3 , and ddrug4 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 and foods fortified with ddrug1 concomitant administration of ddrug2 with a therapeutic ddrug3 containing # mg of elemental ddrug4 { as feso4 } or HD00489 supplemented with # mg of elemental DB01592 reduced extent of absorption by 80 % and 31 % , respectively .",
        "label": "NA"
    },
    {
        "text": "DB00390 : coadministration of ddrug1 , a p_glycoprotein substrate , with oral DB00872 resulted in a reduction in clearance and an increase in ddrug3 cmax and auc values .",
        "label": "NA"
    },
    {
        "text": "intrathecal injection of ddrug0 at doses of # to # micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of HD00144 , and a high dose of DB01183 { 40 micrograms } completely blocked the tail-flick inhibition induced by intraventricular ddrug3 { 16 micrograms } .",
        "label": "NA"
    },
    {
        "text": "DB00563 : DB01050 , as well as other ddrug2 , probably reduces the tubular secretion of ddrug3 based on in vitro studies in rabbit kidney slices .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 : in normal volunteers { n = 9 } , pretreatment with ddrug2 or ddrug3 did not affect DB00712 pharmacokinetics except that a small { 13 % } but statistically significant increase in the area under the serum concentration curve of ddrug5 resulted with DB00501 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , DB00295 } , ddrug36 , ddrug37 { ddrug38 } , DB01045 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : based on reports of profound hypotension and loss of consciousness when ddrug1 was administered with ddrug2 , the concomitant use of DB00714 with drugs of the ddrug4 { including , for example , ddrug5 , DB00889 , ddrug7 , ddrug8 , and ddrug9 } is contraindicated .",
        "label": "advise"
    },
    {
        "text": "the use of DB00318 may result in additive cns depressant effects when coadministered with ddrug1 , HD00388 , ddrug3 or other drugs that produce cns depression .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : HD00401 enhance the adrenergic effect of DB00368 .",
        "label": "effect"
    },
    {
        "text": "concomitant administration of ddrug0 and ddrug1 , ddrug2 , ddrug3 , or an ddrug4 / DB00396 oral HD00349 produced minor changes in the pharmacokinetics of ddrug7 , which were considered to be without clinical significance .",
        "label": "NA"
    },
    {
        "text": "-lsb- a pharmacological analysis of the effect of ddrug0 on stimulated gastric secretion -rsb- chronic experiments on dogs with gastric fistulas were carried out to study the influence of ddrug1 and HD00197 on DB00183 - and ddrug4 - induced gastric acid secretion .",
        "label": "NA"
    },
    {
        "text": "concomitant use of DB01373 supplements and DB00123 may increase ddrug2 absorption",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 , as with other ddrug1 , should be administered with extreme caution to patients being treated with HD00275 , ddrug3 , or drugs known to prolong the qtc interval because the action of HD00355 on the cardiovascular system may be potentiated by these agents .",
        "label": "effect"
    },
    {
        "text": "the effects DB00482 on the pharmacokinetics and/or pharmacodynamics of ddrug1 , ddrug2 , ddrug3 , ddrug4 , DB01124 , and ddrug6 have been studied in vivo and clinically important interactions have not been found .",
        "label": "NA"
    },
    {
        "text": "discontinuation of DB00501 in well-controlled patients receiving ddrug1 and ddrug2 may decrease the plasma levels and efficacy of the HD00216 .",
        "label": "NA"
    },
    {
        "text": "to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma { hiv-nhl } , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the DB00531 , ddrug1 , ddrug2 , and ddrug3 { chop } chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen { i , e , , ddrug4 , DB00997 , ddrug6 , and ddrug7 with ddrug8 plus ddrug9 } without receiving ddrug10 therapy .",
        "label": "NA"
    },
    {
        "text": "HD00326 : ddrug1 like other ddrug2 , has been shown to affect bleeding parameters in patients receiving HD00738 , and serious clinical bleeding has been reported .",
        "label": "NA"
    },
    {
        "text": "tablet if a patient receiving DB00575 is also taking HD00043 , the effect of ddrug2 may be reduced , thus necessitating an increase in dosage .",
        "label": "effect"
    },
    {
        "text": "ddrug0 , and the ddrug1 DB00904 { ddrug3 } and ddrug4 { ddrug5 } have all been used with DB01008 .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of ddrug0 and ddrug1 resulted in slight increases in plasma DB00280 levels and slight decreases in plasma DB00908 levels .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 : DB00673 , when given as a regimen of 125 mg with DB01234 coadministered orally as # mg on day 1 , and ddrug4 when given as # mg/day with ddrug5 coadministered orally as # mg on days # through 5 , increased the auc of ddrug6 , a cyp3a4 substrate by # - fold , on days # and 5 .",
        "label": "mechanism"
    },
    {
        "text": "as with other ddrug0 , it should be noted that ddrug1 may be capable of potentiating HD00261 such as ddrug3 , ddrug4 , and DB02325 .",
        "label": "NA"
    },
    {
        "text": "- a HD00766 such as ddrug1 { ddrug2 } , ddrug3 { DB00623 , ddrug5 } , ddrug6 { ddrug7 } , ddrug8 { ddrug9 } , and others ;",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , ddrug3 , or ddrug4 , with ddrug5 , with metal cations such as ddrug6 , or with ddrug7 containing ddrug8 or DB01593 , or with formulations containing divalent and trivalent cations such as DB00900 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 : DB00586 does not alter glucose metabolism in normal subjects nor does it alter the effects of oral HD00062 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : co-administration with high doses of DB00501 -lsb- 800 mg twice daily -rsb- increased the cmax of DB00533 by 21 % , the auc0 - 120hr by 23 % and the t1/2 by 15 % .",
        "label": "mechanism"
    },
    {
        "text": "patients receiving other ddrug0 , ddrug1 , HD00557 , or other HD00261 { including ddrug4 } concomitantly with ddrug5 and ddrug6 tablets may exhibit an additive cns depression .",
        "label": "NA"
    },
    {
        "text": "ddrug0 or ddrug1 : no formal pharmacokinetic studies have been performed examining the addition of DB00906 to regimens containing DB01174 or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and HD00340 may reduce or reverse the pressor effect of DB00668 .",
        "label": "effect"
    },
    {
        "text": "also , bleeding and/or increased prothrombin time have been reported in a few patients taking HD00422 s concomitantly with DB00227 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , DB00636 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , DB00277 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "conclusion : DB00604 can be administered safely to patients receiving low therapeutic dosages of DB00472 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the oral combination of DB01032 before intramuscular injection of ddrug2 produces an increase in DB00319 peak serum level of about 30 % .",
        "label": "NA"
    },
    {
        "text": "pharmacokinetic data indicate that oral DB01026 inhibits the metabolism of DB00637 , resulting in elevated plasma levels of ddrug2 and its active metabolite ddrug3 which may prolong qt intervals .",
        "label": "effect"
    },
    {
        "text": "in the first double-blind comparative study { 28-week } of ddrug0 and DB00734 , DB00334 # to # mg/day proved to be significantly more effective than ddrug3 # to # mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms .",
        "label": "NA"
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of ddrug0 such as DB00565 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and HD00540 } , ddrug11 salts , ddrug12 , local ddrug13 , ddrug14 , and ddrug15 .",
        "label": "effect"
    },
    {
        "text": "following the administration of DB00450 , the dose of other HD00545 should be reduced .",
        "label": "advise"
    },
    {
        "text": "these drugs include the ddrug0 and other ddrug1 , ddrug2 , ddrug3 , HD00221 , HD00220 , oral ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , and ddrug11 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : co - administration of DB00682 and DB00439 to healthy volunteers did not result in any changes in prothrombin time or clotting factor vii when compared to co-administration of ddrug3 and placebo .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may also interfere with the absorption of oral DB14503 supplements and DB14539 .",
        "label": "NA"
    },
    {
        "text": "reported examples of this interaction include the following : ddrug0 s : DB00091 { ddrug2 substrate } administered in combination with oral DB01118 has been reported to produce persistently elevated plasma concentrations of ddrug4 resulting in elevated creatinine , despite reduction in dose of ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 , and HD00249 : drugs such as ddrug3 , ddrug4 , and ddrug5 may increase the risk of developing peripheral_neuropathies or other ddrug6 - associated adverse events by interfering with the renal clearance of DB00943 { thereby raising systemic exposure } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 may enhance the effects of : other HD00459 s , ddrug4 , general ddrug5 , ddrug6 such as ddrug7 , HD00460 , or other ddrug9 , causing increased cns depression .",
        "label": "NA"
    },
    {
        "text": "certain drugs , including ddrug0 { HD00203 } , ddrug2 , ddrug3 , and ddrug4 may potentiate the hypoglycemic action of ddrug5 and other oral HD00394 .",
        "label": "effect"
    },
    {
        "text": "if treatment with inhibitors of cyp3a4 activity { such as ddrug0 , ddrug1 , ddrug2 , DB00224 , ddrug4 , ddrug5 , etc , } is indicated , reduction of the DB01222 dose should be considered .",
        "label": "advise"
    },
    {
        "text": "because both of these drugs have negative inotropic properties and the effects of coadministration with DB01195 are unknown , neither DB00280 nor ddrug2 should be administered concurrently with ddrug3 unless , in the judgment of the physician , the benefits of this combination outweigh the risks .",
        "label": "NA"
    },
    {
        "text": "DB00612 should be used with care when ddrug1 or inhibitors of av conduction , such as certain ddrug2 { particularly of the ddrug3 -lsb- ddrug4 -rsb- and ddrug5 -lsb- ddrug6 -rsb- classes } , or HD00428 , such as ddrug8 , are used concurrently .",
        "label": "advise"
    },
    {
        "text": "therefore , co-administration of ddrug0 with other drugs that are metabolized by this isozyme , including HD00216 , ddrug2 , ddrug3 , and ddrug4 { e , g , , ddrug5 , ddrug6 and ddrug7 } , or that inhibit this enzyme { e , g , , DB00908 } , should be approached with caution .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 : ddrug2 may enhance the activity of HD00351 or HD00571 ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the effect of an ddrug1 - and DB09104 - containing ddrug3 { ddrug4 } * on the pharmacokinetics of DB01101 was investigated in # cancer patients .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : since ddrug1 is a ddrug2 , it is possible that ddrug3 , such as the ddrug4 { ddrug5 , HD00340 , ddrug7 } or ddrug8 , may diminish the effectiveness of DB00714 .",
        "label": "effect"
    },
    {
        "text": "other concomitant therapy : although specific interaction studies were not performed , in clinical studies , HD00503 was used concomitantly with ddrug1 , HD00505 , ddrug3 , ddrug4 , and ddrug5 { ddrug6 } without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / ddrug1 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , DB00248 , ddrug10 , ddrug11 pain medication { e , g , , ddrug12 } , drugs used to aid sleep , drowsiness-causing ddrug13 { e , g , , DB14487 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , DB00863 : in normal volunteers { n = 9 } , pretreatment with ddrug2 or ddrug3 did not affect ddrug4 pharmacokinetics except that a small { 13 % } but statistically significant increase in the area under the serum concentration curve of ddrug5 resulted with DB00501 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { e , g , ddrug1 and DB13179 } : agents of the HD00625 , of which ddrug4 { ddrug5 } injection , usp is a member , have been shown to interact with ddrug6 of the ddrug7 , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00580 # mg bid for # days produced significant decreases in DB14507 serum clearance { 25 % } and renal clearance { 30 % } with a 34 % higher serum exposure compared to ddrug3 alone .",
        "label": "mechanism"
    },
    {
        "text": "hypotension was more likely to occur if the HD00411 were a ddrug1 , e , g , , ddrug2 , while left ventricular failure and av conduction disturbances , including complete heart block , were more likely to occur with either ddrug3 or DB00343 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 may enhance the effects of : other ddrug3 s , ddrug4 , general HD00264 , ddrug6 such as ddrug7 , HD00460 , or other ddrug9 , causing increased cns depression .",
        "label": "NA"
    },
    {
        "text": "DB00695 has a tendency to antagonize the skeletal muscle relaxing effect of DB01199 and may potentiate the action of ddrug2 .",
        "label": "effect"
    },
    {
        "text": "oral HD00326 : in some normal volunteers , the concomitant administration of ddrug1 and DB00682 , ddrug3 , or ddrug4 resulted in prolongation of prothrombin time .",
        "label": "NA"
    },
    {
        "text": "the incidence of akathisia in clinical trials of the weekly dosage schedule was greater { # % , 4/47 patients } when DB00433 was administered on the same day as DB00762 than when these drugs were given on separate days { # % , 1/80 patients } .",
        "label": "effect"
    },
    {
        "text": "both HD00021 and HD00022 enhance the locomotor and/or stereotypic effects of stimulants .",
        "label": "NA"
    },
    {
        "text": "no interaction with the HD00042 DB00458 was shown in a single-dose study with ddrug2 without coadministered ddrug3 / ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : a clinical study in # insulin-dependent diabetic patients demonstrated no effect of ddrug1 on ddrug2 absorption from the peritoneal cavity or on ddrug3 s ability to control blood glucose when HD00071 was administered intraperitoneally with DB00702 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { cns } drugs including DB02325 , ddrug2 , ddrug3 , ddrug4 , blood pressure medications { ddrug5 , ddrug6 , ddrug7 } , motion sickness medications , ddrug8 , ddrug9 , ddrug10 , sleeping pills and HD00262",
        "label": "NA"
    },
    {
        "text": "coadministration of DB00342 with DB01167 has led to elevated plasma concentrations of ddrug2 , resulting in rare instances of life - threatening cardiac dysrhythmias and one death .",
        "label": "mechanism"
    },
    {
        "text": "like ddrug0 { 40 mg/kg } , ddrug1 { 40 mg/kg } decreases the intravenous self-administration of DB00295 and ddrug3 and the oral self-administration of ddrug4 and DB00184 in rats ;",
        "label": "NA"
    },
    {
        "text": "the mode of toxic action of the pesticide HD00076 : the metabolism of HD00077 to ddrug2 .",
        "label": "NA"
    },
    {
        "text": "no depressant effect on blood levels in humans was noted when ddrug0 was administered with any of the following drugs : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 { ddrug6 } , DB01124 , ddrug8 or DB00682 .",
        "label": "NA"
    },
    {
        "text": "however , concomitant administration of DB00945 with DB00482 may result in an increased rate of gi ulceration or other complications , compared to use of ddrug2 alone .",
        "label": "effect"
    },
    {
        "text": "drugs that may alter DB00619 plasma concentrations drugs that may increase ddrug1 plasma concentrations : caution is recommended when administering ddrug2 with inhibitors of the cyp3a4 family { e , g , , DB01026 , ddrug4 , ddrug5 , ddrug6 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { DB00400 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , DB00231 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : increased serum ddrug1 levels and symptoms of ddrug2 toxicity have been reported in patients receiving concomitant DB14507 and HD00471 therapy .",
        "label": "effect"
    },
    {
        "text": "concomitant administration of ddrug0 capsules and ddrug1 resulted in substantial increases in plasma concentrations of DB00307 , probably at least partially related to cyp3a4 inhibition by DB01241 .",
        "label": "NA"
    },
    {
        "text": "HD00703 : potential interactions between DB00776 and other ddrug2 were assessed in clinical studies .",
        "label": "NA"
    },
    {
        "text": "DB01118 or DB00661 : the risk of myopathy/rhabdomyolysis is increased when either ddrug2 or ddrug3 is used concomitantly with a closely related member of the ddrug4 { see warnings , myopathy/rhabdomyolysis } .",
        "label": "NA"
    },
    {
        "text": "HD00445 such as ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , ddrug5 { e , g , , ddrug6 } , ddrug7 { e , g , , DB01037 } , and ddrug9 { e , g , , ddrug10 } : using these medicines with ddrug11 may increase the chance of side effects .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , DB00949 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , DB00277 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a study of # healthy male volunteers , ddrug1 treatment potentiated the blood glucose lowering effect of DB01016 { a ddrug3 similar to DB00672 } in # of the # subjects .",
        "label": "NA"
    },
    {
        "text": "DB00321 in combination with ddrug1 enhances the manifestation of corneal lesions in rats epidural injection ddrug2 may potentiate the cns-depressive effect of ddrug3 , ddrug4 or other HD00562 .",
        "label": "NA"
    },
    {
        "text": "other drugs : based on the results of drug interaction studies , no dosage adjustment is recommended when ddrug0 { DB00625 } is given with the following : ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , DB00220 , ddrug10 , and ddrug11 .",
        "label": "NA"
    },
    {
        "text": "DB00930 was found to have no significant effect on the bioavailability of DB00390 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , and ddrug6 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the anorectic and stimulatory effects of HD00401 may be inhibited by DB14509 .",
        "label": "effect"
    },
    {
        "text": "in a study in which patients with active ra were treated for up to # weeks with concurrent ddrug0 and DB00026 therapy , a 7 % rate of serious infections was observed , which was higher than that observed with DB09145 alone { 0 % } .",
        "label": "NA"
    },
    {
        "text": "in patients receiving ddrug0 { ddrug1 } or ddrug2 { ddrug3 } , the concomitant administration of 300 - 600 mg of DB00437 per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of ddrug5 or DB00993 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 , DB00575 , ddrug2 salts , and ddrug3 may either potentiate or weaken the blood-glucose-lowering effect of HD00071 .",
        "label": "effect"
    },
    {
        "text": "the concomitant use of transdermal ddrug0 with ddrug1 or other potent 3a4 inhibitors such as DB01026 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and nefazadone may result in an increase in DB00813 plasma concentrations .",
        "label": "NA"
    },
    {
        "text": "these in vitro studies suggest that concomitant administration of ddrug0 and DB00709 in humans may result in sub-therapeutic concentrations of active phosphorylated DB00943 , which may lead to a decreased ddrug3 effect of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "DB00207 did not affect the prothrombin time response to a single dose of DB00682 .",
        "label": "NA"
    },
    {
        "text": "DB00682 and HD00326 : increased prothrombin time , with or without clinical bleeding , has been reported when ddrug2 is administered concomitantly .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the addition of DB00906 to patients taking ddrug2 chronically had no effect on ddrug3 pharmacokinetics , but DB00313 significantly decreased ddrug5 binding in vitro from # to # % , which resulted in an increase of approximately 40 % in the free tiagabine concentration .",
        "label": "NA"
    },
    {
        "text": "in clinical trials , ddrug0 was used with ddrug1 , ddrug2 , ddrug3 , oral ddrug4 , and supplemental ddrug5 , in a pharmacokinetic substudy in patients with congestive heart failure receiving ddrug6 or DB00390 in whom therapy with ddrug8 was initiated , apparent oral clearance values for DB00695 { n = 23 } and ddrug10 { n = 30 } were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 toxicity has been reported in patients receiving DB14507 concomitantly with drugs which cause elimination of sodium , including HD00106 .",
        "label": "effect"
    },
    {
        "text": "and DB00900 , { DB00900 } , chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of ddrug2 , resulting in systemic levels considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the effect of steady-state DB00176 l50 mg bid on the pharmacokinetics of a single dose of DB00277 { 375 mg } as # mg ddrug3 was evaluated in # healthy non-smoking , male volunteers .",
        "label": "NA"
    },
    {
        "text": "drug interactions : the central ddrug0 syndrome can occur when anticholinergic agents such as ddrug1 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain ddrug2 such as ddrug3 , the HD00219 and other ddrug5 , ddrug6 , certain ddrug7 such as the ddrug8 salts , and HD00388 .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 may potentiate the hypoglycemic action of ddrug1 , eg , DB01124 and DB00672 , by inhibiting their metabolism in the liver .",
        "label": "NA"
    },
    {
        "text": "caution should be used when administering or taking ddrug0 with DB01026 and other strong cyp3a4 inhibitors such as , but not limited to , ddrug2 , DB01211 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { ddrug12 } , and ddrug13 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , DB00316 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , DB01035 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "other drugs : based on the results of drug interaction studies , no dosage adjustment is recommended when DB00625 { ddrug1 } is given with the following : ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , and DB00495 .",
        "label": "NA"
    },
    {
        "text": "increased toxicity { cns depression } : HD00261 , ddrug1 , ddrug2 , HD00219 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 should not be used concomitantly with other drugs known to prolong the qt interval : certain HD00303 , including those of class ia { such as DB00908 and ddrug3 } and class iii { such as ddrug4 } ;",
        "label": "NA"
    },
    {
        "text": "administration of HD00532 with ddrug1 containing ddrug2 , ddrug3 , or ddrug4 , with ddrug5 , with metal cations such as ddrug6 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as DB00900 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "mechanism"
    },
    {
        "text": "HD00118 toxicity may be aggravated by the initial release of norepinephrine caused by HD00438 injection .",
        "label": "effect"
    },
    {
        "text": "DB01045 may decrease serum ddrug1 concentration , especially in patients with renal dysfunction , by increasing the non-renal clearance of DB00390 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , HD00002 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { DB00701 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { ddrug1 , DB00458 , ddrug3 } : metabolism may be inhibited by HD00710 , increasing plasma levels of ddrug5 ;",
        "label": "mechanism"
    },
    {
        "text": "DB00564 , DB01068 , ddrug2",
        "label": "NA"
    },
    {
        "text": "HD00445 such as ddrug1 { e , g , , DB01247 } , ddrug3 { e , g , , ddrug4 } , ddrug5 { e , g , , ddrug6 } , ddrug7 { e , g , , ddrug8 } , and ddrug9 { e , g , , ddrug10 } : using these medicines with ddrug11 may increase the chance of side effects .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { DB01045 } , st , johns wort , DB00231 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "coadministration of oral ddrug0 , DB00829 , ddrug2 , or ddrug3 did not seem to change the pharmacokinetic profile of DB00736 .",
        "label": "NA"
    },
    {
        "text": "the following drugs have been coadministered with DB00195 and have not altered its pharmacokinetics : ddrug1 , ddrug2 , DB00310 , and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "DB00316 / ddrug1 , ddrug2 / ddrug3 , DB01174 / ddrug5 , ddrug6 / ddrug7 , ddrug8 / ddrug9 , ddrug10 / ddrug11 , and ddrug12 / ddrug13 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : interaction with drugs that inhibit metabolism via cytochrome cyp2b6 3a { cyp3a } : the metabolism of DB01215 to the major circulating metabolite ddrug2 and the metabolism of other HD00695 is catalyzed by cyp3a .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB01032 is known to interact with the metabolism or renal tubular excretion of many drugs { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 agents , ddrug14 , and DB00495 } .",
        "label": "mechanism"
    },
    {
        "text": "DB00564 : coadministration of ddrug1 { 200 mg bid } , a potent cyp3a4 inducer , with DB01238 { 30 mg qd } resulted in an approximate 70 % decrease in cmax and auc values of both ddrug3 and its active metabolite , ddrug4 .",
        "label": "NA"
    },
    {
        "text": "while all the HD00113 { ddrug1 } , e , g , , ddrug2 , ddrug3 , ddrug4 , DB01104 , and ddrug6 , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in the fed state , DB01058 { 40 mg/kg } increased mean maximum plasma concentration and area under the curve of DB13871 by about 50 % in healthy subjects { n = 10 } compared with a separate group of subjects { n = 6 } given ddrug3 alone .",
        "label": "mechanism"
    },
    {
        "text": "data from in vitro studies of HD00100 other than ddrug1 suggest a possible drug interaction for the following : ddrug2 , ddrug3 , ddrug4 , DB00622 , and ddrug6 .",
        "label": "int"
    },
    {
        "text": "DB00486 should be administered with caution to patients who are taking other ddrug1 or HD00261 , including ddrug3 , ddrug4 and ddrug5 , or to those with a history of psychiatric disorder { including manic-depressive illness and schizophrenia } .",
        "label": "advise"
    },
    {
        "text": "although no studies have been conducted , concomitant administration of DB01167 and ddrug1 may alter the metabolism of DB00252 ;",
        "label": "NA"
    },
    {
        "text": "because DB14507 may enhance the serotonergic effects of DB01175 , caution should be exercised when ddrug2 and ddrug3 are coadministered .",
        "label": "effect"
    },
    {
        "text": "or with ddrug0 containing DB01593 may substantially interfere with drug absorption and result in insufficient plasma and tissue HD00533 concentrations .",
        "label": "mechanism"
    },
    {
        "text": "the following are examples of drugs known to inhibit the metabolism of other related ddrug0 , presumably through inhibition of cyp3a : DB01149 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , and some HD00093 .",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with other cyp3a4 inhibitors { e , g , , ddrug1 # mg bid , DB00661 # mg qd , ddrug3 # mg tid , DB00196 # mg qd } resulted in increases in cmax of ddrug5 ranging from # - to # - fold and auc from # - to # - fold .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : based on reports of profound hypotension and loss of consciousness when ddrug1 was administered with ddrug2 , the concomitant use of DB00714 with drugs of the ddrug4 { including , for example , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and DB00969 } is contraindicated .",
        "label": "advise"
    },
    {
        "text": "coadministration of ddrug0 with oral DB00683 or DB00897 has resulted in elevated plasma concentrations of the latter two drugs .",
        "label": "NA"
    },
    {
        "text": "because ddrug0 is eliminated from the body via conjugation with glutathione , use of DB00316 prior to { # hours } or concurrent with DB01008 may result in reduced ddrug3 clearance based upon the known property of ddrug4 to decrease glutathione levels in the blood and tissues .",
        "label": "mechanism"
    },
    {
        "text": "caution should be exercised when the following drugs are administered concomitantly with ddrug0 { ddrug1 } given with DB01235 or DB00190 - ddrug4 combination products .",
        "label": "NA"
    },
    {
        "text": "all subjects received DB00701 { 1,200 mg twice a day } for # days , followed by a 7-day washout period , followed by either DB00615 { 300 mg once a day -lsb- qd -rsb- } { cohort 1 } or ddrug2 { 600 mg qd } { cohort 2 } for # days .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of HD00071 : ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , ddrug5 , ddrug6 , ddrug7 } , DB00951 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "and DB00822 when HD00314 is given with ddrug2 agents or ddrug3 drugs , including ddrug4 combined with local ddrug5 , close supervision and careful adjustment of dosages are required .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 : ddrug2 and HD00374 containing ddrug4 or DB01370 , as well as formulations containing divalent and trivalent cations such as ddrug6 { ddrug7 } , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with ddrug8 and interfere with its bioavailability .",
        "label": "NA"
    },
    {
        "text": "in patients receiving concurrent therapy with DB00575 , if therapy is to be discontinued , it is suggested that DB00612 be discontinued for several days before the withdrawal of ddrug2 .",
        "label": "NA"
    },
    {
        "text": "DB00819 increases ddrug1 excretion and the DB14507 may be decreased .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 : ddrug2 and ddrug3 containing DB14513 or ddrug5 , as well as formulations containing divalent and trivalent cations such as ddrug6 { DB00900 } , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with ddrug8 and interfere with its bioavailability .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 : e , g , , DB01023 , ddrug3 , DB00622",
        "label": "NA"
    },
    {
        "text": "in vitro studies indicate that ddrug0 does not inhibit p-glycoprotein-mediated transport of DB00390 or DB00570 and that ddrug3 is not a substrate for p-glycoprotein-mediated transport .",
        "label": "NA"
    },
    {
        "text": "drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on ddrug0 therapy : ddrug1 , HD00175 , ddrug3 , oral ddrug4 containing ddrug5 , ddrug6 - containing preparations and the numerous preparations containing HD00328 .",
        "label": "NA"
    },
    {
        "text": "because the HD00153 HD00152 is given exclusively by the oral route in man , we have carried out studies in mice on the antitumour activity , acute toxicity and pharmacokinetics of oral ddrug2 , either alone or in combination with the chemosensitizer ddrug3 .",
        "label": "NA"
    },
    {
        "text": "if the usual amounts of nondepolarizing relaxants are given , the time for recovery from neuromuscular blockade will be longer in the presence of DB00228 than when DB01159 or ddrug2 with a balanced technique are used .",
        "label": "NA"
    },
    {
        "text": "routine administration of HD00602 or toxoids should be deferred until HD00579 therapy is discontinued if possible .",
        "label": "advise"
    },
    {
        "text": "other concomitant therapy : although specific interaction studies were not performed , in clinical studies , HD00503 was used concomitantly with ddrug1 , ddrug2 , HD00506 , ddrug4 , and ddrug5 { ddrug6 } without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "animals dosed with ddrug0 did not display the 2 - 3 hour lag phase in either HD00078 synthesis or in citrate and fluoride accumulation characteristic of animals dosed with HD00079 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : no significant differences were observed in mean DB00252 auc , c max , c min or t max { although c max increased by 11 % } when extended ddrug2 capsules { 100 mg tid } were coadministered with DB00978 { 400 mg qd } for five days in # healthy males .",
        "label": "NA"
    },
    {
        "text": "method : this study was a multicenter randomized double-blind study of # patients who were randomly assigned 1:1:1 to receive DB01590 tablets at doses of # mg , # mg , or # mg twice daily with ddrug1 and DB00898 .",
        "label": "NA"
    },
    {
        "text": "elevated ddrug0 serum levels have been reported with the concomitant use of HD00532 and DB00091 .",
        "label": "mechanism"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / ddrug1 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , DB00248 , ddrug10 , ddrug11 pain medication { e , g , , ddrug12 } , drugs used to aid sleep , drowsiness-causing HD00388 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { DB00682 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { DB00472 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "core temperature was decreased in rats in a dose-dependent manner when ddrug0 was administered to rats treated with DB00822 # hours before the DB00898 challenge .",
        "label": "NA"
    },
    {
        "text": "it has been reported that results of studies in animals indicate that DB00988 - induced ventricular arrhythmias during anesthesia can be reversed by DB00571 .",
        "label": "effect"
    },
    {
        "text": "since the pharmacokinetics of DB01008 were studied in patients treated with DB00252 , the clearance of ddrug2 at the recommended dose may be lower and exposure { auc } higher in patients not treated with ddrug3 .",
        "label": "mechanism"
    },
    {
        "text": "as with some other HD00541 , the time of onset of neuromuscular block induced by DB01135 is lengthened and the duration of block is shortened in patients receiving ddrug2 or ddrug3 .",
        "label": "NA"
    },
    {
        "text": "in controlled clinical trials of DB01060 , # patients received concomitant DB00437 and ddrug2 .",
        "label": "NA"
    },
    {
        "text": "therefore , administration of ddrug0 with HD00374 containing ddrug2 , DB14513 , or ddrug4 ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 { cns } drugs including ddrug1 , ddrug2 , ddrug3 , ddrug4 , blood pressure medications { DB00206 , ddrug6 , ddrug7 } , motion sickness medications , ddrug8 , HD00543 , ddrug10 , sleeping pills and ddrug11",
        "label": "NA"
    },
    {
        "text": "decreasing the concentration of HD00068 , exhibiting # % { m/m } of immobilised DB00151 { cmc-cys # } from 1 % { m/v } to # % { m/v } decreased the r-value of ddrug2 from # to # .",
        "label": "NA"
    },
    {
        "text": "other no clinically important pharmacokinetic interactions occurred when DB00542 was administered concomitantly with ddrug1 , ddrug2 , ddrug3 , DB00390 , ddrug5 , ddrug6 , ddrug7 , or ddrug8 .",
        "label": "NA"
    },
    {
        "text": "at least # weeks should elapse between discontinuation of DB01191 and initiation of treatment with a HD00455 .",
        "label": "advise"
    },
    {
        "text": "the HD00100 , including ddrug1 , produce additive cns depressant effects when co-administered with other ddrug2 , ddrug3 , ddrug4 , DB00898 , and other drugs which themselves produce cns depression .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : in clinical drug interaction studies , ddrug1 did not have clinically important effects on the pharmacokinetics of DB00904 or DB00889 .",
        "label": "NA"
    },
    {
        "text": "in a phase i trial using escalating doses of ddrug0 { 110 - 200 mg/m2 } and ddrug1 { 50 or # mg/m2 } given as sequential infusions , myelosuppression was more profound when DB01229 was given after DB00515 than with the alternate sequence { ie , ddrug4 before ddrug5 } .",
        "label": "effect"
    },
    {
        "text": "oral HD00283 : ddrug1 , when given once daily for # days as a 100-mg capsule with an oral ddrug2 containing # mcg of ddrug3 and # mg of DB00717 , decreased the auc of ddrug5 by 43 % , and decreased the auc of ddrug6 by 8 % ;",
        "label": "NA"
    },
    {
        "text": "plasma levels of several closely related ddrug0 have been reported to be increased by the concomitant administration of ddrug1 or hepatic enzyme inhibitors { e , g , , ddrug2 , DB00472 } and decreased by the concomitant administration of hepatic enzyme inducers { e , g , , ddrug4 , ddrug5 } , and such an effect may be anticipated with HD00551 as well .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 , DB00201 , and ddrug2 may increase plasma levels of DB00363 , potentially resulting in adverse effects .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : doses of DB00126 { ddrug2 } # g/day have been reported to increase plasma concentration of HD00706 by ~ 47 % , possibly by inhibiting conjugation ;",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : DB00316 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , DB00091 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "HD00569 : ddrug1 { DB01170 , ddrug3 , ddrug4 , ddrug5 , fruit juices , etc , } lower absorption of ddrug6 .",
        "label": "NA"
    },
    {
        "text": "capsules DB00328 # mg t , i , d , produced a clinically relevant elevation of plasma ddrug1 and reduction in renal ddrug2 clearance in psychiatric patients and normal subjects with steady state plasma DB14507 concentrations .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : since ddrug1 is a ddrug2 , it is possible that HD00339 , such as the ddrug4 { ddrug5 , HD00340 , ddrug7 } or ddrug8 , may diminish the effectiveness of ddrug9 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , including oral ddrug1 : HD00220 may decrease the hepatic metabolism of certain HD00175 , thereby increasing their effect .",
        "label": "mechanism"
    },
    {
        "text": "therefore , coadministration of ddrug0 with drugs that strongly induce cyp3a4 activity { e , g , , ddrug1 , ddrug2 , DB00252 } may result in reduced plasma concentrations of DB00673 that may result in decreased efficacy of ddrug5 .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } DB00501 { ddrug8 } ddrug9 DB00472 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 : in one study , DB00712 was given to adult diabetics who were already receiving DB01016 { n = 4 } , ddrug3 { n = 2 } ddrug4 with ddrug5 { n = 3 } or ddrug6 with ddrug7 { n = 6 } .",
        "label": "NA"
    },
    {
        "text": "the possibility of hypotensive effects with DB00584 or ddrug1 can be minimized by either discontinuing the HD00295 or increasing the salt intake prior to initiation of treatment with ddrug3 or ddrug4 .",
        "label": "effect"
    },
    {
        "text": "serum DB00065 concentrations appeared to be unaffected by baseline use of medications for the treatment of crohn s disease including ddrug1 , HD00002 { ddrug3 or ddrug4 } and aminosalicylates .",
        "label": "NA"
    },
    {
        "text": "DB00501 treatment should be stopped during treatment with DB00445 .",
        "label": "advise"
    },
    {
        "text": "these increased exposures of ddrug0 and DB00977 should be taken into consideration when selecting an oral HD00349 for women taking ddrug3 .",
        "label": "NA"
    },
    {
        "text": "may interact with the following : ddrug0 , DB00375 { use with ddrug2 may prevent the HD00295 from working properly ;",
        "label": "NA"
    },
    {
        "text": "the clearance of HD00328 may be increased with concurrent use of HD00175 .",
        "label": "mechanism"
    },
    {
        "text": "DB00863 # mg twice daily did not interact significantly with DB00401 { auc was decreased by 15 - 20 % } .",
        "label": "NA"
    },
    {
        "text": "however , since ddrug0 , ddrug1 , and HD00794 are all associated with gastrointestinal irritation , caution should be exercised in the concomitant use of ddrug3 or HD00203 with ddrug5 .",
        "label": "NA"
    },
    {
        "text": "the administration of local ddrug0 containing ddrug1 or DB00368 to patients receiving HD00275 or ddrug4 may produce severe , prolonged hypertension .",
        "label": "effect"
    },
    {
        "text": "by decreasing the gastrointestinal absorption of ddrug0 , HD00234 may decrease serum concentrations of DB00794 and its metabolites , with a consequent possible decrease in anticonvulsant effect .",
        "label": "mechanism"
    },
    {
        "text": "renal function should be monitored carefully if high doses of HD00249 are to be administered with ddrug1 because of the increased potential of nephrotoxicity and ototoxicity of HD00447 .",
        "label": "NA"
    },
    {
        "text": "the following are examples of drugs known to inhibit the metabolism of other related HD00100 , presumably through inhibition of cyp3a : ddrug1 , ddrug2 , DB00501 , ddrug4 , ddrug5 , and some ddrug6 .",
        "label": "mechanism"
    },
    {
        "text": "the aim of this paper was to study the interaction between HD00163 and both ddrug1 or its synthetic analogue ddrug2 , or HD00166 , on the antinonciceptive effect of these peptides in mice after intracisternal injection .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 : DB00559 has no significant pharmacokinetic interactions with DB00390 and ddrug5 , and ddrug6 has no significant effect on plasma levels of ddrug7 .",
        "label": "NA"
    },
    {
        "text": "however , other published reports describe modest elevations { less than two-fold } of DB00363 and metabolite concentrations when ddrug1 was taken with ddrug2 , ddrug3 , and DB01104 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { DB00316 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , DB00277 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "coadministration with compounds that are potent inducers of cyp3a4 { eg , DB01174 , ddrug1 , ddrug2 , ddrug3 } may result in decreased plasma levels of DB01232 .",
        "label": "mechanism"
    },
    {
        "text": "avoid the use of preparations such as ddrug0 and local ddrug1 which contain any HD00800 { e , g , , ddrug3 , ddrug4 } , since it has been reported that HD00043 can potentiate the effects of catecholamines .",
        "label": "advise"
    },
    {
        "text": "the pharmacokinetics and protein binding of ddrug0 , ddrug1 , and DB00829 were not altered when ddrug3 and DB01320 were concurrently administered in single submaximal doses .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { HD00022 } and HD00021 : comparison of antiaddictive efficacy , toxicity , and mechanisms of action .",
        "label": "NA"
    },
    {
        "text": "DB00673 increased the auc of ddrug1 by 25 % on day # and decreased the auc of DB00683 by 19 % on day # relative to the dosing of ddrug3 on days # through 3 .",
        "label": "mechanism"
    },
    {
        "text": "while all the HD00113 { ddrug1 } , e , g , , ddrug2 , ddrug3 , DB00715 , and ddrug5 , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .",
        "label": "NA"
    },
    {
        "text": "DB00294 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and DB00126 .",
        "label": "int"
    },
    {
        "text": "the safety and efficacy of concomitant use of DB00704 and DB00822 is unknown , and the concomitant use of two potentially hepatotoxic medications is not ordinarily recommended unless the probable benefits outweigh the known risks .",
        "label": "effect"
    },
    {
        "text": "the following are examples of drugs known to inhibit the metabolism of other related HD00100 , presumably through inhibition of cyp3a : ddrug1 , DB00176 , ddrug3 , ddrug4 , ddrug5 , and some ddrug6 .",
        "label": "mechanism"
    },
    {
        "text": "concomitant use of HD00388 with ddrug1 , HD00043 , ddrug3 , or other ddrug4 may have an additive effect .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , DB00949 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , DB00295 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , ddrug3 , or ddrug4 , with ddrug5 , with metal cations such as ddrug6 , or with ddrug7 containing ddrug8 or DB01593 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of HD00532 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { e , g , , DB01026 , ddrug2 , ddrug3 , ddrug4 , etc , } : in vitro and animal studies with the combination of ddrug5 and HD00319 suggest that ddrug7 may induce fungal resistance to ddrug8 .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 : the effect of oral HD00283 on the pharmacokinetics of DB00320 { ddrug3 } injection , usp has not been studied .",
        "label": "NA"
    },
    {
        "text": "DB00562 may interact with ddrug1 , ddrug2 s , ddrug3 { allergy , cold , and sinus medicines } , diabetic drugs , ddrug4 , ddrug5 , ddrug6 like ddrug7 or DB01050 , and high blood pressure medications .",
        "label": "int"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 HD00871 : ddrug9 ddrug10 ddrug11 , DB00897 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "concomitant administration of DB00969 and moderate cyp1a2 inhibitors , including ddrug1 and DB00501 , has not been evaluated , but should be avoided unless clinically necessary because of similar potential drug interactions .",
        "label": "advise"
    },
    {
        "text": "ddrug0 has been reported to significantly alter the metabolism of nonsedating HD00388 DB00342 and ddrug3 when taken concomitantly .",
        "label": "NA"
    },
    {
        "text": "the plasma concentration of ddrug0 may increase when the drug is given concomitantly with hepatic enzyme inhibitors { e , g , , ddrug1 , ddrug2 } and decrease by concomitant administration of hepatic enzyme inducers { e , g , , HD00026 , ddrug4 } , and adjustment of the dosage of DB00458 may therefore be necessary .",
        "label": "NA"
    },
    {
        "text": "if DB01151 is to be combined with other HD00595 such as ddrug2 or ddrug3 / ddrug4 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of ddrug5 and ddrug6 { e , g , , ddrug7 or ddrug8 } are additive .",
        "label": "effect"
    },
    {
        "text": "protein binding in vitro , DB00586 interferes minimally or not at all with the protein binding of ddrug1 { 20 % decrease in binding } , DB01124 , ddrug3 { 10 % decrease in binding } , or ddrug4 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 / ddrug1 : the coadministration of ddrug2 or DB01174 will not affect plasma concentrations of DB11094 , but may reduce endogenous plasma levels of ddrug5 / ergocalcitriol by accelerating metabolism .",
        "label": "NA"
    },
    {
        "text": "drugs that reduce the number of blood platelets by causing bone marrow depression { such as HD00251 } or drugs which inhibit platelet function { eg , DB00945 and other ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 } may increase the bleeding tendency produced by ddrug7 without altering prothrombin time determinations .",
        "label": "NA"
    },
    {
        "text": "although ddrug0 has a lower affinity for ddrug1 than for DB01592 , DB01609 should not be taken with ddrug4 - containing ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { ddrug1 , ddrug2 , DB00384 , and others } or DB14500 supplements can increase the risk of hyperkalemia .",
        "label": "NA"
    },
    {
        "text": "antiacid , ddrug0 , ddrug1 , ddrug2 , ddrug3 , indanavir , ddrug4 , DB00252 , phenobarbitol , ddrug6 , DB00615 , ddrug8 , ritanovir , ddrug9 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 / ddrug1 : long-term suppression of gastric acid secretion by HD00586 or HD00587 { eg , ddrug4 and ddrug5 } is likely to reduce ddrug6 exposure .",
        "label": "NA"
    },
    {
        "text": "risk of anaphylactic reaction : although it is known that patients on ddrug0 may be refractory to DB00668 in the treatment of anaphylactic shock , HD00254 can , in addition , interfere with the modulation of allergic reaction and lead to an increased severity and/or frequency of attacks .",
        "label": "NA"
    },
    {
        "text": "while all the HD00113 { ddrug1 } , e , g , , ddrug2 , ddrug3 , ddrug4 , and DB00176 , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .",
        "label": "NA"
    },
    {
        "text": "in patients receiving ddrug0 { ddrug1 } or ddrug2 { DB00993 } , the concomitant administration of 300 - 600 mg of ddrug4 per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of DB01033 or ddrug6 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration of DB00390 , a p_glycoprotein substrate , with oral DB00872 resulted in a reduction in clearance and an increase in ddrug3 cmax and auc values .",
        "label": "mechanism"
    },
    {
        "text": "although the interactions observed in these studies do not appear to be of major clinical importance , DB00187 should be titrated with caution in patients being treated concurrently with ddrug1 , ddrug2 , ddrug3 or DB00682 .",
        "label": "advise"
    },
    {
        "text": "HD00884 , such as ddrug1 and DB01138 , can inhibit renal tubular secretion of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "although the interactions observed in these studies do not appear to be of major clinical importance , DB00187 should be titrated with caution in patients being treated concurrently with ddrug1 , DB00295 , ddrug3 or ddrug4 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 - and/or ddrug1 - containing ddrug2 , products containing ddrug3 { DB01592 } , ddrug5 containing ddrug6 or other metal cations , or ddrug7 { ddrug8 } chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after DB01155 .",
        "label": "advise"
    },
    {
        "text": "hypertensive crises have resulted when HD00399 have been used concomitantly within14 days following use of HD00275 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 should be used with care when ddrug1 or inhibitors of av conduction , such as certain ddrug2 { particularly of the ddrug3 -lsb- DB00661 -rsb- and ddrug5 -lsb- DB00343 -rsb- classes } , or ddrug7 , such as ddrug8 , are used concurrently .",
        "label": "NA"
    },
    {
        "text": "no depressant effect on blood levels in humans was noted when ddrug0 was administered with any of the following drugs : ddrug1 , ddrug2 , DB00636 , ddrug4 , ddrug5 { ddrug6 } , ddrug7 , DB00252 or ddrug9 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as DB00415 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { DB00295 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "because ddrug0 has not been shown to produce any additional effect beyond that obtained with DB00945 alone and because ddrug2 increases the rate of excretion of ddrug3 , the concomitant use of ddrug4 and HD00328 is not recommended .",
        "label": "NA"
    },
    {
        "text": "patients who begin taking ddrug0 or who increase their DB00586 dose or any other ddrug2 while taking ddrug3 , ddrug4 , or DB00091 may develop toxicity characteristics for these drugs .",
        "label": "NA"
    },
    {
        "text": "by decreasing the gastrointestinal absorption of DB00794 , HD00234 may decrease serum concentrations of ddrug2 and its metabolites , with a consequent possible decrease in anticonvulsant effect .",
        "label": "NA"
    },
    {
        "text": "in vitro data in human plasma indicate that DB00590 has no effect on protein binding of ddrug1 , ddrug2 , DB00252 or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "DB00405 can interact with ddrug1 or other ddrug2 { may potentiate the cns depressant effects of either these medications or ddrug3 } , ddrug4 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug5 } , and HD00445 { concurrent use with ddrug7 may prolong and intensify the anticholinergic and cns depressant effects of ddrug8 } .",
        "label": "effect"
    },
    {
        "text": "DB00997 may interact with drugs known to interact with the conventional formulation of HD00473 .",
        "label": "NA"
    },
    {
        "text": "single doses of either DB01432 or DB00375 ddrug2 bind the ddrug3 and reduce its absorption from the gastrointestinal tract by up to # and # percent , respectively .",
        "label": "NA"
    },
    {
        "text": "in addition , DB01026 alone can inhibit adrenal HD00579 synthesis and may cause adrenal_insufficiency during corticosteroid withdrawal .",
        "label": "effect"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other HD00216 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } HD00220 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "cytochrome p-450 inducers , such as ddrug0 , DB00564 and ddrug2 , induce ddrug3 metabolism , causing an approximately 30 % decrease in plasma DB01068 levels .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , as with other HD00360 , should be administered with extreme caution to patients being treated with ddrug2 , HD00043 , or drugs known to prolong the qtc interval because the action of ddrug4 on the cardiovascular system may be potentiated by these agents .",
        "label": "advise"
    },
    {
        "text": "ddrug0 may interact with the following medications : DB00316 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { DB00091 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 increased the auc of ddrug2 , a sensitive cyp3a4 substrate , by # - fold on day # and # - fold on day 5 , when a single oral dose of DB00683 # mg was coadministered on day # and day # of a regimen of DB00673 # mg on day # and # mg/day on days # through 5 .",
        "label": "NA"
    },
    {
        "text": "in in vivo studies , 10 - to 30-mg/day doses of DB01238 had no significant effect on metabolism by cyp2d6 { ddrug1 } , cyp2c9 { ddrug2 } , cyp2c19 { DB00338 , ddrug4 } , and cyp3a4 { ddrug5 } substrates .",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , ddrug3 , or ddrug4 , with ddrug5 , with metal cations such as ddrug6 , or with ddrug7 containing DB01592 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of HD00532 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "the mean qt c interval { msec } was # with ddrug0 alone and # with DB00342 plus DB00954 .",
        "label": "effect"
    },
    {
        "text": "no depressant effect on blood levels in humans was noted when ddrug0 was administered with any of the following drugs : ddrug1 , DB01190 , ddrug3 , ddrug4 , ddrug5 { ddrug6 } , ddrug7 , ddrug8 or DB00682 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , DB00091 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , DB00503 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "since DB00964 may reduce pulse and blood pressure , caution in using drugs such as HD00254 { ophthalmic and systemic } , ddrug2 , and ddrug3 is advised .",
        "label": "advise"
    },
    {
        "text": "ddrug0 also should be used cautiously with other drugs { e , g , , HD00118 , ddrug2 } that sensitize the myocardium to the actions of HD00390 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with DB02325 , ddrug2 s , ddrug3 { allergy , cold , and sinus medicines } , diabetic drugs , ddrug4 , ddrug5 , ddrug6 like DB00788 or ddrug8 , and high blood pressure medications .",
        "label": "NA"
    },
    {
        "text": "these include DB01032 , DB01432 , and some ddrug2 { e , g , ddrug3 , rifamipicin , ddrug4 and ddrug5 } .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of DB00861 and DB00316 in dogs , but not in rats , at approximately # times the recommended maximum human therapeutic dose of each { 40 to # mg/kg/day of ddrug2 / ddrug3 } resulted in greater gastrointestinal toxicity than when either drug was administered alone .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : DB00695 administered concurrently with DB01197 does not alter the pharmacokinetics of ddrug3 in renally impaired hypertensive patients .",
        "label": "NA"
    },
    {
        "text": "DB01174 : decreases DB00945 effectiveness by enzyme induction .",
        "label": "mechanism"
    },
    {
        "text": "since the concomitant administration of DB00682 with DB01118 increases the prothrombin time by 100 % after # to # days , the dose of the ddrug2 should be reduced by one-third to one-half , and prothrombin times should be monitored closely .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , HD00246 and HD00218 : concomitant treatment with ddrug3 , ddrug4 , or ddrug5 may potentiate a possible hypokalemic effect of ddrug6",
        "label": "NA"
    },
    {
        "text": "ddrug0 should be administered with caution to patients who are taking other HD00826 or HD00261 , including ddrug3 , ddrug4 and ddrug5 , or to those with a history of psychiatric disorder { including manic-depressive illness and schizophrenia } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : immediate release capsules : there have been rare reports of an interaction between ddrug1 and DB01115 { with a decreased plasma level of DB00908 } .",
        "label": "NA"
    },
    {
        "text": "in a phase i trial using escalating doses of DB01229 { 110 - 200 mg/m2 } and ddrug1 { 50 or # mg/m2 } given as sequential infusions , myelosuppression was more profound when ddrug2 was given after ddrug3 than with the alternate sequence { ie , ddrug4 before DB00515 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 and HD00218 : concomitant treatment with HD00741 , ddrug4 , or ddrug5 may potentiate a possible hypokalemic effect of ddrug6",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , DB00776 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , DB00295 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "since ddrug0 { ddrug1 } may interact with concurrently administered ddrug2 , periodic serum level determinations of these drugs may be necessary { eg , DB00593 may elevate DB00252 serum levels and ddrug5 has been reported to both increase and decrease ddrug6 levels } .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , DB00860 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { HD00531 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "use of ddrug0 with ddrug1 { e , g , , DB00421 , ddrug3 , or ddrug4 } , DB14500 supplements , or potassium-containing salt substitutes may lead to significant increases in serum potassium .",
        "label": "NA"
    },
    {
        "text": "DB00661 also significantly decreased the incidence of lymphatic invasion of adenocarcinomas , which was enhanced by DB11724 .",
        "label": "effect"
    },
    {
        "text": "DB00753 or ddrug1 administered with DB06690 / ddrug3 to achieve # mac -lsb- minimum alveolar concentration -rsb- may prolong the clinically effective duration of action of initial and maintenance doses of ddrug4 and decrease the required infusion rate of ddrug5 .",
        "label": "NA"
    },
    {
        "text": "the concurrent use of DB00986 injection with other ddrug1 or medications with anticholinergic activity , such as ddrug2 , HD00769 , or ddrug4 , may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects .",
        "label": "effect"
    },
    {
        "text": "ddrug0 - HD00544 may sterilize the bowel and decrease the DB01022 contribution to the body by the intestinal microflora .",
        "label": "NA"
    },
    {
        "text": "if DB01239 is given concomitantly with ddrug1 , the HD00023 dose should be reduced { by approx , 50 % } , because ddrug3 amplifies the therapeutic actions and side-effects of ddrug4 massively .",
        "label": "NA"
    },
    {
        "text": "effect of ddrug0 on the pharmacokinetics of other drugs : DB01068 does not appear to alter the pharmacokinetics of ddrug2 , ddrug3 , or DB01174 .",
        "label": "NA"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / ddrug1 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , HD00516 pain medication { e , g , , DB00318 } , drugs used to aid sleep , drowsiness-causing ddrug13 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "in some patients , a DB00822 - like reaction may be produced by the ingestion of DB02325 .",
        "label": "NA"
    },
    {
        "text": "DB14513 - and/or ddrug1 - containing ddrug2 , products containing ddrug3 { DB01592 } , ddrug5 containing ddrug6 or other metal cations , or ddrug7 { ddrug8 } chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after ddrug9 .",
        "label": "NA"
    },
    {
        "text": "in addition , DB00776 and HD00888 induce a subgroup of the cytochrome cyp2b6 3a family { cyp3a4 and cyp3a5 } responsible for the metabolism of ddrug2 and oral ddrug3 , resulting in a lower plasma concentration of these drugs .",
        "label": "NA"
    },
    {
        "text": "cohort # then received ddrug0 plus DB00615 for # days , and cohort # received ddrug2 plus DB01045 for # days .",
        "label": "NA"
    },
    {
        "text": "urinary alkalinizing agents { ddrug0 , some HD00217 } increase the concentration of the non-ionized species of the DB00182 molecule , thereby decreasing urinary excretion .",
        "label": "mechanism"
    },
    {
        "text": "drug interaction studies have shown that DB00736 does not have any clinically significant interactions with ddrug1 , ddrug2 , ddrug3 , DB01211 or ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 or other HD00628 { concurrent use with DB12789 may result in uterine hypertonus , possibly causing uterine rupture or cervical laceration , especially in the absence of adequate cervical dilatation ;",
        "label": "effect"
    },
    {
        "text": "an increase in serum ddrug0 concentration has been reported during concomitant administration of DB14507 with DB00796 , so careful monitoring of serum ddrug3 levels is recommended during concomitant use .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : coadministration of ddrug1 and DB00661 resulted in a 24 % increase in plasma concentrations of DB00918 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : since DB00714 is a ddrug2 , it is possible that HD00339 , such as the ddrug4 { ddrug5 , ddrug6 , ddrug7 } or ddrug8 , may diminish the effectiveness of ddrug9 .",
        "label": "NA"
    },
    {
        "text": "{ HD00217 may decrease arterial responsiveness to DB00368 .",
        "label": "effect"
    },
    {
        "text": "caution should be used when DB00969 and DB01026 are administered concomitantly .",
        "label": "advise"
    },
    {
        "text": "increases in plasma levels of ddrug0 , and in the frequency and severity of side effects , particularly HD00315 , have been reported when ddrug2 was added to the HD00317 regimen .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB11094 dosage must be determined with care in patients undergoing treatment with HD00118 , as hypercalcemia in such patients may precipitate cardiac arrhythmias .",
        "label": "advise"
    },
    {
        "text": "HD00293 such as ddrug1 , ddrug2 , or DB00594 , or ddrug4 supplements should be given only for documented hypokalemia , and then with caution , since they may lead to a significant increase of serum potassium .",
        "label": "NA"
    },
    {
        "text": "ddrug0 HD00897 # , 25 , and # mg , each dose administered once daily for # days , had no effect on the plasma concentration of ddrug2 as measured by auc0 - 24hr in patients receiving single weekly DB00563 doses of # to # mg for rheumatoid arthritis .",
        "label": "NA"
    },
    {
        "text": "in vitro studies have shown no binding displacement between DB00494 and other highly bound drugs , such as ddrug1 , ddrug2 , ddrug3 , and DB00829 .",
        "label": "NA"
    },
    {
        "text": "DB00091 - DB00125 may counteract the antinaturetic effect of ddrug2 .",
        "label": "NA"
    },
    {
        "text": "a similar association , though less marked , has been suggested with HD00026 , phenyl-butazone , ddrug1 , ddrug2 and possibly with ddrug3 , DB00415 , and ddrug5 { 72 }",
        "label": "NA"
    },
    {
        "text": "the effects of DB01221 and of ddrug1 anesthesia on HD00118 tolerance in dogs .",
        "label": "NA"
    },
    {
        "text": "- when ddrug0 or ddrug1 is used concurrently with ddrug2 { e , g , HD00419 } , an interval of at least # hours should be maintained between the two medicines , since the absorption of HD00414 or ddrug5 is impaired",
        "label": "NA"
    },
    {
        "text": "other drugs : in healthy volunteers , ddrug0 , ddrug1 , DB01016 , ddrug3 , ddrug4 , hormone replacement therapy { a combination of conjugated ddrug5 and ddrug6 } , ddrug7 { ddrug8 and ddrug9 } and ddrug10 did not affect the pharmacokinetics of DB00204 .",
        "label": "NA"
    },
    {
        "text": "repeated oral administration of DB11390 in sheep : interactions of ddrug1 with HD00159 , ddrug3 , and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 : coadministration of ddrug2 with HD00872 resulted in a 47 % decrease in DB00977 and an 18 % decrease in ddrug5 plasma concentrations .",
        "label": "NA"
    },
    {
        "text": "HD00399 may reduce the antihypertensive effects of ddrug1 , ddrug2 , DB00968 and ddrug4 .",
        "label": "effect"
    },
    {
        "text": "due to high inter-patient variability and limited sampling , the extent of the increase in HD00413 levels in patients receiving concurrent DB00762 and ddrug2 is uncertain .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : patients on HD00218 , especially those with intravascular volume depletion , may occasionally experience an excessive reduction of blood pressure after initiation of therapy with DB00492 .",
        "label": "effect"
    },
    {
        "text": "DB14507 - coadministration of racemic ddrug1 { 40 mg/day for # days } and ddrug2 { 30 mmol/day for # days } had no significant effect on the pharmacokinetics of DB00215 or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "drugs that should not be coadministered with DB00220 ddrug1 : ddrug2 , ddrug3 ddrug4 : ddrug5 , DB00342 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "label": "advise"
    },
    {
        "text": "ddrug0 : drugs such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , DB01611 and others that interfere with platelet-aggregation reactions { the main hemostatic defense of heparinized patients } may induce bleeding and should be used with caution in patients receiving DB01109 .",
        "label": "effect"
    },
    {
        "text": "both DB00390 and DB01136 slow av conduction .",
        "label": "effect"
    },
    {
        "text": "in patients receiving ddrug0 { DB01033 } or ddrug2 { DB00993 } , the concomitant administration of 300 - 600 mg of ddrug4 per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of ddrug5 or ddrug6 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 # mg qd or DB00999 / ddrug2 50/100 mg qd was co-administered with ddrug3 { 500 mcg bid } for # days { following # days of HD00295 use at half dose } .",
        "label": "NA"
    },
    {
        "text": "nephrotoxicity has been reported following concomitant administration of ddrug0 with HD00447 or potent HD00218 such as ddrug3 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of ddrug1 , DB00252 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , certain ddrug7 , ddrug8 , DB00277 and ddrug10 , thereby delaying elimination and increasing blood levels of these drugs .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may increase the ototoxic potential of other drugs such as HD00494 and some HD00495 .",
        "label": "NA"
    },
    {
        "text": "if a patient requires ddrug0 and ddrug1 therapy , it is suggested that ddrug2 , ddrug3 , or ddrug4 { ddrug5 and ddrug6 } be used as alternatives to DB00501 , as these agents have no effect on the pharmacokinetic profile of DB00204 .",
        "label": "NA"
    },
    {
        "text": "effects of ddrug0 on low-dose HD00717 a group of # nonsmoking , healthy white female volunteers established on an oral ddrug2 regimen containing # mg ddrug3 and # mg ddrug4 for at least # months received # mg/day of DB00949 from midcycle { day 15 } to midcycle { day 14 } of two consecutive oral ddrug6 cycles .",
        "label": "NA"
    },
    {
        "text": "HD00203 : in in vitro studies , m1 was shown to cause increases ranging from # - 50 % in the free fraction of ddrug1 and DB01050 at concentrations in the clinical range .",
        "label": "NA"
    },
    {
        "text": "DB00559 is also expected to reduce plasma concentrations of other ddrug1 that have significant metabolism by cyp3a4 , such as ddrug2 and DB01076 .",
        "label": "mechanism"
    },
    {
        "text": "the serum concentration of DB00252 increased dramatically from # to # microg/ml when ddrug1 was coadministered , although the daily dosage of ddrug2 and other HD00096 had not changed .",
        "label": "NA"
    },
    {
        "text": "nephrotoxic agents : concomitant administration of DB00369 and agents with nephrotoxic potential -lsb- e , g , , intravenous ddrug1 { e , g , , ddrug2 , ddrug3 , and ddrug4 } , ddrug5 , ddrug6 , intravenous ddrug7 , DB00512 , and ddrug9 -rsb- is contraindicated .",
        "label": "advise"
    },
    {
        "text": "increased hepatotoxicity of DB00316 by concomitant administration of DB00201 in the rat .",
        "label": "effect"
    },
    {
        "text": "drugs decreasing ddrug0 effect : ddrug1 , HD00239 , ddrug3 , or ddrug4 may partially counteract the anticoagulant action of DB01109 .",
        "label": "effect"
    },
    {
        "text": "a pharmacokinetic interaction between DB00343 and DB00091 has been observed during studies involving renal and cardiac transplant patients .",
        "label": "int"
    },
    {
        "text": "ddrug0 : a clinical study in # insulin-dependent diabetic patients demonstrated no effect of DB00702 on ddrug2 absorption from the peritoneal cavity or on ddrug3 s ability to control blood glucose when HD00071 was administered intraperitoneally with ddrug5 .",
        "label": "NA"
    },
    {
        "text": "drug interactions : the central HD00315 syndrome can occur when anticholinergic agents such as ddrug1 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain HD00424 such as ddrug3 , the ddrug4 and other ddrug5 , ddrug6 , certain ddrug7 such as the ddrug8 salts , and ddrug9 .",
        "label": "effect"
    },
    {
        "text": "agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of ddrug0 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 { 2 } , ddrug7 , DB05246 , and ddrug9 thus , if a patient has been titrated to a stable dosage on HD00472 , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for ddrug11 may be necessary .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : etodolac has no apparent pharmacokinetic interaction when administered with DB00695 or DB00999 .",
        "label": "NA"
    },
    {
        "text": "- ddrug0 { e , g , , DB01022 , ddrug2 } use of DB00891 with these medicines may increase the chance of side effects affecting the blood",
        "label": "NA"
    },
    {
        "text": "although ddrug0 used alone has little or no effect on pupil size , mydriasis resulting from concomitant therapy with DB01210 and DB00668 may occur .",
        "label": "effect"
    },
    {
        "text": "DB00575 may enhance the cns-depressive effects of DB02325 , ddrug2 or other ddrug3 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : serum DB00252 levels may be increased by DB00945 .",
        "label": "effect"
    },
    {
        "text": "because the HD00239 have been shown to depress plasma prothrombin activity , patients who are on HD00025 therapy may require downward adjustment of their ddrug2 dosage .",
        "label": "advise"
    },
    {
        "text": "ddrug0 HD00608 are inhibited by HD00401 .",
        "label": "effect"
    },
    {
        "text": "elevated serum levels of DB00091 have been reported with concomitant use of ddrug1 with DB01059 .",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , ddrug3 , or ddrug4 , with ddrug5 , with metal cations such as ddrug6 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { DB00900 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of HD00532 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "formulation of fluorescence labelled ddrug0 and HD00071 in unconjugated HD00072 { 1 % m/v } did not significantly improve the permeation , however in the presence of 1 % { m/v } ddrug3 # a significantly improved permeation was observed { r = # } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 had no effect on the pharmacokinetics of either DB00199 or DB01026 .",
        "label": "NA"
    },
    {
        "text": "DB00877 works differently from the ddrug1 currently available , and except for increased lipid levels , the adverse reaction profile of ddrug2 does not appear to overlap to any great extent with that associated with DB00091 or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 / HD00024 / ddrug2 / ddrug3 : co-administration of ddrug4 with ddrug5 , ddrug6 , ddrug7 , and HD00263 is likely to lead to an enhancement of effects .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - administration of # mg/day DB01175 for # days in healthy volunteers resulted in a 50 % increase in cmax and 82 % increase in auc of the HD00693 ddrug3 { given in a single dose of # mg } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 s : ddrug1 should be administered at least # hours after or # hours before dosing with DB00537 because plasma concentrations of ddrug3 are decreased when administered with ddrug4 containing ddrug5 , ddrug6 , or DB01370 .",
        "label": "NA"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { ddrug1 s } , ddrug2 , ddrug3 { ddrug4 may decrease the effects of these medicines } , ddrug5 { using these medicines with ddrug6 may result in increased cns depressant effects } , ddrug7 , ddrug8 { using these medicines with ddrug9 may change the amount of either medicine that you need to take } , and oral ddrug10 containing HD00220 { ddrug12 may decrease the effectiveness of these oral HD00283 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : DB01118 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 ddrug11 , DB00897 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "DB00990 is extensively metabolized by ppig 3a4 , but coadministration of DB01026 , a potent inhibitor of ppig 3a4 , has no significant effect on ddrug2 pharmacokinetics .",
        "label": "NA"
    },
    {
        "text": "specific effects of ddrug0 on other ddrug1 ddrug2 : DB00949 causes an increase in steady-state DB00252 plasma concentrations .",
        "label": "mechanism"
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , DB14513 , or ddrug4 , with ddrug5 , with metal cations such as ddrug6 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of HD00532 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "when used in therapeutic doses , DB00207 had a modest effect on the pharmacokinetics of ddrug1 , DB00564 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { intravenous and oral } , ddrug12 , ddrug13 / ddrug14 or ddrug15 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : ddrug1 contraindicated since the coadministration of this product with DB01232 in an HD00056 regimen reduces the plasma concentrations of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "it is recommended that DB00490 not be used concomitantly with ddrug1 because the effects of concomitant administration of ddrug2 with most other HD00456 have not been studied , the concomitant use of ddrug4 with other cns-active drugs should be approached with caution .",
        "label": "NA"
    },
    {
        "text": "in a controlled clinical trial , a 20 % reduction of the DB00252 dose at the initiation of DB00949 therapy resulted in ddrug2 levels comparable to those prior to ddrug3 administration .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { DB00252 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , DB00812 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : HD00403 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } DB01235 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "ddrug0 { DB00999 } alone or in combination with DB00384 : concomitant use of ddrug3 alone or in combination with ddrug4 is contraindicated .",
        "label": "NA"
    },
    {
        "text": "no significant drug interactions have been reported in studies of ddrug0 given with other drugs such as DB01016 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , and oral ddrug6 in healthy volunteers , or given with DB00584 to patients with heart failure { nyha class ii and iii } .",
        "label": "NA"
    },
    {
        "text": "agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of ddrug0 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 , DB01174 , ddrug6 { 2 } , ddrug7 , ddrug8 , and ddrug9 thus , if a patient has been titrated to a stable dosage on HD00472 , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for ddrug11 may be necessary .",
        "label": "NA"
    },
    {
        "text": "hepatic enzyme inducers , inhibitors and substrates : drugs which induce cytochrome p450 3a4 { cyp 3a4 } enzyme activity { e , g , , HD00026 , ddrug1 , ddrug2 , ddrug3 } may enhance the metabolism of HD00175 and require that the dosage of the ddrug5 be increased .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : in vitro and/or in vivo data indicate that ddrug1 , ddrug2 , and oral DB01026 markedly inhibit the metabolism of DB00604 , which can result in an increase in plasma ddrug5 levels and prolongation of the qt interval on the ecg .",
        "label": "mechanism"
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a ddrug0 , including ddrug1 , with multivalent cation-containing products such as ddrug2 or ddrug3 ddrug4 , DB00364 , ddrug6 chewable/buffered tablets or pediatric powder , or products containing DB01373 , ddrug8 , or ddrug9 may substantially decrease the absorption of ddrug10 , resulting in serum and urine levels considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "HD00227 , such as DB00206 , may have an additive effect when given with ddrug2 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - combined administration of racemic ddrug1 { 40 mg } and ddrug2 { 200 mg } decreased the cmax and auc of DB01026 by 21 % and 10 % , respectively , and did not significantly affect the pharmacokinetics of DB00215 .",
        "label": "NA"
    },
    {
        "text": "based on adult data , lower doses of ddrug0 may be needed following coadministration of drugs which are reported to decrease ddrug1 elimination { e , g , , DB00501 and ddrug3 } and higher ddrug4 doses may be needed following coadministration of drugs that increase ddrug5 elimination { e , g , , ddrug6 and DB00252 } .",
        "label": "NA"
    },
    {
        "text": "because prostaglandins play an important role in hemostasis , and ddrug0 affect platelet function as well , concurrent therapy with all ddrug1 , including DB00586 , and DB00682 requires close monitoring of patients to be certain that no change in their ddrug4 dosage is required .",
        "label": "advise"
    },
    {
        "text": "co-administration of cyp3a4 inhibitors { eg , DB01026 , ddrug1 , ddrug2 , grapefruit juice , ddrug3 } with DB01023 may lead to several - fold increases in the plasma levels of ddrug5 , either due to an increase in bioavailability or due to a decrease in metabolism .",
        "label": "NA"
    },
    {
        "text": "for comprehensive information concerning laboratory test alterations associated with DB00503 , physicians should refer to the complete prescribing information for DB00503 { ddrug2 } .",
        "label": "NA"
    },
    {
        "text": "the physician should be cautious when administering DB00712 to patients taking HD00326 .",
        "label": "advise"
    },
    {
        "text": "serum ddrug0 concentrations increase when DB00365 is initiated in a patient maintained on DB00277 .",
        "label": "mechanism"
    },
    {
        "text": "when initiating a multi-day course of DB00365 in a patient maintained on ddrug1 , the DB00277 maintenance dose should be halved for the period of concurrent use of ddrug3 and monitoring of serum ddrug4 concentrations should be initiated as a guide to further dosage adjustments .",
        "label": "NA"
    },
    {
        "text": "therefore , extreme caution should be exercised when administering DB00988 to patients receiving DB13984 or ddrug2 .",
        "label": "advise"
    },
    {
        "text": "cardiac effects of ddrug0 are antagonized by HD00244 , such as DB00571 and ddrug3 .",
        "label": "NA"
    },
    {
        "text": "if leprosy-associated inflammatory reactions develop in patients being treated with DB00250 and DB00845 , it is still advisable to continue treatment with both drugs .",
        "label": "advise"
    },
    {
        "text": "HD00574 may also interfere with the absorption of oral ddrug1 supplements and DB14539 .",
        "label": "mechanism"
    },
    {
        "text": "therefore , the combined use of DB00227 with HD00550 should generally be avoided .",
        "label": "advise"
    },
    {
        "text": "ddrug0 including ddrug1 , ddrug2 , and DB01626 hc1 : concomitant use of DB00135 and non-selective ddrug5 may cause hypertension .",
        "label": "NA"
    },
    {
        "text": "the clearance of ddrug0 metabolized by glucuronidation { e , g , , DB00186 , ddrug2 , ddrug3 } is unlikely to be affected by DB00176 .",
        "label": "NA"
    },
    {
        "text": "additive cns depression may occur when HD00388 are administered concomitantly with other ddrug1 including HD00026 , ddrug3 , and ddrug4 .",
        "label": "effect"
    },
    {
        "text": "drug interaction studies have shown that DB00736 does not have any clinically significant interactions with ddrug1 , ddrug2 , DB00908 , ddrug4 or ddrug5 .",
        "label": "NA"
    },
    {
        "text": "therefore , prothrombin time should be carefully monitored in patients receiving DB01167 and DB04665 - like drugs simultaneously .",
        "label": "advise"
    },
    {
        "text": "possible extrarenal mechanisms of action of ddrug0 on HD00191 and DB08948 transport were also examined .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in clinical drug interaction studies , DB00673 did not have clinically important effects on the pharmacokinetics of ddrug2 or DB00889 .",
        "label": "NA"
    },
    {
        "text": "concurrent administration of ddrug0 and ddrug1 significantly reduces the level of exposure to ddrug2 , but it is unclear how soon after DB00900 administration DB00224 may be given safely .",
        "label": "NA"
    },
    {
        "text": "the concomitant use of DB02325 or other HD00389 may have an additive effect .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : concomitant administration of HD00374 containing DB14513 or ddrug3 with ddrug4 chewable/dispersible buffered tablets or pediatric powder for oral solution may potentiate adverse events associated with the ddrug5 components .",
        "label": "NA"
    },
    {
        "text": "ddrug0 can interact with ddrug1 or other ddrug2 { may potentiate the cns depressant effects of either these medications or ddrug3 } , HD00444 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with HD00388 } , and ddrug6 { concurrent use with ddrug7 may prolong and intensify the anticholinergic and cns depressant effects of ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "the absorption of oral DB01155 is significantly reduced by the concomitant administration of an DB06724 containing ddrug2 and ddrug3 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and foods fortified with ddrug1 concomitant administration of DB00535 with a therapeutic ddrug3 containing # mg of elemental ddrug4 { as feso4 } or ddrug5 supplemented with # mg of elemental DB01592 reduced extent of absorption by 80 % and 31 % , respectively .",
        "label": "mechanism"
    },
    {
        "text": "other no clinically important pharmacokinetic interactions occurred when DB00542 was administered concomitantly with DB00999 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , or ddrug8 .",
        "label": "NA"
    },
    {
        "text": "because ddrug0 binds bile acids , ddrug1 HD00524 may interfere with normal fat digestion and absorption and thus may prevent absorption of HD00465 such as a , d , e , and k.",
        "label": "NA"
    },
    {
        "text": "in clinical studies where patients were on chronic ddrug0 therapy , DB00978 had no measurable effect on the mean distribution of ddrug2 concentrations or the mean estimates of DB00277 clearance .",
        "label": "NA"
    },
    {
        "text": "the HD00146 - induced neuronal damage produced a tolerance to the disruptive effects of DB00182 and a supersensitivity to the disruptive effects of ddrug2 in rats responding in a schedule controlled paradigm .",
        "label": "effect"
    },
    {
        "text": "no interaction with the ddrug0 ddrug1 was shown in a single-dose study with DB00494 without coadministered ddrug3 / HD00682 .",
        "label": "NA"
    },
    {
        "text": "the concomitant use of transdermal ddrug0 with ddrug1 or other potent 3a4 inhibitors such as ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB00220 , and nefazadone may result in an increase in DB00813 plasma concentrations .",
        "label": "NA"
    },
    {
        "text": "therefore , when ddrug0 and HD00518 are used concomitantly , the patient should be observed closely to determine if the desired effect of the HD00295 is obtained .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : HD00532 , including ddrug2 , decrease the clearance of ddrug3 , the less active isomer of racemic DB00682 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration of HD00377 did not have any effect on either the safety or efficacy of DB00308 in the clinical trials .",
        "label": "NA"
    },
    {
        "text": "effects of other ddrug0 on ddrug1 ddrug2 : ddrug3 causes an approximate doubling of the clearance of ddrug4 { ddrug5 } at steady state and , therefore , the addition of DB00252 causes an approximate 45 % decrease in the steady-state trough concentrations of ddrug7 as compared to the same dose of DB00949 given as monotherapy .",
        "label": "NA"
    },
    {
        "text": "DB00199 : in healthy individuals , plasma concentrations of ddrug1 increased approximately 40 % with coadministration of DB01076 and ddrug3 , a known inhibitor of cytochrome p450 3a4 .",
        "label": "NA"
    },
    {
        "text": "the effectiveness of ddrug0 - only pills is reduced by hepatic enzyme-inducing drugs such as the HD00282 ddrug2 , DB00564 , and ddrug4 , and the ddrug5 ddrug6 .",
        "label": "NA"
    },
    {
        "text": "when DB00572 and DB00733 are used together , the signs of atropinization { flushing , mydriasis , tachycardia , dryness of the mouth and nose } may occur earlier than might be expected than when ddrug2 is used alone because ddrug3 may potentiate the effect of ddrug4 .",
        "label": "effect"
    },
    {
        "text": "DB00252 increases the clearance of DB01008 by 15 % or more , possibly due to the induction of glutathione-s-transferase .",
        "label": "mechanism"
    },
    {
        "text": "DB00261 alone had no effect on platelet aggregation , but did slightly enhance the inhibition of platelet aggregation by DB00945 .",
        "label": "effect"
    },
    {
        "text": "the risk of using DB01200 in combination with other drugs has not been systematically evaluated , but DB02325 may potentiate the side effects of ddrug2 .",
        "label": "NA"
    },
    {
        "text": "endothelium-intact aortic rings from high - DB00783 rats were supersensitive to ddrug1 when compared to vehicle - , ddrug2 - and DB00396 + high - ddrug4 - treated rats { pd2 values = # + / # , # + / # , # + / # and # + / # , respectively } .",
        "label": "NA"
    },
    {
        "text": "specific drug interaction studies have not been performed with ddrug0 and HD00672 other than ddrug2 and DB00495 .",
        "label": "NA"
    },
    {
        "text": "these increased exposures of DB00717 and ddrug1 should be taken into consideration when selecting an oral ddrug2 for women taking DB00580 .",
        "label": "NA"
    },
    {
        "text": "to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma { hiv-nhl } , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the ddrug0 , DB00997 , ddrug2 , and ddrug3 { chop } chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen { i , e , , ddrug4 , ddrug5 , ddrug6 , and ddrug7 with ddrug8 plus DB00290 } without receiving ddrug10 therapy .",
        "label": "NA"
    },
    {
        "text": "DB00233 may decrease the amount of ddrug1 { ddrug2 , DB00390 } that gets absorbed into your body .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 DB00564 { ddrug6 } DB00501 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : ddrug1 ; DB00753 ; ddrug3 ; certain ddrug4 , especially the ddrug5 and ddrug6 ; DB14507 ; ddrug8 salts ; ddrug9 ; and ddrug10 .",
        "label": "NA"
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the ddrug0 of drugs may be potentiated by ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , the ddrug6 , ddrug7 and HD00560 , ddrug9 and the HD00043 , and by other ddrug11 .",
        "label": "NA"
    },
    {
        "text": "however , because some HD00532 have been reported to enhance the anticoagulant effects of ddrug1 or its derivatives in patients , the prothrombin time or other suitable coagulation test should be closely monitored if a HD00751 is administered concomitantly with ddrug3 or its derivatives .",
        "label": "NA"
    },
    {
        "text": "ddrug0 treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than DB00502 , and to broadly the same extent as DB00734 .",
        "label": "NA"
    },
    {
        "text": "ingestion of ddrug0 may increase serum concentrations of ddrug1 and DB00563 and increase DB00091 s nephrotoxicity .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as DB00415 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , DB01045 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "DB00994 has no effect on the blood pressure or metabolic responses to DB01285 in sheep .",
        "label": "NA"
    },
    {
        "text": "HD00282 : ddrug1 ddrug2 DB00564",
        "label": "NA"
    },
    {
        "text": "HD00010 , at ph # , was used to chemically modify exposed histidine residues on HD00011 .",
        "label": "NA"
    },
    {
        "text": "the effectiveness of ddrug0 - only pills is reduced by hepatic enzyme-inducing drugs such as the ddrug1 ddrug2 , ddrug3 , and HD00026 , and the HD00886 ddrug6 .",
        "label": "NA"
    },
    {
        "text": "effects of other ddrug0 on ddrug1 ddrug2 : ddrug3 causes an approximate doubling of the clearance of ddrug4 { DB00949 } at steady state and , therefore , the addition of ddrug6 causes an approximate 45 % decrease in the steady-state trough concentrations of DB00949 as compared to the same dose of ddrug8 given as monotherapy .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - and/or ddrug1 - containing ddrug2 , products containing ddrug3 { DB01592 } , HD00752 containing ddrug6 or other metal cations , or ddrug7 { ddrug8 } chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after ddrug9 .",
        "label": "NA"
    },
    {
        "text": "no differences in adverse events or qtc interval were observed when subjects were administered DB00950 alone or in combination with either ddrug1 or DB01026 .",
        "label": "NA"
    },
    {
        "text": "drugs that reportedly may increase oral HD00025 response , ie , increased prothrombin response , in man include : DB02325 * ;",
        "label": "effect"
    },
    {
        "text": "lethargy and somnolence have been reported following doses of DB00704 and DB00679 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { DB00400 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , DB01045 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and HD00466 { hypertension } - in clinical studies of patients with hypertension , the addition of ddrug2 # to # mg to HD00106 and ddrug4 increased mean serum potassium slightly { about # # meq/l } .",
        "label": "NA"
    },
    {
        "text": "HD00128 : ddrug1 , DB00864 , ddrug3",
        "label": "NA"
    },
    {
        "text": "however , in a study of # normal subjects , concurrent administration of ddrug0 decreased DB01009 protein binding and increased ddrug2 plasma clearance from # l/kg/h without ddrug3 to # l/kg/h with DB00945 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , DB00949 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , DB00295 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "DB00712 pretreatment attenuated the hypotensive effect of a single dose of ddrug1 but not DB00335 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { DB01076 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , DB00231 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "in a pharmacokinetic study , # healthy female subjects received DB00176 in escalating doses from # to # mg per day for # days , with coadministration of DB00969 # mg on the last day .",
        "label": "NA"
    },
    {
        "text": "consequently , concomitant administration of DB00673 with strong cyp3a4 inhibitors { e , g , , ddrug1 , ddrug2 , ddrug3 , DB13179 , ddrug5 , ddrug6 , ddrug7 } should be approached with caution .",
        "label": "advise"
    },
    {
        "text": "ddrug0 DB01026 ddrug2 ddrug3 ddrug4 HD00324 ddrug6 ddrug7 large quantities of grapefruit juice { # quart daily }",
        "label": "NA"
    },
    {
        "text": "DB00294 may interact with the following medications : DB00316 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "int"
    },
    {
        "text": "therefore , when DB00700 and HD00203 are used concomitantly , patients should be observed to determine whether the desired effect on blood pressure is obtained .",
        "label": "advise"
    },
    {
        "text": "DB00715 : coadministration of once daily doses of DB00673 , as a tablet formulation comparable to # mg or # mg of the capsule formulation , with ddrug2 # mg once daily , resulted in a decrease in auc by approximately 25 % and cmax , by approximately 20 % of both ddrug3 and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "antiacid , ddrug0 , ddrug1 , ddrug2 , ddrug3 , indanavir , ddrug4 , DB00252 , phenobarbitol , ddrug6 , ddrug7 , DB01045 , ritanovir , ddrug9 .",
        "label": "NA"
    },
    {
        "text": "while all the HD00113 { ddrug1 } , e , g , , ddrug2 , DB01175 , ddrug4 , ddrug5 , and ddrug6 , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { e , g , , ddrug1 , ddrug2 , DB00257 , ddrug4 , etc , } : in vitro and animal studies with the combination of ddrug5 and ddrug6 suggest that HD00319 may induce fungal resistance to ddrug8 .",
        "label": "NA"
    },
    {
        "text": "before taking DB00222 , tell your doctor if you are taking any of the following medicines : - ddrug1 or another ddrug2 such as ddrug3 { ddrug4 } , ddrug5 { ddrug6 , others } , ddrug7 { ddrug8 } , DB01397 { ddrug10 } , or ddrug11 { ddrug12 } ;",
        "label": "advise"
    },
    {
        "text": "agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of HD00472 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 { 2 } , ddrug7 , ddrug8 , and DB00277 thus , if a patient has been titrated to a stable dosage on ddrug10 , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for ddrug11 may be necessary .",
        "label": "mechanism"
    },
    {
        "text": "concomitant use of ddrug0 and drugs that inhibit cyp3a4 { eg , ddrug1 , ddrug2 , ddrug3 , DB01211 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 } may increase exposure to DB01254 and should be avoided .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : other ddrug1 drugs , such as ddrug2 , ddrug3 , DB00280 , and ddrug5 , have been used concurrently with DB01118 .",
        "label": "NA"
    },
    {
        "text": "DB00196 , and the ddrug1 ddrug2 { ddrug3 } and ddrug4 { DB00889 } have all been used with ddrug6 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : HD00606 { ddrug2 , ddrug3 , ddrug4 , ddrug5 , fruit juices , etc , } lower absorption of HD00401 .",
        "label": "mechanism"
    },
    {
        "text": "DB00695 may decrease arterial responsiveness to DB00368 .",
        "label": "effect"
    },
    {
        "text": "hypotension was more likely to occur if the ddrug0 were a HD00412 , e , g , , ddrug2 , while left ventricular failure and av conduction disturbances , including complete heart block , were more likely to occur with either DB00661 or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , DB00091 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { HD00531 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "in patients with mild to moderate hypertension , administration of # mg daily of ddrug0 with the ddrug1 DB00542 , # to # mg for # weeks , was associated with an average increase in mean arterial pressure of about # mm hg compared to HD00471 alone .",
        "label": "NA"
    },
    {
        "text": "based on adult data , lower doses of DB00201 may be needed following coadministration of drugs which are reported to decrease ddrug1 elimination { e , g , , ddrug2 and ddrug3 } and higher ddrug4 doses may be needed following coadministration of drugs that increase ddrug5 elimination { e , g , , ddrug6 and DB00252 } .",
        "label": "NA"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : DB01118 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : DB01045 ddrug10 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "HD00512 reduce the renal clearance of DB14507 and add a high risk of ddrug2 toxicity .",
        "label": "mechanism"
    },
    {
        "text": "this interaction , which has not been investigated using higher doses of ddrug0 , may be more pronounced if a # mg daily dose is co-administered , particularly since ddrug1 exhibits non-linear pharmacokinetics over the dosage range 100 - 300 mg , if ddrug2 is co-administered with DB00176 tablets , the initial DB00404 dosage should be at least halved and titration to the lowest effective dose is recommended .",
        "label": "NA"
    },
    {
        "text": "HD00343 prolong and intensify the effects of HD00388 .",
        "label": "effect"
    },
    {
        "text": "DB00695 has a tendency to antagonize the skeletal muscle relaxing effect of ddrug1 and may potentiate the action of DB00202 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 , including ddrug1 , may enhance the effects of oral HD00326 , including DB00682 or its derivatives or similar agents .",
        "label": "NA"
    },
    {
        "text": "co-administration of DB01217 and DB00675 resulted in a reduction of ddrug2 plasma levels by 27 % compared with those achieved with ddrug3 alone .",
        "label": "mechanism"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : ddrug1 ; ddrug2 ; ddrug3 ; certain ddrug4 , especially the ddrug5 and HD00384 ; ddrug7 ; DB14513 salts ; ddrug9 ; and ddrug10 .",
        "label": "NA"
    },
    {
        "text": "if a HD00295 is also used , the risk of DB14507 toxicity may be increased .",
        "label": "effect"
    },
    {
        "text": "in single and multiple dose studies in healthy subjects receiving both DB00682 and DB00533 , prothrombin time { measured as inr } was increased by approximately 8 % to 11 % .",
        "label": "effect"
    },
    {
        "text": "-lsb- stimulation by ddrug0 -- an analog of the octapeptide cholecystokinin -- of ddrug1 binding after the long-term administration of ddrug2 -rsb- it has been established in experiments on white male rats that prolonged administration { twice a day for # days } of ddrug3 { # mg/kg } and ddrug4 { # mg/kg } resulted in the reduced interaction between ddrug5 and low affinity binding sites for DB00714 in subcortical structures , whereas HD00136 binding with high affinity binding sites for ddrug8 increased both in the frontal cortex and subcortical structures of the forebrain .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , DB01167 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { DB00701 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "using in situ hybridization , we observed that HD00015 caused a rapid and transient dose-dependent increase in arc mrna level in the striatum and cortex that was abolished by pretreatment with the specific drd1 antagonist ddrug1 but not by an ddrug2 DB00363 .",
        "label": "NA"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of DB00732 include : DB00228 ; ddrug2 ; ddrug3 ; certain ddrug4 , especially the ddrug5 and ddrug6 ; ddrug7 ; ddrug8 salts ; ddrug9 ; and ddrug10 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : ddrug1 , ddrug2 , ddrug3 , or HD00239 may interfere with the bactericidal effect of HD00124 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 administration to three cancer patients over a dose range of # mg to # mg led to a dose-dependent inhibition of DB01435 elimination # the effect of alternate-day administration of # mg of DB00068 on drug metabolism in ms patients is unknown .",
        "label": "NA"
    },
    {
        "text": "DB00333 : coadministration of DB00701 and ddrug2 can decrease plasma levels of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : DB00228 ; ddrug2 ; ddrug3 ; certain ddrug4 , especially the ddrug5 and ddrug6 ; ddrug7 ; ddrug8 salts ; ddrug9 ; and DB00908 .",
        "label": "NA"
    },
    {
        "text": "when administered concurrently , the following drugs may interact with HD00867 : HD00264 , general : exaggeration of the hypotension induced by general ddrug2 .",
        "label": "int"
    },
    {
        "text": "DB00446 has been shown to be antagonistic to ddrug1 , including DB00438 , based on in vitro studies and time kill curves with enteric gram-negative bacilli .",
        "label": "effect"
    },
    {
        "text": "while it is not known whether this interaction occurs with HD00550 other than DB01241 , myopathy and rhabdomyolysis have occasionally been associated with the use of ddrug2 alone , including ddrug3 .",
        "label": "NA"
    },
    {
        "text": "also , concomitant administration of ddrug0 with products containing ddrug1 , DB00152 containing ddrug3 , or ddrug4 { DB00900 } chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels .",
        "label": "NA"
    },
    {
        "text": "may interact with thyroid medication { e , g , , ddrug0 } , ddrug1 - containing products , ddrug2 , HD00613 { e , g , , ddrug4 , ddrug5 } , and ddrug6 { e , g , , ddrug7 , DB00338 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 : ddrug3 has no significant pharmacokinetic interactions with ddrug4 and ddrug5 , and DB00678 has no significant effect on plasma levels of DB00559 .",
        "label": "NA"
    },
    {
        "text": "- HD00175 , DB01285 : intensified electrolyte depletion , particularly hypokalemia",
        "label": "NA"
    },
    {
        "text": "if ddrug0 is to be combined with other HD00595 such as ddrug2 or ddrug3 / ddrug4 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of ddrug5 and ddrug6 { e , g , , DB00475 or ddrug8 } are additive .",
        "label": "NA"
    },
    {
        "text": "DB00531 used concurrently with DB00694 may also result in increased cardiotoxicity .",
        "label": "effect"
    },
    {
        "text": "the extent to which ddrug0 - HD00312 interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the HD00278 involved .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 : ddrug3 has no significant pharmacokinetic interactions with ddrug4 and DB00393 , and ddrug6 has no significant effect on plasma levels of DB00559 .",
        "label": "NA"
    },
    {
        "text": "plasma concentrations { auc 0 - 24 hrs } of DB00199 decreased 15 % with coadministration of DB00455 relative to that observed with ddrug2 alone .",
        "label": "mechanism"
    },
    {
        "text": "concomitant use of DB01247 and other HD00595 is generally not recommended because of possible potentiating effects .",
        "label": "advise"
    },
    {
        "text": "therefore , patients without a functioning ddrug0 gland who are on thyroid replacement therapy may need to increase their thyroid dose if HD00220 or ddrug2 - containing oral HD00283 are given .",
        "label": "NA"
    },
    {
        "text": "the ecg changes and/or hypokalemia that may result from the administration of HD00357 { such as ddrug1 or ddrug2 } can be acutely worsened by ddrug3 , especially when the recommended dose of the HD00359 is exceeded .",
        "label": "NA"
    },
    {
        "text": "particular caution is necessary when using ddrug0 in cases of mixed drug overdosage since the toxic effects { such as convulsions and cardiac dysrhythmias } of other drugs taken in overdose { especially ddrug1 } may emerge with the reversal of the DB12537 effect by DB01205 .",
        "label": "NA"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { ddrug1 s } , ddrug2 , ddrug3 { ddrug4 may decrease the effects of these medicines } , ddrug5 { using these medicines with ddrug6 may result in increased cns depressant effects } , DB00313 , ddrug8 { using these medicines with ddrug9 may change the amount of either medicine that you need to take } , and oral ddrug10 containing HD00220 { ddrug12 may decrease the effectiveness of these oral ddrug13 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "a # { 17 } % decrease in the steady-state auc of ddrug0 was observed when DB00900 was administered # hours prior to DB01004 , but not when the two drugs were administered simultaneously { n = 12 } .",
        "label": "mechanism"
    },
    {
        "text": "the onset of neuromuscular blockade by DB00202 was unaffected by DB00187 , but the duration of neuromuscular blockade was prolonged from # minutes to # minutes .",
        "label": "effect"
    },
    {
        "text": "agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of ddrug0 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 { 2 } , ddrug7 , ddrug8 , and DB00277 thus , if a patient has been titrated to a stable dosage on ddrug10 , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for HD00472 may be necessary .",
        "label": "NA"
    },
    {
        "text": "ddrug0 DB01026 ddrug2 ddrug3 ddrug4 ddrug5 ddrug6 DB00091 large quantities of grapefruit juice { # quart daily }",
        "label": "NA"
    },
    {
        "text": "in addition to the interactions noted above , chronic { # weeks } oral DB01118 administration impairs metabolism of ddrug1 , DB00514 , and ddrug3 .",
        "label": "NA"
    },
    {
        "text": "therefore , coadministration of ddrug0 with drugs that strongly induce cyp3a4 activity { e , g , , ddrug1 , ddrug2 , DB00252 } may result in reduced plasma concentrations of ddrug4 that may result in decreased efficacy of DB00673 .",
        "label": "NA"
    },
    {
        "text": "DB00964 should not be used in patients receiving HD00343 , .",
        "label": "advise"
    },
    {
        "text": "oral ddrug0 : DB00673 , when given once daily for # days as a 100-mg capsule with an oral ddrug2 containing # mcg of DB00977 and # mg of ddrug4 , decreased the auc of ddrug5 by 43 % , and decreased the auc of ddrug6 by 8 % ;",
        "label": "mechanism"
    },
    {
        "text": "when ddrug0 was coadministered with DB00252 , ddrug2 , or h2antagonists , reduced plasma concentrations of DB01167 were reported .",
        "label": "NA"
    },
    {
        "text": "concomitant use of ddrug0 and drugs that inhibit cyp3a4 { eg , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , DB00224 , ddrug8 , ddrug9 , ddrug10 , ddrug11 } may increase exposure to DB01254 and should be avoided .",
        "label": "NA"
    },
    {
        "text": "there are rare reports , however , from marketing experiences , of changes in effects of HD00071 or oral HD00062 in the presence of ddrug2 that necessitated changes in the doses of such agents .",
        "label": "NA"
    },
    {
        "text": "although not studied systematically in clinical trials , no drug interactions were observed when DB01339 , ddrug1 , or ddrug2 were administered following varying degrees of recovery from single doses or infusions of DB00565 .",
        "label": "NA"
    },
    {
        "text": "pharmacokinetic data from these patients demonstrated a decrease in DB01229 clearance of approximately 33 % when DB01229 was administered following ddrug2 .",
        "label": "NA"
    },
    {
        "text": "effects of ddrug0 on ddrug1 the rate and extent of absorption of a # mg dose of DB00949 as monotherapy given as tablets was not affected when coadministered with HD00374 .",
        "label": "NA"
    },
    {
        "text": "in clinical studies performed with DB00569 , the concomitant use of oral ddrug1 { ddrug2 } , ddrug3 { ddrug4 } , ddrug5 { ddrug6 } , and DB00390 did not significantly affect the pharmacokinetics/pharmacodynamics of ddrug8 .",
        "label": "NA"
    },
    {
        "text": "to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma { hiv-nhl } , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the ddrug0 , ddrug1 , DB00541 , and DB00898 { chop } chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen { i , e , , ddrug4 , ddrug5 , ddrug6 , and ddrug7 with ddrug8 plus ddrug9 } without receiving ddrug10 therapy .",
        "label": "NA"
    },
    {
        "text": "in controlled clinical trials of ddrug0 , # patients received concomitant DB00437 and DB01060 .",
        "label": "NA"
    },
    {
        "text": "this observed increase in the bioavailability of DB00950 may be due to transport-related effects , such as p-glycoprotein , in vivo animal studies also suggest that in addition to enhancing absorption , ddrug1 decreases ddrug2 gastrointestinal secretion , while DB00199 may also decrease biliary excretion .",
        "label": "NA"
    },
    {
        "text": "absorption of HD00239 is impaired by ddrug1 containing ddrug2 , ddrug3 , or ddrug4 , and DB01592 - containing preparations .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 , ddrug1 and DB00201 may enhance the effects of : other ddrug3 s , ddrug4 , general ddrug5 , HD00262 such as ddrug7 , ddrug8 , or other ddrug9 , causing increased cns depression .",
        "label": "effect"
    },
    {
        "text": "- ddrug0 { e , g , , ddrug1 } use of DB00563 with DB00891 may increase the chance of side effects affecting the liver and/or the side effects of ddrug4",
        "label": "effect"
    },
    {
        "text": "HD00445 such as ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , ddrug5 { e , g , , ddrug6 } , ddrug7 { e , g , , ddrug8 } , and ddrug9 { e , g , , DB00752 } : using these medicines with ddrug11 may increase the chance of side effects .",
        "label": "NA"
    },
    {
        "text": "when used in therapeutic doses , DB00207 had a modest effect on the pharmacokinetics of ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { intravenous and oral } , ddrug12 , ddrug13 / DB01015 or ddrug15 .",
        "label": "mechanism"
    },
    {
        "text": "DB00501 , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , certain ddrug7 , DB00281 , ddrug9 and ddrug10 , thereby delaying elimination and increasing blood levels of these drugs .",
        "label": "mechanism"
    },
    {
        "text": "while HD00022 and HD00021 have similar affinities for kappa opioid and possibly nicotinic receptors , ddrug2 has much lower affinities than ddrug3 for n_methyl_d_aspartate and sigma-2 receptors , sodium channels , and the 5-ht transporter .",
        "label": "NA"
    },
    {
        "text": "in in vivo studies , 10 - to 30-mg/day doses of DB01238 had no significant effect on metabolism by cyp2d6 { DB00514 } , cyp2c9 { ddrug2 } , cyp2c19 { ddrug3 , ddrug4 } , and cyp3a4 { ddrug5 } substrates .",
        "label": "NA"
    },
    {
        "text": "results : the geometric mean { 90 % confidence interval } whole blood DB00877 area under the plasma concentration time-curve increased 60 % { 35 % -90 % } , from # to # ng x h/ml , and maximum concentration increased 43 % { 14 % -81 % } , from # to # ng/ml , with DB00343 coadministration , whereas the mean elimination half-life of ddrug2 decreased slightly , from # to # hours .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may have a clinically important interaction with the following other drugs : ddrug1 : when DB00476 and DB00898 were administered several hours apart so that peak concentrations of each would coincide , ddrug4 did not increase the impairment of mental and motor skills caused by ddrug5 .",
        "label": "NA"
    },
    {
        "text": "when DB01167 was coadministered with DB00252 , ddrug2 , or h2antagonists , reduced plasma concentrations of ddrug3 were reported .",
        "label": "mechanism"
    },
    {
        "text": "- a HD00764 such as ddrug1 { ddrug2 , ddrug3 , others } , ddrug4 { ddrug5 , others } , DB00860 { ddrug7 , ddrug8 , others } , and others ;",
        "label": "NA"
    },
    {
        "text": "the effects of DB00696 may be potentiated by ddrug1 which inhibits the metabolism of DB00201 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration of DB00701 and ddrug2 can decrease plasma levels of DB00333 .",
        "label": "NA"
    },
    {
        "text": "there have been case reports of increased steady-state levels of DB00908 , ddrug1 , and ddrug2 during concomitant therapy with DB01118 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : studies in normal volunteers have shown that DB00712 like other ddrug2 , can interfere with the effects of DB00695 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : as with other ddrug1 , renal excretion of DB00447 is inhibited by DB01032 and resulted in an approximate 80 % increase in the auc for ddrug4 .",
        "label": "mechanism"
    },
    {
        "text": "a clinical interaction study was also conducted with DB00969 and the cyp3a4 substrate DB00604 .",
        "label": "NA"
    },
    {
        "text": "in a comparison of ddrug0 tolerance in dogs anesthetized with ddrug1 , ddrug2 , or DB00312 , the dosage of ddrug4 needed to cause ventricular tachycardia was significantly higher , as was the ld50 of ddrug5 , with ddrug6 or HD00117 than with ddrug8 .",
        "label": "NA"
    },
    {
        "text": "because both of these drugs have negative inotropic properties and the effects of coadministration with ddrug0 are unknown , neither DB00280 nor DB00661 should be administered concurrently with ddrug3 unless , in the judgment of the physician , the benefits of this combination outweigh the risks .",
        "label": "NA"
    },
    {
        "text": "in a phase i trial using escalating doses of ddrug0 { 110 - 200 mg/m2 } and ddrug1 { 50 or # mg/m2 } given as sequential infusions , myelosuppression was more profound when ddrug2 was given after DB00515 than with the alternate sequence { ie , DB01229 before ddrug5 } .",
        "label": "NA"
    },
    {
        "text": "DB00334 is associated with significantly fewer extrapyramidal symptoms than ddrug1 and DB00734 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00586 decreases DB14507 renal clearance and increases ddrug3 plasma levels .",
        "label": "mechanism"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { ddrug1 s } , ddrug2 , ddrug3 { ddrug4 may decrease the effects of these medicines } , ddrug5 { using these medicines with ddrug6 may result in increased cns depressant effects } , ddrug7 , ddrug8 { using these medicines with ddrug9 may change the amount of either medicine that you need to take } , and oral HD00283 containing HD00220 { ddrug12 may decrease the effectiveness of these oral ddrug13 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "DB00241 , ddrug1 and ddrug2 may enhance the effects of : other ddrug3 s , ddrug4 , general ddrug5 , HD00262 such as ddrug7 , ddrug8 , or other ddrug9 , causing increased cns depression .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , DB01086 and ddrug7 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , ddrug12 } , HD00297 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "therefore , extreme caution should be exercised when administering ddrug0 to patients receiving DB13984 or HD00648 .",
        "label": "NA"
    },
    {
        "text": "both ddrug0 and ddrug1 are sequestered in fat and , like HD00021 , HD00022 probably has an active metabolite .",
        "label": "NA"
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a ddrug0 , including ddrug1 , with multivalent cation-containing products such as ddrug2 or ddrug3 ddrug4 , DB00364 , ddrug6 chewable/buffered tablets or pediatric powder , or products containing ddrug7 , ddrug8 , or ddrug9 may substantially decrease the absorption of DB00537 , resulting in serum and urine levels considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "as with other ddrug0 , it should be noted that DB00502 may be capable of potentiating ddrug2 such as HD00264 , ddrug4 , and ddrug5 .",
        "label": "effect"
    },
    {
        "text": "when initiating a multi-day course of ddrug0 in a patient maintained on ddrug1 , the ddrug2 maintenance dose should be halved for the period of concurrent use of DB00365 and monitoring of serum DB00277 concentrations should be initiated as a guide to further dosage adjustments .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , DB01174 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , DB00812 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "exposed histidines on HD00011 are available for DB01593 chelation , and these have been exploited in the development of a novel purification protocol for ddrug2 using ddrug3 - chelating chromatography .",
        "label": "NA"
    },
    {
        "text": "HD00500 : reports suggest that HD00203 may diminish the antihypertensive effect of ddrug2 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { DB01203 , porpranolol , ddrug2 } may exacerbate rebound hypertension when DB01018 is withdrawn .",
        "label": "effect"
    },
    {
        "text": "infusion requirements of DB00565 in patients administered ddrug1 prior to infusions of ddrug2 were comparable to or slightly greater than when DB00202 was not administered .",
        "label": "NA"
    },
    {
        "text": "for a 4-fold range of DB01590 doses there were no differential effects on DB00091 dosing or pharmacokinetics .",
        "label": "NA"
    },
    {
        "text": "in a comparison of ddrug0 tolerance in dogs anesthetized with ddrug1 , ddrug2 , or DB00312 , the dosage of ddrug4 needed to cause ventricular tachycardia was significantly higher , as was the ld50 of DB01092 , with ddrug6 or ddrug7 than with ddrug8 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the concomitant use of DB00813 { ddrug2 transdermal system } with other ddrug3 , including but not limited to other HD00263 , ddrug5 , ddrug6 , ddrug7 { e , g , , ddrug8 } , general ddrug9 , ddrug10 , ddrug11 , and ddrug12 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .",
        "label": "effect"
    },
    {
        "text": "endothelium-intact aortic rings from high - ddrug0 rats were supersensitive to ddrug1 when compared to vehicle - , DB00396 - and ddrug3 + high - DB00783 - treated rats { pd2 values = # + / # , # + / # , # + / # and # + / # , respectively } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { DB00316 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { DB00701 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 / ddrug1 : ddrug2 did not have any clinically important effect on the pharmacokinetics of DB00860 or DB00898 .",
        "label": "NA"
    },
    {
        "text": "products containing DB01373 and other multivalent cations { such as ddrug1 , ddrug2 , DB01592 } are likely to interfere with absorption of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "DB14507 toxicity was usually reversible upon discontinuation of ddrug1 and the HD00471 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 absorption : the following agents may bind and decrease absorption of ddrug1 from the gastrointestinal tract : ddrug2 , ddrug3 resin , DB00375 , ddrug5 , ddrug6 , soybean flour { e , g , , infant formula } , DB00364 .",
        "label": "NA"
    },
    {
        "text": "however , in a well-controlled study of patients with lymphoma on combination therapy , DB00437 did not increase the marrow toxicity of patients treated with ddrug1 , ddrug2 , ddrug3 , DB01168 and/or ddrug5 .",
        "label": "NA"
    },
    {
        "text": "HD00175 : ddrug1 : DB00673 , when given as a regimen of 125 mg with ddrug3 coadministered orally as # mg on day 1 , and ddrug4 when given as # mg/day with ddrug5 coadministered orally as # mg on days # through 5 , increased the auc of ddrug6 , a cyp3a4 substrate by # - fold , on days # and 5 .",
        "label": "NA"
    },
    {
        "text": "DB00876 { up to # mg b , i , d , or # mg q , d , } doses have been safely used concomitantly with a HD00688 { ddrug2 } .",
        "label": "NA"
    },
    {
        "text": "HD00461 { cns } drugs including ddrug1 , ddrug2 , ddrug3 , ddrug4 , blood pressure medications { ddrug5 , ddrug6 , ddrug7 } , motion sickness medications , ddrug8 , ddrug9 , HD00024 , sleeping pills and ddrug11",
        "label": "NA"
    },
    {
        "text": "ddrug0 - and/or ddrug1 - containing ddrug2 , products containing ddrug3 { ddrug4 } , HD00752 containing ddrug6 or other metal cations , or ddrug7 { DB00900 } chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after ddrug9 .",
        "label": "NA"
    },
    {
        "text": "clinical trials have indicated that DB00003 can be effectively and safely used in conjunction with standard cystic_fibrosis therapies including oral , inhaled and/or parenteral ddrug1 , ddrug2 , enzyme supplements , ddrug3 , oral or inhaled HD00175 , and ddrug5 .",
        "label": "NA"
    },
    {
        "text": "the results of a study of coadministration of DB00330 { 50 mg/kg } with an DB06723 containing ddrug2 to # patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ddrug3 of approximately 20 % and 13 % , respectively , suggesting that the oral absorption of ddrug4 may be reduced by these ddrug5 .",
        "label": "mechanism"
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a ddrug0 , including ddrug1 , with multivalent cation-containing products such as ddrug2 or ddrug3 ddrug4 , DB00364 , ddrug6 chewable/buffered tablets or pediatric powder , or products containing ddrug7 , ddrug8 , or DB01593 may substantially decrease the absorption of ddrug10 , resulting in serum and urine levels considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "no interaction with the ddrug0 ddrug1 was shown in a single-dose study with DB00494 without coadministered DB01235 / ddrug4 .",
        "label": "NA"
    },
    {
        "text": "DB00199 use in patients who are receiving high doses of ddrug1 may be associated with an increase in serum DB00277 levels and potential ddrug3 toxicity .",
        "label": "NA"
    },
    {
        "text": "in patients with chronic hepatitis c treated with ddrug0 in combination with ddrug1 , DB00008 treatment did not affect DB00811 distribution or clearance .",
        "label": "NA"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : ddrug1 ; ddrug2 ; ddrug3 ; certain ddrug4 , especially the HD00249 and ddrug6 ; DB14507 ; ddrug8 salts ; ddrug9 ; and ddrug10 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - DB00134 may protect against the ototoxic effects of DB00798 .",
        "label": "effect"
    },
    {
        "text": "at steady state , HD00897 # mg once daily had no effect on the anti-platelet activity of low-dose { 81 mg once daily } DB00945 , as assessed by ex vivo platelet aggregation and serum thromboxane_b2 generation in clotting blood .",
        "label": "NA"
    },
    {
        "text": "poor metabolizers of DB04840 : interactions of ddrug1 with strong inhibitors of cyp2d6 { such as ddrug2 , ddrug3 , ddrug4 , and ddrug5 } have not been studied , but these drugs would be expected to increase blood levels of the r { + } enantiomer of DB01136 .",
        "label": "NA"
    },
    {
        "text": "although trough ddrug0 plasma levels were unaffected , given the enzyme-inducing properties of DB00564 , the possibility that ddrug2 might increase the clearance of DB01175 should be considered if the two drugs are coadministered .",
        "label": "NA"
    },
    {
        "text": "evoked hind limb digital extensor tension { hoof twitch } was maintained at 40 % of baseline for # h by DB13295 infusion in # horses anaesthetised with DB01159 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the concomitant administration of ddrug1 with the HD00226 DB01016 has , on rare occasions , resulted in severe hypoglycemia .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : while studies have not shown DB00586 to interact with ddrug2 , caution should be exercised , nonetheless , since interactions have been seen with other HD00203 .",
        "label": "advise"
    },
    {
        "text": "drug interactions , general : although there have been no formal interaction studies , intravenous DB00800 has been administered safely with drugs such as HD00118 and sublingual ddrug2 .",
        "label": "NA"
    },
    {
        "text": "DB00876 { up to # mg b , i , d , or # mg q , d , } doses have been safely used concomitantly with a ddrug1 { DB00999 } .",
        "label": "NA"
    },
    {
        "text": "however , administration of ddrug0 { 90 mg kg { -1 } body weight } to rats # hours prior to HD00077 { 100 mg kg { -1 } body weight } was ineffective in preventing HD00078 synthesis and did not diminish fluoride or citrate accumulation in vivo .",
        "label": "NA"
    },
    {
        "text": "use of ddrug0 with ddrug1 { e , g , , ddrug2 , DB00384 , or ddrug4 } , DB14500 supplements , or potassium-containing salt substitutes may lead to significant increases in serum potassium .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 , ddrug2 salts , and DB02325 may either potentiate or weaken the blood-glucose-lowering effect of HD00071 .",
        "label": "effect"
    },
    {
        "text": "DB00318 in combination with other ddrug1 , general ddrug2 , ddrug3 , ddrug4 , ddrug5 , or other ddrug6 { including DB02325 } has additive depressant effects .",
        "label": "effect"
    },
    {
        "text": "the aim of this paper was to study the interaction between HD00163 and both HD00164 or its synthetic analogue ddrug2 , or ddrug3 , on the antinonciceptive effect of these peptides in mice after intracisternal injection .",
        "label": "NA"
    },
    {
        "text": "a similar association , though less marked , has been suggested with HD00026 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , and possibly with ddrug6 and HD00239 72 .",
        "label": "NA"
    },
    {
        "text": "plasma HD00312 concentrations may need to be monitored and the dose of the ddrug1 may need to be reduced if a ddrug2 is co-administered with DB00476 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , or other products containing ddrug1 or DB01593 , ddrug3 or ddrug4 should not be administered concomitantly with , or within # hours of , the administration of DB01059 , because they may interfere with absorption resulting in lower serum and urine levels of ddrug6 .",
        "label": "advise"
    },
    {
        "text": "in some patients , the administration of a ddrug0 can reduce the diuretic , natriuretic , and antihypertensive effects of HD00105 , ddrug2 and HD00029 .",
        "label": "NA"
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a HD00533 , including ddrug1 , with multivalent cation-containing products such as ddrug2 or ddrug3 ddrug4 , ddrug5 , ddrug6 chewable/buffered tablets or pediatric powder , or products containing ddrug7 , ddrug8 , or DB01593 may substantially decrease the absorption of ddrug10 , resulting in serum and urine levels considerably lower than desired .",
        "label": "mechanism"
    },
    {
        "text": "and ddrug0 e , g , , DB00661 } , cyp1a2 inducers { ddrug2 } and cyp1a2 inhibitors { ddrug3 and DB01211 } .",
        "label": "NA"
    },
    {
        "text": "DB14513 - and/or ddrug1 - containing ddrug2 , products containing ddrug3 { ddrug4 } , ddrug5 containing ddrug6 or other metal cations , or ddrug7 { ddrug8 } chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after DB01155 .",
        "label": "advise"
    },
    {
        "text": "concurrent administration of DB00501 and HD00043 can produce clinically significant increases in the plasma levels of the ddrug2 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 such as ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , ddrug5 { e , g , , ddrug6 } , ddrug7 { e , g , , DB01037 } , and ddrug9 { e , g , , ddrug10 } : using these medicines with DB00150 may increase the chance of side effects .",
        "label": "NA"
    },
    {
        "text": "- ddrug0 { e , g , , DB00252 } use of ddrug2 with ddrug3 may increase the chance of side effects affecting the liver and/or the side effects of DB00252",
        "label": "NA"
    },
    {
        "text": "the hypoglycemic action of HD00226 may be potentiated by certain drugs including ddrug1 and other drugs that are highly protein bound , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , and HD00520 .",
        "label": "effect"
    },
    {
        "text": "although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 { eg , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , DB00802 , ddrug14 , and ddrug15 } may have elevated plasma concentrations when coadministered with DB01232 ;",
        "label": "mechanism"
    },
    {
        "text": "DB14513 / DB01370 - containing ddrug2 : absorption of ddrug3 is moderately reduced { approximately 25 % } when coadministered with ddrug4 / ddrug5 - containing ddrug6 .",
        "label": "NA"
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of ddrug0 such as DB00565 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 } , ddrug11 salts , ddrug12 , local HD00264 , ddrug14 , and ddrug15 .",
        "label": "effect"
    },
    {
        "text": "it is assumed that increased interaction between HD00136 and high affinity binding sites for DB00714 on dopamine2 - and serotonin2-receptors underlies the antipsychotic action of ddrug2 after their prolonged administration .",
        "label": "NA"
    },
    {
        "text": "before taking DB00222 , tell your doctor if you are taking any of the following medicines : - ddrug1 or another ddrug2 such as ddrug3 { HD00756 } , ddrug5 { ddrug6 , others } , ddrug7 { ddrug8 } , ddrug9 { ddrug10 } , or ddrug11 { ddrug12 } ;",
        "label": "advise"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { DB00400 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , DB00860 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "although the magnitude of changes in DB00829 plasma exposure when coadministered with DB00580 were not sufficient to warrant dosage adjustments , patients may experience enhanced sedative side effects caused by increased exposure of ddrug2 under this circumstance .",
        "label": "NA"
    },
    {
        "text": "DB00201 ddrug1 ddrug2 , like other HD00532 , may inhibit the metabolism of ddrug4 and ddrug5 .",
        "label": "NA"
    },
    {
        "text": "if taken # hour before DB00224 { ddrug1 } , DB00900 does not affect ddrug3 exposure , despite persistent buffering effects .",
        "label": "NA"
    },
    {
        "text": "both ddrug0 and HD00022 block DB00295 - induced and ddrug3 - induced dopamine release in the nucleus accumbens ;",
        "label": "effect"
    },
    {
        "text": "there is limited experience with concomitant HD00366 such as ddrug1 , ddrug2 , HD00106 , and ddrug4 { both ddrug5 - like and loop } .",
        "label": "NA"
    },
    {
        "text": "HD00021 , but not HD00022 , decreases heart rate at high doses .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { e , g , ddrug1 and DB13179 } : agents of the ddrug3 , of which DB00320 { ddrug5 } injection , usp is a member , have been shown to interact with ddrug6 of the ddrug7 , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .",
        "label": "NA"
    },
    {
        "text": "studies in healthy volunteers have shown that DB00284 has no effect on either the pharmacokinetics or pharmacodynamics of DB00390 , ddrug2 , ddrug3 , or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "DB00819 reduces urinary excretion of DB00908 and may enhance its effect .",
        "label": "mechanism"
    },
    {
        "text": "human pharmacokinetics data indicate that oral DB01026 potently inhibits the metabolism of ddrug1 resulting in a mean eight-fold increase in auc of DB00604 .",
        "label": "NA"
    },
    {
        "text": "DB00612 should be used with care when ddrug1 or inhibitors of av conduction , such as certain ddrug2 { particularly of the ddrug3 -lsb- ddrug4 -rsb- and HD00427 -lsb- ddrug6 -rsb- classes } , or ddrug7 , such as ddrug8 , are used concurrently .",
        "label": "advise"
    },
    {
        "text": "DB00521 should be used with caution in patients who are receiving a HD00481 orally because of the potential for additive effects on systemic beta-blockade .",
        "label": "advise"
    },
    {
        "text": "the harmonic mean elimination half-life was # and # hours for DB00533 + ddrug1 and placebo + DB00390 treatments , respectively .",
        "label": "NA"
    },
    {
        "text": "immediate and extended release tablets the hypoglycemic action of ddrug0 may be potentiated by certain drugs including ddrug1 , some HD00768 and other drugs that are highly protein bound , ddrug3 , ddrug4 , ddrug5 , DB01032 , ddrug7 , ddrug8 , and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral ddrug0 , HD00106 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 { e , g , , ddrug9 } , HD00807 .",
        "label": "NA"
    },
    {
        "text": "in a study in which patients with active ra were treated for up to # weeks with concurrent DB00026 and DB00005 therapy , a 7 % rate of serious infections was observed , which was higher than that observed with ddrug2 alone { 0 % } .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : HD00710 may increase the serum concentration of DB01037 .",
        "label": "mechanism"
    },
    {
        "text": "this may occur because DB00861 competitively displaces HD00519 from protein binding sites .",
        "label": "mechanism"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect : ddrug0 , ddrug1 , ddrug2 , ddrug3 , HD00571 { e , g , , ddrug5 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , HD00810 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "adverse reactions related to HD00893 s , such as cns , cardiac , and systemic { eg , flu-like } effects may be more severe in the elderly and caution should be exercised in the use of DB00008 in this population .",
        "label": "NA"
    },
    {
        "text": "DB00825 / ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 and ddrug5 combinations , ddrug6 , DB00328 } .",
        "label": "NA"
    },
    {
        "text": "because oral ddrug0 may interfere with the hepatic metabolism of DB00252 , toxic levels of the ddrug2 may occur when an oral HD00025 and ddrug4 are administered concurrently .",
        "label": "NA"
    },
    {
        "text": "note : dissolution of aerosol particles of ddrug0 in DB06761 , a model HD00013 .",
        "label": "NA"
    },
    {
        "text": "may interact with thyroid medication { e , g , , DB00451 } , DB11119 - containing products , ddrug2 , ddrug3 { e , g , , ddrug4 , ddrug5 } , and ddrug6 { e , g , , ddrug7 , ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "in the presence of DB01092 { 10 { -5 } m } , HD00140 { 10 { -8 } m } failed to cause the first contraction ;",
        "label": "effect"
    },
    {
        "text": "human pharmacokinetics data indicate that oral DB01026 potently inhibits the metabolism of ddrug1 resulting in an eight-fold increase in the mean auc of DB00604 .",
        "label": "NA"
    },
    {
        "text": "when ddrug0 therapy is initiated , a reduction in HD00579 dosage may be required , and increased amounts may be required when HD00183 is terminated .",
        "label": "NA"
    },
    {
        "text": "serum DB00065 concentrations appeared to be unaffected by baseline use of medications for the treatment of crohn s disease including ddrug1 , ddrug2 { ddrug3 or DB00537 } and aminosalicylates .",
        "label": "NA"
    },
    {
        "text": "DB00294 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { DB00400 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "int"
    },
    {
        "text": "ddrug0 HD00524 may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation , the discontinuance of ddrug2 ddrug3 could pose a hazard to health if a potentially toxic drug such as ddrug4 has been filtrated to a maintenance level while the patient was taking DB01432 ddrug6 .",
        "label": "NA"
    },
    {
        "text": "although no clinical studies have been conducted , it is likely that the metabolism of ddrug0 may be affected by the known cyp3a4 inducers { such as ddrug1 , DB01174 , ddrug3 } , cyp3a4 inhibitors { azole antimycotics e , g , , DB01026 ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the concurrent administration of DB00647 does not affect the bioavailability of DB00939 .",
        "label": "NA"
    },
    {
        "text": "use in conjunction with other ddrug0 : the addition of DB00949 to ddrug2 { ddrug3 } affects the steady-state plasma concentrations of HD00714 .",
        "label": "NA"
    },
    {
        "text": "DB00649 and ddrug1 ddrug2 can antagonize the in vitro antiviral activity of ddrug3 and DB00495 against hiv .",
        "label": "NA"
    },
    {
        "text": "certain concomitant medications { such as DB01045 , HD00282 , st .",
        "label": "NA"
    },
    {
        "text": "in a comparison of ddrug0 tolerance in dogs anesthetized with ddrug1 , ddrug2 , or ddrug3 , the dosage of DB01092 needed to cause ventricular tachycardia was significantly higher , as was the ld50 of ddrug5 , with ddrug6 or HD00117 than with ddrug8 .",
        "label": "NA"
    },
    {
        "text": "in vitro displacement studies with highly protein-bound drugs such as ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , DB00252 , ddrug8 , ddrug9 , and ddrug10 showed no influence on the extent of DB00731 protein binding .",
        "label": "NA"
    },
    {
        "text": "during clinical trials , DB01088 was used concurrently with ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , HD00796 , ddrug7 , ddrug8 , and other medications .",
        "label": "NA"
    },
    {
        "text": "the successive application of DB00145 { 5 or # mg/kg egg weight { e , w , } and ddrug1 { 15 mg/kg e , w , } in a # min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of HD00195 alone .",
        "label": "NA"
    },
    {
        "text": "HD00025 therapy should be monitored , particularly during the first few weeks , after initiating therapy with ddrug1 in patients receiving DB00682 or similar agents .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of DB00280 and ddrug1 resulted in slight increases in plasma ddrug2 levels and slight decreases in plasma DB00908 levels .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - coadministration of racemic ddrug1 { 40 mg/day for # days } and ddrug2 { 30 mmol/day for # days } had no significant effect on the pharmacokinetics of DB00215 or DB14507 .",
        "label": "NA"
    },
    {
        "text": "DB00930 was found to have no significant effect on the bioavailability of ddrug1 , ddrug2 , ddrug3 , DB00908 , ddrug5 , and ddrug6 .",
        "label": "NA"
    },
    {
        "text": "ulcerans was between # and # mg/l , while corresponding values for DB01045 and DB00615 were in the range of # # mg/l and # # mg/l respectively .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with ddrug1 , ddrug2 s , ddrug3 { allergy , cold , and sinus medicines } , diabetic drugs , ddrug4 , ddrug5 , HD00203 like ddrug7 or DB01050 , and high blood pressure medications .",
        "label": "NA"
    },
    {
        "text": "as with other ddrug0 , it should be noted that DB00502 may be capable of potentiating HD00261 such as ddrug3 , ddrug4 , and ddrug5 .",
        "label": "effect"
    },
    {
        "text": "in vitro displacement studies with highly protein-bound drugs such as ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB00682 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 showed no influence on the extent of DB00731 protein binding .",
        "label": "NA"
    },
    {
        "text": "patients on DB14507 treatment should be closely monitored when DB00482 is introduced or withdrawn .",
        "label": "advise"
    },
    {
        "text": "in comparison with DB00502 , the adverse events reported significantly more frequently with ddrug1 in > or = # % of patients were dry mouth , bodyweight gain and increased appetite and compared with ddrug2 , only bodyweight gain occurred significantly more frequently with DB00334 .",
        "label": "NA"
    },
    {
        "text": "administration of HD00532 with ddrug1 containing ddrug2 , ddrug3 , or ddrug4 , with DB00364 , with metal cations such as ddrug6 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "mechanism"
    },
    {
        "text": "DB00435 has been administered with ddrug1 , ddrug2 , ddrug3 , HD00356 , ddrug5 , and high-frequency ventilation .",
        "label": "NA"
    },
    {
        "text": "other concomitant therapy although specific interaction studies were not performed , DB01216 doses of # mg or more were concomitantly used in clinical studies with ddrug1 , ddrug2 , a-blockers , ddrug3 , ddrug4 , ddrug5 , ddrug6 , HD00378 , ddrug8 , cardiac ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 { also referred to as ddrug14 } , and ddrug15 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "HD00114 : weakness hyperreflexia , and incoordination have been reported rarely when HD00277 have been co-administered with ddrug2 { e , g.",
        "label": "NA"
    },
    {
        "text": "endothelium-intact aortic rings from high - ddrug0 rats were supersensitive to DB00368 when compared to vehicle - , DB00396 - and ddrug3 + high - ddrug4 - treated rats { pd2 values = # + / # , # + / # , # + / # and # + / # , respectively } .",
        "label": "NA"
    },
    {
        "text": "potential differences in DB00091 dosing and pharmacokinetics at different levels of DB01590 exposure were assessed in the context of anova .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of ddrug0 and DB06724 , ddrug2 , ddrug3 , or an ddrug4 / ddrug5 oral ddrug6 produced minor changes in the pharmacokinetics of DB01155 , which were considered to be without clinical significance .",
        "label": "NA"
    },
    {
        "text": "other concomitant therapy although specific interaction studies were not performed , DB01216 doses of # mg or more were concomitantly used in clinical studies with ddrug1 , ddrug2 , a-blockers , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , cardiac ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 { also referred to as HD00203 } , and ddrug15 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : HD00610 , as well as a metabolite of ddrug2 , slow DB00182 metabolism .",
        "label": "mechanism"
    },
    {
        "text": "both ddrug0 and HD00022 decrease extracellular levels of dopamine in the nucleus accumbens , but only HD00021 increases extracellular levels of serotonin in the nucleus accumbens .",
        "label": "NA"
    },
    {
        "text": "acute symptoms should be treated with a short-acting , inhaled HD00743 such as DB01001 { the physician should provide the patient with such medication and instruct the patient in how it should be used } .",
        "label": "NA"
    },
    {
        "text": "in post-marketing experience , bleeding events have been reported , predominantly in the elderly , in association with increases in prothrombin time in patients receiving HD00897 concurrently with DB00682 .",
        "label": "effect"
    },
    {
        "text": "other drugs : in healthy volunteers , ddrug0 , ddrug1 , ddrug2 , DB00863 , ddrug4 , hormone replacement therapy { a combination of conjugated ddrug5 and ddrug6 } , ddrug7 { ddrug8 and DB09104 } and ddrug10 did not affect the pharmacokinetics of ddrug11 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 altered coagulation parameters and/or bleeding have been reported in patients taking ddrug1 concomitantly with HD00469 such as ddrug3 and DB00946 .",
        "label": "NA"
    },
    {
        "text": "the concomitant use of DB00698 is not recommended since ddrug1 may antagonize the antibacterial effect of DB01059 in the urinary tract .",
        "label": "NA"
    },
    {
        "text": "however , the antagonism of the DB00277 - induced anxiogenic effects by ddrug1 was only observed in the time spent in the light zone , and ddrug2 - induced anxiogenic effects were neither reversed by ddrug3 nor by HD00186 .",
        "label": "NA"
    },
    {
        "text": "HD00100 : combination ddrug1 may decrease the clearance of some ddrug2 { ddrug3 , ddrug4 , DB00829 } and increase the clearance of others { ddrug6 , ddrug7 , ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "other drugs : in healthy volunteers , DB00381 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , hormone replacement therapy { a combination of conjugated ddrug5 and ddrug6 } , ddrug7 { ddrug8 and ddrug9 } and ddrug10 did not affect the pharmacokinetics of DB00204 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 can interact with DB02325 or other ddrug2 { may potentiate the cns depressant effects of either these medications or ddrug3 } , ddrug4 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with HD00388 } , and ddrug6 { concurrent use with ddrug7 may prolong and intensify the anticholinergic and cns depressant effects of ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "therapeutic drug monitoring { tdm } of DB00798 therapy , and bone scintigraphy employing ddrug1 as the HD00174 was carried out in # patients .",
        "label": "NA"
    },
    {
        "text": "coadministration of DB00637 with DB01026 tablets is therefore contraindicated .",
        "label": "advise"
    },
    {
        "text": "interactions may occur between ddrug0 supplements and DB00945 and other ddrug2 and herbs such as garlic { allium sativum } and ddrug3 { DB01381 } .",
        "label": "NA"
    },
    {
        "text": "other drugs : in healthy volunteers , DB00381 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , hormone replacement therapy { a combination of conjugated ddrug5 and HD00642 } , ddrug7 { ddrug8 and ddrug9 } and ddrug10 did not affect the pharmacokinetics of ddrug11 .",
        "label": "NA"
    },
    {
        "text": "the interaction of HD00040 and synthetic DB00107 on placental vessels was studied in vitro .",
        "label": "NA"
    },
    {
        "text": "other concomitant therapy although specific interaction studies were not performed , ddrug0 doses of # mg or more were concomitantly used in clinical studies with ddrug1 , ddrug2 , a-blockers , ddrug3 , ddrug4 , HD00282 , ddrug6 , ddrug7 , ddrug8 , cardiac ddrug9 , ddrug10 , HD00727 , ddrug12 , ddrug13 { also referred to as ddrug14 } , and ddrug15 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the concomitant use of ddrug1 { ddrug2 transdermal system } with other ddrug3 , including but not limited to other ddrug4 , ddrug5 , HD00214 , ddrug7 { e , g , , ddrug8 } , general ddrug9 , ddrug10 , ddrug11 , and DB02325 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .",
        "label": "NA"
    },
    {
        "text": "in general , these are drugs that have one or more pharmacologic activities similar to HD00406 , including HD00407 such as ddrug2 and ddrug3 , ddrug4 and ddrug5 .",
        "label": "NA"
    },
    {
        "text": "hypotension was more likely to occur if the ddrug0 were a HD00412 , e , g , , ddrug2 , while left ventricular failure and av conduction disturbances , including complete heart block , were more likely to occur with either ddrug3 or DB00343 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 / ddrug1 / HD00214 / ddrug3 : co-administration of ddrug4 with ddrug5 , ddrug6 , ddrug7 , and HD00263 is likely to lead to an enhancement of effects .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { e , g , , ddrug1 , ddrug2 , ddrug3 , DB00196 , etc , } : in vitro and animal studies with the combination of ddrug5 and ddrug6 suggest that ddrug7 may induce fungal resistance to DB00681 .",
        "label": "NA"
    },
    {
        "text": "based on adult data , lower doses of ddrug0 may be needed following coadministration of drugs which are reported to decrease ddrug1 elimination { e , g , , ddrug2 and ddrug3 } and higher ddrug4 doses may be needed following coadministration of drugs that increase DB00201 elimination { e , g , , DB01174 and ddrug7 } .",
        "label": "NA"
    },
    {
        "text": "however , co administration of DB00950 with either ddrug1 or DB00199 led to increased plasma concentrations of ddrug3 .",
        "label": "mechanism"
    },
    {
        "text": "HD00026 , ddrug1 , and ddrug2 decrease the half-life of DB00254 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , DB00812 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and DB00126 .",
        "label": "NA"
    },
    {
        "text": "the uptake inhibitors ddrug0 and DB01151 { 3 mumol/liter } potentiated the positive inotropic effects of DB00368 in nonfailing myocardium { p < # } but not in functional class iv myocardium .",
        "label": "effect"
    },
    {
        "text": "this drug may interact with ddrug0 or other ddrug1 { may potentiate the cns depressant effects of either these medications or ddrug2 } , HD00444 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug4 } , and ddrug5 { concurrent use with HD00388 may prolong and intensify the anticholinergic and cns depressant effects of ddrug7 } .",
        "label": "NA"
    },
    {
        "text": "because oral ddrug0 may interfere with the hepatic metabolism of ddrug1 , toxic levels of the HD00329 may occur when an oral HD00025 and ddrug4 are administered concurrently .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : HD00610 , as well as a metabolite of DB00614 , slow ddrug3 metabolism .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of DB01155 and ddrug1 , ddrug2 , ddrug3 , or an ddrug4 / DB00396 oral ddrug6 produced minor changes in the pharmacokinetics of ddrug7 , which were considered to be without clinical significance .",
        "label": "mechanism"
    },
    {
        "text": "the absorption of oral DB01155 is significantly reduced by the concomitant administration of an ddrug1 containing ddrug2 and DB14513 .",
        "label": "mechanism"
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as DB01135 include certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , HD00384 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 } , ddrug10 salts , ddrug11 , local ddrug12 , ddrug13 , and ddrug14 .",
        "label": "effect"
    },
    {
        "text": "HD00244 : experience in over # patients in a non-comparative clinical trial has shown that concomitant administration of ddrug1 and HD00228 is usually well tolerated , but there have been occasional literature reports suggesting that the combination may increase the likelihood of congestive heart failure , severe hypotension or exacerbation of angina .",
        "label": "NA"
    },
    {
        "text": "particular caution should be observed with ddrug0 since there are conflicting results for the effect of ddrug1 on the availability of DB00390 and DB01396 .",
        "label": "NA"
    },
    {
        "text": "coadministration of single , oral doses of DB00962 with DB00199 { 10 mg and # mg , respectively } , a strong , selective cyp3a4 inhibitor produced a 34 % increase in ddrug2 s maximal plasma concentrations and a 20 % increase in the area under the plasma concentration-time curve .",
        "label": "mechanism"
    },
    {
        "text": "coadministration of DB00580 and DB00717 1/35 increased the exposure of ddrug2 and ddrug3 by 20 % and 34 % , respectively .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 or HD00648 increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered ddrug2 , such as DB00988 .",
        "label": "effect"
    },
    {
        "text": "the addition of ddrug0 in a limited number of patients in three well-controlled studies caused no systematic changes in DB01174 or DB00794 concentrations when compared to placebo .",
        "label": "NA"
    },
    {
        "text": "in a drug interaction study , co-administration of orally inhaled DB01410 and oral ddrug1 , an inhibitor of cytochrome p450 3a4 , had no effect on the pharmacokinetics of either ddrug2 or DB00199 .",
        "label": "NA"
    },
    {
        "text": "DB14513 - and DB01370 - containing ddrug2 , administered concomitantly with ddrug3 , significantly decreased the bioavailability { 48 % } of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "intravenous DB00738 : treatment with DB00943 should be interrupted when the use of a drug that has the potential to cause pancreatitis is required .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00252 ddrug2 DB00564",
        "label": "NA"
    },
    {
        "text": "it is , however , possible that concomitant use of other known ddrug0 such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 and HD00239 might increase the photosensitivity reaction of actinic_keratosis treated with the DB00855 for topical solution .",
        "label": "effect"
    },
    {
        "text": "there have been reports of interactions of DB00199 with ddrug1 , DB00091 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , and ddrug13 .",
        "label": "int"
    },
    {
        "text": "co-administration of DB00204 with ddrug1 resulted in increases in ddrug2 peak plasma levels of 42 % , although overall exposure to DB00204 was not significantly increased .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , DB00446 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , ddrug8 { HD00398 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "the hypoglycemic action of ddrug0 may be potentiated by certain drugs including HD00518 and other drugs that are highly protein bound , HD00328 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , and ddrug8 .",
        "label": "NA"
    },
    {
        "text": "the following agents may increase certain actions or side effects of HD00522 , ddrug1 ddrug2 of class { e , g , ddrug3 } , HD00388 ddrug5 { e , g , ddrug6 } , ddrug7 .",
        "label": "NA"
    },
    {
        "text": "- ddrug0 and DB00375 HD00510 : ddrug3 and ddrug4 ddrug5 have the potential of binding ddrug6 and reducing ddrug7 absorption from the gastrointestinal tract",
        "label": "NA"
    },
    {
        "text": "ddrug0 significantly decreased the auc { ss } of ddrug1 by 82 % , but DB00701 had no effect on DB01045 pharmacokinetics .",
        "label": "NA"
    },
    {
        "text": "- a HD00380 such as ddrug1 { ddrug2 } , ddrug3 { ddrug4 } , ddrug5 { DB01193 } , ddrug7 { ddrug8 } , and others ;",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of ddrug0 : ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , ddrug5 , ddrug6 , DB00871 } , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , HD00810 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "in combination with other HD00389 , DB01452 may still kill even experienced users , particularly if their tolerance to the drug has reduced or the strength of their usual dose has increased .",
        "label": "effect"
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a ddrug0 , including DB00537 , with multivalent cation-containing products such as ddrug2 or ddrug3 ddrug4 , ddrug5 , ddrug6 chewable/buffered tablets or pediatric powder , or products containing ddrug7 , DB01592 , or ddrug9 may substantially decrease the absorption of ddrug10 , resulting in serum and urine levels considerably lower than desired .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 or DB00228 administered with ddrug2 / DB09140 to achieve # mac -lsb- minimum alveolar concentration -rsb- may prolong the clinically effective duration of action of initial and maintenance doses of ddrug4 and decrease the required infusion rate of ddrug5 .",
        "label": "NA"
    },
    {
        "text": "interactions with ddrug0 : ddrug1 { eg , ddrug2 , ddrug3 , ddrug4 , DB01209 and ddrug6 } should not be administered to a patient who has received or is receiving a course of therapy with a ddrug7 such as DB00854 .",
        "label": "advise"
    },
    {
        "text": "drug interactions : the central ddrug0 syndrome can occur when anticholinergic agents such as ddrug1 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain ddrug2 such as ddrug3 , the ddrug4 and other HD00031 , HD00043 , certain ddrug7 such as the ddrug8 salts , and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "capsules DB00328 # mg t , i , d , produced a clinically relevant elevation of plasma DB14507 and reduction in renal ddrug2 clearance in psychiatric patients and normal subjects with steady state plasma ddrug3 concentrations .",
        "label": "mechanism"
    },
    {
        "text": "HD00303 : ddrug1 , ddrug2 , ddrug3 , DB01182 , ddrug5 contraindicated due to potential for serious and/or life-threatening reactions .",
        "label": "NA"
    },
    {
        "text": "specific and aspecific treatments of DB14513 depletion are tricky using for example ddrug1 , pharmacological doses of ddrug2 , physiological doses of ddrug3 and of DB11127 .",
        "label": "NA"
    },
    {
        "text": "suppression by DB00661 of ddrug1 - enhanced peritoneal metastasis of intestinal adenocarcinomas induced by HD00037 in wistar rats .",
        "label": "NA"
    },
    {
        "text": "in clinical trials , ddrug0 was used with ddrug1 , ddrug2 , HD00326 , oral ddrug4 , and supplemental ddrug5 , in a pharmacokinetic substudy in patients with congestive heart failure receiving ddrug6 or DB00390 in whom therapy with ddrug8 was initiated , apparent oral clearance values for ddrug9 { n = 23 } and ddrug10 { n = 30 } were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .",
        "label": "NA"
    },
    {
        "text": "these medications have included ddrug0 , DB00682 , ddrug2 , ddrug3 , ddrug4 , intravenous and oral ddrug5 , DB00208 , and ddrug7 .",
        "label": "NA"
    },
    {
        "text": "although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of DB00964 # % ophthalmic solution , the possibility of an additive or potentiating effect with ddrug1 { ddrug2 , ddrug3 , HD00344 , ddrug5 , ddrug6 } should be considered .",
        "label": "advise"
    },
    {
        "text": "ddrug0 { ddrug1 } , DB00572 or other ddrug3 , or ddrug4 : concurrent use with DB01102 may produce additive inotropic and/or chronotropic effects .",
        "label": "NA"
    },
    {
        "text": "sinus bradycardia has been reported with oral DB01118 in combination with ddrug1 { HD00302 substrate } given for local ddrug3 .",
        "label": "NA"
    },
    {
        "text": "effect of DB00829 and ddrug1 on the antinociceptive effect of ddrug2 , DB04817 and ddrug4 in mice .",
        "label": "NA"
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the ddrug0 of drugs may be potentiated by DB02325 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , the ddrug6 , HD00559 and ddrug8 , ddrug9 and the ddrug10 , and by other ddrug11 .",
        "label": "NA"
    },
    {
        "text": "DB00332 inhalation aerosol has been used concomitantly with other drugs , including ddrug1 , HD00246 , and ddrug3 , commonly used in the treatment of chronic obstructive pulmonary disease .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and foods fortified with DB01592 concomitant administration of DB00535 with a therapeutic ddrug3 containing # mg of elemental ddrug4 { as feso4 } or ddrug5 supplemented with # mg of elemental ddrug6 reduced extent of absorption by 80 % and 31 % , respectively .",
        "label": "NA"
    },
    {
        "text": "in many of these cases , DB00921 was misused by self-injection of crushed DB00921 tablets .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a pharmacokinetic study , maximum plasma concentrations of DB01023 were considerably lower in epileptic patients on long-term ddrug2 therapy { eg , ddrug3 , ddrug4 , or DB01174 } than in healthy volunteers .",
        "label": "mechanism"
    },
    {
        "text": "DB00318 in combination with other ddrug1 , general ddrug2 , ddrug3 , ddrug4 , ddrug5 , or other HD00261 { including ddrug7 } has additive depressant effects .",
        "label": "effect"
    },
    {
        "text": "the effects of supplementary oral ddrug0 and DB01592 , as well as the interaction between both at the absorption site , fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either # or # micrograms/kg of DB11588 and # or # mg/kg of ddrug3 over a period of # days in a total of # rats .",
        "label": "NA"
    },
    {
        "text": "potential ddrug0 , DB00637 , and DB00604 interactions",
        "label": "NA"
    },
    {
        "text": "the minimal inhibitory concentrations of DB01190 and DB00798 alone and in combinations were determined by a microdilution method for # aerobic , facultative , and anaerobic clinical isolates .",
        "label": "NA"
    },
    {
        "text": "gastrointestinal transit time { lactulose hydrogen breath test } was measured in # volunteers with oral and intravenous placebo , oral placebo and intravenous ddrug0 { # mg x kg { -1 } } , and oral HD00090 { 4 mg } and intravenous DB00295 { # mg x kg { -1 } } in a double blind , cross-over study .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { DB00316 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , DB00091 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "in DB01195 clinical trials , patients who were receiving HD00378 concurrently did not experience an increased incidence of side effects .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of ddrug0 : ddrug1 , ddrug2 , ddrug3 , HD00571 { e , g , , ddrug5 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , HD00810 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 , DB00627 { ddrug3 , ddrug4 , HD00270 : skeletal muscle .",
        "label": "NA"
    },
    {
        "text": "ddrug0 ddrug1 may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation , the discontinuance of ddrug2 HD00524 could pose a hazard to health if a potentially toxic drug such as ddrug4 has been filtrated to a maintenance level while the patient was taking DB01432 ddrug6 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , HD00002 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , DB00295 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 DB00683 , ddrug2 ddrug3 ergot derivatives DB00582",
        "label": "NA"
    },
    {
        "text": "this may indicate that DB01050 could enhance the toxicity of DB00563 .",
        "label": "effect"
    },
    {
        "text": "effects of ddrug0 on low-dose ddrug1 a group of # nonsmoking , healthy white female volunteers established on an oral ddrug2 regimen containing # mg DB00977 and # mg ddrug4 for at least # months received # mg/day of ddrug5 from midcycle { day 15 } to midcycle { day 14 } of two consecutive oral HD00349 cycles .",
        "label": "NA"
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the HD00555 of drugs may be potentiated by ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , the ddrug6 , ddrug7 and ddrug8 , ddrug9 and the ddrug10 , and by other HD00561 .",
        "label": "effect"
    },
    {
        "text": "note : dissolution of aerosol particles of DB01222 in DB06761 , a model ddrug2 .",
        "label": "NA"
    },
    {
        "text": "blood levels of ddrug0 increased 24 % when DB00757 was coadministered with DB00501 { nonselective inhibitor of cytochrome p-450 } for # days , and decreased 28 % with coadministration of ddrug3 { potent inducer of cytochrome p-450 } for # days .",
        "label": "mechanism"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : HD00403 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { DB00564 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "the 20 % v/v solution of DB02325 was prepared in water from a stock solution of 95 % DB00898 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 / ddrug1 : DB00437 inhibits the enzymatic oxidation of ddrug3 and ddrug4 to HD00271 .",
        "label": "NA"
    },
    {
        "text": "however , because some HD00532 have been reported to enhance the anticoagulant effects of ddrug1 or its derivatives in patients , the prothrombin time or other suitable coagulation test should be closely monitored if a ddrug2 is administered concomitantly with DB00682 or its derivatives .",
        "label": "NA"
    },
    {
        "text": "another oral ddrug0 , DB01026 , inhibits the metabolism of DB00637 , resulting in elevated plasma concentrations of ddrug3 and its active metabolite ddrug4 which may prolong qt intervals .",
        "label": "mechanism"
    },
    {
        "text": "therefore , administration of ddrug0 with HD00374 containing ddrug2 , ddrug3 , or DB01370 ;",
        "label": "NA"
    },
    {
        "text": "HD00216 { ddrug1 } , ddrug2 or other ddrug3 , or ddrug4 : concurrent use with DB01102 may produce additive inotropic and/or chronotropic effects .",
        "label": "NA"
    },
    {
        "text": "ddrug0 should be used with care when ddrug1 or inhibitors of av conduction , such as certain ddrug2 { particularly of the ddrug3 -lsb- DB00661 -rsb- and ddrug5 -lsb- ddrug6 -rsb- classes } , or HD00428 , such as ddrug8 , are used concurrently .",
        "label": "NA"
    },
    {
        "text": "for example , since DB01432 may reduce the gastrointestinal absorption of both the oral HD00326 and ddrug2 , the net effects are unpredictable .",
        "label": "mechanism"
    },
    {
        "text": "HD00343 ddrug1 , as well as a metabolite of DB00614 , slow ddrug3 metabolism .",
        "label": "NA"
    },
    {
        "text": "this interaction should be given consideration in patients taking HD00897 concomitantly with HD00106 .",
        "label": "advise"
    },
    {
        "text": "- a HD00535 { ddrug1 } such as ddrug2 { ddrug3 , ddrug4 , ddrug5 , others } , ddrug6 { ddrug7 , ddrug8 , ddrug9 } , ddrug10 { ddrug11 , ddrug12 } , ddrug13 { ddrug14 } , ddrug15 { ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , and DB00788 { ddrug22 , ddrug23 , ddrug24 } ;",
        "label": "NA"
    },
    {
        "text": "previous studies have demonstrated a significant reduction in the oral bioavailability of ddrug0 and DB00537 when administered concomitantly with an intravenous ddrug2 such as DB00295 .",
        "label": "mechanism"
    },
    {
        "text": "the effect of DB00091 on DB00343 plasma concentrations has not been evaluated .",
        "label": "NA"
    },
    {
        "text": "in a clinical pharmacology study , ddrug0 or DB00605 was administered to hypertensive patients receiving DB00584 .",
        "label": "NA"
    },
    {
        "text": "caution should be exercised when considering the use of DB00187 and DB00661 in patients with depressed myocardial function .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : concomitant administration of ddrug1 containing DB14513 or DB01370 with ddrug4 chewable/dispersible buffered tablets or pediatric powder for oral solution may potentiate adverse events associated with the ddrug5 components .",
        "label": "NA"
    },
    {
        "text": "or with DB00152 containing ddrug1 may substantially interfere with drug absorption and result in insufficient plasma and tissue HD00533 concentrations .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , DB00776 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { HD00712 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 / ddrug1 : pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between ddrug2 and concomitantly administered ddrug3 { # mg orally given # and # hours prior to initiation of ddrug4 # g/kg/min , over # hours } or DB00316 { 1000 mg orally given 12 , # and # hours prior to , and # and # hours subsequent to , initiation of DB00278 # g/kg/min , over # hours } .",
        "label": "NA"
    },
    {
        "text": "however , due to possible pharmacodynamic interactions , when co-administered with ddrug0 , a reduction in dosage of ddrug1 on the concomitant DB01086 , ddrug3 , ddrug4 or HD00023 may be required .",
        "label": "NA"
    },
    {
        "text": "thus in order to avoid bleeding , reduced dosage of DB01109 is recommended during treatment with DB11598 { human } .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : following concomitant administration of a single dose of ddrug1 to subjects receiving multiple doses of DB01045 , m1 peak levels were increased { ~ 40 % } over those seen when DB01097 was given alone .",
        "label": "NA"
    },
    {
        "text": "exert particular caution in combining DB01239 with other ddrug1 { HD00043 and ddrug3 } : particularly the elderly may develop delirium , high fever , severe obstipation , even ileus and glaucoma .",
        "label": "advise"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , DB00812 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , DB00231 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "unmodified ddrug0 { 1 % m/v } significantly improved the transport ratio { r = p { app } polymer / p { app } control } of ddrug1 to # and 1 % { m/v } HD00072 conjugated with DB00151 further enhanced the permeation .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { e , g , , ddrug1 , DB00384 , or ddrug3 } , ddrug4 supplements , or DB14500 - containing salt substitutes may lead to significant increases in serum potassium .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : interaction with drugs that inhibit metabolism via cytochrome cyp2b6 3a { cyp3a } : the metabolism of ddrug1 to the major circulating metabolite HD00696 and the metabolism of other HD00695 is catalyzed by cyp3a .",
        "label": "NA"
    },
    {
        "text": "in addition , results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance { ddrug0 , ddrug1 , ddrug2 , DB01234 , or ddrug4 } with DB00520 may result in clinically meaningful reductions in ddrug6 concentrations .",
        "label": "mechanism"
    },
    {
        "text": "there is limited experience with concomitant HD00366 such as ddrug1 , ddrug2 , ddrug3 , and HD00218 { both ddrug5 - like and loop } .",
        "label": "NA"
    },
    {
        "text": "HD00350 { such as ddrug1 , ddrug2 , or ddrug3 } : concurrent use with DB01102 may have a proarrhythmic effect .",
        "label": "NA"
    },
    {
        "text": "the concurrent use of two or more drugs with anticholinergic activity -- such as an ddrug0 { eg , DB00477 } , an ddrug2 { eg , ddrug3 } , and/or a HD00042 { eg , ddrug5 } -- commonly results in excessive anticholinergic effects , including dry mouth and associated dental complications , blurred vision , and , in patients exposed to high temperature and humidity , hyperpyrexia .",
        "label": "effect"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { ddrug1 s } , ddrug2 , ddrug3 { ddrug4 may decrease the effects of these medicines } , HD00458 { using these medicines with HD00026 may result in increased cns depressant effects } , ddrug7 , ddrug8 { using these medicines with ddrug9 may change the amount of either medicine that you need to take } , and oral ddrug10 containing ddrug11 { ddrug12 may decrease the effectiveness of these oral ddrug13 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , ddrug3 ddrug4 : DB00637 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 HD00100 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "other cardiovascular agents : ddrug0 and ddrug1 iv have been used concomitantly with ddrug2 , ddrug3 , DB14049 , ddrug5 , ddrug6 , DB00457 and ddrug8 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "immediate and extended release tablets the hypoglycemic action of ddrug0 may be potentiated by certain drugs including HD00518 , some ddrug2 and other drugs that are highly protein bound , ddrug3 , HD00297 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma ddrug0 concentrations include : acute DB02325 intake , ddrug2 , chboramphenicol , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , HD00219 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { DB00295 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , DB00277 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "drugs such as DB13179 and ddrug1 may inhibit the metabolism of HD00175 and thus decrease their clearance .",
        "label": "mechanism"
    },
    {
        "text": "no interaction with the HD00042 ddrug1 was shown in a single-dose study with ddrug2 without coadministered ddrug3 / HD00682 .",
        "label": "NA"
    },
    {
        "text": "to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma { hiv-nhl } , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the DB00531 , ddrug1 , ddrug2 , and ddrug3 { chop } chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen { i , e , , ddrug4 , ddrug5 , ddrug6 , and DB00898 with ddrug8 plus ddrug9 } without receiving ddrug10 therapy .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 HD00388 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 DB00472 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "in eight hiv-infected patients , the steady-state auc of DB00537 was decreased an average of 26 % { 95 % ci = 14 % , 37 % } when ddrug1 was administered # hours prior to a marketed chewable/dispersible tablet formulation of DB00900 .",
        "label": "NA"
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of HD00539 such as ddrug1 include certain ddrug2 { e , g , , HD00249 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 } , ddrug11 salts , ddrug12 , local ddrug13 , ddrug14 , and ddrug15 .",
        "label": "effect"
    },
    {
        "text": "however , there are limited in vivo data suggesting a modest cyp2d6 inhibitory effect for DB01175 , i , e , , coadministration of ddrug1 { 20 mg/day for # days } with the ddrug2 ddrug3 { single dose of # mg } , a substrate for cyp2d6 , resulted in a 40 % increase in cmax and a 100 % increase in auc of DB01151 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , DB00316 and ddrug2 may enhance the effects of : other ddrug3 s , DB02325 , general ddrug5 , ddrug6 such as ddrug7 , ddrug8 , or other ddrug9 , causing increased cns depression .",
        "label": "effect"
    },
    {
        "text": "DB00562 may interact with ddrug1 , ddrug2 s , ddrug3 { allergy , cold , and sinus medicines } , diabetic drugs , ddrug4 , DB00368 , ddrug6 like ddrug7 or ddrug8 , and high blood pressure medications .",
        "label": "int"
    },
    {
        "text": "other cardiovascular agents : DB00584 and ddrug1 iv have been used concomitantly with HD00673 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 and ddrug8 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , DB00091 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , DB00220 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "HD00532 , including ddrug1 , may enhance the effects of the oral HD00025 ddrug3 or its derivatives .",
        "label": "NA"
    },
    {
        "text": "may interact with the following : HD00244 { these medicines may make your condition worse and prevent the HD00815 from working properly } and ddrug2 , ddrug3 , ddrug4 , and ddrug5 { these medicines may increase the risk of heart problems } .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of HD00071 : ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , ddrug5 , ddrug6 , ddrug7 } , ddrug8 , HD00808 , ddrug10 , ddrug11 , ddrug12 , ddrug13 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : DB01118 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 DB00683 , ddrug12 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : DB00316 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { DB00252 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "caution should be exercised when taking this medicine certain HD00002 , such as ddrug1 , ddrug2 , or DB00207 .",
        "label": "NA"
    },
    {
        "text": "the lower rate of absorption in the groups receiving # mg DB01592 instead of # mg of ddrug1 per kg diet resulted in a decreased renal excretion of DB14574 .",
        "label": "mechanism"
    },
    {
        "text": "the potential effects of increased plasma concentrations of DB00683 or other HD00100 metabolized via cyp3a4 { ddrug2 , ddrug3 } should be considered when coadministering these agents with ddrug4 .",
        "label": "NA"
    },
    {
        "text": "in a study in normal volunteers , concomitant administration of DB00490 and DB00502 resulted in increased serum ddrug2 concentrations .",
        "label": "mechanism"
    },
    {
        "text": "{ concurrent use with HD00029 is not recommended , as they may provoke DB14507 toxicity because of reduced renal clearance .",
        "label": "NA"
    },
    {
        "text": "no significant drug interactions have been reported in studies of ddrug0 given with other drugs such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , DB00999 , and oral ddrug6 in healthy volunteers , or given with DB00584 to patients with heart failure { nyha class ii and iii } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 should be administered with caution to patients who are taking other ddrug1 or HD00261 , including ddrug3 , HD00026 and ddrug5 , or to those with a history of psychiatric disorder { including manic-depressive illness and schizophrenia } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , DB01076 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , DB01232 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 has been shown to induce the metabolism of HD00346 and DB01124 , which are metabolized through cyp2c9 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , DB00636 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { HD00531 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "interactions for DB11094 analogues { ddrug1 , ddrug2 , ddrug3 , and ddrug4 } : DB01432 : ddrug6 has been reported to reduce intestinal absorption of ddrug7 ;",
        "label": "NA"
    },
    {
        "text": "there is no pharmacokinetic interaction between DB00898 and DB01205 .",
        "label": "NA"
    },
    {
        "text": "DB00091 , ddrug1 and ddrug2 concentrations should be monitored at the initiation of DB01167 therapy and frequently thereafter , and the dose of these three drug products adjusted appropriately .",
        "label": "advise"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : ddrug1 ; ddrug2 ; DB01159 ; certain HD00002 , especially the ddrug5 and ddrug6 ; ddrug7 ; ddrug8 salts ; ddrug9 ; and ddrug10 .",
        "label": "NA"
    },
    {
        "text": "medications can interfere with folate utilization , including : HD00740 { such as ddrug1 , and ddrug2 } ddrug3 { sometimes prescribed to control blood sugar in type # diabetes } DB00795 { used to control inflammation associated with crohn_disease and ulcerative colitis } ddrug5 { a ddrug6 } ddrug7 there has been concern about the interaction between ddrug8 and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "administration of HD00029 to hypoparathyroid patients who are concurrently being treated with DB01070 may cause hypercalcemia .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , DB01167 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { HD00712 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the concomitant administration of DB00270 { ddrug2 } and DB00390 in a single-dose pharmacokinetic study did not affect renal , nonrenal and total body clearance of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "however , there has been one report of prolonged prothrombin time when DB00490 was added to the regimen of a patient treated with DB00682 .",
        "label": "effect"
    },
    {
        "text": "DB00949 treatment resulted in a 42 % decrease in the ddrug1 auc 0 - 24 , but no clinically relevant effect was observed on the pharmacokinetic parameters of DB00977 .",
        "label": "NA"
    },
    {
        "text": "DB00277 : the pharmacokinetics of ddrug1 { DB01223 # mg/kg infused over # minutes } were unchanged following a single oral dose of ddrug3 { 400 mg } in # healthy subjects .",
        "label": "NA"
    },
    {
        "text": "when ddrug0 or ddrug1 is used at the same time as other medicines or substances the following interactions must be taken into account : - HD00414 and ddrug3 may enhance the action of HD00240 .",
        "label": "effect"
    },
    {
        "text": "nevertheless , caution is indicated in the coadministration of HD00313 with any of the HD00114 and also in switching from one class to the other .",
        "label": "advise"
    },
    {
        "text": "HD00374 and DB01575 : ddrug2 and ddrug3 can reduce absorption of ddrug4 ;",
        "label": "NA"
    },
    {
        "text": "in patients receiving nonselective ddrug0 { ddrug1 } { e , g , , DB01037 } in combination with ddrug3 { e , g , , ddrug4 , ddrug5 , ddrug6 , ddrug7 , DB00285 } , there have been reports of serious , sometimes fatal , reactions .",
        "label": "effect"
    },
    {
        "text": "when ddrug0 and ddrug1 are used together , the signs of atropinization { flushing , mydriasis , tachycardia , dryness of the mouth and nose } may occur earlier than might be expected than when ddrug2 is used alone because DB00733 may potentiate the effect of DB00572 .",
        "label": "effect"
    },
    {
        "text": "medications can interfere with folate utilization , including : ddrug0 { such as ddrug1 , and ddrug2 } ddrug3 { sometimes prescribed to control blood sugar in type # diabetes } DB00795 { used to control inflammation associated with crohn_disease and ulcerative colitis } ddrug5 { a ddrug6 } ddrug7 there has been concern about the interaction between DB00115 and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "clinical interaction studies with DB00501 and DB00682 indicated that the coadministration of ddrug2 with these drugs does not result in clinically - significant drug interactions .",
        "label": "NA"
    },
    {
        "text": "DB14507 reversible increases in serum ddrug1 concentrations and toxicity have been reported during concomitant administration of ddrug2 with HD00106 , and with some ddrug4 .",
        "label": "NA"
    },
    {
        "text": "nucleoside analogues DB00900 co-administration of DB00811 and ddrug2 is not recommended .",
        "label": "NA"
    },
    {
        "text": "the disposition of DB00277 was not altered by concomitant DB00341 administration .",
        "label": "NA"
    },
    {
        "text": "because cyp 3a4 inhibitors may increase plasma concentrations of DB00921 , patients already on ppig 3a4 inhibitors such as HD00270 { e , g.",
        "label": "NA"
    },
    {
        "text": "ddrug0 : as with other ddrug1 , concomitant administration of DB00784 and DB00945 is not generally recommended because of the potential of increased adverse effects .",
        "label": "advise"
    },
    {
        "text": "HD00871 : ddrug1 contraindicated since the coadministration of this product with ddrug2 in an ddrug3 regimen reduces the plasma concentrations of DB01232 .",
        "label": "NA"
    },
    {
        "text": "therefore , administration of ddrug0 with HD00374 containing DB01373 , ddrug3 , or ddrug4 ;",
        "label": "NA"
    },
    {
        "text": "the growth of pseudomonas aeruginosa , particularly serotype o11 , in DB00652 and DB00792",
        "label": "NA"
    },
    {
        "text": "drug interactions : the central ddrug0 syndrome can occur when anticholinergic agents such as ddrug1 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain ddrug2 such as ddrug3 , the ddrug4 and other HD00031 , ddrug6 , certain ddrug7 such as the ddrug8 salts , and HD00388 .",
        "label": "NA"
    },
    {
        "text": "the lower rate of absorption in the groups receiving # mg ddrug0 instead of # mg of DB01592 per kg diet resulted in a decreased renal excretion of DB14574 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , HD00002 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { HD00712 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { cns } drugs including DB02325 , ddrug2 , ddrug3 , ddrug4 , blood pressure medications { ddrug5 , ddrug6 , HD00254 } , motion sickness medications , ddrug8 , ddrug9 , ddrug10 , sleeping pills and ddrug11",
        "label": "NA"
    },
    {
        "text": "although ddrug0 has a lower affinity for DB01370 than for DB01592 , ddrug3 should not be taken with ddrug4 - containing ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00482 can be used with low dose DB00945 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 - DB00120 and the HD00830 ddrug3 may have synergistic antidepressant activity if used concomitantly .",
        "label": "NA"
    },
    {
        "text": "however , in a study of # normal subjects , concurrent administration of ddrug0 decreased ddrug1 protein binding and increased DB01009 plasma clearance from # l/kg/h without ddrug3 to # l/kg/h with DB00945 .",
        "label": "NA"
    },
    {
        "text": "in addition to bleeding associated with DB01109 and ddrug1 , drugs that alter platelet function { such as DB00945 , ddrug3 and ddrug4 } may increase the risk of bleeding if administered prior to , during , or after ddrug5 therapy .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 ddrug2 can antagonize the in vitro antiviral activity of DB00649 and DB00495 against hiv .",
        "label": "NA"
    },
    {
        "text": "concurrent administration of ddrug0 and DB00900 significantly reduces the level of exposure to ddrug2 , but it is unclear how soon after ddrug3 administration DB00224 may be given safely .",
        "label": "NA"
    },
    {
        "text": "ddrug0 should not be taken closely in time with DB01370 and DB14513 containing ddrug3 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { DB01194 ophthalmic suspension } 1 % contains a HD00441 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : other HD00304 drugs , such as ddrug2 , DB01035 , ddrug4 , and ddrug5 , have been used concurrently with ddrug6 .",
        "label": "NA"
    },
    {
        "text": "no clinically significant effect of ddrug0 , ddrug1 , or DB14507 was seen on the pharmacokinetics of DB01238 { see clinical pharmacology : drug - drug interactions } .",
        "label": "NA"
    },
    {
        "text": "while all the HD00113 { ddrug1 } , e , g , , DB00472 , ddrug3 , and ddrug4 , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .",
        "label": "NA"
    },
    {
        "text": "because severe hypoglycemia has been reported in patients concomitantly receiving oral DB01110 { an ddrug1 } and oral HD00062 , such a potential interaction involving the latter agents when used concomitantly with ddrug3 tablets { an ddrug4 } can not be ruled out .",
        "label": "effect"
    },
    {
        "text": "there was no evidence of drug interactions in clinical studies in which DB00841 was administered concurrently with other drugs , including ddrug1 , ddrug2 , DB00421 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , and ddrug13 .",
        "label": "NA"
    },
    {
        "text": "if signs and symptoms suggestive of ddrug0 toxicity occur when DB00467 and ddrug2 are given concomitantly , physicians are advised to obtain serum ddrug3 levels and adjust DB00390 doses appropriately .",
        "label": "NA"
    },
    {
        "text": "DB14507 generally should not be given with HD00218 because they reduce ddrug2 s renal clearance and add a high risk of ddrug3 toxicity .",
        "label": "advise"
    },
    {
        "text": "DB11058 interferes with the absorption of HD00527 , including ddrug2 .",
        "label": "mechanism"
    },
    {
        "text": "clinically significant effects have been reported with the HD00043 when used concomitantly with DB00501 .",
        "label": "effect"
    },
    {
        "text": "however , there were 16 % and 32 % increases in the auc and cmax , respectively , of the combined moieties of HD00453 and HD00454 .",
        "label": "NA"
    },
    {
        "text": "interactions may also occur with the following : HD00515 / ddrug1 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 pain medication { e , g , , DB00318 } , drugs used to aid sleep , drowsiness-causing ddrug13 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "we compared DB00224 pharmacokinetics and gastric ph in # human immunodeficiency virus-positive patients by use of # mg of ddrug1 alone versus # mg of ddrug2 administered # h after DB00900 administration .",
        "label": "NA"
    },
    {
        "text": "- a HD00535 { ddrug1 } such as ddrug2 { ddrug3 , ddrug4 , ddrug5 , others } , ddrug6 { ddrug7 , ddrug8 , ddrug9 } , ddrug10 { DB00586 , ddrug12 } , ddrug13 { ddrug14 } , ddrug15 { ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , and ddrug21 { ddrug22 , ddrug23 , ddrug24 } ;",
        "label": "NA"
    },
    {
        "text": "HD00377 , HD00802 : e , g , , ddrug2 , ddrug3 , ddrug4",
        "label": "NA"
    },
    {
        "text": "other concomitant therapy although specific interaction studies were not performed , DB01216 doses of # mg or more were concomitantly used in clinical studies with ddrug1 , ddrug2 , a-blockers , HD00651 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , cardiac ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 { also referred to as ddrug14 } , and ddrug15 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "interactions with other ddrug0 : significant decreases in the auc of ddrug1 { 20 % } and DB00224 { 84 % } occurred following simultaneous administration of these agents with DB00900 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 can interact with ddrug1 or other HD00261 { may potentiate the cns depressant effects of either these medications or HD00388 } , ddrug4 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug5 } , and ddrug6 { concurrent use with ddrug7 may prolong and intensify the anticholinergic and cns depressant effects of ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : when ddrug1 is administered with DB00945 , its protein binding is reduced , although the clearance of free DB00749 is not altered .",
        "label": "NA"
    },
    {
        "text": "coadministration of oral ddrug0 , ddrug1 , ddrug2 , or DB00908 did not seem to change the pharmacokinetic profile of DB00736 .",
        "label": "NA"
    },
    {
        "text": "the possibility of hypotensive effects with ddrug0 or DB09477 can be minimized by either discontinuing the HD00295 or increasing the salt intake prior to initiation of treatment with ddrug3 or ddrug4 .",
        "label": "effect"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : DB01045 ddrug10 DB00683 , ddrug12 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "with combined use , clinicians should be aware , when DB00252 is added , of the potential for reexacerbation of pulmonary symptomatology due to lowered serum DB00277 concentrations .",
        "label": "effect"
    },
    {
        "text": "ddrug0 , HD00502 , ddrug2 { ddrug3 , DB00199 , ddrug5 : skeletal muscle .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { DB00682 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 DB00472 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , HD00668 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , DB00295 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "while all the HD00113 { ddrug1 } , e , g , , DB00472 , ddrug3 , ddrug4 , and ddrug5 , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .",
        "label": "NA"
    },
    {
        "text": "DB00563 : concomitant administration of ddrug1 and some HD00203 has been reported to reduce the clearance of ddrug3 , enhancing the toxicity of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "DB00771 may decrease the effect of ddrug1 , DB01235 , and ddrug3 .",
        "label": "effect"
    },
    {
        "text": "while no in vivo drug-drug interaction studies were conducted between DB01215 and inducers of cyp3a , compounds that are potent cytochrome_p450_family_3_subfamily_a inducers { such as DB00564 , ddrug2 , ddrug3 , and ddrug4 } would be expected to decrease ddrug5 concentrations .",
        "label": "mechanism"
    },
    {
        "text": "inhibitors of this isoenzyme { e , g , , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , grapefruit juice , ddrug7 , ddrug8 , ddrug9 , DB00549 } should be cautiously coadministered with DB00204 as they can potentially increase ddrug12 levels .",
        "label": "advise"
    },
    {
        "text": "the results of a study of coadministration of DB00330 { 50 mg/kg } with an ddrug1 containing DB06724 to # patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ddrug3 of approximately 20 % and 13 % , respectively , suggesting that the oral absorption of ddrug4 may be reduced by these ddrug5 .",
        "label": "NA"
    },
    {
        "text": "with simultaneous dosing of DB00862 # mg and DB01162 # mg , # of # subjects experienced a standing systolic blood pressure of less than # mm hg .",
        "label": "effect"
    },
    {
        "text": "ddrug0 - combined administration of racemic DB00215 { 40 mg/day for # days } and the cyp1a2 substrate DB00277 { single dose of # mg } did not affect the pharmacokinetics of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "HD00361 { ddrug1 } and DB01274 may interfere with the effect of each other when administered concurrently .",
        "label": "effect"
    },
    {
        "text": "coadministration of DB00580 { 40 mg bid { day 1 } and # mg qd { days 2 - 7 } } with ddrug1 { 10 mg ddrug2 bid } resulted in 21 % increase in ddrug3 auc0 - 12 and a 16 % increase in DB01016 cmax leading to a 16 % decrease in glucose auc0 - 24 .",
        "label": "NA"
    },
    {
        "text": "patients should be warned of the potential danger of the intravenous self-administration of ddrug0 while under treatment with DB01183 or DB00921 .",
        "label": "NA"
    },
    {
        "text": "although the mechanism of interaction between DB00573 and DB00945 is not totally known , enzyme induction and displacement of ddrug2 from plasma alb binding sites are possibilities .",
        "label": "mechanism"
    },
    {
        "text": "toxicology studies of ddrug0 - related deaths reveal frequent involvement of other HD00389 , including DB02325 , ddrug3 such as ddrug4 { ddrug5 } , and , to a rising degree , ddrug6 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , DB00091 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , DB00295 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "elevated serum levels of DB00091 have been reported with the concomitant use of some HD00532 and ddrug2 .",
        "label": "NA"
    },
    {
        "text": "HD00320 : ddrug1 - induced hypokalemia may enhance the curariform effect of ddrug2 { e , g , , DB01199 } .",
        "label": "NA"
    },
    {
        "text": "interactions for ddrug0 analogues { ddrug1 , ddrug2 , ddrug3 , and DB00146 } : DB01432 : ddrug6 has been reported to reduce intestinal absorption of ddrug7 ;",
        "label": "NA"
    },
    {
        "text": "the appropriate dose for DB00220 incombination with DB00238 , with respectto safety and efficacy , has not been established .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 : in one study , ddrug1 was given to adult diabetics who were already receiving ddrug2 { n = 4 } , ddrug3 { n = 2 } DB00672 with ddrug5 { n = 3 } or DB01016 with ddrug7 { n = 6 } .",
        "label": "NA"
    },
    {
        "text": "DB00294 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , DB01232 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "int"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { ddrug1 s } , ddrug2 , DB01285 { ddrug4 may decrease the effects of these medicines } , ddrug5 { using these medicines with HD00026 may result in increased cns depressant effects } , ddrug7 , ddrug8 { using these medicines with ddrug9 may change the amount of either medicine that you need to take } , and oral ddrug10 containing ddrug11 { ddrug12 may decrease the effectiveness of these oral ddrug13 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a ddrug0 , including ddrug1 , with multivalent cation-containing products such as ddrug2 or ddrug3 ddrug4 , ddrug5 , ddrug6 chewable/buffered tablets or pediatric powder , or products containing ddrug7 , DB01592 , or ddrug9 may substantially decrease the absorption of DB00537 , resulting in serum and urine levels considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "it is known that cyp1a2 is inhibited by several medicinal products , including DB00176 , and such medicinal products could theoretically adversely influence the clearance of DB00261 .",
        "label": "mechanism"
    },
    {
        "text": "because of the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of ddrug0 , DB00476 and DB00679 should not be co-administered .",
        "label": "advise"
    },
    {
        "text": "HD00374 may interfere with the absorption of DB00424 .",
        "label": "mechanism"
    },
    {
        "text": "in the first double-blind comparative study { 28-week } of ddrug0 and ddrug1 , DB00334 # to # mg/day proved to be significantly more effective than DB00734 # to # mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms .",
        "label": "NA"
    },
    {
        "text": "DB01026 did not affect the conversion of ddrug1 to the active metabolite after intravenous administration of ddrug2 , and DB00199 had no clinically significant effect after oral administration .",
        "label": "NA"
    },
    {
        "text": "seizures have been reported in patients taking another ddrug0 and the HD00535 DB08981 concurrently .",
        "label": "NA"
    },
    {
        "text": "therefore , co-administration of DB01156 with drugs that are metabolized by cyp2d6 isoenzyme including certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } , ddrug8 { e , g , , ddrug9 , DB00734 , ddrug11 } , ddrug12 { e , g , , ddrug13 } , and ddrug14 { e , g , , ddrug15 , ddrug16 } , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : hallucinations have been reported when DB00465 was used in patients taking HD00826 { ddrug3 , ddrug4 , ddrug5 } .",
        "label": "effect"
    },
    {
        "text": "effects of DB00949 on low-dose ddrug1 a group of # nonsmoking , healthy white female volunteers established on an oral HD00349 regimen containing # mg ddrug3 and # mg ddrug4 for at least # months received # mg/day of ddrug5 from midcycle { day 15 } to midcycle { day 14 } of two consecutive oral ddrug6 cycles .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - combined administration of a single dose of ddrug1 { 600 mg } , both a cyp3a4 substrate and a potent inhibitor of cyp3a4 , and ddrug2 { 20 mg } did not affect the pharmacokinetics of either DB00503 or DB01175 .",
        "label": "NA"
    },
    {
        "text": "- when ddrug0 or ddrug1 is used concurrently with HD00418 { e , g , ddrug3 } , an interval of at least # hours should be maintained between the two medicines , since the absorption of HD00414 or ddrug5 is impaired",
        "label": "NA"
    },
    {
        "text": "these results would seem to dictate against the clinical use of DB00563 with DB00023 , or during the period following ddrug2 therapy when plasma asparagine levels are below normal .",
        "label": "advise"
    },
    {
        "text": "little or no change in the pharmacokinetics of either drug was observed when DB00220 was coadministered with ddrug1 or DB00649 .",
        "label": "NA"
    },
    {
        "text": "DB00486 should be administered with caution to patients who are taking other HD00826 or ddrug2 , including ddrug3 , ddrug4 and ddrug5 , or to those with a history of psychiatric disorder { including manic-depressive illness and schizophrenia } .",
        "label": "advise"
    },
    {
        "text": "the interaction between DB00978 and DB00501 has not been studied .",
        "label": "NA"
    },
    {
        "text": "certain drugs , including HD00518 { ddrug1 } , ddrug2 , ddrug3 , and ddrug4 may potentiate the hypoglycemic action of ddrug5 and other oral HD00394 .",
        "label": "effect"
    },
    {
        "text": "no differences in adverse events or qtc interval were observed when subjects were administered ddrug0 alone or in combination with either DB00199 or DB01026 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - and/or ddrug1 - containing ddrug2 , products containing ddrug3 { ddrug4 } , ddrug5 containing ddrug6 or other metal cations , or ddrug7 { DB00900 } chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after DB01155 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { DB00316 } , ddrug3 such as ddrug4 and DB00759 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and DB00495 ddrug2 can antagonize the in vitro antiviral activity of DB00649 and ddrug4 against hiv .",
        "label": "NA"
    },
    {
        "text": "DB00782 and DB01081 , by decreasing gut motility , may increase ddrug2 absorption .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the concomitant use of ddrug1 { ddrug2 transdermal system } with other HD00389 , including but not limited to other ddrug4 , ddrug5 , ddrug6 , HD00262 { e , g , , ddrug8 } , general ddrug9 , ddrug10 , ddrug11 , and ddrug12 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .",
        "label": "NA"
    },
    {
        "text": "therefore , co-administration of DB00363 with other drugs that are metabolized by this isozyme , including ddrug1 , ddrug2 , ddrug3 , and HD00310 { e , g , , ddrug5 , ddrug6 and ddrug7 } , or that inhibit this enzyme { e , g , , ddrug8 } , should be approached with caution .",
        "label": "advise"
    },
    {
        "text": "medications can interfere with folate utilization , including : ddrug0 { such as ddrug1 , and ddrug2 } ddrug3 { sometimes prescribed to control blood sugar in type # diabetes } ddrug4 { used to control inflammation associated with crohn_disease and ulcerative colitis } DB00384 { a ddrug6 } DB00563 there has been concern about the interaction between ddrug8 and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "the anticoagulant effect of DB01109 is enhanced by concurrent treatment with DB11598 { human } in patients with hereditary antithrombin iii deficiency .",
        "label": "effect"
    },
    {
        "text": "DB00682 : increased inr { international normalized ratio } when DB01097 and ddrug2 were co-administered has been rarely reported .",
        "label": "NA"
    },
    {
        "text": "the majority of patients in ra clinical studies received one or more of the following concomitant medications with DB01281 : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , DB14154 , ddrug8 , ddrug9 , ddrug10 , and ddrug11 .",
        "label": "NA"
    },
    {
        "text": "dose adjustment of DB01012 may be required and pth and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong cyp3a4 inhibitor { e , g , , ddrug1 , ddrug2 , DB01167 ;",
        "label": "advise"
    },
    {
        "text": "immediate and extended release tablets the hypoglycemic action of ddrug0 may be potentiated by certain drugs including HD00518 , some ddrug2 and other drugs that are highly protein bound , ddrug3 , ddrug4 , ddrug5 , ddrug6 , HD00519 , ddrug8 , and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of ddrug0 such as DB00565 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 } , ddrug11 salts , DB14507 , local ddrug13 , ddrug14 , and ddrug15 .",
        "label": "effect"
    },
    {
        "text": "effect of other drugs on the pharmacokinetics of ddrug0 : literature reports suggest that DB00863 , an agent that decreases stomach acidity , does not greatly alter DB01068 pharmacokinetics .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : administration of ddrug1 # hours prior to or concurrent with oral DB01004 was associated with a # { 114 } % increase in the steady-state auc of DB00900 { n = 12 } .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } DB01026 { ddrug14 } DB01235 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "increases in prothrombin time have been noted in patients receiving long - term DB00682 therapy after DB00499 was initiated .",
        "label": "effect"
    },
    {
        "text": "HD00239 : concomitant treatment with DB00982 and ddrug2 should be avoided because ddrug3 use has been associated with a number of cases of idiopathic_intracranial_hypertension { benign intracranial hypertension } , some of which involved concomitant use of ddrug4",
        "label": "NA"
    },
    {
        "text": "no important interactions to date DB00922 does not have clinically important pharmacokinetic interactions with ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 or DB01167 .",
        "label": "NA"
    },
    {
        "text": "inhibitors of cyp3a4 { eg , DB01026 } or cyp2d6 { eg , DB00908 , ddrug2 , or ddrug3 } can inhibit ddrug4 elimination and cause increased blood levels .",
        "label": "NA"
    },
    {
        "text": "may interact with thyroid medication { e , g , , ddrug0 } , DB11119 - containing products , ddrug2 , HD00613 { e , g , , ddrug4 , ddrug5 } , and ddrug6 { e , g , , ddrug7 , ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "it is , however , possible that concomitant use of other known ddrug0 such as ddrug1 , HD00029 , ddrug3 , ddrug4 , ddrug5 and ddrug6 might increase the photosensitivity reaction of actinic_keratosis treated with the DB00855 for topical solution .",
        "label": "effect"
    },
    {
        "text": "drug interactions with HD00374 administration of # mg of ddrug1 { 2 x # mg capsule } within # minutes of an ddrug2 and DB14513 containing ddrug4 { ddrug5 } decreased ddrug6 auc by 41 % and cmax by 43 % .",
        "label": "NA"
    },
    {
        "text": "DB01037 - DB00120 and the ddrug2 ddrug3 may have synergistic antidepressant activity if used concomitantly .",
        "label": "NA"
    },
    {
        "text": "since DB00201 is frequently co-administered with DB00316 , it is of clinical interest to study the effect of ddrug2 on the hepatotoxicity of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "HD00829 including ddrug1 , ddrug2 , and ddrug3 hc1 : concomitant use of DB00135 and non-selective ddrug5 may cause hypertension .",
        "label": "NA"
    },
    {
        "text": "to determine whether injection of ddrug0 would permit larger doses of DB00515 to be administered , a fixed # - g/m2 dose of HD00158 was given intravenously over three hours concurrently with escalating doses of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "other concomitant therapy although specific interaction studies were not performed , DB01216 doses of # mg or more were concomitantly used in clinical studies with ddrug1 , ddrug2 , a-blockers , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , cardiac ddrug9 , ddrug10 , HD00727 , ddrug12 , ddrug13 { also referred to as ddrug14 } , and ddrug15 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "in clinical trials , ddrug0 was used with DB00390 , ddrug2 , ddrug3 , oral ddrug4 , and supplemental ddrug5 , in a pharmacokinetic substudy in patients with congestive heart failure receiving ddrug6 or ddrug7 in whom therapy with ddrug8 was initiated , apparent oral clearance values for DB00695 { n = 23 } and ddrug10 { n = 30 } were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .",
        "label": "NA"
    },
    {
        "text": "interactions with HD00841 : ddrug1 { eg , ddrug2 , ddrug3 , ddrug4 , DB01209 and ddrug6 } should not be administered to a patient who has received or is receiving a course of therapy with a ddrug7 such as ddrug8 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a single { 400 mg } and multiple dose { 400 mg tid } study of ddrug1 in epileptic patients { n = 8 } maintained on DB00252 monotherapy for at least # months , DB00996 had no effect on the steady-state trough plasma concentrations of ddrug4 and ddrug5 had no effect on ddrug6 pharmacokinetics .",
        "label": "NA"
    },
    {
        "text": "- a ddrug0 { HD00615 } such as ddrug2 { ddrug3 , ddrug4 , ddrug5 , others } , ddrug6 { ddrug7 , ddrug8 , ddrug9 } , ddrug10 { ddrug11 , ddrug12 } , ddrug13 { ddrug14 } , ddrug15 { ddrug16 } , DB00461 { ddrug18 } , ddrug19 { ddrug20 } , and ddrug21 { ddrug22 , ddrug23 , ddrug24 } ;",
        "label": "NA"
    },
    {
        "text": "HD00500 reports suggest that HD00203 may diminish the antihypertensive effect of ddrug2 .",
        "label": "NA"
    },
    {
        "text": "these results suggest that the hepatoxicity of DB00898 in alcoholic beverages is enhanced by interaction with its congeners and HD00176 ;",
        "label": "effect"
    },
    {
        "text": "to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma { hiv-nhl } , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the ddrug0 , ddrug1 , DB00541 , and ddrug3 { chop } chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen { i , e , , ddrug4 , DB00997 , ddrug6 , and ddrug7 with ddrug8 plus ddrug9 } without receiving ddrug10 therapy .",
        "label": "NA"
    },
    {
        "text": "before taking DB00222 , tell your doctor if you are taking any of the following medicines : - ddrug1 or another ddrug2 such as ddrug3 { ddrug4 } , ddrug5 { DB01399 , others } , ddrug7 { ddrug8 } , ddrug9 { ddrug10 } , or ddrug11 { ddrug12 } ;",
        "label": "advise"
    },
    {
        "text": "the following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral HD00811 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , HD00445 , ddrug6 , ddrug7 , ddrug8 { e , g , , ddrug9 } , ddrug10 .",
        "label": "NA"
    },
    {
        "text": "caution should be used when administering or taking ddrug0 with DB01026 and other strong cyp3a4 inhibitors such as , but not limited to , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { HD00691 } , and ddrug13 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and HD00147 similarly inhibit and stimulate HD00148 - or ddrug3 - induced proliferation of prostatic epithelium .",
        "label": "effect"
    },
    {
        "text": "HD00445 such as ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , ddrug5 { e , g , , ddrug6 } , ddrug7 { e , g , , ddrug8 } , and ddrug9 { e , g , , ddrug10 } : using these medicines with DB00150 may increase the chance of side effects .",
        "label": "NA"
    },
    {
        "text": "observations from drug interaction studies with DB01232 may not be predictive for DB01232 .",
        "label": "NA"
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of ddrug0 such as DB00565 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 } , DB14513 salts , ddrug12 , local ddrug13 , ddrug14 , and ddrug15 .",
        "label": "effect"
    },
    {
        "text": "in a controlled clinical trial , a 20 % reduction of the ddrug0 dose at the initiation of DB00949 therapy resulted in DB00252 levels comparable to those prior to ddrug3 administration .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } DB00501 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { DB01026 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit ddrug0 binding to serum proteins or alter the concentrations of serum binding proteins : ddrug1 and related ddrug2 , DB00023 , ddrug4 , ddrug5 and ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , DB00675 .",
        "label": "NA"
    },
    {
        "text": "interactions with HD00841 : ddrug1 { eg , ddrug2 , DB00844 , ddrug4 , ddrug5 and ddrug6 } should not be administered to a patient who has received or is receiving a course of therapy with a ddrug7 such as ddrug8 .",
        "label": "NA"
    },
    {
        "text": "in a single subject given one dose of ddrug0 # hours after a dose of DB00900 - placebo tablets , a greater than 50 % reduction in the auc of DB00537 was observed .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 : ddrug2 and ddrug3 containing DB14513 or ddrug5 , as well as formulations containing divalent and trivalent cations such as DB00900 { ddrug7 } , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with ddrug8 and interfere with its bioavailability .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may have a clinically important interaction with the following other drugs : ddrug1 : when ddrug2 and DB00898 were administered several hours apart so that peak concentrations of each would coincide , ddrug4 did not increase the impairment of mental and motor skills caused by DB02325 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : population pharmacokinetic analyses indicate that DB00906 clearance is 60 % greater in patients taking DB00252 with or without other enzyme - inducing ddrug3 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : concurrent administration of certain HD00537 , such as HD00538 and ddrug3 , would be expected to compromise the beneficial effects of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "therefore you may need to take a DB00115 supplement while taking DB00233 .",
        "label": "advise"
    },
    {
        "text": "until data on possible interactions between ddrug0 and ddrug1 are obtained , DB00280 should not be administered within # hours before or # hours after DB00661 administration .",
        "label": "advise"
    },
    {
        "text": "fifteen to # minutes of exposure to # mac DB00753 or DB00228 had minimal effects on the duration of action of initial doses of ddrug2 and therefore , no adjustment to the initial dose should be necessary when ddrug3 is administered shortly after initiation of volatile agents .",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , ddrug3 , or DB01373 , with ddrug5 , with metal cations such as ddrug6 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as DB00900 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "therefore , co-administration of ddrug0 with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index , including certain ddrug1 { ddrug2 -lsb- ddrug3 -rsb- , such as ddrug4 , ddrug5 , and ddrug6 } , HD00219 and ddrug8 { e , g , , ddrug9 , DB01195 } , should be approached with caution .",
        "label": "NA"
    },
    {
        "text": "if ddrug0 is to be combined with other ddrug1 such as HD00262 or ddrug3 / ddrug4 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of ddrug5 and ddrug6 { e , g , , ddrug7 or DB00829 } are additive .",
        "label": "NA"
    },
    {
        "text": "improvements in general cognitive function seen with DB00334 treatment in a 1-year controlled study of patients with early-phase schizophrenia , were significantly greater than changes seen with either DB00734 or ddrug2 .",
        "label": "NA"
    },
    {
        "text": "HD00645 did not inhibit the antitumor activity of four HD00646 { ddrug2 , ddrug3 , ddrug4 , ddrug5 } in four murine models .",
        "label": "NA"
    },
    {
        "text": "it is , however , possible that concomitant use of other known ddrug0 such as ddrug1 , ddrug2 , ddrug3 , HD00219 , ddrug5 and ddrug6 might increase the photosensitivity reaction of actinic_keratosis treated with the DB00855 for topical solution .",
        "label": "effect"
    },
    {
        "text": "other ddrug0 { e , g , HD00026 , ddrug2 , ddrug3 and general ddrug4 } have additive or potentiating effects with DB00450 .",
        "label": "effect"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / ddrug1 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , DB14507 , ddrug11 pain medication { e , g , , DB00318 } , drugs used to aid sleep , drowsiness-causing ddrug13 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "study objective : to evaluate the effect of DB00472 on the pharmacokinetics and cardiovascular safety of DB00604 at steady state in healthy men .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and DB00759 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as HD00269 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "there have been greater than two-fold increases of previously stable plasma levels of HD00043 when DB00472 has been administered in combination with these agents .",
        "label": "mechanism"
    },
    {
        "text": "DB00501 } and many that are substrates for cyp2b6 2d6 { many other ddrug1 , ddrug2 , and the HD00310 ddrug4 and ddrug5 } .",
        "label": "NA"
    },
    {
        "text": "drugs that lower seizure threshold : concurrent administration of DB01156 and agents { e , g , , ddrug1 , other ddrug2 , DB00277 , systemic ddrug4 , etc , } that lower seizure threshold should be undertaken only with extreme caution .",
        "label": "advise"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : HD00870 ddrug8 : DB01045 ddrug10 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "drugs that should not be coadministered with DB00220 ddrug1 : ddrug2 , ddrug3 ddrug4 : DB00637 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "label": "advise"
    },
    {
        "text": "ddrug0 - and/or ddrug1 - containing ddrug2 , products containing ddrug3 { DB01592 } , ddrug5 containing ddrug6 or other metal cations , or DB00900 { ddrug8 } chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after ddrug9 .",
        "label": "NA"
    },
    {
        "text": "HD00282 { ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 } : increase the metabolism of DB00977 and/or some ddrug7 , leading to possible decrease in contraceptive effectiveness .",
        "label": "mechanism"
    },
    {
        "text": "the cns effects of DB00241 may be enhanced by HD00445 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , DB01167 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and DB00126 .",
        "label": "NA"
    },
    {
        "text": "drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on ddrug0 therapy : ddrug1 , HD00175 , ddrug3 , oral HD00283 containing ddrug5 , ddrug6 - containing preparations and the numerous preparations containing ddrug7 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 s : ddrug1 should be administered at least # hours after or # hours before dosing with DB00537 because plasma concentrations of ddrug3 are decreased when administered with ddrug4 containing ddrug5 , DB01373 , or ddrug7 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00501 can inhibit the metabolism of DB00608 , increasing its plasma level .",
        "label": "mechanism"
    },
    {
        "text": "since DB01166 is extensively metabolized by cyp4f3 isoenzymes , caution should be exercised when ddrug1 is coadministered with inhibitors of c , p , a , such as ddrug2 and DB00199 or inhibitors of cyp2c19 such as ddrug4 .",
        "label": "NA"
    },
    {
        "text": "therefore , DB00727 or other ddrug1 { as used for management of angina } or other drugs having vasodilator activity should , if possible , be discontinued before starting DB01197 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 , DB01575 - pectin , ddrug2 , ddrug3 , ddrug4 , certain anticancer drugs , and DB01233 may interfere with intestinal ddrug6 absorption , resulting in unexpectedly low serum concentrations .",
        "label": "NA"
    },
    {
        "text": "DB01061 should not be administered concomitantly with DB00479 , ddrug2 , ddrug3 , ddrug4 , or ddrug5 .",
        "label": "advise"
    },
    {
        "text": "interaction of ddrug0 with other drugs : ddrug1 : co-administration of DB00501 { 800 mg/day } to patients taking DB00906 chronically had no effect on ddrug4 pharmacokinetics .",
        "label": "NA"
    },
    {
        "text": "the concomitant use of HD00649 s , vasoconstricting agents { such as DB01253 } and some ddrug2 may result in severe hypertension .",
        "label": "NA"
    },
    {
        "text": "since ddrug0 { ddrug1 } may interact with concurrently administered HD00703 , periodic serum level determinations of these drugs may be necessary { eg , ddrug3 may elevate DB00252 serum levels and ddrug5 has been reported to both increase and decrease ddrug6 levels } .",
        "label": "NA"
    },
    {
        "text": "dose-response curves { derived from the results of using the tablets as well as pure powders } showed that DB00792 was responsible for the inhibitory activity , which was partially antagonized by DB00652 .",
        "label": "effect"
    },
    {
        "text": "although additional drug interaction studies have not been conducted , the most common medications used concomitantly with DB00261 in clinical trials were ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and DB00437 .",
        "label": "NA"
    },
    {
        "text": "if it is necessary to continue the HD00295 , initiate therapy with DB00722 at a dose of # mg daily , and provide close medical supervision after the initial dose until blood pressure has stabilized .",
        "label": "advise"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 DB00264 HD00388 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "ddrug0 can interact with ddrug1 or other ddrug2 { may potentiate the cns depressant effects of either these medications or ddrug3 } , ddrug4 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug5 } , and HD00445 { concurrent use with ddrug7 may prolong and intensify the anticholinergic and cns depressant effects of HD00388 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , DB00091 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , DB00295 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "the fraction of DB00611 absorbed is unaffected by the concomitant administration of a ddrug1 { DB00935 } , but the rate of absorption is decreased .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the addition of ddrug1 to patients taking ddrug2 chronically had no effect on DB00906 pharmacokinetics , but DB00313 significantly decreased ddrug5 binding in vitro from # to # % , which resulted in an increase of approximately 40 % in the free tiagabine concentration .",
        "label": "NA"
    },
    {
        "text": "patients receiving other ddrug0 , ddrug1 , ddrug2 , or other ddrug3 { including DB02325 } concomitantly with DB00956 and ddrug6 tablets may exhibit an additive cns depression .",
        "label": "effect"
    },
    {
        "text": "because prostaglandins play an important role in hemostasis , and ddrug0 affect platelet function as well , concurrent therapy with all HD00203 , including ddrug2 , and DB00682 requires close monitoring of patients to be certain that no change in their ddrug4 dosage is required .",
        "label": "advise"
    },
    {
        "text": "DB00564 overdose recognized by a HD00042 assay .",
        "label": "NA"
    },
    {
        "text": "accordingly , careful patient monitoring and dose adjustment of ddrug0 is recommended in patients concomitantly taking DB00567 and DB00331 .",
        "label": "advise"
    },
    {
        "text": "DB00390 - in subjects who had received # days of # mg/day racemic DB00215 , combined administration of ddrug2 and ddrug3 { single dose of # mg } did not significantly affect the pharmacokinetics of either ddrug4 or ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , HD00002 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , DB00220 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "however , due to possible pharmacodynamic interactions , when co-administered with DB00633 , a reduction in dosage of ddrug1 on the concomitant DB01086 , ddrug3 , ddrug4 or ddrug5 may be required .",
        "label": "NA"
    },
    {
        "text": "concomitant use of ddrug0 and drugs that inhibit cyp3a4 { eg , ddrug1 , ddrug2 , DB00199 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 } may increase exposure to DB01254 and should be avoided .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in normal volunteers , there was no clinically significant pharmacokinetic or pharmacodynamic interaction with concomitant administration of single doses of DB00227 and DB00571 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - although DB01175 did not potentiate the cognitive and motor effects of ddrug2 in a clinical trial , as with other HD00281 , the use of ddrug4 by patients taking ddrug5 is not recommended .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , such as DB01032 and DB01138 , can inhibit renal tubular secretion of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "additionally , DB00715 did not alter the pharmacokinetics of ddrug1 , reflecting the absence of a role of cyp2d6 in DB00962 s metabolism .",
        "label": "NA"
    },
    {
        "text": "these results suggest that exposure to environmental HD00162 may alter the biological and behavioral responsiveness of an animal to DB02325 .",
        "label": "effect"
    },
    {
        "text": "the concurrent use of two or more drugs with anticholinergic activity -- such as an HD00513 { eg , ddrug1 } , an ddrug2 { eg , ddrug3 } , and/or a ddrug4 { eg , DB00321 } -- commonly results in excessive anticholinergic effects , including dry mouth and associated dental complications , blurred vision , and , in patients exposed to high temperature and humidity , hyperpyrexia .",
        "label": "effect"
    },
    {
        "text": "if ddrug0 is to be combined with other HD00595 such as ddrug2 or HD00596 / ddrug4 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of ddrug5 and ddrug6 { e , g , , ddrug7 or ddrug8 } are additive .",
        "label": "NA"
    },
    {
        "text": "these agents include medications such as : HD00326 , HD00679 including ddrug2 , sali-cylates , ddrug3 { including ddrug4 } , ddrug5 , or ddrug6 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , DB00390 , ddrug2 , and ddrug3 the in vitro binding of DB00682 to plasma proteins is only slightly reduced by ddrug5 { # % control vs # % } when ddrug6 plasma concentrations reach # to10 m g/ml .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of ddrug0 : ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , ddrug5 , DB01001 , ddrug7 } , ddrug8 , ddrug9 , DB00052 , ddrug11 , ddrug12 , ddrug13 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "until data on possible interactions between DB00661 and DB00280 are obtained , ddrug2 should not be administered within # hours before or # hours after ddrug3 administration .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in one study of # healthy volunteers , administration of DB00633 for # minutes at a plasma concentration of # { one } ng/ml resulted in no clinically meaningful increases in the magnitude or neuromuscular blockade associated with DB00728 administration .",
        "label": "NA"
    },
    {
        "text": "HD00285 , such as DB00988 and ddrug2 ;",
        "label": "NA"
    },
    {
        "text": "intravenous infusion of DB01088 had no effect on the pharmacokinetics of DB00390 .",
        "label": "NA"
    },
    {
        "text": "in vitro studies indicate that , at therapeutic concentrations of HD00372 { 300 m g/ml } , the binding of DB00465 was reduced from approximately # % to # % , representing a potential twofold increase in unbound ddrug2 plasma levels .",
        "label": "mechanism"
    },
    {
        "text": "co-administration of ddrug0 , ddrug1 , ddrug2 , ddrug3 , DB00390 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 and ddrug10 did not result in clinically significant increases in DB09026 exposure .",
        "label": "NA"
    },
    {
        "text": "DB01045 : co-administration of ddrug1 with ddrug2 # mg daily , a potent inducer of hepatic metabolism , produced an approximate 50 % decrease in DB00533 plasma concentrations .",
        "label": "NA"
    },
    {
        "text": "in the same study it was shown that DB00900 and ddrug1 had no significant effect on the intracellular phosphorylation of DB00943 in peripheral blood mononuclear cells .",
        "label": "NA"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : DB01118 , DB00908 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "ddrug0 : clinical studies , as well as post-marketing observations , have shown that HD00203 can reduce the natriuretic effect of ddrug2 and HD00217 in some patients .",
        "label": "effect"
    },
    {
        "text": "for the HD00151 now available in the united states { ddrug1 , DB01115 and ddrug3 } , these data appeared well after clinical patterns of use evolved .",
        "label": "NA"
    },
    {
        "text": "drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving ddrug0 metabolized similarly to ddrug1 or on the basis of in vitro studies with ddrug2 or other ddrug3 { caution is recommended during coadministration with ddrug4 } : available data from clinical studies of ddrug5 other than DB00404 suggest a possible drug interaction with ddrug7 for the following : ddrug8 , DB00951 , ddrug10 such as ddrug11 and ddrug12 , and grapefruit juice .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 : DB00364 and ddrug3 containing ddrug4 or ddrug5 , as well as formulations containing divalent and trivalent cations such as ddrug6 { ddrug7 } , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with DB00978 and interfere with its bioavailability .",
        "label": "mechanism"
    },
    {
        "text": "caution should be exercised if an HD00383 is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones , such as DB01026 , ddrug2 , and ddrug3 .",
        "label": "advise"
    },
    {
        "text": "drugs decreasing ddrug0 effect : ddrug1 , HD00239 , DB00184 , or ddrug4 may partially counteract the anticoagulant action of ddrug5 .",
        "label": "NA"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { HD00403 s } , ddrug2 , ddrug3 { ddrug4 may decrease the effects of these medicines } , ddrug5 { using these medicines with ddrug6 may result in increased cns depressant effects } , ddrug7 , ddrug8 { using these medicines with ddrug9 may change the amount of either medicine that you need to take } , and oral ddrug10 containing HD00220 { ddrug12 may decrease the effectiveness of these oral ddrug13 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { ddrug1 , ddrug2 , and possibly HD00370 } : concomitant administration with DB00945 may increase the risk of gastrointestinal ulceration .",
        "label": "effect"
    },
    {
        "text": "clinical studies in healthy volunteers show that the pharmacokinetics of DB00520 are not altered by ddrug1 , ddrug2 , DB01024 , ddrug4 , or ddrug5 .",
        "label": "NA"
    },
    {
        "text": "no clinically important pharmacokinetic interactions occurred when DB00722 was used concomitantly with DB00571 or ddrug2 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 , and ddrug2 : drugs such as HD00795 , ddrug4 , and ddrug5 may increase the risk of developing peripheral_neuropathies or other DB00943 - associated adverse events by interfering with the renal clearance of ddrug7 { thereby raising systemic exposure } .",
        "label": "effect"
    },
    {
        "text": "in renal and cardiac transplant recipients , a reduction of DB00091 dose ranging from 15 % to 48 % was necessary to maintain ddrug1 trough concentrations similar to those seen prior to the addition of DB00343 .",
        "label": "mechanism"
    },
    {
        "text": "DB00294 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , HD00282 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "int"
    },
    {
        "text": "other ddrug0 { including DB00065 } used in combination with DB00026 may also result in similar toxicities .",
        "label": "effect"
    },
    {
        "text": "drugs that lower seizure threshold : concurrent administration of DB01156 and agents { e , g , , HD00031 , other ddrug2 , ddrug3 , systemic ddrug4 , etc , } that lower seizure threshold should be undertaken only with extreme caution .",
        "label": "advise"
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit ddrug0 binding to serum proteins or alter the concentrations of serum binding proteins : HD00657 and related ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , DB00333 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 HD00897 # , 25 , and # mg administered once daily for # days increased plasma DB00277 concentrations { auc { 0 - } } by # to 60 % in healthy subjects administered a single 300-mg dose of ddrug3 .",
        "label": "mechanism"
    },
    {
        "text": "other no clinically important pharmacokinetic interactions occurred when DB00542 was administered concomitantly with ddrug1 , ddrug2 , ddrug3 , ddrug4 , DB00571 , ddrug6 , ddrug7 , or ddrug8 .",
        "label": "NA"
    },
    {
        "text": "- ddrug0 { e , g , , HD00901 } use of ddrug2 with DB00891 may increase the chance of side effects affecting the liver and/or the blood",
        "label": "NA"
    },
    {
        "text": "in the first study , concomitant administration of # mg ddrug0 and # g DB01432 resulted in decreases of more than 22 % for auc and 40 % for cmax when compared to dosing HD00503 alone .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00712 like other ddrug2 , has been shown to affect bleeding parameters in patients receiving HD00738 , and serious clinical bleeding has been reported .",
        "label": "effect"
    },
    {
        "text": "in a comparison of ddrug0 tolerance in dogs anesthetized with ddrug1 , ddrug2 , or ddrug3 , the dosage of ddrug4 needed to cause ventricular tachycardia was significantly higher , as was the ld50 of DB01092 , with ddrug6 or ddrug7 than with DB00312 .",
        "label": "NA"
    },
    {
        "text": "the clearance of HD00100 metabolized by glucuronidation { e , g , , DB00186 , ddrug2 , ddrug3 } is unlikely to be affected by ddrug4 .",
        "label": "NA"
    },
    {
        "text": "drug interactions with ddrug0 administration of # mg of DB00950 { 2 x # mg capsule } within # minutes of an ddrug2 and ddrug3 containing DB06724 { ddrug5 } decreased ddrug6 auc by 41 % and cmax by 43 % .",
        "label": "mechanism"
    },
    {
        "text": "caution should be used when administering or taking DB00530 with ddrug1 and other strong cyp3a4 inhibitors such as , but not limited to , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { HD00691 } , and ddrug13 .",
        "label": "advise"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 DB00264 ddrug4 ddrug5 { DB00564 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "in # other schizophrenic patients treated with oral ddrug0 and ddrug1 , discontinuation of DB01045 produced a mean # - fold increase in DB00502 concentrations .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 - combined administration of racemic DB00215 { 40 mg/day for # days } and DB00564 { titrated to # mg/day for # days } did not significantly affect the pharmacokinetics of ddrug3 , a cyp3a4 substrate .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : concomitant administration of DB00586 and DB00945 is not recommended because ddrug3 is displaced from its binding sites during the concomitant administration of ddrug4 , resulting in lower plasma concentrations , peak plasma levels , and auc values .",
        "label": "advise"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { ddrug1 s } , DB00564 , ddrug3 { ddrug4 may decrease the effects of these medicines } , ddrug5 { using these medicines with ddrug6 may result in increased cns depressant effects } , ddrug7 , ddrug8 { using these medicines with HD00026 may change the amount of either medicine that you need to take } , and oral ddrug10 containing ddrug11 { ddrug12 may decrease the effectiveness of these oral ddrug13 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "DB01217 did not alter the pharmacokinetics of DB01435 .",
        "label": "NA"
    },
    {
        "text": "high-dose DB00091 resulting in concentrations above # ng/ml administered with oral ddrug1 has led to an 80 % increase in ddrug2 exposure with a 38 % decrease in total body clearance of DB00773 compared to ddrug4 alone .",
        "label": "NA"
    },
    {
        "text": "in vivo interaction studies in humans have demonstrated that DB00390 and ddrug1 do not affect the pk properties of ddrug2 , nor does ddrug3 affect the pk properties of ddrug4 or DB00682 .",
        "label": "NA"
    },
    {
        "text": "if a patient requires ddrug0 and ddrug1 therapy , it is suggested that ddrug2 , DB00863 , or ddrug4 { ddrug5 and ddrug6 } be used as alternatives to DB00501 , as these agents have no effect on the pharmacokinetic profile of ddrug8 .",
        "label": "NA"
    },
    {
        "text": "endothelium-intact aortic rings from high - ddrug0 rats were supersensitive to ddrug1 when compared to vehicle - , ddrug2 - and DB00396 + high - DB00783 - treated rats { pd2 values = # + / # , # + / # , # + / # and # + / # , respectively } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00533 # mg once daily for # days does not alter the plasma concentration profile or renal elimination of DB00390 after a single # mg oral dose .",
        "label": "NA"
    },
    {
        "text": "population pharmacokinetic analyses revealed that DB00563 , ddrug1 , ddrug2 , and ddrug3 did not influence DB01281 clearance .",
        "label": "NA"
    },
    {
        "text": "similarly , DB00898 decreased the rate of elimination of DB01213 { by approximately 50 % } by the same mechanism .",
        "label": "mechanism"
    },
    {
        "text": "of particular importance , sufficient time must elapse before initiating HD00312 treatment in a patient being withdrawn from DB00472 , given the long half-life of the parent and active metabolite { at least # weeks may be necessary } .",
        "label": "advise"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { DB00252 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , DB00295 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : sporadic cases of seizures have been reported during concomitant use of DB00465 and ddrug2 { DB00252 , ddrug4 } .",
        "label": "effect"
    },
    {
        "text": "the effects of HD00052 { ddrug1 } on DB03401 { ddrug3 } - induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura_2 microfluorometry .",
        "label": "NA"
    },
    {
        "text": "hormonal ddrug0 co-administration of ddrug1 with an oral ddrug2 has been shown to influence the plasma concentrations of the two hormonal components , DB00977 { ee } and DB00367 { lng } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the concomitant administration of DB00537 with the ddrug2 DB01016 has , on rare occasions , resulted in severe hypoglycemia .",
        "label": "effect"
    },
    {
        "text": "thus , careful monitoring of clinical status is warranted when DB01045 is administered or discontinued in DB00502 - treated patients .",
        "label": "advise"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { DB00316 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , DB00949 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 HD00388 ddrug5 { ddrug6 } DB00501 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "ddrug0 , DB00563 , ddrug2 : ddrug3 , like other HD00203 , may affect renal prostaglandins and increase the toxicity of certain drugs .",
        "label": "NA"
    },
    {
        "text": "may interact with thyroid medication { e , g , , ddrug0 } , DB11119 - containing products , ddrug2 , ddrug3 { e , g , , ddrug4 , ddrug5 } , and HD00587 { e , g , , ddrug7 , ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "concomitant use of ddrug0 and drugs that inhibit cyp3a4 { eg , ddrug1 , DB01167 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 } may increase exposure to DB01254 and should be avoided .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral antidiabetes products , HD00106 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , HD00806 { e , g , , ddrug8 } , ddrug9 .",
        "label": "NA"
    },
    {
        "text": "DB01026 tablets may alter the metabolism of DB00091 , ddrug2 , and ddrug3 , resulting in elevated plasma concentrations of the latter drugs .",
        "label": "mechanism"
    },
    {
        "text": "pharmacokinetics of DB01202 were also not affected by DB00252 .",
        "label": "NA"
    },
    {
        "text": "since blood level of DB00136 / ergocalcitriol will be reduced , higher doses of DB00136 may be necessary if these drugs are administered simultaneously .",
        "label": "NA"
    },
    {
        "text": "- the action of HD00416 and ddrug1 may be enhanced by HD00414 or ddrug3 .",
        "label": "effect"
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a ddrug0 , including ddrug1 , with multivalent cation-containing products such as ddrug2 or ddrug3 HD00374 , ddrug5 , ddrug6 chewable/buffered tablets or pediatric powder , or products containing DB01373 , ddrug8 , or ddrug9 may substantially decrease the absorption of ddrug10 , resulting in serum and urine levels considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "by contrast , DB03566 { 1 mm } and DB01917 { 1 mm } had no significant effect on the translocation when added alone .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 , DB00627 { ddrug3 , DB00199 , ddrug5 : skeletal muscle .",
        "label": "NA"
    },
    {
        "text": "similarly , the effects of ddrug0 on ddrug1 , DB00313 and sodium plasma DB00313 concentrations are unpredictable",
        "label": "NA"
    },
    {
        "text": "ddrug0 / ddrug1 : pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between DB00278 and concomitantly administered ddrug3 { # mg orally given # and # hours prior to initiation of ddrug4 # g/kg/min , over # hours } or DB00316 { 1000 mg orally given 12 , # and # hours prior to , and # and # hours subsequent to , initiation of ddrug6 # g/kg/min , over # hours } .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 : in one study , ddrug1 was given to adult diabetics who were already receiving ddrug2 { n = 4 } , ddrug3 { n = 2 } DB00672 with DB00914 { n = 3 } or ddrug6 with ddrug7 { n = 6 } .",
        "label": "NA"
    },
    {
        "text": "administration of repeat doses of ddrug0 had no effect on the repeat dose pharmacokinetics of ddrug1 , DB00390 or an ddrug3 / levonorgestrol oral HD00750 in healthy subjects .",
        "label": "NA"
    },
    {
        "text": "and ddrug0 when HD00314 is given with ddrug2 agents or ddrug3 drugs , including DB00668 combined with local ddrug5 , close supervision and careful adjustment of dosages are required .",
        "label": "NA"
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of HD00539 such as ddrug1 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , HD00384 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 } , ddrug11 salts , ddrug12 , local ddrug13 , ddrug14 , and ddrug15 .",
        "label": "effect"
    },
    {
        "text": "in addition , ddrug0 and ddrug1 induce a subgroup of the cytochrome cyp2b6 3a family { cyp3a4 and cyp3a5 } responsible for the metabolism of HD00890 and oral HD00283 , resulting in a lower plasma concentration of these drugs .",
        "label": "NA"
    },
    {
        "text": "therefore , co-administration of DB01156 with drugs that are metabolized by cyp2d6 isoenzyme including certain ddrug1 { e , g , , ddrug2 , DB00458 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } , ddrug8 { e , g , , ddrug9 , ddrug10 , ddrug11 } , ddrug12 { e , g , , ddrug13 } , and ddrug14 { e , g , , ddrug15 , ddrug16 } , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : in normal volunteers , concomitant administration of DB00861 and ddrug2 resulted in an approximate 50 % increase in plasma levels of DB00316 .",
        "label": "NA"
    },
    {
        "text": "tablet if a patient receiving ddrug0 is also taking HD00043 , the effect of DB00575 may be reduced , thus necessitating an increase in dosage .",
        "label": "NA"
    },
    {
        "text": "other drug interactions ddrug0 , DB00199 and ddrug2 had no effect on the pharmacokinetics of HD00888 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - there have been rare postmarketing reports describing patients with weakness , hyperreflexia , and incoordination following the use of a ddrug1 { HD00278 } and DB00669 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 , including oral , injectable , transdermal , and implantable ddrug1 : an interaction study demonstrated that co-administration of ddrug2 and the oral ddrug3 ddrug4 produced average decreases of DB00717 and DB00977 levels of 14 % and 31 % , respectively .",
        "label": "NA"
    },
    {
        "text": "therefore , if DB00390 is administered with DB00872 , the clinician should be alert to the possibility of increases in ddrug2 levels .",
        "label": "mechanism"
    },
    {
        "text": "when combined with DB01165 , HD00050 exhibited strong synergistic activity while only additive effects were observed with the combination of ddrug2 { or ddrug3 } and ddrug4 .",
        "label": "effect"
    },
    {
        "text": "DB01432 increases enterohepatic elimination of ddrug1 and may reduce its serum levels and HD00309 / 2 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 , and HD00249 : drugs such as HD00795 , ddrug4 , and ddrug5 may increase the risk of developing peripheral_neuropathies or other ddrug6 - associated adverse events by interfering with the renal clearance of ddrug7 { thereby raising systemic exposure } .",
        "label": "NA"
    },
    {
        "text": "in a comparison of HD00118 tolerance in dogs anesthetized with ddrug1 , ddrug2 , or ddrug3 , the dosage of ddrug4 needed to cause ventricular tachycardia was significantly higher , as was the ld50 of ddrug5 , with ddrug6 or HD00117 than with ddrug8 .",
        "label": "NA"
    },
    {
        "text": "therefore , DB00736 may interfere with the absorption of drugs where gastric ph is an important determinant of bioavailability { eg , DB01026 , ddrug2 salts and ddrug3 } .",
        "label": "mechanism"
    },
    {
        "text": "in separate studies of patients receiving maintenance doses of ddrug0 , DB00999 , or ddrug2 , ddrug3 administration for # days had no effect on the pharmacodynamics of ddrug4 { prothrombin time } or pharmacokinetics of DB00390 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 enhance the renal toxicity of HD00663 in animals , # ddrug2 interferes with the action of ddrug3 preparations by chelating the DB01593 , 7",
        "label": "NA"
    },
    {
        "text": "concurrent use of DB00611 with ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , and HD00388 } may result in increased ddrug6 effects .",
        "label": "effect"
    },
    {
        "text": "administration of ddrug0 with HD00374 containing ddrug2 , ddrug3 , or ddrug4 , with ddrug5 , with metal cations such as ddrug6 , or with ddrug7 containing DB01592 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 should be used with caution in patients receiving - HD00305 blocking agents { e , g , , ddrug3 , a ddrug4 inhibitor } or ddrug5 antagonists { e , g , , DB00661 , a ddrug7 substrate , and ddrug8 , a ddrug9 inhibitor } because of the possible potentiation of bradycardia , sinus arrest , and av block ;",
        "label": "NA"
    },
    {
        "text": "DB00334 treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than ddrug1 , and to broadly the same extent as DB00734 .",
        "label": "NA"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , ddrug3 ddrug4 : ddrug5 , DB00342 antimigraine : ddrug7 ddrug8 : DB01045 ddrug10 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "in two controlled crossover clinical pharmacology studies in healthy male { n = 12 in each study } a nd female { n = 12 in each study } volunteers , DB00967 # mg { # times the daily dose } once daily was coadministered with ddrug1 # mg every # hours or DB01026 # mg every # hours for # days .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : no clinically significant changes in DB00978 pharmacokinetics { auc , c max , or t max } were observed when a single dose of ddrug2 # mg was given after multiple doses of DB00338 { 20 mg qd } in # healthy volunteers .",
        "label": "NA"
    },
    {
        "text": "co-administration of ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , DB00482 , ddrug6 , ddrug7 , ddrug8 , ddrug9 and ddrug10 did not result in clinically significant increases in DB09026 exposure .",
        "label": "NA"
    },
    {
        "text": "because there is a theoretical basis that these effects may be additive , use of DB00201 - containing or HD00274 { like ddrug2 or ddrug3 } and ddrug4 within # hours is contraindicated .",
        "label": "NA"
    },
    {
        "text": "therefore , ddrug0 has the potential for interaction with HD00850 and HD00851 .",
        "label": "NA"
    },
    {
        "text": "concomitant use of ddrug0 with DB02325 , ddrug2 , ddrug3 , or other HD00389 may have an additive effect .",
        "label": "NA"
    },
    {
        "text": "a dose increase of ddrug0 / DB00503 to 533/133 mg twice daily with food isrecommended in combination with DB00238 .",
        "label": "advise"
    },
    {
        "text": "before taking DB00222 , tell your doctor if you are taking any of the following medicines : - ddrug1 or another HD00372 such as ddrug3 { ddrug4 } , ddrug5 { ddrug6 , others } , ddrug7 { ddrug8 } , ddrug9 { ddrug10 } , or ddrug11 { ddrug12 } ;",
        "label": "advise"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / HD00517 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , HD00516 pain medication { e , g , , ddrug12 } , drugs used to aid sleep , drowsiness-causing ddrug13 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , DB00273 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { DB00295 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 HD00510 : absorption of DB00999 is impaired in the presence of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 , and DB01045 may decrease DB00363 plasma levels , resulting in a decrease in effectiveness of a previously effective ddrug4 dose .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : coadministration of ddrug1 and DB00220 resulted in a 32 % decrease in DB00220 plasma auc and a 207 % increase in ddrug4 plasma a , c.",
        "label": "NA"
    },
    {
        "text": "conclusions : HD00093 inhibit the metabolism of ddrug1 that are metabolized by cyp3a4 { i , e , , ddrug2 , ddrug3 , ddrug4 , DB00641 } .",
        "label": "mechanism"
    },
    {
        "text": "DB00956 increases DB00996 auc values by 14 % .",
        "label": "mechanism"
    },
    {
        "text": "the hypoglycemic action of ddrug0 may be potentiated by certain drugs including HD00518 and other drugs that are highly protein bound , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , and HD00520 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in healthy subjects given single # mg doses of DB00567 and ddrug2 , plasma DB00331 mean cmax and auc increased by an average of 34 % and 24 % , respectively , and ddrug4 mean renal clearance decreased by 14 % .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a study in # patients with congestive heart failure where DB01009 and DB00390 were concomitantly administered , ddrug3 did not alter the serum levels of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : DB01118 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : HD00870 ddrug8 : ddrug9 ddrug10 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "in rheumatoid arthritis , concomitant medications besides DB00563 were ddrug1 , DB00158 , ddrug3 and/or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "DB00637 ddrug1 , ddrug2 DB00604 ergot derivatives ddrug4",
        "label": "NA"
    },
    {
        "text": "while all the HD00113 { ddrug1 } , e , g , , ddrug2 , DB01104 , ddrug4 , and ddrug5 , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .",
        "label": "NA"
    },
    {
        "text": "for adult-onset diabetics , dosage adjustment of HD00786 may be necessary during and after HD00688 therapy ;",
        "label": "advise"
    },
    {
        "text": "ddrug0 : it has been reported that DB00437 prolongs the half-life of the ddrug2 , DB00266 .",
        "label": "mechanism"
    },
    {
        "text": "the purpose of this study was to evaluate the effect of ddrug0 { ddrug1 } and HD00067 { ddrug3 } conjugates on the intestinal permeation of ddrug4 { HD00070 } and model peptide drugs , ddrug6 and ddrug7 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : potential interaction of DB01026 and DB00951 may exist .",
        "label": "int"
    },
    {
        "text": "nephrotoxic agents : concomitant administration of DB00369 and agents with nephrotoxic potential -lsb- e , g , , intravenous ddrug1 { e , g , , ddrug2 , ddrug3 , and ddrug4 } , DB00681 , ddrug6 , intravenous ddrug7 , ddrug8 , and ddrug9 -rsb- is contraindicated .",
        "label": "advise"
    },
    {
        "text": "DB00405 can interact with ddrug1 or other HD00261 { may potentiate the cns depressant effects of either these medications or ddrug3 } , ddrug4 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug5 } , and ddrug6 { concurrent use with ddrug7 may prolong and intensify the anticholinergic and cns depressant effects of ddrug8 } .",
        "label": "int"
    },
    {
        "text": "HD00374 and DB00364 : ddrug2 and ddrug3 containing ddrug4 or ddrug5 , as well as formulations containing divalent and trivalent cations such as ddrug6 { ddrug7 } , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with ddrug8 and interfere with its bioavailability .",
        "label": "NA"
    },
    {
        "text": "these pharmacokinetic effects seen during ddrug0 coadministration can result in increased clinical effects { e , g , , prolonged sodation } of both DB00683 and DB00897 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : immediate release capsules : since there have been isolated reports of patients with elevated DB00390 levels , and there is a possible interaction between ddrug2 and ddrug3 , it is recommended that ddrug4 levels be monitored when initiating , adjusting , and discontinuing DB01115 to avoid possible over - or under-digitalization .",
        "label": "NA"
    },
    {
        "text": "based on the chemical resemblance of DB01167 and ddrug1 , coadministration of DB00637 with ddrug3 is contraindicated .",
        "label": "NA"
    },
    {
        "text": "in uninfected volunteers , 46 % developed rash while receiving DB00625 and DB01211 .",
        "label": "effect"
    },
    {
        "text": "drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving ddrug0 metabolized similarly to ddrug1 or on the basis of in vitro studies with ddrug2 or other ddrug3 { caution is recommended during coadministration with ddrug4 } : available data from clinical studies of ddrug5 other than DB00404 suggest a possible drug interaction with ddrug7 for the following : ddrug8 , ddrug9 , ddrug10 such as DB00199 and ddrug12 , and grapefruit juice .",
        "label": "NA"
    },
    {
        "text": "the intensity , uniformity and time course of ddrug0 interference by ddrug1 , ddrug2 , ddrug3 , DB01563 and ddrug5 were systematically investigated in # patients receiving DB04665 therapy .",
        "label": "NA"
    },
    {
        "text": "additive adverse effects resulting from cholinergic blockade may occur when DB00424 is administered concomitantly with other ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 or some HD00388 .",
        "label": "effect"
    },
    {
        "text": "agents increasing serum potassium : DB00584 and ddrug1 iv attenuate potassium loss caused by HD00675 .",
        "label": "effect"
    },
    {
        "text": "however , the antagonism of the DB00277 - induced anxiogenic effects by ddrug1 was only observed in the time spent in the light zone , and ddrug2 - induced anxiogenic effects were neither reversed by HD00184 nor by ddrug4 .",
        "label": "NA"
    },
    {
        "text": "drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving ddrug0 metabolized similarly to ddrug1 or on the basis of in vitro studies with ddrug2 or other ddrug3 { caution is recommended during coadministration with ddrug4 } : available data from clinical studies of ddrug5 other than ddrug6 suggest a possible drug interaction with ddrug7 for the following : ddrug8 , DB00951 , ddrug10 such as ddrug11 and DB01211 , and grapefruit juice .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and DB00759 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , DB01232 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "both DB00625 and ddrug1 have been compared to triple therapy with the ddrug2 DB00224 over # weeks as initial therapy , with similar responses being observed with ddrug4 regimens and superiority observed with ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : sporadic cases of seizures have been reported during concomitant use of DB00465 and HD00703 { ddrug3 , ddrug4 } .",
        "label": "effect"
    },
    {
        "text": "concurrent administration of low-dose DB00988 and HD00512 may produce an additive or potentiating effect on urine flow .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { HD00548 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as HD00269 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "recovery from 50 % twitch to 75 % fade recovery took # + / - # min for DB13295 alone and # + / - # min for ddrug1 plus HD00198 .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 : ddrug1 has been safely used in diabetic patients without significantly lowering their blood glucose levels or altering their need for HD00071 or oral HD00062 .",
        "label": "NA"
    },
    {
        "text": "nephrotoxicity has been reported following concomitant administration of other ddrug0 with potent HD00218 such as DB00695 .",
        "label": "NA"
    },
    {
        "text": "interactions with other ddrug0 : significant decreases in the auc of DB00705 { 20 % } and DB00224 { 84 % } occurred following simultaneous administration of these agents with ddrug3 .",
        "label": "NA"
    },
    {
        "text": "studies have shown that DB00448 does not have clinically significant interactions with other drugs metabolized by the cytochrome cyp2b6 system , such as ddrug1 , DB01435 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , or ddrug10 in healthy subjects .",
        "label": "NA"
    },
    {
        "text": "DB00501 is reported to reduce hepatic metabolism of certain ddrug1 , thereby delaying elimination and increasing steady-state concentrations of these HD00096 .",
        "label": "NA"
    },
    {
        "text": "drugs which inhibit cyp 3a4 { e , g , , ddrug0 , ddrug1 such as DB00199 } have the potential to result in increased plasma concentrations of HD00175 .",
        "label": "mechanism"
    },
    {
        "text": "however , because bleeding has been reported when DB01050 and other HD00518 have been administered to patients on ddrug2 , the physician should be cautious when administering ddrug3 to patients on ddrug4 .",
        "label": "NA"
    },
    {
        "text": "DB00472 , ddrug1 , ddrug2 , DB01104 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { e , g , , ddrug1 } and HD00224 containing carbohydrate-splitting enzymes { e , g , , HD00225 , ddrug4 } may reduce the effect of ddrug5 and should not be taken concomitantly .",
        "label": "NA"
    },
    {
        "text": "binding to plasma proteins is reduced by DB00682 and clotibrate and increased by DB01124 .",
        "label": "NA"
    },
    {
        "text": "no interactions have been observed with ddrug0 , ddrug1 , HD00029 and HD00105 and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "in addition , studies in healthy volunteers have shown that ddrug0 does not affect the pharmacokinetics or pharmacodynamics of DB00682 , or the pharmacokinetics of ddrug2 { 40 mg twice daily } , ddrug3 , ddrug4 , or oral HD00283 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 ddrug1 ddrug2 DB01211 ddrug4 ddrug5 DB01149 ddrug7 large quantities of grapefruit juice { # quart daily }",
        "label": "NA"
    },
    {
        "text": "the use of DB01135 before ddrug1 to attenuate some of the side effects of DB00202 has not been studied .",
        "label": "NA"
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of HD00472 are the following : ddrug1 , HD00270 , ddrug3 , ddrug4 { 1 } , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 { 1 } , ddrug10 , ddrug11 , grapefruit juice , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21 , ddrug22 , ddrug23 , ddrug24 { 1 } , ddrug25 , ddrug26 .",
        "label": "mechanism"
    },
    {
        "text": "hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose ddrug0 and HD00251 , specifically , DB00851 , ddrug3 , ddrug4 and ddrug5 .",
        "label": "NA"
    },
    {
        "text": "specific drug interaction studies have not been performed with ddrug0 and HD00672 other than DB00709 and ddrug3 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : when used in the perioperative period , DB00319 has been implicated in the prolongation of the neuromuscular blockade of DB01339 .",
        "label": "effect"
    },
    {
        "text": "DB00637 ddrug1 , ddrug2 ddrug3 ergot derivatives DB00582",
        "label": "NA"
    },
    {
        "text": "- DB00563 { e , g , , ddrug1 } use of ddrug2 with DB00891 may increase the chance of side effects affecting the liver and/or the side effects of ddrug4",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } HD00220 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 HD00542 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "ddrug0 { ddrug1 , ddrug2 , DB01174 , ddrug4 , ddrug5 } : increase the metabolism of ddrug6 and/or some HD00526 , leading to possible decrease in contraceptive effectiveness .",
        "label": "mechanism"
    },
    {
        "text": "however , in another study in healthy volunteers , the pharmacokinetics of DB00611 were significantly altered { 29 % decrease in auc and 38 % decrease in cmax } when a 1-mg dose of DB00611 was administered # minute after a 20-mg dose of ddrug2 nasal spray .",
        "label": "NA"
    },
    {
        "text": "ddrug0 pharmacokinetic parameter values were not affected by administration of DB00996 # hours after DB00295 .",
        "label": "NA"
    },
    {
        "text": "no significant drug interactions have been reported in studies of ddrug0 given with other drugs such as ddrug1 , ddrug2 , ddrug3 , DB00682 , ddrug5 , and oral HD00283 in healthy volunteers , or given with ddrug7 to patients with heart failure { nyha class ii and iii } .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { DB00564 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { DB01167 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "medications can interfere with folate utilization , including : ddrug0 { such as ddrug1 , and ddrug2 } ddrug3 { sometimes prescribed to control blood sugar in type # diabetes } DB00795 { used to control inflammation associated with crohn_disease and ulcerative colitis } ddrug5 { a ddrug6 } ddrug7 there has been concern about the interaction between ddrug8 and DB00158 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB13871 concentrations in bile and cystic fluid were increased { about 2-fold } in hydatid cyst patients treated with DB00501 { 10 mg/kg/day } { n = 7 } compared with ddrug3 { 20 mg/kg/day } alone { n = 12 } .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : potentiation of DB00682 - type { ddrug2 and HD00302 substrate } ddrug4 response is almost always seen in patients receiving ddrug5 and can result in serious or fatal bleeding .",
        "label": "NA"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { ddrug1 s } , ddrug2 , ddrug3 { ddrug4 may decrease the effects of these medicines } , HD00458 { using these medicines with ddrug6 may result in increased cns depressant effects } , ddrug7 , ddrug8 { using these medicines with ddrug9 may change the amount of either medicine that you need to take } , and oral ddrug10 containing ddrug11 { HD00026 may decrease the effectiveness of these oral ddrug13 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "in vitro , DB00571 appears to be displaced from its binding sites by DB00343 .",
        "label": "mechanism"
    },
    {
        "text": "the concurrent administration of DB00437 and DB00415 increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ddrug2 alone .",
        "label": "effect"
    },
    {
        "text": "caution should be exercised if an HD00383 is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones , such as ddrug1 , DB00421 , and ddrug3 .",
        "label": "advise"
    },
    {
        "text": "however , another HD00383 has been found to produce a less than two-second increase in prothrombin time in healthy volunteers receiving low doses of DB00682 .",
        "label": "effect"
    },
    {
        "text": "in addition , drugs that are actively secreted via this route { e , g , , ddrug0 , ddrug1 and DB00594 } should be co-administered with care as they might increase DB00204 levels .",
        "label": "advise"
    },
    {
        "text": "studies with ddrug0 in combination with ddrug1 indicate that the dose of the HD00471 can be reduced when it is given with a HD00295 .",
        "label": "advise"
    },
    {
        "text": "concomitant administration of ddrug0 and DB00945 is not recommended because DB00788 is displaced from its binding sites during the concomitant administration of ddrug3 , resulting in lower plasma concentrations and peak plasma levels .",
        "label": "NA"
    },
    {
        "text": "reports in the literature suggest that plasma levels of ddrug0 { and its active metabolite HD00891 } may be increased when DB01229 and ddrug3 are used in combination .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : increased serum DB14507 levels and symptoms of ddrug2 toxicity have been reported in patients receiving HD00106 during therapy with ddrug4 .",
        "label": "NA"
    },
    {
        "text": "decreases in tbg concentrations are observed in nephrosis , acromegaly and after HD00857 or HD00579 therapy .",
        "label": "NA"
    },
    {
        "text": "other drugs drug interactions have been reported with concomitant administration of DB00199 and other medications , including ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , DB00637 , and ddrug10 .",
        "label": "int"
    },
    {
        "text": "drug interactions : the central ddrug0 syndrome can occur when anticholinergic agents such as ddrug1 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain HD00424 such as ddrug3 , the ddrug4 and other HD00031 , ddrug6 , certain ddrug7 such as the ddrug8 salts , and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 may enhance the effects of : other HD00459 s , ddrug4 , general HD00264 , ddrug6 such as ddrug7 , ddrug8 , or other ddrug9 , causing increased cns depression .",
        "label": "NA"
    },
    {
        "text": "formulation of fluorescence labelled ddrug0 and ddrug1 in unconjugated HD00072 { 1 % m/v } did not significantly improve the permeation , however in the presence of 1 % { m/v } HD00068 # a significantly improved permeation was observed { r = # } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the concomitant use of ddrug1 { ddrug2 transdermal system } with other ddrug3 , including but not limited to other ddrug4 , ddrug5 , ddrug6 , ddrug7 { e , g , , ddrug8 } , general HD00264 , ddrug10 , ddrug11 , and DB02325 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .",
        "label": "NA"
    },
    {
        "text": "higher concentrations of DB01234 { 10 { -8 } - 10 { -6 } m } or ddrug1 { 3 x 10 { -8 } - 10 { -7 } m } enhance the mitogenic activity of HD00148 .",
        "label": "effect"
    },
    {
        "text": "this drug may interact with ddrug0 or other HD00261 { may potentiate the cns depressant effects of either these medications or ddrug2 } , ddrug3 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug4 } , and ddrug5 { concurrent use with HD00388 may prolong and intensify the anticholinergic and cns depressant effects of ddrug7 } .",
        "label": "NA"
    },
    {
        "text": "DB00435 has been administered with DB00797 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , and high-frequency ventilation .",
        "label": "NA"
    },
    {
        "text": "the actions of the HD00100 may be potentiated by ddrug1 , HD00543 , ddrug3 , ddrug4 or other ddrug5 .",
        "label": "effect"
    },
    {
        "text": "data suggest that coadministration of oral DB01026 and DB00604 can result in prolongation of the qt interval on the ecg .",
        "label": "effect"
    },
    {
        "text": "although not studied with DB00969 , inhibition of n-acetyltransferase may have clinically relevant consequences for drugs such as ddrug1 , ddrug2 , and DB01275 .",
        "label": "effect"
    },
    {
        "text": "effects of DB00199 on ddrug1 the coadministration of ddrug2 { 1000 mg/day } for # days did not alter the pharmacokinetic parameters of cmax , cmin , auc , ci/kg or tmax at DB00949 daily doses of # or # mg/day in # otherwise healthy subjects with epilepsy .",
        "label": "NA"
    },
    {
        "text": "in vitro studies evaluating the minimum inhibitory concentration { mic } of ddrug0 , ddrug1 , ddrug2 , ddrug3 / flucoxacillin , ddrug4 , DB00798 , and ddrug6 demonstrated no evidence of incompatibility of these HD00002 with ddrug8 .",
        "label": "NA"
    },
    {
        "text": "objective : to report a case of rhabdomyolysis resulting from concomitant use of DB01211 and DB00641 .",
        "label": "NA"
    },
    {
        "text": "the pressor effects of HD00439 such as DB00988 or ddrug2 are enhanced by ddrug3 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 can interact with ddrug1 or other ddrug2 { may potentiate the cns depressant effects of either these medications or ddrug3 } , HD00444 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug5 } , and ddrug6 { concurrent use with ddrug7 may prolong and intensify the anticholinergic and cns depressant effects of HD00388 } .",
        "label": "NA"
    },
    {
        "text": "there is no information regarding the effect on DB00709 pharmacokinetics of higher doses of DB01643 / ddrug2 such as those used to treat pneumocystis carinii pneumonia .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { e , g , , DB09278 } and ddrug2 containing carbohydrate-splitting enzymes { e , g , , ddrug3 , DB00085 } may reduce the effect of ddrug5 and should not be taken concomitantly .",
        "label": "NA"
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of HD00472 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 { 1 } , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 { 1 } , ddrug10 , ddrug11 , grapefruit juice , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21 , DB01369 , ddrug23 , ddrug24 { 1 } , ddrug25 , ddrug26 .",
        "label": "mechanism"
    },
    {
        "text": "co-medications that induce cyp 3a4 { e , g , , ddrug0 , DB00252 , ddrug2 , ddrug3 , or st , john s wort } may significantly decrease exposure to DB00990 .",
        "label": "mechanism"
    },
    {
        "text": "interactions with other cns agents : concurrent use of DB00854 with all ddrug1 { eg , ddrug2 , ddrug3 , ddrug4 , other ddrug5 , general ddrug6 , ddrug7 , HD00043 , ddrug9 , ddrug10 , ddrug11 and ddrug12 } may result in additive central nervous system depressant effects .",
        "label": "effect"
    },
    {
        "text": "ddrug0 and DB01211 { and possibly other ddrug2 } and ddrug3 may increase ddrug4 absorption in patients who inactivate DB00390 by bacterial metabolism in the lower intestine , so that ddrug6 intoxication may result .",
        "label": "NA"
    },
    {
        "text": "caution should be exercised if an HD00383 is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones , such as ddrug1 , ddrug2 , and DB00501 .",
        "label": "advise"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / HD00517 , drugs used to treat an overactive thyroid , HD00254 { e , g , , ddrug3 } , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 pain medication { e , g , , ddrug12 } , drugs used to aid sleep , drowsiness-causing ddrug13 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : as with other HD00487 , ddrug2 inhibits the renal excretion of DB00535 , resulting in an approximate doubling in a , c , a 54 % increase in peak ddrug4 plasma levels , and a 50 % prolongation in the apparent elimination half-life .",
        "label": "mechanism"
    },
    {
        "text": "DB01032 : as with other ddrug1 , co-administration of ddrug2 with DB01066 resulted in an increase in the plasma exposure of ddrug4 , with a 49 % increase in mean cmax , a 122 % increase in mean auc , and a 53 % increase in half-life .",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , ddrug3 , or ddrug4 , with ddrug5 , with metal cations such as ddrug6 , or with ddrug7 containing DB01592 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { DB00900 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 : ddrug2 and ddrug3 containing DB14513 or ddrug5 , as well as formulations containing divalent and trivalent cations such as ddrug6 { ddrug7 } , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with DB00978 and interfere with its bioavailability .",
        "label": "mechanism"
    },
    {
        "text": "on the basis of the metabolism of ddrug0 by cytochrome p450 3a4 , ddrug1 , ddrug2 , ddrug3 , DB01241 , grapefruit juice , and other inhibitors of cyp3a4 would be expected to lead to an increase in plasma DB00307 concentrations .",
        "label": "mechanism"
    },
    {
        "text": "other drugs : in healthy volunteers , ddrug0 , ddrug1 , ddrug2 , ddrug3 , DB00338 , hormone replacement therapy { a combination of conjugated ddrug5 and ddrug6 } , DB06724 { ddrug8 and ddrug9 } and ddrug10 did not affect the pharmacokinetics of ddrug11 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 : DB00364 and ddrug3 containing ddrug4 or DB01370 , as well as formulations containing divalent and trivalent cations such as ddrug6 { ddrug7 } , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with ddrug8 and interfere with its bioavailability .",
        "label": "NA"
    },
    {
        "text": "careful observation is required when DB00915 is administered concurrently with HD00289 .",
        "label": "advise"
    },
    {
        "text": "the results from a study in which eight hiv-infected individuals were treated with ddrug0 , # + / - # mg/kg/day , showed that the pharmacokinetics of DB00495 were not affected during concomitant administration of DB01167 , # mg b , i , d.",
        "label": "NA"
    },
    {
        "text": "adequate monitoring of DB00277 plasma concentrations should be considered when therapy with HD00897 is initiated or changed in patients receiving ddrug2 .",
        "label": "NA"
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma DB00252 concentrations include : acute ddrug1 intake , ddrug2 , chboramphenicol , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , HD00297 , ddrug20 , ddrug21",
        "label": "mechanism"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } DB00501 { ddrug8 } HD00220 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , ddrug3 , or ddrug4 , with ddrug5 , with metal cations such as ddrug6 , or with DB00152 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { DB00900 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "concurrent use of HD00219 may antagonize the anorectic effect of DB00937 .",
        "label": "effect"
    },
    {
        "text": "HD00374 or HD00498 : the effect of increased gastric ph on the bioavailability of ddrug2 was evaluated in # healthy adult volunteers .",
        "label": "NA"
    },
    {
        "text": "the administration of local HD00449 containing ddrug1 or ddrug2 to patients receiving HD00275 or ddrug4 may produce severe , prolonged hypertension .",
        "label": "NA"
    },
    {
        "text": "DB00995 should be avoided by patients with a history of serious reaction to any ddrug1 , including ddrug2 and DB09276 .",
        "label": "advise"
    },
    {
        "text": "the serum estrogen concentrations of DB00783 + HD00168 - treated rats decreased by 50 % , while those of the ddrug2 - treated rats increased { 2 - to 5-fold } .",
        "label": "mechanism"
    },
    {
        "text": "the following agents may increase certain actions or side effects of ddrug0 , ddrug1 ddrug2 of class { e , g , DB00908 } , ddrug4 ddrug5 { e , g , ddrug6 } , HD00100 .",
        "label": "NA"
    },
    {
        "text": "however , since ddrug0 , ddrug1 , and HD00794 are all associated with gastrointestinal irritation , caution should be exercised in the concomitant use of ddrug3 or ddrug4 with DB00710 .",
        "label": "NA"
    },
    {
        "text": "HD00444 or other medications with anticholinergic activity - anticholinergic effects may be potentiated when these medications are used concurrently with DB01231 ;",
        "label": "NA"
    },
    {
        "text": "potential drug interactions for ddrug0 include , increased sedation if DB00366 is combined with other HD00545 .",
        "label": "effect"
    },
    {
        "text": "additive cns depression may occur when ddrug0 are administered concomitantly with other HD00261 including HD00026 , ddrug3 , and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "in general , these are drugs that have one or more pharmacologic activities similar to HD00406 , including ddrug1 such as ddrug2 and ddrug3 , ddrug4 and HD00408 .",
        "label": "NA"
    },
    {
        "text": "DB00224 and DB00900 formulations containing buffer should be administered at least one hour apart on an empty stomach .",
        "label": "advise"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , HD00668 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and DB00126 .",
        "label": "NA"
    },
    {
        "text": "- a HD00535 { ddrug1 } such as ddrug2 { ddrug3 , ddrug4 , ddrug5 , others } , ddrug6 { ddrug7 , ddrug8 , ddrug9 } , ddrug10 { ddrug11 , ddrug12 } , ddrug13 { DB00749 } , ddrug15 { ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , and ddrug21 { ddrug22 , ddrug23 , ddrug24 } ;",
        "label": "NA"
    },
    {
        "text": "methods : DB14539 { 100 mg } and DB01576 { 20 mg } were administered orally to # healthy male and female volunteers in a four-session , placebo-controlled , within-subject , crossover design .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 - ddrug2 may decrease hepatic toxicity in those with DB00316 overdosage or in those taking DB00563 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 } , ddrug1 { e , g , DB00199 } , and ddrug3 { e , g , ddrug4 , ddrug5 and ddrug6 } should have their dose of DB00921 or ddrug8 adjusted .",
        "label": "NA"
    },
    {
        "text": "since DB00593 { ddrug1 } may interact with concurrently administered ddrug2 , periodic serum level determinations of these drugs may be necessary { eg , ddrug3 may elevate DB00252 serum levels and ddrug5 has been reported to both increase and decrease ddrug6 levels } .",
        "label": "NA"
    },
    {
        "text": "a pharmacokinetic study evaluating the administration of a single dose of DB00700 # mg with ddrug1 # mg bid , a potent inhibitor of the cyp3a4 pathway , showed a # - fold increase in cmax of DB00700 and a # - fold increase in auc of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "renal function should be monitored carefully if high doses of HD00249 are to be administered with DB01413 because of the increased potential of nephrotoxicity and ototoxicity of ddrug2 .",
        "label": "advise"
    },
    {
        "text": "in patients taking an ddrug0 { eg , ddrug1 , ddrug2 , DB01174 or ddrug4 } , the concomitant use of ddrug5 may reduce seizure control by lowering the plasma levels of the HD00329 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - concomitant intake of DB01432 and DB01022 may reduce the absorption of ddrug3 .",
        "label": "mechanism"
    },
    {
        "text": "these results suggest that the analgesic effect of DB00611 may be diminished when it is administered shortly after DB00669 nasal spray , but by # minutes any such reduction in effect should be minimal .",
        "label": "effect"
    },
    {
        "text": "ddrug0 toxicity was usually reversible upon discontinuation of DB14507 and the HD00471 .",
        "label": "effect"
    },
    {
        "text": "in clinical trials , ddrug0 was used with ddrug1 , HD00218 , ddrug3 , oral ddrug4 , and supplemental ddrug5 , in a pharmacokinetic substudy in patients with congestive heart failure receiving ddrug6 or DB00390 in whom therapy with ddrug8 was initiated , apparent oral clearance values for ddrug9 { n = 23 } and ddrug10 { n = 30 } were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .",
        "label": "NA"
    },
    {
        "text": "in simultaneous treatment with HD00825 and HD00027 , the anticoagulant effect should be carefully titrated and monitored .",
        "label": "advise"
    },
    {
        "text": "use lowest possible dose of ddrug0 with careful monitoring , or consider HD00095 that are not primarily metabolized by cyp3a4 , such as DB00175 , ddrug3 , or ddrug4 in combination with ddrug5 .",
        "label": "NA"
    },
    {
        "text": "in both species , ddrug0 , but not HD00156 , antagonized the rate-decreasing effects of DB00295 on fi and fr responding .",
        "label": "NA"
    },
    {
        "text": "these increased exposures of ddrug0 and ddrug1 should be taken into consideration when selecting an oral HD00349 for women taking DB00580 .",
        "label": "advise"
    },
    {
        "text": "in addition , neuromuscular blocking action is enhanced by general ddrug0 , local HD00264 like ddrug2 , ddrug3 , ddrug4 , HD00588 , ddrug6 , and ddrug7 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , DB00091 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and DB00126 .",
        "label": "NA"
    },
    {
        "text": "in a study in diabetics with microalbuminuria DB00700 # mg combined with the HD00471 ddrug2 # mg increased the frequency of hyperkalemia { serum potassium # meq/l } from 17 % on ddrug3 alone to 38 % .",
        "label": "NA"
    },
    {
        "text": "long acting ddrug0 : DB01115 may be safely co-administered with DB14049 , but there have been no controlled studies to evaluate the antianginal effectiveness of this combination .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration of DB00503 with ddrug2 resulted in a 152 % increase in DB00220 plasma auc and very little change in ddrug4 plasma a , c.",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , DB01026 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , DB00220 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "hypothermia as an index of the DB00822 - DB00898 reaction in the rat .",
        "label": "NA"
    },
    {
        "text": "increased toxicity { cns depression } : ddrug0 , ddrug1 , HD00043 , HD00219 .",
        "label": "NA"
    },
    {
        "text": "similarly , the effects of ddrug0 on DB01174 , ddrug2 and sodium plasma DB00313 concentrations are unpredictable",
        "label": "NA"
    },
    {
        "text": "ddrug0 , DB01575 - pectin , DB00795 , ddrug3 , ddrug4 , certain anticancer drugs , and ddrug5 may interfere with intestinal ddrug6 absorption , resulting in unexpectedly low serum concentrations .",
        "label": "NA"
    },
    {
        "text": "in addition to this pharmacological interaction , this report describes a novel chemical reaction between ddrug0 { a DB12537 } and DB00898 under acidic conditions similar to those found in vivo , resulting in a 3-ethoxylated product .",
        "label": "NA"
    },
    {
        "text": "inhibitors of cyp3a4 { eg , ddrug0 } or cyp2d6 { eg , ddrug1 , ddrug2 , or DB00715 } can inhibit DB01238 elimination and cause increased blood levels .",
        "label": "mechanism"
    },
    {
        "text": "drugs that may alter ddrug0 plasma concentrations drugs that may increase DB00619 plasma concentrations : caution is recommended when administering ddrug2 with inhibitors of the cyp3a4 family { e , g , , ddrug3 , ddrug4 , ddrug5 , DB01211 } .",
        "label": "NA"
    },
    {
        "text": "HD00041 produced significantly increased vasoconstriction after a single administration of DB00107 .",
        "label": "effect"
    },
    {
        "text": "cohort # then received ddrug0 plus ddrug1 for # days , and cohort # received DB00701 plus DB01045 for # days .",
        "label": "NA"
    },
    {
        "text": "this defect in the failing heart can be mimicked by the effects of uptake blocking agents , such as DB00907 and DB01151 , in the nonfailing heart only .",
        "label": "NA"
    },
    {
        "text": "in clinical trials , DB01240 was used with ddrug1 , ddrug2 , ddrug3 , oral HD00337 , and supplemental ddrug5 , in a pharmacokinetic substudy in patients with congestive heart failure receiving ddrug6 or ddrug7 in whom therapy with ddrug8 was initiated , apparent oral clearance values for ddrug9 { n = 23 } and ddrug10 { n = 30 } were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .",
        "label": "NA"
    },
    {
        "text": "nephrotoxic agents : concomitant administration of DB00369 and agents with nephrotoxic potential -lsb- e , g , , intravenous ddrug1 { e , g , , ddrug2 , ddrug3 , and ddrug4 } , ddrug5 , DB00529 , intravenous ddrug7 , ddrug8 , and ddrug9 -rsb- is contraindicated .",
        "label": "advise"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , DB01167 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , DB00503 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "other drugs : in healthy volunteers , ddrug0 , ddrug1 , DB01016 , ddrug3 , ddrug4 , hormone replacement therapy { a combination of conjugated ddrug5 and ddrug6 } , DB06724 { ddrug8 and ddrug9 } and ddrug10 did not affect the pharmacokinetics of ddrug11 .",
        "label": "NA"
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the ddrug0 of drugs may be potentiated by ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , the HD00558 , ddrug7 and ddrug8 , ddrug9 and the ddrug10 , and by other HD00561 .",
        "label": "NA"
    },
    {
        "text": "in a comparison of ddrug0 tolerance in dogs anesthetized with ddrug1 , HD00119 , or ddrug3 , the dosage of ddrug4 needed to cause ventricular tachycardia was significantly higher , as was the ld50 of ddrug5 , with ddrug6 or ddrug7 than with DB00312 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : as with other HD00203 , concomitant administration of DB00784 and ddrug3 is not generally recommended because of the potential of increased adverse effects .",
        "label": "NA"
    },
    {
        "text": "may lead to loss of virologic response and possible resistance to ddrug0 or to the class of HD00269 or other coadministered HD00268 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { DB00091 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , DB00295 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "this appears to be the only clinically relevant interaction of this kind with DB00358 , although theoretically , coadministration of other drugs known to alter cardiac conduction { eg , ddrug1 or ddrug2 , ddrug3 , ddrug4 or HD00863 , ddrug6 and ddrug7 } might also contribute to a prolongation of the qtc interval .",
        "label": "effect"
    },
    {
        "text": "caution is advised when DB01169 is coadministered with other medications that can prolong the qt interval { e , g , certain ddrug1 or ddrug2 } or lead to electrolyte abnormalities { such as ddrug3 or DB00681 } .",
        "label": "advise"
    },
    {
        "text": "drugs that may alter ddrug0 plasma concentrations drugs that may increase ddrug1 plasma concentrations : caution is recommended when administering DB00619 with inhibitors of the cyp3a4 family { e , g , , ddrug3 , ddrug4 , ddrug5 , DB01211 } .",
        "label": "advise"
    },
    {
        "text": "the following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral HD00811 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , HD00806 { e , g , , ddrug9 } , ddrug10 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and DB00572 may interact with HD00343 in studies with male rats , ddrug3 was found to inhibit the hepatic microsomal enzyme system at a dose of # mg/kg/day .",
        "label": "int"
    },
    {
        "text": "ddrug0 { e , g , , ddrug1 , DB01110 , ddrug3 , ddrug4 , etc , } : in vitro and animal studies with the combination of ddrug5 and HD00319 suggest that ddrug7 may induce fungal resistance to ddrug8 .",
        "label": "NA"
    },
    {
        "text": "other cardiovascular agents : ddrug0 and DB00584 iv have been used concomitantly with HD00673 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 and ddrug8 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "these results suggest that both DB01234 and ddrug1 , and possibly other ddrug2 and HD00150 , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of ddrug4 and ddrug5 .",
        "label": "NA"
    },
    {
        "text": "nephrotoxic agents : concomitant administration of DB00369 and agents with nephrotoxic potential -lsb- e , g , , intravenous ddrug1 { e , g , , ddrug2 , ddrug3 , and DB00479 } , ddrug5 , ddrug6 , intravenous ddrug7 , ddrug8 , and ddrug9 -rsb- is contraindicated .",
        "label": "advise"
    },
    {
        "text": "exposed histidines on ddrug0 are available for ddrug1 chelation , and these have been exploited in the development of a novel purification protocol for HD00011 using DB01593 - chelating chromatography .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 DB00564 { ddrug6 } ddrug7 { ddrug8 } ddrug9 DB00472 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "when DB00476 was administered { at a dose of # mg bid } in conjunction with a single 50-mg dose of ddrug1 , a cyp2d6 substrate , the auc of DB01151 increased 3-fold .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - and/or ddrug1 - containing ddrug2 , products containing ddrug3 { ddrug4 } , HD00752 containing ddrug6 or other metal cations , or ddrug7 { ddrug8 } chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after DB01155 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , HD00282 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { DB01045 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "however , co-administration of DB00476 with DB01370 - and ddrug2 - containing ddrug3 { 51 meq } or ddrug4 with ddrug5 , had no significant effect on the rate or extent of ddrug6 absorption after administration of a 40-mg oral dose .",
        "label": "NA"
    },
    {
        "text": "other cardiovascular agents : DB00584 and ddrug1 iv have been used concomitantly with ddrug2 , ddrug3 , ddrug4 , HD00674 , ddrug6 , ddrug7 and ddrug8 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / ddrug1 , drugs used to treat an overactive thyroid , HD00254 { e , g , , ddrug3 } , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 pain medication { e , g , , DB00318 } , drugs used to aid sleep , drowsiness-causing ddrug13 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "refer to the package insert for DB14507 preparations before use of such preparations with DB00999 .",
        "label": "advise"
    },
    {
        "text": "- a HD00535 { ddrug1 } such as ddrug2 { ddrug3 , ddrug4 , ddrug5 , others } , ddrug6 { ddrug7 , ddrug8 , ddrug9 } , ddrug10 { ddrug11 , ddrug12 } , ddrug13 { ddrug14 } , ddrug15 { ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , and ddrug21 { DB00788 , ddrug23 , ddrug24 } ;",
        "label": "NA"
    },
    {
        "text": "concomitantly administered ddrug0 - fortified infant formula { # mg elemental DB01592 / 6 oz } has no significant effect on DB00535 pharmacokinetics .",
        "label": "NA"
    },
    {
        "text": "it is , therefore , advisable to monitor DB00390 concentrations in patients receiving DB01026 .",
        "label": "advise"
    },
    {
        "text": "when ddrug0 is co-administered with inducers of drug clearance , such as ddrug1 , ddrug2 , ddrug3 , DB01234 , or ddrug5 , use of a daily dose of # mg of DB00520 should be considered",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a study of # healthy male volunteers , ddrug1 treatment potentiated the blood glucose lowering effect of ddrug2 { a HD00226 similar to DB00672 } in # of the # subjects .",
        "label": "NA"
    },
    {
        "text": "DB00930 was found to have no significant effect on the bioavailability of ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , and DB00682 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : based on reports of profound hypotension and loss of consciousness when ddrug1 was administered with ddrug2 , the concomitant use of DB00714 with drugs of the ddrug4 { including , for example , ddrug5 , ddrug6 , DB00757 , ddrug8 , and ddrug9 } is contraindicated .",
        "label": "advise"
    },
    {
        "text": "plasma exposure { auc } to DB00580 was increased 62 % when coadministered with DB00196 and 38 % when coadministered with ddrug2 .",
        "label": "mechanism"
    },
    {
        "text": "- although not a true drug interaction , HD00043 may precipitate seizures in susceptible patients and DB01320 dosage may need to be adjusted",
        "label": "effect"
    },
    {
        "text": "in addition to this pharmacological interaction , this report describes a novel chemical reaction between DB00231 { a ddrug1 } and DB00898 under acidic conditions similar to those found in vivo , resulting in a 3-ethoxylated product .",
        "label": "mechanism"
    },
    {
        "text": "HD00121 was more potent in lysing human red blood cells , whereas DB00681 was more potent in inhibiting yeast cell growth ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 interferes with the absorption of HD00527 , including HD00689 .",
        "label": "NA"
    },
    {
        "text": "similarly , DB00731 had no influence on the serum protein binding of DB00571 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and ddrug7 in vitro .",
        "label": "NA"
    },
    {
        "text": "there is thus an enhancement effect of HD00041 upon the reaction of placental vessels to DB00107 in vitro .",
        "label": "effect"
    },
    {
        "text": "DB00501 } and many that are substrates for cyp2b6 2d6 { many other ddrug1 , ddrug2 , and the ddrug3 ddrug4 and DB01195 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : when a single 375-mg dose of DB00673 was administered on day9 of a 14-day regimen of # mg/day of DB01045 , a strong cyp3a4 inducer , the auc of ddrug3 decreased approximately 11-fold and the mean terminal half-life decreased approximately 3-fold .",
        "label": "mechanism"
    },
    {
        "text": "the immediate release , but not the coat-core formulation of DB00401 increased plasma DB00908 concentrations by about 20 % .",
        "label": "mechanism"
    },
    {
        "text": "in clinical studies where patients were on chronic ddrug0 therapy , DB00978 had no measurable effect on the mean distribution of DB00277 concentrations or the mean estimates of ddrug3 clearance .",
        "label": "NA"
    },
    {
        "text": "this article looks at five commonly used HD00084 in turn { ddrug1 , ddrug2 , ddrug3 , DB00563 , ddrug5 } , discussing the main , non-infection , unwanted effects , ways to avoid them and what to do if problems arise .",
        "label": "NA"
    },
    {
        "text": "in addition , DB00334 is not associated with a risk of agranulocytosis as seen with ddrug1 or clinically significant hyperprolactinemia as seen with DB00734 or prolongation of the qt interval .",
        "label": "NA"
    },
    {
        "text": "however , administration of DB01213 { 90 mg kg { -1 } body weight } to rats # hours prior to ddrug1 { 100 mg kg { -1 } body weight } was ineffective in preventing HD00078 synthesis and did not diminish fluoride or citrate accumulation in vivo .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with ddrug1 , HD00403 s , ddrug3 { allergy , cold , and sinus medicines } , diabetic drugs , ddrug4 , ddrug5 , ddrug6 like DB00788 or ddrug8 , and high blood pressure medications .",
        "label": "NA"
    },
    {
        "text": "the influence of DB00683 and DB00829 on antinociceptive effect of ddrug2 { 10 mg/kg } , ddrug3 { 500 mg/kg } and ddrug4 { 10 mg/kg } was investigated in a mouse model using the tail-flick and hot-plate tests .",
        "label": "NA"
    },
    {
        "text": "ddrug0 has been reported to decrease the clearance of DB00897 and ddrug2 and thus may increase the pharmacologic effect of these HD00100 .",
        "label": "NA"
    },
    {
        "text": "this drug may interact with ddrug0 or other HD00261 { may potentiate the cns depressant effects of either these medications or ddrug2 } , ddrug3 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug4 } , and HD00445 { concurrent use with ddrug6 may prolong and intensify the anticholinergic and cns depressant effects of ddrug7 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : HD00401 potentiate the analgesic effect of DB00454 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , HD00668 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { DB00701 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "possible drug interactions of HD00590 with DB00202 or with other ddrug2 .",
        "label": "int"
    },
    {
        "text": "using in situ hybridization , we observed that HD00015 caused a rapid and transient dose-dependent increase in arc mrna level in the striatum and cortex that was abolished by pretreatment with the specific drd1 antagonist ddrug1 but not by an HD00017 ddrug3 .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of DB00969 and moderate cyp1a2 inhibitors , including HD00279 and ddrug2 , has not been evaluated , but should be avoided unless clinically necessary because of similar potential drug interactions .",
        "label": "advise"
    },
    {
        "text": "DB01576 with ddrug1 or DB00344 and possibly other ddrug3 cause striking and sustained increases in the concentration of ddrug4 in the brain ;",
        "label": "mechanism"
    },
    {
        "text": "DB13984 or ddrug1 increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered ddrug2 , such as DB00988 .",
        "label": "effect"
    },
    {
        "text": "HD00485 - ddrug1 containing side chains of n-methylthiotetrazole { DB00267 , ddrug3 , ddrug4 , ddrug5 , ddrug6 } or methylthiadiazole { ddrug7 } can cause vitamin_k_deficiency and hypoprothrombinemia .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { DB01076 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , DB00295 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "DB00683 used at doses of # mg/kg and # mg/kg decreased the antinociceptive effect of ddrug1 , ddrug2 { only in the tail-flick test } and DB00328 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { DB01076 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { DB01045 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : ddrug1 ; ddrug2 ; ddrug3 ; certain ddrug4 , especially the ddrug5 and HD00384 ; ddrug7 ; ddrug8 salts ; ddrug9 ; and DB00908 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB01432 binds both ddrug2 and ddrug3 in the intestine , thus impairing absorption of these HD00809 .",
        "label": "NA"
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as DB01135 include certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB01627 , ddrug7 , ddrug8 , and ddrug9 } , ddrug10 salts , ddrug11 , local ddrug12 , ddrug13 , and ddrug14 .",
        "label": "effect"
    },
    {
        "text": "it is , however , possible that concomitant use of other known HD00299 such as ddrug1 , ddrug2 , ddrug3 , HD00219 , ddrug5 and ddrug6 might increase the photosensitivity reaction of actinic_keratosis treated with the ddrug7 for topical solution .",
        "label": "NA"
    },
    {
        "text": "intravenous ddrug0 { DB00640 } has been effectively administered in the presence of other cardioactive drugs , such as ddrug2 , ddrug3 , HD00245 , and ddrug5 , without any change in the adverse reaction profile .",
        "label": "NA"
    },
    {
        "text": "also , concomitant administration of ddrug0 with products containing ddrug1 , ddrug2 containing DB01593 , or DB00900 { ddrug5 } chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels .",
        "label": "NA"
    },
    {
        "text": "the extent to which ddrug0 - HD00312 interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the HD00278 involved .",
        "label": "NA"
    },
    {
        "text": "ingestion of ddrug0 may increase serum concentrations of DB00390 and DB00563 and increase ddrug3 s nephrotoxicity .",
        "label": "NA"
    },
    {
        "text": "ddrug0 / ddrug1 : DB00533 did not have any clinically important effect on the pharmacokinetics of ddrug3 or DB00898 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the pharmacokinetics of DB00918 were not affected by coadministration of DB00571 .",
        "label": "NA"
    },
    {
        "text": "conclusions : HD00093 inhibit the metabolism of HD00095 that are metabolized by cyp3a4 { i , e , , ddrug2 , ddrug3 , ddrug4 , ddrug5 } .",
        "label": "NA"
    },
    {
        "text": "the effects of mixing DB01306 with HD00813 of animal source or ddrug2 preparations produced by other manufacturers have not been studied .",
        "label": "NA"
    },
    {
        "text": "among # subjects who received DB00006 in clinical trials and were tested for antibodies , # subjects had treatment-emergent positive DB00006 antibody tests .",
        "label": "NA"
    },
    {
        "text": "no dose adjustment is necessary when DB00074 is added to triple-immunosuppression regimens including ddrug1 , HD00175 , and either ddrug3 or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : combination HD00432 may decrease the clearance of some ddrug2 { ddrug3 , DB00475 , ddrug5 } and increase the clearance of others { ddrug6 , ddrug7 , ddrug8 } .",
        "label": "mechanism"
    },
    {
        "text": "drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on ddrug0 therapy : ddrug1 , ddrug2 , ddrug3 , oral ddrug4 containing HD00220 , ddrug6 - containing preparations and the numerous preparations containing HD00328 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - combined administration of racemic ddrug1 { titrated to # mg/day for # days } and the cyp3a4 substrate DB00897 { single dose of # mg } did not significantly affect the pharmacokinetics of either DB00215 or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , DB01232 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and DB00126 .",
        "label": "NA"
    },
    {
        "text": "HD00679 : drugs such as ddrug1 , DB09255 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 and others that interfere with platelet-aggregation reactions { the main hemostatic defense of heparinized patients } may induce bleeding and should be used with caution in patients receiving ddrug8 .",
        "label": "NA"
    },
    {
        "text": "if ddrug0 is to be combined with other HD00595 such as ddrug2 or ddrug3 / HD00214 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of ddrug5 and ddrug6 { e , g , , ddrug7 or ddrug8 } are additive .",
        "label": "NA"
    },
    {
        "text": "the HD00074 { ddrug1 and ddrug2 } , a new class of oral HD00075 , are insulin sensitizers .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and ddrug7 raise the serum DB00390 concentration due to a reduction in clearance and/or in volume of distribution of the drug , with the implication that HD00118 intoxication may result .",
        "label": "NA"
    },
    {
        "text": "since ddrug0 is extensively metabolized by cyp4f3 isoenzymes , caution should be exercised when ddrug1 is coadministered with inhibitors of c , p , a , such as ddrug2 and DB00199 or inhibitors of cyp2c19 such as DB00338 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 increased the auc of DB00683 , a sensitive cyp3a4 substrate , by # - fold on day # and # - fold on day 5 , when a single oral dose of ddrug3 # mg was coadministered on day # and day # of a regimen of DB00673 # mg on day # and # mg/day on days # through 5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : elevated serum levels of DB00091 have been reported with concomitant use of ddrug2 with other members of the HD00678 .",
        "label": "NA"
    },
    {
        "text": "however , the systemic administration of some ddrug0 has been shown to elevate plasma concentrations of ddrug1 , interfere with the metabolism of ddrug2 , and enhance the effects of the oral ddrug3 DB00682 and its derivatives , and has been associated with transient elevations in serum creatinine in patients receiving systemic DB00091 concomitantly .",
        "label": "NA"
    },
    {
        "text": "approximately 2/3 of the patients in the phase # study received either prophylactic low dose ddrug0 { DB01109 up to 15,000 units/day } or prophylactic doses of HD00658 as indicated in the prescribing information for the specific products .",
        "label": "NA"
    },
    {
        "text": "HD00223 { e , g , , ddrug1 } and ddrug2 containing carbohydrate-splitting enzymes { e , g , , ddrug3 , ddrug4 } may reduce the effect of DB00284 and should not be taken concomitantly .",
        "label": "mechanism"
    },
    {
        "text": "other concomitant therapy although specific interaction studies were not performed , ddrug0 doses of # mg or more were concomitantly used in clinical studies with ddrug1 , ddrug2 , a-blockers , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , cardiac ddrug9 , ddrug10 , ddrug11 , ddrug12 , HD00728 { also referred to as HD00203 } , and ddrug15 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "DB00486 has been shown to have an additive cns depressant effect when given with either ddrug1 , ddrug2 , ddrug3 or DB00318 .",
        "label": "effect"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { HD00403 s } , ddrug2 , ddrug3 { ddrug4 may decrease the effects of these medicines } , ddrug5 { using these medicines with ddrug6 may result in increased cns depressant effects } , ddrug7 , ddrug8 { using these medicines with ddrug9 may change the amount of either medicine that you need to take } , and oral ddrug10 containing ddrug11 { ddrug12 may decrease the effectiveness of these oral HD00283 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in vitro data indicate that DB01149 inhibits the metabolism of DB00604 , which can result in an increase in plasma ddrug3 levels and prolongation of the qt interval on the ecg .",
        "label": "mechanism"
    },
    {
        "text": "HD00269 : ddrug1 , ddrug2 , ddrug3 , and ddrug4 have been shown to decrease plasma levels of HD00710 ;",
        "label": "NA"
    },
    {
        "text": "-lsb- the gaba-ergic system and brain edema -rsb- it has been shown in rats with experimental toxic and traumatic edemas that ddrug0 { 1 mg/kg } removes the antiedematous action of ddrug1 , HD00133 , ddrug3 and ddrug4 and reduces the action of DB00692 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : concomitant administration of DB00465 oral and DB01032 resulted in decreased clearance of ddrug3 and significant increases in ddrug4 plasma levels { total auc increased approximately threefold from # to # m g/h/ml } and terminal half-life increased approximately twofold from # to # hours .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : DB00227 , DB00641",
        "label": "NA"
    },
    {
        "text": "ddrug0 in combination with other ddrug1 , general ddrug2 , ddrug3 , HD00262 , ddrug5 , or other ddrug6 { including DB02325 } has additive depressant effects .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : although the results of a clinical study did not indicate a safe problem associated with the administration of ddrug1 { ddrug2 } injection , usp to subjects already receiving ddrug3 , there have been reports that DB00571 may potentiate the vasoconstrictive action of DB00201 by blocking the vasodilating property of epinephrine .",
        "label": "effect"
    },
    {
        "text": "the use of ddrug0 or ddrug1 with ddrug2 preparations may increase the effect of either the HD00711 or DB00956 .",
        "label": "NA"
    },
    {
        "text": "DB14513 - and ddrug1 - containing ddrug2 , administered concomitantly with ddrug3 , significantly decreased the bioavailability { 48 % } of DB00978 .",
        "label": "NA"
    },
    {
        "text": "therefore , co-administration of DB00476 with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index , including certain ddrug1 { ddrug2 -lsb- HD00313 -rsb- , such as ddrug4 , ddrug5 , and ddrug6 } , ddrug7 and ddrug8 { e , g , , ddrug9 , ddrug10 } , should be approached with caution .",
        "label": "advise"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 HD00100 ddrug11 , DB00897 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "these results suggest that acute dosing with DB00363 would not affect behaviors most closely associated with DB03575 intoxication .",
        "label": "NA"
    },
    {
        "text": "DB00682 : concomitant administration of DB00080 { 6 mg/kg once every # hours for # days } and ddrug2 { 25 mg single oral dose } had no significant effect on the pharmacokinetics of either drug , and the inr was not significantly altered .",
        "label": "NA"
    },
    {
        "text": "a similar association , though less marked , has been suggested with ddrug0 , phenyl-butazone , ddrug1 , DB00564 and possibly with ddrug3 , DB00415 , and ddrug5 { 72 }",
        "label": "NA"
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of HD00472 are the following : ddrug1 , ddrug2 , ddrug3 , DB01211 { 1 } , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 { 1 } , ddrug10 , ddrug11 , grapefruit juice , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21 , ddrug22 , ddrug23 , ddrug24 { 1 } , ddrug25 , ddrug26 .",
        "label": "mechanism"
    },
    {
        "text": "DB01032 or DB00501 : concomitant administration of ddrug2 or ddrug3 decreases the elimination of ddrug4 , most likely by inhibition of renal tubular secretion of ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00320 , ddrug2 , ddrug3 , DB00353 contraindicated due to potential for serious and life-threatening reactions such as acute ddrug5 toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues .",
        "label": "NA"
    },
    {
        "text": "DB00152 , or other products containing ddrug1 or ddrug2 , ddrug3 or ddrug4 should not be administered concomitantly with , or within # hours of , the administration of ddrug5 , because they may interfere with absorption resulting in lower serum and urine levels of DB01059 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may have additive effects with ddrug1 and other ddrug2 , e , g , , HD00214 , ddrug4 , ddrug5 , HD00557 .",
        "label": "NA"
    },
    {
        "text": "pharmacokinetic interaction between single oral doses of DB00343 and DB00877 in healthy volunteers .",
        "label": "mechanism"
    },
    {
        "text": "interactions may occur between DB00159 supplements and ddrug1 and other HD00330 and herbs such as garlic { allium sativum } and ddrug3 { ddrug4 } .",
        "label": "int"
    },
    {
        "text": "the hypoglycemic action of HD00222 may be potentiated by certain drugs including ddrug1 and other drugs that are highly protein bound , ddrug2 , ddrug3 , DB00446 , ddrug5 , ddrug6 , ddrug7 , and ddrug8 .",
        "label": "effect"
    },
    {
        "text": "no effects on plasma concentrations of DB00501 or DB01026 were observed .",
        "label": "NA"
    },
    {
        "text": "furthermore , ddrug0 , DB00252 , ddrug2 , and other inducers of cyp3a4 may cause a reduction in plasma DB00307 concentrations .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 , ddrug1 and DB00390 concentrations should be monitored at the initiation of DB01167 therapy and frequently thereafter , and the dose of these three drug products adjusted appropriately .",
        "label": "advise"
    },
    {
        "text": "ddrug0 may interact with the following medications : DB00316 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , DB01601 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "DB00695 should not be used concomitantly with DB00903 because of the possibility of ototoxicity .",
        "label": "advise"
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing DB01370 , ddrug3 , or ddrug4 , with ddrug5 , with metal cations such as ddrug6 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { DB00900 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "coadministration of DB00252 with # mg ddrug1 tablets in epileptic patients lowered the DB00401 plasma concentrations to undetectable levels .",
        "label": "NA"
    },
    {
        "text": "in addition , studies in healthy volunteers have shown that ddrug0 does not affect the pharmacokinetics or pharmacodynamics of ddrug1 , or the pharmacokinetics of ddrug2 { 40 mg twice daily } , DB00252 , ddrug4 , or oral HD00283 .",
        "label": "NA"
    },
    {
        "text": "a study of interaction between DB00187 and DB00682 showed that concomitant administration of ddrug2 and ddrug3 does not alter ddrug4 plasma levels .",
        "label": "NA"
    },
    {
        "text": "because ddrug0 has not been shown to produce any additional effect beyond that obtained with ddrug1 alone and because ddrug2 increases the rate of excretion of DB00573 , the concomitant use of ddrug4 and HD00328 is not recommended .",
        "label": "NA"
    },
    {
        "text": "DB00316 / ddrug1 , ddrug2 / ddrug3 , ddrug4 / ddrug5 , ddrug6 / ddrug7 , ddrug8 / ddrug9 , ddrug10 / ddrug11 , and ddrug12 / DB01174 .",
        "label": "NA"
    },
    {
        "text": "HD00318 : DB00681 - induced hypokalemia may potentiate ddrug2 toxicity .",
        "label": "NA"
    },
    {
        "text": "in clinical studies , coadministration of ddrug0 with ddrug1 , DB00227 , or ddrug3 did not interfere with the lipid-lowering activity of the HD00383 .",
        "label": "NA"
    },
    {
        "text": "both ddrug0 and ddrug1 have been compared to triple therapy with the ddrug2 ddrug3 over # weeks as initial therapy , with similar responses being observed with DB00238 regimens and superiority observed with DB00625 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and HD00147 similarly inhibit and stimulate ddrug2 - or HD00071 - induced proliferation of prostatic epithelium .",
        "label": "effect"
    },
    {
        "text": "ddrug0 { e , g , ddrug1 and DB13179 } : agents of the ddrug3 , of which ddrug4 { ddrug5 } injection , usp is a member , have been shown to interact with ddrug6 of the HD00626 , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .",
        "label": "NA"
    },
    {
        "text": "and ddrug0 e , g , , ddrug1 } , cyp1a2 inducers { DB00338 } and cyp1a2 inhibitors { DB14029 and ddrug4 } .",
        "label": "NA"
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of HD00539 such as ddrug1 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 } , ddrug11 salts , ddrug12 , local HD00264 , ddrug14 , and ddrug15 .",
        "label": "effect"
    },
    {
        "text": "in separate single or multiple dose pharmacokinetic interaction studies with ddrug0 , ddrug1 , DB00571 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , and ddrug8 , the bioavailability of DB14207 was not altered by coadministration of ddrug10 with any one of these drugs .",
        "label": "NA"
    },
    {
        "text": "the use of HD00203 in patients who are receiving HD00106 may potentiate renal disease states .",
        "label": "effect"
    },
    {
        "text": "an adequate period of observation must be provided for any patient in whom either HD00735 { such as ddrug1 } or large doses of ddrug2 { such as # mg of DB00683 } have been used .",
        "label": "NA"
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a ddrug0 , including ddrug1 , with multivalent cation-containing products such as ddrug2 or DB01370 ddrug4 , ddrug5 , ddrug6 chewable/buffered tablets or pediatric powder , or products containing DB01373 , ddrug8 , or ddrug9 may substantially decrease the absorption of ddrug10 , resulting in serum and urine levels considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "in DB00368 - precontracted arteries from dietary-obese rats , responses to DB02709 were not attenuated by endothelial denudation , indicating an action independent of the endothelium .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , such as ddrug1 and DB01138 , can inhibit renal tubular secretion of DB00698 .",
        "label": "mechanism"
    },
    {
        "text": "nephrotoxic agents : concomitant administration of DB00369 and agents with nephrotoxic potential -lsb- e , g , , intravenous HD00249 { e , g , , ddrug2 , ddrug3 , and ddrug4 } , ddrug5 , ddrug6 , intravenous ddrug7 , ddrug8 , and ddrug9 -rsb- is contraindicated .",
        "label": "advise"
    },
    {
        "text": "while all the ddrug0 { HD00114 } , e , g , , ddrug2 , ddrug3 , DB00472 , ddrug5 , and ddrug6 , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .",
        "label": "NA"
    },
    {
        "text": "- a HD00535 { ddrug1 } such as ddrug2 { DB01050 , ddrug4 , ddrug5 , others } , ddrug6 { ddrug7 , ddrug8 , ddrug9 } , ddrug10 { ddrug11 , ddrug12 } , ddrug13 { ddrug14 } , ddrug15 { ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , and ddrug21 { ddrug22 , ddrug23 , ddrug24 } ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 - combined administration of racemic DB00215 { 40 mg } and ddrug2 { 200 mg } decreased the cmax and auc of DB01026 by 21 % and 10 % , respectively , and did not significantly affect the pharmacokinetics of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "prolonged recovery time may occur if ddrug0 and/or HD00543 are used concurrently with DB01221 .",
        "label": "effect"
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit ddrug0 binding to serum proteins or alter the concentrations of serum binding proteins : HD00657 and related ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , DB00784 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 .",
        "label": "NA"
    },
    {
        "text": "the concomitant administration of HD00272 and ddrug1 has been associated with a decrease in the excretion of oxypurines { hypoxanthine and xanthine } and an increase in urinary uric_acid excretion compared with that observed with DB00437 alone .",
        "label": "NA"
    },
    {
        "text": "use of DB00694 in a patient who has previously received DB00997 increases the risk of cardiotoxicity .",
        "label": "effect"
    },
    {
        "text": "if a patient requires ddrug0 and HD00637 therapy , it is suggested that ddrug2 , ddrug3 , or HD00374 { ddrug5 and ddrug6 } be used as alternatives to ddrug7 , as these agents have no effect on the pharmacokinetic profile of ddrug8 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - although ddrug1 did not potentiate the cognitive and motor effects of ddrug2 in a clinical trial , as with other ddrug3 , the use of DB02325 by patients taking DB01175 is not recommended .",
        "label": "advise"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { DB00682 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { DB01026 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "in a study of # schizophrenic patients coadministered oral DB00502 and DB01045 , plasma ddrug2 levels were decreased by a mean of 70 % and mean scores on the brief psychiatric rating scale were increased from baseline .",
        "label": "mechanism"
    },
    {
        "text": "HD00343 prolong and intensify the anticholinergic { drying } effects of HD00388 .",
        "label": "effect"
    },
    {
        "text": "in another study with intravenous administration of ddrug0 , DB00673 was given as # mg on day # and # mg/day on days # and 3 , and DB00683 # mg iv was given prior to the administration of the 3-day regimen of ddrug3 and on days 4 , 8 , and 15 .",
        "label": "NA"
    },
    {
        "text": "tacrolimus DB01023 may increase the blood concentration of DB00864 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , DB01601 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { HD00531 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "absorption of HD00239 is impaired by HD00374 containing ddrug2 , ddrug3 , or ddrug4 , and ddrug5 - containing preparations .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 : coadministration of DB01076 and an oral ddrug2 increased auc values for DB00717 and ddrug4 by approximately 30 % and 20 % .",
        "label": "mechanism"
    },
    {
        "text": "nonetheless , the range of individual ddrug0 clearance values in the presence of DB00993 { 12 - 57 ml/h } or DB00688 { 7 - 54 ml/h } did not extend outside the range observed with dual therapy { 10 - 78 ml/h } .",
        "label": "NA"
    },
    {
        "text": "HD00374 , ddrug1 , metal cations , DB00152 ddrug3 form chelates with alkaline earth and transition metal cations .",
        "label": "NA"
    },
    {
        "text": "if ddrug0 is to be combined with other HD00595 such as HD00262 or ddrug3 / ddrug4 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of ddrug5 and ddrug6 { e , g , , ddrug7 or ddrug8 } are additive .",
        "label": "NA"
    },
    {
        "text": "to determine whether ddrug0 has a direct effect on the distribution of DB01147 , the elimination and distribution of ddrug2 was studied in six patients , five lacking kidney function and one with a partially impaired renal function , in the presence or absence of DB01032 .",
        "label": "NA"
    },
    {
        "text": "if DB01151 is to be combined with other ddrug1 such as ddrug2 or ddrug3 / ddrug4 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of ddrug5 and HD00100 { e , g , , ddrug7 or ddrug8 } are additive .",
        "label": "NA"
    },
    {
        "text": "this drug may interact with ddrug0 or other ddrug1 { may potentiate the cns depressant effects of either these medications or ddrug2 } , HD00444 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug4 } , and HD00445 { concurrent use with ddrug6 may prolong and intensify the anticholinergic and cns depressant effects of ddrug7 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 toxicity has been reported in patients receiving DB14507 concomitantly with drugs which cause elimination of sodium , including HD00106 .",
        "label": "effect"
    },
    {
        "text": "however , it is considered to be unlikely that this decrease of phosphorylated ddrug0 concentration is of clinical significance , as DB00709 is a more efficient substrate for dck than DB00943 .",
        "label": "NA"
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit ddrug0 binding to serum proteins or alter the concentrations of serum binding proteins : ddrug1 and related ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , DB00784 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , DB00675 .",
        "label": "NA"
    },
    {
        "text": "in addition , results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance { ddrug0 , DB00238 , ddrug2 , ddrug3 , or ddrug4 } with ddrug5 may result in clinically meaningful reductions in DB00520 concentrations .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , DB00529 , and ddrug2 : drugs such as ddrug3 , ddrug4 , and ddrug5 may increase the risk of developing peripheral_neuropathies or other DB00943 - associated adverse events by interfering with the renal clearance of ddrug7 { thereby raising systemic exposure } .",
        "label": "NA"
    },
    {
        "text": "this small decrease in excretion of DB00996 by DB00501 is not expected to be of clinical importance .",
        "label": "mechanism"
    },
    {
        "text": "cardiovasculars : ddrug0 : in patients receiving ddrug1 therapy , administration of oral DB01118 regularly results in an increase in serum DB00390 concentration that may reach toxic levels with resultant clinical toxicity .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { DB00316 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , DB01232 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "animal experience indicates that DB00628 prolongs the sleeping time after DB01355 or after ddrug2 , increases the inhibitory effects of ddrug3 , but does not exhibit maoa inhibition .",
        "label": "effect"
    },
    {
        "text": "plasma levels of several closely related HD00043 have been reported to be increased by the concomitant administration of ddrug1 or hepatic enzyme inhibitors { e , g , , ddrug2 , ddrug3 } and decreased by the concomitant administration of hepatic enzyme inducers { e , g , , ddrug4 , ddrug5 } , and such an effect may be anticipated with HD00551 as well .",
        "label": "NA"
    },
    {
        "text": "there was no evidence of drug interactions in clinical studies in which DB00841 was administered concurrently with other drugs , including HD00573 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , and ddrug13 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 and DB00201 may enhance the effects of : other HD00459 s , ddrug4 , general ddrug5 , ddrug6 such as ddrug7 , ddrug8 , or other ddrug9 , causing increased cns depression .",
        "label": "effect"
    },
    {
        "text": "enhanced DB00277 clearance secondary to DB00252 therapy .",
        "label": "mechanism"
    },
    {
        "text": "DB00861 decreased the hyperuricemic effect of DB00999 .",
        "label": "effect"
    },
    {
        "text": "there is one report suggesting that the concomitant use of DB00656 { ddrug1 } and DB00490 may have caused 3 - to 6-fold elevations on sgpt { alt } in a few patients .",
        "label": "effect"
    },
    {
        "text": "when DB00328 is given to patients receiving ddrug1 , the plasma levels of DB00328 are likely to be increased .",
        "label": "NA"
    },
    {
        "text": "other no clinically important pharmacokinetic interactions occurred when DB00542 was administered concomitantly with ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , DB00788 , or ddrug8 .",
        "label": "NA"
    },
    {
        "text": "similarly , DB00731 had no influence on the serum protein binding of ddrug1 , ddrug2 , ddrug3 , DB00682 , ddrug5 , ddrug6 , and ddrug7 in vitro .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of ddrug0 : ddrug1 , ddrug2 , HD00218 , ddrug4 { e , g , , ddrug5 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , HD00810 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "a possible interaction between DB01016 and ddrug1 , a HD00754 , has been reported , resulting in a potentiation of the hypoglycemic action of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : co-administration of ddrug1 # mg b , i , d , for # days decreased the plasma concentrations of both DB14055 { a cyp2c9 substrate } and DB08496 { a cyp3a4 substrate } by # and 38 % , respectively .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , certain HD00043 , ddrug8 , DB00277 and ddrug10 , thereby delaying elimination and increasing blood levels of these drugs .",
        "label": "NA"
    },
    {
        "text": "oral HD00283 DB00533 did not have any clinically important effect on the pharmacokinetics of ddrug2 and ddrug3 .",
        "label": "NA"
    },
    {
        "text": "- a ddrug0 { HD00725 } such as DB01247 { ddrug3 } , ddrug4 { ddrug5 } , or ddrug6 { ddrug7 } ;",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 DB00264 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } HD00220 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a ddrug0 , including ddrug1 , with multivalent cation-containing products such as ddrug2 or DB01370 ddrug4 , ddrug5 , ddrug6 chewable/buffered tablets or pediatric powder , or products containing ddrug7 , ddrug8 , or ddrug9 may substantially decrease the absorption of DB00537 , resulting in serum and urine levels considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "HD00532 , including DB00827 , may enhance the effects of oral ddrug2 , such as ddrug3 or its derivatives .",
        "label": "NA"
    },
    {
        "text": "population pharmacokinetic studies showed higher concentrations of DB01166 among patients concurrently treated with DB00343 , an inhibitor of c , p , a , .",
        "label": "mechanism"
    },
    {
        "text": "DB00771 may decrease the effect of HD00219 , ddrug2 , and ddrug3 .",
        "label": "effect"
    },
    {
        "text": "additionally , HD00474 , such as ddrug1 and DB00358 , may antagonize the activity of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "patients receiving catecholamine-depleting drugs , such as ddrug0 or DB01170 , should be closely monitored , because the added beta-adrenergic blocking action of DB00612 may produce excessive reduction of sympathetic activity .",
        "label": "effect"
    },
    {
        "text": "if a patient requires DB00204 and ddrug1 therapy , it is suggested that ddrug2 , DB00863 , or ddrug4 { ddrug5 and ddrug6 } be used as alternatives to ddrug7 , as these agents have no effect on the pharmacokinetic profile of ddrug8 .",
        "label": "NA"
    },
    {
        "text": "the effect may be mediated by the known inhibition of DB00501 on hepatic cytochrome p-450 , the enzyme system probably responsible for the first-pass metabolism of DB01115 .",
        "label": "NA"
    },
    {
        "text": "other concomitant therapy in healthy subjects there were no clinically significant interactions when DB01023 was given concomitantly with DB00328 or ddrug2 .",
        "label": "NA"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : ddrug1 ; ddrug2 ; ddrug3 ; certain ddrug4 , especially the HD00249 and ddrug6 ; ddrug7 ; ddrug8 salts ; ddrug9 ; and DB00908 .",
        "label": "NA"
    },
    {
        "text": "adequate monitoring of ddrug0 plasma concentrations should be considered when therapy with HD00897 is initiated or changed in patients receiving DB00277 .",
        "label": "advise"
    },
    {
        "text": "in clinical trials , ddrug0 was used with ddrug1 , ddrug2 , ddrug3 , oral HD00337 , and supplemental ddrug5 , in a pharmacokinetic substudy in patients with congestive heart failure receiving ddrug6 or ddrug7 in whom therapy with ddrug8 was initiated , apparent oral clearance values for ddrug9 { n = 23 } and DB00390 { n = 30 } were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of ddrug0 : ddrug1 , ddrug2 , ddrug3 , HD00571 { e , g , , ddrug5 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , ddrug11 , HD00220 , ddrug13 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "five days of DB00204 treatment did not significantly affect steady-state pharmacokinetic variables of DB00390 compared with placebo ;",
        "label": "NA"
    },
    {
        "text": "however , because some HD00532 have been reported to enhance the effects of ddrug1 or its derivatives , prothrombin time or other suitable anticoagulation test should be monitored closely if a HD00751 is administered with ddrug3 or its derivatives .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and HD00408 could exaggerate the prolongation of the qt interval observed with HD00406 .",
        "label": "effect"
    },
    {
        "text": "caution should be used when administering or taking ddrug0 with DB01026 and other strong cyp3a4 inhibitors such as , but not limited to , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , DB13179 { ddrug12 } , and ddrug13 .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect : ddrug0 , ddrug1 , DB01406 , ddrug3 , ddrug4 { e , g , , ddrug5 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , HD00810 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "there was a small increase in plasma concentrations of DB01101 and one metabolite { HD00468 } ;",
        "label": "NA"
    },
    {
        "text": "there are rare reports , however , from marketing experiences , of changes in effects of ddrug0 or oral HD00062 in the presence of DB00586 that necessitated changes in the doses of such agents .",
        "label": "effect"
    },
    {
        "text": "ddrug0 including ddrug1 , DB00780 , and ddrug3 hc1 : concomitant use of DB00135 and non-selective ddrug5 may cause hypertension .",
        "label": "NA"
    },
    {
        "text": "DB00467 does not affect the clearance of the active s-isomer , and changes in clotting time have not been observed when ddrug1 and DB00682 were coadministered .",
        "label": "NA"
    },
    {
        "text": "interactions may also occur with the following : HD00515 / ddrug1 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , ddrug4 , ddrug5 , ddrug6 , ddrug7 , DB01578 , ddrug9 , ddrug10 , ddrug11 pain medication { e , g , , ddrug12 } , drugs used to aid sleep , drowsiness-causing ddrug13 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "DB00310 and related drugs may increase the responsiveness to DB01199 .",
        "label": "effect"
    },
    {
        "text": "DB00921 and DB01183 should be prescribed with caution to patients on ddrug2 or other drugs that act on the central nervous system , regardless of whether these drugs are taken on the advice of a physician or are taken as drugs of abuse .",
        "label": "NA"
    },
    {
        "text": "these drugs include the HD00217 and other HD00218 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , oral ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , and ddrug11 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 , ddrug2 { ddrug3 , DB00199 , HD00270 : skeletal muscle .",
        "label": "NA"
    },
    {
        "text": "HD00093 { e , g , ddrug1 and ddrug2 } : agents of the HD00625 , of which ddrug4 { ddrug5 } injection , usp is a member , have been shown to interact with ddrug6 of the ddrug7 , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : studies of concomitant administration of DB00712 and DB00390 to healthy men { n = 14 } did not show a change in the steady state serum levels of either drug .",
        "label": "NA"
    },
    {
        "text": "total body clearance of ddrug0 was reduced by an average 22 % and 51 % when ddrug1 and DB00688 , respectively , were added to a regimen consisting of ddrug3 , usp { modified } and HD00175 .",
        "label": "NA"
    },
    {
        "text": "HD00385 : concomitant use of ddrug1 and HD00175 may produce severe weakness in patients with myasthenia gravis .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of HD00071 : ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , ddrug5 , ddrug6 , DB00871 } , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 therapy : urinary excretion of ddrug1 is increased , and efficacy is reduced , by HD00569 used in DB06799 therapy .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a single { 400 mg } and multiple dose { 400 mg tid } study of ddrug1 in epileptic patients { n = 8 } maintained on DB00252 monotherapy for at least # months , ddrug3 had no effect on the steady-state trough plasma concentrations of ddrug4 and ddrug5 had no effect on DB00996 pharmacokinetics .",
        "label": "NA"
    },
    {
        "text": "when the DB00611 was administered # minutes after the ddrug1 nasal spray , the auc of DB00611 increased 11 % and cmax decreased 18 % .",
        "label": "NA"
    },
    {
        "text": "ddrug0 HD00610 , as well as a metabolite of DB00614 , slow ddrug3 metabolism .",
        "label": "NA"
    },
    {
        "text": "both ddrug0 and HD00022 block ddrug2 - induced and DB00184 - induced dopamine release in the nucleus accumbens ;",
        "label": "effect"
    },
    {
        "text": "other drug interactions oral ddrug0 DB01202 { 500 mg twice daily } did not influence the pharmacokinetics of an oral ddrug2 containing # mg ddrug3 and # mg DB00367 , or of the luteinizing hormone and progesterone levels , indicating that impairment of contraceptive efficacy is unlikely .",
        "label": "NA"
    },
    {
        "text": "- a HD00535 { ddrug1 } such as ddrug2 { ddrug3 , ddrug4 , ddrug5 , others } , ddrug6 { ddrug7 , ddrug8 , ddrug9 } , ddrug10 { ddrug11 , ddrug12 } , ddrug13 { ddrug14 } , ddrug15 { ddrug16 } , ddrug17 { ddrug18 } , DB00991 { ddrug20 } , and ddrug21 { ddrug22 , ddrug23 , ddrug24 } ;",
        "label": "NA"
    },
    {
        "text": "to avoid this interaction , ddrug0 or DB00224 should be given # hour prior to dosing with DB00900 .",
        "label": "advise"
    },
    {
        "text": "injection : ddrug0 injection , like other injectable HD00100 , produces depression of the central nervous system when administered with ddrug2 , ddrug3 , ddrug4 , ddrug5 , and other ddrug6 , when ddrug7 is used concomitantly with injectable DB00186 , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00501 coadministration leads to an increased peak plasma concentration and auc of ddrug2 , there is no effect on ddrug3 absorption when it is coadministered with DB00863 .",
        "label": "NA"
    },
    {
        "text": "in order to avoid the occurrence of severe hypersensitivity reactions , all patients treated with DB01229 should be premedicated with ddrug1 { such as ddrug2 } , diphen-hydramine and HD00727 { such as ddrug4 or ddrug5 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 in combination with other HD00424 , general ddrug2 , ddrug3 , ddrug4 , ddrug5 , or other ddrug6 { including DB02325 } has additive depressant effects .",
        "label": "NA"
    },
    {
        "text": "in vitro binding studies with human serum proteins indicate that DB01067 binds differently than DB01124 and does not interact with ddrug2 or ddrug3 .",
        "label": "NA"
    },
    {
        "text": "DB01241 other HD00550 ddrug2 { ddrug3 } { = 1 g/day }",
        "label": "NA"
    },
    {
        "text": "ddrug0 , DB00575 , ddrug2 salts , and ddrug3 may either potentiate or weaken the blood-glucose-lowering effect of HD00071 .",
        "label": "effect"
    },
    {
        "text": "based on the results of these studies , it is concluded that ddrug0 may be safely coadministered with both DB00495 and DB00900 .",
        "label": "NA"
    },
    {
        "text": "- a ddrug0 { HD00615 } such as ddrug2 { ddrug3 , ddrug4 , ddrug5 , others } , ddrug6 { ddrug7 , ddrug8 , ddrug9 } , ddrug10 { ddrug11 , ddrug12 } , DB00749 { ddrug14 } , ddrug15 { ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , and ddrug21 { ddrug22 , ddrug23 , ddrug24 } ;",
        "label": "NA"
    },
    {
        "text": "a rare , but serious , constellation of symptoms , termed serotonin syndrome , has been reported with the concomitant use of ddrug0 { HD00114 } and agents for migraine therapy , such as DB00669 { ddrug3 } and ddrug4 .",
        "label": "effect"
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma DB00252 concentrations include : acute ddrug1 intake , ddrug2 , chboramphenicol , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , DB01124 , ddrug21",
        "label": "mechanism"
    },
    {
        "text": "in one survey , # % of patients taking DB00598 in combination with HD00043 experienced tremor , as compared to # % reported to occur with ddrug2 alone .",
        "label": "effect"
    },
    {
        "text": "ddrug0 and ddrug1 { congestive heart failure post-myocardial infarction } - in ephesus , # { 91 % } patients receiving DB00700 # to # mg also received ddrug3 or ddrug4 { HD00685 / ddrug6 } .",
        "label": "NA"
    },
    {
        "text": "consequently , it is recommended that DB00176 not be used in combination with either DB00857 , ddrug2 , or ddrug3 .",
        "label": "advise"
    },
    {
        "text": "if replacing ddrug0 by HD00380 therapy , the introduction of HD00378 should be delayed for several days after ddrug3 administration has stopped .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB01009 , like other ddrug2 , may cause changes in the elimination of DB00563 leading to elevated serum levels of the drug and increased toxicity .",
        "label": "mechanism"
    },
    {
        "text": "DB00977 DB00717",
        "label": "NA"
    },
    {
        "text": "DB00542 has been used concomitantly with ddrug1 , ddrug2 , HD00218 , ddrug4 , and ddrug5 , without evidence of clinically important adverse interactions .",
        "label": "NA"
    },
    {
        "text": "ddrug0 should be administered with caution to patients who are taking other ddrug1 or HD00261 , including ddrug3 , ddrug4 and HD00424 , or to those with a history of psychiatric disorder { including manic-depressive illness and schizophrenia } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : concurrent administration of # mg or # mg DB01012 with # mg DB00321 increased ddrug3 exposure and ddrug4 { active metabolite } exposure by approximately 20 % in cyp2d6 extensive metabolizers .",
        "label": "mechanism"
    },
    {
        "text": "the co-administration of ddrug0 with iv ddrug1 such as ddrug2 , ddrug3 , DB00235 , or iv HD00106 has not been evaluated { these drugs were not co-administered with ddrug6 in clinical trials } .",
        "label": "NA"
    },
    {
        "text": "HD00532 , including DB01059 , may enhance the effects of oral ddrug2 , including ddrug3 or its derivatives or similar agents .",
        "label": "NA"
    },
    {
        "text": "the concomitant administration of either DB00907 or DB00182 , compounds which inhibit neuronal reuptake of norepinephrine , disrupts the behavioral response of the genetically nervous e-strain subjects to a far greater extent than the stable a-strain subjects .",
        "label": "NA"
    },
    {
        "text": "HD00244 : coadministration of ddrug1 did not have any effect on either the safety or efficacy of DB00308 in the clinical trials .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of ddrug0 and ddrug1 , DB00501 , ddrug3 , or an HD00183 / ddrug5 oral ddrug6 produced minor changes in the pharmacokinetics of ddrug7 , which were considered to be without clinical significance .",
        "label": "NA"
    },
    {
        "text": "previous studies have demonstrated a significant reduction in the oral bioavailability of DB00685 and DB00537 when administered concomitantly with an intravenous ddrug2 such as ddrug3 .",
        "label": "NA"
    },
    {
        "text": "the effects of concomitant administration of DB01195 and DB00571 on the pr interval were less than additive .",
        "label": "effect"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other HD00216 ddrug3 ddrug4 DB00564 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "ddrug0 : co-administration of # mg twice-daily DB01026 with DB09026 resulted in an approximate 80 % increase in plasma levels of ddrug3 .",
        "label": "mechanism"
    },
    {
        "text": "other drugs : in small groups of patients { 7 - 10 / interaction study } , the concomitant administration of ddrug0 , ddrug1 , ddrug2 , ddrug3 , DB00860 , ddrug5 , or ddrug6 did not significantly affect the peak levels and auc values of DB00586 .",
        "label": "NA"
    },
    {
        "text": "ingestion of DB00586 may increase serum concentrations of DB00390 and ddrug2 and increase ddrug3 s nephrotoxicity .",
        "label": "mechanism"
    },
    {
        "text": "since DB01166 is extensively metabolized by cyp4f3 isoenzymes , caution should be exercised when ddrug1 is coadministered with inhibitors of c , p , a , such as ddrug2 and ddrug3 or inhibitors of cyp2c19 such as DB00338 .",
        "label": "NA"
    },
    {
        "text": "toxicology studies of ddrug0 - related deaths reveal frequent involvement of other ddrug1 , including ddrug2 , ddrug3 such as DB00829 { ddrug5 } , and , to a rising degree , DB00333 .",
        "label": "NA"
    },
    {
        "text": "like HD00021 { 40 mg/kg } , ddrug1 { 40 mg/kg } decreases the intravenous self-administration of ddrug2 and DB00907 and the oral self-administration of ddrug4 and ddrug5 in rats ;",
        "label": "NA"
    },
    {
        "text": "in separate single or multiple dose pharmacokinetic interaction studies with ddrug0 , ddrug1 , ddrug2 , ddrug3 , DB00501 , ddrug5 , ddrug6 , ddrug7 , and ddrug8 , the bioavailability of DB14207 was not altered by coadministration of ddrug10 with any one of these drugs .",
        "label": "NA"
    },
    {
        "text": "however , due to possible pharmacodynamic interactions , when co-administered with DB00633 , a reduction in dosage of ddrug1 on the concomitant ddrug2 , ddrug3 , ddrug4 or HD00023 may be required .",
        "label": "NA"
    },
    {
        "text": "in patients receiving DB01033 { ddrug1 } or ddrug2 { ddrug3 } , the concomitant administration of 300 - 600 mg of DB00437 per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of ddrug5 or ddrug6 .",
        "label": "NA"
    },
    {
        "text": "absorption of HD00239 is impaired by ddrug1 containing ddrug2 , ddrug3 , or DB14513 , and ddrug5 - containing preparations .",
        "label": "mechanism"
    },
    {
        "text": "clinical studies with ddrug0 have identified potentially significant interactions with DB00196 and DB14507 .",
        "label": "NA"
    },
    {
        "text": "however , coadministration of ddrug0 { 20 mg } and DB00503 { 600 mg } , a potent inhibitor of cyp3a4 , did not significantly affect the pharmacokinetics of DB01175 .",
        "label": "NA"
    },
    {
        "text": "the oral DB01234 doses should be reduced by approximately 50 % when coadministered with ddrug1 , to achieve exposures of ddrug2 similar to those obtained when it is given without DB00673 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 / DB01167 , ddrug2 , including DB00199",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , DB00224 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { HD00531 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "DB14513 - and/or ddrug1 - containing ddrug2 , products containing ddrug3 { ddrug4 } , ddrug5 containing ddrug6 or other metal cations , or DB00900 { ddrug8 } chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after ddrug9 .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { DB00501 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 HD00542 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "DB00825 / ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 and ddrug5 combinations , DB01050 , ddrug7 } .",
        "label": "NA"
    },
    {
        "text": "a similar association , though less marked , has been suggested with ddrug0 , ddrug1 , DB00252 , ddrug3 , ddrug4 , ddrug5 , and possibly with DB00415 and ddrug7 72 .",
        "label": "NA"
    },
    {
        "text": "drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving ddrug0 metabolized similarly to ddrug1 or on the basis of in vitro studies with ddrug2 or other ddrug3 { caution is recommended during coadministration with ddrug4 } : available data from clinical studies of HD00100 other than ddrug6 suggest a possible drug interaction with ddrug7 for the following : ddrug8 , DB00951 , ddrug10 such as ddrug11 and ddrug12 , and grapefruit juice .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , and the HD00457 DB00904 { ddrug3 } and ddrug4 { ddrug5 } have all been used with ddrug6 .",
        "label": "NA"
    },
    {
        "text": "interactions with ddrug0 : ddrug1 { eg , DB00652 , ddrug3 , ddrug4 , ddrug5 and ddrug6 } should not be administered to a patient who has received or is receiving a course of therapy with a ddrug7 such as DB00854 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 augments the action of HD00781 s and the muscle relaxant effects of HD00249 .",
        "label": "NA"
    },
    {
        "text": "no differences in adverse events or qtc interval were observed when subjects were administered DB00950 alone or in combination with either DB00199 or ddrug2 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and DB00281 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , DB01035 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "avoid the use of preparations such as HD00799 and local ddrug1 which contain any ddrug2 { e , g , , ddrug3 , ddrug4 } , since it has been reported that HD00043 can potentiate the effects of catecholamines .",
        "label": "advise"
    },
    {
        "text": "after multiple dosing , DB00060 { ddrug1 # mcg i m once weekly } reduced DB00108 clearance by approximately 30 % .",
        "label": "mechanism"
    },
    {
        "text": "presumably , DB00252 acts as a stimulator of DB04665 metabolism and has been reported to cause decreased serum levels of the ddrug2 and increased prothrombin-proconvertin concentrations .",
        "label": "mechanism"
    },
    {
        "text": "when ddrug0 is given to patients receiving DB01032 , the plasma levels of DB00328 are likely to be increased .",
        "label": "NA"
    },
    {
        "text": "DB01069 : coadministration of a single dose of ddrug1 and ddrug2 { 10 and # mg , respectively } resulted in a 15 % decrease in maximal plasma concentrations of DB00962 , but no change in the area under the plasma concentration-time curve .",
        "label": "NA"
    },
    {
        "text": "use of DB00722 with ddrug1 { e , g , , DB00421 , ddrug3 , or ddrug4 } , ddrug5 supplements , or potassium-containing salt substitutes may lead to significant increases in serum potassium .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : based on reports of profound hypotension and loss of consciousness when DB00714 was administered with ddrug2 , the concomitant use of ddrug3 with drugs of the ddrug4 { including , for example , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and DB00969 } is contraindicated .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may have additive effects with ddrug1 and other HD00261 , e , g , , ddrug3 , ddrug4 , ddrug5 , HD00557 .",
        "label": "NA"
    },
    {
        "text": "these drugs include the HD00217 and other HD00218 , ddrug2 , ddrug3 , thyroid products , ddrug4 , oral ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 .",
        "label": "NA"
    },
    {
        "text": "for ddrug0 auc { 0-infinity } , auc { 0 - 24 } , and cmax , the geometric mean ratios { 90 % confidence interval } for { DB00533 + DB00390 / placebo + ddrug3 } were # { # , # } , # { # , # } , and # { # , # } , respectively .",
        "label": "NA"
    },
    {
        "text": "ddrug0 increased the auc of DB00683 by 25 % on day # and decreased the auc of ddrug2 by 19 % on day # relative to the dosing of DB00673 on days # through 3 .",
        "label": "NA"
    },
    {
        "text": "however , the peak plasma level of DB00331 was reduced by approximately 20 % when taking DB00284 due to a slight delay in the absorption of ddrug2 .",
        "label": "mechanism"
    },
    {
        "text": "DB00731 is a potential inhibitor of the cyp2c9 isoenzyme in vivo as indicated by its ability to inhibit the in vitro metabolism of DB01124 .",
        "label": "mechanism"
    },
    {
        "text": "drug interactions with ddrug0 administration of # mg of ddrug1 { 2 x # mg capsule } within # minutes of an DB01370 and ddrug3 containing DB06724 { ddrug5 } decreased ddrug6 auc by 41 % and cmax by 43 % .",
        "label": "NA"
    },
    {
        "text": "DB00668 should not be administered concomitantly with other HD00390 { such as ddrug2 } because of possible additive effects and increased toxicity .",
        "label": "advise"
    },
    {
        "text": "therefore , cyp3a4 substrates known to have a narrow therapeutic index such as ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , or HD00443 { ddrug11 , ddrug12 } should be administered with caution in patients receiving DB01254 .",
        "label": "advise"
    },
    {
        "text": "elevated plasma levels of DB00277 have been reported with concomitant HD00533 use .",
        "label": "mechanism"
    },
    {
        "text": "in a parallel group drug interaction study comparing the intravenous prodrug form of ddrug0 at # mg bid { n = 10 } vs placebo { n = 9 } , DB00580 had no effect on in vitro DB00945 - mediated inhibition of arachidonate - or collagen-stimulated platelet aggregation .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 and DB00201 may enhance the effects of : other ddrug3 s , ddrug4 , general ddrug5 , ddrug6 such as DB00475 , ddrug8 , or other ddrug9 , causing increased cns depression .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { DB01076 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , DB00277 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 or ddrug1 excess may decrease the effect of ddrug2 , and an DB11119 deficiency can increase the effect of DB00389 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 / ddrug1 : ddrug2 inhibits the enzymatic oxidation of ddrug3 and DB00993 to HD00271 .",
        "label": "NA"
    },
    {
        "text": "HD00290 , other , especially DB01119 , or pre ddrug2 and anesthetic agents used in surgery or ddrug3 , nondepolarizing , used in surgery",
        "label": "NA"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : DB00228 ; ddrug2 ; DB01159 ; certain ddrug4 , especially the ddrug5 and ddrug6 ; ddrug7 ; ddrug8 salts ; ddrug9 ; and ddrug10 .",
        "label": "NA"
    },
    {
        "text": "interactions with ddrug0 : ddrug1 { eg , ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 } should not be administered to a patient who has received or is receiving a course of therapy with a HD00843 such as DB00854 .",
        "label": "advise"
    },
    {
        "text": "the effect of DB00187 on the duration of DB00202 - induced neuromuscular blockade was studied in patients undergoing surgery .",
        "label": "NA"
    },
    {
        "text": "DB00294 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { DB01076 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "int"
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma ddrug0 concentrations include : acute DB02325 intake , ddrug2 , chboramphenicol , ddrug3 , ddrug4 , ddrug5 , ddrug6 , DB00822 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21",
        "label": "NA"
    },
    {
        "text": "consider additive sedative effects and confusional states to emerge , if DB01239 is given with ddrug1 or HD00521 .",
        "label": "effect"
    },
    {
        "text": "there was no evidence of drug interactions in clinical studies in which DB00841 was administered concurrently with other drugs , including ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , DB00295 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , and ddrug13 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00224 { 800 mg t , i , d , } co-administered with ddrug2 # mg resulted in a 16-fold increase in ddrug3 auc , a 7-fold increase in ddrug4 cmax and a 2-fold increase in DB00862 half-life .",
        "label": "NA"
    },
    {
        "text": "and HD00208 e , g , , DB00661 } , cyp1a2 inducers { ddrug2 } and cyp1a2 inhibitors { ddrug3 and ddrug4 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 , DB14507 salts , and ddrug3 may either potentiate or weaken the blood-glucose-lowering effect of HD00071 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : since both DB00459 and HD00239 can cause increased intracranial pressure , their combined use is contraindicated .",
        "label": "effect"
    },
    {
        "text": "recovery from 50 % twitch to 75 % fade recovery took # + / - # min for ddrug0 alone and # + / - # min for DB13295 plus HD00198 .",
        "label": "effect"
    },
    {
        "text": "n = 17 } were not different and neither were DB00996 pharmacokinetic parameters affected by DB00313 .",
        "label": "NA"
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of HD00472 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 { 1 } , ddrug5 , ddrug6 , DB00705 , ddrug8 , ddrug9 { 1 } , ddrug10 , ddrug11 , grapefruit juice , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21 , ddrug22 , ddrug23 , ddrug24 { 1 } , ddrug25 , ddrug26 .",
        "label": "mechanism"
    },
    {
        "text": "DB11716 reduced the antitumour activity of oral HD00152 by dose modifying factors { dmf } of # # .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , DB00091 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { HD00712 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "discontinuation of DB00501 in well-controlled patients receiving HD00043 and ddrug2 may decrease the plasma levels and efficacy of the ddrug3 .",
        "label": "NA"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / ddrug1 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 pain medication { e , g , , DB00318 } , drugs used to aid sleep , drowsiness-causing ddrug13 { e , g , , DB14487 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "objectives : to examine the effects of acute DB14539 pretreatment on the subjective and behavioral effects of DB01576 .",
        "label": "NA"
    },
    {
        "text": "the in vitro interaction between DB00238 and the ddrug1 DB00682 is complex .",
        "label": "int"
    },
    {
        "text": "drug interactions : the central ddrug0 syndrome can occur when anticholinergic agents such as ddrug1 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain HD00424 such as ddrug3 , the ddrug4 and other ddrug5 , ddrug6 , certain ddrug7 such as the ddrug8 salts , and HD00388 .",
        "label": "NA"
    },
    {
        "text": "and ddrug0 when HD00314 is given with ddrug2 agents or HD00316 drugs , including ddrug4 combined with local ddrug5 , close supervision and careful adjustment of dosages are required .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of ddrug1 , ddrug2 , ddrug3 , DB01115 , ddrug5 , ddrug6 , certain ddrug7 , ddrug8 , ddrug9 and DB00916 , thereby delaying elimination and increasing blood levels of these drugs .",
        "label": "NA"
    },
    {
        "text": "ddrug0 can interact with ddrug1 or other HD00261 { may potentiate the cns depressant effects of either these medications or ddrug3 } , ddrug4 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with HD00388 } , and ddrug6 { concurrent use with ddrug7 may prolong and intensify the anticholinergic and cns depressant effects of ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "this appears to be the only clinically relevant interaction of this kind with DB00358 , although theoretically , coadministration of other drugs known to alter cardiac conduction { eg , HD00862 or ddrug2 , ddrug3 , ddrug4 or ddrug5 , ddrug6 and ddrug7 } might also contribute to a prolongation of the qtc interval .",
        "label": "effect"
    },
    {
        "text": "while additional research is needed , the initial clinical data in kidney recipients suggest that ddrug0 , in combination with ddrug1 or DB00864 , might have the potential to reduce the frequency of rejection episodes , permit reductions in DB00091 or ddrug4 dosage , and permit steroid withdrawal { kelly , 1999 } .",
        "label": "NA"
    },
    {
        "text": "DB00542 has been used concomitantly with HD00395 , ddrug2 , ddrug3 , ddrug4 , and ddrug5 , without evidence of clinically important adverse interactions .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { DB01076 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { DB00295 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "although ddrug0 has a lower affinity for DB01370 than for ddrug2 , DB01609 should not be taken with ddrug4 - containing ddrug5 .",
        "label": "NA"
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of ddrug0 such as DB00565 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , DB00803 , and ddrug10 } , ddrug11 salts , ddrug12 , local ddrug13 , ddrug14 , and ddrug15 .",
        "label": "effect"
    },
    {
        "text": "patients who begin taking ddrug0 or who increase their DB00586 dose or any other HD00615 while taking ddrug3 , ddrug4 , or ddrug5 may develop toxicity characteristics for these drugs .",
        "label": "NA"
    },
    {
        "text": "however , co-administration of ddrug0 with ddrug1 - and ddrug2 - containing HD00374 { 51 meq } or ddrug4 with DB00927 , had no significant effect on the rate or extent of ddrug6 absorption after administration of a 40-mg oral dose .",
        "label": "NA"
    },
    {
        "text": "because ddrug0 has not been shown to produce any additional effect beyond that obtained with DB00945 alone and because ddrug2 increases the rate of excretion of DB00573 , the concomitant use of ddrug4 and ddrug5 is not recommended .",
        "label": "NA"
    },
    {
        "text": "it is , however , possible that concomitant use of other known HD00299 such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 might increase the photosensitivity reaction of actinic_keratosis treated with the DB00855 for topical solution .",
        "label": "effect"
    },
    {
        "text": "ddrug0 altered coagulation parameters and/or bleeding have been reported in patients taking DB01101 concomitantly with ddrug2 such as ddrug3 and DB00946 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as DB00415 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , DB00776 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit DB00451 binding to serum proteins or alter the concentrations of serum binding proteins : ddrug1 and related ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , DB00812 , ddrug15 , ddrug16 , ddrug17 .",
        "label": "mechanism"
    },
    {
        "text": "when ddrug0 and DB00733 are used together , the signs of atropinization { flushing , mydriasis , tachycardia , dryness of the mouth and nose } may occur earlier than might be expected than when ddrug2 is used alone because ddrug3 may potentiate the effect of DB00572 .",
        "label": "NA"
    },
    {
        "text": "drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving ddrug0 metabolized similarly to ddrug1 or on the basis of in vitro studies with ddrug2 or other ddrug3 { caution is recommended during coadministration with ddrug4 } : available data from clinical studies of HD00100 other than DB00404 suggest a possible drug interaction with ddrug7 for the following : ddrug8 , ddrug9 , ddrug10 such as ddrug11 and ddrug12 , and grapefruit juice .",
        "label": "NA"
    },
    {
        "text": "an interaction study with ddrug0 showed no clinically significant effect of DB01217 on DB00682 pharmacokinetics or anticoagulant activity .",
        "label": "NA"
    },
    {
        "text": "if concomitant treatment with DB00998 and an HD00278 is clinically warranted , appropriate observation of the patient is advised .",
        "label": "advise"
    },
    {
        "text": "drugs that inhibit cytochrome p450iid6 , such as DB00908 , might increase the plasma concentrations of ddrug1 in patients that are on chronic DB01195 therapy ;",
        "label": "NA"
    },
    {
        "text": "interactions may also occur with the following : HD00515 / ddrug1 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , ddrug4 , ddrug5 , ddrug6 , DB00226 , ddrug8 , ddrug9 , ddrug10 , ddrug11 pain medication { e , g , , ddrug12 } , drugs used to aid sleep , drowsiness-causing ddrug13 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 , ddrug2 , ddrug3 , DB00254 , ddrug5 , ddrug6 , and ddrug7 have no influence in vitro on the protein binding of DB00586 in human serum .",
        "label": "NA"
    },
    {
        "text": "DB00701 significantly increased the area under the curve at steady state { auc { ss } } of DB00615 by # - fold and the auc { ss } of ddrug2 by # - fold .",
        "label": "mechanism"
    },
    {
        "text": "other cardiovascular agents : DB00584 and ddrug1 iv have been used concomitantly with ddrug2 , ddrug3 , DB14049 , ddrug5 , ddrug6 , ddrug7 and ddrug8 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "because of the potential for adverse reactions from the drugs in nursing infants , a decision must be made whether to discontinue nursing or discontinue DB00008 and DB00811 treatment .",
        "label": "NA"
    },
    {
        "text": "due to a theoretical risk of a pharmacodynamic interaction , use of DB00201 - containing or HD00274 { like ddrug2 or ddrug3 } and ddrug4 within # hours of each other should be avoided { see a href = frova_od , htm # ci contraindications } .",
        "label": "NA"
    },
    {
        "text": "DB01026 - combined administration of racemic DB00215 { 40 mg } and ddrug2 { 200 mg } decreased the cmax and auc of ddrug3 by 21 % and 10 % , respectively , and did not significantly affect the pharmacokinetics of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "repeated oral administration of ddrug0 in sheep : interactions of DB11390 with ddrug2 , DB11473 , and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "more than # parkinsons disease patients in clinical trials have used DB01037 in combination with ddrug1 and DB01235 / ddrug3 .",
        "label": "NA"
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma ddrug0 concentrations include : acute DB02325 intake , ddrug2 , chboramphenicol , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , DB00812 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21",
        "label": "NA"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of DB00732 include : DB00228 ;",
        "label": "effect"
    },
    {
        "text": "interactions with ddrug0 : ddrug1 { eg , ddrug2 , ddrug3 , DB00611 , ddrug5 and ddrug6 } should not be administered to a patient who has received or is receiving a course of therapy with a ddrug7 such as DB00854 .",
        "label": "advise"
    },
    {
        "text": "neuropathy has occurred more frequently in patients with a history of neuropathy or neurotoxic drug therapy , including DB00649 , and these patients may be at increased risk of neuropathy during DB00900 therapy { see adverse reactions } .",
        "label": "NA"
    },
    {
        "text": "HD00343 prolong and intensify the anticholinergic effects of HD00388 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { DB00316 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and DB00126 .",
        "label": "NA"
    },
    {
        "text": "DB00316 / DB00277 , ddrug2 / ddrug3 , ddrug4 / ddrug5 , ddrug6 / ddrug7 , ddrug8 / ddrug9 , ddrug10 / ddrug11 , and ddrug12 / ddrug13 .",
        "label": "NA"
    },
    {
        "text": "drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on HD00849 therapy : ddrug1 , ddrug2 , HD00220 , oral ddrug4 containing ddrug5 , ddrug6 - containing preparations and the numerous preparations containing ddrug7 .",
        "label": "NA"
    },
    {
        "text": "DB01373 supplements and HD00374 lotensin can attenuate potassium loss .",
        "label": "NA"
    },
    {
        "text": "products containing DB01373 and other multivalent cations { such as DB01370 , ddrug2 , ddrug3 } are likely to interfere with absorption of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "synergism between HD00659 { e , g , , ddrug1 } , DB01364 , and other ddrug3 has been reported .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : enhanced bone marrow suppression by DB00531 and other HD00273 has been reported among patients with neoplastic disease , except leukemia , in the presence of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "there is limited experience with concomitant HD00366 such as HD00266 , ddrug2 , ddrug3 , and ddrug4 { both ddrug5 - like and loop } .",
        "label": "NA"
    },
    {
        "text": "HD00388 may have additive effects with DB02325 and other ddrug2 , e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 .",
        "label": "effect"
    },
    {
        "text": "therefore , co-administration of DB01156 with drugs that are metabolized by cyp2d6 isoenzyme including certain ddrug1 { e , g , , ddrug2 , ddrug3 , DB01151 , ddrug5 , ddrug6 , ddrug7 } , ddrug8 { e , g , , ddrug9 , ddrug10 , ddrug11 } , ddrug12 { e , g , , ddrug13 } , and ddrug14 { e , g , , ddrug15 , ddrug16 } , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .",
        "label": "advise"
    },
    {
        "text": "DB00294 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , DB01174 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "int"
    },
    {
        "text": "in patients taking DB00695 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and various chemotherapy agents , no effect was shown on the clearance of HD00644 .",
        "label": "NA"
    },
    {
        "text": "in patients receiving another HD00739 in combination with ddrug1 { HD00725 } , there have been reports of serious , sometimes fatal , reactions including hyperthermia , rigidity , myoclonus , autonomic instability with possible rapid fluctuations of vital signs , and mental status changes that include extreme agitation progressing to delirium and coma .",
        "label": "effect"
    },
    {
        "text": "although additional drug interaction studies have not been conducted , the most common medications used concomitantly with DB00261 in clinical trials were ddrug1 , ddrug2 , ddrug3 , DB01592 , ddrug5 , ddrug6 , and ddrug7 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { DB00091 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , DB00812 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 : in normal volunteers { n = 9 } , pretreatment with ddrug2 or ddrug3 did not affect ddrug4 pharmacokinetics except that a small { 13 % } but statistically significant increase in the area under the serum concentration curve of DB00712 resulted with DB00501 .",
        "label": "mechanism"
    },
    {
        "text": "increases of 22 % with HD00888 and 47 % with DB00776 were observed .",
        "label": "NA"
    },
    {
        "text": "with simultaneous dosing of DB00862 # mg and DB01162 # mg , # of # subjects experienced a standing systolic blood pressure of less than # mm hg .",
        "label": "effect"
    },
    {
        "text": "DB14507 : increased serum ddrug1 levels and symptoms of ddrug2 toxicity have been reported in patients receiving HD00106 during therapy with ddrug4 .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 : coadministration of ddrug1 and an oral HD00349 increased auc values for DB00717 and ddrug4 by approximately 30 % and 20 % .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of DB00307 capsules and ddrug1 resulted in substantial increases in plasma concentrations of ddrug2 , probably at least partially related to cyp3a4 inhibition by DB01241 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { DB00321 , ddrug2 , ddrug3 } : metabolism may be inhibited by HD00710 , increasing plasma levels of ddrug5 ;",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 has been reported to decrease the clearance of DB00897 and DB00683 and thus may increase the pharmacologic effect of these ddrug3 .",
        "label": "NA"
    },
    {
        "text": "DB01247 should be administered with caution to patients receiving ddrug1 { DB00822 , wyeth-ayerst laboratories } .",
        "label": "advise"
    },
    {
        "text": "DB01200 may interact with ddrug1 , HD00340 , and certain other agents .",
        "label": "int"
    },
    {
        "text": "when ddrug0 is co-administered with inducers of drug clearance , such as DB00625 , ddrug2 , ddrug3 , ddrug4 , or ddrug5 , use of a daily dose of # mg of DB00520 should be considered",
        "label": "NA"
    },
    {
        "text": "DB00238 and DB01045 should not beadministered concomitantly becausedecreases in ddrug2 plasmaconcentrations may reduce the efficacy ofthe drug .",
        "label": "advise"
    },
    {
        "text": "injection : ddrug0 injection , like other injectable HD00100 , produces depression of the central nervous system when administered with DB00898 , ddrug3 , ddrug4 , ddrug5 , and other ddrug6 , when ddrug7 is used concomitantly with injectable ddrug8 , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : based on reports of profound hypotension and loss of consciousness when DB00714 was administered with ddrug2 , the concomitant use of ddrug3 with drugs of the ddrug4 { including , for example , ddrug5 , ddrug6 , ddrug7 , DB00377 , and ddrug9 } is contraindicated .",
        "label": "NA"
    },
    {
        "text": "DB00619 will increase plasmaconcentration of other cyp3a4 metabolized drugs { e , g , , triazolo - HD00100 , ddrug2 , certain ddrug3 , etc , } .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 - DB00125 may increase the absorption of DB01050 if taken concomitantly .",
        "label": "mechanism"
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit ddrug0 binding to serum proteins or alter the concentrations of serum binding proteins : ddrug1 and related ddrug2 , ddrug3 , ddrug4 , HD00220 and ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , DB00675 .",
        "label": "NA"
    },
    {
        "text": "however , in a well-controlled study of patients with lymphoma on combination therapy , DB00437 did not increase the marrow toxicity of patients treated with ddrug1 , ddrug2 , DB00290 , ddrug4 and/or ddrug5 .",
        "label": "NA"
    },
    {
        "text": "in separate single or multiple dose pharmacokinetic interaction studies with ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB00782 , ddrug7 , and ddrug8 , the bioavailability of DB14207 was not altered by coadministration of ddrug10 with any one of these drugs .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { cns } drugs including ddrug1 , ddrug2 , ddrug3 , ddrug4 , blood pressure medications { DB00206 , ddrug6 , ddrug7 } , motion sickness medications , ddrug8 , ddrug9 , ddrug10 , sleeping pills and HD00262",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and DB00759 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , DB00224 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "use of ddrug0 with ddrug1 { e , g , , ddrug2 , ddrug3 , or DB00594 } , DB14500 supplements , or potassium-containing salt substitutes may lead to significant increases in serum potassium .",
        "label": "NA"
    },
    {
        "text": "however , due to possible pharmacodynamic interactions , when co-administered with ddrug0 , a reduction in dosage of DB00633 on the concomitant ddrug2 , ddrug3 , ddrug4 or HD00023 may be required .",
        "label": "advise"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as DB00415 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , DB00295 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , including DB01059 , may enhance the effects of oral ddrug2 , including DB00682 or its derivatives or similar agents .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , DB00091 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , DB00295 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "discontinuing DB00375 could pose a hazard to health if a potentially toxic drug that is significantly bound to the HD00524 has been titrated to a maintenance level while the patient was taking ddrug2 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : available data suggest that there is no significant effect of DB00313 on the clearance of ddrug2 at steady state , therefore , the addition of ddrug3 is not expected to cause a clinically important effect on DB00949 { ddrug5 } plasma concentrations .",
        "label": "NA"
    },
    {
        "text": "in patients receiving a potent cyp3a4 inducer such as DB01045 or DB00252 , a dose increase to # mg daily should be considered in the absence of severe adverse drug reaction , and clinical response and adverse events should be carefully monitored { see clinical pharmacology-pharmacokinetics-drug-drug interactions and dosage and administration-dosage adjustment sections } .",
        "label": "NA"
    },
    {
        "text": "in a single-dose crossover study examining ddrug0 # mg and DB00338 # mg each administered alone and concomitantly with ddrug2 # gram , absorption of the ddrug3 was delayed and their bioavailability was reduced by 17 % and 16 % , respectively , when administered concomitantly with DB00364 .",
        "label": "NA"
    },
    {
        "text": "DB00683 used at doses of # mg/kg and # mg/kg decreased the antinociceptive effect of DB00295 , ddrug2 { only in the tail-flick test } and ddrug3 .",
        "label": "effect"
    },
    {
        "text": "DB01032 : as with other ddrug1 , renal excretion of DB00447 is inhibited by ddrug3 and resulted in an approximate 80 % increase in the auc for ddrug4 .",
        "label": "NA"
    },
    {
        "text": "h-2 antagonists : in studies with human volunteers , co-administration of ddrug0 or DB00863 with ddrug2 had no substantive effect on DB01050 serum concentrations .",
        "label": "NA"
    },
    {
        "text": "although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of DB00964 # % ophthalmic solution , the possibility of an additive or potentiating effect with ddrug1 { DB02325 , ddrug3 , ddrug4 , ddrug5 , ddrug6 } should be considered .",
        "label": "advise"
    },
    {
        "text": "ddrug0 , such as DB01032 and ddrug2 , can inhibit renal tubular secretion of DB00698 .",
        "label": "mechanism"
    },
    {
        "text": "although neither ddrug0 nor HD00147 affected the proliferation of prostatic epithelium in rpmi1640 containing HD00149 alone , they modify the mitogenic effect of ddrug3 and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "concurrent administration of drugs possessing nephrotoxic { e , g , , ddrug0 , DB00328 } , myelotoxic { e , g , , ddrug2 chemotherapy } , cardiotoxic { e , g , , ddrug3 } or hepatotoxic { e , g , , ddrug4 , ddrug5 } effects with DB00041 may increase toxicity in these organ systems .",
        "label": "effect"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of ddrug0 : HD00175 , ddrug2 , ddrug3 , ddrug4 { e , g , , ddrug5 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , HD00810 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "during administration of multiple oral doses of DB01195 to healthy subjects stabilized on a maintenance dose of DB00390 , a 13 % -19 % increase in plasma ddrug2 levels occurred at six hours postdose .",
        "label": "mechanism"
    },
    {
        "text": "oral HD00283 : ddrug1 , when given once daily for # days as a 100-mg capsule with an oral ddrug2 containing # mcg of ddrug3 and # mg of ddrug4 , decreased the auc of DB00977 by 43 % , and decreased the auc of ddrug6 by 8 % ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 { ddrug1 , ddrug2 , DB00540 } : metabolism may be inhibited by HD00710 , increasing plasma levels of ddrug5 ;",
        "label": "mechanism"
    },
    {
        "text": "the plasma concentration of DB00458 may increase when the drug is given concomitantly with hepatic enzyme inhibitors { e , g , , ddrug1 , ddrug2 } and decrease by concomitant administration of hepatic enzyme inducers { e , g , , ddrug3 , DB00252 } , and adjustment of the dosage of ddrug5 may therefore be necessary .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 did not affect the conversion of DB00678 to the active metabolite after intravenous administration of ddrug2 , and DB00199 had no clinically significant effect after oral administration .",
        "label": "NA"
    },
    {
        "text": "ddrug0 supplements and HD00293 benazepril can attenuate potassium loss caused by HD00029 .",
        "label": "effect"
    },
    {
        "text": "DB00836 and ddrug1 { # and # mg/kg , s , c , } inhibited the HD00169 { # mg/kg , p , o , } - induced diarrhea in cecectomized rats .",
        "label": "effect"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , DB00908 ddrug4 : DB00637 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "further , these results confirm that the diabetic chinese hamster 's alpha and beta cells respond normally to DB00277 , but are relatively insensitive to DB09341 .",
        "label": "NA"
    },
    {
        "text": "in patients taking ddrug0 , ddrug1 , ddrug2 , HD00106 , ddrug4 , ddrug5 , ddrug6 , and various chemotherapy agents , no effect was shown on the clearance of HD00644 .",
        "label": "NA"
    },
    {
        "text": "the clearance of HD00100 metabolized by glucuronidation { e , g , , ddrug1 , ddrug2 , ddrug3 } is unlikely to be affected by DB00176 .",
        "label": "NA"
    },
    {
        "text": "administration of repeat doses of ddrug0 had no effect on the repeat dose pharmacokinetics of ddrug1 , ddrug2 or an DB00977 / levonorgestrol oral HD00750 in healthy subjects .",
        "label": "NA"
    },
    {
        "text": "ddrug0 alone or in combination with DB01015 : concomitant use of DB00440 alone or in combination with ddrug3 is contraindicated .",
        "label": "NA"
    },
    {
        "text": "we conclude that HD00090 prevents DB00295 - induced increases in gastrointestinal transit time by means of selective peripheral opioid anitagonism without affecting central opioid analgesia .",
        "label": "effect"
    },
    {
        "text": "in vitro studies have shown that the metabolism of DB01248 may be modified by the concomitant administration of compounds that induce , inhibit , or are metabolized by cytochrome p450 3a4 , such as ddrug1 , ddrug2 , ddrug3 , DB00199 , and ddrug5 .",
        "label": "mechanism"
    },
    {
        "text": "blood levels of HD00644 increased 24 % when ddrug1 was coadministered with DB00501 { nonselective inhibitor of cytochrome p-450 } for # days , and decreased 28 % with coadministration of ddrug3 { potent inducer of cytochrome p-450 } for # days .",
        "label": "NA"
    },
    {
        "text": "additionally , DB00187 should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as ddrug1 , DB00668 , and ddrug3 because of the danger of blocking cardiac contractility when systemic vascular resistance is high .",
        "label": "advise"
    },
    {
        "text": "HD00303 : ddrug1 , ddrug2 { systemic } and DB00908",
        "label": "NA"
    },
    {
        "text": "DB01004 : administration of DB00900 # hours prior to or concurrent with oral ddrug2 was associated with a # { 114 } % increase in the steady-state auc of ddrug3 { n = 12 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { HD00548 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , DB00220 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "administration of DB00252 to patients receiving DB00988 has been reported to lead to hypotension and bradycardia .",
        "label": "effect"
    },
    {
        "text": "interactions attributed to the combined use of DB00181 injection and epidural DB00295 include hypotension and dyspnea .",
        "label": "effect"
    },
    {
        "text": "the co-administration of DB04899 with iv ddrug1 such as ddrug2 , ddrug3 , ddrug4 , or iv HD00106 has not been evaluated { these drugs were not co-administered with ddrug6 in clinical trials } .",
        "label": "NA"
    },
    {
        "text": "these drugs include the HD00217 and other HD00218 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , oral ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , and ddrug11 .",
        "label": "NA"
    },
    {
        "text": "concomitant use of ddrug0 supplements and DB00123 may increase DB01373 absorption",
        "label": "NA"
    },
    {
        "text": "administration of DB01045 concomitantly with oral DB01118 has been shown to result in decreases in serum concentrations of ddrug2 and ddrug3 .",
        "label": "NA"
    },
    {
        "text": "it was concluded that , although HD00198 did augment the neuromuscular blockade of DB13295 , the effect was minimal .",
        "label": "effect"
    },
    {
        "text": "conclusions : DB00334 demonstrated superior antipsychotic efficacy compared with DB00502 in the treatment of acute phase schizophrenia , and in the treatment of some patients with first-episode or treatment-resistant schizophrenia .",
        "label": "NA"
    },
    {
        "text": "it is recommended that DB00490 not be used concomitantly with HD00343 because the effects of concomitant administration of ddrug2 with most other ddrug3 have not been studied , the concomitant use of ddrug4 with other cns-active drugs should be approached with caution .",
        "label": "advise"
    },
    {
        "text": "the following are examples of drugs known to inhibit the metabolism of other related HD00100 , presumably through inhibition of cyp3a : DB01149 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , and some ddrug6 .",
        "label": "mechanism"
    },
    {
        "text": "drugs decreasing DB01109 effect : ddrug1 , ddrug2 , ddrug3 , or HD00388 may partially counteract the anticoagulant action of ddrug5 .",
        "label": "NA"
    },
    {
        "text": "DB14507 reversible increases in serum ddrug1 concentrations and toxicity have been reported during concomitant administration of ddrug2 with ddrug3 , and with some HD00466 .",
        "label": "NA"
    },
    {
        "text": "{ 1968 , 1970 } , the higher serum concentrations of HD00124 and ddrug1 reached after administration of DB01032 are due not only to slower renal elimination but also to an altered distribution in the body .",
        "label": "mechanism"
    },
    {
        "text": "administration of HD00077 { 100 mg kg { -1 } body weight } to rats in vivo resulted in HD00078 synthesis in the kidney , which was preceded by an elevation in fluoride levels and followed by citrate accumulation .",
        "label": "NA"
    },
    {
        "text": "conversely , decreases in plasma levels of the HD00043 have been reported upon discontinuation of DB00501 which may result in the loss of the therapeutic efficacy of the ddrug2 6 .",
        "label": "mechanism"
    },
    {
        "text": "drugs that reduce the number of blood platelets by causing bone marrow depression { such as HD00251 } or drugs which inhibit platelet function { eg , ddrug1 and other ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 } may increase the bleeding tendency produced by HD00326 without altering prothrombin time determinations .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : ddrug1 should be used with caution in patients receiving - ddrug2 blocking agents { e , g , , ddrug3 , a ddrug4 inhibitor } or HD00306 antagonists { e , g , , ddrug6 , a HD00302 substrate , and ddrug8 , a ddrug9 inhibitor } because of the possible potentiation of bradycardia , sinus arrest , and av block ;",
        "label": "NA"
    },
    {
        "text": "although concomitant use of DB00363 and ddrug1 is not recommended , it should be noted that discontinuation of concomitant DB00564 administration may result in an increase in ddrug3 plasma levels .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 : in one study , DB00712 was given to adult diabetics who were already receiving ddrug2 { n = 4 } , ddrug3 { n = 2 } ddrug4 with DB00914 { n = 3 } or ddrug6 with ddrug7 { n = 6 } .",
        "label": "NA"
    },
    {
        "text": "other drugs : based on the results of drug interaction studies , no dosage adjustment is recommended when ddrug0 { DB00625 } is given with the following : ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , DB00715 , and ddrug11 .",
        "label": "NA"
    },
    {
        "text": "since bacteriostatic drugs , such as the HD00592 of ddrug1 , may interfere with the bactericidal action of HD00124 , it is not advisable to administer these drugs concomitantly .",
        "label": "effect"
    },
    {
        "text": "the extent of plasma protein binding of ddrug0 in human plasma is not affected by the presence of therapeutic concentrations of ddrug1 { 15 mcg / ml } , nor is the binding of DB00252 affected by the presence of DB01117 .",
        "label": "NA"
    },
    {
        "text": "intraventricular injection of DB01183 at doses of # to # micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular HD00144 and ddrug2 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : in subjects receiving DB00682 , no significant change in clotting time was observed when DB00365 was coadministered .",
        "label": "NA"
    },
    {
        "text": "twelve strains of staphylococcus aureus { a frequent cause of infection in ddrug0 , but not in DB00652 and DB00792 , addicts } were completely inhibited by the drug combination .",
        "label": "effect"
    },
    {
        "text": "coadministration with compounds that are potent inducers of cyp3a4 { eg , ddrug0 , ddrug1 , DB01234 , ddrug3 } may result in decreased plasma levels of DB01232 .",
        "label": "mechanism"
    },
    {
        "text": "an alternative non-cyp3a4 substrate HD00905 may be considered in patients taking cyp3a4 inducers such as ddrug1 , ddrug2 , DB00564 , and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "in separate studies of patients receiving maintenance doses of DB00682 , ddrug1 , or ddrug2 , DB01029 administration for # days had no effect on the pharmacodynamics of ddrug4 { prothrombin time } or pharmacokinetics of ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , DB00220 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and DB00126 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 is also expected to reduce plasma concentrations of other HD00434 that have significant metabolism by cyp3a4 , such as DB00227 and ddrug3 .",
        "label": "NA"
    },
    {
        "text": "DB01285 may accentuate the electrolyte loss associated with HD00295 therapy .",
        "label": "effect"
    },
    {
        "text": "because prostaglandins play an important role in hemostasis , and ddrug0 affect platelet function as well , concurrent therapy with all ddrug1 , including DB00586 , and ddrug3 requires close monitoring of patients to be certain that no change in their HD00025 dosage is required .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a study in healthy volunteers , a six-day course of DB01045 at # mg/day followed by a single # mg dose of DB00270 resulted in a reduction in ddrug3 levels to below detectable limits .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : the concomitant use of DB01244 and HD00228 has been well tolerated in patients with stable angina .",
        "label": "NA"
    },
    {
        "text": "coadministration of DB00647 decreased the maximum plasma concentration of DB00404 by 6 % , decreased clearance by 38 % , and increased half-life by 58 % .",
        "label": "mechanism"
    },
    {
        "text": "HD00100 : combination ddrug1 may decrease the clearance of some ddrug2 { DB00404 , ddrug4 , ddrug5 } and increase the clearance of others { ddrug6 , ddrug7 , ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a HD00533 , including ddrug1 , with multivalent cation-containing products such as ddrug2 or ddrug3 ddrug4 , ddrug5 , ddrug6 chewable/buffered tablets or pediatric powder , or products containing ddrug7 , ddrug8 , or ddrug9 may substantially decrease the absorption of DB00537 , resulting in serum and urine levels considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "if possible , HD00591 should be withdrawn at least # hours before initiating HD00579 therapy .",
        "label": "advise"
    },
    {
        "text": "studies in healthy volunteers have shown that DB00284 has no effect on either the pharmacokinetics or pharmacodynamics of ddrug1 , ddrug2 , ddrug3 , or DB00863 .",
        "label": "NA"
    },
    {
        "text": "drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving ddrug0 metabolized similarly to ddrug1 or on the basis of in vitro studies with ddrug2 or other ddrug3 { caution is recommended during coadministration with ddrug4 } : available data from clinical studies of HD00100 other than ddrug6 suggest a possible drug interaction with ddrug7 for the following : ddrug8 , ddrug9 , ddrug10 such as ddrug11 and DB01211 , and grapefruit juice .",
        "label": "NA"
    },
    {
        "text": "there was no evidence of drug interactions in clinical studies in which DB00841 was administered concurrently with other drugs , including ddrug1 , DB00695 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , and ddrug13 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , DB00661 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and ddrug7 raise the serum DB00390 concentration due to a reduction in clearance and/or in volume of distribution of the drug , with the implication that ddrug9 intoxication may result .",
        "label": "mechanism"
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as ddrug0 include certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 } , DB14513 salts , ddrug11 , local ddrug12 , DB01035 , and ddrug14 .",
        "label": "NA"
    },
    {
        "text": "in common with other HD00544 , DB01060 may reduce the efficacy of oral ddrug2",
        "label": "NA"
    },
    {
        "text": "DB01200 may interact with HD00339 , ddrug2 , and certain other agents .",
        "label": "int"
    },
    {
        "text": "DB00472 and DB01171 increased blood ddrug2 at different times after the glucose overload .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { ddrug1 , ddrug2 , ddrug3 } : metabolism may be inhibited by HD00710 , increasing plasma levels of HD00711 ;",
        "label": "NA"
    },
    {
        "text": "- ddrug0 and ddrug1 ddrug2 : HD00511 and ddrug4 ddrug5 have the potential of binding ddrug6 and reducing HD00295 absorption from the gastrointestinal tract",
        "label": "NA"
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as DB01135 include certain HD00002 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 } , ddrug10 salts , ddrug11 , local ddrug12 , ddrug13 , and ddrug14 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , DB00776 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { HD00531 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "the interaction of DB01609 with DB01005 has not been formally studied .",
        "label": "NA"
    },
    {
        "text": "although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 { eg , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , DB00864 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , and ddrug15 } may have elevated plasma concentrations when coadministered with DB01232 ;",
        "label": "mechanism"
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a ddrug0 , including DB00537 , with multivalent cation-containing products such as ddrug2 or DB01370 ddrug4 , ddrug5 , ddrug6 chewable/buffered tablets or pediatric powder , or products containing ddrug7 , ddrug8 , or ddrug9 may substantially decrease the absorption of ddrug10 , resulting in serum and urine levels considerably lower than desired .",
        "label": "mechanism"
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma DB00252 concentrations include : acute ddrug1 intake , DB01118 , chboramphenicol , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 - and/or ddrug1 - containing ddrug2 , products containing DB01373 { ddrug4 } , ddrug5 containing ddrug6 or other metal cations , or ddrug7 { DB00900 } chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after ddrug9 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , HD00002 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as HD00269 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "upon administration of # mg of DB00862 with # mg tid ddrug1 , the cmax and auc of DB00224 were reduced by 40 % and 30 % , respectively .",
        "label": "NA"
    },
    {
        "text": "in general , these are drugs that have one or more pharmacologic activities similar to ddrug0 , including HD00407 such as ddrug2 and DB01035 , ddrug4 and ddrug5 .",
        "label": "NA"
    },
    {
        "text": "HD00082 showed the most potent inhibition { 66 % inhibition at # microm } , which was far more potent than that of crude DB09372 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { HD00203 } : concomitant use of ddrug2 { or other HD00598 } and ddrug4 increases the risk of gastrointestinal side effects .",
        "label": "NA"
    },
    {
        "text": "cytochrome p-450 inducers , such as ddrug0 , DB00564 and ddrug2 , induce DB01068 metabolism , causing an approximately 30 % decrease in plasma ddrug4 levels .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : ddrug1 s plasma half-life may be prolonged by ddrug2 , since DB00437 and DB00672 may compete for excretion in the renal tubule .",
        "label": "mechanism"
    },
    {
        "text": "resistance to the neuromuscular blocking action of HD00541 has been demonstrated in patients chronically administered ddrug1 or DB00564 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : DB00862 { 10 mg and # mg } did not potentiate the increase in bleeding time caused by DB00945 { two # mg tablets } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 has additive effects with DB02325 and other ddrug2 { ddrug3 , HD00024 , ddrug5 , etc } .",
        "label": "NA"
    },
    {
        "text": "in patients , the concomitant administration of DB00390 with DB00204 was associated with a higher occurrence of torsade de pointes .",
        "label": "effect"
    },
    {
        "text": "ddrug0 , ddrug1 , DB00715 , DB01104 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : based on reports of profound hypotension and loss of consciousness when ddrug1 was administered with ddrug2 , the concomitant use of DB00714 with drugs of the ddrug4 { including , for example , DB00904 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 } is contraindicated .",
        "label": "advise"
    },
    {
        "text": "ddrug0 / ddrug1 : ddrug2 inhibits the enzymatic oxidation of DB01033 and DB00993 to ddrug5 .",
        "label": "NA"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : ddrug1 ; ddrug2 ; ddrug3 ; certain ddrug4 , especially the ddrug5 and ddrug6 ; DB14507 ; ddrug8 salts ; ddrug9 ; and DB00908 .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 DB00564 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 DB14507 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "ddrug0 : because DB01076 does not affect the pharmacokinetics of DB01435 , interactions with other ddrug3 metabolized via the same cytochrome isozymes are not expected .",
        "label": "NA"
    },
    {
        "text": "inhibitors of this isoenzyme { e , g , , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB00343 , grapefruit juice , ddrug7 , ddrug8 , ddrug9 , ddrug10 } should be cautiously coadministered with ddrug11 as they can potentially increase DB00204 levels .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : there was no significant difference between DB01238 coadministered with DB00898 and placebo coadministered with ddrug3 on performance of gross motor skills or stimulus response in healthy subjects .",
        "label": "NA"
    },
    {
        "text": "this drug may interact with ddrug0 or other HD00261 { may potentiate the cns depressant effects of either these medications or ddrug2 } , ddrug3 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug4 } , and ddrug5 { concurrent use with ddrug6 may prolong and intensify the anticholinergic and cns depressant effects of HD00388 } .",
        "label": "NA"
    },
    {
        "text": "guardians of children who have been prescribed DB00983 should be alerted to the general concern regarding asthmas therapy compliance , especially neglect of anti-inflammatory therapy and overuse of HD00744 .",
        "label": "NA"
    },
    {
        "text": "the clinical significance of this reduction is not known , hence ddrug0 is not recommended to be ingested simultaneously with DB14513 / ddrug2 - containing HD00374 .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 : coadministration of DB01076 and an oral ddrug2 increased auc values for ddrug3 and DB00977 by approximately 30 % and 20 % .",
        "label": "mechanism"
    },
    {
        "text": "coadministration of DB01045 with DB00343 lowered the ddrug2 plasma concentrations to undetectable levels .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : combination HD00432 may decrease the clearance of some ddrug2 { ddrug3 , ddrug4 , ddrug5 } and increase the clearance of others { ddrug6 , ddrug7 , DB00231 } .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 has been reported to decrease the clearance of ddrug1 and DB00683 and thus may increase the pharmacologic effect of these HD00100 .",
        "label": "NA"
    },
    {
        "text": "the blockade of the spinal endorphinergic system by intrathecal DB01183 on the production of tail-flick inhibition induced by intraventricular ddrug1 and DB00295 was then studied .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { DB00316 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , DB01167 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "the concomitant use of transdermal DB00813 with DB00503 or other potent 3a4 inhibitors such as ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and nefazadone may result in an increase in ddrug7 plasma concentrations .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { DB01076 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , DB01232 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of DB01211 with DB01100 is contraindicated .",
        "label": "advise"
    },
    {
        "text": "HD00630 and ddrug1 may interact with ddrug2 in studies with male rats , HD00631 was found to inhibit the hepatic microsomal enzyme system at a dose of # mg/kg/day .",
        "label": "NA"
    },
    {
        "text": "the emerging roles of HD00109 in HD00056 therapy .",
        "label": "NA"
    },
    {
        "text": "studies with ddrug0 in combination with HD00218 indicate that the dose of the HD00471 can be reduced when it is given with a ddrug3 .",
        "label": "NA"
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the HD00555 of drugs may be potentiated by ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , the ddrug6 , ddrug7 and ddrug8 , ddrug9 and the HD00043 , and by other ddrug11 .",
        "label": "effect"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / ddrug1 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , ddrug4 , ddrug5 , ddrug6 , DB00226 , ddrug8 , ddrug9 , ddrug10 , ddrug11 pain medication { e , g , , ddrug12 } , drugs used to aid sleep , drowsiness-causing ddrug13 { e , g , , DB14487 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "DB00284 has been shown to change the bioavailabillty DB00390 when they are co-administered , which may require ddrug2 dose adjustment .",
        "label": "mechanism"
    },
    {
        "text": "a study of interaction between ddrug0 and ddrug1 showed that concomitant administration of DB00187 and DB00682 does not alter ddrug4 plasma levels .",
        "label": "NA"
    },
    {
        "text": "and HD00208 e , g , , ddrug1 } , cyp1a2 inducers { ddrug2 } and cyp1a2 inhibitors { ddrug3 and DB01211 } .",
        "label": "NA"
    },
    {
        "text": "should it be decided to discontinue therapy in patients receiving HD00254 and ddrug1 concurrently , the ddrug2 should be discontinued slowly over several days before the gradual withdrawal of DB00575 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - in subjects who had received # days of # mg/day racemic ddrug1 , combined administration of DB00215 and ddrug3 { single dose of # mg } did not significantly affect the pharmacokinetics of either ddrug4 or DB00390 .",
        "label": "NA"
    },
    {
        "text": "therefore , co-administration of DB00476 with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index , including certain ddrug1 { ddrug2 -lsb- ddrug3 -rsb- , such as ddrug4 , ddrug5 , and ddrug6 } , HD00219 and ddrug8 { e , g , , ddrug9 , ddrug10 } , should be approached with caution .",
        "label": "advise"
    },
    {
        "text": "drug-drug interactions given the primary cns effects of ddrug0 , caution should be used when ddrug1 is taken in combination with other HD00365 and DB02325 .",
        "label": "NA"
    },
    {
        "text": "there have been reports of interactions of DB00199 with ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , DB00342 , and ddrug13 .",
        "label": "int"
    },
    {
        "text": "dose reduction of ddrug0 to half the standard dose and a dose increase of DB00224 to # mg { three 333-mg capsules } every # hours are recommended when DB00615 and ddrug3 are coadministered .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : because of the relationship of DB00982 to ddrug2 , patients should be advised against taking ddrug3 containing DB00162 to avoid additive toxic effects",
        "label": "NA"
    },
    {
        "text": "drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving ddrug0 metabolized similarly to ddrug1 or on the basis of in vitro studies with ddrug2 or other ddrug3 { caution is recommended during coadministration with ddrug4 } : available data from clinical studies of ddrug5 other than ddrug6 suggest a possible drug interaction with ddrug7 for the following : DB00343 , ddrug9 , ddrug10 such as ddrug11 and DB01211 , and grapefruit juice .",
        "label": "NA"
    },
    {
        "text": "intermediate doses of HD00156 or DB03575 produced transient increases in fi responding in monkeys and sustained increases in fi responding in pigeons ;",
        "label": "NA"
    },
    {
        "text": "DB01577 , like HD00146 , produced depletions of striatal dopamine but these actions were potentiated by ddrug2 pretreatment .",
        "label": "NA"
    },
    {
        "text": "consequently , it is recommended that DB00176 not be used in combination with either ddrug1 , DB00637 , or ddrug3 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 # mg qd or DB00999 / ddrug2 50/100 mg qd was co-administered with DB00204 { 500 mcg bid } for # days { following # days of ddrug4 use at half dose } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with DB00316 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , ddrug12 } , HD00297 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "we conclude that the prophylactic and antidotal properties of DB01213 seen in animals treated with ddrug1 derive from its capacity to inhibit the nad + - dependent oxidation responsible for converting ddrug2 to HD00077 in the committed step of the toxic pathway .",
        "label": "NA"
    },
    {
        "text": "drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on HD00849 therapy : HD00657 , ddrug2 , ddrug3 , oral ddrug4 containing ddrug5 , ddrug6 - containing preparations and the numerous preparations containing ddrug7 .",
        "label": "NA"
    },
    {
        "text": "using in situ hybridization , we observed that ddrug0 caused a rapid and transient dose-dependent increase in arc mrna level in the striatum and cortex that was abolished by pretreatment with the specific drd1 antagonist HD00016 but not by an ddrug2 DB00363 .",
        "label": "NA"
    },
    {
        "text": "drug-drug interactions between DB01202 and other ddrug1 { ddrug2 } ddrug3 ddrug4 { 3000 mg daily } had no effect on the pharmacokinetic disposition of DB00252 in patients with refractory epilepsy .",
        "label": "NA"
    },
    {
        "text": "DB01109 injection should not be mixed with ddrug1 , DB00450 , ddrug3 , or ddrug4 , since it has been reported that these drugs are incompatible with ddrug5 and a precipitate may form .",
        "label": "NA"
    },
    {
        "text": "DB00451 administration to a digitalized , hypothyroid patient may increase the dose requirement of DB00390 .",
        "label": "advise"
    },
    {
        "text": "interactions of DB14574 and DB01592 in absorption and retention .",
        "label": "mechanism"
    },
    {
        "text": "the concomitant use of ddrug0 with HD00118 and HD00411 s may have additive effects on prolonging atrioventricular conduction time .",
        "label": "NA"
    },
    {
        "text": "the behavioral effects of the stereoisomers of HD00154 { ddrug1 } were compared with those of ddrug2 { DB03575 } in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio { fi fr } schedule of food presentation .",
        "label": "NA"
    },
    {
        "text": "DB01195 has been administered to patients receiving ddrug1 or HD00244 without adverse effects .",
        "label": "NA"
    },
    {
        "text": "when initiating a multi-day course of DB00365 in a patient maintained on DB00277 , the ddrug2 maintenance dose should be halved for the period of concurrent use of ddrug3 and monitoring of serum ddrug4 concentrations should be initiated as a guide to further dosage adjustments .",
        "label": "NA"
    },
    {
        "text": "DB01045 and DB00682 : a drug interaction .",
        "label": "int"
    },
    {
        "text": "on the basis of the metabolism of DB00307 by cytochrome p450 3a4 , ddrug1 , ddrug2 , ddrug3 , DB01241 , grapefruit juice , and other inhibitors of cyp3a4 would be expected to lead to an increase in plasma ddrug5 concentrations .",
        "label": "NA"
    },
    {
        "text": "studies with HD00106 in combination with ddrug1 indicate that the dose of the ddrug2 can be reduced when it is given with a HD00295 .",
        "label": "NA"
    },
    {
        "text": "patients currently receiving DB00343 therapy should be carefully monitored for a change in pharmacological effect when initiating and discontinuing therapy with DB00501 .",
        "label": "advise"
    },
    {
        "text": "- DB01432 and DB00375 ddrug2 : ddrug3 and ddrug4 ddrug5 have the potential of binding ddrug6 and reducing ddrug7 absorption from the gastrointestinal tract",
        "label": "NA"
    },
    {
        "text": "mice from the 20th generation of three lines divergently selected for response to DB00312 - induced sedation times -lsb- long-sedation time { lst } , short sedation time { sst } , and randomly bred control { rbc } -rsb- were used to study DB00907 - induced behavioral sensitization .",
        "label": "NA"
    },
    {
        "text": "standard therapy includes HD00002 , such as HD00284 and ddrug2 ;",
        "label": "NA"
    },
    {
        "text": "DB00996 is not appreciably metabolized nor does it interfere with the metabolism of commonly coadministered HD00703 .",
        "label": "NA"
    },
    {
        "text": "no depressant effect on blood levels in humans was noted when ddrug0 was administered with any of the following drugs : DB00945 , ddrug2 , ddrug3 , ddrug4 , ddrug5 { ddrug6 } , ddrug7 , DB00252 or ddrug9 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 , ddrug2 , and ddrug3 the in vitro binding of DB00682 to plasma proteins is only slightly reduced by ddrug5 { # % control vs # % } when DB00465 plasma concentrations reach # to10 m g/ml .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : clinical studies , as well as post-marketing observations , have shown that ddrug1 can reduce the natriuretic effect of DB00695 and HD00217 in some patients .",
        "label": "NA"
    },
    {
        "text": "however , a crossover study in healthy subjects receiving either DB00501 # mg q , i , d , or # mg h , s , concomitantly with a # mg b , i , d , dosage of ddrug1 { ddrug2 , key pharmaceuticals , inc , } demonstrated less alteration in steady-state DB00277 peak serum levels with the # mg h , s , regimen , particularly in subjects aged # years and older .",
        "label": "NA"
    },
    {
        "text": "HD00532 , including ddrug1 , may enhance the effects of the oral ddrug2 DB00682 or its derivatives .",
        "label": "effect"
    },
    {
        "text": "when used in therapeutic doses , DB00207 had a modest effect on the pharmacokinetics of ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , DB00203 , ddrug11 { intravenous and oral } , ddrug12 , ddrug13 / ddrug14 or ddrug15 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , DB01086 and ddrug7 } , DB02362 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "HD00248 , ddrug1 , ddrug2 { consider DB00404 dose reduction } .",
        "label": "advise"
    },
    {
        "text": "these results suggest that both ddrug0 and ddrug1 , and possibly other HD00115 and ddrug3 , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of ddrug4 and HD00148 .",
        "label": "effect"
    },
    {
        "text": "HD00491 : co-administration of a single dose of intravenously administered DB00927 { 20 mg } reduced the oral absorption of a single # mg dose of ddrug2 administered following a meal , as evidenced by a 27 % decrease in mean cmax and a 22 % decrease in mean auc .",
        "label": "NA"
    },
    {
        "text": "background : the effects of combined administration of DB11724 and DB00661 { ddrug2 } , a ddrug3 , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by ddrug4 { ddrug5 } and the labeling index of intestinal_cancer were investigated in male wistar rats .",
        "label": "NA"
    },
    {
        "text": "however , due to possible pharmacodynamic interactions , when co-administered with ddrug0 , a reduction in dosage of DB00633 on the concomitant ddrug2 , ddrug3 , HD00604 or ddrug5 may be required .",
        "label": "advise"
    },
    {
        "text": "the gastrointestinal absorption of DB00501 and ddrug1 is accelerated when they are coadministered with DB00604 .",
        "label": "mechanism"
    },
    {
        "text": "the concomitant use of transdermal ddrug0 with ddrug1 or other potent 3a4 inhibitors such as ddrug2 , ddrug3 , DB13179 , ddrug5 , ddrug6 , and nefazadone may result in an increase in DB00813 plasma concentrations .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : since ddrug1 is a ddrug2 , it is possible that ddrug3 , such as the ddrug4 { ddrug5 , HD00340 , ddrug7 } or DB01233 , may diminish the effectiveness of ddrug9 .",
        "label": "NA"
    },
    {
        "text": "DB01576 with ddrug1 or ddrug2 and possibly other HD00609 cause striking and sustained increases in the concentration of ddrug4 in the brain ;",
        "label": "mechanism"
    },
    {
        "text": "the results raise the possibility that the ethanolysis reaction may occur in the stomach of people who consume DB02325 and HD00201 on a regular basis .",
        "label": "mechanism"
    },
    {
        "text": "DB00316 / ddrug1 , ddrug2 / ddrug3 , ddrug4 / ddrug5 , ddrug6 / ddrug7 , DB00908 / ddrug9 , ddrug10 / ddrug11 , and ddrug12 / ddrug13 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 , ddrug2 , HD00297 , or ddrug4 may interfere with the bactericidal effect of HD00124 .",
        "label": "effect"
    },
    {
        "text": "HD00374 containing ddrug1 and ddrug2 reduce the oral absorption of DB00467 by 75 % .",
        "label": "NA"
    },
    {
        "text": "HD00295 : ddrug1 , given concomitantly with DB01009 , produces a reduction in urinary potassium and chloride excretion compared to ddrug3 alone .",
        "label": "NA"
    },
    {
        "text": "drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on ddrug0 therapy : ddrug1 , HD00175 , ddrug3 , oral ddrug4 containing HD00220 , ddrug6 - containing preparations and the numerous preparations containing ddrug7 .",
        "label": "NA"
    },
    {
        "text": "because there are no data on the compatibility of DB01306 and crystalline HD00664 preparations , ddrug2 should not be mixed with these preparations .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : administration of ddrug1 with DB00220 resulted in the appearance of unchanged DB00342 in plasma ;",
        "label": "NA"
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of HD00539 such as ddrug1 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , DB00803 , and ddrug10 } , ddrug11 salts , ddrug12 , local ddrug13 , ddrug14 , and ddrug15 .",
        "label": "effect"
    },
    {
        "text": "DB00681 or ddrug1 { HD00732 and related drugs , ddrug3 and ddrug4 } enhanced hypokalemia .",
        "label": "NA"
    },
    {
        "text": "lack of an effect of DB00207 on the disposition of DB00495 and ddrug2 in hiv-infected patients .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , DB00812 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , DB00277 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { cns } drugs including ddrug1 , HD00216 , ddrug3 , ddrug4 , blood pressure medications { ddrug5 , DB00968 , ddrug7 } , motion sickness medications , ddrug8 , ddrug9 , ddrug10 , sleeping pills and ddrug11",
        "label": "NA"
    },
    {
        "text": "therefore , co-administration of ddrug0 with other drugs that are metabolized by this isoenzyme , including other ddrug1 , ddrug2 , DB00564 , and ddrug4 { eg , ddrug5 , ddrug6 , and ddrug7 } , or that inhibit this enzyme { eg , DB00908 } , should be approached with caution .",
        "label": "NA"
    },
    {
        "text": "effects of ddrug0 on low-dose ddrug1 a group of # nonsmoking , healthy white female volunteers established on an oral ddrug2 regimen containing # mg ddrug3 and # mg ddrug4 for at least # months received # mg/day of DB00949 from midcycle { day 15 } to midcycle { day 14 } of two consecutive oral HD00349 cycles .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , DB00295 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { DB01045 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "DB01032 or ddrug1 : concomitant administration of ddrug2 or DB00501 decreases the elimination of ddrug4 , most likely by inhibition of renal tubular secretion of ddrug5 .",
        "label": "NA"
    },
    {
        "text": "may interact with addictive medications , especially HD00458 with habituating potential { prolonged concurrent use may increase the risk of habituation } , ddrug1 or cns depression producing medications { concurrent use may increase the cns depressant effects of either these medications or DB01031 } .",
        "label": "NA"
    },
    {
        "text": "DB00199 has been reported to decrease the clearance of ddrug1 and DB00683 and thus may increase the pharmacologic effect of these ddrug3 .",
        "label": "mechanism"
    },
    {
        "text": "international normalized ratio { inr } elevations and/or bleeding events have been reported in some patients taking DB00682 while on DB00317 therapy .",
        "label": "effect"
    },
    {
        "text": "DB01241 other ddrug1 DB00627 { ddrug3 } { = 1 g/day }",
        "label": "NA"
    },
    {
        "text": "HD00326 : ddrug1 like other HD00233 , has been shown to affect bleeding parameters in patients receiving ddrug3 , and serious clinical bleeding has been reported .",
        "label": "NA"
    },
    {
        "text": "two studies were conducted in hiv-infected subjects to assess the potential for DB00207 to interact with ddrug1 and DB00900 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the concomitant use of ddrug1 { ddrug2 transdermal system } with other HD00389 , including but not limited to other ddrug4 , ddrug5 , ddrug6 , ddrug7 { e , g , , ddrug8 } , general ddrug9 , ddrug10 , HD00320 , and ddrug12 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .",
        "label": "NA"
    },
    {
        "text": "because their vasospastic effects may be additive , coadministration of DB00952 and other HD00277 within # hours of each other is not recommended .",
        "label": "advise"
    },
    {
        "text": "the HD00001 are a rapidly growing class of HD00002 with a broad spectrum of activity against gram-negative and some gram-positive aerobic bacteria .",
        "label": "NA"
    },
    {
        "text": "DB00294 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , DB00091 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "int"
    },
    {
        "text": "in addition , neuromuscular blocking action is enhanced by general HD00264 , local ddrug1 like ddrug2 , DB00721 , ddrug4 , ddrug5 , ddrug6 , and ddrug7 .",
        "label": "NA"
    },
    {
        "text": "such individuals are referred to as poor metabolizers of drugs such as DB04840 , DB00514 , and the ddrug2 .",
        "label": "NA"
    },
    {
        "text": "DB00269 may interact with ddrug1 , DB00945 , ddrug3 , ddrug4 , ddrug5 supplements , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , and ddrug13 .",
        "label": "int"
    },
    {
        "text": "a similar association , though less marked , has been suggested with ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , and possibly with DB00415 and HD00239 72 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , HD00351 ddrug2 may enhance the activity of ddrug3 or HD00571 ;",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with other cyp3a4 inhibitors { e , g , , ddrug1 # mg bid , ddrug2 # mg qd , ddrug3 # mg tid , DB00196 # mg qd } resulted in increases in cmax of DB00700 ranging from # - to # - fold and auc from # - to # - fold .",
        "label": "NA"
    },
    {
        "text": "in a study in normal volunteers , it was found that chronic concurrent administration of # g of DB00945 per day decreases DB00328 blood levels approximately 20 % .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 - and DB01370 - containing ddrug2 , administered concomitantly with ddrug3 , significantly decreased the bioavailability { 48 % } of DB00978 .",
        "label": "NA"
    },
    {
        "text": "co-administration of DB09026 did not significantly affect the pharmacokinetics of ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , DB01076 , ddrug9 or ddrug10 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of ddrug1 , ddrug2 , ddrug3 , DB01115 , ddrug5 , ddrug6 , certain ddrug7 , ddrug8 , DB00277 and ddrug10 , thereby delaying elimination and increasing blood levels of these drugs .",
        "label": "NA"
    },
    {
        "text": "DB01118 taken concomitantly with ddrug1 for less than seven days increases plasma concentrations of ddrug2 and n_acetyl DB01035 by 55 % and 33 % , respectively .",
        "label": "NA"
    },
    {
        "text": "HD00679 : drugs such as ddrug1 , ddrug2 , ddrug3 , DB01050 , ddrug5 , ddrug6 , ddrug7 and others that interfere with platelet-aggregation reactions { the main hemostatic defense of heparinized patients } may induce bleeding and should be used with caution in patients receiving ddrug8 .",
        "label": "NA"
    },
    {
        "text": "DB00295 : combination HD00432 may increase the clearance of ddrug2 .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of ddrug0 : ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , DB00668 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 { e , g , , in oral HD00283 } .",
        "label": "NA"
    },
    {
        "text": "HD00026 may decrease the effectiveness of oral ddrug1 , certain HD00002 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and ddrug7 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , DB00316 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , HD00029 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "drugs that inhibit cyp3a4 { DB01026 } cyp3a4 is a major metabolic pathway for elimination of DB00402 .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 : pharmacokinetic drug-drug interactions between DB00278 and DB00682 { # mg single oral dose } have not been demonstrated .",
        "label": "NA"
    },
    {
        "text": "HD00356 enhance the renal toxicity of ddrug1 in animals , # ddrug2 interferes with the action of ddrug3 preparations by chelating the DB01593 , 7",
        "label": "NA"
    },
    {
        "text": "ddrug0 including DB00752 , ddrug2 , and ddrug3 hc1 : concomitant use of ddrug4 and non-selective HD00343 may cause hypertension .",
        "label": "NA"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { ddrug1 s } , ddrug2 , ddrug3 { ddrug4 may decrease the effects of these medicines } , ddrug5 { using these medicines with ddrug6 may result in increased cns depressant effects } , ddrug7 , DB00313 { using these medicines with ddrug9 may change the amount of either medicine that you need to take } , and oral ddrug10 containing ddrug11 { HD00026 may decrease the effectiveness of these oral ddrug13 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "a # to 45 % increase in auc and cmax of DB00401 was observed with concomitant administration of HD00881 twice daily .",
        "label": "mechanism"
    },
    {
        "text": "immediate and extended release tablets the hypoglycemic action of HD00222 may be potentiated by certain drugs including ddrug1 , some ddrug2 and other drugs that are highly protein bound , ddrug3 , ddrug4 , ddrug5 , DB01032 , ddrug7 , ddrug8 , and ddrug9 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with ddrug1 , ddrug2 s , ddrug3 { allergy , cold , and sinus medicines } , diabetic drugs , DB14507 , ddrug5 , ddrug6 like ddrug7 or DB01050 , and high blood pressure medications .",
        "label": "NA"
    },
    {
        "text": "bleeding from a number of sites may be a complication of DB00682 treatment and gi bleeding a complication of DB01009 treatment .",
        "label": "NA"
    },
    {
        "text": "because DB00176 reduces the clearance of both ddrug1 and its active metabolite , DB14028 , there is a strong likelihood of substantial accumulation of both species during chronic co-administration .",
        "label": "mechanism"
    },
    {
        "text": "although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic ddrug0 , including HD00269 , ddrug2 , and ddrug3 , the effect of DB00523 gel on the steady-state concentrations of these drugs is not known .",
        "label": "NA"
    },
    {
        "text": "drug-drug interactions DB01001 - DB00289 should be administered with caution to patients being treated with systemically-administered { oral or intravenous } ddrug2 { or other ddrug3 } because the action of ddrug4 on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure .",
        "label": "NA"
    },
    {
        "text": "drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving ddrug0 metabolized similarly to ddrug1 or on the basis of in vitro studies with ddrug2 or other ddrug3 { caution is recommended during coadministration with ddrug4 } : available data from clinical studies of ddrug5 other than ddrug6 suggest a possible drug interaction with ddrug7 for the following : ddrug8 , ddrug9 , ddrug10 such as DB00199 and DB01211 , and grapefruit juice .",
        "label": "NA"
    },
    {
        "text": "therefore , concomitant use of DB00465 and DB01032 is contraindicated .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : the effect of ddrug1 on blood pressure response to DB00571 and DB00335 was evaluated in men with mild uncomplicated hypertension { n = 10 } .",
        "label": "NA"
    },
    {
        "text": "administration of DB00700 with other cyp3a4 inhibitors { e , g , , ddrug1 # mg bid , ddrug2 # mg qd , DB01232 # mg tid , ddrug4 # mg qd } resulted in increases in cmax of ddrug5 ranging from # - to # - fold and auc from # - to # - fold .",
        "label": "mechanism"
    },
    {
        "text": "in addition , DB00569 neither influenced the pharmacodynamics of ddrug1 , DB00945 , ddrug3 , and ddrug4 , nor the pharmacokinetics of ddrug5 at steady state .",
        "label": "NA"
    },
    {
        "text": "HD00399 may reduce the antihypertensive effects of ddrug1 , ddrug2 , ddrug3 and DB00657 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : in vitro data indicate that DB00224 and ddrug2 markedly inhibit the metabolism of ddrug3 which can result in an increase in plasma DB00604 levels and prolongation of the qt interval on the ecg .",
        "label": "NA"
    },
    {
        "text": "an alternative non-cyp3a4 substrate HD00905 may be considered in patients taking cyp3a4 inducers such as ddrug1 , ddrug2 , ddrug3 , and DB01174 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as DB00415 and ddrug5 , ddrug6 { ddrug7 , DB01174 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "DB02325 - although ddrug1 did not potentiate the cognitive and motor effects of ddrug2 in a clinical trial , as with other ddrug3 , the use of ddrug4 by patients taking DB01175 is not recommended .",
        "label": "NA"
    },
    {
        "text": "clinical implications of DB00682 interactions with five HD00024 .",
        "label": "int"
    },
    {
        "text": "ddrug0 { DB00421 , ddrug2 , ddrug3 , and others } or DB14500 supplements can increase the risk of hyperkalemia .",
        "label": "NA"
    },
    {
        "text": "caution should also be applied for other HD00391 , and for DB01223 and ddrug2 and ddrug3 , which may also precipitate arrhythmias .",
        "label": "NA"
    },
    {
        "text": "DB01061 should not be administered concomitantly with ddrug1 , ddrug2 , ddrug3 , DB00955 , or ddrug5 .",
        "label": "advise"
    },
    {
        "text": "certain drugs , including ddrug0 { ddrug1 } , HD00328 , ddrug3 , and ddrug4 may potentiate the hypoglycemic action of DB00731 and other oral ddrug6 .",
        "label": "effect"
    },
    {
        "text": "DB01394 DB00233 and heavy ddrug2 intake for longer than # weeks may produce malabsorption of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 - pectin , ddrug2 , DB00994 , ddrug4 , certain anticancer drugs , and ddrug5 may interfere with intestinal DB00390 absorption , resulting in unexpectedly low serum concentrations .",
        "label": "mechanism"
    },
    {
        "text": "DB00380 does not influence the pharmacokinetics of DB00997 .",
        "label": "NA"
    },
    {
        "text": "DB00612 should be used with care when ddrug1 or inhibitors of av conduction , such as certain HD00085 { particularly of the ddrug3 -lsb- ddrug4 -rsb- and ddrug5 -lsb- ddrug6 -rsb- classes } , or ddrug7 , such as ddrug8 , are used concurrently .",
        "label": "advise"
    },
    {
        "text": "DB00277 decreased the binding of DB00316 by a net change of # % { percentage increase in fdf , # % } at # micromol/l ;",
        "label": "mechanism"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } DB00501 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 DB14507 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "ddrug0 or oral ddrug1 : ddrug2 may enhance the blood-sugar-reducing effect of HD00071 and oral HD00484 .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 : DB00673 , when given once daily for # days as a 100-mg capsule with an oral ddrug2 containing # mcg of ddrug3 and # mg of DB00717 , decreased the auc of ddrug5 by 43 % , and decreased the auc of ddrug6 by 8 % ;",
        "label": "mechanism"
    },
    {
        "text": "when ddrug0 at an increased dose { 1000 mg every # hours } was given with DB00625 { 600 mg once daily } , the ddrug2 auc and cmin were decreased on average by 33 - 46 % and 39 - 57 % , respectively , compared to when DB00224 { 800 mg every # hours } was given alone .",
        "label": "NA"
    },
    {
        "text": "potential drug interactions between ddrug0 and other ddrug1 { ddrug2 , ddrug3 , DB00555 , ddrug5 , ddrug6 , ddrug7 and ddrug8 } were also assessed by evaluating the serum concentrations of ddrug9 and these HD00714 during placebo-controlled clinical studies .",
        "label": "NA"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / ddrug1 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , DB00248 , ddrug10 , ddrug11 pain medication { e , g , , DB00318 } , drugs used to aid sleep , drowsiness-causing ddrug13 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "it is , however , possible that concomitant use of other known HD00299 such as ddrug1 , ddrug2 , HD00222 , ddrug4 , ddrug5 and ddrug6 might increase the photosensitivity reaction of actinic_keratosis treated with the ddrug7 for topical solution .",
        "label": "NA"
    },
    {
        "text": "therapeutic drug monitoring { tdm } of DB00798 therapy , and bone scintigraphy employing HD00173 as the ddrug2 was carried out in # patients .",
        "label": "NA"
    },
    {
        "text": "HD00233 { ddrug1 } - a drug interaction study of ddrug2 with an HD00615 has not been conducted .",
        "label": "NA"
    },
    {
        "text": "DB01026 : co-administration of # mg twice-daily ddrug1 with ddrug2 resulted in an approximate 80 % increase in plasma levels of DB09026 .",
        "label": "NA"
    },
    {
        "text": "drug interactions : the central ddrug0 syndrome can occur when anticholinergic agents such as ddrug1 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain ddrug2 such as ddrug3 , the ddrug4 and other HD00031 , ddrug6 , certain ddrug7 such as the DB00908 salts , and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 can interact with ddrug1 or other ddrug2 { may potentiate the cns depressant effects of either these medications or HD00388 } , ddrug4 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug5 } , and HD00445 { concurrent use with ddrug7 may prolong and intensify the anticholinergic and cns depressant effects of ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , HD00002 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , DB00231 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and DB00281 } , DB02362 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "co-administration of ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , DB00178 , ddrug8 , ddrug9 and ddrug10 did not result in clinically significant increases in DB09026 exposure .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , DB00788 and other ddrug2 have been reported to reduce the tubular secretion of ddrug3 in an animal model , possibly increasing the toxicity of DB00563 .",
        "label": "NA"
    },
    {
        "text": "oral HD00326 : in some normal volunteers , the concomitant administration of ddrug1 and ddrug2 , DB01418 , or ddrug4 resulted in prolongation of prothrombin time .",
        "label": "NA"
    },
    {
        "text": "injection : ddrug0 injection , like other injectable HD00100 , produces depression of the central nervous system when administered with ddrug2 , ddrug3 , ddrug4 , HD00343 , and other ddrug6 , when ddrug7 is used concomitantly with injectable ddrug8 , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .",
        "label": "effect"
    },
    {
        "text": "in patients given very high doses { 3900 mg } of DB00945 daily , increases in serum ddrug1 levels were seen when DB00585 , # mg b , i , d , , was administered concurrently .",
        "label": "mechanism"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : HD00403 s { ddrug1 } other ddrug2 ddrug3 HD00388 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "deaths from severe enterocolitis , diarrhea , and dehydration have been reported in elderly patients receiving weekly DB00650 and DB00544 .",
        "label": "effect"
    },
    {
        "text": "although DB01233 may increase the bioavailability of DB01235 by increasing gastric emptying , ddrug2 may also adversely affect disease control by its dopamine receptor antagonistic properties .",
        "label": "mechanism"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect : ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , ddrug5 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , HD00810 { e , g , , in oral HD00283 } .",
        "label": "NA"
    },
    {
        "text": "in clinical trials , ddrug0 was used with ddrug1 , ddrug2 , ddrug3 , oral ddrug4 , and supplemental DB09140 , in a pharmacokinetic substudy in patients with congestive heart failure receiving ddrug6 or ddrug7 in whom therapy with ddrug8 was initiated , apparent oral clearance values for ddrug9 { n = 23 } and DB00390 { n = 30 } were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .",
        "label": "NA"
    },
    {
        "text": "in eight hiv-infected patients , the steady-state auc of ddrug0 was decreased an average of 26 % { 95 % ci = 14 % , 37 % } when DB00537 was administered # hours prior to a marketed chewable/dispersible tablet formulation of DB00900 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : elevated DB00564 levels have been reported in postmarketing experience when DB00671 is administered concomitantly .",
        "label": "mechanism"
    },
    {
        "text": "like ddrug0 , DB01189 does not predispose to premature ventricular arrhythmias in the presence of exogenously infused DB00668 in swine .",
        "label": "NA"
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a ddrug0 , including DB00537 , with multivalent cation-containing products such as ddrug2 or ddrug3 ddrug4 , ddrug5 , DB00900 chewable/buffered tablets or pediatric powder , or products containing ddrug7 , ddrug8 , or ddrug9 may substantially decrease the absorption of ddrug10 , resulting in serum and urine levels considerably lower than desired .",
        "label": "mechanism"
    },
    {
        "text": "h-2 antagonists : in studies with human volunteers , co-administration of DB00501 or DB00863 with ddrug2 had no substantive effect on ddrug3 serum concentrations .",
        "label": "NA"
    },
    {
        "text": "effects of ddrug0 on low-dose ddrug1 a group of # nonsmoking , healthy white female volunteers established on an oral ddrug2 regimen containing # mg ddrug3 and # mg DB06730 for at least # months received # mg/day of ddrug5 from midcycle { day 15 } to midcycle { day 14 } of two consecutive oral HD00349 cycles .",
        "label": "NA"
    },
    {
        "text": "it is recommended to avoid concurrent administration of DB00330 with DB06723 containing ddrug2 for at least # hours following ddrug3 administration .",
        "label": "advise"
    },
    {
        "text": "because of the low dietary DB14574 concentration as compared to the DB01592 contents of the diets , no effect of ddrug2 on ddrug3 absorption and excretion occurred .",
        "label": "NA"
    },
    {
        "text": "therefore , co-administration of ddrug0 with other drugs that are metabolized by this isozyme , including ddrug1 , ddrug2 , DB00564 , and ddrug4 { e , g , , ddrug5 , ddrug6 and ddrug7 } , or that inhibit this enzyme { e , g , , DB00908 } , should be approached with caution .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , HD00002 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { DB01045 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : HD00855 may potentiate the toxic effects of HD00118 .",
        "label": "effect"
    },
    {
        "text": "DB00813 anesthesia : severe hypotension has been reported during ddrug1 anesthesia with concomitant use of a ddrug2 and a HD00038 .",
        "label": "NA"
    },
    {
        "text": "both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when DB00802 is administered in combination with other ddrug1 such as HD00026 , ddrug3 , ddrug4 , or inhalation general ddrug5 .",
        "label": "effect"
    },
    {
        "text": "the intensity , uniformity and time course of HD00025 interference by ddrug1 , ddrug2 , ddrug3 , ddrug4 and DB04833 were systematically investigated in # patients receiving ddrug6 therapy .",
        "label": "NA"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : ddrug1 ; ddrug2 ; ddrug3 ; certain ddrug4 , especially the ddrug5 and HD00384 ; DB14507 ; ddrug8 salts ; ddrug9 ; and ddrug10 .",
        "label": "NA"
    },
    {
        "text": "DB00995 should not be used together with ddrug1 { ddrug2 , DB00859 } , another arthritis medication .",
        "label": "advise"
    },
    {
        "text": "interactions for ddrug0 { ddrug1 } : ddrug2 therapy : DB00627 may potentiate the effects of HD00877 and vasoactive drugs resulting in postural hypotension .",
        "label": "effect"
    },
    {
        "text": "in clinical studies performed with ddrug0 , the concomitant use of oral ddrug1 { ddrug2 } , HD00679 { ddrug4 } , ddrug5 { ddrug6 } , and ddrug7 did not significantly affect the pharmacokinetics/pharmacodynamics of DB00569 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 such as ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , DB01168 { e , g , , ddrug6 } , ddrug7 { e , g , , ddrug8 } , and ddrug9 { e , g , , ddrug10 } : using these medicines with DB00150 may increase the chance of side effects .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : enteric coated DB00945 should not be given concurrently with HD00374 , since an increase in the ph of the stomach may effect the enteric coating of the tablets .",
        "label": "advise"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , DB01167 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { DB01045 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "however , the systemic administration of some HD00532 has been shown to elevate plasma concentrations of ddrug1 , interfere with the metabolism of DB00201 , and enhance the effects of the oral ddrug3 ddrug4 and its derivatives , and has been associated with transient elevations in serum creatinine in patients receiving systemic ddrug5 concomitantly .",
        "label": "mechanism"
    },
    {
        "text": "studies in rats have shown that DB00994 administration attenuates certain types of ddrug1 dependent hypertension , including DB01285 hypertension .",
        "label": "effect"
    },
    {
        "text": "other HD00532 have demonstrated moderate to marked interference with the metabolism of ddrug1 , resulting in a reduced clearance , a prolongation of plasma half-life , and an increase in symptoms that accompany high levels of DB00201 .",
        "label": "NA"
    },
    {
        "text": "- a ddrug0 { HD00615 } such as ddrug2 { ddrug3 , ddrug4 , ddrug5 , others } , ddrug6 { ddrug7 , ddrug8 , ddrug9 } , ddrug10 { ddrug11 , ddrug12 } , ddrug13 { ddrug14 } , ddrug15 { ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , and ddrug21 { ddrug22 , ddrug23 , DB00788 } ;",
        "label": "NA"
    },
    {
        "text": "therefore , cyp3a4 substrates known to have a narrow therapeutic index such as ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB01100 , ddrug7 , ddrug8 , ddrug9 , or ddrug10 { ddrug11 , ddrug12 } should be administered with caution in patients receiving DB01254 .",
        "label": "advise"
    },
    {
        "text": "these drugs include the HD00217 and other HD00218 , ddrug2 , phe-nothiazines , ddrug3 , ddrug4 , oral ddrug5 , ddrug6 , ddrug7 , sympathomimet-ics , ddrug8 , and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "no dose adjustment is necessary when ddrug0 is added to triple-immunosuppression regimens including DB00091 , ddrug2 , and either ddrug3 or DB00688 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and DB00759 , ddrug6 { ddrug7 , ddrug8 , DB00564 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 including DB00752 , DB00780 , and ddrug3 hc1 : concomitant use of ddrug4 and non-selective ddrug5 may cause hypertension .",
        "label": "NA"
    },
    {
        "text": "the following are examples of drugs known to inhibit the metabolism of other related ddrug0 , presumably through inhibition of cyp3a : ddrug1 , ddrug2 , DB00501 , ddrug4 , ddrug5 , and some HD00093 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB01032 increases both free and bound ddrug2 by reducing the plasma clearance of DB01009 to about one-third , as well as decreasing its protein binding .",
        "label": "NA"
    },
    {
        "text": "tablets simultaneous administration of DB00364 and DB00695 tablets may reduce the natriuretic and antihypertensive effects of ddrug2 .",
        "label": "effect"
    },
    {
        "text": "HD00532 have also been shown to interfere with the metabolism of DB00201 .",
        "label": "mechanism"
    },
    {
        "text": "the following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral antidiabetes products , HD00106 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 { e , g , , DB00104 } , ddrug9 .",
        "label": "NA"
    },
    {
        "text": "therefore , co-administration of DB01156 with drugs that are metabolized by cyp2d6 isoenzyme including certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } , ddrug8 { e , g , , ddrug9 , ddrug10 , ddrug11 } , ddrug12 { e , g , , ddrug13 } , and HD00310 { e , g , , ddrug15 , ddrug16 } , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .",
        "label": "advise"
    },
    {
        "text": "HD00445 such as ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , ddrug5 { e , g , , ddrug6 } , DB01037 { e , g , , ddrug8 } , and ddrug9 { e , g , , ddrug10 } : using these medicines with ddrug11 may increase the chance of side effects .",
        "label": "NA"
    },
    {
        "text": "DB00390 , ddrug1 , ddrug2 : DB00586 , like other ddrug4 , may affect renal prostaglandins and increase the toxicity of certain drugs .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : DB00316 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , DB00231 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { ddrug1 , ddrug2 , ddrug3 , ddrug4 , DB00273 } : increase the metabolism of ddrug6 and/or some HD00526 , leading to possible decrease in contraceptive effectiveness .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , DB01076 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , DB01045 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "HD00679 : drugs such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , DB01611 and others that interfere with platelet-aggregation reactions { the main hemostatic defense of heparinized patients } may induce bleeding and should be used with caution in patients receiving ddrug8 .",
        "label": "NA"
    },
    {
        "text": "the effect of DB01202 on DB01032 was not studied .",
        "label": "NA"
    },
    {
        "text": "since blood level of DB00136 / ergocalcitriol will be reduced , higher doses of DB00136 may be necessary if these drugs are administered simultaneously .",
        "label": "NA"
    },
    {
        "text": "oral HD00283 : ddrug1 , when given once daily for # days as a 100-mg capsule with an oral ddrug2 containing # mcg of DB00977 and # mg of ddrug4 , decreased the auc of ddrug5 by 43 % , and decreased the auc of ddrug6 by 8 % ;",
        "label": "NA"
    },
    {
        "text": "infusion requirements of ddrug0 in patients administered ddrug1 prior to infusions of DB00565 were comparable to or slightly greater than when DB00202 was not administered .",
        "label": "NA"
    },
    {
        "text": "effects of ddrug0 on ddrug1 the coadministration of DB00199 { 1000 mg/day } for # days did not alter the pharmacokinetic parameters of cmax , cmin , auc , ci/kg or tmax at DB00949 daily doses of # or # mg/day in # otherwise healthy subjects with epilepsy .",
        "label": "NA"
    },
    {
        "text": "DB00682 - administration of # mg/day racemic DB00215 for # days did not affect the pharmacokinetics of ddrug2 , a cyp3a4 substrate .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { DB00316 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , DB00295 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "while all the ddrug0 { HD00114 } , e , g , , ddrug2 , ddrug3 , DB00715 , and ddrug5 , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .",
        "label": "NA"
    },
    {
        "text": "in another drug interaction study , co-administration of orally inhaled ddrug0 and oral DB01026 , a potent inhibitor of cytochrome p450 3a4 , increased the exposure { auc } of ddrug2 by approximately # - fold at steady state , while levels of DB01410 remained unchanged .",
        "label": "NA"
    },
    {
        "text": "the hypoglycemic action of ddrug0 may be potentiated by certain drugs including HD00518 and other drugs that are highly protein bound , ddrug2 , ddrug3 , ddrug4 , ddrug5 , HD00519 , ddrug7 , and ddrug8 .",
        "label": "NA"
    },
    {
        "text": "in vitro displacement studies with highly protein-bound drugs such as ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , DB00945 , ddrug9 , and ddrug10 showed no influence on the extent of DB00731 protein binding .",
        "label": "NA"
    },
    {
        "text": "DB01032 : may decrease renal tubular secretion of ddrug1 resulting in increased blood levels and/or DB00415 toxicity .",
        "label": "NA"
    },
    {
        "text": "concurrent use with DB01032 or other drugs significantly eliminated by active renal tubular secretion may result in increased plasma concentrations of DB00299 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may partially counteract the anticoagulation effects of DB01109 or DB00682 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { DB00316 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { HD00548 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB01032 is known to interact with the metabolism or renal tubular excretion of many drugs { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , HD00100 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 agents , ddrug14 , and ddrug15 } .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 , ddrug1 , and DB01159 decrease the ed50 of DB01135 by 30 % to 45 % .",
        "label": "mechanism"
    },
    {
        "text": "HD00829 including ddrug1 , DB00780 , and ddrug3 hc1 : concomitant use of ddrug4 and non-selective ddrug5 may cause hypertension .",
        "label": "NA"
    },
    {
        "text": "HD00248 , ddrug1 , DB00501 { consider ddrug3 dose reduction } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local HD00264 { e , g , , ddrug6 and ddrug7 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , ddrug12 } , HD00297 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - related adverse effects have occurred in patients consuming DB00201 while on therapy with DB00467 .",
        "label": "effect"
    },
    {
        "text": "and ddrug0 when HD00314 is given with HD00315 agents or ddrug3 drugs , including ddrug4 combined with local ddrug5 , close supervision and careful adjustment of dosages are required .",
        "label": "NA"
    },
    {
        "text": "- ddrug0 : in some patients , the administration of a HD00292 can reduce the diuretic , natriuretic , and antihypertensive effects of ddrug2 , ddrug3 and HD00029 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : when a single 125-mg dose of ddrug1 was administered on day5 of a 10-day regimen of # mg/day of DB01026 , a strong cyp3a4 inhibitor , the auc of DB00673 increased approximately 5-fold and the mean terminal half-life of ddrug4 increased approximately 3-fold .",
        "label": "NA"
    },
    {
        "text": "hypersensitivity reactions : patients with a history of severe hypersensitivity reactions to products containing cremophor el { eg , DB00091 for injection concentrate and DB00444 for injection concentrate } should not be treated with ddrug2 .",
        "label": "NA"
    },
    {
        "text": "intrathecal injection of DB01183 at doses of # to # micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of ddrug1 , and a high dose of ddrug2 { 40 micrograms } completely blocked the tail-flick inhibition induced by intraventricular HD00144 { 16 micrograms } .",
        "label": "NA"
    },
    {
        "text": "administration of DB00561 to patients who are receiving HD00316 or ddrug2 may result in an additive pressor effect .",
        "label": "effect"
    },
    {
        "text": "the concomitant use of transdermal DB00813 with ddrug1 or other potent 3a4 inhibitors such as DB01026 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and nefazadone may result in an increase in ddrug7 plasma concentrations .",
        "label": "mechanism"
    },
    {
        "text": "however , a crossover study in healthy subjects receiving either DB00501 # mg q , i , d , or # mg h , s , concomitantly with a # mg b , i , d , dosage of DB00277 { ddrug2 , key pharmaceuticals , inc , } demonstrated less alteration in steady-state ddrug3 peak serum levels with the # mg h , s , regimen , particularly in subjects aged # years and older .",
        "label": "mechanism"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 DB00564 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { DB01026 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "a dose increase of ddrug0 / DB00503 to 533/133 mg { 4 capsules or # ml } twice daily taken with food is recommended when used in combination with DB00625 .",
        "label": "advise"
    },
    {
        "text": "DB00637 ddrug1 , DB00897 ddrug3 ergot derivatives ddrug4",
        "label": "NA"
    },
    {
        "text": "ddrug0 { cns } drugs including ddrug1 , HD00216 , ddrug3 , ddrug4 , blood pressure medications { ddrug5 , ddrug6 , HD00254 } , motion sickness medications , ddrug8 , ddrug9 , ddrug10 , sleeping pills and ddrug11",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with DB00316 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , DB01035 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "the hypoglycemic action of HD00226 may be potentiated by certain drugs including ddrug1 and other drugs that are highly protein bound , HD00328 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , and ddrug8 .",
        "label": "effect"
    },
    {
        "text": "while additional research is needed , the initial clinical data in kidney recipients suggest that DB00877 , in combination with ddrug1 or ddrug2 , might have the potential to reduce the frequency of rejection episodes , permit reductions in ddrug3 or DB00864 dosage , and permit steroid withdrawal { kelly , 1999 } .",
        "label": "NA"
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit DB00451 binding to serum proteins or alter the concentrations of serum binding proteins : ddrug1 and related ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 , ddrug7 , ddrug8 , ddrug9 , DB00939 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 .",
        "label": "mechanism"
    },
    {
        "text": "aim and background : the pharmacokinetic interaction between DB00877 , a HD00083 metabolized by cyp3a4 , and the ddrug2 ddrug3 was studied in # healthy subjects .",
        "label": "NA"
    },
    {
        "text": "therapeutic concentrations of DB00390 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 andtolbutamide did not alter DB00465 protein binding .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - administration of # mg/day DB01175 for # days in healthy volunteers resulted in a 50 % increase in cmax and 82 % increase in auc of the ddrug2 DB00264 { given in a single dose of # mg } .",
        "label": "mechanism"
    },
    {
        "text": "these pharmacokinetic effects seen during DB00343 coadministration can result in increased clinical effects { e , g , , prolonged sodation } of both DB00683 and ddrug2 .",
        "label": "effect"
    },
    {
        "text": "plasma ddrug0 concentration should be monitored when DB00951 and ddrug2 are co administered , and appropriate dosage adjustments of DB00313 should be made .",
        "label": "NA"
    },
    {
        "text": "ddrug0 DB00683 , ddrug2 DB00604 ergot derivatives ddrug4",
        "label": "NA"
    },
    {
        "text": "HD00223 { e , g , , ddrug1 } and ddrug2 containing carbohydrate-splitting enzymes { e , g , , ddrug3 , DB00085 } may reduce the effect of ddrug5 and should not be taken concomitantly .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , and the ddrug1 ddrug2 { ddrug3 } and DB00889 { ddrug5 } have all been used with DB01008 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the co-administration of DB00176 tablets and DB00829 is generally not advisable .",
        "label": "advise"
    },
    {
        "text": "ddrug0 , HD00351 HD00401 may enhance the activity of ddrug3 or ddrug4 ;",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 DB00264 ddrug4 ddrug5 { ddrug6 } ddrug7 { DB00501 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "ddrug0 / nutrition / herb interactions : food : cns effects of ddrug1 may be enhanced if HD00710 are used concurrently with DB00201 .",
        "label": "effect"
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit ddrug0 binding to serum proteins or alter the concentrations of serum binding proteins : ddrug1 and related ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , DB00850 , ddrug14 , ddrug15 , ddrug16 , DB00675 .",
        "label": "NA"
    },
    {
        "text": "DB00052 - concomitant use of DB00130 and ddrug2 may enhance nutrient absorption in those with severe short bowel syndrome .",
        "label": "NA"
    },
    {
        "text": "this decrease in absorption results in a 36 % and 50 % lower auc for DB00685 and DB00537 , respectively , which could cause clinical failures .",
        "label": "NA"
    },
    {
        "text": "in rheumatoid arthritis , concomitant medications besides DB00563 were ddrug1 , ddrug2 , ddrug3 and/or HD00543 .",
        "label": "NA"
    },
    {
        "text": "with oral ddrug0 treatment , HD00235 such as DB00205 have been noted to possibly increase the likelihood of hematologic reactions",
        "label": "NA"
    },
    {
        "text": "ddrug0 , including oral , injectable , transdermal , and implantable ddrug1 : an interaction study demonstrated that co-administration of DB00559 and the oral ddrug3 ddrug4 produced average decreases of DB00717 and ddrug6 levels of 14 % and 31 % , respectively .",
        "label": "NA"
    },
    {
        "text": "concurrent administration of ddrug0 and ddrug1 significantly reduces the level of exposure to DB00224 , but it is unclear how soon after DB00900 administration ddrug4 may be given safely .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of DB01039 { equivalent to # mg ddrug1 } with DB01076 { 20 mg } once daily for # days resulted in approximately 17 % decrease { range from 67 % decrease to 44 % increase } in ddrug3 auc values in # healthy males .",
        "label": "mechanism"
    },
    {
        "text": "the effect of ddrug0 on the DB00682 requirement of our patient appeared to be maximal # to # days after the initiation of ddrug2 and extended a similar length of time after DB01045 withdrawal .",
        "label": "NA"
    },
    {
        "text": "in addition , DB00569 neither influenced the pharmacodynamics of ddrug1 , ddrug2 , DB00554 , and ddrug4 , nor the pharmacokinetics of ddrug5 at steady state .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as HD00269 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { HD00531 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "when intravenous ddrug0 and ddrug1 were concomitantly administered in normal subjects , no effect on DB00295 blood levels was seen , but DB00187 steady-state blood levels were increased by 46 % in the presence of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "since DB00593 { ddrug1 } may interact with concurrently administered HD00703 , periodic serum level determinations of these drugs may be necessary { eg , ddrug3 may elevate ddrug4 serum levels and ddrug5 has been reported to both increase and decrease ddrug6 levels } .",
        "label": "int"
    },
    {
        "text": "DB00318 in combination with other ddrug1 , general ddrug2 , ddrug3 , ddrug4 , HD00460 , or other ddrug6 { including ddrug7 } has additive depressant effects .",
        "label": "effect"
    },
    {
        "text": "however , appropriate monitoring of blood glucose should be performed when initiating DB00702 in diabetic patients and HD00071 dosage should be adjusted if needed .",
        "label": "advise"
    },
    {
        "text": "in this study we investigated the effect of DB14152 on high threshold voltage-dependent ca { 2 + } channel subtypes using their ddrug1 DB00393 { l-type } , ddrug3 { n-type } , or ddrug4 { p-type } in bovine chromaffin cells .",
        "label": "NA"
    },
    {
        "text": "a number of drugs , including DB00903 , have been shown to displace DB00682 from plasma protein ;",
        "label": "mechanism"
    },
    {
        "text": "HD00374 containing ddrug1 , DB01370 , or ddrug3 ;",
        "label": "NA"
    },
    {
        "text": "DB00580 caused a statistically significant increase in plasma exposures of DB08496 and ddrug2 { 12 % and 15 % , respectively } , and in the pharmacodynamic effects { prothrombin time , measured as inr } of ddrug3 .",
        "label": "mechanism"
    },
    {
        "text": "DB00609 has been found to temporarily raise serum concentrations of DB00951 .",
        "label": "mechanism"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of ddrug0 : ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , ddrug5 , DB01001 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , HD00810 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "drugs that induce hepatic enzymes such as DB01174 , ddrug1 and ddrug2 may increase the clearance of HD00175 and may require increases in ddrug4 dose to achieve the desired response .",
        "label": "mechanism"
    },
    {
        "text": "plasma concentrations of HD00639 are reduced when given concurrently with DB00951 .",
        "label": "mechanism"
    },
    {
        "text": "several HD00043 have been reported to block the pharmacologic effects of DB01170 , ddrug2 , or similar agents , and such an effect may be anticipated with ddrug3 because of its structural similarity to other ddrug4 .",
        "label": "effect"
    },
    {
        "text": "the results of a study of coadministration of ddrug0 { 50 mg/kg } with an ddrug1 containing DB06724 to # patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ddrug3 of approximately 20 % and 13 % , respectively , suggesting that the oral absorption of DB00330 may be reduced by these ddrug5 .",
        "label": "NA"
    },
    {
        "text": "the hypoglycemic action of HD00222 may be potentiated by certain drugs including ddrug1 and other drugs that are highly protein bound , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , and HD00520 .",
        "label": "effect"
    },
    {
        "text": "conclusions : single-dose DB00343 coadministration leads to higher ddrug1 exposure , presumably by inhibition of the first-pass metabolism of DB00877 .",
        "label": "NA"
    },
    {
        "text": "a pharmacokinetic study evaluating the administration of a single dose of ddrug0 # mg with DB01026 # mg bid , a potent inhibitor of the cyp3a4 pathway , showed a # - fold increase in cmax of ddrug2 and a # - fold increase in auc of DB00700 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , DB00091 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , DB00277 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the effect of DB00712 on blood pressure response to ddrug2 and DB00335 was evaluated in men with mild uncomplicated hypertension { n = 10 } .",
        "label": "NA"
    },
    {
        "text": "human pharmacokinetic data indicate that oral DB01026 markedly inhibits the metabolism of ddrug1 , resulting in a mean eight-fold increase in auc of DB00604 .",
        "label": "NA"
    },
    {
        "text": "the concomitant intake of ddrug0 and DB00659 does not affect the pharmacokinetics of either DB02325 or ddrug3 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { e , g , , DB01026 , ddrug2 , ddrug3 , ddrug4 , etc , } : in vitro and animal studies with the combination of ddrug5 and ddrug6 suggest that ddrug7 may induce fungal resistance to DB00681 .",
        "label": "NA"
    },
    {
        "text": "DB00598 blunts the reflex tachycardia produced by DB00727 without preventing its hypotensive effect .",
        "label": "effect"
    },
    {
        "text": "DB00152 containing DB01593 ;",
        "label": "NA"
    },
    {
        "text": "studies have shown that DB00448 does not have clinically significant interactions with other drugs metabolized by the cytochrome cyp2b6 system , such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , DB01211 , or ddrug10 in healthy subjects .",
        "label": "NA"
    },
    {
        "text": "HD00374 : administration of DB00712 to volunteers under fasting conditions , or with ddrug2 suspension yielded similar serum ddrug3 time profiles in young subjects { n = 12 } .",
        "label": "NA"
    },
    {
        "text": "accordingly , DB00829 and DB00176 should not ordinarily be co-administered .",
        "label": "advise"
    },
    {
        "text": "HD00084 , ddrug1 , ddrug2 { DB00627 , ddrug4 , ddrug5 : skeletal muscle .",
        "label": "NA"
    },
    {
        "text": "agents causing renin release DB01197 's effect will be augmented by HD00366 that cause renin release .",
        "label": "effect"
    },
    {
        "text": "gastrointestinal transit time { lactulose hydrogen breath test } was measured in # volunteers with oral and intravenous placebo , oral placebo and intravenous DB00295 { # mg x kg { -1 } } , and oral HD00090 { 4 mg } and intravenous ddrug2 { # mg x kg { -1 } } in a double blind , cross-over study .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , DB01026 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , DB00295 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "in a drug interaction study , co-administration of orally inhaled ddrug0 and oral ddrug1 , an inhibitor of cytochrome p450 3a4 , had no effect on the pharmacokinetics of either HD00528 or DB00199 .",
        "label": "NA"
    },
    {
        "text": "conversely , DB00937 may interfere with ddrug1 { i , e , , DB01170 , ddrug3 } .",
        "label": "int"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } DB00501 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } DB01235 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "because severe hypoglycemia has been reported in patients concomitantly receiving oral ddrug0 { an ddrug1 } and oral HD00062 , such a potential interaction involving the latter agents when used concomitantly with DB01026 tablets { an ddrug4 } can not be ruled out .",
        "label": "NA"
    },
    {
        "text": "both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ddrug0 is administered in combination with other HD00261 such as ddrug2 , ddrug3 , ddrug4 , or inhalation general HD00264 .",
        "label": "NA"
    },
    {
        "text": "therefore , patients on DB00571 should be observed when DB00375 tablets are either added or deleted from a therapeutic regimen .",
        "label": "advise"
    },
    {
        "text": "such individuals are referred to as poor metabolizers of drugs such as DB04840 , DB00514 , the ddrug2 , and ddrug3 .",
        "label": "NA"
    },
    {
        "text": "the gastrointestinal absorption of ddrug0 and DB00863 is accelerated when they are coadministered with DB00604 .",
        "label": "mechanism"
    },
    {
        "text": "DB01394 may increase sensitivity to the HD00261 .",
        "label": "effect"
    },
    {
        "text": "DB14507 generally should not be given with HD00218 because they reduce its renal clearance and add a high risk of ddrug2 toxicity .",
        "label": "mechanism"
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , ddrug3 , or ddrug4 , with ddrug5 , with metal cations such as DB01592 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as DB00900 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "another study showed that ddrug0 had no clinically significant effect on plasma concentrations of the oral ddrug1 DB00977 and DB00367 { cyp3a4 substrates } .",
        "label": "NA"
    },
    {
        "text": "this drug may interact with DB02325 or other ddrug1 { may potentiate the cns depressant effects of either these medications or ddrug2 } , ddrug3 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug4 } , and HD00445 { concurrent use with ddrug6 may prolong and intensify the anticholinergic and cns depressant effects of ddrug7 } .",
        "label": "NA"
    },
    {
        "text": "DB11058 - concomitant intake of ddrug1 and ddrug2 may reduce the absorption of DB01022 .",
        "label": "NA"
    },
    {
        "text": "it is recommended to avoid concurrent administration of ddrug0 with DB06723 containing HD00374 for at least # hours following ddrug3 administration .",
        "label": "NA"
    },
    {
        "text": "agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of ddrug0 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 { 2 } , DB00794 , ddrug8 , and ddrug9 thus , if a patient has been titrated to a stable dosage on ddrug10 , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for HD00472 may be necessary .",
        "label": "NA"
    },
    {
        "text": "in three separate controlled , parallel group clinical pharmacology studies , DB00967 at the clinical dose of # mg has been coadministered with ddrug1 # mg followed by # mg once daily for # days { n = 18 } or with ddrug2 # mg once daily for # days after a # day pretreatment period with DB00472 { n = 18 } or with ddrug4 # mg every # hours for # days { n = 18 } under steady state conditions to normal healthy male and female volunteers .",
        "label": "NA"
    },
    {
        "text": "effects of other ddrug0 on DB00949 DB00252 : ddrug3 causes an approximate doubling of the clearance of ddrug4 { ddrug5 } at steady state and , therefore , the addition of ddrug6 causes an approximate 45 % decrease in the steady-state trough concentrations of ddrug7 as compared to the same dose of ddrug8 given as monotherapy .",
        "label": "NA"
    },
    {
        "text": "no interaction was noted with the ddrug0 DB01037 in two multiple-dose interaction studies when ddrug2 was coadministered with a DB01235 / ddrug4 { n = 29 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a short-term controlled study in # normal volunteers , DB01009 did not significantly interfere with the effect of DB00682 on prothrombin time .",
        "label": "NA"
    },
    {
        "text": "close observation of the patient is recommended when a HD00380 is administered to patients receiving catecholamine-depleting drugs such as DB00206 , because of possible additive effects and the production of hypotension and/or marked bradycardia , which may produce vertigo , syncope or postural hypotension .",
        "label": "advise"
    },
    {
        "text": "administration of ddrug0 with HD00374 containing ddrug2 , ddrug3 , or ddrug4 , with ddrug5 , with metal cations such as ddrug6 , or with ddrug7 containing ddrug8 or DB01593 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of DB01155 with ddrug1 resulted in a 45 % increase in systemic exposure to DB01155 .",
        "label": "NA"
    },
    {
        "text": "drug / laboratory test interactions certain endocrine and liver function tests may be affected by HD00183 - containing oral HD00283 .",
        "label": "NA"
    },
    {
        "text": "co-administration with DB00625 or ddrug1 had a modest effect on the pharmacokinetics of DB00207 .",
        "label": "mechanism"
    },
    {
        "text": "no depressant effect on blood levels in humans was noted when ddrug0 was administered with any of the following drugs : DB00945 , ddrug2 , ddrug3 , ddrug4 , ddrug5 { ddrug6 } , ddrug7 , ddrug8 or DB00682 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , DB00636 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { DB00701 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "DB00682 and ddrug1 : increased prothrombin time , with or without clinical bleeding , has been reported when DB00671 is administered concomitantly .",
        "label": "effect"
    },
    {
        "text": "ddrug0 { e , g , , ddrug1 , ddrug2 , or DB00594 } , DB14500 supplements , or ddrug5 - containing salt substitutes may lead to significant increases in serum potassium .",
        "label": "NA"
    },
    {
        "text": "therefore , co-administration of ddrug0 with other drugs that are metabolized by this isozyme , including ddrug1 , ddrug2 , ddrug3 , and ddrug4 { e , g , , ddrug5 , ddrug6 and DB01228 } , or that inhibit this enzyme { e , g , , DB00908 } , should be approached with caution .",
        "label": "NA"
    },
    {
        "text": "if a patient requires ddrug0 and HD00637 therapy , it is suggested that ddrug2 , DB00863 , or ddrug4 { ddrug5 and ddrug6 } be used as alternatives to ddrug7 , as these agents have no effect on the pharmacokinetic profile of ddrug8 .",
        "label": "NA"
    },
    {
        "text": "intravenous DB00640 { ddrug1 } has been effectively administered in the presence of other cardioactive drugs , such as ddrug2 , HD00244 , ddrug4 , and ddrug5 , without any change in the adverse reaction profile .",
        "label": "NA"
    },
    {
        "text": "when used in therapeutic doses , DB00207 had a modest effect on the pharmacokinetics of ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { intravenous and oral } , ddrug12 , ddrug13 / ddrug14 or DB00495 .",
        "label": "mechanism"
    },
    {
        "text": "drugs that have been reported to diminish oral HD00025 response , ie , decreased prothrom-bin time response , in man significantly include : HD00327 ;",
        "label": "effect"
    },
    {
        "text": "DB00363 may potentiate the hypotensive effects of HD00448 and the anticholinergic effects of ddrug2 - type drugs .",
        "label": "effect"
    },
    {
        "text": "the co-administration of ddrug0 with iv ddrug1 such as ddrug2 , DB00325 , ddrug4 , or iv ddrug5 has not been evaluated { these drugs were not co-administered with DB04899 in clinical trials } .",
        "label": "NA"
    },
    {
        "text": "DB00501 } and many that are substrates for cyp2b6 2d6 { many other ddrug1 , ddrug2 , and the type 1c antiarrhythrnics propatenone and DB01195 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { ddrug1 - or DB14513 - containing } : concomitant administration of 300-mg DB00535 capsules with # ml ddrug4 suspension reduces the rate { cmax } and extent { auc } of absorption by approximately 40 % .",
        "label": "NA"
    },
    {
        "text": "other concomitant therapy : although specific interaction studies were not performed , in clinical studies , HD00503 was used concomitantly with ddrug1 , ddrug2 , ddrug3 , ddrug4 , and HD00233 { ddrug6 } without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "although it has not been established that there is an interaction between ddrug0 and ddrug1 or other HD00565 , caution is advised when ddrug3 is initiated in patients taking a ddrug4 or any other HD00564 .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : HD00403 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } DB01026 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "ddrug0 injection should not be mixed with DB00997 , ddrug2 , ddrug3 , or ddrug4 , since it has been reported that these drugs are incompatible with DB01109 and a precipitate may form .",
        "label": "NA"
    },
    {
        "text": "in general , these are drugs that have one or more pharmacologic activities similar to HD00406 , including ddrug1 such as ddrug2 and DB01035 , ddrug4 and ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : since DB00714 is a ddrug2 , it is possible that ddrug3 , such as the ddrug4 { ddrug5 , ddrug6 , HD00341 } or ddrug8 , may diminish the effectiveness of ddrug9 .",
        "label": "NA"
    },
    {
        "text": "both DB00625 and DB00238 have been compared to triple therapy with the ddrug2 ddrug3 over # weeks as initial therapy , with similar responses being observed with ddrug4 regimens and superiority observed with ddrug5 .",
        "label": "NA"
    },
    {
        "text": "modification of HD00011 with HD00010 abolished both its cytotoxic activity and the ability of the toxin to bind zn-sepharose gel .",
        "label": "NA"
    },
    {
        "text": "particular caution should be exercised in using preparations containing ddrug0 , DB11085 , or ddrug2 in combination with DB00210 gel .",
        "label": "NA"
    },
    {
        "text": "effects of ddrug0 on DB00949 the coadministration of ddrug2 { 1000 mg/day } for # days did not alter the pharmacokinetic parameters of cmax , cmin , auc , ci/kg or tmax at DB00949 daily doses of # or # mg/day in # otherwise healthy subjects with epilepsy .",
        "label": "NA"
    },
    {
        "text": "although there was no effect of ddrug0 on the plasma auc of ddrug1 or HD00346 determined on day 3 , there was a 34 % decrease in ddrug3 { a cyp2c9 substrate } trough concentration accompanied by a 14 % decrease in the prothrombin time { reported as international normalized ratio or inr } # days after completion of dosing with DB00673 .",
        "label": "NA"
    },
    {
        "text": "DB00269 may interact with ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 supplements , ddrug6 , ddrug7 , DB00091 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , and ddrug13 .",
        "label": "int"
    },
    {
        "text": "no significant drug interactions have been reported in studies of ddrug0 given with other drugs such as ddrug1 , DB01115 , ddrug3 , ddrug4 , ddrug5 , and oral HD00283 in healthy volunteers , or given with ddrug7 to patients with heart failure { nyha class ii and iii } .",
        "label": "NA"
    },
    {
        "text": "since ddrug0 { ddrug1 } may interact with concurrently administered ddrug2 , periodic serum level determinations of these drugs may be necessary { eg , ddrug3 may elevate DB00252 serum levels and ddrug5 has been reported to both increase and decrease DB00593 levels } .",
        "label": "NA"
    },
    {
        "text": "HD00575 { eg , ddrug1 } and other drugs , including ether , ddrug2 , ddrug3 , ddrug4 and ddrug5 , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with DB01111 parenteral .",
        "label": "effect"
    },
    {
        "text": "rhabdomyolysis secondary to a drug interaction between DB00641 and DB01211 .",
        "label": "effect"
    },
    {
        "text": "patients who begin taking DB00586 or who increase their ddrug1 dose or any other HD00615 while taking ddrug3 , ddrug4 , or ddrug5 may develop toxicity characteristics for these drugs .",
        "label": "NA"
    },
    {
        "text": "micro-dosed DB00396 preparations : micro-dosed ddrug1 preparations { minipills that do not contain an HD00183 } may be an inadequate method of contraception during ddrug3 therapy .",
        "label": "NA"
    },
    {
        "text": "ddrug0 should be avoided by patients with a history of serious reaction to any HD00386 , including ddrug2 and DB09276 .",
        "label": "NA"
    },
    {
        "text": "the extent to which HD00278 - HD00312 interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the ddrug2 involved .",
        "label": "int"
    },
    {
        "text": "the absorption of DB00256 may be affected by the simultaneous administration of indigestion remedies , ddrug1 or DB01593 supplements .",
        "label": "mechanism"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / HD00517 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , ddrug4 , DB00365 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 pain medication { e , g , , ddrug12 } , drugs used to aid sleep , drowsiness-causing ddrug13 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : concomitant administration of ddrug1 and DB06723 does not interfere with the rate or extent of the absorption of DB01009 administered as ddrug4 .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of ddrug0 : ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , ddrug5 , ddrug6 , ddrug7 } , DB00951 , ddrug9 , ddrug10 , ddrug11 , HD00220 , ddrug13 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "HD00409 and ddrug1 could exaggerate the prolongation of the qt interval observed with HD00406 .",
        "label": "effect"
    },
    {
        "text": "antiacid , ddrug0 , ddrug1 , ddrug2 , DB00472 , indanavir , ddrug4 , ddrug5 , phenobarbitol , ddrug6 , ddrug7 , ddrug8 , ritanovir , DB01232 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , DB00390 , ddrug2 , and ddrug3 the in vitro binding of ddrug4 to plasma proteins is only slightly reduced by ddrug5 { # % control vs # % } when DB00465 plasma concentrations reach # to10 m g/ml .",
        "label": "NA"
    },
    {
        "text": "the following precautions should be kept in mind in the treatment of anticholinesterase poisoning although they do not bear directly on the use of DB00572 and DB00733 .",
        "label": "advise"
    },
    {
        "text": "while additional research is needed , the initial clinical data in kidney recipients suggest that DB00877 , in combination with ddrug1 or DB00864 , might have the potential to reduce the frequency of rejection episodes , permit reductions in ddrug3 or ddrug4 dosage , and permit steroid withdrawal { kelly , 1999 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , DB01045 { ddrug40 } , st , johns wort , ddrug41 , DB00277 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "increasing the DB00224 dose to # mg every # hours does not compensate for the increased ddrug1 metabolism due to DB00625 .",
        "label": "NA"
    },
    {
        "text": "we examined the effect of exogenous DB00783 on the changes in serum steroid hormone levels induced by a nonlethal dose of escherichia coli ddrug1 in male rats and the deaths due to nonlethal and lethal doses of HD00168 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { HD00712 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { HD00531 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "the pharmacokinetics of ddrug0 and its major metabolite HD00212 were unaffected following co-administration with DB00659 .",
        "label": "NA"
    },
    {
        "text": "DB01075 has additive effects with ddrug1 and other ddrug2 { ddrug3 , ddrug4 , HD00262 , etc } .",
        "label": "effect"
    },
    {
        "text": "in a comparison of HD00118 tolerance in dogs anesthetized with ddrug1 , ddrug2 , or ddrug3 , the dosage of ddrug4 needed to cause ventricular tachycardia was significantly higher , as was the ld50 of ddrug5 , with DB01221 or ddrug7 than with ddrug8 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : concurrent administration of DB00026 { an ddrug2 } and another HD00242 has been associated with an increased risk of serious infections , an increased risk of neutropenia and no additional benefit compared to these medicinal products alone .",
        "label": "effect"
    },
    {
        "text": "co-administration of ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 and DB00381 did not result in clinically significant increases in DB09026 exposure .",
        "label": "NA"
    },
    {
        "text": "all subjects received DB00701 { 1,200 mg twice a day } for # days , followed by a 7-day washout period , followed by either ddrug1 { 300 mg once a day -lsb- qd -rsb- } { cohort 1 } or DB01045 { 600 mg qd } { cohort 2 } for # days .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ten patients who were stabilized on oral HD00326 were given DB01018 , 1 - 2 mg/day , for # weeks .",
        "label": "NA"
    },
    {
        "text": "HD00388 may have additive effects with ddrug1 and other ddrug2 , e , g , , ddrug3 , HD00024 , ddrug5 , ddrug6 .",
        "label": "effect"
    },
    {
        "text": "these agents include medications such as : ddrug0 , HD00679 including ddrug2 , sali-cylates , ddrug3 { including DB00465 } , ddrug5 , or ddrug6 .",
        "label": "NA"
    },
    {
        "text": "DB01167 decreases DB01008 clearance by up to 25 % , and may produce aucs # m min in some patients .",
        "label": "mechanism"
    },
    {
        "text": "drugs whose absorption can be affected by the level of acidity in the stomach : drugs such as DB01026 and ddrug1 should be administered at least # hours prior to dosing with DB00900 .",
        "label": "advise"
    },
    {
        "text": "inhibitors of this isoenzyme { e , g , , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , grapefruit juice , ddrug7 , ddrug8 , DB00468 , ddrug10 } should be cautiously coadministered with ddrug11 as they can potentially increase DB00204 levels .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB01118 should be used with caution in patients receiving - ddrug2 blocking agents { e , g , , ddrug3 , a ddrug4 inhibitor } or ddrug5 antagonists { e , g , , ddrug6 , a HD00302 substrate , and ddrug8 , a ddrug9 inhibitor } because of the possible potentiation of bradycardia , sinus arrest , and av block ;",
        "label": "NA"
    },
    {
        "text": "however , because some ddrug0 have been reported to enhance the effects of DB00682 or its derivatives , prothrombin time or other suitable anticoagulation test should be monitored closely if a HD00751 is administered with ddrug3 or its derivatives .",
        "label": "NA"
    },
    {
        "text": "hyperpyrexia has been reported when HD00314 is administered with ddrug1 agents or with DB06454 drugs , particularly during hot weather .",
        "label": "NA"
    },
    {
        "text": "antiacid , DB01211 , ddrug1 , ddrug2 , ddrug3 , indanavir , ddrug4 , ddrug5 , phenobarbitol , ddrug6 , ddrug7 , DB01045 , ritanovir , ddrug9 .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 : DB00580 { 40 mg bid } did not induce the metabolism of the combination oral HD00349 ddrug3 / ddrug4 { 1 mg / 35 mcg combination , ddrug5 1/35 } .",
        "label": "NA"
    },
    {
        "text": "in a comparison of ddrug0 tolerance in dogs anesthetized with ddrug1 , ddrug2 , or ddrug3 , the dosage of ddrug4 needed to cause ventricular tachycardia was significantly higher , as was the ld50 of DB01092 , with ddrug6 or HD00117 than with ddrug8 .",
        "label": "NA"
    },
    {
        "text": "antiacid , ddrug0 , ddrug1 , ddrug2 , ddrug3 , indanavir , ddrug4 , ddrug5 , phenobarbitol , DB00564 , DB00615 , ddrug8 , ritanovir , ddrug9 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the concomitant use of ddrug1 { ddrug2 transdermal system } with other ddrug3 , including but not limited to other ddrug4 , ddrug5 , ddrug6 , HD00262 { e , g , , ddrug8 } , general ddrug9 , HD00219 , ddrug11 , and ddrug12 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .",
        "label": "NA"
    },
    {
        "text": "ddrug0 or ddrug1 : when ddrug2 is administered immediately following HD00374 or HD00498 , the absorption of ddrug5 is slightly enhanced .",
        "label": "NA"
    },
    {
        "text": "therefore , increased monitoring of DB00390 is recommended when initiating , adjusting , or discontinuing DB01136 .",
        "label": "advise"
    },
    {
        "text": "immediate and extended release tablets the hypoglycemic action of ddrug0 may be potentiated by certain drugs including HD00518 , some ddrug2 and other drugs that are highly protein bound , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and HD00520 .",
        "label": "NA"
    },
    {
        "text": "DB00995 should be avoided by patients with a history of serious reaction to any HD00386 , including ddrug2 and ddrug3 .",
        "label": "advise"
    },
    {
        "text": "{ in some patients , the HD00787 can reduce the diuretic , natriuretic , and antihypertensive effects of HD00105 , ddrug2 , and ddrug3 .",
        "label": "effect"
    },
    {
        "text": "the hypoglycemic action of HD00222 may be potentiated by certain drugs including ddrug1 and other drugs that are highly protein bound , HD00328 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , and ddrug8 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : DB00580 # mg bid for # days produced significant decreases in ddrug2 serum clearance { 25 % } and renal clearance { 30 % } with a 34 % higher serum exposure compared to DB14507 alone .",
        "label": "NA"
    },
    {
        "text": "HD00374 : concomitant administration of ddrug1 containing ddrug2 or ddrug3 with DB00900 chewable/dispersible buffered tablets or pediatric powder for oral solution may potentiate adverse events associated with the ddrug5 components .",
        "label": "NA"
    },
    {
        "text": "the absorption of ddrug0 , ddrug1 , ddrug2 , ddrug3 , and DB01241 was significantly decreased when given simultaneously with DB00375 ;",
        "label": "mechanism"
    },
    {
        "text": "epidemiological studies of the case-control and cohort design that have demonstrated an association between use of ddrug0 that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an HD00615 or DB00945 potentiated the risk of bleeding .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : since HD00718 may bind other drugs given concurrently , patients should take DB01039 at least # hour before or 4 - 6 hours after a ddrug3 to avoid impeding its absorption .",
        "label": "NA"
    },
    {
        "text": "care should be taken when using immunoanalytical methods to measure plasma DB00252 concentrations following DB01320 administration .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : based on reports of profound hypotension and loss of consciousness when ddrug1 was administered with DB00904 , the concomitant use of ddrug3 with drugs of the ddrug4 { including , for example , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and DB00969 } is contraindicated .",
        "label": "NA"
    },
    {
        "text": "when concomitant treatment with HD00482 and DB00575 is to be terminated , the ddrug2 should be discontinued first .",
        "label": "advise"
    },
    {
        "text": "ddrug0 - concomitant intake of DB01432 and ddrug2 may reduce the absorption of DB01022 .",
        "label": "NA"
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of ddrug0 such as DB00565 include certain HD00002 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 } , ddrug11 salts , ddrug12 , local ddrug13 , ddrug14 , and ddrug15 .",
        "label": "effect"
    },
    {
        "text": "injection of DB00783 # min before a nonlethal dose of ddrug1 changed the serum sex steroid hormone response of male rats to HD00168 .",
        "label": "NA"
    },
    {
        "text": "HD00043 have been reported to blunt the hypotensive effect of systemic DB00575 , it is not known whether the concurrent use of these agents with ddrug2 in humans can lead to resulting interference with the iop lowering effect .",
        "label": "effect"
    },
    {
        "text": "ddrug0 DB00683 , DB00897 ddrug3 ergot derivatives ddrug4",
        "label": "NA"
    },
    {
        "text": "the in vitro interaction between DB00238 and the HD00875 ddrug2 is complex .",
        "label": "NA"
    },
    {
        "text": "-lsb- the gaba-ergic system and brain edema -rsb- it has been shown in rats with experimental toxic and traumatic edemas that ddrug0 { 1 mg/kg } removes the antiedematous action of DB00829 , ddrug2 , ddrug3 and ddrug4 and reduces the action of DB00692 .",
        "label": "NA"
    },
    {
        "text": "in # separate studies , DB00950 # mg twice daily { 240 mg total daily dose } was co-administered with either ddrug1 # mg every # hours or DB01026 # mg once daily under steady-state conditions to healthy volunteers { n = 24 , each study } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - and ddrug1 - containing HD00374 , administered concomitantly with DB00978 , significantly decreased the bioavailability { 48 % } of ddrug4 .",
        "label": "mechanism"
    },
    {
        "text": "absorption of ddrug0 is impaired by ddrug1 containing DB01370 , ddrug3 , or ddrug4 , and DB01592 - containing preparations .",
        "label": "NA"
    },
    {
        "text": "inhibitors or substrates of cyp2d6 { i , e , , ddrug0 , ddrug1 -lsb- HD00114 -rsb- } may increase the plasma concentration of DB01142 when administered concomitantly .",
        "label": "mechanism"
    },
    {
        "text": "use of DB00722 with ddrug1 { e , g , , ddrug2 , ddrug3 , or DB00594 } , ddrug5 supplements , or potassium-containing salt substitutes may lead to significant increases in serum potassium .",
        "label": "effect"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of ddrug0 : ddrug1 , ddrug2 , HD00218 , ddrug4 { e , g , , ddrug5 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , ddrug11 , HD00220 , ddrug13 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "no important interactions to date DB00922 does not have clinically important pharmacokinetic interactions with ddrug1 , ddrug2 , DB01023 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 or ddrug9 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , DB00456 , ddrug6 , and ddrug7 have no influence in vitro on the protein binding of DB00586 in human serum .",
        "label": "NA"
    },
    {
        "text": "DB00563 renal tubular transport of ddrug1 may be inhibited by concomitant administration of DB00537 , potentially leading to increased plasma levels of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , HD00002 such as ddrug4 and ddrug5 , ddrug6 { DB00252 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with other cyp3a4 inhibitors { e , g , , ddrug1 # mg bid , DB00661 # mg qd , DB01232 # mg tid , ddrug4 # mg qd } resulted in increases in cmax of ddrug5 ranging from # - to # - fold and auc from # - to # - fold .",
        "label": "NA"
    },
    {
        "text": "- a sulfa-based drug such as DB01015 - ddrug1 { ddrug2 , ddrug3 } , ddrug4 { DB14033 } , or ddrug6 { ddrug7 } ;",
        "label": "NA"
    },
    {
        "text": "medications can interfere with folate utilization , including : HD00740 { such as ddrug1 , and ddrug2 } ddrug3 { sometimes prescribed to control blood sugar in type # diabetes } ddrug4 { used to control inflammation associated with crohn_disease and ulcerative colitis } ddrug5 { a ddrug6 } ddrug7 there has been concern about the interaction between ddrug8 and DB00158 .",
        "label": "NA"
    },
    {
        "text": "this drug may interact with ddrug0 or other ddrug1 { may potentiate the cns depressant effects of either these medications or ddrug2 } , ddrug3 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug4 } , and HD00445 { concurrent use with HD00388 may prolong and intensify the anticholinergic and cns depressant effects of ddrug7 } .",
        "label": "NA"
    },
    {
        "text": "the effectiveness of ddrug0 - only pills is reduced by hepatic enzyme-inducing drugs such as the HD00282 ddrug2 , ddrug3 , and ddrug4 , and the HD00886 ddrug6 .",
        "label": "NA"
    },
    {
        "text": "in monkeys , the effects of ddrug0 , but not HD00156 or ddrug2 , were antagonized by DB01183 ;",
        "label": "NA"
    },
    {
        "text": "DB01037 - ddrug1 and the HD00830 ddrug3 may have synergistic antidepressant activity if used concomitantly .",
        "label": "NA"
    },
    {
        "text": "simultaneous administration of DB01254 with HD00374 should be avoided .",
        "label": "advise"
    },
    {
        "text": "HD00093 e , g , , DB00199 ;",
        "label": "NA"
    },
    {
        "text": "in patients taking an ddrug0 { eg , DB00313 , ddrug2 , ddrug3 or ddrug4 } , the concomitant use of ddrug5 may reduce seizure control by lowering the plasma levels of the HD00329 .",
        "label": "NA"
    },
    {
        "text": "if DB01115 therapy is initiated in a patient currently receiving DB00501 , cautious titration is advised .",
        "label": "advise"
    },
    {
        "text": "both DB00224 and DB01072 are associated with indirect { unconjugated } hyperbilirubinemia .",
        "label": "NA"
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a ddrug0 , including ddrug1 , with multivalent cation-containing products such as DB14513 or ddrug3 ddrug4 , ddrug5 , ddrug6 chewable/buffered tablets or pediatric powder , or products containing ddrug7 , DB01592 , or ddrug9 may substantially decrease the absorption of ddrug10 , resulting in serum and urine levels considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "ddrug0 to healthy volunteers under steady-state conditions had no relevant effect on either drug s bioavailability , auc and cmax , differences were 20 % between ddrug1 given singly and in combination with DB00571 , and between ddrug3 given singly and in combination with DB00270 .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { DB00501 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { DB01026 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "the plasma concentration of ddrug0 may increase when the drug is given concomitantly with hepatic enzyme inhibitors { e , g , , ddrug1 , DB00472 } and decrease by concomitant administration of hepatic enzyme inducers { e , g , , HD00026 , ddrug4 } , and adjustment of the dosage of ddrug5 may therefore be necessary .",
        "label": "NA"
    },
    {
        "text": "there have been reports of interactions of DB00199 with ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , DB00280 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , and ddrug13 .",
        "label": "int"
    },
    {
        "text": "ddrug0 : co-administration of DB00601 and HD00851 was not associated with serotonin syndrome in phase 1 , # or # studies .",
        "label": "NA"
    },
    {
        "text": "if HD00374 are required during DB00535 therapy , ddrug2 should be taken at least # hours before or after the ddrug3 .",
        "label": "NA"
    },
    {
        "text": "these agents include medications such as : HD00326 , ddrug1 including ddrug2 , sali-cylates , ddrug3 { including DB00465 } , ddrug5 , or ddrug6 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 { HD00302 substrate } in combination with DB01118 has been associated with reports of myopathy/rhabdomyolysis .",
        "label": "NA"
    },
    {
        "text": "in patients taking an ddrug0 { eg , ddrug1 , DB00564 , ddrug3 or ddrug4 } , the concomitant use of ddrug5 may reduce seizure control by lowering the plasma levels of the HD00329 .",
        "label": "NA"
    },
    {
        "text": "DB00562 may interact with ddrug1 , ddrug2 s , ddrug3 { allergy , cold , and sinus medicines } , diabetic drugs , ddrug4 , ddrug5 , ddrug6 like DB00788 or ddrug8 , and high blood pressure medications .",
        "label": "int"
    },
    {
        "text": "ddrug0 : HD00100 gi motility agents ddrug2 DB00857",
        "label": "NA"
    },
    {
        "text": "ddrug0 s : ddrug1 should be administered at least # hours after or # hours before dosing with ddrug2 because plasma concentrations of ddrug3 are decreased when administered with HD00374 containing ddrug5 , DB01373 , or ddrug7 .",
        "label": "NA"
    },
    {
        "text": "if a patient requires DB00204 and HD00637 therapy , it is suggested that ddrug2 , ddrug3 , or ddrug4 { ddrug5 and ddrug6 } be used as alternatives to ddrug7 , as these agents have no effect on the pharmacokinetic profile of ddrug8 .",
        "label": "NA"
    },
    {
        "text": "dose adjustment of ddrug0 may be required and pth and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong cyp3a4 inhibitor { e , g , , DB01026 , DB00199 , ddrug3 ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , DB00860 { ddrug38 } , DB01045 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "DB00715 : coadministration of a single dose of DB00962 # mg and ddrug2 # mg daily for # days did not produce any interaction on psychomotor performance .",
        "label": "NA"
    },
    {
        "text": "during clinical trials , DB01088 was used concurrently with ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , HD00175 , and other medications .",
        "label": "NA"
    },
    {
        "text": "HD00263 are strong HD00389 , but regular users develop physiological tolerance allowing gradually increased dosages .",
        "label": "NA"
    },
    {
        "text": "- a HD00295 { water pill } such as ddrug1 { ddrug2 , ddrug3 } , ddrug4 { DB00880 } , and others ;",
        "label": "NA"
    },
    {
        "text": "in a phase i trial using escalating doses of DB01229 { 110 - 200 mg/m2 } and DB00515 { 50 or # mg/m2 } given as sequential infusions , myelosuppression was more profound when ddrug2 was given after ddrug3 than with the alternate sequence { ie , ddrug4 before ddrug5 } .",
        "label": "NA"
    },
    {
        "text": "in vitro studies evaluating the minimum inhibitory concentration { mic } of ddrug0 , ddrug1 , ddrug2 , DB00415 / flucoxacillin , ddrug4 , ddrug5 , and ddrug6 demonstrated no evidence of incompatibility of these ddrug7 with DB00702 .",
        "label": "NA"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / ddrug1 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , ddrug4 , DB00365 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 pain medication { e , g , , ddrug12 } , drugs used to aid sleep , drowsiness-causing HD00388 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : some individuals receiving ddrug1 may experience a reversible enhancement of the pressor response to indirect-acting ddrug2 , HD00649 or HD00853 .",
        "label": "NA"
    },
    {
        "text": "to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma { hiv-nhl } , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the DB00531 , ddrug1 , ddrug2 , and DB00898 { chop } chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen { i , e , , ddrug4 , ddrug5 , ddrug6 , and ddrug7 with ddrug8 plus ddrug9 } without receiving ddrug10 therapy .",
        "label": "NA"
    },
    {
        "text": "HD00071 or oral HD00484 : ddrug2 may enhance the blood-sugar-reducing effect of ddrug3 and oral ddrug4 .",
        "label": "NA"
    },
    {
        "text": "there was no evidence of drug interactions in clinical studies in which DB00841 was administered concurrently with other drugs , including ddrug1 , ddrug2 , ddrug3 , DB00281 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , and ddrug13 .",
        "label": "NA"
    },
    {
        "text": "serum DB14507 levels should be monitored frequently if DB00700 is administered concomitantly with ddrug2 .",
        "label": "NA"
    },
    {
        "text": "other drugs : in small groups of patients { 7 - 10 / interaction study } , the concomitant administration of ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , or DB01396 did not significantly affect the peak levels and auc values of DB00586 .",
        "label": "NA"
    },
    {
        "text": "the combination of therapeutic doses of intravenous ddrug0 and DB00661 in DB01159 a-chloralose anesthetized swine has resulted in ventricular fibrillation and cardiovascular collapse in association with marked hyperkalemia .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral HD00811 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 { e , g , , ddrug9 } , HD00807 .",
        "label": "NA"
    },
    {
        "text": "dose reduction of DB00615 to half the standard dose and a dose increase of ddrug1 to # mg { three 333-mg capsules } every # hours are recommended when ddrug2 and DB00224 are coadministered .",
        "label": "NA"
    },
    {
        "text": "when used in external subcutaneous infusion pumps for ddrug0 , DB01306 should not be mixed with any other HD00813 or diluent .",
        "label": "NA"
    },
    {
        "text": "in a clinical pharmacology study , DB00328 or ddrug1 was administered to hypertensive patients receiving DB00584 .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 : ddrug1 , when given once daily for # days as a 100-mg capsule with an oral ddrug2 containing # mcg of DB00977 and # mg of DB00717 , decreased the auc of ddrug5 by 43 % , and decreased the auc of ddrug6 by 8 % ;",
        "label": "NA"
    },
    {
        "text": "in clinical studies performed with DB00569 , the concomitant use of oral HD00326 { ddrug2 } , ddrug3 { ddrug4 } , ddrug5 { ddrug6 } , and ddrug7 did not significantly affect the pharmacokinetics/pharmacodynamics of ddrug8 .",
        "label": "NA"
    },
    {
        "text": "coadministration of DB00343 with DB01045 or any known cyp3a4 inducer should be avoided when possible , and alternative therapy considered .",
        "label": "advise"
    },
    {
        "text": "antiacid , ddrug0 , ddrug1 , ddrug2 , ddrug3 , indanavir , ddrug4 , ddrug5 , phenobarbitol , DB00564 , ddrug7 , DB01045 , ritanovir , ddrug9 .",
        "label": "NA"
    },
    {
        "text": "thus patients receiving oral HD00326 and DB00176 tablets should have their prothrombin time monitored and their ddrug2 dose adjusted accordingly .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : available data suggest that there is no significant effect of ddrug1 on the clearance of ddrug2 at steady state , therefore , the addition of DB00313 is not expected to cause a clinically important effect on ddrug4 { DB00949 } plasma concentrations .",
        "label": "NA"
    },
    {
        "text": "concomitant use of HD00026 usually depresses DB00400 activity and may necessitate raising the dosage .",
        "label": "effect"
    },
    {
        "text": "however , # mg of DB00863 q12h for # days increased the DB01415 c max by 23 % and ddrug2 auc by 16 % .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : in a clinical pharmacology study , coadministration of an ddrug1 { ddrug2 , DB09104 , and ddrug4 } with ddrug5 reduced serum levels and urinary excretion of ddrug6 as compared with ddrug7 administered alone , suggesting that ddrug8 may impair absorption of DB00492 .",
        "label": "NA"
    },
    {
        "text": "the availability of potent ddrug0 { HD00112 } - based regimens for HD00056 therapy and concerns regarding ddrug3 { ddrug4 } - related metabolic disturbances have led to significant shifts in treatment practices in hiv infection .",
        "label": "NA"
    },
    {
        "text": "DB00405 can interact with ddrug1 or other ddrug2 { may potentiate the cns depressant effects of either these medications or HD00388 } , ddrug4 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug5 } , and ddrug6 { concurrent use with ddrug7 may prolong and intensify the anticholinergic and cns depressant effects of ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , including DB00827 , may enhance the effects of oral HD00326 , such as ddrug3 or its derivatives .",
        "label": "effect"
    },
    {
        "text": "drug interactions : the central ddrug0 syndrome can occur when anticholinergic agents such as ddrug1 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain HD00424 such as DB00454 , the ddrug4 and other ddrug5 , ddrug6 , certain ddrug7 such as the ddrug8 salts , and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "compounds in these categories result in a decreased efficacy of DB01200 : HD00219 , ddrug2 , ddrug3 , ddrug4 .",
        "label": "effect"
    },
    {
        "text": "serum concentration of ddrug0 and DB01396 may increase when patients take HD00477 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 including coumarin derivatives , indandione derivatives , and ddrug1 such as HD00233 { ddrug3 } , and ddrug4 may increase the risk of bleeding when administered concomitantly with DB00407 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : { oral agents and HD00071 } - dosage adjustment of the HD00509 may be required .",
        "label": "NA"
    },
    {
        "text": "drug interactions with ddrug0 administration of # mg of ddrug1 { 2 x # mg capsule } within # minutes of an DB01370 and ddrug3 containing ddrug4 { ddrug5 } decreased DB00950 auc by 41 % and cmax by 43 % .",
        "label": "NA"
    },
    {
        "text": "DB00199 use in patients who are receiving high doses of DB00277 may be associated with an increase in serum ddrug2 levels and potential ddrug3 toxicity .",
        "label": "effect"
    },
    {
        "text": "limited data in patients receiving known enzyme inducers { DB00252 , ddrug1 , ddrug2 } indicate only a 30 % increase in the rate of DB01195 elimination .",
        "label": "mechanism"
    },
    {
        "text": "the effect of foods highly fortified with elemental DB01592 { primarily ddrug1 - fortified breakfast cereals } on DB00535 absorption has not been studied .",
        "label": "NA"
    },
    {
        "text": "-lsb- the effect of DB00501 on the renal excretion of HD00190 and ddrug2 in dogs -rsb- the intravenous injection of ddrug3 in a dose of # mg/kg enhanced ddrug4 and ddrug5 excretion in chronic canine experiments .",
        "label": "NA"
    },
    {
        "text": "HD00254 : in controlled clinical studies , HD00878 have been frequently administered concomitantly with ddrug2 .",
        "label": "NA"
    },
    {
        "text": "DB00956 : coadministration of DB00996 { 125 to # mg ;",
        "label": "NA"
    },
    {
        "text": "DB00669 - there have been rare postmarketing reports describing patients with weakness , hyperreflexia , and incoordination following the use of a ddrug1 { HD00278 } and ddrug3 .",
        "label": "NA"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : ddrug1 ; ddrug2 ; ddrug3 ; certain ddrug4 , especially the ddrug5 and ddrug6 ; ddrug7 ; DB14513 salts ; ddrug9 ; and DB00908 .",
        "label": "NA"
    },
    {
        "text": "these results would seem to dictate against the clinical use of DB00563 with ddrug1 , or during the period following DB00023 therapy when plasma asparagine levels are below normal .",
        "label": "NA"
    },
    {
        "text": "micro-dosed ddrug0 preparations : micro-dosed ddrug1 preparations { minipills that do not contain an HD00183 } may be an inadequate method of contraception during DB00982 therapy .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , DB00295 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , DB01045 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 toxicity has been reported to have occurred in a patient on chronic DB01174 treatment following the initiation of DB00586 therapy .",
        "label": "effect"
    },
    {
        "text": "agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of HD00472 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 { 2 } , DB00794 , ddrug8 , and ddrug9 thus , if a patient has been titrated to a stable dosage on ddrug10 , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for ddrug11 may be necessary .",
        "label": "mechanism"
    },
    {
        "text": "these data suggest that ddrug0 are negatively coupled to three types of calcium channels in bovine chromaffin cell , including an ddrug1 - sensitive { n-type } channel , an HD00048 - sensitive { p-type } channel and ddrug3 / HD00047 / ddrug5 - resistant { presumptive q-type } channel .",
        "label": "NA"
    },
    {
        "text": "other chemotherapy agents in a separate study , concomitant administration of DB01259 with DB01101 did not meaningfully alter the pharmacokinetics of either agent { or the metabolites of ddrug2 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 / ddrug1 - containing ddrug2 : absorption of ddrug3 is moderately reduced { approximately 25 % } when coadministered with ddrug4 / DB01370 - containing HD00701 .",
        "label": "NA"
    },
    {
        "text": "since bacteriostatic drugs , such as the ddrug0 of HD00002 , may interfere with the bactericidal action of HD00124 , it is not advisable to administer these drugs concomitantly .",
        "label": "NA"
    },
    {
        "text": "HD00216 , HD00351 ddrug2 may enhance the activity of ddrug3 or ddrug4 ;",
        "label": "NA"
    },
    {
        "text": "other drugs : in healthy volunteers , ddrug0 , ddrug1 , DB01016 , ddrug3 , ddrug4 , hormone replacement therapy { a combination of conjugated HD00220 and ddrug6 } , ddrug7 { ddrug8 and ddrug9 } and ddrug10 did not affect the pharmacokinetics of ddrug11 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , DB00446 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , DB01035 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 / ddrug1 : the coadministration of DB00252 or ddrug3 will not affect plasma concentrations of ddrug4 , but may reduce endogenous plasma levels of DB00136 / ergocalcitriol by accelerating metabolism .",
        "label": "mechanism"
    },
    {
        "text": "DB00199 { 500 mg t , i , d } produced a 4-fold increase in DB00862 auc and a 3-fold increase in cmax when co-administered with ddrug2 # mg in healthy volunteers .",
        "label": "mechanism"
    },
    {
        "text": "although studies designed to examine drug interactions have not been done , it was noted that HD00579 or ddrug1 treatment of relapses for periods of up to # days has been administered to patients { n = 180 } receiving DB00068 .",
        "label": "NA"
    },
    {
        "text": "since there have been conflicting results regarding the effect of DB00390 levels , it is recommended that ddrug1 levels be monitored when initiating , adjusting , and discontinuing DB00343 therapy to avoid possible over - or under-digitalization .",
        "label": "NA"
    },
    {
        "text": "particular caution is necessary when using DB01205 in cases of mixed drug overdosage since the toxic effects { such as convulsions and cardiac dysrhythmias } of other drugs taken in overdose { especially HD00733 } may emerge with the reversal of the ddrug2 effect by ddrug3 .",
        "label": "effect"
    },
    {
        "text": "DB00311 may increase the action of ddrug1 , ddrug2 , ddrug3 , and DB00908 .",
        "label": "effect"
    },
    {
        "text": "DB00788 and other ddrug1 can reduce the antihypertensive effect of DB00571 and other ddrug3 .",
        "label": "effect"
    },
    {
        "text": "HD00548 may displace acidic drugs such as DB00252 or ddrug2 from their binding sites .",
        "label": "mechanism"
    },
    {
        "text": "patients receiving other ddrug0 , HD00031 , ddrug2 , or other HD00261 { including ddrug4 } concomitantly with ddrug5 and ddrug6 tablets may exhibit an additive cns depression .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB01076 increases the auc for ddrug2 and DB00977 .",
        "label": "mechanism"
    },
    {
        "text": "a daily dose of # mg of DB11390 / kg of body weight for # days did not affect the plasma enzymes or the antiprothrombinemic effect of HD00160 in wethers .",
        "label": "NA"
    },
    {
        "text": "HD00095 : DB00227 , ddrug2 warning potential for serious reactions such as risk of myopathy including rhabdomyolysis .",
        "label": "NA"
    },
    {
        "text": "the DB00495 study dosed subjects with # mg/day of DB00207 { n = 7 } { later changed to # mg/day -lsb- n = 5 -rsb- } for days # to # of a 21-day course of # mg , five times/day of ddrug2 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - concomitant intake of DB11058 and DB01022 may reduce the absorption of ddrug3 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : the safety and effectiveness of DB00278 with HD00362 have not been established .",
        "label": "NA"
    },
    {
        "text": "in some patients , the administration of a HD00292 can reduce the diuretic , natriuretic , and antihypertensive effects of ddrug1 , HD00293 and ddrug3 .",
        "label": "effect"
    },
    {
        "text": "however , because some HD00532 have been reported to enhance the anticoagulant effects of DB00682 or its derivatives in patients , the prothrombin time or other suitable coagulation test should be closely monitored if a ddrug2 is administered concomitantly with ddrug3 or its derivatives .",
        "label": "effect"
    },
    {
        "text": "there is no pharmacokinetic interaction between DB00962 and DB14487 following the administration of a single dose { 10 mg and # mg , respectively } of each drug .",
        "label": "NA"
    },
    {
        "text": "no significant drug interactions have been reported in studies of DB00796 given with other drugs such as ddrug1 , DB01115 , ddrug3 , ddrug4 , ddrug5 , and oral ddrug6 in healthy volunteers , or given with ddrug7 to patients with heart failure { nyha class ii and iii } .",
        "label": "NA"
    },
    {
        "text": "the administration of local HD00449 containing ddrug1 or ddrug2 to patients receiving ddrug3 or HD00043 may produce severe , prolonged hypertension .",
        "label": "NA"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of DB00732 include : ddrug1 ; ddrug2 ; DB01159 ; certain ddrug4 , especially the ddrug5 and ddrug6 ; ddrug7 ; ddrug8 salts ; ddrug9 ; and ddrug10 .",
        "label": "effect"
    },
    {
        "text": "antiacid , ddrug0 , DB00900 , ddrug2 , ddrug3 , indanavir , ddrug4 , ddrug5 , phenobarbitol , ddrug6 , DB00615 , ddrug8 , ritanovir , ddrug9 .",
        "label": "NA"
    },
    {
        "text": "prior administration of DB01213 { 90 mg kg { -1 } body weight } was shown to prevent the conversion of HD00079 { 100 mg kg { -1 } body weight } to ddrug2 in vivo and to eliminate the fluoride and citrate elevations seen in ddrug3 - intoxicated animals .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , DB00091 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and DB00126 .",
        "label": "NA"
    },
    {
        "text": "patients receiving concomitant DB00227 and DB00199 should be carefully monitored ;",
        "label": "advise"
    },
    {
        "text": "two percent of patients treated concurrently with DB09145 and DB00026 developed neutropenia { anc # x 109/l } .",
        "label": "effect"
    },
    {
        "text": "other drugs : in healthy volunteers , DB00381 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , hormone replacement therapy { a combination of conjugated ddrug5 and ddrug6 } , ddrug7 { ddrug8 and DB09104 } and ddrug10 did not affect the pharmacokinetics of ddrug11 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , DB00224 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and DB00126 .",
        "label": "NA"
    },
    {
        "text": "HD00461 { cns } drugs including ddrug1 , ddrug2 , ddrug3 , ddrug4 , blood pressure medications { ddrug5 , DB00968 , ddrug7 } , motion sickness medications , ddrug8 , ddrug9 , ddrug10 , sleeping pills and ddrug11",
        "label": "NA"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : ddrug1 ; ddrug2 ; ddrug3 ; certain ddrug4 , especially the HD00249 and ddrug6 ; ddrug7 ; DB14513 salts ; ddrug9 ; and ddrug10 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { ddrug1 } , ddrug2 or other ddrug3 , or HD00318 : concurrent use with DB01102 may produce additive inotropic and/or chronotropic effects .",
        "label": "NA"
    },
    {
        "text": "therefore , when DB00328 and ddrug1 are used concomitantly , serum DB00390 levels should be closely monitored .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB02325 { # g/kg body weight : approximately # ml of absolute alcohol in a # kg person } and DB00862 plasma levels were not altered when dosed simultaneously .",
        "label": "NA"
    },
    {
        "text": "DB11326 may interact with the ddrug1 preparation causing a gritty substance to form or may interact with the preservative in the DB00249 preparation causing a toxic effect in the eye .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and DB00421 raise the serum DB00390 concentration due to a reduction in clearance and/or in volume of distribution of the drug , with the implication that ddrug9 intoxication may result .",
        "label": "mechanism"
    },
    {
        "text": "evidence supporting the conclusion that it is inadvisable to co-administer DB00176 and ddrug1 is derived from a study in which healthy volunteers taking # mg/day of ddrug2 were administered a single oral dose of # mg of DB00829 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 : ddrug2 and HD00374 containing ddrug4 or ddrug5 , as well as formulations containing divalent and trivalent cations such as ddrug6 { ddrug7 } , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with DB00978 and interfere with its bioavailability .",
        "label": "NA"
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of HD00539 such as ddrug1 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and HD00540 } , ddrug11 salts , ddrug12 , local ddrug13 , ddrug14 , and ddrug15 .",
        "label": "effect"
    },
    {
        "text": "other cardiovascular agents : ddrug0 and ddrug1 iv have been used concomitantly with ddrug2 , ddrug3 , DB14049 , ddrug5 , ddrug6 , ddrug7 and DB00390 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "DB00900 { ddrug1 } chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with , or within # hours of , the administration of ddrug2 , because these products may interfere with absorption resulting in lower serum and urine levels of DB01059 .",
        "label": "NA"
    },
    {
        "text": "HD00378 may exacerbate the hypertensive response seen with DB00575 withdrawl .",
        "label": "effect"
    },
    {
        "text": "DB00252 , ddrug1 , and ddrug2 may decrease ddrug3 plasma levels , resulting in a decrease in effectiveness of a previously effective DB00363 dose .",
        "label": "NA"
    },
    {
        "text": "haemodynamic effects of DB09341 and ddrug1 were additive when DB09099 was co-administered but not under basal conditions .",
        "label": "NA"
    },
    {
        "text": "since there have been conflicting results regarding the effect of ddrug0 levels , it is recommended that DB00390 levels be monitored when initiating , adjusting , and discontinuing DB00343 therapy to avoid possible over - or under-digitalization .",
        "label": "advise"
    },
    {
        "text": "in vitro studies evaluating the minimum inhibitory concentration { mic } of ddrug0 , ddrug1 , ddrug2 , DB00415 / flucoxacillin , ddrug4 , ddrug5 , and ddrug6 demonstrated no evidence of incompatibility of these HD00002 with ddrug8 .",
        "label": "NA"
    },
    {
        "text": "results of studies in multiple sclerosis patients taking ddrug0 and concomitant ddrug1 { DB02325 # mcg i m once weekly } or DB05259 were inconclusive with regard to the need for dose adjustment of the ddrug4 or ddrug5 .",
        "label": "NA"
    },
    {
        "text": "in a comparison of ddrug0 tolerance in dogs anesthetized with DB01221 , ddrug2 , or ddrug3 , the dosage of ddrug4 needed to cause ventricular tachycardia was significantly higher , as was the ld50 of ddrug5 , with ddrug6 or ddrug7 than with DB00312 .",
        "label": "NA"
    },
    {
        "text": "hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose ddrug0 and HD00251 , specifically , ddrug2 , ddrug3 , ddrug4 and HD00253 .",
        "label": "NA"
    },
    {
        "text": "toxicologic and toxicokinetic studies in rats did not demonstrate any alterations in the clearance or toxicologic profile of either DB00563 or DB00026 when the two agents were administered together .",
        "label": "NA"
    },
    {
        "text": "HD00512 reduce the renal clearance of DB14507 and add a high risk of ddrug2 toxicity .",
        "label": "mechanism"
    },
    {
        "text": "upon administration of # mg of DB00862 with # mg tid DB00224 , the cmax and auc of ddrug2 were reduced by 40 % and 30 % , respectively .",
        "label": "mechanism"
    },
    {
        "text": "oral ddrug0 : in one study , ddrug1 was given to adult diabetics who were already receiving ddrug2 { n = 4 } , ddrug3 { n = 2 } ddrug4 with ddrug5 { n = 3 } or DB01016 with DB00914 { n = 6 } .",
        "label": "NA"
    },
    {
        "text": "physiological changes resulting from smoking cessation , with or without DB00184 replacement , may alter the pharmacokinetics of certain concomitant medications , such as ddrug1 and DB00277 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 : DB00983 should be administered with extreme caution in patients being treated with ddrug3 or ddrug4 because the action of DB00983 on the cardiovascular system may be potentiated by these agents .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration of once daily doses of DB00673 , as a tablet formulation comparable to # mg or # mg of the capsule formulation , with DB00715 # mg once daily , resulted in a decrease in auc by approximately 25 % and cmax , by approximately 20 % of both ddrug3 and ddrug4 .",
        "label": "mechanism"
    },
    {
        "text": "since the pharmacokinetics of ddrug0 were studied in patients treated with ddrug1 , the clearance of DB01008 at the recommended dose may be lower and exposure { auc } higher in patients not treated with DB00252 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00977 may inhibit the metabolism of DB00277 , leading to increased plasma concentrations .",
        "label": "mechanism"
    },
    {
        "text": "DB01174 : coadministration of DB00949 with ddrug2 causes an increase in ddrug3 plasma concentrations , in # otherwise healthy male volunteers ingesting ddrug4 , the steady-state trough { cmin } ddrug5 concentration was # micrograms/ml .",
        "label": "NA"
    },
    {
        "text": "- ddrug0 , oral { diabetes medicine you take by mouth } use of oral HD00899 with DB00891 may increase the chance of side effects affecting the blood and/or the side effects or oral ddrug3",
        "label": "effect"
    },
    {
        "text": "ddrug0 : reports suggest that HD00203 may diminish the antihypertensive effect of HD00499 .",
        "label": "effect"
    },
    {
        "text": "other concomitant therapy although specific interaction studies were not performed , DB01216 doses of # mg or more were concomitantly used in clinical studies with ddrug1 , ddrug2 , a-blockers , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , cardiac ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 { also referred to as ddrug14 } , and HD00729 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "thus , the interaction observed between ddrug0 and DB00342 is not expected for DB00954 .",
        "label": "NA"
    },
    {
        "text": "- a sulfa-based drug such as DB01015 - ddrug1 { ddrug2 , ddrug3 } , DB00263 { ddrug5 } , or ddrug6 { ddrug7 } ;",
        "label": "NA"
    },
    {
        "text": "co-administration of ddrug0 and DB00675 resulted in a reduction of ddrug2 plasma levels by 27 % compared with those achieved with DB01217 alone .",
        "label": "NA"
    },
    {
        "text": "ddrug0 therapy : urinary excretion of HD00401 is increased , and efficacy is reduced , by HD00569 used in ddrug3 therapy .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : in a clinical pharmacology study , coadministration of an ddrug1 { ddrug2 , ddrug3 , and ddrug4 } with ddrug5 reduced serum levels and urinary excretion of DB14207 as compared with ddrug7 administered alone , suggesting that HD00374 may impair absorption of ddrug9 .",
        "label": "NA"
    },
    {
        "text": "as with other HD00482 , if DB01136 is to be administered orally with ddrug2 of the ddrug3 or ddrug4 type , it is recommended that ecg and blood pressure be monitored .",
        "label": "NA"
    },
    {
        "text": "therefore , co-administration of DB00476 with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index , including certain ddrug1 { ddrug2 -lsb- ddrug3 -rsb- , such as ddrug4 , ddrug5 , and ddrug6 } , ddrug7 and ddrug8 { e , g , , DB01182 , ddrug10 } , should be approached with caution .",
        "label": "advise"
    },
    {
        "text": "human pharmacokinetics data indicate that oral DB01026 potently inhibits the metabolism of DB00604 resulting in an eight-fold increase in the mean auc of ddrug2 .",
        "label": "mechanism"
    },
    {
        "text": "HD00401 may enhance the effects of HD00043 .",
        "label": "effect"
    },
    {
        "text": "administration of ddrug0 with HD00374 containing ddrug2 , ddrug3 , or ddrug4 , with ddrug5 , with metal cations such as ddrug6 , or with DB00152 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral ddrug0 , HD00106 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 { e , g , , DB00104 } , ddrug10 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , in the absence of DB09341 or DB00277 , caused excessive gcg release in the diabetics and undetectable insulin release in either diabetics or normals .",
        "label": "NA"
    },
    {
        "text": "DB00227 therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking HD00326 .",
        "label": "NA"
    },
    {
        "text": "-lsb- stimulation by ddrug0 -- an analog of the octapeptide cholecystokinin -- of ddrug1 binding after the long-term administration of ddrug2 -rsb- it has been established in experiments on white male rats that prolonged administration { twice a day for # days } of DB00502 { # mg/kg } and ddrug4 { # mg/kg } resulted in the reduced interaction between ddrug5 and low affinity binding sites for DB00714 in subcortical structures , whereas ddrug7 binding with high affinity binding sites for ddrug8 increased both in the frontal cortex and subcortical structures of the forebrain .",
        "label": "NA"
    },
    {
        "text": "if signs and symptoms suggestive of DB00390 toxicity occur when DB00467 and ddrug2 are given concomitantly , physicians are advised to obtain serum ddrug3 levels and adjust ddrug4 doses appropriately .",
        "label": "NA"
    },
    {
        "text": "no depressant effect on blood levels in humans was noted when DB00375 was administered with any of the following drugs : ddrug1 , ddrug2 , DB00636 , ddrug4 , ddrug5 { ddrug6 } , ddrug7 , ddrug8 or ddrug9 .",
        "label": "NA"
    },
    {
        "text": "interaction of DB01190 and DB00798 in vitro .",
        "label": "int"
    },
    {
        "text": "HD00219 and ddrug1 may reduce or reverse the pressor effect of DB00668 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 with DB01151 or DB00344 and possibly other ddrug3 cause striking and sustained increases in the concentration of ddrug4 in the brain ;",
        "label": "NA"
    },
    {
        "text": "DB01016 : in a randomized , multiple-dose crossover study , patients with type # diabetes were administered # mg DB00731 three times a day before meals for # day in combination with ddrug2 # mg daily .",
        "label": "NA"
    },
    {
        "text": "it is recommended that serum DB14507 levels be monitored frequently if DB00584 is administered concomitantly with ddrug2 .",
        "label": "NA"
    },
    {
        "text": "the results indicate that a spinal DB01183 - sensitive endorphinergic system is involved in the production of ddrug1 but not ddrug2 - induced tail-flick inhibition , and suggest that intraventricular HD00144 and ddrug4 elicit their pharmacological actions via the activation of different descending pain inhibitory systems ;",
        "label": "NA"
    },
    {
        "text": "moreover , additional interaction studies with DB00627 and ddrug1 have not demonstrated any effect on ddrug2 plasma levels , and administration to a patient population chronically receiving DB00390 resulted in no difference in the extent of bioavailability of ddrug4 relative to control data .",
        "label": "NA"
    },
    {
        "text": "specific effects of ddrug0 on other HD00703 DB00252 : ddrug3 causes an increase in steady-state ddrug4 plasma concentrations .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration of ddrug1 , a p_glycoprotein substrate , with oral DB00872 resulted in a reduction in clearance and an increase in DB00390 cmax and auc values .",
        "label": "NA"
    },
    {
        "text": "poor metabolizers of ddrug0 : interactions of DB01136 with strong inhibitors of cyp2d6 { such as ddrug2 , ddrug3 , ddrug4 , and DB01182 } have not been studied , but these drugs would be expected to increase blood levels of the r { + } enantiomer of ddrug6 .",
        "label": "NA"
    },
    {
        "text": "DB00375 - concomitant intake of ddrug1 and DB01022 may reduce the absorption of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 HD00524 may delay or reduce the absorption of concomitant oral medication such as ddrug2 , ddrug3 , ddrug4 { acidic } or ddrug5 { basic } , as well as ddrug6 ddrug7 , ddrug8 , thyroid and ddrug9 preparations , ddrug10 and ddrug11 , and HD00118 .",
        "label": "NA"
    },
    {
        "text": "other drug interactions : no pharmacokinetic interactions were observed between DB00862 and the following drugs : DB01016 , ddrug2 , ddrug3 , ddrug4 , and ddrug5 .",
        "label": "NA"
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the ddrug0 of drugs may be potentiated by ddrug1 , ddrug2 , ddrug3 , ddrug4 , HD00557 , the ddrug6 , HD00559 and ddrug8 , ddrug9 and the ddrug10 , and by other ddrug11 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , DB01174 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { HD00531 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00465 iv/im reduced the ddrug2 response to DB00695 in normovolemic healthy subjects by approximately 20 % { mean sodium and urinary output decreased 17 % } .",
        "label": "effect"
    },
    {
        "text": "specific effects of DB00949 on other ddrug1 DB00252 : ddrug3 causes an increase in steady-state ddrug4 plasma concentrations .",
        "label": "NA"
    },
    {
        "text": "HD00264 / ddrug1 / ddrug2 / HD00263 : co-administration of ddrug4 with ddrug5 , ddrug6 , ddrug7 , and ddrug8 is likely to lead to an enhancement of effects .",
        "label": "NA"
    },
    {
        "text": "DB14513 / ddrug1 - containing ddrug2 : absorption of DB00943 is moderately reduced { approximately 25 % } when coadministered with ddrug4 / ddrug5 - containing ddrug6 .",
        "label": "NA"
    },
    {
        "text": "DB00284 may affect ddrug1 bioavailabillty and may require dose adjustment of ddrug2 by 16 % { 90 % confidence interval : 8 - 23 % } , decrease mean c max ddrug3 by 26 % { 90 % confidence interval : 16 - 34 % } and decrease mean trough concentrations of DB00390 by 9 % { 90 % confidence limit : 19 % decrease to 2 % increase } .",
        "label": "NA"
    },
    {
        "text": "the vasodilating effects of DB01020 may be additive with those of other HD00337 .",
        "label": "effect"
    },
    {
        "text": "DB00571 : may decrease HD00373 anti-inflammatory action by competing for the same receptors .",
        "label": "effect"
    },
    {
        "text": "and { ii } the effects of HD00121 were more efficiently inhibited by added cholesterol , the major membrane sterol in human cells , whereas the effects of DB00681 were more efficiently inhibited by ergosterol , the major membrane sterol in yeast .",
        "label": "NA"
    },
    {
        "text": "in a study in which the # mg ddrug0 orally disintegrating tablet was administered with and without DB00782 { an ddrug2 with multiple effects on the gi tract } to healthy volunteers , the auc of DB01068 was 10 % lower and the cmax of ddrug4 was 20 % lower when the orally disintegrating tablet was given with ddrug5 compared to when it was given alone .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { HD00548 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { DB01045 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "interactions with other cns agents : concurrent use of DB00854 with all ddrug1 { eg , ddrug2 , ddrug3 , ddrug4 , other ddrug5 , general ddrug6 , ddrug7 , ddrug8 , HD00219 , ddrug10 , ddrug11 and ddrug12 } may result in additive central nervous system depressant effects .",
        "label": "effect"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect : ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , ddrug5 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , DB00052 , ddrug11 , ddrug12 , HD00810 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "DB00836 and DB00295 { # and # mg/kg , s , c.",
        "label": "NA"
    },
    {
        "text": "when other HD00363 or ddrug1 are used concomitantly , there is the potential for DB01240 to increase the risk of bleeding .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , DB00636 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as HD00269 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "caution should also be taken in concurrent or serial use of other HD00249 and ddrug1 because they may enhance neomycin s nephrotoxicity and/or ototoxicity and potentiate DB00994 neuromuscular blocking effects .",
        "label": "NA"
    },
    {
        "text": "a rare , but serious , constellation of symptoms , termed serotonin syndrome , has been reported with the concomitant use of ddrug0 { ddrug1 } and agents for migraine therapy , such as DB00669 { ddrug3 } and DB00320 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 and DB00201 may enhance the effects of : other ddrug3 s , ddrug4 , general ddrug5 , ddrug6 such as ddrug7 , HD00460 , or other ddrug9 , causing increased cns depression .",
        "label": "effect"
    },
    {
        "text": "patients receiving HD00388 should be advised against the concurrent use of other HD00545 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 at 1 % { m/v } in the presence of free DB00151 had no significant effect on the r-value of HD00070 compared to ddrug3 alone .",
        "label": "NA"
    },
    {
        "text": "DB14513 - and ddrug1 - containing ddrug2 , administered concomitantly with DB00978 , significantly decreased the bioavailability { 48 % } of ddrug4 .",
        "label": "mechanism"
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit ddrug0 binding to serum proteins or alter the concentrations of serum binding proteins : ddrug1 and related ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 , ddrug7 , ddrug8 , HD00115 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , DB00675 .",
        "label": "NA"
    },
    {
        "text": "although inhibition of cyp 3a4/5 by HD00889 and HD00888 did occur at high concentrations , it is not likely to be of clinical significance .",
        "label": "NA"
    },
    {
        "text": "- ddrug0 and ddrug1 ddrug2 : HD00511 and ddrug4 ddrug5 have the potential of binding HD00029 and reducing ddrug7 absorption from the gastrointestinal tract",
        "label": "mechanism"
    },
    {
        "text": "medications can interfere with folate utilization , including : ddrug0 { such as ddrug1 , and ddrug2 } ddrug3 { sometimes prescribed to control blood sugar in type # diabetes } ddrug4 { used to control inflammation associated with crohn_disease and ulcerative colitis } ddrug5 { a HD00295 } ddrug7 there has been concern about the interaction between ddrug8 and DB00158 .",
        "label": "NA"
    },
    {
        "text": "DB00277 - combined administration of racemic DB00215 { 40 mg/day for # days } and the cyp1a2 substrate ddrug2 { single dose of # mg } did not affect the pharmacokinetics of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "therefore , when DB00999 and HD00294 are used concomitantly , the patient should be observed closely to determine if the desired effect of the ddrug2 is obtained .",
        "label": "advise"
    },
    {
        "text": "DB00405 can interact with ddrug1 or other ddrug2 { may potentiate the cns depressant effects of either these medications or ddrug3 } , ddrug4 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug5 } , and ddrug6 { concurrent use with HD00388 may prolong and intensify the anticholinergic and cns depressant effects of ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "in addition to bleeding associated with ddrug0 and ddrug1 , drugs that alter platelet function { such as ddrug2 , ddrug3 and DB00054 } may increase the risk of bleeding if administered prior to , during , or after DB00009 therapy .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : DB01364 may enhance the metabolic clearance of HD00175 , resulting in decreased blood levels and lessened physiologic activity , thus requiring an increase in ddrug3 dosage .",
        "label": "mechanism"
    },
    {
        "text": "no depressant effect on blood levels in humans was noted when ddrug0 was administered with any of the following drugs : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 { ddrug6 } , DB01124 , DB00252 or ddrug9 .",
        "label": "NA"
    },
    {
        "text": "pharmacokinetic interaction studies with DB00341 in adults were conducted with DB00852 , ddrug2 , ddrug3 , ddrug4 and ddrug5 .",
        "label": "NA"
    },
    {
        "text": "- in isolated cases , a pronounced though reversible , impairment of renal function { accompanied by a corresponding increase in the serum creatinine level } has been reported in organ transplant patients receiving HD00417 therapy and concomitant DB01393 .",
        "label": "effect"
    },
    {
        "text": "results of preliminary studies in humans and rats suggest that nonabsorbable HD00374 given concurrently with DB00581 may inhibit the desired ddrug2 - induced drop in colonic ph .",
        "label": "mechanism"
    },
    {
        "text": "- ddrug0 { e , g , , DB00313 } use of DB00891 with these medicines may increase the chance of side effects affecting the liver",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 should be used with caution in patients receiving - HD00305 blocking agents { e , g , , ddrug3 , a ddrug4 inhibitor } or HD00306 antagonists { e , g , , ddrug6 , a ddrug7 substrate , and ddrug8 , a ddrug9 inhibitor } because of the possible potentiation of bradycardia , sinus arrest , and av block ;",
        "label": "NA"
    },
    {
        "text": "concomitant administration of DB00962 { 10 mg } and DB00501 { 800 mg } produced an 85 % increase in the mean cmax and auc of ddrug2 .",
        "label": "mechanism"
    },
    {
        "text": "no interaction trials have been conducted with DB01117 and DB00615 .",
        "label": "NA"
    },
    {
        "text": "in the first double-blind comparative study { 28-week } of DB00334 and DB00734 , ddrug2 # to # mg/day proved to be significantly more effective than ddrug3 # to # mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and DB00759 , ddrug6 { DB00252 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "- drugs that may decrease plasma DB00252 concentrations include : ddrug1 , chronic ddrug2 abuse , DB00206",
        "label": "mechanism"
    },
    {
        "text": "the behavioral effects of the stereoisomers of HD00154 { ddrug1 } were compared with those of DB03575 { ddrug3 } in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio { fi fr } schedule of food presentation .",
        "label": "NA"
    },
    {
        "text": "most cases of serious or fatal adverse events involving DB00854 reported to the manufacturer or the fda have involved either the administration of large initial doses or too frequent doses of the drug to nonopioid tolerant patients , or the simultaneous administration of DB00854 with other drugs affecting respiration .",
        "label": "NA"
    },
    {
        "text": "specific and aspecific treatments of ddrug0 depletion are tricky using for example HD00193 , pharmacological doses of ddrug2 , physiological doses of DB11094 and of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "consequently , concomitant administration of DB00673 with strong cyp3a4 inhibitors { e , g , , ddrug1 , DB01167 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } should be approached with caution .",
        "label": "advise"
    },
    {
        "text": "ddrug0 { ddrug1 , DB00594 , ddrug3 , and others } or DB14500 supplements can increase the risk of hyperkalemia .",
        "label": "NA"
    },
    {
        "text": "it is recommended that DB00490 not be used concomitantly with ddrug1 because the effects of concomitant administration of DB00490 with most other ddrug3 have not been studied , the concomitant use of ddrug4 with other cns-active drugs should be approached with caution .",
        "label": "NA"
    },
    {
        "text": "other drugs : in healthy volunteers , DB00381 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , hormone replacement therapy { a combination of conjugated ddrug5 and ddrug6 } , ddrug7 { ddrug8 and ddrug9 } and DB00277 did not affect the pharmacokinetics of ddrug11 .",
        "label": "NA"
    },
    {
        "text": "additional reductions in blood pressure may occur when DB01240 is administered with ddrug1 , HD00366 , or other ddrug3 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 , ddrug1 : HD00401 may enhance the activity of ddrug3 or HD00571 ;",
        "label": "effect"
    },
    {
        "text": "endothelium-intact aortic rings from high - DB00783 rats were supersensitive to ddrug1 when compared to vehicle - , DB00396 - and ddrug3 + high - ddrug4 - treated rats { pd2 values = # + / # , # + / # , # + / # and # + / # , respectively } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 : ddrug2 should be administered with extreme caution in patients being treated with HD00275 or ddrug4 because the action of DB00983 on the cardiovascular system may be potentiated by these agents .",
        "label": "NA"
    },
    {
        "text": "due to its nephrotoxicity , DB00798 may cause abnormal renal uptake to be seen on HD00173 bone scintigraphy .",
        "label": "mechanism"
    },
    {
        "text": "drug/laboratory test interactions the urine of patients who take DB00749 can give a false-positive reaction for urinary bilirubin { urobilin } due to the presence of phenolic metabolites of DB00749 .",
        "label": "NA"
    },
    {
        "text": "- ddrug0 and ddrug1 ddrug2 : HD00511 and ddrug4 HD00510 have the potential of binding ddrug6 and reducing ddrug7 absorption from the gastrointestinal tract",
        "label": "NA"
    },
    {
        "text": "particular caution should be exercised in using preparations containing ddrug0 , ddrug1 , or DB00645 in combination with DB00210 gel .",
        "label": "NA"
    },
    {
        "text": "DB00619 will increase plasmaconcentration of other cyp3a4 metabolized drugs { e , g , , triazolo - ddrug1 , ddrug2 , certain HD00095 , etc , } .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : immediate release capsules : there have been rare reports of an interaction between DB00908 and DB01115 { with a decreased plasma level of ddrug3 } .",
        "label": "mechanism"
    },
    {
        "text": "- a ddrug0 { HD00725 } such as ddrug2 { ddrug3 } , DB00752 { ddrug5 } , or ddrug6 { ddrug7 } ;",
        "label": "NA"
    },
    {
        "text": "DB00950 had no effect on the pharmacokinetics of either DB00199 or ddrug2 .",
        "label": "NA"
    },
    {
        "text": "the hypoglycemic effect of DB01124 has been reported to increase when HD00548 is given concurrently .",
        "label": "effect"
    },
    {
        "text": "- a HD00380 such as ddrug1 { ddrug2 } , ddrug3 { ddrug4 } , DB01193 { ddrug6 } , ddrug7 { ddrug8 } , and others ;",
        "label": "NA"
    },
    {
        "text": "drug interactions with HD00374 administration of # mg of ddrug1 { 2 x # mg capsule } within # minutes of an DB01370 and ddrug3 containing ddrug4 { ddrug5 } decreased ddrug6 auc by 41 % and cmax by 43 % .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect : HD00175 , ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , ddrug5 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , HD00810 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { DB00682 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } DB00501 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "these data suggest that DB14152 are negatively coupled to three types of calcium channels in bovine chromaffin cell , including an HD00047 - sensitive { n-type } channel , an ddrug2 - sensitive { p-type } channel and ddrug3 / ddrug4 / ddrug5 - resistant { presumptive q-type } channel .",
        "label": "NA"
    },
    {
        "text": "DB00604 should not be used concomitantly with other drugs known to prolong the qt interval : certain ddrug1 , including those of class ia { such as ddrug2 and ddrug3 } and class iii { such as DB00489 } ;",
        "label": "advise"
    },
    {
        "text": "these pharmacokinetic effects seen during DB00343 coadministration can result in increased clinical effects { e , g , , prolonged sodation } of both ddrug1 and DB00897 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 , nondepolarizing { e , g , , DB01199 } : possible increased responsiveness to the HD00784 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the effect of steady-state ddrug1 l50 mg bid on the pharmacokinetics of a single dose of DB00277 { 375 mg } as # mg DB01223 was evaluated in # healthy non-smoking , male volunteers .",
        "label": "NA"
    },
    {
        "text": "in clinical studies performed with ddrug0 , the concomitant use of oral ddrug1 { ddrug2 } , ddrug3 { ddrug4 } , ddrug5 { ddrug6 } , and DB00390 did not significantly affect the pharmacokinetics/pharmacodynamics of DB00569 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 may enhance the effects of : other ddrug3 s , ddrug4 , general ddrug5 , ddrug6 such as DB00475 , ddrug8 , or other HD00261 , causing increased cns depression .",
        "label": "NA"
    },
    {
        "text": "if concomitant treatment with DB00669 and an HD00278 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } is clinically warranted , appropriate observation of the patient is advised .",
        "label": "advise"
    },
    {
        "text": "there has been little experience with the coadministration of ddrug0 and either DB00280 or DB00661 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 is not recommended for use in patients who have received HD00725 within # days because severe and unpredictable potentiation by ddrug3 has been reported with HD00726",
        "label": "NA"
    },
    {
        "text": "there are no significant effects on ddrug0 pharmacokinetics if the DB06724 is administered # hours before or # hours after DB00535 .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } DB01235 ddrug16 HD00542 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "DB00458 and DB01068 did not change fasting or overload glycemia .",
        "label": "NA"
    },
    {
        "text": "lack of an effect of ddrug0 on the disposition of DB00495 and DB00900 in hiv-infected patients .",
        "label": "NA"
    },
    {
        "text": "the administration of lower doses of DB00862 with HD00266 has not been completely evaluated to determine if they can be safely administered together .",
        "label": "NA"
    },
    {
        "text": "clinical studies have shown that DB00328 does not influence the hypoprothrombinemia produced by HD00326 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00945 may decrease the effects of ddrug2 , DB01138 , and ddrug4 .",
        "label": "effect"
    },
    {
        "text": "the elimination half life of DB00683 and ddrug1 also increased { # # fold } during coadministration with DB00343 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : DB00997 caused a decrease in DB00943 phosphorylation { 50 % inhibition of total phosphate formation } in u937/molt # cells .",
        "label": "effect"
    },
    {
        "text": "as with other ddrug0 , if DB01136 is to be administered orally with HD00377 of the ddrug3 or ddrug4 type , it is recommended that ecg and blood pressure be monitored .",
        "label": "NA"
    },
    {
        "text": "no depressant effect on blood levels in humans was noted when DB00375 was administered with any of the following drugs : ddrug1 , ddrug2 , ddrug3 , DB00968 , ddrug5 { ddrug6 } , ddrug7 , ddrug8 or ddrug9 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 { hypertension } - in clinical studies of patients with hypertension , the addition of DB00700 # to # mg to ddrug3 and HD00466 increased mean serum potassium slightly { about # # meq/l } .",
        "label": "effect"
    },
    {
        "text": "DB00294 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { DB00252 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "int"
    },
    {
        "text": "in patients taking an ddrug0 { eg , ddrug1 , ddrug2 , ddrug3 or DB00252 } , the concomitant use of DB00358 may reduce seizure control by lowering the plasma levels of the ddrug6 .",
        "label": "effect"
    },
    {
        "text": "clinical studies with DB00482 have identified potentially significant interactions with DB00196 and ddrug2 .",
        "label": "int"
    },
    {
        "text": "DB00978 is unlikely to have a significant effect on DB00252 metabolism .",
        "label": "NA"
    },
    {
        "text": "a dose adjustment is not needed when DB00495 is administered with DB00220 .",
        "label": "advise"
    },
    {
        "text": "prior administration of DB01213 { 90 mg kg { -1 } body weight } was shown to prevent the conversion of ddrug1 { 100 mg kg { -1 } body weight } to HD00078 in vivo and to eliminate the fluoride and citrate elevations seen in ddrug3 - intoxicated animals .",
        "label": "NA"
    },
    {
        "text": "due to wide interindividual variability in the dose adjustment required , it is recommended that DB00091 concentrations be monitored closely after initiation of DB01136 therapy and that the dose of ddrug2 be adjusted as appropriate .",
        "label": "advise"
    },
    {
        "text": "although there was no effect of ddrug0 on the plasma auc of HD00347 or ddrug2 determined on day 3 , there was a 34 % decrease in HD00348 { a cyp2c9 substrate } trough concentration accompanied by a 14 % decrease in the prothrombin time { reported as international normalized ratio or inr } # days after completion of dosing with ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a study in # patients with congestive heart failure where DB01009 and ddrug2 were concomitantly administered , ddrug3 did not alter the serum levels of DB00390 .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect : ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , ddrug5 , DB01001 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , HD00810 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "potential drug interactions between DB01202 and other ddrug1 { DB00564 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 and ddrug8 } were also assessed by evaluating the serum concentrations of ddrug9 and these ddrug10 during placebo-controlled clinical studies .",
        "label": "NA"
    },
    {
        "text": "when such drugs are withdrawn from patients receiving DB00284 in combination with ddrug1 or HD00071 , patients should be observed closely for any evidence of hypoglycemia .",
        "label": "NA"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { HD00403 s } , ddrug2 , ddrug3 { ddrug4 may decrease the effects of these medicines } , ddrug5 { using these medicines with HD00026 may result in increased cns depressant effects } , ddrug7 , ddrug8 { using these medicines with ddrug9 may change the amount of either medicine that you need to take } , and oral ddrug10 containing ddrug11 { ddrug12 may decrease the effectiveness of these oral ddrug13 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "HD00044 - induced oxidative stress in rat brain and liver is prevented by DB00163 or ddrug2 .",
        "label": "effect"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , ddrug3 ddrug4 : DB00637 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 ddrug11 , ddrug12 gi motility agents : DB00604",
        "label": "NA"
    },
    {
        "text": "injection : ddrug0 injection , like other injectable ddrug1 , produces depression of the central nervous system when administered with ddrug2 , ddrug3 , HD00026 , ddrug5 , and other HD00216 , when ddrug7 is used concomitantly with injectable ddrug8 , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : no clinically significant changes occurred in heart rate or corrected qt intervals , or in DB00342 metabolite or ddrug2 pharmacokinetics , during concurrent administration of DB00978 and ddrug4 at steady-state in # healthy males .",
        "label": "NA"
    },
    {
        "text": "ddrug0 / ddrug1 : the coadministration of DB00252 or ddrug3 will not affect plasma concentrations of DB11094 , but may reduce endogenous plasma levels of ddrug5 / ergocalcitriol by accelerating metabolism .",
        "label": "NA"
    },
    {
        "text": "the concomitant administration of DB00559 and HD00433 is contraindicated .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : coadministration of single doses of DB00402 # mg and DB00186 # mg did not have clinically relevant effects on the pharmacodynamics or pharmacokinetics of either drug .",
        "label": "NA"
    },
    {
        "text": "HD00093 { e , g , ddrug1 and ddrug2 } : agents of the ddrug3 , of which ddrug4 { ddrug5 } injection , usp is a member , have been shown to interact with ddrug6 of the HD00626 , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , DB00860 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and DB00126 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 , DB14507 salts , and ddrug3 may either potentiate or weaken the blood-glucose-lowering effect of HD00071 .",
        "label": "effect"
    },
    {
        "text": "DB01221 is clinically compatible with the commonly used general and local HD00822 when an adequate respiratory exchange is maintained .",
        "label": "NA"
    },
    {
        "text": "therefore , when ddrug0 and HD00700 are used concomitantly , the patient should be observed closely to determine if the desired effect of the HD00295 is obtained .",
        "label": "NA"
    },
    {
        "text": "ddrug0 should not be used concomitantly with other drugs known to prolong the qt interval : certain HD00303 , including those of class ia { such as ddrug2 and DB01035 } and class iii { such as ddrug4 } ;",
        "label": "NA"
    },
    {
        "text": "- a ddrug0 { HD00615 } such as ddrug2 { ddrug3 , DB01050 , ddrug5 , others } , ddrug6 { ddrug7 , ddrug8 , ddrug9 } , ddrug10 { ddrug11 , ddrug12 } , ddrug13 { ddrug14 } , ddrug15 { ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , and ddrug21 { ddrug22 , ddrug23 , ddrug24 } ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 : concomitant use of HD00591 and HD00175 may produce severe weakness in patients with myasthenia gravis .",
        "label": "effect"
    },
    {
        "text": "therefore , HD00432 , including oral , injectable , transdermal , and implantable forms , may not be reliable when DB00559 is co-administered .",
        "label": "effect"
    },
    {
        "text": "therefore , when DB00939 is given to a patient receiving ddrug1 , the dosage of DB00682 should be reduced to prevent excessive prolongation of the prothrombin time .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , DB00091 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , DB00231 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "before taking ddrug0 , tell your doctor if you are taking any of the following medicines : - DB00945 or another ddrug2 such as ddrug3 { ddrug4 } , DB01399 { ddrug6 , others } , ddrug7 { ddrug8 } , ddrug9 { ddrug10 } , or ddrug11 { ddrug12 } ;",
        "label": "NA"
    },
    {
        "text": "specific and aspecific treatments of ddrug0 depletion are tricky using for example HD00193 , pharmacological doses of DB00165 , physiological doses of ddrug3 and of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "patients who are treated with DB00601 and concomitant HD00851 should be closely observed for signs and symptoms of serotonin syndrome { e , g , , cognitive dysfunction , hyperpyrexia , hyperreflexia , incoordination } .",
        "label": "effect"
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 : ddrug3 has no significant pharmacokinetic interactions with DB00390 and ddrug5 , and ddrug6 has no significant effect on plasma levels of DB00559 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and DB00215 - in a controlled study , a single dose of ddrug2 # mg co-administered with racemic ddrug3 # mg given once daily for # days was associated with a mean increase in qtc values of approximately # msec compared to DB01100 given alone .",
        "label": "NA"
    },
    {
        "text": "the similarity of the ddrug0 - associated adverse event profile between study # { without co-administered ddrug1 } and study # { with co-administered DB02325 } indicates that this alteration in clearance does not necessitate reduction of the DB00108 dose to maintain safety , general } .",
        "label": "NA"
    },
    {
        "text": "in clinical studies , coadministration of DB00930 with ddrug1 , ddrug2 , or ddrug3 did not interfere with the lipid-lowering activity of the HD00383 .",
        "label": "NA"
    },
    {
        "text": "may interact with the following : ddrug0 { these medicines may make your condition worse and prevent the HD00815 from working properly } and DB00280 , ddrug3 , ddrug4 , and ddrug5 { these medicines may increase the risk of heart problems } .",
        "label": "NA"
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma ddrug0 concentrations include : acute DB02325 intake , ddrug2 , chboramphenicol , ddrug3 , DB00501 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21",
        "label": "NA"
    },
    {
        "text": "ddrug0 : administration of HD00620 concomitantly with ddrug2 has been associated with an increase in DB00091 - induced toxicity , possibly due to decreased synthesis of renal prostacyclin .",
        "label": "NA"
    },
    {
        "text": "however , since ddrug0 , ddrug1 , and HD00794 are all associated with gastrointestinal irritation , caution should be exercised in the concomitant use of DB00945 or ddrug4 with ddrug5 .",
        "label": "NA"
    },
    {
        "text": "the concurrent use of two or more drugs with anticholinergic activity -- such as an ddrug0 { eg , ddrug1 } , an HD00514 { eg , ddrug3 } , and/or a HD00042 { eg , ddrug5 } -- commonly results in excessive anticholinergic effects , including dry mouth and associated dental complications , blurred vision , and , in patients exposed to high temperature and humidity , hyperpyrexia .",
        "label": "effect"
    },
    {
        "text": "therefore , co-administration of DB01156 with drugs that are metabolized by cyp2d6 isoenzyme including certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } , ddrug8 { e , g , , DB00502 , ddrug10 , ddrug11 } , ddrug12 { e , g , , ddrug13 } , and ddrug14 { e , g , , ddrug15 , ddrug16 } , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .",
        "label": "advise"
    },
    {
        "text": "reciprocal interactions may occur with concomitant use of DB01213 and drugs that increase or inhibit the cytochrome cyp2b6 system { e , g , , DB00252 , ddrug2 , ddrug3 , ddrug4 } , though this has not been studied",
        "label": "mechanism"
    },
    {
        "text": "DB00877 works differently from the HD00128 currently available , and except for increased lipid levels , the adverse reaction profile of ddrug2 does not appear to overlap to any great extent with that associated with ddrug3 or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 in combination with other ddrug1 , general HD00264 , ddrug3 , ddrug4 , ddrug5 , or other HD00261 { including ddrug7 } has additive depressant effects .",
        "label": "NA"
    },
    {
        "text": "like ddrug0 { 40 mg/kg } , ddrug1 { 40 mg/kg } decreases the intravenous self-administration of DB00295 and DB00907 and the oral self-administration of ddrug4 and ddrug5 in rats ;",
        "label": "NA"
    },
    {
        "text": "drug interactions : the central ddrug0 syndrome can occur when anticholinergic agents such as DB00810 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain ddrug2 such as ddrug3 , the ddrug4 and other ddrug5 , HD00043 , certain ddrug7 such as the ddrug8 salts , and ddrug9 .",
        "label": "effect"
    },
    {
        "text": "HD00282 : DB00252 ddrug2 ddrug3",
        "label": "NA"
    },
    {
        "text": "DB00458 may potentiate the effects of HD00545 .",
        "label": "effect"
    },
    {
        "text": "DB01432 ddrug1 may delay or reduce the absorption of concomitant oral medication such as ddrug2 , DB00682 , ddrug4 { acidic } or ddrug5 { basic } , as well as ddrug6 ddrug7 , ddrug8 , thyroid and ddrug9 preparations , ddrug10 and ddrug11 , and ddrug12 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : DB01032 , a renal tubular secretion blocking agent , administered at a dose of # mg four times a day , did not change the pharmacokinetics of DB01202 # mg twice daily .",
        "label": "NA"
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of HD00472 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 { 1 } , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 { 1 } , ddrug10 , ddrug11 , grapefruit juice , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21 , ddrug22 , DB13179 , ddrug24 { 1 } , ddrug25 , ddrug26 .",
        "label": "mechanism"
    },
    {
        "text": "the use of DB00514 may result in additive cns depressant effects when coadministered with DB02325 , ddrug2 , ddrug3 or other drugs that produce cns depression .",
        "label": "effect"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } HD00220 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } DB01235 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 may enhance the effects of : other ddrug3 s , ddrug4 , general HD00264 , HD00262 such as ddrug7 , ddrug8 , or other ddrug9 , causing increased cns depression .",
        "label": "NA"
    },
    {
        "text": "drugs that induce hepatic enzymes such as ddrug0 , DB00252 and ddrug2 may increase the clearance of ddrug3 and may require increases in HD00579 dose to achieve the desired response .",
        "label": "advise"
    },
    {
        "text": "however , the systemic administration of some ddrug0 has been shown to elevate plasma concentrations of ddrug1 , interfere with the metabolism of ddrug2 , and enhance the effects of the oral HD00025 DB00682 and its derivatives , and has been associated with transient elevations in serum creatinine in patients receiving systemic ddrug5 concomitantly .",
        "label": "NA"
    },
    {
        "text": "other drugs : in healthy volunteers , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , hormone replacement therapy { a combination of conjugated HD00220 and ddrug6 } , ddrug7 { ddrug8 and DB09104 } and ddrug10 did not affect the pharmacokinetics of ddrug11 .",
        "label": "NA"
    },
    {
        "text": "drug interaction with DB00199 and DB01026 ddrug2 has been shown to exhibit minimal { ca , 5 % } metabolism .",
        "label": "NA"
    },
    {
        "text": "systemic exposure to DB00316 is expected to be increased when coadministered with DB00619 .",
        "label": "mechanism"
    },
    {
        "text": "in a pharmacokinetic study , # healthy female subjects received DB01026 # mg twice daily for # days , with coadministration of DB00969 # mg on the last day .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : potential interactions between DB00776 and other HD00714 were assessed in clinical studies .",
        "label": "NA"
    },
    {
        "text": "ddrug0 attenuates , but HD00022 potentiates , the acute locomotor effects of DB00295 ;",
        "label": "effect"
    },
    {
        "text": "ddrug0 s : after repeated co-administration of DB00776 , the auc of DB01023 was lowered by 28 % -lsb- 90 % ci : 20 - 33 -rsb- .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { DB00400 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , DB00277 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "in vivo interaction studies in humans have demonstrated that DB00390 and ddrug1 do not affect the pk properties of DB00261 , nor does ddrug3 affect the pk properties of ddrug4 or ddrug5 .",
        "label": "NA"
    },
    {
        "text": "in a patient with a nonfunctioning thyroid gland who is receiving thyroid replacement therapy , free DB00451 may be decreased when HD00220 are started thus increasing ddrug2 requirements .",
        "label": "mechanism"
    },
    {
        "text": "however , neither ddrug0 nor DB00829 appears to affect DB01219 metabolism .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : seizures have been reported in patients taking DB00467 concomitantly with the ddrug2 DB08981 .",
        "label": "effect"
    },
    {
        "text": "other cardiovascular agents : ddrug0 and ddrug1 iv have been used concomitantly with ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB01275 , ddrug7 and DB00390 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "in separate studies of patients receiving maintenance doses of ddrug0 , ddrug1 , or ddrug2 , ddrug3 administration for # days had no effect on the pharmacodynamics of DB00682 { prothrombin time } or pharmacokinetics of DB00390 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 or ddrug1 : the risk of myopathy/rhabdomyolysis is increased when either ddrug2 or DB00661 is used concomitantly with a closely related member of the HD00861 { see warnings , myopathy/rhabdomyolysis } .",
        "label": "effect"
    },
    {
        "text": "drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving ddrug0 metabolized similarly to ddrug1 or on the basis of in vitro studies with ddrug2 or other ddrug3 { caution is recommended during coadministration with ddrug4 } : available data from clinical studies of HD00100 other than ddrug6 suggest a possible drug interaction with ddrug7 for the following : DB00343 , ddrug9 , ddrug10 such as ddrug11 and ddrug12 , and grapefruit juice .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , DB00316 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , ddrug8 { HD00398 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "plasma concentrations of HD00279 are decreased when administered with ddrug1 containing DB14513 , ddrug3 , or ddrug4 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : the addition of DB00906 to patients taking DB00313 chronically had no effect on ddrug3 pharmacokinetics , but ddrug4 significantly decreased ddrug5 binding in vitro from # to # % , which resulted in an increase of approximately 40 % in the free tiagabine concentration .",
        "label": "NA"
    },
    {
        "text": "we demonstrate that the conversion of HD00079 to HD00077 by an nad + - dependent oxidation is the rate-limiting step in the synthesis of the toxic product , ddrug2 from ddrug3 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 may enhance the effects of : other ddrug3 s , DB02325 , general ddrug5 , HD00262 such as ddrug7 , ddrug8 , or other ddrug9 , causing increased cns depression .",
        "label": "NA"
    },
    {
        "text": "DB00390 : in patients with hypercholesterolemia , concomitant administration of DB00227 and ddrug2 resulted in no effect on ddrug3 plasma concentrations .",
        "label": "NA"
    },
    {
        "text": "immediate and extended release tablets the hypoglycemic action of ddrug0 may be potentiated by certain drugs including ddrug1 , some HD00768 and other drugs that are highly protein bound , ddrug3 , ddrug4 , ddrug5 , ddrug6 , HD00519 , ddrug8 , and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "the potential for drug interactions with DB00879 has been studied in combination with DB00224 , ddrug2 , ddrug3 , and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "the action of the HD00100 may be potentiated by ddrug1 , ddrug2 , DB02325 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , or other drugs that produce cns depression .",
        "label": "effect"
    },
    {
        "text": "use of ddrug0 DB00945 and DB01109 have been administered concomitantly with and following infusions of ddrug3 in the management of acute myocardial infarction or pulmonary embolism .",
        "label": "NA"
    },
    {
        "text": "background : the effects of combined administration of DB11724 and ddrug1 { ddrug2 } , a HD00038 , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by ddrug4 { ddrug5 } and the labeling index of intestinal_cancer were investigated in male wistar rats .",
        "label": "NA"
    },
    {
        "text": "literature reports indicate that coadministration of DB00328 may reduce the natriuretic and antihypertensive effects of DB00695 in some patients by inhibiting prostaglandin synthesis .",
        "label": "effect"
    },
    {
        "text": "- DB04948 may enhance the cns depressive effects of ddrug1 , ddrug2 and other HD00024",
        "label": "effect"
    },
    {
        "text": "the ddrug0 { ddrug1 and DB01132 } , a new class of oral HD00075 , are insulin sensitizers .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00477 blocks dopamine and norepinephrine reuptake , thus inhibiting the central stimulant effects of ddrug2 , and can be used to treat DB00182 poisoning .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 HD00388 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 HD00542 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "however , DB01088 has the potential to increase the hypotensive effect of ddrug1 and HD00366 .",
        "label": "effect"
    },
    {
        "text": "the hypoglycemic action of ddrug0 may be potentiated by certain drugs including HD00518 and other drugs that are highly protein bound , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , and HD00520 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - although ddrug1 did not potentiate the cognitive and motor effects of ddrug2 in a clinical trial , as with other HD00281 , the use of ddrug4 by patients taking DB01175 is not recommended .",
        "label": "advise"
    },
    {
        "text": "ddrug0 - and/or ddrug1 - containing ddrug2 , products containing ddrug3 { ddrug4 } , ddrug5 containing DB01593 or other metal cations , or ddrug7 { DB00900 } chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after ddrug9 .",
        "label": "NA"
    },
    {
        "text": "DB00501 { 400 mg b , i , d , } had no effect on DB00862 bioavailability { auc } and maximum concentration { cmax } of ddrug2 when co-administered with # mg ddrug3 in healthy volunteers .",
        "label": "NA"
    },
    {
        "text": "the ddrug0 , including DB00404 , produce additive cns depressant effects when co-administered with other ddrug2 , ddrug3 , ddrug4 , DB00898 , and other drugs which themselves produce cns depression .",
        "label": "effect"
    },
    {
        "text": "since DB00442 is primarily eliminated by the kidneys , coadministration of DB00442 with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either ddrug2 or the coadministered drug .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { ddrug1 } : population pharmacokinetic analyses indicate that DB00906 clearance is 60 % greater in patients taking ddrug3 { DB00794 } with or without other enzyme-inducing ddrug5 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 such as ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , DB00780 } , ddrug5 { e , g , , ddrug6 } , ddrug7 { e , g , , ddrug8 } , and ddrug9 { e , g , , ddrug10 } : using these medicines with DB00150 may increase the chance of side effects .",
        "label": "NA"
    },
    {
        "text": "HD00445 such as DB01247 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , ddrug5 { e , g , , ddrug6 } , ddrug7 { e , g , , ddrug8 } , and ddrug9 { e , g , , ddrug10 } : using these medicines with ddrug11 may increase the chance of side effects .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the concomitant use of DB00813 { ddrug2 transdermal system } with other ddrug3 , including but not limited to other ddrug4 , ddrug5 , ddrug6 , ddrug7 { e , g , , HD00100 } , general ddrug9 , ddrug10 , ddrug11 , and ddrug12 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : DB01118 should be used with caution in patients receiving - ddrug2 blocking agents { e , g , , ddrug3 , a HD00302 inhibitor } or ddrug5 antagonists { e , g , , ddrug6 , a ddrug7 substrate , and ddrug8 , a ddrug9 inhibitor } because of the possible potentiation of bradycardia , sinus arrest , and av block ;",
        "label": "NA"
    },
    {
        "text": "the effect of DB00204 on the steady-state pharmacokinetics of DB00390 was evaluated in a randomized , double-blind study .",
        "label": "NA"
    },
    {
        "text": "ddrug0 ddrug1 ddrug2 DB01211 DB00976 ddrug5 ddrug6 ddrug7 large quantities of grapefruit juice { # quart daily }",
        "label": "NA"
    },
    {
        "text": "based on the results of these studies , it is concluded that DB00207 may be safely coadministered with both DB00495 and ddrug2 .",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , DB14513 , or ddrug4 , with ddrug5 , with metal cations such as ddrug6 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as DB00900 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "drugs that reduce the number of blood platelets by causing bone marrow depression { such as HD00251 } or drugs which inhibit platelet function { eg , ddrug1 and other ddrug2 , ddrug3 , HD00331 , ddrug5 , ddrug6 } may increase the bleeding tendency produced by ddrug7 without altering prothrombin time determinations .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : anticoagulant activity should be monitored , particularly in the first few days after initiating or changing HD00897 therapy in patients receiving DB00682 or similar agents , since these patients are at an increased risk of bleeding complications .",
        "label": "advise"
    },
    {
        "text": "ddrug0 { e , g , , HD00219 , ddrug2 , ddrug3 } and ddrug4 may reduce the therapeutic effects of DB01235 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 absorption : the following agents may bind and decrease absorption of ddrug1 from the gastrointestinal tract : HD00845 , ddrug3 resin , ddrug4 , ddrug5 , ddrug6 , soybean flour { e , g , , infant formula } , DB00364 .",
        "label": "NA"
    },
    {
        "text": "- a HD00762 { ddrug1 } such as ddrug2 { ddrug3 } , ddrug4 { ddrug5 } , or DB00780 { ddrug7 } ;",
        "label": "NA"
    },
    {
        "text": "drug/laboratory tests interactions because false positive readings were reported with the ames n-multistix sg dipstick test for urinary protein when DB00996 was added to other HD00703 , the more specific sulfosalicylic_acid precipitation procedure is recommended to determine the presence of urine protein",
        "label": "NA"
    },
    {
        "text": "the pressor effects of HD00439 such as ddrug1 or ddrug2 are enhanced by HD00438 .",
        "label": "effect"
    },
    {
        "text": "interactions with HD00841 : ddrug1 { eg , ddrug2 , ddrug3 , DB00611 , ddrug5 and ddrug6 } should not be administered to a patient who has received or is receiving a course of therapy with a ddrug7 such as ddrug8 .",
        "label": "NA"
    },
    {
        "text": "these drugs include the ddrug0 and other HD00218 , HD00175 , phe-nothiazines , ddrug3 , ddrug4 , oral ddrug5 , ddrug6 , ddrug7 , sympathomimet-ics , ddrug8 , and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "- a ddrug0 { HD00615 } such as ddrug2 { ddrug3 , ddrug4 , ddrug5 , others } , ddrug6 { HD00760 , ddrug8 , ddrug9 } , ddrug10 { ddrug11 , ddrug12 } , ddrug13 { ddrug14 } , ddrug15 { ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , and ddrug21 { ddrug22 , ddrug23 , ddrug24 } ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 / DB01370 - containing HD00701 : absorption of ddrug3 is moderately reduced { approximately 25 % } when coadministered with ddrug4 / ddrug5 - containing ddrug6 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with ddrug1 , ddrug2 s , ddrug3 { allergy , cold , and sinus medicines } , diabetic drugs , ddrug4 , DB00368 , ddrug6 like DB00788 or ddrug8 , and high blood pressure medications .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00906 had no effect on the steady-state plasma concentrations of DB00564 or its epoxide metabolite in patients with epilepsy .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , DB00228 , and ddrug2 decrease the ed50 of DB01135 by 30 % to 45 % .",
        "label": "mechanism"
    },
    {
        "text": "cardiac effects of DB00988 are antagonized by HD00244 , such as ddrug2 and ddrug3 .",
        "label": "effect"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : DB00228 ; DB00753 ; ddrug3 ; certain ddrug4 , especially the ddrug5 and ddrug6 ; ddrug7 ; ddrug8 salts ; ddrug9 ; and ddrug10 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , DB00295 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , DB00277 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "before taking ddrug0 , tell your doctor if you are taking any of the following medicines : - ddrug1 or another HD00372 such as ddrug3 { ddrug4 } , ddrug5 { ddrug6 , others } , ddrug7 { ddrug8 } , ddrug9 { ddrug10 } , or ddrug11 { DB06724 } ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 : based on reports of profound hypotension and loss of consciousness when DB00714 was administered with ddrug2 , the concomitant use of ddrug3 with drugs of the ddrug4 { including , for example , DB00904 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 } is contraindicated .",
        "label": "NA"
    },
    {
        "text": "coingestion of ddrug0 with ddrug1 , ddrug2 with DB00316 , and ddrug4 with DB01174 at high to toxic concentrations decreases the binding of the target drug .",
        "label": "NA"
    },
    {
        "text": "HD00622 : DB00320 { ddrug2 } injection , usp should not be used with ddrug3 because the combination may cause synergistic elevation of blood pressure .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { ddrug1 , ddrug2 , ddrug3 , DB00252 , ddrug5 } : increase the metabolism of DB00977 and/or some ddrug7 , leading to possible decrease in contraceptive effectiveness .",
        "label": "mechanism"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / ddrug1 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , DB01208 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 pain medication { e , g , , ddrug12 } , drugs used to aid sleep , drowsiness-causing HD00388 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "experience with ddrug0 { HD00203 } suggests the potential for interactions with ddrug2 and HD00106 .",
        "label": "int"
    },
    {
        "text": "the co-administration of DB04899 with iv ddrug1 such as ddrug2 , DB00325 , ddrug4 , or iv ddrug5 has not been evaluated { these drugs were not co-administered with ddrug6 in clinical trials } .",
        "label": "NA"
    },
    {
        "text": "drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on ddrug0 therapy : HD00657 , ddrug2 , ddrug3 , oral ddrug4 containing HD00220 , ddrug6 - containing preparations and the numerous preparations containing ddrug7 .",
        "label": "NA"
    },
    {
        "text": "DB00252 / DB01174 : the coadministration of ddrug2 or ddrug3 will not affect plasma concentrations of ddrug4 , but may reduce endogenous plasma levels of ddrug5 / ergocalcitriol by accelerating metabolism .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , including oral , injectable , transdermal , and implantable ddrug1 : an interaction study demonstrated that co-administration of ddrug2 and the oral HD00431 ddrug4 produced average decreases of ddrug5 and DB00977 levels of 14 % and 31 % , respectively .",
        "label": "NA"
    },
    {
        "text": "because moderate cyp3a4 inhibitors { e , g , , DB00343 } result in 2-fold increase in plasma concentrations of DB00673 , concomitant administration should also be approached with caution .",
        "label": "advise"
    },
    {
        "text": "trough plasma ddrug0 levels were also 20 % higher when DB00201 and DB00467 were administered concomitantly .",
        "label": "mechanism"
    },
    {
        "text": "other drugs : in healthy volunteers , ddrug0 , ddrug1 , ddrug2 , DB00863 , ddrug4 , hormone replacement therapy { a combination of conjugated ddrug5 and ddrug6 } , DB06724 { ddrug8 and ddrug9 } and ddrug10 did not affect the pharmacokinetics of ddrug11 .",
        "label": "NA"
    },
    {
        "text": "DB00405 can interact with ddrug1 or other ddrug2 { may potentiate the cns depressant effects of either these medications or ddrug3 } , ddrug4 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with HD00388 } , and ddrug6 { concurrent use with ddrug7 may prolong and intensify the anticholinergic and cns depressant effects of ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 / ddrug1 : pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between DB00278 and concomitantly administered DB00945 { # mg orally given # and # hours prior to initiation of ddrug4 # g/kg/min , over # hours } or ddrug5 { 1000 mg orally given 12 , # and # hours prior to , and # and # hours subsequent to , initiation of ddrug6 # g/kg/min , over # hours } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a clinical pharmacology study , coadministration of an ddrug1 { ddrug2 , ddrug3 , and ddrug4 } with DB00492 reduced serum levels and urinary excretion of ddrug6 as compared with ddrug7 administered alone , suggesting that HD00374 may impair absorption of ddrug9 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration of ddrug1 with DB00220 resulted in an 83 % increase in DB00220 plasma auc and a 51 % increase in ddrug4 plasma a , c.",
        "label": "NA"
    },
    {
        "text": "ddrug0 , and the HD00457 ddrug2 { ddrug3 } and DB00889 { ddrug5 } have all been used with ddrug6 .",
        "label": "NA"
    },
    {
        "text": "there was no significant difference in the pharmacodynamic effect of DB00682 administered alone and ddrug1 administered with DB00749 as measured by prothrombin time .",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , ddrug3 , or ddrug4 , with ddrug5 , with metal cations such as DB01592 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of HD00532 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "cns-active drugs ddrug0 : DB00962 # mg potentiated the cns-impairing effects of DB00898 # g/kg on balance testing and reaction time for # hour after ddrug3 administration and on the digit symbol substitution test { dsst } , symbol copying test , and the variability component of the divided attention test for # hours after ddrug4 administration .",
        "label": "effect"
    },
    {
        "text": "the following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral antidiabetes products , HD00106 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , DB00647 , ddrug6 , ddrug7 { e , g , , ddrug8 } , ddrug9 .",
        "label": "NA"
    },
    {
        "text": "to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma { hiv-nhl } , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the ddrug0 , ddrug1 , ddrug2 , and ddrug3 { chop } chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen { i , e , , DB00531 , ddrug5 , ddrug6 , and ddrug7 with ddrug8 plus ddrug9 } without receiving HD00056 therapy .",
        "label": "NA"
    },
    {
        "text": "several ddrug0 have been reported to block the pharmacologic effects of DB01170 , ddrug2 , or similar agents , and such an effect may be anticipated with HD00551 because of its structural similarity to other ddrug4 .",
        "label": "NA"
    },
    {
        "text": "DB00203 - theoretically , DB00125 supplements taken concomitantly with ddrug2 , may potentiate the effects of the drug .",
        "label": "NA"
    },
    {
        "text": "DB00459 : interferes with the contraceptive effect of microdosed HD00237 - containing minipill preparations .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , DB02362 { ddrug9 } - containing preparations { e , g , , sunscreens and some DB00152 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "serum DB00065 concentrations appeared to be unaffected by baseline use of medications for the treatment of crohn s disease including ddrug1 , ddrug2 { DB00916 or ddrug4 } and aminosalicylates .",
        "label": "NA"
    },
    {
        "text": "coadministration of DB00969 and strong cyp3a4 inhibitors , such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , and DB01167 has not been evaluated but should be undertaken with caution because of similar potential drug interactions .",
        "label": "advise"
    },
    {
        "text": "DB00625 has the potential to decrease plasma concentrations of DB01167 and ddrug2 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : a literature article reported that when a 60-mg controlled-release DB00295 capsule was administered # hours prior to a 600-mg ddrug2 capsule { n = 12 } , mean ddrug3 auc increased by 44 % compared to DB00996 administered without ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 and DB00201 may enhance the effects of : other ddrug3 s , DB02325 , general ddrug5 , ddrug6 such as ddrug7 , ddrug8 , or other ddrug9 , causing increased cns depression .",
        "label": "effect"
    },
    {
        "text": "in patients receiving DB00999 alone , DB00204 auc increased by 27 % and cmax by 21 % .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : it has been reported that DB00437 prolongs the half-life of the HD00025 , ddrug3 .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 : in one study , ddrug1 was given to adult diabetics who were already receiving ddrug2 { n = 4 } , ddrug3 { n = 2 } ddrug4 with DB00914 { n = 3 } or DB01016 with ddrug7 { n = 6 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB01118 should be used with caution in patients receiving - ddrug2 blocking agents { e , g , , ddrug3 , a ddrug4 inhibitor } or ddrug5 antagonists { e , g , , ddrug6 , a ddrug7 substrate , and ddrug8 , a HD00302 inhibitor } because of the possible potentiation of bradycardia , sinus arrest , and av block ;",
        "label": "NA"
    },
    {
        "text": "in a single-dose crossover study examining ddrug0 # mg and DB00338 # mg each administered alone and concomitantly with DB00364 # gram , absorption of the ddrug3 was delayed and their bioavailability was reduced by 17 % and 16 % , respectively , when administered concomitantly with ddrug4 .",
        "label": "NA"
    },
    {
        "text": "we conclude that the prophylactic and antidotal properties of DB01213 seen in animals treated with ddrug1 derive from its capacity to inhibit the nad + - dependent oxidation responsible for converting HD00079 to ddrug3 in the committed step of the toxic pathway .",
        "label": "NA"
    },
    {
        "text": "pharmacokinetic studies have demonstrated that DB00338 and ddrug1 significantly increased the systemic exposure of DB01166 and/or its major metabolites .",
        "label": "mechanism"
    },
    {
        "text": "- ddrug0 : DB00328 blunts the increases in urine volume and sodium excretion seen during ddrug2 treatment and inhibits the DB00887 - induced increase in plasma renin activity .",
        "label": "effect"
    },
    {
        "text": "ddrug0 can interact with ddrug1 or other ddrug2 { may potentiate the cns depressant effects of either these medications or HD00388 } , HD00444 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug5 } , and ddrug6 { concurrent use with ddrug7 may prolong and intensify the anticholinergic and cns depressant effects of ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "HD00113 { ddrug1 } : ddrug2 { e , g , , ddrug3 , DB00176 , ddrug5 , ddrug6 } have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with ddrug7 .",
        "label": "NA"
    },
    {
        "text": "therefore , close monitoring of prothrombin time is recommended and adjustment of the HD00025 dose may be necessary when ddrug1 capsules are administered concomitantly with DB00682 .",
        "label": "NA"
    },
    {
        "text": "HD00402 agents decrease blood levels and increase excretion of HD00401 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : DB00977 may inhibit the metabolism of DB00860 , leading to increased plasma concentrations .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 } , HD00093 { e , g , ddrug2 } , and ddrug3 { e , g , ddrug4 , ddrug5 and ddrug6 } should have their dose of ddrug7 or DB01183 adjusted .",
        "label": "NA"
    },
    {
        "text": "-lsb- stimulation by DB00403 -- an analog of the octapeptide cholecystokinin -- of HD00136 binding after the long-term administration of ddrug2 -rsb- it has been established in experiments on white male rats that prolonged administration { twice a day for # days } of ddrug3 { # mg/kg } and ddrug4 { # mg/kg } resulted in the reduced interaction between ddrug5 and low affinity binding sites for ddrug6 in subcortical structures , whereas ddrug7 binding with high affinity binding sites for ddrug8 increased both in the frontal cortex and subcortical structures of the forebrain .",
        "label": "NA"
    },
    {
        "text": "ddrug0 # mg qd or ddrug1 / ddrug2 50/100 mg qd was co-administered with DB00204 { 500 mcg bid } for # days { following # days of HD00295 use at half dose } .",
        "label": "NA"
    },
    {
        "text": "DB00753 or ddrug1 administered with ddrug2 / DB09140 to achieve # mac -lsb- minimum alveolar concentration -rsb- may prolong the clinically effective duration of action of initial and maintenance doses of ddrug4 and decrease the required infusion rate of ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 , including DB00467 , decrease the clearance of DB08496 , the less active isomer of racemic ddrug4 .",
        "label": "mechanism"
    },
    {
        "text": "HD00026 may decrease the effectiveness of oral ddrug1 , certain ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and HD00378 .",
        "label": "effect"
    },
    {
        "text": "in separate studies of patients receiving maintenance doses of ddrug0 , ddrug1 , or ddrug2 , DB01029 administration for # days had no effect on the pharmacodynamics of DB00682 { prothrombin time } or pharmacokinetics of ddrug5 .",
        "label": "NA"
    },
    {
        "text": "potential drug interactions between DB01202 and other ddrug1 { ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 and ddrug8 } were also assessed by evaluating the serum concentrations of DB01202 and these ddrug10 during placebo-controlled clinical studies .",
        "label": "NA"
    },
    {
        "text": "DB00501 at # mg bid { the usual prescription dose } co-administered with DB00204 { 500 mcg bid } for # days has been shown to increase ddrug2 plasma levels by 58 % .",
        "label": "mechanism"
    },
    {
        "text": "concomitant use of DB01254 and drugs that inhibit cyp3a4 { eg , ddrug1 , ddrug2 , DB00199 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 } may increase exposure to ddrug12 and should be avoided .",
        "label": "mechanism"
    },
    {
        "text": "other concomitant therapy although specific interaction studies were not performed , ddrug0 doses of # mg or more were concomitantly used in clinical studies with ddrug1 , ddrug2 , a-blockers , ddrug3 , ddrug4 , HD00282 , ddrug6 , ddrug7 , ddrug8 , cardiac ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 { also referred to as ddrug14 } , and HD00729 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB01009 does not alter DB00945 absorption ;",
        "label": "NA"
    },
    {
        "text": "in patients receiving DB01033 { ddrug1 } or ddrug2 { DB00993 } , the concomitant administration of 300 - 600 mg of ddrug4 per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of ddrug5 or ddrug6 .",
        "label": "NA"
    },
    {
        "text": "nephrotoxicity has been reported following concomitant administration of ddrug0 with HD00447 or potent ddrug2 such as DB00695 .",
        "label": "NA"
    },
    {
        "text": "to investigate the effects of antimicrobial combinations of HD00006 with four kinds of ddrug1 { DB00415 , ddrug3 , ddrug4 and ddrug5 } , the fractional inhibitory concentration index { fici } was determined by checkerboard assay for each strain .",
        "label": "NA"
    },
    {
        "text": "absorption of ddrug0 is impaired by HD00374 containing ddrug2 , ddrug3 , or DB14513 , and ddrug5 - containing preparations .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , DB00091 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , DB01232 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "in clinical studies , DB00716 has been co-administered with other anti-asthma medications , including inhaled and oral HD00650 , and inhaled ddrug2 , with no evidence of increased frequency of adverse events or laboratory abnormalities .",
        "label": "NA"
    },
    {
        "text": "ddrug0 has the potential to decrease plasma concentrations of DB01167 and DB01026 .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of ddrug0 : ddrug1 , ddrug2 , ddrug3 , HD00571 { e , g , , ddrug5 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , HD00809 , ddrug12 , ddrug13 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { DB00252 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and DB00126 .",
        "label": "NA"
    },
    {
        "text": "DB00495 should either be temporarily discontinued or decreased by 50 % when coadministered with ddrug1 on the day of DB00369 infusion .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , HD00668 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , DB00295 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "the following agents may increase certain actions or side effects of HD00522 , ddrug1 ddrug2 of class { e , g , ddrug3 } , ddrug4 ddrug5 { e , g , HD00219 } , ddrug7 .",
        "label": "NA"
    },
    {
        "text": "the following medications have been administered in clinical trials with DB00074 with no increase in adverse reactions : atg/alg , ddrug1 , ddrug2 , DB00091 , ddrug4 , and ddrug5 .",
        "label": "NA"
    },
    {
        "text": "HD00321 : acute pulmonary toxicity has been reported in patients receiving intravenous DB00681 and ddrug2 .",
        "label": "NA"
    },
    {
        "text": "use of DB00722 with ddrug1 { e , g , , ddrug2 , ddrug3 , or ddrug4 } , DB14500 supplements , or potassium-containing salt substitutes may lead to significant increases in serum potassium .",
        "label": "effect"
    },
    {
        "text": "- ddrug0 { e , g , , ddrug1 } use of DB00252 with DB00891 may increase the chance of side effects affecting the liver and/or the side effects of ddrug4",
        "label": "effect"
    },
    {
        "text": "close observation of the patient is recommended when a HD00380 is administered to patients receiving catecholamine-depleting drugs such as DB00206 , because of possible additive effects and the production of hypotension and/or marked bradycardia , which may produce vertigo , syncope , or postural hypotension .",
        "label": "advise"
    },
    {
        "text": "similarly , DB00731 had no influence on the serum protein binding of ddrug1 , DB01016 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and ddrug7 in vitro .",
        "label": "NA"
    },
    {
        "text": "DB00284 may affect DB00390 bioavailabillty and may require dose adjustment of ddrug2 by 16 % { 90 % confidence interval : 8 - 23 % } , decrease mean c max ddrug3 by 26 % { 90 % confidence interval : 16 - 34 % } and decrease mean trough concentrations of ddrug4 by 9 % { 90 % confidence limit : 19 % decrease to 2 % increase } .",
        "label": "NA"
    },
    {
        "text": "the hypoglycemic action of ddrug0 may be potentiated by certain drugs including HD00518 and other drugs that are highly protein bound , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , HD00275 , and ddrug8 .",
        "label": "NA"
    },
    {
        "text": "background : the effects of combined administration of ddrug0 and ddrug1 { DB00661 } , a HD00038 , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by ddrug4 { ddrug5 } and the labeling index of intestinal_cancer were investigated in male wistar rats .",
        "label": "NA"
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit ddrug0 binding to serum proteins or alter the concentrations of serum binding proteins : ddrug1 and related ddrug2 , ddrug3 , DB00636 , ddrug5 and ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , DB00675 .",
        "label": "NA"
    },
    {
        "text": "DB00328 given concomitantly with ddrug1 has been reported to increase the serum concentration and prolong the half-life of DB00390 .",
        "label": "NA"
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma ddrug0 concentrations include : acute DB02325 intake , ddrug2 , chboramphenicol , ddrug3 , ddrug4 , ddrug5 , DB00266 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21",
        "label": "NA"
    },
    {
        "text": "DB13295 was again given by infusion to maintain 40 % twitch for a second hour , then # mg HD00198 / kg bwt were given i , v.",
        "label": "NA"
    },
    {
        "text": "while it is not known whether this interaction occurs with HD00550 other than ddrug1 , myopathy and rhabdomyolysis have occasionally been associated with the use of ddrug2 alone , including DB00636 .",
        "label": "NA"
    },
    {
        "text": "before taking DB00222 , tell your doctor if you are taking any of the following medicines : - ddrug1 or another ddrug2 such as HD00755 { ddrug4 } , ddrug5 { ddrug6 , others } , ddrug7 { ddrug8 } , ddrug9 { ddrug10 } , or ddrug11 { ddrug12 } ;",
        "label": "advise"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , DB00091 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , DB00860 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of ddrug0 are the following : ddrug1 , ddrug2 , ddrug3 , DB01045 , ddrug5 , ddrug6 { 2 } , ddrug7 , ddrug8 , and ddrug9 thus , if a patient has been titrated to a stable dosage on ddrug10 , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for HD00472 may be necessary .",
        "label": "NA"
    },
    {
        "text": "limited clinical experience indicates that requirements for HD00265 are reduced by # to 50 % for the first sixty { 60 } minutes following ddrug1 induction the concomitant use of ddrug2 with DB00802 can significantly inhibit ddrug4 clearance and may increase the risk of prolonged or delayed respiratory depression .",
        "label": "NA"
    },
    {
        "text": "caution should be used when administering or taking DB00530 with ddrug1 and other strong cyp3a4 inhibitors such as , but not limited to , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , DB13179 { ddrug12 } , and ddrug13 .",
        "label": "advise"
    },
    {
        "text": "information on concurrent usage of DB00335 and DB00945 is limited .",
        "label": "NA"
    },
    {
        "text": "conclusions : ddrug0 inhibit the metabolism of HD00095 that are metabolized by cyp3a4 { i , e , , ddrug2 , ddrug3 , DB00227 , ddrug5 } .",
        "label": "NA"
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of HD00539 such as ddrug1 include certain ddrug2 { e , g , , ddrug3 , HD00239 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 } , ddrug11 salts , ddrug12 , local ddrug13 , ddrug14 , and ddrug15 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : DB14513 - containing preparations { eg , HD00374 } may cause hypermagnesemia and should therefore not be taken during therapy with ddrug3 by patients on chronic renal dialysis .",
        "label": "NA"
    },
    {
        "text": "in both species , HD00157 , but not HD00156 , antagonized the rate-decreasing effects of ddrug2 on fi and fr responding .",
        "label": "NA"
    },
    {
        "text": "the majority of patients in ra clinical studies received one or more of the following concomitant medications with DB01281 : ddrug1 , ddrug2 , ddrug3 , ddrug4 , DB00993 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , and ddrug11 .",
        "label": "NA"
    },
    {
        "text": "urinary acidifying agents these agents { ddrug0 , DB09449 , etc , } increase the concentration of the ionized species of the DB00182 molecule , thereby increasing urinary excretion .",
        "label": "mechanism"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , HD00326 { ddrug1 s } , ddrug2 , ddrug3 { ddrug4 may decrease the effects of these medicines } , ddrug5 { using these medicines with ddrug6 may result in increased cns depressant effects } , ddrug7 , ddrug8 { using these medicines with ddrug9 may change the amount of either medicine that you need to take } , and oral ddrug10 containing ddrug11 { HD00026 may decrease the effectiveness of these oral ddrug13 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : DB01045 ddrug10 ddrug11 , DB00897 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "the administration of local HD00449 containing ddrug1 or DB00368 to patients receiving ddrug3 or ddrug4 may produce severe , prolonged hypertension .",
        "label": "NA"
    },
    {
        "text": "HD00586 and HD00587 { ddrug2 }",
        "label": "NA"
    },
    {
        "text": "drug interactions : the central ddrug0 syndrome can occur when anticholinergic agents such as ddrug1 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain ddrug2 such as ddrug3 , the ddrug4 and other HD00031 , ddrug6 , certain HD00303 such as the ddrug8 salts , and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { cns } drugs including DB02325 , ddrug2 , ddrug3 , ddrug4 , blood pressure medications { ddrug5 , DB00968 , ddrug7 } , motion sickness medications , ddrug8 , ddrug9 , ddrug10 , sleeping pills and ddrug11",
        "label": "NA"
    },
    {
        "text": "objective : our objective was to characterize the steady-state pharmacokinetics of DB01590 and ddrug1 { inn , DB00091 } when coadministered in de novo kidney allograft recipients during the first year after transplantation .",
        "label": "NA"
    },
    {
        "text": "effects of other ddrug0 on ddrug1 ddrug2 : DB00252 causes an approximate doubling of the clearance of ddrug4 { ddrug5 } at steady state and , therefore , the addition of ddrug6 causes an approximate 45 % decrease in the steady-state trough concentrations of ddrug7 as compared to the same dose of DB00949 given as monotherapy .",
        "label": "NA"
    },
    {
        "text": "ddrug0 should be avoided by patients with a history of serious reaction to any HD00386 , including HD00387 and ddrug3 .",
        "label": "NA"
    },
    {
        "text": "nonetheless , the range of individual DB00074 clearance values in the presence of ddrug1 { 12 - 57 ml/h } or DB00688 { 7 - 54 ml/h } did not extend outside the range observed with dual therapy { 10 - 78 ml/h } .",
        "label": "NA"
    },
    {
        "text": "both ddrug0 and DB00238 have been compared to triple therapy with the ddrug2 DB00224 over # weeks as initial therapy , with similar responses being observed with ddrug4 regimens and superiority observed with ddrug5 .",
        "label": "NA"
    },
    {
        "text": "however , co-administration of ddrug0 with ddrug1 - and DB14513 - containing ddrug3 { 51 meq } or ddrug4 with DB00927 , had no significant effect on the rate or extent of ddrug6 absorption after administration of a 40-mg oral dose .",
        "label": "NA"
    },
    {
        "text": "ddrug0 has no effect on the pharmacokinetics of DB01167 , DB00681 , or the active metabolite of mycophenolate .",
        "label": "NA"
    },
    {
        "text": "the aim of this paper was to study the interaction between ddrug0 and both ddrug1 or its synthetic analogue HD00165 , or HD00166 , on the antinonciceptive effect of these peptides in mice after intracisternal injection .",
        "label": "NA"
    },
    {
        "text": "effects of DB00949 on low-dose ddrug1 a group of # nonsmoking , healthy white female volunteers established on an oral ddrug2 regimen containing # mg ddrug3 and # mg ddrug4 for at least # months received # mg/day of DB00949 from midcycle { day 15 } to midcycle { day 14 } of two consecutive oral ddrug6 cycles .",
        "label": "NA"
    },
    {
        "text": "effect of ddrug0 on the pharmacokinetics of other drugs : DB01068 does not appear to alter the pharmacokinetics of ddrug2 , DB00564 , or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "other ddrug0 { eg , ddrug1 , DB01035 , ddrug3 , ddrug4 } have occasionally been used concurrently with DB00280 .",
        "label": "NA"
    },
    {
        "text": "- ddrug0 : ddrug1 should generally not be given with ddrug2 { such as DB00887 } because they reduce its renal clearance and add a high risk of DB14507 toxicity .",
        "label": "NA"
    },
    {
        "text": "grapefruit juice increases DB00977 concentrations and would be expected to increase DB00396 serum levels as well ;",
        "label": "NA"
    },
    {
        "text": "it is recommended to avoid concurrent administration of ddrug0 with ddrug1 containing HD00374 for at least # hours following DB00330 administration .",
        "label": "NA"
    },
    {
        "text": "there has been little experience with the coadministration of DB01195 and either DB00280 or ddrug2 .",
        "label": "NA"
    },
    {
        "text": "drug-drug interactions : the pharmacokinetic and pharmacodynamic interactions between DB00346 and other HD00266 have not been determined .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - although ddrug1 did not potentiate the cognitive and motor effects of DB02325 in a clinical trial , as with other ddrug3 , the use of ddrug4 by patients taking DB01175 is not recommended .",
        "label": "NA"
    },
    {
        "text": "DB00908 at # mg bid decreased the bioavailability { auc } of DB00401 by 26 % , but not the peak concentration .",
        "label": "mechanism"
    },
    {
        "text": "in addition , the beneficial effects of DB01235 in parkinsons disease have been reported to be reversed by ddrug1 and DB01113 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 / ddrug1 : pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between ddrug2 and concomitantly administered DB00945 { # mg orally given # and # hours prior to initiation of DB00278 # g/kg/min , over # hours } or ddrug5 { 1000 mg orally given 12 , # and # hours prior to , and # and # hours subsequent to , initiation of ddrug6 # g/kg/min , over # hours } .",
        "label": "NA"
    },
    {
        "text": "the effects of ddrug0 and of HD00117 anesthesia on HD00118 tolerance in dogs .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , HD00668 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , DB01232 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "- the action of HD00416 and HD00071 may be enhanced by ddrug2 or ddrug3 .",
        "label": "NA"
    },
    {
        "text": "because there is a theoretical basis that these effects may be additive , use of ddrug0 - containing or ddrug1 { like DB00320 or ddrug3 } and DB00952 within # hours is contraindicated .",
        "label": "advise"
    },
    {
        "text": "ddrug0 ddrug1 ddrug2 DB01211 ddrug4 ddrug5 ddrug6 DB00091 large quantities of grapefruit juice { # quart daily }",
        "label": "NA"
    },
    {
        "text": "to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma { hiv-nhl } , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the ddrug0 , DB00997 , ddrug2 , and ddrug3 { chop } chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen { i , e , , ddrug4 , ddrug5 , DB00444 , and ddrug7 with ddrug8 plus ddrug9 } without receiving ddrug10 therapy .",
        "label": "NA"
    },
    {
        "text": "in addition , neuromuscular blocking action is enhanced by general ddrug0 , local HD00264 like ddrug2 , DB00721 , ddrug4 , ddrug5 , ddrug6 , and ddrug7 .",
        "label": "NA"
    },
    {
        "text": "however , due to possible pharmacodynamic interactions , when co-administered with ddrug0 , a reduction in dosage of ddrug1 on the concomitant DB01086 , ddrug3 , HD00604 or ddrug5 may be required .",
        "label": "NA"
    },
    {
        "text": "suppression by ddrug0 of DB11724 - enhanced peritoneal metastasis of intestinal adenocarcinomas induced by HD00037 in wistar rats .",
        "label": "NA"
    },
    {
        "text": "because there is a theoretical basis that these effects may be additive , use of ddrug0 - containing or HD00274 { like ddrug2 or ddrug3 } and DB00952 within # hours is contraindicated .",
        "label": "advise"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , DB01076 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , DB00295 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , including oral , injectable , transdermal , and implantable ddrug1 : an interaction study demonstrated that co-administration of DB00559 and the oral HD00431 ddrug4 produced average decreases of ddrug5 and ddrug6 levels of 14 % and 31 % , respectively .",
        "label": "NA"
    },
    {
        "text": "a dose increase of DB01601 / ddrug1 to 533/133 mg { 4 capsules or # ml } twice daily taken with food is recommended when used in combination with DB00625 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 / HD00214 : ddrug2 , DB00897",
        "label": "NA"
    },
    {
        "text": "in vitro activity of HD00050 , either singly or in combination with DB01165 , against mycobacterium ulcerans .",
        "label": "NA"
    },
    {
        "text": "in a study of schizophrenic patients who received DB00363 under steady state conditions , ddrug1 or DB00715 was added in # and # patients , respectively .",
        "label": "NA"
    },
    {
        "text": "toxicology studies of ddrug0 - related deaths reveal frequent involvement of other ddrug1 , including DB02325 , HD00100 such as ddrug4 { ddrug5 } , and , to a rising degree , ddrug6 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { e , g , , HD00219 , ddrug2 , ddrug3 } and DB00951 may reduce the therapeutic effects of ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : potentiation of DB00682 - type { ddrug2 and ddrug3 substrate } ddrug4 response is almost always seen in patients receiving DB01118 and can result in serious or fatal bleeding .",
        "label": "NA"
    },
    {
        "text": "in patients receiving nonselective ddrug0 { ddrug1 } { e , g , , DB01037 } in combination with ddrug3 { e , g , , ddrug4 , ddrug5 , ddrug6 , DB01104 , ddrug8 } , there have been reports of serious , sometimes fatal , reactions .",
        "label": "effect"
    },
    {
        "text": "other drugs : in healthy volunteers , ddrug0 , ddrug1 , ddrug2 , ddrug3 , DB00338 , hormone replacement therapy { a combination of conjugated ddrug5 and HD00642 } , ddrug7 { ddrug8 and ddrug9 } and ddrug10 did not affect the pharmacokinetics of ddrug11 .",
        "label": "NA"
    },
    {
        "text": "lack of interaction between DB01137 and DB00497 : pharmacokinetics and drug disposition .",
        "label": "NA"
    },
    {
        "text": "potential interactions between DB01229 , a substrate of cyp3a4 , and HD00269 { ddrug2 , ddrug3 , ddrug4 , and ddrug5 } , which are substrates and/or inhibitors of cyp3a4 , have not been evaluated in clinical trials .",
        "label": "NA"
    },
    {
        "text": "caution should be used when administering or taking DB00530 with ddrug1 and other strong cyp3a4 inhibitors such as , but not limited to , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , DB00220 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { ddrug12 } , and ddrug13 .",
        "label": "advise"
    },
    {
        "text": "however , other published reports describe modest elevations { less than two-fold } of DB00363 and metabolite concentrations when ddrug1 was taken with ddrug2 , DB00472 , and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "for these reasons , it is felt that , in most subjects who have had an unsatisfactory lipid response to either drug alone , the possible benefits of combined therapy with DB00227 and a HD00549 do not outweigh the risks of severe myopathy , rhabdomyolysis , and acute renal failure .",
        "label": "effect"
    },
    {
        "text": "DB00187 concentrations were equivocally higher when given with DB00682 , but this is not likely to be clinically important .",
        "label": "mechanism"
    },
    {
        "text": "DB00908 : coadministration of a 10-mg single dose of DB01238 with ddrug2 { 166 mg/day for # days } , a potent inhibitor of cyp2d6 , increased the auc of ddrug3 by 112 % but decreased the auc of its active metabolite , ddrug4 , by 35 % .",
        "label": "NA"
    },
    {
        "text": "therefore , co-administration of ddrug0 with other drugs that are metabolized by this isoenzyme , including other ddrug1 , ddrug2 , ddrug3 , and ddrug4 { eg , ddrug5 , ddrug6 , and DB01228 } , or that inhibit this enzyme { eg , DB00908 } , should be approached with caution .",
        "label": "NA"
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of HD00472 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 { 1 } , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 { 1 } , ddrug10 , ddrug11 , grapefruit juice , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , DB00647 , ddrug21 , ddrug22 , ddrug23 , ddrug24 { 1 } , ddrug25 , ddrug26 .",
        "label": "mechanism"
    },
    {
        "text": "vasospastic reactions have been reported with therapeutic doses of DB00201 - containing drugs when co-administered with these HD00002 .",
        "label": "effect"
    },
    {
        "text": "HD00485 - ddrug1 containing side chains of n-methylthiotetrazole { ddrug2 , ddrug3 , ddrug4 , DB01326 , ddrug6 } or methylthiadiazole { ddrug7 } can cause vitamin_k_deficiency and hypoprothrombinemia .",
        "label": "NA"
    },
    {
        "text": "caution should be used when administering or taking ddrug0 with DB01026 and other strong cyp3a4 inhibitors such as , but not limited to , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , DB01232 , ddrug10 , ddrug11 { ddrug12 } , and ddrug13 .",
        "label": "NA"
    },
    {
        "text": "in a multiple-dose study , DB00467 caused a dose-related increase in the mean elimination half-life of ddrug1 , thereby decreasing the clearance of ddrug2 by up to 80 % and leading to a five-fold increase in the auc and the half-life of DB00201 .",
        "label": "NA"
    },
    {
        "text": "hormonal ddrug0 co-administration of DB00776 with an oral HD00349 has been shown to influence the plasma concentrations of the two hormonal components , ddrug3 { ee } and ddrug4 { lng } .",
        "label": "mechanism"
    },
    {
        "text": "the adverse effects of DB00762 , such as myelosuppression and diarrhea , would be expected to be exacerbated by other HD00251 having similar adverse effects .",
        "label": "effect"
    },
    {
        "text": "ddrug0 { ddrug1 , DB03585 , and possibly ddrug3 } : concomitant administration with DB00945 may increase the risk of gastrointestinal ulceration .",
        "label": "effect"
    },
    {
        "text": "ddrug0 including DB00752 , ddrug2 , and ddrug3 hc1 : concomitant use of DB00135 and non-selective ddrug5 may cause hypertension .",
        "label": "NA"
    },
    {
        "text": "drugs metabolized by cytochrome p450 enzymes the drug interaction study evaluating the effect of DB00365 on DB00277 indicates that ddrug2 inhibits ddrug3 metabolism , which is mediated by cyp1a2 .",
        "label": "NA"
    },
    {
        "text": "in addition to bleeding associated with ddrug0 and ddrug1 , drugs that alter platelet function { such as ddrug2 , DB00975 and ddrug4 } may increase the risk of bleeding if administered prior to , during , or after DB00009 therapy .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : coadministration of DB01026 { 200 mg/day for # days } with a 15-mg single dose of DB01238 increased the auc of ddrug3 and its active metabolite by 63 % and 77 % , respectively .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 , ddrug1 , DB00091 : DB00586 , like other ddrug4 , may affect renal prostaglandins and increase the toxicity of certain drugs .",
        "label": "NA"
    },
    {
        "text": "HD00827 and ddrug1 - although not reported , ddrug2 , via its metabolism to histamine , might decrease the efficacy of ddrug3 and HD00586 .",
        "label": "NA"
    },
    {
        "text": "if taken # hour before DB00224 { ddrug1 } , ddrug2 does not affect HD00033 exposure , despite persistent buffering effects .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { DB00091 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { HD00712 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "like HD00021 { 40 mg/kg } , ddrug1 { 40 mg/kg } decreases the intravenous self-administration of DB00295 and ddrug3 and the oral self-administration of ddrug4 and ddrug5 in rats ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a single { 400 mg } and multiple dose { 400 mg tid } study of DB00996 in epileptic patients { n = 8 } maintained on DB00252 monotherapy for at least # months , ddrug3 had no effect on the steady-state trough plasma concentrations of ddrug4 and ddrug5 had no effect on ddrug6 pharmacokinetics .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : animal studies wshow that DB00945 given with ddrug2 , including DB01050 , yields a net decrease in anti-inflammatory activity with lowered blood levels of the non-aspirin drug .",
        "label": "effect"
    },
    {
        "text": "drug interactions : the central HD00315 syndrome can occur when anticholinergic agents such as ddrug1 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain ddrug2 such as ddrug3 , the ddrug4 and other ddrug5 , ddrug6 , certain HD00303 such as the ddrug8 salts , and ddrug9 .",
        "label": "effect"
    },
    {
        "text": "all HD00285 should be used cautiously in patients taking HD00445 .",
        "label": "advise"
    },
    {
        "text": "drugs decreasing ddrug0 effect : HD00118 , ddrug2 , ddrug3 , or ddrug4 may partially counteract the anticoagulant action of DB01109 .",
        "label": "effect"
    },
    {
        "text": "plasma exposure of ddrug0 { 10 mg bid } was increased by 28 % following administration of DB00580 { 40 mg bid } for # days , while plasma exposure of ddrug2 { 40 mg bid } was not substantially increased following administration of DB00829 { 10 mg bid } for # days .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , in the presence of DB09341 and DB00277 , caused excessive gcg release but nearly normal insulin release in the diabetics .",
        "label": "NA"
    },
    {
        "text": "DB00564 : DB00949 causes a decrease in the steady-state ddrug2 plasma concentrations and an increase in the steady-state ddrug3 plasma concentration .",
        "label": "NA"
    },
    {
        "text": "effects of ddrug0 on low-dose ddrug1 a group of # nonsmoking , healthy white female volunteers established on an oral ddrug2 regimen containing # mg DB00977 and # mg DB06730 for at least # months received # mg/day of ddrug5 from midcycle { day 15 } to midcycle { day 14 } of two consecutive oral ddrug6 cycles .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { DB06767 , ddrug2 , etc , } increase the concentration of the ionized species of the DB00182 molecule , thereby increasing urinary excretion .",
        "label": "mechanism"
    },
    {
        "text": "DB00908 : coadministration of a 10-mg single dose of ddrug1 with ddrug2 { 166 mg/day for # days } , a potent inhibitor of cyp2d6 , increased the auc of DB01238 by 112 % but decreased the auc of its active metabolite , ddrug4 , by 35 % .",
        "label": "NA"
    },
    {
        "text": "other cardiovascular agents : ddrug0 and DB00584 iv have been used concomitantly with ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB01275 , ddrug7 and ddrug8 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "drug interactions , general : although there have been no formal interaction studies , intravenous DB00800 has been administered safely with drugs such as ddrug1 and sublingual DB00727 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { DB00091 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , DB00220 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "DB01432 ddrug1 may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation , the discontinuance of ddrug2 HD00524 could pose a hazard to health if a potentially toxic drug such as ddrug4 has been filtrated to a maintenance level while the patient was taking ddrug5 ddrug6 .",
        "label": "NA"
    },
    {
        "text": "however , severe reactions , such as hypotension requiring treatment , dyspnea requiring HD00650 , angioedema , or generalized urticaria require immediate discontinuation of DB01229 and aggressive symptomatic therapy .",
        "label": "NA"
    },
    {
        "text": "avoid the use of preparations such as ddrug0 and local ddrug1 which contain any ddrug2 { e , g , , DB00668 , ddrug4 } , since it has been reported that HD00043 can potentiate the effects of catecholamines .",
        "label": "advise"
    },
    {
        "text": "both the toxicity of HD00121 and the therapeutic value of ddrug1 can be rationalized at the cellular and molecular level by the following observations : { i } these HD00122 showed differential effects on cells ;",
        "label": "NA"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / ddrug1 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , ddrug4 , ddrug5 , DB01170 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 pain medication { e , g , , DB00318 } , drugs used to aid sleep , drowsiness-causing ddrug13 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "the effects of ddrug0 are antagonized by HD00246 such as ddrug2 and DB00277 .",
        "label": "NA"
    },
    {
        "text": "in vitro binding studies with human serum proteins indicate that DB01067 binds differently than ddrug1 and does not interact with ddrug2 or DB00266 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , DB00636 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , DB00860 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "DB00996 had no effect on DB00788 pharmacokinetic parameters .",
        "label": "NA"
    },
    {
        "text": "ddrug0 can interact with ddrug1 or other ddrug2 { may potentiate the cns depressant effects of either these medications or ddrug3 } , HD00444 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug5 } , and ddrug6 { concurrent use with HD00388 may prolong and intensify the anticholinergic and cns depressant effects of ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as DB00415 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , DB00220 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "however , a crossover study in healthy subjects receiving either ddrug0 # mg q , i , d , or # mg h , s , concomitantly with a # mg b , i , d , dosage of ddrug1 { HD00531 , key pharmaceuticals , inc , } demonstrated less alteration in steady-state DB00277 peak serum levels with the # mg h , s , regimen , particularly in subjects aged # years and older .",
        "label": "NA"
    },
    {
        "text": "DB00366 may enhance the effects of DB00668 .",
        "label": "effect"
    },
    {
        "text": "concomitant administration of DB01155 and ddrug1 , ddrug2 , ddrug3 , or an ddrug4 / ddrug5 oral HD00349 produced minor changes in the pharmacokinetics of ddrug7 , which were considered to be without clinical significance .",
        "label": "mechanism"
    },
    {
        "text": "also , concomitant administration of HD00532 with products containing ddrug1 , DB00152 containing ddrug3 , or ddrug4 { ddrug5 } chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels .",
        "label": "NA"
    },
    {
        "text": "ddrug0 can interact with ddrug1 or other HD00261 { may potentiate the cns depressant effects of either these medications or ddrug3 } , ddrug4 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug5 } , and HD00445 { concurrent use with ddrug7 may prolong and intensify the anticholinergic and cns depressant effects of ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "a similar association , though less marked , has been suggested with ddrug0 , ddrug1 , ddrug2 , ddrug3 , DB00400 , ddrug5 , and possibly with ddrug6 and HD00239 72 .",
        "label": "NA"
    },
    {
        "text": "other concomitant therapies : in clinical trials , the safety profile in subjects treated with DB00659 concomitantly with ddrug1 , ddrug2 and HD00024 { including ddrug4 } , or ddrug5 was similar to that of subjects taking placebo with these concomitant medications .",
        "label": "NA"
    },
    {
        "text": "racemic DB00215 did not alter the mean auc or cmax of DB01100 .",
        "label": "NA"
    },
    {
        "text": "plasma concentrations of HD00279 are decreased when administered with ddrug1 containing ddrug2 , DB01373 , or ddrug4 .",
        "label": "mechanism"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of ddrug0 : ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , ddrug5 , ddrug6 , ddrug7 } , DB00951 , ddrug9 , DB00052 , ddrug11 , ddrug12 , ddrug13 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "DB00562 may interact with ddrug1 , HD00403 s , ddrug3 { allergy , cold , and sinus medicines } , diabetic drugs , ddrug4 , ddrug5 , ddrug6 like ddrug7 or ddrug8 , and high blood pressure medications .",
        "label": "int"
    },
    {
        "text": "in a study with concomitant administration of DB00945 and ddrug1 , the bioavailability of unbound DB14207 was not altered .",
        "label": "NA"
    },
    {
        "text": "DB00284 has been shown to change the bioavailabillty ddrug1 when they are co-administered , which may require DB00390 dose adjustment .",
        "label": "NA"
    },
    {
        "text": "hepatic enzyme inducers , inhibitors and substrates : drugs which induce cytochrome p450 3a4 { cyp 3a4 } enzyme activity { e , g , , ddrug0 , ddrug1 , DB00564 , ddrug3 } may enhance the metabolism of HD00175 and require that the dosage of the ddrug5 be increased .",
        "label": "mechanism"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { ddrug1 s } , ddrug2 , ddrug3 { ddrug4 may decrease the effects of these medicines } , ddrug5 { using these medicines with ddrug6 may result in increased cns depressant effects } , ddrug7 , DB00313 { using these medicines with ddrug9 may change the amount of either medicine that you need to take } , and oral ddrug10 containing ddrug11 { ddrug12 may decrease the effectiveness of these oral HD00283 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 { eg , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , DB00908 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , and ddrug15 } may have elevated plasma concentrations when coadministered with DB01232 ;",
        "label": "mechanism"
    },
    {
        "text": "single doses of either ddrug0 or DB00375 ddrug2 bind the DB00999 and reduce its absorption from the gastrointestinal tract by up to # and # percent , respectively .",
        "label": "mechanism"
    },
    {
        "text": "after stopping DB00176 tablets , at least # weeks should be allowed before starting a HD00725 .",
        "label": "advise"
    },
    {
        "text": "prior administration of ddrug0 { 90 mg kg { -1 } body weight } was shown to prevent the conversion of HD00079 { 100 mg kg { -1 } body weight } to HD00078 in vivo and to eliminate the fluoride and citrate elevations seen in ddrug3 - intoxicated animals .",
        "label": "NA"
    },
    {
        "text": "interactions may also occur with the following : HD00515 / ddrug1 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , DB00248 , ddrug10 , ddrug11 pain medication { e , g , , ddrug12 } , drugs used to aid sleep , drowsiness-causing ddrug13 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "DB01026 / ddrug1 , HD00375 , including ddrug3",
        "label": "NA"
    },
    {
        "text": "ddrug0 : based on reports of profound hypotension and loss of consciousness when DB00714 was administered with ddrug2 , the concomitant use of ddrug3 with drugs of the ddrug4 { including , for example , ddrug5 , ddrug6 , DB00757 , ddrug8 , and ddrug9 } is contraindicated .",
        "label": "NA"
    },
    {
        "text": "- a sulfa-based drug such as DB01015 - DB00440 { ddrug2 , ddrug3 } , ddrug4 { ddrug5 } , or ddrug6 { ddrug7 } ;",
        "label": "NA"
    },
    {
        "text": "drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on ddrug0 therapy : ddrug1 , ddrug2 , ddrug3 , oral HD00283 containing ddrug5 , ddrug6 - containing preparations and the numerous preparations containing HD00328 .",
        "label": "NA"
    },
    {
        "text": "the results indicate that a spinal DB01183 - sensitive endorphinergic system is involved in the production of HD00144 but not ddrug2 - induced tail-flick inhibition , and suggest that intraventricular ddrug3 and ddrug4 elicit their pharmacological actions via the activation of different descending pain inhibitory systems ;",
        "label": "NA"
    },
    {
        "text": "HD00340 { such as ddrug1 } and ddrug2 can suppress the DB00988 rgic renal and mesenteric vasodilation induced with low dose dopamine infusion .",
        "label": "effect"
    },
    {
        "text": "DB00575 may enhance the cns-depressive effects of ddrug1 , HD00026 or other ddrug3 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 - HD00485 containing side chains of n-methylthiotetrazole { ddrug2 , ddrug3 , ddrug4 , DB01326 , ddrug6 } or methylthiadiazole { ddrug7 } can cause vitamin_k_deficiency and hypoprothrombinemia .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may displace acidic drugs such as DB00252 or DB01124 from their binding sites .",
        "label": "NA"
    },
    {
        "text": "with oral DB00250 treatment , HD00235 such as ddrug2 have been noted to possibly increase the likelihood of hematologic reactions",
        "label": "effect"
    },
    {
        "text": "this interaction should be given consideration in patients taking DB00580 concomitantly with HD00500 .",
        "label": "advise"
    },
    {
        "text": "DB01115 : DB00862 # mg , when co-administered with slow-release ddrug2 # mg or # mg once daily , did not affect the relative bioavailability { auc } or maximum concentration { cmax } of ddrug3 , a drug that is metabolized via cyp3a4 .",
        "label": "NA"
    },
    {
        "text": "and ddrug0 e , g , , DB00661 } , cyp1a2 inducers { DB00338 } and cyp1a2 inhibitors { ddrug3 and ddrug4 } .",
        "label": "NA"
    },
    {
        "text": "in study 1 , patients with colorectal cancer were given ddrug0 / DB00544 / ddrug2 { bolus-ifl } with or without DB00112 .",
        "label": "NA"
    },
    {
        "text": "no depressant effect on blood levels in humans was noted when DB00375 was administered with any of the following drugs : ddrug1 , ddrug2 , ddrug3 , ddrug4 , DB00627 { ddrug6 } , ddrug7 , ddrug8 or ddrug9 .",
        "label": "NA"
    },
    {
        "text": "agents affecting cytochrome p450 3a4 isoenzyme system DB00813 is metabolized mainly via the human cytochrome p450 3a4 isoenzyme system { cyp3a4 } , therefore potential interactions may occur when DB00813 is given concurrently with agents that affect cyp3a4 activity .",
        "label": "NA"
    },
    {
        "text": "HD00100 : combination ddrug1 may decrease the clearance of some ddrug2 { ddrug3 , ddrug4 , ddrug5 } and increase the clearance of others { DB00186 , ddrug7 , ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00564 , ddrug2 , DB00252",
        "label": "NA"
    },
    {
        "text": "there is a significant increase in exposure to ddrug0 when DB00619 is coadministered with DB01026 { cyp3a4 inhibitor } .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 and ddrug1 : DB00983 should be administered with extreme caution in patients being treated with HD00275 or ddrug4 because the action of ddrug5 on the cardiovascular system may be potentiated by these agents .",
        "label": "advise"
    },
    {
        "text": "these drugs include the ddrug0 and other HD00218 , HD00175 , ddrug3 , ddrug4 , ddrug5 , oral ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , and ddrug11 .",
        "label": "NA"
    },
    {
        "text": "products containing ddrug0 and other multivalent cations { such as ddrug1 , DB14513 , ddrug3 } are likely to interfere with absorption of DB00710 .",
        "label": "mechanism"
    },
    {
        "text": "potential drug interactions for DB00366 include , increased sedation if ddrug1 is combined with other HD00545 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { e , g , DB00199 and DB13179 } : agents of the ddrug3 , of which ddrug4 { ddrug5 } injection , usp is a member , have been shown to interact with ddrug6 of the ddrug7 , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .",
        "label": "NA"
    },
    {
        "text": "although acid-base and electrolyte disturbances were not reported in the clinical trials with DB00869 , these disturbances have been reported with oral ddrug1 and have , in some instances , resulted in drug interactions { e , g , , toxicity associated with high-dose HD00372 therapy } .",
        "label": "NA"
    },
    {
        "text": "interactions may occur between ddrug0 supplements and ddrug1 and other HD00330 and herbs such as garlic { allium sativum } and ddrug3 { DB01381 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : HD00203 have produced an elevation of plasma ddrug2 levels and a reduction in renal DB14507 clearance .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : DB00862 # mg , when co-administered with slow-release DB01115 # mg or # mg once daily , did not affect the relative bioavailability { auc } or maximum concentration { cmax } of ddrug3 , a drug that is metabolized via cyp3a4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : no clinically significant changes occurred in heart rate or corrected qt intervals , or in ddrug1 metabolite or DB00978 pharmacokinetics , during concurrent administration of ddrug3 and DB00342 at steady-state in # healthy males .",
        "label": "NA"
    },
    {
        "text": "drug/laboratory test interactions as with DB00456 , high concentrations of DB01331 { # micrograms/ml } may interfere with measurement of serum and urine creatinine levels by the jaff reaction , and produce false increases of modest degree in the levels of creatinine reported .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of HD00071 : HD00175 , ddrug2 , ddrug3 , ddrug4 { e , g , , ddrug5 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - although DB01175 did not potentiate the cognitive and motor effects of DB02325 in a clinical trial , as with other ddrug3 , the use of ddrug4 by patients taking ddrug5 is not recommended .",
        "label": "NA"
    },
    {
        "text": "these effects were not observed when DB00862 # mg was taken # hours before the HD00903 .",
        "label": "NA"
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of ddrug0 such as DB00565 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 } , ddrug11 salts , ddrug12 , local ddrug13 , ddrug14 , and DB00908 .",
        "label": "effect"
    },
    {
        "text": "drugs that reduce the number of blood platelets by causing bone marrow depression { such as ddrug0 } or drugs which inhibit platelet function { eg , ddrug1 and other HD00330 , ddrug3 , ddrug4 , ddrug5 , ddrug6 } may increase the bleeding tendency produced by HD00326 without altering prothrombin time determinations .",
        "label": "effect"
    },
    {
        "text": "no depressant effect on blood levels in humans was noted when ddrug0 was administered with any of the following drugs : ddrug1 , ddrug2 , ddrug3 , ddrug4 , DB00627 { ddrug6 } , ddrug7 , DB00252 or ddrug9 .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 : in one study , DB00712 was given to adult diabetics who were already receiving ddrug2 { n = 4 } , ddrug3 { n = 2 } ddrug4 with ddrug5 { n = 3 } or ddrug6 with DB00914 { n = 6 } .",
        "label": "NA"
    },
    {
        "text": "HD00670 : ddrug1 / DB00503 combination",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { DB00091 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and DB00126 .",
        "label": "NA"
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a ddrug0 , including ddrug1 , with multivalent cation-containing products such as ddrug2 or DB01370 ddrug4 , ddrug5 , ddrug6 chewable/buffered tablets or pediatric powder , or products containing ddrug7 , DB01592 , or ddrug9 may substantially decrease the absorption of ddrug10 , resulting in serum and urine levels considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "potential drug interactions between ddrug0 and other ddrug1 { ddrug2 , ddrug3 , ddrug4 , DB01174 , ddrug6 , ddrug7 and ddrug8 } were also assessed by evaluating the serum concentrations of DB01202 and these ddrug10 during placebo-controlled clinical studies .",
        "label": "NA"
    },
    {
        "text": "patients receiving other ddrug0 , ddrug1 , HD00557 , or other ddrug3 { including DB02325 } concomitantly with ddrug5 and ddrug6 tablets may exhibit an additive cns depression .",
        "label": "NA"
    },
    {
        "text": "in a study in which patients with active ra were treated for up to # weeks with concurrent DB09145 and DB00026 therapy , a 7 % rate of serious infections was observed , which was higher than that observed with ddrug2 alone { 0 % } .",
        "label": "effect"
    },
    {
        "text": "ddrug0 { cns } drugs including ddrug1 , ddrug2 , HD00388 , ddrug4 , blood pressure medications { ddrug5 , ddrug6 , ddrug7 } , motion sickness medications , ddrug8 , ddrug9 , HD00024 , sleeping pills and ddrug11",
        "label": "NA"
    },
    {
        "text": "DB01576 with DB01151 or ddrug2 and possibly other ddrug3 cause striking and sustained increases in the concentration of ddrug4 in the brain ;",
        "label": "mechanism"
    },
    {
        "text": "patients receiving HD00071 or oral HD00484 should be closely watched during initiation of thyroid replacement therapy .",
        "label": "NA"
    },
    {
        "text": "DB00026 : concurrent administration of ddrug1 { an ddrug2 } and another HD00242 has been associated with an increased risk of serious infections , an increased risk of neutropenia and no additional benefit compared to these medicinal products alone .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : when DB09026 was co-administered with ddrug2 , the auc and cmax of DB00695 were reduced by about 30 % and 50 % , respectively .",
        "label": "NA"
    },
    {
        "text": "other ddrug0 { eg , DB00908 , ddrug2 , ddrug3 , ddrug4 } have occasionally been used concurrently with DB00280 .",
        "label": "NA"
    },
    {
        "text": "DB00196 , and the HD00457 ddrug2 { ddrug3 } and ddrug4 { ddrug5 } have all been used with ddrug6 .",
        "label": "NA"
    },
    {
        "text": "DB00318 in combination with other ddrug1 , general ddrug2 , HD00219 , ddrug4 , ddrug5 , or other ddrug6 { including ddrug7 } has additive depressant effects .",
        "label": "effect"
    },
    {
        "text": "plasma levels of several closely related ddrug0 have been reported to be increased by the concomitant administration of ddrug1 or hepatic enzyme inhibitors { e , g , , DB00501 , ddrug3 } and decreased by the concomitant administration of hepatic enzyme inducers { e , g , , ddrug4 , ddrug5 } , and such an effect may be anticipated with HD00551 as well .",
        "label": "mechanism"
    },
    {
        "text": "other concomitant therapy although specific interaction studies were not performed , ddrug0 doses of # mg or more were concomitantly used in clinical studies with ddrug1 , ddrug2 , a-blockers , ddrug3 , ddrug4 , HD00282 , ddrug6 , ddrug7 , ddrug8 , cardiac ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 { also referred to as HD00203 } , and ddrug15 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the HD00555 of drugs may be potentiated by ddrug1 , ddrug2 , ddrug3 , HD00556 , ddrug5 , the ddrug6 , ddrug7 and ddrug8 , ddrug9 and the ddrug10 , and by other ddrug11 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : in a prospective study involving six-healthy-male volunteers , DB00954 did not affect the metabolism of DB00342 .",
        "label": "NA"
    },
    {
        "text": "although there are no study data to evaluate the possibility , ddrug0 , including DB00325 and DB00727 , may have an additive effect with ddrug3 on the risk of developing methemoglobinemia .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : altered serum levels of DB00252 { increased and decreased } have been reported in patients receiving concomitant DB00537 .",
        "label": "mechanism"
    },
    {
        "text": "HD00831 - DB00120 may potentiate the tardive dyskinesia side reactions of ddrug2 if used concomitantly with them .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : HD00401 may delay intestinal absorption of DB01174 ;",
        "label": "mechanism"
    },
    {
        "text": "in a study in which the # mg ddrug0 orally disintegrating tablet was administered with and without DB00782 { an HD00554 with multiple effects on the gi tract } to healthy volunteers , the auc of ddrug3 was 10 % lower and the cmax of ddrug4 was 20 % lower when the orally disintegrating tablet was given with ddrug5 compared to when it was given alone .",
        "label": "NA"
    },
    {
        "text": "after the coadministration of # mg oral DB01026 twice daily and one # mg dose of DB00455 to # subjects , the auc and cmax of ddrug2 averaged 302 % { # s , d , } and 251 % { # s , d , } , respectively , of those obtained after co-treatment with placebo .",
        "label": "mechanism"
    },
    {
        "text": "drug-drug interactions given the primary cns effects of ddrug0 , caution should be used when DB01238 is taken in combination with other HD00365 and ddrug3 .",
        "label": "advise"
    },
    {
        "text": "the pharmacokinetics and protein binding of DB01320 , ddrug1 , and ddrug2 were not altered when ddrug3 and DB01320 were concurrently administered in single submaximal doses .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration of DB00918 and DB00661 resulted in a 24 % increase in plasma concentrations of ddrug3 .",
        "label": "mechanism"
    },
    {
        "text": "several drug interaction studies have been completed with both DB01232 and DB01232 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : HD00401 may antagonize the hypotensive effects of HD00255 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : HD00902 bid did not show a significant effect on the plasma exposure or renal clearance of DB00563 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration of once daily doses of DB00673 , as a tablet formulation comparable to # mg or # mg of the capsule formulation , with ddrug2 # mg once daily , resulted in a decrease in auc by approximately 25 % and cmax , by approximately 20 % of both ddrug3 and DB00715 .",
        "label": "NA"
    },
    {
        "text": "in vivo interaction studies in humans have demonstrated that ddrug0 and ddrug1 do not affect the pk properties of ddrug2 , nor does ddrug3 affect the pk properties of DB00390 or DB00682 .",
        "label": "NA"
    },
    {
        "text": "injection : DB00186 injection , like other injectable ddrug1 , produces depression of the central nervous system when administered with ddrug2 , ddrug3 , ddrug4 , ddrug5 , and other HD00216 , when ddrug7 is used concomitantly with injectable ddrug8 , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .",
        "label": "effect"
    },
    {
        "text": "caution should be used when administering or taking DB00530 with ddrug1 and other strong cyp3a4 inhibitors such as , but not limited to , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { ddrug12 } , and DB00582 .",
        "label": "advise"
    },
    {
        "text": "drug-drug interactions between DB01202 and other ddrug1 { ddrug2 } DB00252 ddrug4 { 3000 mg daily } had no effect on the pharmacokinetic disposition of ddrug5 in patients with refractory epilepsy .",
        "label": "NA"
    },
    {
        "text": "drugs which inhibit cyp 3a4 { e , g , , DB01026 , ddrug1 such as ddrug2 } have the potential to result in increased plasma concentrations of HD00175 .",
        "label": "mechanism"
    },
    {
        "text": "the effects DB00482 on the pharmacokinetics and/or pharmacodynamics of ddrug1 , ddrug2 , ddrug3 , DB00252 , ddrug5 , and ddrug6 have been studied in vivo and clinically important interactions have not been found .",
        "label": "NA"
    },
    {
        "text": "ddrug0 should not be taken closely in time with DB01370 and ddrug2 containing HD00374 .",
        "label": "NA"
    },
    {
        "text": "although concomitant use of ddrug0 and DB00564 is not recommended , it should be noted that discontinuation of concomitant ddrug2 administration may result in an increase in DB00363 plasma levels .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 , ddrug2 , ddrug3 , and DB00503 have been shown to decrease plasma levels of HD00710 ;",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 , or other products containing ddrug1 or ddrug2 , HD00374 or ddrug4 should not be administered concomitantly with , or within # hours of , the administration of ddrug5 , because they may interfere with absorption resulting in lower serum and urine levels of DB01059 .",
        "label": "NA"
    },
    {
        "text": "DB00715 : coadministration of once daily doses of ddrug1 , as a tablet formulation comparable to # mg or # mg of the capsule formulation , with ddrug2 # mg once daily , resulted in a decrease in auc by approximately 25 % and cmax , by approximately 20 % of both DB00673 and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma ddrug0 concentrations include : acute DB02325 intake , DB01118 , chboramphenicol , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21",
        "label": "NA"
    },
    {
        "text": "although these results do not indicate a significant interaction between ddrug0 and ddrug1 or ddrug2 , the administration of DB00465 to patients taking HD00326 should be done extremely cautiously , and patients should be closely monitored .",
        "label": "advise"
    },
    {
        "text": "ddrug0 and oral ddrug1 : concomitant administration of DB00162 and/or other oral ddrug3 with DB00459 must be avoided because of the risk of hypervitaminosis a.",
        "label": "advise"
    },
    {
        "text": "however , no deleterious interactions were seen when DB01205 was administered after ddrug1 , inhalational HD00264 , ddrug3 and muscle relaxant antagonists administered in conjunction with sedation or anesthesia .",
        "label": "NA"
    },
    {
        "text": "effects of other HD00703 on ddrug1 DB00252 : ddrug3 causes an approximate doubling of the clearance of ddrug4 { ddrug5 } at steady state and , therefore , the addition of ddrug6 causes an approximate 45 % decrease in the steady-state trough concentrations of ddrug7 as compared to the same dose of ddrug8 given as monotherapy .",
        "label": "NA"
    },
    {
        "text": "reports suggest that ddrug0 may diminish the antihypertensive effect of HD00106 , including DB00722 .",
        "label": "NA"
    },
    {
        "text": "agents causing renin release : the antihypertensive effect of DB00584 and ddrug1 iv is augmented by ddrug2 that cause renin release { e , g , , HD00218 } .",
        "label": "effect"
    },
    {
        "text": "trough plasma DB00467 levels were also 20 % higher when DB00201 and ddrug2 were administered concomitantly .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , DB01174 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , DB00860 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma ddrug0 concentrations include : acute DB02325 intake , ddrug2 , chboramphenicol , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , DB00656",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 DB00564 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { DB00472 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of DB00964 # % ophthalmic solution , the possibility of an additive or potentiating effect with HD00261 { ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 } should be considered .",
        "label": "advise"
    },
    {
        "text": "and DB00822 when ddrug1 is given with HD00315 agents or ddrug3 drugs , including ddrug4 combined with local ddrug5 , close supervision and careful adjustment of dosages are required .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { ddrug1 , ddrug2 , DB01174 , ddrug4 , ddrug5 } : increase the metabolism of DB00977 and/or some ddrug7 , leading to possible decrease in contraceptive effectiveness .",
        "label": "mechanism"
    },
    {
        "text": "DB00586 : administration of morning and lunch doses of DB00731 # mg in combination with a single 75-mg dose of ddrug2 in healthy volunteers resulted in no significant changes to the pharmacokinetics of either agent .",
        "label": "NA"
    },
    {
        "text": "when DB00476 was administered { at a dose of # mg bid } in conjunction with a single 50-mg dose of DB01151 , a cyp2d6 substrate , the auc of ddrug2 increased 3-fold .",
        "label": "mechanism"
    },
    {
        "text": "nonetheless , the range of individual DB00074 clearance values in the presence of DB00993 { 12 - 57 ml/h } or ddrug2 { 7 - 54 ml/h } did not extend outside the range observed with dual therapy { 10 - 78 ml/h } .",
        "label": "NA"
    },
    {
        "text": "marked symptomatic orthostatic hypotension has been reported when HD00377 and HD00817 were used in combination .",
        "label": "effect"
    },
    {
        "text": "while all the ddrug0 { HD00114 } , e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , and DB00715 , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .",
        "label": "NA"
    },
    {
        "text": "the concomitant use of transdermal ddrug0 with ddrug1 or other potent 3a4 inhibitors such as ddrug2 , DB01167 , ddrug4 , ddrug5 , ddrug6 , and nefazadone may result in an increase in DB00813 plasma concentrations .",
        "label": "NA"
    },
    {
        "text": "other interactions : DB00862 had no effect on the pharmacodynamics of DB01016 { glucose and irdn concentrations } and ddrug2 { prothrombin time or other pharmacodynamic parameters } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : it has not been established if there is a pharmacokinetic interaction between DB00459 and HD00236 .",
        "label": "NA"
    },
    {
        "text": "however , interactions may be expected , and DB00346 should not be used in combination with other HD00266 .",
        "label": "advise"
    },
    {
        "text": "fifteen to # minutes of exposure to # mac ddrug0 or DB00228 had minimal effects on the duration of action of initial doses of DB00565 and therefore , no adjustment to the initial dose should be necessary when ddrug3 is administered shortly after initiation of volatile agents .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , DB00091 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , DB00812 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , DB00224 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , DB00277 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "therefore , cyp3a4 substrates known to have a narrow therapeutic index such as ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , DB00864 , or ddrug10 { ddrug11 , ddrug12 } should be administered with caution in patients receiving DB01254 .",
        "label": "advise"
    },
    {
        "text": "oral HD00062 : in one study , ddrug1 was given to adult diabetics who were already receiving ddrug2 { n = 4 } , ddrug3 { n = 2 } DB00672 with ddrug5 { n = 3 } or ddrug6 with ddrug7 { n = 6 } .",
        "label": "NA"
    },
    {
        "text": "- ddrug0 { e , g , , DB00252 } use of DB00252 with ddrug3 may increase the chance of side effects affecting the liver and/or the side effects of ddrug4",
        "label": "NA"
    },
    {
        "text": "ddrug0 ddrug1 DB00199 ddrug3 ddrug4 HD00324 ddrug6 ddrug7 large quantities of grapefruit juice { # quart daily }",
        "label": "NA"
    },
    {
        "text": "conjugation at ddrug0 with ddrug1 moieties significantly improves the intestinal permeation of the hydrophilic molecule HD00070 and the model peptide drugs DB00781 and ddrug4 in vitro , therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB01032 is known to interact with the metabolism or renal tubular excretion of many drugs { e , g , , ddrug2 , DB00787 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 agents , ddrug14 , and ddrug15 } .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 , DB00415 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and ddrug7 have no influence in vitro on the protein binding of DB00586 in human serum .",
        "label": "NA"
    },
    {
        "text": "a study in six healthy volunteers has shown a significant increase in peak DB00343 plasma levels { 58 % } and auc { 53 % } after a 1-week course of DB00501 # mg/day and a single dose of ddrug2 60 mg .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 { congestive heart failure post-myocardial infarction } - in ephesus , # { 91 % } patients receiving ddrug2 # to # mg also received HD00106 or ddrug4 { HD00685 / ddrug6 } .",
        "label": "NA"
    },
    {
        "text": "patients receiving HD00244 along with either oral or intravenous HD00085 should be monitored for possible atrioventricular conduction disturbances , left ventricular failure and hypotension .",
        "label": "advise"
    },
    {
        "text": "HD00026 and ddrug1 should not be administered to patients receiving HD00027 .",
        "label": "advise"
    },
    {
        "text": "therefore , DB00535 for oral suspension can be administered with DB01592 - fortified infant formula .",
        "label": "NA"
    },
    {
        "text": "DB00220 and DB01045 should not be coadministered .",
        "label": "advise"
    },
    {
        "text": "like ddrug0 { 40 mg/kg } , ddrug1 { 40 mg/kg } decreases the intravenous self-administration of ddrug2 and DB00907 and the oral self-administration of ddrug4 and DB00184 in rats ;",
        "label": "NA"
    },
    {
        "text": "however , the systemic administration of some HD00532 has been shown to elevate plasma concentrations of ddrug1 , interfere with the metabolism of ddrug2 , and enhance the effects of the oral ddrug3 DB00682 and its derivatives , and has been associated with transient elevations in serum creatinine in patients receiving systemic ddrug5 concomitantly .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , DB00636 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { DB01045 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / ddrug1 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 pain medication { e , g , , DB00318 } , drugs used to aid sleep , drowsiness-causing HD00388 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : concomitant administration of ddrug1 and DB06723 does not interfere with the rate or extent of the absorption of ddrug3 administered as HD00760 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 may enhance the effects of : other ddrug3 s , ddrug4 , general HD00264 , ddrug6 such as DB00475 , ddrug8 , or other ddrug9 , causing increased cns depression .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in normal volunteers , the concomitant administration of DB00861 and ddrug2 had no effect on the diuretic activity of DB00695 .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of ddrug0 and ddrug1 , ddrug2 , ddrug3 , or an ddrug4 / ddrug5 oral HD00349 produced minor changes in the pharmacokinetics of DB01155 , which were considered to be without clinical significance .",
        "label": "NA"
    },
    {
        "text": "drug/laboratory test interactions as with other HD00124 , the administration of DB00319 may result in a false-positive reaction for glucose in the urine using a copper-reduction method .",
        "label": "NA"
    },
    {
        "text": "consequently , it is recommended that DB00176 not be used in combination with either ddrug1 , ddrug2 , or DB00604 .",
        "label": "advise"
    },
    {
        "text": "data suggest that coadministration of oral DB01026 and DB00604 can result in prolongation of the qt interval on the ecg .",
        "label": "effect"
    },
    {
        "text": "ddrug0 - and/or ddrug1 - containing HD00374 , products containing DB01373 { ddrug4 } , ddrug5 containing ddrug6 or other metal cations , or ddrug7 { ddrug8 } chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after ddrug9 .",
        "label": "NA"
    },
    {
        "text": "HD00093 { e , g , ddrug1 and DB13179 } : agents of the ddrug3 , of which ddrug4 { ddrug5 } injection , usp is a member , have been shown to interact with ddrug6 of the ddrug7 , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .",
        "label": "NA"
    },
    {
        "text": "DB00435 has been administered with ddrug1 , DB00988 , ddrug3 , ddrug4 , ddrug5 , and high-frequency ventilation .",
        "label": "NA"
    },
    {
        "text": "DB01075 has additive effects with DB02325 and other ddrug2 { ddrug3 , ddrug4 , ddrug5 , etc } .",
        "label": "effect"
    },
    {
        "text": "based on adult data , lower doses of ddrug0 may be needed following coadministration of drugs which are reported to decrease ddrug1 elimination { e , g , , ddrug2 and DB01026 } and higher ddrug4 doses may be needed following coadministration of drugs that increase ddrug5 elimination { e , g , , DB01174 and ddrug7 } .",
        "label": "NA"
    },
    {
        "text": "the co-administration of ddrug0 with iv HD00337 such as ddrug2 , ddrug3 , DB00235 , or iv ddrug5 has not been evaluated { these drugs were not co-administered with ddrug6 in clinical trials } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a study of healthy male volunteers no significant pharmacokinetic interaction occurred when DB01197 and DB00437 were administered concomitantly for # days .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : although DB00332 is minimally absorbed into the systemic circulation , there is some potential for an additive interaction with concomitantly used HD00814 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { DB00316 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { DB00295 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "erythromycin co-administration of ddrug0 { DB01023 } with ddrug2 resulted in approximately # - fold increase in the auc and cmax , and about 2 - fold prolongation in the half - life of DB01023 .",
        "label": "NA"
    },
    {
        "text": "HD00374 : concomitant administration of ddrug1 s and DB09104 s does not interfere with absorption of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as DB01135 include certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 } , ddrug10 salts , ddrug11 , local HD00264 , ddrug13 , and ddrug14 .",
        "label": "effect"
    },
    {
        "text": "hypersensitivity reactions : patients with a history of severe hypersensitivity reactions to products containing cremophor el { eg , ddrug0 for injection concentrate and DB00444 for injection concentrate } should not be treated with DB01229 .",
        "label": "advise"
    },
    {
        "text": "drug-drug interactions between ddrug0 and other ddrug1 { HD00714 } DB00252 ddrug4 { 3000 mg daily } had no effect on the pharmacokinetic disposition of ddrug5 in patients with refractory epilepsy .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 , and ddrug2 : drugs such as ddrug3 , ddrug4 , and HD00249 may increase the risk of developing peripheral_neuropathies or other ddrug6 - associated adverse events by interfering with the renal clearance of DB00943 { thereby raising systemic exposure } .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : DB00564 , DB01174 , ddrug3",
        "label": "NA"
    },
    {
        "text": "DB01167 ddrug1 ddrug2 DB01211 ddrug4 ddrug5 ddrug6 ddrug7 large quantities of grapefruit juice { # quart daily }",
        "label": "NA"
    },
    {
        "text": "drug interactions with ddrug0 administration of # mg of DB00950 { 2 x # mg capsule } within # minutes of an ddrug2 and ddrug3 containing ddrug4 { HD00467 } decreased ddrug6 auc by 41 % and cmax by 43 % .",
        "label": "mechanism"
    },
    {
        "text": "DB00328 and HD00293 each may be associated with increased serum potassium levels .",
        "label": "NA"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , ddrug3 HD00388 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 ddrug11 , DB00897 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "the concurrent use of two or more drugs with anticholinergic activity -- such as an ddrug0 { eg , ddrug1 } , an HD00514 { eg , ddrug3 } , and/or a ddrug4 { eg , DB00321 } -- commonly results in excessive anticholinergic effects , including dry mouth and associated dental complications , blurred vision , and , in patients exposed to high temperature and humidity , hyperpyrexia .",
        "label": "effect"
    },
    {
        "text": "the concurrent administration of DB00437 and ddrug1 increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving DB00415 alone .",
        "label": "NA"
    },
    {
        "text": "drug interactions with ddrug0 administration of # mg of ddrug1 { 2 x # mg capsule } within # minutes of an DB01370 and ddrug3 containing ddrug4 { HD00467 } decreased ddrug6 auc by 41 % and cmax by 43 % .",
        "label": "NA"
    },
    {
        "text": "therefore , it would be expected that a dosing schedule of HD00503 given at bedtime and DB01432 given before the evening meal would not result in a significant decrease in the clinical effect of ddrug2 .",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing DB01370 , ddrug3 , or ddrug4 , with ddrug5 , with metal cations such as DB01592 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "extended release tablets : administration of DB01115 with DB00390 increased ddrug2 levels in # of # normal volunteers .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , including oral , injectable , transdermal , and implantable ddrug1 : an interaction study demonstrated that co-administration of DB00559 and the oral ddrug3 ddrug4 produced average decreases of ddrug5 and DB00977 levels of 14 % and 31 % , respectively .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the concomitant use of ddrug1 { ddrug2 transdermal system } with other ddrug3 , including but not limited to other ddrug4 , HD00024 , ddrug6 , HD00262 { e , g , , ddrug8 } , general ddrug9 , ddrug10 , ddrug11 , and ddrug12 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of ddrug0 : ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , DB00668 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , HD00810 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "use lowest possible dose of ddrug0 with careful monitoring , or consider ddrug1 that are not primarily metabolized by cyp3a4 , such as ddrug2 , ddrug3 , or DB01098 in combination with DB00224 .",
        "label": "NA"
    },
    {
        "text": "the hypoglycemic action of ddrug0 may be potentiated by certain drugs including HD00518 and other drugs that are highly protein bound , HD00328 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , and ddrug8 .",
        "label": "NA"
    },
    {
        "text": "HD00509 requirements { i , e , , HD00071 } may be altered .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and HD00466 { congestive heart failure post-myocardial infarction } - in ephesus , # { 91 % } patients receiving ddrug2 # to # mg also received ddrug3 or ddrug4 { ddrug5 / HD00686 } .",
        "label": "NA"
    },
    {
        "text": "DB00604 was well tolerated when administered alone or with DB00472 .",
        "label": "NA"
    },
    {
        "text": "HD00254 , ddrug1 , ddrug2 salts , and ddrug3 may either potentiate or weaken the blood-glucose-lowering effect of HD00071 .",
        "label": "effect"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { ddrug1 s } , ddrug2 , ddrug3 { ddrug4 may decrease the effects of these medicines } , ddrug5 { using these medicines with ddrug6 may result in increased cns depressant effects } , ddrug7 , ddrug8 { using these medicines with ddrug9 may change the amount of either medicine that you need to take } , and oral ddrug10 containing ddrug11 { HD00026 may decrease the effectiveness of these oral HD00283 , and you may need to change to a different type of birth control } .",
        "label": "effect"
    },
    {
        "text": "DB00917 may augment the activity of other HD00629 .",
        "label": "effect"
    },
    {
        "text": "DB00575 may enhance the cns-depressive effects of ddrug1 , ddrug2 or other HD00024 .",
        "label": "effect"
    },
    {
        "text": "in em individuals treated with DB00715 or ddrug1 , the auc of DB00289 is approximately 6 - to 8-fold and css , max is about 3 - to 4-fold greater than ddrug3 alone .",
        "label": "mechanism"
    },
    {
        "text": "after prolonged administration of HD00137 the displacing effect of DB00403 , an analog of cholecystokinin octapeptide , was replaced by the stimulant action on ddrug2 binding .",
        "label": "NA"
    },
    {
        "text": "injection : DB00186 injection , like other injectable ddrug1 , produces depression of the central nervous system when administered with ddrug2 , HD00219 , ddrug4 , ddrug5 , and other ddrug6 , when ddrug7 is used concomitantly with injectable ddrug8 , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .",
        "label": "effect"
    },
    {
        "text": "oral ddrug0 : DB01244 has been safely used in diabetic patients without significantly lowering their blood glucose levels or altering their need for HD00071 or oral ddrug3 .",
        "label": "NA"
    },
    {
        "text": "these data indicate that ddrug0 does not influence the plasma concentration of other ddrug1 and that these HD00714 do not influence the pharmacokinetics of DB01202 .",
        "label": "NA"
    },
    {
        "text": "DB01563 and ddrug1 interact pharmacologically with orally administered HD00028 , but the effect is not clinically significant .",
        "label": "int"
    },
    {
        "text": "poor metabolizers of ddrug0 : interactions of DB01136 with strong inhibitors of cyp2d6 { such as DB00908 , ddrug3 , ddrug4 , and ddrug5 } have not been studied , but these drugs would be expected to increase blood levels of the r { + } enantiomer of ddrug6 .",
        "label": "NA"
    },
    {
        "text": "may interact with thyroid medication { e , g , , ddrug0 } , ddrug1 - containing products , HD00374 , ddrug3 { e , g , , ddrug4 , ddrug5 } , and HD00587 { e , g , , ddrug7 , ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "in patients taking an ddrug0 { eg , ddrug1 , DB00564 , ddrug3 or ddrug4 } , the concomitant use of DB00358 may reduce seizure control by lowering the plasma levels of the ddrug6 .",
        "label": "effect"
    },
    {
        "text": "other drugs : in healthy volunteers , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , hormone replacement therapy { a combination of conjugated ddrug5 and ddrug6 } , ddrug7 { ddrug8 and ddrug9 } and DB00277 did not affect the pharmacokinetics of DB00204 .",
        "label": "NA"
    },
    {
        "text": "in patients with mild to moderate hypertension , administration of # mg daily of HD00897 with the HD00471 ddrug2 , # to # mg for # weeks , was associated with an average increase in mean arterial pressure of about # mm hg compared to ddrug3 alone .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , DB01068 , DB00593",
        "label": "NA"
    },
    {
        "text": "ddrug0 { ddrug1 } { e , g , , ddrug2 , ddrug3 , ddrug4 , DB01104 } have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with HD00277 .",
        "label": "effect"
    },
    {
        "text": "in vitro studies evaluating the minimum inhibitory concentration { mic } of ddrug0 , ddrug1 , ddrug2 , ddrug3 / flucoxacillin , ddrug4 , ddrug5 , and ddrug6 demonstrated no evidence of incompatibility of these HD00002 with DB00702 .",
        "label": "NA"
    },
    {
        "text": "drugs which induce cyp3a4 activity { eg , ddrug0 , DB01045 , ddrug2 } would be expected to increase the clearance of DB00625 resulting in lowered plasma concentrations .",
        "label": "mechanism"
    },
    {
        "text": "drug interactions : ddrug0 may interact with some drugs , like ddrug1 { ddrug2 } : ddrug3 could theoretically affect ddrug4 pharmacodynamics - ddrug5 - jzqyavbxjcqsok_uhfffaoysa_n - ddrug6 : ddrug7 and DB00898 cause additive cns depression - HD00043 : ddrug10 increases the effect of ddrug11",
        "label": "NA"
    },
    {
        "text": "HD00870 : ddrug1 , DB01253 , ddrug3 , ddrug4 contraindicated due to potential for serious and life-threatening reactions such as acute ddrug5 toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues .",
        "label": "NA"
    },
    {
        "text": "concomitant use of ddrug0 and drugs that inhibit cyp3a4 { eg , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , DB01232 , ddrug11 } may increase exposure to DB01254 and should be avoided .",
        "label": "NA"
    },
    {
        "text": "however , other published reports describe modest elevations { less than two-fold } of ddrug0 and metabolite concentrations when DB00363 was taken with ddrug2 , DB00472 , and ddrug4 .",
        "label": "mechanism"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of ddrug0 : ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , ddrug5 , ddrug6 , DB00871 } , ddrug8 , ddrug9 , ddrug10 , HD00809 , ddrug12 , ddrug13 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "we propose these pharmacokinetic changes to be the underlying mechanism for the reduction of oral HD00152 cytotoxicity by DB11716 .",
        "label": "mechanism"
    },
    {
        "text": "the intensity , uniformity and time course of ddrug0 interference by ddrug1 , ddrug2 , DB01437 , ddrug4 and ddrug5 were systematically investigated in # patients receiving DB04665 therapy .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in vitro and/or in vivo data indicate that DB00196 , ddrug2 , and oral DB01026 markedly inhibit the metabolism of ddrug4 , which can result in an increase in plasma ddrug5 levels and prolongation of the qt interval on the ecg .",
        "label": "NA"
    },
    {
        "text": "caution should be exercised when administering DB00461 with ddrug1 since interactions have been seen with other HD00203 .",
        "label": "NA"
    },
    {
        "text": "however , the antagonism of the ddrug0 - induced anxiogenic effects by ddrug1 was only observed in the time spent in the light zone , and HD00188 - induced anxiogenic effects were neither reversed by HD00184 nor by ddrug4 .",
        "label": "NA"
    },
    {
        "text": "a drug-drug interaction study evaluated the effect of the use of DB00250 gel , 5 % , in combination with double_strength { 160 mg/800 mg } ddrug1 / ddrug2 { DB01643 / ddrug4 } .",
        "label": "NA"
    },
    {
        "text": "the administration of local ddrug0 containing ddrug1 or DB00368 to patients receiving ddrug3 , ddrug4 or HD00219 may produce severe , prolonged hypotension or hypertension .",
        "label": "effect"
    },
    {
        "text": "the action of the HD00100 may be potentiated by ddrug1 , ddrug2 , ddrug3 , ddrug4 , HD00275 , ddrug6 , ddrug7 , ddrug8 , or other drugs that produce cns depression .",
        "label": "effect"
    },
    {
        "text": "- ddrug0 : DB14507 should generally not be given with ddrug2 { such as DB00887 } because they reduce its renal clearance and add a high risk of ddrug4 toxicity .",
        "label": "advise"
    },
    {
        "text": "- ddrug0 and ddrug1 ddrug2 : ddrug3 and DB00375 ddrug5 have the potential of binding ddrug6 and reducing HD00295 absorption from the gastrointestinal tract",
        "label": "NA"
    },
    {
        "text": "the administration of local HD00449 containing ddrug1 or ddrug2 to patients receiving HD00275 or ddrug4 may produce severe , prolonged hypertension .",
        "label": "NA"
    },
    {
        "text": "agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of ddrug0 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 { 2 } , ddrug7 , ddrug8 , and DB00277 thus , if a patient has been titrated to a stable dosage on HD00472 , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for ddrug11 may be necessary .",
        "label": "NA"
    },
    {
        "text": "potential drug interactions between ddrug0 and other ddrug1 { ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 and ddrug8 } were also assessed by evaluating the serum concentrations of DB01202 and these HD00714 during placebo-controlled clinical studies .",
        "label": "NA"
    },
    {
        "text": "moreover , additional interaction studies with ddrug0 and DB00571 have not demonstrated any effect on DB01095 plasma levels , and administration to a patient population chronically receiving ddrug3 resulted in no difference in the extent of bioavailability of ddrug4 relative to control data .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } DB00501 { ddrug8 } ddrug9 ddrug10 { DB00472 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "caution should be used when administering or taking ddrug0 with DB01026 and other strong cyp3a4 inhibitors such as , but not limited to , DB01072 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { ddrug12 } , and ddrug13 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 potentiates other HD00632 such as DB00202 or ddrug3 and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "the use of ddrug0 should be considered in place of HD00586 or HD00587 in patients receiving ddrug3 therapy .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in three pharmacokinetic studies including # normal , healthy subjects , DB00277 clearance and concentration were not significantly altered by the addition of DB00978 .",
        "label": "NA"
    },
    {
        "text": "these data suggest that ddrug0 are negatively coupled to three types of calcium channels in bovine chromaffin cell , including an ddrug1 - sensitive { n-type } channel , an HD00048 - sensitive { p-type } channel and DB00393 / ddrug4 / ddrug5 - resistant { presumptive q-type } channel .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00402 # mg administered daily for # days did not affect the pharmacokinetics of ddrug2 or ddrug3 nor were there any changes in the pharmacodynamic profile { prothrombin time } following a single # mg oral dose of DB00682",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , DB00636 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { HD00712 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and DB00563 - ddrug2 may decrease hepatic toxicity in those with DB00316 overdosage or in those taking ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , another DB11753 , is structurally similar to ddrug2 and may possibly have some of the same drug interactions as DB01045 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in some patients , the administration of a HD00292 can reduce the diuretic , natriuretic , and antihypertensive effects of ddrug2 , ddrug3 and HD00029 .",
        "label": "effect"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : HD00403 s { ddrug1 } other HD00216 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving HD00100 metabolized similarly to ddrug1 or on the basis of in vitro studies with DB00404 or other ddrug3 { caution is recommended during coadministration with ddrug4 } : available data from clinical studies of ddrug5 other than ddrug6 suggest a possible drug interaction with ddrug7 for the following : ddrug8 , ddrug9 , ddrug10 such as ddrug11 and ddrug12 , and grapefruit juice .",
        "label": "NA"
    },
    {
        "text": "DB00364 or divalent or trivalent cations such as DB01592 ;",
        "label": "NA"
    },
    {
        "text": "the adverse experience profile seen with HD00393 was similar to that seen with DB00181 tablets .",
        "label": "NA"
    },
    {
        "text": "HD00026 may decrease the effectiveness of oral ddrug1 , certain ddrug2 , ddrug3 , ddrug4 , HD00175 , ddrug6 , and ddrug7 .",
        "label": "effect"
    },
    {
        "text": "cardiac effects of ddrug0 are antagonized by HD00244 , such as ddrug2 and DB00264 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { DB00316 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , DB00273 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "HD00303 : ddrug1 , DB01244 , ddrug3 , ddrug4 , ddrug5 contraindicated due to potential for serious and/or life-threatening reactions .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , DB00446 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , ddrug8 { HD00398 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "in the presence of these HD00246 , larger doses of DB00640 may be required or ddrug2 may not be effective .",
        "label": "advise"
    },
    {
        "text": "ddrug0 / ddrug1 : the coadministration of ddrug2 or DB01174 will not affect plasma concentrations of ddrug4 , but may reduce endogenous plasma levels of DB00136 / ergocalcitriol by accelerating metabolism .",
        "label": "mechanism"
    },
    {
        "text": "in separate studies of patients receiving maintenance doses of DB00682 , ddrug1 , or ddrug2 , ddrug3 administration for # days had no effect on the pharmacodynamics of ddrug4 { prothrombin time } or pharmacokinetics of DB00390 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local HD00264 { e , g , , ddrug6 and ddrug7 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , DB01035 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "DB00641 and other ddrug1 : co-administration of DB00559 decreased the plasma concentrations of ddrug3 { a cyp3a4 substrate } , and its active - hydroxy acid metabolite , by approximately 50 % .",
        "label": "NA"
    },
    {
        "text": "caution should be exercised when administering DB00773 with drugs that are known to inhibit phosphatase activities { e , g , , HD00713 } .",
        "label": "advise"
    },
    {
        "text": "the absorption of ddrug0 , ddrug1 , DB01053 , ddrug3 , and ddrug4 was significantly decreased when given simultaneously with DB00375 ;",
        "label": "mechanism"
    },
    {
        "text": "- a HD00764 such as ddrug1 { DB00635 , ddrug3 , others } , ddrug4 { ddrug5 , others } , ddrug6 { ddrug7 , ddrug8 , others } , and others ;",
        "label": "NA"
    },
    {
        "text": "DB00701 inhibits the ermbt , and ddrug1 and DB00615 are equipotent inducers of the ermbt .",
        "label": "NA"
    },
    {
        "text": "oral HD00283 multiple doses of ddrug1 had no effect on the pharmacokinetics of DB00977 , the estrogenic component in most oral ddrug3 .",
        "label": "NA"
    },
    {
        "text": "drugs which require a dose reduction when coadminstered with ddrug0 HD00871 : DB00615",
        "label": "NA"
    },
    {
        "text": "administration of HD00532 with HD00374 containing ddrug2 , ddrug3 , or ddrug4 , with ddrug5 , with metal cations such as ddrug6 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "thus , the selective regulation of voltage-dependent ca { 2 + } subtypes by DB14152 in bovine chromaffin cell could be the cellular basis of antistress effects induced by DB02701 .",
        "label": "NA"
    },
    {
        "text": "use of ddrug0 ddrug1 and DB01109 have been administered concomitantly with and following infusions of DB00009 in the management of acute myocardial infarction or pulmonary embolism .",
        "label": "NA"
    },
    {
        "text": "it has been reported that DB01167 enhances the anticoagulant effect of DB04665 - like drugs .",
        "label": "effect"
    },
    {
        "text": "inhibitors of endogenous prostaglandin synthesis it has been reported that DB00328 may reduce the antihypertensive effect of DB01197 , especially in cases of low renin hypertension .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : ddrug1 is known to slow the metabolism of ddrug2 and increase its serum levels DB00564 levels should be determined prior to concurrent administration with DB00951 , signs and symptoms of ddrug5 toxicity should be monitored closely , and appropriate dosage adjustment of the ddrug6 should be made .",
        "label": "advise"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , DB00564 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , DB01045 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : when a single 125-mg dose of DB00673 was administered on day5 of a 10-day regimen of # mg/day of DB01026 , a strong cyp3a4 inhibitor , the auc of ddrug3 increased approximately 5-fold and the mean terminal half-life of ddrug4 increased approximately 3-fold .",
        "label": "mechanism"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of ddrug0 : ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , ddrug5 , ddrug6 , DB00871 } , ddrug8 , ddrug9 , ddrug10 , ddrug11 , HD00220 , ddrug13 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "in addition , results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance { DB00625 , ddrug1 , ddrug2 , ddrug3 , or ddrug4 } with ddrug5 may result in clinically meaningful reductions in DB00520 concentrations .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { DB00682 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { DB00501 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of DB00732 include : ddrug1 ; ddrug2 ; ddrug3 ; certain ddrug4 , especially the HD00249 and ddrug6 ; ddrug7 ; ddrug8 salts ; ddrug9 ; and ddrug10 .",
        "label": "effect"
    },
    {
        "text": "DB00661 : coadministration of DB00918 and ddrug2 resulted in a 24 % increase in plasma concentrations of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "comparison of ddrug0 pharmacokinetics in patients treated with # mg/m2 plus HD00158 to those in patients treated with # mg/m2 without ddrug2 indicated that there were no changes in the elimination rate constant , volume of distribution , or total body clearance of DB00515 .",
        "label": "NA"
    },
    {
        "text": "patients receiving other HD00424 , ddrug1 , ddrug2 , or other HD00261 { including ddrug4 } concomitantly with ddrug5 and ddrug6 tablets may exhibit an additive cns depression .",
        "label": "NA"
    },
    {
        "text": "if concomitant treatment with DB00918 and an HD00278 is clinically warranted , appropriate observation of the patient is advised .",
        "label": "advise"
    },
    {
        "text": "the co-administration of DB04899 with iv HD00337 such as ddrug2 , ddrug3 , ddrug4 , or iv ddrug5 has not been evaluated { these drugs were not co-administered with ddrug6 in clinical trials } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the concomitant use of ddrug1 { ddrug2 transdermal system } with other HD00389 , including but not limited to other ddrug4 , ddrug5 , HD00214 , ddrug7 { e , g , , ddrug8 } , general ddrug9 , ddrug10 , ddrug11 , and ddrug12 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .",
        "label": "NA"
    },
    {
        "text": "before taking DB00222 , tell your doctor if you are taking any of the following medicines : - ddrug1 or another ddrug2 such as ddrug3 { ddrug4 } , ddrug5 { ddrug6 , others } , ddrug7 { ddrug8 } , ddrug9 { ddrug10 } , or DB01294 { ddrug12 } ;",
        "label": "advise"
    },
    {
        "text": "ddrug0 : when healthy subjects were administered DB00731 # mg three times daily before meals for four days in combination with a single dose of DB00682 # mg on day 2 , there were no alterations in the pharmacokinetics of either agent .",
        "label": "NA"
    },
    {
        "text": "immediate and extended release tablets the hypoglycemic action of ddrug0 may be potentiated by certain drugs including HD00518 , some ddrug2 and other drugs that are highly protein bound , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , HD00275 , and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : concomitant administration of DB00945 with DB00580 may result in an increased risk of gi ulceration and complications compared to ddrug3 alone .",
        "label": "effect"
    },
    {
        "text": "ddrug0 { cns } drugs including ddrug1 , ddrug2 , ddrug3 , ddrug4 , blood pressure medications { ddrug5 , ddrug6 , HD00254 } , motion sickness medications , ddrug8 , HD00543 , ddrug10 , sleeping pills and ddrug11",
        "label": "NA"
    },
    {
        "text": "h-2 antagonists : in studies with human volunteers , co-administration of DB00501 or ddrug1 with ddrug2 had no substantive effect on DB01050 serum concentrations .",
        "label": "NA"
    },
    {
        "text": "DB00988 - induced renal and mesenteric vasodilation is not antagonized by either ddrug1 or HD00244 .",
        "label": "NA"
    },
    {
        "text": "additional reductions in blood pressure may occur when DB01240 is administered with HD00218 , ddrug2 , or other ddrug3 .",
        "label": "effect"
    },
    {
        "text": "DB01432 ddrug1 may delay or reduce the absorption of concomitant oral medication such as ddrug2 , ddrug3 , ddrug4 { acidic } or ddrug5 { basic } , as well as ddrug6 ddrug7 , ddrug8 , thyroid and ddrug9 preparations , HD00220 and ddrug11 , and ddrug12 .",
        "label": "mechanism"
    },
    {
        "text": "however , it adversely affected response duration suggesting that ddrug0 should not be administered with DB00488 and/or DB00515 #",
        "label": "NA"
    },
    {
        "text": "DB00501 } and many that are substrates for cyp2b6 2d6 { many other ddrug1 , ddrug2 , and the ddrug3 DB01182 and ddrug5 } .",
        "label": "NA"
    },
    {
        "text": "therefore , co-administration of DB00363 with other drugs that are metabolized by this isozyme , including ddrug1 , ddrug2 , ddrug3 , and ddrug4 { e , g , , ddrug5 , ddrug6 and ddrug7 } , or that inhibit this enzyme { e , g , , DB00908 } , should be approached with caution .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : HD00203 have produced an elevation of plasma DB14507 levels and a reduction in renal ddrug3 clearance .",
        "label": "mechanism"
    },
    {
        "text": "DB01026 : coadministration of ddrug1 { 200 mg/day for # days } with a 15-mg single dose of DB01238 increased the auc of ddrug3 and its active metabolite by 63 % and 77 % , respectively .",
        "label": "NA"
    },
    {
        "text": "conclusions : ddrug0 inhibit the metabolism of HD00095 that are metabolized by cyp3a4 { i , e , , ddrug2 , ddrug3 , ddrug4 , DB00641 } .",
        "label": "NA"
    },
    {
        "text": "the extent of plasma protein binding of DB01117 in human plasma is not affected by the presence of therapeutic concentrations of DB00252 { 15 mcg / ml } , nor is the binding of ddrug2 affected by the presence of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in healthy subjects receiving the cyp3a4 inducer , DB00564 , at # mg twice daily for # days and # mg twice daily for # days , systemic exposure { auc } to DB01259 was decreased approximately 72 % .",
        "label": "mechanism"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { ddrug1 s } , ddrug2 , ddrug3 { ddrug4 may decrease the effects of these medicines } , ddrug5 { using these medicines with HD00026 may result in increased cns depressant effects } , ddrug7 , ddrug8 { using these medicines with ddrug9 may change the amount of either medicine that you need to take } , and oral ddrug10 containing HD00220 { ddrug12 may decrease the effectiveness of these oral ddrug13 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "interactions for ddrug0 { ddrug1 , ddrug2 , DB00136 , and ddrug4 } : DB01432 : ddrug6 has been reported to reduce intestinal absorption of ddrug7 ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the effect of DB00580 on the anticoagulant effect of DB00682 { 1 - # mg/day } was studied in healthy subjects by coadministration of ddrug3 # mg bid for # days .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and foods fortified with DB01592 concomitant administration of ddrug2 with a therapeutic ddrug3 containing # mg of elemental ddrug4 { as feso4 } or HD00489 supplemented with # mg of elemental ddrug6 reduced extent of absorption by 80 % and 31 % , respectively .",
        "label": "NA"
    },
    {
        "text": "DB00125 , in the presence of DB09341 and ddrug2 , caused excessive gcg release but nearly normal insulin release in the diabetics .",
        "label": "NA"
    },
    {
        "text": "further , no effects on either DB00682 levels or prothrombin times were observed in a study involving concomitant administration of ddrug1 and DB01095 .",
        "label": "NA"
    },
    {
        "text": "DB01100 and ddrug1 - in a controlled study , a single dose of ddrug2 # mg co-administered with racemic DB00215 # mg given once daily for # days was associated with a mean increase in qtc values of approximately # msec compared to ddrug4 given alone .",
        "label": "NA"
    },
    {
        "text": "coadministration of DB00580 { 10 mg bid for # days } with DB01016 { 5 mg qd or # mg bid } did not affect the pharmacokinetics { exposure } of ddrug2 .",
        "label": "NA"
    },
    {
        "text": "HD00320 : DB00681 - induced hypokalemia may enhance the curariform effect of ddrug2 { e , g , , ddrug3 } .",
        "label": "NA"
    },
    {
        "text": "then , the effects of metabotropic glutamate receptor { mglur } agonists , ddrug0 and HD00019 , on the above behavioral changes induced by DB03575 were found .",
        "label": "NA"
    },
    {
        "text": "the availability of potent HD00110 { ddrug1 } - based regimens for ddrug2 therapy and concerns regarding HD00058 { ddrug4 } - related metabolic disturbances have led to significant shifts in treatment practices in hiv infection .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , DB00220 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , DB00277 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : following concomitant administration of a single dose of DB01097 to subjects receiving multiple doses of DB01045 , m1 peak levels were increased { ~ 40 % } over those seen when ddrug3 was given alone .",
        "label": "mechanism"
    },
    {
        "text": "although no clinical studies have been conducted , it is likely that the metabolism of DB01002 may be affected by the known cyp3a4 inducers { such as ddrug1 , ddrug2 , DB01045 } , cyp3a4 inhibitors { azole antimycotics e , g , , ddrug4 ;",
        "label": "mechanism"
    },
    {
        "text": "injection : DB00186 injection , like other injectable ddrug1 , produces depression of the central nervous system when administered with ddrug2 , ddrug3 , HD00026 , ddrug5 , and other ddrug6 , when ddrug7 is used concomitantly with injectable ddrug8 , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .",
        "label": "effect"
    },
    {
        "text": "DB00502 reduced or eliminated the increases in fi responding produced by intermediate doses of either ddrug1 or ddrug2 in pigeons , but did not antagonize the decreases in fi or fr responding produced by high doses of pgpep1 or either stereoisomer of HD00155 .",
        "label": "NA"
    },
    {
        "text": "DB00158 in large amounts may counteract the antiepileptic effect of DB01174 , ddrug2 and ddrug3 , and increase the frequency of seizures in susceptible pediatric patients .",
        "label": "effect"
    },
    {
        "text": "on the basis of the metabolism of DB00307 by cytochrome p450 3a4 , DB01026 , ddrug2 , ddrug3 , ddrug4 , grapefruit juice , and other inhibitors of cyp3a4 would be expected to lead to an increase in plasma ddrug5 concentrations .",
        "label": "NA"
    },
    {
        "text": "DB00683 used at doses of # mg/kg and # mg/kg decreased the antinociceptive effect of ddrug1 , DB04817 { only in the tail-flick test } and ddrug3 .",
        "label": "effect"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 HD00388 ddrug5 { ddrug6 } ddrug7 { DB00501 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "pharmacokinetic studies indicate that administration of DB00822 or DB00829 does not affect the pharmacokinetics of ddrug2 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 : ddrug3 has no significant pharmacokinetic interactions with DB00390 and ddrug5 , and DB00678 has no significant effect on plasma levels of ddrug7 .",
        "label": "NA"
    },
    {
        "text": "renal clearance measurements of DB00345 can not be made with any significant accuracy in patients receiving HD00297 , ddrug2 , or ddrug3 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 has been shown to be antagonistic to HD00497 , including DB00438 , based on in vitro studies and time kill curves with enteric gram-negative bacilli .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 : DB00983 should be administered with extreme caution in patients being treated with ddrug3 or HD00043 because the action of ddrug5 on the cardiovascular system may be potentiated by these agents .",
        "label": "advise"
    },
    {
        "text": "in the same study it was shown that ddrug0 and DB00649 had no significant effect on the intracellular phosphorylation of DB00943 in peripheral blood mononuclear cells .",
        "label": "NA"
    },
    {
        "text": "DB00501 } and many that are substrates for cyp2b6 2d6 { many other ddrug1 , HD00219 , and the ddrug3 ddrug4 and ddrug5 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , HD00668 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , DB00277 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / ddrug1 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , DB14507 , ddrug11 pain medication { e , g , , ddrug12 } , drugs used to aid sleep , drowsiness-causing HD00388 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "patients stabilized on oral HD00326 who are found to require DB00451 replacement therapy should be watched very closely when thyroid is started .",
        "label": "advise"
    },
    {
        "text": "ddrug0 works differently from the ddrug1 currently available , and except for increased lipid levels , the adverse reaction profile of ddrug2 does not appear to overlap to any great extent with that associated with DB00091 or DB00864 .",
        "label": "NA"
    },
    {
        "text": "absorption of HD00239 is impaired by ddrug1 containing DB01370 , ddrug3 , or ddrug4 , and ddrug5 - containing preparations .",
        "label": "mechanism"
    },
    {
        "text": "because of DB00529 s tendency to cause renal impairment , the use of ddrug1 should be avoided in combination with potentially nephrotoxic drugs such as HD00249 , ddrug3 and intravenous ddrug4 unless the potential benefits outweigh the risks to the patient .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 , DB01601 , ddrug3 , and ddrug4 have been shown to decrease plasma levels of HD00710 ;",
        "label": "mechanism"
    },
    {
        "text": "DB00695 may increase the ototoxic potential of HD00447 , especially in the presence of impaired renal function .",
        "label": "effect"
    },
    {
        "text": "ddrug0 , HD00043 , and ddrug2 may increase anticholinergic effect of DB00771 .",
        "label": "effect"
    },
    {
        "text": "concurrent administration of DB03585 and HD00657 may result in elevated serum levels of ddrug2 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : HD00401 potentiate the analgesic effect of DB00454 .",
        "label": "effect"
    },
    {
        "text": "furthermore , ddrug0 , ddrug1 , DB01174 , and other inducers of cyp3a4 may cause a reduction in plasma DB00307 concentrations .",
        "label": "mechanism"
    },
    {
        "text": "HD00091 is a novel HD00092 that may selectively prevent ddrug2 - induced gastrointestinal effects without reversing analgesia .",
        "label": "NA"
    },
    {
        "text": "methods : from the beginning of the experiment , rats were given # weekly subcutaneous injections of HD00039 { # mg/kg body weight } and subcutaneous injections of ddrug1 { 40 microg/kg body weight } every other day , and from week 16 , intraperitoneal injections of DB00661 { 10 or # mg/kg body weight } every other day until the end fo the experiment in week 45 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as DB00415 and ddrug5 , ddrug6 { DB00252 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { DB00252 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { DB00295 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 / ddrug1 - containing HD00701 : absorption of ddrug3 is moderately reduced { approximately 25 % } when coadministered with DB14513 / ddrug5 - containing ddrug6 .",
        "label": "NA"
    },
    {
        "text": "considerable caution should be exercised if DB00754 is administered concurrently with HD00704 { ddrug2 } since paranoid symptoms have been reported during therapy with this combination .",
        "label": "advise"
    },
    {
        "text": "therefore , close monitoring of prothrombin time is recommended and adjustment of the ddrug0 dose may be necessary when DB00499 capsules are administered concomitantly with DB00682 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : DB00906 causes a slight decrease { about 10 % } in steady-state DB00313 concentrations .",
        "label": "mechanism"
    },
    {
        "text": "concomitant administration of an ddrug0 - containing DB06724 had no significant effect in the bioavailability of HD00866 .",
        "label": "NA"
    },
    {
        "text": "some HD00532 , including DB00537 , have also been shown to interfere with the metabolism of ddrug2 .",
        "label": "NA"
    },
    {
        "text": "DB01432 and ddrug1 ddrug2 : absorption of DB00999 is impaired in the presence of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "- DB00532 { e , g , , ddrug1 } use of DB00891 with these medicines may increase the chance of side effects of these medicines",
        "label": "NA"
    },
    {
        "text": "ddrug0 { DB00321 , ddrug2 , ddrug3 } : metabolism may be inhibited by ddrug4 , increasing plasma levels of HD00711 ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 { e , g , , ddrug1 , ddrug2 , or DB00594 } , ddrug4 supplements , or DB14500 - containing salt substitutes may lead to significant increases in serum potassium .",
        "label": "NA"
    },
    {
        "text": "HD00586 and ddrug1 { HD00792 }",
        "label": "NA"
    },
    {
        "text": "the biochemical toxicology of HD00077 , a known metabolite of the major ingredient of the pesticide ddrug1 { HD00079 } , was investigated in vivo and in vitro .",
        "label": "NA"
    },
    {
        "text": "ddrug0 such as ddrug1 { e , g , , DB01247 } , ddrug3 { e , g , , ddrug4 } , ddrug5 { e , g , , ddrug6 } , ddrug7 { e , g , , ddrug8 } , and ddrug9 { e , g , , ddrug10 } : using these medicines with DB00150 may increase the chance of side effects .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , DB00446 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some DB00152 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "the concurrent use of two or more drugs with anticholinergic activity -- such as an HD00513 { eg , ddrug1 } , an HD00514 { eg , ddrug3 } , and/or a ddrug4 { eg , ddrug5 } -- commonly results in excessive anticholinergic effects , including dry mouth and associated dental complications , blurred vision , and , in patients exposed to high temperature and humidity , hyperpyrexia .",
        "label": "effect"
    },
    {
        "text": "however , co-administration of ddrug0 with DB01370 - and ddrug2 - containing HD00374 { 51 meq } or ddrug4 with ddrug5 , had no significant effect on the rate or extent of ddrug6 absorption after administration of a 40-mg oral dose .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00862 # mg , when co-administered with slow-release ddrug2 # mg or # mg once daily , did not affect the relative bioavailability { auc } or maximum concentration { cmax } of DB01115 , a drug that is metabolized via cyp3a4 .",
        "label": "NA"
    },
    {
        "text": "medications can interfere with folate utilization , including : ddrug0 { such as DB00252 , and ddrug2 } ddrug3 { sometimes prescribed to control blood sugar in type # diabetes } ddrug4 { used to control inflammation associated with crohn_disease and ulcerative colitis } ddrug5 { a ddrug6 } DB00563 there has been concern about the interaction between ddrug8 and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { ddrug1 s } , DB00564 , ddrug3 { ddrug4 may decrease the effects of these medicines } , ddrug5 { using these medicines with ddrug6 may result in increased cns depressant effects } , ddrug7 , ddrug8 { using these medicines with ddrug9 may change the amount of either medicine that you need to take } , and oral ddrug10 containing HD00220 { ddrug12 may decrease the effectiveness of these oral ddrug13 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , a HD00616 , may antagonize the bactercidal effect of HD00284 and concurrent use of these drugs should be avoided .",
        "label": "NA"
    },
    {
        "text": "when DB00520 is co-administered with inducers of drug clearance , such as ddrug1 , ddrug2 , ddrug3 , DB01234 , or ddrug5 , use of a daily dose of # mg of ddrug6 should be considered",
        "label": "advise"
    },
    {
        "text": "DB01118 taken concomitantly with DB00908 increases ddrug2 serum concentration by 33 % after two days .",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 to patients receiving DB13984 or HD00683 such as ddrug3 which sensitize the myocardium , may induce cardiac arrhythmia , .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00439 plasma concentrations were not affected by co-administration of DB00501 .",
        "label": "NA"
    },
    {
        "text": "the availability of potent HD00110 { ddrug1 } - based regimens for HD00056 therapy and concerns regarding ddrug3 { ddrug4 } - related metabolic disturbances have led to significant shifts in treatment practices in hiv infection .",
        "label": "NA"
    },
    {
        "text": "in normal volunteers receiving DB00328 , the administration of DB00861 decreased the renal clearance and significantly increased the plasma levels of ddrug2 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 in combination with other ddrug1 , general ddrug2 , HD00219 , ddrug4 , ddrug5 , or other ddrug6 { including DB02325 } has additive depressant effects .",
        "label": "NA"
    },
    {
        "text": "a study in eight healthy volunteers has shown a 50 % increase in mean peak DB00393 plasma concentrations and a 90 % increase in mean area under the curve , after a one week course of DB00501 at 1,000 mg/day and ddrug2 at # mg/day .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { e , g , DB00199 and ddrug2 } : agents of the HD00625 , of which ddrug4 { ddrug5 } injection , usp is a member , have been shown to interact with ddrug6 of the ddrug7 , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , ddrug3 , or ddrug4 , with DB00364 , with metal cations such as ddrug6 , or with DB00152 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "background : the effects of combined administration of ddrug0 and ddrug1 { ddrug2 } , a HD00038 , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by ddrug4 { HD00039 } and the labeling index of intestinal_cancer were investigated in male wistar rats .",
        "label": "NA"
    },
    {
        "text": "in rheumatoid arthritis , concomitant medications besides DB00563 were ddrug1 , ddrug2 , HD00175 and/or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "- when HD00414 or ddrug1 is used concurrently with HD00418 { e , g , ddrug3 } , an interval of at least # hours should be maintained between the two medicines , since the absorption of ddrug4 or ddrug5 is impaired",
        "label": "advise"
    },
    {
        "text": "DB00612 should be used with care when ddrug1 or inhibitors of av conduction , such as certain ddrug2 { particularly of the ddrug3 -lsb- ddrug4 -rsb- and ddrug5 -lsb- DB00343 -rsb- classes } , or ddrug7 , such as ddrug8 , are used concurrently .",
        "label": "advise"
    },
    {
        "text": "DB00673 , when given as a regimen of # mg on day # and # mg/day on days # and 3 , increased the auc of DB00959 , a cyp3a4 substrate , by # - fold on day # and by # - fold on day 3 , when ddrug2 was coadministered intravenously as # mg on day # and orally as # mg on days # and 3 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 - ddrug1 containing side chains of n-methylthiotetrazole { DB00267 , ddrug3 , ddrug4 , ddrug5 , ddrug6 } or methylthiadiazole { DB01327 } can cause vitamin_k_deficiency and hypoprothrombinemia .",
        "label": "NA"
    },
    {
        "text": "the intensity , uniformity and time course of HD00025 interference by ddrug1 , ddrug2 , ddrug3 , DB01563 and ddrug5 were systematically investigated in # patients receiving ddrug6 therapy .",
        "label": "NA"
    },
    {
        "text": "however , co-administration of ddrug0 with DB01370 - and ddrug2 - containing ddrug3 { 51 meq } or ddrug4 with ddrug5 , had no significant effect on the rate or extent of DB00476 absorption after administration of a 40-mg oral dose .",
        "label": "NA"
    },
    {
        "text": "these agents include medications such as : ddrug0 , HD00679 including ddrug2 , sali-cylates , HD00203 { including ddrug4 } , ddrug5 , or ddrug6 .",
        "label": "NA"
    },
    {
        "text": "it is recommended that the combination of intravenous DB01219 and ddrug1 , such as DB00661 , not be used together during the management of malignant hyperthermia crisis until the relevance of these findings to humans is established .",
        "label": "advise"
    },
    {
        "text": "immediate and extended release tablets the hypoglycemic action of HD00222 may be potentiated by certain drugs including ddrug1 , some ddrug2 and other drugs that are highly protein bound , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , HD00275 , and ddrug9 .",
        "label": "effect"
    },
    {
        "text": "in a phase i trial using escalating doses of ddrug0 { 110 - 200 mg/m2 } and DB00515 { 50 or # mg/m2 } given as sequential infusions , myelosuppression was more profound when ddrug2 was given after ddrug3 than with the alternate sequence { ie , DB01229 before ddrug5 } .",
        "label": "NA"
    },
    {
        "text": "other reported interactions with ddrug0 : DB00813 { ddrug2 substrate } in combination with DB01118 may cause hypotension , bradycardia , and decreased cardiac output .",
        "label": "NA"
    },
    {
        "text": "a direct causal relationship has not been established , but physicians should consider the possibility that DB00586 may alter a diabetic patient s response to ddrug1 or oral HD00062 .",
        "label": "effect"
    },
    {
        "text": "there have been greater than 2-fold increases in previously stable plasma levels of other HD00216 , including DB00540 , when ddrug2 has been administered in combination with these agents .",
        "label": "NA"
    },
    {
        "text": "it may increase excretion of HD00026 , ddrug1 , and ddrug2 and may also increase the toxicity of HD00328 .",
        "label": "NA"
    },
    {
        "text": "medications can interfere with folate utilization , including : ddrug0 { such as ddrug1 , and ddrug2 } DB00331 { sometimes prescribed to control blood sugar in type # diabetes } ddrug4 { used to control inflammation associated with crohn_disease and ulcerative colitis } ddrug5 { a HD00295 } ddrug7 there has been concern about the interaction between ddrug8 and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "DB00563 : caution should be used if DB00861 is administered concomitantly with ddrug2 .",
        "label": "NA"
    },
    {
        "text": "the extent to which HD00278 - HD00312 interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the ddrug2 involved .",
        "label": "effect"
    },
    {
        "text": "DB00158 in large amounts may counteract the antiepileptic effect of ddrug1 , DB00252 and ddrug3 , and increase the frequency of seizures in susceptible pediatric patients .",
        "label": "effect"
    },
    {
        "text": "these medications have included ddrug0 , ddrug1 , HD00207 , ddrug3 , ddrug4 , intravenous and oral ddrug5 , ddrug6 , and DB00945 .",
        "label": "NA"
    },
    {
        "text": "persons taking most ddrug0 , ddrug1 and DB00205 invalidate ddrug3 and DB00115 diagnostic blood assays .",
        "label": "NA"
    },
    {
        "text": "if ddrug0 is to be combined with other ddrug1 such as ddrug2 or ddrug3 / HD00214 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of ddrug5 and ddrug6 { e , g , , ddrug7 or DB00829 } are additive .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in healthy subjects receiving DB01026 , a cyp3a4 inhibitor , at # mg twice daily for # days , systemic exposure { auc } to DB01259 was increased to approximately # - fold of control and half-life increased to # - fold of control .",
        "label": "mechanism"
    },
    {
        "text": "therefore , when DB00999 and ddrug1 are used concomitantly , the patient should be observed closely to determine if the desired effect of the HD00295 is obtained .",
        "label": "NA"
    },
    {
        "text": "concomitant use of ddrug0 and drugs that inhibit cyp3a4 { eg , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB01072 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 } may increase exposure to DB01254 and should be avoided .",
        "label": "NA"
    },
    {
        "text": "during concomitant therapy with DB01050 , the patient should be observed closely for signs of renal failure , as well as to assure HD00295 efficacy .",
        "label": "NA"
    },
    {
        "text": "when administered concurrently , the following drugs may interact with HD00867 : ddrug1 , general : exaggeration of the hypotension induced by general HD00264 .",
        "label": "NA"
    },
    {
        "text": "DB09341 , alone and in the presence of DB00277 , caused subnormal irdn release and less suppression of glucagon release in the diabectics than in the normals .",
        "label": "NA"
    },
    {
        "text": "also , concomitant administration of ddrug0 with products containing ddrug1 , DB00152 containing DB01593 , or ddrug4 { ddrug5 } chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels .",
        "label": "NA"
    },
    {
        "text": "immediate and extended release tablets the hypoglycemic action of ddrug0 may be potentiated by certain drugs including ddrug1 , some ddrug2 and other drugs that are highly protein bound , ddrug3 , HD00297 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and HD00520 .",
        "label": "NA"
    },
    {
        "text": "particular caution is necessary when using DB01205 in cases of mixed drug overdosage since the toxic effects { such as convulsions and cardiac dysrhythmias } of other drugs taken in overdose { especially ddrug1 } may emerge with the reversal of the DB12537 effect by ddrug3 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 ddrug1 ddrug2 ddrug3 ddrug4 HD00324 ddrug6 DB00091 large quantities of grapefruit juice { # quart daily }",
        "label": "NA"
    },
    {
        "text": "because of DB00529 s tendency to cause renal impairment , the use of DB00529 should be avoided in combination with potentially nephrotoxic drugs such as ddrug2 , ddrug3 and intravenous ddrug4 unless the potential benefits outweigh the risks to the patient .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a single dose study { n = 6 } , ingestion of an DB06724 containing # - gram of DB09104 with 500-mg of ddrug3 increased the cmax and auc of ddrug4 by 125 % and 36 % , respectively , a number of compounds are inhibitors of cyp2c9 including ddrug5 , ddrug6 and ddrug7 .",
        "label": "NA"
    },
    {
        "text": "background : the effects of combined administration of DB11724 and ddrug1 { ddrug2 } , a ddrug3 , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by ddrug4 { HD00039 } and the labeling index of intestinal_cancer were investigated in male wistar rats .",
        "label": "NA"
    },
    {
        "text": "there is limited experience with concomitant ddrug0 such as HD00266 , ddrug2 , ddrug3 , and ddrug4 { both HD00722 - like and loop } .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of DB01039 { equivalent to # mg ddrug1 } with ddrug2 { 20 mg } once daily for # days resulted in approximately 17 % decrease { range from 67 % decrease to 44 % increase } in DB01076 auc values in # healthy males .",
        "label": "NA"
    },
    {
        "text": "other concomitant therapy although specific interaction studies were not performed , ddrug0 doses of # mg or more were concomitantly used in clinical studies with ddrug1 , ddrug2 , a-blockers , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , HD00506 , cardiac ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 { also referred to as HD00203 } , and ddrug15 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 to patients who are receiving HD00316 or HD00653 may result in an additive pressor effect .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 and HD00218 : concomitant treatment with ddrug3 , ddrug4 , or ddrug5 may potentiate a possible hypokalemic effect of HD00742",
        "label": "NA"
    },
    {
        "text": "-lsb- stimulation by ddrug0 -- an analog of the octapeptide cholecystokinin -- of ddrug1 binding after the long-term administration of ddrug2 -rsb- it has been established in experiments on white male rats that prolonged administration { twice a day for # days } of DB00502 { # mg/kg } and ddrug4 { # mg/kg } resulted in the reduced interaction between ddrug5 and low affinity binding sites for ddrug6 in subcortical structures , whereas ddrug7 binding with high affinity binding sites for DB00714 increased both in the frontal cortex and subcortical structures of the forebrain .",
        "label": "NA"
    },
    {
        "text": "patients receiving other HD00459 s , general ddrug1 , HD00219 , ddrug3 , ddrug4 , ddrug5 or other ddrug6 { including ddrug7 } concomitantly with ddrug8 may exhibit an additive cns depression .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , DB00273 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , DB00295 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "use lowest possible dose of DB01076 with careful monitoring , or consider ddrug1 that are not primarily metabolized by cyp3a4 , such as ddrug2 , ddrug3 , or DB01098 in combination with ddrug5 .",
        "label": "NA"
    },
    {
        "text": "however , there are limited in vivo data suggesting a modest cyp2d6 inhibitory effect for ddrug0 , i , e , , coadministration of ddrug1 { 20 mg/day for # days } with the HD00042 ddrug3 { single dose of # mg } , a substrate for cyp2d6 , resulted in a 40 % increase in cmax and a 100 % increase in auc of DB01151 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : a study in # healthy volunteers has shown a significant increase in peak DB01115 plasma levels { 80 % } and area-under-the-curve { 74 % } after a # week course of DB00501 at # mg per day and ddrug3 at # mg per day .",
        "label": "NA"
    },
    {
        "text": "if ddrug0 is to be combined with other ddrug1 such as ddrug2 or ddrug3 / ddrug4 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of DB01151 and ddrug6 { e , g , , DB00475 or ddrug8 } are additive .",
        "label": "effect"
    },
    {
        "text": "may interact HD00326 { altered hypo-prothrombinemic effect } , ddrug1 , ddrug2 and other inducers of hepatic microsomal enzyme oxidation system { decreased effect of ddrug3 } , HD00175 { increased effect of ddrug5 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 has additive effects with DB02325 and other HD00261 { ddrug3 , ddrug4 , ddrug5 , etc } .",
        "label": "NA"
    },
    {
        "text": "however , caution should be used when administering DB00482 with DB00682 since these patients are at increased risk of bleeding complications .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : no clinically significant changes occurred in heart rate or corrected qt intervals , or in DB00342 metabolite or DB00978 pharmacokinetics , during concurrent administration of ddrug3 and ddrug4 at steady-state in # healthy males .",
        "label": "NA"
    },
    {
        "text": "drug interactions : the central ddrug0 syndrome can occur when anticholinergic agents such as ddrug1 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain ddrug2 such as ddrug3 , the ddrug4 and other ddrug5 , HD00043 , certain ddrug7 such as the DB00908 salts , and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "- DB04948 may enhance the effects of HD00858 therapy",
        "label": "effect"
    },
    {
        "text": "clearance of ddrug0 decreased by about 27 % when HD00645 was administered intravenously concomitantly with DB00335 .",
        "label": "mechanism"
    },
    {
        "text": "although it has not been established that there is an interaction between ddrug0 and ddrug1 or other HD00565 , caution is advised when DB00363 is initiated in patients taking a ddrug4 or any other ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and HD00326 : increased prothrombin time , with or without clinical bleeding , has been reported when DB00671 is administered concomitantly .",
        "label": "effect"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of ddrug0 : ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , ddrug5 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , HD00810 { e , g , , in oral HD00283 } .",
        "label": "NA"
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a HD00533 , including ddrug1 , with multivalent cation-containing products such as DB14513 or ddrug3 ddrug4 , ddrug5 , ddrug6 chewable/buffered tablets or pediatric powder , or products containing ddrug7 , ddrug8 , or ddrug9 may substantially decrease the absorption of ddrug10 , resulting in serum and urine levels considerably lower than desired .",
        "label": "mechanism"
    },
    {
        "text": "drugs decreasing DB01109 effect : ddrug1 , HD00239 , ddrug3 , or ddrug4 may partially counteract the anticoagulant action of ddrug5 .",
        "label": "NA"
    },
    {
        "text": "in vitro studies indicate that ddrug0 does not inhibit p-glycoprotein-mediated transport of DB00390 or ddrug2 and that DB00303 is not a substrate for p-glycoprotein-mediated transport .",
        "label": "NA"
    },
    {
        "text": "the safety and efficacy of DB00026 used in combination with DB02325 has not been studied .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with DB00316 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , DB01035 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of DB00732 include : ddrug1 ; ddrug2 ; ddrug3 ; certain ddrug4 , especially the ddrug5 and ddrug6 ; ddrug7 ; DB14513 salts ; ddrug9 ; and ddrug10 .",
        "label": "effect"
    },
    {
        "text": "since ddrug0 and HD00293 , including DB00594 , may each be associated with increased serum potassium levels , the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { DB00701 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { HD00531 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and DB00281 } , ddrug8 { HD00398 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "DB01118 may suppress certain cyp450 enzymes , including ddrug1 , ddrug2 , HD00301 , and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / ddrug1 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , HD00516 pain medication { e , g , , ddrug12 } , drugs used to aid sleep , drowsiness-causing HD00388 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { HD00403 s } , ddrug2 , ddrug3 { ddrug4 may decrease the effects of these medicines } , ddrug5 { using these medicines with ddrug6 may result in increased cns depressant effects } , ddrug7 , ddrug8 { using these medicines with ddrug9 may change the amount of either medicine that you need to take } , and oral HD00283 containing ddrug11 { ddrug12 may decrease the effectiveness of these oral ddrug13 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "ergot derivatives : DB00320 , ddrug1 , ddrug2 , DB00353",
        "label": "NA"
    },
    {
        "text": "in addition , neuromuscular blocking action is enhanced by general HD00264 , local ddrug1 like DB00281 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and ddrug7 .",
        "label": "NA"
    },
    {
        "text": "these drugs include the ddrug0 and other HD00218 , ddrug2 , HD00219 , ddrug4 , ddrug5 , oral ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , and ddrug11 .",
        "label": "NA"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / HD00517 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , DB00571 } , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 pain medication { e , g , , ddrug12 } , drugs used to aid sleep , drowsiness-causing ddrug13 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "the administration of local ddrug0 containing DB00668 or ddrug2 to patients receiving ddrug3 , HD00043 or ddrug5 may produce severe , prolonged hypotension or hypertension .",
        "label": "effect"
    },
    {
        "text": "co-administration of ddrug0 and HD00249 or other agents interfering with neuromuscular transmission { e , g , , HD00436 } should only be performed with caution as the effect of the ddrug3 may be potentiated .",
        "label": "NA"
    },
    {
        "text": "in clinical trials , ddrug0 was used with ddrug1 , ddrug2 , ddrug3 , oral ddrug4 , and supplemental ddrug5 , in a pharmacokinetic substudy in patients with congestive heart failure receiving ddrug6 or ddrug7 in whom therapy with ddrug8 was initiated , apparent oral clearance values for DB00695 { n = 23 } and DB00390 { n = 30 } were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 or ddrug1 : when ddrug2 is administered immediately following ddrug3 or HD00498 , the absorption of DB00954 is slightly enhanced .",
        "label": "NA"
    },
    {
        "text": "as with other ddrug0 , it should be noted that ddrug1 may be capable of potentiating HD00261 such as HD00264 , ddrug4 , and ddrug5 .",
        "label": "NA"
    },
    {
        "text": "the purpose of this study was to evaluate the effect of ddrug0 { HD00072 } and ddrug2 { ddrug3 } conjugates on the intestinal permeation of ddrug4 { ddrug5 } and model peptide drugs , DB00781 and ddrug7 .",
        "label": "NA"
    },
    {
        "text": "seizure , associated with increased DB00281 concentrations , has been reported with concomitant administration of intravenous DB01118 .",
        "label": "NA"
    },
    {
        "text": "or with DB00152 containing DB01593 may substantially interfere with drug absorption and result in insufficient plasma and tissue ddrug2 concentrations .",
        "label": "NA"
    },
    {
        "text": "DB00501 } and many that are substrates for cyp2b6 2d6 { many other ddrug1 , ddrug2 , and the ddrug3 ddrug4 and DB01195 } .",
        "label": "NA"
    },
    {
        "text": "DB00501 } and many that are substrates for cyp2b6 2d6 { many other HD00216 , ddrug2 , and the ddrug3 ddrug4 and ddrug5 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : concomitant administration of ddrug1 and some HD00203 has been reported to reduce the clearance of DB00563 , enhancing the toxicity of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "co-administration of cyp3a4 inhibitors { eg , ddrug0 , ddrug1 , DB00199 , grapefruit juice , ddrug3 } with DB01023 may lead to several - fold increases in the plasma levels of ddrug5 , either due to an increase in bioavailability or due to a decrease in metabolism .",
        "label": "NA"
    },
    {
        "text": "DB00440 alone or in combination with ddrug1 : concomitant use of ddrug2 alone or in combination with DB01015 is contraindicated .",
        "label": "NA"
    },
    {
        "text": "the behavioral effects of the stereoisomers of ddrug0 { HD00155 } were compared with those of ddrug2 { DB03575 } in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio { fi fr } schedule of food presentation .",
        "label": "NA"
    },
    {
        "text": "if a patient requires ddrug0 and ddrug1 therapy , it is suggested that DB00338 , ddrug3 , or ddrug4 { ddrug5 and ddrug6 } be used as alternatives to ddrug7 , as these agents have no effect on the pharmacokinetic profile of DB00204 .",
        "label": "NA"
    },
    {
        "text": "HD00303 : other ddrug1 drugs , such as ddrug2 , ddrug3 , DB00280 , and ddrug5 , have been used concurrently with ddrug6 .",
        "label": "NA"
    },
    {
        "text": "therefore , co-administration of DB00476 with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index , including certain HD00216 { ddrug2 -lsb- ddrug3 -rsb- , such as ddrug4 , ddrug5 , and ddrug6 } , ddrug7 and ddrug8 { e , g , , ddrug9 , ddrug10 } , should be approached with caution .",
        "label": "advise"
    },
    {
        "text": "interactions with ddrug0 : ddrug1 { eg , ddrug2 , DB00844 , ddrug4 , ddrug5 and ddrug6 } should not be administered to a patient who has received or is receiving a course of therapy with a ddrug7 such as DB00854 .",
        "label": "advise"
    },
    {
        "text": "DB00522 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local HD00264 { e , g , , ddrug6 and ddrug7 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "int"
    },
    {
        "text": "in pigeons , DB01183 did not systematically alter the effects of ddrug1 , HD00156 or ddrug3 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in patients with mild to moderate hypertension , administration of DB00673 once daily , as a tablet formulation comparable to # mg of the capsule formulation , with ddrug2 # mg # times daily for # days , resulted in a 2-fold increase of ddrug3 auc and a simultaneous # - fold increase of DB00343 auc .",
        "label": "NA"
    },
    {
        "text": "plasma levels of several closely related ddrug0 have been reported to be increased by the concomitant administration of DB00422 or hepatic enzyme inhibitors { e , g , , ddrug2 , DB00472 } and decreased by the concomitant administration of hepatic enzyme inducers { e , g , , ddrug4 , ddrug5 } , and such an effect may be anticipated with ddrug6 as well .",
        "label": "NA"
    },
    {
        "text": "also , due to the potential for additive effects such as bradycardia and av block , caution is warranted in patients receiving DB00575 with agents known to affect sinus node function or av nodal conduction { e , g , , ddrug1 , ddrug2 , and HD00254 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : DB00402 # mg administered daily for # days did not affect the pharmacokinetics of DB08496 or ddrug3 nor were there any changes in the pharmacodynamic profile { prothrombin time } following a single # mg oral dose of ddrug4",
        "label": "NA"
    },
    {
        "text": "it is recommended that the dose of DB00615 be reduced to one-half the usual dose when administered with DB00220 .",
        "label": "advise"
    },
    {
        "text": "there was a small decrease in the clearance of DB00341 caused by a 400-mg dose of DB00277 ;",
        "label": "mechanism"
    },
    {
        "text": "toxicology studies of ddrug0 - related deaths reveal frequent involvement of other HD00389 , including ddrug2 , ddrug3 such as ddrug4 { ddrug5 } , and , to a rising degree , DB00333 .",
        "label": "NA"
    },
    {
        "text": "drug interactions with ddrug0 : concomitant use of DB00800 with HD00254 should be avoided .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : in a clinical pharmacology study , coadministration of an ddrug1 { ddrug2 , ddrug3 , and DB11074 } with ddrug5 reduced serum levels and urinary excretion of ddrug6 as compared with ddrug7 administered alone , suggesting that HD00374 may impair absorption of ddrug9 .",
        "label": "NA"
    },
    {
        "text": "in patients receiving nonselective HD00275 { ddrug1 } { e , g , , ddrug2 } in combination with ddrug3 { e , g , , ddrug4 , ddrug5 , ddrug6 , DB01104 , ddrug8 } , there have been reports of serious , sometimes fatal , reactions .",
        "label": "effect"
    },
    {
        "text": "co-administration : concomitant use of ddrug0 with ddrug1 , HD00364 , and other HD00326 may increase the risk of bleeding .",
        "label": "NA"
    },
    {
        "text": "in clinical studies performed with ddrug0 , the concomitant use of oral HD00326 { ddrug2 } , ddrug3 { DB00945 } , ddrug5 { ddrug6 } , and ddrug7 did not significantly affect the pharmacokinetics/pharmacodynamics of ddrug8 .",
        "label": "NA"
    },
    {
        "text": "in vitro studies evaluating the minimum inhibitory concentration { mic } of ddrug0 , ddrug1 , ddrug2 , ddrug3 / flucoxacillin , ddrug4 , ddrug5 , and HD00795 demonstrated no evidence of incompatibility of these ddrug7 with DB00702 .",
        "label": "NA"
    },
    {
        "text": "nevertheless , the possibility of additive negative inotropic effects of HD00378 and DB01195 should be recognized .",
        "label": "effect"
    },
    {
        "text": "interactions with other cns agents : concurrent use of DB00854 with all ddrug1 { eg , ddrug2 , ddrug3 , ddrug4 , other ddrug5 , general HD00264 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 and ddrug12 } may result in additive central nervous system depressant effects .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : as with some other HD00532 , concurrent administration of ddrug2 with ddrug3 may lead to elevated serum concentrations of DB00277 and prolongation of its elimination half-life .",
        "label": "NA"
    },
    {
        "text": "coadministration of DB00969 and strong cyp3a4 inhibitors , such as ddrug1 , DB00976 , ddrug3 , ddrug4 , and ddrug5 has not been evaluated but should be undertaken with caution because of similar potential drug interactions .",
        "label": "advise"
    },
    {
        "text": "ddrug0 - and DB01370 - containing ddrug2 , administered concomitantly with DB00978 , significantly decreased the bioavailability { 48 % } of ddrug4 .",
        "label": "mechanism"
    },
    {
        "text": "drug interactions with ddrug0 administration of # mg of ddrug1 { 2 x # mg capsule } within # minutes of an ddrug2 and ddrug3 containing ddrug4 { HD00467 } decreased DB00950 auc by 41 % and cmax by 43 % .",
        "label": "NA"
    },
    {
        "text": "DB00334 is associated with significantly fewer extrapyramidal symptoms than DB00502 and ddrug2 .",
        "label": "NA"
    },
    {
        "text": "concurrent use of ddrug0 with ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , and HD00388 } may result in increased HD00461 effects .",
        "label": "NA"
    },
    {
        "text": "there have been reports of ddrug0 - related side effects in patients on concomitant therapy with DB01059 and DB00277 .",
        "label": "effect"
    },
    {
        "text": "however , the antagonism of the ddrug0 - induced anxiogenic effects by HD00187 was only observed in the time spent in the light zone , and ddrug2 - induced anxiogenic effects were neither reversed by ddrug3 nor by HD00186 .",
        "label": "NA"
    },
    {
        "text": "digoxin when given concomitantly with DB01023 the pharmacokinetics of DB00390 in patients with heart failure were not significantly altered .",
        "label": "NA"
    },
    {
        "text": "in clinical studies performed with ddrug0 , the concomitant use of oral HD00326 { ddrug2 } , HD00679 { ddrug4 } , ddrug5 { ddrug6 } , and ddrug7 did not significantly affect the pharmacokinetics/pharmacodynamics of ddrug8 .",
        "label": "NA"
    },
    {
        "text": "because ddrug0 may enhance the serotonergic effects of DB01175 , caution should be exercised when DB01175 and ddrug3 are coadministered .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the combined use of DB01039 and HD00095 should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination .",
        "label": "advise"
    },
    {
        "text": "other no clinically important pharmacokinetic interactions occurred when DB00542 was administered concomitantly with ddrug1 , ddrug2 , DB00695 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , or ddrug8 .",
        "label": "NA"
    },
    {
        "text": "these data suggest that DB14152 are negatively coupled to three types of calcium channels in bovine chromaffin cell , including an ddrug1 - sensitive { n-type } channel , an HD00048 - sensitive { p-type } channel and ddrug3 / ddrug4 / ddrug5 - resistant { presumptive q-type } channel .",
        "label": "NA"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : DB01118 , ddrug3 ddrug4 : DB00637 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "although additional drug interaction studies have not been conducted , the most common medications used concomitantly with DB00261 in clinical trials were ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB01005 , and ddrug7 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 should be used with care when HD00425 or inhibitors of av conduction , such as certain HD00085 { particularly of the ddrug3 -lsb- ddrug4 -rsb- and ddrug5 -lsb- ddrug6 -rsb- classes } , or ddrug7 , such as ddrug8 , are used concurrently .",
        "label": "NA"
    },
    {
        "text": "DB00782 and ddrug1 , by decreasing gut motility , may increase DB00390 absorption .",
        "label": "mechanism"
    },
    {
        "text": "when ddrug0 or ddrug1 is used at the same time as other medicines or substances the following interactions must be taken into account : - ddrug2 and HD00415 may enhance the action of HD00240 .",
        "label": "effect"
    },
    {
        "text": "concomitant crohn s disease medications were ddrug0 , HD00805 , HD00175 , ddrug3 / ddrug4 and aminosalicylates .",
        "label": "NA"
    },
    {
        "text": "there is one reported case of a patient with acute delirium associated with the simultaneous use of DB00623 and oral DB00575 .",
        "label": "effect"
    },
    {
        "text": "DB01167 ddrug1 ddrug2 ddrug3 DB00976 ddrug5 ddrug6 ddrug7 large quantities of grapefruit juice { # quart daily }",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : DB00316 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , DB00636 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "human pharmacokinetics data indicate that oral DB01026 potently inhibits the metabolism of DB00604 resulting in a mean eight-fold increase in auc of ddrug2 .",
        "label": "mechanism"
    },
    {
        "text": "inhibitors of this isoenzyme { e , g , , ddrug0 , ddrug1 , HD00269 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , grapefruit juice , ddrug7 , ddrug8 , ddrug9 , ddrug10 } should be cautiously coadministered with DB00204 as they can potentially increase ddrug12 levels .",
        "label": "advise"
    },
    {
        "text": "DB00486 has been shown to have an additive cns depressant effect when given with either ddrug1 , HD00865 , ddrug3 or ddrug4 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : since ddrug1 is a HD00338 , it is possible that ddrug3 , such as the ddrug4 { ddrug5 , ddrug6 , ddrug7 } or ddrug8 , may diminish the effectiveness of DB00714 .",
        "label": "NA"
    },
    {
        "text": "blunting of the antihypertensive effect of HD00232 by HD00233 has been reported .",
        "label": "effect"
    },
    {
        "text": "DB01232 steady-state cmax , a , c , and cmin were increased 21 % , decreased 19 % , and decreased 48 % , respectively , by concomitant DB00701 .",
        "label": "mechanism"
    },
    {
        "text": "the following agents may increase certain actions or side effects of ddrug0 , ddrug1 HD00428 of class { e , g , ddrug3 } , HD00388 ddrug5 { e , g , ddrug6 } , ddrug7 .",
        "label": "NA"
    },
    {
        "text": "additive adverse effects resulting from cholinergic blockade may occur when DB00424 is administered concomitantly with other ddrug1 , ddrug2 , DB00502 , ddrug4 , ddrug5 , ddrug6 or some ddrug7 .",
        "label": "effect"
    },
    {
        "text": "we demonstrate that the conversion of ddrug0 to ddrug1 by an nad + - dependent oxidation is the rate-limiting step in the synthesis of the toxic product , HD00078 from HD00079 .",
        "label": "NA"
    },
    {
        "text": "- a ddrug0 { HD00615 } such as ddrug2 { ddrug3 , ddrug4 , ddrug5 , others } , ddrug6 { ddrug7 , ddrug8 , ddrug9 } , DB00586 { ddrug11 , ddrug12 } , ddrug13 { ddrug14 } , ddrug15 { ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , and ddrug21 { ddrug22 , ddrug23 , ddrug24 } ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 { ddrug1 } : ddrug2 { e , g , , ddrug3 , DB00176 , ddrug5 , ddrug6 } have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with HD00277 .",
        "label": "effect"
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma DB00252 concentrations include : acute ddrug1 intake , ddrug2 , chboramphenicol , ddrug3 , ddrug4 , DB00829 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21",
        "label": "mechanism"
    },
    {
        "text": "- ddrug0 and ddrug1 ddrug2 : HD00511 and DB00375 ddrug5 have the potential of binding ddrug6 and reducing ddrug7 absorption from the gastrointestinal tract",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 may enhance the effects of : other ddrug3 s , DB02325 , general ddrug5 , ddrug6 such as ddrug7 , ddrug8 , or other HD00261 , causing increased cns depression .",
        "label": "NA"
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma DB00252 concentrations include : acute ddrug1 intake , ddrug2 , chboramphenicol , DB00475 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21",
        "label": "mechanism"
    },
    {
        "text": "concomitant administration of DB00307 capsules and ddrug1 resulted in substantial increases in plasma concentrations of DB00307 , probably at least partially related to cyp3a4 inhibition by ddrug3 .",
        "label": "NA"
    },
    {
        "text": "in vitro studies have shown DB01128 can displace HD00422 s , such as ddrug2 , from their protein-binding sites .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local HD00264 { e , g , , ddrug6 and ddrug7 } , DB02362 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "because DB00876 is not metabolized by the cytochrome cyp2b6 system , inhibitors of cyp450 enzyme would not be expected to affect its metabolism , and ddrug1 and DB00196 , potent inhibitors of cytochrome_p450_family_3_subfamily_a and 2c9 , respectively , have been shown to have no effect on ddrug3 pharmacokinetics .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of DB00195 with the oral ddrug1 ddrug2 has been shown not to potentiate the anticoagulant effect of DB00682 .",
        "label": "NA"
    },
    {
        "text": "DB00467 interferes with the metabolism of DB00277 resulting in a 42 % to 74 % dose-related decrease in ddrug2 clearance and a subsequent 260 % to 350 % increase in serum theophylline levels .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : in healthy subjects given single # mg doses of DB00567 and ddrug2 , plasma ddrug3 mean cmax and auc increased by an average of 34 % and 24 % , respectively , and DB00331 mean renal clearance decreased by 14 % .",
        "label": "NA"
    },
    {
        "text": "h-2 antagonists : in studies with human volunteers , co-administration of DB00501 or ddrug1 with DB01050 had no substantive effect on ddrug3 serum concentrations .",
        "label": "NA"
    },
    {
        "text": "DB00091 : elevated serum levels of ddrug1 have been reported with concomitant use of ddrug2 with other members of the HD00678 .",
        "label": "NA"
    },
    {
        "text": "therefore , close monitoring of prothrombin time is recommended , and adjustment of the HD00025 dose may be necessary when DB00501 is administered concomitantly .",
        "label": "advise"
    },
    {
        "text": "ddrug0 { HD00114 } : ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , DB01104 } have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with ddrug7 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , DB00091 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , DB00295 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : some individuals receiving ddrug1 may experience a reversible enhancement of the pressor response to indirect-acting HD00571 , ddrug3 or HD00853 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { eg , DB01199 } and other drugs , including ether , ddrug2 , ddrug3 , DB01245 and ddrug5 , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with ddrug6 parenteral .",
        "label": "NA"
    },
    {
        "text": "caution should be observed when DB00913 is coadministered with other HD00263 , ddrug2 , ddrug3 , or ddrug4 , as these agents may increase respiratory and circulatory depression .",
        "label": "advise"
    },
    {
        "text": "ddrug0 and DB00717 : coadministration of ddrug2 with HD00872 resulted in a 47 % decrease in ddrug4 and an 18 % decrease in ddrug5 plasma concentrations .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , DB00776 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and DB00126 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , DB01174 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { DB01045 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "due to wide interindividual variability in the dose adjustment required , it is recommended that ddrug0 concentrations be monitored closely after initiation of DB01136 therapy and that the dose of DB00091 be adjusted as appropriate .",
        "label": "advise"
    },
    {
        "text": "DB11119 { 123i and 131i } , HD00848 : uptake of radiolabeled ions may be decreased .",
        "label": "NA"
    },
    {
        "text": "therefore , coadministration of ddrug0 with drugs that strongly induce cyp3a4 activity { e , g , , DB01045 , ddrug2 , ddrug3 } may result in reduced plasma concentrations of DB00673 that may result in decreased efficacy of ddrug5 .",
        "label": "NA"
    },
    {
        "text": "the effect of foods highly fortified with elemental ddrug0 { primarily DB01592 - fortified breakfast cereals } on DB00535 absorption has not been studied .",
        "label": "NA"
    },
    {
        "text": "an alternative non-cyp3a4 substrate HD00905 may be considered in patients taking cyp3a4 inducers such as DB01045 , ddrug2 , ddrug3 , and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00501 coadministration leads to an increased peak plasma concentration and auc of ddrug2 , there is no effect on DB00604 absorption when it is coadministered with ddrug4 .",
        "label": "NA"
    },
    {
        "text": "other concomitant therapy : although specific interaction studies were not performed , in clinical studies , HD00503 was used concomitantly with HD00504 , ddrug2 , ddrug3 , ddrug4 , and ddrug5 { ddrug6 } without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "in healthy volunteers , the pharmacokinetics of a 1-mg dose of DB00611 administered as DB00611 were not affected by the coadministration of a single 6-mg subcutaneous dose of ddrug2 .",
        "label": "NA"
    },
    {
        "text": "intrathecal injection of ddrug0 at doses of # to # micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of ddrug1 , and a high dose of DB01183 { 40 micrograms } completely blocked the tail-flick inhibition induced by intraventricular HD00144 { 16 micrograms } .",
        "label": "effect"
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a ddrug0 , including ddrug1 , with multivalent cation-containing products such as DB14513 or ddrug3 ddrug4 , ddrug5 , ddrug6 chewable/buffered tablets or pediatric powder , or products containing DB01373 , ddrug8 , or ddrug9 may substantially decrease the absorption of ddrug10 , resulting in serum and urine levels considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { e , g , , DB01026 , ddrug2 , ddrug3 , ddrug4 , etc , } : in vitro and animal studies with the combination of ddrug5 and ddrug6 suggest that HD00319 may induce fungal resistance to ddrug8 .",
        "label": "NA"
    },
    {
        "text": "DB00294 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , DB00295 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "int"
    },
    {
        "text": "particular caution should be observed with HD00573 since there are conflicting results for the effect of DB00375 on the availability of ddrug2 and ddrug3 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : coadministration of DB01026 with DB00220 resulted in a 35 % increase in ddrug3 plasma a , c.",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 HD00524 may delay or reduce the absorption of concomitant oral medication such as ddrug2 , ddrug3 , ddrug4 { acidic } or ddrug5 { basic } , as well as ddrug6 ddrug7 , ddrug8 , thyroid and ddrug9 preparations , ddrug10 and HD00526 , and ddrug12 .",
        "label": "NA"
    },
    {
        "text": "DB00269 may interact with ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 supplements , ddrug6 , ddrug7 , ddrug8 , ddrug9 , DB00184 , ddrug11 , ddrug12 , and ddrug13 .",
        "label": "int"
    },
    {
        "text": "ddrug0 : concurrent administration of certain HD00537 , such as ddrug2 and ddrug3 , would be expected to compromise the beneficial effects of DB00604 .",
        "label": "effect"
    },
    {
        "text": "DB00162 and oral ddrug1 : concomitant administration of ddrug2 and/or other oral HD00150 with ddrug4 must be avoided because of the risk of hypervitaminosis a.",
        "label": "NA"
    },
    {
        "text": "ddrug0 { e , g , ddrug1 and ddrug2 } : agents of the ddrug3 , of which ddrug4 { DB00320 } injection , usp is a member , have been shown to interact with HD00002 of the ddrug7 , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .",
        "label": "NA"
    },
    {
        "text": "caution is advised in patients receiving concomitant high-dose DB00945 and HD00442 , as anorexia , tachypnea , lethargy and coma have been rarely reported due to a possible drug interaction .",
        "label": "advise"
    },
    {
        "text": "there is little if any clinically significant interaction between DB00284 and DB00331 .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 : DB00580 { 40 mg bid } did not induce the metabolism of the combination oral ddrug2 ddrug3 / ddrug4 { 1 mg / 35 mcg combination , DB00717 1/35 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : combination ddrug1 may decrease the clearance of some ddrug2 { ddrug3 , ddrug4 , DB00829 } and increase the clearance of others { ddrug6 , ddrug7 , DB00231 } .",
        "label": "NA"
    },
    {
        "text": "DB00891 may interact with any of the following : - DB00316 { e , g , , ddrug2 } { with long-term , high-dose use } or",
        "label": "int"
    },
    {
        "text": "ddrug0 : because ddrug1 can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine , and because renal excretion is the primary elimination route of HD00720 including DB01039 , there is a risk that an interaction will lead to deterioration .",
        "label": "NA"
    },
    {
        "text": "in addition , neuromuscular blocking action is enhanced by general ddrug0 , local HD00264 like ddrug2 , ddrug3 , HD00254 , ddrug5 , ddrug6 , and ddrug7 .",
        "label": "NA"
    },
    {
        "text": "the purpose of this study was to evaluate the effect of ddrug0 { HD00072 } and ddrug2 { ddrug3 } conjugates on the intestinal permeation of ddrug4 { ddrug5 } and model peptide drugs , ddrug6 and HD00071 .",
        "label": "NA"
    },
    {
        "text": "drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on ddrug0 therapy : HD00657 , ddrug2 , HD00220 , oral ddrug4 containing ddrug5 , ddrug6 - containing preparations and the numerous preparations containing ddrug7 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00501 does not affect the pharmacokinetics of ddrug2 when coadministered with DB00828 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration of DB00564 { 200 mg bid } , a potent cyp3a4 inducer , with ddrug2 { 30 mg qd } resulted in an approximate 70 % decrease in cmax and auc values of both DB01238 and its active metabolite , ddrug4 .",
        "label": "NA"
    },
    {
        "text": "because the HD00153 ddrug1 is given exclusively by the oral route in man , we have carried out studies in mice on the antitumour activity , acute toxicity and pharmacokinetics of oral HD00152 , either alone or in combination with the chemosensitizer ddrug3 .",
        "label": "NA"
    },
    {
        "text": "intravenous ddrug0 { DB00640 } has been effectively administered in the presence of other cardioactive drugs , such as ddrug2 , HD00244 , ddrug4 , and ddrug5 , without any change in the adverse reaction profile .",
        "label": "NA"
    },
    {
        "text": "another oral HD00820 , DB01026 , inhibits the metabolism of ddrug2 , resulting in elevated plasma concentrations of ddrug3 and its active metabolite ddrug4 which may prolong qt intervals .",
        "label": "NA"
    },
    {
        "text": "HD00374 , DB00364 , metal cations , ddrug2 ddrug3 form chelates with alkaline earth and transition metal cations .",
        "label": "NA"
    },
    {
        "text": "background : the effects of combined administration of ddrug0 and ddrug1 { DB00661 } , a ddrug3 , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by HD00037 { ddrug5 } and the labeling index of intestinal_cancer were investigated in male wistar rats .",
        "label": "NA"
    },
    {
        "text": "talk to your doctor if you are taking certain HD00002 such as ddrug1 , DB01211 or ddrug3 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , DB01167 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , DB01601 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "since DB00316 in high doses has been associated with hepatotoxicity , concomitant administration of DB00861 and ddrug2 should be used cautiously , with careful monitoring of patients .",
        "label": "NA"
    },
    {
        "text": "therefore , when ddrug0 and HD00294 are used concomitantly , the patient should be observed closely to determine if the desired effect of the HD00295 is obtained",
        "label": "NA"
    },
    {
        "text": "similarly , the effects of DB00252 on DB01174 , ddrug2 and sodium plasma ddrug3 concentrations are unpredictable",
        "label": "effect"
    },
    {
        "text": "ddrug0 in combination with DB00575 enhances the manifestation of corneal lesions in rats epidural injection ddrug2 may potentiate the cns-depressive effect of ddrug3 , HD00026 or other ddrug5 .",
        "label": "NA"
    },
    {
        "text": "these results suggest that both ddrug0 and HD00147 , and possibly other ddrug2 and ddrug3 , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of ddrug4 and HD00148 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , DB00636 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , DB00295 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "effects of HD00391 are increased with ddrug1 and HD00479 .",
        "label": "effect"
    },
    {
        "text": "the co-administration of ddrug0 with iv ddrug1 such as ddrug2 , DB00325 , ddrug4 , or iv HD00106 has not been evaluated { these drugs were not co-administered with ddrug6 in clinical trials } .",
        "label": "NA"
    },
    {
        "text": "in separate single or multiple dose pharmacokinetic interaction studies with ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , DB01233 , ddrug6 , ddrug7 , and ddrug8 , the bioavailability of ddrug9 was not altered by coadministration of DB00492 with any one of these drugs .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , including DB00779 , may enhance the effects of the oral ddrug2 DB00682 or its derivatives .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : when DB01076 and HD00382 suspension were coadministered , plasma concentrations of ddrug3 decreased approximately 35 % .",
        "label": "mechanism"
    },
    {
        "text": "hepatic enzyme inducers , inhibitors and substrates : drugs which induce cytochrome p450 3a4 { cyp 3a4 } enzyme activity { e , g , , ddrug0 , ddrug1 , ddrug2 , DB01045 } may enhance the metabolism of ddrug4 and require that the dosage of the HD00579 be increased .",
        "label": "NA"
    },
    {
        "text": "exert particular caution in combining DB01239 with other ddrug1 { ddrug2 and HD00523 } : particularly the elderly may develop delirium , high fever , severe obstipation , even ileus and glaucoma .",
        "label": "advise"
    },
    {
        "text": "unmodified HD00072 { 1 % m/v } significantly improved the transport ratio { r = p { app } polymer / p { app } control } of HD00070 to # and 1 % { m/v } ddrug2 conjugated with ddrug3 further enhanced the permeation .",
        "label": "NA"
    },
    {
        "text": "the hypoglycemic action of ddrug0 may be potentiated by certain drugs including HD00518 and other drugs that are highly protein bound , ddrug2 , HD00297 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , and ddrug8 .",
        "label": "NA"
    },
    {
        "text": "it is recommended that plasma ddrug0 levels be monitored when DB01009 is coadministered with DB14507 .",
        "label": "advise"
    },
    {
        "text": "while no in vivo drug-drug interaction studies were conducted between ddrug0 and inducers of cyp3a , compounds that are potent cytochrome_p450_family_3_subfamily_a inducers { such as ddrug1 , ddrug2 , ddrug3 , and HD00026 } would be expected to decrease DB01215 concentrations .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect : ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , ddrug5 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , HD00809 , ddrug12 , ddrug13 { e , g , , in oral HD00283 } .",
        "label": "NA"
    },
    {
        "text": "since the pharmacokinetics of DB01008 were studied in patients treated with ddrug1 , the clearance of ddrug2 at the recommended dose may be lower and exposure { auc } higher in patients not treated with DB00252 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - DB01022 can antagonize the effect of DB00682",
        "label": "effect"
    },
    {
        "text": "the duration of the period following treatment with DB00092 before one should consider starting other HD00258 therapy has not been evaluated .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , HD00002 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , DB00091 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "in # separate studies , ddrug0 # mg twice daily { 240 mg total daily dose } was co-administered with either DB00199 # mg every # hours or DB01026 # mg once daily under steady-state conditions to healthy volunteers { n = 24 , each study } .",
        "label": "NA"
    },
    {
        "text": "in general , these are drugs that have one or more pharmacologic activities similar to HD00406 , including ddrug1 such as ddrug2 and ddrug3 , HD00345 and ddrug5 .",
        "label": "NA"
    },
    {
        "text": "if DB00252 or other hepatic enzyme inducers are taken concurrently with DB00280 or ddrug2 , lower plasma levels of ddrug3 may occur .",
        "label": "mechanism"
    },
    {
        "text": "additionally , ddrug0 , such as DB00608 and ddrug2 , may antagonize the activity of DB00564 .",
        "label": "effect"
    },
    {
        "text": "therefore , co-administration of ddrug0 with drugs that are metabolized by cyp2d6 isoenzyme including certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } , ddrug8 { e , g , , DB00502 , ddrug10 , ddrug11 } , HD00254 { e , g , , ddrug13 } , and ddrug14 { e , g , , ddrug15 , ddrug16 } , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .",
        "label": "NA"
    },
    {
        "text": "in two combined 12-week placebo controlled trials that included DB01274 doses of # mcg twice daily , # mcg twice daily , and # mcg once daily , # of # ddrug1 - treated subjects received concomitant DB00277 at study entry .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : concurrent administration of certain ddrug1 , such as HD00538 and DB00804 , would be expected to compromise the beneficial effects of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { DB00316 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { DB01045 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { DB01076 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , DB00220 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "DB00898 : clinical evidence has shown that ddrug1 can be formed with concurrent ingestion of DB00459 and ddrug3 .",
        "label": "NA"
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as ddrug0 include certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 } , DB14513 salts , ddrug11 , local HD00264 , ddrug13 , and ddrug14 .",
        "label": "NA"
    },
    {
        "text": "drugs that may alter ddrug0 plasma concentrations drugs that may increase DB00619 plasma concentrations : caution is recommended when administering DB00619 with inhibitors of the cyp3a4 family { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and DB01183 should be prescribed with caution to patients on HD00100 or other drugs that act on the central nervous system , regardless of whether these drugs are taken on the advice of a physician or are taken as drugs of abuse .",
        "label": "advise"
    },
    {
        "text": "the concomitant use of transdermal DB00813 with ddrug1 or other potent 3a4 inhibitors such as ddrug2 , ddrug3 , DB13179 , ddrug5 , ddrug6 , and nefazadone may result in an increase in ddrug7 plasma concentrations .",
        "label": "mechanism"
    },
    {
        "text": "patients should be warned of the potential danger of the intravenous self-administration of HD00100 while under treatment with ddrug1 or DB00921 .",
        "label": "advise"
    },
    {
        "text": "DB00224 concentration DB00615 concentration",
        "label": "NA"
    },
    {
        "text": "in addition , several ddrug0 s that are cytochrome cyp2b6 inducers can decrease plasma concentrations of DB00776 and HD00888 .",
        "label": "NA"
    },
    {
        "text": "DB00701 inhibits the ermbt , and DB01045 and ddrug2 are equipotent inducers of the ermbt .",
        "label": "NA"
    },
    {
        "text": "the extent to which ddrug0 - HD00312 interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the HD00278 involved .",
        "label": "NA"
    },
    {
        "text": "{ see clinical pharmacology } coadministration of DB01006 and ddrug1 # mg daily resulted in a reduction of DB01006 plasma levels by 38 % on average .",
        "label": "NA"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { ddrug1 s } , ddrug2 , ddrug3 { ddrug4 may decrease the effects of these medicines } , ddrug5 { using these medicines with ddrug6 may result in increased cns depressant effects } , DB00313 , ddrug8 { using these medicines with ddrug9 may change the amount of either medicine that you need to take } , and oral ddrug10 containing ddrug11 { HD00026 may decrease the effectiveness of these oral ddrug13 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "additive cns depression may occur when HD00388 are administered concomitantly with other ddrug1 including ddrug2 , HD00262 , and ddrug4 .",
        "label": "effect"
    },
    {
        "text": "drug interactions : the central ddrug0 syndrome can occur when anticholinergic agents such as ddrug1 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain ddrug2 such as ddrug3 , the ddrug4 and other ddrug5 , ddrug6 , certain HD00303 such as the DB00908 salts , and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "concomitant treatment with ddrug0 { DB01223 , ddrug2 } , ddrug3 , or ddrug4 may potentiate any hypokalemic effect of HD00355 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 or ddrug1 : concomitant administration of DB01032 or ddrug3 decreases the elimination of DB00943 , most likely by inhibition of renal tubular secretion of ddrug5 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : DB00951 may increase serum levels of DB00252 .",
        "label": "mechanism"
    },
    {
        "text": "DB14513 - and/or ddrug1 - containing HD00374 , products containing ddrug3 { ddrug4 } , ddrug5 containing ddrug6 or other metal cations , or ddrug7 { ddrug8 } chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after ddrug9 .",
        "label": "NA"
    },
    {
        "text": "in clinical trials , ddrug0 was used with ddrug1 , HD00218 , ddrug3 , oral ddrug4 , and supplemental ddrug5 , in a pharmacokinetic substudy in patients with congestive heart failure receiving ddrug6 or ddrug7 in whom therapy with ddrug8 was initiated , apparent oral clearance values for ddrug9 { n = 23 } and DB00390 { n = 30 } were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .",
        "label": "NA"
    },
    {
        "text": "plasma levels of several closely related ddrug0 have been reported to be increased by the concomitant administration of DB00422 or hepatic enzyme inhibitors { e , g , , DB00501 , ddrug3 } and decreased by the concomitant administration of hepatic enzyme inducers { e , g , , ddrug4 , ddrug5 } , and such an effect may be anticipated with ddrug6 as well .",
        "label": "NA"
    },
    {
        "text": "interactions may also occur with the following : HD00515 / ddrug1 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , DB01208 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 pain medication { e , g , , ddrug12 } , drugs used to aid sleep , drowsiness-causing ddrug13 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "the data do not suggest the need for dose adjustment of either DB02325 or DB00563 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { DB01045 } , st , johns wort , ddrug41 , ddrug42 { HD00531 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "administration of DB01156 tablets to patients receiving either ddrug1 or DB00915 concurrently should be undertaken with caution , using small initial doses and small gradual dose increases .",
        "label": "advise"
    },
    {
        "text": "administration of DB01045 concomitantly with oral ddrug1 has been shown to result in decreases in serum concentrations of ddrug2 and HD00307 .",
        "label": "NA"
    },
    {
        "text": "in clinical trials , ddrug0 was used with ddrug1 , ddrug2 , HD00326 , oral ddrug4 , and supplemental DB09140 , in a pharmacokinetic substudy in patients with congestive heart failure receiving ddrug6 or ddrug7 in whom therapy with ddrug8 was initiated , apparent oral clearance values for ddrug9 { n = 23 } and ddrug10 { n = 30 } were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { cns } drugs including ddrug1 , ddrug2 , HD00388 , ddrug4 , blood pressure medications { ddrug5 , DB00968 , ddrug7 } , motion sickness medications , ddrug8 , ddrug9 , ddrug10 , sleeping pills and ddrug11",
        "label": "NA"
    },
    {
        "text": "the results from a study in which eight hiv-infected individuals were treated with DB00495 , # + / - # mg/kg/day , showed that the pharmacokinetics of ddrug1 were not affected during concomitant administration of DB01167 , # mg b , i , d.",
        "label": "NA"
    },
    {
        "text": "ddrug0 : increased serum ddrug1 levels and symptoms of DB14507 toxicity have been reported in patients receiving concomitant ddrug3 and HD00471 therapy .",
        "label": "NA"
    },
    {
        "text": "as a consequence , when DB00328 and DB14507 are given concomitantly , the patient should be carefully observed for signs of ddrug2 toxicity .",
        "label": "advise"
    },
    {
        "text": "DB00238 and DB01026 should not beadministered concomitantly becausedecreases in ddrug2 plasmaconcentrations may reduce the efficacy of the drug .",
        "label": "advise"
    },
    {
        "text": "ddrug0 - DB00125 may counteract the antinaturetic effect of DB00091 .",
        "label": "effect"
    },
    {
        "text": "drugs that inhibit both aldehyde oxidase and cyp3a4 ddrug0 : DB00501 inhibits both aox1 { in vitro } and cyp3a4 { in vitro and in vivo } , the primary and secondary enzymes , respectively , responsible for DB00962 metabolism .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : DB01032 is known to interact with the metabolism or renal tubular excretion of many drugs { e , g , , ddrug2 , ddrug3 , HD00529 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 agents , ddrug14 , and ddrug15 } .",
        "label": "mechanism"
    },
    {
        "text": "concomitant ddrug0 , DB00997 , ddrug2 , and ddrug3 chemotherapy plus HD00055 therapy in patients with human immunodeficiency virus-related , non-hodgkin lymphoma .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : DB00316 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , DB00277 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of HD00539 such as ddrug1 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 } , DB14513 salts , ddrug12 , local ddrug13 , ddrug14 , and ddrug15 .",
        "label": "effect"
    },
    {
        "text": "DB00564 : coadministration of ddrug1 { 200 mg bid } , a potent cyp3a4 inducer , with ddrug2 { 30 mg qd } resulted in an approximate 70 % decrease in cmax and auc values of both ddrug3 and its active metabolite , HD00368 .",
        "label": "NA"
    },
    {
        "text": "HD00423 altered coagulation parameters and/or bleeding have been reported in patients taking DB01101 concomitantly with ddrug2 such as ddrug3 and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in vitro and/or in vivo data indicate that ddrug1 , DB01167 , and oral ddrug3 markedly inhibit the metabolism of ddrug4 , which can result in an increase in plasma DB00604 levels and prolongation of the qt interval on the ecg .",
        "label": "NA"
    },
    {
        "text": "HD00423 altered coagulation parameters and/or bleeding have been reported in patients taking ddrug1 concomitantly with HD00469 such as ddrug3 and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "a study in six healthy volunteers has shown a significant increase in peak ddrug0 plasma levels { 58 % } and auc { 53 % } after a 1-week course of DB00501 # mg/day and a single dose of DB00343 60 mg .",
        "label": "mechanism"
    },
    {
        "text": "refer to the package insert for DB14507 preparations before use of such preparations with DB00880",
        "label": "advise"
    },
    {
        "text": "comparison of DB00515 pharmacokinetics in patients treated with # mg/m2 plus HD00158 to those in patients treated with # mg/m2 without ddrug2 indicated that there were no changes in the elimination rate constant , volume of distribution , or total body clearance of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "although DB01210 used alone has little or no effect on pupil size , mydriasis resulting from concomitant therapy with ddrug1 and DB00668 may occur .",
        "label": "NA"
    },
    {
        "text": "however , coadministration of DB01175 { 20 mg } and DB00503 { 600 mg } , a potent inhibitor of cyp3a4 , did not significantly affect the pharmacokinetics of ddrug2 .",
        "label": "NA"
    },
    {
        "text": "conjugation at ddrug0 with DB00151 moieties significantly improves the intestinal permeation of the hydrophilic molecule ddrug2 and the model peptide drugs ddrug3 and HD00071 in vitro , therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with ddrug1 , ddrug2 s , HD00404 { allergy , cold , and sinus medicines } , diabetic drugs , ddrug4 , ddrug5 , ddrug6 like ddrug7 or DB01050 , and high blood pressure medications .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00564 causes an approximate 50 % increase in the clearance of ddrug2 at steady state and , therefore , the addition of ddrug3 results in an approximate 40 % decrease in the steady-state trough concentrations of ddrug4 as compared to the same dose of DB00949 given as monotherapy .",
        "label": "NA"
    },
    {
        "text": "failure of DB00994 to modify DB01285 induced hypertension in sheep .",
        "label": "NA"
    },
    {
        "text": "DB00285 : coadministration of a single dose of DB00962 # mg and multiple doses of ddrug2 er { extended release } # mg did not result in any significant changes in the pharmacokinetics of either ddrug3 or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "an encephalopathic syndrome { characterized by weakness , lethargy , fever , tremulousness and confusion , extrapyramidal symptoms , leukocytosis , elevated serum enzymes , bun , and fbs } followed by irreversible brain damage has occurred in a few patients treated with DB14507 plus DB00502 .",
        "label": "effect"
    },
    {
        "text": "DB00310 and related drugs may decrease arterial responsiveness to DB00368 .",
        "label": "effect"
    },
    {
        "text": "therefore , when ddrug0 and HD00294 are used concomitantly , the patient should be observed closely to determine if the desired effect of the HD00295 is obtained .",
        "label": "NA"
    },
    {
        "text": "in rheumatoid arthritis , concomitant medications besides ddrug0 were HD00518 , ddrug2 , ddrug3 and/or HD00543 .",
        "label": "NA"
    },
    {
        "text": "DB00277 HD00897 # , 25 , and # mg administered once daily for # days increased plasma ddrug2 concentrations { auc { 0 - } } by # to 60 % in healthy subjects administered a single 300-mg dose of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "DB00694 should not be used in patients who have previously received the recommended maximum cumulative doses of DB00997 or ddrug2 .",
        "label": "advise"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / ddrug1 , drugs used to treat an overactive thyroid , HD00254 { e , g , , ddrug3 } , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 pain medication { e , g , , ddrug12 } , drugs used to aid sleep , drowsiness-causing ddrug13 { e , g , , DB14487 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "taking DB01612 after drinking DB02325 may worsen side effects and may cause severe hypotension and cardiovascular collapse .",
        "label": "effect"
    },
    {
        "text": "the intensity , uniformity and time course of ddrug0 interference by ddrug1 , ddrug2 , ddrug3 , ddrug4 and DB04833 were systematically investigated in # patients receiving DB04665 therapy .",
        "label": "NA"
    },
    {
        "text": "may interact with thyroid medication { e , g , , ddrug0 } , DB11119 - containing products , HD00374 , ddrug3 { e , g , , ddrug4 , ddrug5 } , and ddrug6 { e , g , , ddrug7 , ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "therapeutic concentrations of ddrug0 , ddrug1 , DB01050 , ddrug3 , ddrug4 , ddrug5 , ddrug6 andtolbutamide did not alter DB00465 protein binding .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : co-administration of HD00897 with DB01045 # mg daily , a potent inducer of hepatic metabolism , produced an approximate 50 % decrease in ddrug3 plasma concentrations .",
        "label": "mechanism"
    },
    {
        "text": "DB00876 has been shown to have no effect on the pharmacokinetics of ddrug1 and the pharmacodynamics of ddrug2 and DB01016 .",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , ddrug3 , or ddrug4 , with ddrug5 , with metal cations such as ddrug6 , or with DB00152 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as DB00900 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "in clinical trials , ddrug0 was used with DB00390 , ddrug2 , ddrug3 , oral ddrug4 , and supplemental ddrug5 , in a pharmacokinetic substudy in patients with congestive heart failure receiving DB00695 or ddrug7 in whom therapy with ddrug8 was initiated , apparent oral clearance values for ddrug9 { n = 23 } and ddrug10 { n = 30 } were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .",
        "label": "NA"
    },
    {
        "text": "the plasma concentration of ddrug0 may increase when the drug is given concomitantly with hepatic enzyme inhibitors { e , g , , DB00501 , ddrug2 } and decrease by concomitant administration of hepatic enzyme inducers { e , g , , ddrug3 , ddrug4 } , and adjustment of the dosage of DB00458 may therefore be necessary .",
        "label": "NA"
    },
    {
        "text": "compounds in these categories result in a decreased efficacy of ddrug0 : ddrug1 , ddrug2 , DB01233 , DB01100 .",
        "label": "NA"
    },
    {
        "text": "drug interactions : the central ddrug0 syndrome can occur when anticholinergic agents such as ddrug1 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain ddrug2 such as ddrug3 , the HD00219 and other ddrug5 , ddrug6 , certain HD00303 such as the ddrug8 salts , and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "like HD00021 { 40 mg/kg } , HD00022 { 40 mg/kg } decreases the intravenous self-administration of ddrug2 and ddrug3 and the oral self-administration of ddrug4 and ddrug5 in rats ;",
        "label": "NA"
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a HD00533 , including ddrug1 , with multivalent cation-containing products such as ddrug2 or ddrug3 ddrug4 , ddrug5 , ddrug6 chewable/buffered tablets or pediatric powder , or products containing DB01373 , ddrug8 , or ddrug9 may substantially decrease the absorption of ddrug10 , resulting in serum and urine levels considerably lower than desired .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 { ddrug1 , ddrug2 } : requirements for HD00071 or oral HD00075 may be reduced in hypothyroid patients with diabetes mellitus and may subsequently increase with the initiation of thyroid hormone replacement therapy .",
        "label": "NA"
    },
    {
        "text": "coingestion of ddrug0 with DB00277 , ddrug2 with DB00316 , and ddrug4 with ddrug5 at high to toxic concentrations decreases the binding of the target drug .",
        "label": "NA"
    },
    {
        "text": "HD00575 { eg , ddrug1 } and other drugs , including ether , DB00202 , ddrug3 , ddrug4 and ddrug5 , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with ddrug6 parenteral .",
        "label": "NA"
    },
    {
        "text": "DB00176 has also been shown to inhibit cyp2b6 1a2 , an isoform also involved in HD00312 metabolism .",
        "label": "mechanism"
    },
    {
        "text": "when DB01174 is added to or withdrawn from treatment , dosage adjustment of DB00573 may be required .",
        "label": "advise"
    },
    {
        "text": "ddrug0 { eg , DB01199 } and other drugs , including ether , DB00202 , ddrug3 , ddrug4 and ddrug5 , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with ddrug6 parenteral .",
        "label": "NA"
    },
    {
        "text": "caution should be used when administering or taking DB00530 with ddrug1 and other strong cyp3a4 inhibitors such as , but not limited to , ddrug2 , ddrug3 , DB00224 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { ddrug12 } , and ddrug13 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : the concomitant use of ddrug1 { DB00813 transdermal system } with other ddrug3 , including but not limited to other ddrug4 , ddrug5 , ddrug6 , ddrug7 { e , g , , ddrug8 } , general ddrug9 , ddrug10 , ddrug11 , and DB02325 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .",
        "label": "effect"
    },
    {
        "text": "DB01064 should be used with caution , if at all , when potent inhalational ddrug1 such as ddrug2 are employed because of potential to sensitize the myocardium to effects of HD00399 .",
        "label": "NA"
    },
    {
        "text": "if ddrug0 is to be combined with other ddrug1 such as HD00262 or ddrug3 / ddrug4 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of ddrug5 and ddrug6 { e , g , , DB00475 or ddrug8 } are additive .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , DB00864 and ddrug2 concentrations should be monitored at the initiation of DB01167 therapy and frequently thereafter , and the dose of these three drug products adjusted appropriately .",
        "label": "advise"
    },
    {
        "text": "DB00248 should not be administered concurrently with d2-antagonists , such as ddrug1 , HD00340 , ddrug3 , or ddrug4 .",
        "label": "advise"
    },
    {
        "text": "DB00559 is also expected to reduce plasma concentrations of other HD00434 that have significant metabolism by cyp3a4 , such as ddrug2 and ddrug3 .",
        "label": "mechanism"
    },
    {
        "text": "DB01026 increased mean DB00969 plasma concentrations { auc } by 29 % .",
        "label": "mechanism"
    },
    {
        "text": "in some patients , the administration of DB00328 can reduce the diuretic , natriuretic , and antihypertensive effects of ddrug1 , ddrug2 , and HD00029 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , DB01174 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , DB00295 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "concomitant use of DB00943 and DB00709 is not recommended .",
        "label": "advise"
    },
    {
        "text": "coadministration of DB01175 and DB00264 had no clinically significant effects on blood pressure or heart rate .",
        "label": "NA"
    },
    {
        "text": "in vivo interaction studies in humans have demonstrated that DB00390 and DB00682 do not affect the pk properties of ddrug2 , nor does ddrug3 affect the pk properties of ddrug4 or ddrug5 .",
        "label": "NA"
    },
    {
        "text": "this drug may interact with ddrug0 or other ddrug1 { may potentiate the cns depressant effects of either these medications or ddrug2 } , ddrug3 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with HD00388 } , and HD00445 { concurrent use with ddrug6 may prolong and intensify the anticholinergic and cns depressant effects of ddrug7 } .",
        "label": "NA"
    },
    {
        "text": "the net effect of these interactions is summarized in the following table : HD00715 ddrug1 DB00949",
        "label": "NA"
    },
    {
        "text": "coadministration of DB00580 and ddrug1 1/35 increased the exposure of DB00717 and ddrug3 by 20 % and 34 % , respectively .",
        "label": "NA"
    },
    {
        "text": "a drug-drug interaction study with DB01045 in healthy volunteers has shown a 30 % decrease in DB00520 trough concentrations .",
        "label": "mechanism"
    },
    {
        "text": "there have been greater than 2-fold increases in previously stable plasma levels of other HD00216 , including ddrug1 , when DB00472 has been administered in combination with these agents .",
        "label": "mechanism"
    },
    {
        "text": "descending epsilon and mu systems for HD00144 and DB00295 , respectively , are proposed .",
        "label": "NA"
    },
    {
        "text": "ddrug0 with ddrug1 or DB00344 and possibly other HD00609 cause striking and sustained increases in the concentration of ddrug4 in the brain ;",
        "label": "NA"
    },
    {
        "text": "other reported interactions with ddrug0 : ddrug1 { HD00302 substrate } in combination with DB01118 may cause hypotension , bradycardia , and decreased cardiac output .",
        "label": "NA"
    },
    {
        "text": "conjugation at ddrug0 with DB00151 moieties significantly improves the intestinal permeation of the hydrophilic molecule ddrug2 and the model peptide drugs DB00781 and ddrug4 in vitro , therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future .",
        "label": "NA"
    },
    {
        "text": "during controlled hypotensive anesthesia using DB00598 in association with DB01159 , high concentrations { 3 % or above } of ddrug2 should not be used because the degree of hypotension will be increased and because of the possibility of a large reduction in cardiac output and an increase in central venous pressure .",
        "label": "effect"
    },
    {
        "text": "the use of HD00374 should be considered in place of HD00586 or ddrug2 in patients receiving ddrug3 therapy .",
        "label": "NA"
    },
    {
        "text": "- a ddrug0 { HD00615 } such as ddrug2 { ddrug3 , ddrug4 , ddrug5 , others } , ddrug6 { ddrug7 , ddrug8 , ddrug9 } , ddrug10 { DB00586 , ddrug12 } , ddrug13 { ddrug14 } , ddrug15 { ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , and ddrug21 { ddrug22 , ddrug23 , ddrug24 } ;",
        "label": "NA"
    },
    {
        "text": "therapeutic drug monitoring { tdm } of ddrug0 therapy , and bone scintigraphy employing HD00173 as the HD00174 was carried out in # patients .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { DB01026 } DB01235 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "the concurrent use of DB00986 injection with other ddrug1 or medications with anticholinergic activity , such as HD00219 , ddrug3 , or ddrug4 , may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects .",
        "label": "effect"
    },
    {
        "text": "ddrug0 potentiates other HD00632 such as ddrug2 or HD00661 and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 : limited clinical data suggest a higher incidence of adverse experiences in patients receiving DB01156 concurrently with either DB01235 or ddrug4 .",
        "label": "effect"
    },
    {
        "text": "no dose adjustment is necessary when ddrug0 is added to triple-immunosuppression regimens including ddrug1 , HD00175 , and either DB00993 or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "the concomitant use of other cyp3a4 inhibitors such as ddrug0 and DB00199 with transdermal ddrug2 may also result in an increase in DB00813 plasma concentrations , which could increase or prolong adverse drug effects and may cause serious respiratory depression .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { ddrug1 , ddrug2 , DB00540 } : metabolism may be inhibited by ddrug4 , increasing plasma levels of HD00711 ;",
        "label": "NA"
    },
    {
        "text": "DB01627 has been shown to have neuromuscular blocking properties that may enhance the action of other HD00547 .",
        "label": "effect"
    },
    {
        "text": "interactions with ddrug0 : ddrug1 { eg , ddrug2 , ddrug3 , ddrug4 , ddrug5 and DB00921 } should not be administered to a patient who has received or is receiving a course of therapy with a ddrug7 such as DB00854 .",
        "label": "advise"
    },
    {
        "text": "in clinical trials , DB01240 was used with ddrug1 , ddrug2 , HD00326 , oral ddrug4 , and supplemental ddrug5 , in a pharmacokinetic substudy in patients with congestive heart failure receiving ddrug6 or ddrug7 in whom therapy with ddrug8 was initiated , apparent oral clearance values for ddrug9 { n = 23 } and ddrug10 { n = 30 } were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .",
        "label": "NA"
    },
    {
        "text": "this drug may interact with ddrug0 or other ddrug1 { may potentiate the cns depressant effects of either these medications or ddrug2 } , ddrug3 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug4 } , and HD00445 { concurrent use with ddrug6 may prolong and intensify the anticholinergic and cns depressant effects of HD00388 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB14507 toxicity has been reported in patients receiving ddrug2 concomitantly with drugs which cause elimination of sodium , including HD00106 .",
        "label": "NA"
    },
    {
        "text": "patients receiving catecholamine-depleting drugs , such as DB00206 or DB01170 , should be closely monitored , because the added beta-adrenergic blocking action of ddrug2 may produce excessive reduction of sympathetic activity .",
        "label": "NA"
    },
    {
        "text": "expected to substantially decrease plasma levels of DB00625 ; has not been studied in combination with DB00625 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 / ddrug1 : long-term suppression of gastric acid secretion by ddrug2 or HD00587 { eg , ddrug4 and ddrug5 } is likely to reduce DB01254 exposure .",
        "label": "effect"
    },
    {
        "text": "endothelium-intact aortic rings from high - DB00783 rats were supersensitive to DB00368 when compared to vehicle - , ddrug2 - and ddrug3 + high - ddrug4 - treated rats { pd2 values = # + / # , # + / # , # + / # and # + / # , respectively } .",
        "label": "effect"
    },
    {
        "text": "the fraction of DB00611 absorbed is unaffected by the concomitant administration of a HD00462 { ddrug2 } , but the rate of absorption is decreased .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { eg , DB01199 } and other drugs , including ether , ddrug2 , ddrug3 , ddrug4 and DB09154 , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with ddrug6 parenteral .",
        "label": "NA"
    },
    {
        "text": "phase ii clinical trial data , where ddrug0 and ddrug1 have been used concomitantly , indicate that DB00317 may exacerbate the neutropenic effect of DB00361 .",
        "label": "effect"
    },
    {
        "text": "for example , when HD00286 are administered concomitantly with DB00665 , prothrombin time should be carefully monitored and if necessary , the dosage of ddrug2 should be reduced .",
        "label": "advise"
    },
    {
        "text": "no interaction was noted with the HD00681 ddrug1 in two multiple-dose interaction studies when ddrug2 was coadministered with a DB01235 / ddrug4 { n = 29 } .",
        "label": "NA"
    },
    {
        "text": "in healthy subjects , no significant drug-drug interaction was observed when ddrug0 was coadministered with either DB00571 or DB00829 .",
        "label": "NA"
    },
    {
        "text": "DB11119 or ddrug1 excess may decrease the effect of DB00389 , and an ddrug3 deficiency can increase the effect of ddrug4 .",
        "label": "effect"
    },
    {
        "text": "other concomitant therapy although specific interaction studies were not performed , ddrug0 doses of # mg or more were concomitantly used in clinical studies with DB00316 , ddrug2 , a-blockers , ddrug3 , ddrug4 , ddrug5 , ddrug6 , HD00378 , ddrug8 , cardiac ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 { also referred to as ddrug14 } , and ddrug15 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "interconversion between DB00201 and DB00277 has been reported in preterm neonates .",
        "label": "NA"
    },
    {
        "text": "HD00143 , such as DB00661 , ddrug2 and ddrug3 , inhibit platelet activation in vitro , and decrease platelet adhesion intravascularly .",
        "label": "NA"
    },
    {
        "text": "persons taking most ddrug0 , DB00563 and ddrug2 invalidate DB00158 and ddrug4 diagnostic blood assays .",
        "label": "NA"
    },
    {
        "text": "therefore , co-administration of ddrug0 with drugs that are metabolized by cyp2d6 isoenzyme including certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } , ddrug8 { e , g , , ddrug9 , DB00734 , ddrug11 } , HD00254 { e , g , , ddrug13 } , and ddrug14 { e , g , , ddrug15 , ddrug16 } , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .",
        "label": "NA"
    },
    {
        "text": "other drugs : based on the results of drug interaction studies , no dosage adjustment is recommended when DB00625 { ddrug1 } is given with the following : ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB00196 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , and ddrug11 .",
        "label": "NA"
    },
    {
        "text": "DB01032 : ddrug1 , a renal tubular secretion blocking agent , administered at a dose of # mg four times a day , did not change the pharmacokinetics of DB01202 # mg twice daily .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : DB00316 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , DB00295 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { DB01076 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , DB01045 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , ddrug3 , or ddrug4 , with DB00364 , with metal cations such as ddrug6 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as DB00900 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "ddrug0 such as ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , ddrug5 { e , g , , ddrug6 } , ddrug7 { e , g , , ddrug8 } , and ddrug9 { e , g , , DB00752 } : using these medicines with DB00150 may increase the chance of side effects .",
        "label": "NA"
    },
    {
        "text": "specific drug interaction studies have not been performed with DB00625 and ddrug1 other than DB00709 and ddrug3 .",
        "label": "NA"
    },
    {
        "text": "HD00374 : concomitant administration of ddrug1 and DB06723 does not interfere with the rate or extent of the absorption of ddrug3 administered as ddrug4 .",
        "label": "NA"
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit DB00451 binding to serum proteins or alter the concentrations of serum binding proteins : ddrug1 and related ddrug2 , ddrug3 , DB00636 , ddrug5 and ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 .",
        "label": "mechanism"
    },
    {
        "text": "the serum concentration of ddrug0 increased dramatically from # to # microg/ml when ddrug1 was coadministered , although the daily dosage of DB00252 and other HD00096 had not changed .",
        "label": "NA"
    },
    {
        "text": "using in situ hybridization , we observed that HD00015 caused a rapid and transient dose-dependent increase in arc mrna level in the striatum and cortex that was abolished by pretreatment with the specific drd1 antagonist HD00016 but not by an ddrug2 ddrug3 .",
        "label": "effect"
    },
    {
        "text": "if ddrug0 is given concomitantly with ddrug1 , the ddrug2 dose should be reduced { by approx , 50 % } , because DB01239 amplifies the therapeutic actions and side-effects of HD00263 massively .",
        "label": "effect"
    },
    {
        "text": "the reddish color is due to the formation of a nonabsorbable complex between DB00535 or its breakdown products and DB01592 in the gastrointestinal tract .",
        "label": "mechanism"
    },
    {
        "text": "in another drug interaction study , co-administration of orally inhaled DB01410 and oral DB01026 , a potent inhibitor of cytochrome p450 3a4 , increased the exposure { auc } of ddrug2 by approximately # - fold at steady state , while levels of ddrug3 remained unchanged .",
        "label": "mechanism"
    },
    {
        "text": "HD00388 : DB00637 * , ddrug2 * contraindicated due to potential for serious and/or life-threatening cardiac arrhythmias .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , DB00273 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { DB01045 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { such as ddrug1 } and HD00219 can suppress the DB00988 rgic renal and mesenteric vasodilation induced with low dose dopamine infusion .",
        "label": "effect"
    },
    {
        "text": "agents causing renin release : the antihypertensive effect of ddrug0 and DB00584 iv is augmented by HD00366 that cause renin release { e , g , , ddrug3 } .",
        "label": "effect"
    },
    {
        "text": "intrathecal injection of DB01183 at doses of # to # micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of HD00144 , and a high dose of ddrug2 { 40 micrograms } completely blocked the tail-flick inhibition induced by intraventricular ddrug3 { 16 micrograms } .",
        "label": "effect"
    },
    {
        "text": "- a HD00380 such as DB00571 { ddrug2 } , ddrug3 { ddrug4 } , ddrug5 { ddrug6 } , ddrug7 { ddrug8 } , and others ;",
        "label": "NA"
    },
    {
        "text": "data from in vitro studies of HD00100 other than ddrug1 suggest a possible drug interaction for the following : ddrug2 , ddrug3 , DB01118 , ddrug5 , and ddrug6 .",
        "label": "int"
    },
    {
        "text": "effects of other antiepilepsy drugs { HD00714 } on ddrug1 : DB00564 : population pharmacokinetic analyses indicate that ddrug3 clearance is 60 % greater in patients taking ddrug4 with or without other enzyme - inducing ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 with ddrug1 or DB00344 and possibly other ddrug3 cause striking and sustained increases in the concentration of DB01576 in the brain ;",
        "label": "NA"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : ddrug1 ; ddrug2 ; ddrug3 ; certain ddrug4 , especially the ddrug5 and ddrug6 ; ddrug7 ; DB14513 salts ; DB01035 ; and ddrug10 .",
        "label": "NA"
    },
    {
        "text": "cytochrome p-450 inducers , such as ddrug0 , ddrug1 and DB01174 , induce ddrug3 metabolism , causing an approximately 30 % decrease in plasma DB01068 levels .",
        "label": "NA"
    },
    {
        "text": "in patients receiving nonselective ddrug0 { ddrug1 } { e , g , , DB01037 } in combination with HD00603 { e , g , , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 } , there have been reports of serious , sometimes fatal , reactions .",
        "label": "effect"
    },
    {
        "text": "in vitro data in human plasma indicate that DB00590 has no effect on protein binding of ddrug1 , ddrug2 , ddrug3 or DB00328 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 can interact with DB02325 or other ddrug2 { may potentiate the cns depressant effects of either these medications or ddrug3 } , ddrug4 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with HD00388 } , and ddrug6 { concurrent use with ddrug7 may prolong and intensify the anticholinergic and cns depressant effects of ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the ddrug0 of drugs may be potentiated by ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , the ddrug6 , ddrug7 and ddrug8 , ddrug9 and the HD00043 , and by other HD00561 .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { DB00564 } ddrug7 { ddrug8 } HD00220 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of ddrug0 are the following : ddrug1 , ddrug2 , DB00949 , ddrug4 , ddrug5 , ddrug6 { 2 } , ddrug7 , ddrug8 , and ddrug9 thus , if a patient has been titrated to a stable dosage on HD00472 , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for ddrug11 may be necessary .",
        "label": "NA"
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of HD00472 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 { 1 } , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 { 1 } , ddrug10 , ddrug11 , grapefruit juice , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21 , ddrug22 , ddrug23 , ddrug24 { 1 } , DB00661 , ddrug26 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , DB01076 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , DB00220 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "initial doses of HD00852 , such as ddrug1 or DB00668 , should be reduced and titrated to achieve the desired response .",
        "label": "NA"
    },
    {
        "text": "oral DB00994 may enhance the effect of DB04665 in ddrug2 by decreasing vitamin k availability .",
        "label": "effect"
    },
    {
        "text": "although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic ddrug0 , including ddrug1 , ddrug2 , and HD00270 , the effect of DB00523 gel on the steady-state concentrations of these drugs is not known .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , DB00390 , ddrug2 , and ddrug3 the in vitro binding of ddrug4 to plasma proteins is only slightly reduced by DB00465 { # % control vs # % } when ddrug6 plasma concentrations reach # to10 m g/ml .",
        "label": "NA"
    },
    {
        "text": "in well-controlled patients undergoing concurrent therapy with DB00501 , a decrease in the steady-state serum concentrations of HD00043 may occur when cime-tidine therapy is discontinued .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 should be used with care when ddrug1 or inhibitors of av conduction , such as certain HD00085 { particularly of the ddrug3 -lsb- ddrug4 -rsb- and HD00427 -lsb- ddrug6 -rsb- classes } , or ddrug7 , such as ddrug8 , are used concurrently .",
        "label": "NA"
    },
    {
        "text": "agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of ddrug0 are the following : ddrug1 , HD00473 , ddrug3 , ddrug4 , ddrug5 , ddrug6 { 2 } , ddrug7 , ddrug8 , and ddrug9 thus , if a patient has been titrated to a stable dosage on HD00472 , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for ddrug11 may be necessary .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : increased serum DB14507 levels and symptoms of ddrug2 toxicity have been reported in patients receiving concomitant ddrug3 and HD00471 therapy .",
        "label": "NA"
    },
    {
        "text": "although ddrug0 has a lower affinity for ddrug1 than for ddrug2 , DB01609 should not be taken with ddrug4 - containing HD00589 .",
        "label": "NA"
    },
    {
        "text": "drug interactions : the central ddrug0 syndrome can occur when anticholinergic agents such as ddrug1 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain ddrug2 such as DB00454 , the ddrug4 and other ddrug5 , ddrug6 , certain HD00303 such as the ddrug8 salts , and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "therefore , co-administration of DB00476 with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index , including certain ddrug1 { ddrug2 -lsb- ddrug3 -rsb- , such as ddrug4 , ddrug5 , and DB00458 } , ddrug7 and ddrug8 { e , g , , ddrug9 , ddrug10 } , should be approached with caution .",
        "label": "advise"
    },
    {
        "text": "both ddrug0 and ddrug1 have been compared to triple therapy with the ddrug2 DB00224 over # weeks as initial therapy , with similar responses being observed with ddrug4 regimens and superiority observed with DB00625 .",
        "label": "NA"
    },
    {
        "text": "co-administration of DB00204 with DB00661 resulted in increases in ddrug2 peak plasma levels of 42 % , although overall exposure to ddrug3 was not significantly increased .",
        "label": "mechanism"
    },
    {
        "text": "no depressant effect on blood levels in humans was noted when ddrug0 was administered with any of the following drugs : ddrug1 , ddrug2 , ddrug3 , DB00968 , ddrug5 { ddrug6 } , ddrug7 , DB00252 or ddrug9 .",
        "label": "NA"
    },
    {
        "text": "additional reductions in blood pressure may occur when ddrug0 is administered with ddrug1 , HD00366 , or other HD00337 .",
        "label": "NA"
    },
    {
        "text": "since higher doses of ddrug0 { 400 mg daily } may result in higher increases in cmax and auc , a single # mg dose of DB00862 should not be exceeded in a 24-hour period when used in combination with DB01026 # mg daily .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : potentiation of DB00682 - type { ddrug2 and ddrug3 substrate } HD00025 response is almost always seen in patients receiving ddrug5 and can result in serious or fatal bleeding .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in some patients , the administration of a HD00292 can reduce the diuretic , natriuretic , and antihypertensive effects of HD00105 , ddrug3 and ddrug4 .",
        "label": "effect"
    },
    {
        "text": "DB00321 in combination with DB00575 enhances the manifestation of corneal lesions in rats epidural injection ddrug2 may potentiate the cns-depressive effect of ddrug3 , ddrug4 or other ddrug5 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : immediate release capsules : since there have been isolated reports of patients with elevated ddrug1 levels , and there is a possible interaction between ddrug2 and DB01115 , it is recommended that DB00390 levels be monitored when initiating , adjusting , and discontinuing ddrug5 to avoid possible over - or under-digitalization .",
        "label": "NA"
    },
    {
        "text": "in a 12-week endoscopy study conducted in oa patients there was no difference in the cumulative incidence of endoscopic gastroduodenal ulcers in patients taking low-dose { 81 mg } enteric coated ddrug0 plus HD00897 # mg daily , as compared to those taking DB01050 # mg daily alone .",
        "label": "NA"
    },
    {
        "text": "the aim of this paper was to study the interaction between ddrug0 and both HD00164 or its synthetic analogue ddrug2 , or HD00166 , on the antinonciceptive effect of these peptides in mice after intracisternal injection .",
        "label": "NA"
    },
    {
        "text": "the plasma concentration of DB00458 may increase when the drug is given concomitantly with hepatic enzyme inhibitors { e , g , , ddrug1 , DB00472 } and decrease by concomitant administration of hepatic enzyme inducers { e , g , , ddrug3 , ddrug4 } , and adjustment of the dosage of ddrug5 may therefore be necessary .",
        "label": "mechanism"
    },
    {
        "text": "hypotension : patients on diuretic therapy : patients on HD00218 and especially those in whom diuretic therapy was recently instituted , may occasionally experience an excessive reduction of blood pressure after initiation of therapy with DB00584 or ddrug2 .",
        "label": "effect"
    },
    {
        "text": "however , ddrug0 has the potential to increase the hypotensive effect of HD00337 and HD00366 .",
        "label": "NA"
    },
    {
        "text": "DB00903 may increase the ototoxic potential of other drugs such as HD00494 and some ddrug2 .",
        "label": "effect"
    },
    {
        "text": "pediatric use the safety and effectiveness of DB00008 , alone or in combination with DB00811 in patients below the age of # years have not been established .",
        "label": "NA"
    },
    {
        "text": "because there is a theoretical basis that these effects may be additive , use of DB00201 - containing or HD00274 { like ddrug2 or ddrug3 } and ddrug4 within # hours of each other should be avoided .",
        "label": "NA"
    },
    {
        "text": "interactions for ddrug0 { ddrug1 , ddrug2 , DB00136 , and ddrug4 } : DB01432 : ddrug6 has been reported to reduce intestinal absorption of ddrug7 ;",
        "label": "NA"
    },
    {
        "text": "DB00714 - prior ingestion of ddrug1 may decrease the HD00627 response to ddrug3 in the treatment of poisoning .",
        "label": "NA"
    },
    {
        "text": "potential drug interactions between DB01202 and other ddrug1 { ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB00252 , ddrug7 and ddrug8 } were also assessed by evaluating the serum concentrations of ddrug9 and these ddrug10 during placebo-controlled clinical studies .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 s plasma half-life may be prolonged by DB00437 , since ddrug3 and DB00672 may compete for excretion in the renal tubule .",
        "label": "NA"
    },
    {
        "text": "drug-drug interactions ddrug0 - DB00289 should be administered with caution to patients being treated with systemically-administered { oral or intravenous } DB01001 { or other ddrug3 } because the action of ddrug4 on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure .",
        "label": "advise"
    },
    {
        "text": "patients taking DB00280 and DB00199 concomitantly may develop increased serum concentrations of ddrug2 resulting in excessive widening of the qrs complex and/or prolongation of the q-t interval .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , DB00636 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { DB00295 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : combination HD00432 may decrease the clearance of some ddrug2 { ddrug3 , ddrug4 , DB00829 } and increase the clearance of others { ddrug6 , ddrug7 , ddrug8 } .",
        "label": "mechanism"
    },
    {
        "text": "the effects of HD00052 { ddrug1 } on ddrug2 { HD00053 } - induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura_2 microfluorometry .",
        "label": "NA"
    },
    {
        "text": "medications can interfere with folate utilization , including : HD00740 { such as ddrug1 , and ddrug2 } ddrug3 { sometimes prescribed to control blood sugar in type # diabetes } ddrug4 { used to control inflammation associated with crohn_disease and ulcerative colitis } ddrug5 { a ddrug6 } ddrug7 there has been concern about the interaction between DB00115 and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "- ddrug0 : pretreatment with DB01032 reduces both the natriuresis and hyperreninemia produced by DB00887 .",
        "label": "effect"
    },
    {
        "text": "no significant drug interactions have been reported in studies of DB00796 given with other drugs such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , DB00999 , and oral ddrug6 in healthy volunteers , or given with ddrug7 to patients with heart failure { nyha class ii and iii } .",
        "label": "NA"
    },
    {
        "text": "a possible interaction between ddrug0 and DB00537 , a HD00754 , has been reported , resulting in a potentiation of the hypoglycemic action of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : HD00403 s { ddrug1 } other ddrug2 ddrug3 ddrug4 DB00564 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of HD00539 such as ddrug1 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 } , ddrug11 salts , ddrug12 , local ddrug13 , ddrug14 , and DB00908 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : concomitant administration of DB06723 s and ddrug2 s does not interfere with absorption of DB00939 .",
        "label": "NA"
    },
    {
        "text": "monitoring of liver enzymes is recommended when DB00625 is used in combination with DB00503 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { DB00091 , ddrug23 } , hiv drugs classified as ddrug24 { DB00701 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect : ddrug0 , ddrug1 , DB01406 , ddrug3 , ddrug4 { e , g , , ddrug5 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 { e , g , , in oral HD00283 } .",
        "label": "NA"
    },
    {
        "text": "HD00461 { cns } drugs including ddrug1 , ddrug2 , ddrug3 , ddrug4 , blood pressure medications { ddrug5 , ddrug6 , ddrug7 } , motion sickness medications , ddrug8 , ddrug9 , ddrug10 , sleeping pills and HD00262",
        "label": "NA"
    },
    {
        "text": "HD00477 may decrease thyroidal uptake of HD00478 , a rebound in uptake may occur up to # days after sudden withdrawal of ddrug2 .",
        "label": "effect"
    },
    {
        "text": "oral ddrug0 : DB01244 has been safely used in diabetic patients without significantly lowering their blood glucose levels or altering their need for ddrug2 or oral HD00062 .",
        "label": "NA"
    },
    {
        "text": "other concomitant therapy : although specific interaction studies were not performed , in clinical studies , HD00503 was used concomitantly with ddrug1 , ddrug2 , ddrug3 , HD00218 , and ddrug5 { ddrug6 } without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "therefore , co-administration of ddrug0 with drugs that are metabolized by cyp2d6 isoenzyme including certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } , HD00031 { e , g , , ddrug9 , ddrug10 , ddrug11 } , HD00254 { e , g , , ddrug13 } , and ddrug14 { e , g , , ddrug15 , ddrug16 } , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .",
        "label": "NA"
    },
    {
        "text": "HD00254 not only block the therapeutic effects of HD00358 , but may produce severe bronchospasm in copd patients .",
        "label": "effect"
    },
    {
        "text": "in bioavailability studies with normal subjects , the concurrent administration of HD00374 at therapeutic levels did not significantly influence the bioavailability of HD00563 tablets .",
        "label": "NA"
    },
    {
        "text": "although DB01609 has a lower affinity for DB01370 than for ddrug2 , ddrug3 should not be taken with ddrug4 - containing ddrug5 .",
        "label": "NA"
    },
    {
        "text": "therefore , DB01026 should be administered with caution with intranasal DB01410 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : concurrent administration of # mg or # mg DB01012 with # mg ddrug2 increased ddrug3 exposure and DB00540 { active metabolite } exposure by approximately 20 % in cyp2d6 extensive metabolizers .",
        "label": "NA"
    },
    {
        "text": "DB00681 or HD00621 { ddrug2 and related drugs , ddrug3 and ddrug4 } enhanced hypokalemia .",
        "label": "NA"
    },
    {
        "text": "- a sulfa-based drug such as DB01015 - ddrug1 { ddrug2 , ddrug3 } , ddrug4 { ddrug5 } , or ddrug6 { DB00795 } ;",
        "label": "NA"
    },
    {
        "text": "there is one report suggesting that the concomitant use of ddrug0 { DB00656 } and DB00490 may have caused 3 - to 6-fold elevations on sgpt { alt } in a few patients .",
        "label": "effect"
    },
    {
        "text": "the following agents may increase certain actions or side effects of ddrug0 , ddrug1 HD00428 of class { e , g , ddrug3 } , ddrug4 ddrug5 { e , g , ddrug6 } , HD00100 .",
        "label": "NA"
    },
    {
        "text": "the principal drugs given { number of patients in parentheses } were : ddrug0 { 115 } , HD00024 and ddrug2 { 103 } , HD00778 { 52 } , oral ddrug4 { 45 } , cough and cold preparations { 45 } , ddrug5 { 38 } , ddrug6 { 29 } , ddrug7 { 24 } , oral ddrug8 { 18 } , ddrug9 { 13 } , ddrug10 { 10 } , and ddrug11 { 10 } .",
        "label": "NA"
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma DB00252 concentrations include : acute ddrug1 intake , ddrug2 , chboramphenicol , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , HD00745 , ddrug19 , ddrug20 , ddrug21",
        "label": "mechanism"
    },
    {
        "text": "HD00377 may also have an additive effect when given with DB00335 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , DB00949 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { DB01045 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "in vitro binding studies with human serum proteins indicate that DB01067 binds differently than ddrug1 and does not interact with HD00372 or ddrug3 .",
        "label": "NA"
    },
    {
        "text": "use of HD00287 ddrug1 and ddrug2 have been administered concomitantly with and following infusions of DB00009 in the management of acute myocardial infarction or pulmonary embolism .",
        "label": "NA"
    },
    {
        "text": "interactions with other cns agents : concurrent use of DB00854 with all HD00389 { eg , ddrug2 , ddrug3 , ddrug4 , other ddrug5 , general ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 and ddrug12 } may result in additive central nervous system depressant effects .",
        "label": "effect"
    },
    {
        "text": "therefore , co-administration of HD00043 with other drugs that are metabolized by this isoenzyme , including other ddrug1 , ddrug2 , DB00564 , and ddrug4 { eg , ddrug5 , ddrug6 , and ddrug7 } , or that inhibit this enzyme { eg , ddrug8 } , should be approached with caution .",
        "label": "advise"
    },
    {
        "text": "although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 { eg , HD00377 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , and ddrug15 } may have elevated plasma concentrations when coadministered with DB01232 ;",
        "label": "mechanism"
    },
    {
        "text": "drug interactions with HD00374 administration of # mg of ddrug1 { 2 x # mg capsule } within # minutes of an ddrug2 and ddrug3 containing ddrug4 { ddrug5 } decreased DB00950 auc by 41 % and cmax by 43 % .",
        "label": "NA"
    },
    {
        "text": "HD00223 { e , g , , ddrug1 } and ddrug2 containing carbohydrate-splitting enzymes { e , g , , HD00225 , ddrug4 } may reduce the effect of ddrug5 and should not be taken concomitantly .",
        "label": "NA"
    },
    {
        "text": "no information is available about the use of DB00611 concurrently with HD00343 .",
        "label": "NA"
    },
    {
        "text": "DB00316 had no effect on plasma levels of DB00861 .",
        "label": "NA"
    },
    {
        "text": "such individuals are referred to as poor metabolizers of drugs such as ddrug0 , DB00514 , the ddrug2 , and DB00363 .",
        "label": "NA"
    },
    {
        "text": "because of ddrug0 s tendency to cause renal impairment , the use of DB00529 should be avoided in combination with potentially nephrotoxic drugs such as HD00249 , ddrug3 and intravenous ddrug4 unless the potential benefits outweigh the risks to the patient .",
        "label": "advise"
    },
    {
        "text": "drugs that should not be coadministered with DB00220 ddrug1 : ddrug2 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 ddrug11 , ddrug12 gi motility agents : DB00604",
        "label": "advise"
    },
    {
        "text": "DB00862 { 20 mg } did not potentiate the hypotensive effects of ddrug1 during the 4-hour observation period in healthy volunteers when administered with DB02325 { # g/kg body weight } .",
        "label": "NA"
    },
    {
        "text": "DB00714 - prior ingestion of DB01231 may decrease the ddrug2 response to ddrug3 in the treatment of poisoning .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { DB01076 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { DB00701 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "DB00294 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , HD00668 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "int"
    },
    {
        "text": "DB00207 had no significant impact on the cmax and auc of ddrug1 , although it significantly decreased the ddrug2 tmax by 44 % and increased the intracellular exposure to phosphorylated DB00495 by 110 % .",
        "label": "mechanism"
    },
    {
        "text": "DB00295 prolonged gastrointestinal transit time from # to # minutes { p = # } ; this was prevented by HD00090 { p = # } .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , DB00091 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , DB01601 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration of DB00503 with DB00220 resulted in a 152 % increase in ddrug3 plasma auc and very little change in ddrug4 plasma a , c.",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 and foods fortified with ddrug1 concomitant administration of DB00535 with a therapeutic ddrug3 containing # mg of elemental ddrug4 { as feso4 } or HD00489 supplemented with # mg of elemental ddrug6 reduced extent of absorption by 80 % and 31 % , respectively .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a study of # healthy male volunteers , DB00459 treatment potentiated the blood glucose lowering effect of ddrug2 { a ddrug3 similar to DB00672 } in # of the # subjects .",
        "label": "NA"
    },
    {
        "text": "DB00645 : combination HD00432 may increase the clearance of ddrug2 .",
        "label": "NA"
    },
    {
        "text": "in this study we investigated the effect of ddrug0 on high threshold voltage-dependent ca { 2 + } channel subtypes using their HD00046 DB00393 { l-type } , ddrug3 { n-type } , or ddrug4 { p-type } in bovine chromaffin cells .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : a report of severe DB00316 toxicity was reported in a patient receiving DB00951 .",
        "label": "effect"
    },
    {
        "text": "the extent to which ddrug0 - HD00312 interactions may pose clinical problems will depend on the degree of inhibition , and the pharmacokinetics of the HD00278 involved .",
        "label": "NA"
    },
    {
        "text": "DB00501 } and many that are substrates for cyp2b6 2d6 { many other ddrug1 , ddrug2 , and the HD00310 ddrug4 and ddrug5 } .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { DB00682 } other ddrug2 ddrug3 ddrug4 ddrug5 { DB00564 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "other binding proteins may be elevated in serum , { i , e , , corticosteroid binding globulin { cbg } , sex hormone binding globulin { shbg } } leading to increased total circulating HD00175 and HD00578 , respectively .",
        "label": "NA"
    },
    {
        "text": "plasma ddrug0 concentrations may need to be monitored and the dose of the HD00312 may need to be reduced if a ddrug2 is co-administered with DB00476 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as HD00269 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and DB00126 .",
        "label": "NA"
    },
    {
        "text": "therefore , co-administration of ddrug0 with drugs that are metabolized by cyp2d6 isoenzyme including certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } , ddrug8 { e , g , , DB00502 , ddrug10 , ddrug11 } , ddrug12 { e , g , , DB00264 } , and ddrug14 { e , g , , ddrug15 , ddrug16 } , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .",
        "label": "NA"
    },
    {
        "text": "interaction of DB00906 with other drugs : ddrug1 : co-administration of DB00501 { 800 mg/day } to patients taking ddrug3 chronically had no effect on ddrug4 pharmacokinetics .",
        "label": "NA"
    },
    {
        "text": "if the usual amounts of nondepolarizing relaxants are given , the time for recovery from neuromuscular blockade will be longer in the presence of ddrug0 than when DB01159 or DB06690 with a balanced technique are used .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 : ddrug2 , when given as a regimen of 125 mg with DB01234 coadministered orally as # mg on day 1 , and DB00673 when given as # mg/day with ddrug5 coadministered orally as # mg on days # through 5 , increased the auc of ddrug6 , a cyp3a4 substrate by # - fold , on days # and 5 .",
        "label": "NA"
    },
    {
        "text": "the gradual withdrawal of HD00776 or a HD00777 could be substituted .",
        "label": "NA"
    },
    {
        "text": "in patients taking an ddrug0 { eg , ddrug1 , ddrug2 , ddrug3 or ddrug4 } , the concomitant use of DB00358 may reduce seizure control by lowering the plasma levels of the HD00329 .",
        "label": "NA"
    },
    {
        "text": "DB00727 : ddrug1 { DB00270 } has been safely coadministered with ddrug3 .",
        "label": "NA"
    },
    {
        "text": "the effects of DB00696 may be potentiated by DB13179 which inhibits the metabolism of ddrug2 .",
        "label": "mechanism"
    },
    {
        "text": "the antimicrobial effect of a HD00051 , HD00050 , either alone or in combination with ddrug2 , was evaluated in vitro against two type strains and six clinical isolates of mycobacterium ulcerans .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , DB00812 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { HD00531 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "DB00455 { 10 mg once daily } has been coadministered with therapeutic doses of DB00199 , ddrug2 , and ddrug3 in controlled clinical pharmacology studies in adult volunteers .",
        "label": "NA"
    },
    {
        "text": "medications can interfere with folate utilization , including : ddrug0 { such as DB00252 , and ddrug2 } ddrug3 { sometimes prescribed to control blood sugar in type # diabetes } ddrug4 { used to control inflammation associated with crohn_disease and ulcerative colitis } DB00384 { a ddrug6 } ddrug7 there has been concern about the interaction between ddrug8 and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "these drugs include the ddrug0 and other ddrug1 , HD00175 , ddrug3 , ddrug4 , HD00220 , oral ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , and ddrug11 .",
        "label": "NA"
    },
    {
        "text": "drug interactions : the central ddrug0 syndrome can occur when anticholinergic agents such as ddrug1 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain ddrug2 such as ddrug3 , the HD00219 and other HD00031 , ddrug6 , certain ddrug7 such as the ddrug8 salts , and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "the iv ddrug0 dose should be reduced by approximately 25 % , and the oral DB00959 dose should be reduced by approximately 50 % when coadministered with DB00673 to achieve exposures of ddrug3 similar to those obtained when it is given without ddrug4 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 : concomitant treatment with ddrug3 , ddrug4 , or HD00218 may potentiate a possible hypokalemic effect of HD00742",
        "label": "effect"
    },
    {
        "text": "DB00501 } and many that are substrates for cyp2b6 2d6 { many other ddrug1 , ddrug2 , and the ddrug3 DB01182 and ddrug5 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : since ddrug1 is a ddrug2 , it is possible that HD00339 , such as the ddrug4 { ddrug5 , ddrug6 , ddrug7 } or ddrug8 , may diminish the effectiveness of DB00714 .",
        "label": "NA"
    },
    {
        "text": "DB01004 : administration of ddrug1 # hours prior to or concurrent with oral ddrug2 was associated with a # { 114 } % increase in the steady-state auc of DB00900 { n = 12 } .",
        "label": "NA"
    },
    {
        "text": "differential actions of intrathecal ddrug0 on blocking the tail-flick inhibition induced by intraventricular HD00144 and DB00295 in rats .",
        "label": "NA"
    },
    {
        "text": "other drugs drug interactions have been reported with concomitant administration of DB00199 and other medications , including ddrug1 , ddrug2 , DB00564 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 .",
        "label": "int"
    },
    {
        "text": "injection : DB00186 injection , like other injectable ddrug1 , produces depression of the central nervous system when administered with ddrug2 , ddrug3 , ddrug4 , ddrug5 , and other ddrug6 , when DB00747 is used concomitantly with injectable ddrug8 , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .",
        "label": "NA"
    },
    {
        "text": "HD00025 therapy should be monitored , particularly during the first few weeks , after initiating therapy with DB00580 in patients receiving ddrug2 or similar agents .",
        "label": "NA"
    },
    {
        "text": "DB00981 pretreatment augmented the depressant effect of DB02325 on the early components p1 and n1 , while attenuating ddrug2 's influence on components p2 and p3 .",
        "label": "effect"
    },
    {
        "text": "medications can interfere with folate utilization , including : ddrug0 { such as ddrug1 , and DB00794 } ddrug3 { sometimes prescribed to control blood sugar in type # diabetes } ddrug4 { used to control inflammation associated with crohn_disease and ulcerative colitis } ddrug5 { a ddrug6 } ddrug7 there has been concern about the interaction between DB00115 and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "increases in plasma levels of ddrug0 , and in the frequency and severity of side effects , particularly HD00315 , have been reported when DB00501 was added to the ddrug3 regimen .",
        "label": "NA"
    },
    {
        "text": "the majority of patients in ra clinical studies received one or more of the following concomitant medications with DB01281 : ddrug1 , ddrug2 , HD00175 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , and ddrug11 .",
        "label": "NA"
    },
    {
        "text": "use lowest possible dose of DB01076 with careful monitoring , or consider ddrug1 that are not primarily metabolized by cyp3a4 , such as ddrug2 , DB01095 , or ddrug4 in combination with ddrug5 .",
        "label": "NA"
    },
    {
        "text": "coadministration of ddrug0 and ddrug1 1/35 increased the exposure of DB00717 and DB00977 by 20 % and 34 % , respectively .",
        "label": "NA"
    },
    {
        "text": "clinical trials have indicated that DB00003 can be effectively and safely used in conjunction with standard cystic_fibrosis therapies including oral , inhaled and/or parenteral ddrug1 , ddrug2 , enzyme supplements , ddrug3 , oral or inhaled ddrug4 , and HD00651 .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : HD00403 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { DB01167 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "- a HD00535 { ddrug1 } such as ddrug2 { ddrug3 , ddrug4 , ddrug5 , others } , ddrug6 { ddrug7 , ddrug8 , ddrug9 } , ddrug10 { ddrug11 , ddrug12 } , ddrug13 { ddrug14 } , ddrug15 { ddrug16 } , ddrug17 { DB00461 } , ddrug19 { ddrug20 } , and ddrug21 { ddrug22 , ddrug23 , ddrug24 } ;",
        "label": "NA"
    },
    {
        "text": "no depressant effect on blood levels in humans was noted when ddrug0 was administered with any of the following drugs : ddrug1 , ddrug2 , DB00636 , ddrug4 , ddrug5 { ddrug6 } , ddrug7 , ddrug8 or DB00682 .",
        "label": "NA"
    },
    {
        "text": "in a study in diabetics with microalbuminuria DB00700 # mg combined with the ddrug1 DB00584 # mg increased the frequency of hyperkalemia { serum potassium # meq/l } from 17 % on ddrug3 alone to 38 % .",
        "label": "effect"
    },
    {
        "text": "the pressor effects of DB00696 and other HD00690 can combine to cause dangerous hypertension .",
        "label": "effect"
    },
    {
        "text": "pharmacokinetic studies indicate that administration of ddrug0 or DB00829 does not affect the pharmacokinetics of DB00659 .",
        "label": "NA"
    },
    {
        "text": "to avoid this interaction , DB00705 or DB00224 should be given # hour prior to dosing with ddrug2 .",
        "label": "NA"
    },
    {
        "text": "like ddrug0 { 40 mg/kg } , ddrug1 { 40 mg/kg } decreases the intravenous self-administration of ddrug2 and ddrug3 and the oral self-administration of DB00898 and DB00184 in rats ;",
        "label": "NA"
    },
    {
        "text": "the effects of ddrug0 are antagonized by HD00246 such as DB00201 and ddrug3 .",
        "label": "NA"
    },
    {
        "text": "the ec50 values for DB01064 , which is not a substrate for DB00368 uptake-1 , were reduced in myocardium in functional classes ii to iii and iv compared with those in nonfailing myocardium .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB01032 is known to interact with the metabolism or renal tubular excretion of many drugs { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , DB00695 , ddrug13 agents , ddrug14 , and ddrug15 } .",
        "label": "mechanism"
    },
    {
        "text": "in the case that you are taking DB00390 while taking DB00233 , higher doses of ddrug2 may be needed .",
        "label": "advise"
    },
    {
        "text": "ddrug0 } , ddrug1 { e , g , ddrug2 } , and ddrug3 { e , g , ddrug4 , ddrug5 and ddrug6 } should have their dose of DB00921 or DB01183 adjusted .",
        "label": "NA"
    },
    {
        "text": "drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on ddrug0 therapy : ddrug1 , ddrug2 , ddrug3 , oral ddrug4 containing HD00220 , DB11119 - containing preparations and the numerous preparations containing ddrug7 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { cns } drugs including ddrug1 , ddrug2 , ddrug3 , ddrug4 , blood pressure medications { ddrug5 , DB00968 , ddrug7 } , motion sickness medications , ddrug8 , ddrug9 , HD00024 , sleeping pills and ddrug11",
        "label": "NA"
    },
    {
        "text": "other cardiovascular agents : ddrug0 and DB00584 iv have been used concomitantly with ddrug2 , DB00968 , ddrug4 , ddrug5 , ddrug6 , ddrug7 and ddrug8 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { e , g , , DB09278 } and HD00224 containing carbohydrate-splitting enzymes { e , g , , ddrug3 , ddrug4 } may reduce the effect of ddrug5 and should not be taken concomitantly .",
        "label": "NA"
    },
    {
        "text": "unmodified ddrug0 { 1 % m/v } significantly improved the transport ratio { r = p { app } polymer / p { app } control } of HD00070 to # and 1 % { m/v } HD00072 conjugated with ddrug3 further enhanced the permeation .",
        "label": "NA"
    },
    {
        "text": "patients taking these drugs with DB00190 and ddrug1 or ddrug2 - DB01235 combination products should be carefully observed for loss of therapeutic response .",
        "label": "NA"
    },
    {
        "text": "DB00999 { ddrug1 } alone or in combination with DB00384 : concomitant use of ddrug3 alone or in combination with ddrug4 is contraindicated .",
        "label": "NA"
    },
    {
        "text": "DB14507 - a drug interaction study of DB00700 with ddrug2 has not been conducted .",
        "label": "NA"
    },
    {
        "text": "when DB00520 is co-administered with inducers of drug clearance , such as ddrug1 , ddrug2 , DB00252 , ddrug4 , or ddrug5 , use of a daily dose of # mg of ddrug6 should be considered",
        "label": "advise"
    },
    {
        "text": "DB00908 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and ddrug7 raise the serum DB00390 concentration due to a reduction in clearance and/or in volume of distribution of the drug , with the implication that ddrug9 intoxication may result .",
        "label": "mechanism"
    },
    {
        "text": "drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving ddrug0 metabolized similarly to ddrug1 or on the basis of in vitro studies with DB00404 or other HD00100 { caution is recommended during coadministration with ddrug4 } : available data from clinical studies of ddrug5 other than ddrug6 suggest a possible drug interaction with ddrug7 for the following : ddrug8 , ddrug9 , ddrug10 such as ddrug11 and ddrug12 , and grapefruit juice .",
        "label": "NA"
    },
    {
        "text": "drugs that reduce the number of blood platelets by causing bone marrow depression { such as HD00251 } or drugs which inhibit platelet function { eg , ddrug1 and other ddrug2 , DB00975 , ddrug4 , ddrug5 , ddrug6 } may increase the bleeding tendency produced by ddrug7 without altering prothrombin time determinations .",
        "label": "NA"
    },
    {
        "text": "ddrug0 s : DB00900 should be administered at least # hours after or # hours before dosing with ddrug2 because plasma concentrations of ddrug3 are decreased when administered with ddrug4 containing ddrug5 , DB01373 , or ddrug7 .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 : in one study , ddrug1 was given to adult diabetics who were already receiving ddrug2 { n = 4 } , ddrug3 { n = 2 } DB00672 with ddrug5 { n = 3 } or ddrug6 with DB00914 { n = 6 } .",
        "label": "NA"
    },
    {
        "text": "an immune response to DB00087 may interfere with subsequent diagnostic serum tests that utilize HD00259",
        "label": "NA"
    },
    {
        "text": "co-administration of DB09026 did not significantly affect the pharmacokinetics of ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , DB00335 , ddrug8 , ddrug9 or ddrug10 .",
        "label": "NA"
    },
    {
        "text": "these medications have included ddrug0 , ddrug1 , ddrug2 , HD00208 , ddrug4 , intravenous and oral ddrug5 , DB00208 , and ddrug7 .",
        "label": "NA"
    },
    {
        "text": "use lowest possible dose of DB01076 with careful monitoring , or consider ddrug1 that are not primarily metabolized by cyp3a4 , such as DB00175 , ddrug3 , or ddrug4 in combination with ddrug5 .",
        "label": "NA"
    },
    {
        "text": "the clinical significance of this reduction is not known , hence DB00943 is not recommended to be ingested simultaneously with ddrug1 / DB01370 - containing ddrug3 .",
        "label": "advise"
    },
    {
        "text": "HD00444 antagonize the effects of HD00618 .",
        "label": "NA"
    },
    {
        "text": "we conclude that the prophylactic and antidotal properties of ddrug0 seen in animals treated with ddrug1 derive from its capacity to inhibit the nad + - dependent oxidation responsible for converting HD00079 to HD00077 in the committed step of the toxic pathway .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , DB00220 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , DB00231 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ventricular tachycardia induced by DB01092 was generally converted to sinus rhythm following administration of ddrug1 , ddrug2 , or ddrug3 but not after administration of HD00120 alone or after ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with DB00316 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , ddrug8 { HD00398 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : potentiation of ddrug1 - type { HD00097 and ddrug3 substrate } HD00025 response is almost always seen in patients receiving ddrug5 and can result in serious or fatal bleeding .",
        "label": "NA"
    },
    {
        "text": "the purpose of this study was to evaluate the effect of ddrug0 { ddrug1 } and ddrug2 { HD00068 } conjugates on the intestinal permeation of ddrug4 { ddrug5 } and model peptide drugs , DB00781 and ddrug7 .",
        "label": "NA"
    },
    {
        "text": "these results suggest that both ddrug0 and HD00147 , and possibly other ddrug2 and ddrug3 , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of HD00071 and ddrug5 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , DB01167 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , DB00812 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and DB01211 { and possibly other ddrug2 } and ddrug3 may increase DB00390 absorption in patients who inactivate ddrug5 by bacterial metabolism in the lower intestine , so that ddrug6 intoxication may result .",
        "label": "mechanism"
    },
    {
        "text": "in a patient with a nonfunctioning thyroid gland who is receiving thyroid replacement therapy , free DB00451 may be decreased when ddrug1 are started thus increasing DB00451 requirements .",
        "label": "NA"
    },
    {
        "text": "patients taking ddrug0 and DB00199 concomitantly may develop increased serum concentrations of DB00280 resulting in excessive widening of the qrs complex and/or prolongation of the q-t interval .",
        "label": "NA"
    },
    {
        "text": "additive depressant effect when used with general ddrug0 , ddrug1 , ddrug2 , HD00214 , ddrug4 , and other HD00611 .",
        "label": "NA"
    },
    {
        "text": "DB00788 had no effect on plasma levels of DB00861 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , DB01167 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { DB00295 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "serious anticholinergic symptoms { severe dry mouth , urinary retention , blurred vision } have been associated with elevations in the serum levels of HD00043 when DB00501 is added to the drug regimen .",
        "label": "effect"
    },
    {
        "text": "DB00503 { 600 mg b , i , d , } co-administered with ddrug1 # mg resulted in a 49-fold increase in ddrug2 auc and a 13-fold increase in DB00862 cmax .",
        "label": "NA"
    },
    {
        "text": "strong inducers of cytochrome p450 enzymes { i , e , ddrug0 , DB00252 and ddrug2 } have been shown to decrease the plasma levels of HD00888 { 29 - 40 % } .",
        "label": "NA"
    },
    {
        "text": "recovery of hoof twitch from 50 % to 75 % took # + / - # min for DB13295 alone and # + / - # min for ddrug1 plus HD00198 { p = # } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may enhance the effects of DB02325 , ddrug2 , and other HD00261 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { cns } drugs including ddrug1 , ddrug2 , ddrug3 , HD00031 , blood pressure medications { ddrug5 , ddrug6 , ddrug7 } , motion sickness medications , ddrug8 , ddrug9 , HD00024 , sleeping pills and ddrug11",
        "label": "NA"
    },
    {
        "text": "patients using cyp3a4 metabolized ddrug0 should have cholesterol levels monitored after DB00559 is initiated to see whether the HD00435 dose needs adjustment .",
        "label": "NA"
    },
    {
        "text": "injection : ddrug0 injection , like other injectable HD00100 , produces depression of the central nervous system when administered with ddrug2 , ddrug3 , ddrug4 , ddrug5 , and other HD00216 , when ddrug7 is used concomitantly with injectable ddrug8 , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .",
        "label": "effect"
    },
    {
        "text": "tablets : the ddrug0 , including ddrug1 , produce cns-depressant effects when administered with such medications as HD00026 or DB02325 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the rate and extent of absorption of DB00537 was bioequivalent when DB00537 was given alone or when ddrug3 was given # hours after ddrug4 at the dose that maximally suppresses gastric acid secretion .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , or other products containing ddrug1 or ddrug2 , ddrug3 or DB00364 should not be administered concomitantly with , or within # hours of , the administration of DB01059 , because they may interfere with absorption resulting in lower serum and urine levels of ddrug6 .",
        "label": "advise"
    },
    {
        "text": "treatment with HD00061 can directly interfere with blood glucose levels or may interact with HD00062 .",
        "label": "int"
    },
    {
        "text": "DB00625 has the potential to decrease plasma concentrations of ddrug1 and DB01026 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 has been reported to significantly alter the metabolism of nonsedating ddrug1 DB00342 and DB00637 when taken concomitantly .",
        "label": "NA"
    },
    {
        "text": "the blood pressure effect of ddrug0 tended to be greater in patients on DB00335 than in patients on no other HD00876 therapy .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , DB00295 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and DB00126 .",
        "label": "NA"
    },
    {
        "text": "HD00056 regimens consisted of two HD00057 and one ddrug2 .",
        "label": "NA"
    },
    {
        "text": "patients taking DB00704 may not benefit from ddrug1 containing medicines , such as cough and cold preparations , antidiarrheal preparations , and HD00726 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , DB01076 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and DB00126 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : seizures have been reported in patients taking DB00467 concomitantly with the HD00535 ddrug3 .",
        "label": "NA"
    },
    {
        "text": "if a patient requires DB00204 and ddrug1 therapy , it is suggested that ddrug2 , ddrug3 , or ddrug4 { ddrug5 and ddrug6 } be used as alternatives to DB00501 , as these agents have no effect on the pharmacokinetic profile of ddrug8 .",
        "label": "advise"
    },
    {
        "text": "in patients receiving ddrug0 { ddrug1 } or DB00993 { ddrug3 } , the concomitant administration of 300 - 600 mg of ddrug4 per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of DB01033 or ddrug6 .",
        "label": "NA"
    },
    {
        "text": "DB00908 : coadministration of a 10-mg single dose of ddrug1 with ddrug2 { 166 mg/day for # days } , a potent inhibitor of cyp2d6 , increased the auc of ddrug3 by 112 % but decreased the auc of its active metabolite , HD00367 , by 35 % .",
        "label": "NA"
    },
    {
        "text": "DB00199 has been reported to decrease the clearance of ddrug1 and ddrug2 and thus may increase the pharmacologic effect of these HD00100 .",
        "label": "effect"
    },
    {
        "text": "the purpose of this study was to evaluate the effect of HD00066 { ddrug1 } and ddrug2 { ddrug3 } conjugates on the intestinal permeation of ddrug4 { ddrug5 } and model peptide drugs , ddrug6 and HD00071 .",
        "label": "NA"
    },
    {
        "text": "HD00175 may also potentiate the replication of some organisms contained in HD00601 .",
        "label": "effect"
    },
    {
        "text": "the hypoglycemic action of HD00226 may be potentiated by certain drugs including HD00518 and other drugs that are highly protein bound , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , and ddrug8 .",
        "label": "effect"
    },
    {
        "text": "the extent of plasma protein binding of DB01117 in human plasma is not affected by the presence of therapeutic concentrations of ddrug1 { 15 mcg / ml } , nor is the binding of DB00252 affected by the presence of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "studies have shown that DB00448 does not have clinically significant interactions with other drugs metabolized by the cytochrome cyp2b6 system , such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB00571 , ddrug7 , ddrug8 , ddrug9 , or ddrug10 in healthy subjects .",
        "label": "NA"
    },
    {
        "text": "DB00338 should be taken as directed and DB00537 should be taken with a main meal of the day , preferably the evening meal , .",
        "label": "NA"
    },
    {
        "text": "drugs that cause significant sustained elevation in gastric ph { HD00536 such as ddrug1 or ddrug2 } may reduce plasma concentrations of DB00317 and therefore potentially may reduce efficacy .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 - there have been rare postmarketing reports describing patients with weakness , hyperreflexia , and incoordination following the use of a HD00692 { ddrug2 } and DB00669 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 HD00610 , as well as a metabolite of ddrug2 , slow DB00182 metabolism .",
        "label": "mechanism"
    },
    {
        "text": "administration of DB00668 to patients receiving ddrug1 or ddrug2 such as DB01159 which sensitize the myocardium , may induce cardiac arrhythmia , .",
        "label": "effect"
    },
    {
        "text": "since DB00328 and ddrug1 , including DB00594 , may each be associated with increased serum potassium levels , the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently .",
        "label": "effect"
    },
    {
        "text": "ddrug0 and ddrug1 : ddrug2 and ddrug3 containing ddrug4 or ddrug5 , as well as formulations containing divalent and trivalent cations such as DB00900 { ddrug7 } , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with DB00978 and interfere with its bioavailability .",
        "label": "mechanism"
    },
    {
        "text": "these results suggest that both ddrug0 and ddrug1 , and possibly other ddrug2 and HD00150 , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of HD00071 and ddrug5 .",
        "label": "effect"
    },
    {
        "text": "although no interaction between ddrug0 and DB00854 has been observed , it is not recommended for use with HD00343 .",
        "label": "advise"
    },
    {
        "text": "two studies were conducted in hiv-infected subjects to assess the potential for DB00207 to interact with DB00495 and ddrug2 .",
        "label": "NA"
    },
    {
        "text": "plasma exposure of DB00829 { 10 mg bid } was increased by 28 % following administration of DB00580 { 40 mg bid } for # days , while plasma exposure of ddrug2 { 40 mg bid } was not substantially increased following administration of ddrug3 { 10 mg bid } for # days .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : drugs such as DB00945 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 and others that interfere with platelet-aggregation reactions { the main hemostatic defense of heparinized patients } may induce bleeding and should be used with caution in patients receiving DB01109 .",
        "label": "effect"
    },
    {
        "text": "the plasma concentration of ddrug0 may increase when the drug is given concomitantly with hepatic enzyme inhibitors { e , g , , ddrug1 , DB00472 } and decrease by concomitant administration of hepatic enzyme inducers { e , g , , ddrug3 , ddrug4 } , and adjustment of the dosage of DB00458 may therefore be necessary .",
        "label": "NA"
    },
    {
        "text": "administration of HD00551 has been reported to increase the plasma levels of DB01174 , if given concomitantly .",
        "label": "mechanism"
    },
    {
        "text": "in a comparison of ddrug0 tolerance in dogs anesthetized with DB01221 , ddrug2 , or ddrug3 , the dosage of DB01092 needed to cause ventricular tachycardia was significantly higher , as was the ld50 of ddrug5 , with ddrug6 or ddrug7 than with ddrug8 .",
        "label": "effect"
    },
    {
        "text": "the clinical significance of this reduction is not known , hence ddrug0 is not recommended to be ingested simultaneously with ddrug1 / DB01370 - containing HD00374 .",
        "label": "NA"
    },
    {
        "text": "DB00269 may interact with ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 supplements , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , DB00675 , and ddrug13 .",
        "label": "int"
    },
    {
        "text": "DB00196 , and the ddrug1 DB00904 { ddrug3 } and ddrug4 { ddrug5 } have all been used with ddrug6 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { ddrug1 } : ddrug2 { e , g , , ddrug3 , ddrug4 , DB00715 , ddrug6 } have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with HD00277 .",
        "label": "effect"
    },
    {
        "text": "DB00612 should not be combined with other HD00228 .",
        "label": "advise"
    },
    {
        "text": "co-administration : concomitant use of ddrug0 with HD00363 , HD00364 , and other ddrug3 may increase the risk of bleeding .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of ddrug0 : ddrug1 , ddrug2 , ddrug3 , HD00571 { e , g , , ddrug5 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , DB00052 , ddrug11 , ddrug12 , ddrug13 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : concurrent administration of # mg or # mg ddrug1 with # mg ddrug2 increased DB00321 exposure and DB00540 { active metabolite } exposure by approximately 20 % in cyp2d6 extensive metabolizers .",
        "label": "NA"
    },
    {
        "text": "drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving ddrug0 metabolized similarly to ddrug1 or on the basis of in vitro studies with ddrug2 or other ddrug3 { caution is recommended during coadministration with ddrug4 } : available data from clinical studies of ddrug5 other than DB00404 suggest a possible drug interaction with ddrug7 for the following : ddrug8 , ddrug9 , ddrug10 such as ddrug11 and DB01211 , and grapefruit juice .",
        "label": "NA"
    },
    {
        "text": "in addition , results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance { ddrug0 , ddrug1 , DB00252 , ddrug3 , or ddrug4 } with DB00520 may result in clinically meaningful reductions in ddrug6 concentrations .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : ddrug1 is known to slow the metabolism of ddrug2 and increase its serum levels ddrug3 levels should be determined prior to concurrent administration with DB00951 , signs and symptoms of DB00564 toxicity should be monitored closely , and appropriate dosage adjustment of the ddrug6 should be made .",
        "label": "NA"
    },
    {
        "text": "however , since ddrug0 , HD00203 , and ddrug2 are all associated with gastrointestinal irritation , caution should be exercised in the concomitant use of DB00945 or ddrug4 with ddrug5 .",
        "label": "NA"
    },
    {
        "text": "the harmonic mean elimination half-life was # and # hours for DB00533 + DB00390 and placebo + ddrug2 treatments , respectively .",
        "label": "NA"
    },
    {
        "text": "drug/laboratory test interactions HD00485 , including HD00493 , are known to occasionally induce a positive direct coombs test .",
        "label": "NA"
    },
    {
        "text": "while ddrug0 and ddrug1 have similar affinities for kappa opioid and possibly nicotinic receptors , HD00022 has much lower affinities than HD00021 for n_methyl_d_aspartate and sigma-2 receptors , sodium channels , and the 5-ht transporter .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : as with some other HD00532 , concurrent administration of DB00537 with ddrug3 may lead to elevated serum concentrations of ddrug4 and prolongation of its elimination half-life .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 { ddrug2 , ddrug3 , ddrug4 , DB00126 , fruit juices , etc , } lower absorption of HD00401 .",
        "label": "mechanism"
    },
    {
        "text": "HD00374 or DB00364 substantially interfere with the absorption of some ddrug2 , resulting in low urine levels .",
        "label": "NA"
    },
    {
        "text": "similarly , DB00829 decreased the antinociceptive effect of ddrug1 { only in the tail-flick test } and DB00328 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 should not be used concomitantly with other drugs known to prolong the qt interval : certain HD00303 , including those of class ia { such as ddrug2 and ddrug3 } and class iii { such as DB00489 } ;",
        "label": "NA"
    },
    {
        "text": "in two combined 12-week placebo controlled trials that included ddrug0 doses of # mcg twice daily , # mcg twice daily , and # mcg once daily , # of # DB01274 - treated subjects received concomitant DB00277 at study entry .",
        "label": "NA"
    },
    {
        "text": "at # hours postdose , a similar proportion of patients treated with DB00563 alone { 94 % } and subsequently treated with ddrug1 co-administered with # mg of DB00533 { 88 % } had ddrug3 plasma concentrations below the measurable limit { 5 ng/ml } .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of an DB01370 - containing ddrug1 had no significant effect in the bioavailability of HD00866 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and DB00375 ddrug2 : absorption of DB00999 is impaired in the presence of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "the results indicate that a spinal DB01183 - sensitive endorphinergic system is involved in the production of ddrug1 but not ddrug2 - induced tail-flick inhibition , and suggest that intraventricular ddrug3 and DB00295 elicit their pharmacological actions via the activation of different descending pain inhibitory systems ;",
        "label": "NA"
    },
    {
        "text": "DB00945 : concomitant ddrug1 may decrease the metabolic clearance of DB00627 .",
        "label": "NA"
    },
    {
        "text": "endothelium-intact aortic rings from high - ddrug0 rats were supersensitive to DB00368 when compared to vehicle - , ddrug2 - and DB00396 + high - ddrug4 - treated rats { pd2 values = # + / # , # + / # , # + / # and # + / # , respectively } .",
        "label": "NA"
    },
    {
        "text": "DB00220 steady-state cmax , a , c , and cmin were increased by 12 % , 15 % , and 14 % , respectively , by concomitant DB00701 .",
        "label": "mechanism"
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing DB01370 , ddrug3 , or ddrug4 , with ddrug5 , with metal cations such as ddrug6 , or with ddrug7 containing DB01592 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration { n = 18 } of DB00788 capsules { 250 mg } with ddrug2 { 125 mg } appears to increase the amount of DB00996 absorbed by 12 % to 15 % .",
        "label": "NA"
    },
    {
        "text": "while ddrug0 and HD00021 have similar affinities for kappa opioid and possibly nicotinic receptors , HD00022 has much lower affinities than ddrug3 for n_methyl_d_aspartate and sigma-2 receptors , sodium channels , and the 5-ht transporter .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { HD00548 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , DB00295 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , DB00860 { ddrug38 } , ddrug39 { DB01045 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "erythromycin co-administration of ddrug0 { DB01023 } with DB00199 resulted in approximately # - fold increase in the auc and cmax , and about 2 - fold prolongation in the half - life of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - DB01083 may decrease the absorption of DB01022 .",
        "label": "mechanism"
    },
    {
        "text": "drug interactions with ddrug0 administration of # mg of ddrug1 { 2 x # mg capsule } within # minutes of an DB01370 and DB14513 containing ddrug4 { ddrug5 } decreased ddrug6 auc by 41 % and cmax by 43 % .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 , and HD00249 : drugs such as ddrug3 , DB00529 , and ddrug5 may increase the risk of developing peripheral_neuropathies or other ddrug6 - associated adverse events by interfering with the renal clearance of ddrug7 { thereby raising systemic exposure } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 should be used with care when ddrug1 or inhibitors of av conduction , such as certain HD00085 { particularly of the HD00426 -lsb- ddrug4 -rsb- and ddrug5 -lsb- ddrug6 -rsb- classes } , or ddrug7 , such as ddrug8 , are used concurrently .",
        "label": "NA"
    },
    {
        "text": "DB00321 : concurrent administration of # mg or # mg DB01012 with # mg ddrug2 increased ddrug3 exposure and ddrug4 { active metabolite } exposure by approximately 20 % in cyp2d6 extensive metabolizers .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { HD00203 } - a drug interaction study of DB00700 with an ddrug3 has not been conducted .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00951 is known to slow the metabolism of ddrug2 and increase its serum levels ddrug3 levels should be determined prior to concurrent administration with ddrug4 , signs and symptoms of ddrug5 toxicity should be monitored closely , and appropriate dosage adjustment of the HD00329 should be made .",
        "label": "NA"
    },
    {
        "text": "however , as with other HD00203 , concomitant administration of DB00749 and ddrug2 is not generally recommended because of the potential of increased adverse effects .",
        "label": "NA"
    },
    {
        "text": "if DB01151 is to be combined with other ddrug1 such as ddrug2 or ddrug3 / ddrug4 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of ddrug5 and ddrug6 { e , g , , DB00475 or ddrug8 } are additive .",
        "label": "NA"
    },
    {
        "text": "before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : ddrug0 { e , g , , ddrug1 , ddrug2 } , ddrug3 , DB00091 , ddrug5 drugs { e , g , , ddrug6 } , ddrug7 , DB00512 .",
        "label": "NA"
    },
    {
        "text": "since ddrug0 { ddrug1 } may interact with concurrently administered ddrug2 , periodic serum level determinations of these drugs may be necessary { eg , ddrug3 may elevate DB00252 serum levels and DB00313 has been reported to both increase and decrease ddrug6 levels } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : DB00316 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { HD00531 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of ddrug0 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB00252 { 2 } , ddrug7 , ddrug8 , and ddrug9 thus , if a patient has been titrated to a stable dosage on ddrug10 , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for HD00472 may be necessary .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 concentrations are increased by about 15 % when DB00390 and DB01136 are administered concomitantly .",
        "label": "mechanism"
    },
    {
        "text": "blood glucose concentrations should be carefully monitored when DB01167 and oral HD00062 are coadministered .",
        "label": "advise"
    },
    {
        "text": "if DB01151 is to be combined with other ddrug1 such as ddrug2 or ddrug3 / HD00214 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of ddrug5 and ddrug6 { e , g , , ddrug7 or ddrug8 } are additive .",
        "label": "effect"
    },
    {
        "text": "profound hypotensive episodes may occur when DB01119 infection and DB01275 are used concomitantly .",
        "label": "effect"
    },
    {
        "text": "DB00294 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , DB00220 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "int"
    },
    {
        "text": "although the interaction between ddrug0 and other potent cyp3a4 inhibitors { e , g , , DB01167 , ddrug2 , and ddrug3 } has not been studied , increased exposures to ddrug4 may be expected when DB00918 is used concomitantly with these medications .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : DB00951 is known to slow the metabolism of ddrug2 and increase its serum levels ddrug3 levels should be determined prior to concurrent administration with ddrug4 , signs and symptoms of DB00564 toxicity should be monitored closely , and appropriate dosage adjustment of the ddrug6 should be made .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of ddrug0 : ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , ddrug5 , ddrug6 , DB00871 } , ddrug8 , ddrug9 , DB00052 , ddrug11 , ddrug12 , ddrug13 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "- a ddrug0 { HD00615 } such as ddrug2 { ddrug3 , ddrug4 , ddrug5 , others } , DB01009 { ddrug7 , ddrug8 , ddrug9 } , ddrug10 { ddrug11 , ddrug12 } , ddrug13 { ddrug14 } , ddrug15 { ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , and ddrug21 { ddrug22 , ddrug23 , ddrug24 } ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and DB00759 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , DB00860 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration of DB01026 { 200 mg/day for # days } with a 15-mg single dose of ddrug2 increased the auc of DB01238 and its active metabolite by 63 % and 77 % , respectively .",
        "label": "NA"
    },
    {
        "text": "HD00569 : ddrug1 { ddrug2 , ddrug3 , HD00605 , ddrug5 , fruit juices , etc , } lower absorption of ddrug6 .",
        "label": "NA"
    },
    {
        "text": "unmodified ddrug0 { 1 % m/v } significantly improved the transport ratio { r = p { app } polymer / p { app } control } of HD00070 to # and 1 % { m/v } ddrug2 conjugated with DB00151 further enhanced the permeation .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { DB01076 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { HD00712 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "it is recommended that DB00996 be taken at least # hours following HD00467 administration .",
        "label": "advise"
    },
    {
        "text": "in general , these are drugs that have one or more pharmacologic activities similar to ddrug0 , including HD00407 such as ddrug2 and ddrug3 , HD00345 and ddrug5 .",
        "label": "NA"
    },
    {
        "text": "the effectiveness of HD00237 - only pills is reduced by hepatic enzyme-inducing drugs such as the ddrug1 DB00252 , ddrug3 , and ddrug4 , and the ddrug5 ddrug6 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 can interact with ddrug1 or other ddrug2 { may potentiate the cns depressant effects of either these medications or ddrug3 } , HD00444 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug5 } , and HD00445 { concurrent use with ddrug7 may prolong and intensify the anticholinergic and cns depressant effects of ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "specific and aspecific treatments of ddrug0 depletion are tricky using for example ddrug1 , pharmacological doses of DB00165 , physiological doses of DB11094 and of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "administration of DB00668 to patients receiving ddrug1 or HD00683 such as ddrug3 which sensitize the myocardium , may induce cardiac arrhythmia , .",
        "label": "effect"
    },
    {
        "text": "the concomitant intake of ddrug0 and ddrug1 does not affect the pharmacokinetics of either DB02325 or DB00659 .",
        "label": "NA"
    },
    {
        "text": "administration of DB00561 to patients who are receiving ddrug1 or HD00653 may result in an additive pressor effect .",
        "label": "effect"
    },
    {
        "text": "however , in a well-controlled study of patients with lymphoma on combination therapy , DB00437 did not increase the marrow toxicity of patients treated with DB00531 , ddrug2 , ddrug3 , ddrug4 and/or ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : since the excretion of DB05262 is similar to that of urate , HD00272 , which increase the excretion of urate , are also likely to increase the excretion of ddrug3 and thus lower the degree of inhibition of xanthine oxidase .",
        "label": "NA"
    },
    {
        "text": "DB00313 and DB00996 are not .",
        "label": "NA"
    },
    {
        "text": "DB00580 caused a statistically significant increase in plasma exposures of ddrug1 and DB14055 { 12 % and 15 % , respectively } , and in the pharmacodynamic effects { prothrombin time , measured as inr } of ddrug3 .",
        "label": "mechanism"
    },
    {
        "text": "in separate single or multiple dose pharmacokinetic interaction studies with ddrug0 , ddrug1 , DB00571 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , and ddrug8 , the bioavailability of ddrug9 was not altered by coadministration of DB00492 with any one of these drugs .",
        "label": "NA"
    },
    {
        "text": "the hypoglycemic action of ddrug0 may be potentiated by certain drugs including HD00518 and other drugs that are highly protein bound , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , HD00275 , and ddrug8 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 can interact with ddrug1 or other ddrug2 { may potentiate the cns depressant effects of either these medications or ddrug3 } , ddrug4 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug5 } , and HD00445 { concurrent use with ddrug7 may prolong and intensify the anticholinergic and cns depressant effects of HD00388 } .",
        "label": "NA"
    },
    {
        "text": "drugs that reduce the number of blood platelets by causing bone marrow depression { such as HD00251 } or drugs which inhibit platelet function { eg , ddrug1 and other ddrug2 , ddrug3 , ddrug4 , DB00636 , ddrug6 } may increase the bleeding tendency produced by ddrug7 without altering prothrombin time determinations .",
        "label": "NA"
    },
    {
        "text": "the antimicrobial effect of a ddrug0 , HD00050 , either alone or in combination with DB01165 , was evaluated in vitro against two type strains and six clinical isolates of mycobacterium ulcerans .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { DB00295 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , DB01045 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "- ddrug0 : interaction studies in humans have shown DB00887 to have no effect on DB00682 metabolism or on plasma prothrombin activity .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the pharmacokinetics of ddrug1 { DB01223 # mg/kg infused over # minutes } were unchanged following a single oral dose of DB00518 { 400 mg } in # healthy subjects .",
        "label": "NA"
    },
    {
        "text": "drugs which inhibit cyp 3a4 { e , g , , DB01026 , HD00093 such as ddrug2 } have the potential to result in increased plasma concentrations of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "administration of HD00532 with ddrug1 containing ddrug2 , ddrug3 , or ddrug4 , with ddrug5 , with metal cations such as ddrug6 , or with DB00152 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "mechanism"
    },
    {
        "text": "caution should be used when HD00302 inhibitors are co-administered with DB01023 .",
        "label": "NA"
    },
    {
        "text": "in addition , ddrug0 neither influenced the pharmacodynamics of ddrug1 , DB00945 , ddrug3 , and ddrug4 , nor the pharmacokinetics of DB00390 at steady state .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - and/or ddrug1 - containing ddrug2 , products containing DB01373 { ddrug4 } , ddrug5 containing DB01593 or other metal cations , or ddrug7 { ddrug8 } chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after ddrug9 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : DB00316 { ddrug2 } , HD00002 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "DB11119 or ddrug1 excess may decrease the effect of ddrug2 , and an ddrug3 deficiency can increase the effect of DB00389 .",
        "label": "NA"
    },
    {
        "text": "differential regulation of tyrosine phosphorylation in tumor cells by HD00007 , a homodimeric disintegrin , and monomeric disintegrins HD00008 and ddrug2 .",
        "label": "NA"
    },
    {
        "text": "1 hour after starting the DB00497 or DB01137 # mg p , o.",
        "label": "NA"
    },
    {
        "text": "ddrug0 - taking DB00592 and a HD00766 together may increase the risk of convulsions { seizures } .",
        "label": "effect"
    },
    {
        "text": "in a comparison of ddrug0 tolerance in dogs anesthetized with ddrug1 , ddrug2 , or ddrug3 , the dosage of ddrug4 needed to cause ventricular tachycardia was significantly higher , as was the ld50 of ddrug5 , with DB01221 or ddrug7 than with DB00312 .",
        "label": "NA"
    },
    {
        "text": "when DB01118 is added to ddrug1 therapy , plasma DB01195 levels may increase two-fold or more in some patients , if ddrug3 dosage is not reduced .",
        "label": "NA"
    },
    {
        "text": "{ DB00328 } HD00218 are used concomitantly , the patient should be observed closely to determine if the desired effect of the ddrug2 is obtained .",
        "label": "NA"
    },
    {
        "text": "in patients receiving nonselective HD00275 { ddrug1 } { e , g , , ddrug2 } in combination with ddrug3 { e , g , , DB00472 , ddrug5 , ddrug6 , ddrug7 , ddrug8 } , there have been reports of serious , sometimes fatal , reactions .",
        "label": "effect"
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing DB01370 , ddrug3 , or ddrug4 , with ddrug5 , with metal cations such as ddrug6 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of HD00532 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of HD00530 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , certain ddrug7 , ddrug8 , ddrug9 and DB00916 , thereby delaying elimination and increasing blood levels of these drugs .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - prior ingestion of DB01231 may decrease the ddrug2 response to DB00714 in the treatment of poisoning .",
        "label": "effect"
    },
    {
        "text": "however , the antagonism of the ddrug0 - induced anxiogenic effects by HD00187 was only observed in the time spent in the light zone , and HD00188 - induced anxiogenic effects were neither reversed by ddrug3 nor by ddrug4 .",
        "label": "NA"
    },
    {
        "text": "HD00106 and ddrug1 { hypertension } - in clinical studies of patients with hypertension , the addition of ddrug2 # to # mg to ddrug3 and HD00466 increased mean serum potassium slightly { about # # meq/l } .",
        "label": "NA"
    },
    {
        "text": "oral HD00326 may potentiate the hypoglycemic action of ddrug1 , eg , ddrug2 and DB00672 , by inhibiting their metabolism in the liver .",
        "label": "mechanism"
    },
    {
        "text": "co-administration of DB00083 and ddrug1 or other agents interfering with neuromuscular transmission { e , g , , HD00436 } should only be performed with caution as the effect of the ddrug3 may be potentiated .",
        "label": "advise"
    },
    {
        "text": "in addition , there have been cases reported in which concomitant use of DB00681 and DB14539 was followed by cardiac enlargement and congestive heart failure .",
        "label": "effect"
    },
    {
        "text": "in clinical trials , ddrug0 was used with ddrug1 , ddrug2 , ddrug3 , oral ddrug4 , and supplemental DB09140 , in a pharmacokinetic substudy in patients with congestive heart failure receiving DB00695 or ddrug7 in whom therapy with ddrug8 was initiated , apparent oral clearance values for ddrug9 { n = 23 } and ddrug10 { n = 30 } were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .",
        "label": "NA"
    },
    {
        "text": "other drugs : based on the results of drug interaction studies , no dosage adjustment is recommended when ddrug0 { DB00625 } is given with the following : ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB00196 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , and ddrug11 .",
        "label": "NA"
    },
    {
        "text": "medications can interfere with folate utilization , including : HD00740 { such as ddrug1 , and ddrug2 } ddrug3 { sometimes prescribed to control blood sugar in type # diabetes } ddrug4 { used to control inflammation associated with crohn_disease and ulcerative colitis } ddrug5 { a HD00295 } ddrug7 there has been concern about the interaction between ddrug8 and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "this drug may interact with ddrug0 or other HD00261 { may potentiate the cns depressant effects of either these medications or HD00388 } , ddrug3 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug4 } , and ddrug5 { concurrent use with ddrug6 may prolong and intensify the anticholinergic and cns depressant effects of ddrug7 } .",
        "label": "NA"
    },
    {
        "text": "although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 { eg , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , DB00813 , ddrug13 , ddrug14 , and ddrug15 } may have elevated plasma concentrations when coadministered with DB01232 ;",
        "label": "mechanism"
    },
    {
        "text": "may interact ddrug0 { altered hypo-prothrombinemic effect } , HD00026 , ddrug2 and other inducers of hepatic microsomal enzyme oxidation system { decreased effect of ddrug3 } , ddrug4 { increased effect of HD00175 } .",
        "label": "NA"
    },
    {
        "text": "the principal drugs given { number of patients in parentheses } were : ddrug0 { 115 } , ddrug1 and ddrug2 { 103 } , ddrug3 { 52 } , oral ddrug4 { 45 } , cough and cold preparations { 45 } , HD00203 { 38 } , ddrug6 { 29 } , HD00779 { 24 } , oral ddrug8 { 18 } , ddrug9 { 13 } , ddrug10 { 10 } , and ddrug11 { 10 } .",
        "label": "NA"
    },
    {
        "text": "clinical experience with concomitant administration of DB00559 and ddrug1 in patients with pulmonary arterial hypertension did not show clinically relevant changes in inr or ddrug2 dose { baseline vs , end of the clinical studies } , and the need to change the DB00682 dose during the trials due to changes in inr or due to adverse events was similar among ddrug4 - and placebo-treated patients .",
        "label": "NA"
    },
    {
        "text": "- a HD00535 { ddrug1 } such as ddrug2 { ddrug3 , ddrug4 , ddrug5 , others } , ddrug6 { HD00760 , ddrug8 , ddrug9 } , ddrug10 { ddrug11 , ddrug12 } , ddrug13 { ddrug14 } , ddrug15 { ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , and ddrug21 { ddrug22 , ddrug23 , ddrug24 } ;",
        "label": "NA"
    },
    {
        "text": "to determine whether injection of HD00158 would permit larger doses of ddrug1 to be administered , a fixed # - g/m2 dose of ddrug2 was given intravenously over three hours concurrently with escalating doses of DB00515 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local HD00264 { e , g , , ddrug6 and ddrug7 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , HD00029 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { cns } drugs including ddrug1 , HD00216 , ddrug3 , ddrug4 , blood pressure medications { ddrug5 , ddrug6 , ddrug7 } , motion sickness medications , ddrug8 , HD00543 , ddrug10 , sleeping pills and ddrug11",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { DB00091 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , DB00860 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "because ddrug0 is eliminated from the body via conjugation with glutathione , use of ddrug1 prior to { # hours } or concurrent with DB01008 may result in reduced ddrug3 clearance based upon the known property of DB00316 to decrease glutathione levels in the blood and tissues .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { DB00564 , ddrug2 , ddrug3 , ddrug4 , ddrug5 } : increase the metabolism of DB00977 and/or some ddrug7 , leading to possible decrease in contraceptive effectiveness .",
        "label": "mechanism"
    },
    {
        "text": "HD00871 : ddrug1 contraindicated since the coadministration of this product with ddrug2 in an HD00056 regimen reduces the plasma concentrations of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "HD00488 and foods fortified with ddrug1 concomitant administration of DB00535 with a therapeutic ddrug3 containing # mg of elemental ddrug4 { as feso4 } or ddrug5 supplemented with # mg of elemental ddrug6 reduced extent of absorption by 80 % and 31 % , respectively .",
        "label": "NA"
    },
    {
        "text": "patients receiving catecholamine-depleting drugs , such as DB00206 or ddrug1 , should be closely monitored , because the added beta-adrenergic blocking action of DB00612 may produce excessive reduction of sympathetic activity .",
        "label": "effect"
    },
    {
        "text": "a clinical study in healthy male volunteers { n = 24 } demonstrated that mixing DB01306 with HD00812 immediately before injection produced some attenuation in the peak concentration of ddrug2 , but that the time to peak and the total bioavailability of ddrug3 were not significantly affected .",
        "label": "NA"
    },
    {
        "text": "DB01233 : when coadministered with DB00828 , ddrug2 , a drug which increases gastrointestinal motility , lowers the serum concentration and urinary excretion of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "if DB01151 is to be combined with other ddrug1 such as ddrug2 or ddrug3 / ddrug4 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of ddrug5 and ddrug6 { e , g , , ddrug7 or DB00829 } are additive .",
        "label": "NA"
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of HD00472 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 { 1 } , ddrug5 , DB01406 , ddrug7 , ddrug8 , ddrug9 { 1 } , ddrug10 , ddrug11 , grapefruit juice , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21 , ddrug22 , ddrug23 , ddrug24 { 1 } , ddrug25 , ddrug26 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 should be used with care when ddrug1 or inhibitors of av conduction , such as certain HD00085 { particularly of the ddrug3 -lsb- DB00661 -rsb- and ddrug5 -lsb- ddrug6 -rsb- classes } , or ddrug7 , such as ddrug8 , are used concurrently .",
        "label": "NA"
    },
    {
        "text": "the reduced risk of adverse events and therapeutic superiority compared with DB00502 and ddrug1 in the treatment of negative and depressive symptoms support the choice of DB00334 as a first-line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a study of healthy volunteers , DB00608 significantly reduced the bioavailability of DB00415 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : combination ddrug1 may decrease the clearance of some ddrug2 { DB00404 , ddrug4 , ddrug5 } and increase the clearance of others { ddrug6 , ddrug7 , DB00231 } .",
        "label": "NA"
    },
    {
        "text": "the doses of ddrug0 required to antagonize the effects of HD00157 were more than # times higher than those required to antagonize the effects of DB00295 .",
        "label": "NA"
    },
    {
        "text": "in clinical trials , ddrug0 was used with ddrug1 , ddrug2 , ddrug3 , oral ddrug4 , and supplemental ddrug5 , in a pharmacokinetic substudy in patients with congestive heart failure receiving DB00695 or ddrug7 in whom therapy with ddrug8 was initiated , apparent oral clearance values for ddrug9 { n = 23 } and DB00390 { n = 30 } were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , DB00563 , DB00091 : ddrug3 , like other ddrug4 , may affect renal prostaglandins and increase the toxicity of certain drugs .",
        "label": "NA"
    },
    {
        "text": "another oral HD00820 , ddrug1 , inhibits the metabolism of ddrug2 , resulting in elevated plasma concentrations of ddrug3 and its active metabolite HD00821 which may prolong qt intervals .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of ddrug0 : ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , ddrug5 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , DB00052 , ddrug11 , ddrug12 , ddrug13 { e , g , , in oral HD00283 } .",
        "label": "NA"
    },
    {
        "text": "then , the effects of metabotropic glutamate receptor { mglur } agonists , HD00018 and ddrug1 , on the above behavioral changes induced by DB03575 were found .",
        "label": "NA"
    },
    {
        "text": "while additional research is needed , the initial clinical data in kidney recipients suggest that DB00877 , in combination with ddrug1 or ddrug2 , might have the potential to reduce the frequency of rejection episodes , permit reductions in DB00091 or ddrug4 dosage , and permit steroid withdrawal { kelly , 1999 } .",
        "label": "NA"
    },
    {
        "text": "the purpose of this study was to evaluate the effect of ddrug0 { ddrug1 } and ddrug2 { HD00068 } conjugates on the intestinal permeation of HD00069 { ddrug5 } and model peptide drugs , ddrug6 and ddrug7 .",
        "label": "NA"
    },
    {
        "text": "HD00275 and HD00043 : ddrug2 should be administered with extreme caution in patients being treated with ddrug3 or ddrug4 because the action of ddrug5 on the cardiovascular system may be potentiated by these agents .",
        "label": "NA"
    },
    {
        "text": "therefore , DB00601 has the potential for interaction with HD00850 and ddrug2 .",
        "label": "int"
    },
    {
        "text": "ddrug0 { DB00812 , ddrug2 , and possibly ddrug3 } : concomitant administration with DB00945 may increase the risk of gastrointestinal ulceration .",
        "label": "effect"
    },
    {
        "text": "in comparison with ddrug0 , the adverse events reported significantly more frequently with ddrug1 in > or = # % of patients were dry mouth , bodyweight gain and increased appetite and compared with DB00734 , only bodyweight gain occurred significantly more frequently with DB00334 .",
        "label": "NA"
    },
    {
        "text": "based on the chemical resemblance of ddrug0 and DB01026 , coadministration of DB00637 with ddrug3 is contraindicated .",
        "label": "NA"
    },
    {
        "text": "DB00201 - related adverse effects have occurred in patients consuming ddrug1 while on therapy with DB00467 .",
        "label": "NA"
    },
    {
        "text": "DB00332 inhalation aerosol has been used concomitantly with other drugs , including HD00660 , ddrug2 , and ddrug3 , commonly used in the treatment of chronic obstructive pulmonary disease .",
        "label": "NA"
    },
    {
        "text": "however , co administration of ddrug0 with either DB01026 or ddrug2 led to increased plasma concentrations of DB00950 .",
        "label": "NA"
    },
    {
        "text": "interactions may also occur with the following : HD00515 / ddrug1 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , ddrug4 , DB00365 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 pain medication { e , g , , ddrug12 } , drugs used to aid sleep , drowsiness-causing ddrug13 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in normal volunteers , concomitant administration of DB00861 and DB00999 resulted in significantly increased plasma levels of ddrug3 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 , HD00246 and ddrug2 : concomitant treatment with HD00741 , ddrug4 , or ddrug5 may potentiate a possible hypokalemic effect of ddrug6",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of ddrug0 : ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , ddrug5 , DB01001 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 { e , g , , in oral HD00283 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : DB00316 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , DB01076 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "DB00668 may antagonize the neuron blockade produced by DB01170 resulting in decreased antihypertensive effect and requiring increased dosage of the latter .",
        "label": "effect"
    },
    {
        "text": "in addition , other HD00532 have been reported to decrease the cyp3a4-mediated metabolism of DB00091 .",
        "label": "mechanism"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 DB00683 , ddrug12 gi motility agents : DB00604",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 DB00472 { ddrug11 } sporal { ddrug12 } ddrug13 { DB01026 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "before taking ddrug0 , tell your doctor if you are taking any of the following medicines : - DB00945 or another ddrug2 such as ddrug3 { ddrug4 } , ddrug5 { ddrug6 , others } , ddrug7 { ddrug8 } , DB01397 { ddrug10 } , or ddrug11 { ddrug12 } ;",
        "label": "NA"
    },
    {
        "text": "the use of HD00374 should be considered in place of ddrug1 or ddrug2 in patients receiving DB01254 therapy .",
        "label": "NA"
    },
    {
        "text": "in vitro displacement studies with highly protein-bound drugs such as ddrug0 , ddrug1 , DB01197 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 showed no influence on the extent of DB00731 protein binding .",
        "label": "NA"
    },
    {
        "text": "injection : ddrug0 injection , like other injectable ddrug1 , produces depression of the central nervous system when administered with ddrug2 , ddrug3 , ddrug4 , ddrug5 , and other ddrug6 , when DB00747 is used concomitantly with injectable DB00186 , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .",
        "label": "effect"
    },
    {
        "text": "ddrug0 { eg , DB01199 } and other drugs , including ether , ddrug2 , ddrug3 , ddrug4 and ddrug5 , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with DB01111 parenteral .",
        "label": "effect"
    },
    {
        "text": "aim and background : the pharmacokinetic interaction between ddrug0 , a HD00083 metabolized by cyp3a4 , and the HD00038 ddrug3 was studied in # healthy subjects .",
        "label": "NA"
    },
    {
        "text": "concurrent use of DB00611 with ddrug1 { e , g , , ddrug2 , ddrug3 , HD00262 , and ddrug5 } may result in increased ddrug6 effects .",
        "label": "effect"
    },
    {
        "text": "an increase in serum ddrug0 concentration has been reported during concomitant administration of ddrug1 with DB00796 , so careful monitoring of serum DB14507 levels is recommended during concomitant use .",
        "label": "NA"
    },
    {
        "text": "although the occurrence has not been reported with DB01332 , nephrotoxicity has been reported following concomitant administration of other HD00485 and ddrug2 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : if DB00459 is given concurrently with DB00252 , the protein binding of ddrug3 may be reduced .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : steady-state trough concentrations of ddrug1 were about 56 % higher when # mg DB01234 was coadministered with each dose of DB00518 { 15 mg/kg/day } in eight neurocysticercosis patients .",
        "label": "mechanism"
    },
    {
        "text": "DB00458 : coadministration of single doses of DB00962 # mg and ddrug2 # mg produced additive effects on decreased alertness and impaired psychomotor performance for # to # hours after administration .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : combination HD00432 may decrease the clearance of some ddrug2 { ddrug3 , ddrug4 , ddrug5 } and increase the clearance of others { ddrug6 , DB00842 , ddrug8 } .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 is also expected to reduce plasma concentrations of other ddrug1 that have significant metabolism by cyp3a4 , such as DB00227 and DB01076 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 : upon concomitant administration of # mg of DB00862 with # mg bid DB00503 , the cmax and auc of ddrug4 were reduced by approximately 20 % .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , HD00002 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , DB00503 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { cns } drugs including ddrug1 , ddrug2 , HD00388 , ddrug4 , blood pressure medications { ddrug5 , ddrug6 , HD00254 } , motion sickness medications , ddrug8 , ddrug9 , ddrug10 , sleeping pills and ddrug11",
        "label": "NA"
    },
    {
        "text": "no interactions have been observed with ddrug0 , HD00085 , ddrug2 and HD00105 and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when DB00802 is administered in combination with other ddrug1 such as ddrug2 , ddrug3 , ddrug4 , or inhalation general HD00264 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 in combination with ddrug1 enhances the manifestation of corneal lesions in rats epidural injection DB00575 may potentiate the cns-depressive effect of DB02325 , ddrug4 or other ddrug5 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : clinical studies , as well as post-marketing observations , have shown that HD00203 can reduce the natriuretic effect of DB00695 and ddrug3 in some patients .",
        "label": "effect"
    },
    {
        "text": "ddrug0 - combined administration of racemic ddrug1 { titrated to # mg/day for # days } and the cyp3a4 substrate ddrug2 { single dose of # mg } did not significantly affect the pharmacokinetics of either DB00215 or DB00897 .",
        "label": "NA"
    },
    {
        "text": "other HD00532 have demonstrated moderate to marked interference with the metabolism of DB00201 , resulting in a reduced clearance , a prolongation of plasma half-life , and an increase in symptoms that accompany high levels of ddrug2 .",
        "label": "mechanism"
    },
    {
        "text": "DB01432 and ddrug1 HD00510 : absorption of ddrug3 is impaired in the presence of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "these data indicate that DB01202 does not influence the plasma concentration of other HD00714 and that these ddrug2 do not influence the pharmacokinetics of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "the possibility of hypotensive effects with DB00542 can be minimized by either discontinuing the HD00295 or increasing the salt intake prior to initiation of treatment with ddrug2 .",
        "label": "NA"
    },
    {
        "text": "DB00753 , ddrug1 , and ddrug2 decrease the ed50 of DB01135 by 30 % to 45 % .",
        "label": "mechanism"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 DB00472 { ddrug11 } sporal { ddrug12 } DB01026 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of HD00472 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 { 1 } , ddrug5 , ddrug6 , ddrug7 , ddrug8 , DB00199 { 1 } , ddrug10 , ddrug11 , grapefruit juice , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21 , ddrug22 , ddrug23 , ddrug24 { 1 } , ddrug25 , ddrug26 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 , or other products containing ddrug1 or ddrug2 , ddrug3 or DB00364 should not be administered concomitantly with , or within # hours of , the administration of ddrug5 , because they may interfere with absorption resulting in lower serum and urine levels of DB01059 .",
        "label": "NA"
    },
    {
        "text": "DB00682 , ddrug1 , ddrug2 , and DB01109 the in vitro binding of ddrug4 to plasma proteins is only slightly reduced by ddrug5 { # % control vs # % } when ddrug6 plasma concentrations reach # to10 m g/ml .",
        "label": "NA"
    },
    {
        "text": "however , because some ddrug0 have been reported to enhance the effects of ddrug1 or its derivatives , prothrombin time or other suitable anticoagulation test should be monitored closely if a HD00751 is administered with DB00682 or its derivatives .",
        "label": "advise"
    },
    {
        "text": "in a single-dose crossover study examining ddrug0 # mg and ddrug1 # mg each administered alone and concomitantly with ddrug2 # gram , absorption of the HD00587 was delayed and their bioavailability was reduced by 17 % and 16 % , respectively , when administered concomitantly with DB00364 .",
        "label": "mechanism"
    },
    {
        "text": "as with other ddrug0 , it should be noted that ddrug1 may be capable of potentiating HD00261 such as ddrug3 , HD00344 , and ddrug5 .",
        "label": "NA"
    },
    {
        "text": "although the mechanism of interaction between ddrug0 and DB00945 is not totally known , enzyme induction and displacement of DB00573 from plasma alb binding sites are possibilities .",
        "label": "NA"
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit DB00451 binding to serum proteins or alter the concentrations of serum binding proteins : ddrug1 and related ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , DB00850 , ddrug14 , ddrug15 , ddrug16 , ddrug17 .",
        "label": "mechanism"
    },
    {
        "text": "in order to provide information for the appropriate package insert labeling of ddrug0 { ddrug1 } in the us , a comprehensive review was made of DB09389 { # mg } and DB00717 { # mg } , with the clinical differences indicated where applicable .",
        "label": "NA"
    },
    {
        "text": "concomitant use of DB01254 and drugs that inhibit cyp3a4 { eg , DB01026 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 } may increase exposure to ddrug12 and should be avoided .",
        "label": "mechanism"
    },
    {
        "text": "oral ddrug0 : based on auc and half-life , multiple-dose pharmacokinetic profiles of ddrug1 and DB00977 following administration of tablets containing # mg of DB00717 and # mcg of ddrug4 were similar with and without coadministration of ddrug5 { 400 mg tid ;",
        "label": "NA"
    },
    {
        "text": "HD00219 and ddrug1 may reduce or reverse the pressor effect of DB00668 .",
        "label": "effect"
    },
    {
        "text": "the results of a study of coadministration of ddrug0 { 50 mg/kg } with an ddrug1 containing ddrug2 to # patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ddrug3 of approximately 20 % and 13 % , respectively , suggesting that the oral absorption of DB00330 may be reduced by these HD00701 .",
        "label": "NA"
    },
    {
        "text": "DB00095 should not be used with other HD00084 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 , other , especially DB01119 , or pre DB01086 and anesthetic agents used in surgery or ddrug3 , nondepolarizing , used in surgery",
        "label": "NA"
    },
    {
        "text": "ddrug0 : concomitant treatment with ddrug1 and HD00239 should be avoided because DB00982 use has been associated with a number of cases of idiopathic_intracranial_hypertension { benign intracranial hypertension } , some of which involved concomitant use of ddrug4",
        "label": "NA"
    },
    {
        "text": "ddrug0 : co-administration of DB00864 and DB00559 has not been studied in man .",
        "label": "NA"
    },
    {
        "text": "therefore , the efficacy of oral HD00283 during administration of DB00673 may be reduced .",
        "label": "effect"
    },
    {
        "text": "DB00907 sometimes proves to be fatal when used in combination with DB01452 .",
        "label": "effect"
    },
    {
        "text": "oral HD00326 interaction studies with DB00682 and ddrug2 failed to identify any clinically important effects on the serum concentrations or clinical effects of these ddrug3 .",
        "label": "NA"
    },
    {
        "text": "if ddrug0 is to be combined with other ddrug1 such as ddrug2 or HD00596 / ddrug4 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of ddrug5 and ddrug6 { e , g , , ddrug7 or DB00829 } are additive .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - although DB01175 did not potentiate the cognitive and motor effects of ddrug2 in a clinical trial , as with other ddrug3 , the use of DB02325 by patients taking ddrug5 is not recommended .",
        "label": "NA"
    },
    {
        "text": "because prostaglandins play an important role in hemostasis , and HD00203 affect platelet function as well , concurrent therapy with all ddrug1 , including ddrug2 , and ddrug3 requires close monitoring of patients to be certain that no change in their HD00025 dosage is required .",
        "label": "NA"
    },
    {
        "text": "these increased exposures of DB00717 and ddrug1 should be taken into consideration when selecting an oral HD00349 for women taking ddrug3 .",
        "label": "NA"
    },
    {
        "text": "DB00501 } and many that are substrates for cyp2b6 2d6 { many other HD00216 , ddrug2 , and the ddrug3 ddrug4 and ddrug5 } .",
        "label": "NA"
    },
    {
        "text": "similarly , in the 1-year monthly comparison study , DB00945 and HD00233 were taken by 39 % of the # patients .",
        "label": "NA"
    },
    {
        "text": "although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 { eg , ddrug0 , ddrug1 , DB00280 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , and ddrug15 } may have elevated plasma concentrations when coadministered with DB01232 ;",
        "label": "mechanism"
    },
    {
        "text": "DB01432 ddrug1 may delay or reduce the absorption of concomitant oral medication such as ddrug2 , ddrug3 , ddrug4 { acidic } or ddrug5 { basic } , as well as ddrug6 ddrug7 , ddrug8 , thyroid and HD00525 preparations , ddrug10 and ddrug11 , and ddrug12 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , HD00282 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , DB00295 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "DB00328 has been reported to decrease the tubular secretion of DB00563 and to potentiate its toxicity .",
        "label": "mechanism"
    },
    {
        "text": "the antihypertensive effects of DB00968 , ddrug1 , ddrug2 , and ddrug3 may be reduced by HD00391 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 , DB01575 - pectin , ddrug2 , DB00994 , ddrug4 , certain anticancer drugs , and ddrug5 may interfere with intestinal ddrug6 absorption , resulting in unexpectedly low serum concentrations .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and DB04833 interact pharmacologically with orally administered HD00028 , but the effect is not clinically significant .",
        "label": "int"
    },
    {
        "text": "ddrug0 : HD00401 enhance the adrenergic effect of DB00368 .",
        "label": "effect"
    },
    {
        "text": "plasma levels of several closely related ddrug0 have been reported to be increased by the concomitant administration of DB00422 or hepatic enzyme inhibitors { e , g , , ddrug2 , ddrug3 } and decreased by the concomitant administration of hepatic enzyme inducers { e , g , , ddrug4 , DB00252 } , and such an effect may be anticipated with ddrug6 as well .",
        "label": "NA"
    },
    {
        "text": "DB01032 given concurrently increases DB00788 anion plasma levels and extends its plasma half-life significantly .",
        "label": "mechanism"
    },
    {
        "text": "lymphocytopenia has been reported in patients receiving DB00762 , and it is possible that the administration of DB01234 as antiemetic prophylaxis may have enhanced the likelihood of this effect .",
        "label": "effect"
    },
    {
        "text": "the pharmacokinetics of ddrug0 were not affected by coadministration of DB01115 or DB00999",
        "label": "NA"
    },
    {
        "text": "there was no evidence of drug interactions in clinical studies in which DB00841 was administered concurrently with other drugs , including ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , DB01109 , ddrug10 , ddrug11 , ddrug12 , and ddrug13 .",
        "label": "NA"
    },
    {
        "text": "there have been a number of reports in the post-marketing experience of coma and death associated with the concomitant intravenous misuse of DB00921 and HD00100 by addicts .",
        "label": "effect"
    },
    {
        "text": "another study showed that DB00969 had no clinically significant effect on plasma concentrations of the oral ddrug1 DB00977 and ddrug3 { cyp3a4 substrates } .",
        "label": "NA"
    },
    {
        "text": "in controlled clinical trials , however , HD00378 including DB00264 were concurrently administered with ddrug2 and were well tolerated .",
        "label": "NA"
    },
    {
        "text": "data from in vitro studies of ddrug0 suggest a possible drug interaction with DB00404 for the following : DB01104 and ddrug3 .",
        "label": "int"
    },
    {
        "text": "ddrug0 : combination ddrug1 may decrease the clearance of some ddrug2 { ddrug3 , ddrug4 , DB00829 } and increase the clearance of others { ddrug6 , DB00842 , ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "other concomitant therapy although specific interaction studies were not performed , ddrug0 doses of # mg or more were concomitantly used in clinical studies with ddrug1 , DB00945 , a-blockers , ddrug3 , ddrug4 , ddrug5 , ddrug6 , HD00378 , ddrug8 , cardiac ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 { also referred to as ddrug14 } , and ddrug15 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "there have been reports of interactions of DB00199 with ddrug1 , ddrug2 , ddrug3 , DB01355 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , and ddrug13 .",
        "label": "int"
    },
    {
        "text": "may interact ddrug0 { altered hypo-prothrombinemic effect } , HD00026 , ddrug2 and other inducers of hepatic microsomal enzyme oxidation system { decreased effect of DB00255 } , ddrug4 { increased effect of ddrug5 } .",
        "label": "NA"
    },
    {
        "text": "however , in another study in healthy volunteers , the pharmacokinetics of DB00611 were significantly altered { 29 % decrease in auc and 38 % decrease in cmax } when a 1-mg dose of ddrug1 was administered # minute after a 20-mg dose of DB00669 nasal spray .",
        "label": "NA"
    },
    {
        "text": "when DB00448 was administered concomitantly with ddrug1 { cyp1a2 , cyp3a } , a minor increase { 10 % } in the clearance of DB00277 was seen .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , including oral , injectable , transdermal , and implantable ddrug1 : an interaction study demonstrated that co-administration of ddrug2 and the oral HD00431 DB00717 produced average decreases of ddrug5 and ddrug6 levels of 14 % and 31 % , respectively .",
        "label": "NA"
    },
    {
        "text": "DB00152 , or other products containing ddrug1 or ddrug2 , ddrug3 or ddrug4 should not be administered concomitantly with , or within # hours of , the administration of DB01059 , because they may interfere with absorption resulting in lower serum and urine levels of ddrug6 .",
        "label": "advise"
    },
    {
        "text": "DB01045 , an inducer of drug metabolism , decreased the concentrations of DB00678 and its active metabolite .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { DB00400 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , DB00295 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "hormonal HD00283 co-administration of DB00776 with an oral ddrug2 has been shown to influence the plasma concentrations of the two hormonal components , ddrug3 { ee } and ddrug4 { lng } .",
        "label": "NA"
    },
    {
        "text": "background : the effects of combined administration of ddrug0 and DB00661 { ddrug2 } , a ddrug3 , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by HD00037 { ddrug5 } and the labeling index of intestinal_cancer were investigated in male wistar rats .",
        "label": "NA"
    },
    {
        "text": "to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma { hiv-nhl } , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the ddrug0 , ddrug1 , ddrug2 , and DB00898 { chop } chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen { i , e , , ddrug4 , ddrug5 , ddrug6 , and ddrug7 with ddrug8 plus DB00290 } without receiving ddrug10 therapy .",
        "label": "NA"
    },
    {
        "text": "the results of a study of coadministration of ddrug0 { 50 mg/kg } with an DB06723 containing ddrug2 to # patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ddrug3 of approximately 20 % and 13 % , respectively , suggesting that the oral absorption of DB00330 may be reduced by these ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { e , g , , ddrug1 , ddrug2 , ddrug3 , ddrug4 , etc , } : in vitro and animal studies with the combination of ddrug5 and HD00319 suggest that ddrug7 may induce fungal resistance to DB00681 .",
        "label": "NA"
    },
    {
        "text": "DB00486 should be administered with caution to patients who are taking other ddrug1 or ddrug2 , including ddrug3 , HD00026 and ddrug5 , or to those with a history of psychiatric disorder { including manic-depressive illness and schizophrenia } .",
        "label": "advise"
    },
    {
        "text": "the cmax of DB00717 was 13 % higher when it was coadministered with DB00996 ;",
        "label": "mechanism"
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of HD00472 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 { 1 } , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 { 1 } , ddrug10 , ddrug11 , grapefruit juice , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21 , ddrug22 , ddrug23 , DB00313 { 1 } , ddrug25 , ddrug26 .",
        "label": "mechanism"
    },
    {
        "text": "DB01242 should not be used with HD00343 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : in vitro and/or in vivo data show that ddrug1 , DB00199 , and ddrug3 markedly inhibit the metabolism of DB00604 , which can result in an increase in plasma ddrug5 levels and prolongation of the qt interval on the ecg .",
        "label": "mechanism"
    },
    {
        "text": "- ddrug0 { e , g , , HD00900 } use of ddrug2 with DB00891 may increase the chance of side effects affecting the liver and/or the side effects of ddrug4",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 : ddrug2 and ddrug3 containing ddrug4 or DB01370 , as well as formulations containing divalent and trivalent cations such as ddrug6 { ddrug7 } , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with DB00978 and interfere with its bioavailability .",
        "label": "mechanism"
    },
    {
        "text": "it is , however , possible that concomitant use of other known HD00299 such as DB00400 , ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 might increase the photosensitivity reaction of actinic_keratosis treated with the ddrug7 for topical solution .",
        "label": "NA"
    },
    {
        "text": "acute dosing with DB00363 failed to alter the behavioral effects of DB03575 in either procedure even when tested up to doses that produced pharmacological effects alone .",
        "label": "NA"
    },
    {
        "text": "co-administration of DB00682 and DB00439 did not alter the pharmacokinetics of ddrug2 .",
        "label": "NA"
    },
    {
        "text": "like ddrug0 { 40 mg/kg } , HD00022 { 40 mg/kg } decreases the intravenous self-administration of ddrug2 and DB00907 and the oral self-administration of ddrug4 and ddrug5 in rats ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 usually does not alter the plasma levels of DB00390 , however , serum ddrug2 levels should be evaluated after concomitant therapy with DB00622 is initiated .",
        "label": "NA"
    },
    {
        "text": "HD00423 altered coagulation parameters and/or bleeding have been reported in patients taking ddrug1 concomitantly with ddrug2 such as DB00682 and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "no drug interaction studies have been conducted for DB01014 , however the use of orally administered HD00002 could , theoretically , interfere with the release of ddrug2 in the colon .",
        "label": "NA"
    },
    {
        "text": "in addition , neuromuscular blocking action is enhanced by general ddrug0 , local HD00264 like ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and DB00871 .",
        "label": "NA"
    },
    {
        "text": "in a single-dose crossover study examining DB00448 # mg and ddrug1 # mg each administered alone and concomitantly with DB00364 # gram , absorption of the ddrug3 was delayed and their bioavailability was reduced by 17 % and 16 % , respectively , when administered concomitantly with ddrug4 .",
        "label": "NA"
    },
    {
        "text": "the following drugs have been coadministered with DB00195 and have not altered its pharmacokinetics : DB00501 , ddrug2 , ddrug3 , and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : HD00532 may enhance the effects of the oral HD00025 , ddrug3 , or its derivatives .",
        "label": "effect"
    },
    {
        "text": "ddrug0 { such as ddrug1 , ddrug2 , or DB00908 } : concurrent use with DB01102 may have a proarrhythmic effect .",
        "label": "NA"
    },
    {
        "text": "if concomitant treatment with DB00669 and an ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB00215 , ddrug7 } is clinically warranted , appropriate observation of the patient is advised .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : DB01026 has been reported to decrease the metabolism of certain ddrug2 by up to 60 % , leading to increased risk of HD00579 side effects .",
        "label": "NA"
    },
    {
        "text": "1 , ddrug0 { HD00179 } , the active metabolite of DB11094 , is a potent inhibitor of breast_cancer cell growth both in vivo and in vitro .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { 5 - 35 micromol/l } induced concentration-dependent relaxation of mesenteric arteries preconstricted with DB00368 { 8 micromol/l } or DB00761 { 125 mmol/l } from both lean and dietary-obese rats .",
        "label": "NA"
    },
    {
        "text": "other drugs : based on the results of drug interaction studies , no dosage adjustment is recommended when DB00625 { ddrug1 } is given with the following : ddrug2 , ddrug3 , DB00341 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , and ddrug11 .",
        "label": "NA"
    },
    {
        "text": "therefore , cyp3a4 substrates known to have a narrow therapeutic index such as ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , or ddrug10 { ddrug11 , DB00320 } should be administered with caution in patients receiving DB01254 .",
        "label": "advise"
    },
    {
        "text": "since ddrug0 { ddrug1 } may interact with concurrently administered HD00703 , periodic serum level determinations of these drugs may be necessary { eg , ddrug3 may elevate ddrug4 serum levels and DB00313 has been reported to both increase and decrease ddrug6 levels } .",
        "label": "NA"
    },
    {
        "text": "aim and background : the pharmacokinetic interaction between DB00877 , a ddrug1 metabolized by cyp3a4 , and the HD00038 ddrug3 was studied in # healthy subjects .",
        "label": "NA"
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma DB00252 concentrations include : acute ddrug1 intake , ddrug2 , chboramphenicol , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , DB00951 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : coadministration of DB00949 with DB01174 causes an increase in ddrug3 plasma concentrations , in # otherwise healthy male volunteers ingesting ddrug4 , the steady-state trough { cmin } ddrug5 concentration was # micrograms/ml .",
        "label": "mechanism"
    },
    {
        "text": "no depressant effect on blood levels in humans was noted when ddrug0 was administered with any of the following drugs : DB00945 , ddrug2 , ddrug3 , DB00968 , ddrug5 { ddrug6 } , ddrug7 , ddrug8 or ddrug9 .",
        "label": "NA"
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a HD00533 , including ddrug1 , with multivalent cation-containing products such as ddrug2 or DB01370 ddrug4 , ddrug5 , ddrug6 chewable/buffered tablets or pediatric powder , or products containing ddrug7 , ddrug8 , or ddrug9 may substantially decrease the absorption of ddrug10 , resulting in serum and urine levels considerably lower than desired .",
        "label": "mechanism"
    },
    {
        "text": "co-administration of ddrug0 with DB00661 resulted in increases in DB00204 peak plasma levels of 42 % , although overall exposure to ddrug3 was not significantly increased .",
        "label": "NA"
    },
    {
        "text": "effect of DB00829 and DB00683 on the antinociceptive effect of ddrug2 , ddrug3 and ddrug4 in mice .",
        "label": "NA"
    },
    {
        "text": "in in vivo studies , 10 - to 30-mg/day doses of DB01238 had no significant effect on metabolism by cyp2d6 { ddrug1 } , cyp2c9 { ddrug2 } , cyp2c19 { ddrug3 , ddrug4 } , and cyp3a4 { DB00514 } substrates .",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , ddrug3 , or DB01373 , with ddrug5 , with metal cations such as ddrug6 , or with ddrug7 containing ddrug8 or DB01593 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of ddrug0 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB00252 { 2 } , ddrug7 , ddrug8 , and ddrug9 thus , if a patient has been titrated to a stable dosage on HD00472 , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for ddrug11 may be necessary .",
        "label": "NA"
    },
    {
        "text": "DB01294 : ddrug1 , given concomitantly with DB00467 or # minutes following ddrug3 administration , decreased ddrug4 bioavailability by approximately 25 % .",
        "label": "NA"
    },
    {
        "text": "DB00863 also has no effect on DB00876 pharmacokinetics .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { HD00548 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { DB00295 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 absorption : the following agents may bind and decrease absorption of DB00451 from the gastrointestinal tract : ddrug2 , ddrug3 resin , ddrug4 , ddrug5 , ddrug6 , soybean flour { e , g , , infant formula } , DB00364 .",
        "label": "mechanism"
    },
    {
        "text": "a case report of one patient taking ddrug0 # mg and DB00224 # mg three times a day resulted in increases in DB01118 concentrations from # mg/l to # mg/l .",
        "label": "NA"
    },
    {
        "text": "HD00320 , nondepolarizing { e , g , , DB01199 } : possible increased responsiveness to the ddrug2 .",
        "label": "NA"
    },
    {
        "text": "HD00175 : ddrug1 : ddrug2 , when given as a regimen of 125 mg with ddrug3 coadministered orally as # mg on day 1 , and ddrug4 when given as # mg/day with ddrug5 coadministered orally as # mg on days # through 5 , increased the auc of DB01234 , a cyp3a4 substrate by # - fold , on days # and 5 .",
        "label": "NA"
    },
    {
        "text": "-lsb- the effect of ddrug0 on the activity of mixed-function mono-oxidases in the liver microsomes -rsb- the effects of the HD00189 -- the drug DB00091 -- on hepatic cyp4b1 activities were studied .",
        "label": "NA"
    },
    {
        "text": "since the concomitant administration of these two drugs can lead to ddrug0 intoxication , prior to administering DB00822 to a patient on ddrug2 therapy , a baseline DB00252 serum level should be obtained .",
        "label": "NA"
    },
    {
        "text": "DB00945 should be used cautiously in conjunction with HD00580 in patients suffering from hypopro-thrombinemia .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : drugs such as ddrug1 , ddrug2 , ddrug3 , DB01050 , ddrug5 , ddrug6 , ddrug7 and others that interfere with platelet-aggregation reactions { the main hemostatic defense of heparinized patients } may induce bleeding and should be used with caution in patients receiving DB01109 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : HD00401 inhibit the hypotensive effect of HD00392 .",
        "label": "effect"
    },
    {
        "text": "particular caution is necessary when using ddrug0 in cases of mixed drug overdosage since the toxic effects { such as convulsions and cardiac dysrhythmias } of other drugs taken in overdose { especially HD00733 } may emerge with the reversal of the ddrug2 effect by DB01205 .",
        "label": "NA"
    },
    {
        "text": "may interact with addictive medications , especially HD00458 with habituating potential { prolonged concurrent use may increase the risk of habituation } , DB02325 or cns depression producing medications { concurrent use may increase the cns depressant effects of either these medications or ddrug2 } .",
        "label": "NA"
    },
    {
        "text": "decreased core temperature in female rats was investigated as one possible index of the DB00822 - DB00898 reaction { der } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { ddrug1 , DB00594 , ddrug3 , and others } or DB14500 supplements can increase the risk of hyperkalemia .",
        "label": "NA"
    },
    {
        "text": "inducers and inhibitors of hepatic metabolism : DB01045 reduced plasma concentrations of DB01136 by about 70 % .",
        "label": "mechanism"
    },
    {
        "text": "concurrent administration of DB00005 { another tnf - blocking agent } and DB00026 { an ddrug2 } has been associated with an increased risk of serious infections , and increased risk of neutropenia and no additional benefit compared to these medicinal products alone .",
        "label": "effect"
    },
    {
        "text": "therefore , DB00601 has the potential for interaction with ddrug1 and HD00851 .",
        "label": "int"
    },
    {
        "text": "HD00295 : DB00999 , given concomitantly with ddrug2 , produces a reduction in urinary potassium and chloride excretion compared to ddrug3 alone .",
        "label": "NA"
    },
    {
        "text": "drug-drug interactions : no clinically significant drug interactions have been found with DB00277 at a low dose , ddrug1 , ddrug2 , ddrug3 , or DB00199 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a study in healthy volunteers , no clinically relevant pharmacokinetic or pharmacodynamic interaction between ddrug1 and racemic DB00682 was seen when two single oral doses of ddrug3 { # mg/kg body weight } were administered during # days of multipledose treatment with # mg b , i , d , DB00270 .",
        "label": "NA"
    },
    {
        "text": "patients receiving other ddrug0 , HD00031 , ddrug2 , or other ddrug3 { including DB02325 } concomitantly with ddrug5 and ddrug6 tablets may exhibit an additive cns depression .",
        "label": "NA"
    },
    {
        "text": "the following specific interactions have been reported : itraconazole co-administration of another extended release formulation of ddrug0 with DB01167 resulted in approximately 8-fold increase in the auc , more than 6 - fold increase in the cmax , and 2-fold prolongation in the half - life of DB01023 .",
        "label": "NA"
    },
    {
        "text": "pharmacologic studies indicate that there may be additive effects in prolonging av conduction when using HD00254 or ddrug1 concomitantly with DB00343 .",
        "label": "effect"
    },
    {
        "text": "therefore , co-administration of DB00363 with other drugs that are metabolized by this isozyme , including ddrug1 , ddrug2 , DB00564 , and ddrug4 { e , g , , ddrug5 , ddrug6 and ddrug7 } , or that inhibit this enzyme { e , g , , ddrug8 } , should be approached with caution .",
        "label": "advise"
    },
    {
        "text": "ddrug0 { e , g , , ddrug1 , ddrug2 , ddrug3 , ddrug4 , etc , } : in vitro and animal studies with the combination of DB00681 and HD00319 suggest that ddrug7 may induce fungal resistance to ddrug8 .",
        "label": "NA"
    },
    {
        "text": "use in conjunction with other ddrug0 : the addition of DB00949 to ddrug2 { HD00714 } affects the steady-state plasma concentrations of ddrug4 .",
        "label": "mechanism"
    },
    {
        "text": "if a patient requires ddrug0 and ddrug1 therapy , it is suggested that ddrug2 , DB00863 , or ddrug4 { ddrug5 and ddrug6 } be used as alternatives to ddrug7 , as these agents have no effect on the pharmacokinetic profile of DB00204 .",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with HD00374 containing ddrug2 , ddrug3 , or ddrug4 , with ddrug5 , with metal cations such as DB01592 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "in patients who have received HD00542 , ddrug1 may temporarily mask the residual effects of HD00654 .",
        "label": "NA"
    },
    {
        "text": "in pigeons , DB01183 did not systematically alter the effects of ddrug1 , ddrug2 or DB03575 .",
        "label": "NA"
    },
    {
        "text": "influence of coadministration of DB00472 on DB00604 pharmacokinetics and qtc intervals in healthy volunteers .",
        "label": "NA"
    },
    {
        "text": "DB01241 other ddrug1 ddrug2 { DB00627 } { = 1 g/day }",
        "label": "NA"
    },
    {
        "text": "therefore , the combination of DB01009 and DB01032 is not recommended .",
        "label": "advise"
    },
    {
        "text": "haemodynamic effects of ddrug0 and HD00071 were additive when DB09099 was co-administered but not under basal conditions .",
        "label": "NA"
    },
    {
        "text": "concomitant use of ddrug0 and drugs that inhibit cyp3a4 { eg , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , DB00976 } may increase exposure to DB01254 and should be avoided .",
        "label": "NA"
    },
    {
        "text": "in addition , studies in healthy volunteers have shown that DB00204 does not affect the pharmacokinetics or pharmacodynamics of ddrug1 , or the pharmacokinetics of ddrug2 { 40 mg twice daily } , DB00252 , ddrug4 , or oral ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { HD00548 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , DB00812 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { DB00400 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , DB01232 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "HD00024 and ddrug1 { e , g , , DB00829 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and DB00421 raise the serum ddrug8 concentration due to a reduction in clearance and/or in volume of distribution of the drug , with the implication that HD00118 intoxication may result .",
        "label": "NA"
    },
    {
        "text": "the optimal dosing interval for coadministration with DB00900 should be determined by consulting the appropriate HD00533 package insert .",
        "label": "NA"
    },
    {
        "text": "interactions for ddrug0 { DB00153 , ddrug2 , ddrug3 , and ddrug4 } : DB01432 : ddrug6 has been reported to reduce intestinal absorption of ddrug7 ;",
        "label": "NA"
    },
    {
        "text": "the use of DB00565 before ddrug1 to attenuate some of the side effects of DB00202 has not been studied .",
        "label": "NA"
    },
    {
        "text": "in clinical studies , coadministration of DB00930 with DB01076 , ddrug2 , or ddrug3 did not interfere with the lipid-lowering activity of the ddrug4 .",
        "label": "NA"
    },
    {
        "text": "DB00615 : coadministration of ddrug1 and ddrug2 resulted in a 32 % decrease in DB00220 plasma auc and a 207 % increase in ddrug4 plasma a , c.",
        "label": "NA"
    },
    {
        "text": "in addition , studies in healthy volunteers have shown that ddrug0 does not affect the pharmacokinetics or pharmacodynamics of ddrug1 , or the pharmacokinetics of ddrug2 { 40 mg twice daily } , ddrug3 , DB00277 , or oral HD00283 .",
        "label": "NA"
    },
    {
        "text": "this might be explained by a blockade by DB01032 of the elimination of DB01147 by the liver .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 salts may reduce the bioavailability of DB00190 and DB01235 .",
        "label": "NA"
    },
    {
        "text": "in patients receiving nonselective ddrug0 { HD00546 } { e , g , , ddrug2 } in combination with ddrug3 { e , g , , ddrug4 , ddrug5 , ddrug6 , ddrug7 , DB00285 } , there have been reports of serious , sometimes fatal , reactions .",
        "label": "effect"
    },
    {
        "text": "DB00612 should be used with care when ddrug1 or inhibitors of av conduction , such as certain ddrug2 { particularly of the ddrug3 -lsb- DB00661 -rsb- and ddrug5 -lsb- ddrug6 -rsb- classes } , or ddrug7 , such as ddrug8 , are used concurrently .",
        "label": "advise"
    },
    {
        "text": "interactions may occur between DB00159 supplements and ddrug1 and other ddrug2 and herbs such as garlic { allium sativum } and ddrug3 { DB01381 } .",
        "label": "int"
    },
    {
        "text": "ddrug0 may interact with the following medications : DB00316 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , DB00091 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "plasma concentrations of HD00279 are decreased when administered with HD00374 containing ddrug2 , ddrug3 , or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "- a ddrug0 { HD00615 } such as ddrug2 { ddrug3 , ddrug4 , ddrug5 , others } , ddrug6 { ddrug7 , ddrug8 , ddrug9 } , ddrug10 { ddrug11 , ddrug12 } , ddrug13 { DB00749 } , ddrug15 { ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , and ddrug21 { ddrug22 , ddrug23 , ddrug24 } ;",
        "label": "NA"
    },
    {
        "text": "when ddrug0 and DB00733 are used together , the signs of atropinization { flushing , mydriasis , tachycardia , dryness of the mouth and nose } may occur earlier than might be expected than when DB00572 is used alone because ddrug3 may potentiate the effect of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "the concentrations of ddrug0 , the active metabolite of DB00762 , were on average 33 % higher in patients receiving bolus-ifl in combination with DB00112 when compared with bolus-ifl alone .",
        "label": "NA"
    },
    {
        "text": "before taking DB00222 , tell your doctor if you are taking any of the following medicines : - DB00945 or another ddrug2 such as ddrug3 { ddrug4 } , ddrug5 { ddrug6 , others } , ddrug7 { ddrug8 } , ddrug9 { ddrug10 } , or ddrug11 { ddrug12 } ;",
        "label": "advise"
    },
    {
        "text": "if treatment with inhibitors of cyp3a4 activity { such as ddrug0 , ddrug1 , ddrug2 , ddrug3 , DB01232 , ddrug5 , etc , } is indicated , reduction of the DB01222 dose should be considered .",
        "label": "advise"
    },
    {
        "text": "DB00574 may increase slightly the effect of ddrug1 , e , g , , DB01170 , ddrug3 , ddrug4 .",
        "label": "effect"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { DB00682 } other ddrug2 ddrug3 HD00388 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "although there was no clinical evidence in the vehicle-controlled studies of drug interactions with systemic HD00268 , including HD00269 , ddrug2 , and ddrug3 , the effect of ddrug4 gel on the steady-state concentrations of these drugs is not known .",
        "label": "NA"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : DB00228 ; ddrug2 ; ddrug3 ; certain HD00002 , especially the ddrug5 and ddrug6 ; ddrug7 ; ddrug8 salts ; ddrug9 ; and ddrug10 .",
        "label": "NA"
    },
    {
        "text": "the majority of patients in ra clinical studies received one or more of the following concomitant medications with DB01281 : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB00608 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , and ddrug11 .",
        "label": "NA"
    },
    {
        "text": "however , preliminary results from an 8-week trial showed comparable cognitive enhancing effects of DB00334 and DB00734 treatment in patients with schizophrenia or schizoaffective disorder .",
        "label": "NA"
    },
    {
        "text": "DB00357 accelerates the metabolism of DB01234 ;",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { DB00091 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , DB01232 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "HD00295 : ddrug1 , given concomitantly with ddrug2 , produces a reduction in urinary potassium and chloride excretion compared to DB00999 alone .",
        "label": "NA"
    },
    {
        "text": "HD00444 : concurrent administration of certain HD00537 , such as ddrug2 and ddrug3 , would be expected to compromise the beneficial effects of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on ddrug0 therapy : ddrug1 , HD00175 , HD00220 , oral ddrug4 containing ddrug5 , ddrug6 - containing preparations and the numerous preparations containing ddrug7 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , HD00802 : e , g , , ddrug2 , DB01115 , ddrug4",
        "label": "NA"
    },
    {
        "text": "DB00955 should not be administered concomitantly with potent ddrug1 such as ddrug2 and DB00903 as the potential for ototoxicity is enhanced by the combination .",
        "label": "advise"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 HD00303 : ddrug2 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 HD00100 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "HD00423 altered coagulation parameters and/or bleeding have been reported in patients taking ddrug1 concomitantly with ddrug2 such as ddrug3 and DB00946 .",
        "label": "NA"
    },
    {
        "text": "HD00343 : HD00610 , as well as a metabolite of ddrug2 , slow ddrug3 metabolism .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 : ddrug2 and ddrug3 containing ddrug4 or DB01370 , as well as formulations containing divalent and trivalent cations such as ddrug6 { DB00900 } , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with ddrug8 and interfere with its bioavailability .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 may enhance the effects of : other ddrug3 s , ddrug4 , general ddrug5 , ddrug6 such as DB00475 , HD00460 , or other ddrug9 , causing increased cns depression .",
        "label": "NA"
    },
    {
        "text": "drugs which require a dose reduction when coadminstered with DB00220 ddrug1 : DB00615",
        "label": "advise"
    },
    {
        "text": "ddrug0 : the concomitant administration of DB00270 { ddrug2 } and ddrug3 in a single-dose pharmacokinetic study did not affect renal , nonrenal and total body clearance of DB00390 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { DB00316 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { DB00091 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "- DB04948 may enhance the cns depressive effects of ddrug1 , HD00026 and other ddrug3",
        "label": "effect"
    },
    {
        "text": "patients receiving other ddrug0 s , general HD00264 , ddrug2 , ddrug3 , ddrug4 , ddrug5 or other ddrug6 { including ddrug7 } concomitantly with DB00327 may exhibit an additive cns depression .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : concomitant administration of DB00196 at # mg qd resulted in a two-fold increase in DB00482 plasma concentration .",
        "label": "mechanism"
    },
    {
        "text": "to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma { hiv-nhl } , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the ddrug0 , ddrug1 , ddrug2 , and ddrug3 { chop } chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen { i , e , , ddrug4 , ddrug5 , DB00444 , and ddrug7 with ddrug8 plus ddrug9 } without receiving HD00056 therapy .",
        "label": "NA"
    },
    {
        "text": "co-administration with ddrug0 such as DB01026 or DB01167 is not recommended .",
        "label": "NA"
    },
    {
        "text": "DB00008 contains DB06770 .",
        "label": "NA"
    },
    {
        "text": "it has been reported that the addition of DB00384 to a maintenance schedule of DB00328 resulted in reversible acute renal failure in two of four healthy volunteers .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { DB00400 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { HD00712 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "patients on oral HD00075 receiving ddrug1 treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their HD00430 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a pharmacokinetic study , maximum plasma concentrations of DB01023 were considerably lower in epileptic patients on long-term ddrug2 therapy { eg , DB00252 , ddrug4 , or ddrug5 } than in healthy volunteers .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 , ddrug1 , and ddrug2 : drugs such as HD00795 , ddrug4 , and ddrug5 may increase the risk of developing peripheral_neuropathies or other ddrug6 - associated adverse events by interfering with the renal clearance of DB00943 { thereby raising systemic exposure } .",
        "label": "mechanism"
    },
    {
        "text": "the intake of DB00695 and DB00364 should be separated by at least two hours .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : elevated serum levels of ddrug1 have been reported with concomitant use of DB00091 with other members of the HD00678 .",
        "label": "mechanism"
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as DB01135 include certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 } , ddrug10 salts , ddrug11 , local ddrug12 , DB01035 , and ddrug14 .",
        "label": "effect"
    },
    {
        "text": "medications can interfere with folate utilization , including : ddrug0 { such as ddrug1 , and DB00794 } DB00331 { sometimes prescribed to control blood sugar in type # diabetes } ddrug4 { used to control inflammation associated with crohn_disease and ulcerative colitis } ddrug5 { a ddrug6 } ddrug7 there has been concern about the interaction between ddrug8 and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "these increased exposures of DB00717 and DB00977 should be taken into consideration when selecting an oral ddrug2 for women taking ddrug3 .",
        "label": "NA"
    },
    {
        "text": "however , the absolute number of DB02325 - related deaths is far greater than the number of deaths in ddrug1 or DB01452 users .",
        "label": "NA"
    },
    {
        "text": "DB14513 - and/or ddrug1 - containing ddrug2 , products containing ddrug3 { ddrug4 } , ddrug5 containing ddrug6 or other metal cations , or ddrug7 { DB00900 } chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after ddrug9 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , DB01167 , ddrug6 , and ddrug7 raise the serum ddrug8 concentration due to a reduction in clearance and/or in volume of distribution of the drug , with the implication that HD00118 intoxication may result .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , certain ddrug7 , DB00281 , DB00277 and ddrug10 , thereby delaying elimination and increasing blood levels of these drugs .",
        "label": "NA"
    },
    {
        "text": "HD00026 may decrease the effectiveness of oral ddrug1 , certain ddrug2 , ddrug3 , DB00277 , ddrug5 , ddrug6 , and ddrug7 .",
        "label": "effect"
    },
    {
        "text": "immediate and extended release tablets the hypoglycemic action of HD00222 may be potentiated by certain drugs including ddrug1 , some ddrug2 and other drugs that are highly protein bound , HD00328 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 .",
        "label": "effect"
    },
    {
        "text": "after the coadministration of # mg oral DB01026 twice daily and one # mg dose of ddrug1 to # subjects , the auc and cmax of DB00455 averaged 302 % { # s , d , } and 251 % { # s , d , } , respectively , of those obtained after co-treatment with placebo .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other HD00216 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { DB01026 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "acute DB14539 administration does not affect subjective responses to DB01576 in humans .",
        "label": "NA"
    },
    {
        "text": "because severe hypoglycemia has been reported in patients concomitantly receiving oral ddrug0 { an ddrug1 } and oral HD00062 , such a potential interaction involving the latter agents when used concomitantly with ddrug3 tablets { an DB03366 } can not be ruled out .",
        "label": "NA"
    },
    {
        "text": "HD00244 : experience in over # patients in a non-comparative clinical trial has shown that concomitant administration of DB01115 and ddrug2 is usually well tolerated , but there have been occasional literature reports suggesting that the combination may increase the likelihood of congestive heart failure , severe hypotension or exacerbation of angina .",
        "label": "NA"
    },
    {
        "text": "in a study in hypertensive patients , addition of ddrug0 to existing DB00999 therapy did not result in any unexpected adverse effects , and DB00270 had an additional antihypertensive effect .",
        "label": "NA"
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the ddrug0 of drugs may be potentiated by ddrug1 , HD00543 , ddrug3 , ddrug4 , ddrug5 , the ddrug6 , ddrug7 and HD00560 , ddrug9 and the ddrug10 , and by other ddrug11 .",
        "label": "NA"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { HD00403 s } , ddrug2 , ddrug3 { ddrug4 may decrease the effects of these medicines } , ddrug5 { using these medicines with ddrug6 may result in increased cns depressant effects } , ddrug7 , ddrug8 { using these medicines with HD00026 may change the amount of either medicine that you need to take } , and oral ddrug10 containing ddrug11 { ddrug12 may decrease the effectiveness of these oral ddrug13 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "serious cardiac dysrhythmias , some resulting in death , have occurred in patients receiving DB00342 concomitantly with other HD00093 .",
        "label": "effect"
    },
    {
        "text": "coingestion of ddrug0 with DB00277 , ddrug2 with ddrug3 , and ddrug4 with DB01174 at high to toxic concentrations decreases the binding of the target drug .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : concomitant administration of ddrug1 and some HD00203 has been reported to reduce the clearance of ddrug3 , enhancing the toxicity of DB00563 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : combination ddrug1 may decrease the clearance of some ddrug2 { ddrug3 , DB00475 , ddrug5 } and increase the clearance of others { ddrug6 , ddrug7 , DB00231 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of ddrug1 , ddrug2 , ddrug3 , ddrug4 , DB00475 , ddrug6 , certain ddrug7 , ddrug8 , DB00277 and ddrug10 , thereby delaying elimination and increasing blood levels of these drugs .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the effect of an DB06723 - and DB09104 - containing ddrug3 { ddrug4 } * on the pharmacokinetics of ddrug5 was investigated in # cancer patients .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 { and possibly other HD00093 } and ddrug3 may increase DB00390 absorption in patients who inactivate ddrug5 by bacterial metabolism in the lower intestine , so that ddrug6 intoxication may result .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 or oral ddrug1 : HD00482 may enhance the blood-sugar-reducing effect of ddrug3 and oral HD00484 .",
        "label": "effect"
    },
    {
        "text": "improvements in general cognitive function seen with DB00334 treatment in a 1-year controlled study of patients with early-phase schizophrenia , were significantly greater than changes seen with either ddrug1 or DB00502 .",
        "label": "NA"
    },
    {
        "text": "concomitant use of DB00943 with DB00900 is not recommended .",
        "label": "advise"
    },
    {
        "text": "- DB04948 may enhance the cns depressive effects of DB02325 , ddrug2 and other ddrug3",
        "label": "effect"
    },
    {
        "text": "coadministration of ddrug0 and DB00717 1/35 increased the exposure of DB00717 and ddrug3 by 20 % and 34 % , respectively .",
        "label": "NA"
    },
    {
        "text": "- drugs that may decrease plasma ddrug0 concentrations include : DB00564 , chronic ddrug2 abuse , DB00206",
        "label": "NA"
    },
    {
        "text": "in a study in diabetics with microalbuminuria ddrug0 # mg combined with the HD00471 DB00584 # mg increased the frequency of hyperkalemia { serum potassium # meq/l } from 17 % on ddrug3 alone to 38 % .",
        "label": "NA"
    },
    {
        "text": "plasma levels of HD00065 may become subtherapeutic during DB00515 therapy .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : based on reports of profound hypotension and loss of consciousness when DB00714 was administered with ddrug2 , the concomitant use of ddrug3 with drugs of the ddrug4 { including , for example , ddrug5 , DB00889 , ddrug7 , ddrug8 , and ddrug9 } is contraindicated .",
        "label": "NA"
    },
    {
        "text": "- DB01022 { e , g , , ddrug1 , ddrug2 } use of DB00891 with these medicines may increase the chance of side effects affecting the blood",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and DB00759 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { DB00295 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { e , g , DB00199 and ddrug2 } : agents of the ddrug3 , of which DB00320 { ddrug5 } injection , usp is a member , have been shown to interact with ddrug6 of the ddrug7 , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 : ddrug1 , when given once daily for # days as a 100-mg capsule with an oral HD00349 containing # mcg of DB00977 and # mg of ddrug4 , decreased the auc of ddrug5 by 43 % , and decreased the auc of ddrug6 by 8 % ;",
        "label": "NA"
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of HD00472 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 { 1 } , DB01764 , ddrug6 , ddrug7 , ddrug8 , ddrug9 { 1 } , ddrug10 , ddrug11 , grapefruit juice , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21 , ddrug22 , ddrug23 , ddrug24 { 1 } , ddrug25 , ddrug26 .",
        "label": "mechanism"
    },
    {
        "text": "because of its primary cns effect , caution should be used when ddrug0 is taken with other HD00365 and DB02325 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , DB01076 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , DB00277 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "intravenous DB00640 { ddrug1 } has been effectively administered in the presence of other cardioactive drugs , such as DB00908 , ddrug3 , ddrug4 , and ddrug5 , without any change in the adverse reaction profile .",
        "label": "NA"
    },
    {
        "text": "because the potential interaction of DB00625 with oral ddrug1 has not been fully characterized , a reliable method of barrier contraception should be used in addition to oral HD00283 .",
        "label": "NA"
    },
    {
        "text": "some reports have shown that the concomitant administration of HD00217 with DB11094 causes hypercalcemia .",
        "label": "effect"
    },
    {
        "text": "ddrug0 , a HD00616 , may antagonize the bactericidal effect of HD00284 and concurrent use of these drugs should be avoided .",
        "label": "NA"
    },
    {
        "text": "therefore , patients without a functioning DB00451 gland who are on thyroid replacement therapy may need to increase their thyroid dose if ddrug1 or ddrug2 - containing oral HD00283 are given .",
        "label": "advise"
    },
    {
        "text": "therefore , plasma concentrations of DB00252 should also be monitored when it is given concurrently with DB01167 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , HD00002 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , DB00776 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "administration of HD00532 with ddrug1 containing ddrug2 , DB14513 , or ddrug4 , with ddrug5 , with metal cations such as ddrug6 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 such as ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , ddrug5 { e , g , , ddrug6 } , ddrug7 { e , g , , ddrug8 } , and DB00752 { e , g , , ddrug10 } : using these medicines with DB00150 may increase the chance of side effects .",
        "label": "NA"
    },
    {
        "text": "DB00542 , like other ddrug1 , has had less than additive effects with HD00397 , presumably because both drugs lower blood pressure by inhibiting parts of the renin-angiotensin system",
        "label": "effect"
    },
    {
        "text": "therefore , co-administration of DB01156 with drugs that are metabolized by cyp2d6 isoenzyme including certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } , ddrug8 { e , g , , ddrug9 , ddrug10 , ddrug11 } , ddrug12 { e , g , , ddrug13 } , and ddrug14 { e , g , , DB01182 , ddrug16 } , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .",
        "label": "advise"
    },
    {
        "text": "in some patients , the administration of DB00328 can reduce the diuretic , natriuretic , and antihypertensive effects of ddrug1 , HD00293 , and ddrug3 .",
        "label": "effect"
    },
    {
        "text": "increasing the ddrug0 dose to # mg every # hours does not compensate for the increased DB00224 metabolism due to DB00625 .",
        "label": "mechanism"
    },
    {
        "text": "avoid the use of preparations such as ddrug0 and local HD00264 which contain any ddrug2 { e , g , , ddrug3 , DB00368 } , since it has been reported that ddrug5 can potentiate the effects of catecholamines .",
        "label": "NA"
    },
    {
        "text": "therefore , co-administration of DB01156 with drugs that are metabolized by cyp2d6 isoenzyme including certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } , ddrug8 { e , g , , ddrug9 , ddrug10 , DB00679 } , ddrug12 { e , g , , ddrug13 } , and ddrug14 { e , g , , ddrug15 , ddrug16 } , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .",
        "label": "advise"
    },
    {
        "text": "because there are no data on the compatibility of ddrug0 and crystalline HD00664 preparations , DB01306 should not be mixed with these preparations .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration of DB01045 and DB01117 suspension results in a significant decrease in average steady - state plasma ddrug3 concentrations .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , DB01076 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as HD00269 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : administration of DB00900 # hours prior to or concurrent with oral ddrug2 was associated with a # { 114 } % increase in the steady-state auc of DB00900 { n = 12 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 : ddrug2 and ddrug3 containing ddrug4 or ddrug5 , as well as formulations containing divalent and trivalent cations such as ddrug6 { DB00900 } , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with DB00978 and interfere with its bioavailability .",
        "label": "mechanism"
    },
    {
        "text": "therefore , co-administration of DB01156 with drugs that are metabolized by cyp2d6 isoenzyme including certain HD00216 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } , ddrug8 { e , g , , ddrug9 , ddrug10 , ddrug11 } , ddrug12 { e , g , , ddrug13 } , and ddrug14 { e , g , , ddrug15 , ddrug16 } , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .",
        "label": "advise"
    },
    {
        "text": "single doses of either ddrug0 or ddrug1 HD00510 bind the DB00999 and reduce its absorption from the gastrointestinal tract by up to # and # percent , respectively .",
        "label": "NA"
    },
    {
        "text": "concomitant ddrug0 , ddrug1 , DB00541 , and ddrug3 chemotherapy plus HD00055 therapy in patients with human immunodeficiency virus-related , non-hodgkin lymphoma .",
        "label": "NA"
    },
    {
        "text": "likewise , DB00996 pharmacokinetics were unaltered by DB00564 administration .",
        "label": "NA"
    },
    {
        "text": "DB00107 or other ddrug1 { concurrent use with DB12789 may result in uterine hypertonus , possibly causing uterine rupture or cervical laceration , especially in the absence of adequate cervical dilatation ;",
        "label": "effect"
    },
    {
        "text": "before taking ddrug0 , tell your doctor if you are taking any of the following medicines : - ddrug1 or another HD00372 such as ddrug3 { ddrug4 } , ddrug5 { ddrug6 , others } , ddrug7 { HD00757 } , ddrug9 { ddrug10 } , or ddrug11 { ddrug12 } ;",
        "label": "NA"
    },
    {
        "text": "other drug interactions : no pharmacokinetic interactions were observed between ddrug0 and the following drugs : DB01016 , DB00682 , ddrug3 , ddrug4 , and ddrug5 .",
        "label": "NA"
    },
    {
        "text": "HD00100 : combination ddrug1 may decrease the clearance of some ddrug2 { ddrug3 , ddrug4 , ddrug5 } and increase the clearance of others { ddrug6 , DB00842 , ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "since DB00593 { ddrug1 } may interact with concurrently administered ddrug2 , periodic serum level determinations of these drugs may be necessary { eg , DB00593 may elevate ddrug4 serum levels and ddrug5 has been reported to both increase and decrease ddrug6 levels } .",
        "label": "NA"
    },
    {
        "text": "because DB00573 has not been shown to produce any additional effect beyond that obtained with ddrug1 alone and because DB00945 increases the rate of excretion of ddrug3 , the concomitant use of ddrug4 and ddrug5 is not recommended .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of HD00071 : ddrug1 , DB01406 , ddrug3 , ddrug4 { e , g , , ddrug5 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "in separate studies of patients receiving maintenance doses of ddrug0 , ddrug1 , or ddrug2 , DB01029 administration for # days had no effect on the pharmacodynamics of ddrug4 { prothrombin time } or pharmacokinetics of DB00390 .",
        "label": "NA"
    },
    {
        "text": "however , in vivo drug interaction studies of DB01026 with DB11094 have not been investigated .",
        "label": "NA"
    },
    {
        "text": "talk to your doctor if you are taking certain HD00002 such as DB00199 , ddrug2 or ddrug3 .",
        "label": "NA"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / ddrug1 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , DB00571 } , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , HD00516 pain medication { e , g , , ddrug12 } , drugs used to aid sleep , drowsiness-causing ddrug13 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "no interaction was noted with the ddrug0 ddrug1 in two multiple-dose interaction studies when DB00494 was coadministered with a DB01235 / ddrug4 { n = 29 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 reports suggest that HD00203 may diminish the antihypertensive effect of HD00500 .",
        "label": "effect"
    },
    {
        "text": "an adequate period of observation must be provided for any patient in whom either ddrug0 { such as ddrug1 } or large doses of HD00736 { such as # mg of DB00683 } have been used .",
        "label": "NA"
    },
    {
        "text": "in vitro studies evaluating the minimum inhibitory concentration { mic } of ddrug0 , ddrug1 , ddrug2 , ddrug3 / flucoxacillin , ddrug4 , ddrug5 , and HD00795 demonstrated no evidence of incompatibility of these HD00002 with ddrug8 .",
        "label": "NA"
    },
    {
        "text": "HD00388 may have additive effects with ddrug1 and other ddrug2 , e , g , , ddrug3 , ddrug4 , ddrug5 , HD00557 .",
        "label": "effect"
    },
    {
        "text": "DB00501 } and many that are substrates for cyp2b6 2d6 { many other ddrug1 , ddrug2 , and the ddrug3 ddrug4 and DB01195 } .",
        "label": "NA"
    },
    {
        "text": "this article looks at five commonly used HD00084 in turn { HD00175 , ddrug2 , ddrug3 , ddrug4 , ddrug5 } , discussing the main , non-infection , unwanted effects , ways to avoid them and what to do if problems arise .",
        "label": "NA"
    },
    {
        "text": "in patients taking DB00586 and ddrug1 concomitantly , DB14507 toxicity may develop .",
        "label": "NA"
    },
    {
        "text": "if ddrug0 is to be combined with other ddrug1 such as ddrug2 or ddrug3 / HD00214 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of DB01151 and ddrug6 { e , g , , ddrug7 or ddrug8 } are additive .",
        "label": "NA"
    },
    {
        "text": "DB00207 had no significant impact on the cmax and auc of ddrug1 , although it significantly decreased the DB00495 tmax by 44 % and increased the intracellular exposure to phosphorylated ddrug3 by 110 % .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : DB14513 - containing preparations { eg , ddrug2 } may cause hypermagnesemia and should therefore not be taken during therapy with DB11094 by patients on chronic renal dialysis .",
        "label": "effect"
    },
    {
        "text": "ddrug0 ddrug1 , as well as a metabolite of DB00614 , slow DB00182 metabolism .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : in a clinical pharmacology study , coadministration of an ddrug1 { ddrug2 , ddrug3 , and DB11074 } with DB00492 reduced serum levels and urinary excretion of ddrug6 as compared with ddrug7 administered alone , suggesting that ddrug8 may impair absorption of ddrug9 .",
        "label": "mechanism"
    },
    {
        "text": "in this study we investigated the effect of DB14152 on high threshold voltage-dependent ca { 2 + } channel subtypes using their HD00046 ddrug2 { l-type } , ddrug3 { n-type } , or ddrug4 { p-type } in bovine chromaffin cells .",
        "label": "NA"
    },
    {
        "text": "DB00542 , like other HD00106 , has had less than additive effects with ddrug2 , presumably because both drugs lower blood pressure by inhibiting parts of the renin-angiotensin system",
        "label": "NA"
    },
    {
        "text": "ddrug0 : studies in animals demonstrate that the acute toxicity of DB01156 is enhanced by the ddrug2 DB00780 .",
        "label": "effect"
    },
    {
        "text": "- when ddrug0 or ddrug1 is used concurrently with HD00418 { e , g , ddrug3 } , an interval of at least # hours should be maintained between the two medicines , since the absorption of ddrug4 or HD00415 is impaired",
        "label": "NA"
    },
    {
        "text": "the pharmacokinetics of DB00704 and its major metabolite ddrug1 were unaffected following co-administration with DB00659 .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of ddrug0 and ddrug1 , ddrug2 , ddrug3 , or an HD00183 / ddrug5 oral ddrug6 produced minor changes in the pharmacokinetics of DB01155 , which were considered to be without clinical significance .",
        "label": "NA"
    },
    {
        "text": "drug interaction with ddrug0 and DB01026 DB00950 has been shown to exhibit minimal { ca , 5 % } metabolism .",
        "label": "NA"
    },
    {
        "text": "the plasma concentration of DB00458 may increase when the drug is given concomitantly with hepatic enzyme inhibitors { e , g , , DB00501 , ddrug2 } and decrease by concomitant administration of hepatic enzyme inducers { e , g , , ddrug3 , ddrug4 } , and adjustment of the dosage of ddrug5 may therefore be necessary .",
        "label": "mechanism"
    },
    {
        "text": "the influence of DB00683 and ddrug1 on antinociceptive effect of ddrug2 { 10 mg/kg } , ddrug3 { 500 mg/kg } and DB00328 { 10 mg/kg } was investigated in a mouse model using the tail-flick and hot-plate tests .",
        "label": "NA"
    },
    {
        "text": "DB00294 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , DB00231 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "int"
    },
    {
        "text": "ddrug0 absorption : the following agents may bind and decrease absorption of DB00451 from the gastrointestinal tract : ddrug2 , ddrug3 resin , ddrug4 , ddrug5 , DB01344 , soybean flour { e , g , , infant formula } , ddrug7 .",
        "label": "mechanism"
    },
    {
        "text": "ironically , HD00100 are often used in the treatment of DB01452 addiction while they cause much more severe withdrawal symptoms .",
        "label": "NA"
    },
    {
        "text": "and HD00208 e , g , , ddrug1 } , cyp1a2 inducers { DB00338 } and cyp1a2 inhibitors { ddrug3 and ddrug4 } .",
        "label": "NA"
    },
    {
        "text": "in patients taking ddrug0 , ddrug1 , DB00343 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and various chemotherapy agents , no effect was shown on the clearance of HD00644 .",
        "label": "NA"
    },
    {
        "text": "because there is a theoretical basis that these effects may be additive , use of DB00201 - containing or ddrug1 { like ddrug2 or ddrug3 } and DB00952 within # hours is contraindicated .",
        "label": "advise"
    },
    {
        "text": "HD00322 : ddrug1 , ddrug2 , ddrug3 , or ddrug4 may interfere with the bactericidal effect of HD00124 .",
        "label": "NA"
    },
    {
        "text": "when DB01432 HD00524 is given for long periods of time , concomitant supplementation with water-miscible { or parenteral } forms of ddrug2 should be considered .",
        "label": "NA"
    },
    {
        "text": "DB00520 reduced the blood auc0 - 12 of ddrug1 by approximately 20 % , peak blood concentration { cmax } by 16 % , and 12-hour blood concentration { c12hr } by 26 % in healthy subjects when ddrug2 { 2 doses of # mg/kg # hours apart } was administered on the 10th day of ddrug3 # mg daily , as compared to results from a control period in which DB00864 was administered alone .",
        "label": "NA"
    },
    {
        "text": "if ddrug0 is to be combined with other HD00595 such as ddrug2 or ddrug3 / ddrug4 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of ddrug5 and HD00100 { e , g , , ddrug7 or ddrug8 } are additive .",
        "label": "NA"
    },
    {
        "text": "the action of the HD00100 may be potentiated by ddrug1 , HD00388 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , or other drugs that produce cns depression .",
        "label": "effect"
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma DB00252 concentrations include : acute ddrug1 intake , ddrug2 , chboramphenicol , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , DB00593 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21",
        "label": "mechanism"
    },
    {
        "text": "injection : ddrug0 injection , like other injectable HD00100 , produces depression of the central nervous system when administered with ddrug2 , ddrug3 , ddrug4 , ddrug5 , and other ddrug6 , when DB00747 is used concomitantly with injectable ddrug8 , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .",
        "label": "NA"
    },
    {
        "text": "-lsb- stimulation by ddrug0 -- an analog of the octapeptide cholecystokinin -- of ddrug1 binding after the long-term administration of ddrug2 -rsb- it has been established in experiments on white male rats that prolonged administration { twice a day for # days } of ddrug3 { # mg/kg } and ddrug4 { # mg/kg } resulted in the reduced interaction between HD00136 and low affinity binding sites for ddrug6 in subcortical structures , whereas ddrug7 binding with high affinity binding sites for DB00714 increased both in the frontal cortex and subcortical structures of the forebrain .",
        "label": "NA"
    },
    {
        "text": "in europe , DB00393 was observed to occasionally intensify the effect of HD00880 taken concomitantly by patients suffering from hypertension ;",
        "label": "effect"
    },
    {
        "text": "the concomitant intake of DB02325 and DB00659 does not affect the pharmacokinetics of either ddrug2 or ddrug3 .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 : in pharmacokinetic studies of DB00227 in hypercholesterolemic noninsulin dependent diabetic patients , there was no drug interaction with ddrug2 or with DB00672",
        "label": "NA"
    },
    {
        "text": "concomitant DB00531 , ddrug1 , ddrug2 , and ddrug3 chemotherapy plus HD00055 therapy in patients with human immunodeficiency virus-related , non-hodgkin lymphoma .",
        "label": "NA"
    },
    {
        "text": "DB01118 , DB00280 , ddrug2",
        "label": "NA"
    },
    {
        "text": "consequently , DB01215 should be avoided in patients receiving ddrug1 and DB01167 , which are very potent inhibitors of cyp3a .",
        "label": "advise"
    },
    {
        "text": "in patients receiving HD00724 , the addition of DB00573 to therapy could prolong the prothrombin time .",
        "label": "effect"
    },
    {
        "text": "DB00668 also should be used cautiously with other drugs { e , g , , HD00118 , ddrug2 } that sensitize the myocardium to the actions of ddrug3 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , ddrug8 { HD00398 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , HD00029 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "HD00326 including coumarin derivatives , indandione derivatives , and ddrug1 such as ddrug2 { ddrug3 } , and DB00945 may increase the risk of bleeding when administered concomitantly with ddrug5 .",
        "label": "NA"
    },
    {
        "text": "short-term pharmacokinetic studies have demonstrated that concomitant administration of DB00682 and ddrug1 { DB00749 capsules and tablets } results in reduced protein binding of ddrug3 , but there was no change in the clearance of free ddrug4 .",
        "label": "mechanism"
    },
    {
        "text": "neurochemical and functional consequences following HD00145 { ddrug1 } and DB01577 .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other HD00216 DB00264 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "-lsb- a pharmacological analysis of the effect of ddrug0 on stimulated gastric secretion -rsb- chronic experiments on dogs with gastric fistulas were carried out to study the influence of ddrug1 and ddrug2 on DB00183 - and DB05381 - induced gastric acid secretion .",
        "label": "NA"
    },
    {
        "text": "caution should also be applied for other HD00391 , and for ddrug1 and DB00277 and ddrug3 , which may also precipitate arrhythmias .",
        "label": "NA"
    },
    {
        "text": "DB00266 and DB00682 may decrease hypoprothrombinemic effect .",
        "label": "NA"
    },
    {
        "text": "in a study of schizophrenic patients who received DB00363 under steady state conditions , DB00176 or ddrug2 was added in # and # patients , respectively .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : concomitant administration of ddrug1 and DB00945 is not recommended because DB00586 is displaced from its binding sites during the concomitant administration of ddrug4 , resulting in lower plasma concentrations , peak plasma levels , and auc values .",
        "label": "NA"
    },
    {
        "text": "some ddrug0 , including DB00537 , have also been shown to interfere with the metabolism of DB00201 .",
        "label": "mechanism"
    },
    {
        "text": "HD00485 - ddrug1 containing side chains of n-methylthiotetrazole { ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 } or methylthiadiazole { DB01327 } can cause vitamin_k_deficiency and hypoprothrombinemia .",
        "label": "NA"
    },
    {
        "text": "DB00698 interferes with the therapeutic action of DB00779 .",
        "label": "effect"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } HD00220 ddrug10 { ddrug11 } sporal { ddrug12 } DB01026 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "in neither case were the pharmacokinetics of DB00669 affected by coadministration with DB00611 .",
        "label": "NA"
    },
    {
        "text": "as noted below , a sub - for DB00176 in combination with DB00404 , a drug that is known to be metabolized by the iiia4 isozyme .",
        "label": "NA"
    },
    {
        "text": "no important interactions to date DB00922 does not have clinically important pharmacokinetic interactions with ddrug1 , HD00254 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 or ddrug9 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 ddrug1 DB00365 , like other ddrug3 , may inhibit the metabolism of DB00201 and ddrug5 .",
        "label": "mechanism"
    },
    {
        "text": "drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving ddrug0 metabolized similarly to ddrug1 or on the basis of in vitro studies with ddrug2 or other ddrug3 { caution is recommended during coadministration with ddrug4 } : available data from clinical studies of ddrug5 other than ddrug6 suggest a possible drug interaction with DB00404 for the following : ddrug8 , DB00951 , ddrug10 such as ddrug11 and ddrug12 , and grapefruit juice .",
        "label": "int"
    },
    {
        "text": "HD00548 may displace acidic drugs such as ddrug1 or DB01124 from their binding sites .",
        "label": "mechanism"
    },
    {
        "text": "DB01195 has been used in a large number of patients receiving HD00218 without apparent interaction .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , HD00502 , DB00627 { ddrug3 , ddrug4 , ddrug5 : skeletal muscle .",
        "label": "NA"
    },
    {
        "text": "in a study in which the # mg ddrug0 orally disintegrating tablet was administered with and without ddrug1 { an ddrug2 with multiple effects on the gi tract } to healthy volunteers , the auc of ddrug3 was 10 % lower and the cmax of DB01068 was 20 % lower when the orally disintegrating tablet was given with DB00782 compared to when it was given alone .",
        "label": "mechanism"
    },
    {
        "text": "DB00294 may interact with the following medications : ddrug1 { ddrug2 } , HD00002 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "int"
    },
    {
        "text": "HD00374 , ddrug1 - pectin , ddrug2 , ddrug3 , ddrug4 , certain anticancer drugs , and ddrug5 may interfere with intestinal DB00390 absorption , resulting in unexpectedly low serum concentrations .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and DB00759 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , DB00273 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "caution is warranted and therapeutic concentration monitoring is recommended for HD00303 when coadministered with DB00224 .",
        "label": "advise"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / HD00517 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 pain medication { e , g , , DB00318 } , drugs used to aid sleep , drowsiness-causing ddrug13 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : there was no significant difference between DB01238 coadministered with ddrug2 and placebo coadministered with DB00898 on performance of gross motor skills or stimulus response in healthy subjects .",
        "label": "NA"
    },
    {
        "text": "ddrug0 / ddrug1 : an increase in the frequency of skin rash has been reported among patients receiving DB00415 or ddrug3 concurrently with DB00437 compared to patients who are not receiving both drugs .",
        "label": "effect"
    },
    {
        "text": "a similar association , though less marked , has been suggested with ddrug0 , ddrug1 , ddrug2 , ddrug3 , DB00400 , ddrug5 , and possibly with DB00415 and ddrug7 72 .",
        "label": "NA"
    },
    {
        "text": "because prostaglandins play an important role in hemostasis , and ddrug0 affect platelet function as well , concurrent therapy with all HD00203 , including ddrug2 , and ddrug3 requires close monitoring of patients to be certain that no change in their HD00025 dosage is required .",
        "label": "NA"
    },
    {
        "text": "- drugs whose efficacy is impaired by DB00252 include : HD00326 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , oral ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 .",
        "label": "effect"
    },
    {
        "text": "DB00233 may decrease the amount of ddrug1 { DB00390 , ddrug3 } that gets absorbed into your body .",
        "label": "mechanism"
    },
    {
        "text": "DB00522 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , ddrug8 { HD00398 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "int"
    },
    {
        "text": "effects of ddrug0 on low-dose HD00717 a group of # nonsmoking , healthy white female volunteers established on an oral ddrug2 regimen containing # mg ddrug3 and # mg DB06730 for at least # months received # mg/day of ddrug5 from midcycle { day 15 } to midcycle { day 14 } of two consecutive oral ddrug6 cycles .",
        "label": "NA"
    },
    {
        "text": "the purpose of this study was to evaluate the effect of ddrug0 { ddrug1 } and HD00067 { ddrug3 } conjugates on the intestinal permeation of HD00069 { ddrug5 } and model peptide drugs , ddrug6 and ddrug7 .",
        "label": "NA"
    },
    {
        "text": "seizures have been reported in patients taking another HD00534 and the ddrug1 DB08981 concurrently .",
        "label": "effect"
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of ddrug0 such as DB00565 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , DB01190 , ddrug9 , and ddrug10 } , ddrug11 salts , ddrug12 , local ddrug13 , ddrug14 , and ddrug15 .",
        "label": "effect"
    },
    {
        "text": "oral DB00994 inhibits the gastrointestinal absorption of ddrug1 , oral ddrug2 , ddrug3 and DB00544 .",
        "label": "mechanism"
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit ddrug0 binding to serum proteins or alter the concentrations of serum binding proteins : ddrug1 and related ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 , ddrug7 , ddrug8 , ddrug9 , DB00939 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , DB00675 .",
        "label": "NA"
    },
    {
        "text": "HD00461 { cns } drugs including DB02325 , ddrug2 , ddrug3 , ddrug4 , blood pressure medications { ddrug5 , ddrug6 , ddrug7 } , motion sickness medications , ddrug8 , ddrug9 , ddrug10 , sleeping pills and ddrug11",
        "label": "NA"
    },
    {
        "text": "DB01026 } , ddrug1 { e , g , ddrug2 } , and ddrug3 { e , g , ddrug4 , ddrug5 and ddrug6 } should have their dose of ddrug7 or DB01183 adjusted .",
        "label": "NA"
    },
    {
        "text": "ddrug0 should be used with care when ddrug1 or inhibitors of av conduction , such as certain ddrug2 { particularly of the HD00426 -lsb- DB00661 -rsb- and ddrug5 -lsb- ddrug6 -rsb- classes } , or ddrug7 , such as ddrug8 , are used concurrently .",
        "label": "NA"
    },
    {
        "text": "interaction of DB01221 and DB01159 in rats .",
        "label": "int"
    },
    {
        "text": "DB01083 - ddrug1 may decrease the absorption of DB01022 .",
        "label": "NA"
    },
    {
        "text": "patients taking both DB00712 and a HD00380 should be monitored to ensure that a satisfactory hypotensive effect is achieved .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : the stimulatory effects of HD00401 may be inhibited by DB14509 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 including coumarin derivatives , indandione derivatives , and ddrug1 such as ddrug2 { HD00203 } , and DB00945 may increase the risk of bleeding when administered concomitantly with ddrug5 .",
        "label": "NA"
    },
    {
        "text": "-lsb- the gaba-ergic system and brain edema -rsb- it has been shown in rats with experimental toxic and traumatic edemas that ddrug0 { 1 mg/kg } removes the antiedematous action of ddrug1 , ddrug2 , HD00134 and ddrug4 and reduces the action of DB00692 .",
        "label": "NA"
    },
    {
        "text": "in a study with concomitant administration of DB00945 and DB00492 , the bioavailability of unbound ddrug2 was not altered .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - HD00485 containing side chains of n-methylthiotetrazole { ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB04570 } or methylthiadiazole { ddrug7 } can cause vitamin_k_deficiency and hypoprothrombinemia .",
        "label": "NA"
    },
    {
        "text": "- a HD00535 { ddrug1 } such as ddrug2 { ddrug3 , ddrug4 , HD00759 , others } , ddrug6 { ddrug7 , ddrug8 , ddrug9 } , ddrug10 { ddrug11 , ddrug12 } , ddrug13 { ddrug14 } , ddrug15 { ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , and ddrug21 { ddrug22 , ddrug23 , ddrug24 } ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the concomitant use of ddrug1 { DB00813 transdermal system } with other HD00389 , including but not limited to other ddrug4 , ddrug5 , ddrug6 , ddrug7 { e , g , , ddrug8 } , general ddrug9 , ddrug10 , ddrug11 , and ddrug12 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .",
        "label": "effect"
    },
    {
        "text": "there have been isolated reports of patients experiencing increases in their prothrombin times when DB01077 was added to DB00682 therapy .",
        "label": "effect"
    },
    {
        "text": "HD00303 : other ddrug1 drugs , such as ddrug2 , ddrug3 , ddrug4 , and DB00252 , have been used concurrently with ddrug6 .",
        "label": "NA"
    },
    {
        "text": "DB01577 , like ddrug1 , produced depletions of striatal dopamine but these actions were potentiated by DB01626 pretreatment .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : DB01294 , given concomitantly with ddrug2 or # minutes following ddrug3 administration , decreased DB00467 bioavailability by approximately 25 % .",
        "label": "NA"
    },
    {
        "text": "these agents include medications such as : HD00326 , ddrug1 including ddrug2 , sali-cylates , ddrug3 { including ddrug4 } , DB00975 , or ddrug6 .",
        "label": "NA"
    },
    {
        "text": "may interact with thyroid medication { e , g , , ddrug0 } , DB11119 - containing products , ddrug2 , ddrug3 { e , g , , DB00927 , ddrug5 } , and ddrug6 { e , g , , ddrug7 , ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "medications can interfere with folate utilization , including : ddrug0 { such as ddrug1 , and DB00794 } ddrug3 { sometimes prescribed to control blood sugar in type # diabetes } DB00795 { used to control inflammation associated with crohn_disease and ulcerative colitis } ddrug5 { a ddrug6 } ddrug7 there has been concern about the interaction between ddrug8 and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "the concomitant administration of HD00272 and DB00437 has been associated with a decrease in the excretion of oxypurines { hypoxanthine and xanthine } and an increase in urinary uric_acid excretion compared with that observed with ddrug2 alone .",
        "label": "mechanism"
    },
    {
        "text": "while all the ddrug0 { HD00114 } , e , g , , DB00472 , ddrug3 , and ddrug4 , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .",
        "label": "NA"
    },
    {
        "text": "- HD00330 : in some patients , the administration of a ddrug1 can reduce the diuretic , natriuretic , and antihypertensive effects of HD00105 , ddrug3 and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "in clinical trials , ddrug0 was used with ddrug1 , ddrug2 , ddrug3 , oral HD00337 , and supplemental ddrug5 , in a pharmacokinetic substudy in patients with congestive heart failure receiving ddrug6 or ddrug7 in whom therapy with DB01240 was initiated , apparent oral clearance values for ddrug9 { n = 23 } and ddrug10 { n = 30 } were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .",
        "label": "NA"
    },
    {
        "text": "DB00316 diminished the binding of DB00277 to human serum by a net change of # % { percentage increase in free drug fraction -lsb- fdf -rsb- , # % } at # micromol/l and by a net change of # % { percentage increase in fdf , # % } at # micromol/l .",
        "label": "mechanism"
    },
    {
        "text": "no important interactions to date DB00922 does not have clinically important pharmacokinetic interactions with ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , DB00898 or ddrug9 .",
        "label": "NA"
    },
    {
        "text": "although clinical studies have not been performed , based on the involvement of the cytochrome p-450 3a family in ddrug0 metabolism , inhibitors of this enzyme system , notably oral HD00247 , should be used cautiously in patients receiving DB01068 .",
        "label": "advise"
    },
    {
        "text": "therefore , DB01161 should not be used in any condition in which a HD00508 is being employed .",
        "label": "advise"
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the ddrug0 of drugs may be potentiated by ddrug1 , ddrug2 , ddrug3 , HD00556 , ddrug5 , the ddrug6 , ddrug7 and HD00560 , ddrug9 and the ddrug10 , and by other ddrug11 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB01045 contraindicated since the coadministration of this product with ddrug2 in an ddrug3 regimen reduces the plasma concentrations of DB01232 .",
        "label": "NA"
    },
    {
        "text": "DB00196 and DB01026 : ddrug2 and ddrug3 are predominantly ppig 3a4 and 2c9 inhibitors , respectively .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a clinical pharmacology study , coadministration of an ddrug1 { ddrug2 , ddrug3 , and DB11074 } with ddrug5 reduced serum levels and urinary excretion of DB14207 as compared with ddrug7 administered alone , suggesting that ddrug8 may impair absorption of ddrug9 .",
        "label": "NA"
    },
    {
        "text": "blood levels of HD00644 increased 24 % when ddrug1 was coadministered with ddrug2 { nonselective inhibitor of cytochrome p-450 } for # days , and decreased 28 % with coadministration of DB01045 { potent inducer of cytochrome p-450 } for # days .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as DB00415 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , DB00231 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , and the ddrug1 DB00904 { ddrug3 } and ddrug4 { DB00889 } have all been used with ddrug6 .",
        "label": "NA"
    },
    {
        "text": "the hypotensive effect of ddrug0 is augmented by that of most other HD00885 , including ddrug2 , negative inotropic agents , and inhaled HD00264 .",
        "label": "NA"
    },
    {
        "text": "concurrent administration of DB00488 and ddrug1 may cause severe orthostatic hypotension , ddrug2 , an inhibitor of microsomal drug metabolism , increased DB00488 s half-life and toxicity in a rat model .",
        "label": "NA"
    },
    {
        "text": "and ddrug0 when HD00314 is given with ddrug2 agents or ddrug3 drugs , including ddrug4 combined with local HD00264 , close supervision and careful adjustment of dosages are required .",
        "label": "NA"
    },
    {
        "text": "HD00569 : ddrug1 { ddrug2 , DB00206 , ddrug4 , ddrug5 , fruit juices , etc , } lower absorption of ddrug6 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a clinical pharmacology study , coadministration of an ddrug1 { DB06723 , ddrug3 , and ddrug4 } with DB00492 reduced serum levels and urinary excretion of ddrug6 as compared with ddrug7 administered alone , suggesting that ddrug8 may impair absorption of ddrug9 .",
        "label": "mechanism"
    },
    {
        "text": "DB00562 may interact with ddrug1 , ddrug2 s , ddrug3 { allergy , cold , and sinus medicines } , diabetic drugs , ddrug4 , ddrug5 , HD00203 like ddrug7 or ddrug8 , and high blood pressure medications .",
        "label": "int"
    },
    {
        "text": "- a ddrug0 { HD00615 } such as ddrug2 { ddrug3 , ddrug4 , ddrug5 , others } , ddrug6 { ddrug7 , ddrug8 , ddrug9 } , ddrug10 { ddrug11 , ddrug12 } , ddrug13 { ddrug14 } , ddrug15 { ddrug16 } , ddrug17 { ddrug18 } , DB00991 { ddrug20 } , and ddrug21 { ddrug22 , ddrug23 , ddrug24 } ;",
        "label": "NA"
    },
    {
        "text": "DB00501 : co-administration with high doses of ddrug1 -lsb- 800 mg twice daily -rsb- increased the cmax of DB00533 by 21 % , the auc0 - 120hr by 23 % and the t1/2 by 15 % .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { DB00316 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , DB00295 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "the following agents may increase certain actions or side effects of HD00522 , DB00915 ddrug2 of class { e , g , ddrug3 } , ddrug4 ddrug5 { e , g , ddrug6 } , ddrug7 .",
        "label": "NA"
    },
    {
        "text": "DB00753 or ddrug1 administered with ddrug2 / ddrug3 to achieve # mac -lsb- minimum alveolar concentration -rsb- may prolong the clinically effective duration of action of initial and maintenance doses of DB00565 and decrease the required infusion rate of ddrug5 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as DB00415 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , DB00812 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in healthy individuals , plasma concentrations of DB01076 increased approximately 40 % with coadministration of ddrug2 and DB00199 , a known inhibitor of cytochrome p450 3a4 .",
        "label": "NA"
    },
    {
        "text": "if you are also using a ddrug0 inhaler , take DB00901 first and then wait about # minutes before using the HD00429 inhaler .",
        "label": "advise"
    },
    {
        "text": "since DB00375 is an HD00572 , it may have a strong affinity for anions other than the bile acids .",
        "label": "NA"
    },
    {
        "text": "agents increasing serum potassium : DB00722 attenuates potassium loss caused by HD00675 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : the mixing of DB00319 with an HD00494 in vitro can result in substantial inactivation of the ddrug3 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : in vitro and/or in vivo data show that ddrug1 , ddrug2 , and DB13179 markedly inhibit the metabolism of ddrug4 , which can result in an increase in plasma DB00604 levels and prolongation of the qt interval on the ecg .",
        "label": "NA"
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma ddrug0 concentrations include : acute DB02325 intake , ddrug2 , chboramphenicol , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , HD00328 , ddrug18 , ddrug19 , ddrug20 , ddrug21",
        "label": "NA"
    },
    {
        "text": "the concomitant use of HD00244 with ddrug1 and HD00411 s may have additive effects on prolonging atrioventricular conduction time .",
        "label": "effect"
    },
    {
        "text": "- ddrug0 : DB00887 may potentiate the effect of various HD00448 , necessitating a reduction in the dosage of these drugs .",
        "label": "effect"
    },
    {
        "text": "DB00248 should not be administered concurrently with d2-antagonists , such as ddrug1 , ddrug2 , HD00463 , or ddrug4 .",
        "label": "advise"
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of HD00539 such as DB00565 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 } , ddrug11 salts , ddrug12 , local ddrug13 , ddrug14 , and ddrug15 .",
        "label": "effect"
    },
    {
        "text": "other concomitant therapy although specific interaction studies were not performed , DB01216 doses of # mg or more were concomitantly used in clinical studies with ddrug1 , ddrug2 , a-blockers , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , cardiac DB14049 , ddrug10 , ddrug11 , ddrug12 , ddrug13 { also referred to as ddrug14 } , and ddrug15 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "serum DB00277 concentrations increase when DB00365 is initiated in a patient maintained on ddrug2 .",
        "label": "NA"
    },
    {
        "text": "concurrent use of HD00375 and DB00682 in clinical practice has been associated with increased anticoagulant effects .",
        "label": "effect"
    },
    {
        "text": "these HD00002 should be used in the myasthenic patient only where definitely indicated , and then careful adjustment should be made of adjunctive HD00874 dosage .",
        "label": "advise"
    },
    {
        "text": "an increase in serum DB14507 concentration has been reported during concomitant administration of ddrug1 with DB00796 , so careful monitoring of serum ddrug3 levels is recommended during concomitant use .",
        "label": "NA"
    },
    {
        "text": "DB00316 / ddrug1 , DB00281 / ddrug3 , ddrug4 / ddrug5 , ddrug6 / ddrug7 , ddrug8 / ddrug9 , ddrug10 / ddrug11 , and ddrug12 / ddrug13 .",
        "label": "NA"
    },
    {
        "text": "effect of DB00829 and ddrug1 on the antinociceptive effect of ddrug2 , ddrug3 and DB00328 in mice .",
        "label": "NA"
    },
    {
        "text": "drugs that may alter DB00619 plasma concentrations drugs that may increase ddrug1 plasma concentrations : caution is recommended when administering ddrug2 with inhibitors of the cyp3a4 family { e , g , , ddrug3 , ddrug4 , DB00199 , ddrug6 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { DB01045 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and DB00126 .",
        "label": "NA"
    },
    {
        "text": "HD00234 modifies ddrug1 metabolism with increased serum levels of DB00252 .",
        "label": "mechanism"
    },
    {
        "text": "the administration of local HD00449 containing DB00668 or ddrug2 to patients receiving ddrug3 or ddrug4 may produce severe , prolonged hypertension .",
        "label": "NA"
    },
    {
        "text": "no interaction was noted with the ddrug0 DB01037 in two multiple-dose interaction studies when ddrug2 was coadministered with a ddrug3 / HD00680 { n = 29 } .",
        "label": "NA"
    },
    {
        "text": "DB00169 administration to rachitic chicks was effective in significantly elevating duodenal HD00141 absorption , acting primarily to enhance serosal transport .",
        "label": "mechanism"
    },
    {
        "text": "a single dose of liquid DB06724 did not affect the c max or auc of DB01415 ;",
        "label": "NA"
    },
    {
        "text": "results of studies in multiple sclerosis patients taking ddrug0 and concomitant DB00060 { ddrug2 # mcg i m once weekly } or ddrug3 were inconclusive with regard to the need for dose adjustment of the ddrug4 or DB05259 .",
        "label": "NA"
    },
    {
        "text": "caution should be exercised when taking this medicine certain HD00002 , such as ddrug1 , DB01211 , or ddrug3 .",
        "label": "NA"
    },
    {
        "text": "DB00682 : HD00532 , including ddrug2 , decrease the clearance of ddrug3 , the less active isomer of racemic ddrug4 .",
        "label": "NA"
    },
    {
        "text": "in a controlled clinical trial , a 20 % reduction of the DB00252 dose at the initiation of ddrug1 therapy resulted in ddrug2 levels comparable to those prior to DB00949 administration .",
        "label": "NA"
    },
    {
        "text": "ddrug0 can interact with ddrug1 or other HD00261 { may potentiate the cns depressant effects of either these medications or HD00388 } , ddrug4 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug5 } , and ddrug6 { concurrent use with ddrug7 may prolong and intensify the anticholinergic and cns depressant effects of ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "DB00681 or ddrug1 { ddrug2 and related drugs , ddrug3 and DB00695 } enhanced hypokalemia .",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with HD00374 containing ddrug2 , ddrug3 , or ddrug4 , with ddrug5 , with metal cations such as ddrug6 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as DB00900 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a HD00533 , including ddrug1 , with multivalent cation-containing products such as ddrug2 or ddrug3 ddrug4 , DB00364 , ddrug6 chewable/buffered tablets or pediatric powder , or products containing ddrug7 , ddrug8 , or ddrug9 may substantially decrease the absorption of ddrug10 , resulting in serum and urine levels considerably lower than desired .",
        "label": "mechanism"
    },
    {
        "text": "these medications have included DB01109 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , intravenous and oral ddrug5 , DB00208 , and ddrug7 .",
        "label": "NA"
    },
    {
        "text": "DB00294 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { DB00295 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "int"
    },
    {
        "text": "ddrug0 : a clinical study in # insulin-dependent diabetic patients demonstrated no effect of DB00702 on HD00071 absorption from the peritoneal cavity or on ddrug3 s ability to control blood glucose when ddrug4 was administered intraperitoneally with ddrug5 .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral ddrug0 , HD00106 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , HD00806 { e , g , , ddrug9 } , ddrug10 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 levels may be decreased ; increased dosages may be required to prevent symptoms of ddrug1 withdrawal , DB00333 maintained patients beginning DB00238 therapy should be monitored forevidence of withdrawal and ddrug4 dose should be adjusted accordingly .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : potentiation of ddrug1 - type { HD00097 and ddrug3 substrate } ddrug4 response is almost always seen in patients receiving DB01118 and can result in serious or fatal bleeding .",
        "label": "NA"
    },
    {
        "text": "- a ddrug0 { HD00615 } such as ddrug2 { ddrug3 , ddrug4 , ddrug5 , others } , ddrug6 { ddrug7 , ddrug8 , ddrug9 } , ddrug10 { ddrug11 , DB00586 } , ddrug13 { ddrug14 } , ddrug15 { ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , and ddrug21 { ddrug22 , ddrug23 , ddrug24 } ;",
        "label": "NA"
    },
    {
        "text": "HD00399 may reduce the antihypertensive effects of DB00206 , ddrug2 , ddrug3 and ddrug4 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 and ddrug1 : limited clinical data suggest a higher incidence of adverse experiences in patients receiving DB01156 concurrently with either ddrug3 or DB00915 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : patients on HD00218 , especially those in whom diuretic therapy was recently instituted , may occasionally experience an excessive reduction of blood pressure after initiation of therapy with DB00542 .",
        "label": "effect"
    },
    {
        "text": "consequently , the combination of DB00563 with DB00459 is also contraindicated .",
        "label": "advise"
    },
    {
        "text": "HD00245 : coadministration of HD00377 did not have any effect on either the safety or efficacy of ddrug2 in the clinical trials .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 DB00564 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 HD00542 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "ddrug0 absorption : the following agents may bind and decrease absorption of DB00451 from the gastrointestinal tract : ddrug2 , ddrug3 resin , ddrug4 , DB01373 , ddrug6 , soybean flour { e , g , , infant formula } , ddrug7 .",
        "label": "mechanism"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 DB14507 HD00542 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "considering that the involvement of reactive oxygen species { ros } has been implicated in the toxicity of various pesticides , this study was designed to investigate the possibility of oxidative stress induction by HD00044 , a HD00045 .",
        "label": "NA"
    },
    {
        "text": "beta-blocking agents a pharmacokinetic study of DB01023 in conjunction with DB00264 demonstrated no significant effects on the pharmacokinetics of ddrug2 .",
        "label": "NA"
    },
    {
        "text": "this study demonstrated that the potent cytochrome p450 enzyme-inducer DB00252 did indeed have a marked effect on the metabolism of DB01224 , resulting in a 5-fold increase in clearance when administered concomitantly to patients with dsm-iv-diagnosed schizophrenia , schizoaffective disorder , or bipolar disorder .",
        "label": "mechanism"
    },
    {
        "text": "the concomitant use of transdermal DB00813 with ddrug1 or other potent 3a4 inhibitors such as ddrug2 , ddrug3 , ddrug4 , DB01211 , ddrug6 , and nefazadone may result in an increase in ddrug7 plasma concentrations .",
        "label": "mechanism"
    },
    {
        "text": "the benefits and risks of using DB01039 with HD00128 and other potentially nephrotoxic agents should be carefully considered , and the lowest effective dose employed",
        "label": "advise"
    },
    {
        "text": "ddrug0 and ddrug1 { and possibly other ddrug2 } and DB00759 may increase ddrug4 absorption in patients who inactivate ddrug5 by bacterial metabolism in the lower intestine , so that HD00118 intoxication may result .",
        "label": "NA"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / HD00517 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , ddrug4 , ddrug5 , ddrug6 , ddrug7 , DB01578 , ddrug9 , ddrug10 , ddrug11 pain medication { e , g , , ddrug12 } , drugs used to aid sleep , drowsiness-causing ddrug13 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "DB01432 HD00524 may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation , the discontinuance of ddrug2 ddrug3 could pose a hazard to health if a potentially toxic drug such as ddrug4 has been filtrated to a maintenance level while the patient was taking ddrug5 ddrug6 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local HD00264 { e , g , , ddrug6 and ddrug7 } , ddrug8 { HD00398 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "DB00915 , ddrug1 , and ddrug2 may increase anticholinergic effect of DB00771 .",
        "label": "effect"
    },
    {
        "text": "the results indicate that a spinal ddrug0 - sensitive endorphinergic system is involved in the production of HD00144 but not DB00295 - induced tail-flick inhibition , and suggest that intraventricular ddrug3 and ddrug4 elicit their pharmacological actions via the activation of different descending pain inhibitory systems ;",
        "label": "NA"
    },
    {
        "text": "DB00316 / ddrug1 , ddrug2 / ddrug3 , ddrug4 / ddrug5 , ddrug6 / ddrug7 , ddrug8 / ddrug9 , DB00277 / ddrug11 , and ddrug12 / ddrug13 .",
        "label": "NA"
    },
    {
        "text": "during DB01118 administration , systemic clearance of DB00390 was reduced from # + / - # ml/min { mean + / - standard deviation } to # + / - # ml/min { p less than # } .",
        "label": "mechanism"
    },
    {
        "text": "concomitant administration of DB01241 with DB00307 capsules is not recommended .",
        "label": "advise"
    },
    {
        "text": "coadministration with DB00580 increased exposure of DB00338 { auc } by 46 % .",
        "label": "mechanism"
    },
    {
        "text": "antiacid , ddrug0 , DB00900 , ddrug2 , ddrug3 , indanavir , ddrug4 , ddrug5 , phenobarbitol , ddrug6 , ddrug7 , ddrug8 , ritanovir , DB01232 .",
        "label": "NA"
    },
    {
        "text": "DB09341 and HD00071 exert additive ocular and renal vasodilator effects on healthy humans .",
        "label": "NA"
    },
    {
        "text": "other significant inhibitors of cyp2d6 , such as DB00472 or DB00715 , would be expected to have similar effects and , therefore , should be accompanied by similar dose reductions .",
        "label": "NA"
    },
    {
        "text": "interactions with HD00841 : ddrug1 { eg , DB00652 , ddrug3 , ddrug4 , ddrug5 and ddrug6 } should not be administered to a patient who has received or is receiving a course of therapy with a ddrug7 such as ddrug8 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : concurrent administration of DB00945 and ddrug2 resulted in 50 % lower serum DB00712 concentrations .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of ddrug0 : ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , ddrug5 , ddrug6 , DB00871 } , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 { e , g , , in oral HD00283 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : as with some other ddrug1 , concurrent administration of DB00537 with DB00277 may lead to elevated serum concentrations of ddrug4 and prolongation of its elimination half-life .",
        "label": "mechanism"
    },
    {
        "text": "DB00641 and other HD00434 : co-administration of ddrug2 decreased the plasma concentrations of ddrug3 { a cyp3a4 substrate } , and its active - hydroxy acid metabolite , by approximately 50 % .",
        "label": "NA"
    },
    {
        "text": "DB00930 decreased the cmax and auc of sustained-release ddrug1 { DB00661 } by approximately 31 % and 11 % , respectively .",
        "label": "mechanism"
    },
    {
        "text": "HD00264 / ddrug1 / ddrug2 / ddrug3 : co-administration of ddrug4 with ddrug5 , HD00024 , ddrug7 , and ddrug8 is likely to lead to an enhancement of effects .",
        "label": "NA"
    },
    {
        "text": "separating the doses of DB06724 and DB00978 minimizes this decrease in bioavailability ;",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : the concomitant use of ddrug1 { ddrug2 transdermal system } with other HD00389 , including but not limited to other ddrug4 , ddrug5 , ddrug6 , ddrug7 { e , g , , ddrug8 } , general ddrug9 , ddrug10 , ddrug11 , and DB02325 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .",
        "label": "NA"
    },
    {
        "text": "medications can interfere with folate utilization , including : ddrug0 { such as ddrug1 , and ddrug2 } ddrug3 { sometimes prescribed to control blood sugar in type # diabetes } DB00795 { used to control inflammation associated with crohn_disease and ulcerative colitis } ddrug5 { a HD00295 } ddrug7 there has been concern about the interaction between ddrug8 and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : DB00228 ; ddrug2 ; ddrug3 ; certain ddrug4 , especially the ddrug5 and ddrug6 ; ddrug7 ; ddrug8 salts ; DB01035 ; and ddrug10 .",
        "label": "NA"
    },
    {
        "text": "DB00695 : clinical studies , as well as random observations , have shown that DB01050 can reduce the natriuretic effect of ddrug2 and ddrug3 in some patients .",
        "label": "NA"
    },
    {
        "text": "the extent of plasma protein binding of ddrug0 in human plasma is not affected by the presence of therapeutic concentrations of DB00252 { 15 mcg / ml } , nor is the binding of ddrug2 affected by the presence of DB01117 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { e , g , ddrug1 and ddrug2 } : agents of the HD00625 , of which DB00320 { ddrug5 } injection , usp is a member , have been shown to interact with ddrug6 of the ddrug7 , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { DB01076 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , DB01232 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , DB14513 , or ddrug4 , with ddrug5 , with metal cations such as ddrug6 , or with ddrug7 containing ddrug8 or DB01593 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : as with other ddrug1 , co-administration of DB01032 with DB01066 resulted in an increase in the plasma exposure of ddrug4 , with a 49 % increase in mean cmax , a 122 % increase in mean auc , and a 53 % increase in half-life .",
        "label": "mechanism"
    },
    {
        "text": "there is no experience with co-administration of DB00006 and plasma expanders such as DB09255 .",
        "label": "NA"
    },
    {
        "text": "DB01026 at # mg daily { the maximum approved prescription dose } co-administered with ddrug1 { 500 mcg bid } for # days has been shown to increase DB00204 cmax by 53 % in males and 97 % in females , and auc by 41 % in males and 69 % in females .",
        "label": "NA"
    },
    {
        "text": "on the basis of the metabolism of ddrug0 by cytochrome p450 3a4 , ddrug1 , DB01167 , ddrug3 , ddrug4 , grapefruit juice , and other inhibitors of cyp3a4 would be expected to lead to an increase in plasma DB00307 concentrations .",
        "label": "mechanism"
    },
    {
        "text": "dual effect of DB01092 on the HD00139 - induced contraction and norepinephrine release in the guinea-pig vas deferens .",
        "label": "NA"
    },
    {
        "text": "DB01190 has been shown to have neuromuscular blocking properties that may enhance the action of other HD00547 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 can interact with DB02325 or other ddrug2 { may potentiate the cns depressant effects of either these medications or ddrug3 } , ddrug4 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug5 } , and ddrug6 { concurrent use with HD00388 may prolong and intensify the anticholinergic and cns depressant effects of ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "the objective of this study was to determine if there is a pharmacokinetic interaction when ddrug0 is given with DB00615 or DB01045 and to determine the effects of these drugs on the erythromycin breath test { ermbt } .",
        "label": "NA"
    },
    {
        "text": "the mean clearances of DB00204 were 16 % and 15 % lower in patients on HD00029 and inhibitors of tubular organic cation transport , respectively .",
        "label": "mechanism"
    },
    {
        "text": "during controlled hypotensive anesthesia using DB00598 in association with ddrug1 , high concentrations { 3 % or above } of DB01159 should not be used because the degree of hypotension will be increased and because of the possibility of a large reduction in cardiac output and an increase in central venous pressure .",
        "label": "NA"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / ddrug1 , drugs used to treat an overactive thyroid , HD00254 { e , g , , ddrug3 } , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , HD00516 pain medication { e , g , , ddrug12 } , drugs used to aid sleep , drowsiness-causing ddrug13 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "interactions may also occur with the following : HD00515 / ddrug1 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , DB00571 } , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 pain medication { e , g , , ddrug12 } , drugs used to aid sleep , drowsiness-causing ddrug13 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "consequently , ddrug0 should be avoided in patients receiving DB01026 and DB01167 , which are very potent inhibitors of cyp3a .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 HD00388 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 DB14507 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , DB01232 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { HD00531 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : when DB00731 # mg before meals was administered in combination with a single 1-mg dose of DB00390 to healthy volunteers , there were no clinically relevant changes in the pharmacokinetics of either agent .",
        "label": "NA"
    },
    {
        "text": "no dose adjustment is necessary when DB00074 is added to triple-immunosuppression regimens including DB00091 , ddrug2 , and either ddrug3 or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "HD00851 : co-administration of DB00601 and ddrug2 was not associated with serotonin syndrome in phase 1 , # or # studies .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { cns } drugs including ddrug1 , ddrug2 , ddrug3 , ddrug4 , blood pressure medications { ddrug5 , ddrug6 , ddrug7 } , motion sickness medications , ddrug8 , HD00543 , HD00024 , sleeping pills and ddrug11",
        "label": "NA"
    },
    {
        "text": "the addition of DB00906 in a limited number of patients in three well-controlled studies caused no systematic changes in DB01174 or ddrug2 concentrations when compared to placebo .",
        "label": "NA"
    },
    {
        "text": "agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of HD00472 are the following : ddrug1 , ddrug2 , ddrug3 , DB01045 , ddrug5 , ddrug6 { 2 } , ddrug7 , ddrug8 , and ddrug9 thus , if a patient has been titrated to a stable dosage on ddrug10 , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for ddrug11 may be necessary .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB00404 , and ddrug7 raise the serum DB00390 concentration due to a reduction in clearance and/or in volume of distribution of the drug , with the implication that ddrug9 intoxication may result .",
        "label": "mechanism"
    },
    {
        "text": "HD00175 , ddrug1 and ddrug2 : concomitant treatment with HD00741 , ddrug4 , or ddrug5 may potentiate a possible hypokalemic effect of ddrug6",
        "label": "NA"
    },
    {
        "text": "intravenous ddrug0 { DB00640 } has been effectively administered in the presence of other cardioactive drugs , such as DB00908 , ddrug3 , ddrug4 , and ddrug5 , without any change in the adverse reaction profile .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of ddrug0 and ddrug1 , DB00501 , ddrug3 , or an ddrug4 / ddrug5 oral HD00349 produced minor changes in the pharmacokinetics of ddrug7 , which were considered to be without clinical significance .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : DB00316 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { HD00548 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 { hypertension } - in clinical studies of patients with hypertension , the addition of DB00700 # to # mg to HD00106 and ddrug4 increased mean serum potassium slightly { about # # meq/l } .",
        "label": "effect"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 HD00303 : ddrug2 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : DB01045 ddrug10 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "DB09098 / DB00052 : excessive concurrent use of ddrug2 may accelerate epiphyseal closure .",
        "label": "NA"
    },
    {
        "text": "in a study in which the # mg ddrug0 orally disintegrating tablet was administered with and without ddrug1 { an HD00554 with multiple effects on the gi tract } to healthy volunteers , the auc of DB01068 was 10 % lower and the cmax of ddrug4 was 20 % lower when the orally disintegrating tablet was given with ddrug5 compared to when it was given alone .",
        "label": "NA"
    },
    {
        "text": "- HD00326 : interaction studies in humans have shown DB00887 to have no effect on ddrug2 metabolism or on plasma prothrombin activity .",
        "label": "NA"
    },
    {
        "text": "studies have shown that DB00448 does not have clinically significant interactions with other drugs metabolized by the cytochrome cyp2b6 system , such as ddrug1 , ddrug2 , DB00328 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , or ddrug10 in healthy subjects .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , DB00091 } , hiv drugs classified as ddrug24 { DB00701 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "the hypoglycemic action of ddrug0 may be potentiated by certain drugs including HD00518 and other drugs that are highly protein bound , ddrug2 , ddrug3 , DB00446 , ddrug5 , ddrug6 , ddrug7 , and ddrug8 .",
        "label": "NA"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : ddrug1 ; DB00753 ; DB01159 ; certain ddrug4 , especially the ddrug5 and ddrug6 ; ddrug7 ; ddrug8 salts ; ddrug9 ; and ddrug10 .",
        "label": "NA"
    },
    {
        "text": "other drugs : in healthy volunteers , ddrug0 , ddrug1 , ddrug2 , ddrug3 , DB00338 , hormone replacement therapy { a combination of conjugated HD00220 and ddrug6 } , ddrug7 { ddrug8 and ddrug9 } and ddrug10 did not affect the pharmacokinetics of ddrug11 .",
        "label": "NA"
    },
    {
        "text": "renal clearance measurements of DB00345 can not be made with any significant accuracy in patients receiving ddrug1 , ddrug2 , or HD00298 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : DB01009 , like other HD00203 , may cause changes in the elimination of ddrug3 leading to elevated serum levels of the drug and increased toxicity .",
        "label": "NA"
    },
    {
        "text": "to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma { hiv-nhl } , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the ddrug0 , ddrug1 , DB00541 , and ddrug3 { chop } chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen { i , e , , ddrug4 , ddrug5 , ddrug6 , and DB00898 with ddrug8 plus ddrug9 } without receiving ddrug10 therapy .",
        "label": "NA"
    },
    {
        "text": "DB01118 taken concomitantly with ddrug1 increases the serum DB00390 concentration by 70 % after one day .",
        "label": "NA"
    },
    {
        "text": "when DB00303 is co-administered with DB01032 { 500 mg p , o , every # hours } , ddrug2 competes for active tubular secretion and reduces the renal clearance of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 with ddrug1 or ddrug2 and possibly other HD00609 cause striking and sustained increases in the concentration of DB01576 in the brain ;",
        "label": "NA"
    },
    {
        "text": "therefore , patients without a functioning ddrug0 gland who are on thyroid replacement therapy may need to increase their thyroid dose if ddrug1 or HD00183 - containing oral HD00283 are given .",
        "label": "NA"
    },
    {
        "text": "drugs that should not be coadministered with DB00220 ddrug1 : ddrug2 , DB00908 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "label": "advise"
    },
    {
        "text": "clinical studies in healthy volunteers show that the pharmacokinetics of DB00520 are not altered by DB01167 , ddrug2 , ddrug3 , ddrug4 , or ddrug5 .",
        "label": "NA"
    },
    {
        "text": "thus , when HD00897 and ddrug1 are administered concurrently , subjects should be observed carefully for signs of DB14507 toxicity .",
        "label": "NA"
    },
    {
        "text": "if ddrug0 are required during DB00535 therapy , ddrug2 should be taken at least # hours before or after the DB06724 .",
        "label": "NA"
    },
    {
        "text": "the pharmacokinetics and protein binding of ddrug0 , DB00252 , and ddrug2 were not altered when ddrug3 and DB01320 were concurrently administered in single submaximal doses .",
        "label": "NA"
    },
    {
        "text": "inhibitors of this isoenzyme { e , g , , ddrug0 , ddrug1 , ddrug2 , HD00311 , ddrug4 , ddrug5 , ddrug6 , grapefruit juice , ddrug7 , ddrug8 , ddrug9 , ddrug10 } should be cautiously coadministered with ddrug11 as they can potentially increase DB00204 levels .",
        "label": "NA"
    },
    {
        "text": "thus , when DB01050 and DB14507 are administered concurrently , subjects should be observed carefully for signs of ddrug2 toxicity .",
        "label": "advise"
    },
    {
        "text": "HD00374 : concomitant administration of ddrug1 may reduce plasma levels of DB00861 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration of ddrug1 { using an experimental soft-gelatin capsule formulation of ddrug2 1200 mg } with ddrug3 resulted in an 18 % increase in DB00220 plasma auc and a 4-fold increase in DB01232 plasma a , c.",
        "label": "NA"
    },
    {
        "text": "effects of other HD00703 on DB00949 ddrug2 : ddrug3 causes an approximate doubling of the clearance of ddrug4 { ddrug5 } at steady state and , therefore , the addition of ddrug6 causes an approximate 45 % decrease in the steady-state trough concentrations of ddrug7 as compared to the same dose of ddrug8 given as monotherapy .",
        "label": "NA"
    },
    {
        "text": "drug-drug interactions between ddrug0 and other ddrug1 { ddrug2 } DB00252 DB01202 { 3000 mg daily } had no effect on the pharmacokinetic disposition of ddrug5 in patients with refractory epilepsy .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : patients on HD00579 therapy may exhibit a diminished response to toxoids and ddrug2 or HD00600 due to inhibition of antibody response .",
        "label": "effect"
    },
    {
        "text": "during concomitant therapy of DB00784 with DB00695 , the patient should be observed closely for signs of renal failure , as well as to assure diuretic efficacy .",
        "label": "advise"
    },
    {
        "text": "although neither ddrug0 nor HD00147 affected the proliferation of prostatic epithelium in rpmi1640 containing ddrug2 alone , they modify the mitogenic effect of ddrug3 and HD00071 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : in a clinical pharmacology study , coadministration of an ddrug1 { ddrug2 , DB09104 , and ddrug4 } with DB00492 reduced serum levels and urinary excretion of ddrug6 as compared with ddrug7 administered alone , suggesting that ddrug8 may impair absorption of ddrug9 .",
        "label": "mechanism"
    },
    {
        "text": "oral ddrug0 : multiple dose administration of DB00906 { 8 mg/day monotherapy } did not alter the pharmacokinetics of oral HD00283 in healthy women of childbearing age .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 - in a controlled study , a single dose of ddrug2 # mg co-administered with racemic DB00215 # mg given once daily for # days was associated with a mean increase in qtc values of approximately # msec compared to DB01100 given alone .",
        "label": "NA"
    },
    {
        "text": "although concomitant use of ddrug0 and ddrug1 is not recommended , it should be noted that discontinuation of concomitant DB00564 administration may result in an increase in DB00363 plasma levels .",
        "label": "mechanism"
    },
    {
        "text": "the concomitant use of ddrug0 or HD00587 with DB01254 is not recommended .",
        "label": "advise"
    },
    {
        "text": "HD00128 : DB00091 , ddrug2 , ddrug3",
        "label": "NA"
    },
    {
        "text": "ddrug0 { DB00900 } chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with , or within # hours of , the administration of ddrug2 , because these products may interfere with absorption resulting in lower serum and urine levels of DB01059 .",
        "label": "NA"
    },
    {
        "text": "notably , systemic exposure { auc0 - 12 } of HD00584 { ddrug1 } was more than doubled in the presence of DB01643 / ddrug3 .",
        "label": "NA"
    },
    {
        "text": "DB00357 diminishes the effect of ddrug1 and DB00682 .",
        "label": "effect"
    },
    {
        "text": "the possibility of hypotensive effects with ddrug0 can be minimized by either discontinuing the HD00295 or increasing the salt intake prior to initiation of treatment with DB00542 .",
        "label": "advise"
    },
    {
        "text": "- ddrug0 and ddrug1 ddrug2 : ddrug3 and DB00375 ddrug5 have the potential of binding HD00029 and reducing ddrug7 absorption from the gastrointestinal tract",
        "label": "mechanism"
    },
    {
        "text": "the absorption of oral ddrug0 is significantly reduced by the concomitant administration of an DB06724 containing DB01370 and ddrug3 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 should be used with caution in patients receiving - HD00305 blocking agents { e , g , , ddrug3 , a HD00302 inhibitor } or ddrug5 antagonists { e , g , , ddrug6 , a ddrug7 substrate , and ddrug8 , a ddrug9 inhibitor } because of the possible potentiation of bradycardia , sinus arrest , and av block ;",
        "label": "NA"
    },
    {
        "text": "standard therapy includes ddrug0 , such as HD00284 and DB00798 ;",
        "label": "NA"
    },
    {
        "text": "HD00388 may enhance the effects of HD00043 , ddrug2 , ddrug3 , and other ddrug4 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 { e , g , , ddrug1 , ddrug2 , DB00734 } and ddrug4 may reduce the therapeutic effects of DB01235 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 { ddrug1 } : population pharmacokinetic analyses indicate that ddrug2 clearance is 60 % greater in patients taking ddrug3 { DB00794 } with or without other enzyme-inducing HD00714 .",
        "label": "NA"
    },
    {
        "text": "HD00106 and ddrug1 { congestive heart failure post-myocardial infarction } - in ephesus , # { 91 % } patients receiving ddrug2 # to # mg also received ddrug3 or HD00466 { ddrug5 / ddrug6 } .",
        "label": "NA"
    },
    {
        "text": "the steady state plasma concentrations of ddrug0 and DB01151 have been reported to be increased an average of 31 % and 20 % , respectively , by the concomitant administration of DB00404 tablets in doses up to # mg/day .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : concomitant administration of DB00199 and ddrug2 has been reported to result in elevated DB00390 serum levels .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : since ddrug1 is a ddrug2 , it is possible that ddrug3 , such as the HD00137 { ddrug5 , ddrug6 , ddrug7 } or ddrug8 , may diminish the effectiveness of DB00714 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 : coadministration of ddrug2 with HD00872 resulted in a 47 % decrease in ddrug4 and an 18 % decrease in DB00717 plasma concentrations .",
        "label": "NA"
    },
    {
        "text": "may interact ddrug0 { altered hypo-prothrombinemic effect } , ddrug1 , DB01045 and other inducers of hepatic microsomal enzyme oxidation system { decreased effect of DB00255 } , ddrug4 { increased effect of ddrug5 } .",
        "label": "NA"
    },
    {
        "text": "products containing DB01373 and other ddrug1 likely will interfere with absorption of DB00630 .",
        "label": "mechanism"
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma ddrug0 concentrations include : acute DB02325 intake , ddrug2 , chboramphenicol , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , HD00220 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21",
        "label": "NA"
    },
    {
        "text": "in patients taking ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , DB01016 , ddrug6 , and various chemotherapy agents , no effect was shown on the clearance of HD00644 .",
        "label": "NA"
    },
    {
        "text": "plasma levels of several closely related HD00043 have been reported to be increased by the concomitant administration of ddrug1 or hepatic enzyme inhibitors { e , g , , ddrug2 , DB00472 } and decreased by the concomitant administration of hepatic enzyme inducers { e , g , , ddrug4 , ddrug5 } , and such an effect may be anticipated with ddrug6 as well .",
        "label": "mechanism"
    },
    {
        "text": "the concomitant use of other cyp3a4 inhibitors such as DB00343 and ddrug1 with transdermal DB00813 may also result in an increase in ddrug3 plasma concentrations , which could increase or prolong adverse drug effects and may cause serious respiratory depression .",
        "label": "mechanism"
    },
    {
        "text": "both HD00021 and ddrug1 block ddrug2 - induced and DB00184 - induced dopamine release in the nucleus accumbens ;",
        "label": "effect"
    },
    {
        "text": "DB01118 may suppress certain cyp450 enzymes , including ddrug1 , ddrug2 , ddrug3 , and HD00302 .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { DB00564 } ddrug7 { ddrug8 } ddrug9 ddrug10 { DB00472 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "the administration of local HD00449 containing ddrug1 or ddrug2 to patients receiving ddrug3 or HD00043 may produce severe , prolonged hypertension .",
        "label": "NA"
    },
    {
        "text": "DB00294 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , DB00091 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "int"
    },
    {
        "text": "other drugs : based on the results of drug interaction studies , no dosage adjustment is recommended when ddrug0 { DB00625 } is given with the following : ddrug2 , ddrug3 , ddrug4 , DB00927 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , and ddrug11 .",
        "label": "NA"
    },
    {
        "text": "in patients receiving nonselective HD00275 { ddrug1 } { e , g , , ddrug2 } in combination with ddrug3 { e , g , , ddrug4 , ddrug5 , DB00715 , ddrug7 , ddrug8 } , there have been reports of serious , sometimes fatal , reactions .",
        "label": "effect"
    },
    {
        "text": "ddrug0 have been reported to blunt the hypotensive effect of systemic DB00575 , it is not known whether the concurrent use of these agents with DB00484 in humans can lead to resulting interference with the iop lowering effect .",
        "label": "NA"
    },
    {
        "text": "however , the antagonism of the DB00277 - induced anxiogenic effects by ddrug1 was only observed in the time spent in the light zone , and HD00188 - induced anxiogenic effects were neither reversed by ddrug3 nor by ddrug4 .",
        "label": "NA"
    },
    {
        "text": "DB00294 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as HD00269 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "int"
    },
    {
        "text": "in patients receiving DB00573 and a HD00429 concomitantly , any reduction in ddrug2 dosage should be gradual in order to avoid the possible complications of sudden ddrug3 withdrawal .",
        "label": "advise"
    },
    {
        "text": "drug interactions : the central ddrug0 syndrome can occur when anticholinergic agents such as ddrug1 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain HD00424 such as ddrug3 , the ddrug4 and other ddrug5 , ddrug6 , certain HD00303 such as the ddrug8 salts , and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "- a ddrug0 { HD00725 } such as ddrug2 { ddrug3 } , ddrug4 { ddrug5 } , or ddrug6 { DB00780 } ;",
        "label": "NA"
    },
    {
        "text": "{ in some patients , the HD00787 can reduce the diuretic , natriuretic , and antihypertensive effects of ddrug1 , HD00643 , and ddrug3 .",
        "label": "effect"
    },
    {
        "text": "ingestion of DB00586 may increase serum concentrations of ddrug1 and ddrug2 and increase DB00091 s nephrotoxicity .",
        "label": "effect"
    },
    {
        "text": "DB00393 had no effect on DB14152 response .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , DB00446 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , HD00029 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , DB01026 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { DB00295 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "recovery of hoof twitch from 50 % to 75 % took # + / - # min for ddrug0 alone and # + / - # min for DB13295 plus HD00198 { p = # } .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , DB01174 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , DB00295 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "in one survey , # % of patients taking ddrug0 in combination with HD00043 experienced tremor , as compared to # % reported to occur with DB00598 alone .",
        "label": "NA"
    },
    {
        "text": "in addition , ddrug0 and HD00888 induce a subgroup of the cytochrome cyp2b6 3a family { cyp3a4 and cyp3a5 } responsible for the metabolism of HD00890 and oral ddrug3 , resulting in a lower plasma concentration of these drugs .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 { DB00320 } injection , usp should not be used with HD00623 because the combination may cause synergistic elevation of blood pressure .",
        "label": "effect"
    },
    {
        "text": "ddrug0 / ddrug1 : DB00683 , DB00897",
        "label": "NA"
    },
    {
        "text": "such individuals are referred to as poor metabolizers of drugs such as ddrug0 , ddrug1 , the HD00043 , and DB00363 .",
        "label": "NA"
    },
    {
        "text": "there have been reports of DB00277 - related side-effects in patients on concomitant ddrug1 - HD00533 therapy .",
        "label": "NA"
    },
    {
        "text": "HD00444 : concurrent administration of certain ddrug1 , such as HD00538 and ddrug3 , would be expected to compromise the beneficial effects of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "- a HD00764 such as DB00898 { ddrug2 , ddrug3 , others } , ddrug4 { ddrug5 , others } , ddrug6 { ddrug7 , ddrug8 , others } , and others ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a clinical pharmacology study , coadministration of an ddrug1 { ddrug2 , DB09104 , and ddrug4 } with ddrug5 reduced serum levels and urinary excretion of DB14207 as compared with ddrug7 administered alone , suggesting that ddrug8 may impair absorption of ddrug9 .",
        "label": "NA"
    },
    {
        "text": "if DB01239 is given concomitantly with HD00263 , the ddrug2 dose should be reduced { by approx , 50 % } , because ddrug3 amplifies the therapeutic actions and side-effects of ddrug4 massively .",
        "label": "advise"
    },
    {
        "text": "using in situ hybridization , we observed that ddrug0 caused a rapid and transient dose-dependent increase in arc mrna level in the striatum and cortex that was abolished by pretreatment with the specific drd1 antagonist ddrug1 but not by an HD00017 DB00363 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , DB01601 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , DB00231 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { cns } drugs including ddrug1 , ddrug2 , ddrug3 , ddrug4 , blood pressure medications { ddrug5 , ddrug6 , HD00254 } , motion sickness medications , ddrug8 , ddrug9 , ddrug10 , sleeping pills and HD00262",
        "label": "NA"
    },
    {
        "text": "formulation of fluorescence labelled ddrug0 and HD00071 in unconjugated ddrug2 { 1 % m/v } did not significantly improve the permeation , however in the presence of 1 % { m/v } HD00068 # a significantly improved permeation was observed { r = # } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in vitro and/or in vivo data indicate that DB00196 , DB01167 , and oral ddrug3 markedly inhibit the metabolism of ddrug4 , which can result in an increase in plasma ddrug5 levels and prolongation of the qt interval on the ecg .",
        "label": "NA"
    },
    {
        "text": "other drugs : based on the results of drug interaction studies , no dosage adjustment is recommended when DB00625 { ddrug1 } is given with the following : ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , DB00220 , ddrug10 , and ddrug11 .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of DB00280 and DB00908 resulted in slight increases in plasma ddrug2 levels and slight decreases in plasma ddrug3 levels .",
        "label": "mechanism"
    },
    {
        "text": "based on anecdotal reports , there may be an interaction between DB00921 and HD00100 .",
        "label": "int"
    },
    {
        "text": "the influence of ddrug0 and DB00829 on antinociceptive effect of ddrug2 { 10 mg/kg } , DB04817 { 500 mg/kg } and ddrug4 { 10 mg/kg } was investigated in a mouse model using the tail-flick and hot-plate tests .",
        "label": "NA"
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the ddrug0 of drugs may be potentiated by ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , the ddrug6 , ddrug7 and HD00560 , ddrug9 and the ddrug10 , and by other HD00561 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 should be administered with caution to patients who are taking other HD00826 or ddrug2 , including DB02325 , ddrug4 and ddrug5 , or to those with a history of psychiatric disorder { including manic-depressive illness and schizophrenia } .",
        "label": "NA"
    },
    {
        "text": "HD00491 : co-administration of a single dose of intravenously administered ddrug1 { 20 mg } reduced the oral absorption of a single # mg dose of DB01066 administered following a meal , as evidenced by a 27 % decrease in mean cmax and a 22 % decrease in mean auc .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : clinical evidence has shown that ddrug1 can be formed with concurrent ingestion of DB00459 and DB00898 .",
        "label": "mechanism"
    },
    {
        "text": "hypotension : patients on diuretic therapy : patients on HD00218 and especially those in whom diuretic therapy was recently instituted , may occasionally experience an excessive reduction of blood pressure after initiation of therapy with ddrug1 or DB09477 .",
        "label": "effect"
    },
    {
        "text": "although clinical studies have not established a cause and effect relationship , physicians should be aware that variable effects an blood coagulation have been reported very rarely in patients receiving oral HD00326 and DB00475 .",
        "label": "effect"
    },
    {
        "text": "- drugs whose efficacy is impaired by DB00252 include : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , oral ddrug8 , ddrug9 , ddrug10 , DB00277 , ddrug12 .",
        "label": "effect"
    },
    {
        "text": "DB00311 may increase the action of ddrug1 , ddrug2 , DB01035 , and ddrug4 .",
        "label": "effect"
    },
    {
        "text": "DB00446 has been shown to be antagonistic to HD00497 , including ddrug2 , based on in vitro studies and time kill curves with enteric gram-negative bacilli .",
        "label": "effect"
    },
    {
        "text": "steady-state serum concentrations of HD00043 are reported to fluctuate significantly when DB00501 is either added or deleted from the drug regimen .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 / ddrug1 / ddrug2 / HD00263 : co-administration of ddrug4 with HD00264 , ddrug6 , ddrug7 , and ddrug8 is likely to lead to an enhancement of effects .",
        "label": "NA"
    },
    {
        "text": "background : the effects of combined administration of ddrug0 and DB00661 { ddrug2 } , a HD00038 , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by ddrug4 { ddrug5 } and the labeling index of intestinal_cancer were investigated in male wistar rats .",
        "label": "NA"
    },
    {
        "text": "in addition , neuromuscular blocking action is enhanced by general ddrug0 , local HD00264 like DB00281 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and ddrug7 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - induced oxidative stress in rat brain and liver is prevented by DB00163 or DB00437 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : a relationship of functional antagonism exists between HD00464 , which promote calcium absorption , and HD00175 , which inhibit calcium absorption .",
        "label": "mechanism"
    },
    {
        "text": "since bacteriostatic drugs may interfere with the bactericidal action of HD00284 , it is advisable to avoid giving HD00239 in conjunction with ddrug2 .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other HD00216 ddrug3 ddrug4 ddrug5 { DB00564 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "if these agents are to be administered concurrently , DB00091 concentrations should be monitored , especially when DB00343 therapy is initiated , adjusted , or discontinued .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : because of the relationship of ddrug1 to ddrug2 , patients should be advised against taking HD00818 containing DB00162 to avoid additive toxic effects",
        "label": "NA"
    },
    {
        "text": "ddrug0 { such as DB01195 , ddrug2 , or ddrug3 } : concurrent use with DB01102 may have a proarrhythmic effect .",
        "label": "NA"
    },
    {
        "text": "conclusions : ddrug0 inhibit the metabolism of HD00095 that are metabolized by cyp3a4 { i , e , , DB01076 , ddrug3 , ddrug4 , ddrug5 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , DB00091 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , DB01232 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "as with other ddrug0 , if DB01136 is to be administered orally with ddrug2 of the ddrug3 or DB00343 type , it is recommended that ecg and blood pressure be monitored .",
        "label": "advise"
    },
    {
        "text": "the similarity of the ddrug0 - associated adverse event profile between study # { without co-administered DB02325 } and study # { with co-administered ddrug2 } indicates that this alteration in clearance does not necessitate reduction of the DB00108 dose to maintain safety , general } .",
        "label": "NA"
    },
    {
        "text": "when used in therapeutic doses , DB00207 had a modest effect on the pharmacokinetics of DB01076 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { intravenous and oral } , ddrug12 , ddrug13 / ddrug14 or ddrug15 .",
        "label": "mechanism"
    },
    {
        "text": "HD00254 , ddrug1 , ddrug2 salts , and ddrug3 may either potentiate or weaken the blood-glucose-lowering effect of HD00071 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 and ddrug1 : ddrug2 should be administered with extreme caution in patients being treated with HD00275 or HD00043 because the action of ddrug5 on the cardiovascular system may be potentiated by these agents .",
        "label": "NA"
    },
    {
        "text": "it is , however , possible that concomitant use of other known HD00299 such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 and HD00239 might increase the photosensitivity reaction of actinic_keratosis treated with the ddrug7 for topical solution .",
        "label": "NA"
    },
    {
        "text": "DB00405 can interact with ddrug1 or other ddrug2 { may potentiate the cns depressant effects of either these medications or ddrug3 } , HD00444 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug5 } , and ddrug6 { concurrent use with ddrug7 may prolong and intensify the anticholinergic and cns depressant effects of ddrug8 } .",
        "label": "int"
    },
    {
        "text": "ddrug0 : in vitro and/or in vivo data indicate that ddrug1 , ddrug2 , and oral DB01026 markedly inhibit the metabolism of ddrug4 , which can result in an increase in plasma DB00604 levels and prolongation of the qt interval on the ecg .",
        "label": "NA"
    },
    {
        "text": "if you are also using a HD00429 inhaler , take DB00901 first and then wait about # minutes before using the ddrug2 inhaler .",
        "label": "advise"
    },
    {
        "text": "the effects of supplementary oral ddrug0 and DB01592 , as well as the interaction between both at the absorption site , fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either # or # micrograms/kg of ddrug2 and # or # mg/kg of DB01592 over a period of # days in a total of # rats .",
        "label": "NA"
    },
    {
        "text": "HD00175 , ddrug1 and ddrug2 : concomitant treatment with ddrug3 , ddrug4 , or HD00218 may potentiate a possible hypokalemic effect of ddrug6",
        "label": "NA"
    },
    {
        "text": "HD00424 may potentiate the hypotensive effects of DB00575 .",
        "label": "effect"
    },
    {
        "text": "because oral HD00326 may interfere with the hepatic metabolism of ddrug1 , toxic levels of the ddrug2 may occur when an oral ddrug3 and DB00252 are administered concurrently .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : a clinical study in # insulin-dependent diabetic patients demonstrated no effect of DB00702 on ddrug2 absorption from the peritoneal cavity or on HD00071 s ability to control blood glucose when ddrug4 was administered intraperitoneally with ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 : coadministration of DB00220 with HD00872 resulted in a 47 % decrease in ddrug4 and an 18 % decrease in ddrug5 plasma concentrations .",
        "label": "mechanism"
    },
    {
        "text": "when combined with ddrug0 , HD00050 exhibited strong synergistic activity while only additive effects were observed with the combination of ddrug2 { or ddrug3 } and DB01165 .",
        "label": "NA"
    },
    {
        "text": "in addition , several HD00715 s that are cytochrome cyp2b6 inducers can decrease plasma concentrations of DB00776 and ddrug2 .",
        "label": "mechanism"
    },
    {
        "text": "the administration of local ddrug0 containing DB00668 or ddrug2 to patients receiving ddrug3 or HD00043 may produce severe , prolonged hypertension .",
        "label": "effect"
    },
    {
        "text": "DB11058 interferes with the absorption of ddrug1 , including HD00689 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : the concomitant use of ddrug1 { DB00813 transdermal system } with other ddrug3 , including but not limited to other ddrug4 , ddrug5 , ddrug6 , ddrug7 { e , g , , ddrug8 } , general HD00264 , ddrug10 , ddrug11 , and ddrug12 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .",
        "label": "effect"
    },
    {
        "text": "in in vivo studies , 10 - to 30-mg/day doses of ddrug0 had no significant effect on metabolism by cyp2d6 { ddrug1 } , cyp2c9 { ddrug2 } , cyp2c19 { DB00338 , ddrug4 } , and cyp3a4 { DB00514 } substrates .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : population pharmacokinetic analyses indicate that ddrug1 clearance is 60 % greater in patients taking DB00252 with or without other enzyme - inducing HD00714 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 such as DB01247 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , ddrug5 { e , g , , ddrug6 } , ddrug7 { e , g , , ddrug8 } , and ddrug9 { e , g , , ddrug10 } : using these medicines with DB00150 may increase the chance of side effects .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - HD00485 containing side chains of n-methylthiotetrazole { ddrug2 , ddrug3 , DB01330 , ddrug5 , ddrug6 } or methylthiadiazole { ddrug7 } can cause vitamin_k_deficiency and hypoprothrombinemia .",
        "label": "NA"
    },
    {
        "text": "DB01235 and DB00915 : limited clinical data suggest a higher incidence of adverse experiences in patients receiving ddrug2 concurrently with either ddrug3 or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , DB00908 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 DB00683 , ddrug12 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and DB00759 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , DB00812 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "pretreatment of megakaryocytes with extracellular HD00054 { 50 microm } also inhibited HD00053 - induced responses .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : the addition of ddrug1 to patients taking DB00313 chronically had no effect on DB00906 pharmacokinetics , but ddrug4 significantly decreased ddrug5 binding in vitro from # to # % , which resulted in an increase of approximately 40 % in the free tiagabine concentration .",
        "label": "NA"
    },
    {
        "text": "there have been reports of interactions of DB00199 with ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , DB00313 , ddrug12 , and ddrug13 .",
        "label": "int"
    },
    {
        "text": "DB00571 to healthy volunteers under steady-state conditions had no relevant effect on either drug s bioavailability , auc and cmax , differences were 20 % between ddrug1 given singly and in combination with ddrug2 , and between ddrug3 given singly and in combination with DB00270 .",
        "label": "NA"
    },
    {
        "text": "the concurrent use of two or more drugs with anticholinergic activity -- such as an HD00513 { eg , ddrug1 } , an ddrug2 { eg , DB00376 } , and/or a ddrug4 { eg , ddrug5 } -- commonly results in excessive anticholinergic effects , including dry mouth and associated dental complications , blurred vision , and , in patients exposed to high temperature and humidity , hyperpyrexia .",
        "label": "effect"
    },
    {
        "text": "apparent oral clearance and volume of distribution of DB00877 decreased with 38 % and 45 % , respectively , when ddrug1 was given with DB00343 .",
        "label": "NA"
    },
    {
        "text": "intravenous ddrug0 { DB00640 } has been effectively administered in the presence of other cardioactive drugs , such as ddrug2 , ddrug3 , ddrug4 , and HD00209 , without any change in the adverse reaction profile .",
        "label": "NA"
    },
    {
        "text": "there was no evidence of drug interactions in clinical studies in which DB00841 was administered concurrently with other drugs , including ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , DB00572 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , and ddrug13 .",
        "label": "NA"
    },
    {
        "text": "co-administration : concomitant use of DB00278 with ddrug1 , HD00364 , and other ddrug3 may increase the risk of bleeding .",
        "label": "effect"
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of HD00472 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 { 1 } , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 { 1 } , ddrug10 , ddrug11 , grapefruit juice , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21 , ddrug22 , ddrug23 , ddrug24 { 1 } , ddrug25 , DB00744 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 { ddrug1 } alone or in combination with ddrug2 : concomitant use of DB00999 alone or in combination with DB00384 is contraindicated .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { e , g , , HD00896 } - taking ddrug2 and ddrug3 together may decrease the effects of DB00592 .",
        "label": "NA"
    },
    {
        "text": "therefore , co-administration of ddrug0 with other drugs that are metabolized by this isoenzyme , including other HD00216 , ddrug2 , ddrug3 , and ddrug4 { eg , ddrug5 , ddrug6 , and ddrug7 } , or that inhibit this enzyme { eg , DB00908 } , should be approached with caution .",
        "label": "NA"
    },
    {
        "text": "other potentially important drug interactions : ddrug0 : ddrug1 metabolized by hepatic oxidation { e , g , , ddrug2 , ddrug3 , DB00897 elc , } should be used with caution because the clearance of these drugs is likely to be reduced by DB00176 .",
        "label": "mechanism"
    },
    {
        "text": "the 1-year risk of relapse { rehospitalisation } was significantly lower with DB00334 than with DB00502 treatment .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of ddrug0 and ddrug1 , DB00501 , ddrug3 , or an ddrug4 / DB00396 oral ddrug6 produced minor changes in the pharmacokinetics of ddrug7 , which were considered to be without clinical significance .",
        "label": "NA"
    },
    {
        "text": "DB00318 in combination with other HD00424 , general ddrug2 , ddrug3 , ddrug4 , ddrug5 , or other ddrug6 { including ddrug7 } has additive depressant effects .",
        "label": "effect"
    },
    {
        "text": "HD00488 and foods fortified with ddrug1 concomitant administration of ddrug2 with a therapeutic ddrug3 containing # mg of elemental ddrug4 { as feso4 } or HD00489 supplemented with # mg of elemental ddrug6 reduced extent of absorption by 80 % and 31 % , respectively .",
        "label": "NA"
    },
    {
        "text": "in a phase i trial using escalating doses of ddrug0 { 110 - 200 mg/m2 } and ddrug1 { 50 or # mg/m2 } given as sequential infusions , myelosuppression was more profound when DB01229 was given after ddrug3 than with the alternate sequence { ie , ddrug4 before DB00515 } .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 DB00472 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } DB01235 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "DB01032 : as with other HD00487 , renal excretion of ddrug2 is inhibited by ddrug3 and resulted in an approximate 80 % increase in the auc for ddrug4 .",
        "label": "NA"
    },
    {
        "text": "drug interactions : ddrug0 may interact with some drugs , like ddrug1 { ddrug2 } : ddrug3 could theoretically affect DB00875 pharmacodynamics - ddrug5 - jzqyavbxjcqsok_uhfffaoysa_n - DB00898 : ddrug7 and ddrug8 cause additive cns depression - ddrug9 : ddrug10 increases the effect of ddrug11",
        "label": "NA"
    },
    {
        "text": "DB01032 prolonged action of DB00292",
        "label": "NA"
    },
    {
        "text": "coadministration of DB00580 with doses higher than # mg qd DB00338 has not been studied .",
        "label": "NA"
    },
    {
        "text": "the risk of hypoglycemia secondary to this mechanism may be increased if DB00437 and DB00672 are given concomitantly in the presence of renal insufficiency .",
        "label": "effect"
    },
    {
        "text": "the purpose of this study was to evaluate the effect of ddrug0 { HD00072 } and ddrug2 { HD00068 } conjugates on the intestinal permeation of ddrug4 { ddrug5 } and model peptide drugs , ddrug6 and ddrug7 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00501 has been reported to produce clinically significant fluctuations in steady-state serum concentrations of various HD00043 .",
        "label": "mechanism"
    },
    {
        "text": "HD00183 - containing therapies should not be used with DB01217 as they may diminish its pharmacologic action .",
        "label": "advise"
    },
    {
        "text": "DB00619 will increase plasmaconcentration of other cyp3a4 metabolized drugs { e , g , , triazolo - ddrug1 , HD00798 , certain ddrug3 , etc , } .",
        "label": "mechanism"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : ddrug1 ; ddrug2 ; ddrug3 ; certain HD00002 , especially the ddrug5 and HD00384 ; ddrug7 ; ddrug8 salts ; ddrug9 ; and ddrug10 .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 : ddrug1 , when given once daily for # days as a 100-mg capsule with an oral HD00349 containing # mcg of ddrug3 and # mg of ddrug4 , decreased the auc of ddrug5 by 43 % , and decreased the auc of DB00717 by 8 % ;",
        "label": "NA"
    },
    {
        "text": "avoid the use of preparations such as HD00799 and local ddrug1 which contain any HD00800 { e , g , , ddrug3 , ddrug4 } , since it has been reported that ddrug5 can potentiate the effects of catecholamines .",
        "label": "NA"
    },
    {
        "text": "drugs that should not be coadministered with DB00220 ddrug1 : ddrug2 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 HD00100 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "label": "advise"
    },
    {
        "text": "ddrug0 - related adverse effects have occurred in patients when DB00277 and DB00467 were coadministered .",
        "label": "effect"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of ddrug0 : ddrug1 , DB01406 , ddrug3 , ddrug4 { e , g , , ddrug5 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , HD00810 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "thus , when HD00203 and DB14507 are administered concurrently , subjects should be observed carefully for signs of ddrug2 toxicity .",
        "label": "effect"
    },
    {
        "text": "as with other ddrug0 , if DB01136 is to be administered orally with ddrug2 of the DB00661 or ddrug4 type , it is recommended that ecg and blood pressure be monitored .",
        "label": "advise"
    },
    {
        "text": "a drug-drug interaction study evaluated the effect of the use of DB00250 gel , 5 % , in combination with double_strength { 160 mg/800 mg } ddrug1 / ddrug2 { ddrug3 / DB01015 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the concomitant use of ddrug1 { ddrug2 transdermal system } with other ddrug3 , including but not limited to other HD00263 , HD00024 , ddrug6 , ddrug7 { e , g , , ddrug8 } , general ddrug9 , ddrug10 , ddrug11 , and ddrug12 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .",
        "label": "NA"
    },
    {
        "text": "HD00330 : in some patients , the administration of a ddrug1 can reduce the diuretic , natriuretic , and antihypertensive effects of ddrug2 , ddrug3 and HD00029 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , DB00091 } , hiv drugs classified as HD00269 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "in clinical studies , coadministration of DB00930 with ddrug1 , ddrug2 , or DB00641 did not interfere with the lipid-lowering activity of the ddrug4 .",
        "label": "NA"
    },
    {
        "text": "in a placebo-controlled trial in normal volunteers , the administration of a single # mg dose of DB00590 on day # of a four-day regimen of oral DB00501 { 400 mg twice daily } resulted in a 10 % increase in mean auc of ddrug2 { p = # } , and a slight but not statistically significant increase in mean cmax and mean half-life of ddrug3 .",
        "label": "mechanism"
    },
    {
        "text": "interactions for HD00464 { ddrug1 , ddrug2 , ddrug3 , and ddrug4 } : DB01432 : ddrug6 has been reported to reduce intestinal absorption of ddrug7 ;",
        "label": "NA"
    },
    {
        "text": "drug interactions : the central ddrug0 syndrome can occur when anticholinergic agents such as DB00810 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain ddrug2 such as DB00454 , the ddrug4 and other ddrug5 , ddrug6 , certain ddrug7 such as the ddrug8 salts , and ddrug9 .",
        "label": "effect"
    },
    {
        "text": "drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving ddrug0 metabolized similarly to ddrug1 or on the basis of in vitro studies with ddrug2 or other ddrug3 { caution is recommended during coadministration with ddrug4 } : available data from clinical studies of ddrug5 other than DB00404 suggest a possible drug interaction with ddrug7 for the following : ddrug8 , ddrug9 , HD00093 such as ddrug11 and ddrug12 , and grapefruit juice .",
        "label": "NA"
    },
    {
        "text": "HD00175 , ddrug1 and ddrug2 : concomitant treatment with ddrug3 , ddrug4 , or ddrug5 may potentiate a possible hypokalemic effect of HD00742",
        "label": "NA"
    },
    {
        "text": "cytochrome p-450 inducers , such as DB00252 , ddrug1 and ddrug2 , induce ddrug3 metabolism , causing an approximately 30 % decrease in plasma DB01068 levels .",
        "label": "NA"
    },
    {
        "text": "treatment with DB00494 coadministered with DB01235 / ddrug2 does not change these effects .",
        "label": "NA"
    },
    {
        "text": "results : DB00203 has demonstrated effectiveness in men with erectile dysfunction associated with prostatectomy , radiation therapy , diabetes mellitus , certain neurologic disorders , and drug therapy { eg , ddrug1 -lsb- HD00114 -rsb- } .",
        "label": "NA"
    },
    {
        "text": "in addition , DB01202 does not affect the in vitro glucuronidation of DB00313 .",
        "label": "NA"
    },
    {
        "text": "avoid the use of preparations such as ddrug0 and local HD00264 which contain any ddrug2 { e , g , , ddrug3 , ddrug4 } , since it has been reported that HD00043 can potentiate the effects of catecholamines .",
        "label": "advise"
    },
    {
        "text": "oral ddrug0 : based on auc and half-life , multiple-dose pharmacokinetic profiles of ddrug1 and ddrug2 following administration of tablets containing # mg of DB00717 and # mcg of DB00977 were similar with and without coadministration of ddrug5 { 400 mg tid ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , HD00002 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , DB01045 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "because ddrug0 is eliminated from the body via conjugation with glutathione , use of DB00316 prior to { # hours } or concurrent with ddrug2 may result in reduced DB01008 clearance based upon the known property of ddrug4 to decrease glutathione levels in the blood and tissues .",
        "label": "NA"
    },
    {
        "text": "while no in vivo drug-drug interaction studies were conducted between ddrug0 and inducers of cyp3a , compounds that are potent cytochrome_p450_family_3_subfamily_a inducers { such as ddrug1 , ddrug2 , DB01045 , and ddrug4 } would be expected to decrease DB01215 concentrations .",
        "label": "NA"
    },
    {
        "text": "DB01432 ddrug1 may delay or reduce the absorption of concomitant oral medication such as ddrug2 , ddrug3 , ddrug4 { acidic } or ddrug5 { basic } , as well as ddrug6 DB01053 , ddrug8 , thyroid and ddrug9 preparations , ddrug10 and ddrug11 , and ddrug12 .",
        "label": "mechanism"
    },
    {
        "text": "DB00343 , DB01115 , ddrug2",
        "label": "NA"
    },
    {
        "text": "ddrug0 : doses of ddrug1 { DB00126 } # g/day have been reported to increase plasma concentration of HD00706 by ~ 47 % , possibly by inhibiting conjugation ;",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 , ddrug1 , or DB01045 increased metabolic clearance of DB00687 because of the induction of hepatic enzymes .",
        "label": "mechanism"
    },
    {
        "text": "HD00870 : ddrug1 , ddrug2 , DB00201 , ddrug4 contraindicated due to potential for serious and life-threatening reactions such as acute ddrug5 toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues .",
        "label": "NA"
    },
    {
        "text": "the clearance of HD00100 metabolized by glucuronidation { e , g , , ddrug1 , ddrug2 , DB00231 } is unlikely to be affected by ddrug4 .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other HD00216 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 DB00472 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB01032 is known to interact with the metabolism or renal tubular excretion of many drugs { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , DB00927 , ddrug12 , ddrug13 agents , ddrug14 , and ddrug15 } .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 ddrug1 ddrug2 ddrug3 ddrug4 HD00324 DB01149 ddrug7 large quantities of grapefruit juice { # quart daily }",
        "label": "NA"
    },
    {
        "text": "ddrug0 { e , g , DB00199 and ddrug2 } : agents of the ddrug3 , of which ddrug4 { ddrug5 } injection , usp is a member , have been shown to interact with ddrug6 of the HD00626 , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .",
        "label": "NA"
    },
    {
        "text": "this observed increase in the bioavailability of ddrug0 may be due to transport-related effects , such as p-glycoprotein , in vivo animal studies also suggest that in addition to enhancing absorption , ddrug1 decreases DB00950 gastrointestinal secretion , while DB00199 may also decrease biliary excretion .",
        "label": "NA"
    },
    {
        "text": "interaction between DB00978 and DB00091 has not been studied .",
        "label": "NA"
    },
    {
        "text": "prior administration of ddrug0 { 90 mg kg { -1 } body weight } was shown to prevent the conversion of ddrug1 { 100 mg kg { -1 } body weight } to HD00078 in vivo and to eliminate the fluoride and citrate elevations seen in HD00079 - intoxicated animals .",
        "label": "NA"
    },
    {
        "text": "interactions for DB11094 analogues { ddrug1 , ddrug2 , DB00136 , and ddrug4 } : ddrug5 : ddrug6 has been reported to reduce intestinal absorption of ddrug7 ;",
        "label": "NA"
    },
    {
        "text": "injection : ddrug0 injection , like other injectable ddrug1 , produces depression of the central nervous system when administered with ddrug2 , ddrug3 , HD00026 , ddrug5 , and other ddrug6 , when ddrug7 is used concomitantly with injectable DB00186 , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .",
        "label": "NA"
    },
    {
        "text": "DB00945 : as with other ddrug1 , concomitant administration of DB00784 and ddrug3 is not generally recommended because of the potential of increased adverse effects .",
        "label": "NA"
    },
    {
        "text": "the response to HD00770 may be blunted by HD00219 and ddrug2 which cause a rise in prolactin .",
        "label": "effect"
    },
    {
        "text": "ddrug0 { cns } drugs including ddrug1 , ddrug2 , ddrug3 , ddrug4 , blood pressure medications { DB00206 , ddrug6 , ddrug7 } , motion sickness medications , HD00542 , ddrug9 , ddrug10 , sleeping pills and ddrug11",
        "label": "NA"
    },
    {
        "text": "DB00522 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , DB01035 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "int"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , HD00668 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , DB00295 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "because ddrug0 has not been shown to produce any additional effect beyond that obtained with DB00945 alone and because ddrug2 increases the rate of excretion of ddrug3 , the concomitant use of DB00573 and ddrug5 is not recommended .",
        "label": "NA"
    },
    {
        "text": "this did not result in any statistically or clinically relevant changes in the pharmacokinetic parameters of either DB00201 or its major metabolite , HD00859 .",
        "label": "NA"
    },
    {
        "text": "DB01032 : as with other ddrug1 , the renal excretion of DB00567 is inhibited by ddrug3 .",
        "label": "NA"
    },
    {
        "text": "oral HD00326 interaction studies with ddrug1 and DB01418 failed to identify any clinically important effects on the serum concentrations or clinical effects of these ddrug3 .",
        "label": "NA"
    },
    {
        "text": "if HD00488 are required during ddrug1 therapy , DB00535 should be taken at least # hours before or after the supplement .",
        "label": "advise"
    },
    {
        "text": "if concomitant treatment with DB00669 and an ddrug1 { e , g , , ddrug2 , ddrug3 , DB00715 , ddrug5 , ddrug6 , ddrug7 } is clinically warranted , appropriate observation of the patient is advised .",
        "label": "advise"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and DB00759 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , DB00295 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "therefore , co-administration of ddrug0 with other drugs that are metabolized by this isoenzyme , including other ddrug1 , ddrug2 , ddrug3 , and ddrug4 { eg , ddrug5 , DB01195 , and ddrug7 } , or that inhibit this enzyme { eg , DB00908 } , should be approached with caution .",
        "label": "NA"
    },
    {
        "text": "data from a randomized trial of DB00488 and DB00515 plus or minus ddrug2 in ovarian_cancer indicated that ddrug3 significantly reduced neurotoxicity ;",
        "label": "effect"
    },
    {
        "text": "the concurrent use of ddrug0 injection with other HD00444 or medications with anticholinergic activity , such as HD00219 , ddrug3 , or ddrug4 , may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects .",
        "label": "NA"
    },
    {
        "text": "injection : ddrug0 injection , like other injectable ddrug1 , produces depression of the central nervous system when administered with ddrug2 , HD00219 , ddrug4 , ddrug5 , and other HD00216 , when ddrug7 is used concomitantly with injectable ddrug8 , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration of DB00224 with DB00220 resulted in an 83 % increase in ddrug3 plasma auc and a 51 % increase in ddrug4 plasma a , c.",
        "label": "mechanism"
    },
    {
        "text": "DB00615 , another DB11753 , is structurally similar to ddrug2 and may possibly have some of the same drug interactions as ddrug3 .",
        "label": "NA"
    },
    {
        "text": "concomitant use of DB01254 and drugs that inhibit cyp3a4 { eg , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , DB01149 , ddrug9 , ddrug10 , ddrug11 } may increase exposure to ddrug12 and should be avoided .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : ddrug1 { ddrug2 , DB00206 , ddrug4 , ddrug5 , fruit juices , etc , } lower absorption of HD00401 .",
        "label": "mechanism"
    },
    {
        "text": "therefore , concurrent use of DB00776 with HD00432 may render these ddrug2 less effective .",
        "label": "effect"
    },
    {
        "text": "drug-drug interactions : no clinically significant drug interactions have been found with DB00277 at a low dose , ddrug1 , ddrug2 , DB01026 , or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "other drugs : in healthy volunteers , ddrug0 , ddrug1 , ddrug2 , DB00863 , ddrug4 , hormone replacement therapy { a combination of conjugated ddrug5 and HD00642 } , ddrug7 { ddrug8 and ddrug9 } and ddrug10 did not affect the pharmacokinetics of ddrug11 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : co-administration of DB00559 # mg b , i , d , for # days decreased the plasma concentrations of both DB14055 { a cyp2c9 substrate } and ddrug3 { a cyp3a4 substrate } by # and 38 % , respectively .",
        "label": "mechanism"
    },
    {
        "text": "the similarity of the DB00108 - associated adverse event profile between study # { without co-administered DB02325 } and study # { with co-administered ddrug2 } indicates that this alteration in clearance does not necessitate reduction of the ddrug3 dose to maintain safety , general } .",
        "label": "NA"
    },
    {
        "text": "given the anticonvulsant properties of DB00564 , HD00472 may reduce the thyroid function as has been reported with other ddrug2 .",
        "label": "NA"
    },
    {
        "text": "DB00903 may increase the ototoxic potential of other drugs such as ddrug1 and some HD00495 .",
        "label": "effect"
    },
    {
        "text": "although HD00115 have been shown to reduce ddrug1 - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with ddrug2 may reduce the antitumor effectiveness of ddrug3 and thus should be avoided , # ddrug4 and other HD00255 may potentiate the hypotension seen with ddrug6 .",
        "label": "NA"
    },
    {
        "text": "DB00091 : concomitant administration of DB00622 and ddrug2 levels .",
        "label": "NA"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 HD00871 : ddrug9 ddrug10 DB00683 , ddrug12 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "the concurrent use of two or more drugs with anticholinergic activity -- such as an ddrug0 { eg , DB00477 } , an ddrug2 { eg , DB00376 } , and/or a ddrug4 { eg , ddrug5 } -- commonly results in excessive anticholinergic effects , including dry mouth and associated dental complications , blurred vision , and , in patients exposed to high temperature and humidity , hyperpyrexia .",
        "label": "effect"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 DB00264 ddrug4 DB00564 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the concomitant use of ddrug1 { DB00813 transdermal system } with other ddrug3 , including but not limited to other ddrug4 , HD00024 , ddrug6 , ddrug7 { e , g , , ddrug8 } , general ddrug9 , ddrug10 , ddrug11 , and ddrug12 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .",
        "label": "effect"
    },
    {
        "text": "administration of ddrug0 with other cyp3a4 inhibitors { e , g , , DB00199 # mg bid , ddrug2 # mg qd , ddrug3 # mg tid , DB00196 # mg qd } resulted in increases in cmax of ddrug5 ranging from # - to # - fold and auc from # - to # - fold .",
        "label": "NA"
    },
    {
        "text": "compromised ddrug0 uptake-1 in functional class iv can not be further increased by DB00907 and DB01151 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and oral HD00150 : concomitant administration of DB00162 and/or other oral ddrug3 with ddrug4 must be avoided because of the risk of hypervitaminosis a.",
        "label": "NA"
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a ddrug0 , including DB00537 , with multivalent cation-containing products such as ddrug2 or ddrug3 ddrug4 , DB00364 , ddrug6 chewable/buffered tablets or pediatric powder , or products containing ddrug7 , ddrug8 , or ddrug9 may substantially decrease the absorption of ddrug10 , resulting in serum and urine levels considerably lower than desired .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : enhanced bone marrow suppression by DB00531 and other ddrug2 has been reported among patients with neoplastic disease , except leukemia , in the presence of DB00437 .",
        "label": "effect"
    },
    {
        "text": "however , as with other HD00203 , concomitant administration of ddrug1 and DB00945 is not generally recommended because of the potential of increased adverse effects .",
        "label": "NA"
    },
    {
        "text": "the administration of local HD00449 containing ddrug1 or DB00368 to patients receiving ddrug3 , ddrug4 or ddrug5 may produce severe , prolonged hypotension or hypertension .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a single dose study { n = 6 } , ingestion of an ddrug1 containing # - gram of DB09104 with 500-mg of ddrug3 increased the cmax and auc of DB00784 by 125 % and 36 % , respectively , a number of compounds are inhibitors of cyp2c9 including ddrug5 , ddrug6 and ddrug7 .",
        "label": "NA"
    },
    {
        "text": "both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when DB00802 is administered in combination with other ddrug1 such as ddrug2 , HD00262 , ddrug4 , or inhalation general ddrug5 .",
        "label": "effect"
    },
    {
        "text": "to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma { hiv-nhl } , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the DB00531 , ddrug1 , ddrug2 , and ddrug3 { chop } chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen { i , e , , ddrug4 , ddrug5 , ddrug6 , and ddrug7 with DB00541 plus ddrug9 } without receiving ddrug10 therapy .",
        "label": "NA"
    },
    {
        "text": "DB00891 may interact with any of the following : - ddrug1 { e , g , , DB00316 } { with long-term , high-dose use } or",
        "label": "int"
    },
    {
        "text": "concomitant administration of DB01039 { equivalent to 145 mg ddrug1 } with ddrug2 { 40 mg } once daily for # days has been shown to increase the mean cmax and auc values for DB00175 by 36 % { range from 69 % decrease to 321 % increase } and 28 % { range from 54 % decrease to 128 % increase } , respectively , and for # - hydroxy-iso-pravastatin by 55 % { range from 32 % decrease to 314 % increase } and 39 % { range from 24 % decrease to 261 % increase } , respectively in # healthy adults .",
        "label": "NA"
    },
    {
        "text": "- a HD00762 { ddrug1 } such as ddrug2 { ddrug3 } , ddrug4 { ddrug5 } , or ddrug6 { DB00780 } ;",
        "label": "NA"
    },
    {
        "text": "DB01050 - DB00125 may increase the absorption of ddrug2 if taken concomitantly .",
        "label": "NA"
    },
    {
        "text": "DB01045 may decrease serum DB00390 concentration , especially in patients with renal dysfunction , by increasing the non-renal clearance of ddrug2 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : DB00701 , ddrug2 , ddrug3 , and ddrug4 have been shown to decrease plasma levels of HD00710 ;",
        "label": "mechanism"
    },
    {
        "text": "if concomitant treatment with DB00952 and an HD00278 is clinically warranted , appropriate observation of the patient is advised .",
        "label": "advise"
    },
    {
        "text": "caution is advised when beginning , discontinuing , or changing the dose of HD00234 in patients receiving DB00794 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 should be used with care when ddrug1 or inhibitors of av conduction , such as certain HD00085 { particularly of the ddrug3 -lsb- ddrug4 -rsb- and ddrug5 -lsb- ddrug6 -rsb- classes } , or ddrug7 , such as DB00280 , are used concurrently .",
        "label": "NA"
    },
    {
        "text": "HD00645 did not inhibit the antitumor activity of four ddrug1 { ddrug2 , DB00544 , ddrug4 , ddrug5 } in four murine models .",
        "label": "NA"
    },
    {
        "text": "DB01032 : as with other ddrug1 , renal excretion of ddrug2 is inhibited by ddrug3 and resulted in an approximate 80 % increase in the auc for DB00447 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 causes an approximate 50 % increase in the clearance of ddrug2 at steady state and , therefore , the addition of DB00564 results in an approximate 40 % decrease in the steady-state trough concentrations of ddrug4 as compared to the same dose of DB00949 given as monotherapy .",
        "label": "NA"
    },
    {
        "text": "the potentiating action of ddrug0 must be considered when the drug is used in conjunction with ddrug1 such as ddrug2 , HD00790 and HD00026 .",
        "label": "NA"
    },
    {
        "text": "oral doses of DB01213 { 10 - 20 mg/kg } , via akr1a1 inhibition , significantly reduced the rate of elimination of DB00898 { by approximately 40 % } given to healthy volunteers in moderate doses .",
        "label": "mechanism"
    },
    {
        "text": "potential drug interactions between ddrug0 and other ddrug1 { ddrug2 , ddrug3 , ddrug4 , DB01174 , ddrug6 , ddrug7 and ddrug8 } were also assessed by evaluating the serum concentrations of ddrug9 and these HD00714 during placebo-controlled clinical studies .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { DB00564 } ddrug7 { DB00501 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "caution should be exercised during the administration of DB00668 to patients anaesthetised with HD00780 as arrhythmias may be precipitated .",
        "label": "advise"
    },
    {
        "text": "while all the selective ddrug0 { HD00114 } , e , g , , ddrug2 , DB01104 , and ddrug4 , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .",
        "label": "NA"
    },
    {
        "text": "patients who have been treated with HD00343 within two to three weeks prior to the administration of ddrug1 should receive initial doses of DB00988 no greater than one-tenth { 1/10 } of the usual dose .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : some individuals receiving DB00601 may experience a reversible enhancement of the pressor response to indirect-acting ddrug2 , ddrug3 or HD00853 .",
        "label": "effect"
    },
    {
        "text": "DB00294 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { HD00531 } , and ddrug44 .",
        "label": "int"
    },
    {
        "text": "because a similar interaction is likely , DB00220 should also not be administered concurrently with DB00637 .",
        "label": "advise"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } HD00220 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 DB14507 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the effects of DB00682 and HD00203 on gi bleeding are synergistic , such that users of both drugs together have a risk of serious gi bleeding higher than users of either drug alone .",
        "label": "effect"
    },
    {
        "text": "ddrug0 - in subjects who had received # days of # mg/day racemic DB00215 , combined administration of ddrug2 and ddrug3 { single dose of # mg } did not significantly affect the pharmacokinetics of either ddrug4 or DB00390 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration of a single dose of DB00962 # mg and multiple doses of DB00285 er { extended release } # mg did not result in any significant changes in the pharmacokinetics of either ddrug3 or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "effects of ddrug0 are increased with HD00343 and HD00479 .",
        "label": "NA"
    },
    {
        "text": "cohort # then received DB00701 plus ddrug1 for # days , and cohort # received ddrug2 plus DB01045 for # days .",
        "label": "NA"
    },
    {
        "text": "in both species , HD00157 , but not ddrug1 , antagonized the rate-decreasing effects of DB00295 on fi and fr responding .",
        "label": "effect"
    },
    {
        "text": "ddrug0 , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , certain HD00043 , ddrug8 , ddrug9 and DB00916 , thereby delaying elimination and increasing blood levels of these drugs .",
        "label": "NA"
    },
    {
        "text": "before taking ddrug0 , tell your doctor if you are taking any of the following medicines : - DB00945 or another ddrug2 such as ddrug3 { ddrug4 } , ddrug5 { ddrug6 , others } , DB14006 { ddrug8 } , ddrug9 { ddrug10 } , or ddrug11 { ddrug12 } ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 { e , g , , ddrug1 , HD00340 , ddrug3 } and ddrug4 may reduce the therapeutic effects of DB01235 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : the concomitant use of ddrug1 { DB00813 transdermal system } with other ddrug3 , including but not limited to other ddrug4 , ddrug5 , ddrug6 , ddrug7 { e , g , , HD00100 } , general ddrug9 , ddrug10 , ddrug11 , and ddrug12 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .",
        "label": "effect"
    },
    {
        "text": "the hypoglycemic action of HD00226 may be potentiated by certain drugs including ddrug1 and other drugs that are highly protein bound , ddrug2 , ddrug3 , DB00446 , ddrug5 , ddrug6 , ddrug7 , and ddrug8 .",
        "label": "effect"
    },
    {
        "text": "this drug may interact with ddrug0 or other HD00261 { may potentiate the cns depressant effects of either these medications or ddrug2 } , ddrug3 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug4 } , and ddrug5 { concurrent use with ddrug6 may prolong and intensify the anticholinergic and cns depressant effects of HD00388 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 did not interfere with the absorption or disposition of the HD00226 DB01016 in diabetic patients .",
        "label": "NA"
    },
    {
        "text": "concurrent administration of ddrug0 and HD00288 may cause severe orthostatic hypotension , ddrug2 , an inhibitor of microsomal drug metabolism , increased DB00488 s half-life and toxicity in a rat model .",
        "label": "NA"
    },
    {
        "text": "- drugs that may decrease plasma ddrug0 concentrations include : DB00564 , chronic DB02325 abuse , ddrug3",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00982 has not been shown to alter the pharmacokinetics of DB00252 in a study in seven healthy volunteers .",
        "label": "NA"
    },
    {
        "text": "DB00294 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , DB00636 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "int"
    },
    {
        "text": "however , there are limited in vivo data suggesting a modest cyp2d6 inhibitory effect for ddrug0 , i , e , , coadministration of DB01175 { 20 mg/day for # days } with the ddrug2 ddrug3 { single dose of # mg } , a substrate for cyp2d6 , resulted in a 40 % increase in cmax and a 100 % increase in auc of DB01151 .",
        "label": "NA"
    },
    {
        "text": "it is recommended not to exceed a single # mg DB00862 dose in a 24-hour period when used in combination with DB00224 .",
        "label": "advise"
    },
    {
        "text": "DB00668 should not be administered concomitantly with other ddrug1 { such as DB01064 } because of possible additive effects and increased toxicity .",
        "label": "advise"
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the ddrug0 of drugs may be potentiated by ddrug1 , HD00543 , ddrug3 , ddrug4 , ddrug5 , the ddrug6 , ddrug7 and ddrug8 , HD00275 and the ddrug10 , and by other ddrug11 .",
        "label": "NA"
    },
    {
        "text": "similarly dialyzed were ddrug0 , DB00908 , and ddrug2 , both alone at therapeutic concentrations in serum and with DB00898 at three different concentrations in serum .",
        "label": "NA"
    },
    {
        "text": "more than # parkinsons disease patients in clinical trials have used ddrug0 in combination with DB00494 and DB01235 / ddrug3 .",
        "label": "NA"
    },
    {
        "text": "other ddrug0 { e , g , ddrug1 , HD00262 , ddrug3 and general ddrug4 } have additive or potentiating effects with DB00450 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 - although ddrug1 did not potentiate the cognitive and motor effects of ddrug2 in a clinical trial , as with other HD00281 , the use of DB02325 by patients taking ddrug5 is not recommended .",
        "label": "NA"
    },
    {
        "text": "in vitro studies demonstrated no evidence of incompatibility of DB01109 with DB00702 .",
        "label": "NA"
    },
    {
        "text": "in contrast , preliminary results from an 8-week controlled study suggested DB00734 # to # mg/day was superior to DB00334 # to # mg/day against positive and anxiety/depressive symptoms { p < # } , although consistent with the first study , both agents demonstrated similar efficacy on measures of overall psychopathology .",
        "label": "NA"
    },
    {
        "text": "combined treatment with HD00179 and HD00181 enhances the degree of apoptosis assessed using morphological markers that identify chromatin and nuclear matrix protein condensation .",
        "label": "effect"
    },
    {
        "text": "DB01057 potentiates other ddrug1 such as ddrug2 or ddrug3 and HD00662 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : ddrug1 { ddrug2 , ddrug3 , HD00605 , ddrug5 , fruit juices , etc , } lower absorption of HD00401 .",
        "label": "mechanism"
    },
    {
        "text": "HD00043 may block the antihypertensive action of DB01170 and similarly acting compounds .",
        "label": "effect"
    },
    {
        "text": "may lead to loss of virologic response and possible resistance to DB00224 or to the class of ddrug1 or other coadministered HD00268 .",
        "label": "NA"
    },
    {
        "text": "in an emergency situation when opioid analgesia must be administered to a patient receiving DB00704 , the amount of HD00023 required may be greater than usual , and the resulting respiratory_failure may be deeper and more prolonged .",
        "label": "effect"
    },
    {
        "text": "the data suggest that HD00022 has a narrower spectrum of actions and will have a substantially greater therapeutic index than HD00021 .",
        "label": "NA"
    },
    {
        "text": "although the interaction between ddrug0 and other potent cyp3a4 inhibitors { e , g , , ddrug1 , ddrug2 , and DB00199 } has not been studied , increased exposures to DB00918 may be expected when ddrug5 is used concomitantly with these medications .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { HD00114 } : ddrug2 { e , g , , ddrug3 , ddrug4 , DB00715 , ddrug6 } have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with ddrug7 .",
        "label": "NA"
    },
    {
        "text": "in this study we investigated the effect of ddrug0 on high threshold voltage-dependent ca { 2 + } channel subtypes using their HD00046 ddrug2 { l-type } , ddrug3 { n-type } , or HD00048 { p-type } in bovine chromaffin cells .",
        "label": "NA"
    },
    {
        "text": "administration of DB00206 during therapy with a HD00042 has been shown to produce a stimulating effect in some depressed patients .",
        "label": "effect"
    },
    {
        "text": "studies in healthy volunteers have shown that DB00284 has no effect on either the pharmacokinetics or pharmacodynamics of ddrug1 , ddrug2 , DB00571 , or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "in patients receiving nonselective HD00275 { ddrug1 } { e , g , , ddrug2 } in combination with HD00603 { e , g , , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 } , there have been reports of serious , sometimes fatal , reactions .",
        "label": "effect"
    },
    {
        "text": "results of studies in multiple sclerosis patients taking ddrug0 and concomitant ddrug1 { ddrug2 # mcg i m once weekly } or DB05259 were inconclusive with regard to the need for dose adjustment of the HD00868 or ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { ddrug1 } , ddrug2 or other HD00352 , or ddrug4 : concurrent use with DB01102 may produce additive inotropic and/or chronotropic effects .",
        "label": "NA"
    },
    {
        "text": "the hypotensive effect of ddrug0 is augmented by that of most other ddrug1 , including HD00877 , negative inotropic agents , and inhaled HD00264 .",
        "label": "NA"
    },
    {
        "text": "DB00233 may also decrease the absorption of DB00115 , which can lead to a deficiency .",
        "label": "mechanism"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } DB01235 DB14507 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "these in vitro studies suggest that concomitant administration of DB00943 and ddrug1 in humans may result in sub-therapeutic concentrations of active phosphorylated ddrug2 , which may lead to a decreased HD00056 effect of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "phase ii clinical trial data , where ddrug0 and DB00361 have been used concomitantly , indicate that DB00317 may exacerbate the neutropenic effect of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "therefore , co-administration of DB01156 with drugs that are metabolized by cyp2d6 isoenzyme including certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB00472 , ddrug7 } , ddrug8 { e , g , , ddrug9 , ddrug10 , ddrug11 } , ddrug12 { e , g , , ddrug13 } , and ddrug14 { e , g , , ddrug15 , ddrug16 } , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .",
        "label": "advise"
    },
    {
        "text": "although it has not been established that there is an interaction between DB00363 and ddrug1 or other ddrug2 , caution is advised when ddrug3 is initiated in patients taking a DB12537 or any other ddrug5 .",
        "label": "NA"
    },
    {
        "text": "drugs that should not be coadministered with DB00220 ddrug1 : ddrug2 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : DB01045 ddrug10 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "label": "advise"
    },
    {
        "text": "because prostaglandina play an important role in hemostasis and DB01009 has an effect on platelet function as well , concurent therapy with ddrug1 and DB00682 requires close monitoring of patients on both drugs .",
        "label": "NA"
    },
    {
        "text": "- a HD00762 { ddrug1 } such as ddrug2 { ddrug3 } , DB00752 { ddrug5 } , or ddrug6 { ddrug7 } ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a pharmacokinetic study , maximum plasma concentrations of DB01023 were considerably lower in epileptic patients on long-term ddrug2 therapy { eg , ddrug3 , DB00564 , or ddrug5 } than in healthy volunteers .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : DB01032 interferes with renal tubular secretion of DB00537 and produces an increase in the level of ddrug3 in serum .",
        "label": "mechanism"
    },
    {
        "text": "therefore , administration of HD00532 with ddrug1 containing ddrug2 , DB14513 , or ddrug4 ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 may enhance the effects of : other ddrug3 s , ddrug4 , general ddrug5 , HD00262 such as ddrug7 , HD00460 , or other ddrug9 , causing increased cns depression .",
        "label": "NA"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , DB00908 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 HD00100 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "these agents include medications such as : ddrug0 , HD00679 including ddrug2 , sali-cylates , ddrug3 { including ddrug4 } , DB00975 , or ddrug6 .",
        "label": "NA"
    },
    {
        "text": "HD00043 : use of HD00221 with ddrug2 and other ddrug3 may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed .",
        "label": "NA"
    },
    {
        "text": "these data suggest that DB14152 are negatively coupled to three types of calcium channels in bovine chromaffin cell , including an ddrug1 - sensitive { n-type } channel , an ddrug2 - sensitive { p-type } channel and ddrug3 / HD00047 / ddrug5 - resistant { presumptive q-type } channel .",
        "label": "NA"
    },
    {
        "text": "- when ddrug0 or ddrug1 is used concurrently with ddrug2 { e , g , HD00419 } , an interval of at least # hours should be maintained between the two medicines , since the absorption of ddrug4 or HD00415 is impaired",
        "label": "NA"
    },
    {
        "text": "HD00374 containing DB06723 and ddrug2 reduce the oral absorption of ddrug3 by 75 % .",
        "label": "NA"
    },
    {
        "text": "the action of the HD00100 may be potentiated by ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , HD00219 , ddrug8 , or other drugs that produce cns depression .",
        "label": "effect"
    },
    {
        "text": "in a phase i trial using escalating doses of ddrug0 { 110 - 200 mg/m2 } and DB00515 { 50 or # mg/m2 } given as sequential infusions , myelosuppression was more profound when DB01229 was given after ddrug3 than with the alternate sequence { ie , ddrug4 before ddrug5 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may increase slightly the effect of HD00448 , e , g , , ddrug2 , ddrug3 , DB00206 .",
        "label": "NA"
    },
    {
        "text": "since HD00026 are potentiated by the HD00385 , they should be used cautiously in the treatment of convulsions .",
        "label": "advise"
    },
    {
        "text": "the action of DB01394 is potentiated by HD00570 .",
        "label": "mechanism"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , DB00908 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : DB01045 ddrug10 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "DB00252 / DB01174 : the coadministration of ddrug2 or ddrug3 will not affect plasma concentrations of ddrug4 , but may reduce endogenous plasma levels of ddrug5 / ergocalcitriol by accelerating metabolism .",
        "label": "NA"
    },
    {
        "text": "to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma { hiv-nhl } , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the ddrug0 , DB00997 , ddrug2 , and ddrug3 { chop } chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen { i , e , , ddrug4 , ddrug5 , ddrug6 , and DB00898 with ddrug8 plus ddrug9 } without receiving ddrug10 therapy .",
        "label": "NA"
    },
    {
        "text": "in separate single or multiple dose pharmacokinetic interaction studies with ddrug0 , ddrug1 , ddrug2 , DB00999 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , and ddrug8 , the bioavailability of ddrug9 was not altered by coadministration of DB00492 with any one of these drugs .",
        "label": "NA"
    },
    {
        "text": "clinical trials have indicated that DB00003 can be effectively and safely used in conjunction with standard cystic_fibrosis therapies including oral , inhaled and/or parenteral ddrug1 , ddrug2 , enzyme supplements , HD00489 , oral or inhaled ddrug4 , and ddrug5 .",
        "label": "NA"
    },
    {
        "text": "DB01032 : as with other HD00501 , the renal excretion of ddrug2 is inhibited by ddrug3 .",
        "label": "NA"
    },
    {
        "text": "DB00753 potentiates the muscle relaxant effect of all HD00542 , most notably ddrug2 , and mac { minimum alveolar concentration } is reduced by concomitant administration of n 2o .",
        "label": "effect"
    },
    {
        "text": "ddrug0 and ddrug1 : DB00364 and ddrug3 containing ddrug4 or ddrug5 , as well as formulations containing divalent and trivalent cations such as DB00900 { ddrug7 } , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with ddrug8 and interfere with its bioavailability .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , DB00316 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , DB01035 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { e , g , ddrug1 and DB13179 } : agents of the ddrug3 , of which ddrug4 { ddrug5 } injection , usp is a member , have been shown to interact with HD00002 of the ddrug7 , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .",
        "label": "NA"
    },
    {
        "text": "coingestion of ddrug0 with ddrug1 , ddrug2 with ddrug3 , and DB00313 with DB01174 at high to toxic concentrations decreases the binding of the target drug .",
        "label": "effect"
    },
    {
        "text": "if ddrug0 is to be combined with other ddrug1 such as ddrug2 or HD00596 / ddrug4 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of DB01151 and ddrug6 { e , g , , ddrug7 or ddrug8 } are additive .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration of a single dose of ddrug1 # mg and multiple doses of DB00285 er { extended release } # mg did not result in any significant changes in the pharmacokinetics of either DB00962 or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "while all the ddrug0 { HD00114 } , e , g , , ddrug2 , seriraline , and DB00715 , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .",
        "label": "NA"
    },
    {
        "text": "drug interaction with ddrug0 : a multiple-dose study was conducted to assess the effect of DB00472 # mg bid on the pharmacokinetics of DB01215 # mg qhs after seven days .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { HD00114 } : ddrug2 { e , g , , ddrug3 , DB00176 , ddrug5 , ddrug6 } have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with ddrug7 .",
        "label": "NA"
    },
    {
        "text": "DB01033 / DB00993 : ddrug2 inhibits the enzymatic oxidation of ddrug3 and ddrug4 to ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , DB01167 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , DB01232 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 administration of DB01432 or DB09278 in patients { n = 13 } and volunteers { n = 96 } resulted in a rapid and significant decrease in plasma m1 { the active metabolite of ddrug4 } concentration .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { DB00682 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 HD00542 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 ddrug1 did not have any clinically important effect on the pharmacokinetics of DB00977 and DB00717 .",
        "label": "NA"
    },
    {
        "text": "drug-drug interactions between ddrug0 and other HD00703 { ddrug2 } DB00252 ddrug4 { 3000 mg daily } had no effect on the pharmacokinetic disposition of ddrug5 in patients with refractory epilepsy .",
        "label": "NA"
    },
    {
        "text": "DB00203 dose should not exceed a maximum of # mg in a 48 - hour period in patients receiving concomitant DB00224 therapy .",
        "label": "advise"
    },
    {
        "text": "the literature provides considerable evidence indicating that several , but not all ddrug0 , are indeed HD00131 and some are HD00132 as well .",
        "label": "NA"
    },
    {
        "text": "because HD00239 have been shown to depress plasma prothrombin activity , patients who are on HD00025 therapy may require downward adjustment of their ddrug2 dosage .",
        "label": "advise"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / HD00517 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , ddrug4 , ddrug5 , ddrug6 , DB00226 , ddrug8 , ddrug9 , ddrug10 , ddrug11 pain medication { e , g , , ddrug12 } , drugs used to aid sleep , drowsiness-causing ddrug13 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 should be used with caution in patients receiving - ddrug2 blocking agents { e , g , , DB00571 , a ddrug4 inhibitor } or ddrug5 antagonists { e , g , , DB00661 , a ddrug7 substrate , and ddrug8 , a ddrug9 inhibitor } because of the possible potentiation of bradycardia , sinus arrest , and av block ;",
        "label": "NA"
    },
    {
        "text": "influence of DB00783 and ddrug1 on the sensitivity of rat thoracic aorta to DB00368 .",
        "label": "NA"
    },
    {
        "text": "it is suggested that in patients receiving ddrug0 , alternatives to DB00252 should be used if HD00329 therapy is needed .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 : e , g , , DB01023 , DB01115 , ddrug4",
        "label": "NA"
    },
    {
        "text": "in three separate controlled , parallel group clinical pharmacology studies , ddrug0 at the clinical dose of # mg has been coadministered with DB00207 # mg followed by # mg once daily for # days { n = 18 } or with ddrug2 # mg once daily for # days after a # day pretreatment period with ddrug3 { n = 18 } or with DB00501 # mg every # hours for # days { n = 18 } under steady state conditions to normal healthy male and female volunteers .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration of ddrug1 with DB00220 resulted in a 35 % increase in DB00220 plasma a , c.",
        "label": "NA"
    },
    {
        "text": "in a study involving healthy subjects receiving DB01195 and ddrug1 concurrently , plasma ddrug2 levels were increased about 20 % and DB00571 levels were increased about 30 % compared to control values .",
        "label": "NA"
    },
    {
        "text": "inhibitors of this isoenzyme { e , g , , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , HD00640 , ddrug6 , grapefruit juice , ddrug7 , ddrug8 , ddrug9 , ddrug10 } should be cautiously coadministered with DB00204 as they can potentially increase ddrug12 levels .",
        "label": "advise"
    },
    {
        "text": "DB00127 , and to a lesser extent , DB03566 , enhanced the translocating action of oleic_acid and increased its effectiveness in transferring the phosphohydrolase from the soluble to the microsomal fraction .",
        "label": "NA"
    },
    {
        "text": "the biochemical toxicology of HD00077 , a known metabolite of the major ingredient of the pesticide HD00076 { ddrug2 } , was investigated in vivo and in vitro .",
        "label": "NA"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : ddrug1 ; ddrug2 ; ddrug3 ; certain HD00002 , especially the ddrug5 and ddrug6 ; ddrug7 ; DB14513 salts ; ddrug9 ; and ddrug10 .",
        "label": "NA"
    },
    {
        "text": "drug/laboratory test interaction after treatment with DB00415 , a false-positive reaction for glucose in the urine may occur with DB06778 tests { benedicts solution , fehlings solution , or clinitest tablets } but not with enzyme based tests such as clinistix and glucose enzymatic test strip usp .",
        "label": "NA"
    },
    {
        "text": "HD00374 or HD00633 : when ddrug2 is administered immediately following ddrug3 or ddrug4 , the absorption of ddrug5 is slightly enhanced .",
        "label": "NA"
    },
    {
        "text": "recommendations were to avoid administration of diffusible HD00167 treatment during the cure , and to improve the general conditions of patients before the cure of DB12864 .",
        "label": "NA"
    },
    {
        "text": "effects of other ddrug0 on ddrug1 ddrug2 : ddrug3 causes an approximate doubling of the clearance of DB00949 { ddrug5 } at steady state and , therefore , the addition of DB00252 causes an approximate 45 % decrease in the steady-state trough concentrations of ddrug7 as compared to the same dose of ddrug8 given as monotherapy .",
        "label": "NA"
    },
    {
        "text": "since ddrug0 is extensively metabolized by cyp4f3 isoenzymes , caution should be exercised when ddrug1 is coadministered with inhibitors of c , p , a , such as DB01026 and DB00199 or inhibitors of cyp2c19 such as ddrug4 .",
        "label": "NA"
    },
    {
        "text": "poor metabolizers of ddrug0 : interactions of ddrug1 with strong inhibitors of cyp2d6 { such as ddrug2 , ddrug3 , ddrug4 , and DB01182 } have not been studied , but these drugs would be expected to increase blood levels of the r { + } enantiomer of DB01136 .",
        "label": "effect"
    },
    {
        "text": "aims/hypothesis : there is evidence that HD00071 and DB09341 cause renal and ocular vasodilation .",
        "label": "NA"
    },
    {
        "text": "while no in vivo drug-drug interaction studies were conducted between DB01215 and inducers of cyp3a , compounds that are potent cytochrome_p450_family_3_subfamily_a inducers { such as ddrug1 , DB00252 , ddrug3 , and ddrug4 } would be expected to decrease ddrug5 concentrations .",
        "label": "mechanism"
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the ddrug0 of drugs may be potentiated by ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , the ddrug6 , ddrug7 and HD00560 , HD00275 and the ddrug10 , and by other ddrug11 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and DB00759 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , DB01232 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "DB00564 - combined administration of racemic DB00215 { 40 mg/day for # days } and ddrug2 { titrated to # mg/day for # days } did not significantly affect the pharmacokinetics of ddrug3 , a cyp3a4 substrate .",
        "label": "NA"
    },
    {
        "text": "however , the antagonism of the DB00277 - induced anxiogenic effects by HD00187 was only observed in the time spent in the light zone , and ddrug2 - induced anxiogenic effects were neither reversed by ddrug3 nor by ddrug4 .",
        "label": "effect"
    },
    {
        "text": "concomitant ddrug0 , ddrug1 , ddrug2 , and DB00898 chemotherapy plus HD00055 therapy in patients with human immunodeficiency virus-related , non-hodgkin lymphoma .",
        "label": "NA"
    },
    {
        "text": "because DB00176 reduces the clearance of both DB00829 and its active metabolite , ddrug2 , there is a strong likelihood of substantial accumulation of both species during chronic co-administration .",
        "label": "mechanism"
    },
    {
        "text": "since ddrug0 is primarily eliminated by the kidneys , coadministration of DB00442 with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either DB00442 or the coadministered drug .",
        "label": "NA"
    },
    {
        "text": "no important interactions to date DB00922 does not have clinically important pharmacokinetic interactions with ddrug1 , ddrug2 , ddrug3 , DB00390 , ddrug5 , ddrug6 , ddrug7 , ddrug8 or ddrug9 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 / ddrug1 : ddrug2 inhibits the enzymatic oxidation of DB01033 and ddrug4 to HD00271 .",
        "label": "NA"
    },
    {
        "text": "experience with co-administration of ddrug0 and DB00813 in patients is limited , therefore , consideration should be given to temporarily suspending use of HD00095 in patients receiving ddrug3 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , DB00776 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , DB00860 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 ddrug1 , ddrug2 DB00604 ergot derivatives DB00582",
        "label": "NA"
    },
    {
        "text": "since DB01088 inhibits platelet function , there is a potential for increased risk of bleeding , particularly in patients maintained on HD00326 .",
        "label": "effect"
    },
    {
        "text": "these include ddrug0 , DB01432 , and some ddrug2 { e , g , ddrug3 , rifamipicin , ddrug4 and DB00446 } .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other HD00216 ddrug3 HD00388 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "however , because bleeding has been reported when DB01050 and other ddrug1 have been administered to patients on ddrug2 , the physician should be cautious when administering ddrug3 to patients on HD00326 .",
        "label": "NA"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : DB01118 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 HD00871 : ddrug9 ddrug10 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "although there are no study data to evaluate the possibility , HD00883 , including ddrug1 and ddrug2 , may have an additive effect with DB00435 on the risk of developing methemoglobinemia .",
        "label": "effect"
    },
    {
        "text": "however , in a well-controlled study of patients with lymphoma on combination therapy , DB00437 did not increase the marrow toxicity of patients treated with ddrug1 , DB00997 , ddrug3 , ddrug4 and/or ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , DB01076 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , DB00295 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of ddrug0 : ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , DB00668 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , ddrug11 , HD00220 , ddrug13 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "DB00612 should be used with care when ddrug1 or inhibitors of av conduction , such as certain ddrug2 { particularly of the HD00426 -lsb- ddrug4 -rsb- and ddrug5 -lsb- ddrug6 -rsb- classes } , or ddrug7 , such as ddrug8 , are used concurrently .",
        "label": "advise"
    },
    {
        "text": "during administration of multiple oral doses of DB01195 to healthy subjects stabilized on a maintenance dose of ddrug1 , a 13 % -19 % increase in plasma DB00390 levels occurred at six hours postdose .",
        "label": "NA"
    },
    {
        "text": "thus patients receiving oral ddrug0 and DB00176 tablets should have their prothrombin time monitored and their HD00025 dose adjusted accordingly .",
        "label": "NA"
    },
    {
        "text": "- a ddrug0 { HD00615 } such as ddrug2 { ddrug3 , ddrug4 , ddrug5 , others } , ddrug6 { ddrug7 , ddrug8 , ddrug9 } , ddrug10 { ddrug11 , ddrug12 } , ddrug13 { ddrug14 } , ddrug15 { DB00328 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , and ddrug21 { ddrug22 , ddrug23 , ddrug24 } ;",
        "label": "NA"
    },
    {
        "text": "other drugs : based on the results of drug interaction studies , no dosage adjustment is recommended when ddrug0 { DB00625 } is given with the following : ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , DB00709 , ddrug8 , ddrug9 , ddrug10 , and ddrug11 .",
        "label": "NA"
    },
    {
        "text": "both ddrug0 and DB00238 have been compared to triple therapy with the ddrug2 ddrug3 over # weeks as initial therapy , with similar responses being observed with ddrug4 regimens and superiority observed with DB00625 .",
        "label": "NA"
    },
    {
        "text": "DB00950 should not be taken closely in time with ddrug1 and DB14513 containing ddrug3 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 may interact with the following medications : DB00316 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , DB01232 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "although there is no documentation of such , a similar interaction between DB00754 and the HD00423 may occur .",
        "label": "NA"
    },
    {
        "text": "the concomitant administration of HD00532 including DB01059 with ddrug2 { a ddrug3 } has , on rare occasions , resulted in severe hypoglycemia .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 : DB00559 has no significant pharmacokinetic interactions with ddrug4 and ddrug5 , and DB00678 has no significant effect on plasma levels of ddrug7 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - induced renal and mesenteric vasodilation is not antagonized by either HD00647 or HD00244 .",
        "label": "NA"
    },
    {
        "text": "in healthy volunteers , the pharmacokinetics of a 1-mg dose of DB00611 administered as ddrug1 were not affected by the coadministration of a single 6-mg subcutaneous dose of DB00669 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { ddrug1 - or DB14513 - containing } : concomitant administration of 300-mg ddrug3 capsules with # ml HD00382 suspension reduces the rate { cmax } and extent { auc } of absorption by approximately 40 % .",
        "label": "NA"
    },
    {
        "text": "toxicology studies of DB01452 - related deaths reveal frequent involvement of other ddrug1 , including ddrug2 , ddrug3 such as DB00829 { ddrug5 } , and , to a rising degree , ddrug6 .",
        "label": "effect"
    },
    {
        "text": "however , if ddrug0 is to be initiated after cessation of DB01109 therapy , allow sufficient time for heparin effect on the aptt to decrease prior to initiation of DB00278 therapy .",
        "label": "NA"
    },
    {
        "text": "however , the systemic administration of some ddrug0 has been shown to elevate plasma concentrations of ddrug1 , interfere with the metabolism of DB00201 , and enhance the effects of the oral HD00025 ddrug4 and its derivatives , and has been associated with transient elevations in serum creatinine in patients receiving systemic ddrug5 concomitantly .",
        "label": "NA"
    },
    {
        "text": "furthermore it has been proposed that DB00951 resulted in induction of p-450iie1 in the patients liver which , in turn , resulted in a greater proportion of the ingested DB00316 being converted to the toxic metabolites .",
        "label": "mechanism"
    },
    {
        "text": "DB00615 did not significantly affect DB00701 's pharmacokinetics .",
        "label": "NA"
    },
    {
        "text": "the DB01076 cmax values were not significantly affected by DB01039 .",
        "label": "NA"
    },
    {
        "text": "co-administration : concomitant use of DB00278 with HD00363 , ddrug2 , and other ddrug3 may increase the risk of bleeding .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : in healthy individuals , plasma concentrations of ddrug1 increased approximately 40 % with coadministration of DB01076 and DB00199 , a known inhibitor of cytochrome p450 3a4 .",
        "label": "mechanism"
    },
    {
        "text": "as with other drugs that block angiotensin ii or its effects , concomitant use of ddrug0 { e , g , , DB00421 , ddrug2 , ddrug3 } , DB14500 supplements , or salt substitutes containing potassium may lead to increases in serum potassium .",
        "label": "NA"
    },
    {
        "text": "DB00625 has demonstrated superiority over DB00220 in nucleoside-experienced patients , although combining these # agents may represent the best approach in these circumstances .",
        "label": "NA"
    },
    {
        "text": "drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on HD00849 therapy : ddrug1 , ddrug2 , ddrug3 , oral HD00283 containing ddrug5 , ddrug6 - containing preparations and the numerous preparations containing ddrug7 .",
        "label": "NA"
    },
    {
        "text": "like HD00021 { 40 mg/kg } , ddrug1 { 40 mg/kg } decreases the intravenous self-administration of ddrug2 and ddrug3 and the oral self-administration of ddrug4 and DB00184 in rats ;",
        "label": "NA"
    },
    {
        "text": "plasma ddrug0 concentration should be monitored when DB00951 and DB00313 are co administered , and appropriate dosage adjustments of ddrug3 should be made .",
        "label": "advise"
    },
    {
        "text": "clinical trials have indicated that ddrug0 can be effectively and safely used in conjunction with standard cystic_fibrosis therapies including oral , inhaled and/or parenteral HD00002 , ddrug2 , enzyme supplements , ddrug3 , oral or inhaled HD00175 , and ddrug5 .",
        "label": "NA"
    },
    {
        "text": "increasing the ddrug0 dose to # mg every # hours does not compensate for the increased DB00224 metabolism due to DB00625 .",
        "label": "mechanism"
    },
    {
        "text": "even when an ddrug0 and a HD00284 - type drug are administered separately by different routes , a reduction in HD00494 serum half-life or serum levels has been reported in patients with impaired renal function and in some patients with normal renal function .",
        "label": "NA"
    },
    {
        "text": "if ddrug0 is to be combined with other ddrug1 such as ddrug2 or ddrug3 / ddrug4 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of DB01151 and ddrug6 { e , g , , ddrug7 or DB00829 } are additive .",
        "label": "effect"
    },
    {
        "text": "when ddrug0 and DB00187 were concomitantly administered intravenously to normal volunteers , there was a 10 - 20 % increase in DB00390 blood levels at some time points .",
        "label": "NA"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : ddrug1 ; DB00753 ; ddrug3 ; certain ddrug4 , especially the ddrug5 and ddrug6 ; ddrug7 ; ddrug8 salts ; ddrug9 ; and DB00908 .",
        "label": "NA"
    },
    {
        "text": "caution should be exercised when the following drugs are administered concomitantly with DB00190 { ddrug1 } given with DB01235 or ddrug3 - ddrug4 combination products .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { e , g , ddrug1 and ddrug2 } : agents of the HD00625 , of which ddrug4 { DB00320 } injection , usp is a member , have been shown to interact with ddrug6 of the ddrug7 , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .",
        "label": "NA"
    },
    {
        "text": "DB01432 and DB09278 administration of ddrug2 or ddrug3 in patients { n = 13 } and volunteers { n = 96 } resulted in a rapid and significant decrease in plasma m1 { the active metabolite of ddrug4 } concentration .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and HD00466 { hypertension } - in clinical studies of patients with hypertension , the addition of DB00700 # to # mg to ddrug3 and ddrug4 increased mean serum potassium slightly { about # # meq/l } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : it has been reported that ddrug1 prolongs the half-life of the HD00025 , DB00266 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and HD00340 may reduce or reverse the pressor effect of DB00668 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , HD00282 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , DB00277 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "hormonal ddrug0 co-administration of ddrug1 with an oral HD00349 has been shown to influence the plasma concentrations of the two hormonal components , DB00977 { ee } and ddrug4 { lng } .",
        "label": "NA"
    },
    {
        "text": "analysis of the concentration of ddrug0 following ultracentrifugation indicated that there is rapid equilibration of DB01222 between the DB06761 and aqueous phase .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 : based on auc and half-life , multiple-dose pharmacokinetic profiles of ddrug1 and ddrug2 following administration of tablets containing # mg of ddrug3 and # mcg of DB00977 were similar with and without coadministration of DB00996 { 400 mg tid ;",
        "label": "NA"
    },
    {
        "text": "based on adult data , lower doses of ddrug0 may be needed following coadministration of drugs which are reported to decrease ddrug1 elimination { e , g , , ddrug2 and ddrug3 } and higher DB00201 doses may be needed following coadministration of drugs that increase ddrug5 elimination { e , g , , ddrug6 and DB00252 } .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : DB11094 dosage must be determined with care in patients undergoing treatment with HD00118 , as hypercalcemia in such patients may precipitate cardiac arrhythmias .",
        "label": "advise"
    },
    {
        "text": "these drugs include the ddrug0 and other ddrug1 , ddrug2 , phe-nothiazines , HD00221 , HD00220 , oral ddrug5 , ddrug6 , ddrug7 , sympathomimet-ics , ddrug8 , and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , DB00316 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , DB02362 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 : ddrug1 { 40 mg bid } did not induce the metabolism of the combination oral HD00349 ddrug3 / DB00977 { 1 mg / 35 mcg combination , ddrug5 1/35 } .",
        "label": "NA"
    },
    {
        "text": "influence of DB00783 and DB00396 on the sensitivity of rat thoracic aorta to ddrug2 .",
        "label": "NA"
    },
    {
        "text": "the antihypertensive effects of ddrug0 , ddrug1 , ddrug2 , and HD00392 may be reduced by HD00391 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : increased serum DB14507 levels and symptoms of ddrug2 toxicity have been reported in patients receiving HD00106 during therapy with ddrug4 .",
        "label": "NA"
    },
    {
        "text": "in renal and cardiac transplant recipients , a reduction of ddrug0 dose ranging from 15 % to 48 % was necessary to maintain DB00091 trough concentrations similar to those seen prior to the addition of DB00343 .",
        "label": "NA"
    },
    {
        "text": "combination HD00432 may also decrease the plasma concentration of DB00316 .",
        "label": "mechanism"
    },
    {
        "text": "concomitant single dose administration of DB00580 # mg with multiple doses of DB01026 and ddrug2 produced a significant increase in exposure of ddrug3 .",
        "label": "mechanism"
    },
    {
        "text": "oral ddrug0 : DB00580 { 40 mg bid } did not induce the metabolism of the combination oral ddrug2 ddrug3 / DB00977 { 1 mg / 35 mcg combination , ddrug5 1/35 } .",
        "label": "NA"
    },
    {
        "text": "DB00501 at doses of # mg bid { otc dose } resulted in a 13 % increase in DB00204 plasma levels { 500 mcg single dose } .",
        "label": "mechanism"
    },
    {
        "text": "DB00673 increased the auc of DB00683 by 25 % on day # and decreased the auc of ddrug2 by 19 % on day # relative to the dosing of ddrug3 on days # through 3 .",
        "label": "mechanism"
    },
    {
        "text": "ventricular tachycardia induced by ddrug0 was generally converted to sinus rhythm following administration of ddrug1 , DB01221 , or ddrug3 but not after administration of HD00120 alone or after ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { cns } drugs including ddrug1 , ddrug2 , ddrug3 , ddrug4 , blood pressure medications { ddrug5 , DB00968 , ddrug7 } , motion sickness medications , ddrug8 , HD00543 , ddrug10 , sleeping pills and ddrug11",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as DB00415 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , DB01232 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "DB00563 HD00897 # , 25 , and # mg , each dose administered once daily for # days , had no effect on the plasma concentration of ddrug2 as measured by auc0 - 24hr in patients receiving single weekly ddrug3 doses of # to # mg for rheumatoid arthritis .",
        "label": "NA"
    },
    {
        "text": "HD00282 : in a pharmacokinetic study , maximum plasma concentrations of ddrug1 were considerably lower in epileptic patients on long-term ddrug2 therapy { eg , DB00252 , ddrug4 , or ddrug5 } than in healthy volunteers .",
        "label": "NA"
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of ddrug0 such as ddrug1 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 } , DB14513 salts , ddrug12 , local ddrug13 , ddrug14 , and DB00908 .",
        "label": "NA"
    },
    {
        "text": "before taking ddrug0 , tell your doctor if you are taking any of the following medicines : - ddrug1 or another HD00372 such as ddrug3 { HD00756 } , ddrug5 { ddrug6 , others } , ddrug7 { ddrug8 } , ddrug9 { ddrug10 } , or ddrug11 { ddrug12 } ;",
        "label": "NA"
    },
    {
        "text": "HD00100 : combination HD00432 may decrease the clearance of some ddrug2 { ddrug3 , ddrug4 , ddrug5 } and increase the clearance of others { ddrug6 , ddrug7 , ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "however , a crossover study in healthy subjects receiving either DB00501 # mg q , i , d , or # mg h , s , concomitantly with a # mg b , i , d , dosage of ddrug1 { HD00531 , key pharmaceuticals , inc , } demonstrated less alteration in steady-state ddrug3 peak serum levels with the # mg h , s , regimen , particularly in subjects aged # years and older .",
        "label": "mechanism"
    },
    {
        "text": "in vitro studies indicate cyp3a4 isoform and cyp1a2 isoform mediate the metabolism of ddrug0 to HD00839 and HD00840 , respectively .",
        "label": "NA"
    },
    {
        "text": "although additional drug interaction studies have not been conducted , the most common medications used concomitantly with DB00261 in clinical trials were ddrug1 , ddrug2 , ddrug3 , ddrug4 , DB00863 , ddrug6 , and ddrug7 .",
        "label": "NA"
    },
    {
        "text": "patients taking DB00951 when DB00822 is given should be observed for the appearance of unsteady gait or marked changes in mental status ;",
        "label": "advise"
    },
    {
        "text": "in another study with intravenous administration of DB00683 , DB00673 was given as # mg on day # and # mg/day on days # and 3 , and ddrug2 # mg iv was given prior to the administration of the 3-day regimen of ddrug3 and on days 4 , 8 , and 15 .",
        "label": "NA"
    },
    {
        "text": "pharmacological/pharmacodynamic interactions with DB00564 concomitant administration of ddrug1 and DB14507 may increase the risk of neurotoxic side effects .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the concomitant administration of ddrug1 { DB00270 } and ddrug3 in a single-dose pharmacokinetic study did not affect renal , nonrenal and total body clearance of DB00390 .",
        "label": "NA"
    },
    {
        "text": "both DB00625 and ddrug1 have been compared to triple therapy with the HD00111 ddrug3 over # weeks as initial therapy , with similar responses being observed with ddrug4 regimens and superiority observed with ddrug5 .",
        "label": "NA"
    },
    {
        "text": "aim and background : the pharmacokinetic interaction between ddrug0 , a ddrug1 metabolized by cyp3a4 , and the HD00038 DB00343 was studied in # healthy subjects .",
        "label": "NA"
    },
    {
        "text": "HD00461 { cns } drugs including ddrug1 , HD00216 , ddrug3 , ddrug4 , blood pressure medications { ddrug5 , ddrug6 , ddrug7 } , motion sickness medications , ddrug8 , ddrug9 , ddrug10 , sleeping pills and ddrug11",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB01364 may enhance the metabolic clearance of ddrug2 , resulting in decreased blood levels and lessened physiologic activity , thus requiring an increase in HD00579 dosage .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a clinical pharmacology study , coadministration of an ddrug1 { ddrug2 , DB09104 , and ddrug4 } with ddrug5 reduced serum levels and urinary excretion of ddrug6 as compared with DB00492 administered alone , suggesting that ddrug8 may impair absorption of ddrug9 .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of HD00071 : ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , ddrug5 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , HD00809 , ddrug12 , ddrug13 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "although in vivo studies have not been done to see if DB00749 clearance is changed by coadministration of DB00812 , it is not recommended that they be coadministered .",
        "label": "advise"
    },
    {
        "text": "HD00512 reduce the renal clearance of ddrug1 and add a high risk of DB14507 toxicity .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : seizures have been reported in patients taking ddrug1 concomitantly with the HD00535 DB08981 .",
        "label": "NA"
    },
    {
        "text": "before taking ddrug0 , tell your doctor if you are taking any of the following medicines : - DB00945 or another HD00372 such as ddrug3 { ddrug4 } , ddrug5 { ddrug6 , others } , ddrug7 { ddrug8 } , ddrug9 { ddrug10 } , or ddrug11 { ddrug12 } ;",
        "label": "NA"
    },
    {
        "text": "DB00563 : ddrug1 , as well as other HD00233 , probably reduces the tubular secretion of ddrug3 based on in vitro studies in rabbit kidney slices .",
        "label": "NA"
    },
    {
        "text": "may interact with thyroid medication { e , g , , ddrug0 } , DB11119 - containing products , ddrug2 , ddrug3 { e , g , , ddrug4 , ddrug5 } , and ddrug6 { e , g , , ddrug7 , DB00338 } .",
        "label": "NA"
    },
    {
        "text": "caution should be used when administering or taking DB00530 with DB01026 and other strong cyp3a4 inhibitors such as , but not limited to , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { ddrug12 } , and ddrug13 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 , DB01575 - pectin , ddrug2 , ddrug3 , ddrug4 , certain anticancer drugs , and ddrug5 may interfere with intestinal DB00390 absorption , resulting in unexpectedly low serum concentrations .",
        "label": "mechanism"
    },
    {
        "text": "limited clinical data in angina patients receiving concomitant HD00406 and DB00390 therapy indicate no discernible changes in serum digoxin levels .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a study of young healthy male subjects no evidence of a direct pharmacokinetic DB01197 - DB00390 interaction could be found .",
        "label": "NA"
    },
    {
        "text": "the effect of DB00390 on DB01609 pharmacokinetics has not been studied .",
        "label": "NA"
    },
    {
        "text": "certain drugs including ddrug0 , ddrug1 , ddrug2 , and HD00391 may reduce the hypoglycemic action of DB00731 and other oral ddrug5 .",
        "label": "effect"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 DB00472 { ddrug11 } sporal { DB01167 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "DB01100 and DB00215 - in a controlled study , a single dose of ddrug2 # mg co-administered with racemic ddrug3 # mg given once daily for # days was associated with a mean increase in qtc values of approximately # msec compared to ddrug4 given alone .",
        "label": "NA"
    },
    {
        "text": "the concomitant use of HD00244 with HD00118 and ddrug2 s may have additive effects on prolonging atrioventricular conduction time .",
        "label": "effect"
    },
    {
        "text": "we compared ddrug0 pharmacokinetics and gastric ph in # human immunodeficiency virus-positive patients by use of # mg of ddrug1 alone versus # mg of DB00224 administered # h after DB00900 administration .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : HD00403 s { DB00682 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { DB00316 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , HD00668 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "DB13984 or HD00648 increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered ddrug2 , such as ddrug3 .",
        "label": "NA"
    },
    {
        "text": "in separate studies of patients receiving maintenance doses of ddrug0 , ddrug1 , or DB00390 , DB01029 administration for # days had no effect on the pharmacodynamics of ddrug4 { prothrombin time } or pharmacokinetics of ddrug5 .",
        "label": "NA"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : DB00228 ; ddrug2 ; ddrug3 ; certain ddrug4 , especially the ddrug5 and ddrug6 ; ddrug7 ; DB14513 salts ; ddrug9 ; and ddrug10 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { eg , ddrug1 } and other drugs , including ether , DB00202 , ddrug3 , ddrug4 and ddrug5 , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with DB01111 parenteral .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : DB00316 { ddrug2 } , ddrug3 such as ddrug4 and DB00759 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "HD00343 HD00610 , as well as a metabolite of ddrug2 , slow ddrug3 metabolism .",
        "label": "NA"
    },
    {
        "text": "injection : ddrug0 injection , like other injectable ddrug1 , produces depression of the central nervous system when administered with ddrug2 , ddrug3 , ddrug4 , HD00343 , and other ddrug6 , when DB00747 is used concomitantly with injectable ddrug8 , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .",
        "label": "NA"
    },
    {
        "text": "data from a randomized trial of ddrug0 and DB00515 plus or minus ddrug2 in ovarian_cancer indicated that DB00165 significantly reduced neurotoxicity ;",
        "label": "NA"
    },
    {
        "text": "agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of HD00472 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 , DB01174 , ddrug6 { 2 } , ddrug7 , ddrug8 , and ddrug9 thus , if a patient has been titrated to a stable dosage on ddrug10 , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for ddrug11 may be necessary .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 or oral HD00484 : initiating thyroid replacement therapy may cause increases in HD00071 or oral ddrug3 requirements .",
        "label": "NA"
    },
    {
        "text": "the gastrointestinal absorption of DB00501 and DB00863 is accelerated when they are coadministered with ddrug2 .",
        "label": "NA"
    },
    {
        "text": "another oral HD00820 , ddrug1 , inhibits the metabolism of ddrug2 , resulting in elevated plasma concentrations of DB00637 and its active metabolite ddrug4 which may prolong qt intervals .",
        "label": "NA"
    },
    {
        "text": "-lsb- the effect of ddrug0 on the renal excretion of ddrug1 and ddrug2 in dogs -rsb- the intravenous injection of DB00501 in a dose of # mg/kg enhanced ddrug4 and DB08948 excretion in chronic canine experiments .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 should be administered with caution to patients who are taking other HD00826 or ddrug2 , including ddrug3 , HD00026 and ddrug5 , or to those with a history of psychiatric disorder { including manic-depressive illness and schizophrenia } .",
        "label": "NA"
    },
    {
        "text": "because HD00239 have been shown to depress plasma prothrombin activity , patients who are on ddrug1 therapy may require downward adjustment of their HD00025 dosage .",
        "label": "NA"
    },
    {
        "text": "in patients receiving DB01033 { ddrug1 } or ddrug2 { ddrug3 } , the concomitant administration of 300 - 600 mg of ddrug4 per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of ddrug5 or DB00993 .",
        "label": "NA"
    },
    {
        "text": "other cardiovascular agents : ddrug0 and DB00584 iv have been used concomitantly with ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 and DB00390 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "there have been case reports of increased steady-state levels of ddrug0 , DB01035 , and ddrug2 during concomitant therapy with DB01118 .",
        "label": "NA"
    },
    {
        "text": "the behavioral effects of the stereoisomers of ddrug0 { HD00155 } were compared with those of DB03575 { ddrug3 } in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio { fi fr } schedule of food presentation .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : HD00608 are inhibited by HD00401 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , HD00668 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , DB00860 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "DB00313 DB01202 { 1500 mg twice daily } did not alter the pharmacokinetics of ddrug2 in healthy volunteers .",
        "label": "NA"
    },
    {
        "text": "- a HD00766 such as ddrug1 { ddrug2 } , ddrug3 { ddrug4 , ddrug5 } , ddrug6 { DB00433 } , ddrug8 { ddrug9 } , and others ;",
        "label": "NA"
    },
    {
        "text": "ventricular tachycardia induced by ddrug0 was generally converted to sinus rhythm following administration of HD00117 , ddrug2 , or ddrug3 but not after administration of ddrug4 alone or after DB00312 .",
        "label": "NA"
    },
    {
        "text": "DB00985 may decrease HD00627 response to ddrug2 .",
        "label": "NA"
    },
    {
        "text": "interactions for ddrug0 { ddrug1 , ddrug2 , ddrug3 , and DB00146 } : DB01432 : ddrug6 has been reported to reduce intestinal absorption of ddrug7 ;",
        "label": "NA"
    },
    {
        "text": "HD00340 { such as ddrug1 } and HD00219 can suppress the ddrug3 rgic renal and mesenteric vasodilation induced with low dose dopamine infusion .",
        "label": "NA"
    },
    {
        "text": "the following drug interactions have been identified involving ddrug0 tablets and other drugs metabolized by the cyp3a4 enzyme system : DB01026 tablets inhibit the metabolism of ddrug2 , resulting in an increased plasma concentration of DB00342 and a delay in the elimination of its acid metabolite .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { DB00682 } other HD00216 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "ddrug0 : increased serum ddrug1 levels and symptoms of ddrug2 toxicity have been reported in patients receiving HD00106 during therapy with DB14507 .",
        "label": "effect"
    },
    {
        "text": "- HD00330 : in some patients , the administration of a ddrug1 can reduce the diuretic , natriuretic , and antihypertensive effects of ddrug2 , HD00293 and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "products containing ddrug0 and other HD00260 likely will interfere with absorption of DB00630 .",
        "label": "mechanism"
    },
    {
        "text": "therefore , cyp3a4 substrates known to have a narrow therapeutic index such as ddrug0 , ddrug1 , ddrug2 , ddrug3 , DB00091 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , or ddrug10 { ddrug11 , ddrug12 } should be administered with caution in patients receiving DB01254 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 including ddrug1 , ddrug2 , and DB01626 hc1 : concomitant use of ddrug4 and non-selective HD00343 may cause hypertension .",
        "label": "NA"
    },
    {
        "text": "the DB00564 steady-state cmin decreased 31 % to # 1 micrograms/ml when DB00949 { 3000 mg/day , divided into three doses } was coadministered .",
        "label": "mechanism"
    },
    {
        "text": "caution should also be taken in concurrent or serial use of other ddrug0 and HD00384 because they may enhance neomycin s nephrotoxicity and/or ototoxicity and potentiate DB00994 neuromuscular blocking effects .",
        "label": "NA"
    },
    {
        "text": "these data suggest that DB14152 are negatively coupled to three types of calcium channels in bovine chromaffin cell , including an ddrug1 - sensitive { n-type } channel , an ddrug2 - sensitive { p-type } channel and DB00393 / ddrug4 / ddrug5 - resistant { presumptive q-type } channel .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : DB00316 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , DB00273 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "in a single study , rats given high intraperitoneal doses of an HD00455 plus DB00822 experienced severe toxicity , including convulsions and death .",
        "label": "effect"
    },
    {
        "text": "therefore , DB01039 should be taken at least # hour before or 4 - 6 hours after a HD00719 to avoid impeding its absorption .",
        "label": "advise"
    },
    {
        "text": "garlic capsules garlic capsules should not be used while taking ddrug0 { DB01232 } as the sole ddrug2 due to the risk of decreased DB01232 plasma concentrations .",
        "label": "NA"
    },
    {
        "text": "concomitant use of HD00388 with ddrug1 , ddrug2 , HD00026 , or other ddrug4 may have an additive effect .",
        "label": "effect"
    },
    {
        "text": "HD00043 may enhance the seizure risk in patients taking DB00193",
        "label": "effect"
    },
    {
        "text": "ddrug0 : because HD00175 may increase blood glucose concentrations , dosage adjustments of HD00075 may be required .",
        "label": "effect"
    },
    {
        "text": "similarly dialyzed were DB01174 , ddrug1 , and ddrug2 , both alone at therapeutic concentrations in serum and with DB00898 at three different concentrations in serum .",
        "label": "NA"
    },
    {
        "text": "particular caution should be exercised in using preparations containing DB02701 , ddrug1 , or ddrug2 in combination with DB00210 gel .",
        "label": "NA"
    },
    {
        "text": "DB01026 / DB01167 , ddrug2 , including ddrug3",
        "label": "NA"
    },
    {
        "text": "high-dose DB00091 resulting in concentrations above # ng/ml administered with oral ddrug1 has led to an 80 % increase in DB00773 exposure with a 38 % decrease in total body clearance of ddrug3 compared to ddrug4 alone .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the addition of ddrug1 to patients taking DB00313 chronically had no effect on ddrug3 pharmacokinetics , but ddrug4 significantly decreased DB00906 binding in vitro from # to # % , which resulted in an increase of approximately 40 % in the free tiagabine concentration .",
        "label": "NA"
    },
    {
        "text": "tablets : the HD00100 , including ddrug1 , produce cns-depressant effects when administered with such medications as HD00026 or ddrug3 .",
        "label": "effect"
    },
    {
        "text": "HD00575 { eg , ddrug1 } and other drugs , including ether , ddrug2 , HD00576 , ddrug4 and ddrug5 , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with ddrug6 parenteral .",
        "label": "NA"
    },
    {
        "text": "drug interactions : the central HD00315 syndrome can occur when anticholinergic agents such as ddrug1 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain ddrug2 such as ddrug3 , the ddrug4 and other ddrug5 , HD00043 , certain ddrug7 such as the ddrug8 salts , and ddrug9 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : when DB00176 { 100 mg qd } and ddrug2 { 1 mg q , d , were co-administered to steady state , plasma concentration and other pharmacokinetics parameters { auc , cmax , t1/2 , } of DB00404 were approximately twice those observed when ddrug4 was administered alone ;",
        "label": "NA"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , ddrug3 HD00388 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 ddrug11 , ddrug12 gi motility agents : DB00604",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , DB01167 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , DB01045 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "HD00445 such as ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , ddrug5 { e , g , , DB01168 } , ddrug7 { e , g , , ddrug8 } , and ddrug9 { e , g , , ddrug10 } : using these medicines with ddrug11 may increase the chance of side effects .",
        "label": "NA"
    },
    {
        "text": "ddrug0 or HD00648 increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered HD00439 , such as ddrug3 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 including coumarin derivatives , indandione derivatives , and HD00353 such as ddrug2 { ddrug3 } , and ddrug4 may increase the risk of bleeding when administered concomitantly with DB00407 .",
        "label": "effect"
    },
    {
        "text": "like DB00753 , ddrug1 does not predispose to premature ventricular arrhythmias in the presence of exogenously infused DB00668 in swine .",
        "label": "NA"
    },
    {
        "text": "nevertheless , caution is indicated in the co-administration of HD00313 with any of the HD00114 and also in switching from one class to the other .",
        "label": "advise"
    },
    {
        "text": "in a ten-subject study , coadministration of DB00343 { 120 mg bid } with ddrug1 resulted in a 3 - 4 times increase in mean DB00227 auc and cmax vs , ddrug3 alone ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB01032 is known to interact with the metabolism or renal tubular excretion of many drugs { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , DB00563 , ddrug11 , ddrug12 , ddrug13 agents , ddrug14 , and ddrug15 } .",
        "label": "mechanism"
    },
    {
        "text": "DB01211 concentration DB00224 concentration",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00939 enhances the effect of DB00682 .",
        "label": "NA"
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a ddrug0 , including ddrug1 , with multivalent cation-containing products such as ddrug2 or ddrug3 ddrug4 , ddrug5 , DB00900 chewable/buffered tablets or pediatric powder , or products containing ddrug7 , ddrug8 , or DB01593 may substantially decrease the absorption of ddrug10 , resulting in serum and urine levels considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { 5 mg/kg , s , c , } completely antagonized the inhibitory effect of DB00836 and partly antagonized the effect of DB00295 .",
        "label": "NA"
    },
    {
        "text": "using ddrug0 with HD00318 { heart medicine } may cause hypercalcemia { too much DB01373 in the blood } , which could increase the chance of developing an irregular heartbeat .",
        "label": "NA"
    },
    {
        "text": "ddrug0 s : DB00900 should be administered at least # hours after or # hours before dosing with ddrug2 because plasma concentrations of ddrug3 are decreased when administered with HD00374 containing ddrug5 , ddrug6 , or ddrug7 .",
        "label": "NA"
    },
    {
        "text": "catecholamine-depleting drugs { e , g , , DB00206 } may have an additive effect when given with HD00410 agents .",
        "label": "effect"
    },
    {
        "text": "the literature provides considerable evidence indicating that several , but not all HD00130 , are indeed ddrug1 and some are HD00132 as well .",
        "label": "NA"
    },
    {
        "text": "if signs and symptoms suggestive of ddrug0 toxicity occur when DB00467 and DB00390 are given concomitantly , physicians are advised to obtain serum ddrug3 levels and adjust ddrug4 doses appropriately .",
        "label": "effect"
    },
    {
        "text": "the potential effects of DB00328 and HD00293 on potassium kinetics and renal function should be considered when these agents are administered concurrently .",
        "label": "effect"
    },
    {
        "text": "in vitro studies have shown no binding displacement between DB00494 and other highly bound drugs , such as DB00682 , ddrug2 , ddrug3 , and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "drugs that inhibit cytochrome p450iid6 , such as DB00908 , might increase the plasma concentrations of DB01195 in patients that are on chronic ddrug2 therapy ;",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may enhance the effects of HD00043 , ddrug2 , ddrug3 , and other HD00261 .",
        "label": "NA"
    },
    {
        "text": "HD00828 - including ddrug1 , DB00752 and ddrug3 hc1 .",
        "label": "NA"
    },
    {
        "text": "other drugs : based on the results of drug interaction studies , no dosage adjustment is recommended when DB00625 { ddrug1 } is given with the following : ddrug2 , DB00207 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , and ddrug11 .",
        "label": "NA"
    },
    {
        "text": "while no in vivo drug-drug interaction studies were conducted between ddrug0 and inducers of cyp3a , compounds that are potent cytochrome_p450_family_3_subfamily_a inducers { such as DB00564 , ddrug2 , ddrug3 , and ddrug4 } would be expected to decrease DB01215 concentrations .",
        "label": "NA"
    },
    {
        "text": "absorption of ddrug0 is impaired by ddrug1 containing ddrug2 , DB01373 , or ddrug4 , and DB01592 - containing preparations .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00951 is known to slow the metabolism of ddrug2 and increase its serum levels DB00564 levels should be determined prior to concurrent administration with ddrug4 , signs and symptoms of ddrug5 toxicity should be monitored closely , and appropriate dosage adjustment of the ddrug6 should be made .",
        "label": "NA"
    },
    {
        "text": "data from several studies , ie , timi-ii , isis-2 , currently do not suggest any clinical interaction between DB00945 and HD00378 in the acute myocardial infarction setting .",
        "label": "NA"
    },
    {
        "text": "the following agents may increase certain actions or side effects of HD00522 , ddrug1 HD00428 of class { e , g , ddrug3 } , ddrug4 ddrug5 { e , g , ddrug6 } , ddrug7 .",
        "label": "NA"
    },
    {
        "text": "it is recommended that the combination of intravenous ddrug0 and HD00377 , such as DB00661 , not be used together during the management of malignant hyperthermia crisis until the relevance of these findings to humans is established .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB01050 produced an elevation of plasma DB14507 levels and a reduction in renal ddrug3 clearance in a study of eleven normal volunteers .",
        "label": "mechanism"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : DB00228 ; ddrug2 ; ddrug3 ; certain ddrug4 , especially the ddrug5 and HD00384 ; ddrug7 ; ddrug8 salts ; ddrug9 ; and ddrug10 .",
        "label": "NA"
    },
    {
        "text": "DB01234 and ddrug1 similarly inhibit and stimulate ddrug2 - or HD00071 - induced proliferation of prostatic epithelium .",
        "label": "effect"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , DB00908 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 HD00871 : ddrug9 ddrug10 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB01032 is known to interact with the metabolism or renal tubular excretion of many drugs { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 agents , DB00277 , and ddrug15 } .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 and ddrug1 : ddrug2 and HD00374 containing ddrug4 or ddrug5 , as well as formulations containing divalent and trivalent cations such as DB00900 { ddrug7 } , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with ddrug8 and interfere with its bioavailability .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : a clinical study in # insulin-dependent diabetic patients demonstrated no effect of ddrug1 on HD00071 absorption from the peritoneal cavity or on ddrug3 s ability to control blood glucose when ddrug4 was administered intraperitoneally with DB00702 .",
        "label": "NA"
    },
    {
        "text": "although the occurrence has not been reported with DB01332 , nephrotoxicity has been reported following concomitant administration of other ddrug1 and HD00249 .",
        "label": "NA"
    },
    {
        "text": "DB00604 should not be used concomitantly with other drugs known to prolong the qt interval : certain HD00303 , including those of class ia { such as ddrug2 and ddrug3 } and class iii { such as ddrug4 } ;",
        "label": "advise"
    },
    {
        "text": "additional DB01592 significantly inhibited the absorption of DB14574 in both dietary ddrug2 treatments .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 renal tubular transport of ddrug1 may be inhibited by concomitant administration of DB00537 , potentially leading to increased plasma levels of DB00563 .",
        "label": "NA"
    },
    {
        "text": "both HD00022 and ddrug1 are sequestered in fat and , like HD00021 , ddrug3 probably has an active metabolite .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a study in # patients with congestive heart failure where ddrug1 and DB00390 were concomitantly administered , DB01009 did not alter the serum levels of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { eg , ddrug1 } and other drugs , including ether , ddrug2 , ddrug3 , DB01245 and ddrug5 , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with DB01111 parenteral .",
        "label": "effect"
    },
    {
        "text": "in three separate controlled , parallel group clinical pharmacology studies , DB00967 at the clinical dose of # mg has been coadministered with ddrug1 # mg followed by # mg once daily for # days { n = 18 } or with ddrug2 # mg once daily for # days after a # day pretreatment period with ddrug3 { n = 18 } or with DB00501 # mg every # hours for # days { n = 18 } under steady state conditions to normal healthy male and female volunteers .",
        "label": "NA"
    },
    {
        "text": "in monkeys , the effects of ddrug0 , but not ddrug1 or DB03575 , were antagonized by DB01183 ;",
        "label": "NA"
    },
    {
        "text": "the administration of local HD00449 containing ddrug1 or ddrug2 to patients receiving ddrug3 , ddrug4 or HD00219 may produce severe , prolonged hypotension or hypertension .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : the effect of an DB06723 - and ddrug2 - containing ddrug3 { ddrug4 } * on the pharmacokinetics of DB01101 was investigated in # cancer patients .",
        "label": "NA"
    },
    {
        "text": "patients on HD00773 therapy may require dosage adjustment of the anticoagulant during and after DB00400 therapy .",
        "label": "advise"
    },
    {
        "text": "ddrug0 and ddrug1 administration of ddrug2 or DB09278 in patients { n = 13 } and volunteers { n = 96 } resulted in a rapid and significant decrease in plasma m1 { the active metabolite of DB01097 } concentration .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { DB00316 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { HD00531 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "this drug may interact with DB02325 or other ddrug1 { may potentiate the cns depressant effects of either these medications or ddrug2 } , ddrug3 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug4 } , and ddrug5 { concurrent use with HD00388 may prolong and intensify the anticholinergic and cns depressant effects of ddrug7 } .",
        "label": "NA"
    },
    {
        "text": "toxicology studies of ddrug0 - related deaths reveal frequent involvement of other HD00389 , including ddrug2 , HD00100 such as ddrug4 { ddrug5 } , and , to a rising degree , ddrug6 .",
        "label": "NA"
    },
    {
        "text": "like HD00021 { 40 mg/kg } , ddrug1 { 40 mg/kg } decreases the intravenous self-administration of ddrug2 and ddrug3 and the oral self-administration of DB00898 and ddrug5 in rats ;",
        "label": "NA"
    },
    {
        "text": "- a HD00762 { ddrug1 } such as DB01247 { ddrug3 } , ddrug4 { ddrug5 } , or ddrug6 { ddrug7 } ;",
        "label": "NA"
    },
    {
        "text": "in long surgical procedures during DB00228 or DB00753 anesthesia , less frequent maintenance dosing , lower maintenance doses , or reduced infusion rates of ddrug2 may be necessary .",
        "label": "NA"
    },
    {
        "text": "in vitro studies indicate that ddrug0 does not inhibit p-glycoprotein-mediated transport of ddrug1 or DB00570 and that DB00303 is not a substrate for p-glycoprotein-mediated transport .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : bioavailability is mildly reduced { approximately 10 % } when DB00943 and DB01233 are coadministered .",
        "label": "mechanism"
    },
    {
        "text": "thus , when HD00203 and DB14507 are administered concurrently , subjects should be observed carefully for signs of ddrug2 toxicity .",
        "label": "advise"
    },
    {
        "text": "plasma concentrations of ddrug0 are decreased when administered with HD00374 containing ddrug2 , DB01373 , or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : disturbances of blood glucose , including hyperglycemia and hypoglycemia , have been reported in patients treated concomitantly with HD00532 and an HD00772 .",
        "label": "effect"
    },
    {
        "text": "the gonadotropin levels may be transiently elevated by DB00421 , minimally elevated by DB01235 , and suppressed by oral ddrug2 and ddrug3 .",
        "label": "NA"
    },
    {
        "text": "because of reports of prolongation of the prothrombin time beyond the therapeutic range in patients taking concurrent ddrug0 and DB00682 , it is suggested that the prothrombin time be monitored carefully , and the dose of ddrug2 or other DB04665 - like drugs should be adjusted accordingly , in patients taking both drugs .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration of single doses of DB00962 # mg and DB00679 # mg produced additive effects on decreased alertness and impaired psychomotor performance for # to # hours after administration .",
        "label": "effect"
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma DB00252 concentrations include : acute ddrug1 intake , ddrug2 , chboramphenicol , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , DB01159 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : DB00316 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { DB00701 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "however , there are limited in vivo data suggesting a modest cyp2d6 inhibitory effect for ddrug0 , i , e , , coadministration of DB01175 { 20 mg/day for # days } with the ddrug2 DB01151 { single dose of # mg } , a substrate for cyp2d6 , resulted in a 40 % increase in cmax and a 100 % increase in auc of ddrug4 .",
        "label": "mechanism"
    },
    {
        "text": "plasma levels of several closely related ddrug0 have been reported to be increased by the concomitant administration of DB00422 or hepatic enzyme inhibitors { e , g , , ddrug2 , ddrug3 } and decreased by the concomitant administration of hepatic enzyme inducers { e , g , , ddrug4 , ddrug5 } , and such an effect may be anticipated with HD00551 as well .",
        "label": "mechanism"
    },
    {
        "text": "in patients receiving another HD00739 in combination with HD00275 { ddrug2 } , there have been reports of serious , sometimes fatal , reactions including hyperthermia , rigidity , myoclonus , autonomic instability with possible rapid fluctuations of vital signs , and mental status changes that include extreme agitation progressing to delirium and coma .",
        "label": "effect"
    },
    {
        "text": "- a sulfa-based drug such as DB01015 - ddrug1 { DB01015 , ddrug3 } , ddrug4 { ddrug5 } , or ddrug6 { ddrug7 } ;",
        "label": "NA"
    },
    {
        "text": "drug interactions : the central ddrug0 syndrome can occur when anticholinergic agents such as DB00810 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain ddrug2 such as ddrug3 , the ddrug4 and other ddrug5 , ddrug6 , certain ddrug7 such as the DB00908 salts , and ddrug9 .",
        "label": "effect"
    },
    {
        "text": "when DB00390 and DB00187 were concomitantly administered intravenously to normal volunteers , there was a 10 - 20 % increase in ddrug2 blood levels at some time points .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 is a substrate for both HD00301 and HD00302 .",
        "label": "NA"
    },
    {
        "text": "tablets : the ddrug0 , including DB00186 , produce cns-depressant effects when administered with such medications as HD00026 or ddrug3 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , DB00091 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , DB01232 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 : in pharmacokinetic studies of ddrug1 in hypercholesterolemic noninsulin dependent diabetic patients , there was no drug interaction with DB01067 or with DB00672",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB00404 , and ddrug7 raise the serum ddrug8 concentration due to a reduction in clearance and/or in volume of distribution of the drug , with the implication that HD00118 intoxication may result .",
        "label": "NA"
    },
    {
        "text": "in separate studies of patients receiving maintenance doses of ddrug0 , DB00999 , or ddrug2 , DB01029 administration for # days had no effect on the pharmacodynamics of ddrug4 { prothrombin time } or pharmacokinetics of ddrug5 .",
        "label": "NA"
    },
    {
        "text": "in DB01118 - treated patients who require additional HD00304 therapy , the initial dose of such agents should be approximately half of the usual recommended dose .",
        "label": "NA"
    },
    {
        "text": "some HD00532 have also been shown to interfere with the metabolism of DB00201 .",
        "label": "mechanism"
    },
    {
        "text": "the effect of ddrug0 on plasma ddrug1 has not been studied , but cases of increased DB14507 plasma levels during DB00465 therapy have been reported .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , DB01076 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , DB01232 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "this drug may interact with ddrug0 or other ddrug1 { may potentiate the cns depressant effects of either these medications or HD00388 } , ddrug3 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug4 } , and HD00445 { concurrent use with ddrug6 may prolong and intensify the anticholinergic and cns depressant effects of ddrug7 } .",
        "label": "NA"
    },
    {
        "text": "the hypoglycemic action of HD00222 may be potentiated by certain drugs including ddrug1 and other drugs that are highly protein bound , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , HD00275 , and ddrug8 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { DB00091 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , DB01045 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "however , in another study in healthy volunteers , the pharmacokinetics of ddrug0 were significantly altered { 29 % decrease in auc and 38 % decrease in cmax } when a 1-mg dose of DB00611 was administered # minute after a 20-mg dose of DB00669 nasal spray .",
        "label": "mechanism"
    },
    {
        "text": "administration of ddrug0 tablets to patients receiving either DB01235 or DB00915 concurrently should be undertaken with caution , using small initial doses and small gradual dose increases .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a single { 400 mg } and multiple dose { 400 mg tid } study of DB00996 in epileptic patients { n = 8 } maintained on ddrug2 monotherapy for at least # months , DB00996 had no effect on the steady-state trough plasma concentrations of ddrug4 and ddrug5 had no effect on ddrug6 pharmacokinetics .",
        "label": "NA"
    },
    {
        "text": "it is recommended that serum DB14507 levels be monitored frequently if DB00722 is administered concomitantly with ddrug2 .",
        "label": "NA"
    },
    {
        "text": "certain endocrine and liver function tests may be affected by HD00183 - containing oral HD00283 .",
        "label": "NA"
    },
    {
        "text": "therefore , it would be expected that a dosing schedule of ddrug0 given at bedtime and DB01432 given before the evening meal would not result in a significant decrease in the clinical effect of HD00503 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { HD00548 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , DB00224 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "pretreatment of healthy volunteers with multiple doses of DB01045 followed by a single dose of ddrug1 , increased DB00619 oral-dose clearance by # - fold , which significantly { p # } decreased mean cmax and auc { 0 - 8 } .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 : in one study , ddrug1 was given to adult diabetics who were already receiving DB01016 { n = 4 } , ddrug3 { n = 2 } DB00672 with ddrug5 { n = 3 } or ddrug6 with ddrug7 { n = 6 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 should be used with caution in patients receiving - ddrug2 blocking agents { e , g , , ddrug3 , a HD00302 inhibitor } or ddrug5 antagonists { e , g , , DB00661 , a ddrug7 substrate , and ddrug8 , a ddrug9 inhibitor } because of the possible potentiation of bradycardia , sinus arrest , and av block ;",
        "label": "NA"
    },
    {
        "text": "use of DB00722 with ddrug1 { e , g , , ddrug2 , DB00384 , or ddrug4 } , ddrug5 supplements , or potassium-containing salt substitutes may lead to significant increases in serum potassium .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : when multiple doses of DB01076 and DB00390 were coadministered , steady-state plasma ddrug3 concentrations increased by approximately 20 % .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 ddrug1 DB00199 ddrug3 DB00976 ddrug5 ddrug6 ddrug7 large quantities of grapefruit juice { # quart daily }",
        "label": "NA"
    },
    {
        "text": "no depressant effect on blood levels in humans was noted when ddrug0 was administered with any of the following drugs : DB00945 , ddrug2 , DB00636 , ddrug4 , ddrug5 { ddrug6 } , ddrug7 , ddrug8 or ddrug9 .",
        "label": "NA"
    },
    {
        "text": "in order to maintain ddrug0 levels , limit adverse experiences , and achieve the DB00949 dose of # mg/day , a DB00252 dose reduction of approximately 40 % was necessary for eight of these # subjects .",
        "label": "advise"
    },
    {
        "text": "DB00979 may interfere with the anti-glaucoma action of ddrug1 or DB01085 ;",
        "label": "effect"
    },
    {
        "text": "interactions for DB00627 { ddrug1 } : HD00876 therapy : ddrug3 may potentiate the effects of ddrug4 and vasoactive drugs resulting in postural hypotension .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { ddrug1 } { e , g , , DB00472 , ddrug3 , ddrug4 , ddrug5 } have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with HD00277 .",
        "label": "effect"
    },
    {
        "text": "thus , the interaction observed between DB00199 and ddrug1 is not expected for DB00954 .",
        "label": "NA"
    },
    {
        "text": "effect of ddrug0 on the pharmacokinetics of other drugs : DB01068 does not appear to alter the pharmacokinetics of DB00252 , ddrug3 , or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : there have been reports of increased anticoagulant effects when DB00199 and oral HD00326 were used concomitantly .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : since ddrug1 is contraindicated in patients with DB01109 - induced thrombocytopenia , the co-administration of DB00278 and ddrug4 is unlikely for this indication .",
        "label": "NA"
    },
    {
        "text": "patients who begin taking DB00586 or who increase their ddrug1 dose or any other ddrug2 while taking ddrug3 , ddrug4 , or DB00091 may develop toxicity characteristics for these drugs .",
        "label": "effect"
    },
    {
        "text": "the ddrug0 , including DB00404 , produce additive cns depressant effects when co-administered with other ddrug2 , ddrug3 , HD00130 , ddrug5 , and other drugs which themselves produce cns depression .",
        "label": "effect"
    },
    {
        "text": "inhibitors of this isoenzyme { e , g , , ddrug0 , ddrug1 , ddrug2 , ddrug3 , DB01118 , ddrug5 , ddrug6 , grapefruit juice , ddrug7 , ddrug8 , ddrug9 , ddrug10 } should be cautiously coadministered with DB00204 as they can potentially increase ddrug12 levels .",
        "label": "advise"
    },
    {
        "text": "oral HD00062 : in one study , ddrug1 was given to adult diabetics who were already receiving ddrug2 { n = 4 } , ddrug3 { n = 2 } ddrug4 with DB00914 { n = 3 } or ddrug6 with ddrug7 { n = 6 } .",
        "label": "NA"
    },
    {
        "text": "the majority of patients in ra clinical studies received one or more of the following concomitant medications with DB01281 : ddrug1 , HD00203 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , and ddrug11 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the concomitant administration of DB00537 with the HD00226 ddrug3 has , on rare occasions , resulted in severe hypoglycemia .",
        "label": "effect"
    },
    {
        "text": "ddrug0 , ddrug1 - pectin , DB00795 , ddrug3 , ddrug4 , certain anticancer drugs , and DB01233 may interfere with intestinal ddrug6 absorption , resulting in unexpectedly low serum concentrations .",
        "label": "NA"
    },
    {
        "text": "drugs that should not be coadministered with DB00220 ddrug1 : ddrug2 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : HD00870 ddrug8 : ddrug9 ddrug10 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "label": "advise"
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of HD00472 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 { 1 } , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 { 1 } , ddrug10 , DB00176 , grapefruit juice , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21 , ddrug22 , ddrug23 , ddrug24 { 1 } , ddrug25 , ddrug26 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : ddrug1 is known to slow the metabolism of DB00564 and increase its serum levels ddrug3 levels should be determined prior to concurrent administration with DB00951 , signs and symptoms of ddrug5 toxicity should be monitored closely , and appropriate dosage adjustment of the ddrug6 should be made .",
        "label": "NA"
    },
    {
        "text": "concomitant ddrug0 , DB00997 , ddrug2 , and DB00898 chemotherapy plus ddrug4 therapy in patients with human immunodeficiency virus-related , non-hodgkin lymphoma .",
        "label": "NA"
    },
    {
        "text": "other drugs : in healthy volunteers , ddrug0 , DB00252 , ddrug2 , ddrug3 , ddrug4 , hormone replacement therapy { a combination of conjugated ddrug5 and HD00642 } , ddrug7 { ddrug8 and ddrug9 } and ddrug10 did not affect the pharmacokinetics of ddrug11 .",
        "label": "NA"
    },
    {
        "text": "HD00388 may partially counteract the anticoagulation effects of DB01109 or ddrug2 .",
        "label": "effect"
    },
    {
        "text": "toxicology studies of DB01452 - related deaths reveal frequent involvement of other ddrug1 , including ddrug2 , HD00100 such as ddrug4 { ddrug5 } , and , to a rising degree , ddrug6 .",
        "label": "effect"
    },
    {
        "text": "before taking DB00222 , tell your doctor if you are taking any of the following medicines : - ddrug1 or another ddrug2 such as ddrug3 { ddrug4 } , DB01399 { ddrug6 , others } , ddrug7 { ddrug8 } , ddrug9 { ddrug10 } , or ddrug11 { ddrug12 } ;",
        "label": "advise"
    },
    {
        "text": "and HD00218 , such as DB00695 .",
        "label": "NA"
    },
    {
        "text": "reported examples of this interaction include the following : ddrug0 : DB01045 is a potent inducer of HD00302 .",
        "label": "NA"
    },
    {
        "text": "the auc and cmax of both the { r } and { s } isomers of DB00682 were unaffected by concurrent dosing of # mg HD00503 .",
        "label": "NA"
    },
    {
        "text": "other binding proteins may be elevated in serum , i , e , , corticosteroid binding globulin { cbg } , sex hormone-binding globulin { shbg } , leading to increased total circulating HD00175 and HD00578 , respectively .",
        "label": "NA"
    },
    {
        "text": "pharmacokinetic interaction studies with DB00341 in adults were conducted with ddrug1 , ddrug2 , ddrug3 , ddrug4 and DB00207 .",
        "label": "NA"
    },
    {
        "text": "drug interactions : the central HD00315 syndrome can occur when anticholinergic agents such as ddrug1 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain ddrug2 such as DB00454 , the ddrug4 and other ddrug5 , ddrug6 , certain ddrug7 such as the ddrug8 salts , and ddrug9 .",
        "label": "effect"
    },
    {
        "text": "DB00008 and DB00811 are excreted by the kidney , and the risk of toxic reactions to this therapy may be greater in patients with impaired renal function .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { e , g , , HD00896 } - taking ddrug2 and DB11156 together may decrease the effects of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "DB00199 and ddrug1 { and possibly other ddrug2 } and ddrug3 may increase DB00390 absorption in patients who inactivate ddrug5 by bacterial metabolism in the lower intestine , so that ddrug6 intoxication may result .",
        "label": "mechanism"
    },
    {
        "text": "in order to provide information for the appropriate package insert labeling of HD00003 { ddrug1 } in the us , a comprehensive review was made of ddrug2 { # mg } and DB00717 { # mg } , with the clinical differences indicated where applicable .",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with HD00374 containing ddrug2 , ddrug3 , or DB01373 , with ddrug5 , with metal cations such as ddrug6 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "results of preliminary studies in humans and rats suggest that nonabsorbable HD00374 given concurrently with ddrug1 may inhibit the desired DB00581 - induced drop in colonic ph .",
        "label": "NA"
    },
    {
        "text": "drugs that induce hepatic enzymes such as ddrug0 , DB00252 and ddrug2 may increase the clearance of HD00175 and may require increases in ddrug4 dose to achieve the desired response .",
        "label": "mechanism"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of ddrug0 : ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , DB00668 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , DB00052 , ddrug11 , ddrug12 , ddrug13 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / ddrug1 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , DB00571 } , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 pain medication { e , g , , ddrug12 } , drugs used to aid sleep , drowsiness-causing ddrug13 { e , g , , DB14487 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "at 75 % recovery of fade , hoof twitch was # + / - 3 % for DB13295 alone and # + / - 4 % for ddrug1 plus HD00198 .",
        "label": "NA"
    },
    {
        "text": "- a HD00380 such as ddrug1 { ddrug2 } , DB00335 { ddrug4 } , ddrug5 { ddrug6 } , ddrug7 { ddrug8 } , and others ;",
        "label": "NA"
    },
    {
        "text": "if replacing DB00575 by HD00380 therapy , the introduction of ddrug2 should be delayed for several days after ddrug3 administration has stopped .",
        "label": "NA"
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of HD00539 such as ddrug1 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 } , ddrug11 salts , ddrug12 , local ddrug13 , DB01035 , and ddrug15 .",
        "label": "effect"
    },
    {
        "text": "a possible interaction between ddrug0 and DB00537 , a ddrug2 , has been reported , resulting in a potentiation of the hypoglycemic action of DB01016 .",
        "label": "NA"
    },
    {
        "text": "effect of DB01032 on the apparent volume of distribution and elimination of DB01147 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration of DB00949 with ddrug2 causes an increase in ddrug3 plasma concentrations , in # otherwise healthy male volunteers ingesting ddrug4 , the steady-state trough { cmin } DB01174 concentration was # micrograms/ml .",
        "label": "NA"
    },
    {
        "text": "DB01229 - in one report , DB00130 at a dose of # grams three times daily , given # hours after receiving ddrug2 , appeared to prevent the development of myalgia and arthralgia , adverse reactions of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : administration of ddrug1 to volunteers under fasting conditions , or with DB06724 suspension yielded similar serum DB00712 time profiles in young subjects { n = 12 } .",
        "label": "NA"
    },
    {
        "text": "some reports have shown that the concomitant administration of HD00217 with DB11094 causes hypercalcemia .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : DB00390 concentrations are increased by about 15 % when ddrug2 and DB01136 are administered concomitantly .",
        "label": "NA"
    },
    {
        "text": "patients who begin taking DB00586 or who increase their ddrug1 dose or any other ddrug2 while taking DB00390 , ddrug4 , or ddrug5 may develop toxicity characteristics for these drugs .",
        "label": "effect"
    },
    {
        "text": "several ddrug0 have been reported to block the pharmacologic effects of DB01170 , DB00575 , or similar agents , and such an effect may be anticipated with ddrug3 because of its structural similarity to other ddrug4 .",
        "label": "NA"
    },
    {
        "text": "results of studies in multiple sclerosis patients taking DB00108 and concomitant ddrug1 { ddrug2 # mcg i m once weekly } or ddrug3 were inconclusive with regard to the need for dose adjustment of the ddrug4 or DB05259 .",
        "label": "NA"
    },
    {
        "text": "coingestion of ddrug0 with ddrug1 , DB01174 with DB00316 , and ddrug4 with ddrug5 at high to toxic concentrations decreases the binding of the target drug .",
        "label": "effect"
    },
    {
        "text": "DB00649 and DB00495 ddrug2 can antagonize the in vitro antiviral activity of ddrug3 and ddrug4 against hiv .",
        "label": "NA"
    },
    {
        "text": "in vitro studies demonstrated that the plasma protein binding of ddrug0 was not affected by DB00682 or DB00645 , indicating no potential for protein binding-based drug interactions .",
        "label": "NA"
    },
    {
        "text": "patients receiving other ddrug0 s , general ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 or other ddrug6 { including DB02325 } concomitantly with DB00327 may exhibit an additive cns depression .",
        "label": "effect"
    },
    {
        "text": "the following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral HD00811 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB00647 , ddrug7 , ddrug8 { e , g , , ddrug9 } , ddrug10 .",
        "label": "NA"
    },
    {
        "text": "coadministration of DB01026 tablets with DB00683 or ddrug2 has resulted in elevated plasma concentrations of the latter two drugs .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , DB00091 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { DB01045 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "these increases should be considered when selecting an oral HD00349 for a woman taking DB01076 .",
        "label": "advise"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / ddrug1 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , ddrug4 , ddrug5 , ddrug6 , DB00226 , ddrug8 , ddrug9 , ddrug10 , ddrug11 pain medication { e , g , , ddrug12 } , drugs used to aid sleep , drowsiness-causing HD00388 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 : ddrug1 { 40 mg bid } did not induce the metabolism of the combination oral ddrug2 DB00717 / ddrug4 { 1 mg / 35 mcg combination , DB00717 1/35 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , DB00446 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , HD00029 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "HD00254 : in controlled clinical studies , ddrug1 have been frequently administered concomitantly with DB00622 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : concomitant DB00945 may decrease the metabolic clearance of DB00627 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : available data suggest that there is no significant effect of DB00313 on the clearance of DB00949 at steady state , therefore , the addition of ddrug3 is not expected to cause a clinically important effect on ddrug4 { ddrug5 } plasma concentrations .",
        "label": "NA"
    },
    {
        "text": "in # separate studies , DB00950 # mg twice daily { 240 mg total daily dose } was co-administered with either DB00199 # mg every # hours or ddrug2 # mg once daily under steady-state conditions to healthy volunteers { n = 24 , each study } .",
        "label": "NA"
    },
    {
        "text": "- drugs whose efficacy is impaired by ddrug0 include : ddrug1 , HD00175 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , oral ddrug8 , DB01045 , ddrug10 , ddrug11 , ddrug12 .",
        "label": "NA"
    },
    {
        "text": "- ddrug0 { e , g , , HD00900 } use of ddrug2 with ddrug3 may increase the chance of side effects affecting the liver and/or the side effects of DB00563",
        "label": "NA"
    },
    {
        "text": "cimetidine co-administration of ddrug0 with DB00501 { a non-specific cyp-450 inhibitor } resulted in an increase of approximately 50 % in the auc and the cmax , of DB01023 .",
        "label": "NA"
    },
    {
        "text": "the effects of medicinal products with similar properties such as inotropes DB00235 , ddrug1 , ddrug2 , ddrug3 and ddrug4 may be exacerbated by DB00261 .",
        "label": "effect"
    },
    {
        "text": "in clinical trials , ddrug0 was used with ddrug1 , HD00218 , ddrug3 , oral ddrug4 , and supplemental ddrug5 , in a pharmacokinetic substudy in patients with congestive heart failure receiving ddrug6 or ddrug7 in whom therapy with DB01240 was initiated , apparent oral clearance values for ddrug9 { n = 23 } and ddrug10 { n = 30 } were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 / ddrug1 : long-term suppression of gastric acid secretion by HD00586 or ddrug3 { eg , DB00927 and ddrug5 } is likely to reduce ddrug6 exposure .",
        "label": "NA"
    },
    {
        "text": "although it has not been established that there is an interaction between ddrug0 and ddrug1 or other ddrug2 , caution is advised when DB00363 is initiated in patients taking a ddrug4 or any other HD00564 .",
        "label": "advise"
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a HD00533 , including ddrug1 , with multivalent cation-containing products such as ddrug2 or ddrug3 ddrug4 , ddrug5 , DB00900 chewable/buffered tablets or pediatric powder , or products containing ddrug7 , ddrug8 , or ddrug9 may substantially decrease the absorption of ddrug10 , resulting in serum and urine levels considerably lower than desired .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 ddrug1 DB00199 DB01211 ddrug4 ddrug5 ddrug6 ddrug7 large quantities of grapefruit juice { # quart daily }",
        "label": "NA"
    },
    {
        "text": "behavioral responses to repeated DB00907 exposure in mice selectively bred for differential sensitivity to DB00312 .",
        "label": "NA"
    },
    {
        "text": "serum ddrug0 concentrations appeared to be unaffected by baseline use of medications for the treatment of crohn s disease including HD00175 , ddrug2 { DB00916 or ddrug4 } and aminosalicylates .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as DB00415 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , DB01232 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "HD00106 and HD00466 { hypertension } - in clinical studies of patients with hypertension , the addition of ddrug2 # to # mg to ddrug3 and ddrug4 increased mean serum potassium slightly { about # # meq/l } .",
        "label": "NA"
    },
    {
        "text": "medications can interfere with folate utilization , including : ddrug0 { such as ddrug1 , and ddrug2 } DB00331 { sometimes prescribed to control blood sugar in type # diabetes } ddrug4 { used to control inflammation associated with crohn_disease and ulcerative colitis } DB00384 { a ddrug6 } ddrug7 there has been concern about the interaction between ddrug8 and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "in clinical studies , coadministration of ddrug0 with DB01076 , ddrug2 , or ddrug3 did not interfere with the lipid-lowering activity of the HD00383 .",
        "label": "NA"
    },
    {
        "text": "DB00321 in combination with ddrug1 enhances the manifestation of corneal lesions in rats epidural injection DB00575 may potentiate the cns-depressive effect of ddrug3 , ddrug4 or other ddrug5 .",
        "label": "NA"
    },
    {
        "text": "HD00461 { cns } drugs including ddrug1 , ddrug2 , ddrug3 , HD00031 , blood pressure medications { ddrug5 , ddrug6 , ddrug7 } , motion sickness medications , ddrug8 , ddrug9 , ddrug10 , sleeping pills and ddrug11",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , DB00503 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , DB00231 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "the results indicate that a spinal ddrug0 - sensitive endorphinergic system is involved in the production of HD00144 but not ddrug2 - induced tail-flick inhibition , and suggest that intraventricular ddrug3 and DB00295 elicit their pharmacological actions via the activation of different descending pain inhibitory systems ;",
        "label": "NA"
    },
    {
        "text": "coadministration of DB00580 and ddrug1 1/35 increased the exposure of ddrug2 and DB00977 by 20 % and 34 % , respectively .",
        "label": "NA"
    },
    {
        "text": "elevated serum levels of ddrug0 have been reported with the concomitant use of some HD00532 and DB00091 .",
        "label": "mechanism"
    },
    {
        "text": "physiological changes resulting from smoking cessation , with or without ddrug0 replacement , may alter the pharmacokinetics of certain concomitant medications , such as HD00043 and DB00277 .",
        "label": "NA"
    },
    {
        "text": "however , in a follow-up study in normal subjects , single-dose administration of DB00375 and ddrug1 and twice-a-day administration for # days of both agents did not affect the extent of DB00571 absorption , but had a small yet statistically significant effect on its rate of absorption ;",
        "label": "NA"
    },
    {
        "text": "it was shown that HD00163 antagonized evidently the antinociceptive effect of HD00164 and their analogue .",
        "label": "effect"
    },
    {
        "text": "in common with other HD00544 , ddrug1 may reduce the efficacy of oral HD00283",
        "label": "effect"
    },
    {
        "text": "ddrug0 : co-administration of DB00559 # mg b , i , d , and DB01026 , a potent cyp3a4 inhibitor , increased the plasma concentrations of ddrug3 by approximately 2-fold .",
        "label": "mechanism"
    },
    {
        "text": "conjugation at HD00072 with DB00151 moieties significantly improves the intestinal permeation of the hydrophilic molecule ddrug2 and the model peptide drugs ddrug3 and ddrug4 in vitro , therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future .",
        "label": "NA"
    },
    {
        "text": "coingestion of ddrug0 with DB00277 , DB01174 with ddrug3 , and ddrug4 with ddrug5 at high to toxic concentrations decreases the binding of the target drug .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00975 may counteract the anticholinesterase effect of HD00632 , thereby potentially aggravating myasthenia gravis .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , HD00668 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as HD00269 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "the co-administration of ddrug0 with iv ddrug1 such as DB00727 , ddrug3 , ddrug4 , or iv ddrug5 has not been evaluated { these drugs were not co-administered with DB04899 in clinical trials } .",
        "label": "NA"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , HD00326 { ddrug1 s } , ddrug2 , ddrug3 { ddrug4 may decrease the effects of these medicines } , ddrug5 { using these medicines with HD00026 may result in increased cns depressant effects } , ddrug7 , ddrug8 { using these medicines with ddrug9 may change the amount of either medicine that you need to take } , and oral ddrug10 containing ddrug11 { ddrug12 may decrease the effectiveness of these oral ddrug13 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "interactions with ddrug0 : ddrug1 { eg , ddrug2 , DB00844 , ddrug4 , ddrug5 and ddrug6 } should not be administered to a patient who has received or is receiving a course of therapy with a HD00843 such as ddrug8 .",
        "label": "NA"
    },
    {
        "text": "if DB01045 therapy is required , DB00270 concentrations and therapeutic effects are likely to be markedly reduced or abolished as a consequence of increased metabolism and higher clearance of ddrug2 .",
        "label": "mechanism"
    },
    {
        "text": "plasma was analyzed for ddrug0 , and urine was analyzed for ddrug1 and its two metabolites , HD00088 and HD00089 by means of hplc .",
        "label": "NA"
    },
    {
        "text": "DB00522 may interact with ddrug1 { e , g , , DB00316 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "int"
    },
    {
        "text": "ddrug0 { ddrug1 } : DB00238 may decrease plasma levels of HD00710 ;",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 { e , g , , ddrug1 , ddrug2 , ddrug3 } and DB00951 may reduce the therapeutic effects of DB01235 .",
        "label": "effect"
    },
    {
        "text": "to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma { hiv-nhl } , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the DB00531 , ddrug1 , ddrug2 , and ddrug3 { chop } chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen { i , e , , ddrug4 , ddrug5 , ddrug6 , and ddrug7 with ddrug8 plus DB00290 } without receiving ddrug10 therapy .",
        "label": "NA"
    },
    {
        "text": "drug interactions : ddrug0 may interact with some drugs , like ddrug1 { ddrug2 } : ddrug3 could theoretically affect ddrug4 pharmacodynamics - ddrug5 - jzqyavbxjcqsok_uhfffaoysa_n - ddrug6 : DB00875 and DB00898 cause additive cns depression - ddrug9 : ddrug10 increases the effect of ddrug11",
        "label": "effect"
    },
    {
        "text": "it is recommended that serum ddrug0 levels be monitored frequently if DB00584 is administered concomitantly with DB14507 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : ddrug1 increases the metabolism of DB00977 and some HD00526 { ddrug4 } resulting in decreased contraceptive effectiveness and increased menstrual irregularities .",
        "label": "NA"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , HD00326 { ddrug1 s } , ddrug2 , ddrug3 { ddrug4 may decrease the effects of these medicines } , ddrug5 { using these medicines with ddrug6 may result in increased cns depressant effects } , ddrug7 , ddrug8 { using these medicines with ddrug9 may change the amount of either medicine that you need to take } , and oral ddrug10 containing HD00220 { ddrug12 may decrease the effectiveness of these oral ddrug13 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "the plasma maximum concentration and area under the plasma concentration-time curve of ddrug0 , ddrug1 , and HD00087 were unchanged after coadministration of DB00877 , and no potentiation of the effects of ddrug4 on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { DB00316 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as HD00269 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in an interaction study of rheumatoid_arthritis patients taking ddrug1 , DB00482 did not have a significant effect on the pharmacokinetics of DB00563 .",
        "label": "NA"
    },
    {
        "text": "concomitant ddrug0 , ddrug1 , DB00541 , and DB00898 chemotherapy plus ddrug4 therapy in patients with human immunodeficiency virus-related , non-hodgkin lymphoma .",
        "label": "NA"
    },
    {
        "text": "in clinical trials , ddrug0 was used with ddrug1 , ddrug2 , HD00326 , oral ddrug4 , and supplemental ddrug5 , in a pharmacokinetic substudy in patients with congestive heart failure receiving ddrug6 or ddrug7 in whom therapy with ddrug8 was initiated , apparent oral clearance values for DB00695 { n = 23 } and ddrug10 { n = 30 } were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .",
        "label": "NA"
    },
    {
        "text": "use lowest possible dose of DB01076 with careful monitoring , or consider ddrug1 that are not primarily metabolized by cyp3a4 , such as ddrug2 , ddrug3 , or ddrug4 in combination with DB00224 .",
        "label": "advise"
    },
    {
        "text": "HD00008 alone had no effect on tyrosine phosphorylation in t24 cells , but dose-dependently inhibits the effects of HD00007 when both are added simultaneously .",
        "label": "effect"
    },
    {
        "text": "oral ddrug0 caution should be exercised when HD00423 are given in conjunction with DB01039 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 increase the rate of absorption of DB00852 , while DB01575 decreases it .",
        "label": "mechanism"
    },
    {
        "text": "a similar association , though less marked , has been suggested with ddrug0 , phenyl-butazone , ddrug1 , DB00564 and possibly with DB00400 , ddrug4 , and ddrug5 { 72 }",
        "label": "NA"
    },
    {
        "text": "- HD00420 or HD00421 { with hepatotoxic potential } must not be administered together with ddrug2 or ddrug3 .",
        "label": "NA"
    },
    {
        "text": "there have been reports of DB00277 - related side effects in patients on concomitant therapy with HD00532 and ddrug2 .",
        "label": "NA"
    },
    {
        "text": "DB00977 and DB00717",
        "label": "NA"
    },
    {
        "text": "co-administration of DB00083 and ddrug1 or other agents interfering with neuromuscular transmission { e , g , , ddrug2 } should only be performed with caution as the effect of the HD00437 may be potentiated .",
        "label": "NA"
    },
    {
        "text": "concomitant use of DB01254 and drugs that inhibit cyp3a4 { eg , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , DB00976 } may increase exposure to ddrug12 and should be avoided .",
        "label": "mechanism"
    },
    {
        "text": "there have been no reported cases from spontaneous reports of drug interaction between HD00114 and ddrug1 { DB00320 } injection , usp .",
        "label": "NA"
    },
    {
        "text": "another oral ddrug0 , ddrug1 , inhibits the metabolism of ddrug2 , resulting in elevated plasma concentrations of DB00637 and its active metabolite HD00821 which may prolong qt intervals .",
        "label": "NA"
    },
    {
        "text": "nephrotoxicity has been reported following concomitant administration of ddrug0 with ddrug1 or potent HD00218 such as DB00695 .",
        "label": "NA"
    },
    {
        "text": "a similar association , though less marked , has been suggested with ddrug0 , phenyl-butazone , DB00252 , ddrug2 and possibly with ddrug3 , DB00415 , and ddrug5 { 72 }",
        "label": "NA"
    },
    {
        "text": "drug-drug interactions ddrug0 - DB00289 should be administered with caution to patients being treated with systemically-administered { oral or intravenous } ddrug2 { or other HD00381 } because the action of ddrug4 on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure .",
        "label": "NA"
    },
    {
        "text": "in addition to the interactions noted above , chronic { # weeks } oral DB01118 administration impairs metabolism of DB00252 , ddrug2 , and ddrug3 .",
        "label": "NA"
    },
    {
        "text": "HD00569 : ddrug1 { ddrug2 , ddrug3 , ddrug4 , DB00126 , fruit juices , etc , } lower absorption of ddrug6 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 may enhance the effects of : other ddrug3 s , DB02325 , general HD00264 , ddrug6 such as ddrug7 , ddrug8 , or other ddrug9 , causing increased cns depression .",
        "label": "NA"
    },
    {
        "text": "concurrent administration of DB00488 and ddrug1 may cause severe orthostatic hypotension , DB00501 , an inhibitor of microsomal drug metabolism , increased ddrug3 s half-life and toxicity in a rat model .",
        "label": "NA"
    },
    {
        "text": "DB01061 should not be administered concomitantly with ddrug1 , DB00537 , ddrug3 , ddrug4 , or ddrug5 .",
        "label": "advise"
    },
    {
        "text": "if DB01151 is to be combined with other ddrug1 such as ddrug2 or HD00596 / ddrug4 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of ddrug5 and ddrug6 { e , g , , ddrug7 or ddrug8 } are additive .",
        "label": "effect"
    },
    {
        "text": "in large , well controlled trials in patients with schizophrenia or related psychoses , DB00334 # to # mg/day was significantly superior to DB00502 # to # mg/day in overall improvements in psychopathology rating scales and in the treatment of depressive and negative symptoms , and was comparable in effects on positive psychotic symptoms .",
        "label": "NA"
    },
    {
        "text": "interactions with ddrug0 : ddrug1 { eg , ddrug2 , ddrug3 , ddrug4 , ddrug5 and DB00921 } should not be administered to a patient who has received or is receiving a course of therapy with a HD00843 such as ddrug8 .",
        "label": "NA"
    },
    {
        "text": "the reduced risk of adverse events and therapeutic superiority compared with DB00502 and DB00734 in the treatment of negative and depressive symptoms support the choice of ddrug2 as a first-line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , HD00002 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , DB00273 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : as with other HD00487 , co-administration of ddrug2 with ddrug3 resulted in an increase in the plasma exposure of DB01066 , with a 49 % increase in mean cmax , a 122 % increase in mean auc , and a 53 % increase in half-life .",
        "label": "NA"
    },
    {
        "text": "however , in a well-controlled study of patients with lymphoma on combination therapy , ddrug0 did not increase the marrow toxicity of patients treated with ddrug1 , DB00997 , ddrug3 , ddrug4 and/or DB00888 .",
        "label": "NA"
    },
    {
        "text": "the concurrent use of HD00444 with DB00956 may produce paralytic ileus .",
        "label": "effect"
    },
    {
        "text": "HD00026 and DB01437 should not be administered to patients receiving ddrug2 .",
        "label": "NA"
    },
    {
        "text": "although not studied with DB00969 , inhibition of n-acetyltransferase may have clinically relevant consequences for drugs such as ddrug1 , DB01035 , and ddrug3 .",
        "label": "effect"
    },
    {
        "text": "HD00233 have been reported to decrease the tubular secretion of DB00563 and to potentiate its toxicity .",
        "label": "mechanism"
    },
    {
        "text": "the therapeutic efficacy of HD00043 may be compromised in these patients when DB00501 is discontinued .",
        "label": "effect"
    },
    {
        "text": "other potentially important drug interactions : ddrug0 : ddrug1 metabolized by hepatic oxidation { e , g , , ddrug2 , DB00683 , ddrug4 elc , } should be used with caution because the clearance of these drugs is likely to be reduced by DB00176 .",
        "label": "mechanism"
    },
    {
        "text": "patients in a clinical study who were on established therapy with ddrug0 , to which DB09145 was added , were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ddrug2 ci or DB00795 alone .",
        "label": "NA"
    },
    {
        "text": "the concomitant administration of DB01609 and DB00126 has not been formally studied .",
        "label": "NA"
    },
    {
        "text": "HD00532 , including ddrug1 , may enhance the effects of oral HD00326 , including ddrug3 or its derivatives or similar agents .",
        "label": "effect"
    },
    {
        "text": "HD00374 containing ddrug1 and DB09104 reduce the oral absorption of ddrug3 by 75 % .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , DB01601 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , DB00277 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "when used in therapeutic doses , DB00207 had a modest effect on the pharmacokinetics of ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , DB00683 , ddrug9 , ddrug10 , ddrug11 { intravenous and oral } , ddrug12 , ddrug13 / ddrug14 or ddrug15 .",
        "label": "mechanism"
    },
    {
        "text": "DB01026 tablets may alter the metabolism of ddrug1 , DB00864 , and ddrug3 , resulting in elevated plasma concentrations of the latter drugs .",
        "label": "mechanism"
    },
    {
        "text": "coadministration of DB00220 and drugs that inhibit cytochrome_p450_family_3_subfamily_a may increase DB00220 plasma concentrations .",
        "label": "NA"
    },
    {
        "text": "may interact with thyroid medication { e , g , , DB00451 } , ddrug1 - containing products , ddrug2 , ddrug3 { e , g , , ddrug4 , ddrug5 } , and ddrug6 { e , g , , ddrug7 , DB00338 } .",
        "label": "NA"
    },
    {
        "text": "- a HD00766 such as ddrug1 { ddrug2 } , ddrug3 { ddrug4 , HD00767 } , ddrug6 { ddrug7 } , ddrug8 { ddrug9 } , and others ;",
        "label": "NA"
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit ddrug0 binding to serum proteins or alter the concentrations of serum binding proteins : HD00657 and related ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , DB00252 , ddrug16 , ddrug17 .",
        "label": "NA"
    },
    {
        "text": "patients receiving other HD00459 s , general ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 or other ddrug6 { including ddrug7 } concomitantly with DB00327 may exhibit an additive cns depression .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , HD00282 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , DB01045 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "care should be taken if ddrug0 is used concomitantly with HD00411 s of the DB00661 type .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : concomitant administration of DB09104 and ddrug2 does not interfere with the rate or extent of the absorption of DB01009 administered as ddrug4 .",
        "label": "NA"
    },
    {
        "text": "the administration of local ddrug0 containing DB00668 or ddrug2 to patients receiving ddrug3 , ddrug4 or HD00219 may produce severe , prolonged hypotension or hypertension .",
        "label": "effect"
    },
    {
        "text": "the effects of medicinal products with similar properties such as inotropes ddrug0 , ddrug1 , DB01427 , ddrug3 and ddrug4 may be exacerbated by DB00261 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , DB01086 and ddrug7 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , DB01035 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of ddrug0 { equivalent to 145 mg DB01039 } with DB00175 { 40 mg } once daily for # days has been shown to increase the mean cmax and auc values for ddrug3 by 36 % { range from 69 % decrease to 321 % increase } and 28 % { range from 54 % decrease to 128 % increase } , respectively , and for # - hydroxy-iso-pravastatin by 55 % { range from 32 % decrease to 314 % increase } and 39 % { range from 24 % decrease to 261 % increase } , respectively in # healthy adults .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : co-administration of DB00559 # mg b , i , d , for # days decreased the plasma concentrations of both ddrug2 { a cyp2c9 substrate } and DB08496 { a cyp3a4 substrate } by # and 38 % , respectively .",
        "label": "mechanism"
    },
    {
        "text": "high-dose DB00091 resulting in concentrations above # ng/ml administered with oral ddrug1 has led to an 80 % increase in ddrug2 exposure with a 38 % decrease in total body clearance of ddrug3 compared to DB00773 alone .",
        "label": "NA"
    },
    {
        "text": "no information is available about the interaction of DB00567 and DB00331 following multiple doses of either drug .",
        "label": "NA"
    },
    {
        "text": "however , caution should be exercised because there have been a few spontaneous reports of prolonged prothrombin times , with or without bleeding , in DB00749 - treated patients receiving concomitant DB00682 therapy .",
        "label": "effect"
    },
    {
        "text": "DB00712 did not affect the pharmacokinetic profile of either drug , and the mechanism under lying the interference with DB00571 s hypotensive effect is unknown .",
        "label": "int"
    },
    {
        "text": "ddrug0 { ddrug1 - or ddrug2 - containing } : concomitant administration of 300-mg DB00535 capsules with # ml HD00382 suspension reduces the rate { cmax } and extent { auc } of absorption by approximately 40 % .",
        "label": "mechanism"
    },
    {
        "text": "HD00319 { e , g , , ddrug1 , ddrug2 , ddrug3 , ddrug4 , etc , } : in vitro and animal studies with the combination of ddrug5 and ddrug6 suggest that ddrug7 may induce fungal resistance to DB00681 .",
        "label": "NA"
    },
    {
        "text": "since DB00964 may reduce pulse and blood pressure , caution in using drugs such as ddrug1 { ophthalmic and systemic } , HD00255 , and ddrug3 is advised .",
        "label": "advise"
    },
    {
        "text": "in order to provide information for the appropriate package insert labeling of HD00003 { ddrug1 } in the us , a comprehensive review was made of DB09389 { # mg } and ddrug3 { # mg } , with the clinical differences indicated where applicable .",
        "label": "NA"
    },
    {
        "text": "other drugs : in healthy volunteers , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , hormone replacement therapy { a combination of conjugated ddrug5 and HD00642 } , ddrug7 { ddrug8 and ddrug9 } and DB00277 did not affect the pharmacokinetics of ddrug11 .",
        "label": "NA"
    },
    {
        "text": "both HD00021 and ddrug1 ameliorate HD00023 withdrawal signs .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of HD00071 : ddrug1 , ddrug2 , ddrug3 , HD00571 { e , g , , ddrug5 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "antiacid , ddrug0 , ddrug1 , ddrug2 , ddrug3 , indanavir , DB01026 , ddrug5 , phenobarbitol , ddrug6 , ddrug7 , DB01045 , ritanovir , ddrug9 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00252 DB01174 ddrug3",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB01045 increases the metabolism of ddrug2 and some ddrug3 { DB00717 } resulting in decreased contraceptive effectiveness and increased menstrual irregularities .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 { ddrug1 } : the concomitant administration of a HD00771 with a HD00533 may increase the risks of cns stimulation and convulsions .",
        "label": "effect"
    },
    {
        "text": "DB00682 : co-administration of DB00559 # mg b , i , d , for # days decreased the plasma concentrations of both ddrug2 { a cyp2c9 substrate } and ddrug3 { a cyp3a4 substrate } by # and 38 % , respectively .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : as with other HD00487 , DB01032 inhibits the renal excretion of ddrug3 , resulting in an approximate doubling in a , c , a 54 % increase in peak ddrug4 plasma levels , and a 50 % prolongation in the apparent elimination half-life .",
        "label": "NA"
    },
    {
        "text": "HD00388 may enhance the effects of ddrug1 , ddrug2 , DB02325 , and other ddrug4 .",
        "label": "effect"
    },
    {
        "text": "agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of ddrug0 are the following : ddrug1 , ddrug2 , DB00949 , ddrug4 , ddrug5 , ddrug6 { 2 } , ddrug7 , ddrug8 , and ddrug9 thus , if a patient has been titrated to a stable dosage on ddrug10 , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for HD00472 may be necessary .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { DB00316 } , ddrug3 such as DB00415 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "when ddrug0 was coadministered with ddrug1 , DB01045 , or h2antagonists , reduced plasma concentrations of DB01167 were reported .",
        "label": "NA"
    },
    {
        "text": "by the nonlinear kinetic characteristics for DB00661 and ddrug1 { and probably for DB01115 , as well } and the derivative implications for decreased dosing frequency requirements ;",
        "label": "NA"
    },
    {
        "text": "these data suggest that ddrug0 are negatively coupled to three types of calcium channels in bovine chromaffin cell , including an ddrug1 - sensitive { n-type } channel , an HD00048 - sensitive { p-type } channel and ddrug3 / ddrug4 / HD00049 - resistant { presumptive q-type } channel .",
        "label": "NA"
    },
    {
        "text": "DB11326 may interact with the DB00249 preparation causing a gritty substance to form or may interact with the preservative in the ddrug2 preparation causing a toxic effect in the eye .",
        "label": "mechanism"
    },
    {
        "text": "the results of the ermbt after # weeks of DB00615 and DB01045 therapy were increased # and 156 % , respectively .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as HD00269 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , DB00277 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "HD00100 : combination ddrug1 may decrease the clearance of some ddrug2 { ddrug3 , DB00475 , ddrug5 } and increase the clearance of others { ddrug6 , ddrug7 , ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "DB00819 may increase the effects of other HD00235 .",
        "label": "effect"
    },
    {
        "text": "on the contrary , HD00163 and HD00166 were agonists in induction of analgesia .",
        "label": "effect"
    },
    {
        "text": "ddrug0 DB01026 ddrug2 ddrug3 DB00976 ddrug5 ddrug6 ddrug7 large quantities of grapefruit juice { # quart daily }",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 DB00564 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } DB01235 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "it may be necessary to adjust the dosage of oral HD00326 upon beginning or stopping DB00822 , since ddrug2 may prolong prothrombin time .",
        "label": "advise"
    },
    {
        "text": "drugs that may have their plasma concentration altered by ddrug0 DB00619 increases the mean cmax and auc of DB00641 { cyp3a4 substrate } 2 - and # - fold , respectively , suggesting an inhibition of the cyp3a4 by ddrug3 .",
        "label": "mechanism"
    },
    {
        "text": "in clinical trials , ddrug0 was used with ddrug1 , ddrug2 , ddrug3 , oral ddrug4 , and supplemental ddrug5 , in a pharmacokinetic substudy in patients with congestive heart failure receiving ddrug6 or ddrug7 in whom therapy with DB01240 was initiated , apparent oral clearance values for DB00695 { n = 23 } and ddrug10 { n = 30 } were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of DB00343 with ddrug1 has been reported to result in elevated serum levels of DB00564 { 40 % to 72 % increase } , resulting in toxicity in some cases .",
        "label": "NA"
    },
    {
        "text": "DB00520 has no effect on the pharmacokinetics of ddrug1 , DB00681 , or the active metabolite of mycophenolate .",
        "label": "NA"
    },
    {
        "text": "caution is advised when ddrug0 is coadministered with other medications that can prolong the qt interval { e , g , certain ddrug1 or DB00679 } or lead to electrolyte abnormalities { such as HD00218 or ddrug4 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , DB02362 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , DB01035 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , DB00949 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and DB00126 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 : limited clinical data suggest a higher incidence of adverse experiences in patients receiving ddrug2 concurrently with either DB01235 or DB00915 .",
        "label": "NA"
    },
    {
        "text": "DB02709 { 5 - 35 micromol/l } induced concentration-dependent relaxation of mesenteric arteries preconstricted with ddrug1 { 8 micromol/l } or DB00761 { 125 mmol/l } from both lean and dietary-obese rats .",
        "label": "NA"
    },
    {
        "text": "objective : our objective was to characterize the steady-state pharmacokinetics of DB01590 and DB00091 { inn , ddrug2 } when coadministered in de novo kidney allograft recipients during the first year after transplantation .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - combined administration of a single dose of DB00503 { 600 mg } , both a cyp3a4 substrate and a potent inhibitor of cyp3a4 , and DB01175 { 20 mg } did not affect the pharmacokinetics of either ddrug3 or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , DB00564 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , DB00295 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma DB00252 concentrations include : acute DB02325 intake , ddrug2 , chboramphenicol , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21",
        "label": "mechanism"
    },
    {
        "text": "animals dosed with HD00077 did not display the 2 - 3 hour lag phase in either HD00078 synthesis or in citrate and fluoride accumulation characteristic of animals dosed with ddrug2 .",
        "label": "NA"
    },
    {
        "text": "DB00284 did not interfere with the absorption or disposition of the ddrug1 DB01016 in diabetic patients .",
        "label": "NA"
    },
    {
        "text": "at a median follow-up of # months , the combination of DB01217 and ddrug1 did not demonstrate any efficacy benefit when compared with DB00675 in all patients as well as in the hormone receptor-positive subpopulation .",
        "label": "NA"
    },
    {
        "text": "DB00945 should be used cautiously in conjunction with HD00175 in hypoprothrombinemia .",
        "label": "advise"
    },
    {
        "text": "increased nephrotoxicity has been reported following concomitant administration of HD00485 and HD00447 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 - concomitant use of DB00130 and DB00328 may ameliorate increased intestinal permeability caused by ddrug3 .",
        "label": "effect"
    },
    {
        "text": "in vitro studies have shown that the metabolism of DB01248 may be modified by the concomitant administration of compounds that induce , inhibit , or are metabolized by cytochrome p450 3a4 , such as DB00091 , ddrug2 , ddrug3 , ddrug4 , and ddrug5 .",
        "label": "mechanism"
    },
    {
        "text": "- drugs whose efficacy is impaired by DB00252 include : ddrug1 , ddrug2 , ddrug3 , ddrug4 , DB00254 , ddrug6 , ddrug7 , oral ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 .",
        "label": "effect"
    },
    {
        "text": "therefore , co-administration of DB00476 with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index , including certain ddrug1 { ddrug2 -lsb- ddrug3 -rsb- , such as DB00540 , ddrug5 , and ddrug6 } , ddrug7 and ddrug8 { e , g , , ddrug9 , ddrug10 } , should be approached with caution .",
        "label": "advise"
    },
    {
        "text": "the pharmacokinetics of DB01215 { cmax and auc } were not affected during multiple-dose DB00472 , suggesting no clinically significant pharmacokinetic interaction .",
        "label": "NA"
    },
    {
        "text": "DB00514 is a substrate for both HD00301 and ddrug2 .",
        "label": "NA"
    },
    {
        "text": "other drugs : in healthy volunteers , DB00381 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , hormone replacement therapy { a combination of conjugated HD00220 and ddrug6 } , ddrug7 { ddrug8 and ddrug9 } and ddrug10 did not affect the pharmacokinetics of ddrug11 .",
        "label": "NA"
    },
    {
        "text": "concomitant use of ddrug0 and drugs that inhibit cyp3a4 { eg , ddrug1 , ddrug2 , ddrug3 , ddrug4 , DB00503 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 } may increase exposure to DB01254 and should be avoided .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , DB01076 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , DB00231 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "dose adjustment of ddrug0 may be required and pth and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong cyp3a4 inhibitor { e , g , , DB01026 , ddrug2 , DB01167 ;",
        "label": "NA"
    },
    {
        "text": "interaction between DB00145 and HD00195 in the development of spontaneous motility in chick embryos .",
        "label": "effect"
    },
    {
        "text": "HD00303 : ddrug1 , ddrug2 , DB01195 , ddrug4 , ddrug5 contraindicated due to potential for serious and/or life-threatening reactions .",
        "label": "NA"
    },
    {
        "text": "interactions for ddrug0 analogues { ddrug1 , ddrug2 , DB00136 , and ddrug4 } : DB01432 : ddrug6 has been reported to reduce intestinal absorption of ddrug7 ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration of HD00244 did not have any effect on either the safety or efficacy of DB00308 in the clinical trials .",
        "label": "NA"
    },
    {
        "text": "co-medications that induce cyp 3a4 { e , g , , ddrug0 , ddrug1 , DB00564 , ddrug3 , or st , john s wort } may significantly decrease exposure to DB00990 .",
        "label": "mechanism"
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , ddrug3 , or DB01373 , with ddrug5 , with metal cations such as ddrug6 , or with ddrug7 containing DB01592 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "in addition , drugs that are actively secreted via this route { e , g , , ddrug0 , DB00331 and ddrug2 } should be co-administered with care as they might increase DB00204 levels .",
        "label": "advise"
    },
    {
        "text": "although studies designed to examine drug interactions have not been done , it was noted that HD00579 or DB01285 treatment of relapses for periods of up to # days has been administered to patients { n = 180 } receiving ddrug2 .",
        "label": "NA"
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a ddrug0 , including DB00537 , with multivalent cation-containing products such as DB14513 or ddrug3 ddrug4 , ddrug5 , ddrug6 chewable/buffered tablets or pediatric powder , or products containing ddrug7 , ddrug8 , or ddrug9 may substantially decrease the absorption of ddrug10 , resulting in serum and urine levels considerably lower than desired .",
        "label": "mechanism"
    },
    {
        "text": "since ddrug0 is frequently co-administered with ddrug1 , it is of clinical interest to study the effect of DB00201 on the hepatotoxicity of DB00316 .",
        "label": "NA"
    },
    {
        "text": "HD00245 : coadministration of ddrug1 did not have any effect on either the safety or efficacy of DB00308 in the clinical trials .",
        "label": "NA"
    },
    {
        "text": "ddrug0 should be used with care when HD00425 or inhibitors of av conduction , such as certain ddrug2 { particularly of the ddrug3 -lsb- ddrug4 -rsb- and HD00427 -lsb- ddrug6 -rsb- classes } , or ddrug7 , such as ddrug8 , are used concurrently .",
        "label": "NA"
    },
    {
        "text": "although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 { eg , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , and DB00897 } may have elevated plasma concentrations when coadministered with DB01232 ;",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : coadministration of ddrug1 with DB00220 resulted in a 152 % increase in ddrug3 plasma auc and very little change in DB00503 plasma a , c.",
        "label": "NA"
    },
    {
        "text": "to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma { hiv-nhl } , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the ddrug0 , ddrug1 , DB00541 , and ddrug3 { chop } chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen { i , e , , ddrug4 , ddrug5 , ddrug6 , and ddrug7 with ddrug8 plus DB00290 } without receiving ddrug10 therapy .",
        "label": "NA"
    },
    {
        "text": "higher concentrations of DB01234 { 10 { -8 } - 10 { -6 } m } or HD00147 { 3 x 10 { -8 } - 10 { -7 } m } enhance the mitogenic activity of ddrug2 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 / ddrug1 : long-term suppression of gastric acid secretion by HD00586 or ddrug3 { eg , ddrug4 and DB00338 } is likely to reduce ddrug6 exposure .",
        "label": "NA"
    },
    {
        "text": "consequently , concomitant administration of DB00673 with strong cyp3a4 inhibitors { e , g , , ddrug1 , ddrug2 , ddrug3 , ddrug4 , DB01211 , ddrug6 , ddrug7 } should be approached with caution .",
        "label": "advise"
    },
    {
        "text": "the concomitant use of HD00586 or ddrug1 with DB01254 is not recommended .",
        "label": "advise"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , HD00282 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , DB00812 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "the potentiating action of DB00557 must be considered when the drug is used in conjunction with HD00389 such as ddrug2 , ddrug3 and ddrug4 .",
        "label": "effect"
    },
    {
        "text": "studies in healthy volunteers have shown that DB00284 has no effect on either the pharmacokinetics or pharmacodynamics of ddrug1 , DB01115 , ddrug3 , or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "DB01432 and DB00375 ddrug2 : absorption of ddrug3 is impaired in the presence of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { such as DB00502 } and ddrug2 can suppress the DB00988 rgic renal and mesenteric vasodilation induced with low dose dopamine infusion .",
        "label": "effect"
    },
    {
        "text": "coingestion of DB00316 with DB00277 , ddrug2 with ddrug3 , and ddrug4 with ddrug5 at high to toxic concentrations decreases the binding of the target drug .",
        "label": "effect"
    },
    {
        "text": "the bioavailability of the capsule formulation of DB01150 was not affected when administered # minutes following an DB06724 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration of ddrug1 with DB00220 resulted in a 152 % increase in DB00220 plasma auc and very little change in ddrug4 plasma a , c.",
        "label": "NA"
    },
    {
        "text": "- a HD00766 such as ddrug1 { ddrug2 } , ddrug3 { ddrug4 , ddrug5 } , ddrug6 { ddrug7 } , DB01069 { ddrug9 } , and others ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 { congestive heart failure post-myocardial infarction } - in ephesus , # { 91 % } patients receiving ddrug2 # to # mg also received HD00106 or ddrug4 { ddrug5 / HD00686 } .",
        "label": "NA"
    },
    {
        "text": "other concomitant therapy although specific interaction studies were not performed , DB01216 doses of # mg or more were concomitantly used in clinical studies with ddrug1 , ddrug2 , a-blockers , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , cardiac ddrug9 , ddrug10 , ddrug11 , ddrug12 , HD00728 { also referred to as ddrug14 } , and ddrug15 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "this drug may interact with DB02325 or other ddrug1 { may potentiate the cns depressant effects of either these medications or HD00388 } , ddrug3 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug4 } , and ddrug5 { concurrent use with ddrug6 may prolong and intensify the anticholinergic and cns depressant effects of ddrug7 } .",
        "label": "NA"
    },
    {
        "text": "this drug may interact with DB02325 or other ddrug1 { may potentiate the cns depressant effects of either these medications or ddrug2 } , ddrug3 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug4 } , and ddrug5 { concurrent use with ddrug6 may prolong and intensify the anticholinergic and cns depressant effects of HD00388 } .",
        "label": "NA"
    },
    {
        "text": "DB00405 can interact with ddrug1 or other HD00261 { may potentiate the cns depressant effects of either these medications or ddrug3 } , ddrug4 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug5 } , and ddrug6 { concurrent use with ddrug7 may prolong and intensify the anticholinergic and cns depressant effects of ddrug8 } .",
        "label": "effect"
    },
    {
        "text": "renal clearance measurements of DB00345 can not be made with any significant accuracy in patients receiving ddrug1 , DB00721 , or ddrug3 .",
        "label": "effect"
    },
    {
        "text": "concomitant administration of DB01026 tablets with DB00252 may alter the metabolism of one or both of the drugs .",
        "label": "mechanism"
    },
    {
        "text": "if DB01306 is mixed with HD00812 , ddrug2 should be drawn into the syringe first .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 coadministration leads to an increased peak plasma concentration and auc of ddrug2 , there is no effect on DB00604 absorption when it is coadministered with DB00863 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , DB00564 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , DB00295 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 contraindicated since the coadministration of this product with ddrug2 in an HD00056 regimen reduces the plasma concentrations of DB01232 .",
        "label": "NA"
    },
    {
        "text": "because ddrug0 is not metabolized by the cytochrome cyp2b6 system , inhibitors of cyp450 enzyme would not be expected to affect its metabolism , and DB01026 and DB00196 , potent inhibitors of cytochrome_p450_family_3_subfamily_a and 2c9 , respectively , have been shown to have no effect on ddrug3 pharmacokinetics .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { DB00316 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , DB00231 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "these medications have included ddrug0 , ddrug1 , ddrug2 , ddrug3 , HD00209 , intravenous and oral ddrug5 , ddrug6 , and DB00945 .",
        "label": "NA"
    },
    {
        "text": "nevertheless , the effects of DB00358 on travelers receiving comedication , particularly diabetics or patients using HD00326 , should be checked before departure .",
        "label": "advise"
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the ddrug0 of drugs may be potentiated by ddrug1 , ddrug2 , HD00026 , ddrug4 , ddrug5 , the ddrug6 , HD00559 and ddrug8 , ddrug9 and the ddrug10 , and by other ddrug11 .",
        "label": "NA"
    },
    {
        "text": "it is recommended that DB00490 not be used concomitantly with ddrug1 because the effects of concomitant administration of ddrug2 with most other ddrug3 have not been studied , the concomitant use of DB00490 with other cns-active drugs should be approached with caution .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : because DB01076 does not affect the pharmacokinetics of ddrug2 , interactions with other HD00096 metabolized via the same cytochrome isozymes are not expected .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB01050 , as well as other HD00233 , probably reduces the tubular secretion of ddrug3 based on in vitro studies in rabbit kidney slices .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 may potentiate the hypoglycemic action of HD00062 , eg , DB01124 and ddrug3 , by inhibiting their metabolism in the liver .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 , DB01118 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and ddrug7 raise the serum ddrug8 concentration due to a reduction in clearance and/or in volume of distribution of the drug , with the implication that HD00118 intoxication may result .",
        "label": "NA"
    },
    {
        "text": "diminished urinary excretion of ddrug0 has been reported during the concomitant administration of DB01032 and DB01059 .",
        "label": "mechanism"
    },
    {
        "text": "in patients receiving nonselective HD00275 { ddrug1 } { e , g , , ddrug2 } in combination with ddrug3 { e , g , , ddrug4 , DB00176 , ddrug6 , ddrug7 , ddrug8 } , there have been reports of serious , sometimes fatal , reactions .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : concomitant administration of ddrug1 oral and DB01032 resulted in decreased clearance of DB00465 and significant increases in ddrug4 plasma levels { total auc increased approximately threefold from # to # m g/h/ml } and terminal half-life increased approximately twofold from # to # hours .",
        "label": "NA"
    },
    {
        "text": "HD00852 : some individuals receiving ddrug1 may experience a reversible enhancement of the pressor response to indirect-acting ddrug2 , HD00649 or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "another oral ddrug0 , DB01026 , inhibits the metabolism of ddrug2 , resulting in elevated plasma concentrations of ddrug3 and its active metabolite HD00821 which may prolong qt intervals .",
        "label": "NA"
    },
    {
        "text": "coadministration of DB00311 with other ddrug1 , ddrug2 , and HD00175 may cause hypokalemia .",
        "label": "effect"
    },
    {
        "text": "micro-dosed ddrug0 preparations : micro-dosed DB00396 preparations { minipills that do not contain an HD00183 } may be an inadequate method of contraception during ddrug3 therapy .",
        "label": "NA"
    },
    {
        "text": "clinical trials have indicated that DB00003 can be effectively and safely used in conjunction with standard cystic_fibrosis therapies including oral , inhaled and/or parenteral HD00002 , ddrug2 , enzyme supplements , ddrug3 , oral or inhaled ddrug4 , and ddrug5 .",
        "label": "NA"
    },
    {
        "text": "in clinical trials , ddrug0 was used with ddrug1 , ddrug2 , ddrug3 , oral HD00337 , and supplemental ddrug5 , in a pharmacokinetic substudy in patients with congestive heart failure receiving DB00695 or ddrug7 in whom therapy with ddrug8 was initiated , apparent oral clearance values for ddrug9 { n = 23 } and ddrug10 { n = 30 } were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .",
        "label": "NA"
    },
    {
        "text": "the effects of supplementary oral DB14574 and DB01592 , as well as the interaction between both at the absorption site , fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either # or # micrograms/kg of ddrug2 and # or # mg/kg of ddrug3 over a period of # days in a total of # rats .",
        "label": "NA"
    },
    {
        "text": "co-administration of DB00559 decreased the plasma concentrations of DB01016 by approximately 40 % .",
        "label": "mechanism"
    },
    {
        "text": "-lsb- the gaba-ergic system and brain edema -rsb- it has been shown in rats with experimental toxic and traumatic edemas that ddrug0 { 1 mg/kg } removes the antiedematous action of ddrug1 , ddrug2 , ddrug3 and HD00135 and reduces the action of DB00692 .",
        "label": "NA"
    },
    {
        "text": "objective : our objective was to examine the interaction between ddrug0 and DB01124 to confirm that DB00176 inhibits cyp2c9 .",
        "label": "NA"
    },
    {
        "text": "in a study in # patients with mild to moderate hypertension where the antihypertensive effects of ddrug0 alone were compared to DB00722 given concomitantly with DB00328 , the use of ddrug3 was associated with a reduced antihypertensive effect , although the difference between the two regimens was not significant .",
        "label": "NA"
    },
    {
        "text": "DB00503 : coadministration of ddrug1 with DB00220 resulted in a 152 % increase in ddrug3 plasma auc and very little change in ddrug4 plasma a , c.",
        "label": "NA"
    },
    {
        "text": "because DB00682 is metabolized by cyp2c9 and cyp3a4 , patients who require anticoagulation should receive low-molecular weight or standard DB01109 .",
        "label": "NA"
    },
    {
        "text": "drug/laboratory test interactions a false-positive reaction for ketones in the urine may occur with tests using DB00325 , but not with those using DB00325 .",
        "label": "NA"
    },
    {
        "text": "DB00207 had no significant impact on the cmax and auc of DB00495 , although it significantly decreased the ddrug2 tmax by 44 % and increased the intracellular exposure to phosphorylated ddrug3 by 110 % .",
        "label": "NA"
    },
    {
        "text": "the aim of this paper was to study the interaction between ddrug0 and both HD00164 or its synthetic analogue HD00165 , or ddrug3 , on the antinonciceptive effect of these peptides in mice after intracisternal injection .",
        "label": "NA"
    },
    {
        "text": "ddrug0 increased the auc of ddrug1 by 25 % on day # and decreased the auc of DB00683 by 19 % on day # relative to the dosing of DB00673 on days # through 3 .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral ddrug0 , HD00106 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB00647 , ddrug7 , ddrug8 { e , g , , ddrug9 } , ddrug10 .",
        "label": "NA"
    },
    {
        "text": "however , co-administration of ddrug0 with ddrug1 - and DB14513 - containing HD00374 { 51 meq } or ddrug4 with ddrug5 , had no significant effect on the rate or extent of ddrug6 absorption after administration of a 40-mg oral dose .",
        "label": "NA"
    },
    {
        "text": "because of the potential for DB01097 levels to continue to increase with multiple dosing , caution should be used if patients are to be receiving both ddrug1 and DB01045 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , and the HD00457 ddrug2 { ddrug3 } and ddrug4 { ddrug5 } have all been used with DB01008 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the oral combination of ddrug1 before intramuscular injection of DB00319 produces an increase in DB00319 peak serum level of about 30 % .",
        "label": "NA"
    },
    {
        "text": "studies have shown that DB00448 does not have clinically significant interactions with other drugs metabolized by the cytochrome cyp2b6 system , such as DB00682 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , or ddrug10 in healthy subjects .",
        "label": "NA"
    },
    {
        "text": "seizures have been reported in patients taking another HD00534 and the HD00535 ddrug2 concurrently .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : clinical studies , as well as post marketing observations , have shown that HD00203 can reduce the natriuretic effect of ddrug2 and HD00217 in some patients .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { DB01076 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and DB00126 .",
        "label": "NA"
    },
    {
        "text": "drugs that cause significant sustained elevation in gastric ph { ddrug0 such as DB00863 or ddrug2 } may reduce plasma concentrations of DB00317 and therefore potentially may reduce efficacy .",
        "label": "mechanism"
    },
    {
        "text": "to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma { hiv-nhl } , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the ddrug0 , DB00997 , ddrug2 , and ddrug3 { chop } chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen { i , e , , ddrug4 , ddrug5 , ddrug6 , and ddrug7 with DB00541 plus ddrug9 } without receiving ddrug10 therapy .",
        "label": "NA"
    },
    {
        "text": "DB00313 : DB00949 causes an increase in steady-state ddrug2 concentrations .",
        "label": "NA"
    },
    {
        "text": "the effectiveness of ddrug0 - only pills is reduced by hepatic enzyme-inducing drugs such as the ddrug1 ddrug2 , ddrug3 , and ddrug4 , and the HD00886 DB01045 .",
        "label": "NA"
    },
    {
        "text": "antiacid , ddrug0 , ddrug1 , ddrug2 , ddrug3 , indanavir , ddrug4 , ddrug5 , phenobarbitol , ddrug6 , DB00615 , ddrug8 , ritanovir , DB01232 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 HD00524 may delay or reduce the absorption of concomitant oral medication such as ddrug2 , ddrug3 , ddrug4 { acidic } or ddrug5 { basic } , as well as ddrug6 DB01053 , ddrug8 , thyroid and ddrug9 preparations , ddrug10 and ddrug11 , and ddrug12 .",
        "label": "NA"
    },
    {
        "text": "when the ddrug0 was administered # minutes after the DB00669 nasal spray , the auc of DB00611 increased 11 % and cmax decreased 18 % .",
        "label": "NA"
    },
    {
        "text": "the ddrug0 , including DB00404 , produce additive cns depressant effects when co-administered with other ddrug2 , HD00282 , ddrug4 , ddrug5 , and other drugs which themselves produce cns depression .",
        "label": "effect"
    },
    {
        "text": "in a study in normal volunteers , concomitant administration of DB00490 and ddrug1 resulted in increased serum DB00502 concentrations .",
        "label": "NA"
    },
    {
        "text": "however , # mg of DB00863 q12h for # days increased the ddrug1 c max by 23 % and DB01415 auc by 16 % .",
        "label": "mechanism"
    },
    {
        "text": "response to HD00571 may be enhanced by DB01394 .",
        "label": "effect"
    },
    {
        "text": "caution should be taken when DB00496 is used concomitantly with medications that are predominantly metabolized by cyp2d6 and which have a narrow therapeutic window , such as ddrug1 , ddrug2 and HD00043 { see clinical pharmacology } .",
        "label": "advise"
    },
    {
        "text": "ddrug0 , ddrug1 and HD00666 should not be administered during DB00095 treatment .",
        "label": "advise"
    },
    {
        "text": "products containing DB01373 and other multivalent cations { such as ddrug1 , ddrug2 , ddrug3 } are likely to interfere with absorption of DB00710 .",
        "label": "mechanism"
    },
    {
        "text": "these studies indicate that DB01026 or ddrug1 co-administration enhances DB00950 gastrointestinal absorption .",
        "label": "mechanism"
    },
    {
        "text": "HD00445 such as ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , ddrug5 { e , g , , ddrug6 } , ddrug7 { e , g , , ddrug8 } , and DB00752 { e , g , , ddrug10 } : using these medicines with ddrug11 may increase the chance of side effects .",
        "label": "NA"
    },
    {
        "text": "although a dose adjustment of DB00207 is not recommended when administered in combination with DB00220 , close monitoring for known side effects of ddrug2 , such as liver enzyme abnormalities and hearing impairment , is warranted .",
        "label": "advise"
    },
    {
        "text": "in a study in diabetics with microalbuminuria DB00700 # mg combined with the ddrug1 ddrug2 # mg increased the frequency of hyperkalemia { serum potassium # meq/l } from 17 % on DB00584 alone to 38 % .",
        "label": "NA"
    },
    {
        "text": "additive depressant effect when used with general ddrug0 , HD00024 , ddrug2 , ddrug3 , ddrug4 , and other HD00611 .",
        "label": "NA"
    },
    {
        "text": "DB00294 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as DB00415 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "int"
    },
    {
        "text": "in addition , studies in healthy volunteers have shown that ddrug0 does not affect the pharmacokinetics or pharmacodynamics of DB00682 , or the pharmacokinetics of DB00571 { 40 mg twice daily } , ddrug3 , ddrug4 , or oral ddrug5 .",
        "label": "NA"
    },
    {
        "text": "the use of ddrug0 should be considered in place of HD00586 or ddrug2 in patients receiving DB01254 therapy .",
        "label": "advise"
    },
    {
        "text": "however , due to possible pharmacodynamic interactions , when co-administered with ddrug0 , a reduction in dosage of DB00633 on the concomitant DB01086 , ddrug3 , ddrug4 or ddrug5 may be required .",
        "label": "advise"
    },
    {
        "text": "- the action of HD00416 and ddrug1 may be enhanced by ddrug2 or HD00415 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 , ddrug1 , DB00501 { consider DB00404 dose reduction } .",
        "label": "advise"
    },
    {
        "text": "data from a randomized trial of DB00488 and ddrug1 plus or minus DB00165 in ovarian_cancer indicated that ddrug3 significantly reduced neurotoxicity ;",
        "label": "NA"
    },
    {
        "text": "if the two drugs are coadministered , the HD00379 should be withdrawn several days before the gradual withdrawal of DB00575 .",
        "label": "advise"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other HD00216 ddrug3 ddrug4 ddrug5 { ddrug6 } DB00501 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "DB00390 - in subjects who had received # days of # mg/day racemic ddrug1 , combined administration of DB00215 and ddrug3 { single dose of # mg } did not significantly affect the pharmacokinetics of either ddrug4 or ddrug5 .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : HD00403 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } DB00501 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "close supervision and careful adjustment of dosage are required when DB01242 is administered with ddrug1 or HD00390 .",
        "label": "advise"
    },
    {
        "text": "DB01118 is known to raise serum DB00390 levels .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : concomitant administration of ddrug1 s and DB09104 s does not interfere with absorption of DB00939 .",
        "label": "NA"
    },
    {
        "text": "HD00326 , oral : co-administration of ddrug1 and ddrug2 usually results in inhibition of response to DB00682 , although there have been some conflicting reports .",
        "label": "NA"
    },
    {
        "text": "may lead to loss of virologic response and possible resistance to DB00224 or to the class of HD00269 or other coadministered ddrug2 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { e , g , ddrug1 and ddrug2 } : agents of the ddrug3 , of which ddrug4 { DB00320 } injection , usp is a member , have been shown to interact with ddrug6 of the HD00626 , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .",
        "label": "mechanism"
    },
    {
        "text": "the present work involved the administration of both DB00977 and DB00367 to groups of rats , followed by determination of the homocysteine excretion rate in urine .",
        "label": "NA"
    },
    {
        "text": "the administration of local ddrug0 containing DB00668 or ddrug2 to patients receiving HD00275 or ddrug4 may produce severe , prolonged hypertension .",
        "label": "effect"
    },
    {
        "text": "ddrug0 { HD00203 } : concomitant use of ddrug2 { or other ddrug3 } and HD00175 increases the risk of gastrointestinal side effects .",
        "label": "NA"
    },
    {
        "text": "administration of HD00532 with ddrug1 containing ddrug2 , ddrug3 , or ddrug4 , with ddrug5 , with metal cations such as ddrug6 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { DB00900 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "mechanism"
    },
    {
        "text": "plasma levels of several closely related ddrug0 have been reported to be increased by the concomitant administration of ddrug1 or hepatic enzyme inhibitors { e , g , , ddrug2 , DB00472 } and decreased by the concomitant administration of hepatic enzyme inducers { e , g , , ddrug4 , DB00252 } , and such an effect may be anticipated with ddrug6 as well .",
        "label": "NA"
    },
    {
        "text": "ddrug0 in combination with other ddrug1 , general ddrug2 , ddrug3 , ddrug4 , HD00460 , or other ddrug6 { including DB02325 } has additive depressant effects .",
        "label": "NA"
    },
    {
        "text": "a similar association , though less marked , has been suggested with ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , DB00273 , and possibly with ddrug6 and HD00239 72 .",
        "label": "NA"
    },
    {
        "text": "in vitro data suggest that ddrug0 , when compared to DB01026 , has a less pronounced effect on the biotransformation system responsible for the metabolism of DB00637 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , DB00564 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , DB00812 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "HD00024 and HD00262 { e , g , , ddrug2 } .",
        "label": "NA"
    },
    {
        "text": "also , concomitant administration of HD00532 with products containing ddrug1 , ddrug2 containing DB01593 , or ddrug4 { ddrug5 } chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels .",
        "label": "mechanism"
    },
    {
        "text": "some HD00532 , including DB00537 , have been associated with transient elevations in serum creatinine in patients receiving ddrug2 concomitantly .",
        "label": "NA"
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma DB00252 concentrations include : acute ddrug1 intake , ddrug2 , chboramphenicol , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , DB00656",
        "label": "mechanism"
    },
    {
        "text": "in vitro data suggest that DB01167 , when compared to ddrug1 , has a less pronounced effect on the biotransformation system responsible for the metabolism of DB00637 .",
        "label": "mechanism"
    },
    {
        "text": "because of the increased risk of adverse reactions in patients who have been taking ddrug0 on a regular basis , it is particularly important that physicians query patients or their guardians carefully about DB12537 , ddrug2 and ddrug3 use as part of the history prior to any procedure in which the use of DB01205 is planned .",
        "label": "NA"
    },
    {
        "text": "HD00532 have been shown to interfere with the metabolism of DB00201 .",
        "label": "mechanism"
    },
    {
        "text": "HD00326 : DB00712 like other ddrug2 , has been shown to affect bleeding parameters in patients receiving ddrug3 , and serious clinical bleeding has been reported .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { e , g , , DB09278 } and ddrug2 containing carbohydrate-splitting enzymes { e , g , , HD00225 , ddrug4 } may reduce the effect of ddrug5 and should not be taken concomitantly .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the reports that the concomitant use of DB00437 and HD00029 may contribute to the enhancement of ddrug3 toxicity in some patients have been reviewed in an attempt to establish a cause-and-effect relationship and a mechanism of causation .",
        "label": "effect"
    },
    {
        "text": "the pharmacokinetics and protein binding of ddrug0 , DB00252 , and ddrug2 were not altered when DB00829 and ddrug4 were concurrently administered in single submaximal doses .",
        "label": "NA"
    },
    {
        "text": "certain HD00002 , especially the ddrug1 and HD00384 ;",
        "label": "NA"
    },
    {
        "text": "therefore concomitant administration of DB01167 with DB00604 is contraindicated .",
        "label": "advise"
    },
    {
        "text": "although clinical evidence to date has not demonstrated renal precipitation of oxypurines in patients either on DB00437 alone or in combination with HD00272 , the possibility should be kept in mind .",
        "label": "NA"
    },
    {
        "text": "DB00241 , ddrug1 and ddrug2 may enhance the effects of : other ddrug3 s , ddrug4 , general HD00264 , ddrug6 such as ddrug7 , ddrug8 , or other ddrug9 , causing increased cns depression .",
        "label": "effect"
    },
    {
        "text": "because DB14507 may enhance the serotonergic effects of ddrug1 , caution should be exercised when DB01175 and ddrug3 are coadministered .",
        "label": "NA"
    },
    {
        "text": "DB00199 has been reported to significantly alter the metabolism of nonsedating ddrug1 DB00342 and ddrug3 when taken concomitantly .",
        "label": "mechanism"
    },
    {
        "text": "as with other ddrug0 , if ddrug1 is to be administered orally with HD00377 of the DB00661 or ddrug4 type , it is recommended that ecg and blood pressure be monitored .",
        "label": "NA"
    },
    {
        "text": "DB00622 usually does not alter the plasma levels of DB00390 , however , serum ddrug2 levels should be evaluated after concomitant therapy with ddrug3 is initiated .",
        "label": "NA"
    },
    {
        "text": "a drug-drug interaction study evaluated the effect of the use of ddrug0 gel , 5 % , in combination with double_strength { 160 mg/800 mg } DB00440 / ddrug2 { ddrug3 / DB01015 } .",
        "label": "NA"
    },
    {
        "text": "drugs that may alter ddrug0 plasma concentrations drugs that may increase DB00619 plasma concentrations : caution is recommended when administering ddrug2 with inhibitors of the cyp3a4 family { e , g , , ddrug3 , ddrug4 , DB00199 , ddrug6 } .",
        "label": "NA"
    },
    {
        "text": "when DB01167 was coadministered with ddrug1 , DB01045 , or h2antagonists , reduced plasma concentrations of ddrug3 were reported .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , HD00668 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , DB00224 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the auc of ddrug1 was increased about 4-fold when DB00437 at # mg/day was coadministered with a single 200-mg dose of DB00900 to two patients with renal impairment { clcr = 15 and # ml/min } .",
        "label": "mechanism"
    },
    {
        "text": "the effects of HD00043 on DB00575 s analgesic actions are not known .",
        "label": "NA"
    },
    {
        "text": "this drug may interact with DB02325 or other ddrug1 { may potentiate the cns depressant effects of either these medications or ddrug2 } , ddrug3 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug4 } , and HD00445 { concurrent use with ddrug6 may prolong and intensify the anticholinergic and cns depressant effects of ddrug7 } .",
        "label": "NA"
    },
    {
        "text": "however , HD00147 stimulated , but did not significantly inhibit , proliferation in the presence of HD00071 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : combination ddrug1 may decrease the clearance of some HD00100 { ddrug3 , ddrug4 , ddrug5 } and increase the clearance of others { DB00186 , ddrug7 , ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "HD00244 may also interact with HD00391 .",
        "label": "int"
    },
    {
        "text": "co-administration of DB01026 , a strong inhibitor of cyp3a4 , increased ddrug1 exposure following a single # mg dose of DB01012 by # fold .",
        "label": "NA"
    },
    {
        "text": "no interaction with the HD00042 ddrug1 was shown in a single-dose study with ddrug2 without coadministered DB01235 / ddrug4 .",
        "label": "NA"
    },
    {
        "text": "these medications have included DB01109 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , intravenous and oral ddrug5 , ddrug6 , and DB00945 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : plasma ddrug1 levels and DB00390 clearance at steady-state were not affected by co-administration of # mg HD00503 .",
        "label": "NA"
    },
    {
        "text": "total body clearance of ddrug0 was reduced by an average 22 % and 51 % when DB00993 and ddrug2 , respectively , were added to a regimen consisting of ddrug3 , usp { modified } and HD00175 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 / ddrug1 - containing HD00701 : absorption of DB00943 is moderately reduced { approximately 25 % } when coadministered with ddrug4 / ddrug5 - containing ddrug6 .",
        "label": "NA"
    },
    {
        "text": "as with other ddrug0 , if ddrug1 is to be administered orally with ddrug2 of the DB00661 or DB00343 type , it is recommended that ecg and blood pressure be monitored .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : since ddrug1 is a HD00338 , it is possible that ddrug3 , such as the ddrug4 { ddrug5 , ddrug6 , ddrug7 } or DB01233 , may diminish the effectiveness of ddrug9 .",
        "label": "NA"
    },
    {
        "text": "the gonadotropin levels may be transiently elevated by ddrug0 , minimally elevated by DB01235 , and suppressed by oral ddrug2 and DB00390 .",
        "label": "NA"
    },
    {
        "text": "extended release tablets : administration of DB01115 with ddrug1 increased DB00390 levels in # of # normal volunteers .",
        "label": "NA"
    },
    {
        "text": "DB00207 had no significant effect on DB00900 pharmacokinetics .",
        "label": "NA"
    },
    {
        "text": "ddrug0 or ddrug1 : the risk of myopathy/rhabdomyolysis is increased when either DB01118 or ddrug3 is used concomitantly with a closely related member of the HD00861 { see warnings , myopathy/rhabdomyolysis } .",
        "label": "effect"
    },
    {
        "text": "the drug interaction between DB00682 and DB01045 is not well known .",
        "label": "int"
    },
    {
        "text": "ddrug0 , such as DB00988 and DB01064 ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 in combination with ddrug1 enhances the manifestation of corneal lesions in rats epidural injection DB00575 may potentiate the cns-depressive effect of ddrug3 , ddrug4 or other HD00562 .",
        "label": "effect"
    },
    {
        "text": "other cardiovascular agents : ddrug0 and DB00584 iv have been used concomitantly with ddrug2 , ddrug3 , DB14049 , ddrug5 , ddrug6 , ddrug7 and ddrug8 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "serum concentration of DB00390 and ddrug1 may increase when patients take HD00477 .",
        "label": "mechanism"
    },
    {
        "text": "this drug may interact with ddrug0 or other ddrug1 { may potentiate the cns depressant effects of either these medications or ddrug2 } , HD00444 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with HD00388 } , and ddrug5 { concurrent use with ddrug6 may prolong and intensify the anticholinergic and cns depressant effects of ddrug7 } .",
        "label": "NA"
    },
    {
        "text": "using DB00258 with HD00318 { heart medicine } may cause hypercalcemia { too much ddrug2 in the blood } , which could increase the chance of developing an irregular heartbeat .",
        "label": "effect"
    },
    {
        "text": "DB00501 } and many that are substrates for cyp2b6 2d6 { many other HD00216 , ddrug2 , and the ddrug3 ddrug4 and ddrug5 } .",
        "label": "NA"
    },
    {
        "text": "because ddrug0 has not been shown to produce any additional effect beyond that obtained with ddrug1 alone and because DB00945 increases the rate of excretion of ddrug3 , the concomitant use of ddrug4 and HD00328 is not recommended .",
        "label": "NA"
    },
    {
        "text": "studies have shown that DB00448 does not have clinically significant interactions with other drugs metabolized by the cytochrome cyp2b6 system , such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , DB00829 , ddrug9 , or ddrug10 in healthy subjects .",
        "label": "NA"
    },
    {
        "text": "ddrug0 should be used with care when ddrug1 or inhibitors of av conduction , such as certain HD00085 { particularly of the ddrug3 -lsb- ddrug4 -rsb- and ddrug5 -lsb- DB00343 -rsb- classes } , or ddrug7 , such as ddrug8 , are used concurrently .",
        "label": "NA"
    },
    {
        "text": "DB00091 doses , trough concentrations , and auc exhibited similar temporal patterns during the course of the study regardless of the co-administered DB01590 dose level { p = # , # , and # , respectively } .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of ddrug0 { equivalent to # mg DB01039 } with DB01076 { 20 mg } once daily for # days resulted in approximately 17 % decrease { range from 67 % decrease to 44 % increase } in ddrug3 auc values in # healthy males .",
        "label": "mechanism"
    },
    {
        "text": "results from existing clinical trials suggest no significant interactions between DB05259 and other therapies commonly used in ms patients , including the concurrent use of HD00175 for up to # days .",
        "label": "NA"
    },
    {
        "text": "when combined with DB01165 , ddrug1 exhibited strong synergistic activity while only additive effects were observed with the combination of DB01045 { or ddrug3 } and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , HD00599 and ddrug2 should not be administered during DB00095 treatment .",
        "label": "advise"
    },
    {
        "text": "ddrug0 should be used with care when ddrug1 or inhibitors of av conduction , such as certain ddrug2 { particularly of the ddrug3 -lsb- ddrug4 -rsb- and ddrug5 -lsb- DB00343 -rsb- classes } , or ddrug7 , such as DB00280 , are used concurrently .",
        "label": "NA"
    },
    {
        "text": "when such drugs are withdrawn from patients receiving DB00284 in combination with HD00222 or ddrug2 , patients should be observed closely for any evidence of hypoglycemia .",
        "label": "NA"
    },
    {
        "text": "there does not appear to be an increase in adverse events in subjects who received oral HD00283 and DB00455 .",
        "label": "NA"
    },
    {
        "text": "administration of HD00330 concomitantly with ddrug1 has been associated with an increase in DB00091 - induced toxicity , possibly due to decreased synthesis of renal prostacyclin .",
        "label": "NA"
    },
    {
        "text": "while additional research is needed , the initial clinical data in kidney recipients suggest that ddrug0 , in combination with ddrug1 or ddrug2 , might have the potential to reduce the frequency of rejection episodes , permit reductions in DB00091 or DB00864 dosage , and permit steroid withdrawal { kelly , 1999 } .",
        "label": "NA"
    },
    {
        "text": "HD00870 : ddrug1 , ddrug2 , ddrug3 , DB00353 contraindicated due to potential for serious and life-threatening reactions such as acute ddrug5 toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues .",
        "label": "NA"
    },
    {
        "text": "DB00951 { ddrug1 } is also reported to affect DB01026 concentrations adversely .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with DB00316 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , HD00029 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "HD00093 { e , g , ddrug1 and ddrug2 } : agents of the ddrug3 , of which DB00320 { ddrug5 } injection , usp is a member , have been shown to interact with ddrug6 of the ddrug7 , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : other HD00304 drugs , such as ddrug2 , ddrug3 , ddrug4 , and ddrug5 , have been used concurrently with DB01118 .",
        "label": "NA"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 HD00303 : ddrug2 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 DB00683 , ddrug12 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "the potentiating action of DB00557 must be considered when the drug is used in conjunction with ddrug1 such as ddrug2 , HD00790 and ddrug4 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : DB01032 is known to interact with the metabolism or renal tubular excretion of many drugs { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , DB00636 , ddrug10 , ddrug11 , ddrug12 , ddrug13 agents , ddrug14 , and ddrug15 } .",
        "label": "mechanism"
    },
    {
        "text": "the superiority of DB00625 over DB00224 - based regimens has been observed in comparative data in a subset of patients with high viral loads .",
        "label": "NA"
    },
    {
        "text": "the neurochemical and functional consequences following HD00146 administration to the rat were evaluated and compared to similar effects following DB01577 administration .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : potentiation of ddrug1 - type { ddrug2 and HD00302 substrate } HD00025 response is almost always seen in patients receiving ddrug5 and can result in serious or fatal bleeding .",
        "label": "NA"
    },
    {
        "text": "when used in therapeutic doses , DB00207 had a modest effect on the pharmacokinetics of ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { intravenous and oral } , ddrug12 , DB00440 / ddrug14 or ddrug15 .",
        "label": "mechanism"
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of HD00472 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 { 1 } , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 { 1 } , ddrug10 , ddrug11 , grapefruit juice , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , DB00468 , ddrug22 , ddrug23 , ddrug24 { 1 } , ddrug25 , ddrug26 .",
        "label": "mechanism"
    },
    {
        "text": "before taking ddrug0 , tell your doctor if you are taking any of the following medicines : - ddrug1 or another HD00372 such as ddrug3 { ddrug4 } , ddrug5 { DB01399 , others } , ddrug7 { ddrug8 } , ddrug9 { ddrug10 } , or ddrug11 { ddrug12 } ;",
        "label": "NA"
    },
    {
        "text": "a possible interaction between DB01016 and DB00537 , a ddrug2 , has been reported , resulting in a potentiation of the hypoglycemic action of ddrug3 .",
        "label": "int"
    },
    {
        "text": "ddrug0 absorption : the following agents may bind and decrease absorption of ddrug1 from the gastrointestinal tract : ddrug2 , ddrug3 resin , ddrug4 , ddrug5 , DB01344 , soybean flour { e , g , , infant formula } , DB00364 .",
        "label": "NA"
    },
    {
        "text": "wait # weeks after stopping DB01175 before starting a HD00737 .",
        "label": "advise"
    },
    {
        "text": "therefore , when DB00774 and HD00518 are used concomitantly , the patient should be observed closely to determine if the desired effect of the ddrug2 is obtained .",
        "label": "advise"
    },
    {
        "text": "intravenous DB00863 was shown to double the bioavailability of oral DB00630 .",
        "label": "mechanism"
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , ddrug3 , or ddrug4 , with DB00364 , with metal cations such as ddrug6 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { DB00900 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "however , co-administration of ddrug0 with ddrug1 - and DB14513 - containing ddrug3 { 51 meq } or ddrug4 with ddrug5 , had no significant effect on the rate or extent of DB00476 absorption after administration of a 40-mg oral dose .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : no significant differences were observed in mean ddrug1 auc , c max , c min or t max { although c max increased by 11 % } when extended DB00252 capsules { 100 mg tid } were coadministered with DB00978 { 400 mg qd } for five days in # healthy males .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : no significant differences were observed in mean DB00455 auc , c max , c min or t max { although c max increased by 11 % } when extended DB00199 capsules { 100 mg tid } were coadministered with ddrug3 { 400 mg qd } for five days in # healthy males .",
        "label": "NA"
    },
    {
        "text": "we conclude that the prophylactic and antidotal properties of ddrug0 seen in animals treated with HD00079 derive from its capacity to inhibit the nad + - dependent oxidation responsible for converting ddrug2 to HD00077 in the committed step of the toxic pathway .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : reports suggest that HD00203 may diminish the antihypertensive effect of HD00106 .",
        "label": "effect"
    },
    {
        "text": "drugs that should not be coadministered with DB00220 ddrug1 : ddrug2 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 ddrug11 , DB00897 gi motility agents : ddrug13",
        "label": "advise"
    },
    {
        "text": "in patients who have been reported to be well controlled on HD00043 receiving concurrent DB00501 therapy , discontinuation of ddrug2 has been reported to decrease established steady-state serum ddrug3 levels and compromise their therapeutic effects .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 : ddrug2 should be administered with extreme caution in patients being treated with ddrug3 or HD00043 because the action of DB00983 on the cardiovascular system may be potentiated by these agents .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the concomitant use of ddrug1 { ddrug2 transdermal system } with other HD00389 , including but not limited to other ddrug4 , ddrug5 , ddrug6 , ddrug7 { e , g , , ddrug8 } , general HD00264 , ddrug10 , ddrug11 , and ddrug12 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .",
        "label": "NA"
    },
    {
        "text": "in a drug interaction study , co-administration of orally inhaled DB01410 and oral DB00199 , an inhibitor of cytochrome p450 3a4 , had no effect on the pharmacokinetics of either ddrug2 or ddrug3 .",
        "label": "NA"
    },
    {
        "text": "protein binding in vitro , DB00586 interferes minimally or not at all with the protein binding of ddrug1 { 20 % decrease in binding } , ddrug2 , DB00860 { 10 % decrease in binding } , or ddrug4 .",
        "label": "mechanism"
    },
    {
        "text": "HD00043 { ddrug1 , ddrug2 , ddrug3 } : metabolism may be inhibited by HD00710 , increasing plasma levels of ddrug5 ;",
        "label": "mechanism"
    },
    {
        "text": "blunting of the antihypertensive effect of HD00232 by ddrug1 including DB00328 has been reported .",
        "label": "effect"
    },
    {
        "text": "it is suggested to monitor both DB01026 and DB00252 .",
        "label": "advise"
    },
    {
        "text": "potentiation of the hypotensive effects of DB14049 for patients with ischemic_heart_disease has not been evaluated , and concomitant use of DB00862 and ddrug2 is contraindicated .",
        "label": "NA"
    },
    {
        "text": "conjugation at HD00072 with ddrug1 moieties significantly improves the intestinal permeation of the hydrophilic molecule HD00070 and the model peptide drugs ddrug3 and ddrug4 in vitro , therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future .",
        "label": "NA"
    },
    {
        "text": "while all the selective HD00311 { ddrug1 } , e , g , , DB00472 , ddrug3 , and ddrug4 , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .",
        "label": "NA"
    },
    {
        "text": "the results indicate that a spinal DB01183 - sensitive endorphinergic system is involved in the production of ddrug1 but not DB00295 - induced tail-flick inhibition , and suggest that intraventricular ddrug3 and ddrug4 elicit their pharmacological actions via the activation of different descending pain inhibitory systems ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 - and/or ddrug1 - containing ddrug2 , products containing ddrug3 { ddrug4 } , ddrug5 containing DB01593 or other metal cations , or ddrug7 { ddrug8 } chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after DB01155 .",
        "label": "advise"
    },
    {
        "text": "oral HD00062 : in one study , DB00712 was given to adult diabetics who were already receiving ddrug2 { n = 4 } , ddrug3 { n = 2 } ddrug4 with ddrug5 { n = 3 } or ddrug6 with ddrug7 { n = 6 } .",
        "label": "NA"
    },
    {
        "text": "agents affecting sympathetic activity the sympathetic nervous system may be especially important in supporting blood pressure in patients receiving DB01197 alone or with HD00218 .",
        "label": "NA"
    },
    {
        "text": "results with DB00682 wshow no evidence of interaction with either single or repeated doses of DB00776 .",
        "label": "NA"
    },
    {
        "text": "HD00884 , such as DB01032 and ddrug2 , can inhibit renal tubular secretion of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "the effectiveness of ddrug0 - only pills is reduced by hepatic enzyme-inducing drugs such as the ddrug1 ddrug2 , DB00564 , and ddrug4 , and the HD00886 ddrug6 .",
        "label": "NA"
    },
    {
        "text": "microdosed minipill HD00237 preparations are not recommended for use with DB00459 .",
        "label": "advise"
    },
    {
        "text": "total body clearance of ddrug0 was reduced by an average 22 % and 51 % when DB00993 and DB00688 , respectively , were added to a regimen consisting of ddrug3 , usp { modified } and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "DB00584 iv has been used concomitantly with HD00118 without evidence of clinically significant adverse reactions .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , DB01167 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , DB00224 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "method : this study was a multicenter randomized double-blind study of # patients who were randomly assigned 1:1:1 to receive ddrug0 tablets at doses of # mg , # mg , or # mg twice daily with DB00091 and DB00898 .",
        "label": "NA"
    },
    {
        "text": "reports in the literature suggest that plasma levels of ddrug0 { and its active metabolite ddrug1 } may be increased when DB01229 and DB00997 are used in combination .",
        "label": "mechanism"
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit DB00451 binding to serum proteins or alter the concentrations of serum binding proteins : ddrug1 and related ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , HD00328 , ddrug17 .",
        "label": "mechanism"
    },
    {
        "text": "interactions for ddrug0 { DB00153 , ddrug2 , ddrug3 , and ddrug4 } : DB01432 : ddrug6 has been reported to reduce intestinal absorption of ddrug7 ;",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of ddrug0 : ddrug1 , ddrug2 , HD00218 , ddrug4 { e , g , , ddrug5 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , DB00052 , ddrug11 , ddrug12 , ddrug13 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "the effects ddrug0 on the pharmacokinetics and/or pharmacodynamics of ddrug1 , DB01026 , ddrug3 , ddrug4 , ddrug5 , and DB00682 have been studied in vivo and clinically important interactions have not been found .",
        "label": "NA"
    },
    {
        "text": "experience with co-administration of HD00095 and DB00813 in patients is limited , therefore , consideration should be given to temporarily suspending use of ddrug2 in patients receiving ddrug3 .",
        "label": "NA"
    },
    {
        "text": "hormonal HD00283 co-administration of ddrug1 with an oral ddrug2 has been shown to influence the plasma concentrations of the two hormonal components , ddrug3 { ee } and DB00367 { lng } .",
        "label": "NA"
    },
    {
        "text": "however , when any additional drug , including DB00328 , is added to the treatment of patients on HD00025 therapy , the patients should be observed for alterations of the prothrombin time .",
        "label": "advise"
    },
    {
        "text": "the concomitant use of DB01109 or DB00945 during the first # hours following symptom onset were prohibited in the ninds plat stroke trial .",
        "label": "NA"
    },
    {
        "text": "HD00401 may decrease the hypotensive effect of HD00255 .",
        "label": "effect"
    },
    {
        "text": "HD00175 may increase the clearance of chronic high dose DB00945 .",
        "label": "effect"
    },
    {
        "text": "corresponding values for free DB00313 cmin concentrations were # 3 , # 4 , and # 6 micrograms/ml for 0 , 1200 , and # mg/day DB00949 , respectively .",
        "label": "NA"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { ddrug1 s } , ddrug2 , ddrug3 { HD00026 may decrease the effects of these medicines } , HD00458 { using these medicines with ddrug6 may result in increased cns depressant effects } , ddrug7 , ddrug8 { using these medicines with ddrug9 may change the amount of either medicine that you need to take } , and oral ddrug10 containing ddrug11 { ddrug12 may decrease the effectiveness of these oral ddrug13 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "the in vitro anti-cryptosporidial activity of ddrug0 alone and in combination with DB00207 and DB01017 was investigated .",
        "label": "NA"
    },
    {
        "text": "therefore , when DB00903 and ddrug1 are used concomitantly , the patient should be observed closely to determine if the desired effect of the HD00295 is obtained .",
        "label": "NA"
    },
    {
        "text": "DB00906 has shown no clinically important potentiation of the pharmacodynamic effects of triazo lam or DB02325 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , DB01115 , DB00661",
        "label": "NA"
    },
    {
        "text": "HD00072 at 1 % { m/v } in the presence of free DB00151 had no significant effect on the r-value of ddrug2 compared to ddrug3 alone .",
        "label": "NA"
    },
    {
        "text": "therefore , DB00220 should be administered { with food } one hour after or more than two hours before DB00900 .",
        "label": "advise"
    },
    {
        "text": "other concomitant therapies : in clinical trials , the safety profile in subjects treated with DB00659 concomitantly with ddrug1 , ddrug2 and ddrug3 { including ddrug4 } , or HD00215 was similar to that of subjects taking placebo with these concomitant medications .",
        "label": "NA"
    },
    {
        "text": "DB00999 { ddrug1 } alone or in combination with ddrug2 : concomitant use of DB00999 alone or in combination with ddrug4 is contraindicated .",
        "label": "NA"
    },
    {
        "text": "- drugs that may either increase or decrease plasma DB00252 concentrations include : ddrug1 , vaiproic acid , and HD00746 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : concomitant administration of DB00199 and DB00390 has been reported to result in elevated ddrug3 serum levels .",
        "label": "mechanism"
    },
    {
        "text": "administration of DB00343 concomitantly with DB00571 in five normal volunteers resulted in increased ddrug2 levels in all subjects and bioavailability of ddrug3 was increased approximately 50 % .",
        "label": "mechanism"
    },
    {
        "text": "other drug interactions oral HD00283 DB01202 { 500 mg twice daily } did not influence the pharmacokinetics of an oral ddrug2 containing # mg ddrug3 and # mg ddrug4 , or of the luteinizing hormone and progesterone levels , indicating that impairment of contraceptive efficacy is unlikely .",
        "label": "NA"
    },
    {
        "text": "DB00294 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { DB00091 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "int"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { DB00501 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } DB01026 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "hypotension was more likely to occur if the ddrug0 were a ddrug1 , e , g , , ddrug2 , while left ventricular failure and av conduction disturbances , including complete heart block , were more likely to occur with either DB00661 or DB00343 .",
        "label": "NA"
    },
    {
        "text": "it is recommended that ddrug0 not be used concomitantly with ddrug1 because the effects of concomitant administration of DB00490 with most other HD00456 have not been studied , the concomitant use of ddrug4 with other cns-active drugs should be approached with caution .",
        "label": "NA"
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the HD00555 of drugs may be potentiated by ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , the ddrug6 , ddrug7 and HD00560 , ddrug9 and the ddrug10 , and by other ddrug11 .",
        "label": "effect"
    },
    {
        "text": "the following agents may increase certain actions or side effects of HD00522 , ddrug1 ddrug2 of class { e , g , ddrug3 } , ddrug4 HD00617 { e , g , ddrug6 } , ddrug7 .",
        "label": "NA"
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit DB00451 binding to serum proteins or alter the concentrations of serum binding proteins : ddrug1 and related ddrug2 , ddrug3 , ddrug4 , HD00220 and ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 .",
        "label": "mechanism"
    },
    {
        "text": "oral ddrug0 : in one study , ddrug1 was given to adult diabetics who were already receiving DB01016 { n = 4 } , DB00331 { n = 2 } ddrug4 with ddrug5 { n = 3 } or ddrug6 with ddrug7 { n = 6 } .",
        "label": "NA"
    },
    {
        "text": "conjugation at ddrug0 with ddrug1 moieties significantly improves the intestinal permeation of the hydrophilic molecule HD00070 and the model peptide drugs ddrug3 and HD00071 in vitro , therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future .",
        "label": "NA"
    },
    {
        "text": "ddrug0 such as ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , ddrug5 { e , g , , DB01168 } , ddrug7 { e , g , , ddrug8 } , and ddrug9 { e , g , , ddrug10 } : using these medicines with DB00150 may increase the chance of side effects .",
        "label": "NA"
    },
    {
        "text": "- a HD00535 { ddrug1 } such as DB01050 { ddrug3 , ddrug4 , ddrug5 , others } , ddrug6 { ddrug7 , ddrug8 , ddrug9 } , ddrug10 { ddrug11 , ddrug12 } , ddrug13 { ddrug14 } , ddrug15 { ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , and ddrug21 { ddrug22 , ddrug23 , ddrug24 } ;",
        "label": "NA"
    },
    {
        "text": "the effect of DB00996 on DB00501 was not evaluated .",
        "label": "NA"
    },
    {
        "text": "DB00334 treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than DB00502 , and to broadly the same extent as ddrug2 .",
        "label": "NA"
    },
    {
        "text": "HD00621 are a major contributing factor to HD00118 toxicity .",
        "label": "effect"
    },
    {
        "text": "ddrug0 - and/or ddrug1 - containing ddrug2 , products containing DB01373 { ddrug4 } , ddrug5 containing ddrug6 or other metal cations , or DB00900 { ddrug8 } chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after ddrug9 .",
        "label": "NA"
    },
    {
        "text": "other drug interactions oral ddrug0 DB01202 { 500 mg twice daily } did not influence the pharmacokinetics of an oral ddrug2 containing # mg DB00977 and # mg ddrug4 , or of the luteinizing hormone and progesterone levels , indicating that impairment of contraceptive efficacy is unlikely .",
        "label": "NA"
    },
    {
        "text": "there have been no reported cases from spontaneous reports of drug interaction between HD00114 and DB00320 { ddrug2 } injection , usp .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , DB00636 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , DB00220 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "concurrent administration of drugs possessing nephrotoxic { e , g , , ddrug0 , ddrug1 } , myelotoxic { e , g , , ddrug2 chemotherapy } , cardiotoxic { e , g , , DB00997 } or hepatotoxic { e , g , , DB00563 , ddrug5 } effects with ddrug6 may increase toxicity in these organ systems .",
        "label": "NA"
    },
    {
        "text": "dose adjustment is not recommended , DB01202 had no effect on plasma concentrations of DB00564 , ddrug2 , ddrug3 , or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the concomitant use of DB00813 { ddrug2 transdermal system } with other HD00389 , including but not limited to other ddrug4 , ddrug5 , ddrug6 , ddrug7 { e , g , , ddrug8 } , general ddrug9 , ddrug10 , ddrug11 , and ddrug12 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .",
        "label": "effect"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { DB00501 } HD00220 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , DB01026 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { DB01045 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { DB00400 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , DB00224 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "to determine whether DB01032 has a direct effect on the distribution of ddrug1 , the elimination and distribution of DB01147 was studied in six patients , five lacking kidney function and one with a partially impaired renal function , in the presence or absence of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "results of studies in multiple sclerosis patients taking ddrug0 and concomitant ddrug1 { DB02325 # mcg i m once weekly } or ddrug3 were inconclusive with regard to the need for dose adjustment of the ddrug4 or DB05259 .",
        "label": "NA"
    },
    {
        "text": "- a ddrug0 { HD00615 } such as ddrug2 { ddrug3 , ddrug4 , ddrug5 , others } , ddrug6 { ddrug7 , ddrug8 , ddrug9 } , ddrug10 { ddrug11 , ddrug12 } , ddrug13 { ddrug14 } , ddrug15 { ddrug16 } , ddrug17 { DB00461 } , ddrug19 { ddrug20 } , and ddrug21 { ddrug22 , ddrug23 , ddrug24 } ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 : potentiation of ddrug1 - type { ddrug2 and ddrug3 substrate } HD00025 response is almost always seen in patients receiving DB01118 and can result in serious or fatal bleeding .",
        "label": "NA"
    },
    {
        "text": "- drugs with ototoxic potential : especially in the presence of impaired renal function , the use of parenterally administered DB00887 in patients to whom HD00447 are also being given should be avoided , except in life-threatening conditions .",
        "label": "advise"
    },
    {
        "text": "ddrug0 / ddrug1 / ddrug2 / HD00263 : co-administration of ddrug4 with ddrug5 , HD00024 , ddrug7 , and ddrug8 is likely to lead to an enhancement of effects .",
        "label": "NA"
    },
    {
        "text": "plasma levels of several closely related HD00043 have been reported to be increased by the concomitant administration of ddrug1 or hepatic enzyme inhibitors { e , g , , ddrug2 , ddrug3 } and decreased by the concomitant administration of hepatic enzyme inducers { e , g , , HD00026 , ddrug5 } , and such an effect may be anticipated with ddrug6 as well .",
        "label": "mechanism"
    },
    {
        "text": "HD00218 : patients on ddrug1 , especially those with intravascular volume depletion , may occasionally experience an excessive reduction of blood pressure after initiation of therapy with DB00492 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 should be used with caution in patients receiving - ddrug2 blocking agents { e , g , , ddrug3 , a HD00302 inhibitor } or HD00306 antagonists { e , g , , ddrug6 , a ddrug7 substrate , and ddrug8 , a ddrug9 inhibitor } because of the possible potentiation of bradycardia , sinus arrest , and av block ;",
        "label": "NA"
    },
    {
        "text": "DB01045 : coadministration of ddrug1 and DB01117 suspension results in a significant decrease in average steady - state plasma ddrug3 concentrations .",
        "label": "NA"
    },
    {
        "text": "in patients receiving ddrug0 { DB01033 } or ddrug2 { ddrug3 } , the concomitant administration of 300 - 600 mg of ddrug4 per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of ddrug5 or DB00993 .",
        "label": "NA"
    },
    {
        "text": "coadministration of DB00580 { 40 mg bid { day 1 } and # mg qd { days 2 - 7 } } with DB01016 { 5 mg qd } did not affect either the pharmacokinetics { exposure } or the pharmacodynamics { blood glucose and insulin levels } of ddrug2 .",
        "label": "NA"
    },
    {
        "text": "DB01167 ddrug1 ddrug2 ddrug3 ddrug4 HD00324 ddrug6 ddrug7 large quantities of grapefruit juice { # quart daily }",
        "label": "NA"
    },
    {
        "text": "specific drug interaction studies have not been performed with DB00625 and HD00672 other than ddrug2 and ddrug3 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : clinical studies , as well as post-marketing observations , have shown that ddrug1 can reduce the natriuretic effect of DB00695 and HD00217 in some patients .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a single { 400 mg } and multiple dose { 400 mg tid } study of ddrug1 in epileptic patients { n = 8 } maintained on ddrug2 monotherapy for at least # months , DB00996 had no effect on the steady-state trough plasma concentrations of DB00252 and ddrug5 had no effect on ddrug6 pharmacokinetics .",
        "label": "NA"
    },
    {
        "text": "co-administration of DB00864 and DB00559 resulted in markedly increased plasma concentrations of ddrug2 in animals .",
        "label": "mechanism"
    },
    {
        "text": "DB00390 , ddrug1 , DB00091 : ddrug3 , like other ddrug4 , may affect renal prostaglandins and increase the toxicity of certain drugs .",
        "label": "NA"
    },
    {
        "text": "there have been reports of interactions of DB00199 with DB00564 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , and ddrug13 .",
        "label": "int"
    },
    {
        "text": "potential drug interactions between ddrug0 and other ddrug1 { ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB00252 , ddrug7 and ddrug8 } were also assessed by evaluating the serum concentrations of DB01202 and these ddrug10 during placebo-controlled clinical studies .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the concomitant use of ddrug1 { ddrug2 transdermal system } with other HD00389 , including but not limited to other ddrug4 , ddrug5 , ddrug6 , ddrug7 { e , g , , ddrug8 } , general ddrug9 , HD00219 , ddrug11 , and ddrug12 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .",
        "label": "NA"
    },
    {
        "text": "DB00501 , ddrug1 , and ddrug2 may increase plasma levels of DB00363 , potentially resulting in adverse effects .",
        "label": "mechanism"
    },
    {
        "text": "DB00562 may interact with DB02325 , ddrug2 s , ddrug3 { allergy , cold , and sinus medicines } , diabetic drugs , ddrug4 , ddrug5 , ddrug6 like ddrug7 or ddrug8 , and high blood pressure medications .",
        "label": "int"
    },
    {
        "text": "ddrug0 , HD00502 , ddrug2 { DB00627 , ddrug4 , ddrug5 : skeletal muscle .",
        "label": "NA"
    },
    {
        "text": "if treatment with inhibitors of cyp3a4 activity { such as ddrug0 , HD00446 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , etc , } is indicated , reduction of the DB01222 dose should be considered .",
        "label": "advise"
    },
    {
        "text": "in patients taking ddrug0 , ddrug1 , ddrug2 , ddrug3 , DB00661 , ddrug5 , ddrug6 , and various chemotherapy agents , no effect was shown on the clearance of HD00644 .",
        "label": "NA"
    },
    {
        "text": "in vitro studies evaluating the minimum inhibitory concentration { mic } of DB00512 , ddrug1 , ddrug2 , ddrug3 / flucoxacillin , ddrug4 , ddrug5 , and ddrug6 demonstrated no evidence of incompatibility of these ddrug7 with DB00702 .",
        "label": "NA"
    },
    {
        "text": "antiacid , DB01211 , ddrug1 , ddrug2 , ddrug3 , indanavir , ddrug4 , ddrug5 , phenobarbitol , ddrug6 , ddrug7 , ddrug8 , ritanovir , DB01232 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : when DB00731 # mg three times daily before meals was administered in combination with DB00331 # mg three times daily to patients with type # diabetes , there were no clinically relevant changes in the pharmacokinetics of either agent .",
        "label": "NA"
    },
    {
        "text": "DB00375 - concomitant intake of ddrug1 and ddrug2 may reduce the absorption of DB01022 .",
        "label": "NA"
    },
    {
        "text": "in clinical studies performed with ddrug0 , the concomitant use of oral ddrug1 { DB00682 } , ddrug3 { DB00945 } , ddrug5 { ddrug6 } , and ddrug7 did not significantly affect the pharmacokinetics/pharmacodynamics of ddrug8 .",
        "label": "NA"
    },
    {
        "text": "the ecg changes and/or hypokalemia that may result from the administration of ddrug0 { such as ddrug1 or HD00029 } can be acutely worsened by ddrug3 , especially when the recommended dose of the HD00359 is exceeded .",
        "label": "NA"
    },
    {
        "text": "specific and aspecific treatments of DB14513 depletion are tricky using for example ddrug1 , pharmacological doses of ddrug2 , physiological doses of DB11094 and of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma ddrug0 concentrations include : acute DB02325 intake , ddrug2 , chboramphenicol , DB00475 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 : DB00364 and ddrug3 containing ddrug4 or ddrug5 , as well as formulations containing divalent and trivalent cations such as ddrug6 { DB00900 } , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with ddrug8 and interfere with its bioavailability .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : a case of severe hypoglycemia has been reported in a type ii diabetic patient maintained on DB00839 { 1 gm/day } # days after the addition of DB01142 { 75 mg/day } .",
        "label": "effect"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , HD00326 { ddrug1 s } , ddrug2 , ddrug3 { ddrug4 may decrease the effects of these medicines } , ddrug5 { using these medicines with ddrug6 may result in increased cns depressant effects } , ddrug7 , ddrug8 { using these medicines with HD00026 may change the amount of either medicine that you need to take } , and oral ddrug10 containing ddrug11 { ddrug12 may decrease the effectiveness of these oral ddrug13 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "however , the absolute number of DB02325 - related deaths is far greater than the number of deaths in DB00182 or ddrug2 users .",
        "label": "NA"
    },
    {
        "text": "co-administration of DB00559 decreased the plasma concentrations of HD00433 { a cyp3a4 substrate } by approximately 50 % .",
        "label": "mechanism"
    },
    {
        "text": "administration of DB00700 with other cyp3a4 inhibitors { e , g , , DB00199 # mg bid , ddrug2 # mg qd , ddrug3 # mg tid , ddrug4 # mg qd } resulted in increases in cmax of ddrug5 ranging from # - to # - fold and auc from # - to # - fold .",
        "label": "mechanism"
    },
    {
        "text": "if a patient requires ddrug0 and HD00637 therapy , it is suggested that ddrug2 , ddrug3 , or ddrug4 { ddrug5 and ddrug6 } be used as alternatives to DB00501 , as these agents have no effect on the pharmacokinetic profile of ddrug8 .",
        "label": "NA"
    },
    {
        "text": "co-administration : concomitant use of DB00278 with ddrug1 , ddrug2 , and other HD00326 may increase the risk of bleeding .",
        "label": "effect"
    },
    {
        "text": "other drugs : in healthy volunteers , ddrug0 , DB00252 , ddrug2 , ddrug3 , ddrug4 , hormone replacement therapy { a combination of conjugated HD00220 and ddrug6 } , ddrug7 { ddrug8 and ddrug9 } and ddrug10 did not affect the pharmacokinetics of ddrug11 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , DB00503 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , DB00277 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect : HD00175 , ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , ddrug5 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , DB00052 , ddrug11 , ddrug12 , ddrug13 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of ddrug0 and DB00908 resulted in slight increases in plasma DB00280 levels and slight decreases in plasma ddrug3 levels .",
        "label": "NA"
    },
    {
        "text": "drug-drug interactions given the primary cns effects of DB01238 , caution should be used when DB01238 is taken in combination with other ddrug2 and ddrug3 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : as with some other HD00532 , concurrent administration of ddrug2 with DB00277 may lead to elevated serum concentrations of ddrug4 and prolongation of its elimination half-life .",
        "label": "mechanism"
    },
    {
        "text": "poor metabolizers of DB04840 : interactions of ddrug1 with strong inhibitors of cyp2d6 { such as DB00908 , ddrug3 , ddrug4 , and ddrug5 } have not been studied , but these drugs would be expected to increase blood levels of the r { + } enantiomer of ddrug6 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB01432 binds both ddrug2 and DB00279 in the intestine , thus impairing absorption of these ddrug4 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , DB01232 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { HD00531 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : ddrug1 ; ddrug2 ; DB01159 ; certain ddrug4 , especially the ddrug5 and ddrug6 ; DB14507 ; ddrug8 salts ; ddrug9 ; and ddrug10 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 should not be administered concomitantly with potent HD00105 such as ddrug2 and DB00903 as the potential for ototoxicity is enhanced by the combination .",
        "label": "NA"
    },
    {
        "text": "drugs which inhibit cyp 3a4 { e , g , , DB01026 , ddrug1 such as DB00199 } have the potential to result in increased plasma concentrations of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "caution should be exercised when the following drugs are administered concomitantly with DB00190 { ddrug1 } given with ddrug2 or ddrug3 - DB01235 combination products .",
        "label": "NA"
    },
    {
        "text": "therefore , co-administration of HD00043 with other drugs that are metabolized by this isoenzyme , including other ddrug1 , ddrug2 , ddrug3 , and ddrug4 { eg , ddrug5 , DB01195 , and ddrug7 } , or that inhibit this enzyme { eg , ddrug8 } , should be approached with caution .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : DB00673 , when given as # mg on day # and # mg/day on days # and 3 , decreased the auc of DB01124 { a cyp2c9 substrate } by 23 % on day 4 , 28 % on day 8 , and 15 % on day 15 , when a single dose of ddrug3 # mg was admini , stered orally prior to the administration of the 3-day regimen of ddrug4 and on days 4,8 , and 15 .",
        "label": "NA"
    },
    {
        "text": "cns-active drugs ddrug0 an additive effect on psychomotor performance was seen with coadministration of DB00402 and DB00898 # g/kg for up to # hours after ddrug3 administration .",
        "label": "effect"
    },
    {
        "text": "however , patients on DB00390 may show elevations of ddrug1 concentrations after initiation of therapy with DB01240 , which may be clinically significant in patients prone to ddrug3 toxicity .",
        "label": "mechanism"
    },
    {
        "text": "DB14507 - coadministration of racemic DB00215 { 40 mg/day for # days } and ddrug2 { 30 mmol/day for # days } had no significant effect on the pharmacokinetics of ddrug3 or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as HD00269 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , DB00231 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "- a HD00764 such as ddrug1 { ddrug2 , HD00765 , others } , ddrug4 { ddrug5 , others } , ddrug6 { ddrug7 , ddrug8 , others } , and others ;",
        "label": "NA"
    },
    {
        "text": "the ddrug0 , including DB00404 , produce additive cns depressant effects when co-administered with other HD00281 , ddrug3 , ddrug4 , ddrug5 , and other drugs which themselves produce cns depression .",
        "label": "effect"
    },
    {
        "text": "therefore , if ddrug0 is administered with DB00872 , the clinician should be alert to the possibility of increases in DB00390 levels .",
        "label": "NA"
    },
    {
        "text": "limited data in patients receiving known enzyme inducers { ddrug0 , ddrug1 , DB00564 } indicate only a 30 % increase in the rate of DB01195 elimination .",
        "label": "mechanism"
    },
    {
        "text": "before taking ddrug0 , tell your doctor if you are taking any of the following medicines : - DB00945 or another ddrug2 such as ddrug3 { ddrug4 } , ddrug5 { ddrug6 , others } , ddrug7 { ddrug8 } , ddrug9 { ddrug10 } , or ddrug11 { DB06724 } ;",
        "label": "NA"
    },
    {
        "text": "DB00269 may interact with ddrug1 , ddrug2 , ddrug3 , ddrug4 , DB01373 supplements , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , and ddrug13 .",
        "label": "int"
    },
    {
        "text": "experience with co-administration of ddrug0 and ddrug1 in patients is limited , therefore , consideration should be given to temporarily suspending use of HD00095 in patients receiving DB00813 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 ddrug1 DB00199 ddrug3 ddrug4 ddrug5 ddrug6 DB00091 large quantities of grapefruit juice { # quart daily }",
        "label": "NA"
    },
    {
        "text": "the effects of medicinal products with similar properties such as inotropes ddrug0 , ddrug1 , ddrug2 , ddrug3 and DB01166 may be exacerbated by DB00261 .",
        "label": "effect"
    },
    {
        "text": "DB00482 should be introduced at the lowest recommended dose in patients receiving DB00196 .",
        "label": "advise"
    },
    {
        "text": "the availability of potent ddrug0 { HD00112 } - based regimens for ddrug2 therapy and concerns regarding ddrug3 { HD00111 } - related metabolic disturbances have led to significant shifts in treatment practices in hiv infection .",
        "label": "NA"
    },
    {
        "text": "another study showed that DB00969 had no clinically significant effect on plasma concentrations of the oral ddrug1 ddrug2 and DB00367 { cyp3a4 substrates } .",
        "label": "NA"
    },
    {
        "text": "based on adult data , lower doses of ddrug0 may be needed following coadministration of drugs which are reported to decrease ddrug1 elimination { e , g , , DB00501 and ddrug3 } and higher ddrug4 doses may be needed following coadministration of drugs that increase DB00201 elimination { e , g , , ddrug6 and ddrug7 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and DB01437 should not be administered to patients receiving HD00027 .",
        "label": "advise"
    },
    {
        "text": "HD00026 may decrease the effectiveness of oral ddrug1 , certain ddrug2 , ddrug3 , ddrug4 , ddrug5 , HD00326 , and ddrug7 .",
        "label": "effect"
    },
    {
        "text": "both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ddrug0 is administered in combination with other HD00261 such as HD00026 , ddrug3 , ddrug4 , or inhalation general ddrug5 .",
        "label": "NA"
    },
    {
        "text": "thus , smaller doses of DB00640 may be effective in the presence of DB00975 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 absorption : the following agents may bind and decrease absorption of DB00451 from the gastrointestinal tract : HD00845 , ddrug3 resin , ddrug4 , ddrug5 , ddrug6 , soybean flour { e , g , , infant formula } , ddrug7 .",
        "label": "mechanism"
    },
    {
        "text": "conjugation at ddrug0 with ddrug1 moieties significantly improves the intestinal permeation of the hydrophilic molecule ddrug2 and the model peptide drugs DB00781 and HD00071 in vitro , therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future .",
        "label": "NA"
    },
    {
        "text": "however , co-administration of ddrug0 with DB01370 - and ddrug2 - containing ddrug3 { 51 meq } or ddrug4 with DB00927 , had no significant effect on the rate or extent of ddrug6 absorption after administration of a 40-mg oral dose .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and DB01045 should not beadministered concomitantly becausedecreases in DB00238 plasmaconcentrations may reduce the efficacy ofthe drug .",
        "label": "NA"
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the HD00555 of drugs may be potentiated by ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , the ddrug6 , ddrug7 and ddrug8 , HD00275 and the ddrug10 , and by other ddrug11 .",
        "label": "effect"
    },
    {
        "text": "in a parallel group drug interaction study comparing the intravenous prodrug form of DB00580 at # mg bid { n = 10 } vs placebo { n = 9 } , ddrug1 had no effect on in vitro DB00945 - mediated inhibition of arachidonate - or collagen-stimulated platelet aggregation .",
        "label": "NA"
    },
    {
        "text": "the co-administration of ddrug0 with iv HD00337 such as DB00727 , ddrug3 , ddrug4 , or iv ddrug5 has not been evaluated { these drugs were not co-administered with ddrug6 in clinical trials } .",
        "label": "NA"
    },
    {
        "text": "patients receiving both DB00328 and DB00695 should be observed closely to determine if the desired diuretic and/or antihypertensive effect of ddrug2 is achieved .",
        "label": "advise"
    },
    {
        "text": "ventricular tachycardia induced by DB01092 was generally converted to sinus rhythm following administration of ddrug1 , ddrug2 , or DB00450 but not after administration of ddrug4 alone or after ddrug5 .",
        "label": "effect"
    },
    {
        "text": "no interaction with the HD00042 ddrug1 was shown in a single-dose study with DB00494 without coadministered ddrug3 / ddrug4 .",
        "label": "NA"
    },
    {
        "text": "effects of DB00199 on DB00949 the coadministration of ddrug2 { 1000 mg/day } for # days did not alter the pharmacokinetic parameters of cmax , cmin , auc , ci/kg or tmax at ddrug3 daily doses of # or # mg/day in # otherwise healthy subjects with epilepsy .",
        "label": "NA"
    },
    {
        "text": "ddrug0 in combination with DB00575 enhances the manifestation of corneal lesions in rats epidural injection ddrug2 may potentiate the cns-depressive effect of ddrug3 , ddrug4 or other HD00562 .",
        "label": "NA"
    },
    {
        "text": "pregnancy HD00220 and ddrug1 - containing oral HD00283 increase tbg concentrations .",
        "label": "NA"
    },
    {
        "text": "DB00405 can interact with ddrug1 or other ddrug2 { may potentiate the cns depressant effects of either these medications or ddrug3 } , ddrug4 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug5 } , and ddrug6 { concurrent use with ddrug7 may prolong and intensify the anticholinergic and cns depressant effects of HD00388 } .",
        "label": "NA"
    },
    {
        "text": "the intensity , uniformity and time course of ddrug0 interference by ddrug1 , DB00418 , ddrug3 , ddrug4 and ddrug5 were systematically investigated in # patients receiving DB04665 therapy .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { DB00252 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , DB00231 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "may interact with wthionamide { HD00581 } and DB00951 { ddrug2 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00681 - induced hypokalemia may enhance the curariform effect of HD00320 { e , g , , ddrug3 } .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : because ddrug1 does not affect the pharmacokinetics of DB01435 , interactions with other HD00096 metabolized via the same cytochrome isozymes are not expected .",
        "label": "NA"
    },
    {
        "text": "in clinical studies , ddrug0 has been co-administered with other anti-asthma medications , including inhaled and oral HD00650 , and inhaled HD00175 , with no evidence of increased frequency of adverse events or laboratory abnormalities .",
        "label": "NA"
    },
    {
        "text": "ddrug0 ddrug1 , DB00897 DB00604 ergot derivatives ddrug4",
        "label": "NA"
    },
    {
        "text": "oral HD00283 and other hormonalmethods of birth control should not be usedas the sole method of contraception inwomen taking DB00238 , since nevirapinemay lower the plasma levels of thesemedications .",
        "label": "advise"
    },
    {
        "text": "to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma { hiv-nhl } , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the ddrug0 , ddrug1 , ddrug2 , and ddrug3 { chop } chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen { i , e , , ddrug4 , ddrug5 , ddrug6 , and ddrug7 with ddrug8 plus DB00290 } without receiving HD00056 therapy .",
        "label": "NA"
    },
    {
        "text": "DB00977 and DB00717 : coadministration of ddrug2 with ddrug3 resulted in a 47 % decrease in ddrug4 and an 18 % decrease in ddrug5 plasma concentrations .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 , ddrug2 , and DB01109 the in vitro binding of DB00682 to plasma proteins is only slightly reduced by ddrug5 { # % control vs # % } when ddrug6 plasma concentrations reach # to10 m g/ml .",
        "label": "NA"
    },
    {
        "text": "other drugs : in healthy volunteers , ddrug0 , DB00252 , ddrug2 , ddrug3 , ddrug4 , hormone replacement therapy { a combination of conjugated ddrug5 and ddrug6 } , DB06724 { ddrug8 and ddrug9 } and ddrug10 did not affect the pharmacokinetics of ddrug11 .",
        "label": "NA"
    },
    {
        "text": "drugs that reduce the number of blood platelets by causing bone marrow depression { such as ddrug0 } or drugs which inhibit platelet function { eg , ddrug1 and other ddrug2 , ddrug3 , ddrug4 , DB00636 , ddrug6 } may increase the bleeding tendency produced by HD00326 without altering prothrombin time determinations .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : concomitant administration of DB00586 and ddrug2 is not recommended because ddrug3 is displaced from its binding sites during the concomitant administration of DB00945 , resulting in lower plasma concentrations , peak plasma levels , and auc values .",
        "label": "NA"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : DB01045 ddrug10 ddrug11 , ddrug12 gi motility agents : DB00604",
        "label": "NA"
    },
    {
        "text": "substances that are potent inhibitors of cyp3a4 activity { eg , DB01026 and ddrug1 } decrease ddrug2 metabolism and increase DB00317 plasma concentrations .",
        "label": "mechanism"
    },
    {
        "text": "HD00220 , including oral HD00283 : ddrug2 may decrease the hepatic metabolism of certain ddrug3 , thereby increasing their effect .",
        "label": "NA"
    },
    {
        "text": "the administration of local ddrug0 containing ddrug1 or DB00368 to patients receiving HD00275 , ddrug4 or ddrug5 may produce severe , prolonged hypotension or hypertension .",
        "label": "effect"
    },
    {
        "text": "- a HD00535 { ddrug1 } such as ddrug2 { ddrug3 , ddrug4 , ddrug5 , others } , ddrug6 { ddrug7 , ddrug8 , ddrug9 } , ddrug10 { ddrug11 , DB00586 } , ddrug13 { ddrug14 } , ddrug15 { ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , and ddrug21 { ddrug22 , ddrug23 , ddrug24 } ;",
        "label": "NA"
    },
    {
        "text": "DB01061 should not be administered concomitantly with ddrug1 , ddrug2 , ddrug3 , ddrug4 , or DB00684 .",
        "label": "advise"
    },
    {
        "text": "results : the geometric mean { 90 % confidence interval } whole blood ddrug0 area under the plasma concentration time-curve increased 60 % { 35 % -90 % } , from # to # ng x h/ml , and maximum concentration increased 43 % { 14 % -81 % } , from # to # ng/ml , with DB00343 coadministration , whereas the mean elimination half-life of DB00877 decreased slightly , from # to # hours .",
        "label": "NA"
    },
    {
        "text": "concurrent use of ddrug0 with ddrug1 { e , g , , ddrug2 , ddrug3 , HD00262 , and ddrug5 } may result in increased HD00461 effects .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { HD00254 } and DB01274 may interfere with the effect of each other when administered concurrently .",
        "label": "effect"
    },
    {
        "text": "however , in a study of # normal subjects , concurrent administration of DB00945 decreased DB01009 protein binding and increased ddrug2 plasma clearance from # l/kg/h without ddrug3 to # l/kg/h with ddrug4 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : coadministration of DB00564 { 200 mg bid } , a potent cyp3a4 inducer , with DB01238 { 30 mg qd } resulted in an approximate 70 % decrease in cmax and auc values of both ddrug3 and its active metabolite , ddrug4 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : DB00681 - induced hypokalemia may enhance the curariform effect of ddrug2 { e , g , , DB01199 } .",
        "label": "effect"
    },
    {
        "text": "ddrug0 or ddrug1 : the risk of myopathy/rhabdomyolysis is increased when either DB01118 or DB00661 is used concomitantly with a closely related member of the ddrug4 { see warnings , myopathy/rhabdomyolysis } .",
        "label": "NA"
    },
    {
        "text": "this allows DB00901 to open air passages , increasing the effectiveness of the HD00429 .",
        "label": "effect"
    },
    {
        "text": "DB00836 and DB00295 { # and # mg/kg , s , c , } inhibited the ddrug2 { # mg/kg , p , o , } - induced diarrhea in cecectomized rats .",
        "label": "NA"
    },
    {
        "text": "plasma concentrations of ddrug0 are decreased when administered with HD00374 containing ddrug2 , ddrug3 , or DB01370 .",
        "label": "NA"
    },
    {
        "text": "we examined the effect of exogenous DB00783 on the changes in serum steroid hormone levels induced by a nonlethal dose of escherichia coli HD00168 in male rats and the deaths due to nonlethal and lethal doses of ddrug2 .",
        "label": "NA"
    },
    {
        "text": "the prior administration of DB00202 does not enhance the duration , but quickens the onset and may increase the depth , of neuromuscular block induced by DB00732 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , DB00812 , ddrug37 { ddrug38 } , DB01045 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : several short-term controlled studies failed to wshow that DB01050 significantly affected prothrombin times or a variety of other clotting factors when administered to individuals on HD00724 .",
        "label": "NA"
    },
    {
        "text": "compounds in these categories result in a decreased efficacy of DB01200 : ddrug1 , ddrug2 , DB01233 , ddrug4 .",
        "label": "effect"
    },
    {
        "text": "on administration of oral DB01118 , the need for HD00118 therapy should be reviewed and the dose reduced by approximately 50 % or discontinued .",
        "label": "advise"
    },
    {
        "text": "for DB00390 auc { 0-infinity } , auc { 0 - 24 } , and cmax , the geometric mean ratios { 90 % confidence interval } for { DB00533 + ddrug2 / placebo + ddrug3 } were # { # , # } , # { # , # } , and # { # , # } , respectively .",
        "label": "NA"
    },
    {
        "text": "if treatment with inhibitors of cyp3a4 activity { such as ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , DB00199 , etc , } is indicated , reduction of the DB01222 dose should be considered .",
        "label": "advise"
    },
    {
        "text": "other drugs : in healthy volunteers , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , hormone replacement therapy { a combination of conjugated ddrug5 and HD00642 } , ddrug7 { ddrug8 and DB09104 } and ddrug10 did not affect the pharmacokinetics of ddrug11 .",
        "label": "NA"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 HD00303 : ddrug2 , DB00908 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { HD00548 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , DB01232 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "therefore , if ddrug0 is co-administered with DB00176 , its dose should be reduced to one third of the usual daily maintenance dose and plasma concentrations of DB00277 should to monitored .",
        "label": "NA"
    },
    {
        "text": "DB01032 : may decrease renal tubular secretion of DB00415 resulting in increased blood levels and/or ddrug2 toxicity .",
        "label": "mechanism"
    },
    {
        "text": "concurrent use of HD00239 with oral HD00283 may render oral ddrug2 less effective .",
        "label": "effect"
    },
    {
        "text": "these drugs include the HD00217 and other ddrug1 , HD00175 , ddrug3 , ddrug4 , ddrug5 , oral ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , and ddrug11 .",
        "label": "NA"
    },
    {
        "text": "the concomitant use of transdermal ddrug0 with DB00503 or other potent 3a4 inhibitors such as ddrug2 , ddrug3 , DB13179 , ddrug5 , ddrug6 , and nefazadone may result in an increase in ddrug7 plasma concentrations .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of an DB01370 - containing DB06724 had no significant effect in the bioavailability of ddrug2 .",
        "label": "NA"
    },
    {
        "text": "DB00612 should be used with care when HD00425 or inhibitors of av conduction , such as certain ddrug2 { particularly of the ddrug3 -lsb- ddrug4 -rsb- and ddrug5 -lsb- ddrug6 -rsb- classes } , or ddrug7 , such as ddrug8 , are used concurrently .",
        "label": "advise"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of ddrug0 : ddrug1 , ddrug2 , HD00218 , ddrug4 { e , g , , ddrug5 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 { e , g , , in oral HD00283 } .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of ddrug0 : ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , DB00668 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , HD00809 , ddrug12 , ddrug13 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "medications can interfere with folate utilization , including : ddrug0 { such as ddrug1 , and ddrug2 } ddrug3 { sometimes prescribed to control blood sugar in type # diabetes } DB00795 { used to control inflammation associated with crohn_disease and ulcerative colitis } DB00384 { a ddrug6 } ddrug7 there has been concern about the interaction between ddrug8 and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "HD00322 : ddrug1 , ddrug2 , ddrug3 , or HD00239 may interfere with the bactericidal effect of ddrug5 .",
        "label": "NA"
    },
    {
        "text": "the effects of concomitant DB00252 administration on the steady-state pharmacokinetics of DB01224 .",
        "label": "NA"
    },
    {
        "text": "when DB00572 and ddrug1 are used together , the signs of atropinization { flushing , mydriasis , tachycardia , dryness of the mouth and nose } may occur earlier than might be expected than when ddrug2 is used alone because DB00733 may potentiate the effect of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , DB01076 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { HD00531 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "- a HD00295 { water pill } such as ddrug1 { DB00999 , ddrug3 } , ddrug4 { ddrug5 } , and others ;",
        "label": "NA"
    },
    {
        "text": "avoid the use of preparations such as HD00799 and local ddrug1 which contain any ddrug2 { e , g , , ddrug3 , DB00368 } , since it has been reported that ddrug5 can potentiate the effects of catecholamines .",
        "label": "NA"
    },
    {
        "text": "HD00219 and HD00340 may reduce or reverse the pressor effect of ddrug2 .",
        "label": "NA"
    },
    {
        "text": "renal function should be carefully monitored , especially if higher dosages of the HD00249 are to be administered or if therapy is prolonged , because of the potential nephrotoxicity and ototoxicity of HD00496 .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 : the effect of oral HD00283 on the pharmacokinetics of ddrug2 { DB00320 } injection , usp has not been studied .",
        "label": "NA"
    },
    {
        "text": "increased toxicity { cns depression } : HD00261 , HD00343 , ddrug2 , ddrug3 .",
        "label": "NA"
    },
    {
        "text": "no important interactions to date DB00922 does not have clinically important pharmacokinetic interactions with ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB01020 , ddrug7 , ddrug8 or ddrug9 .",
        "label": "NA"
    },
    {
        "text": "using in situ hybridization , we observed that ddrug0 caused a rapid and transient dose-dependent increase in arc mrna level in the striatum and cortex that was abolished by pretreatment with the specific drd1 antagonist HD00016 but not by an HD00017 ddrug3 .",
        "label": "NA"
    },
    {
        "text": "there are no clinical data on concomitant use of DB01135 and other nondepolarizing HD00547 .",
        "label": "NA"
    },
    {
        "text": "HD00021 attenuates , but ddrug1 potentiates , the acute locomotor effects of DB00295 ;",
        "label": "effect"
    },
    {
        "text": "in a study of schizophrenic patients who received ddrug0 under steady state conditions , DB00176 or DB00715 was added in # and # patients , respectively .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in vitro and/or in vivo data indicate that DB00196 , ddrug2 , and oral ddrug3 markedly inhibit the metabolism of DB00604 , which can result in an increase in plasma ddrug5 levels and prolongation of the qt interval on the ecg .",
        "label": "mechanism"
    },
    {
        "text": "in addition , results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance { ddrug0 , DB00238 , ddrug2 , ddrug3 , or ddrug4 } with DB00520 may result in clinically meaningful reductions in ddrug6 concentrations .",
        "label": "mechanism"
    },
    {
        "text": "specific effects of DB00949 on other HD00703 ddrug2 : ddrug3 causes an increase in steady-state ddrug4 plasma concentrations .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , oral : co-administration of HD00175 and DB00682 usually results in inhibition of response to ddrug3 , although there have been some conflicting reports .",
        "label": "effect"
    },
    {
        "text": "therefore , co-administration of HD00043 with other drugs that are metabolized by this isoenzyme , including other ddrug1 , ddrug2 , ddrug3 , and ddrug4 { eg , ddrug5 , ddrug6 , and ddrug7 } , or that inhibit this enzyme { eg , DB00908 } , should be approached with caution .",
        "label": "advise"
    },
    {
        "text": "single doses of either DB01432 or ddrug1 ddrug2 bind the DB00999 and reduce its absorption from the gastrointestinal tract by up to # and # percent , respectively .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : concomitant administration of ddrug1 containing ddrug2 or DB01370 with ddrug4 chewable/dispersible buffered tablets or pediatric powder for oral solution may potentiate adverse events associated with the DB06724 components .",
        "label": "NA"
    },
    {
        "text": "ddrug0 should be used with caution , if at all , when potent inhalational HD00264 such as ddrug2 are employed because of potential to sensitize the myocardium to effects of HD00399 .",
        "label": "NA"
    },
    {
        "text": "DB00945 : concomitant administration of ddrug1 and ddrug2 is not recommended because DB00586 is displaced from its binding sites during the concomitant administration of ddrug4 , resulting in lower plasma concentrations , peak plasma levels , and auc values .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and HD00466 { congestive heart failure post-myocardial infarction } - in ephesus , # { 91 % } patients receiving ddrug2 # to # mg also received ddrug3 or ddrug4 { HD00685 / ddrug6 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 binds both DB00451 and DB00279 in the intestine , thus impairing absorption of these ddrug4 .",
        "label": "NA"
    },
    {
        "text": "cns-active drugs ddrug0 an additive effect on psychomotor performance was seen with coadministration of DB00402 and ddrug2 # g/kg for up to # hours after DB00898 administration .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB02325 has been studied in rheumatoid_arthritis patients taking concomitant DB00563 .",
        "label": "NA"
    },
    {
        "text": "in separate single or multiple dose pharmacokinetic interaction studies with DB00310 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , and ddrug8 , the bioavailability of DB14207 was not altered by coadministration of ddrug10 with any one of these drugs .",
        "label": "NA"
    },
    {
        "text": "this drug may interact with ddrug0 or other ddrug1 { may potentiate the cns depressant effects of either these medications or ddrug2 } , HD00444 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug4 } , and ddrug5 { concurrent use with ddrug6 may prolong and intensify the anticholinergic and cns depressant effects of HD00388 } .",
        "label": "NA"
    },
    {
        "text": "in post-marketing experience , bleeding has been reported in patients on concomitant treatment with HD00326 and DB00328 .",
        "label": "effect"
    },
    {
        "text": "the doses of DB01183 required to antagonize the effects of HD00157 were more than # times higher than those required to antagonize the effects of ddrug2 .",
        "label": "effect"
    },
    {
        "text": "caution should be used when administering or taking ddrug0 with DB01026 and other strong cyp3a4 inhibitors such as , but not limited to , ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB01149 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { ddrug12 } , and ddrug13 .",
        "label": "NA"
    },
    {
        "text": "because of reports of prolongation of the prothrombin time beyond the therapeutic range in patients taking concurrent ddrug0 and ddrug1 , it is suggested that the prothrombin time be monitored carefully , and the dose of DB00682 or other DB04665 - like drugs should be adjusted accordingly , in patients taking both drugs .",
        "label": "NA"
    },
    {
        "text": "DB01058 : in the fed state , ddrug1 { 40 mg/kg } increased mean maximum plasma concentration and area under the curve of DB13871 by about 50 % in healthy subjects { n = 10 } compared with a separate group of subjects { n = 6 } given ddrug3 alone .",
        "label": "NA"
    },
    {
        "text": "nephrotoxicity has been reported following concomitant administration of HD00485 with HD00447 or potent ddrug2 such as ddrug3 .",
        "label": "effect"
    },
    {
        "text": "hypotension - patients on diuretic therapy : patients on HD00218 , and especially those in whom diuretic therapy was recently instituted , may occasionally experience an excessive reduction of blood pressure after initiation of therapy with DB00722 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : in a single dose study { n = 6 } , ingestion of an DB06724 containing # - gram of ddrug2 with 500-mg of ddrug3 increased the cmax and auc of DB00784 by 125 % and 36 % , respectively , a number of compounds are inhibitors of cyp2c9 including ddrug5 , ddrug6 and ddrug7 .",
        "label": "NA"
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma DB00252 concentrations include : acute ddrug1 intake , ddrug2 , chboramphenicol , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , DB00422 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21",
        "label": "mechanism"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : ddrug1 ; DB00753 ; ddrug3 ; certain ddrug4 , especially the ddrug5 and ddrug6 ; ddrug7 ; ddrug8 salts ; DB01035 ; and ddrug10 .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { DB00564 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } DB01235 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 to patients receiving DB13984 or ddrug2 such as DB01159 which sensitize the myocardium , may induce cardiac arrhythmia , .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : when DB00749 is administered with DB00945 , its protein binding is reduced , although the clearance of free ddrug3 is not altered .",
        "label": "mechanism"
    },
    {
        "text": "DB01057 potentiates other HD00632 such as ddrug2 or ddrug3 and ddrug4 .",
        "label": "effect"
    },
    {
        "text": "in vivo interaction studies in humans have demonstrated that ddrug0 and ddrug1 do not affect the pk properties of ddrug2 , nor does DB00261 affect the pk properties of DB00390 or ddrug5 .",
        "label": "NA"
    },
    {
        "text": "however , co-administration of DB00476 with ddrug1 - and DB14513 - containing ddrug3 { 51 meq } or ddrug4 with ddrug5 , had no significant effect on the rate or extent of ddrug6 absorption after administration of a 40-mg oral dose .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB01432 binds both DB00451 and ddrug3 in the intestine , thus impairing absorption of these ddrug4 .",
        "label": "mechanism"
    },
    {
        "text": "caution is therefore advised in the coadministration of DB00332 inhalation aerosol with other HD00315 - containing drugs .",
        "label": "advise"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { DB00252 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , DB01045 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "therefore the , combination of DB00026 with other ddrug1 , including DB02325 , may also result i n similar toxicities .",
        "label": "effect"
    },
    {
        "text": "there have been postmarketing reports of drug interactions when ddrug0 is coadministered with DB00604 , resulting in qt prolongation , cardiac arrythmias , ventricular tachycardia , ventricular fibrulation , and torsades de pointes , most like due to inhibition of hepatic metabolism of ddrug2 by DB00199 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : administration of morning and lunch doses of DB00731 # mg in combination with a single 75-mg dose of DB00586 in healthy volunteers resulted in no significant changes to the pharmacokinetics of either agent .",
        "label": "NA"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : ddrug1 ; DB00753 ; ddrug3 ; certain ddrug4 , especially the ddrug5 and ddrug6 ; ddrug7 ; DB14513 salts ; ddrug9 ; and ddrug10 .",
        "label": "NA"
    },
    {
        "text": "if a patient requires ddrug0 and ddrug1 therapy , it is suggested that DB00338 , ddrug3 , or ddrug4 { ddrug5 and ddrug6 } be used as alternatives to DB00501 , as these agents have no effect on the pharmacokinetic profile of ddrug8 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : there have been rare reports of increased prothrombin time in patients taking HD00423 to whom DB01115 was administered .",
        "label": "effect"
    },
    {
        "text": "interaction with HD00389 other than HD00100 has not been specifically studied ;",
        "label": "NA"
    },
    {
        "text": "DB00311 may increase the action of HD00609 , ddrug2 , ddrug3 , and ddrug4 .",
        "label": "effect"
    },
    {
        "text": "inhibitors of cyp1a2 : concomitant use of ddrug0 with DB00176 , an inhibitor of cyp1a2 , results in approximately a 6-fold increase in auc and about a # - fold increase in cmax of DB00476 .",
        "label": "NA"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : ddrug1 ; DB00753 ; ddrug3 ; certain HD00002 , especially the ddrug5 and ddrug6 ; ddrug7 ; ddrug8 salts ; ddrug9 ; and ddrug10 .",
        "label": "NA"
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a HD00533 , including ddrug1 , with multivalent cation-containing products such as ddrug2 or ddrug3 ddrug4 , ddrug5 , ddrug6 chewable/buffered tablets or pediatric powder , or products containing ddrug7 , DB01592 , or ddrug9 may substantially decrease the absorption of ddrug10 , resulting in serum and urine levels considerably lower than desired .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : concomitant administration of DB00575 with HD00482 may potentiate blood-pressure - and heart-rate-lowering effects .",
        "label": "effect"
    },
    {
        "text": "in a drug interaction study , co-administration of orally inhaled ddrug0 and oral DB00199 , an inhibitor of cytochrome p450 3a4 , had no effect on the pharmacokinetics of either HD00528 or ddrug3 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , HD00002 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , DB01232 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "the effects of ddrug0 and HD00019 upon ddrug2 { DB03575 } - induced locomotion and behavioral changes in mice .",
        "label": "NA"
    },
    {
        "text": "DB02709 { 5 - 35 micromol/l } induced concentration-dependent relaxation of mesenteric arteries preconstricted with DB00368 { 8 micromol/l } or ddrug2 { 125 mmol/l } from both lean and dietary-obese rats .",
        "label": "NA"
    },
    {
        "text": "monitor HD00372 levels or the therapeutic effect for which DB00945 is given ;",
        "label": "NA"
    },
    {
        "text": "the HD00100 are a family of ddrug1 and HD00200 .",
        "label": "NA"
    },
    {
        "text": "hypotension was more likely to occur if the ddrug0 were a ddrug1 , e , g , , DB01115 , while left ventricular failure and av conduction disturbances , including complete heart block , were more likely to occur with either DB00661 or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "concomitant use of ddrug0 with ddrug1 , ddrug2 , HD00026 , or other HD00389 may have an additive effect .",
        "label": "NA"
    },
    {
        "text": "DB00580 caused a statistically significant increase in plasma exposures of ddrug1 and ddrug2 { 12 % and 15 % , respectively } , and in the pharmacodynamic effects { prothrombin time , measured as inr } of DB00682 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : in a single dose study in normal volunteers , coadministration of DB00571 had a small effect on the rate but no effect on the extent of DB00270 bioavailability .",
        "label": "NA"
    },
    {
        "text": "moreover , its activity was enhanced when it was combined with either DB00207 or DB01017 with 90 % parasite reduction at the highest concentration tested .",
        "label": "NA"
    },
    {
        "text": "plasma ddrug0 concentrations may need to be monitored and the dose of the ddrug1 may need to be reduced if a HD00312 is co-administered with DB00476 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { DB01076 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , DB00812 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : since ddrug1 is a ddrug2 , it is possible that HD00339 , such as the ddrug4 { ddrug5 , ddrug6 , ddrug7 } or DB01233 , may diminish the effectiveness of ddrug9 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 HD00524 may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation , the discontinuance of DB01432 ddrug3 could pose a hazard to health if a potentially toxic drug such as ddrug4 has been filtrated to a maintenance level while the patient was taking ddrug5 ddrug6 .",
        "label": "NA"
    },
    {
        "text": "these medications have included ddrug0 , ddrug1 , ddrug2 , ddrug3 , HD00209 , intravenous and oral DB14049 , ddrug6 , and ddrug7 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in vitro and/or in vivo data show that ddrug1 , DB00199 , and ddrug3 markedly inhibit the metabolism of ddrug4 , which can result in an increase in plasma DB00604 levels and prolongation of the qt interval on the ecg .",
        "label": "NA"
    },
    {
        "text": "all subjects received ddrug0 { 1,200 mg twice a day } for # days , followed by a 7-day washout period , followed by either DB00615 { 300 mg once a day -lsb- qd -rsb- } { cohort 1 } or DB01045 { 600 mg qd } { cohort 2 } for # days .",
        "label": "NA"
    },
    {
        "text": "ddrug0 can interact with ddrug1 or other ddrug2 { may potentiate the cns depressant effects of either these medications or ddrug3 } , HD00444 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug5 } , and ddrug6 { concurrent use with HD00388 may prolong and intensify the anticholinergic and cns depressant effects of ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "interactions may also occur with the following : HD00515 / ddrug1 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 pain medication { e , g , , ddrug12 } , drugs used to aid sleep , drowsiness-causing ddrug13 { e , g , , DB14487 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , DB00860 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , DB00231 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "however , it is considered to be unlikely that this decrease of phosphorylated DB00709 concentration is of clinical significance , as ddrug1 is a more efficient substrate for dck than DB00943 .",
        "label": "NA"
    },
    {
        "text": "co-administration of ddrug0 , ddrug1 , DB00682 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 and ddrug10 did not result in clinically significant increases in DB09026 exposure .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : clinical evidence has shown that DB00926 can be formed with concurrent ingestion of DB00459 and ddrug3 .",
        "label": "NA"
    },
    {
        "text": "{ concurrent use with HD00029 may enhance the possibility of HD00118 toxicity associated with hypokalemia .",
        "label": "effect"
    },
    {
        "text": "ddrug0 and ddrug1 DB00811 can antagonize the in vitro antiviral activity of DB00649 and ddrug4 against hiv .",
        "label": "effect"
    },
    {
        "text": "the intensity , uniformity and time course of ddrug0 interference by DB01174 , ddrug2 , ddrug3 , ddrug4 and ddrug5 were systematically investigated in # patients receiving DB04665 therapy .",
        "label": "NA"
    },
    {
        "text": "effects of ddrug0 on other antiepilepsy drugs { ddrug1 } : ddrug2 : DB00906 had no effect on the steady-state plasma concentrations of DB00252 in patients with epilepsy .",
        "label": "NA"
    },
    {
        "text": "caution should be exercised when HD00326 are given in conjunction with HD00548 .",
        "label": "advise"
    },
    {
        "text": "the concomitant use of transdermal ddrug0 with ddrug1 or other potent 3a4 inhibitors such as ddrug2 , ddrug3 , ddrug4 , DB01211 , ddrug6 , and nefazadone may result in an increase in DB00813 plasma concentrations .",
        "label": "NA"
    },
    {
        "text": "these studies indicate that ddrug0 or DB00199 co-administration enhances DB00950 gastrointestinal absorption .",
        "label": "mechanism"
    },
    {
        "text": "ventricular tachycardia induced by ddrug0 was generally converted to sinus rhythm following administration of ddrug1 , ddrug2 , or DB00450 but not after administration of ddrug4 alone or after DB00312 .",
        "label": "NA"
    },
    {
        "text": "following oral administration of two 150-mg sustained-release tablets with and without # mg of DB00501 , the pharmacokinetics of ddrug1 and HD00452 were unaffected .",
        "label": "NA"
    },
    {
        "text": "the uptake inhibitors DB00907 and DB01151 { 3 mumol/liter } potentiated the positive inotropic effects of ddrug2 in nonfailing myocardium { p < # } but not in functional class iv myocardium .",
        "label": "NA"
    },
    {
        "text": "caution should be used when administering or taking ddrug0 with DB01026 and other strong cyp3a4 inhibitors such as , but not limited to , ddrug2 , ddrug3 , DB00224 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { ddrug12 } , and ddrug13 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a study in healthy volunteers , no clinically relevant pharmacokinetic or pharmacodynamic interaction between ddrug1 and racemic ddrug2 was seen when two single oral doses of DB00682 { # mg/kg body weight } were administered during # days of multipledose treatment with # mg b , i , d , DB00270 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in some patients with compromised renal function who are being treated with HD00330 , the co-administration of DB00722 may result in a further deterioration of renal function .",
        "label": "effect"
    },
    {
        "text": "there have been inconsistent reports regarding the effects of other drugs { e , g , , ddrug0 , DB00859 } on serum DB00390 concentration .",
        "label": "NA"
    },
    {
        "text": "in patients receiving ddrug0 { ddrug1 } or ddrug2 { DB00993 } , the concomitant administration of 300 - 600 mg of DB00437 per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of ddrug5 or ddrug6 .",
        "label": "NA"
    },
    {
        "text": "while all the ddrug0 { HD00114 } , e , g , , DB00472 , seriraline , and ddrug3 , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .",
        "label": "NA"
    },
    {
        "text": "the potentiating action of ddrug0 must be considered when the drug is used in conjunction with HD00389 such as ddrug2 , ddrug3 and HD00026 .",
        "label": "NA"
    },
    {
        "text": "laboratory tests : the combination of DB00701 and low-dose DB00503 has been associated with elevations of cholesterol and triglycerides , sgot { ast } , and sgpt { alt } in some patients .",
        "label": "effect"
    },
    {
        "text": "because oral ddrug0 may interfere with the hepatic metabolism of ddrug1 , toxic levels of the ddrug2 may occur when an oral HD00025 and DB00252 are administered concurrently .",
        "label": "mechanism"
    },
    {
        "text": "in addition , studies in healthy volunteers have shown that DB00204 does not affect the pharmacokinetics or pharmacodynamics of ddrug1 , or the pharmacokinetics of ddrug2 { 40 mg twice daily } , ddrug3 , ddrug4 , or oral HD00283 .",
        "label": "NA"
    },
    {
        "text": "drug interactions : the central ddrug0 syndrome can occur when anticholinergic agents such as ddrug1 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain HD00424 such as ddrug3 , the ddrug4 and other ddrug5 , HD00043 , certain ddrug7 such as the ddrug8 salts , and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , DB00908 HD00388 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "when intravenous DB00295 and DB00187 were concomitantly administered in normal subjects , no effect on ddrug2 blood levels was seen , but ddrug3 steady-state blood levels were increased by 46 % in the presence of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "population pharmacokinetic analyses revealed that ddrug0 , ddrug1 , ddrug2 , and HD00204 did not influence DB01281 clearance .",
        "label": "NA"
    },
    {
        "text": "given the anticonvulsant properties of DB00564 , ddrug1 may reduce the thyroid function as has been reported with other HD00282 .",
        "label": "NA"
    },
    {
        "text": "although ddrug0 have been shown to reduce DB00041 - induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with ddrug2 may reduce the antitumor effectiveness of ddrug3 and thus should be avoided , # HD00254 and other ddrug5 may potentiate the hypotension seen with ddrug6 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , DB01086 and ddrug7 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , DB01035 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "inhibitors of this isoenzyme { e , g , , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , grapefruit juice , HD00641 , ddrug8 , ddrug9 , ddrug10 } should be cautiously coadministered with DB00204 as they can potentially increase ddrug12 levels .",
        "label": "advise"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , HD00002 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , DB01174 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "the extent to which HD00278 - HD00312 interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the ddrug2 involved .",
        "label": "int"
    },
    {
        "text": "the administration of local ddrug0 containing ddrug1 or ddrug2 to patients receiving HD00275 or HD00043 may produce severe , prolonged hypertension .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { cns } drugs including ddrug1 , HD00216 , ddrug3 , ddrug4 , blood pressure medications { DB00206 , ddrug6 , ddrug7 } , motion sickness medications , ddrug8 , ddrug9 , ddrug10 , sleeping pills and ddrug11",
        "label": "NA"
    },
    {
        "text": "ddrug0 { cns } drugs including ddrug1 , ddrug2 , ddrug3 , ddrug4 , blood pressure medications { ddrug5 , ddrug6 , HD00254 } , motion sickness medications , HD00542 , ddrug9 , ddrug10 , sleeping pills and ddrug11",
        "label": "NA"
    },
    {
        "text": "and HD00208 e , g , , ddrug1 } , cyp1a2 inducers { ddrug2 } and cyp1a2 inhibitors { DB14029 and ddrug4 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : since ddrug1 is a ddrug2 , it is possible that HD00339 , such as the ddrug4 { HD00219 , ddrug6 , ddrug7 } or ddrug8 , may diminish the effectiveness of ddrug9 .",
        "label": "NA"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / HD00517 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , DB14507 , ddrug11 pain medication { e , g , , ddrug12 } , drugs used to aid sleep , drowsiness-causing ddrug13 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "spontaneous reports of serotonin syndrome associated with co-administration of ddrug0 and HD00851 , including ddrug2 such as ddrug3 { HD00114 } , have been reported .",
        "label": "NA"
    },
    {
        "text": "antiacid , ddrug0 , ddrug1 , ddrug2 , DB00472 , indanavir , ddrug4 , ddrug5 , phenobarbitol , ddrug6 , DB00615 , ddrug8 , ritanovir , ddrug9 .",
        "label": "NA"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 HD00303 : ddrug2 , ddrug3 ddrug4 : DB00637 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "reports in the literature suggest that plasma levels of DB00997 { and its active metabolite ddrug1 } may be increased when DB01229 and ddrug3 are used in combination .",
        "label": "NA"
    },
    {
        "text": "there have been postmarketing reports of drug interactions when DB00199 is coadministered with ddrug1 , resulting in qt prolongation , cardiac arrythmias , ventricular tachycardia , ventricular fibrulation , and torsades de pointes , most like due to inhibition of hepatic metabolism of DB00604 by ddrug3 .",
        "label": "NA"
    },
    {
        "text": "in patients with chronic hepatitis c treated with DB00008 in combination with ddrug1 , ddrug2 treatment did not affect DB00811 distribution or clearance .",
        "label": "NA"
    },
    {
        "text": "DB00328 can reduce the antihypertensive effects of ddrug1 and DB00678 .",
        "label": "effect"
    },
    {
        "text": "the use of DB00514 may result in additive cns depressant effects when coadministered with ddrug1 , HD00388 , ddrug3 or other drugs that produce cns depression .",
        "label": "effect"
    },
    {
        "text": "interactions for ddrug0 { ddrug1 , DB00169 , ddrug3 , and ddrug4 } : DB01432 : ddrug6 has been reported to reduce intestinal absorption of ddrug7 ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 : immediate release capsules : since there have been isolated reports of patients with elevated ddrug1 levels , and there is a possible interaction between DB00390 and DB01115 , it is recommended that ddrug4 levels be monitored when initiating , adjusting , and discontinuing ddrug5 to avoid possible over - or under-digitalization .",
        "label": "int"
    },
    {
        "text": "another study showed that DB00969 had no clinically significant effect on plasma concentrations of the oral HD00280 ddrug2 and ddrug3 { cyp3a4 substrates } .",
        "label": "NA"
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit ddrug0 binding to serum proteins or alter the concentrations of serum binding proteins : ddrug1 and related ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 , ddrug7 , DB00695 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , DB00675 .",
        "label": "NA"
    },
    {
        "text": "the effects ddrug0 on the pharmacokinetics and/or pharmacodynamics of ddrug1 , ddrug2 , ddrug3 , DB00252 , ddrug5 , and DB00682 have been studied in vivo and clinically important interactions have not been found .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the effect of an ddrug1 - and ddrug2 - containing DB06724 { ddrug4 } * on the pharmacokinetics of DB01101 was investigated in # cancer patients .",
        "label": "NA"
    },
    {
        "text": "several ddrug0 have been reported to block the pharmacologic effects of DB01170 , ddrug2 , or similar agents , and such an effect may be anticipated with ddrug3 because of its structural similarity to other HD00043 .",
        "label": "NA"
    },
    {
        "text": "this article looks at five commonly used HD00084 in turn { ddrug1 , DB00091 , ddrug3 , ddrug4 , ddrug5 } , discussing the main , non-infection , unwanted effects , ways to avoid them and what to do if problems arise .",
        "label": "NA"
    },
    {
        "text": "DB00321 : concurrent administration of # mg or # mg ddrug1 with # mg ddrug2 increased ddrug3 exposure and DB00540 { active metabolite } exposure by approximately 20 % in cyp2d6 extensive metabolizers .",
        "label": "NA"
    },
    {
        "text": "DB00316 / ddrug1 , ddrug2 / ddrug3 , ddrug4 / ddrug5 , ddrug6 / ddrug7 , ddrug8 / ddrug9 , ddrug10 / ddrug11 , and DB00313 / ddrug13 .",
        "label": "NA"
    },
    {
        "text": "based on adult data , lower doses of ddrug0 may be needed following coadministration of drugs which are reported to decrease ddrug1 elimination { e , g , , ddrug2 and DB01026 } and higher ddrug4 doses may be needed following coadministration of drugs that increase ddrug5 elimination { e , g , , ddrug6 and DB00252 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , DB00529 , and ddrug2 : drugs such as ddrug3 , ddrug4 , and HD00249 may increase the risk of developing peripheral_neuropathies or other ddrug6 - associated adverse events by interfering with the renal clearance of ddrug7 { thereby raising systemic exposure } .",
        "label": "NA"
    },
    {
        "text": "HD00269 : ddrug1 , ddrug2 , DB00220 , and ddrug4 have been shown to decrease plasma levels of ddrug5 ;",
        "label": "NA"
    },
    {
        "text": "the amount of DB00331 absorbed while taking DB00284 was bioequivalent to the amount absorbed when taking placebo , as indicated by the plasma auc values .",
        "label": "NA"
    },
    {
        "text": "- a ddrug0 { HD00615 } such as ddrug2 { ddrug3 , ddrug4 , ddrug5 , others } , ddrug6 { ddrug7 , ddrug8 , ddrug9 } , ddrug10 { ddrug11 , ddrug12 } , ddrug13 { ddrug14 } , ddrug15 { ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , and ddrug21 { DB00788 , ddrug23 , ddrug24 } ;",
        "label": "NA"
    },
    {
        "text": "the concomitant use of HD00586 or HD00587 with ddrug2 is not recommended .",
        "label": "NA"
    },
    {
        "text": "to determine whether injection of HD00158 would permit larger doses of DB00515 to be administered , a fixed # - g/m2 dose of ddrug2 was given intravenously over three hours concurrently with escalating doses of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00673 increased the auc of ddrug2 , a sensitive cyp3a4 substrate , by # - fold on day # and # - fold on day 5 , when a single oral dose of DB00683 # mg was coadministered on day # and day # of a regimen of ddrug4 # mg on day # and # mg/day on days # through 5 .",
        "label": "NA"
    },
    {
        "text": "in a controlled clinical trial , a 20 % reduction of the ddrug0 dose at the initiation of ddrug1 therapy resulted in DB00252 levels comparable to those prior to DB00949 administration .",
        "label": "NA"
    },
    {
        "text": "it is , however , possible that concomitant use of other known ddrug0 such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , HD00297 and ddrug6 might increase the photosensitivity reaction of actinic_keratosis treated with the DB00855 for topical solution .",
        "label": "effect"
    },
    {
        "text": "if the usual amounts of nondepolarizing relaxants are given , the time for recovery from neuromuscular blockade will be longer in the presence of DB00228 than when ddrug1 or DB06690 with a balanced technique are used .",
        "label": "NA"
    },
    {
        "text": "HD00282 : ddrug1 , ddrug2 , DB00252",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00502 blocks dopamine receptors , thus inhibiting the central stimulant effects of HD00401 .",
        "label": "effect"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect : ddrug0 , ddrug1 , ddrug2 , ddrug3 , HD00571 { e , g , , ddrug5 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 { e , g , , in oral HD00283 } .",
        "label": "NA"
    },
    {
        "text": "based on clinical and pharmacokinetic results from the atac trial , DB00675 should not be administered with DB01217 { see clinical pharmacology drug interactions and clinical pharmacology - clinical studies - adjuvant treatment of breast_cancer in postmenopausal women subsections } .",
        "label": "advise"
    },
    {
        "text": "additive adverse effects resulting from cholinergic blockade may occur when DB00424 is administered concomitantly with other ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , HD00043 or some ddrug7 .",
        "label": "effect"
    },
    {
        "text": "injection : DB00186 injection , like other injectable ddrug1 , produces depression of the central nervous system when administered with DB00898 , ddrug3 , ddrug4 , ddrug5 , and other ddrug6 , when ddrug7 is used concomitantly with injectable ddrug8 , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .",
        "label": "effect"
    },
    {
        "text": "some HD00096 / substances are known to accelerate the metabolism of ddrug1 by stimulating the synthesis of HD00302 { enzyme induction } .",
        "label": "NA"
    },
    {
        "text": "although additional drug interaction studies have not been conducted , the most common medications used concomitantly with DB00261 in clinical trials were ddrug1 , ddrug2 , DB00695 , ddrug4 , ddrug5 , ddrug6 , and ddrug7 .",
        "label": "NA"
    },
    {
        "text": "DB00390 - in subjects who had received # days of # mg/day racemic ddrug1 , combined administration of ddrug2 and ddrug3 { single dose of # mg } did not significantly affect the pharmacokinetics of either DB00215 or ddrug5 .",
        "label": "NA"
    },
    {
        "text": "DB00661 : coadministration of ddrug1 and ddrug2 resulted in a 24 % increase in plasma concentrations of DB00918 .",
        "label": "NA"
    },
    {
        "text": "neither racemic DB00682 nor DB00270 binding to plasma proteins in vitro was altered by the addition of the other drug .",
        "label": "NA"
    },
    {
        "text": "DB00501 } and many that are substrates for cyp2b6 2d6 { many other ddrug1 , ddrug2 , and the ddrug3 DB01182 and ddrug5 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and other ddrug1 can reduce the antihypertensive effect of DB00571 and other HD00254 .",
        "label": "NA"
    },
    {
        "text": "thus , the results suggest that HD00044 exposure of rats results in free radical-mediated tissue damage , as indicated by elevated cerebral and hepatic lipid peroxidation , which was prevented by DB00437 and ddrug2 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : DB01118 should be used with caution in patients receiving - HD00305 blocking agents { e , g , , ddrug3 , a ddrug4 inhibitor } or ddrug5 antagonists { e , g , , ddrug6 , a ddrug7 substrate , and ddrug8 , a ddrug9 inhibitor } because of the possible potentiation of bradycardia , sinus arrest , and av block ;",
        "label": "NA"
    },
    {
        "text": "there have been reports of qtc prolongation , with or without tdp , in patients taking DB01118 when HD00001 , ddrug2 , or azoles were administered concomitantly .",
        "label": "NA"
    },
    {
        "text": "- a ddrug0 { HD00615 } such as ddrug2 { ddrug3 , ddrug4 , ddrug5 , others } , ddrug6 { ddrug7 , HD00761 , ddrug9 } , ddrug10 { ddrug11 , ddrug12 } , ddrug13 { ddrug14 } , ddrug15 { ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , and ddrug21 { ddrug22 , ddrug23 , ddrug24 } ;",
        "label": "NA"
    },
    {
        "text": "when initiating a multi-day course of ddrug0 in a patient maintained on DB00277 , the ddrug2 maintenance dose should be halved for the period of concurrent use of DB00365 and monitoring of serum ddrug4 concentrations should be initiated as a guide to further dosage adjustments .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00975 has been reported to increase the plasma levels and cardiovascular effects of DB00640 .",
        "label": "mechanism"
    },
    {
        "text": "therefore , co-administration of ddrug0 with drugs that are metabolized by cyp2d6 isoenzyme including certain ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } , ddrug8 { e , g , , ddrug9 , ddrug10 , DB00679 } , ddrug12 { e , g , , DB00264 } , and ddrug14 { e , g , , ddrug15 , ddrug16 } , should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication .",
        "label": "NA"
    },
    {
        "text": "the literature provides considerable evidence indicating that several , but not all HD00130 , are indeed HD00131 and some are ddrug2 as well .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB00829 , certain ddrug7 , ddrug8 , ddrug9 and DB00916 , thereby delaying elimination and increasing blood levels of these drugs .",
        "label": "NA"
    },
    {
        "text": "although there was no effect of DB00673 on the plasma auc of HD00347 or ddrug2 determined on day 3 , there was a 34 % decrease in ddrug3 { a cyp2c9 substrate } trough concentration accompanied by a 14 % decrease in the prothrombin time { reported as international normalized ratio or inr } # days after completion of dosing with ddrug4 .",
        "label": "NA"
    },
    {
        "text": "in vitro binding studies with human serum proteins indicate that ddrug0 binds differently than DB01124 and does not interact with ddrug2 or DB00266 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 ddrug1 ddrug2 , like other HD00532 , may inhibit the metabolism of DB00201 and ddrug5 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { DB00400 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and DB00126 .",
        "label": "NA"
    },
    {
        "text": "HD00374 or ddrug1 substantially interfere with the absorption of some HD00532 , resulting in low urine levels .",
        "label": "mechanism"
    },
    {
        "text": "in three separate controlled , parallel group clinical pharmacology studies , DB00967 at the clinical dose of # mg has been coadministered with DB00207 # mg followed by # mg once daily for # days { n = 18 } or with ddrug2 # mg once daily for # days after a # day pretreatment period with ddrug3 { n = 18 } or with ddrug4 # mg every # hours for # days { n = 18 } under steady state conditions to normal healthy male and female volunteers .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local HD00264 { e , g , , ddrug6 and ddrug7 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , DB01035 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "drug interactions with ddrug0 administration of # mg of ddrug1 { 2 x # mg capsule } within # minutes of an ddrug2 and DB14513 containing DB06724 { ddrug5 } decreased ddrug6 auc by 41 % and cmax by 43 % .",
        "label": "NA"
    },
    {
        "text": "after # days of co-administration , mean trough concentrations of ddrug0 and its metabolites , ddrug1 and HD00567 , were elevated with DB00176 by about three-fold compared to baseline concentrations .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , like HD00146 , produced depletions of striatal dopamine but these actions were potentiated by DB01626 pretreatment .",
        "label": "NA"
    },
    {
        "text": "in separate single or multiple dose pharmacokinetic interaction studies with ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , and DB00682 , the bioavailability of ddrug9 was not altered by coadministration of DB00492 with any one of these drugs .",
        "label": "NA"
    },
    {
        "text": "cytochrome p-450 inducers , such as DB00252 , ddrug1 and ddrug2 , induce DB01068 metabolism , causing an approximately 30 % decrease in plasma ddrug4 levels .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 may enhance the effects of : other HD00459 s , DB02325 , general ddrug5 , ddrug6 such as ddrug7 , ddrug8 , or other ddrug9 , causing increased cns depression .",
        "label": "NA"
    },
    {
        "text": "these data suggest that ddrug0 are negatively coupled to three types of calcium channels in bovine chromaffin cell , including an HD00047 - sensitive { n-type } channel , an ddrug2 - sensitive { p-type } channel and ddrug3 / ddrug4 / HD00049 - resistant { presumptive q-type } channel .",
        "label": "NA"
    },
    {
        "text": "acid-catalyzed ethanolysis of DB00231 in anhydrous and aqueous DB00898 solutions .",
        "label": "mechanism"
    },
    {
        "text": "effects of other antiepilepsy drugs { ddrug0 } on DB00906 : DB00564 : population pharmacokinetic analyses indicate that ddrug3 clearance is 60 % greater in patients taking ddrug4 with or without other enzyme - inducing ddrug5 .",
        "label": "NA"
    },
    {
        "text": "DB11716 has a complex effect on oral HD00152 pharmacokinetics .",
        "label": "mechanism"
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit DB00451 binding to serum proteins or alter the concentrations of serum binding proteins : ddrug1 and related HD00846 , ddrug3 , ddrug4 , ddrug5 and ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { HD00548 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , DB00277 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "pharmacokinetic data indicate that oral DB01026 inhibits the metabolism of ddrug1 , resulting in elevated plasma levels of DB00637 and its active metabolite ddrug3 which may prolong qt intervals .",
        "label": "NA"
    },
    {
        "text": "a # { 17 } % decrease in the steady-state auc of DB01004 was observed when DB00900 was administered # hours prior to ddrug2 , but not when the two drugs were administered simultaneously { n = 12 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the concomitant use of ddrug1 { DB00813 transdermal system } with other ddrug3 , including but not limited to other ddrug4 , ddrug5 , ddrug6 , ddrug7 { e , g , , ddrug8 } , general ddrug9 , ddrug10 , HD00320 , and ddrug12 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .",
        "label": "effect"
    },
    {
        "text": "in rats , simultaneous ingestion of DB00822 and DB12529 in the diet for # weeks has been reported to cause tumors , and it has been suggested that ddrug2 may react with ddrug3 in the rat stomach to form a nitrosamine , which is tumorigenic .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : although the results of a clinical study did not indicate a safe problem associated with the administration of ddrug1 { DB00320 } injection , usp to subjects already receiving DB00571 , there have been reports that ddrug4 may potentiate the vasoconstrictive action of ddrug5 by blocking the vasodilating property of epinephrine .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration of once daily doses of ddrug1 , as a tablet formulation comparable to # mg or # mg of the capsule formulation , with ddrug2 # mg once daily , resulted in a decrease in auc by approximately 25 % and cmax , by approximately 20 % of both DB00673 and DB00715 .",
        "label": "NA"
    },
    {
        "text": "HD00203 should be used with caution in patients taking DB00091 , and renal function should be carefully monitored .",
        "label": "advise"
    },
    {
        "text": "to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma { hiv-nhl } , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the ddrug0 , ddrug1 , DB00541 , and ddrug3 { chop } chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen { i , e , , DB00531 , ddrug5 , ddrug6 , and ddrug7 with ddrug8 plus ddrug9 } without receiving ddrug10 therapy .",
        "label": "NA"
    },
    {
        "text": "data from in vitro studies of HD00100 other than ddrug1 suggest a possible drug interaction for the following : ddrug2 , ddrug3 , ddrug4 , ddrug5 , and DB01115 .",
        "label": "int"
    },
    {
        "text": "oral HD00326 caution should be exercised when ddrug1 are given in conjunction with DB01039 .",
        "label": "NA"
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit ddrug0 binding to serum proteins or alter the concentrations of serum binding proteins : HD00657 and related ddrug2 , ddrug3 , ddrug4 , HD00220 and ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 ddrug2 may enhance the activity of HD00043 or HD00571 ;",
        "label": "NA"
    },
    {
        "text": "because of ddrug0 s tendency to cause renal impairment , the use of DB00529 should be avoided in combination with potentially nephrotoxic drugs such as ddrug2 , ddrug3 and intravenous DB00738 unless the potential benefits outweigh the risks to the patient .",
        "label": "advise"
    },
    {
        "text": "drug interactions : the central ddrug0 syndrome can occur when anticholinergic agents such as DB00810 are administered concomitantly with drugs that have secondary anticholinergic actions , e , g , , certain ddrug2 such as ddrug3 , the ddrug4 and other ddrug5 , ddrug6 , certain ddrug7 such as the ddrug8 salts , and HD00388 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and DB00759 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { DB00701 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "DB01432 ddrug1 may delay or reduce the absorption of concomitant oral medication such as ddrug2 , ddrug3 , ddrug4 { acidic } or ddrug5 { basic } , as well as DB00759 ddrug7 , ddrug8 , thyroid and ddrug9 preparations , ddrug10 and ddrug11 , and ddrug12 .",
        "label": "mechanism"
    },
    {
        "text": "because of DB00529 s tendency to cause renal impairment , the use of ddrug1 should be avoided in combination with potentially nephrotoxic drugs such as ddrug2 , ddrug3 and intravenous DB00738 unless the potential benefits outweigh the risks to the patient .",
        "label": "NA"
    },
    {
        "text": "concomitant use of prostaglandin synthase inhibiting drugs , eg , DB00328 , may decrease the hypotensive effects of HD00378 .",
        "label": "effect"
    },
    {
        "text": "the possibility of hypotensive effects with ddrug0 can be minimized by either discontinuing the HD00295 or increasing the salt intake approximately one week prior to initiation of treatment with DB01197 { ddrug3 tablets , usp } or initiating therapy with small doses { # or # mg } .",
        "label": "NA"
    },
    {
        "text": "combination of DB01118 with other HD00304 therapy should be reserved for patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to ddrug2 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { DB00400 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { DB01045 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "in vitro studies evaluating the minimum inhibitory concentration { mic } of ddrug0 , ddrug1 , ddrug2 , ddrug3 / flucoxacillin , DB00438 , ddrug5 , and ddrug6 demonstrated no evidence of incompatibility of these HD00002 with ddrug8 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 reversible increases in serum ddrug1 concentrations and toxicity have been reported during concomitant administration of DB14507 with ddrug3 , and with some HD00466 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 - HD00485 containing side chains of n-methylthiotetrazole { ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 } or methylthiadiazole { DB01327 } can cause vitamin_k_deficiency and hypoprothrombinemia .",
        "label": "NA"
    },
    {
        "text": "no significant drug interactions have been reported in studies of DB00796 given with other drugs such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , and oral HD00283 in healthy volunteers , or given with ddrug7 to patients with heart failure { nyha class ii and iii } .",
        "label": "NA"
    },
    {
        "text": "while no in vivo drug-drug interaction studies were conducted between DB01215 and inducers of cyp3a , compounds that are potent cytochrome_p450_family_3_subfamily_a inducers { such as ddrug1 , ddrug2 , DB01045 , and ddrug4 } would be expected to decrease ddrug5 concentrations .",
        "label": "mechanism"
    },
    {
        "text": "short-term pharmacokinetic studies have demonstrated that concomitant administration of ddrug0 and ddrug1 { DB00749 capsules and tablets } results in reduced protein binding of DB00682 , but there was no change in the clearance of free ddrug4 .",
        "label": "NA"
    },
    {
        "text": "plasma concentrations of HD00279 are decreased when administered with ddrug1 containing ddrug2 , ddrug3 , or DB01370 .",
        "label": "mechanism"
    },
    {
        "text": "it is concluded that DB01563 and ddrug1 may be administered safely without additional caution in prothrombin test monitoring during oral HD00025 therapy .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , and the HD00457 ddrug2 { DB00904 } and ddrug4 { ddrug5 } have all been used with ddrug6 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 and ddrug2 may enhance the effects of : other ddrug3 s , ddrug4 , general HD00264 , ddrug6 such as ddrug7 , ddrug8 , or other HD00261 , causing increased cns depression .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : concomitant administration of low-dose DB00945 with HD00897 may result in an increased rate of gi ulceration or other complications , compared to use of ddrug3 alone .",
        "label": "effect"
    },
    {
        "text": "drugs that cause significant sustained elevation in gastric ph { ddrug0 such as ddrug1 or DB00501 } may reduce plasma concentrations of DB00317 and therefore potentially may reduce efficacy .",
        "label": "mechanism"
    },
    {
        "text": "to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma { hiv-nhl } , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the DB00531 , ddrug1 , ddrug2 , and ddrug3 { chop } chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen { i , e , , ddrug4 , ddrug5 , ddrug6 , and ddrug7 with ddrug8 plus ddrug9 } without receiving HD00056 therapy .",
        "label": "NA"
    },
    {
        "text": "because there is a theoretical basis that these effects may be additive , use of ddrug0 - containing or ddrug1 { like ddrug2 or DB00247 } and DB00952 within # hours is contraindicated .",
        "label": "advise"
    },
    {
        "text": "toxicology studies of DB01452 - related deaths reveal frequent involvement of other ddrug1 , including ddrug2 , ddrug3 such as ddrug4 { DB00829 } , and , to a rising degree , ddrug6 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { HD00548 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , DB01232 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "-lsb- the gaba-ergic system and brain edema -rsb- it has been shown in rats with experimental toxic and traumatic edemas that DB00466 { 1 mg/kg } removes the antiedematous action of ddrug1 , HD00133 , ddrug3 and ddrug4 and reduces the action of ddrug5 .",
        "label": "effect"
    },
    {
        "text": "caution in using concomitant drugs such as HD00254 { ophthalmic and systemic } , ddrug1 and/or HD00345 is advised .",
        "label": "NA"
    },
    {
        "text": "this appears to be the only clinically relevant interaction of this kind with DB00358 , although theoretically , coadministration of other drugs known to alter cardiac conduction { eg , ddrug1 or HD00244 , ddrug3 , ddrug4 or ddrug5 , ddrug6 and ddrug7 } might also contribute to a prolongation of the qtc interval .",
        "label": "effect"
    },
    {
        "text": "therefore , coadministration of DB00673 with drugs that strongly induce cyp3a4 activity { e , g , , ddrug1 , DB00564 , ddrug3 } may result in reduced plasma concentrations of ddrug4 that may result in decreased efficacy of ddrug5 .",
        "label": "NA"
    },
    {
        "text": "injection : DB00186 injection , like other injectable HD00100 , produces depression of the central nervous system when administered with ddrug2 , ddrug3 , ddrug4 , ddrug5 , and other ddrug6 , when ddrug7 is used concomitantly with injectable ddrug8 , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .",
        "label": "NA"
    },
    {
        "text": "DB00771 may decrease the effect of ddrug1 , ddrug2 , and DB01026 .",
        "label": "effect"
    },
    {
        "text": "drugs that should not be coadministered with DB00220 ddrug1 : ddrug2 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 DB00683 , ddrug12 gi motility agents : ddrug13",
        "label": "advise"
    },
    {
        "text": "in vitro studies evaluating the minimum inhibitory concentration { mic } of ddrug0 , ddrug1 , ddrug2 , ddrug3 / flucoxacillin , DB00438 , ddrug5 , and ddrug6 demonstrated no evidence of incompatibility of these ddrug7 with DB00702 .",
        "label": "NA"
    },
    {
        "text": "conversely , the HD00423 have been reported to increase the serum levels and prolong the serum half-life of DB00252 by inhibiting its metabolism .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 { ddrug1 } - a drug interaction study of DB00700 with an HD00615 has not been conducted .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : co-administration of ddrug1 with DB01045 # mg daily , a potent inducer of hepatic metabolism , produced an approximate 50 % decrease in DB00533 plasma concentrations .",
        "label": "NA"
    },
    {
        "text": "milk , milk products , and DB01373 - rich foods or drugs may impair the absorption of DB01196 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 s : ddrug1 should be administered at least # hours after or # hours before dosing with ddrug2 because plasma concentrations of DB00537 are decreased when administered with ddrug4 containing ddrug5 , DB01373 , or ddrug7 .",
        "label": "mechanism"
    },
    {
        "text": "agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of ddrug0 are the following : ddrug1 , ddrug2 , ddrug3 , DB01045 , ddrug5 , ddrug6 { 2 } , ddrug7 , ddrug8 , and ddrug9 thus , if a patient has been titrated to a stable dosage on HD00472 , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for ddrug11 may be necessary .",
        "label": "NA"
    },
    {
        "text": "co-administration with DB00625 or DB00196 had a modest effect on the pharmacokinetics of ddrug2 .",
        "label": "NA"
    },
    {
        "text": "the potential for drug interactions with DB00879 has been studied in combination with ddrug1 , ddrug2 , ddrug3 , and DB00300 .",
        "label": "NA"
    },
    {
        "text": "notably , systemic exposure { auc0 - 12 } of ddrug0 { DB03756 } was more than doubled in the presence of ddrug2 / DB01015 .",
        "label": "NA"
    },
    {
        "text": "other concomitant therapy although specific interaction studies were not performed , ddrug0 doses of # mg or more were concomitantly used in clinical studies with DB00316 , ddrug2 , a-blockers , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , cardiac ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 { also referred to as HD00203 } , and ddrug15 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "therefore , patients without a functioning DB00451 gland who are on thyroid replacement therapy may need to increase their thyroid dose if HD00220 or ddrug2 - containing oral ddrug3 are given .",
        "label": "advise"
    },
    {
        "text": "although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 { eg , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB00682 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , and ddrug15 } may have elevated plasma concentrations when coadministered with DB01232 ;",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : weakness hyperreflexia , and incoordination have been reported rarely when HD00277 have been co-administered with HD00114 { e , g.",
        "label": "effect"
    },
    {
        "text": "the safety and efficacy of DB00041 in combination with any HD00251 have not been established .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : clinical studies , as well as post-marketing observations , have shown that HD00203 can reduce the natriuretic effect of DB00695 and ddrug3 in some patients .",
        "label": "effect"
    },
    {
        "text": "in clinical studies performed with DB00569 , the concomitant use of oral ddrug1 { ddrug2 } , ddrug3 { DB00945 } , ddrug5 { ddrug6 } , and ddrug7 did not significantly affect the pharmacokinetics/pharmacodynamics of ddrug8 .",
        "label": "NA"
    },
    {
        "text": "the administration of other HD00687 with HD00203 has been shown to reduce the antihypertensive effect in some patients and result in severe hyperkalemia in patients with impaired renal function .",
        "label": "effect"
    },
    {
        "text": "agents with increased levels in the presence of ddrug0 : ddrug1 increases the plasma levels of the following agents : ddrug2 , ddrug3 { 6 } , and DB00794 thus , if a patient has been titrated to a stable dosage on one of the agents in this category , and then begins a course of the treatment with HD00472 , it is reasonable to expect that a dose decrease for the concomitant agent may be necessary .",
        "label": "NA"
    },
    {
        "text": "both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ddrug0 is administered in combination with other ddrug1 such as ddrug2 , ddrug3 , HD00263 , or inhalation general HD00264 .",
        "label": "NA"
    },
    {
        "text": "HD00084 , ddrug1 , DB00627 { ddrug3 , ddrug4 , ddrug5 : skeletal muscle .",
        "label": "NA"
    },
    {
        "text": "the homodimeric disintegrin HD00007 was compared directly to the monomeric disintegrins HD00008 and ddrug2 for the ability to affect protein tyrosine phosphorylation in tumor cells .",
        "label": "NA"
    },
    {
        "text": "concurrent use of ddrug0 with ddrug1 { e , g , , DB02325 , ddrug3 , ddrug4 , and ddrug5 } may result in increased HD00461 effects .",
        "label": "NA"
    },
    {
        "text": "because of reports of prolongation of the prothrombin time beyond the therapeutic range in patients taking concurrent DB00848 and DB00682 , it is suggested that the prothrombin time be monitored carefully , and the dose of ddrug2 or other ddrug3 - like drugs should be adjusted accordingly , in patients taking both drugs .",
        "label": "advise"
    },
    {
        "text": "however , the peak plasma level of ddrug0 was reduced by approximately 20 % when taking DB00284 due to a slight delay in the absorption of DB00331 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : use of HD00221 with ddrug2 and other HD00043 may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : DB00502 blocks dopamine and norepinephrine reuptake , thus inhibiting the central stimulant effects of HD00401 .",
        "label": "effect"
    },
    {
        "text": "agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of ddrug0 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 , DB01174 , ddrug6 { 2 } , ddrug7 , ddrug8 , and ddrug9 thus , if a patient has been titrated to a stable dosage on ddrug10 , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for HD00472 may be necessary .",
        "label": "NA"
    },
    {
        "text": "ddrug0 / ddrug1 : the coadministration of DB00252 or ddrug3 will not affect plasma concentrations of DB11094 , but may reduce endogenous plasma levels of ddrug5 / ergocalcitriol by accelerating metabolism .",
        "label": "NA"
    },
    {
        "text": "DB00759 , a HD00616 , may antagonize the bactercidal effect of ddrug2 and concurrent use of these drugs should be avoided .",
        "label": "NA"
    },
    {
        "text": "injection : DB00186 injection , like other injectable ddrug1 , produces depression of the central nervous system when administered with ddrug2 , ddrug3 , ddrug4 , HD00343 , and other ddrug6 , when ddrug7 is used concomitantly with injectable ddrug8 , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : DB00199 has been reported to decrease the clearance of DB00897 and , thus , may increase the pharmacologic effect of ddrug3 .",
        "label": "mechanism"
    },
    {
        "text": "tissue culture and animal studies indicate that DB00023 can diminish or abolish the effect of DB00563 on malignant cells # this effect on ddrug2 activity persists as long as plasma asparagine levels are suppressed .",
        "label": "effect"
    },
    {
        "text": "HD00374 : concomitant administration of ddrug1 containing ddrug2 or DB01370 with ddrug4 chewable/dispersible buffered tablets or pediatric powder for oral solution may potentiate adverse events associated with the ddrug5 components .",
        "label": "NA"
    },
    {
        "text": "DB01026 did not affect the conversion of DB00678 to the active metabolite after intravenous administration of ddrug2 , and ddrug3 had no clinically significant effect after oral administration .",
        "label": "NA"
    },
    {
        "text": "among the HD00122 , many , like HD00121 , can not be used clinically because they are toxic ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : DB00316 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { HD00712 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 : ddrug1 { 40 mg bid } did not induce the metabolism of the combination oral ddrug2 ddrug3 / DB00977 { 1 mg / 35 mcg combination , DB00717 1/35 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : HD00518 have been reported to increase steadystate plasma DB14507 levels .",
        "label": "mechanism"
    },
    {
        "text": "discontinuation of ddrug0 in well-controlled patients receiving HD00043 and DB00501 may decrease the plasma levels and efficacy of the ddrug3 .",
        "label": "mechanism"
    },
    {
        "text": "however , it adversely affected response duration suggesting that DB00165 should not be administered with ddrug1 and/or DB00515 #",
        "label": "advise"
    },
    {
        "text": "patients on oral HD00075 receiving DB00188 treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their ddrug2 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : in a study conducted in healthy subjects , mean steady-state ddrug1 plasma levels increased approximately 17 % in subjects receiving ddrug2 # mg bid with DB00482 # mg bid as compared to subjects receiving DB14507 alone .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 , and DB01045 may decrease ddrug3 plasma levels , resulting in a decrease in effectiveness of a previously effective DB00363 dose .",
        "label": "NA"
    },
    {
        "text": "in patients who have been reported to be well controlled on HD00043 receiving concurrent ddrug1 therapy , discontinuation of DB00501 has been reported to decrease established steady-state serum ddrug3 levels and compromise their therapeutic effects .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { DB00252 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { HD00531 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "another oral ddrug0 , ddrug1 , inhibits the metabolism of DB00637 , resulting in elevated plasma concentrations of ddrug3 and its active metabolite HD00821 which may prolong qt intervals .",
        "label": "NA"
    },
    {
        "text": "- a HD00535 { ddrug1 } such as ddrug2 { ddrug3 , ddrug4 , ddrug5 , others } , ddrug6 { ddrug7 , ddrug8 , DB01009 } , ddrug10 { ddrug11 , ddrug12 } , ddrug13 { ddrug14 } , ddrug15 { ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , and ddrug21 { ddrug22 , ddrug23 , ddrug24 } ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the concomitant use of DB00813 { ddrug2 transdermal system } with other ddrug3 , including but not limited to other ddrug4 , HD00024 , ddrug6 , ddrug7 { e , g , , ddrug8 } , general ddrug9 , ddrug10 , ddrug11 , and ddrug12 , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .",
        "label": "effect"
    },
    {
        "text": "although acid-base and electrolyte disturbances were not reported in the clinical trials with ddrug0 , these disturbances have been reported with oral HD00442 and have , in some instances , resulted in drug interactions { e , g , , toxicity associated with high-dose HD00372 therapy } .",
        "label": "NA"
    },
    {
        "text": "DB00390 and ddrug1 use may be rarely associated with ventricular fibrillation when combined with DB00640 .",
        "label": "effect"
    },
    {
        "text": "however , the systemic administration of some HD00532 has been shown to elevate plasma concentrations of ddrug1 , interfere with the metabolism of ddrug2 , and enhance the effects of the oral HD00025 ddrug4 and its derivatives , and has been associated with transient elevations in serum creatinine in patients receiving systemic ddrug5 concomitantly .",
        "label": "NA"
    },
    {
        "text": "drugs which induce cyp3a4 activity { eg , ddrug0 , ddrug1 , DB00615 } would be expected to increase the clearance of DB00625 resulting in lowered plasma concentrations .",
        "label": "mechanism"
    },
    {
        "text": "a 5-mg DB00862 dose should not be exceeded when used in combination with # mg once daily DB01026 .",
        "label": "advise"
    },
    {
        "text": "a potential interaction between oral DB01110 and oral HD00062 leading to severe hypoglycemia has been reported .",
        "label": "effect"
    },
    {
        "text": "{ 1968 , 1970 } , the higher serum concentrations of ddrug0 and DB09008 reached after administration of DB01032 are due not only to slower renal elimination but also to an altered distribution in the body .",
        "label": "mechanism"
    },
    {
        "text": "there have been reports of ddrug0 - related side effects in patients on concomitant therapy with HD00532 and DB00277 .",
        "label": "effect"
    },
    {
        "text": "- ddrug0 and ddrug1 ddrug2 : ddrug3 and DB00375 HD00510 have the potential of binding ddrug6 and reducing ddrug7 absorption from the gastrointestinal tract",
        "label": "NA"
    },
    {
        "text": "during clinical trials , DB01088 was used concurrently with ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , HD00797 , ddrug8 , and other medications .",
        "label": "NA"
    },
    {
        "text": "DB00503 { 600 mg b , i , d , } co-administered with ddrug1 # mg resulted in a 49-fold increase in DB00862 auc and a 13-fold increase in ddrug3 cmax .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , DB00949 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , DB01045 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 s and ddrug1 : the following adverse events were experienced more commonly in patients receiving concomitant HD00290 or HD00337 { n = 94 } compared to patients not receiving these concomitant drugs { n = 456 } : hypotension 10 % vs 4 % , myocardial infarction 3 % vs 1 % , serious pneumonias 5 % vs 3 % , serious falls 9 % vs 3 % , and bone and joint injuries 6 % vs 2 % .",
        "label": "effect"
    },
    {
        "text": "there was no significant difference in the pharmacodynamic effect of ddrug0 administered alone and DB00682 administered with DB00749 as measured by prothrombin time .",
        "label": "NA"
    },
    {
        "text": "the purpose of this study was to evaluate the effect of ddrug0 { HD00072 } and ddrug2 { ddrug3 } conjugates on the intestinal permeation of HD00069 { ddrug5 } and model peptide drugs , ddrug6 and ddrug7 .",
        "label": "NA"
    },
    {
        "text": "may interact with the following : ddrug0 { these medicines may make your condition worse and prevent the HD00815 from working properly } and ddrug2 , DB00908 , ddrug4 , and ddrug5 { these medicines may increase the risk of heart problems } .",
        "label": "NA"
    },
    {
        "text": "effects of other antiepilepsy drugs { ddrug0 } on ddrug1 : ddrug2 : population pharmacokinetic analyses indicate that DB00906 clearance is 60 % greater in patients taking ddrug4 with or without other enzyme - inducing HD00714 .",
        "label": "NA"
    },
    {
        "text": "the results indicate that a statistically significant difference exists between the excreted levels of homocysteine in the urine of both control and DB00367 - treated rats and the levels shown by rats treated with DB00977 .",
        "label": "NA"
    },
    {
        "text": "DB00439 plasma concentrations were also not affected by co-administration of DB00390 .",
        "label": "NA"
    },
    {
        "text": "co-administration of cyp3a4 inhibitors { eg , ddrug0 , DB01167 , ddrug2 , grapefruit juice , ddrug3 } with ddrug4 may lead to several - fold increases in the plasma levels of DB01023 , either due to an increase in bioavailability or due to a decrease in metabolism .",
        "label": "NA"
    },
    {
        "text": "ddrug0 can interact with ddrug1 or other ddrug2 { may potentiate the cns depressant effects of either these medications or ddrug3 } , HD00444 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug5 } , and HD00445 { concurrent use with ddrug7 may prolong and intensify the anticholinergic and cns depressant effects of ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may have additive effects with DB02325 and other HD00261 , e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 .",
        "label": "NA"
    },
    {
        "text": "however , due to possible pharmacodynamic interactions , when co-administered with DB00633 , a reduction in dosage of ddrug1 on the concomitant ddrug2 , ddrug3 , HD00604 or ddrug5 may be required .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : some HD00879 may increase the concentration of HD00573 in the blood .",
        "label": "mechanism"
    },
    {
        "text": "concomitant use of HD00388 with DB02325 , ddrug2 , ddrug3 , or other ddrug4 may have an additive effect .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { DB00316 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , DB00776 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "in a similar study with ddrug0 in healthy volunteers , # of # subjects dosed with DB00862 # mg and DB00706 # mg separated by # hours experienced a standing systolic blood pressure below # mm hg .",
        "label": "effect"
    },
    {
        "text": "may interact with thyroid medication { e , g , , ddrug0 } , ddrug1 - containing products , ddrug2 , HD00613 { e , g , , ddrug4 , ddrug5 } , and ddrug6 { e , g , , DB00448 , ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "patients treated with DB01193 plus HD00229 should , therefore , be observed closely for evidence of marked bradycardia or hypotension which may present as vertigo , syncope/presyncope , or orthostatic changes in blood pressure without compensatory tachycardia .",
        "label": "advise"
    },
    {
        "text": "in the DB00682 study , DB00862 had no effect on the prothrombin time or other pharmacodynamic parameters .",
        "label": "NA"
    },
    {
        "text": "therefore , such combined treatment should be approached with caution and patients should be monitored closely when DB00363 is combined with these drugs , particularly with DB00176 .",
        "label": "advise"
    },
    {
        "text": "short-term pharmacokinetic studies have demonstrated that concomitant administration of DB00682 and DB00749 { ddrug2 capsules and tablets } results in reduced protein binding of ddrug3 , but there was no change in the clearance of free ddrug4 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { DB00252 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { DB01045 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "therefore , extreme caution should be exercised when administering DB00988 to patients receiving ddrug1 or HD00648 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 { e , g , , ddrug1 , ddrug2 , DB00257 , ddrug4 , etc , } : in vitro and animal studies with the combination of ddrug5 and ddrug6 suggest that ddrug7 may induce fungal resistance to DB00681 .",
        "label": "NA"
    },
    {
        "text": "oral HD00326 : in some normal volunteers , the concomitant administration of DB00861 and ddrug2 , ddrug3 , or ddrug4 resulted in prolongation of prothrombin time .",
        "label": "NA"
    },
    {
        "text": "the effect of HD00175 on oral HD00326 is variable .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : in normal volunteers , a small decrease in ddrug1 levels was observed when multiple doses of DB00861 and DB00945 were administered concomitantly .",
        "label": "mechanism"
    },
    {
        "text": "during co-administration , systemic levels of DB01643 and DB01015 were essentially unchanged .",
        "label": "NA"
    },
    {
        "text": "ddrug0 } , ddrug1 { e , g , ddrug2 } , and ddrug3 { e , g , ddrug4 , DB00224 and ddrug6 } should have their dose of ddrug7 or DB01183 adjusted .",
        "label": "NA"
    },
    {
        "text": "a clinical study in healthy male volunteers { n = 24 } demonstrated that mixing ddrug0 with HD00812 immediately before injection produced some attenuation in the peak concentration of DB01306 , but that the time to peak and the total bioavailability of ddrug3 were not significantly affected .",
        "label": "NA"
    },
    {
        "text": "in diabetic patients , the metabolic effects of HD00657 may decrease blood glucose and therefore , HD00071 requirements .",
        "label": "effect"
    },
    {
        "text": "and ddrug0 when ddrug1 is given with HD00315 agents or ddrug3 drugs , including ddrug4 combined with local HD00264 , close supervision and careful adjustment of dosages are required .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : steady-state trough plasma ddrug1 and HD00749 concentrations were not affected by concomitant DB00996 { 400 mg tid ;",
        "label": "NA"
    },
    {
        "text": "aim and background : the pharmacokinetic interaction between ddrug0 , a HD00083 metabolized by cyp3a4 , and the ddrug2 DB00343 was studied in # healthy subjects .",
        "label": "NA"
    },
    {
        "text": "in addition , studies in healthy volunteers have shown that DB00204 does not affect the pharmacokinetics or pharmacodynamics of ddrug1 , or the pharmacokinetics of ddrug2 { 40 mg twice daily } , ddrug3 , DB00277 , or oral ddrug5 .",
        "label": "NA"
    },
    {
        "text": "some ddrug0 , including DB00537 , have been associated with transient elevations in serum creatinine in patients receiving DB00091 concomitantly .",
        "label": "effect"
    },
    {
        "text": "the intensity , uniformity and time course of HD00025 interference by ddrug1 , ddrug2 , ddrug3 , ddrug4 and ddrug5 were systematically investigated in # patients receiving DB04665 therapy .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB01032 interferes with renal tubular secretion of ddrug2 and produces an increase in the level of DB00537 in serum .",
        "label": "mechanism"
    },
    {
        "text": "in a phase i trial using escalating doses of DB01229 { 110 - 200 mg/m2 } and ddrug1 { 50 or # mg/m2 } given as sequential infusions , myelosuppression was more profound when ddrug2 was given after DB00515 than with the alternate sequence { ie , ddrug4 before ddrug5 } .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of ddrug0 and ddrug1 , ddrug2 , DB00338 , or an ddrug4 / ddrug5 oral HD00349 produced minor changes in the pharmacokinetics of ddrug7 , which were considered to be without clinical significance .",
        "label": "NA"
    },
    {
        "text": "patients should be warned of the potential danger of the intravenous self-administration of HD00100 while under treatment with DB01183 or ddrug2 .",
        "label": "advise"
    },
    {
        "text": "a similar association , though less marked , has been suggested with HD00026 , phenyl-butazone , ddrug1 , ddrug2 and possibly with ddrug3 , ddrug4 , and HD00239 { 72 }",
        "label": "NA"
    },
    {
        "text": "while all the ddrug0 { HD00114 } , e , g , , ddrug2 , DB01104 , ddrug4 , and ddrug5 , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .",
        "label": "NA"
    },
    {
        "text": "DB01394 ddrug1 and heavy ddrug2 intake for longer than # weeks may produce malabsorption of DB00115 .",
        "label": "mechanism"
    },
    {
        "text": "toxicology studies of DB01452 - related deaths reveal frequent involvement of other HD00389 , including ddrug2 , ddrug3 such as ddrug4 { ddrug5 } , and , to a rising degree , ddrug6 .",
        "label": "effect"
    },
    {
        "text": "rhabdomyolysis has been observed in patients receiving HD00095 administered alone { at recommended dosages } or concomitantly with HD00084 including ddrug2 .",
        "label": "effect"
    },
    {
        "text": "HD00026 may decrease the effectiveness of oral HD00283 , certain ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , and ddrug7 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 such as ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , ddrug5 { e , g , , ddrug6 } , DB01037 { e , g , , ddrug8 } , and ddrug9 { e , g , , ddrug10 } : using these medicines with DB00150 may increase the chance of side effects .",
        "label": "NA"
    },
    {
        "text": "co-administration of DB09026 did not significantly affect the pharmacokinetics of ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 or DB00999 .",
        "label": "NA"
    },
    {
        "text": "moreover , additional interaction studies with ddrug0 and DB00571 have not demonstrated any effect on ddrug2 plasma levels , and administration to a patient population chronically receiving ddrug3 resulted in no difference in the extent of bioavailability of DB00390 relative to control data .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : coadministration of a 10-mg single dose of ddrug1 with DB00908 { 166 mg/day for # days } , a potent inhibitor of cyp2d6 , increased the auc of DB01238 by 112 % but decreased the auc of its active metabolite , ddrug4 , by 35 % .",
        "label": "NA"
    },
    {
        "text": "however , since DB00945 , ddrug1 , and ddrug2 are all associated with gastrointestinal irritation , caution should be exercised in the concomitant use of ddrug3 or ddrug4 with DB00710 .",
        "label": "NA"
    },
    {
        "text": "antiacid , ddrug0 , ddrug1 , ddrug2 , ddrug3 , indanavir , ddrug4 , DB00252 , phenobarbitol , ddrug6 , ddrug7 , ddrug8 , ritanovir , DB01232 .",
        "label": "NA"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : ddrug1 ; ddrug2 ; ddrug3 ; certain HD00002 , especially the HD00249 and ddrug6 ; ddrug7 ; ddrug8 salts ; ddrug9 ; and ddrug10 .",
        "label": "NA"
    },
    {
        "text": "drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on ddrug0 therapy : ddrug1 , ddrug2 , ddrug3 , oral ddrug4 containing ddrug5 , DB11119 - containing preparations and the numerous preparations containing HD00328 .",
        "label": "NA"
    },
    {
        "text": "in addition to bleeding associated with ddrug0 and HD00286 , drugs that alter platelet function { such as ddrug2 , ddrug3 and DB00054 } may increase the risk of bleeding if administered prior to , during , or after ddrug5 therapy .",
        "label": "NA"
    },
    {
        "text": "HD00532 , including ddrug1 , may enhance the effects of oral ddrug2 , such as DB00682 or its derivatives .",
        "label": "effect"
    },
    {
        "text": "ddrug0 enhance the renal toxicity of HD00663 in animals , # ddrug2 interferes with the action of HD00664 preparations by chelating the ddrug4 , 7",
        "label": "NA"
    },
    {
        "text": "ddrug0 - DB00117 was observed to enhance { in tissue culture } the effect of DB00603 in reducing the number of human breast_cancer cells that were in the s phase .",
        "label": "effect"
    },
    {
        "text": "HD00679 : drugs such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB00975 , ddrug7 and others that interfere with platelet-aggregation reactions { the main hemostatic defense of heparinized patients } may induce bleeding and should be used with caution in patients receiving ddrug8 .",
        "label": "NA"
    },
    {
        "text": "DB00392 can interact with ddrug1 , increasing the metabolism of DB00477 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : concomitant administration of DB00945 with ddrug2 may result in an increased risk of gi ulceration and complications compared to DB00580 alone .",
        "label": "NA"
    },
    {
        "text": "DB00152 , or other products containing ddrug1 or DB01593 , ddrug3 or ddrug4 should not be administered concomitantly with , or within # hours of , the administration of ddrug5 , because they may interfere with absorption resulting in lower serum and urine levels of ddrug6 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a study in healthy volunteers , no clinically relevant pharmacokinetic or pharmacodynamic interaction between DB00270 and racemic DB00682 was seen when two single oral doses of ddrug3 { # mg/kg body weight } were administered during # days of multipledose treatment with # mg b , i , d , ddrug4 .",
        "label": "NA"
    },
    {
        "text": "dose adjustment of DB01012 may be required and pth and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong cyp3a4 inhibitor { e , g , , DB01026 , ddrug2 , ddrug3 ;",
        "label": "advise"
    },
    {
        "text": "oral ddrug0 : based on auc and half-life , multiple-dose pharmacokinetic profiles of ddrug1 and DB00977 following administration of tablets containing # mg of ddrug3 and # mcg of ddrug4 were similar with and without coadministration of DB00996 { 400 mg tid ;",
        "label": "NA"
    },
    {
        "text": "untreated hypothyroidism may interfere with the growth response to DB09098 or DB00052 .",
        "label": "NA"
    },
    {
        "text": "DB00598 has also been reported to produce a false positive test for DB00182 when screening urine for the presence of drugs using the commercially available assay methods toxi-lab a { thin-layer chromatographic assay } and emit-d , a , u , { radioenzymatic assay } .",
        "label": "NA"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , ddrug3 HD00388 : ddrug5 , ddrug6 antimigraine : ddrug7 HD00871 : ddrug9 ddrug10 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "other drug interactions : no pharmacokinetic interactions were observed between ddrug0 and the following drugs : ddrug1 , DB00682 , DB00390 , ddrug4 , and ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : other HD00304 drugs , such as ddrug2 , ddrug3 , ddrug4 , and DB00252 , have been used concurrently with ddrug6 .",
        "label": "NA"
    },
    {
        "text": "caution should be used when administering or taking ddrug0 with DB01026 and other strong cyp3a4 inhibitors such as , but not limited to , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , DB00503 , ddrug9 , ddrug10 , ddrug11 { ddrug12 } , and ddrug13 .",
        "label": "NA"
    },
    {
        "text": "it is recommended that ddrug0 not be used concomitantly with HD00343 because the effects of concomitant administration of DB00490 with most other ddrug3 have not been studied , the concomitant use of ddrug4 with other cns-active drugs should be approached with caution .",
        "label": "NA"
    },
    {
        "text": "concomitant use of DB01254 and drugs that inhibit cyp3a4 { eg , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 } may increase exposure to DB01254 and should be avoided .",
        "label": "NA"
    },
    {
        "text": "an alternative non-cyp3a4 substrate HD00905 may be considered in patients taking cyp3a4 inducers such as ddrug1 , DB00252 , ddrug3 , and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "other interactions : DB00862 had no effect on the pharmacodynamics of ddrug1 { glucose and irdn concentrations } and DB00682 { prothrombin time or other pharmacodynamic parameters } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 : ddrug2 and ddrug3 containing DB14513 or DB01370 , as well as formulations containing divalent and trivalent cations such as ddrug6 { ddrug7 } , chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with ddrug8 and interfere with its bioavailability .",
        "label": "NA"
    },
    {
        "text": "talk to your doctor if you are taking certain HD00002 such as ddrug1 , ddrug2 or DB00207 .",
        "label": "NA"
    },
    {
        "text": "cyclosporine , digoxin , methotrexate ddrug0 , like other HD00203 , through effects on renal prostaglandins , may cause changes in the elimination of these drugs leading to elevated serum levels of DB00091 , ddrug3 , ddrug4 , and increased toxicity .",
        "label": "mechanism"
    },
    {
        "text": "in addition to bleeding associated with ddrug0 and HD00286 , drugs that alter platelet function { such as ddrug2 , DB00975 and ddrug4 } may increase the risk of bleeding if administered prior to , during , or after ddrug5 therapy .",
        "label": "NA"
    },
    {
        "text": "of over # patients enrolled in the DB00710 osteoporosis treatment and prevention studies , 15 % used anti-peptic agents { primarily HD00586 and ddrug2 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { ddrug1 } : population pharmacokinetic analyses indicate that DB00906 clearance is 60 % greater in patients taking ddrug3 { ddrug4 } with or without other enzyme-inducing HD00714 .",
        "label": "NA"
    },
    {
        "text": "because prostaglandina play an important role in hemostasis and ddrug0 has an effect on platelet function as well , concurent therapy with DB01009 and DB00682 requires close monitoring of patients on both drugs .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : increased serum ddrug1 levels and symptoms of DB14507 toxicity have been reported in patients receiving HD00106 during therapy with ddrug4 .",
        "label": "NA"
    },
    {
        "text": "patients taking DB00704 may not benefit from HD00023 containing medicines , such as cough and cold preparations , antidiarrheal preparations , and ddrug2 .",
        "label": "effect"
    },
    {
        "text": "at higher than recommended doses , HD00897 # mg administered once daily for # days increased plasma concentrations by 23 % as measured by auc0 - 24hr in patients receiving DB00563 # to # mg/week for rheumatoid arthritis .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 should be used with care when ddrug1 or inhibitors of av conduction , such as certain HD00085 { particularly of the ddrug3 -lsb- ddrug4 -rsb- and ddrug5 -lsb- ddrug6 -rsb- classes } , or HD00428 , such as ddrug8 , are used concurrently .",
        "label": "NA"
    },
    {
        "text": "DB01394 is inhibited by HD00569 .",
        "label": "mechanism"
    },
    {
        "text": "DB00649 and ddrug1 DB00811 can antagonize the in vitro antiviral activity of ddrug3 and ddrug4 against hiv .",
        "label": "NA"
    },
    {
        "text": "an adequate period of observation must be provided for any patient in whom either ddrug0 { such as DB00829 } or large doses of HD00736 { such as # mg of ddrug3 } have been used .",
        "label": "NA"
    },
    {
        "text": "DB01032 : as with other HD00487 , ddrug2 inhibits the renal excretion of ddrug3 , resulting in an approximate doubling in a , c , a 54 % increase in peak ddrug4 plasma levels , and a 50 % prolongation in the apparent elimination half-life .",
        "label": "NA"
    },
    {
        "text": "repeated doses of DB00375 given prior to a single dose of ddrug1 in human trials have been reported to decrease DB00571 absorption .",
        "label": "NA"
    },
    {
        "text": "an intravenous injection of DB03138 given later also produces a complete and immediately beginning depletion of HD00127 already accumulated in the thyroid , within a period of # min after 99m-tco-4-injection with a corresponding increase in blood levels .",
        "label": "mechanism"
    },
    {
        "text": "concomitant administration with racemic ddrug0 DB00215 - since ddrug2 is the active isomer of racemic ddrug3 { DB00215 } , the two agents should not be coadministered .",
        "label": "NA"
    },
    {
        "text": "all # strains of enterococcus , three strains of clostridium , three strains of escherichia coli , and one strain of proteus rettgeri were resistant to both DB01190 { minimal inhibitory concentration greater than # mug/ml } and DB00798 { minimal inhibitory concentration greater than # mug/ml } .",
        "label": "NA"
    },
    {
        "text": "because DB01432 binds bile acids , ddrug1 HD00524 may interfere with normal fat digestion and absorption and thus may prevent absorption of ddrug3 such as a , d , e , and k.",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a clinical pharmacology study , coadministration of an DB06724 { ddrug2 , ddrug3 , and ddrug4 } with ddrug5 reduced serum levels and urinary excretion of ddrug6 as compared with DB00492 administered alone , suggesting that ddrug8 may impair absorption of ddrug9 .",
        "label": "NA"
    },
    {
        "text": "total body clearance of DB00074 was reduced by an average 22 % and 51 % when ddrug1 and ddrug2 , respectively , were added to a regimen consisting of ddrug3 , usp { modified } and HD00175 .",
        "label": "NA"
    },
    {
        "text": "pharmacokinetic interaction studies with DB00341 in adults were conducted with ddrug1 , DB01435 , ddrug3 , ddrug4 and ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00199 has been reported to decrease the clearance of ddrug2 and , thus , may increase the pharmacologic effect of DB00897 .",
        "label": "effect"
    },
    {
        "text": "DB00580 did not have a statistically significant effect on the pharmacokinetics of DB00252 { a ppig 2c9 and cyp 2c19 substrate } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : when administered to patients on a HD00856 , this parenteral DB01086 may cause hypertension and tachycardia .",
        "label": "effect"
    },
    {
        "text": "ddrug0 and ddrug1 - although not reported , DB00117 , via its metabolism to histamine , might decrease the efficacy of HD00827 and ddrug4 .",
        "label": "effect"
    },
    {
        "text": "risk of anaphylactic reaction : although it is known that patients on HD00254 may be refractory to DB00668 in the treatment of anaphylactic shock , ddrug2 can , in addition , interfere with the modulation of allergic reaction and lead to an increased severity and/or frequency of attacks .",
        "label": "effect"
    },
    {
        "text": "other drugs : in healthy volunteers , ddrug0 , ddrug1 , ddrug2 , DB00863 , ddrug4 , hormone replacement therapy { a combination of conjugated HD00220 and ddrug6 } , ddrug7 { ddrug8 and ddrug9 } and ddrug10 did not affect the pharmacokinetics of ddrug11 .",
        "label": "NA"
    },
    {
        "text": "limited clinical experience indicates that requirements for ddrug0 are reduced by # to 50 % for the first sixty { 60 } minutes following ddrug1 induction the concomitant use of DB00199 with ddrug3 can significantly inhibit DB00802 clearance and may increase the risk of prolonged or delayed respiratory depression .",
        "label": "NA"
    },
    {
        "text": "- a HD00535 { ddrug1 } such as ddrug2 { ddrug3 , ddrug4 , ddrug5 , others } , ddrug6 { ddrug7 , ddrug8 , ddrug9 } , DB00586 { ddrug11 , ddrug12 } , ddrug13 { ddrug14 } , ddrug15 { ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , and ddrug21 { ddrug22 , ddrug23 , ddrug24 } ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 : hallucinations have been reported when DB00465 was used in patients taking ddrug2 { ddrug3 , DB01623 , ddrug5 } .",
        "label": "effect"
    },
    {
        "text": "the pressor effects of HD00439 such as ddrug1 or DB00368 are enhanced by ddrug3 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and foods fortified with ddrug1 concomitant administration of ddrug2 with a therapeutic HD00490 containing # mg of elemental ddrug4 { as feso4 } or HD00489 supplemented with # mg of elemental ddrug6 reduced extent of absorption by 80 % and 31 % , respectively .",
        "label": "NA"
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit ddrug0 binding to serum proteins or alter the concentrations of serum binding proteins : HD00657 and related ddrug2 , ddrug3 , ddrug4 , ddrug5 and ddrug6 , ddrug7 , ddrug8 , ddrug9 , DB00939 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 .",
        "label": "NA"
    },
    {
        "text": "although clinical studies have not been performed , based on the involvement of the cytochrome p-450 3a family in DB01068 metabolism , inhibitors of this enzyme system , notably oral HD00247 , should be used cautiously in patients receiving ddrug2 .",
        "label": "NA"
    },
    {
        "text": "there is no information regarding the effect on DB00709 pharmacokinetics of higher doses of ddrug1 / DB01015 such as those used to treat pneumocystis carinii pneumonia .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - prior ingestion of ddrug1 may decrease the HD00627 response to DB00714 in the treatment of poisoning .",
        "label": "NA"
    },
    {
        "text": "no interaction was noted with the ddrug0 ddrug1 in two multiple-dose interaction studies when DB00494 was coadministered with a ddrug3 / HD00680 { n = 29 } .",
        "label": "NA"
    },
    {
        "text": "may interact with thyroid medication { e , g , , ddrug0 } , ddrug1 - containing products , ddrug2 , ddrug3 { e , g , , ddrug4 , DB00863 } , and ddrug6 { e , g , , ddrug7 , DB00338 } .",
        "label": "NA"
    },
    {
        "text": "blood sampling for the pharmacokinetics of DB01590 and DB00091 was performed on day 1 , on weeks 1 , 2 , 3 , and 4 , and on months 2 , 3 , 6 , 9 , and 12 .",
        "label": "NA"
    },
    {
        "text": "toxicology studies of ddrug0 - related deaths reveal frequent involvement of other ddrug1 , including DB02325 , ddrug3 such as ddrug4 { ddrug5 } , and , to a rising degree , DB00333 .",
        "label": "NA"
    },
    {
        "text": "immediate and extended release tablets the hypoglycemic action of HD00222 may be potentiated by certain drugs including HD00518 , some ddrug2 and other drugs that are highly protein bound , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 .",
        "label": "effect"
    },
    {
        "text": "DB00924 may enhance the effects of DB02325 , ddrug2 , and other ddrug3 .",
        "label": "effect"
    },
    {
        "text": "also , due to the potential for additive effects such as bradycardia and av block , caution is warranted in patients receiving DB00575 with agents known to affect sinus node function or av nodal conduction { e , g , , HD00118 , ddrug2 , and ddrug3 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : caution should be used if DB00861 is administered concomitantly with DB00563 .",
        "label": "advise"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , ddrug3 HD00388 : ddrug5 , DB00342 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "other cardiovascular agents : ddrug0 and ddrug1 iv have been used concomitantly with ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , DB00457 and DB00390 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "ddrug0 can interact with DB02325 or other ddrug2 { may potentiate the cns depressant effects of either these medications or ddrug3 } , ddrug4 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug5 } , and HD00445 { concurrent use with ddrug7 may prolong and intensify the anticholinergic and cns depressant effects of ddrug8 } .",
        "label": "NA"
    },
    {
        "text": "therefore , the concomitant administration of DB00559 and DB01016 is contraindicated , and alternative ddrug2 should be considered .",
        "label": "advise"
    },
    {
        "text": "ddrug0 may enhance the effects of ddrug1 , HD00026 , ddrug3 , and other HD00261 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : DB00316 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , DB01045 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 should be used with caution in patients receiving - HD00305 blocking agents { e , g , , ddrug3 , a ddrug4 inhibitor } or ddrug5 antagonists { e , g , , ddrug6 , a HD00302 substrate , and ddrug8 , a ddrug9 inhibitor } because of the possible potentiation of bradycardia , sinus arrest , and av block ;",
        "label": "NA"
    },
    {
        "text": "urinary alkalinizing agents { DB00819 , some ddrug1 } increase the concentration of the non-ionized species of the DB00182 molecule , thereby decreasing urinary excretion .",
        "label": "mechanism"
    },
    {
        "text": "therefore , concurrent use of DB00776 with ddrug1 may render these HD00283 less effective .",
        "label": "NA"
    },
    {
        "text": "HD00461 { cns } drugs including ddrug1 , ddrug2 , ddrug3 , ddrug4 , blood pressure medications { ddrug5 , ddrug6 , ddrug7 } , motion sickness medications , HD00542 , ddrug9 , ddrug10 , sleeping pills and ddrug11",
        "label": "NA"
    },
    {
        "text": "DB01032 may decrease renal tubular secretion of HD00485 when used concurrently , resulting in increased and more prolonged ddrug2 blood levels .",
        "label": "mechanism"
    },
    {
        "text": "DB00224 : coadministration of ddrug1 with ddrug2 resulted in an 83 % increase in DB00220 plasma auc and a 51 % increase in ddrug4 plasma a , c.",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and DB00759 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , DB00503 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "patients receiving DB00993 and DB00437 concomitantly should have a dose reduction of ddrug2 , to approximately 1/3 to 1/4 the usual dose .",
        "label": "advise"
    },
    {
        "text": "HD00084 , ddrug1 , ddrug2 { ddrug3 , DB00199 , ddrug5 : skeletal muscle .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and DB09278 administration of ddrug2 or ddrug3 in patients { n = 13 } and volunteers { n = 96 } resulted in a rapid and significant decrease in plasma m1 { the active metabolite of DB01097 } concentration .",
        "label": "NA"
    },
    {
        "text": "to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma { hiv-nhl } , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the ddrug0 , ddrug1 , ddrug2 , and DB00898 { chop } chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen { i , e , , ddrug4 , ddrug5 , ddrug6 , and ddrug7 with ddrug8 plus ddrug9 } without receiving HD00056 therapy .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , DB00316 and ddrug2 may enhance the effects of : other ddrug3 s , ddrug4 , general ddrug5 , ddrug6 such as DB00475 , ddrug8 , or other ddrug9 , causing increased cns depression .",
        "label": "effect"
    },
    {
        "text": "effect of DB00533 on the pharmacokinetics of DB00390 in healthy volunteers .",
        "label": "NA"
    },
    {
        "text": "oral HD00283 multiple doses of DB01066 had no effect on the pharmacokinetics of ddrug2 , the estrogenic component in most oral ddrug3 .",
        "label": "NA"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : ddrug1 ; ddrug2 ; ddrug3 ; certain ddrug4 , especially the HD00249 and HD00384 ; ddrug7 ; ddrug8 salts ; ddrug9 ; and ddrug10 .",
        "label": "NA"
    },
    {
        "text": "therefore , concurrent use of DB00945 and DB01009 is not recommended .",
        "label": "advise"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { ddrug1 s } , ddrug2 , ddrug3 { ddrug4 may decrease the effects of these medicines } , HD00458 { using these medicines with ddrug6 may result in increased cns depressant effects } , ddrug7 , ddrug8 { using these medicines with HD00026 may change the amount of either medicine that you need to take } , and oral ddrug10 containing ddrug11 { ddrug12 may decrease the effectiveness of these oral ddrug13 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 can interact with DB02325 or other ddrug2 { may potentiate the cns depressant effects of either these medications or ddrug3 } , ddrug4 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug5 } , and ddrug6 { concurrent use with ddrug7 may prolong and intensify the anticholinergic and cns depressant effects of HD00388 } .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of HD00071 : ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , ddrug5 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , DB00052 , ddrug11 , ddrug12 , ddrug13 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "these drugs include the ddrug0 and other ddrug1 , HD00175 , ddrug3 , ddrug4 , HD00220 , oral ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , and ddrug11 .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of ddrug0 and DB06724 , ddrug2 , ddrug3 , or an HD00183 / ddrug5 oral ddrug6 produced minor changes in the pharmacokinetics of ddrug7 , which were considered to be without clinical significance .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { ddrug1 , ddrug2 } : pregnancy has been reported following concomitant use , however , pharmacokinetic studies have not shown consistent effects with these HD00002 on plasma concentrations of HD00707 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : DB00316 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , DB00295 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 : based on auc and half-life , multiple-dose pharmacokinetic profiles of DB00717 and ddrug2 following administration of tablets containing # mg of ddrug3 and # mcg of ddrug4 were similar with and without coadministration of DB00996 { 400 mg tid ;",
        "label": "NA"
    },
    {
        "text": "- ddrug0 { e , g , , ddrug1 } use of DB00968 with DB00891 may increase the chance of side effects affecting the liver and/or the blood",
        "label": "effect"
    },
    {
        "text": "DB00151 was covalently linked to carbodiimide activated HD00072 .",
        "label": "NA"
    },
    {
        "text": "however , no deleterious interactions were seen when DB01205 was administered after ddrug1 , inhalational ddrug2 , HD00542 and muscle relaxant antagonists administered in conjunction with sedation or anesthesia .",
        "label": "NA"
    },
    {
        "text": "the influence of ddrug0 and DB00829 on antinociceptive effect of DB00295 { 10 mg/kg } , ddrug3 { 500 mg/kg } and ddrug4 { 10 mg/kg } was investigated in a mouse model using the tail-flick and hot-plate tests .",
        "label": "NA"
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma ddrug0 concentrations include : acute DB02325 intake , ddrug2 , chboramphenicol , ddrug3 , ddrug4 , DB00829 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21",
        "label": "NA"
    },
    {
        "text": "in clinical trials , ddrug0 was used with ddrug1 , ddrug2 , ddrug3 , oral ddrug4 , and supplemental DB09140 , in a pharmacokinetic substudy in patients with congestive heart failure receiving ddrug6 or ddrug7 in whom therapy with ddrug8 was initiated , apparent oral clearance values for DB00695 { n = 23 } and ddrug10 { n = 30 } were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .",
        "label": "NA"
    },
    {
        "text": "binding to serum proteins : the following agents may either inhibit ddrug0 binding to serum proteins or alter the concentrations of serum binding proteins : ddrug1 and related HD00846 , ddrug3 , ddrug4 , ddrug5 and ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , DB00675 .",
        "label": "NA"
    },
    {
        "text": "the co-administration of ddrug0 with iv ddrug1 such as ddrug2 , ddrug3 , DB00235 , or iv ddrug5 has not been evaluated { these drugs were not co-administered with DB04899 in clinical trials } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { HD00548 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , DB00295 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "DB01232 : coadministration of ddrug1 { using an experimental soft-gelatin capsule formulation of ddrug2 1200 mg } with DB00220 resulted in an 18 % increase in ddrug4 plasma auc and a 4-fold increase in ddrug5 plasma a , c.",
        "label": "NA"
    },
    {
        "text": "although DB01609 has a lower affinity for ddrug1 than for ddrug2 , DB01609 should not be taken with ddrug4 - containing ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , such as DB00206 , may have an additive effect when given with HD00228 .",
        "label": "effect"
    },
    {
        "text": "in the experiments reported here , we examined the interactions between HD00179 and the ddrug1 DB04468 { ddrug3 } , which also induces apoptosis in mcf-7 cells .",
        "label": "NA"
    },
    {
        "text": "drug-drug interactions : no clinically significant drug interactions have been found with DB00277 at a low dose , ddrug1 , DB00852 , ddrug3 , or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "in rheumatoid arthritis , concomitant medications besides DB00563 were HD00518 , ddrug2 , ddrug3 and/or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , HD00246 and ddrug2 : concomitant treatment with ddrug3 , ddrug4 , or HD00218 may potentiate a possible hypokalemic effect of ddrug6",
        "label": "NA"
    },
    {
        "text": "in the presence of these HD00246 , larger doses of ddrug1 may be required or DB00640 may not be effective .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : ddrug1 { DB01170 , ddrug3 , ddrug4 , ddrug5 , fruit juices , etc , } lower absorption of HD00401 .",
        "label": "mechanism"
    },
    {
        "text": "- a HD00762 { ddrug1 } such as ddrug2 { ddrug3 } , ddrug4 { DB00752 } , or ddrug6 { ddrug7 } ;",
        "label": "NA"
    },
    {
        "text": "when ddrug0 is co-administered with inducers of drug clearance , such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , or DB00564 , use of a daily dose of # mg of DB00520 should be considered",
        "label": "NA"
    },
    {
        "text": "administering HD00053 together with HD00054 { 100 - 500 microm } inhibited insp { 3 } - induced responses { both ca { 2 + } and current responses } in a dose-dependent fashion .",
        "label": "effect"
    },
    {
        "text": "ddrug0 } , ddrug1 { e , g , ddrug2 } , and ddrug3 { e , g , ddrug4 , ddrug5 and DB01232 } should have their dose of ddrug7 or DB01183 adjusted .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other HD00216 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 DB14507 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "ddrug0 { ddrug1 } alone or in combination with DB00384 : concomitant use of DB00999 alone or in combination with ddrug4 is contraindicated .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { e , g , , ddrug1 , DB01110 , ddrug3 , ddrug4 , etc , } : in vitro and animal studies with the combination of DB00681 and ddrug6 suggest that ddrug7 may induce fungal resistance to ddrug8 .",
        "label": "NA"
    },
    {
        "text": "in clinical studies , DB00716 has been co-administered with other anti-asthma medications , including inhaled and oral ddrug1 , and inhaled HD00175 , with no evidence of increased frequency of adverse events or laboratory abnormalities .",
        "label": "NA"
    },
    {
        "text": "when used in therapeutic doses , DB00207 had a modest effect on the pharmacokinetics of ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB00196 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 { intravenous and oral } , ddrug12 , ddrug13 / ddrug14 or ddrug15 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 { e , g , , ddrug1 } - taking DB00592 and DB11156 together may decrease the effects of ddrug4 .",
        "label": "effect"
    },
    {
        "text": "the concomitant use of other cyp3a4 inhibitors such as DB00343 and ddrug1 with transdermal ddrug2 may also result in an increase in DB00813 plasma concentrations , which could increase or prolong adverse drug effects and may cause serious respiratory depression .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { cns } drugs including ddrug1 , ddrug2 , ddrug3 , HD00031 , blood pressure medications { ddrug5 , ddrug6 , ddrug7 } , motion sickness medications , ddrug8 , ddrug9 , ddrug10 , sleeping pills and HD00262",
        "label": "NA"
    },
    {
        "text": "ddrug0 can reduce the antihypertensive effects of DB01197 and DB00678 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 HD00897 # , 25 , and # mg , each dose administered once daily for # days , had no effect on the plasma concentration of DB00563 as measured by auc0 - 24hr in patients receiving single weekly ddrug3 doses of # to # mg for rheumatoid arthritis .",
        "label": "NA"
    },
    {
        "text": "hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose DB00041 and ddrug1 , specifically , ddrug2 , ddrug3 , DB00675 and ddrug5 .",
        "label": "effect"
    },
    {
        "text": "drugs which require a dose reduction when coadminstered with DB00220 HD00871 : ddrug2",
        "label": "advise"
    },
    {
        "text": "interactions may occur between DB00159 supplements and ddrug1 and other ddrug2 and herbs such as garlic { allium sativum } and DB01381 { ddrug4 } .",
        "label": "int"
    },
    {
        "text": "DB01104 neutralized the increase of glycemia induced by oral DB09341 overload .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 : ddrug1 , when given once daily for # days as a 100-mg capsule with an oral ddrug2 containing # mcg of ddrug3 and # mg of DB00717 , decreased the auc of DB00977 by 43 % , and decreased the auc of ddrug6 by 8 % ;",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 HD00388 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } DB01235 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "other potentially important drug interactions : ddrug0 : ddrug1 metabolized by hepatic oxidation { e , g , , DB00404 , ddrug3 , ddrug4 elc , } should be used with caution because the clearance of these drugs is likely to be reduced by DB00176 .",
        "label": "mechanism"
    },
    {
        "text": "{ 1968 , 1970 } , the higher serum concentrations of HD00124 and DB09008 reached after administration of ddrug2 are due not only to slower renal elimination but also to an altered distribution in the body .",
        "label": "NA"
    },
    {
        "text": "DB00501 , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of ddrug1 , ddrug2 , ddrug3 , DB01115 , ddrug5 , ddrug6 , certain ddrug7 , ddrug8 , ddrug9 and ddrug10 , thereby delaying elimination and increasing blood levels of these drugs .",
        "label": "mechanism"
    },
    {
        "text": "- a ddrug0 { HD00615 } such as ddrug2 { ddrug3 , ddrug4 , HD00759 , others } , ddrug6 { ddrug7 , ddrug8 , ddrug9 } , ddrug10 { ddrug11 , ddrug12 } , ddrug13 { ddrug14 } , ddrug15 { ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , and ddrug21 { ddrug22 , ddrug23 , ddrug24 } ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 , ddrug1 , HD00372 , and DB01109 the in vitro binding of ddrug4 to plasma proteins is only slightly reduced by ddrug5 { # % control vs # % } when ddrug6 plasma concentrations reach # to10 m g/ml .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 { and possibly other ddrug2 } and DB00759 may increase ddrug4 absorption in patients who inactivate DB00390 by bacterial metabolism in the lower intestine , so that ddrug6 intoxication may result .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { DB00091 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , DB00277 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "drug/laboratory test interactions a false-positive reaction for ketones in the urine may occur with tests using DB00325 but not with those using DB00325 .",
        "label": "NA"
    },
    {
        "text": "no significant drug interactions have been reported in studies of ddrug0 given with other drugs such as DB01016 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , and oral HD00283 in healthy volunteers , or given with ddrug7 to patients with heart failure { nyha class ii and iii } .",
        "label": "NA"
    },
    {
        "text": "HD00071 or oral ddrug1 : initiating thyroid replacement therapy may cause increases in ddrug2 or oral HD00854 requirements .",
        "label": "NA"
    },
    {
        "text": "toxicology studies of ddrug0 - related deaths reveal frequent involvement of other ddrug1 , including ddrug2 , HD00100 such as ddrug4 { DB00829 } , and , to a rising degree , ddrug6 .",
        "label": "NA"
    },
    {
        "text": "other drugs : based on the results of drug interaction studies , no dosage adjustment is recommended when DB00625 { ddrug1 } is given with the following : ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , DB00709 , ddrug8 , ddrug9 , ddrug10 , and ddrug11 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , DB01076 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { HD00712 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , DB00776 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , DB00295 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB01026 may inhibit both synthetic and catabolic enzymes of DB11094 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 / ddrug1 : long-term suppression of gastric acid secretion by ddrug2 or ddrug3 { eg , DB00927 and ddrug5 } is likely to reduce DB01254 exposure .",
        "label": "effect"
    },
    {
        "text": "absorption of ddrug0 is impaired by HD00374 containing ddrug2 , DB01373 , or ddrug4 , and ddrug5 - containing preparations .",
        "label": "NA"
    },
    {
        "text": "pharmacokinetic data indicate that oral DB01026 inhibits the metabolism of ddrug1 , resulting in elevated plasma levels of ddrug2 and its active metabolite HD00823 which may prolong qt intervals .",
        "label": "NA"
    },
    {
        "text": "other drugs : in healthy volunteers , ddrug0 , ddrug1 , DB01016 , ddrug3 , ddrug4 , hormone replacement therapy { a combination of conjugated ddrug5 and HD00642 } , ddrug7 { ddrug8 and ddrug9 } and ddrug10 did not affect the pharmacokinetics of ddrug11 .",
        "label": "NA"
    },
    {
        "text": "both ddrug0 and ddrug1 block DB00295 - induced and DB00184 - induced dopamine release in the nucleus accumbens ;",
        "label": "NA"
    },
    {
        "text": "no depressant effect on blood levels in humans was noted when DB00375 was administered with any of the following drugs : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 { ddrug6 } , ddrug7 , ddrug8 or DB00682 .",
        "label": "NA"
    },
    {
        "text": "HD00175 and ddrug1 { ddrug2 } : may potentiate DB00681 - induced hypokalemia which may predispose the patient to cardiac dysfunction .",
        "label": "effect"
    },
    {
        "text": "in addition , DB00569 neither influenced the pharmacodynamics of ddrug1 , ddrug2 , ddrug3 , and DB00390 , nor the pharmacokinetics of ddrug5 at steady state .",
        "label": "NA"
    },
    {
        "text": "HD00113 { ddrug1 } { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 } have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with HD00277 .",
        "label": "effect"
    },
    {
        "text": "patients receiving other ddrug0 , ddrug1 , ddrug2 , or other ddrug3 { including ddrug4 } concomitantly with DB00956 and DB00316 tablets may exhibit an additive cns depression .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : other HD00304 drugs , such as ddrug2 , ddrug3 , DB00280 , and ddrug5 , have been used concurrently with ddrug6 .",
        "label": "NA"
    },
    {
        "text": "since ddrug0 is extensively metabolized by cyp4f3 isoenzymes , caution should be exercised when DB01166 is coadministered with inhibitors of c , p , a , such as ddrug2 and DB00199 or inhibitors of cyp2c19 such as ddrug4 .",
        "label": "advise"
    },
    {
        "text": "co-administration of DB09026 did not significantly affect the pharmacokinetics of ddrug1 , ddrug2 , DB00177 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 or ddrug10 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { e , g , , ddrug1 , ddrug2 , ddrug3 , DB00196 , etc , } : in vitro and animal studies with the combination of DB00681 and ddrug6 suggest that ddrug7 may induce fungal resistance to ddrug8 .",
        "label": "NA"
    },
    {
        "text": "spontaneous reports of serotonin syndrome associated with co-administration of DB00601 and HD00851 , including ddrug2 such as ddrug3 { ddrug4 } , have been reported .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , DB01174 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , DB00277 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , HD00668 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , DB01045 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "results demonstrate that DB00776 and its pharmacologically active 10-monohydroxy metabolite { HD00888 } have little or no capacity to function as inhibitors for most of the human cytochrome cyp2b6 enzymes evaluated { cyp1a2 , cyp2a6 , cyp2c9 , cyp2d6 , cyp2e1 , cyp4a9 and cyp4a11 } with the exception of cyp2c19 and cyp3a4/5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , DB00273 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { HD00712 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "however , concomitant administration of DB00945 with ddrug1 may result in an increased rate of gi ulceration or other complications , compared to use of DB00482 alone .",
        "label": "NA"
    },
    {
        "text": "to investigate the effects of antimicrobial combinations of HD00006 with four kinds of ddrug1 { ddrug2 , ddrug3 , ddrug4 and DB00446 } , the fractional inhibitory concentration index { fici } was determined by checkerboard assay for each strain .",
        "label": "NA"
    },
    {
        "text": "ddrug0 HD00524 may delay or reduce the absorption of concomitant oral medication such as ddrug2 , ddrug3 , ddrug4 { acidic } or ddrug5 { basic } , as well as ddrug6 ddrug7 , ddrug8 , thyroid and HD00525 preparations , ddrug10 and ddrug11 , and ddrug12 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 injection should not be mixed with ddrug1 , DB00450 , ddrug3 , or ddrug4 , since it has been reported that these drugs are incompatible with DB01109 and a precipitate may form .",
        "label": "NA"
    },
    {
        "text": "the beneficial effects on arterial thrombus formation from combined therapy with HD00332 and HD00333 must be weighed against an increased risk of inducing hemorrhage .",
        "label": "advise"
    },
    {
        "text": "DB01232 : the combination of ddrug1 , ddrug2 , and DB00495 has been studied { as triple combination } in adults .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : when DB09026 was co-administered with DB00695 , the auc and cmax of ddrug3 were reduced by about 30 % and 50 % , respectively .",
        "label": "mechanism"
    },
    {
        "text": "- ddrug0 and ddrug1 ddrug2 : ddrug3 and ddrug4 HD00510 have the potential of binding ddrug6 and reducing HD00295 absorption from the gastrointestinal tract",
        "label": "NA"
    },
    {
        "text": "ddrug0 should be used with care when ddrug1 or inhibitors of av conduction , such as certain ddrug2 { particularly of the HD00426 -lsb- ddrug4 -rsb- and ddrug5 -lsb- DB00343 -rsb- classes } , or ddrug7 , such as ddrug8 , are used concurrently .",
        "label": "NA"
    },
    {
        "text": "an additive hypotensive effect has been reported with the combination of systemic DB00575 and DB06454 therapy .",
        "label": "effect"
    },
    {
        "text": "and DB00822 when ddrug1 is given with ddrug2 agents or ddrug3 drugs , including DB00668 combined with local ddrug5 , close supervision and careful adjustment of dosages are required .",
        "label": "NA"
    },
    {
        "text": "although neither ddrug0 nor ddrug1 affected the proliferation of prostatic epithelium in rpmi1640 containing HD00149 alone , they modify the mitogenic effect of HD00148 and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "differential actions of intrathecal DB01183 on blocking the tail-flick inhibition induced by intraventricular ddrug1 and DB00295 in rats .",
        "label": "NA"
    },
    {
        "text": "drug interactions : ddrug0 may interact with some drugs , like ddrug1 { ddrug2 } : HD00725 could theoretically affect DB00875 pharmacodynamics - ddrug5 - jzqyavbxjcqsok_uhfffaoysa_n - ddrug6 : ddrug7 and ddrug8 cause additive cns depression - ddrug9 : ddrug10 increases the effect of ddrug11",
        "label": "effect"
    },
    {
        "text": "DB00486 has been shown to have an additive cns depressant effect when given with either ddrug1 , ddrug2 , DB02325 or ddrug4 .",
        "label": "effect"
    },
    {
        "text": "DB00294 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , DB01167 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "int"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { HD00712 } , ddrug39 { DB01045 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing DB01370 , ddrug3 , or ddrug4 , with DB00364 , with metal cations such as ddrug6 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { DB00682 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } HD00220 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "because of its primary cns effect , caution should be used when HD00472 is taken with other HD00365 and ddrug2 .",
        "label": "advise"
    },
    {
        "text": "because of its primary cns effect , caution should be used when HD00472 is taken with other ddrug1 and DB02325 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 { ddrug1 , ddrug2 , ddrug3 , DB00252 , ddrug5 } : increase the metabolism of ddrug6 and/or some HD00526 , leading to possible decrease in contraceptive effectiveness .",
        "label": "mechanism"
    },
    {
        "text": "the potential effects of increased plasma concentrations of ddrug0 or other HD00100 metabolized via cyp3a4 { ddrug2 , DB00897 } should be considered when coadministering these agents with ddrug4 .",
        "label": "NA"
    },
    {
        "text": "plasma DB00313 concentration should be monitored when DB00951 and ddrug2 are co administered , and appropriate dosage adjustments of ddrug3 should be made .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB01045 contraindicated since the coadministration of this product with ddrug2 in an HD00056 regimen reduces the plasma concentrations of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "the administration of local ddrug0 containing ddrug1 or ddrug2 to patients receiving ddrug3 , HD00043 or HD00219 may produce severe , prolonged hypotension or hypertension .",
        "label": "NA"
    },
    {
        "text": "this drug may interact with ddrug0 or other HD00261 { may potentiate the cns depressant effects of either these medications or HD00388 } , ddrug3 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug4 } , and ddrug5 { concurrent use with ddrug6 may prolong and intensify the anticholinergic and cns depressant effects of ddrug7 } .",
        "label": "NA"
    },
    {
        "text": "limited data in patients receiving known enzyme inducers { ddrug0 , DB01174 , ddrug2 } indicate only a 30 % increase in the rate of DB01195 elimination .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 ddrug1 DB00365 , like other ddrug3 , may inhibit the metabolism of ddrug4 and DB01412 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 / ddrug1 : an increase in the frequency of skin rash has been reported among patients receiving DB00415 or DB01060 concurrently with ddrug4 compared to patients who are not receiving both drugs .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , HD00002 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , DB00949 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , DB01167 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , DB00295 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "like ddrug0 { 40 mg/kg } , ddrug1 { 40 mg/kg } decreases the intravenous self-administration of ddrug2 and DB00907 and the oral self-administration of DB00898 and ddrug5 in rats ;",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 - DB00134 may decrease hepatic toxicity in those with DB00316 overdosage or in those taking ddrug4 .",
        "label": "effect"
    },
    {
        "text": "total body clearance of DB00074 was reduced by an average 22 % and 51 % when ddrug1 and DB00688 , respectively , were added to a regimen consisting of ddrug3 , usp { modified } and ddrug4 .",
        "label": "mechanism"
    },
    {
        "text": "there were no clinically significant changes in corrected qt intervals during administration of DB00604 alone or with DB00472 .",
        "label": "NA"
    },
    {
        "text": "coadministration of DB00580 { 40 mg bid { day 1 } and # mg qd { days 2 - 7 } } with DB01016 { 10 mg ddrug2 bid } resulted in 21 % increase in ddrug3 auc0 - 12 and a 16 % increase in ddrug4 cmax leading to a 16 % decrease in glucose auc0 - 24 .",
        "label": "mechanism"
    },
    {
        "text": "there are reports of enhanced as well as diminished effects of HD00326 when given concurrently with HD00175 .",
        "label": "effect"
    },
    {
        "text": "the effects of DB00640 are antagonized by ddrug1 such as ddrug2 and DB00277 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 / ddrug1 : the coadministration of ddrug2 or DB01174 will not affect plasma concentrations of DB11094 , but may reduce endogenous plasma levels of ddrug5 / ergocalcitriol by accelerating metabolism .",
        "label": "NA"
    },
    {
        "text": "therefore , co-administration of ddrug0 with other drugs that are metabolized by this isozyme , including ddrug1 , ddrug2 , ddrug3 , and HD00310 { e , g , , ddrug5 , ddrug6 and ddrug7 } , or that inhibit this enzyme { e , g , , DB00908 } , should be approached with caution .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and DB00759 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , DB00776 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in the presence of DB00501 at # mg qid { n = 12 } the mean apparent oral clearance of DB00996 fell by 14 % and creatinine clearance fell by 10 % .",
        "label": "mechanism"
    },
    {
        "text": "DB01432 ddrug1 may delay or reduce the absorption of concomitant oral medication such as ddrug2 , ddrug3 , ddrug4 { acidic } or ddrug5 { basic } , as well as ddrug6 ddrug7 , DB01174 , thyroid and ddrug9 preparations , ddrug10 and ddrug11 , and ddrug12 .",
        "label": "mechanism"
    },
    {
        "text": "hormonal HD00283 co-administration of ddrug1 with an oral ddrug2 has been shown to influence the plasma concentrations of the two hormonal components , DB00977 { ee } and ddrug4 { lng } .",
        "label": "NA"
    },
    {
        "text": "drug interactions : ddrug0 may interact with some drugs , like ddrug1 { ddrug2 } : HD00725 could theoretically affect ddrug4 pharmacodynamics - ddrug5 - jzqyavbxjcqsok_uhfffaoysa_n - DB00898 : ddrug7 and ddrug8 cause additive cns depression - ddrug9 : ddrug10 increases the effect of ddrug11",
        "label": "NA"
    },
    {
        "text": "1 - nc denotes a mean change of less than 10 % 2 - pediatrics 3 - mean increase in adults at high DB00776 doses in vivo , the plasma levels of DB00252 increased by up to 40 % , when ddrug2 was given at doses above # mg/day .",
        "label": "NA"
    },
    {
        "text": "if treatment with inhibitors of cyp3a4 activity { such as ddrug0 , ddrug1 , DB00503 , ddrug3 , ddrug4 , ddrug5 , etc , } is indicated , reduction of the DB01222 dose should be considered .",
        "label": "advise"
    },
    {
        "text": "if concomitant treatment with DB00669 and an ddrug1 { e , g , , DB00472 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 } is clinically warranted , appropriate observation of the patient is advised .",
        "label": "advise"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , HD00668 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { DB01045 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a clinical pharmacology study , coadministration of an ddrug1 { ddrug2 , DB09104 , and ddrug4 } with ddrug5 reduced serum levels and urinary excretion of ddrug6 as compared with ddrug7 administered alone , suggesting that HD00374 may impair absorption of ddrug9 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 can interact with ddrug1 or other ddrug2 { may potentiate the cns depressant effects of either these medications or ddrug3 } , HD00444 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug5 } , and ddrug6 { concurrent use with ddrug7 may prolong and intensify the anticholinergic and cns depressant effects of HD00388 } .",
        "label": "NA"
    },
    {
        "text": "co-treatment with the potent cyp3a4 inhibitor DB01026 increases DB00530 auc by 2/3 .",
        "label": "mechanism"
    },
    {
        "text": "the effect of concomitant administration of DB00196 and DB01067 has been demonstrated in a placebo-controlled crossover study in normal volunteers .",
        "label": "int"
    },
    {
        "text": "although ddrug0 has a lower affinity for DB01370 than for ddrug2 , ddrug3 should not be taken with ddrug4 - containing HD00589 .",
        "label": "NA"
    },
    {
        "text": "in a comparison of ddrug0 tolerance in dogs anesthetized with ddrug1 , ddrug2 , or ddrug3 , the dosage of ddrug4 needed to cause ventricular tachycardia was significantly higher , as was the ld50 of DB01092 , with DB01221 or ddrug7 than with ddrug8 .",
        "label": "NA"
    },
    {
        "text": "DB00495 should either be temporarily discontinued or decreased by 50 % when coadministered with DB01032 on the day of ddrug2 infusion .",
        "label": "advise"
    },
    {
        "text": "DB01057 potentiates other ddrug1 such as DB00202 or ddrug3 and ddrug4 .",
        "label": "effect"
    },
    {
        "text": "fifteen to # minutes of exposure to # mac ddrug0 or DB00228 had minimal effects on the duration of action of initial doses of ddrug2 and therefore , no adjustment to the initial dose should be necessary when DB00565 is administered shortly after initiation of volatile agents .",
        "label": "NA"
    },
    {
        "text": "DB00316 : in normal volunteers , concomitant administration of DB00861 and ddrug2 resulted in an approximate 50 % increase in plasma levels of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "capsules DB00328 # mg t , i , d , produced a clinically relevant elevation of plasma ddrug1 and reduction in renal DB14507 clearance in psychiatric patients and normal subjects with steady state plasma ddrug3 concentrations .",
        "label": "NA"
    },
    {
        "text": "previous studies have demonstrated a significant reduction in the oral bioavailability of ddrug0 and ddrug1 when administered concomitantly with an intravenous HD00099 such as DB00295 .",
        "label": "NA"
    },
    {
        "text": "the combination of therapeutic doses of intravenous DB01219 and ddrug1 in DB01159 a-chloralose anesthetized swine has resulted in ventricular fibrillation and cardiovascular collapse in association with marked hyperkalemia .",
        "label": "NA"
    },
    {
        "text": "ddrug0 DB01202 { 1500 mg twice daily } did not alter the pharmacokinetics of DB00313 in healthy volunteers .",
        "label": "NA"
    },
    {
        "text": "in addition , the beneficial effects of DB01235 in parkinsons disease have been reported to be reversed by DB00252 and ddrug2 .",
        "label": "effect"
    },
    {
        "text": "DB00945 : as with other HD00203 , concomitant administration of ddrug2 and ddrug3 is not generally recommended because of the potential of increased adverse effects .",
        "label": "NA"
    },
    {
        "text": "the purpose of this study was to evaluate the effect of ddrug0 { ddrug1 } and ddrug2 { ddrug3 } conjugates on the intestinal permeation of HD00069 { ddrug5 } and model peptide drugs , ddrug6 and HD00071 .",
        "label": "NA"
    },
    {
        "text": "administration of HD00532 with ddrug1 containing ddrug2 , ddrug3 , or DB01373 , with ddrug5 , with metal cations such as ddrug6 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "mechanism"
    },
    {
        "text": "drug/laboratory test interactions the following drugs or moieties are known to interfere with laboratory tests performed in patients on ddrug0 therapy : ddrug1 , ddrug2 , HD00220 , oral ddrug4 containing ddrug5 , DB11119 - containing preparations and the numerous preparations containing ddrug7 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : DB00316 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , DB01026 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "although there was no effect of ddrug0 on the plasma auc of HD00347 or HD00346 determined on day 3 , there was a 34 % decrease in ddrug3 { a cyp2c9 substrate } trough concentration accompanied by a 14 % decrease in the prothrombin time { reported as international normalized ratio or inr } # days after completion of dosing with ddrug4 .",
        "label": "NA"
    },
    {
        "text": "other drugs : in small groups of patients { 7 - 10 / interaction study } , the concomitant administration of ddrug0 , DB14154 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , or ddrug6 did not significantly affect the peak levels and auc values of DB00586 .",
        "label": "NA"
    },
    {
        "text": "certain drugs , including ddrug0 { ddrug1 } , ddrug2 , HD00275 , and ddrug4 may potentiate the hypoglycemic action of ddrug5 and other oral HD00394 .",
        "label": "effect"
    },
    {
        "text": "to evaluate the impact of chemotherapy plus haart on the clinical course of patients with hiv-related , systemic , non-hodgkin lymphoma { hiv-nhl } , the authors compared retrospectively a group of # patients with hiv-nhl who were treated with the ddrug0 , ddrug1 , ddrug2 , and ddrug3 { chop } chemotherapy regimen plus haart with a group of # patients who were treated with ddit3 chemotherapy or a chop-like regimen { i , e , , ddrug4 , ddrug5 , ddrug6 , and DB00898 with ddrug8 plus ddrug9 } without receiving HD00056 therapy .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { ddrug1 } : HD00467 reduced the bioavailability of DB00996 { n = 16 } by about 20 % .",
        "label": "mechanism"
    },
    {
        "text": "agents with increased levels in the presence of ddrug0 : ddrug1 increases the plasma levels of the following agents : DB01242 , ddrug3 { 6 } , and ddrug4 thus , if a patient has been titrated to a stable dosage on one of the agents in this category , and then begins a course of the treatment with HD00472 , it is reasonable to expect that a dose decrease for the concomitant agent may be necessary .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { DB01167 } DB01026 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "ddrug0 : concomitant administration of ddrug1 containing DB14513 or ddrug3 with ddrug4 chewable/dispersible buffered tablets or pediatric powder for oral solution may potentiate adverse events associated with the DB06724 components .",
        "label": "NA"
    },
    {
        "text": "in addition , results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance { ddrug0 , ddrug1 , ddrug2 , ddrug3 , or DB00564 } with ddrug5 may result in clinically meaningful reductions in DB00520 concentrations .",
        "label": "NA"
    },
    {
        "text": "it is , however , possible that concomitant use of other known ddrug0 such as ddrug1 , ddrug2 , HD00222 , ddrug4 , ddrug5 and ddrug6 might increase the photosensitivity reaction of actinic_keratosis treated with the DB00855 for topical solution .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : because of the relationship of DB00982 to ddrug2 , patients should be advised against taking HD00818 containing ddrug4 to avoid additive toxic effects",
        "label": "NA"
    },
    {
        "text": "ddrug0 { such as DB00502 } and HD00219 can suppress the ddrug3 rgic renal and mesenteric vasodilation induced with low dose dopamine infusion .",
        "label": "NA"
    },
    {
        "text": "however , the systemic administration of some ddrug0 has been shown to elevate plasma concentrations of ddrug1 , interfere with the metabolism of DB00201 , and enhance the effects of the oral ddrug3 ddrug4 and its derivatives , and has been associated with transient elevations in serum creatinine in patients receiving systemic DB00091 concomitantly .",
        "label": "NA"
    },
    {
        "text": "animal experience indicates that ddrug0 prolongs the sleeping time after ddrug1 or after DB00898 , increases the inhibitory effects of DB00477 , but does not exhibit maoa inhibition .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in post-marketing experience , there have been rare reports of adverse neuropsychiatric events or reduced DB02325 tolerance in patients who were drinking ddrug2 during treatment with DB01156 .",
        "label": "NA"
    },
    {
        "text": "concomitant use of DB01254 and drugs that inhibit cyp3a4 { eg , ddrug1 , ddrug2 , ddrug3 , DB01211 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 } may increase exposure to ddrug12 and should be avoided .",
        "label": "mechanism"
    },
    {
        "text": "- DB00968 { e , g , , ddrug1 } use of ddrug2 with DB00891 may increase the chance of side effects affecting the liver and/or the blood",
        "label": "NA"
    },
    {
        "text": "co-administration of multiple doses of # mg of DB00480 had no effect on the single dose pharmacokinetics of ddrug1 and HD00833 .",
        "label": "NA"
    },
    {
        "text": "until data on possible interactions between DB00661 and ddrug1 are obtained , DB00280 should not be administered within # hours before or # hours after ddrug3 administration .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect : ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , ddrug5 , ddrug6 , DB00871 } , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 { e , g , , in oral HD00283 } .",
        "label": "NA"
    },
    {
        "text": "it is , however , possible that concomitant use of other known ddrug0 such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , HD00297 and HD00239 might increase the photosensitivity reaction of actinic_keratosis treated with the ddrug7 for topical solution .",
        "label": "NA"
    },
    {
        "text": "ddrug0 with DB01151 or ddrug2 and possibly other HD00609 cause striking and sustained increases in the concentration of ddrug4 in the brain ;",
        "label": "NA"
    },
    {
        "text": "single doses of either DB01432 or ddrug1 HD00510 bind the ddrug3 and reduce its absorption from the gastrointestinal tract by up to # and # percent , respectively .",
        "label": "NA"
    },
    {
        "text": "other concomitant therapy although specific interaction studies were not performed , ddrug0 doses of # mg or more were concomitantly used in clinical studies with ddrug1 , ddrug2 , a-blockers , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , cardiac ddrug9 , ddrug10 , HD00727 , ddrug12 , ddrug13 { also referred to as HD00203 } , and ddrug15 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "additive adverse effects resulting from cholinergic blockade may occur when DB00424 is administered concomitantly with other ddrug1 , ddrug2 , ddrug3 , ddrug4 , HD00445 , ddrug6 or some ddrug7 .",
        "label": "effect"
    },
    {
        "text": "an intravenous dose of # mg DB03138 was in respect of competitive suppression of organs actively concentrating HD00127 as effective as intravenous # mg clo-4 - simultaneously or # mg orally # min before the injection of ddrug2 .",
        "label": "NA"
    },
    {
        "text": "if concomitant treatment with DB00669 and an ddrug1 { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , DB01175 } is clinically warranted , appropriate observation of the patient is advised .",
        "label": "advise"
    },
    {
        "text": "ddrug0 ddrug1 ddrug2 ddrug3 DB00976 HD00324 ddrug6 ddrug7 large quantities of grapefruit juice { # quart daily }",
        "label": "NA"
    },
    {
        "text": "when other potent parental HD00448 , such as DB01119 , are used in combination with ddrug2 , patients should be continuously observed for several hours for any excessive fall in blood pressure .",
        "label": "effect"
    },
    {
        "text": "immediate and extended release tablets the hypoglycemic action of HD00222 may be potentiated by certain drugs including ddrug1 , some HD00768 and other drugs that are highly protein bound , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 .",
        "label": "effect"
    },
    {
        "text": "other drug interactions : no pharmacokinetic interactions were observed between ddrug0 and the following drugs : DB01016 , ddrug2 , ddrug3 , ddrug4 , and DB00863 .",
        "label": "NA"
    },
    {
        "text": "DB00501 } and many that are substrates for cyp2b6 2d6 { many other ddrug1 , HD00219 , and the ddrug3 ddrug4 and ddrug5 } .",
        "label": "NA"
    },
    {
        "text": "cyclosporine , digoxin , methotrexate DB00749 , like other ddrug1 , through effects on renal prostaglandins , may cause changes in the elimination of these drugs leading to elevated serum levels of ddrug2 , ddrug3 , DB00563 , and increased toxicity .",
        "label": "mechanism"
    },
    {
        "text": "in some patients , the administration of DB00328 can reduce the diuretic , natriuretic , and antihypertensive effects of HD00105 , ddrug2 , and ddrug3 .",
        "label": "effect"
    },
    {
        "text": "in a comparison of ddrug0 tolerance in dogs anesthetized with ddrug1 , ddrug2 , or DB00312 , the dosage of DB01092 needed to cause ventricular tachycardia was significantly higher , as was the ld50 of ddrug5 , with ddrug6 or ddrug7 than with ddrug8 .",
        "label": "effect"
    },
    {
        "text": "then , the effects of metabotropic glutamate receptor { mglur } agonists , HD00018 and HD00019 , on the above behavioral changes induced by ddrug2 were found .",
        "label": "NA"
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of ddrug0 such as DB00565 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , ddrug5 , ddrug6 , DB01627 , ddrug8 , ddrug9 , and ddrug10 } , ddrug11 salts , ddrug12 , local ddrug13 , ddrug14 , and ddrug15 .",
        "label": "effect"
    },
    {
        "text": "HD00388 may partially counteract the anticoagulation effects of ddrug1 or DB00682 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may increase slightly the effect of HD00448 , e , g , , ddrug2 , DB00968 , ddrug4 .",
        "label": "NA"
    },
    {
        "text": "we demonstrate that the conversion of HD00079 to ddrug1 by an nad + - dependent oxidation is the rate-limiting step in the synthesis of the toxic product , HD00078 from ddrug3 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 has been reported to significantly alter the metabolism of nonsedating HD00388 ddrug2 and DB00637 when taken concomitantly .",
        "label": "NA"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , HD00326 { ddrug1 s } , ddrug2 , ddrug3 { ddrug4 may decrease the effects of these medicines } , ddrug5 { using these medicines with ddrug6 may result in increased cns depressant effects } , ddrug7 , ddrug8 { using these medicines with ddrug9 may change the amount of either medicine that you need to take } , and oral ddrug10 containing ddrug11 { ddrug12 may decrease the effectiveness of these oral HD00283 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "previous studies have demonstrated a significant reduction in the oral bioavailability of DB00685 and ddrug1 when administered concomitantly with an intravenous HD00099 such as ddrug3 .",
        "label": "mechanism"
    },
    {
        "text": "a dose increase of DB01601 / ddrug1 to 533/133 mg twice daily with food isrecommended in combination with DB00238 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : the pharmacokinetics of DB00277 { DB01223 # mg/kg infused over # minutes } were unchanged following a single oral dose of ddrug3 { 400 mg } in # healthy subjects .",
        "label": "NA"
    },
    {
        "text": "DB01026 tablets may alter the metabolism of ddrug1 , ddrug2 , and DB00959 , resulting in elevated plasma concentrations of the latter drugs .",
        "label": "mechanism"
    },
    {
        "text": "persons taking most HD00002 , ddrug1 and ddrug2 invalidate DB00158 and ddrug4 diagnostic blood assays .",
        "label": "NA"
    },
    {
        "text": "in in vivo studies , 10 - to 30-mg/day doses of DB01238 had no significant effect on metabolism by cyp2d6 { ddrug1 } , cyp2c9 { DB00682 } , cyp2c19 { ddrug3 , ddrug4 } , and cyp3a4 { ddrug5 } substrates .",
        "label": "NA"
    },
    {
        "text": "ddrug0 in combination with other HD00424 , general ddrug2 , ddrug3 , ddrug4 , ddrug5 , or other HD00261 { including ddrug7 } has additive depressant effects .",
        "label": "NA"
    },
    {
        "text": "medications can interfere with folate utilization , including : ddrug0 { such as ddrug1 , and DB00794 } ddrug3 { sometimes prescribed to control blood sugar in type # diabetes } ddrug4 { used to control inflammation associated with crohn_disease and ulcerative colitis } ddrug5 { a HD00295 } ddrug7 there has been concern about the interaction between ddrug8 and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "interaction of DB00906 with other drugs : DB00501 : co-administration of ddrug2 { 800 mg/day } to patients taking ddrug3 chronically had no effect on ddrug4 pharmacokinetics .",
        "label": "NA"
    },
    {
        "text": "effects of ddrug0 on low-dose ddrug1 a group of # nonsmoking , healthy white female volunteers established on an oral HD00349 regimen containing # mg ddrug3 and # mg DB06730 for at least # months received # mg/day of ddrug5 from midcycle { day 15 } to midcycle { day 14 } of two consecutive oral ddrug6 cycles .",
        "label": "NA"
    },
    {
        "text": "DB01109 injection should not be mixed with ddrug1 , ddrug2 , ddrug3 , or DB01204 , since it has been reported that these drugs are incompatible with ddrug5 and a precipitate may form .",
        "label": "NA"
    },
    {
        "text": "when DB00520 is co-administered with inducers of drug clearance , such as ddrug1 , ddrug2 , ddrug3 , ddrug4 , or DB00564 , use of a daily dose of # mg of ddrug6 should be considered",
        "label": "advise"
    },
    {
        "text": "controlled and uncontrolled domestic studies suggest that concomitant use of DB00343 and HD00254 is usually well tolerated , but available data are not sufficient to predict the effects of concomitant treatment in patients with left_ventricular_dysfunctions or cardiac conduction abnormalities .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , HD00668 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { HD00712 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of ddrug0 and ddrug1 is not recommended because DB00788 is displaced from its binding sites during the concomitant administration of DB00945 , resulting in lower plasma concentrations and peak plasma levels .",
        "label": "advise"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : ddrug2 , ddrug3 ddrug4 : DB00637 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 ddrug11 , DB00897 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "in order to avoid the occurrence of severe hypersensitivity reactions , all patients treated with DB01229 should be premedicated with HD00175 { such as ddrug2 } , diphen-hydramine and ddrug3 { such as ddrug4 or ddrug5 } .",
        "label": "NA"
    },
    {
        "text": "inhibitors of this isoenzyme { e , g , , ddrug0 , ddrug1 , HD00269 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , grapefruit juice , ddrug7 , ddrug8 , ddrug9 , ddrug10 } should be cautiously coadministered with ddrug11 as they can potentially increase DB00204 levels .",
        "label": "NA"
    },
    {
        "text": "DB00405 can interact with DB02325 or other ddrug2 { may potentiate the cns depressant effects of either these medications or ddrug3 } , ddrug4 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug5 } , and ddrug6 { concurrent use with ddrug7 may prolong and intensify the anticholinergic and cns depressant effects of ddrug8 } .",
        "label": "int"
    },
    {
        "text": "in vitro data suggest that DB01167 , when compared to DB01026 , has a less pronounced effect on the biotransformation system responsible for the metabolism of ddrug2 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , HD00282 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , DB00295 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "other HD00233 that inhibit prostaglandin synthesis have been shown to interfere with ddrug1 in some studies and with HD00293 .",
        "label": "effect"
    },
    {
        "text": "DB00559 is also expected to reduce plasma concentrations of other oral HD00062 that are predominantly metabolized by cyp2c9 or cyp3a4 .",
        "label": "mechanism"
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of ddrug0 such as DB00565 include certain ddrug2 { e , g , , ddrug3 , ddrug4 , DB00781 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , and ddrug10 } , ddrug11 salts , ddrug12 , local ddrug13 , ddrug14 , and ddrug15 .",
        "label": "effect"
    },
    {
        "text": "because the ddrug0 ddrug1 is given exclusively by the oral route in man , we have carried out studies in mice on the antitumour activity , acute toxicity and pharmacokinetics of oral HD00152 , either alone or in combination with the chemosensitizer DB11716 .",
        "label": "NA"
    },
    {
        "text": "certain drugs , including ddrug0 { ddrug1 } , ddrug2 , HD00275 , and ddrug4 may potentiate the hypoglycemic action of DB00731 and other oral ddrug6 .",
        "label": "effect"
    },
    {
        "text": "combinations of DB01190 and DB00798 were indifferent for # strains and synergistic for # strains .",
        "label": "effect"
    },
    {
        "text": "ddrug0 anesthesia : severe hypotension has been reported during DB00813 anesthesia with concomitant use of a ddrug2 and a HD00038 .",
        "label": "effect"
    },
    {
        "text": "DB00798 is an HD00172 used to treat a wide variety of infections caused by gram-negative organisms , but it is potentially toxic to the kidneys .",
        "label": "NA"
    },
    {
        "text": "DB00571 to healthy volunteers under steady-state conditions had no relevant effect on either drug s bioavailability , auc and cmax , differences were 20 % between DB00270 given singly and in combination with ddrug2 , and between ddrug3 given singly and in combination with ddrug4 .",
        "label": "NA"
    },
    {
        "text": "it is not known if the effects of DB00611 are altered by concomitant medications that affect hepatic metabolism of drugs { DB00199 , etc , } , but physicians should be alert to the possibility that a smaller initial dose and longer intervals between doses may be needed .",
        "label": "advise"
    },
    {
        "text": "however , patients with moderate to severe cardiovascular disease or those taking DB14049 therapy are at increased risk for potentially serious cardiovascular adverse effects with DB00203 therapy .",
        "label": "effect"
    },
    {
        "text": "pretreatment of rats with ddrug0 { 100 mg/kg , ip } or DB00163 { 100 mg/kg per day , ig , for # days and a dose of # mg/kg on the 4th day } provided significant protection against the elevation of tbars levels in cerebral and hepatic tissues , induced by single high dose of oral HD00044 administration within # h.",
        "label": "effect"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : DB01118 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 HD00100 ddrug11 , ddrug12 gi motility agents : ddrug13",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 : based on auc and half-life , multiple-dose pharmacokinetic profiles of DB00717 and ddrug2 following administration of tablets containing # mg of ddrug3 and # mcg of DB00977 were similar with and without coadministration of ddrug5 { 400 mg tid ;",
        "label": "NA"
    },
    {
        "text": "DB00294 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , DB01076 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "int"
    },
    {
        "text": "-lsb- stimulation by ddrug0 -- an analog of the octapeptide cholecystokinin -- of ddrug1 binding after the long-term administration of ddrug2 -rsb- it has been established in experiments on white male rats that prolonged administration { twice a day for # days } of ddrug3 { # mg/kg } and ddrug4 { # mg/kg } resulted in the reduced interaction between HD00136 and low affinity binding sites for DB00714 in subcortical structures , whereas ddrug7 binding with high affinity binding sites for ddrug8 increased both in the frontal cortex and subcortical structures of the forebrain .",
        "label": "NA"
    },
    {
        "text": "ddrug0 serum levels should be monitored and appropriate dose adjustments considered for patients given both DB00277 and DB00008 .",
        "label": "advise"
    },
    {
        "text": "the plasma maximum concentration and area under the plasma concentration-time curve of DB00343 , ddrug1 , and ddrug2 were unchanged after coadministration of DB00877 , and no potentiation of the effects of ddrug4 on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen .",
        "label": "NA"
    },
    {
        "text": "the concomitant intake of DB02325 and ddrug1 does not affect the pharmacokinetics of either ddrug2 or DB00659 .",
        "label": "NA"
    },
    {
        "text": "additionally , ddrug0 , such as ddrug1 and DB00358 , may antagonize the activity of DB00564 .",
        "label": "effect"
    },
    {
        "text": "the following are examples of drugs known to inhibit the metabolism of other related HD00100 , presumably through inhibition of cyp3a : ddrug1 , ddrug2 , ddrug3 , ddrug4 , HD00697 , and some ddrug6 .",
        "label": "mechanism"
    },
    {
        "text": "thus , DB01032 should not be administered concurrently with DB00887 .",
        "label": "advise"
    },
    {
        "text": "other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as DB01135 include certain ddrug1 { e , g , , HD00249 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 } , ddrug10 salts , ddrug11 , local ddrug12 , ddrug13 , and ddrug14 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 , a HD00107 , is a HD00108 which has proven efficacy against the positive and negative symptoms of schizophrenia .",
        "label": "NA"
    },
    {
        "text": "other drugs : based on the results of drug interaction studies , no dosage adjustment is recommended when DB00625 { ddrug1 } is given with the following : HD00671 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , and ddrug11 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , DB00273 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , DB00295 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 DB00533 did not have any clinically important effect on the pharmacokinetics of DB00977 and ddrug3 .",
        "label": "NA"
    },
    {
        "text": "because DB01432 binds bile acids , ddrug1 ddrug2 may interfere with normal fat digestion and absorption and thus may prevent absorption of HD00465 such as a , d , e , and k.",
        "label": "NA"
    },
    {
        "text": "ddrug0 { e , g , , ddrug1 } and HD00224 containing carbohydrate-splitting enzymes { e , g , , ddrug3 , DB00085 } may reduce the effect of ddrug5 and should not be taken concomitantly .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB00501 does not affect the pharmacokinetics of DB00828 when coadministered with ddrug3 .",
        "label": "NA"
    },
    {
        "text": "because severe hypoglycemia has been reported in patients concomitantly receiving oral ddrug0 { an DB03366 } and oral HD00062 , such a potential interaction involving the latter agents when used concomitantly with ddrug3 tablets { an ddrug4 } can not be ruled out .",
        "label": "NA"
    },
    {
        "text": "ddrug0 in combination with other ddrug1 , general ddrug2 , HD00219 , ddrug4 , ddrug5 , or other HD00261 { including ddrug7 } has additive depressant effects .",
        "label": "NA"
    },
    {
        "text": "apparent oral clearance and volume of distribution of ddrug0 decreased with 38 % and 45 % , respectively , when DB00877 was given with DB00343 .",
        "label": "mechanism"
    },
    {
        "text": "effect of ddrug0 and DB00683 on the antinociceptive effect of ddrug2 , ddrug3 and DB00328 in mice .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : when coadministered with ddrug1 , DB01233 , a drug which increases gastrointestinal motility , lowers the serum concentration and urinary excretion of DB00828 .",
        "label": "NA"
    },
    {
        "text": "prospective , long-term studies on concomitant administration of HD00897 and DB00945 have not been conducted .",
        "label": "NA"
    },
    {
        "text": "additional drugs that are not recommended for coadministration with DB01232 and DB00503 are included below .",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , DB14513 , or ddrug4 , with ddrug5 , with metal cations such as ddrug6 , or with ddrug7 containing DB01592 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "DB00563 : ddrug1 , like other HD00203 , may cause changes in the elimination of ddrug3 leading to elevated serum levels of the drug and increased toxicity .",
        "label": "NA"
    },
    {
        "text": "toxicology studies of ddrug0 - related deaths reveal frequent involvement of other HD00389 , including ddrug2 , ddrug3 such as DB00829 { ddrug5 } , and , to a rising degree , ddrug6 .",
        "label": "NA"
    },
    {
        "text": "use with ddrug0 : the principal pathway for detoxification of DB00993 is inhibited by DB00437 .",
        "label": "mechanism"
    },
    {
        "text": "these include ddrug0 , DB01432 , and some ddrug2 { e , g , DB00199 , rifamipicin , ddrug4 and ddrug5 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , DB00776 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { DB00295 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { ddrug1 s } , ddrug2 , DB01285 { ddrug4 may decrease the effects of these medicines } , ddrug5 { using these medicines with ddrug6 may result in increased cns depressant effects } , ddrug7 , ddrug8 { using these medicines with ddrug9 may change the amount of either medicine that you need to take } , and oral ddrug10 containing ddrug11 { HD00026 may decrease the effectiveness of these oral ddrug13 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "HD00326 including coumarin derivatives , indandione derivatives , and HD00353 such as ddrug2 { ddrug3 } , and ddrug4 may increase the risk of bleeding when administered concomitantly with ddrug5 .",
        "label": "NA"
    },
    {
        "text": "the concomitant use of ddrug0 is not recommended since DB00698 may antagonize the antibacterial effect of DB01059 in the urinary tract .",
        "label": "effect"
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a ddrug0 , including DB00537 , with multivalent cation-containing products such as ddrug2 or ddrug3 HD00374 , ddrug5 , ddrug6 chewable/buffered tablets or pediatric powder , or products containing ddrug7 , ddrug8 , or ddrug9 may substantially decrease the absorption of ddrug10 , resulting in serum and urine levels considerably lower than desired .",
        "label": "mechanism"
    },
    {
        "text": "DB00695 : clinical studies , as well as random observations , have shown that ddrug1 can reduce the natriuretic effect of ddrug2 and HD00217 in some patients .",
        "label": "NA"
    },
    {
        "text": "as with other HD00366 , the antihypertensive effect of ddrug1 may be blunted by the ddrug2 DB00328",
        "label": "NA"
    },
    {
        "text": "DB00945 : concomitant administration of ddrug1 with ddrug2 may result in an increased risk of gi ulceration and complications compared to DB00580 alone .",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , ddrug3 , or ddrug4 , with DB00364 , with metal cations such as ddrug6 , or with ddrug7 containing ddrug8 or DB01593 , or with formulations containing divalent and trivalent cations such as ddrug10 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , ddrug3 , or ddrug4 , with ddrug5 , with metal cations such as DB01592 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { DB00900 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "additive adverse effects resulting from cholinergic blockade may occur when DB00424 is administered concomitantly with other ddrug1 , DB00915 , ddrug3 , ddrug4 , ddrug5 , ddrug6 or some ddrug7 .",
        "label": "effect"
    },
    {
        "text": "DB01191 should not be administered with other HD00603 .",
        "label": "advise"
    },
    {
        "text": "additionally , DB00187 should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as DB00988 , ddrug2 , and ddrug3 because of the danger of blocking cardiac contractility when systemic vascular resistance is high .",
        "label": "advise"
    },
    {
        "text": "potential drug interactions between DB01202 and other ddrug1 { ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 and ddrug8 } were also assessed by evaluating the serum concentrations of ddrug9 and these HD00714 during placebo-controlled clinical studies .",
        "label": "NA"
    },
    {
        "text": "synergism between ddrug0 { e , g , , ddrug1 } , DB01364 , and other HD00660 has been reported .",
        "label": "effect"
    },
    {
        "text": "comparison of ddrug0 pharmacokinetics in patients treated with # mg/m2 plus ddrug1 to those in patients treated with # mg/m2 without HD00158 indicated that there were no changes in the elimination rate constant , volume of distribution , or total body clearance of DB00515 .",
        "label": "NA"
    },
    {
        "text": "before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : ddrug0 { e , g , , ddrug1 , ddrug2 } , DB00681 , DB00091 , ddrug5 drugs { e , g , , ddrug6 } , ddrug7 , ddrug8 .",
        "label": "NA"
    },
    {
        "text": "the pharmacokinetics of a 1-mg dose of ddrug0 administered as DB00611 were not affected by the coadministration of DB00501 { 300 mg qid } .",
        "label": "NA"
    },
    {
        "text": "the pharmacokinetics of a 1-mg dose of DB00611 administered as ddrug1 were not affected by the coadministration of DB00501 { 300 mg qid } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : co-administration of HD00897 with ddrug2 # mg daily , a potent inducer of hepatic metabolism , produced an approximate 50 % decrease in DB00533 plasma concentrations .",
        "label": "NA"
    },
    {
        "text": "in healthy subjects receiving DB00501 { 1 gm daily } for one week , plasma DB01195 levels increased by about 30 % and half-life increased by about 10 % .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , DB00776 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { DB01045 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "antagonism has been demonstrated between DB01190 and DB00199 in vitro .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : the rate and extent of absorption of DB00537 was bioequivalent when ddrug2 was given alone or when DB00537 was given # hours after ddrug4 at the dose that maximally suppresses gastric acid secretion .",
        "label": "NA"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / HD00517 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 pain medication { e , g , , ddrug12 } , drugs used to aid sleep , drowsiness-causing ddrug13 { e , g , , DB14487 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "these results suggest that both ddrug0 and HD00147 , and possibly other ddrug2 and HD00150 , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of ddrug4 and ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , DB01045 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and DB00126 .",
        "label": "NA"
    },
    {
        "text": "DB00269 may interact with HD00216 , ddrug2 , ddrug3 , ddrug4 , ddrug5 supplements , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , and ddrug13 .",
        "label": "int"
    },
    {
        "text": "oral DB00994 inhibits the gastrointestinal absorption of ddrug1 , oral HD00873 , ddrug3 and ddrug4 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , HD00002 such as DB00415 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "DB14513 - and/or ddrug1 - containing ddrug2 , products containing ddrug3 { ddrug4 } , ddrug5 containing DB01593 or other metal cations , or ddrug7 { ddrug8 } chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after ddrug9 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : marked hypertension and tachycardia have been reported in association with concomitant administration of DB00451 and DB01221 .",
        "label": "effect"
    },
    {
        "text": "DB01118 taken concomitantly with ddrug1 for less than seven days increases plasma concentrations of DB01035 and n_acetyl ddrug3 by 55 % and 33 % , respectively .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : administration of DB00900 # hours prior to or concurrent with oral DB01004 was associated with a # { 114 } % increase in the steady-state auc of ddrug3 { n = 12 } .",
        "label": "mechanism"
    },
    {
        "text": "concomitant use of DB01254 and drugs that inhibit cyp3a4 { eg , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , DB01232 , ddrug11 } may increase exposure to ddrug12 and should be avoided .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : DB01032 is known to interact with the metabolism or renal tubular excretion of many drugs { e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , HD00026 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 agents , ddrug14 , and ddrug15 } .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , DB00776 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , DB01045 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : combination HD00432 may increase the clearance of DB00295 .",
        "label": "mechanism"
    },
    {
        "text": "drug-drug interactions ddrug0 - ddrug1 should be administered with caution to patients being treated with systemically-administered { oral or intravenous } ddrug2 { or other HD00381 } because the action of DB01001 on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure .",
        "label": "NA"
    },
    {
        "text": "coadministration of ddrug0 and DB00333 as compared to a non-matched historicalcontrol group resulted in a 30 % , 27 % , and 25 % decrease in serum DB00701 auc , cmax , andcmin , respectively .",
        "label": "NA"
    },
    {
        "text": "caution should also be applied for other HD00391 , and for ddrug1 and ddrug2 and HD00043 , which may also precipitate arrhythmias .",
        "label": "NA"
    },
    {
        "text": "because there is a theoretical basis that these effects may be additive , use of ddrug0 - containing or ddrug1 { like ddrug2 or DB00247 } and DB00918 within # hours of each other should be avoided .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : ddrug1 , given concomitantly with DB01009 , produces a reduction in urinary potassium and chloride excretion compared to DB00999 alone .",
        "label": "NA"
    },
    {
        "text": "erythromycin co-administration of DB01023 { ddrug1 } with DB00199 resulted in approximately # - fold increase in the auc and cmax , and about 2 - fold prolongation in the half - life of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "to avoid this interaction , DB00705 or ddrug1 should be given # hour prior to dosing with DB00900 .",
        "label": "advise"
    },
    {
        "text": "drugs that induce hepatic enzymes such as ddrug0 , ddrug1 and DB01045 may increase the clearance of HD00175 and may require increases in ddrug4 dose to achieve the desired response .",
        "label": "mechanism"
    },
    {
        "text": "drug-drug interactions ddrug0 - DB00289 should be administered with caution to patients being treated with systemically-administered { oral or intravenous } ddrug2 { or other ddrug3 } because the action of DB01001 on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure .",
        "label": "NA"
    },
    {
        "text": "avoid the use of preparations such as ddrug0 and local HD00264 which contain any HD00800 { e , g , , ddrug3 , ddrug4 } , since it has been reported that ddrug5 can potentiate the effects of catecholamines .",
        "label": "NA"
    },
    {
        "text": "due to high inter-patient variability and limited sampling , the extent of the increase in ddrug0 levels in patients receiving concurrent DB00762 and DB00112 is uncertain .",
        "label": "NA"
    },
    {
        "text": "since ddrug0 { ddrug1 } may interact with concurrently administered HD00703 , periodic serum level determinations of these drugs may be necessary { eg , ddrug3 may elevate ddrug4 serum levels and ddrug5 has been reported to both increase and decrease DB00593 levels } .",
        "label": "NA"
    },
    {
        "text": "antiacid , ddrug0 , ddrug1 , DB00196 , ddrug3 , indanavir , ddrug4 , ddrug5 , phenobarbitol , ddrug6 , ddrug7 , ddrug8 , ritanovir , DB01232 .",
        "label": "NA"
    },
    {
        "text": "HD00303 : other ddrug1 drugs , such as ddrug2 , ddrug3 , ddrug4 , and ddrug5 , have been used concurrently with DB01118 .",
        "label": "NA"
    },
    {
        "text": "DB00574 may increase slightly the effect of HD00448 , e , g , , ddrug2 , ddrug3 , ddrug4 .",
        "label": "effect"
    },
    {
        "text": "to investigate the effects of antimicrobial combinations of HD00006 with four kinds of ddrug1 { ddrug2 , DB01327 , ddrug4 and ddrug5 } , the fractional inhibitory concentration index { fici } was determined by checkerboard assay for each strain .",
        "label": "NA"
    },
    {
        "text": "in the first double-blind comparative study { 28-week } of DB00334 and ddrug1 , ddrug2 # to # mg/day proved to be significantly more effective than DB00734 # to # mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms .",
        "label": "NA"
    },
    {
        "text": "these include ddrug0 , DB01432 , and some ddrug2 { e , g , ddrug3 , rifamipicin , DB00415 and ddrug5 } .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 DB00264 ddrug4 ddrug5 { ddrug6 } ddrug7 { ddrug8 } ddrug9 ddrug10 { ddrug11 } sporal { DB01167 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "drug-drug interactions between ddrug0 and other HD00703 { ddrug2 } ddrug3 ddrug4 { 3000 mg daily } had no effect on the pharmacokinetic disposition of DB00252 in patients with refractory epilepsy .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { HD00712 } , ddrug39 { ddrug40 } , st , johns wort , DB00231 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the ddrug0 of drugs may be potentiated by ddrug1 , ddrug2 , ddrug3 , ddrug4 , HD00557 , the ddrug6 , ddrug7 and ddrug8 , ddrug9 and the ddrug10 , and by other HD00561 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : in a study in healthy volunteers , a one-week course of DB00501 at # mg b , i , d , with a single # mg dose of ddrug2 on the sixth day showed an increase in DB00270 mean peak plasma concentrations { 36 % } and significant increase in area under the curve { 50 % } .",
        "label": "NA"
    },
    {
        "text": "reported examples of this interaction include the following : ddrug0 s : ddrug1 { HD00302 substrate } administered in combination with oral ddrug3 has been reported to produce persistently elevated plasma concentrations of DB00091 resulting in elevated creatinine , despite reduction in dose of ddrug5 .",
        "label": "NA"
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma DB00252 concentrations include : acute ddrug1 intake , ddrug2 , chboramphenicol , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , HD00328 , ddrug18 , ddrug19 , ddrug20 , ddrug21",
        "label": "mechanism"
    },
    {
        "text": "oral ddrug0 : DB00673 , when given once daily for # days as a 100-mg capsule with an oral ddrug2 containing # mcg of ddrug3 and # mg of ddrug4 , decreased the auc of ddrug5 by 43 % , and decreased the auc of DB00717 by 8 % ;",
        "label": "NA"
    },
    {
        "text": "the HD00100 , including ddrug1 , produce additive cns depressant effects when co-administered with other HD00281 , ddrug3 , ddrug4 , ddrug5 , and other drugs which themselves produce cns depression .",
        "label": "effect"
    },
    {
        "text": "no depressant effect on blood levels in humans was noted when DB00375 was administered with any of the following drugs : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 { ddrug6 } , DB01124 , ddrug8 or ddrug9 .",
        "label": "NA"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / ddrug1 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , ddrug4 , DB00365 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , HD00516 pain medication { e , g , , ddrug12 } , drugs used to aid sleep , drowsiness-causing ddrug13 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "DB01432 ddrug1 may delay or reduce the absorption of concomitant oral medication such as ddrug2 , ddrug3 , HD00029 { acidic } or ddrug5 { basic } , as well as ddrug6 ddrug7 , ddrug8 , thyroid and ddrug9 preparations , ddrug10 and ddrug11 , and ddrug12 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , HD00282 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { HD00531 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "drugs which may enhance the neuromuscular blocking action of ddrug0 include : DB00228 ; ddrug2 ; ddrug3 ; certain ddrug4 , especially the HD00249 and ddrug6 ; ddrug7 ; ddrug8 salts ; ddrug9 ; and ddrug10 .",
        "label": "NA"
    },
    {
        "text": "concomitant administration of ddrug0 { equivalent to 145 mg DB01039 } with ddrug2 { 40 mg } once daily for # days has been shown to increase the mean cmax and auc values for DB00175 by 36 % { range from 69 % decrease to 321 % increase } and 28 % { range from 54 % decrease to 128 % increase } , respectively , and for # - hydroxy-iso-pravastatin by 55 % { range from 32 % decrease to 314 % increase } and 39 % { range from 24 % decrease to 261 % increase } , respectively in # healthy adults .",
        "label": "NA"
    },
    {
        "text": "the hypoglycemic action of HD00222 may be potentiated by certain drugs including HD00518 and other drugs that are highly protein bound , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , and ddrug8 .",
        "label": "effect"
    },
    {
        "text": "DB00977 and ddrug1 : coadministration of ddrug2 with ddrug3 resulted in a 47 % decrease in ddrug4 and an 18 % decrease in DB00717 plasma concentrations .",
        "label": "NA"
    },
    {
        "text": "however , because bleeding has been reported when ddrug0 and other ddrug1 have been administered to patients on ddrug2 , the physician should be cautious when administering DB01050 to patients on HD00326 .",
        "label": "advise"
    },
    {
        "text": "the effectiveness of ddrug0 - only pills is reduced by hepatic enzyme-inducing drugs such as the HD00282 ddrug2 , ddrug3 , and HD00026 , and the ddrug5 ddrug6 .",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , ddrug3 , or ddrug4 , with ddrug5 , with metal cations such as ddrug6 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as DB00900 { ddrug11 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of HD00532 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "in a single-dose crossover study examining ddrug0 # mg and DB00338 # mg each administered alone and concomitantly with ddrug2 # gram , absorption of the HD00587 was delayed and their bioavailability was reduced by 17 % and 16 % , respectively , when administered concomitantly with ddrug4 .",
        "label": "NA"
    },
    {
        "text": "in comparison with DB00502 , the adverse events reported significantly more frequently with ddrug1 in > or = # % of patients were dry mouth , bodyweight gain and increased appetite and compared with DB00734 , only bodyweight gain occurred significantly more frequently with ddrug3 .",
        "label": "NA"
    },
    {
        "text": "in controlled clinical trials , however , ddrug0 including DB00264 were concurrently administered with DB01023 and were well tolerated .",
        "label": "NA"
    },
    {
        "text": "in vitro binding studies with human serum proteins indicate that ddrug0 binds differently than ddrug1 and does not interact with HD00372 or DB00266 .",
        "label": "NA"
    },
    {
        "text": "while all the HD00113 { ddrug1 } , e , g , , ddrug2 , ddrug3 , ddrug4 , ddrug5 , and DB00715 , inhibit cyp2b6 2d6 , they may vary in the extent of inhibition .",
        "label": "NA"
    },
    {
        "text": "ddrug0 potentiates other ddrug1 such as ddrug2 or HD00661 and HD00662 .",
        "label": "NA"
    },
    {
        "text": "influence of HD00715 on HD00888 concentration { mean change , 90 % confidence interval }",
        "label": "NA"
    },
    {
        "text": "although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 { eg , ddrug0 , DB00250 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , and ddrug15 } may have elevated plasma concentrations when coadministered with DB01232 ;",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , DB00091 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , DB00224 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { DB00252 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { HD00712 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "poor metabolizers of ddrug0 : interactions of DB01136 with strong inhibitors of cyp2d6 { such as ddrug2 , DB00472 , ddrug4 , and ddrug5 } have not been studied , but these drugs would be expected to increase blood levels of the r { + } enantiomer of ddrug6 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : when DB00176 { 50 mg tid } was administered concomitantly with ddrug2 for two weeks , DB00682 plasma concentrations increased by 98 % and prothrombin times were prolonged .",
        "label": "NA"
    },
    {
        "text": "HD00834 { ddrug1 } has been reported to produce antabuse-like side effects when given concomitantly with DB02325 .",
        "label": "effect"
    },
    {
        "text": "while it is not known whether this interaction occurs with ddrug0 other than ddrug1 , myopathy and rhabdomyolysis have occasionally been associated with the use of HD00550 alone , including DB00636 .",
        "label": "NA"
    },
    {
        "text": "the depression of cardiac contractility , conductivity , and automaticity as well as the vascular dilation associated with HD00264 may be potentiated by HD00377 .",
        "label": "effect"
    },
    {
        "text": "drug-drug interactions given the primary cns effects of ddrug0 , caution should be used when DB01238 is taken in combination with other ddrug2 and DB02325 .",
        "label": "advise"
    },
    {
        "text": "if DB00270 therapy is initiated in a patient currently receiving DB00501 careful monitoring for adverse reactions is advised and downward dose adjustment may be required .",
        "label": "advise"
    },
    {
        "text": "ddrug0 DB00233 and heavy DB02325 intake for longer than # weeks may produce malabsorption of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "as with other HD00617 , it should be noted that ddrug1 may be capable of potentiating HD00261 such as ddrug3 , ddrug4 , and ddrug5 .",
        "label": "effect"
    },
    {
        "text": "the concomitant administration of DB01045 and DB00682 resulted in the need for an unusually high maintenance dose of ddrug2 { 20 mg per day } in order to produce a therapeutic effect .",
        "label": "mechanism"
    },
    {
        "text": "as with some other ddrug0 , the time of onset of neuromuscular block induced by DB01135 is lengthened and the duration of block is shortened in patients receiving ddrug2 or DB00564 .",
        "label": "effect"
    },
    {
        "text": "in patients receiving ddrug0 { ddrug1 } or ddrug2 { DB00993 } , the concomitant administration of 300 - 600 mg of ddrug4 per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of ddrug5 or DB00993 .",
        "label": "NA"
    },
    {
        "text": "tablets : the HD00100 , including ddrug1 , produce cns-depressant effects when administered with such medications as ddrug2 or DB02325 .",
        "label": "effect"
    },
    {
        "text": "no depressant effect on blood levels in humans was noted when ddrug0 was administered with any of the following drugs : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 { ddrug6 } , ddrug7 , DB00252 or DB00682 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : since ddrug1 is a HD00338 , it is possible that ddrug3 , such as the HD00137 { ddrug5 , ddrug6 , ddrug7 } or ddrug8 , may diminish the effectiveness of ddrug9 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 / nutrition / herb interactions : food : cns effects of DB00201 may be enhanced if HD00710 are used concurrently with ddrug3 .",
        "label": "NA"
    },
    {
        "text": "oral ddrug0 : DB00580 { 40 mg bid } did not induce the metabolism of the combination oral ddrug2 DB00717 / ddrug4 { 1 mg / 35 mcg combination , ddrug5 1/35 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : drugs such as ddrug1 , ddrug2 , DB00812 , ddrug4 , ddrug5 , ddrug6 , ddrug7 and others that interfere with platelet-aggregation reactions { the main hemostatic defense of heparinized patients } may induce bleeding and should be used with caution in patients receiving DB01109 .",
        "label": "effect"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { ddrug1 s } , ddrug2 , ddrug3 { ddrug4 may decrease the effects of these medicines } , ddrug5 { using these medicines with ddrug6 may result in increased cns depressant effects } , DB00313 , ddrug8 { using these medicines with ddrug9 may change the amount of either medicine that you need to take } , and oral ddrug10 containing ddrug11 { ddrug12 may decrease the effectiveness of these oral HD00283 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and DB00215 - in a controlled study , a single dose of ddrug2 # mg co-administered with racemic DB00215 # mg given once daily for # days was associated with a mean increase in qtc values of approximately # msec compared to ddrug4 given alone .",
        "label": "NA"
    },
    {
        "text": "may interact with wthionamide { HD00581 } and ddrug1 { HD00582 } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : following co-administration of two 250-mg DB00954 tablets administered once daily with 200-mg ddrug2 tablets administered twice daily for # days to # healthy subjects , the steady-state plasma concentration of DB00277 was not significantly altered .",
        "label": "NA"
    },
    {
        "text": "because of reports of prolongation of the prothrombin time beyond the therapeutic range in patients taking concurrent DB00848 and ddrug1 , it is suggested that the prothrombin time be monitored carefully , and the dose of ddrug2 or other DB04665 - like drugs should be adjusted accordingly , in patients taking both drugs .",
        "label": "NA"
    },
    {
        "text": "it is recommended that ddrug0 not be used concomitantly with HD00343 because the effects of concomitant administration of ddrug2 with most other HD00456 have not been studied , the concomitant use of ddrug4 with other cns-active drugs should be approached with caution .",
        "label": "NA"
    },
    {
        "text": "DB01432 increases enterohepatic elimination of DB01118 and may reduce its serum levels and ddrug2 / 2 .",
        "label": "NA"
    },
    {
        "text": "interactions with other cns agents : concurrent use of DB00854 with all ddrug1 { eg , ddrug2 , ddrug3 , ddrug4 , other ddrug5 , general ddrug6 , HD00026 , ddrug8 , ddrug9 , ddrug10 , ddrug11 and ddrug12 } may result in additive central nervous system depressant effects .",
        "label": "effect"
    },
    {
        "text": "DB00522 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , ddrug8 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , HD00029 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "int"
    },
    {
        "text": "clinical studies in healthy volunteers show that the pharmacokinetics of DB00520 are not altered by ddrug1 , DB00681 , ddrug3 , ddrug4 , or ddrug5 .",
        "label": "NA"
    },
    {
        "text": "concurrent use of DB00611 with ddrug1 { e , g , , DB02325 , ddrug3 , ddrug4 , and ddrug5 } may result in increased ddrug6 effects .",
        "label": "effect"
    },
    {
        "text": "it is suggested that in patients receiving DB00988 , alternatives to DB00252 should be used if ddrug2 therapy is needed .",
        "label": "advise"
    },
    {
        "text": "DB00316 / ddrug1 , ddrug2 / ddrug3 , ddrug4 / ddrug5 , ddrug6 / DB00313 , ddrug8 / ddrug9 , ddrug10 / ddrug11 , and ddrug12 / ddrug13 .",
        "label": "NA"
    },
    {
        "text": "additionally , ddrug0 , such as DB00608 and DB00358 , may antagonize the activity of ddrug3 .",
        "label": "NA"
    },
    {
        "text": "because both of these drugs have negative inotropic properties and the effects of coadministration with ddrug0 are unknown , neither DB00280 nor ddrug2 should be administered concurrently with DB01195 unless , in the judgment of the physician , the benefits of this combination outweigh the risks .",
        "label": "advise"
    },
    {
        "text": "agents with increased levels in the presence of ddrug0 : ddrug1 increases the plasma levels of the following agents : ddrug2 , DB00252 { 6 } , and ddrug4 thus , if a patient has been titrated to a stable dosage on one of the agents in this category , and then begins a course of the treatment with HD00472 , it is reasonable to expect that a dose decrease for the concomitant agent may be necessary .",
        "label": "NA"
    },
    {
        "text": "- ddrug0 : DB14507 should generally not be given with HD00218 { such as ddrug3 } because they reduce its renal clearance and add a high risk of ddrug4 toxicity .",
        "label": "advise"
    },
    {
        "text": "HD00665 , ddrug1 and HD00666 should not be administered during ddrug3 treatment .",
        "label": "NA"
    },
    {
        "text": "- drugs whose efficacy is impaired by ddrug0 include : ddrug1 , HD00175 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , oral HD00283 , ddrug9 , ddrug10 , ddrug11 , ddrug12 .",
        "label": "NA"
    },
    {
        "text": "DB00294 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , DB00295 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "int"
    },
    {
        "text": "agents that are cyp inducers that have been found , or are expected , to decrease plasma levels of HD00472 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , DB00252 { 2 } , ddrug7 , ddrug8 , and ddrug9 thus , if a patient has been titrated to a stable dosage on ddrug10 , and then begins a course of treatment with one of these cyp3a4 inducers , it is reasonable to expect that a dose increase for ddrug11 may be necessary .",
        "label": "mechanism"
    },
    {
        "text": "the iv DB00959 dose should be reduced by approximately 25 % , and the oral ddrug1 dose should be reduced by approximately 50 % when coadministered with ddrug2 to achieve exposures of ddrug3 similar to those obtained when it is given without DB00673 .",
        "label": "NA"
    },
    {
        "text": "we conclude that the prophylactic and antidotal properties of DB01213 seen in animals treated with HD00079 derive from its capacity to inhibit the nad + - dependent oxidation responsible for converting ddrug2 to ddrug3 in the committed step of the toxic pathway .",
        "label": "effect"
    },
    {
        "text": "several clinically important interactions have previously been reported for other HD00084 that are metabolized by the same enzyme and for HD00085 .",
        "label": "NA"
    },
    {
        "text": "intraventricular injection of DB01183 at doses of # to # micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular ddrug1 and DB00295 .",
        "label": "effect"
    },
    {
        "text": "this drug may interact with ddrug0 or other ddrug1 { may potentiate the cns depressant effects of either these medications or HD00388 } , HD00444 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug4 } , and ddrug5 { concurrent use with ddrug6 may prolong and intensify the anticholinergic and cns depressant effects of ddrug7 } .",
        "label": "NA"
    },
    {
        "text": "the action of the HD00100 may be potentiated by ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , HD00281 , or other drugs that produce cns depression .",
        "label": "effect"
    },
    {
        "text": "- a sulfa-based drug such as DB01015 - ddrug1 { ddrug2 , DB01015 } , ddrug4 { ddrug5 } , or ddrug6 { ddrug7 } ;",
        "label": "NA"
    },
    {
        "text": "the net effect of these interactions is summarized in the following table : ddrug0 HD00715 DB00949",
        "label": "NA"
    },
    {
        "text": "toxicology studies of ddrug0 - related deaths reveal frequent involvement of other ddrug1 , including DB02325 , ddrug3 such as ddrug4 { DB00829 } , and , to a rising degree , ddrug6 .",
        "label": "NA"
    },
    {
        "text": "the pharmacokinetics of DB00342 and its acid metabolite and the electrocardiographic qt c interval were measured during both periods : with ddrug1 alone , and with ddrug2 plus DB00954 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 plasma concentrations should be monitored when DB01167 and DB00951 are coadministered .",
        "label": "advise"
    },
    {
        "text": "ddrug0 may have additive effects with DB02325 and other ddrug2 , e , g , , ddrug3 , HD00024 , ddrug5 , ddrug6 .",
        "label": "NA"
    },
    {
        "text": "administration of ddrug0 with ddrug1 containing ddrug2 , ddrug3 , or DB01373 , with ddrug5 , with metal cations such as ddrug6 , or with ddrug7 containing ddrug8 or ddrug9 , or with formulations containing divalent and trivalent cations such as ddrug10 { DB00900 } chewable/buffered tablets or the pediatric powder for oral solution , may substantially interfere with the absorption of ddrug12 , resulting in systemic concentrations considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "coadministration of ddrug0 with # mg DB00401 tablets in epileptic patients lowered the DB00401 plasma concentrations to undetectable levels .",
        "label": "NA"
    },
    {
        "text": "the pharmacokinetics of DB00704 and its major metabolite HD00212 were unaffected following co-administration with ddrug2 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : as with other ddrug1 , renal excretion of ddrug2 is inhibited by DB01032 and resulted in an approximate 80 % increase in the auc for DB00447 .",
        "label": "NA"
    },
    {
        "text": "experience with HD00233 { ddrug1 } suggests the potential for interactions with DB00695 and ddrug3 .",
        "label": "int"
    },
    {
        "text": "however , it adversely affected response duration suggesting that DB00165 should not be administered with DB00488 and/or ddrug2 #",
        "label": "advise"
    },
    {
        "text": "specific and aspecific treatments of ddrug0 depletion are tricky using for example ddrug1 , pharmacological doses of ddrug2 , physiological doses of DB11094 and of DB11127 .",
        "label": "NA"
    },
    {
        "text": "although these results do not indicate a significant interaction between ddrug0 and ddrug1 or DB01109 , the administration of DB00465 to patients taking ddrug4 should be done extremely cautiously , and patients should be closely monitored .",
        "label": "NA"
    },
    {
        "text": "concurrent administration of drugs possessing nephrotoxic { e , g , , HD00249 , ddrug1 } , myelotoxic { e , g , , ddrug2 chemotherapy } , cardiotoxic { e , g , , ddrug3 } or hepatotoxic { e , g , , ddrug4 , ddrug5 } effects with DB00041 may increase toxicity in these organ systems .",
        "label": "effect"
    },
    {
        "text": "HD00445 such as ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , ddrug4 } , DB01168 { e , g , , ddrug6 } , ddrug7 { e , g , , ddrug8 } , and ddrug9 { e , g , , ddrug10 } : using these medicines with ddrug11 may increase the chance of side effects .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : increased serum ddrug1 levels and symptoms of ddrug2 toxicity have been reported in patients receiving HD00106 during therapy with DB14507 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 , another DB11753 , is structurally similar to DB01045 and may possibly have some of the same drug interactions as ddrug3 .",
        "label": "NA"
    },
    {
        "text": "other concomitant therapy although specific interaction studies were not performed , ddrug0 doses of # mg or more were concomitantly used in clinical studies with ddrug1 , ddrug2 , a-blockers , HD00651 , ddrug4 , ddrug5 , ddrug6 , HD00378 , ddrug8 , cardiac ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 { also referred to as ddrug14 } , and ddrug15 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "interactions may occur with the following : adrenocorticoids { cortisone-like medicine } , ddrug0 { ddrug1 s } , ddrug2 , ddrug3 { ddrug4 may decrease the effects of these medicines } , HD00458 { using these medicines with ddrug6 may result in increased cns depressant effects } , ddrug7 , ddrug8 { using these medicines with ddrug9 may change the amount of either medicine that you need to take } , and oral ddrug10 containing ddrug11 { ddrug12 may decrease the effectiveness of these oral HD00283 , and you may need to change to a different type of birth control } .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , like other HD00106 , has had less than additive effects with HD00397 , presumably because both drugs lower blood pressure by inhibiting parts of the renin-angiotensin system",
        "label": "effect"
    },
    {
        "text": "ddrug0 , HD00246 and ddrug2 : concomitant treatment with ddrug3 , HD00356 , or ddrug5 may potentiate a possible hypokalemic effect of ddrug6",
        "label": "NA"
    },
    {
        "text": "in vitro studies evaluating the minimum inhibitory concentration { mic } of DB00512 , ddrug1 , ddrug2 , ddrug3 / flucoxacillin , ddrug4 , ddrug5 , and ddrug6 demonstrated no evidence of incompatibility of these HD00002 with ddrug8 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 - coadministration of racemic DB00215 { 40 mg/day for # days } and ddrug2 { 30 mmol/day for # days } had no significant effect on the pharmacokinetics of ddrug3 or DB14507 .",
        "label": "NA"
    },
    {
        "text": "since animal studies suggest that the action of HD00026 may be prolonged by therapy with DB00672 , ddrug2 should be employed with caution .",
        "label": "effect"
    },
    {
        "text": "the results of a study of coadministration of DB00330 { 50 mg/kg } with an ddrug1 containing ddrug2 to # patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ddrug3 of approximately 20 % and 13 % , respectively , suggesting that the oral absorption of ddrug4 may be reduced by these HD00701 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : HD00401 may delay intestinal absorption of DB00593 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 or ddrug1 : no significant differences were observed in the pharmacokinetics of DB00897 { # mg } and DB00906 { 10 mg } when given together as a single dose .",
        "label": "NA"
    },
    {
        "text": "additive cns depression may occur when HD00388 are administered concomitantly with other ddrug1 including ddrug2 , ddrug3 , and DB02325 .",
        "label": "effect"
    },
    {
        "text": "thus , the results suggest that ddrug0 exposure of rats results in free radical-mediated tissue damage , as indicated by elevated cerebral and hepatic lipid peroxidation , which was prevented by DB00437 and DB00163 .",
        "label": "NA"
    },
    {
        "text": "in rheumatoid arthritis , concomitant medications besides ddrug0 were ddrug1 , ddrug2 , HD00175 and/or HD00543 .",
        "label": "NA"
    },
    {
        "text": "DB00876 has been shown to have no effect on the pharmacokinetics of DB00390 and the pharmacodynamics of ddrug2 and ddrug3 .",
        "label": "NA"
    },
    {
        "text": "if ddrug0 or other hepatic enzyme inducers are taken concurrently with DB00280 or ddrug2 , lower plasma levels of DB00280 may occur .",
        "label": "NA"
    },
    {
        "text": "- drugs whose efficacy is impaired by ddrug0 include : ddrug1 , HD00175 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , DB00695 , oral ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 .",
        "label": "NA"
    },
    {
        "text": "in addition , the beneficial effects of ddrug0 in parkinsons disease have been reported to be reversed by DB00252 and DB01113 .",
        "label": "NA"
    },
    {
        "text": "the oral ddrug0 doses should be reduced by approximately 50 % when coadministered with ddrug1 , to achieve exposures of DB01234 similar to those obtained when it is given without DB00673 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and foods fortified with ddrug1 concomitant administration of DB00535 with a therapeutic ddrug3 containing # mg of elemental DB01592 { as feso4 } or ddrug5 supplemented with # mg of elemental ddrug6 reduced extent of absorption by 80 % and 31 % , respectively .",
        "label": "mechanism"
    },
    {
        "text": "this appears to be the only clinically relevant interaction of this kind with DB00358 , although theoretically , coadministration of other drugs known to alter cardiac conduction { eg , ddrug1 or ddrug2 , ddrug3 , HD00388 or ddrug5 , ddrug6 and ddrug7 } might also contribute to a prolongation of the qtc interval .",
        "label": "effect"
    },
    {
        "text": "drugs that should not be coadministered with ddrug0 ddrug1 : DB01118 , ddrug3 ddrug4 : ddrug5 , ddrug6 antimigraine : ddrug7 ddrug8 : ddrug9 ddrug10 ddrug11 , ddrug12 gi motility agents : DB00604",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , HD00668 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , DB00503 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "since DB01232 is coadministered with ddrug1 , the DB00503 label should be reviewed for additional drugs that should not be coadministered .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : as with other HD00487 , renal excretion of ddrug2 is inhibited by ddrug3 and resulted in an approximate 80 % increase in the auc for DB00447 .",
        "label": "NA"
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of HD00472 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 { 1 } , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 { 1 } , ddrug10 , ddrug11 , grapefruit juice , DB00951 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21 , ddrug22 , ddrug23 , ddrug24 { 1 } , ddrug25 , ddrug26 .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : coadministration of DB00224 with ddrug2 resulted in an 83 % increase in DB00220 plasma auc and a 51 % increase in ddrug4 plasma a , c.",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , DB00273 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and DB00126 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB01118 should be used with caution in patients receiving - ddrug2 blocking agents { e , g , , ddrug3 , a ddrug4 inhibitor } or ddrug5 antagonists { e , g , , ddrug6 , a ddrug7 substrate , and DB00343 , a ddrug9 inhibitor } because of the possible potentiation of bradycardia , sinus arrest , and av block ;",
        "label": "NA"
    },
    {
        "text": "in case of DB00277 toxicity and/or elevated serum ddrug1 levels , the dose of ddrug2 should be reduced while the patient is receiving concomitant DB00199 therapy .",
        "label": "NA"
    },
    {
        "text": "ddrug0 { cns } drugs including ddrug1 , ddrug2 , ddrug3 , ddrug4 , blood pressure medications { ddrug5 , DB00968 , ddrug7 } , motion sickness medications , ddrug8 , ddrug9 , ddrug10 , sleeping pills and HD00262",
        "label": "NA"
    },
    {
        "text": "- drugs whose efficacy is impaired by DB00252 include : ddrug1 , ddrug2 , DB04665 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , oral ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 .",
        "label": "effect"
    },
    {
        "text": "DB00316 / ddrug1 , ddrug2 / ddrug3 , ddrug4 / ddrug5 , DB01174 / ddrug7 , ddrug8 / ddrug9 , ddrug10 / ddrug11 , and ddrug12 / ddrug13 .",
        "label": "NA"
    },
    {
        "text": "although there was no effect of ddrug0 on the plasma auc of ddrug1 or HD00346 determined on day 3 , there was a 34 % decrease in HD00348 { a cyp2c9 substrate } trough concentration accompanied by a 14 % decrease in the prothrombin time { reported as international normalized ratio or inr } # days after completion of dosing with ddrug4 .",
        "label": "NA"
    },
    {
        "text": "therefore , # to # hours should elapse between administration of DB01432 and HD00809 .",
        "label": "advise"
    },
    {
        "text": "ddrug0 , including oral , injectable , transdermal , and implantable ddrug1 : an interaction study demonstrated that co-administration of ddrug2 and the oral ddrug3 DB00717 produced average decreases of ddrug5 and DB00977 levels of 14 % and 31 % , respectively .",
        "label": "NA"
    },
    {
        "text": "ddrug0 works differently from the HD00128 currently available , and except for increased lipid levels , the adverse reaction profile of DB00877 does not appear to overlap to any great extent with that associated with ddrug3 or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 / DB01370 - containing ddrug2 : absorption of ddrug3 is moderately reduced { approximately 25 % } when coadministered with ddrug4 / ddrug5 - containing HD00701 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : based on reports of profound hypotension and loss of consciousness when ddrug1 was administered with ddrug2 , the concomitant use of DB00714 with drugs of the HD00335 { including , for example , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 } is contraindicated .",
        "label": "advise"
    },
    {
        "text": "DB01174 toxicity has been reported to have occurred in a patient on chronic ddrug1 treatment following the initiation of DB00586 therapy .",
        "label": "NA"
    },
    {
        "text": "- drugs that may decrease plasma DB00252 concentrations include : ddrug1 , chronic DB02325 abuse , ddrug3",
        "label": "mechanism"
    },
    {
        "text": "DB00615 , another ddrug1 , is structurally similar to DB01045 and may possibly have some of the same drug interactions as ddrug3 .",
        "label": "NA"
    },
    {
        "text": "based on adult data , lower doses of ddrug0 may be needed following coadministration of drugs which are reported to decrease ddrug1 elimination { e , g , , DB00501 and ddrug3 } and higher DB00201 doses may be needed following coadministration of drugs that increase ddrug5 elimination { e , g , , ddrug6 and ddrug7 } .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect of ddrug0 : ddrug1 , ddrug2 , ddrug3 , ddrug4 { e , g , , ddrug5 , DB01001 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , ddrug11 , HD00220 , ddrug13 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "use in conjunction with other HD00703 : the addition of DB00949 to ddrug2 { ddrug3 } affects the steady-state plasma concentrations of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "- drugs whose efficacy is impaired by DB00252 include : ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , oral ddrug8 , ddrug9 , ddrug10 , ddrug11 , DB11094 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : concomitant administration of ddrug1 containing DB14513 or ddrug3 with DB00900 chewable/dispersible buffered tablets or pediatric powder for oral solution may potentiate adverse events associated with the ddrug5 components .",
        "label": "effect"
    },
    {
        "text": "DB00897 - combined administration of racemic ddrug1 { titrated to # mg/day for # days } and the cyp3a4 substrate ddrug2 { single dose of # mg } did not significantly affect the pharmacokinetics of either DB00215 or ddrug4 .",
        "label": "NA"
    },
    {
        "text": "in patients receiving nonselective ddrug0 { HD00546 } { e , g , , ddrug2 } in combination with ddrug3 { e , g , , ddrug4 , ddrug5 , DB00715 , ddrug7 , ddrug8 } , there have been reports of serious , sometimes fatal , reactions .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , DB00949 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , DB00231 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "because of its lack of platelet effects , DB00482 is not a substitute for DB00945 for cardiovascular prophylaxis .",
        "label": "NA"
    },
    {
        "text": "co-administration of cyp3a4 inhibitors { eg , ddrug0 , ddrug1 , DB00199 , grapefruit juice , ddrug3 } with ddrug4 may lead to several - fold increases in the plasma levels of DB01023 , either due to an increase in bioavailability or due to a decrease in metabolism .",
        "label": "NA"
    },
    {
        "text": "as with other HD00485 , high concentrations of DB01330 may interfere with measurement of serum and urine creatinine levels by jaffe reaction and produce false increases in the levels of creatinine reported .",
        "label": "NA"
    },
    {
        "text": "the following are examples of substances that may reduce the blood-glucose-lowering effect : ddrug0 , DB00627 , ddrug2 , ddrug3 , ddrug4 { e , g , , ddrug5 , ddrug6 , ddrug7 } , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , HD00810 { e , g , , in oral ddrug14 } .",
        "label": "NA"
    },
    {
        "text": "the most commonly occurring drug interactions are listed below : - drugs that may increase plasma DB00252 concentrations include : acute ddrug1 intake , ddrug2 , chboramphenicol , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , HD00220 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21",
        "label": "mechanism"
    },
    {
        "text": "DB00201 ddrug1 DB00365 , like other ddrug3 , may inhibit the metabolism of ddrug4 and ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 or ddrug1 administered with ddrug2 / DB09140 to achieve # mac -lsb- minimum alveolar concentration -rsb- may prolong the clinically effective duration of action of initial and maintenance doses of DB00565 and decrease the required infusion rate of ddrug5 .",
        "label": "NA"
    },
    {
        "text": "other drugs : in healthy volunteers , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , hormone replacement therapy { a combination of conjugated ddrug5 and HD00642 } , DB06724 { ddrug8 and ddrug9 } and ddrug10 did not affect the pharmacokinetics of ddrug11 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : based on reports of profound hypotension and loss of consciousness when ddrug1 was administered with ddrug2 , the concomitant use of DB00714 with drugs of the ddrug4 { including , for example , ddrug5 , ddrug6 , ddrug7 , DB00377 , and ddrug9 } is contraindicated .",
        "label": "advise"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , DB01167 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as HD00269 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "DB00650 may enhance the toxicity of DB00544 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 - and/or DB01370 - containing ddrug2 , products containing ddrug3 { ddrug4 } , ddrug5 containing ddrug6 or other metal cations , or ddrug7 { DB00900 } chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after ddrug9 .",
        "label": "NA"
    },
    {
        "text": "antiacid , DB01211 , ddrug1 , ddrug2 , ddrug3 , indanavir , ddrug4 , ddrug5 , phenobarbitol , ddrug6 , DB00615 , ddrug8 , ritanovir , ddrug9 .",
        "label": "NA"
    },
    {
        "text": "in addition , DB00776 and ddrug1 induce a subgroup of the cytochrome cyp2b6 3a family { cyp3a4 and cyp3a5 } responsible for the metabolism of HD00890 and oral ddrug3 , resulting in a lower plasma concentration of these drugs .",
        "label": "NA"
    },
    {
        "text": "elevated serum levels of ddrug0 have been reported with concomitant use of DB00091 with DB01059 .",
        "label": "mechanism"
    },
    {
        "text": "HD00330 : in some patients , the administration of a ddrug1 can reduce the diuretic , natriuretic , and antihypertensive effects of ddrug2 , HD00293 and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 is associated with significantly fewer extrapyramidal symptoms than DB00502 and DB00734 .",
        "label": "NA"
    },
    {
        "text": "drugs and other substances demonstrated to be cyp 3a inhibitors on the basis of clinical studies involving ddrug0 metabolized similarly to ddrug1 or on the basis of in vitro studies with ddrug2 or other ddrug3 { caution is recommended during coadministration with ddrug4 } : available data from clinical studies of HD00100 other than ddrug6 suggest a possible drug interaction with ddrug7 for the following : ddrug8 , ddrug9 , HD00093 such as ddrug11 and ddrug12 , and grapefruit juice .",
        "label": "NA"
    },
    {
        "text": "in separate single or multiple dose pharmacokinetic interaction studies with ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , and DB00682 , the bioavailability of DB14207 was not altered by coadministration of ddrug10 with any one of these drugs .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : based on reports of profound hypotension and loss of consciousness when ddrug1 was administered with DB00904 , the concomitant use of ddrug3 with drugs of the ddrug4 { including , for example , ddrug5 , ddrug6 , DB00757 , ddrug8 , and ddrug9 } is contraindicated .",
        "label": "NA"
    },
    {
        "text": "initial doses of ddrug0 , such as DB00988 or DB00668 , should be reduced and titrated to achieve the desired response .",
        "label": "NA"
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the ddrug0 of drugs may be potentiated by ddrug1 , ddrug2 , ddrug3 , ddrug4 , HD00557 , the ddrug6 , ddrug7 and HD00560 , ddrug9 and the ddrug10 , and by other ddrug11 .",
        "label": "NA"
    },
    {
        "text": "tell your doctor if you are taking any of the following drugs : ddrug0 s { ddrug1 } other ddrug2 ddrug3 ddrug4 DB00564 { ddrug6 } ddrug7 { ddrug8 } HD00220 ddrug10 { ddrug11 } sporal { ddrug12 } ddrug13 { ddrug14 } ddrug15 ddrug16 ddrug17 birth control pills sleeping pills thyroid medications",
        "label": "NA"
    },
    {
        "text": "ddrug0 - and/or ddrug1 - containing HD00374 , products containing ddrug3 { ddrug4 } , ddrug5 containing ddrug6 or other metal cations , or ddrug7 { ddrug8 } chewable/buffered tablets or the pediatric powder for oral solution should not be taken within # hours before or # hours after DB01155 .",
        "label": "NA"
    },
    {
        "text": "these drugs include the ddrug0 and other HD00218 , HD00175 , ddrug3 , ddrug4 , ddrug5 , oral ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , and ddrug11 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : experience in over # patients in a non-comparative clinical trial has shown that concomitant administration of DB01115 and HD00228 is usually well tolerated , but there have been occasional literature reports suggesting that the combination may increase the likelihood of congestive heart failure , severe hypotension or exacerbation of angina .",
        "label": "effect"
    },
    {
        "text": "the plasma concentration of HD00551 has been reported to be increased by the concomitant administration of DB00502 ;",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 , DB00637 and ddrug2 are all metabolized by the cytochrome p450iiia4 isozyme , and it has been demonstrated that DB01026 , a potent inhibitor of iiia4 , blocks the metabolism of these drugs , resulting in increased plasma concentrations of parent drug .",
        "label": "mechanism"
    },
    {
        "text": "other concomitant therapy although specific interaction studies were not performed , DB01216 doses of # mg or more were concomitantly used in clinical studies with DB00316 , ddrug2 , a-blockers , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , cardiac ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 { also referred to as ddrug14 } , and ddrug15 without evidence of clinically significant adverse interactions .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and DB00215 - in a controlled study , a single dose of DB01100 # mg co-administered with racemic ddrug3 # mg given once daily for # days was associated with a mean increase in qtc values of approximately # msec compared to ddrug4 given alone .",
        "label": "NA"
    },
    {
        "text": "ddrug0 / ddrug1 : the coadministration of ddrug2 or ddrug3 will not affect plasma concentrations of DB11094 , but may reduce endogenous plasma levels of DB00136 / ergocalcitriol by accelerating metabolism .",
        "label": "NA"
    },
    {
        "text": "ddrug0 and ddrug1 : DB01026 and DB00196 are predominantly ppig 3a4 and 2c9 inhibitors , respectively .",
        "label": "NA"
    },
    {
        "text": "although there is little published information on concomitant administration of DB00281 and HD00438 , these drugs are often administered concurrently without any evidence of interactions resulting in adverse effects or diminished efficacy .",
        "label": "NA"
    },
    {
        "text": "coadministration in hiv-infected individuals with a history of injection drug use resulted in decreased plasma levels of DB00333 and signs of HD00099 withdrawal .",
        "label": "NA"
    },
    {
        "text": "DB11156 { e , g , , ddrug1 } - taking DB00592 and ddrug3 together may decrease the effects of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "since the concomitant administration of ddrug0 with DB01118 increases the prothrombin time by 100 % after # to # days , the dose of the HD00025 should be reduced by one-third to one-half , and prothrombin times should be monitored closely .",
        "label": "NA"
    },
    {
        "text": "however , because some ddrug0 have been reported to enhance the anticoagulant effects of ddrug1 or its derivatives in patients , the prothrombin time or other suitable coagulation test should be closely monitored if a HD00751 is administered concomitantly with DB00682 or its derivatives .",
        "label": "advise"
    },
    {
        "text": "when ddrug0 HD00524 is given for long periods of time , concomitant supplementation with water-miscible { or parenteral } forms of HD00527 should be considered .",
        "label": "NA"
    },
    {
        "text": "other drugs : in healthy volunteers , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , hormone replacement therapy { a combination of conjugated HD00220 and ddrug6 } , ddrug7 { DB06723 and ddrug9 } and ddrug10 did not affect the pharmacokinetics of ddrug11 .",
        "label": "NA"
    },
    {
        "text": "the aim of this study was to investigate the effects of low and high doses of DB00783 , and of ddrug1 on the response to DB00368 in rat thoracic aorta .",
        "label": "NA"
    },
    {
        "text": "because the HD00239 have been shown to depress plasma prothrombin activity , patients who are on ddrug1 therapy may require downward adjustment of their HD00025 dosage .",
        "label": "NA"
    },
    {
        "text": "also , concomitant administration of ddrug0 with products containing DB01592 , ddrug2 containing ddrug3 , or ddrug4 { DB00900 } chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels .",
        "label": "NA"
    },
    {
        "text": "ddrug0 or oral ddrug1 : initiating thyroid replacement therapy may cause increases in HD00071 or oral HD00854 requirements .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , DB00316 and ddrug2 may enhance the effects of : other ddrug3 s , ddrug4 , general ddrug5 , ddrug6 such as ddrug7 , ddrug8 , or other HD00261 , causing increased cns depression .",
        "label": "effect"
    },
    {
        "text": "the extent to which HD00278 - HD00312 interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the ddrug2 involved .",
        "label": "int"
    },
    {
        "text": "pharmacodynamic interactions : the cns-depressant action of the ddrug0 of drugs may be potentiated by ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , the ddrug6 , ddrug7 and ddrug8 , HD00275 and the ddrug10 , and by other HD00561 .",
        "label": "NA"
    },
    {
        "text": "these agents include medications such as : ddrug0 , HD00679 including DB00945 , sali-cylates , ddrug3 { including ddrug4 } , ddrug5 , or ddrug6 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : ddrug1 gi motility agents HD00667 DB00857",
        "label": "NA"
    },
    {
        "text": "ddrug0 : an increased risk of hepatitis has been reported to result from combined use of DB00563 and DB00926 .",
        "label": "effect"
    },
    {
        "text": "it would be expected that DB09020 use during therapy with DB00762 would worsen the incidence or severity of diarrhea , but this has not been studied .",
        "label": "effect"
    },
    {
        "text": "in patients receiving nonselective ddrug0 { HD00546 } { e , g , , ddrug2 } in combination with ddrug3 { e , g , , ddrug4 , ddrug5 , ddrug6 , DB01104 , ddrug8 } , there have been reports of serious , sometimes fatal , reactions .",
        "label": "effect"
    },
    {
        "text": "other no clinically important pharmacokinetic interactions occurred when DB00542 was administered concomitantly with ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , or DB00501 .",
        "label": "NA"
    },
    {
        "text": "immediate and extended release tablets the hypoglycemic action of ddrug0 may be potentiated by certain drugs including ddrug1 , some HD00768 and other drugs that are highly protein bound , HD00328 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , and ddrug9 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : combination HD00432 may increase or decrease the effects of HD00708 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : concomitant administration of DB00465 oral and ddrug2 resulted in decreased clearance of ddrug3 and significant increases in DB00465 plasma levels { total auc increased approximately threefold from # to # m g/h/ml } and terminal half-life increased approximately twofold from # to # hours .",
        "label": "NA"
    },
    {
        "text": "the ddrug0 study dosed subjects with # mg/day of DB00207 { n = 7 } { later changed to # mg/day -lsb- n = 5 -rsb- } for days # to # of a 21-day course of # mg , five times/day of DB00495 .",
        "label": "NA"
    },
    {
        "text": "however , it was observed that the pharmacokinetics of DB09145 was unaltered by concomitant DB00563 in rheumatoid_arthritis patients .",
        "label": "NA"
    },
    {
        "text": "DB00609 may potentiate the adverse effects of other HD00702 administered concomitantly .",
        "label": "effect"
    },
    {
        "text": "ddrug0 : DB00467 may raise serum DB00390 levels in some individuals .",
        "label": "mechanism"
    },
    {
        "text": "concomitant administration of ddrug0 and ddrug1 , DB00501 , ddrug3 , or an ddrug4 / ddrug5 oral ddrug6 produced minor changes in the pharmacokinetics of DB01155 , which were considered to be without clinical significance .",
        "label": "NA"
    },
    {
        "text": "- HD00326 : interaction studies in humans have shown ddrug1 to have no effect on DB00682 metabolism or on plasma prothrombin activity .",
        "label": "NA"
    },
    {
        "text": "caution is advised when ddrug0 is coadministered with other medications that can prolong the qt interval { e , g , certain HD00303 or ddrug2 } or lead to electrolyte abnormalities { such as HD00218 or ddrug4 } .",
        "label": "NA"
    },
    {
        "text": "both ddrug0 and ddrug1 have been compared to triple therapy with the ddrug2 DB00224 over # weeks as initial therapy , with similar responses being observed with DB00238 regimens and superiority observed with ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 DB00233 and heavy ddrug2 intake for longer than # weeks may produce malabsorption of DB00115 .",
        "label": "mechanism"
    },
    {
        "text": "oral HD00283 : coadministration of ddrug1 and an oral ddrug2 increased auc values for ddrug3 and DB00977 by approximately 30 % and 20 % .",
        "label": "NA"
    },
    {
        "text": "there was no evidence of drug interactions in clinical studies in which DB00841 was administered concurrently with other drugs , including ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , and DB00316 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { DB01076 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as HD00269 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB14513 - containing preparations { eg , ddrug2 } may cause hypermagnesemia and should therefore not be taken during therapy with DB11094 by patients on chronic renal dialysis .",
        "label": "advise"
    },
    {
        "text": "agents that are cyp3a4 inhibitors that have been found , or are expected , to increase plasma levels of HD00472 are the following : ddrug1 , ddrug2 , ddrug3 , ddrug4 { 1 } , ddrug5 , ddrug6 , ddrug7 , DB00343 , ddrug9 { 1 } , ddrug10 , ddrug11 , grapefruit juice , ddrug12 , ddrug13 , ddrug14 , ddrug15 , ddrug16 , ddrug17 , ddrug18 , ddrug19 , ddrug20 , ddrug21 , ddrug22 , ddrug23 , ddrug24 { 1 } , ddrug25 , ddrug26 .",
        "label": "mechanism"
    },
    {
        "text": "DB00392 may interact with ddrug1 or other HD00261 , causing increased sedative effects .",
        "label": "effect"
    },
    {
        "text": "pharmacokinetic studies have demonstrated that ddrug0 and DB00199 significantly increased the systemic exposure of DB01166 and/or its major metabolites .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : HD00532 have been reported to enhance the effects of the oral HD00025 ddrug3 or its derivatives .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : concurrent administration of certain HD00537 , such as ddrug2 and DB00804 , would be expected to compromise the beneficial effects of ddrug4 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : DB01435 pharmacokinetics were not significantly different before and after DB00906 multiple-dose regimens .",
        "label": "NA"
    },
    {
        "text": "a rare , but serious , constellation of symptoms , termed serotonin syndrome , has been reported with the concomitant use of HD00113 { ddrug1 } and agents for migraine therapy , such as DB00669 { ddrug3 } and ddrug4 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with ddrug1 { e , g , , ddrug2 } , ddrug3 { e , g , , DB00446 } , local ddrug5 { e , g , , ddrug6 and ddrug7 } , DB02362 { ddrug9 } - containing preparations { e , g , , sunscreens and some ddrug10 } , ddrug11 { e , g , , ddrug12 } , ddrug13 { sulfa medicines } , ddrug14 { use of these medicines during the test period will affect the test results } , and pancreatic supplements { use of pancreatic supplements may give false test results } .",
        "label": "NA"
    },
    {
        "text": "the potential for drug interactions with DB00879 has been studied in combination with ddrug1 , DB00649 , ddrug3 , and ddrug4 .",
        "label": "NA"
    },
    {
        "text": "although specific studies have not been performed , coadministration with drugs that are mainly metabolized by cyp3a4 { eg , ddrug0 , ddrug1 , ddrug2 , ddrug3 , ddrug4 , ddrug5 , ddrug6 , ddrug7 , DB00091 , ddrug9 , ddrug10 , ddrug11 , ddrug12 , ddrug13 , ddrug14 , and ddrug15 } may have elevated plasma concentrations when coadministered with DB01232 ;",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 : no drug interactions with other ddrug1 have been identified that would warrant alteration of either the DB00109 dose or the dose of the other HD00677 .",
        "label": "NA"
    },
    {
        "text": "although the interaction between ddrug0 and other potent cyp3a4 inhibitors { e , g , , ddrug1 , DB00503 , and ddrug3 } has not been studied , increased exposures to ddrug4 may be expected when DB00918 is used concomitantly with these medications .",
        "label": "advise"
    },
    {
        "text": "ddrug0 : coadministration of a single dose of DB00962 # mg and multiple doses of ddrug2 er { extended release } # mg did not result in any significant changes in the pharmacokinetics of either ddrug3 or DB00285 .",
        "label": "NA"
    },
    {
        "text": "multivalent cation-containing products : concurrent administration of a ddrug0 , including ddrug1 , with multivalent cation-containing products such as DB14513 or ddrug3 ddrug4 , ddrug5 , ddrug6 chewable/buffered tablets or pediatric powder , or products containing ddrug7 , ddrug8 , or ddrug9 may substantially decrease the absorption of DB00537 , resulting in serum and urine levels considerably lower than desired .",
        "label": "NA"
    },
    {
        "text": "on the basis of the metabolism of ddrug0 by cytochrome p450 3a4 , DB01026 , ddrug2 , ddrug3 , ddrug4 , grapefruit juice , and other inhibitors of cyp3a4 would be expected to lead to an increase in plasma DB00307 concentrations .",
        "label": "mechanism"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , DB00503 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and DB00126 .",
        "label": "NA"
    },
    {
        "text": "care should be taken if DB00598 is used concomitantly with HD00411 s of the ddrug2 type .",
        "label": "advise"
    },
    {
        "text": "ddrug0 { e , g , , ddrug1 , HD00340 , ddrug3 } and DB00951 may reduce the therapeutic effects of ddrug5 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 , DB00390 , ddrug2 , and DB01109 the in vitro binding of ddrug4 to plasma proteins is only slightly reduced by ddrug5 { # % control vs # % } when ddrug6 plasma concentrations reach # to10 m g/ml .",
        "label": "NA"
    },
    {
        "text": "other HD00233 that inhibit prostaglandin synthesis have been shown to interfere with HD00029 in some studies and with ddrug2 .",
        "label": "effect"
    },
    {
        "text": "ddrug0 may interact with the following medications : DB00316 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , DB00220 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "when DB00520 is co-administered with inducers of drug clearance , such as DB00625 , ddrug2 , ddrug3 , ddrug4 , or ddrug5 , use of a daily dose of # mg of ddrug6 should be considered",
        "label": "advise"
    },
    {
        "text": "the half-life of ddrug0 in plasma and brain was longer in the presence of DB01159 than when DB01221 was given alone .",
        "label": "NA"
    },
    {
        "text": "interactions may also occur with the following : ddrug0 / ddrug1 , drugs used to treat an overactive thyroid , ddrug2 { e , g , , ddrug3 } , ddrug4 , ddrug5 , DB01170 , ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 pain medication { e , g , , ddrug12 } , drugs used to aid sleep , drowsiness-causing HD00388 { e , g , , ddrug14 } , any other drugs that may make you drowsy .",
        "label": "NA"
    },
    {
        "text": "the hypotensive effect of DB00325 is augmented by that of most other HD00885 , including ddrug2 , negative inotropic agents , and inhaled ddrug3 .",
        "label": "effect"
    },
    {
        "text": "both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ddrug0 is administered in combination with other ddrug1 such as ddrug2 , HD00262 , ddrug4 , or inhalation general HD00264 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 : the pharmacokinetics of DB00529 and DB01004 were not altered in # patients receiving either concomitant therapy or daily alternating therapy for maintenance of cmv disease .",
        "label": "NA"
    },
    {
        "text": "HD00026 , ddrug1 , or ddrug2 increased metabolic clearance of DB00687 because of the induction of hepatic enzymes .",
        "label": "mechanism"
    },
    {
        "text": "when other potent parental HD00448 , such as ddrug1 , are used in combination with DB01275 , patients should be continuously observed for several hours for any excessive fall in blood pressure .",
        "label": "effect"
    },
    {
        "text": "ddrug0 ddrug1 { 1000 mg twice daily } did not influence the pharmacokinetics of HD00836 and HD00835 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 altered coagulation parameters and/or bleeding have been reported in patients taking DB01101 concomitantly with HD00469 such as ddrug3 and ddrug4 .",
        "label": "effect"
    },
    {
        "text": "potential DB00342 , ddrug1 , and DB00604 interactions",
        "label": "NA"
    },
    {
        "text": "ddrug0 : available data suggest that there is no significant effect of ddrug1 on the clearance of ddrug2 at steady state , therefore , the addition of DB00313 is not expected to cause a clinically important effect on DB00949 { ddrug5 } plasma concentrations .",
        "label": "NA"
    },
    {
        "text": "similarly , DB00731 had no influence on the serum protein binding of ddrug1 , ddrug2 , ddrug3 , ddrug4 , DB00252 , ddrug6 , and ddrug7 in vitro .",
        "label": "NA"
    },
    {
        "text": "therefore , co-administration of ddrug0 with other drugs that are metabolized by this isoenzyme , including other ddrug1 , ddrug2 , ddrug3 , and ddrug4 { eg , DB01182 , ddrug6 , and ddrug7 } , or that inhibit this enzyme { eg , DB00908 } , should be approached with caution .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , HD00002 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , DB01076 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { ddrug33 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { ddrug40 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 may interact with the following medications : ddrug1 { ddrug2 } , ddrug3 such as ddrug4 and ddrug5 , ddrug6 { ddrug7 , ddrug8 , ddrug9 , ddrug10 , ddrug11 , ddrug12 } , ddrug13 { ddrug14 , ddrug15 , ddrug16 } , ddrug17 { ddrug18 } , ddrug19 { ddrug20 } , ddrug21 { ddrug22 , ddrug23 } , hiv drugs classified as ddrug24 { ddrug25 , ddrug26 , ddrug27 , ddrug28 , ddrug29 , ddrug30 , ddrug31 } , ddrug32 { DB00295 , ddrug34 , ddrug35 } , ddrug36 , ddrug37 { ddrug38 } , ddrug39 { DB01045 } , st , johns wort , ddrug41 , ddrug42 { ddrug43 } , and ddrug44 .",
        "label": "NA"
    },
    {
        "text": "HD00093 { e , g , ddrug1 and ddrug2 } : agents of the ddrug3 , of which ddrug4 { DB00320 } injection , usp is a member , have been shown to interact with ddrug6 of the ddrug7 , resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction .",
        "label": "NA"
    },
    {
        "text": "this drug may interact with ddrug0 or other HD00261 { may potentiate the cns depressant effects of either these medications or ddrug2 } , ddrug3 or other medications with anticholinergic activity { anticholinergic effects may be potentiated when these medications are used concurrently with ddrug4 } , and ddrug5 { concurrent use with HD00388 may prolong and intensify the anticholinergic and cns depressant effects of ddrug7 } .",
        "label": "NA"
    },
    {
        "text": "DB00682 - DB01022 can antagonize the effect of ddrug2",
        "label": "NA"
    },
    {
        "text": "conclusions/interpretation : DB09341 and HD00071 can exert additive vasodilator properties on renal and ocular circulation .",
        "label": "NA"
    },
    {
        "text": "if ddrug0 is to be combined with other ddrug1 such as ddrug2 or HD00596 / ddrug4 , careful consideration should be given to the pharmacology of the agents employed since the sedative effects of ddrug5 and ddrug6 { e , g , , DB00475 or ddrug8 } are additive .",
        "label": "NA"
    },
    {
        "text": "however , DB14539 pretreatment did not affect any of the physiological , behavioral , or subjective effects of DB01576 .",
        "label": "NA"
    },
    {
        "text": "ddrug0 ddrug1 ddrug2 ddrug3 DB00976 ddrug5 DB01149 ddrug7 large quantities of grapefruit juice { # quart daily }",
        "label": "NA"
    },
    {
        "text": "results of studies in multiple sclerosis patients taking ddrug0 and concomitant ddrug1 { DB02325 # mcg i m once weekly } or ddrug3 were inconclusive with regard to the need for dose adjustment of the HD00868 or ddrug5 .",
        "label": "NA"
    },
    {
        "text": "this appears to be the only clinically relevant interaction of this kind with DB00358 , although theoretically , coadministration of other drugs known to alter cardiac conduction { eg , ddrug1 or ddrug2 , ddrug3 , ddrug4 or ddrug5 , HD00043 and ddrug7 } might also contribute to a prolongation of the qtc interval .",
        "label": "effect"
    },
    {
        "text": "the optimal dose of DB00224 , when given in combination with DB00625 , is not known .",
        "label": "NA"
    },
    {
        "text": "after # days of co-administration , mean trough concentrations of ddrug0 and its metabolites , HD00566 and ddrug2 , were elevated with DB00176 by about three-fold compared to baseline concentrations .",
        "label": "NA"
    },
    {
        "text": "in a comparison of ddrug0 tolerance in dogs anesthetized with ddrug1 , HD00119 , or ddrug3 , the dosage of ddrug4 needed to cause ventricular tachycardia was significantly higher , as was the ld50 of DB01092 , with ddrug6 or ddrug7 than with ddrug8 .",
        "label": "NA"
    }
]